PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Breig, O; Theoleyre, O; Douablin, A; Baklouti, F				Breig, O.; Theoleyre, O.; Douablin, A.; Baklouti, F.			Subtle distinct regulations of late erythroid molecular events by PI3K/AKT- mediated activation of Spi-1/PU.1 oncogene autoregulation loop	ONCOGENE			English	Article						erythroleukemia; mRNA splicing; cell differentiation; cell signaling	PRE-MESSENGER-RNA; TRANSCRIPTION FACTOR PU.1; FOCUS-FORMING VIRUS; PHOSPHATIDYLINOSITOL 3-KINASE; FRIEND-ERYTHROLEUKEMIA; PHOSPHOINOSITIDE 3-KINASE; TARGET GENES; ERYTHROPOIETIN; KINASE; PHOSPHORYLATION	Spi-1/PU.1 oncogene is downregulated as proerythroblasts undergo terminal differentiation. Insertion of the Friend virus upstream of the Spi-1/PU.1 locus leads to the constitutive upregulation of Spi-1/PU.1, and a subsequent block in the differentiation of the affected erythroblasts. We have shown that sustained overexpression of Spi-1/PU.1 also inhibits the erythroid splicing of protein 4.1R exon 16, irrespective of chemical induction of differentiation. Here, we show a positive feedback loop that couples constitutive phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling to high expression of Spi-1/PU.1 in Friend erythroleukemia cells. Inhibition of PI3K/AKT results in Spi-1/PU.1 downregulation in a stepwise manner and induces cell differentiation. Chromatin immunoprecipitation assays further supported the positive autoregulatory effect of Spi-1/PU.1. Mutational analysis indicated that Ser41, but not Ser148, is necessary for Spi1/PU.1-mediated repression of hemoglobin expression, whereas both Ser residues are required for Spi-1/PU.1 inhibition of the erythroid splicing event. We further show that inhibition of the erythroid transcriptional and splicing events are strictly dependent on distinct Spi-1/PU.1 phosphorylation modifications rather than Spi-1/PU.1 expression level per se. Our data further support the fact that Spi-1/PU.1 inhibits 4.1R erythroid splicing through two different pathways, and bring new insights into the extracellular signal impact triggered by erythropoietin on late erythroid regulatory program, including pre-mRNA splicing. Oncogene (2010) 29, 2807-2816; doi: 10.1038/onc.2010.29; published online 1 March 2010	[Breig, O.; Theoleyre, O.; Douablin, A.; Baklouti, F.] Univ Lyon 1, mRNA Metab Normal & Pathol Cells, CGMC, CNRS,UMR 5534, F-69622 Villeurbanne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Baklouti, F (corresponding author), Univ Lyon 1, mRNA Metab Normal & Pathol Cells, CGMC, CNRS,UMR 5534, Bat Gregor Mendel,16,Rue R, F-69622 Villeurbanne, France.	faouzi.baklouti@univ-lyon1.fr	BAKLOUTI, Faouzi/E-7670-2013	BAKLOUTI, Faouzi/0000-0002-2830-292X	Ligue contre le Cancer, Comite de la Loire; INSERM; Ligue contre le Cancer, Comite du Doubs	Ligue contre le Cancer, Comite de la Loire; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Ligue contre le Cancer, Comite du Doubs	We thank Dr I Merida (Department of Immunology and Oncology, Centro Nacional de Biotecnologia, Madrid, Spain) for pEFbosEGFP_C1 plasmid, Dr F Moreau-Gachelin (Inserm U830, Institut Curie, Paris, France) for anti-Spi-1/PU.1 antibody, G Giraud for helping with the ChIP assay and Dr G Mouchiroud and Dr F Morle (CGMC, Villeurbanne, France) for sharing reagents, including anti-p85 antibody. This work was supported by grants from the 'Ligue contre le Cancer, Comite de la Loire'. Authors were supported by the INSERM, the 'Ligue contre le Cancer, Comite de la Loire', the 'Ligue contre le Cancer, Comite du Doubs'	Afrikanova I, 2002, ONCOGENE, V21, P1272, DOI 10.1038/sj.onc.1205183; Back J, 2004, BLOOD, V103, P3615, DOI 10.1182/blood-2003-11-4089; Baklouti F, 1996, BLOOD, V87, P3934, DOI 10.1182/blood.V87.9.3934.bloodjournal8793934; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; Barnache S, 2001, BLOOD, V98, P2372, DOI 10.1182/blood.V98.8.2372; Bavelloni A, 2000, CELL DEATH DIFFER, V7, P112, DOI 10.1038/sj.cdd.4400591; Blaustein M, 2005, NAT STRUCT MOL BIOL, V12, P1037, DOI 10.1038/nsmb1020; Blaustein M, 2007, INT J BIOCHEM CELL B, V39, P2031, DOI 10.1016/j.biocel.2007.04.004; Blaybel R, 2008, CELL RES, V18, P834, DOI 10.1038/cr.2008.68; Bouscary D, 2003, BLOOD, V101, P3436, DOI 10.1182/blood-2002-07-2332; Cataldi A, 2000, CELL SIGNAL, V12, P667, DOI 10.1016/S0898-6568(00)00109-1; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; CHENG ADY, 1995, GRAVITATION COSMOLOG, V1, P1; Deguillien M, 2001, BLOOD, V98, P3809, DOI 10.1182/blood.V98.13.3809; DELGADO MD, 1994, ONCOGENE, V9, P1723; Delva L, 2004, ONCOGENE, V23, P4389, DOI 10.1038/sj.onc.1207578; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Fisher RC, 2004, LEUKEMIA RES, V28, P83, DOI 10.1016/S0145-2126(03)00178-4; Ghaffari S, 2003, MIL DRUG TH, P65; Jelkmann W, 2007, EUR J HAEMATOL, V78, P183, DOI 10.1111/j.1600-0609.2007.00818.x; Juban G, 2009, MOL CELL BIOL, V29, P2852, DOI 10.1128/MCB.01435-08; Maillet P, 1996, HUM MUTAT, V7, P61, DOI 10.1002/(SICI)1098-1004(1996)7:1<61::AID-HUMU9>3.3.CO;2-T; Moreau-Gachelin F, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-99; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; Myklebust JH, 2002, EXP HEMATOL, V30, P990, DOI 10.1016/S0301-472X(02)00868-8; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Nishigaki K, 2000, J VIROL, V74, P3037, DOI 10.1128/JVI.74.7.3037-3045.2000; Nishigaki K, 2006, J VIROL, V80, P5678, DOI 10.1128/JVI.02651-05; Okuno Y, 2005, MOL CELL BIOL, V25, P2832, DOI 10.1128/MCB.25.7.2832-2845.2005; Patel NA, 2005, J BIOL CHEM, V280, P14302, DOI 10.1074/jbc.M411485200; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; Rieske P, 2001, J BIOL CHEM, V276, P8460, DOI 10.1074/jbc.M007482200; Sanjuan MA, 2001, J CELL BIOL, V153, P207, DOI 10.1083/jcb.153.1.207; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sivertsen EA, 2006, BRIT J HAEMATOL, V135, P117, DOI 10.1111/j.1365-2141.2006.06252.x; Tarn WY, 2007, J BIOMED SCI, V14, P517, DOI 10.1007/s11373-007-9161-7; Theoleyre O, 2004, ONCOGENE, V23, P920, DOI 10.1038/sj.onc.1207206; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	43	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2010	29	19					2807	2816		10.1038/onc.2010.29	http://dx.doi.org/10.1038/onc.2010.29			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	595DW	20190819				2022-12-17	WOS:000277591900006
J	Massip, L; Garand, C; Labbe, A; Perreault, E; Turaga, RVN; Bohr, VA; Lebel, M				Massip, L.; Garand, C.; Labbe, A.; Perreault, E.; Turaga, R. V. N.; Bohr, V. A.; Lebel, M.			Depletion of WRN protein causes RACK1 to activate several protein kinase C isoforms	ONCOGENE			English	Article						Werner syndrome; mass spectrometry; RACK1; PKC activation	WERNER-SYNDROME PROTEIN; OXIDATIVE STRESS; DNA-DAMAGE; FUNCTIONAL INTERACTION; BETA; PHOSPHORYLATION; DELTA; TRANSLOCATION; EPSILON; BREAKS	Werner's syndrome (WS) is a rare autosomal disease characterized by the premature onset of several age-associated pathologies. The protein defective in patients with WS (WRN) is a helicase/exonuclease involved in DNA repair, replication, transcription and telomere maintenance. In this study, we show that a knock down of the WRN protein in normal human fibroblasts induces phosphorylation and activation of several protein kinase C (PKC) enzymes. Using a tandem affinity purification strategy, we found that WRN physically and functionally interacts with receptor for activated C-kinase 1 (RACK1), a highly conserved anchoring protein involved in various biological processes, such as cell growth and proliferation. RACK1 binds strongly to the RQC domain of WRN and weakly to its acidic repeat region. Purified RACK1 has no impact on the helicase activity of WRN, but selectively inhibits WRN exonuclease activity in vitro. Interestingly, knocking down RACK1 increased the cellular frequency of DNA breaks. Depletion of the WRN protein in return caused a fraction of nuclear RACK1 to translocate out of the nucleus to bind and activate PKC delta and PKC beta II in the membrane fraction of cells. In contrast, different DNA-damaging treatments known to activate PKCs did not induce RACK1/PKCs association in cells. Overall, our results indicate that a depletion of the WRN protein in normal fibroblasts causes the activation of several PKCs through translocation and association of RACK1 with such kinases. Oncogene (2010) 29, 1486-1497; doi:10.1038/onc.2009.443; published online 7 December 2009	[Massip, L.; Garand, C.; Labbe, A.; Perreault, E.; Turaga, R. V. N.; Lebel, M.] Univ Laval, Hop Hotel Dieu, Dept Mol Biol Med Biochem & Pathol, Ctr Rech Cancerol, Quebec City, PQ G1R 2J6, Canada; [Bohr, V. A.] NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA	Laval University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Lebel, M (corresponding author), Univ Laval, Hop Hotel Dieu, Dept Mol Biol Med Biochem & Pathol, Ctr Rech Cancerol, 9 McMahon St, Quebec City, PQ G1R 2J6, Canada.	michel.lebel@crhdq.ulaval.ca	Bohr, Vilhelm/AAP-5931-2020; Perreault, Eric/B-7632-2009	Garand, Chantal/0000-0003-0716-6487	Canadian Institutes of Health Research; National Institute on Aging, NIH; Fonds de la Recherche en Sante du Quebec; NATIONAL INSTITUTE ON AGING [ZIAAG000721] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); National Institute on Aging, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Fonds de la Recherche en Sante du Quebec(Fonds de la Recherche en Sante du Quebec); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	We are grateful to Mrs N Roberge for the FACS analyses (Centre de Recherche en Cancerologie, Quebec City, Qc). This study was supported by the Canadian Institutes of Health Research to ML and in part by funds from the intramural Program of the National Institute on Aging, NIH to VAB. ML is a senior scholar from the Fonds de la Recherche en Sante du Quebec.	Battaini F, 1997, TRENDS NEUROSCI, V20, P410, DOI 10.1016/S0166-2236(97)01084-9; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; Besson A, 2002, J BIOL CHEM, V277, P22073, DOI 10.1074/jbc.M111644200; Brosh RM, 2001, EMBO J, V20, P5791; Cheng WH, 2008, MOL BIOL CELL, V19, P3923, DOI 10.1091/mbc.E07-07-0698; Cheng WH, 2007, EXP GERONTOL, V42, P871, DOI 10.1016/j.exger.2007.04.011; Cooper MP, 2000, GENE DEV, V14, P907; Corsini E, 2005, J LEUKOCYTE BIOL, V77, P247, DOI 10.1189/jlb.0504268; Das A, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M703343200; Davis T, 2007, ANN NY ACAD SCI, V1100, P455, DOI 10.1196/annals.1395.051; Davis T, 2009, BIOGERONTOLOGY, V10, P253, DOI 10.1007/s10522-008-9179-x; Deschenes F, 2005, HUM MOL GENET, V14, P3293, DOI 10.1093/hmg/ddi362; Edwards AS, 1999, J BIOL CHEM, V274, P6461, DOI 10.1074/jbc.274.10.6461; Egidy G, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-34; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FARAGHER RGA, 1993, P NATL ACAD SCI USA, V90, P12030, DOI 10.1073/pnas.90.24.12030; Grosso S, 2008, BIOCHEM J, V415, P77, DOI 10.1042/BJ20080463; Indig FE, 2004, J STRUCT BIOL, V146, P251, DOI 10.1016/j.jsb.2003.11.009; Kaneto H, 2005, CURR DIABETES REV, V1, P65, DOI 10.2174/1573399052952613; Karanjawala ZE, 2002, CURR BIOL, V12, P397, DOI 10.1016/S0960-9822(02)00684-X; Karmakar P, 2002, NUCLEIC ACIDS RES, V30, P3583, DOI 10.1093/nar/gkf482; Kohda Y, 2005, J PHARMACOL SCI, V98, P49, DOI 10.1254/jphs.FP0040926; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Li BM, 2000, J BIOL CHEM, V275, P28349, DOI 10.1074/jbc.C000289200; Li CH, 2000, CELL SIGNAL, V12, P435, DOI 10.1016/S0898-6568(00)00096-6; Marciniak RA, 1998, P NATL ACAD SCI USA, V95, P6887, DOI 10.1073/pnas.95.12.6887; Massip L, 2006, EXP GERONTOL, V41, P157, DOI 10.1016/j.exger.2005.10.011; MASSIP L, 2009, FASEB J; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Melcher R, 2000, CYTOGENET CELL GENET, V91, P180, DOI 10.1159/000056841; Min W, 2009, CARDIOVASC DIABETOL, V8, DOI 10.1186/1475-2840-8-8; Nitti M, 2008, MOL ASPECTS MED, V29, P36, DOI 10.1016/j.mam.2007.09.001; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; Opresko PL, 2002, J BIOL CHEM, V277, P41110, DOI 10.1074/jbc.M205396200; Osmanagic-Myers S, 2004, J BIOL CHEM, V279, P18701, DOI 10.1074/jbc.M312382200; Ottaviani E, 2001, COMP BIOCHEM PHYS C, V129, P295, DOI 10.1016/S1532-0456(01)00211-3; Pagano G, 2005, FREE RADICAL RES, V39, P529, DOI 10.1080/10715760500092683; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Pascale A, 1996, J NEUROCHEM, V67, P2471; Pass JM, 2001, AM J PHYSIOL-HEART C, V281, pH2500, DOI 10.1152/ajpheart.2001.281.6.H2500; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sajan MP, 2006, J BIOL CHEM, V281, P17466, DOI 10.1074/jbc.M510803200; Sedding DG, 2008, BIOL CHEM, V389, P279, DOI 10.1515/BC.2008.033; Slager RE, 2008, J HISTOCHEM CYTOCHEM, V56, P7, DOI 10.1369/jhc.7A7249.2007; Stawowy P, 2005, CARDIOVASC RES, V67, P50, DOI 10.1016/j.cardiores.2005.03.002; Szekely AM, 2005, MOL CELL BIOL, V25, P10492, DOI 10.1128/MCB.25.23.10492-10506.2005; Turaga RVN, 2007, AGING CELL, V6, P471, DOI 10.1111/j.1474-9726.2007.00301.x; Turaga RVN, 2009, CELL CYCLE, V8, P2080, DOI 10.4161/cc.8.13.8925; von Kobbe C, 2002, J CELL SCI, V115, P3901, DOI 10.1242/jcs.00076; Wang Z, 2008, MOL CELL PROTEOMICS, V7, P1639, DOI 10.1074/mcp.M700520-MCP200; Yoshida K, 2003, EMBO J, V22, P1431, DOI 10.1093/emboj/cdg134	53	12	12	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2010	29	10					1486	1497		10.1038/onc.2009.443	http://dx.doi.org/10.1038/onc.2009.443			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	566SD	19966859	Green Accepted			2022-12-17	WOS:000275392400007
J	Doronkin, S; Djagaeva, I; Nagle, ME; Reiter, LT; Seagroves, TN				Doronkin, S.; Djagaeva, I.; Nagle, M. E.; Reiter, L. T.; Seagroves, T. N.			Dose-dependent modulation of HIF-1 alpha/sima controls the rate of cell migration and invasion in Drosophila ovary border cells	ONCOGENE			English	Article						hypoxia; metastasis; invasion; HIF-1 alpha; VHL; PHD	GENE DISRUPTION PROJECT; E-CADHERIN; DE-CADHERIN; TRANSCRIPTIONAL ACTIVITY; PROLYL HYDROXYLASE; HYPOXIC RESPONSE; HIF-ALPHA; EXPRESSION; PROTEIN; MECHANISMS	The role of the hypoxic response during metastasis was analysed in migrating border cells of the Drosophila ovary. Acute exposure to 1% O-2 delayed or blocked border cell migration (BCM), whereas prolonged exposure resulted in the first documented accelerated BCM phenotype. Similarly, manipulating the expression levels of sima, the Drosophila hypoxia-inducible factor (HIF)-1 alpha ortholog, revealed that Sima can either block or restore BCM in a dose-dependent manner. In contrast, overexpression of Vhl (Drosophila von Hippel-Lindau) generated a range of phenotypes, including blocked, delayed and accelerated BCM, whereas over-expression of hph (Drosophila HIF prolyl hydroxylase) only accelerated BCM. Mosaic clone analysis of sima or tango (HIF-1 beta ortholog) mutants revealed that cells lacking Hif-1 transcriptional activity were preferentially detected in the leading cell position of the cluster, resulting in either a delay or acceleration of BCM. Moreover, in sima mutant cell clones, there was reduced expression of nuclear slow border cells (Slbo) and basolateral DE-cadherin, proteins essential for proper BCM. These results show that Sima levels de. ne the rate of BCM in part through regulation of Slbo and DE-cadherin, and suggest that dynamic regulation of Hif-1 activity is necessary to maintain invasive potential of migrating epithelial cells. Oncogene (2010) 29, 1123-1134; doi: 10.1038/onc.2009.407; published online 7 December 2009	[Doronkin, S.; Djagaeva, I.; Reiter, L. T.] Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, Memphis, TN 38163 USA; [Nagle, M. E.] Univ Tennessee, Hlth Sci Ctr, Coll Med, Memphis, TN 38163 USA; [Reiter, L. T.] Univ Tennessee, Hlth Sci Ctr, Dept Neurol, Memphis, TN 38163 USA; [Seagroves, T. N.] Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center	Doronkin, S (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Anat & Neurobiol, 855 Monroe Ave,Suite 515, Memphis, TN 38163 USA.	sdoronki@utmem.edu	Seagroves, Tiffany/AAE-3278-2019; Reiter, Lawrence/H-4161-2019	Seagroves, Tiffany/0000-0002-6937-943X; Reiter, Lawrence/0000-0002-4100-2630	Medical Student Research Fellowship (MSRF, NIH); Dorothy K Gerwin and the Maston Callison Bowld Cancer Research; UTHSC Molecular Resource Center; UTHSC Clinical and Translational Science Institute; NATIONAL CANCER INSTITUTE [R01CA138488] Funding Source: NIH RePORTER	Medical Student Research Fellowship (MSRF, NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dorothy K Gerwin and the Maston Callison Bowld Cancer Research; UTHSC Molecular Resource Center; UTHSC Clinical and Translational Science Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Eric Spana of the Duke Model Systems Genomics core facility for generating UAS-Vhl/VHL transgenic fly stocks. Drs Bruce Edgar, Denise Montell and Pernille Rorth generously shared reagents. Several stocks were obtained from the Bloomington Drosophila Stock Center. DE-cadherin antibodies were obtained from the Developmental Studies Hybridoma Bank. MN was supported by a Medical Student Research Fellowship (MSRF, NIH). All work was supported by the Dorothy K Gerwin and the Maston Callison Bowld Cancer Research funds at UTHSC (to TNS), the UTHSC Molecular Resource Center (to LTR) and the UTHSC Clinical and Translational Science Institute.	Adryan B, 2000, ONCOGENE, V19, P2803, DOI 10.1038/sj.onc.1203611; Arquier N, 2006, BIOCHEM J, V393, P471, DOI 10.1042/BJ20050675; Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7; Bellen HJ, 2004, GENETICS, V167, P761, DOI 10.1534/genetics.104.026427; Bianco A, 2007, NATURE, V448, P362, DOI 10.1038/nature05965; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brown JM, 2000, MOL MED TODAY, V6, P157, DOI 10.1016/S1357-4310(00)01677-4; Cameron CM, 2008, EXP BIOL MED, V233, P1044, DOI 10.3181/0709-RM-263; Carthew RW, 2005, CURR OPIN GENET DEV, V15, P358, DOI 10.1016/j.gde.2005.06.002; Centanin L, 2005, EMBO REP, V6, P1070, DOI 10.1038/sj.embor.7400528; Centanin L, 2008, DEV CELL, V14, P547, DOI 10.1016/j.devcel.2008.01.020; Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1; Chi JT, 2006, PLOS MED, V3, P395, DOI 10.1371/journal.pmed.0030047; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Esteban MA, 2006, CANCER RES, V66, P3567, DOI 10.1158/0008-5472.CAN-05-2670; Fong GH, 2008, CELL DEATH DIFFER, V15, P635, DOI 10.1038/cdd.2008.10; Frei C, 2004, DEV CELL, V6, P241, DOI 10.1016/S1534-5807(03)00409-X; Frew IJ, 2007, CURR OPIN CELL BIOL, V19, P685, DOI 10.1016/j.ceb.2007.10.001; Friedl P, 2004, INT J DEV BIOL, V48, P441, DOI 10.1387/ijdb.041821pf; Geisbrecht ER, 2002, NAT CELL BIOL, V4, P616, DOI 10.1038/ncb830; Ginouves A, 2008, P NATL ACAD SCI USA, V105, P4745, DOI 10.1073/pnas.0705680105; Gorr TA, 2004, J BIOL CHEM, V279, P36048, DOI 10.1074/jbc.M405077200; Janardhan HP, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.143jc2; Jang ACC, 2007, J MAMMARY GLAND BIOL, V12, P103, DOI 10.1007/s10911-007-9042-8; Jiang Y, 2005, LEUKEMIA, V19, P1239, DOI 10.1038/sj.leu.2403734; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Lavista-Llanos S, 2002, MOL CELL BIOL, V22, P6842, DOI 10.1128/MCB.22.19.6842-6853.2002; Lecaudey V, 2006, CURR OPIN CELL BIOL, V18, P102, DOI 10.1016/j.ceb.2005.12.001; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Liu GW, 2006, PHYSIOL GENOMICS, V25, P134, DOI 10.1152/physiolgenomics.00262.2005; Manseau L, 1997, DEV DYNAM, V209, P310, DOI 10.1002/(SICI)1097-0177(199707)209:3<310::AID-AJA6>3.3.CO;2-O; Mathieu J, 2007, GENETICS, V176, P1579, DOI 10.1534/genetics.107.071282; Montell DJ, 2006, CURR OPIN GENET DEV, V16, P374, DOI 10.1016/j.gde.2006.06.010; MONTELL DJ, 1992, CELL, V71, P51, DOI 10.1016/0092-8674(92)90265-E; Mortimer NT, 2009, DEV BIOL, V329, P294, DOI 10.1016/j.ydbio.2009.03.001; Niewiadomska P, 1999, J CELL BIOL, V144, P533, DOI 10.1083/jcb.144.3.533; Oda H, 1997, GENES CELLS, V2, P29, DOI 10.1046/j.1365-2443.1997.d01-284.x; Pacquelet A, 2005, J CELL BIOL, V170, P803, DOI 10.1083/jcb.200506131; Pacquelet A, 2003, J CELL BIOL, V160, P313, DOI 10.1083/jcb.200207160; Parent CA, 1999, SCIENCE, V284, P765, DOI 10.1126/science.284.5415.765; Postovit LM, 2008, J CELL BIOCHEM, V103, P1369, DOI 10.1002/jcb.21517; Prasad M, 2007, NAT PROTOC, V2, P2467, DOI 10.1038/nprot.2007.363; Prasad M, 2007, DEV CELL, V12, P997, DOI 10.1016/j.devcel.2007.03.021; Rocha S, 2007, TRENDS BIOCHEM SCI, V32, P389, DOI 10.1016/j.tibs.2007.06.005; Rorth P, 2000, MOL CELL, V6, P23; Rorth P, 1998, MECH DEVELOP, V78, P113, DOI 10.1016/S0925-4773(98)00157-9; Rorth P, 2002, TRENDS CELL BIOL, V12, P325, DOI 10.1016/S0962-8924(02)02311-5; Russell RC, 2007, CELL CYCLE, V6, P56, DOI 10.4161/cc.6.1.3668; Schober M, 2005, DEVELOPMENT, V132, P3493, DOI 10.1242/dev.01911; Seifeddine R, 2008, CANCER RES, V68, P2158, DOI 10.1158/0008-5472.CAN-07-1190; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Spradling AC, 1999, GENETICS, V153, P135; Starz-Gaiano M, 2004, CURR OPIN GENET DEV, V14, P86, DOI 10.1016/j.gde.2003.12.001; Starz-Gaiano M, 2008, DEV CELL, V14, P726, DOI 10.1016/j.devcel.2008.03.005; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; Vidal M, 2006, CURR OPIN GENET DEV, V16, P10, DOI 10.1016/j.gde.2005.12.004; Yang L, 2008, CARCINOGENESIS, V29, P291, DOI 10.1093/carcin/bgm262; Zhong H, 1999, CANCER RES, V59, P5830	59	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2010	29	8					1123	1134		10.1038/onc.2009.407	http://dx.doi.org/10.1038/onc.2009.407			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	560ON	19966858				2022-12-17	WOS:000274912100004
J	Lucs, AV; Muller, WJ; Muthuswamy, SK				Lucs, A. V.; Muller, W. J.; Muthuswamy, S. K.			Shc is required for ErbB2-induced inhibition of apoptosis but is dispensable for cell proliferation and disruption of cell polarity	ONCOGENE			English	Article						ErbB2; apoptosis; 3D culture; taxol; Shc; MCF-10A	HUMAN-BREAST-CANCER; MAMMARY TUMORIGENESIS; ADAPTER PROTEINS; ERBB2; ACTIVATION; RESISTANCE; RECEPTORS; FAMILY; GROWTH; ACTIN	Amplification and overexpression of ErbB2 strongly correlates with aggressive breast cancers. A deeper understanding of pathways downstream of ErbB2 signaling that are required for the transformation of human mammary epithelial cells will identify novel strategies for therapeutic intervention in breast cancer. Using an inducible activation of ErbB2 autophosphorylation qsite mutants and the MCF-10A three-dimensional (3D) culture system, we investigated pathways used by ErbB2 to transform the epithelia. We report that ErbB2 induces cell proliferation and loss of 3D organization by redundant mechanisms, whereas it disrupts apical basal polarity and inhibits apoptosis using Tyr 1201 and Tyr 1226/7, respectively. Signals downstream of Tyr 1226/7 were also sufficient to confer paclitaxel resistance. The Tyr 1226/7 binds Shc, and the knockdown of Shc blocks the ability of ErbB2 to inhibit apoptosis and mediate paclitaxel resistance. Tyr 1226/7 is known to activate the Ras/Erk pathway; however, paclitaxel resistance did not correlate with the activation of Erk or Akt, suggesting the presence of a novel mechanism. Thus, our results show that targeting pathways used by ErbB2 to inhibit cell death is a better option than targeting cell proliferation pathways. Furthermore, we identify a novel function for Shc as a regulator of apoptosis and drug resistance in human mammary epithelial cells transformed by ErbB2. Oncogene (2010) 29, 174-187; doi:10.1038/onc.2009.312; published online 12 October 2009	[Lucs, A. V.; Muthuswamy, S. K.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; [Muller, W. J.] McGill Univ, Goodman Canc Ctr, Montreal, PQ, Canada; [Lucs, A. V.; Muthuswamy, S. K.] SUNY Stony Brook, Dept Microbiol & Mol Genet, Stony Brook, NY 11794 USA; [Muthuswamy, S. K.] Univ Toronto, Dept Med Biophys, Campbell Family Inst Breast Canc Res, Ontario Canc Inst, Toronto, ON M5S 1A1, Canada	Cold Spring Harbor Laboratory; McGill University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Muthuswamy, SK (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	muthuswa@cshl.edu	Muthuswamy, Senthil K/AGY-2834-2022	Muthuswamy, Senthil K/0000-0001-6564-9634	NCI [CA098830, CA105388]; DOD [BC075024, DAMD17-03-1-0196]; Rita Allen Foundation; FACT foundation; Lee K Margaret Lau Chair in Breast Cancer Research; NATIONAL CANCER INSTITUTE [U01CA105388, R56CA098830, R01CA098830] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); Rita Allen Foundation; FACT foundation; Lee K Margaret Lau Chair in Breast Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Muthuswamy Laboratory for critical discussions and comments on the paper. This work was supported by CA098830 and CA105388 Grants from NCI, DOD BC075024 from DOD Breast Cancer Research Program, Rita Allen Foundation, FACT foundation and Lee K Margaret Lau Chair in Breast Cancer Research to SKM and DAMD17-03-1-0196 from DOD Breast Cancer Research Program to AL.	AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Buday L, 2002, CELL SIGNAL, V14, P723, DOI 10.1016/S0898-6568(02)00027-X; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Henson ES, 2006, CLIN CANCER RES, V12, P845, DOI 10.1158/1078-0432.CCR-05-0754; JANES PW, 1994, ONCOGENE, V9, P3601; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kim H, 2005, ONCOGENE, V24, P7599, DOI 10.1038/sj.onc.1208898; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Leung WH, 2007, J IMMUNOL, V179, P95, DOI 10.4049/jimmunol.179.1.95; Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; Nelson JM, 2001, J BIOL CHEM, V276, P14842, DOI 10.1074/jbc.M008786200; Orr GA, 2003, ONCOGENE, V22, P7280, DOI 10.1038/sj.onc.1206934; Pupa SM, 2005, J CELL PHYSIOL, V205, P10, DOI 10.1002/jcp.20387; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Saucier C, 2004, P NATL ACAD SCI USA, V101, P2345, DOI 10.1073/pnas.0308065101; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; THOMAS D, 1995, J BIOL CHEM, V270, P28924, DOI 10.1074/jbc.270.48.28924; Ursini-Siegel J, 2008, EMBO J, V27, P910, DOI 10.1038/emboj.2008.22; Verrills NM, 2006, J NATL CANCER I, V98, P1363, DOI 10.1093/jnci/djj372; Wada T, 2004, ONCOGENE, V23, P2838, DOI 10.1038/sj.onc.1207556; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Zhan LX, 2006, CANCER RES, V66, P5201, DOI 10.1158/0008-5472.CAN-05-4081; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	39	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2010	29	2					174	187		10.1038/onc.2009.312	http://dx.doi.org/10.1038/onc.2009.312			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	544IU	19826412	Green Accepted			2022-12-17	WOS:000273650000002
J	Lee, YG; Lee, SW; Sin, HS; Kim, EJ; Um, SJ				Lee, Y-G; Lee, S-W; Sin, H-S; Kim, E-J; Um, S-J			Kinase activity-independent suppression of p73 alpha by AMP-activated kinase alpha (AMPK alpha)	ONCOGENE			English	Article						p73 alpha; AMPK alpha; transcription; repression; cisplatin	PROTEIN-KINASE; TRANSCRIPTIONAL ACTIVITY; MAMMALIAN-CELLS; GENE-EXPRESSION; UPSTREAM KINASE; NITRIC-OXIDE; P73 FUNCTION; MEMBERS P63; SAM DOMAIN; P53	Although p73 alpha induces many of the same cellular events as p53, it is structurally distinct from p53 in that it possesses a unique COOH-terminal domain. To dissect the function of this domain, we performed yeast two-hybrid screening of a HeLa cDNA library using residues 552-636 of p73a as bait. Among the clones that showed a specific interaction with p73a was AMP-activated protein kinase alpha (AMPK alpha). Additional yeast two-hybrid assays indicated that the beta gamma-binding domain of AMPKa is critical for the interaction with p73 alpha. The interaction was further confirmed in vitro by glutathione S-transferase pull-down, and in vivo by immunoprecipitation and immunofluorescence microscopy. Transient coexpression of AMPKa resulted in downregulation of the effect of p73 alpha, but not of p53, on various p53-responsive promoters. Chromatin immunoprecipitation indicated p73 alpha-dependent recruitment of AMPKa to the p21WAF1 promoter. Treatment with 5-aminoimidazole-4-carboxamide ribonucleotide, an agonist of AMPK alpha, and expression of dominant-negative versions of AMPKa revealed that the repression of p73 alpha was independent of AMPK alpha kinase activity. In addition, cisplatin-induced growth repression was impaired when AMPK alpha was overexpressed. Upon the knock down of AMPKa by siRNA, the induction of p21WAF1 by p73 alpha was significantly increased. Taken together, these data indicate that AMPKa specifically regulates p73 alpha by a direct interaction without affecting its phosphorylation status. From these data, we speculate that AMPKa may provide a molecular clue to understand the repressive role of the C-terminus of p73 alpha in transcription and DNA damage response.	[Lee, Y-G; Lee, S-W; Um, S-J] Sejong Univ, Inst Biosci, Dept Biosci & Biotechnol, Seoul 143747, South Korea; [Sin, H-S; Um, S-J] Sejong Univ, Chebigen Inc, Seoul 143747, South Korea; [Kim, E-J] Dankook Univ, Dept Mol Biol, Gyeonggi Do, South Korea	Sejong University; Sejong University; Dankook University	Um, SJ (corresponding author), Sejong Univ, Inst Biosci, Dept Biosci & Biotechnol, 98 Kunjadong, Seoul 143747, South Korea.	nbrejk@dankook.ac.kr; umsj@sejong.ac.kr						Bentley D, 1999, CURR OPIN CELL BIOL, V11, P347, DOI 10.1016/S0955-0674(99)80048-9; Bronner M, 2004, BIOCHEM J, V384, P295, DOI 10.1042/BJ20040955; Chen H, 2003, J BIOL CHEM, V278, P45021, DOI 10.1074/jbc.M307878200; Cho YS, 2006, J BIOL CHEM, V281, P17588, DOI 10.1074/jbc.M512616200; Culmsee C, 2001, J MOL NEUROSCI, V17, P45, DOI 10.1385/JMN:17:1:45; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dietz S, 2002, FEBS LETT, V525, P93, DOI 10.1016/S0014-5793(02)03093-4; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hardie DG, 1999, BIOCHEM J, V338, P717, DOI 10.1042/0264-6021:3380717; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Imamura K, 2001, BIOCHEM BIOPH RES CO, V287, P562, DOI 10.1006/bbrc.2001.5627; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kemp BE, 2003, BIOCHEM SOC T, V31, P162; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Lau LMS, 2008, ONCOGENE, V27, P997, DOI 10.1038/sj.onc.1210707; Leclerc I, 2002, BIOCHEM SOC T, V30, P307, DOI 10.1042/bst0300307; Lee HK, 2007, EMBO J, V26, P3545, DOI 10.1038/sj.emboj.7601797; Lee M, 2003, J BIOL CHEM, V278, P39653, DOI 10.1074/jbc.M306104200; Leff T, 2003, BIOCHEM SOC T, V31, P224; Liu G, 2005, J BIOL CHEM, V280, P20111, DOI 10.1074/jbc.M413889200; Lizcano JM, 2004, EMBO J, V23, P833, DOI 10.1038/sj.emboj.7600110; Lo WS, 2001, SCIENCE, V293, P1142, DOI 10.1126/science.1062322; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Ozaki T, 1999, CANCER RES, V59, P5902; Pilon G, 2004, J BIOL CHEM, V279, P20767, DOI 10.1074/jbc.M401390200; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Pozniak CD, 2002, J NEUROSCI, V22, P9800; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Sbisa E, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-S1-S20; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Solaz-Fuster MC, 2006, CELL SIGNAL, V18, P1702, DOI 10.1016/j.cellsig.2006.01.021; Stein SC, 2000, BIOCHEM J, V345, P437, DOI 10.1042/0264-6021:3450437; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Turnley AM, 1999, J NEUROCHEM, V72, P1707, DOI 10.1046/j.1471-4159.1999.721707.x; Wang Shaowen, 2004, Novartis Found Symp, V259, P238; Weiske J, 2006, J BIOL CHEM, V281, P27356, DOI 10.1074/jbc.M513452200; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xavier GD, 2000, P NATL ACAD SCI USA, V97, P4023, DOI 10.1073/pnas.97.8.4023; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	47	12	13	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 19	2009	28	7					1040	1052		10.1038/onc.2008.452	http://dx.doi.org/10.1038/onc.2008.452			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	408TH	19079340				2022-12-17	WOS:000263457400010
J	Frech, MS; Torre, KM; Robinson, GW; Furth, PA				Frech, M. S.; Torre, K. M.; Robinson, G. W.; Furth, P. A.			Loss of cyclin D1 in concert with deregulated estrogen receptor a expression induces DNA damage response activation and interrupts mammary gland morphogenesis	ONCOGENE			English	Article						ER alpha; cyclin D1; cyclin E; DNA damage; mammary gland	CARCINOMA IN-SITU; BREAST-CANCER; PRECANCEROUS BREAST; INSTABILITY; LESIONS; CELLS	We have previously shown that increased and deregulated estrogen receptor alpha expression in the mammary gland leads to the development of proliferative disease and cancer. To address the importance of cyclin D1 in ER alpha-mediated mammary tumorigenesis, we crossed ER alpha-overexpressing mice with cyclin D1 knockout mice. Mammary gland morphogenesis was completely interrupted in the ER alpha-overexpressing cyclin D1-deficient triple transgenic mice. In addition to a highly significant reduction in mammary epithelial cell proliferation, cyclin E was upregulated resulting in DNA damage checkpoint activation and apoptosis. This imbalance between proliferative and apoptotic rates in conjunction with remarkable structural defects and cellular disorganization in the terminal end buds interrupted ductal morphogenesis. Interestingly, the structure of the mammary fat pad was fundamentally altered by the consequences of overexpressing ERa in the epithelial cells in the absence of cyclin D1 illustrating how alterations in the epithelial compartment can impact surrounding stromal composition. Transplantation of embryonic ER alpha-overexpressing and cyclin D1-deficient mammary epithelium into the cleared fat pad of wild-type mice did not rescue the aberrant mammary gland phenotype indicating that it was intrinsic to the mammary epithelial cells. In conclusion, although cyclin D1 is not essential for proliferation of normal mammary epithelial cells, ER alpha-overexpressing cells are absolutely dependent on cyclin D1 for proliferation. This differential requirement for cyclin D1 in normal vs abnormal mammary epithelial cells supports the application of cyclin D1 inhibitors as therapeutic interventions in ER alpha-overexpressing breast cancers.	[Frech, M. S.; Torre, K. M.; Furth, P. A.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA; [Robinson, G. W.] NIDDKD, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA	Georgetown University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Frech, MS (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20007 USA.	msf25@georgetown.edu	Robinson, Gertraud/I-2136-2012		NATIONAL CANCER INSTITUTE [R01CA112176] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA112176, R01 CA112176, R01 CA112176-05] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Carthon BC, 2005, MOL CELL BIOL, V25, P1081, DOI 10.1128/MCB.25.3.1081-1088.2005; DANIEL CW, 1995, DEV BIOL, V169, P511, DOI 10.1006/dbio.1995.1165; Deugnier MA, 2002, BREAST CANCER RES, V4, P224, DOI 10.1186/bcr459; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Frech MS, 2005, CANCER RES, V65, P681; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Hinck L, 2005, BREAST CANCER RES, V7, P245, DOI 10.1186/bcr1331; Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153; Minella AC, 2007, ONCOGENE, V26, P6948, DOI 10.1038/sj.onc.1210518; Oh YL, 2001, PATHOL INT, V51, P94, DOI 10.1046/j.1440-1827.2001.01173.x; Peng SY, 1998, J HEPATOL, V29, P281, DOI 10.1016/S0168-8278(98)80014-7; ROBINSON GW, 2000, METHODS MAMMARY GLAN, P301; Shoker BS, 1999, J PATHOL, V188, P237; Shoker BS, 2001, BRIT J CANCER, V84, P1064, DOI 10.1054/bjoc.2001.1705; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Silberstein GB, 2001, BREAST CANCER RES, V3, P218, DOI 10.1186/bcr299; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Sutherland RL, 2004, J MAMMARY GLAND BIOL, V9, P95, DOI 10.1023/B:JOMG.0000023591.45568.77; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	23	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2008	27	22					3186	3193		10.1038/sj.onc.1210974	http://dx.doi.org/10.1038/sj.onc.1210974			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	301LL	18071314	Green Accepted			2022-12-17	WOS:000255897600011
J	Peak, JC; Jones, NP; Hobbs, S; Katan, M; Eccles, SA				Peak, J. C.; Jones, N. P.; Hobbs, S.; Katan, M.; Eccles, S. A.			Phospholipase C gamma 1 regulates the Rap GEF1-Rap1 signalling axis in the control of human prostate carcinoma cell adhesion	ONCOGENE			English	Article						phospholipase c gamma 1; rap GEF1; Rap1; adhesion	C-GAMMA-L; INTEGRIN ALPHA(2)BETA(1); ACTIVATION; RECEPTOR; REQUIREMENT; PLC-GAMMA-1; KINASES; COMPLEX; FAMILY; C3G	C gamma 1 (PLC gamma 1) is activated downstream of a variety of extracellular stimuli and has previously been implicated in the regulation of motility responses central to tumour cell invasion. In this study, we used a novel RNAi vector system to achieve conditional PLC gamma 1 knockdown in PC3LN3 human prostate carcinoma cells for further evaluation of PLC gamma 1 in tumour cell biology. Using this approach, we revealed a role for PLC gamma 1 in the regulation of PC3LN3 cell adhesion that appears to be independent of its effects on tumour cell chemotactic migration and spreading in response to extracellular matrix. Subsequent microarray analysis of PLC gamma 1-knockdown cells revealed Rap GEF1 mRNA to be decreased in response to PLC gamma 1 loss. This translated into a decrease in Rap GEF1 protein levels and a significant loss of Rap1 activity in PLC gamma 1-knockdown cells. Transient knockdown of Rap GEF1 caused a reduction in PC3LN3 adhesion while overexpression of Rap GEF1 rescued the PLC gamma 1 knockdown-induced adhesion defect. These data highlight control of the Rap GEF1-Rap1 molecular switch as a specific requirement for PLC gamma 1-mediated tumour cell adhesion.	[Eccles, S. A.] Canc Res UK Ctr Canc Therapeut, Inst Canc Res, McElwain Labs, Sutton SM2 5NG, Surrey, England; [Jones, N. P.; Katan, M.] Canc Res UK Ctr Cell & Mol Biol, Inst Canc Res, Sutton, Surrey, England	Cancer Research UK; University of London; Institute of Cancer Research - UK; Cancer Research UK; University of London; Institute of Cancer Research - UK	Eccles, SA (corresponding author), Canc Res UK Ctr Canc Therapeut, Inst Canc Res, McElwain Labs, 15 Cotswold Rd, Sutton SM2 5NG, Surrey, England.	Sue.Eccles@icr.ac.uk			Cancer Research UK Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Adams JC, 2001, CELL MOL LIFE SCI, V58, P371, DOI 10.1007/PL00000864; Arai A, 1999, BLOOD, V93, P3713, DOI 10.1182/blood.V93.11.3713.411a36_3713_3722; Aydar E, 2006, CANCER LETT, V242, P245, DOI 10.1016/j.canlet.2005.11.011; Bernardi B, 2006, BLOOD, V107, P2728, DOI 10.1182/blood-2005-07-3023; Bos JL, 2005, CURR OPIN CELL BIOL, V17, P123, DOI 10.1016/j.ceb.2005.02.009; Choi JH, 2007, CELL SIGNAL, V19, P1784, DOI 10.1016/j.cellsig.2007.04.002; de Jong R, 1998, ONCOGENE, V17, P2805, DOI 10.1038/sj.onc.1202207; Guerrero C, 1998, ONCOGENE, V16, P613, DOI 10.1038/sj.onc.1201569; Han JW, 2006, CURR BIOL, V16, P1796, DOI 10.1016/j.cub.2006.08.035; Inoue O, 2003, J CELL BIOL, V160, P769, DOI 10.1083/jcb.200208043; Jones NP, 2007, MOL CELL BIOL, V27, P5790, DOI 10.1128/MCB.00778-07; Jones NP, 2005, J CELL SCI, V118, P2695, DOI 10.1242/jcs.02374; Katagiri K, 2004, J BIOL CHEM, V279, P11875, DOI 10.1074/jbc.M310717200; Mamoune A, 2004, EXP CELL RES, V299, P91, DOI 10.1016/j.yexcr.2004.05.008; Manos EJ, 2001, ONCOGENE, V20, P2781, DOI 10.1038/sj.onc.1204379; Mouneimne G, 2004, J CELL BIOL, V166, P697, DOI 10.1083/jcb.200405156; Nogami M, 2003, FEBS LETT, V536, P71, DOI 10.1016/S0014-5793(03)00013-9; Ohba Y, 2001, EMBO J, V20, P3333, DOI 10.1093/emboj/20.13.3333; Piechulek T, 2005, J BIOL CHEM, V280, P38923, DOI 10.1074/jbc.M509396200; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Regunathan J, 2006, J IMMUNOL, V177, P5365, DOI 10.4049/jimmunol.177.8.5365; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; Shepard CR, 2007, ONCOGENE, V26, P3020, DOI 10.1038/sj.onc.1210115; Turner T, 1997, CLIN CANCER RES, V3, P2275; Tvorogov D, 2005, J CELL SCI, V118, P601, DOI 10.1242/jcs.01643; Vuori K, 1996, MOL CELL BIOL, V16, P2606; Wang ZP, 2006, MOL CELL BIOL, V26, P2130, DOI 10.1128/MCB.26.6.2130-2145.2006; Wells A, 2000, ADV CANCER RES, V78, P31; Zhang X, 1999, P NATL ACAD SCI USA, V96, P9021, DOI 10.1073/pnas.96.16.9021	30	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2008	27	20					2823	2832		10.1038/sj.onc.1210954	http://dx.doi.org/10.1038/sj.onc.1210954			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	295VR	18037957				2022-12-17	WOS:000255502500003
J	Warnock, LJ; Adamson, R; Lynch, CJ; Milner, J				Warnock, L. J.; Adamson, R.; Lynch, C. J.; Milner, J.			Crosstalk between site-specific modifications on p53 and histone H3	ONCOGENE			English	Article						p53 protein; histone H3; phosphorylation; acetylation; methylation	TUMOR-SUPPRESSOR PROTEIN; POSTTRANSLATIONAL MODIFICATIONS; LYSINE METHYLATION; DNA-DAMAGE; PHOSPHORYLATION; ACTIVATION; ACETYLATION; BINDING; REPAIR; TRANSCRIPTION	Previously, we have observed a link between p53 expression and histone H3 post-translational modifications. Here, we ask if specific post-translational modifications of p53 impact upon histone H3 modi. cations in a selective manner. We have also screened for internal co-operative effects within the repertoire of p53 modi. cations. Exogenous p53 constructs were expressed in HCT116 p53(-/-) cells. Four mutant p53 constructs were used, with single 'phosphorylation' mutations at serines 15 and 37 (S15A, S15D, S37A and S37D) and compared with exogenously expressed wild-type p53. The results showed that the replacement of serine 15 with either alanine (S15A) or aspartic acid (S15D) induced phosphorylation at S33P, S37P and S46P. In contrast, phosphorylation mutants p53(S37A) and p53(S37D) were not phosphorylated on S33. S46 phosphorylation appeared specifically enhanced by p53(S37D) relative to p53(S37A). Distal induction of S392 phosphorylation was observed for each of the p53 N-terminal phosphorylation mutants. Analysis of endogenous histone H3 (from the transfected cells) revealed loss of di-methylated K9 following expression of wild type and mutant p53 constructs. Expression of p53 (S15A), (S15D) and (S37A) selectively induced acetylation at K9 and K14. In contrast, wt p53 and p53(S37D) had no effect upon K9 or K14 acetylation. K18 acetylation status was unaffected throughout.	[Warnock, L. J.; Adamson, R.; Lynch, C. J.; Milner, J.] Univ York, YCR P53 Res Grp, Dept Biol, York YO10 5DD, N Yorkshire, England	University of York - UK	Warnock, LJ (corresponding author), Univ York, YCR P53 Res Grp, Dept Biol, Zone 2, York YO10 5DD, N Yorkshire, England.	ljw7@york.ac.uk	Lynch, Cian/AIC-5510-2022; Lynch, Christopher J./E-6875-2010; Lynch, Cian J/K-2191-2017	Lynch, Cian/0000-0003-0187-3527; Lynch, Christopher J./0000-0003-2453-5838; Lynch, Cian J/0000-0003-0187-3527				Allison SJ, 2003, CANCER RES, V63, P6674; An W, 2004, CELL, V117, P735, DOI 10.1016/j.cell.2004.05.009; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Morgunkova A, 2006, CELL CYCLE, V5, P1308, DOI 10.4161/cc.5.12.2820; Okorokov AL, 2002, CARCINOGENESIS, V23, P549, DOI 10.1093/carcin/23.4.549; Okorokov AL, 2006, EMBO J, V25, P5191, DOI 10.1038/sj.emboj.7601382; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Saito S, 2003, J BIOL CHEM, V278, P37536, DOI 10.1074/jbc.M305135200; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; SCHAVOLT KL, 2007, ONCOGENE; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Sims RJ, 2006, GENE DEV, V20, P2779, DOI 10.1101/gad.1468206; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Warnock LJ, 2005, FEBS J, V272, P1669, DOI 10.1111/j.1742-4658.2005.04589.x; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Zhang K, 2005, J CELL BIOCHEM, V96, P1137, DOI 10.1002/jcb.20615; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301; Zhao RB, 2000, GENE DEV, V14, P981	28	12	13	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2008	27	11					1639	1644		10.1038/sj.onc.1210787	http://dx.doi.org/10.1038/sj.onc.1210787			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17891183				2022-12-17	WOS:000253815800016
J	Cowling, VH; Cole, MD				Cowling, V. H.; Cole, M. D.			An N-Myc truncation analogous to c-Myc-S induces cell proliferation independently of transactivation but dependent on Myc homology box II	ONCOGENE			English	Article						c-Myc-S; Myc; transcriptional repression; transactivation; cell proliferation	TRANSFORMATION; TRANSCRIPTION; ASSOCIATION; RECRUITMENT; INHIBITORS; REPRESSES; MECHANISM; APOPTOSIS; COFACTOR; GROWTH	Myc promotes both normal cell proliferation and oncogenic transformation through the activation and repression of target genes. The c-Myc-S protein is a truncated form of c-Myc that is produced in some cells from translation initiation at an internal AUG codon. We report that c-Myc-S and a similar truncated form of N-MycWT can fully rescue the proliferation defect in myc-null fibroblasts, but rescue is dependent on the highly conserved Myc homology box II (MBII). Global gene expression studies show that the N-Myc equivalent of c-Myc-S is defective for virtually all transcriptional activation of Myc target genes but remains active for the majority of transcriptional repression. Repression by Myc-S is dependent on MBII, but it does not bind to several known nuclear cofactors. These data suggest that repression by Myc involves recruitment of a novel MBII-dependent cofactor.	[Cowling, V. H.; Cole, M. D.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Pharmacol & Toxicol, Lebanon, NH 03756 USA; [Cowling, V. H.; Cole, M. D.] Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Genet, Lebanon, NH USA	Dartmouth College; Norris Cotton Cancer Center; Dartmouth College; Norris Cotton Cancer Center	Cole, MD (corresponding author), Dartmouth Med Sch, Norris Cotton Canc Ctr, Dept Pharmacol & Toxicol, 1 Med Ctr Dr,Rubin 6, Lebanon, NH 03756 USA.	mcole@dartmouth.edu		Cowling, Victoria/0000-0001-7638-4870	MRC [G0700240] Funding Source: UKRI; Medical Research Council [G0700240] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Barsyte-Lovejoy D, 2004, ONCOGENE, V23, P3481, DOI 10.1038/sj.onc.1207487; Benassayag C, 2005, MOL CELL BIOL, V25, P9897, DOI 10.1128/MCB.25.22.9897-9909.2005; Brenner C, 2005, EMBO J, V24, P336, DOI 10.1038/sj.emboj.7600509; Cole MD, 2006, SEMIN CANCER BIOL, V16, P241, DOI 10.1016/j.semcancer.2006.08.003; Cowling VH, 2007, MOL CELL BIOL, V27, P2059, DOI 10.1128/MCB.01828-06; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; Cowling VH, 2006, SEMIN CANCER BIOL, V16, P242, DOI 10.1016/j.semcancer.2006.08.001; Cowling VH, 2006, MOL CELL BIOL, V26, P4226, DOI 10.1128/MCB.01959-05; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Eisenman R N, 2000, Harvey Lect, V96, P1; Facchini LM, 1997, MOL CELL BIOL, V17, P100, DOI 10.1128/MCB.17.1.100; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Hirst SK, 2000, ONCOGENE, V19, P5189, DOI 10.1038/sj.onc.1203904; Hurlin PJ, 2006, SEMIN CANCER BIOL, V16, P265, DOI 10.1016/j.semcancer.2006.07.009; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Malynn BA, 2000, GENE DEV, V14, P1390; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; Patel JH, 2007, J BIOL CHEM, V282, P5, DOI 10.1074/jbc.M609138200; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Spotts GD, 1997, MOL CELL BIOL, V17, P1459, DOI 10.1128/MCB.17.3.1459; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Xiao QR, 1998, GENE DEV, V12, P3803, DOI 10.1101/gad.12.24.3803	25	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2008	27	9					1327	1332		10.1038/sj.onc.1210734	http://dx.doi.org/10.1038/sj.onc.1210734			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	266BT	17704800				2022-12-17	WOS:000253407000017
J	Barzon, L; Trevisan, M; Masi, G; Pacenti, M; Sinigaglia, A; Macchi, V; Porzionato, A; De Caro, R; Favia, G; Iacobone, M; Palu, G				Barzon, L.; Trevisan, M.; Masi, G.; Pacenti, M.; Sinigaglia, A.; Macchi, V.; Porzionato, A.; De Caro, R.; Favia, G.; Iacobone, M.; Palu, G.			Detection of polyomaviruses and herpesviruses in human adrenal tumors	ONCOGENE			English	Article						adrenal gland neoplasms; herpesviruses; polyomaviruses; pheochromocytoma; adrenocortical carcinoma; hypercortisolism	EPSTEIN-BARR-VIRUS; GLUCOCORTICOID-RESPONSIVE ELEMENT; SARCOMA-ASSOCIATED HERPESVIRUS; TRANSGENIC MICE; CELL-LINES; JC VIRUS; HUMAN CYTOMEGALOVIRUS; CONTROL REGION; T-ANTIGEN; INFECTION	The presence of polyomaviruses and herpesviruses in adrenal tumors and their role in adrenal tumorigenesis has never been investigated, even though the adrenal gland seems to be a preferential site of infection by these viruses and adrenal steroid hormones have been shown to activate their replication. We examined in a large series of normal adrenal gland tissues (n = 20) and adrenal tumors (n = 107) the presence of herpesviruses and polyomaviruses sequences and gene expression, which were detected in a high proportion of both normal and neoplastic adrenal samples (overall, viruses were found in 15% normal adrenals, 27.8% benign adrenal tumors and 35.3% malignant tumors). The polyomaviruses SV40 and BK virus were more frequently found in malignant adrenal tumors, whereas herpesviruses, especially Epstein-Barr virus and human cytomegalovirus, were more frequently detected in functioning benign adrenocortical tumors, often as coinfection. Moreover, tumors from patients with severe hypercortisolism frequently showed herpesvirus coinfections at high viral genome copy number. Our study suggests that the adrenal gland could be a reservoir of infection for these viruses and that hormone overproduction by the adrenal gland could represent a trigger for virus reactivation. On the other hand, these viruses could also contribute to adrenal cell proliferation and tumorigenesis.	[Barzon, L.; Trevisan, M.; Masi, G.; Pacenti, M.; Sinigaglia, A.; Palu, G.] Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35121 Padua, Italy; [Macchi, V.; Porzionato, A.; De Caro, R.] Univ Padua, Dept Human Anat & Physiol, Padua, Italy; [Favia, G.; Iacobone, M.] Univ Padua, Dept Surg & Gastroenterol Sci, Padua, Italy	University of Padua; University of Padua; University of Padua	Barzon, L (corresponding author), Univ Padua, Dept Histol Microbiol & Med Biotechnol, Via A Gabelli 63, I-35121 Padua, Italy.	luisa.barzon@unipd.it; giorgio.palu@unipd.it	Iacobone, Maurizio/K-8714-2016; Macchi, Veronica/AAV-4514-2020; Masi, Giulia/K-1577-2016; Barzon, Luisa/K-7961-2016; TREVISAN, MARTA/K-6591-2016	Macchi, Veronica/0000-0003-2335-6897; Masi, Giulia/0000-0001-9138-9186; Barzon, Luisa/0000-0003-0720-8456; TREVISAN, MARTA/0000-0002-3148-7240; sinigaglia, alessandro/0000-0002-2386-1757; Iacobone, Maurizio/0000-0002-6057-4642; Pacenti, Monia/0000-0002-9792-9195				Aita K, 2001, ARCH VIROL, V146, P2009, DOI 10.1007/s007050170048; AMSTEY MS, 1977, AM J OBSTET GYNECOL, V15, P159; Barzon I, 2005, EUR J ENDOCRINOL, V153, P629, DOI 10.1530/eje.1.02011; Barzon L, 2003, EUR J ENDOCRINOL, V149, P273, DOI 10.1530/eje.0.1490273; Barzon L, 2004, ENDOCR REV, V25, P1, DOI 10.1210/er.2002-0035; BAUER G, 1983, INT J CANCER, V31, P291, DOI 10.1002/ijc.2910310307; BERGSAGEL DJ, 1992, NEW ENGL J MED, V326, P988, DOI 10.1056/NEJM199204093261504; Biasolo MA, 2003, J MED VIROL, V69, P220, DOI 10.1002/jmv.10285; Bloom DC, 1997, VIROLOGY, V236, P202, DOI 10.1006/viro.1997.8723; Boldorini R, 2005, AM J CLIN PATHOL, V124, P303, DOI 10.1309/RLB1PMV33RK7CGAX; Carbone M, 2005, CANCER RES, V65, P10120, DOI 10.1158/0008-5472.CAN-05-1911; Carbone M, 2003, CANCER RES, V63, P6125; Chang M, 2005, J VIROL, V79, P13538, DOI 10.1128/JVI.79.21.13538-13547.2005; Correa RM, 2004, J MED VIROL, V73, P583, DOI 10.1002/jmv.20129; Dahia PLM, 2006, CURR OPIN ONCOL, V18, P1, DOI 10.1097/01.cco.0000198017.45982.06; FEIGENBAUM L, 1992, J VIROL, V66, P1176, DOI 10.1128/JVI.66.2.1176-1182.1992; Flaegstad T, 1999, CANCER RES, V59, P1160; GLASER R, 1995, NEUROENDOCRINOLOGY, V62, P356, DOI 10.1159/000127025; Gratama JW, 1995, ADV CANCER RES, V67, P197, DOI 10.1016/S0065-230X(08)60714-9; Hornsby PJ, 2002, ENDOCR RES, V28, P777, DOI 10.1081/ERC-120017072; Hoshino Y, 1997, AIDS, V11, P1719, DOI 10.1097/00002030-199714000-00008; Isobe Y, 2004, CANCER RES, V64, P2167, DOI 10.1158/0008-5472.CAN-03-1562; KNECHT H, 1993, BLOOD, V82, P2937; KUPFER SR, 1990, J VIROL, V64, P1984, DOI 10.1128/JVI.64.5.1984-1990.1990; LATHEY JL, 1991, J VIROL, V65, P6371, DOI 10.1128/JVI.65.11.6371-6375.1991; Lee HS, 2004, CLIN CANCER RES, V10, P1698, DOI 10.1158/1078-0432.CCR-1122-3; Libe R, 2005, EUR J ENDOCRINOL, V153, P477, DOI 10.1530/eje.1.02004; Lopez-Rios F, 2004, LANCET, V364, P1157, DOI 10.1016/S0140-6736(04)17102-X; McNeese T, 2005, AM HIST, V40, P52; Mengoli C, 2004, J MED VIROL, V74, P78, DOI 10.1002/jmv.20149; MOENS U, 1994, J VIROL, V68, P2398, DOI 10.1128/JVI.68.4.2398-2408.1994; Moens U, 1999, J GEN VIROL, V80, P585, DOI 10.1099/0022-1317-80-3-585; MORHENN V, 1973, P NATL ACAD SCI USA, V70, P1088, DOI 10.1073/pnas.70.4.1088; NISHIYAMA Y, 1979, J VIROL, V31, P841, DOI 10.1128/JVI.31.3.841-844.1979; Podlech J, 1996, ARCH VIROL, V141, P1999, DOI 10.1007/BF01718210; Pomara G, 2006, EUR J HISTOCHEM, V50, P131; PULAKHANDAM U, 1990, AM J CLIN PATHOL, V93, P651, DOI 10.1093/ajcp/93.5.651; Razzaq F, 2002, HIV Med, V3, P212, DOI 10.1046/j.1468-1293.2002.00114.x; Ressetar HG, 1997, J NEUROVIROL, V3, P66, DOI 10.3109/13550289709015794; RESSETAR HG, 1993, MOL CHEM NEUROPATHOL, V20, P59, DOI 10.1007/BF03160070; SCHUSTER C, 1991, FEBS LETT, V284, P82, DOI 10.1016/0014-5793(91)80767-W; SCHUSTER C, 1991, MOL ENDOCRINOL, V5, P267, DOI 10.1210/mend-5-2-267; SERVENIUS B, 1994, CANCER RES, V54, P5198; SMALL JA, 1986, P NATL ACAD SCI USA, V83, P8288, DOI 10.1073/pnas.83.21.8288; TANAKA J, 1984, VIROLOGY, V136, P448, DOI 10.1016/0042-6822(84)90182-X; TANAKA J, 1984, J GEN VIROL, V65, P1757; Thomas M, 2000, NAT BIOTECHNOL, V18, P39, DOI 10.1038/71894; TISCHLER AS, 1993, LAB INVEST, V68, P541; Watzinger F, 2004, J CLIN MICROBIOL, V42, P5189, DOI 10.1128/JCM.42.11.5189-5198.2004; Zoeteweij JP, 2002, J MED VIROL, V66, P378, DOI 10.1002/jmv.2155; ZUO FR, 1995, P NATL ACAD SCI USA, V92, P8586, DOI 10.1073/pnas.92.19.8586	51	12	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 31	2008	27	6					857	864		10.1038/sj.onc.1210699	http://dx.doi.org/10.1038/sj.onc.1210699			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	258QZ	17684484				2022-12-17	WOS:000252884500015
J	Rapisarda, A; Melillo, G				Rapisarda, A.; Melillo, G.			UVC inhibits HIF-1 alpha protein translation by a DNA damage- and topoisomerase I-independent pathway	ONCOGENE			English	Article						HIF-1; topoisomerase; UVC; translation; DNA damage; cancer therapeutics	HYPOXIA-INDUCIBLE FACTOR-1; RNA-POLYMERASE-II; XERODERMA-PIGMENTOSUM; ULTRAVIOLET-LIGHT; CANCER-THERAPY; TUMOR-GROWTH; HIF-ALPHA; TRANSCRIPTION; ACTIVATION; ATR	Hypoxia inducible factor 1 (HIF-1) is a key player in cancer progression and an attractive target for cancer therapy. Several small molecule inhibitors of HIF-1 alpha also induce a DNA damage response. However, whether or not DNA damage is required for or associated with the inhibition of HIF-1 alpha protein accumulation is poorly understood. In this report we investigated the effects of distinct DNA damaging conditions on the hypoxic induction of HIF-1 alpha protein in cancer cell lines. We demonstrate that in addition to topotecan (TPT), a known inhibitor of HIF-1 alpha, UVC, but not other DNA damaging agents (cisplatin, ionizing radiation and doxorubicin), inhibited HIF-1 alpha protein accumulation in a dose-dependent, p53-independent fashion. Low doses UVC decreased HIF-1 alpha translation without affecting global protein synthesis. Inhibition of HIF-1 alpha by UVC required ongoing RNA transcription, but not DNA replication. Moreover, a functional ATR was required for the activation of DNA damage-dependent responses by both UVC and TPT, but was dispensable for the inhibition of HIF-1 alpha protein. Notably, unlike TPT, inhibition of HIF-1 alpha protein by UVC did not require topoisomerase 1, suggesting a similar yet distinct mode of action. Our data reveal that UVC is a novel signal associated with inhibition of HIF-1 alpha protein accumulation, and they uncouple the DNA damage-dependent signaling pathway exerted by UVC and TPT from HIF-1 alpha inhibition.	Natl Canc Inst, SAIC Frederick Inc, DTP Tumor Hypoxia Lab, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Melillo, G (corresponding author), Natl Canc Inst, SAIC Frederick Inc, DTP Tumor Hypoxia Lab, 1050 Boyles St,Bldg 432,Room 218, Ft Detrick, MD 21702 USA.	melillog@ncifcff.gov			NCI NIH HHS [N01-CO-12400] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berneburg M, 2001, ADV GENET, V43, P71, DOI 10.1016/S0065-2660(01)43004-5; Bregman DB, 1996, P NATL ACAD SCI USA, V93, P11586, DOI 10.1073/pnas.93.21.11586; Brown JM, 1998, CANCER RES, V58, P1408; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; Demidenko ZN, 2005, ONCOGENE, V24, P4829, DOI 10.1038/sj.onc.1208636; Desai SD, 2003, MOL CELL BIOL, V23, P2341, DOI 10.1128/MCB.23.7.2341-2350.2003; DUBOIS MF, 1994, J BIOL CHEM, V269, P13331; Furuta T, 2003, J BIOL CHEM, V278, P20303, DOI 10.1074/jbc.M300198200; Furuta T, 2002, CANCER RES, V62, P4899; Hammond EM, 2004, DNA REPAIR, V3, P1117, DOI 10.1016/j.dnarep.2004.03.035; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang HY, 2005, BIOCHEM J, V385, P371, DOI 10.1042/BJ20041164; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Laine JP, 2006, TRENDS GENET, V22, P430, DOI 10.1016/j.tig.2006.06.006; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Ljungman M, 2005, MUTAT RES-FUND MOL M, V577, P203, DOI 10.1016/j.mrfmmm.2005.02.014; MAYNE LV, 1982, CANCER RES, V42, P1473; Mazan-Mamczarz K, 2006, MOL CELL BIOL, V26, P2716, DOI 10.1128/MCB.26.7.2716-2727.2006; Melillo G, 2006, MOL CANCER RES, V4, P601, DOI 10.1158/1541-7786.MCR-06-0235; Mellon I, 2005, MUTAT RES-FUND MOL M, V577, P155, DOI 10.1016/j.mrfmmm.2005.03.016; Pfeifer GP, 2005, MUTAT RES-FUND MOL M, V571, P19, DOI 10.1016/j.mrfmmm.2004.06.057; Proietti-De-Santis L, 2006, EMBO J, V25, P1915, DOI 10.1038/sj.emboj.7601071; Rapisarda A, 2004, CELL CYCLE, V3, P172; Rapisarda A, 2004, CANCER RES, V64, P6845, DOI 10.1158/0008-5472.CAN-04-2116; Rapisarda A, 2004, CANCER RES, V64, P1475, DOI 10.1158/0008-5472.CAN-03-3139; Rapisarda A, 2002, CANCER RES, V62, P4316; Semenza GL, 2006, EXPERT OPIN THER TAR, V10, P267, DOI 10.1517/14728222.10.2.267; Shechter D, 2004, DNA REPAIR, V3, P901, DOI 10.1016/j.dnarep.2004.03.020; Sim RJ, 2004, GENE DEV, V18, P2437, DOI 10.1101/gad.1235904; Soe K, 2004, DNA REPAIR, V3, P387, DOI 10.1016/j.dnarep.2003.12.003; Tornaletti S, 2005, MUTAT RES-FUND MOL M, V577, P131, DOI 10.1016/j.mrfmmm.2005.03.014; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; Yang J, 2003, CARCINOGENESIS, V24, P1571, DOI 10.1093/carcin/bgg137; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	38	12	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 18	2007	26	48					6875	6884		10.1038/sj.onc.1210489	http://dx.doi.org/10.1038/sj.onc.1210489			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	220WQ	17496931				2022-12-17	WOS:000250188400003
J	Chang, DLF; Qiu, W; Ying, H; Zhang, Y; Chen, CY; Xiao, ZXJ				Chang, D. L. F.; Qiu, W.; Ying, H.; Zhang, Y.; Chen, C-Y; Xiao, Z-X J.			ARF promotes accumulation of retinoblastoma protein through inhibition of MDM2	ONCOGENE			English	Article						ARF; retinoblastoma protein; MDM2; cell; cycle; cancer	TUMOR-SUPPRESSOR; INK4A LOCUS; C-ABL; EXON 1-BETA; NUCLEOLAR LOCALIZATION; SELECTIVE DELETION; DEPENDENT KINASES; NUCLEAR EXPORT; STABILIZES P53; G(1) CONTROL	The INK4a/ARF locus, encoding two tumor suppressor proteins, p16(INK4a) and p14(ARF) (ARF), plays key roles in many cellular processes including cell proliferation, apoptosis, cellular senescence and differentiation. Inactivation of INK4a/ARF is one of the most frequent events during human cancer development. Although p16(INK4a) is a critical component in retinoblastoma protein (Rb)-mediated growth regulatory pathway, p14ARF plays a pivotal role in the activation of p53 upon oncogenic stress signals. A body of evidence indicates that ARF also possesses growth suppression functions independent of p53, the mechanism of which is not well understood. We have recently shown that MDM2 interacts with Rb and promotes proteasome-dependent Rb degradation. In this study, we show that ARF disrupts MDM2 -Rb interaction resulting in Rb accumulation. Wild-type ARF, but not ARF mutant defective in MDM2 interaction, stabilizes Rb and inhibits colony foci formation independent of p53. In addition, ablation of Rb impairs ARF function in growth suppression. Thus, this study demonstrates that ARF plays a direct role in regulation of Rb and suggests that inactivation of ARF may lead to defects in both p53 and Rb pathways in human cancer development.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Grad Program Mol Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA	Boston University; Boston University; Boston University; Boston University	Xiao, ZXJ (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St,K-423, Boston, MA 02118 USA.	jxiao@bu.edu	Ying, Haoqiang/AAK-4325-2020					Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; Bothner B, 2001, J MOL BIOL, V314, P263, DOI 10.1006/jmbi.2001.5110; Boyer SN, 1996, CANCER RES, V56, P4620; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; Carness KH, 2000, ISSUES SCI TECHNOL, V16, P19; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dias SS, 2006, ONCOGENE, V25, P6666, DOI 10.1038/sj.onc.1209671; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Groth A, 2000, J BIOL CHEM, V275, P27473; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hall M, 1996, ADV CANCER RES, V68, P67, DOI 10.1016/S0065-230X(08)60352-8; Higashitsuji H, 2000, NAT MED, V6, P96, DOI 10.1038/71600; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Iida S, 2000, INT J CANCER, V87, P654, DOI 10.1002/1097-0215(20000901)87:5<654::AID-IJC6>3.0.CO;2-P; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kumar R, 1998, GENE CHROMOSOME CANC, V23, P273, DOI 10.1002/(SICI)1098-2264(199811)23:3<273::AID-GCC11>3.0.CO;2-N; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Modestou M, 2001, CANCER RES, V61, P3145; Momand J, 1998, NUCLEIC ACIDS RES, V26, P3453, DOI 10.1093/nar/26.15.3453; Nguyen DX, 2004, EMBO J, V23, P1609, DOI 10.1038/sj.emboj.7600176; Pan W, 2003, ONCOGENE, V22, P5496, DOI 10.1038/sj.onc.1206857; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Quelle DE, 1997, P NATL ACAD SCI USA, V94, P669, DOI 10.1073/pnas.94.2.669; Randerson-Moor JA, 2001, HUM MOL GENET, V10, P55, DOI 10.1093/hmg/10.1.55; Rizos H, 2001, ONCOGENE, V20, P5543, DOI 10.1038/sj.onc.1204728; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Sdek P, 2005, MOL CELL, V20, P699, DOI 10.1016/j.molcel.2005.10.017; Sdek P, 2004, J BIOL CHEM, V279, P53317, DOI 10.1074/jbc.M406062200; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sharpless NE, 2004, ONCOGENE, V23, P379, DOI 10.1038/sj.onc.1207074; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Sionov RV, 2001, MOL CELL BIOL, V21, P5869; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tsai KY, 2002, P NATL ACAD SCI USA, V99, P16865, DOI 10.1073/pnas.262499599; Uchida CH, 2005, EMBO J, V24, P160, DOI 10.1038/sj.emboj.7600486; Viswanathan M, 2001, ORAL ONCOL, V37, P341, DOI 10.1016/S1368-8375(00)00112-3; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Wang IJ, 2001, MOL VIS, V7, P20; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Weber JD, 2000, GENE DEV, V14, P2358, DOI 10.1101/gad.827300; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Ying HQ, 2006, CELL CYCLE, V5, P506, DOI 10.4161/cc.5.5.2515; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	56	12	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 12	2007	26	32					4627	4634		10.1038/sj.onc.1210254	http://dx.doi.org/10.1038/sj.onc.1210254			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	190DJ	17297463				2022-12-17	WOS:000248037900003
J	de Koning, JP; Wakabayashi, Y; Nagase, H; Mao, JH; Balmain, A				de Koning, J. P.; Wakabayashi, Y.; Nagase, H.; Mao, J-H; Balmain, A.			Convergence of congenic mapping and allele-specific alterations in tumors for the resolution of the Skts1 skin tumor susceptibility locus	ONCOGENE			English	Article						congenic; LOH; allele-specific; skin; papilloma; susceptibility	GENETIC ALTERATIONS; MODIFIER LOCI; MOUSE MODELS; LUNG-CANCER; MICE; IDENTIFICATION; RETINOBLASTOMA; CHROMOSOME-7; RESISTANCE; CANDIDATE	Although several familial cancer genes with high-penetrance mutations have been identified, the major genetic component of susceptibility to sporadic cancers is attributable to low-penetrance alleles. These 'weak' tumor susceptibility genes do not segregate as single Mendelian traits and are therefore difficult to find in studies of human populations. Previously, we have proposed that a combination of germline mapping and analysis of allele-specific imbalance in tumors may be used to re. ne the locations of susceptibility genes using mouse models of cancer. Here, we have used linkage analysis and congenic mouse strains to map the major skin tumor susceptibility locus Skts1 within a genetic interval of 0.9 cM on proximal chromosome 7. This interval lies in an apparent recombination cold spot, and corresponds to a physical distance of about 15 Mb. We therefore, used patterns of allele-specific imbalances in tumors from backcross and congenic mice to re. ne the location of Skts1. We demonstrate that this single tumor modi. er locus has a dramatic effect on the allelic preference for imbalance on chromosome 7, with at least 90% of tumors from the congenics showing preferential gain of markers on the chromosome carrying the susceptibility variant. Importantly, these alterations enabled us to re. ne the location of Skts1 at higher resolution than that attained using the congenic mice. We conclude that low-penetrance susceptibility genes can have strong effects on patterns of allele-specific somatic genetic changes in tumors, and that analysis of the directionality of these somatic events provides an important and rapid route to identification of germline genetic variants that confer increased cancer risk.	Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Roswell Pk Canc Inst, Dept Canc, Buffalo, NY 14263 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Roswell Park Cancer Institute	Balmain, A (corresponding author), Univ Calif San Francisco, Dept Biochem & Biophys, 2340 Sutter St,Room S-227, San Francisco, CA 94143 USA.	abalmain@cc.ucsf.edu	Mao, Jian-Hua/EIZ-8595-2022	Mao, Jian-Hua/0000-0001-9320-6021	NATIONAL CANCER INSTITUTE [U01CA084244] Funding Source: NIH RePORTER; NCI NIH HHS [U01 CA84244] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Balmain A, 2003, NAT GENET, V33, P238, DOI 10.1038/ng1107; Cormier RT, 2000, ONCOGENE, V19, P3182, DOI 10.1038/sj.onc.1203646; Demant P, 2003, NAT REV GENET, V4, P721, DOI 10.1038/nrg1157; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dragani TA, 2003, CANCER RES, V63, P3011; Ewart-Toland A, 2005, CARCINOGENESIS, V26, P1368, DOI 10.1093/carcin/bgi085; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fijneman RJA, 1996, NAT GENET, V14, P465, DOI 10.1038/ng1296-465; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; Hienonen T, 2006, INT J CANCER, V118, P505, DOI 10.1002/ijc.21344; KEMP CJ, 1993, CANCER RES, V53, P6022; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Legare ME, 2000, GENOMICS, V70, P62, DOI 10.1006/geno.2000.6368; Mao JH, 2003, CURR OPIN GENET DEV, V13, P14, DOI 10.1016/S0959-437X(03)00005-4; Mao JH, 2006, P NATL ACAD SCI USA, V103, P8125, DOI 10.1073/pnas.0602581103; Nagase H, 2003, CANCER RES, V63, P4849; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; Peto J, 2001, NATURE, V411, P390, DOI 10.1038/35077256; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Saran A, 2004, ONCOGENE, V23, P4130, DOI 10.1038/sj.onc.1207565; Silver L.M., 1995, MOUSE GENETICS CONCE; To MD, 2006, NAT GENET, V38, P926, DOI 10.1038/ng1836; VOGEL SN, 1994, INFECT IMMUN, V62, P4454, DOI 10.1128/IAI.62.10.4454-4459.1994; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185	28	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 14	2007	26	28					4171	4178		10.1038/sj.onc.1210206	http://dx.doi.org/10.1038/sj.onc.1210206			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	178XD	17311004				2022-12-17	WOS:000247252700012
J	Chikamori, M; Fujimoto, J; Tokai-Nishizumi, N; Yamamoto, T				Chikamori, M.; Fujimoto, J.; Tokai-Nishizumi, N.; Yamamoto, T.			Identification of multiple SNT-binding sites on NPM-Alk oncoprotein and their involvement in cell transformation	ONCOGENE			English	Article						NPM-ALK; SNT; cell transformation; tyrosine phosphorylation; oncoprotein; anaplastic large-cell lymphoma	ANAPLASTIC LYMPHOMA KINASE; RECEPTOR TYROSINE KINASE; NERVE GROWTH-FACTOR; NON-HODGKINS-LYMPHOMA; MAP KINASE; PROTEIN; ACTIVATION; GENE; FRS2; DIFFERENTIATION	The t(2;5) chromosomal translocation occurs in anaplastic large-cell lymphoma arising from activated T lymphocytes. This genomic rearrangement generates the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncoprotein that is a chimeric protein consisting of parts of the nuclear protein NPM and ALK receptor protein-tyrosine kinase. We used yeast two-hybrid screening to identify an adaptor protein Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target (SNT)-2 as a new partner that interacted with the cytoplasmic domain of ALK. Immunoprecipitation assay revealed that SNT-1 and SNT-2 interacted with NPM-ALK and kinase-negative NPM-ALK mutant. Y156, Y567 and a 19-amino-acid sequence (aa 631-649) of NPM-ALK were essential for this interaction. The interaction through Y156 and Y567 was dependent on phosphorylation of these tyrosines, whereas the interaction through the 19-amino- acid sequence was independent of phosphorylation. NPM-ALK mutant protein mutated at these three binding sites showed significantly reduced transforming activity. This transformation-defective NPM-ALK mutant still interacted with signal transducing proteins such as phospholipase C-gamma and phosphatidylinositol 3-kinase, which were previously reported to be relevant to NPM-ALK-dependent tumorigenesis. These observations indicate that the three SNT-binding sites of NPM-ALK are important for its transforming activity. This raises a possibility that SNT family proteins play significant roles in cellular transformation triggered by NPM-ALK, which though remains to be verified.	Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo, Japan; Natl Inst Radiol Sci, Res Ctr Radiat Emergency Med, Chiba 260, Japan; Univ Calif San Diego, La Jolla, CA 92093 USA	University of Tokyo; National Institutes for Quantum Science & Technology; University of California System; University of California San Diego	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Div Oncol, Minato Ku, Tokyo, Japan.	tyamamot@ims.u-tokyo.ac.jp						Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bai RY, 2000, BLOOD, V96, P4319, DOI 10.1182/blood.V96.13.4319; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; Fujimoto J, 1996, P NATL ACAD SCI USA, V93, P4181, DOI 10.1073/pnas.93.9.4181; Gotoh N, 2004, FEBS LETT, V564, P14, DOI 10.1016/S0014-5793(04)00287-X; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; HERBST H, 1991, BLOOD, V78, P2666; Huang L, 2004, BIOCHEM BIOPH RES CO, V324, P1011, DOI 10.1016/j.bbrc.2004.09.152; Iwahara T, 1997, ONCOGENE, V14, P439, DOI 10.1038/sj.onc.1200849; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lax I, 2002, MOL CELL, V10, P709, DOI 10.1016/S1097-2765(02)00689-5; McDougall K, 2001, MECH DEVELOP, V103, P145, DOI 10.1016/S0925-4773(01)00337-9; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Morris SW, 1997, ONCOGENE, V14, P2175, DOI 10.1038/sj.onc.1201062; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; SHIOTA M, 1994, ONCOGENE, V9, P1567; Slupianek A, 2001, CANCER RES, V61, P2194; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zhang Q, 2002, J IMMUNOL, V168, P466, DOI 10.4049/jimmunol.168.1.466	21	12	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2007	26	20					2950	2954		10.1038/sj.onc.1210095	http://dx.doi.org/10.1038/sj.onc.1210095			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	164CR	17086210				2022-12-17	WOS:000246210800015
J	Habens, F; Lapham, AS; Dallman, CL; Pickering, BM; Michels, J; Marcusson, EG; Johnson, PWM; Packham, G				Habens, F.; Lapham, A. S.; Dallman, C. L.; Pickering, B. M.; Michels, J.; Marcusson, E. G.; Johnson, P. W. M.; Packham, G.			Distinct promoters mediate constitutive and inducible Bcl-X-L expression in malignant lymphocytes	ONCOGENE			English	Article						Bcl-X-L; Ets; lymphoma; transcription	EPSTEIN-BARR-VIRUS; REL/NF-KAPPA-B; CELL-DEATH; GENE-EXPRESSION; TRANSCRIPTION FACTOR; INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3-KINASE; HEMATOPOIETIC MALIGNANCIES; FAMILY PROTEINS; POOR-PROGNOSIS	Bcl-X-L is a Bcl-2-related survival protein that is essential for normal development. Bcl-X-L expression is rapidly induced by a wide range of survival signals and many cancer cells constitutively express high levels. The Bcl-X gene has a complex organization with multiple promoters giving rise to RNAs with alternate 5' non-codingexons. Here we have investigated the mechanisms that control basal and induced expression of Bcl-X-L in B-lymphoma cells. Antisense experiments demonstrated that Bcl-X-L was essential for survival of Akata6 B-lymphoma cells. The levels of RNAs containing the IB Bcl-X non-coding exon, derived from the distal 1B promoter, correlated with basal expression of Bcl-X-L in primary malignant B cells and this promoter was highly active in B-cell lines. The activity of this promoter was largely dependent on a single Ets binding site and Ets family proteins were bound at this promoter in intact cells. CD40 ligand (CD40L)-induced cell survival was associated with increased Bcl-X-L expression and accumulation of exon IA-containing RNAs, derived from the proximal 1A promoter. Nuclear factor-kappaB (NF-kappa B) inhibition prevented induction of Bcl-X-L protein and exon IA-containingRNAs by CD40L. Therefore, the distal Bcl-X 1B promoter plays a critical role in driving constitutive expression-mediated via Ets family proteins in malignant B cells, whereas NF-kappa B plays a central role in the induction of Bcl-X-L in response to CD40 signalling via the proximal 1A promoter.	Univ Southampton, Southampton Gen Hosp, Sch Med, Canc Res UK,Ctr Clin,Canc Sci Div, Southampton SO16 6YD, Hants, England; ISIS Pharmaceut, Antisense Drug Discovery, Carlsbad, CA 92008 USA	Cancer Research UK; University of Southampton; Isis Pharmaceuticals Inc	Packham, G (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Canc Res UK,Ctr Clin,Canc Sci Div, Somers Canc Res Bldg,MP824, Southampton SO16 6YD, Hants, England.	G.K.Packham@soton.ac.uk	Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Marcusson, Eric/0000-0002-0504-8674; Packham, Graham/0000-0002-9232-5691				Andjelic S, 2000, J IMMUNOL, V165, P3860, DOI 10.4049/jimmunol.165.7.3860; Ban J, 1998, BIOCHEM BIOPH RES CO, V248, P147, DOI 10.1006/bbrc.1998.8907; Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; Dallman C, 2005, METH MOLEC MED, V115, P1; de Nigris F, 2001, CANCER RES, V61, P2267; Deng G, 1998, MOL MED, V4, P158, DOI 10.1007/BF03401913; Derenne S, 2002, BLOOD, V100, P194, DOI 10.1182/blood.V100.1.194; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Dumon S, 1999, ONCOGENE, V18, P4191, DOI 10.1038/sj.onc.1202796; Fennell DA, 2001, BRIT J HAEMATOL, V112, P706, DOI 10.1046/j.1365-2141.2001.02603.x; Friess H, 1998, ANN SURG, V228, P780, DOI 10.1097/00000658-199812000-00009; Glasgow JN, 2000, J NEUROCHEM, V75, P1377, DOI 10.1046/j.1471-4159.2000.0751377.x; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Grillot DAM, 1997, J IMMUNOL, V158, P4750; Heere-Ress E, 2002, INT J CANCER, V99, P29, DOI 10.1002/ijc.10248; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Inman GJ, 2001, J VIROL, V75, P2400, DOI 10.1128/JVI.75.5.2400-2410.2001; Irvin BJ, 2003, J BIOL CHEM, V278, P46378, DOI 10.1074/jbc.M305189200; ISHIDA T, 1995, J IMMUNOL, V155, P5527; Jazirehi AR, 2004, CANCER RES, V64, P7117, DOI 10.1158/0008-5472.CAN-03-3500; Kirito K, 2002, J BIOL CHEM, V277, P8329, DOI 10.1074/jbc.M109824200; Krajewska M, 1996, CANCER RES, V56, P2422; Krajewska M, 1996, AM J PATHOL, V149, P1449; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lee JH, 2002, J BIOL CHEM, V277, P18411, DOI 10.1074/jbc.M201368200; Lohmann CM, 2000, CYTOMETRY, V42, P61, DOI 10.1002/(SICI)1097-0320(20000215)42:1<61::AID-CYTO9>3.0.CO;2-5; MacCarthy-Morrogh L, 2000, ONCOGENE, V19, P5534, DOI 10.1038/sj.onc.1203949; Michels J, 2004, ONCOGENE, V23, P4818, DOI 10.1038/sj.onc.1207648; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Naik P, 1996, GENE DEV, V10, P2105, DOI 10.1101/gad.10.17.2105; Olopade OI, 1997, CANCER J SCI AM, V3, P230; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Pallis M, 1997, LEUKEMIA, V11, P945, DOI 10.1038/sj.leu.2400705; Pecci A, 2001, J BIOL CHEM, V276, P21062, DOI 10.1074/jbc.M008665200; Pena JC, 1998, CANCER RES, V58, P2111; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Sevilla L, 2001, HISTOL HISTOPATHOL, V16, P595, DOI 10.14670/HH-16.595; Sevilla L, 1999, MOL CELL BIOL, V19, P2624; Spender LC, 1999, J VIROL, V73, P4678, DOI 10.1128/JVI.73.6.4678-4688.1999; TAKADA K, 1991, VIRUS GENES, V5, P147, DOI 10.1007/BF00571929; Tamir A, 1999, MOL CELL BIOL, V19, P4452; Taylor JK, 1999, ONCOGENE, V18, P4495, DOI 10.1038/sj.onc.1202836; Tian CX, 2003, BLOOD, V101, P2235, DOI 10.1182/blood-2002-04-1217; Tu YP, 1998, CANCER RES, V58, P256; Tuscano JM, 1996, BLOOD, V88, P1359, DOI 10.1182/blood.V88.4.1359.bloodjournal8841359; Vega MI, 2005, ONCOGENE, V24, P8114, DOI 10.1038/sj.onc.1208954; Viegas LR, 2004, J BIOL CHEM, V279, P9831, DOI 10.1074/jbc.M312402200; WANG ZH, 1995, J IMMUNOL, V155, P3722; Wu LX, 2005, J IMMUNOL, V174, P180, DOI 10.4049/jimmunol.174.1.180; Xerri L, 1996, BRIT J HAEMATOL, V92, P900, DOI 10.1046/j.1365-2141.1996.423958.x	55	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 22	2007	26	13					1910	1919		10.1038/sj.onc.1209979	http://dx.doi.org/10.1038/sj.onc.1209979			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	149AE	16983335				2022-12-17	WOS:000245117700008
J	Tsuchiya, A; Tashiro, E; Yoshida, M; Imoto, M				Tsuchiya, A.; Tashiro, E.; Yoshida, M.; Imoto, M.			Involvement of protein phosphatase 2A nuclear accumulation and subsequent inactivation of activator protein-1 in leptomycin B-inhibited cyclin D1 expression	ONCOGENE			English	Article						leptomycin B; cyclin D1; PP2A; c-jun	ANTI-FUNGAL ANTIBIOTICS; C-JUN; EXPORT SIGNALS; CELL-CYCLE; SERINE/THREONINE PHOSPHATASES; NUCLEOCYTOPLASMIC TRANSPORT; AP-1 ACTIVITY; OKADAIC ACID; HIV-1 REV; IN-VIVO	Leptomycin B (LMB) is a Streptomyces metabolite that causes the specific inhibition of the nuclear export of proteins containing a nuclear export signal (NES). LMB was reported to inhibit cell cycle progression in fission yeast and mammalian cells, however, the mechanism underlying LMB-induced cell cycle arrest is still obscure. In this study, we found that in serum-starved NIH3T3 cells, LMB inhibited serum-induced cyclin D1 expression at the level of transcription. However, this inhibition was reversed by inhibitors of protein phosphatase 2A (PP2A). Furthermore, we found that PP2A accumulated in the nucleus upon treatment with LMB. The finding prompted us to identify the functional NES in PP2A catalytic subunit a. These results indicated that LMB inhibited the chromosomal region maintenance 1(CRM1)-dependent nuclear export of PP2A, resulting in sustained dephosphorylation in the nucleus. Although phosphorylation of c-Jun at Ser-63 is required for activator protein 1 (AP-1)-dependent expression of cyclin D1, it decreased in LMB-treated cells compared to untreated cells. Moreover, the inhibitors of PP2A restored the levels of c-Jun phosphorylated at Ser-63. We propose that inhibition of cyclin D1 expression by LMB is mediated by the LMB-induced nuclear accumulation of PP2A, leading to sustained dephosphorylation of c-Jun at Ser-63, which leads to inactivation of the transcription of the AP-1-responsive cyclin D1 gene.	Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Kohoku Ku, Yokohama, Kanagawa 2238522, Japan; RIKEN, Chem Genet Lab, Wako, Saitama 35101, Japan	Keio University; RIKEN	Imoto, M (corresponding author), Keio Univ, Fac Sci & Technol, Dept Biosci & Informat, Kohoku Ku, 3-14-1 Hiyohi, Yokohama, Kanagawa 2238522, Japan.	imoto@bio.keio.ac.jp	Tashiro, Etsu/C-4903-2014; Imoto, Masaya/F-7957-2014; Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674; Tashiro, Etsu/0000-0003-4533-623X				Al-Murrani SWK, 1999, BIOCHEM J, V341, P293, DOI 10.1042/0264-6021:3410293; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALBERTS AS, 1993, MOL CELL BIOL, V13, P2104, DOI 10.1128/MCB.13.4.2104; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; Bannister AJ, 1995, ONCOGENE, V11, P2509; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Campos M, 1996, J BIOL CHEM, V271, P28478, DOI 10.1074/jbc.271.45.28478; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; Csortos C, 1996, J BIOL CHEM, V271, P2578, DOI 10.1074/jbc.271.5.2578; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; FISCHER U, 1993, EMBO J, V12, P573, DOI 10.1002/j.1460-2075.1993.tb05689.x; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Gama-Carvalho M, 2001, FEBS LETT, V498, P157, DOI 10.1016/S0014-5793(01)02487-5; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Graves PR, 2001, ONCOGENE, V20, P1839, DOI 10.1038/sj.onc.1204259; Haasen D, 1999, PLANT J, V20, P695, DOI 10.1046/j.1365-313X.1999.00644.x; HAMAMOTO T, 1983, J ANTIBIOT, V36, P639, DOI 10.7164/antibiotics.36.639; HAMAMOTO T, 1983, J ANTIBIOT, V36, P646, DOI 10.7164/antibiotics.36.646; HAMAMOTO T, 1985, J ANTIBIOT, V38, P1573, DOI 10.7164/antibiotics.38.1573; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Kutay U, 2005, TRENDS CELL BIOL, V15, P121, DOI 10.1016/j.tcb.2005.01.005; la Cour T, 2003, NUCLEIC ACIDS RES, V31, P393, DOI 10.1093/nar/gkg101; Lecane PS, 2003, PROSTATE, V54, P258, DOI 10.1002/pros.10197; Lubert EJ, 2003, BIOCHEM BIOPH RES CO, V303, P908, DOI 10.1016/S0006-291X(03)00434-0; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Neville M, 1997, CURR BIOL, V7, P767, DOI 10.1016/S0960-9822(06)00335-6; NISHI K, 1994, J BIOL CHEM, V269, P6320; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PAPAVASSILIOU AG, 1995, EMBO J, V14, P2014, DOI 10.1002/j.1460-2075.1995.tb07193.x; Ramirez CJ, 2005, J CELL BIOCHEM, V96, P170, DOI 10.1002/jcb.20520; SCHAAP PJ, 1991, J MOL BIOL, V221, P225; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shiozawa T, 2004, ONCOGENE, V23, P8603, DOI 10.1038/sj.onc.1207849; Sigoillot FD, 2005, J BIOL CHEM, V280, P25611, DOI 10.1074/jbc.M504581200; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Uchida S, 2004, BIOCHEM BIOPH RES CO, V316, P226, DOI 10.1016/j.bbrc.2004.02.039; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; WEIGHARDT F, 1995, J CELL SCI, V108, P545; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Whang YM, 2005, CANCER RES, V65, P3682, DOI 10.1158/0008-5472.CAN-04-2792; Wisdom R, 1999, EMBO J, V18, P188, DOI 10.1093/emboj/18.1.188; Yashiroda Y, 2003, CURR MED CHEM, V10, P741, DOI 10.2174/0929867033457791; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4; YOSHIDA M, 1990, EXP CELL RES, V187, P150, DOI 10.1016/0014-4827(90)90129-X; Zhang MJ, 1998, BIOCHEM BIOPH RES CO, V243, P113, DOI 10.1006/bbrc.1997.8070	57	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 8	2007	26	11					1522	1532		10.1038/sj.onc.1209962	http://dx.doi.org/10.1038/sj.onc.1209962			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	144FV	16964287				2022-12-17	WOS:000244782500002
J	Shao, RX; Kato, N; Lin, LJ; Muroyama, R; Moriyama, M; Ikenoue, T; Watabe, H; Otsuka, M; Guleng, B; Ohta, M; Tanaka, Y; Kondo, S; Dharel, N; Chang, JH; Yoshida, H; Kawabe, T; Omata, M				Shao, R-X; Kato, N.; Lin, L-J; Muroyama, R.; Moriyama, M.; Ikenoue, T.; Watabe, H.; Otsuka, M.; Guleng, B.; Ohta, M.; Tanaka, Y.; Kondo, S.; Dharel, N.; Chang, J-H; Yoshida, H.; Kawabe, T.; Omata, M.			Absence of tyrosine kinase mutations in Japanese colorectal cancer patients	ONCOGENE			English	Article						tyrosine kinase; mutation; colorectal cancer	GENE	Tyrosine kinases, which are important regulators of intracellular signal-transduction pathways, have mutated forms that are often associated with oncogenesis and are attractive targets for therapeutic intervention. Recently, systematic mutational analyses of tyrosine kinases revealed that a minimum of 30% of colorectal cancer contain at least one mutation in the tyrosine kinases. To further explore these mutations, we examined all reported mutations of NTRK3, FES, KDR, EPHA3, NTRK2, JAK1, PDGFRA, EPHA7, EPHA8, ERBB4, FGFR1, MLK4 and GUCY2F genes in the 24 colorectal cancer cell lines. Unexpectedly, among 24 colorectal cancer cell lines, only two cell lines (LoVo and CaR1) harbored mutation C1408T (R470C) in MLK4 gene. The mutation rate was extremely low compared to that previously reported. Therefore, we analyzed mutations in 46 colorectal cancer samples resected from the same number of Japanese patients. Surprisingly, none of the 46 samples contained any of the mutations reported. Based on our study, we advise that a more comprehensive tyrosine kinase gene mutation assay is necessary in the future.	Univ Tokyo, Dept Gastroenterol, Grad Sch Med, Bunkyo Ku, Tokyo 1138655, Japan; Jilin Univ, China Japan Union Hosp, Dept Gastroenterol, Changchun 130023, Jilin Province, Peoples R China; China Med Univ, Affiliated Hosp 2, Dept Gastroenterol, Shenyang, Peoples R China	University of Tokyo; Jilin University; China Medical University	Kato, N (corresponding author), Univ Tokyo, Dept Gastroenterol, Grad Sch Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kato-2im@h.u-tokyo.ac.jp	Otsuka, Motoyuki/H-9067-2019	Otsuka, Motoyuki/0000-0003-2869-2881; Tanaka, Yasuo/0000-0002-2917-3365				Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Shao RX, 2005, J GASTROENTEROL, V40, P918, DOI 10.1007/s00535-005-1661-5; Smith G, 2002, P NATL ACAD SCI USA, V99, P9433, DOI 10.1073/pnas.122612899; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022	7	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2007	26	14					2133	2135		10.1038/sj.onc.1210007	http://dx.doi.org/10.1038/sj.onc.1210007			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	151TJ	17016444				2022-12-17	WOS:000245313400015
J	Nouvion, AL; Thibaut, J; Lohez, OD; Venet, S; Colas, P; Gillet, G; Lalle, P				Nouvion, A-L; Thibaut, J.; Lohez, O. D.; Venet, S.; Colas, P.; Gillet, G.; Lalle, P.			Modulation of Nr-13 antideath activity by peptide aptamers	ONCOGENE			English	Article						Bcl-2; Nr-13; peptide aptamer; apoptosis; ligand	ANTIAPOPTOTIC PROTEIN NR-13; BCL-2 FAMILY; BH3 DOMAIN; APOPTOTIC FUNCTION; STRUCTURAL BASIS; TUMOR-CELLS; BAX; INHIBITOR; CANCER; IDENTIFICATION	Tumor cells are characterized by deregulated proliferation and resistance to proapoptotic stimuli. The Bcl-2 family of antiapoptotic proteins is overexpressed in a large number of chemoresistant tumors. Downregulation or inhibition of antiapoptotic proteins might result in the sensitization of cancer cells to chemotherapeutic agents. In the present study, we took advantage of the peptide aptamer strategy to target Nr-13, a Bcl-2 antiapoptotic protein involved in neoplastic transformation by the Rous sarcoma virus. We isolated peptide aptamers that behave as Nr-13 regulators, in vitro and in mammalian cells in culture. Some of these aptamers have potential proapoptotic activities. These data suggest that peptide aptamers targeting the Bcl-2 family of apoptosis inhibitors may be useful for the development of anticancer molecules.	Univ Lyon 1, CNRS, IBCP,IFR 128 Biosci, UMR 5086,Equipe Apoptose & Oncogenese, F-69367 Lyon 07, France; Aptanomics SA, F-69007 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Gillet, G (corresponding author), Univ Lyon 1, CNRS, IBCP,IFR 128 Biosci, UMR 5086,Equipe Apoptose & Oncogenese, 7 Passage Vercors, F-69367 Lyon 07, France.	g.gillet@ibcp.fr	LALLE, Philippe/G-7734-2018; gillet, germain/A-9095-2013	Lohez, Olivier/0000-0001-9446-9915; Colas, Pierre/0000-0001-7436-3718; GILLET, Germain/0000-0002-1514-327X				Aouacheria A, 2002, ONCOGENE, V21, P1171, DOI 10.1038/sj.onc.1205170; Aouacheria A, 2001, ONCOGENE, V20, P5846, DOI 10.1038/sj.onc.1204740; AOUACHERIA A, 2003, RRD MOLEC CELL BIOL, V4, P59; Buerger C, 2003, J BIOL CHEM, V278, P37610, DOI 10.1074/jbc.M301629200; Butz K, 2000, P NATL ACAD SCI USA, V97, P6693, DOI 10.1073/pnas.110538897; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; Cartron PF, 2005, J BIOL CHEM, V280, P10587, DOI 10.1074/jbc.M409714200; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cohen BA, 1998, P NATL ACAD SCI USA, V95, P14272, DOI 10.1073/pnas.95.24.14272; Colas P, 1996, NATURE, V380, P548, DOI 10.1038/380548a0; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Cosulich SC, 1997, CURR BIOL, V7, P913, DOI 10.1016/S0960-9822(06)00410-6; Cotter FE, 1999, BBA-GENE STRUCT EXPR, V1489, P97, DOI 10.1016/S0167-4781(99)00139-6; Cui QQ, 2005, ONCOGENE, V24, P3864, DOI 10.1038/sj.onc.1208556; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Fabbrizio E, 1999, ONCOGENE, V18, P4357, DOI 10.1038/sj.onc.1202825; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Geourjon C, 1995, COMPUT APPL BIOSCI, V11, P681; Girard-Egrot A, 2004, J MOL BIOL, V335, P321, DOI 10.1016/j.jmb.2003.10.028; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herold MJ, 2006, J BIOL CHEM, V281, P13663, DOI 10.1074/jbc.M600266200; Jiang XJ, 2003, SCIENCE, V299, P223, DOI 10.1126/science.1076807; Juin P, 2004, BBA-MOL CELL RES, V1644, P251, DOI 10.1016/j.bbamcr.2003.10.010; Klevenz B, 2002, CELL MOL LIFE SCI, V59, P1993, DOI 10.1007/PL00012521; Kolonin MG, 1998, P NATL ACAD SCI USA, V95, P14266, DOI 10.1073/pnas.95.24.14266; Kurtz SE, 2003, BIOTECHNOL BIOENG, V82, P38, DOI 10.1002/bit.10538; Lalle P, 2002, BIOCHEM J, V368, P213, DOI 10.1042/BJ20020836; Lanave C, 2004, GENE, V333, P71, DOI 10.1016/j.gene.2004.02.017; Mangeney M, 1996, ONCOGENE, V13, P1441; Mann HH, 2004, J BIOL CHEM, V279, P25294, DOI 10.1074/jbc.M403778200; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; MERRIFIELD RB, 1964, BIOCHEMISTRY-US, V3, P1385, DOI 10.1021/bi00897a032; Moradi-Ameli M, 2002, BIOCHEMISTRY-US, V41, P8540, DOI 10.1021/bi0110286; Nauenburg S, 2001, FASEB J, V15, P592; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Petros AM, 2001, P NATL ACAD SCI USA, V98, P3012, DOI 10.1073/pnas.041619798; Pommier Y, 2004, ONCOGENE, V23, P2934, DOI 10.1038/sj.onc.1207515; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Schmidt S, 2002, FEBS LETT, V523, P35, DOI 10.1016/S0014-5793(02)02928-9; Sun LJ, 1997, P NATL ACAD SCI USA, V94, P4919, DOI 10.1073/pnas.94.10.4919; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; Tao WK, 1997, J BIOL CHEM, V272, P15547, DOI 10.1074/jbc.272.24.15547; Walensky LD, 2004, SCIENCE, V305, P1466, DOI 10.1126/science.1099191; Wang JL, 2000, P NATL ACAD SCI USA, V97, P7124, DOI 10.1073/pnas.97.13.7124; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Zhang H, 2000, J BIOL CHEM, V275, P11092, DOI 10.1074/jbc.275.15.11092	50	12	14	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2007	26	5					701	710		10.1038/sj.onc.1209832	http://dx.doi.org/10.1038/sj.onc.1209832			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	131WM	16909120				2022-12-17	WOS:000243902200007
J	David, G; Dannenberg, JH; Simpson, N; Finnerty, PM; Miao, L; Turner, GM; Ding, Z; Carrasco, R; DePinho, RA				David, G.; Dannenberg, J. -H.; Simpson, N.; Finnerty, P. M.; Miao, L.; Turner, G. M.; Ding, Z.; Carrasco, R.; DePinho, R. A.			Haploinsufficiency of the mSds3 chromatin regulator promotes chromosomal instability and cancer only upon complete neutralization of p53	ONCOGENE			English	Article						mSin3; chromatin; histone deacetylase; mouse model; aneuploidy; p53	PERICENTRIC HETEROCHROMATIN; DEACETYLASE COMPLEX; COREPRESSOR COMPLEX; INTEGRAL COMPONENT; MAMMALIAN-CELLS; ACETYLATION; SUPPRESSOR; GROWTH; MICE; CARCINOGENESIS	The mSin3 corepressor complex has been linked to diverse cancer signaling pathways through its capacity to regulate target gene expression via chromatin modification. mSds3, a cell essential gene, is a key component of the mSin3 complex serving to maintain its inherent histone deacetylase activity. mSds3 also serves an essential role in the establishment of pericentric heterochromatin, and genetic ablation of mSds3 results in chromosome mis-segregation. In contrast, mSin3A nullizygous cells show normal chromosome dynamics and cytogenetic profiles. The integral role of mSds3 in controlling chromosome segregation and mSin3-regulated transcriptional networks prompted efforts to determine the neoplastic impact of loss of one copy of mSds3 or mSin3A. In particular, we assessed whether loss of one copy of mSds3, alone or in combination with p53 mutation, results in aneuploidy and promotes a cancer-prone condition in the mouse. We observe that, in a p53 null background, loss of one mSds3 allele results in accelerated tumor onset and increased tumor burden. Notably, these mSds3(+/-) p53(-/-) tumors exhibit a more complex cytogenetic profile characterized by marked aneuploidy and centromeric associations. The presence of even one copy of p53 is sufficient to suppress the accelerated tumorigenesis in mSds3(+/-) mice, consistent with a key role for p53 in monitoring mitotic fidelity. These observations with Sds3 mutant mice contrast with mSin3A(+/-) p53(-/-) mice, which do not show an accelerated or increased tumor incidence relative to mSin3A(+/+) p53(-/-) controls, correlating with the absence of aneuploidy detected upon mSin3A genetic inactivation. This genetic study establishes that the capacity of mSds3 to cooperate with p53 deficiency in cancer predisposition relates to its specific role in chromosome segregation, rather than its central role in maintaining a functional mSin3A complex.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; NYU, Sch Med, Dept Pharmacol, New York, NY USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Appl Canc Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Belfer Fdn Inst Innovat Canc Sci, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med & Genet, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; New York University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School	DePinho, RA (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St,Mayer 413, Boston, MA 02115 USA.	ron_depinho@dfci.harvard.edu		DePinho, Ronald/0000-0002-5625-577X; , gregory/0000-0002-3371-4558	NCI NIH HHS [R01CA86379] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA086379] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alland L, 2002, MOL CELL BIOL, V22, P2743, DOI 10.1128/MCB.22.8.2743-2750.2002; Artandi SE, 2000, CURR OPIN GENET DEV, V10, P39, DOI 10.1016/S0959-437X(99)00047-7; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bunz F, 2002, CANCER RES, V62, P1129; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Cowley SM, 2005, MOL CELL BIOL, V25, P6990, DOI 10.1128/MCB.25.16.6990-7004.2005; Dannenberg JH, 2005, GENE DEV, V19, P1581, DOI 10.1101/gad.1286905; David G, 2003, GENE DEV, V17, P2396, DOI 10.1101/gad.1109403; Dorland S, 2000, GENETICS, V154, P573; Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Ito A, 2001, EMBO J, V20, P1331, DOI 10.1093/emboj/20.6.1331; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kalitsis P, 2005, GENE CHROMOSOME CANC, V44, P29, DOI 10.1002/gcc.20215; Kuzmichev A, 2002, MOL CELL BIOL, V22, P835, DOI 10.1128/MCB.22.3.835-848.2002; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Marks PA, 2004, ADV CANCER RES, V91, P137, DOI 10.1016/S0065-230X(04)91004-4; Maser RS, 2003, CANCER CELL, V3, P4, DOI 10.1016/S1535-6108(02)00243-X; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; Xin HW, 2004, J BIOL CHEM, V279, P9539, DOI 10.1074/jbc.M311587200	26	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV	2006	25	56					7354	7360		10.1038/sj.onc.1209734	http://dx.doi.org/10.1038/sj.onc.1209734			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110ZE	16767157				2022-12-17	WOS:000242419100004
J	Sprangers, M; Feldhahn, N; Liedtke, S; Jumaa, H; Siebert, R; Muschen, M				Sprangers, M.; Feldhahn, N.; Liedtke, S.; Jumaa, H.; Siebert, R.; Mueschen, M.			SLP65 deficiency results in perpetual V(D)J recombinase activity in pre-B-lymphoblastic leukemia and B-cell lymphoma cells	ONCOGENE			English	Article						V(D)J recombination; pre-B cell receptor; leukemia; SH2-domain; DNA rearrangement	EXPRESSION; REARRANGEMENT; TRANSITION; SELECTION; RECEPTOR	Perpetual V(D)J recombinase activity involving multiple DNA double-strand break events in B-cell lineage leukemia and lymphoma cells may introduce secondary genetic aberrations leading towards malignant progression. Here, we investigated defective negative feedback signaling through the (pre-)B-cell receptor as a possible reason for deregulated V(D)J recombinase activity in B-cell malignancy. On studying 28 cases of pre-B-lymphoblastic leukemia and 27 B-cell lymphomas, expression of the (pre-) B-cell receptor-related linker molecule SLP65 (SH2 domain-containing lymphocyte protein of 65 kDa) was found to be defective in seven and five cases, respectively. SLP65 deficiency correlates with RAG1/2 expression and unremitting V-H gene rearrangement activity. Reconstitution of SLP65 expression in SLP65-deficient leukemia and lymphoma cells results in downregulation of RAG1/2 expression and prevents both de novo V-H-DJ(H) rearrangements and secondary V-H replacement. We conclude that iterative V-H gene rearrangement represents a frequent feature in B-lymphoid malignancy, which can be attributed to SLP65 deficiency in many cases.	Univ Dusseldorf, Lab Mol Stem Cell Biol, D-40225 Dusseldorf, Germany; Max Planck Inst Immunbiol, D-7800 Freiburg, Germany; Univ Hosp Schleswig, Inst Human Genet, Kiel, Germany	Heinrich Heine University Dusseldorf; Max Planck Society; University of Kiel; Schleswig Holstein University Hospital	Muschen, M (corresponding author), Univ Dusseldorf, Lab Mol Stem Cell Biol, Moorenstr 5, D-40225 Dusseldorf, Germany.	markus.mueschen@uni-duesseldorf.de	Siebert, Reiner/A-8049-2010					Feldhahn N, 2005, J EXP MED, V201, P1837, DOI 10.1084/jem.20042101; GRAWUNDER U, 1995, IMMUNITY, V3, P601, DOI 10.1016/1074-7613(95)90131-0; Hayashi K, 2003, IMMUNITY, V18, P825, DOI 10.1016/S1074-7613(03)00142-0; Height SE, 1996, BLOOD, V87, P5242, DOI 10.1182/blood.V87.12.5242.bloodjournal87125242; Imai C, 2004, LEUKEMIA, V18, P922, DOI 10.1038/sj.leu.2403349; Jumaa H, 2003, NATURE, V423, P452, DOI 10.1038/nature01608; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Klein F, 2005, J IMMUNOL, V174, P367, DOI 10.4049/jimmunol.174.1.367; Klein F, 2004, J EXP MED, V199, P673, DOI 10.1084/jem.20031637; Zhang ZX, 2003, IMMUNITY, V19, P21, DOI 10.1016/S1074-7613(03)00170-5	10	12	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 24	2006	25	37					5180	5186		10.1038/sj.onc.1209520	http://dx.doi.org/10.1038/sj.onc.1209520			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	077WZ	16636677				2022-12-17	WOS:000240063700011
J	Guo, X; Stratton, L; Schrader, JW				Guo, X.; Stratton, L.; Schrader, J. W.			Expression of activated M-Ras in hemopoietic stem cells initiates leukemogenic transformation, immortalization and preferential generation of mast cells	ONCOGENE			English	Article						M-Ras; hematopoietic stem cells; leukemia; immortalization; mast cell	GROWTH; M-RAS/R-RAS3; INDUCTION; DISTINCT; KINASE; FAMILY; MUTANT; LINE	Cultures of purified hemopoietic stem cells transduced with an activated mutant of M-Ras contained abnormal cells that, despite the presence of only low levels of growth factors, generated large, dense colonies of macrophages and blast cells. Cells from these colonies survived and grew continuously in the absence of growth factors and generated clonal cell-lines that were mainly composed of well-differentiated mast cells, with a low frequency of undifferentiated cells. When transplanted into sublethally irradiated syngeneic mice, four out of four such clones gave rise to a systemic mastocytosis and mast-cell leukemia. However, the donor clones also generated low percentages of cells with the morphological and cell-surface characteristics of erythrocytes, granulocytes, monocytes and T- and B-lymphocytes. These data indicate that signals downstream of activated M-Ras are sufficient to transform hemopoietic stem cells, and while preserving their capacity to generate other cell-lineages in vivo, result in preferential generation of mast cells.	Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada	University of British Columbia	Schrader, JW (corresponding author), Univ British Columbia, Biomed Res Ctr, 2222 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	john@brc.ubc.ca						Akin C, 2000, EXP HEMATOL, V28, P140, DOI 10.1016/S0301-472X(99)00145-9; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Cortez D, 1996, ONCOGENE, V13, P2589; Drachman JG, 2000, CURR OPIN HEMATOL, V7, P183, DOI 10.1097/00062752-200005000-00010; Ehrhardt A, 2004, MOL CELL BIOL, V24, P6311, DOI 10.1128/MCB.24.14.6311-6323.2004; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Ehrhardt GRA, 1999, BLOOD, V94, P2433, DOI 10.1182/blood.V94.7.2433.419k31_2433_2444; Guo XC, 2005, ONCOGENE, V24, P2330, DOI 10.1038/sj.onc.1208441; Guo XC, 2003, J BIOL CHEM, V278, P22237, DOI 10.1074/jbc.M300847200; Hu ZQ, 1997, BLOOD, V89, P526, DOI 10.1182/blood.V89.2.526; Jiang XY, 2002, BLOOD, V100, P3731, DOI 10.1182/blood-2002-05-1324; Kimmelman A, 1997, ONCOGENE, V15, P2675, DOI 10.1038/sj.onc.1201674; KITAMURA Y, 1979, BLOOD, V53, P492; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; Ohba Y, 2000, J BIOL CHEM, V275, P20020, DOI 10.1074/jbc.M000981200; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Wang DZ, 2000, ONCOGENE, V19, P4647, DOI 10.1038/sj.onc.1203820; Ward KR, 2004, ONCOGENE, V23, P1187, DOI 10.1038/sj.onc.1207226; Yang J, 2005, CANCER RES, V65, P939; Zhang KX, 2004, MOL CANCER RES, V2, P242	20	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2006	25	30					4241	4244		10.1038/sj.onc.1209452	http://dx.doi.org/10.1038/sj.onc.1209452			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	063GA	16501601				2022-12-17	WOS:000239004800012
J	Qiu, J; Wong, J; Tweardy, DJ; Dong, S				Qiu, J.; Wong, J.; Tweardy, D. J.; Dong, S.			Decreased intranuclear mobility of acute myeloid leukemia 1-containing fusion proteins is accompanied by reduced mobility and compartmentalization of core binding factor beta	ONCOGENE			English	Article						AML1; AML1-X; FRAP	ESTROGEN-RECEPTOR-ALPHA; TRANSCRIPTION FACTORS; GENE; AML1; ETO; ACTIVATION; REPRESSION; OLIGOMERIZATION; TRANSLOCATION; DIMERIZATION	Acute myeloid leukemia 1 (AML1) gene on chromosome 21 is involved in several chromosomal translocations, including t(8; 21) and t(16; 21), that produce chimeric fusion proteins AML1-eight twenty-one (ETO) and AML- myeloid transforming gene chromosome 16 (MTG16), which contribute to leukemogenesis. The molecular basis for the leukemogenic effects of these fusion proteins is incompletely understood. Using gel-shift assay, we showed that AML1-ETO and AML1-MTG16 bound to a series of AML1 consensus DNA-binding sites with different affinities. Using fluorescence recovery after photobleaching (FRAP), we demonstrated that a fusion of AML1 with ETO or MTG16 exhibits reduced intranuclear mobility compared with wild-type AML1 or either fusion partner. The dimerization domain (nervy homology region 2) of ETO is responsible for the reduced mobility of AML1-ETO. Dual FRAP studies revealed that CBF beta colocalized with AML1-ETO within the nucleus, resulting in reduced mobility of CBF beta. Therefore, AML1 fusion proteins may interfere with normal AML1 function due to aberrant nuclear dynamics, which leads to spatial and temporal sequestration of CBF beta and perhaps other coregulators critical for myeloid differentiation.	Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine	Dong, S (corresponding author), Baylor Coll Med, Dept Med, Infect Dis Sect, 1 Baylor Plaza,BCM 286,Room N1319, Houston, TX 77030 USA.	sdong@bcm.tmc.edu	Tweardy, David/L-3929-2019	Wong, Jiemin/0000-0002-5311-842X	NATIONAL CANCER INSTITUTE [R21CA119080] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA119080] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adya N, 1998, MOL CELL BIOL, V18, P7432, DOI 10.1128/MCB.18.12.7432; Bangsow C, 2001, GENE, V279, P221, DOI 10.1016/S0378-1119(01)00760-0; Barseguian K, 2002, P NATL ACAD SCI USA, V99, P15434, DOI 10.1073/pnas.242588499; Davis JN, 2003, GENE, V303, P1, DOI 10.1016/S0378-1119(02)01172-1; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Dong S, 2003, ONCOGENE, V22, P858, DOI 10.1038/sj.onc.1206182; Dong S, 2002, BLOOD, V99, P2637, DOI 10.1182/blood.V99.8.2637; Francastel C, 2001, P NATL ACAD SCI USA, V98, P12120, DOI 10.1073/pnas.211444898; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Harrington KS, 2002, J CELL SCI, V115, P4167, DOI 10.1242/jcs.00095; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Hinojos CAD, 2005, TRENDS ENDOCRIN MET, V16, P12, DOI 10.1016/j.tem.2004.11.006; Hug BA, 2002, CANCER RES, V62, P2906; Korgaonkar C, 2002, MOL CELL BIOL, V22, P196, DOI 10.1128/MCB.22.1.196-206.2002; Licht JD, 2001, ONCOGENE, V20, P5660, DOI 10.1038/sj.onc.1204593; Lutterbach B, 2000, GENE, V245, P223, DOI 10.1016/S0378-1119(00)00014-7; McNeil S, 1999, P NATL ACAD SCI USA, V96, P14882, DOI 10.1073/pnas.96.26.14882; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Peterson LF, 2004, ONCOGENE, V23, P4255, DOI 10.1038/sj.onc.1207727; So CW, 2004, BLOOD, V104, P919, DOI 10.1182/blood-2004-03-0992; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Tanaka K, 1998, BLOOD, V91, P1688, DOI 10.1182/blood.V91.5.1688.1688_1688_1699; Westendorf JJ, 1999, J CELL BIOCHEM, P51; Yoon HG, 2003, MOL CELL, V12, P723, DOI 10.1016/j.molcel.2003.08.008; Zaidi SK, 2002, P NATL ACAD SCI USA, V99, P8048, DOI 10.1073/pnas.112664499; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001	30	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2006	25	28					3982	3993		10.1038/sj.onc.1209431	http://dx.doi.org/10.1038/sj.onc.1209431			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	058MJ	16474840				2022-12-17	WOS:000238668800012
J	Leon, A; Omri, B; Gely, A; Klein, C; Crisanti, P				Leon, A; Omri, B; Gely, A; Klein, C; Crisanti, P			QN1/KIAA1009: a new essential protein for chromosome segregation and mitotic spindle assembly	ONCOGENE			English	Article						QN1/KIAA1009; ATPase; mitosis; microtubule-associated motor	NERVE GROWTH-FACTOR; PROLIFERATION ARREST; TRANSCRIPTION FACTOR; CELL-PROLIFERATION; CHECKPOINT; MECHANISMS; EXPRESSION; APOPTOSIS; ANAPHASE; BINDING	We previously reported the involvement of QN1 ( quail neuroretina 1) protein in cell cycle control during retinal development. We show here that QN1 is an ATPase conserved through evolution, from fugu to humans. We show that chicken/quail QN1 protein is orthologous to the KIAA1009 protein in humans, the function of which was not known. We demonstrate here for the first time that QN1/KIAA1009 protein is located at the spindle poles of the mitotic apparatus and at centrosomes during mitosis. The siRNA-mediated depletion of KIAA1009 led to abnormal mitosis with chromosome segregation defects and abnormal centrosome separation leading to the death of PC12 and MCF7 cells. Thus, QN1/KIAA1009 is a new microtubule-associated ATPase involved in cell division.	Univ Paris 06, Inst Biomed Cordeliers, INSERM U598, F-75006 Paris, France; Univ Paris 06, Paris, France; Ctr Cordeliers, IFR 58, Ctr Imagerie, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite	Crisanti, P (corresponding author), Univ Paris 06, Inst Biomed Cordeliers, INSERM U598, 15 Rue Ecole Med, F-75006 Paris, France.	plassiaz@infobiogen.fr		klein, christophe/0000-0001-8015-287X				BIDOU L, 1993, MECH DEVELOP, V43, P159, DOI 10.1016/0925-4773(93)90033-T; Bornens M, 2002, CURR OPIN CELL BIOL, V14, P25, DOI 10.1016/S0955-0674(01)00290-3; Cai ZZ, 1997, J BIOL CHEM, V272, P96; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; Crisanti P, 2001, ONCOGENE, V20, P5475, DOI 10.1038/sj.onc.1204711; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Gollapudi L, 1997, J NEUROSCI RES, V49, P461, DOI 10.1002/(SICI)1097-4547(19970815)49:4<461::AID-JNR7>3.3.CO;2-6; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hsu HL, 1996, J CELL SCI, V109, P277; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; Munnia A, 2001, ONCOGENE, V20, P4853, DOI 10.1038/sj.onc.1204650; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Neron B, 2001, MECH DEVELOP, V102, P107, DOI 10.1016/S0925-4773(01)00297-0; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Nugoli M, 2003, BMC CANCER, V3, DOI 10.1186/1471-2407-3-13; Oberdoerster J, 1998, J PHARMACOL EXP THER, V287, P359; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167	22	12	15	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 23	2006	25	13					1887	1895		10.1038/sj.onc.1209215	http://dx.doi.org/10.1038/sj.onc.1209215			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	024VQ	16302001				2022-12-17	WOS:000236224800005
J	Masselli, A; Wang, JYJ				Masselli, A; Wang, JYJ			Phosphorylation site mutated RB exerts contrasting effects on apoptotic response to different stimuli	ONCOGENE			English	Article						tetracycline-regulated gene expression; p53	RETINOBLASTOMA PROTEIN; CELL-DEATH; G(1) ARREST; INHIBITION; NECROSIS; STAUROSPORINE; ACTIVATION; CLEAVAGE; PRB; DEGRADATION	The retinoblastoma tumor-suppressor protein (RB) is an important regulator of cell cycle and apoptosis. RB is phosphorylated by cyclin-dependent protein kinase during cell cycle progression. A phosphorylation site mutated (PSM)-RB has previously been shown to cause G1 arrest and to interfere with S phase progression. In this study, we examined the effect of inducible PSM-RB expression on the apoptotic response to three different death stimuli: doxorubicin (DOXO), staurosporine (STS) and tumor necrosis factor (TNF) in Rat-16 cells. Induced expression of PSM-RB attenuated caspase activation by DOXO as a result of cell cycle arrest. STS has been shown to cause RB-dependent G1 arrest or apoptosis; however, expression of PSM-RB did not prevent caspase activation by STS. Surprisingly, induced expression of PSM-RB stimulated the apoptotic response to TNF in Rat-16 cells, which mostly undergo necrosis in the absence of PSM-RB. These results show that PSM-RB exerts disparate effects on apoptotic response to different stimuli, and that cell cycle arrest does not always associate with resistance to apoptosis.	Univ Calif San Diego, Sch Med, Div Hematol Oncol & Moores Canc Ctr, Dept Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Wang, JYJ (corresponding author), Univ Calif San Diego, Sch Med, Div Hematol Oncol & Moores Canc Ctr, Dept Med, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA.	jywang@ucsd.edu			NATIONAL CANCER INSTITUTE [R01CA058320] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA058320, CA 58320] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bosco EE, 2004, NUCLEIC ACIDS RES, V32, P25, DOI 10.1093/nar/gkg919; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; BREMNER R, 1995, MOL CELL BIOL, V15, P3256; Cauwels A, 2003, NAT IMMUNOL, V4, P387, DOI 10.1038/ni914; Chau BN, 2002, NAT CELL BIOL, V4, P757, DOI 10.1038/ncb853; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; Chen XM, 2000, JNCI-J NATL CANCER I, V92, P1999, DOI 10.1093/jnci/92.24.1999; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Darnell GA, 2003, MOL CELL BIOL, V23, P6520, DOI 10.1128/MCB.23.18.6520-6532.2003; Denecker G, 2001, CELL DEATH DIFFER, V8, P829, DOI 10.1038/sj.cdd.4400883; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Ferguson KL, 2001, NEUROREPORT, V12, pA55, DOI 10.1097/00001756-200107030-00001; GERA JF, 1993, J IMMUNOL, V151, P3746; Harbour JW, 2000, NAT CELL BIOL, V2, pE65, DOI 10.1038/35008695; Humphreys DT, 1999, CYTOKINE, V11, P773, DOI 10.1006/cyto.1998.0492; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1; Lin Y, 2004, J BIOL CHEM, V279, P10822, DOI 10.1074/jbc.M313141200; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Los M, 2002, MOL BIOL CELL, V13, P978, DOI 10.1091/mbc.01-05-0272; Mayhew CN, 2004, ONCOGENE, V23, P4107, DOI 10.1038/sj.onc.1207503; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; MORGAN DO, 1998, CANC J SCI AM S1, V4, P77; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1997, J CELL PHYSIOL, V173, P233, DOI 10.1002/(SICI)1097-4652(199711)173:2<233::AID-JCP27>3.0.CO;2-F; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Orr MS, 1998, J BIOL CHEM, V273, P3803, DOI 10.1074/jbc.273.7.3803; Panaretakis T, 2002, J BIOL CHEM, V277, P44317, DOI 10.1074/jbc.M205273200; Robertson KD, 2000, NAT GENET, V25, P338, DOI 10.1038/77124; Schneider-Brachert W, 2004, IMMUNITY, V21, P415, DOI 10.1016/j.immuni.2004.08.017; Schnier JB, 1996, P NATL ACAD SCI USA, V93, P5941, DOI 10.1073/pnas.93.12.5941; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Siu WY, 1999, FEBS LETT, V461, P299, DOI 10.1016/S0014-5793(99)01481-7; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; Wagner S, 2005, BIOCHEM PHARMACOL, V69, P1059, DOI 10.1016/j.bcp.2004.12.017; Xiao B, 2003, P NATL ACAD SCI USA, V100, P2363, DOI 10.1073/pnas.0436813100	48	12	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	2006	25	9					1290	1298		10.1038/sj.onc.1209161	http://dx.doi.org/10.1038/sj.onc.1209161			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	017QN	16205627				2022-12-17	WOS:000235708200002
J	Ishiko, J; Mizuki, M; Matsumura, I; Shibayama, H; Sugahara, H; Scholz, G; Serve, H; Kanakura, Y				Ishiko, J; Mizuki, M; Matsumura, I; Shibayama, H; Sugahara, H; Scholz, G; Serve, H; Kanakura, Y			Roles of tyrosine residues 845, 892 and 922 in constitutive activation of murine FLT3 kinase domain mutant	ONCOGENE			English	Article						FLT3; activation loop; receptor tyrosine kinase; leukemia; Hsp90; Cdc37	ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATION; RECEPTOR TYROSINE KINASE; GASTROINTESTINAL STROMAL TUMORS; C-KIT MUTATION; CELL-LINES; INSULIN-RECEPTOR; GENE; IDENTIFICATION; JUXTAMEMBRANE	FLT3 tyrosine kinase domain ( TKD) mutations are detected in similar to 7% of acute myeloid leukemia patients, and suggested to correlate with poor prognosis and confer resistance to FLT3 inhibitors. To explore activation mechanism of FLT3 TKD mutation, we analysed critical tyrosine residues for the constitutive activation and downstream signaling of the mutant by generating a series of single Tyr -> Phe substitution mutant of all 22 cytoplasmic tyrosine residues of murine FLT3 TKD-mutant (mFLT3(Asp838Val)). Tyr845Phe, Tyr892Phe and Tyr922Phe substitutions suppressed the phosphorylation of mFLT3(Asp838Val) itself, the activation of Erk1/2, STAT3 and STAT5, and the factor-independent cell proliferation and survival. In contrast, these three Tyr -> Phe mutations partially suppressed but maintained the ligand-dependent activation and anti-apoptotic activity of wild-type FLT3, suggesting that these tyrosine residues were more critical for the constitutive activation and signaling of mFLT3(Asp838Val). These three Tyr -> Phe mutations also inhibited the constitutive activation of other FLT3 mutants bearing internal tandem duplication, Asp838Tyr or Ile839del. The suppression of mFLT3(Asp838Val) activation and signaling by these substitutions was partially recovered by shifting the culture temperature from 37 to 33 degrees C, or by the introduction of Cdc37 and Hsp90. Taken together, Tyr(845), Tyr(892) and Tyr(922) are the critical residues in mFLT3(Asp838Val) activation, possibly through stabilizing the active conformation of mFLT3(Asp838Val).	Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, Suita, Osaka 5650871, Japan; Univ Melbourne, Royal Melbourne Hosp, Dept Med, Parkville, Vic 3050, Australia; Univ Munster, Dept Med Hematol & Oncol, D-48129 Munster, Germany	Osaka University; Royal Melbourne Hospital; University of Melbourne; University of Munster	Mizuki, M (corresponding author), Osaka Univ, Grad Sch Med, Dept Hematol & Oncol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	mizuki@bldon.med.osaka-u.ac.jp		ISHIKO, JUN/0000-0003-3518-5108; Scholz, Glen/0000-0003-2722-6344				Abu-Duhier FM, 2001, BRIT J HAEMATOL, V113, P983, DOI 10.1046/j.1365-2141.2001.02850.x; Abu-Duhier FM, 2000, BRIT J HAEMATOL, V111, P190, DOI 10.1046/j.1365-2141.2000.02317.x; Beslu N, 1996, J BIOL CHEM, V271, P20075, DOI 10.1074/jbc.271.33.20075; Care RS, 2003, BRIT J HAEMATOL, V121, P775, DOI 10.1046/j.1365-2141.2003.04362.x; CARLESSO N, 1994, ONCOGENE, V9, P149; Fenski R, 2000, BRIT J HAEMATOL, V108, P322; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; Griffith J, 2004, MOL CELL, V13, P169, DOI 10.1016/S1097-2765(03)00505-7; Grundler R, 2003, BLOOD, V102, P646, DOI 10.1182/blood-2002-11-3441; Hashimoto K, 2003, BLOOD, V101, P1094, DOI 10.1182/blood-2002-01-0177; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Hirota S, 2003, GASTROENTEROLOGY, V125, P660, DOI 10.1016/S0016-5085(03)01046-1; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; Kiyoi H, 1999, BLOOD, V93, P3074; Li SQ, 2003, J BIOL CHEM, V278, P26007, DOI 10.1074/jbc.M302425200; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; Ma YS, 2002, BLOOD, V99, P1741, DOI 10.1182/blood.V99.5.1741; MAYER BJ, 1986, J VIROL, V60, P858, DOI 10.1128/JVI.60.3.858-867.1986; Mizuki M, 2003, BLOOD, V101, P3164, DOI 10.1182/blood-2002-06-1677; Mohammadi M, 1996, CELL, V86, P577, DOI 10.1016/S0092-8674(00)80131-2; Moreno I, 2003, HAEMATOLOGICA, V88, P19; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; Nakao M, 1996, LEUKEMIA, V10, P1911; Reilly JT, 2002, BRIT J HAEMATOL, V116, P744, DOI 10.1046/j.0007-1048.2001.03294.x; Schnittger S, 2002, BLOOD, V100, P59, DOI 10.1182/blood.V100.1.59; Scholz G, 2000, MOL CELL BIOL, V20, P6984, DOI 10.1128/MCB.20.18.6984-6995.2000; Scholz GM, 2001, CELL GROWTH DIFFER, V12, P409; Spiekermann K, 2003, BLOOD, V101, P1494, DOI 10.1182/blood-2002-04-1045; Thiede C, 2002, BLOOD, V99, P4326, DOI 10.1182/blood.V99.12.4326; Ueda S, 2002, INT J HEMATOL, V76, P427, DOI 10.1007/BF02982808; Worobec AS, 1998, CANCER, V83, P2120, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2120::AID-CNCR10>3.0.CO;2-C; Yamamoto Y, 2001, BLOOD, V97, P2434, DOI 10.1182/blood.V97.8.2434; Yokota S, 1997, LEUKEMIA, V11, P1605, DOI 10.1038/sj.leu.2400812; Yu JC, 2003, BLOOD, V102, p348A	35	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	2005	24	55					8144	8153		10.1038/sj.onc.1208957	http://dx.doi.org/10.1038/sj.onc.1208957			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	991JL	16091740				2022-12-17	WOS:000233809400006
J	Sekine, I; Sato, M; Sunaga, N; Toyooka, S; Peyton, M; Parsons, R; Wang, WD; Gazdar, AF; Minna, JD				Sekine, I; Sato, M; Sunaga, N; Toyooka, S; Peyton, M; Parsons, R; Wang, WD; Gazdar, AF; Minna, JD			The 3p21 candidate tumor suppressor gene BAF180 is normally expressed in human lung cancer	ONCOGENE			English	Article						BAF180; lung cancer; tumor suppressor gene; chromatin remodeling factor	DNA METHYLATION; CHROMATIN; COMPLEX; HSNF5/INI1; MUTATIONS; MULTIPLE; BRG1	BAF180 encoding a subunit of the human SWI/SNF chromatin remodeling complex maps to 3p21, in a region where frequent allele loss has been detected in lung cancer. BAF180 can be mutated and has tumor suppressing properties in breast cancer. In addition, another member of this complex, hSNF5/INI1, is a known tumor suppressor gene (TSG) for malignant rhabdoid and childhood central nervous system tumors. Thus, BAF180 is a strong candidate TSG for lung cancer. The objective of this study was to determine whether BAF180 mRNA or protein expression was inactivated or abnormal in lung cancers to prompt detailed DNA promoter methylation or mutational analyses. In 30 non-small-cell and 26 small-cell lung cancer cell lines, most of which had 3p21 allele loss, BAF180 mRNA and protein expression were evaluated by RT-PCR using three sets of primers and Western blotting using two anti-BAF180 antibodies. In all cases, BAF180 was expressed and no abnormal size BAF180 protein was detected. Finally, we found no amino-acid sequence coding mutations in five non-small-cell and five small-cell lung cancer cell lines, while we did find a new splicing isoform of BAF180 (AY281068). We conclude that abnormalities of BAF180 are not frequently involved in the pathogenesis of lung cancer.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA; NIA, Genet Lab, NIH, Baltimore, MD 21224 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Minna, JD (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.	John.Minna@UTSouthwestern.edu	Peyton, Michael/A-8728-2008; Sato, MITSUO/I-7280-2014; Wang, Weidong/AAV-2446-2021	Sato, MITSUO/0000-0001-5458-9576; Wang, Weidong/0000-0002-0658-7928; Parsons, Ramon/0000-0002-6656-3514	NATIONAL CANCER INSTITUTE [R01CA071618, P50CA070907] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ae K, 2002, ONCOGENE, V21, P3112, DOI 10.1038/sj.onc.1205414; Alberts B, 2002, MOL BIOL CELL, V4th; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Flaus A, 2001, CURR OPIN GENET DEV, V11, P148, DOI 10.1016/S0959-437X(00)00172-6; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Maitra A, 2001, AM J PATHOL, V159, P119, DOI 10.1016/S0002-9440(10)61679-3; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Varga-Weisz P, 2001, ONCOGENE, V20, P3076, DOI 10.1038/sj.onc.1204332; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wistuba II, 2000, CANCER RES, V60, P1949; Wong AKC, 2000, CANCER RES, V60, P6171; Xue YT, 2000, P NATL ACAD SCI USA, V97, P13015, DOI 10.1073/pnas.240208597; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zochbauer-Muller S, 2002, ONCOLOGIST, V7, P451, DOI 10.1634/theoncologist.7-5-451	21	12	15	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 14	2005	24	16					2735	2738		10.1038/sj.onc.1207694	http://dx.doi.org/10.1038/sj.onc.1207694			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916BC	15735765				2022-12-17	WOS:000228356700015
J	Mashour, GA; Drissel, SN; Frahm, S; Farassati, F; Martuza, RL; Mautner, VF; Rohrborn, AK; Kurtz, A				Mashour, GA; Drissel, SN; Frahm, S; Farassati, F; Martuza, RL; Mautner, VF; Rohrborn, AK; Kurtz, A			Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids	ONCOGENE			English	Article						neurofibromatosis type 1; malignant peripheral nerve sheath tumor; essential fatty acids; fatty-acid binding protein; tumor growth regulation	LIPID-BINDING PROTEIN; NEUROFIBROMATOSIS TYPE-1; DOCOSAHEXAENOIC ACID; RHESUS-MONKEYS; SCHWANN-CELLS; CANCER CELLS; BRAIN; TUMORIGENESIS; EXPRESSION; OMEGA-3-FATTY-ACIDS	Neurofibromatosis type 1 (NF1) is a common genetic disorder of the nervous system resulting in neurofibromas and malignant peripheral nerve sheath tumors (MPNST). In this study, we report the modulation of murine and human MPNST cell growth by the fatty acids docosahexaenoic acid (DHA) and arachidonic acid (AA). DHA demonstrated a tendency to stimulate cell growth at low doses and induce apoptosis at high doses, paralleled by the activation of ERK and caspase-3. Furthermore, high-dose DHA reversed the stimulation of MPNST cell growth by a number of growth factors suggested to have a pathogenic effect in NF1 and inhibited MPNST growth in vivo. AA was found to have a reciprocal activity in vitro, stimulating MPNST cell growth at comparable concentrations and reducing DHA activation of ERK. These findings introduce fatty acids as a possible regulator of MPNST development in NF1 patients.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Mol Neurosurg Lab, Charlestown, MA USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Anesthesia & Crit Care, Boston, MA USA; Univ Bonn, Inst Neuropathol, D-5300 Bonn, Germany; Univ Hamburg, Dept Neurosurg, Hamburg, Germany; Klinikum Nord, Dept Neurol, Hamburg, Germany	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Bonn; University of Hamburg; Klinikum Nurnberg Nord	Kurtz, A (corresponding author), RKI, Stem Cells, Seestr 10, D-13353 Berlin, Germany.	kurtza@rki.de		Kurtz, Andreas/0000-0003-3301-6546	NINDS NIH HHS [NS37895] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS037895] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badache A, 1998, J CELL PHYSIOL, V177, P334, DOI 10.1002/(SICI)1097-4652(199811)177:2<334::AID-JCP15>3.0.CO;2-9; Brand A, 2001, J NEUROCHEM, V76, P910, DOI 10.1046/j.1471-4159.2001.00085.x; Chung BH, 2001, CARCINOGENESIS, V22, P1201, DOI 10.1093/carcin/22.8.1201; Collett ED, 2001, AM J PHYSIOL-CELL PH, V280, pC1066, DOI 10.1152/ajpcell.2001.280.5.C1066; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, P NATL ACAD SCI USA, V88, P9914, DOI 10.1073/pnas.88.22.9914; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Dugoff L, 1996, AM J MED GENET, V66, P7, DOI 10.1002/(SICI)1096-8628(19961202)66:1<7::AID-AJMG2>3.0.CO;2-R; FENG L, 1994, NEURON, V12, P895, DOI 10.1016/0896-6273(94)90341-7; Frahm S, 2004, NEUROBIOL DIS, V16, P85, DOI 10.1016/j.nbd.2004.01.006; Ghebremeskel K, 2000, LIPIDS, V35, P567, DOI 10.1007/s11745-000-557-3; Golubic M, 1998, NUTR CANCER, V30, P97, DOI 10.1080/01635589809514648; GUTMANN DH, 1991, P NATL ACAD SCI USA, V88, P9658, DOI 10.1073/pnas.88.21.9658; Hall J G, 1981, Adv Neurol, V29, P125; Hardman WE, 2002, J NUTR, V132, p3508S, DOI 10.1093/jn/132.11.3508S; Holman RT, 1998, J NUTR, V128, p427S, DOI 10.1093/jn/128.2.427S; Huson S. M., 1994, P160; HUSON SM, 1988, BRAIN, V111, P1355, DOI 10.1093/brain/111.6.1355; Isikoglu M., 2002, Archives of Gynecology and Obstetrics, V267, P41, DOI 10.1007/s004040100239; KURTZ A, 1994, DEVELOPMENT, V120, P2637; Kurtz A, 2002, J CHILD NEUROL, V17, P578, DOI 10.1177/088307380201700807; Li HZ, 2002, CANCER RES, V62, P4507; Liu GM, 2001, P NATL ACAD SCI USA, V98, P7510, DOI 10.1073/pnas.131195198; Mashour GA, 2004, CLIN CANCER RES, V10, P5677, DOI 10.1158/1078-0432.CCR-03-0769; Mashour GA, 2001, ONCOGENE, V20, P97, DOI 10.1038/sj.onc.1204026; McLaughlin ME, 2003, CANCER RES, V63, P752; Miller SJ, 2003, MOL CELL BIOL, V23, P2213, DOI 10.1128/MCB.23.6.2213-2224.2003; NEURINGER M, 1986, P NATL ACAD SCI USA, V83, P4021, DOI 10.1073/pnas.83.11.4021; NEURINGER M, 1984, J CLIN INVEST, V73, P272, DOI 10.1172/JCI111202; Pettersson F, 2004, ONCOGENE, V23, P7053, DOI 10.1038/sj.onc.1207956; REISBICK S, 1990, PHYSIOL BEHAV, V47, P315, DOI 10.1016/0031-9384(90)90149-X; RUYLE M, 1990, P NATL ACAD SCI USA, V87, P7902, DOI 10.1073/pnas.87.20.7902; Shaikh SR, 2003, BIOCHEMISTRY-US, V42, P12028, DOI 10.1021/bi034931+; SWAPP GH, 1973, BRIT J DERMATOL, V88, P431, DOI 10.1111/j.1365-2133.1973.tb15445.x; Theobald HE, 2004, AM J CLIN NUTR, V79, P558; Xu LZ, 1996, J BIOL CHEM, V271, P24711	36	12	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 31	2005	24	14					2367	2374		10.1038/sj.onc.1208425	http://dx.doi.org/10.1038/sj.onc.1208425			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	909RC	15735744				2022-12-17	WOS:000227877400009
J	Dell'Era, P; Nicoli, S; Peri, G; Nieddu, M; Ennas, MG; Presta, M				Dell'Era, P; Nicoli, S; Peri, G; Nieddu, M; Ennas, MG; Presta, M			FGF2-induced upregulation of DNA polymerase-delta p12 subunit in endothelial cells	ONCOGENE			English	Article						FGF2; DNA polymerase; endothelium; angiogenesis	FIBROBLAST-GROWTH-FACTOR; REPLICATION FORK; GENE-EXPRESSION; TUMOR ANGIOGENESIS; SURFACE EXPRESSION; IN-VITRO; IDENTIFICATION; RECONSTITUTION; MECHANISMS; ALPHA	p12 represents the smallest, so far poorly characterized subunit of the mammalian DNA polymerase delta (poldelta) heterotetramer. Previously, to gain a molecular understanding of endothelial cell activation by fibroblast growth factor-2 (FGF2), we identified an upregulated transcript in FGF2-overexpressing murine aortic endothelial cells (FGF2-T-MAE cells) showing 89% identity with human p12. Here, we cloned the open reading frame of the murine p12 cDNA and confirmed the capacity of overexpressed or exogenously added FGF2 to upregulate p12 mRNA and protein in endothelial and NIH3T3 cells with no effect on the other pold subunits. p12 expression was instead unaffected by serum and different mitogens. Also, anti-p12 antibodies decorated FGF2-T-MAE cell nuclei and their chromosome outline during metaphase. Small interfering RNA-mediated knockdown of p12 caused a significant decrease in FGF2-driven proliferation rate of FGF2-T-MAE cells, in keeping with a modulatory role of p12 in pold activity. Immunoistochemistry of FGF2-embedded Matrigel plugs and FGF2-overexpressing tumor xenografts demonstrated a nuclear p12 staining of angiogenic CD31(+) endothelium. p12 immunoreactivity was also observed in the CD45(+)/ CD11b(+) inflammatory infiltrate. Thus, FGF2 upregulates p12 expression in endothelial cells in vitro and in vivo. p12 expression in infiltrating inflammatory cells may suggest additional, cell proliferation-unrelated functions for this pold subunit.	Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, I-25123 Brescia, Italy; IRFMN Mario Negri, Milan, Italy; Univ Cagliari, Dept Sci Appl Biosyst, Unit Biol & Genet, Cagliari, Italy; Univ Cagliari, Dept Cytomorphol, Cagliari, Italy	University of Brescia; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Cagliari; University of Cagliari	Presta, M (corresponding author), Univ Brescia, Dept Biomed Sci & Biotechnol, Unit Gen Pathol & Immunol, Viale Europa 11, I-25123 Brescia, Italy.	presta@med.unibs.it	Dell'Era, Patrizia/ABD-5848-2020; Nicoli, Stefania/P-8627-2019; Presta, Marco/B-4345-2010; Dell'Era, Patrizia/N-6964-2019; Dell'Era, Patrizia/G-5294-2010	Dell'Era, Patrizia/0000-0001-6682-6321; Nieddu, Mariella/0000-0001-8595-7001; PRESTA, Marco/0000-0002-4398-8376; Ennas, Maria Grazia/0000-0002-9448-715X				BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Bastaki M, 1997, ARTERIOSCL THROM VAS, V17, P454, DOI 10.1161/01.ATV.17.3.454; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Dell'Era P, 2002, ONCOGENE, V21, P2433, DOI 10.1038/sj.onc.1205301; Dell'Era P, 2001, ONCOGENE, V20, P2655, DOI 10.1038/sj.onc.1204368; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Giavazzi R, 2001, CANCER RES, V61, P309; Glienke J, 2000, EUR J BIOCHEM, V267, P2820, DOI 10.1046/j.1432-1327.2000.01325.x; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Hughes P, 1999, NUCLEIC ACIDS RES, V27, P2108, DOI 10.1093/nar/27.10.2108; Kahn J, 2000, AM J PATHOL, V156, P1887, DOI 10.1016/S0002-9440(10)65062-6; Karthikeyan R, 2000, J MOL BIOL, V299, P405, DOI 10.1006/jmbi.2000.3744; LARSON RS, 1990, IMMUNOL REV, V114, P181, DOI 10.1111/j.1600-065X.1990.tb00565.x; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Liu L, 2000, J BIOL CHEM, V275, P18739, DOI 10.1074/jbc.M001217200; Ohsaka A, 2001, INFLAMM RES, V50, P270, DOI 10.1007/s000110050753; PASSANITI A, 1992, LAB INVEST, V67, P519; Podust VN, 2002, J BIOL CHEM, V277, P3894, DOI 10.1074/jbc.M109684200; Roland I, 2000, EUR J BIOCHEM, V267, P3567, DOI 10.1046/j.1432-1327.2000.01385.x; Sola Francesco, 1997, Angiogenesis, V1, P102, DOI 10.1023/A:1018309200629; St Croix B, 2000, SCIENCE, V289, P1197; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; Takagi S, 2000, ACTA HAEMATOL-BASEL, V103, P78, DOI 10.1159/000041024; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; Wang JL, 2000, MICROVASC RES, V59, P394, DOI 10.1006/mvre.2000.2242; Wu SM, 1998, J BIOL CHEM, V273, P9561, DOI 10.1074/jbc.273.16.9561; YANG CL, 1992, NUCLEIC ACIDS RES, V20, P735, DOI 10.1093/nar/20.4.735; ZENG XR, 1994, J BIOL CHEM, V269, P24027	32	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 3	2005	24	6					1117	1121		10.1038/sj.onc.1208359	http://dx.doi.org/10.1038/sj.onc.1208359			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	893VS	15608665				2022-12-17	WOS:000226749200019
J	Houlard, M; Romero-Portillo, F; Germani, A; Depaux, A; Regnier-Ricard, F; Gisselbrecht, S; Varin-Blank, N				Houlard, M; Romero-Portillo, F; Germani, A; Depaux, A; Regnier-Ricard, F; Gisselbrecht, S; Varin-Blank, N			Characterization of VIK-1: a new Vav-interacting Kruppel-like protein	ONCOGENE			English	Article						Vav-1 proto-oncogene; Kruppel genes; cell-cycle control	ZINC-FINGER PROTEINS; PROTOONCOGENE PRODUCT; TRANSCRIPTION FACTOR; BINDING PROTEINS; CELLS; GENE; RECEPTOR; DOMAINS; RNA; ASSOCIATION	Binding partners of the Src homology domains of Vav-1 were characterized by a two-hybrid screening of a Jurkat cell cDNA library. One of the isolated clones encoded a new protein named VIK that belongs to the Kruppel-like zinc-finger gene family. Genome mapping showed that a single gene positioned at chromosome 7q22.1 generated three possible isoforms containing alternative domains such as proline-rich and Kruppel-associated box A or B repressor domains. The isolated isoform, VIK-1, did not contain such motifs but presented six tandemly arranged zinc-fingers and consensus Kruppel H-C links. VIK-1 interacted both with Vav-1 and cyclin-dependent kinase 4 through two independent domains and corresponded to a Vav C-Src homology domain (SH)3 partner able to shuttle between the nucleus and the cytoplasm exhibiting functional nuclear addressing and export sequences. The results indicated a restricted expression of the protein during the G1 phase and its overexpression resulted in an inhibition of the cell-cycle progression that was reversed in the presence of Vav 1. Thus, this ubiquitous factor provides a first link between Vav-1 and the cell-cycle machinery.	Hop Cochin, Inst Cochin, Dept Hematol, CNRS,UMR 8104,INSERM,U567, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Varin-Blank, N (corresponding author), Hop Cochin, Inst Cochin, Dept Hematol, CNRS,UMR 8104,INSERM,U567, Batiment G Roussy,27 Rue Faubourg St Jacques, F-75014 Paris, France.	varin@cochin.inserm.fr	Romero, Francisco/K-2101-2014; Varin-Blank, Nadine/G-4396-2013	Romero, Francisco/0000-0002-9588-6881; VARIN-BLANK, Nadine/0000-0003-2769-018X				Bertagnolo V, 1998, FEBS LETT, V441, P480, DOI 10.1016/S0014-5793(98)01593-2; Bieker JJ, 2001, J BIOL CHEM, V276, P34355, DOI 10.1074/jbc.R100043200; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; BUSTELO XR, 1995, MOL CELL BIOL, V15, P1324; Casademunt E, 1999, EMBO J, V18, P6050, DOI 10.1093/emboj/18.21.6050; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Germani A, 1999, MOL CELL BIOL, V19, P3798; Germani A, 2000, ONCOGENE, V19, P5997, DOI 10.1038/sj.onc.1204002; Glassford J, 2001, J BIOL CHEM, V276, P41040, DOI 10.1074/jbc.M105305200; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Hastie ND, 2001, CELL, V106, P391, DOI 10.1016/S0092-8674(01)00469-X; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Hobert O, 1996, ONCOGENE, V12, P1577; HONDA BM, 1980, CELL, V22, P119, DOI 10.1016/0092-8674(80)90160-9; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; HUEBNER K, 1991, AM J HUM GENET, V48, P726; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6; Laity JH, 2000, J MOL BIOL, V295, P719, DOI 10.1006/jmbi.1999.3406; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; Martelli F, 2001, P NATL ACAD SCI USA, V98, P4455, DOI 10.1073/pnas.081061398; Millot GA, 2002, J CELL SCI, V115, P2329; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PANDYA K, 2002, J BIOL CHEM, V13, P13; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PREISS A, 1985, NATURE, V313, P27, DOI 10.1038/313027a0; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; Romero F, 1996, MOL CELL BIOL, V16, P37; Romero F, 1998, J BIOL CHEM, V273, P5923, DOI 10.1074/jbc.273.10.5923; Ryan RF, 1999, MOL CELL BIOL, V19, P4366; Scherer SW, 2003, SCIENCE, V300, P767, DOI 10.1126/science.1083423; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; WIESCHAUS E, 1984, DEV BIOL, V104, P172, DOI 10.1016/0012-1606(84)90046-0; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	43	12	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 6	2005	24	1					28	38		10.1038/sj.onc.1208043	http://dx.doi.org/10.1038/sj.onc.1208043			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	884ZS	15558030				2022-12-17	WOS:000226125800005
J	Haviernik, P; Lahoda, C; Bradley, HL; Hawley, TS; Ramezani, A; Hawley, RG; Stetler-Stevenson, M; Stetler-Stevenson, WG; Bunting, KD				Haviernik, P; Lahoda, C; Bradley, HL; Hawley, TS; Ramezani, A; Hawley, RG; Stetler-Stevenson, M; Stetler-Stevenson, WG; Bunting, KD			Tissue inhibitor of matrix metalloproteinase-1 overexpression in M1 myeloblasts impairs IL-6-induced differentiation	ONCOGENE			English	Article						tissue inhibitor of matrix metalloproteinase; myeloid leukemia; signal transducer and activator of transcription; retroviral vector	ERYTHROID-POTENTIATING ACTIVITY; PANCREATIC-CANCER; GROWTH-FACTOR; TUMOR-GROWTH; BONE-MARROW; CELL-DEATH; IN-VIVO; TIMP-1; EXPRESSION; LEUKEMIA	The balance between matrix metalloproteinase (MMP) and tissue inhibitor of matrix metalloproteinase ( TIMP) is important for extracellular matrix interactions of hematopoietic cells. MMP-independent growth modulating activity for TIMP-1 on B lymphocytes and erythroid progenitors has also been described, but a role for TIMP-1 in myelomonocytic differentiation has not been previously reported. In this study, we demonstrate that TIMP-1 overexpression impairs differentiation of the myeloblastic M1 cell line following interleukin (IL)-6 stimulation. We generated retroviral vectors coexpressing human TIMP-1 and the green fluorescent protein (GFP) and stably transduced murine M1 myeloid cells. TIMP-1 expressing cells showed a large reduction in IL-6-induced macrophage differentiation in vitro that was reversible with a specific monoclonal antibody. The differentiation delay in M1/TIMP-1 cells was also specifically reversible by pharmacologic phosphatidylinositol-3 kinase (PI3-K) inhibition. Additionally, overexpression of a TIMP-1/GFP fusion protein also impaired M1 differentiation and this protein was localized to the cell surface, consistent with an autocrine receptor-mediated mechanism. Surprisingly, TIMP-1 transduced cells had a selective advantage for growth in IL-6, indicating that functional effects on growth and differentiation of M1 cells were primarily through an autocrine mechanism. Intrinsic TIMP-1 expression in myeloid leukemia cells might thus impact upon survival or differentiation.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Hematopoiesis Dept, Rockville, MD 20855 USA; George Washington Univ, Inst Biomed Sci, Genet Program, Washington, DC 20037 USA; Amer Red Cross, Jerome H Holland Lab Biomed Sci, Flow Cytometry Facil, Rockville, MD 20855 USA; George Washington Univ, Dept Anat & Cell Biol, Washington, DC 20037 USA; NIH, Flow Cytometry Unit, Pathol Lab, Div Clin Sci, Bethesda, MD 20892 USA; NIH, Extracellular Matrix Sect, Pathol Lab, Div Clin Sci, Bethesda, MD 20892 USA	American Red Cross; George Washington University; American Red Cross; George Washington University; National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Bunting, KD (corresponding author), Case Western Reserve Univ, Div Hematol Oncol, 10900 Euclid Ave WRB2, Cleveland, OH 44106 USA.	kevin.bunting@case.edu	Stetler-Stevenson, William G/H-6956-2012; Stetler-Stevenson, Maryalice/AAV-7393-2020; Stetler-Stevenson, William/AAE-3501-2020	Stetler-Stevenson, William G/0000-0002-5500-5808; Stetler-Stevenson, William/0000-0002-5500-5808; Bradley, Heath/0000-0001-5796-7595; Hawley, Robert/0000-0003-3512-5818	DIVISION OF CLINICAL SCIENCES - NCI [Z01SC009373] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [ZIASC009179, Z01SC009179] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R21HL071171, R01HL073738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059380] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL073738, R21HL071171] Funding Source: Medline; NIDDK NIH HHS [R01DK059380] Funding Source: Medline	DIVISION OF CLINICAL SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVALOS BR, 1988, BLOOD, V71, P1720; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; Bloomston M, 2002, J SURG RES, V102, P39, DOI 10.1006/jsre.2001.6318; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; CHESLER L, 1995, BLOOD, V86, P4506, DOI 10.1182/blood.V86.12.4506.bloodjournal86124506; de Bont ESJM, 2001, BRIT J HAEMATOL, V113, P296, DOI 10.1046/j.1365-2141.2001.02722.x; DOCHERTY AJP, 1985, NATURE, V318, P66, DOI 10.1038/318066a0; GASSON JC, 1985, NATURE, V315, P768, DOI 10.1038/315768a0; GEWERT DR, 1987, EMBO J, V6, P651, DOI 10.1002/j.1460-2075.1987.tb04804.x; GOLDE DW, 1980, P NATL ACAD SCI-BIOL, V77, P593, DOI 10.1073/pnas.77.1.593; Gronning LM, 2000, BIOL REPROD, V62, P1040, DOI 10.1095/biolreprod62.4.1040; Guedez L, 1996, CRIT REV ONCOGENESIS, V7, P205, DOI 10.1615/CritRevOncog.v7.i3-4.40; Guedez L, 2001, BLOOD, V97, P1796, DOI 10.1182/blood.V97.6.1796; Guedez L, 1998, J CLIN INVEST, V102, P2002, DOI 10.1172/JCI2881; Guedez L, 1998, BLOOD, V92, P1342, DOI 10.1182/blood.V92.4.1342.416k22_1342_1349; HAYAKAWA T, 1992, FEBS LETT, V298, P29, DOI 10.1016/0014-5793(92)80015-9; Hoegy SE, 2001, J BIOL CHEM, V276, P3203, DOI 10.1074/jbc.M008157200; Ismair MG, 1998, LEUKEMIA, V12, P1136, DOI 10.1038/sj.leu.2401042; Janowska-Wieczorek A, 1999, BRIT J HAEMATOL, V105, P402, DOI 10.1046/j.1365-2141.1999.01352.x; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; KHOKHA R, 1994, J NATL CANCER I, V86, P299, DOI 10.1093/jnci/86.4.299; KOOP S, 1994, CANCER RES, V54, P4791; Krishnaraju K, 1998, BLOOD, V92, P1957, DOI 10.1182/blood.V92.6.1957.418k24_1957_1966; Kruger A, 1997, BLOOD, V90, P1993, DOI 10.1182/blood.V90.5.1993; Lambert E, 2003, BIOCHEM J, V372, P767, DOI 10.1042/BJ20030187; Li GY, 1999, CANCER RES, V59, P6267; Lin LI, 2002, BRIT J HAEMATOL, V117, P835, DOI 10.1046/j.1365-2141.2002.03510.x; Liu XW, 2003, J BIOL CHEM, V278, P40364, DOI 10.1074/jbc.M302999200; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NISKANEN E, 1988, BLOOD, V72, P806; NISKANEN E, 1990, EUR J HAEMATOL, V45, P267; Persons DA, 1999, BLOOD, V93, P488, DOI 10.1182/blood.V93.2.488.402k17_488_499; Persons DA, 1998, BLOOD CELL MOL DIS, V24, P167, DOI 10.1006/bcmd.1998.0184; Ries C, 1999, CLIN CANCER RES, V5, P1115; Rigg AS, 2001, CANCER GENE THER, V8, P869, DOI 10.1038/sj.cgt.7700387; Ritter LM, 1999, BIOCHEM BIOPH RES CO, V257, P494, DOI 10.1006/bbrc.1999.0408; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Soloway PD, 1996, ONCOGENE, V13, P2307; STRIFE A, 1987, BLOOD, V69, P1508; Watanabe M, 1996, CANCER, V77, P1676, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1676::AID-CNCR14>3.3.CO;2-#; Yamauchi K, 2001, SURG TODAY, V31, P791, DOI 10.1007/s005950170049; Zhang JY, 2001, LEUKEMIA RES, V25, P463, DOI 10.1016/S0145-2126(00)00157-0; Zhao WQ, 1998, J CELL SCI, V111, P1147	44	12	17	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2004	23	57					9212	9219		10.1038/sj.onc.1208096	http://dx.doi.org/10.1038/sj.onc.1208096			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	878HR	15516987				2022-12-17	WOS:000225638000006
J	Klucky, B; Koch, B; Radolf, M; Steinlein, P; Wintersberger, E				Klucky, B; Koch, B; Radolf, M; Steinlein, P; Wintersberger, E			Polyomavirus tumorantigens have a profound effect on gene expression in mouse fibroblasts	ONCOGENE			English	Article						T antigens; microarray; gene expression	LARGE T-ANTIGEN; SIMIAN-VIRUS-40 SMALL-T; HUMAN CELL-TRANSFORMATION; CYCLIN-A; TRANS-ACTIVATION; MIDDLE-T; S-PHASE; PROTEIN; GROWTH; TRANSACTIVATION	Polyomavirus (Pv) large and small tumorantigens together are competent to induce S phase in growth-arrested mouse fibroblasts. The capacity of the large tumorantigen to bind the pocket proteins, pRB, p130 and p107, is important for the transactivation of DNA synthesis enzymes and the cyclins E and A, while the interference of small tumorantigen with protein phosphatase PP2A causes a destabilization of the cdk2 inhibitor p27, and thus leads to strong cyclin E- and cyclin A-dependent cdk2 activity. Py small tumorantigen, in addition, is able to transactivate cyclin A. Hence, this protein might have a much wider effect on gene expression in arrested mouse fibroblasts than hitherto suspected. This may have a profound part in the known capacity of Py to form tumors in mice. Therefore, it was interesting to gain an insight into the spectrum of transcriptional deregulation by Py tumorantigens. Accordingly, we performed microarray analysis of quiescent mouse fibroblasts in the absence and presence of small or large tumorantigen. We found that the viral proteins can induce or repress a great variety of genes beyond those involved in the S phase induction and DNA synthesis. The results of the microarray analysis were confirmed for selected genes by several methods, including real-time PCR. Interestingly, a mutation of the binding site for pocket proteins in case of LT and for PP2A in case of ST has a variable effect on the deregulation of genes by the viral proteins depending on the gene in question. In fact, some genes are transactivated by LT as well as ST completely independent of an interaction with their major cellular targets, pocket proteins and PP2A, respectively.	Med Univ Vienna, Div Mol Biol, Inst Med Biochem, A-1030 Vienna, Austria; Inst Mol Pathol, A-1030 Vienna, Austria	Medical University of Vienna; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Wintersberger, E (corresponding author), Med Univ Vienna, Div Mol Biol, Inst Med Biochem, Dr Bohrgasse 9, A-1030 Vienna, Austria.	Erhard.Wintersberger@univie.ac.at		Koch, Birgit/0000-0003-4683-3115				ADAMCZEWSKI JP, 1993, J VIROL, V67, P6551, DOI 10.1128/JVI.67.11.6551-6557.1993; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Benjamin TL, 2001, VIROLOGY, V289, P167, DOI 10.1006/viro.2001.1124; BIKEL I, 1992, J VIROL, V66, P1489, DOI 10.1128/JVI.66.3.1489-1494.1992; CAMPBELL KS, 1995, J VIROL, V69, P3721, DOI 10.1128/JVI.69.6.3721-3728.1995; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Damania B, 1998, MOL CELL BIOL, V18, P3926, DOI 10.1128/MCB.18.7.3926; Eckner R, 1996, MOL CELL BIOL, V16, P3454; Felton-Edkins ZA, 2002, J BIOL CHEM, V277, P48182, DOI 10.1074/jbc.M201333200; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; FROST JA, 1994, MOL CELL BIOL, V14, P6244, DOI 10.1128/MCB.14.9.6244; Gottlieb KA, 2001, MICROBIOL MOL BIOL R, V65, P288, DOI 10.1128/MMBR.65.2.288-318.2001; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Kino T, 2001, GENES CELLS, V6, P441, DOI 10.1046/j.1365-2443.2001.00432.x; Kresse H, 2001, J CELL PHYSIOL, V189, P266, DOI 10.1002/jcp.10030; Lecanda F, 2000, J CELL BIOCHEM, V77, P499, DOI 10.1002/(SICI)1097-4644(20000601)77:3<499::AID-JCB14>3.0.CO;2-0; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; LOEKEN MR, 1992, J VIROL, V66, P2551, DOI 10.1128/JVI.66.4.2551-2555.1992; LUKAS J, 1994, J CELL BIOL, V125, P625, DOI 10.1083/jcb.125.3.625; LUTCHMAN M, 1995, CANCER RES, V55, P2270; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MUDRAK I, 1994, MOL CELL BIOL, V14, P1886, DOI 10.1128/MCB.14.3.1886; Nemethova M, 1999, J VIROL, V73, P1734, DOI 10.1128/JVI.73.2.1734-1739.1999; OGRIS E, 1993, J VIROL, V67, P1765, DOI 10.1128/JVI.67.4.1765-1771.1993; OGRIS E, 1993, ONCOGENE, V8, P1277; OGRIS E, 1992, J VIROL, V66, P53, DOI 10.1128/JVI.66.1.53-61.1992; Ohtani K, 1999, ONCOGENE, V18, P2299, DOI 10.1038/sj.onc.1202544; PIPAS JM, 1992, J VIROL, V66, P3979, DOI 10.1128/JVI.66.7.3979-3985.1992; Porras A, 1996, J VIROL, V70, P6902; Porras A, 1999, J VIROL, V73, P3102; Sambrook J, 1989, MOL CLONING LAB MANU; Schuchner S, 2001, J VIROL, V75, P6498, DOI 10.1128/JVI.75.14.6498-6507.2001; Schuchner S, 1999, J VIROL, V73, P9266; Shin CS, 2000, J CELL BIOCHEM, V78, P566, DOI 10.1002/1097-4644(20000915)78:4<566::AID-JCB6>3.0.CO;2-K; SONNTAG E, 1993, CELL, V75, P887; Stander M, 1999, CELL TISSUE RES, V296, P221, DOI 10.1007/s004410051283; Tsuruga H, 1997, GENES CELLS, V2, P381, DOI 10.1046/j.1365-2443.1997.1290327.x; Watanabe G, 1996, P NATL ACAD SCI USA, V93, P12861, DOI 10.1073/pnas.93.23.12861; Yu J, 2001, VIROLOGY, V290, P192, DOI 10.1006/viro.2001.1204	41	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2004	23	27					4707	4721		10.1038/sj.onc.1207640	http://dx.doi.org/10.1038/sj.onc.1207640			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	825ZX	15122341				2022-12-17	WOS:000221799200006
J	Little, KC; Chartrand, P				Little, KC; Chartrand, P			Genomic DNA is captured and amplified during double-strand break (DSB) repair in human cells	ONCOGENE			English	Article						DNA repair; human genome; double-strand break (DSB); amplification; SV40	ATAXIA-TELANGIECTASIA; INTEGRATION SITE; MAMMALIAN CHROMOSOME; BROKEN CHROMOSOMES; SIMIAN-VIRUS-40; SV40; SEQUENCES; IDENTIFICATION; AMPLIFICATION; EXPRESSION	Genomic stability is maintained by the surveillance and repair of DNA damage. Here, we describe a mechanism whereby repair of extrachromosomal DNA double-strand breaks (DSBs) in human cells can be accompanied by capture of genomic DNA fragments. The availability of the human genome sequence enabled us to characterize these inserts in cells from a normal individual and from a patient with ataxia telangiectasia ( AT), deficient for the damage response kinase ATM and prone to genomic instability. We find AT cells exhibit insertions of human chromosomal DNA fragments in excess of 17 kb during DSB repair, whereas we detected no such genomic inserts in normal cells. However, the presence of simian virus 40 (SV40), used to transform these cell lines, resulted in capture of genomic DNA associated with sites of viral integration in both cell types. The genomic instability at sites of SV40 integration was exported to other sites of DNA damage, and acquisition of the viral origin of replication resulted in gene amplification through autonomous replication of the plasmid harbouring the repaired extrachromosomal DSB. Should this same phenomenon apply to the repair of chromsomal DSBs, genome rearrangements made possible via this DSB insertional repair pose risks to genomic integrity, and may contribute to tumorigenic progression.	Hop Notre Dame de Bon Secours, Ctr Rech CHUM, Montreal, PQ H2L 4M1, Canada; McGill Univ, Dept Med, Div Expt Med, Montreal, PQ H3A 1A3, Canada; Univ Montreal, Inst Canc Montreal, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H2L 4M1, Canada	Universite de Montreal; McGill University; Universite de Montreal; Universite de Montreal	Chartrand, P (corresponding author), Hop Notre Dame de Bon Secours, Ctr Rech CHUM, 1560 Rue Sherbrooke Est,Room Y4622, Montreal, PQ H2L 4M1, Canada.	pierre.chartrand@umontreal.ca						Allen C, 2003, DNA REPAIR, V2, P1147, DOI 10.1016/S1568-7864(03)00139-3; BENNER SE, 1991, ANTI-CANCER DRUG, V2, P11, DOI 10.1097/00001813-199102000-00002; Carbone M, 2003, INT J CANCER, V106, P140, DOI 10.1002/ijc.11189; Corbin S, 2002, CANCER RES, V62, P3477; COX R, 1986, MOL BIOL MED, V3, P229; CROCE CM, 1977, P NATL ACAD SCI USA, V74, P315, DOI 10.1073/pnas.74.1.315; Dar ME, 1997, MUTAT RES-DNA REPAIR, V384, P169, DOI 10.1016/S0921-8777(97)00021-9; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Garcea RL, 2003, J VIROL, V77, P5039, DOI 10.1128/JVI.77.9.5039-5045.2003; Gazdar AF, 2002, NAT REV CANCER, V2, P957, DOI 10.1038/nrc947; Gorbunova V, 1997, NUCLEIC ACIDS RES, V25, P4650, DOI 10.1093/nar/25.22.4650; HARA H, 1987, EXP CELL RES, V168, P531, DOI 10.1016/0014-4827(87)90025-5; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Huang KC, 1999, VIROLOGY, V262, P457, DOI 10.1006/viro.1999.9952; HWANG SP, 1980, VIROLOGY, V105, P196, DOI 10.1016/0042-6822(80)90167-1; Jasani B, 2001, SEMIN CANCER BIOL, V11, P49, DOI 10.1006/scbi.2000.0346; KAO CH, 1993, GENE CHROMOSOME CANC, V8, P155, DOI 10.1002/gcc.2870080304; KUCHERLAPATI R, 1978, P NATL ACAD SCI USA, V75, P4460, DOI 10.1073/pnas.75.9.4460; Lednicky JA, 1997, J GEN VIROL, V78, P1697, DOI 10.1099/0022-1317-78-7-1697; Li YL, 2001, ENVIRON MOL MUTAGEN, V37, P128, DOI 10.1002/em.1020; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Lin YF, 2001, NUCLEIC ACIDS RES, V29, P3975, DOI 10.1093/nar/29.19.3975; Lin YF, 2001, GENETICS, V158, P1665; Lobrich M, 2000, GENE CHROMOSOME CANC, V27, P59; MARLHENS F, 1988, ANN GENET-PARIS, V31, P81; MAULBECKER C, 1992, J VIROL, V66, P2195, DOI 10.1128/JVI.66.4.2195-2207.1992; Mendoza SM, 1998, ONCOGENE, V17, P2457, DOI 10.1038/sj.onc.1202179; MEYN MS, 1993, SCIENCE, V260, P1327, DOI 10.1126/science.8493577; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; MURNANE JP, 1985, EXP CELL RES, V158, P119, DOI 10.1016/0014-4827(85)90437-9; Popescu NC, 2003, CANCER LETT, V192, P1, DOI 10.1016/S0304-3835(02)00596-7; POWELL S, 1993, MUTAT RES, V294, P9, DOI 10.1016/0921-8777(93)90053-J; RABIN M, 1984, J VIROL, V49, P445, DOI 10.1128/JVI.49.2.445-451.1984; Ricchetti M, 1999, NATURE, V402, P96, DOI 10.1038/47076; ROSCHEISEN C, 1994, SOMAT CELL MOLEC GEN, V20, P493, DOI 10.1007/BF02255840; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; RUNGER TM, 1992, MUTAT RES, V293, P47, DOI 10.1016/0921-8777(92)90007-P; Salomon S, 1998, EMBO J, V17, P6086, DOI 10.1093/emboj/17.20.6086; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; Schwab M, 1998, BIOESSAYS, V20, P473, DOI 10.1002/(SICI)1521-1878(199806)20:6<473::AID-BIES5>3.3.CO;2-N; Shera KA, 2001, J VIROL, V75, P12339, DOI 10.1128/JVI.75.24.12339-12346.2001; Shivapurkar N, 2002, LANCET, V359, P851, DOI 10.1016/S0140-6736(02)07921-7; Singer MJ, 2000, P NATL ACAD SCI USA, V97, P7921, DOI 10.1073/pnas.130194897; Stewart AR, 1998, J NEUROVIROL, V4, P182; Tachibana A, 2002, BIOCHEM BIOPH RES CO, V297, P275, DOI 10.1016/S0006-291X(02)02191-5; TATSUMIMIYAJIMA J, 1993, MUTAT RES, V294, P317, DOI 10.1016/0921-8777(93)90014-8; Testa JR, 1998, CANCER RES, V58, P4505; Valerie K, 2003, ONCOGENE, V22, P5792, DOI 10.1038/sj.onc.1206679; Vilchez RA, 2003, AM J MED, V114, P675, DOI 10.1016/S0002-9343(03)00087-1; Vilenchik MM, 2003, P NATL ACAD SCI USA, V100, P12871, DOI 10.1073/pnas.2135498100; Wurtele H, 2003, GENE THER, V10, P1791, DOI 10.1038/sj.gt.3302074; YANO O, 1991, CELL STRUCT FUNCT, V16, P63, DOI 10.1247/csf.16.63; Yu X, 1999, MOL CELL, V4, P873, DOI 10.1016/S1097-2765(00)80397-4; Zhou Y, 2003, CANCER RES, V63, P5781	54	12	12	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2004	23	23					4166	4172		10.1038/sj.onc.1207570	http://dx.doi.org/10.1038/sj.onc.1207570			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	822ER	15048077				2022-12-17	WOS:000221520200015
J	Spurgers, KB; Coombes, KR; Meyn, RE; Gold, DL; Logothetis, CJ; Johnson, TJ; McDonnell, TJ				Spurgers, KB; Coombes, KR; Meyn, RE; Gold, DL; Logothetis, CJ; Johnson, TJ; McDonnell, TJ			A comprehensive assessment of p53-responsive genes following adenoviral-p53 gene transfer in Bcl-2-expressing prostate cancer cells	ONCOGENE			English	Article						p53; bcl-2; apoptosis; cell cycle; transcriptome; genomics; adenovirus	WILD-TYPE P53; TUMOR-SUPPRESSOR P53; TRANSCRIPTIONAL REPRESSION; P53-DEPENDENT APOPTOSIS; SUPEROXIDE-DISMUTASE; DEATH INDUCTION; DOWN-REGULATION; 26S PROTEASOME; BREAST-CANCER; BCL-2 FAMILY	The p53 protein can induce cell cycle arrest or apoptosis following activation in response to DNA damage. The function of p53 is largely mediated by regulating the expression of downstream target genes. Adenoviral- p53 gene transfer (Ad-p53) is currently being evaluated in clinical trials as a therapeutic intervention. Tumor response is likely to be influenced by context-dependent variables, such as expression of bcl-2. Bcl-2 is upregulated in a variety of neoplasms, and can inhibit p53-dependent apoptosis. It was therefore of interest to use a global genomic strategy to assess gene expression following Ad-p53 gene transfer and to determine if the expression of specific Ad-p53-responsive genes could be modulated in the context of bcl-2 gene deregulation. cDNA arrays were used to identify p53-responsive genes following Ad-p53 gene transfer in control and bcl-2-overexpressing PC3 prostate cancer cells. A total of 40 transcripts were significantly upregulated by Ad-p53 in both control and bcl-2-transfectant PC3 cells. Conversely, 19 transcripts were significantly repressed in both cell lines. These Adp53-responsive transcripts included previously identified p53 targets, known genes representing candidate p53 targets, and transcripts identified as expressed sequence tags. A subset of 15 transcripts was differentially modulated by Ad-p53 in the context of bcl-2. Some of these genes were also differentially modulated in LNCaP (wt p53) cells following DNA damage. These results document a number of potential p53 targets and mediators of therapeutically relevant genotoxic stress. The findings further suggest that bcl-2 may inhibit cell death at multiple points downstream of p53 activation.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	McDonnell, TJ (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 89,1515 Holcombe Blvd, Houston, TX 77030 USA.	tmcdonne@mdanderson.org		Coombes, Kevin/0000-0002-7630-2123	NATIONAL CANCER INSTITUTE [T32CA060440, P01CA078778, P50CA090270] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90270, P01 CA78778, CA60440] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Amstad PA, 2001, REDOX REP, V6, P351, DOI 10.1179/135100001101536535; [Anonymous], 2003, BIODRUGS, V17, P216; Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Beham A, 1997, ONCOGENE, V15, P2767, DOI 10.1038/sj.onc.1201464; Beham AW, 1998, INT J MOL MED, V1, P953; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruckheimer EM, 2000, ONCOGENE, V19, P5251, DOI 10.1038/sj.onc.1203881; Buzek J, 2002, NUCLEIC ACIDS RES, V30, P2340, DOI 10.1093/nar/30.11.2340; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CARROLL AG, 1993, PROSTATE, V23, P123, DOI 10.1002/pros.2990230206; Chen J, 2000, NEOPLASIA, V2, P235, DOI 10.1038/sj.neo.7900091; Chen SR, 2003, FREE RADICAL BIO MED, V34, P1315, DOI 10.1016/S0891-5849(03)00146-1; Clayman GL, 1999, CLIN CANCER RES, V5, P1715; Clayman GL, 1998, J CLIN ONCOL, V16, P2221, DOI 10.1200/JCO.1998.16.6.2221; Ding HF, 2000, J BIOL CHEM, V275, P38905, DOI 10.1074/jbc.M004714200; Dummer R, 2000, CANCER GENE THER, V7, P1069, DOI 10.1038/sj.cgt.7700214; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; FRITSCHE M, 1993, ONCOGENE, V8, P307; Froesch BA, 1999, J BIOL CHEM, V274, P6469, DOI 10.1074/jbc.274.10.6469; HAINAUT P, 1993, CANCER RES, V53, P4469; HALL PA, 1993, ONCOGENE, V8, P203; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Herrmann JL, 1997, EXP CELL RES, V237, P101, DOI 10.1006/excr.1997.3737; Herrmann JL, 1998, ONCOGENE, V17, P2889, DOI 10.1038/sj.onc.1202221; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda T, 2002, CANCER BIOL THER, V1, P163, DOI 10.4161/cbt.63; HOROSZEWICZ JS, 1983, CANCER RES, V43, P1809; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; ISAACS WB, 1991, CANCER RES, V51, P4716; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; KAIGHN ME, 1979, INVEST UROL, V17, P16; KASTAN MB, 1991, CANCER RES, V51, P6304; Kovach JS, 1996, P NATL ACAD SCI USA, V93, P1093, DOI 10.1073/pnas.93.3.1093; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lang FF, 2003, J CLIN ONCOL, V21, P2508, DOI 10.1200/JCO.2003.21.13.2508; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Lowe SW, 1999, CANC DRUG DISC DEV, V5, P21; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MacCarthy-Morrogh L, 1999, BIOCHEM SOC T, V27, P785, DOI 10.1042/bst0270785; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; Mano Y, 1999, EUR J CANCER, V35, P1214, DOI 10.1016/S0959-8049(99)00124-0; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Moul JV, 1999, EUR UROL, V35, P399, DOI 10.1159/000019916; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Murphy M, 1996, GENE DEV, V10, P2971, DOI 10.1101/gad.10.23.2971; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Olie RA, 2000, CANCER RES, V60, P2805; Pagliaro LC, 2000, WORLD J UROL, V18, P148, DOI 10.1007/s003450050188; Pearson GD, 1998, J BIOL CHEM, V273, P5431, DOI 10.1074/jbc.273.10.5431; Pirollo KF, 2000, ANTI-CANCER DRUG, V11, P419, DOI 10.1097/00001813-200007000-00002; Pollack A, 2003, CANCER-AM CANCER SOC, V97, P1630, DOI 10.1002/cncr.11230; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Robles AI, 2001, CANCER RES, V61, P6660; Rodriguez-Villanueva J, 1998, ONCOGENE, V16, P853, DOI 10.1038/sj.onc.1201610; RUBIN SJ, 1991, J SURG ONCOL, V46, P31, DOI 10.1002/jso.2930460108; Schuler M, 2001, BIOCHEM SOC T, V29, P684, DOI 10.1042/0300-5127:0290684; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Schumacher G, 2001, INT J CANCER, V91, P159, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1026>3.3.CO;2-E; Sheikh MS, 2000, LEUKEMIA, V14, P1509, DOI 10.1038/sj.leu.2401865; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Swisher Stephen G, 2002, Surg Oncol Clin N Am, V11, P521, DOI 10.1016/S1055-3207(02)00028-5; Tanaka K, 1997, MOL BIOL REP, V24, P3, DOI 10.1023/A:1006876904158; TROY CM, 1994, P NATL ACAD SCI USA, V91, P6384, DOI 10.1073/pnas.91.14.6384; Voehringer DW, 2000, ANTIOXID REDOX SIGN, V2, P537, DOI 10.1089/15230860050192314; Voehringer DW, 1999, FREE RADICAL BIO MED, V27, P945, DOI 10.1016/S0891-5849(99)00174-4; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; Wang LQ, 2001, J BIOL CHEM, V276, P43604, DOI 10.1074/jbc.M106570200; Wen SF, 2003, CANCER GENE THER, V10, P224, DOI 10.1038/sj.cgt.7700562; Zhan QM, 1999, ONCOGENE, V18, P297, DOI 10.1038/sj.onc.1202310; ZHANG WW, 1995, HUM GENE THER, V6, P155, DOI 10.1089/hum.1995.6.2-155; ZHANG WW, 1994, CANCER GENE THER, V1, P5; Zhao RB, 2000, GENE DEV, V14, P981	97	12	14	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2004	23	9					1712	1723		10.1038/sj.onc.1207293	http://dx.doi.org/10.1038/sj.onc.1207293			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	800LH	14647426				2022-12-17	WOS:000220029300007
J	Reliene, R; Schiestl, RH				Reliene, R; Schiestl, RH			Mouse models for induced genetic instability at endogenous loci	ONCOGENE			English	Review						genetic instability; homologous recombination; DNA deletions; in vivo; mouse; mutagenicity test	EYED UNSTABLE MUTATION; RETINAL-PIGMENT EPITHELIUM; PRADER-WILLI SYNDROME; INDUCED INTRACHROMOSOMAL RECOMBINATION; CREST-DERIVED MELANOCYTES; LACZ TRANSGENIC MICE; MAMMALIAN SPOT-TEST; SEVERE HEMOPHILIA-A; ATM-DEFICIENT MICE; DNA DOUBLE-STRAND	Exposure to environmental factors and genetic predisposition of an individual may lead individually or in combination to various genetic diseases including cancer. These diseases may be a consequence of genetic instability resulting in large-scale genomic rearrangements, such as DNA deletions, duplications, and translocations. This review focuses on mouse assays detecting genetic instability at endogenous loci. The frequency of DNA deletions by homologous recombination at the pink-eyed unstable ( pun) locus is elevated in mice with mutations in ATM, Trp53, Gadd45, and WRN genes and after exposure to carcinogens. Other quantitative in vivo assays detecting loss of heterozygosity events, such as the mammalian spot assay, Dlb-1 mouse and Aprt mouse assays, are also reviewed. These in vivo test systems may predict hazardous effects of an environmental agent and/or genetic predisposition to cancer.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Environm Hlth, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiat Oncol, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Schiestl, RH (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol, 650 Charles E Young Dr S, Los Angeles, CA 90024 USA.		Reliene, Ramune/AAK-3492-2021		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009519, K02ES000299] Funding Source: NIH RePORTER; NIEHS NIH HHS [KO2 ES00299, R01 ES09519] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMES BN, 1975, MUTAT RES, V31, P347, DOI 10.1016/0165-1161(75)90046-1; ASHBY J, 1991, MUTAT RES, V257, P229, DOI 10.1016/0165-1110(91)90003-E; Aubrecht J, 1999, CARCINOGENESIS, V20, P2229, DOI 10.1093/carcin/20.12.2229; AUBRECHT J, 1995, CARCINOGENESIS, V16, P2841, DOI 10.1093/carcin/16.11.2841; BALLABIO A, 1990, GENOMICS, V8, P263, DOI 10.1016/0888-7543(90)90281-X; Barber R, 2002, P NATL ACAD SCI USA, V99, P6877, DOI 10.1073/pnas.102015399; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; BARTSCH H, 1980, IARC SCI PUBL, V27, P179; Bishop AJR, 2000, CANCER RES, V60, P395; Bishop AJR, 2001, CARCINOGENESIS, V22, P641, DOI 10.1093/carcin/22.4.641; Bishop AJR, 2000, MUTAT RES-FUND MOL M, V457, P31, DOI 10.1016/S0027-5107(00)00118-4; BISHOP AJR, 2003, IN PRESS; BODENSTEIN L, 1987, DEV BIOL, V121, P192, DOI 10.1016/0012-1606(87)90152-7; Brennan RJ, 1998, MUTAT RES-FUND MOL M, V403, P65, DOI 10.1016/S0027-5107(98)00050-5; Brennan RJ, 1997, MUTAT RES-FUND MOL M, V381, P251, DOI 10.1016/S0027-5107(97)00201-7; Brennan RJ, 1996, MUTAT RES-FUND MOL M, V356, P171, DOI 10.1016/0027-5107(96)00051-6; Brennan RJ, 1998, MUTAT RES-FUND MOL M, V397, P271, DOI 10.1016/S0027-5107(97)00225-X; BRENNAN RJ, 1994, MUTAT RES, V308, P159, DOI 10.1016/0027-5107(94)90151-1; Brennan RJ, 1997, MUTAGENESIS, V12, P215, DOI 10.1093/mutage/12.4.215; Brennan RJ, 1999, MUTAT RES-FUND MOL M, V430, P37, DOI 10.1016/S0027-5107(99)00118-9; BRILLIANT MH, 1991, SCIENCE, V252, P566, DOI 10.1126/science.1673574; Brooks RA, 1999, CARCINOGENESIS, V20, P109, DOI 10.1093/carcin/20.1.109; CABLE J, 1995, MECH DEVELOP, V50, P139, DOI 10.1016/0925-4773(94)00331-G; CALABRETTA B, 1982, NATURE, V296, P219, DOI 10.1038/296219a0; Carls N, 1999, CARCINOGENESIS, V20, P2351, DOI 10.1093/carcin/20.12.2351; CARLS N, 1994, MUTAT RES, V320, P293, DOI 10.1016/0165-1218(94)90082-5; CASSIDY SB, 1989, AM J HUM GENET, V44, P806; CATTANACH BM, 1971, CHEMICAL MUTAGENS PR, V2, P535; CHANCE PF, 1993, CELL, V72, P143, DOI 10.1016/0092-8674(93)90058-X; DAVIDSON GE, 1977, ARCH TOXICOL, V38, P99, DOI 10.1007/BF00293667; DEFLORA S, 1984, MUTAT RES, V133, P161, DOI 10.1016/0165-1110(84)90016-2; DEKOK AJ, 1983, MUTAT RES, V120, P81, DOI 10.1016/0165-7992(83)90147-1; DELACHAPELLE A, 1981, HUM GENET, V57, P253, DOI 10.1007/BF00278938; DESERRES FJ, 1981, EVALUATION SHORT TER; Douglas GR, 1999, ENVIRON MOL MUTAGEN, V34, P190, DOI 10.1002/(SICI)1098-2280(1999)34:2/3<190::AID-EM18>3.0.CO;2-#; DUBROVA YE, 1993, NAT GENET, V5, P92, DOI 10.1038/ng0993-92; Engle SJ, 1996, P NATL ACAD SCI USA, V93, P5307, DOI 10.1073/pnas.93.11.5307; FAHRIG R, 1977, ARCH TOXICOL, V38, P87, DOI 10.1007/BF00293666; FAHRIG R, 1975, MOL GEN GENET, V138, P309, DOI 10.1007/BF00264800; FAHRIG R, 1993, ENVIRON HEALTH PERSP, V101, P257, DOI 10.2307/3431735; FAN YJ, 1995, INT J RADIAT BIOL, V68, P177, DOI 10.1080/09553009514551081; Galli A, 1998, GENETICS, V149, P1235; GALLI A, 1995, MOL GEN GENET, V248, P301, DOI 10.1007/BF02191597; Galli A, 1996, MUTAT RES-GENET TOX, V370, P209, DOI 10.1016/S0165-1218(96)00078-X; GONDO Y, 1993, P NATL ACAD SCI USA, V90, P297, DOI 10.1073/pnas.90.1.297; GRASSI G, 1994, CIRCULATION, V90, P248, DOI 10.1161/01.CIR.90.1.248; IVERSON F, 1991, IARC SCI PUBL, V108, P5; Jalili T, 1998, CANCER RES, V58, P2633; Ji YG, 2000, GENOME RES, V10, P597, DOI 10.1101/gr.10.5.597; Kamsler A, 2001, CANCER RES, V61, P1849; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; KOHLER SW, 1991, P NATL ACAD SCI USA, V88, P7958, DOI 10.1073/pnas.88.18.7958; KONG Y, 1992, CELL MOL BIOL, V38, P263; KURIHARA S, 1995, CARDIOLOGY, V86, P102, DOI 10.1159/000176848; Lebel M, 2002, CARCINOGENESIS, V23, P213, DOI 10.1093/carcin/23.1.213; LEDBETTER DH, 1981, NEW ENGL J MED, V304, P325, DOI 10.1056/NEJM198102053040604; Lee SA, 2001, J BIOL CHEM, V276, P11783, DOI 10.1074/jbc.M004517200; LEHRMAN MA, 1985, SCIENCE, V227, P140, DOI 10.1126/science.3155573; LEVIN DE, 1982, P NATL ACAD SCI-BIOL, V79, P7445, DOI 10.1073/pnas.79.23.7445; Liang L, 2000, ENVIRON MOL MUTAGEN, V35, P150, DOI 10.1002/(SICI)1098-2280(2000)35:2<150::AID-EM10>3.3.CO;2-S; Lupski JR, 1998, TRENDS GENET, V14, P417, DOI 10.1016/S0168-9525(98)01555-8; LYON MF, 1992, P NATL ACAD SCI USA, V89, P6968, DOI 10.1073/pnas.89.15.6968; Mazzarella R, 1998, GENOME RES, V8, P1007, DOI 10.1101/gr.8.10.1007; MCCANN J, 1975, P NATL ACAD SCI USA, V72, P5135, DOI 10.1073/pnas.72.12.5135; MELVOLD RW, 1971, MUTAT RES, V12, P171, DOI 10.1016/0027-5107(71)90138-2; MIRSALIS JC, 1993, MUTAGENESIS, V8, P265, DOI 10.1093/mutage/8.3.265; MORRISON V, 1994, MUTAGENESIS, V9, P367, DOI 10.1093/mutage/9.4.367; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; NAYLOR J, 1993, HUM MOL GENET, V2, P1773, DOI 10.1093/hmg/2.11.1773; Naylor JA, 1996, BLOOD, V87, P3255, DOI 10.1182/blood.V87.8.3255.bloodjournal8783255; Nelis E, 1996, EUR J HUM GENET, V4, P25; Niwa O, 1996, J RADIAT RES, V37, P217, DOI 10.1269/jrr.37.217; Niwa O, 2001, P NATL ACAD SCI USA, V98, P1705, DOI 10.1073/pnas.031439298; Noda Y, 2002, MUTAT RES-GEN TOX EN, V513, P205, DOI 10.1016/S1383-5718(01)00313-8; OLEARY LM, 1991, AM J IND MED, V20, P17, DOI 10.1002/ajim.4700200103; PENTAO L, 1992, NAT GENET, V2, P292, DOI 10.1038/ng1292-292; Peter Y, 2001, EMBO J, V20, P1538, DOI 10.1093/emboj/20.7.1538; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; POTTEN CS, 1987, J THEOR BIOL, V127, P381, DOI 10.1016/S0022-5193(87)80136-4; Provost GS, 1996, ENVIRON MOL MUTAGEN, V28, P342, DOI 10.1002/(SICI)1098-2280(1996)28:4<342::AID-EM7>3.0.CO;2-D; Purandare SM, 1997, GENOME RES, V7, P773, DOI 10.1101/gr.7.8.773; PURCHASE IFH, 1978, BRIT J CANCER, V37, P873, DOI 10.1038/bjc.1978.132; Redhead NJ, 1996, HUM GENE THER, V7, P1491, DOI 10.1089/hum.1996.7.13-1491; RELIENE R, IN PRESS GENETIC REC; ROSEMBLAT S, 1994, P NATL ACAD SCI USA, V91, P12071, DOI 10.1073/pnas.91.25.12071; RUSSELL LB, 1977, ARCH TOXICOL, V38, P75; RUSSELL LB, 1957, GENETICS, V42, P161; RUSSELL LB, 1981, MUTAT RES, V86, P355, DOI 10.1016/0165-1110(81)90011-7; RUSSELL WL, 1979, P NATL ACAD SCI USA, V76, P5818, DOI 10.1073/pnas.76.11.5818; SANDS AT, 1995, P NATL ACAD SCI USA, V92, P8517, DOI 10.1073/pnas.92.18.8517; SANKARANARAYANAN K, 1991, MUTAT RES, V258, P3, DOI 10.1016/0165-1110(91)90027-S; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; SCHIESTL RH, 1989, MUTAT RES, V224, P427, DOI 10.1016/0165-1218(89)90067-0; SCHIESTL RH, 1988, GENETICS, V119, P237; Schiestl RH, 1997, P NATL ACAD SCI USA, V94, P4576, DOI 10.1073/pnas.94.9.4576; SCHIESTL RH, 1989, NATURE, V337, P285, DOI 10.1038/337285a0; SCHIESTL RH, 1989, CARCINOGENESIS, V10, P1445, DOI 10.1093/carcin/10.8.1445; SCHIESTL RH, 1994, SCIENCE, V266, P1573, DOI 10.1126/science.7985029; Schiestl RH, 1997, CANCER RES, V57, P4378; SCHLAGER G, 1967, GENETICS, V57, P319; SCHMID CW, 1989, CHROMOSOMES EUKARYOT, V1, P3; SCHMIDT GH, 1990, MUTAT RES, V228, P149, DOI 10.1016/0027-5107(90)90071-B; SEARLE AG, 1977, ARCH TOXICOL, V38, P105, DOI 10.1007/BF00293668; SHAVERWALKER PM, 1995, P NATL ACAD SCI USA, V92, P11470, DOI 10.1073/pnas.92.25.11470; Shiraishi K, 2002, RADIAT RES, V157, P661, DOI 10.1667/0033-7587(2002)157[0661:PIOSRO]2.0.CO;2; Stambrook PJ, 1996, ENVIRON MOL MUTAGEN, V28, P471; STRAKOWSKI SM, 1987, LANCET, V2, P1458; STYLES JA, 1985, MUTAT RES, V154, P183, DOI 10.1016/0165-1110(85)90017-X; Takao N, 2000, FEBS LETT, V472, P133, DOI 10.1016/S0014-5793(00)01422-8; TAO KS, 1993, P NATL ACAD SCI USA, V90, P10681, DOI 10.1073/pnas.90.22.10681; TAO KS, 1993, ENVIRON MOL MUTAGEN, V22, P293, DOI 10.1002/em.2850220419; Turker MS, 1999, CANCER RES, V59, P4781; van Delft JHM, 1998, MUTAT RES-GEN TOX EN, V415, P85, DOI 10.1016/S1383-5718(98)00063-1; Van Sloun PPH, 1998, NUCLEIC ACIDS RES, V26, P4888, DOI 10.1093/nar/26.21.4888; Watters D, 1999, J BIOL CHEM, V274, P34277, DOI 10.1074/jbc.274.48.34277; Wijnhoven SWP, 1998, P NATL ACAD SCI USA, V95, P13759, DOI 10.1073/pnas.95.23.13759; Wijnhoven SWP, 2003, CARCINOGENESIS, V24, P139, DOI 10.1093/carcin/24.1.139; WINTON DJ, 1990, CANCER RES, V50, P7992; WINTON DJ, 1989, MUTAGENESIS, V4, P404, DOI 10.1093/mutage/4.5.404; WINTON DJ, 1988, NATURE, V333, P463, DOI 10.1038/333463a0; WISE CA, 1993, AM J HUM GENET, V53, P853; YEN PH, 1990, CELL, V61, P603, DOI 10.1016/0092-8674(90)90472-Q	123	12	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 13	2003	22	45					7000	7010		10.1038/sj.onc.1206904	http://dx.doi.org/10.1038/sj.onc.1206904			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	731UB	14557804				2022-12-17	WOS:000185903900004
J	Krum, SA; Womack, JE; Lane, TF				Krum, SA; Womack, JE; Lane, TF			Bovine BRCA1 shows classic responses to genotoxic stress but low in vitro transcriptional activation activity	ONCOGENE			English	Article						breast and ovarian cancer; RNA polymerase II; phosphorylation; DNA repair; BRCT; GAL4UAS	MURINE BRCA1; EMBRYONIC LETHALITY; OVARIAN-CANCER; CELL-CYCLE; GENE; PHOSPHORYLATION; BREAST; EXPRESSION; KINASE; DOMAIN	Human BRCA1 has a genetically demonstrated role in DNA repair, and has been proposed to act as a transcriptional activator in a limited number of specialized settings. To gain insight into biologically conserved functional motifs, we isolated an ortholog of BRCA1 from cattle (Bos taurus). The predicted protein product shows 72.5% sequence identity with the human protein and conservation of amino acids involved in BRCA1 structure and function. Although the bovine C-terminus is truncated by seven amino acids as compared to human, bovine BRCA1 protein exhibited a similar cell cycle-regulated nuclear expression pattern. Expression was characteristically low and diffuse in the nucleus of G1/G0 cells, followed by increasing BRCA1-positive nuclear speckles in late S phase and G2/M phase cells. Bovine BRCA1 was phosphorylated and nuclear speckling was enhanced in response to DNA-damaging agents. Consistent with evidence from studies of human BRCA1, bovine BRCA1 was shown to interact with RNA polymerase II in vivo, an activity that was mapped to the C-terminal domain (CTD) (bBRCA(1364-1849)). Interestingly, when tested in the GAL4 transcriptional activation assay, full-length bovine and human BRCA1 lacked any ability to act as transcriptional activators and the CTD of bovine BRCA1 had five-fold lower activity when compared to the more acidic human C-terminus. These results provide evidence that phosphorylation and nuclear relocalization are highly conserved features of the BRCA1 response to genotoxic stress. In addition, bovine BRCA1 binds the RNA polymerase II holoenzyme, but this interaction lacks significant ability to correctly orient or recruit RNA polymerase II for transcription in the classic GAL4 transcriptional activation system.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, 10833 LeConte Ave, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA; Texas A&M Univ, College Stn, TX 77843 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; Texas A&M University System; Texas A&M University College Station; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Lane, TF (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Obstet & Gynecol, 10833 LeConte Ave, Los Angeles, CA 90095 USA.	tlane@mednet.ucla.edu	Krum, Susan A./D-7282-2013	Krum, Susan A./0000-0002-6414-6397; Lane, Timothy F./0000-0002-0210-970X	NIGMS NIH HHS [GM07185] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADKISON LR, 1988, CYTOGENET CELL GENET, V47, P155, DOI 10.1159/000132536; Altiok S, 1999, J BIOL CHEM, V274, P32274, DOI 10.1074/jbc.274.45.32274; Antoniou AC, 2000, GENET EPIDEMIOL, V18, P173; Bachelier R, 2000, INT J CANCER, V88, P519, DOI 10.1002/1097-0215(20001115)88:4<519::AID-IJC2>3.0.CO;2-R; Band MR, 2000, GENOME RES, V10, P1359, DOI 10.1101/gr.145900; BARENDSE W, 1991, CYTOGENET CELL GENET, V58, P2123; Bennett LM, 1999, MAMM GENOME, V10, P19, DOI 10.1007/s003359900935; Benuck ML, 1999, J BIOL CHEM, V274, P25419, DOI 10.1074/jbc.274.36.25419; BERGER B, 1995, P NATL ACAD SCI USA, V92, P8259, DOI 10.1073/pnas.92.18.8259; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brown MA, 1996, ONCOGENE, V12, P2507; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chambers JA, 1996, GENOMICS, V38, P305, DOI 10.1006/geno.1996.0633; Chandler J, 2001, GENESIS, V29, P72, DOI 10.1002/1526-968X(200102)29:2<72::AID-GENE1007>3.0.CO;2-B; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; COX DR, 1990, SCIENCE, V250, P245, DOI 10.1126/science.2218528; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan WH, 2002, J BIOL CHEM, V277, P8061, DOI 10.1074/jbc.M110225200; Featherstone M, 2002, CURR OPIN GENET DEV, V12, P149, DOI 10.1016/S0959-437X(02)00280-0; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; Gatei M, 2000, CANCER RES, V60, P3299; Gatei M, 2001, J BIOL CHEM, V276, P17276, DOI 10.1074/jbc.M011681200; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HORT Y, 1995, GENOMICS, V26, P77, DOI 10.1016/0888-7543(95)80085-Z; Hu YF, 2000, J BIOL CHEM, V275, P40910, DOI 10.1074/jbc.C000607200; Joukov V, 2001, P NATL ACAD SCI USA, V98, P12078, DOI 10.1073/pnas.211427098; Lane TF, 2000, ONCOGENE, V19, P4085, DOI 10.1038/sj.onc.1203760; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Madsen O, 2001, NATURE, V409, P610, DOI 10.1038/35054544; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Mixon M, 2000, ONCOGENE, V19, P5237, DOI 10.1038/sj.onc.1203905; Monteiro ANA, 2000, TRENDS BIOCHEM SCI, V25, P469, DOI 10.1016/S0968-0004(00)01632-7; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; O'Brien KA, 1999, BIOCHEM BIOPH RES CO, V260, P658, DOI 10.1006/bbrc.1999.0892; Orelli BJ, 2001, ONCOGENE, V20, P4433, DOI 10.1038/sj.onc.1204485; Ouchi T, 2000, P NATL ACAD SCI USA, V97, P5208, DOI 10.1073/pnas.080469697; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Perrin-Vidoz L, 2002, HUM MOL GENET, V11, P2805, DOI 10.1093/hmg/11.23.2805; Ruffner H, 1999, MOL CELL BIOL, V19, P4843; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Williamson EA, 2002, ONCOGENE, V21, P3199, DOI 10.1038/sj.onc.1205461; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Yang YP, 1998, GENOME RES, V8, P731, DOI 10.1101/gr.8.7.731; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388	58	12	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 4	2003	22	38					6032	6044		10.1038/sj.onc.1206515	http://dx.doi.org/10.1038/sj.onc.1206515			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	718GY	12955082				2022-12-17	WOS:000185137800012
J	Napolitano, G; Mazzocco, A; Fraldi, A; Majello, B; Lania, L				Napolitano, G; Mazzocco, A; Fraldi, A; Majello, B; Lania, L			Functional inactivation of Cdk9 through oligomerization chain reaction	ONCOGENE			English	Article						Cdk9; OCR; P-TEFb; coiled-coil domain; PML	P-TEFB KINASE; C-TERMINAL DOMAIN; HUMAN CYCLIN T1; HIV-1 TAT; IN-VIVO; TRANSCRIPTIONAL ELONGATION; DEPENDENT TRANSCRIPTION; TAK/P-TEFB; ACTIVATION; RECRUITMENT	The oligomerization chain reaction (OCR) strategy is a recently described technique for inactivation of target proteins that function as homoassociate complexes. This novel strategy is based on the fusion of self-associating coiled-coil (CC) domain of the nuclear factor promyelocytic leukemia (PML) to target proteins. Here, we present the successful application of the OCR strategy for inactivation of the heterodimeric Cdk9/cyclin T1 complex. Cyclin T1/Cdk9 (P-TEFb) complex is a positive regulator of gene transcription, whose function is underlined by the ability to phosphorylate the carboxyl-terminal domain (CTD) of the RNA polymerase II conferring productive transcript elongation. Fusion of the CC domain to Cdk9 leads to the formation of high molecular complexes to which the endogenous cyclin T1 is recruited. The CC-Cdk9 chimera effectively inhibits HIV-1 Tat activation, whose transcription activity is exquisitely dependent upon cyclin T1/Cdk9 function. Furthermore, expression of CC-Cdk9 protein inhibits cell proliferation, as shown by colony-formation assay. Collectively, our findings add further support to the OCR strategy for functional inactivation of hetero-associated factors such as the Cdk9/cyclin T1 complex, and highlight a putative function of Cdk9 in cell growth control.	Univ Naples Federico II, Dept Genet Mol & Gen Biol, I-80134 Naples, Italy	University of Naples Federico II	Lania, L (corresponding author), Univ Naples Federico II, Dept Genet Mol & Gen Biol, Via Mezzocannone 8, I-80134 Naples, Italy.	lania@unina.it	Fraldi, Alessandro/AAB-2243-2021	Fraldi, Alessandro/0000-0002-7795-0720; Napolitano, Giuliana/0000-0002-1637-6016; Majello, Barbara/0000-0003-2789-3585				ALONSO A, 1992, J VIROL, V66, P4617, DOI 10.1128/JVI.66.7.4617-4621.1992; Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Chao SH, 2001, J BIOL CHEM, V276, P31793, DOI 10.1074/jbc.M102306200; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Contegno F, 2002, P NATL ACAD SCI USA, V99, P1865, DOI 10.1073/pnas.042460299; Foskett SM, 2001, J VIROL, V75, P1220, DOI 10.1128/JVI.75.3.1220-1228.2001; Garber ME, 1998, GENE DEV, V12, P3512, DOI 10.1101/gad.12.22.3512; Herrmann CH, 2001, J CELL SCI, V114, P1491; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lis JT, 2000, GENE DEV, V14, P792; Majello B, 1999, ONCOGENE, V18, P4598, DOI 10.1038/sj.onc.1202822; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Marcello A, 2001, J BIOL CHEM, V276, P39220, DOI 10.1074/jbc.M104830200; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Minucci S, 2001, ONCOGENE, V20, P3110, DOI 10.1038/sj.onc.1204336; Napolitano G, 2000, GENE, V254, P139, DOI 10.1016/S0378-1119(00)00278-X; Napolitano G, 2002, J CELL PHYSIOL, V192, P209, DOI 10.1002/jcp.10130; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Salomoni P, 2000, NAT MED, V6, P742, DOI 10.1038/77459; Sano M, 2002, NAT MED, V8, P1310, DOI 10.1038/nm778; Sausville EA, 2002, TRENDS MOL MED, V8, pS32, DOI 10.1016/S1471-4914(02)02308-0; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Shim EY, 2002, GENE DEV, V16, P2135, DOI 10.1101/gad.999002; Simone C, 2002, ONCOGENE, V21, P4137, DOI 10.1038/sj.onc.1205493; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Zhou Q, 1998, EMBO J, V17, P3681, DOI 10.1093/emboj/17.13.3681; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002	34	12	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2003	22	31					4882	4888		10.1038/sj.onc.1206785	http://dx.doi.org/10.1038/sj.onc.1206785			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	704MZ	12894230	Bronze			2022-12-17	WOS:000184344600012
J	Shimizu, H; Seiki, T; Asada, M; Yoshimatsu, K; Koyama, N				Shimizu, H; Seiki, T; Asada, M; Yoshimatsu, K; Koyama, N			alpha 6 beta 1 integrin induces proteasome-mediated cleavage of erbB2 in breast cancer cells	ONCOGENE			English	Article						integrin; erbB2; proteasome; breast cancer	EPIDERMAL-GROWTH-FACTOR; EGF RECEPTOR; ALPHA(2)BETA(1) INTEGRIN; P185(HER2) ONCOPROTEIN; DIFFERENTIATION FACTOR; PROTOONCOGENE PRODUCT; EXTRACELLULAR DOMAIN; CARCINOMA; ACTIVATION; EXPRESSION	ErbB2 and alpha6 integrin have been implicated in malignancy of breast cancer cells. Here we have determined the influence of alpha6beta1 integrin on erbB2 signaling in anchorage-independent growth, using MDA-MB435 breast cancer cells. Firstly, we transfected the cells with erbB2 cDNA, and isolated cells with high or low levels of alpha6beta1 integrin by cell sorting (alpha6H-ErbB and alpha6L-ErbB). We found that an erbB ligand, heregulin beta1, enhanced growth activity of alpha6L-ErbB cells, but not alpha6H-ErbB cells. Secondly, we established cells expressing a beta4 integrin deletion mutant (beta4-Deltacyt), which selectively inhibited alpha6beta1 integrin expression and adhesion to laminin-1. Again, heregulin beta1 enhanced the growth of erbB2 cDNA-transfected beta4-Deltacyt cells, but not mock cells. Western blot analysis revealed that heregulin beta1 stimulated phosphorylation of Akt and its downstream molecules, GSK3beta and p70S6kinase, and that the extent of phosphorylation was greater in ErbB2/beta4-Deltacyt cells than ErbB2/mock cells. Furthermore, we found that the erbB2 cytoplasmic domain was truncated in ErbB2/mock cells, which was independent of ligand stimulation and adhesion, and was suppressed by proteasome inhibitors. These results suggest that alpha6beta1 integrin inhibits erbB2 signals by inducing proteasome-dependent proteolytic cleavage of the erbB2 cytoplasmic domain, and may thereby contribute to the regulation of tumor growth.	Eisai & Co Ltd, Tsukuba Res Labs, Tsukuba, Ibaraki 3002635, Japan	Eisai Co Ltd	Shimizu, H (corresponding author), Eisai & Co Ltd, Tsukuba Res Labs, 5-1-3 Tokodai, Tsukuba, Ibaraki 3002635, Japan.	h4-shimizu@hhc.eisai.co.jp		Koyama, Noriyuki/0000-0002-7509-6583				Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; Aguilar Z, 1999, ONCOGENE, V18, P6050, DOI 10.1038/sj.onc.1202993; Amundadottir LT, 1998, ONCOGENE, V16, P737, DOI 10.1038/sj.onc.1201829; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Bao WJ, 2002, MOL CELL BIOL, V22, P4587, DOI 10.1128/MCB.22.13.4587-4597.2002; Baron V, 2000, J BIOL CHEM, V275, P39318, DOI 10.1074/jbc.M003618200; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CAMPIGLIO M, 1994, J CELL BIOCHEM, V55, P409, DOI 10.1002/jcb.240550402; Carrano AC, 2001, J CELL BIOL, V153, P1381, DOI 10.1083/jcb.153.7.1381; Christianson TA, 1998, CANCER RES, V58, P5123; CLARKE AS, 1995, J BIOL CHEM, V270, P22673, DOI 10.1074/jbc.270.39.22673; Codony-Servat J, 1999, CANCER RES, V59, P1196; DANILENKO DM, 1995, J CLIN INVEST, V95, P842, DOI 10.1172/JCI117734; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; FRIEDRICHS K, 1995, CANCER RES, V55, P901; Gambaletta D, 2000, J BIOL CHEM, V275, P10604, DOI 10.1074/jbc.275.14.10604; Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475; Hijazi MM, 2000, INT J ONCOL, V17, P629; Hintermann E, 2001, J CELL BIOL, V153, P465, DOI 10.1083/jcb.153.3.465; Jeffers M, 1997, MOL CELL BIOL, V17, P799, DOI 10.1128/MCB.17.2.799; KOUKOULIS GK, 1991, AM J PATHOL, V139, P787; Kozlova NI, 2001, ONCOGENE, V20, P4710, DOI 10.1038/sj.onc.1204619; Krane IM, 1996, ONCOGENE, V12, P1781; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lee YJ, 1999, J BIOL CHEM, V274, P22401, DOI 10.1074/jbc.274.32.22401; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; LICHTNER RB, 1995, ONCOGENE, V10, P1823; LIN YZJ, 1991, ONCOGENE, V6, P639; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Manenti S, 2002, BIOCHEM BIOPH RES CO, V294, P976, DOI 10.1016/S0006-291X(02)00594-6; Meng FY, 1998, EMBO J, V17, P4391, DOI 10.1093/emboj/17.15.4391; Miyamoto S, 1996, J CELL BIOL, V135, P1633, DOI 10.1083/jcb.135.6.1633; MORI S, 1995, J BIOL CHEM, V270, P29447, DOI 10.1074/jbc.270.49.29447; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; Mukhopadhyay R, 1999, CLIN EXP METASTAS, V17, P325; NATALI PG, 1992, BRIT J CANCER, V66, P318, DOI 10.1038/bjc.1992.263; Neve RM, 2000, ONCOGENE, V19, P1647, DOI 10.1038/sj.onc.1203470; O'Connor KL, 1998, J CELL BIOL, V143, P1749, DOI 10.1083/jcb.143.6.1749; Ojaniemi M, 1997, J BIOL CHEM, V272, P3780, DOI 10.1074/jbc.272.6.3780; Perez-Tenorio G, 2002, BRIT J CANCER, V86, P540, DOI 10.1038/sj.bjc.6600126; PIGNATELLI M, 1991, J PATHOL, V165, P25, DOI 10.1002/path.1711650106; Plath T, 2000, J CELL BIOL, V150, P1467, DOI 10.1083/jcb.150.6.1467; PUPA SM, 1993, ONCOGENE, V8, P2917; Renshaw MW, 1999, J CELL BIOL, V147, P611, DOI 10.1083/jcb.147.3.611; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Shimizu H, 2002, INT J ONCOL, V21, P1073; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sun H, 1998, CANCER RES, V58, P2224; Tagliabue E, 1996, BRIT J CANCER, V74, P1427, DOI 10.1038/bjc.1996.560; Tagliabue E, 1998, CLIN CANCER RES, V4, P407; Tan M, 1997, CANCER RES, V57, P1199; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; TZAHAR E, 1998, BIOCHIM BIOPHYS ACTA, V1377, P25; Vafa A, 1998, INT J ONCOL, V13, P1191; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; Vogelmann R, 1999, INT J CANCER, V80, P791, DOI 10.1002/(SICI)1097-0215(19990301)80:5<791::AID-IJC25>3.0.CO;2-4; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wewer UM, 1997, AM J PATHOL, V151, P1191; Xu FJ, 1997, CLIN CANCER RES, V3, P1629; Yarwood SJ, 2001, P NATL ACAD SCI USA, V98, P4472, DOI 10.1073/pnas.081069098; Yebra M, 1999, EXP CELL RES, V250, P231, DOI 10.1006/excr.1999.4510; Yu DH, 1996, ONCOGENE, V13, P1359; Yu X, 2000, J CELL SCI, V113, P2139; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027; ZUTTER MM, 1995, P NATL ACAD SCI USA, V92, P7411, DOI 10.1073/pnas.92.16.7411	68	12	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2003	22	6					831	839		10.1038/sj.onc.1206203	http://dx.doi.org/10.1038/sj.onc.1206203			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	643MD	12584562				2022-12-17	WOS:000180864300005
J	Berg, CP; Rothbart, A; Lauber, K; Stein, GM; Engels, IH; Belka, C; Janicke, RU; Schulze-Osthoff, K; Wesselborg, S				Berg, CP; Rothbart, A; Lauber, K; Stein, GM; Engels, IH; Belka, C; Janicke, RU; Schulze-Osthoff, K; Wesselborg, S			Tributyltin (TBT) induces ultra-rapid caspase activation independent of apoptosome formation in human platelets	ONCOGENE			English	Article						organotin; tributyltin; platelets; caspase-9; apoptosome; apoptosis	DRUG-INDUCED APOPTOSIS; CYTOCHROME-C RELEASE; NONSPECIFIC RESISTANCE; DISTINCT PATHWAYS; TERM EXPOSURE; CELL-DEATH; RAT; BIS(TRI-NORMAL-BUTYLTIN)OXIDE; PHOSPHORYLATION; STAUROSPORINE	Activation of caspases has been demonstrated to be involved in thrombocytopenia and prolonged storage of platelet concentrates. Platelets represent enucleate cells that comprise all elements of the mitochondrial apoptosis pathway. However, no apoptotic stimuli capable of activating the endogenous caspase cascade have been identified so far. Using tributyltin (TBT) we could identify a compound that is capable of activating caspase-9 and -3 in platelets. Recent studies implicate that TBT induces apoptosis via the mitochondrial signaling pathway that is characterized by the formation of a high-molecular-weight complex (apoptosome) containing the adapter protein Apaf-1 and active caspase-9. Interestingly, addition of TBT induced the activation of caspase-9 in an ultra-rapid kinetic within the first 2 min. In addition, size exclusion chromatography revealed that TBT-mediated processing of caspase-9 occurs in the absence of the apoptosome. Thus, these data implicate that TBT induces the activation of caspase-9 by a mechanism not involving the formation of the apoptosome.	Univ Tubingen, Dept Internal Med 1, D-72076 Tubingen, Germany; Univ Munster, Div Cell Biol & Immunol, D-4400 Munster, Germany; Univ Tubingen, Dept Radiat & Oncol, Tubingen, Germany	Eberhard Karls University of Tubingen; University of Munster; Eberhard Karls University of Tubingen	Wesselborg, S (corresponding author), Univ Tubingen, Dept Internal Med 1, Otfried Muller Str 10, D-72076 Tubingen, Germany.		Schulze-Osthoff, Klaus/N-9025-2013	Schulze-Osthoff, Klaus/0000-0003-1443-2720; Wesselborg, Sebastian/0000-0002-5236-942X				AW TY, 1990, ARCH BIOCHEM BIOPHYS, V283, P46, DOI 10.1016/0003-9861(90)90610-B; Bantel H, 1999, CANCER RES, V59, P2083; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Berg CP, 2001, CELL DEATH DIFFER, V8, P1197, DOI 10.1038/sj.cdd.4400905; Bratosin D, 2001, CELL DEATH DIFFER, V8, P1143, DOI 10.1038/sj.cdd.4400946; CAIN K, 1977, FEBS LETT, V82, P23, DOI 10.1016/0014-5793(77)80877-6; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHOW SC, 1992, ARCH BIOCHEM BIOPHYS, V298, P143, DOI 10.1016/0003-9861(92)90105-6; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; HARRIS EJ, 1973, FEBS LETT, V29, P339, DOI 10.1016/0014-5793(73)80054-7; Jacobson MD, 1996, J CELL BIOL, V133, P1041, DOI 10.1083/jcb.133.5.1041; Lauber K, 2001, J BIOL CHEM, V276, P29772, DOI 10.1074/jbc.M101524200; Leist M, 2001, CELL DEATH DIFFER, V8, P324, DOI 10.1038/sj.cdd.4400859; Li JZ, 2000, TRANSFUSION, V40, P1320, DOI 10.1046/j.1537-2995.2000.40111320.x; Los M, 1999, IMMUNITY, V10, P629, DOI 10.1016/S1074-7613(00)80062-X; Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishikimi A, 2001, BIOCHEM J, V356, P621, DOI 10.1042/0264-6021:3560621; Nopp A, 2002, CLIN EXP IMMUNOL, V128, P267, DOI 10.1046/j.1365-2249.2002.01824.x; Piguet PF, 2002, APOPTOSIS, V7, P91, DOI 10.1023/A:1014341611412; Plenchette S, 2001, LEUKEMIA, V15, P1572, DOI 10.1038/sj.leu.2402231; POWERS MF, 1991, J BIOL CHEM, V266, P17250; RAFFRAY M, 1993, ARCH TOXICOL, V67, P231, DOI 10.1007/BF01974341; Rao RV, 2002, J BIOL CHEM, V277, P21836, DOI 10.1074/jbc.M202726200; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; SCHULZEOSTHOFF K, 1994, J CELL BIOL, V127, P15, DOI 10.1083/jcb.127.1.15; SEINEN W, 1977, TOXICOL APPL PHARM, V42, P213, DOI 10.1016/0041-008X(77)90211-3; Shcherbina A, 1999, BLOOD, V93, P4222, DOI 10.1182/blood.V93.12.4222.412k34_4222_4231; SNOEIJ NJ, 1988, INT J IMMUNOPHARMACO, V10, P891, DOI 10.1016/0192-0561(88)90014-8; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Stridh H, 1998, FEBS LETT, V429, P351, DOI 10.1016/S0014-5793(98)00630-9; Stridh H, 1999, BIOCHEM BIOPH RES CO, V266, P460, DOI 10.1006/bbrc.1999.1821; Stridh H, 1999, CHEM RES TOXICOL, V12, P874, DOI 10.1021/tx990041c; Vanags DM, 1997, BRIT J HAEMATOL, V99, P824, DOI 10.1046/j.1365-2141.1997.4813284.x; VOS JG, 1990, TOXICOL APPL PHARM, V105, P144, DOI 10.1016/0041-008X(90)90366-3; VOS JG, 1984, TOXICOL APPL PHARM, V75, P387, DOI 10.1016/0041-008X(84)90177-7; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; Wolf BB, 1999, BLOOD, V94, P1683, DOI 10.1182/blood.V94.5.1683.417k37_1683_1692	41	12	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 6	2003	22	5					775	780		10.1038/sj.onc.1206221	http://dx.doi.org/10.1038/sj.onc.1206221			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	639RB	12569371				2022-12-17	WOS:000180642100016
J	Fujita, M; Ichinose, S; Kiyono, T; Tsurumi, T; Omori, A				Fujita, M; Ichinose, S; Kiyono, T; Tsurumi, T; Omori, A			Establishment of latrunculin-A resistance in HeLa cells by expression of R183A D184A mutant beta-actin	ONCOGENE			English	Article							CYTOCHALASIN; MOTILITY; YEAST	Actin plays central roles in cell motility through formation of the actin cytoskeleton. Recently, the very intriguing possibility that actin also contributes to processes in the cell nucleus has been emerging. To dissect its dynamics and functions, several actin-disrupting drugs have been widely and effectively employed. Among them, latrunculin-A has proved particularly useful, supplanting the classical drug cytochalasin-D. One reason is that latrunculin-A appears to bind only to actin monomers impairing the nucleotide exchange, the mode being simpler than with cytochalasin. This property may be especially crucial when studying actin functions as a monomer, as suggested for nuclear actin. Very importantly, actin mutations that cause cells to become resistant to the effects of latrunculin-A have been identified in budding yeast. However, it remains controversial as to whether all of the various phenotypes observed with latrunculin in mammalian cells more complicated than yeast are truly the consequence of its specific actions against actin. Here, we show that the expression of R183A D184A mutant beta-actin specifically confers resistance to the effects of latrunculin-A on actin cytoskeleton formation and cell growth in HeLa cells. The established system provides a strong tool to address the various functions of actin in mammalian cells.			Fujita, M (corresponding author), Natl Canc Ctr, Virol Div, Chuoh Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	mafujita@gan2.res.ncc.go.jp	Kiyono, Tohru/H-5834-2011	Fujita, Masatoshi/0000-0001-6617-2452				Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; Kimura T, 2000, GENES CELLS, V5, P289, DOI 10.1046/j.1365-2443.2000.00326.x; Lamaze C, 1997, J BIOL CHEM, V272, P20332, DOI 10.1074/jbc.272.33.20332; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; Morales M, 2000, NEURON, V27, P539, DOI 10.1016/S0896-6273(00)00064-7; Morton WM, 2000, NAT CELL BIOL, V2, P376, DOI 10.1038/35014075; OHMORI H, 1992, J CELL BIOL, V116, P933, DOI 10.1083/jcb.116.4.933; Rando OJ, 2000, TRENDS CELL BIOL, V10, P92, DOI 10.1016/S0962-8924(99)01713-4; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; TOYAMA S, 1984, CELL, V37, P609, DOI 10.1016/0092-8674(84)90391-X; Wasser M, 2000, NAT CELL BIOL, V2, P268, DOI 10.1038/35010535; WERTMAN KF, 1992, GENETICS, V132, P337; Zhao KJ, 1998, CELL, V95, P625, DOI 10.1016/S0092-8674(00)81633-5	14	12	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2003	22	4					627	631		10.1038/sj.onc.1206173	http://dx.doi.org/10.1038/sj.onc.1206173			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555075				2022-12-17	WOS:000180538200015
J	Inga, A; Nahari, D; Velasco-Miguel, S; Friedberg, EC; Resnick, MA				Inga, A; Nahari, D; Velasco-Miguel, S; Friedberg, EC; Resnick, MA			A novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions	ONCOGENE			English	Article						p53 gene; yeast functional assay; p53 expression; mutational hotspots; enhanced transactivation; Xpc mice	NUCLEOTIDE EXCISION-REPAIR; WILD-TYPE P53; IN-VIVO; HUMAN CANCER; CELL-LINES; IONIZING-RADIATION; GENE-EXPRESSION; TERMINAL DOMAIN; DEFICIENT MICE; BAX PROMOTER	A mutation in codon 122 of the mouse p53 gene resulting in a T to L amino acid substitution (T122-->L) is frequently associated with skin cancer in UV-irradiated mice that are both homozygous mutant for the nucleotide excision repair (NER) gene Xpc (Xpc-/-) and hemizygous mutant for the p53 gene. We investigated the functional consequences of the mouse T122-->L mutation when expressed either in mammalian cells or in the yeast Saccharomyces cerevisiae. Similar to a non-functional allele, high expression of the T122-->L allele in p53-/- mouse embryo fibroblasts and human Saos-2 cells failed to suppress growth. However, the T122-->L mutant p53 showed wild-type transactivation levels with Bax and MDM2 promoters when expressed in either cell type and retained transactivation of the p21 and the c-Fos promoters in one cell line. Using a recently developed rheostatable p53 induction system in yeast we assessed the T122-->L transactivation capacity at low levels of protein expression using 12 different p53 response elements (REs). Compared to wild-type p53 the T122-->L protein manifested an unusual transactivation pattern comprising reduced and enhanced activity with specific REs. The high incidence of the T122-->L mutant allele in the Xpc-/- background suggests that both genetic and epigenetic conditions may facilitate the emergence of particular functional p53 mutations. Furthermore, the approach that we have taken also provides for the dissection of functions that may be retained in many p53 tumor alleles.	NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA; Univ Texas, Dept Pathol, Lab Mol Pathol, SW Med Ctr, Dallas, TX 75390 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Resnick, MA (corresponding author), NIEHS, Genet Mol Lab, NIH, POB 12233,Mail Drop D3-01,TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	Resnick@NIEHS.NIH.GOV	Inga, Alberto/AAC-3815-2022; resnick, Michael/F-1668-2019	Inga, Alberto/0000-0002-8767-1637; resnick, Michael/0000-0002-8473-7506				Ashcroft M, 1999, ONCOGENE, V18, P7637, DOI 10.1038/sj.onc.1203012; Aurelio ON, 2000, MOL CELL BIOL, V20, P770, DOI 10.1128/MCB.20.3.770-778.2000; Blagosklonny MV, 2001, CARCINOGENESIS, V22, P861, DOI 10.1093/carcin/22.6.861; Brachmann RK, 1996, P NATL ACAD SCI USA, V93, P4091, DOI 10.1073/pnas.93.9.4091; Brash DE, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P136; Brash DE, 1998, CANCER SURV, V32, P69; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Cheo DL, 2000, CANCER RES, V60, P1580; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Elkeles A, 1999, MOL CELL BIOL, V19, P2594; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Flaman JM, 1998, ONCOGENE, V16, P1369, DOI 10.1038/sj.onc.1201889; FLAMAN JM, 1995, P NATL ACAD SCI USA, V92, P3963, DOI 10.1073/pnas.92.9.3963; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; FREEMAN J, 1994, EMBO J, V13, P5393, DOI 10.1002/j.1460-2075.1994.tb06874.x; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Hainaut P, 2000, ADV CANCER RES, V77, P81; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; Hill LL, 1999, SCIENCE, V285, P898, DOI 10.1126/science.285.5429.898; Holmquist GP, 1997, MUTAT RES-REV MUTAT, V386, P69, DOI 10.1016/S1383-5742(96)00045-2; Hussain SP, 1999, MUTAT RES-FUND MOL M, V428, P23, DOI 10.1016/S1383-5742(99)00028-9; Inga A, 2001, ONCOGENE, V20, P3409, DOI 10.1038/sj.onc.1204457; Inga A, 2001, ONCOGENE, V20, P501, DOI 10.1038/sj.onc.1204116; Kaeser MD, 2002, P NATL ACAD SCI USA, V99, P95, DOI 10.1073/pnas.012283399; KIESER A, 1994, ONCOGENE, V9, P963; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lane D, 2001, NATURE, V414, P25, DOI 10.1038/35102132; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; LIN JY, 1995, ONCOGENE, V10, P2387; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MacCallum DE, 1996, ONCOGENE, V13, P2575; McLure KG, 1998, EMBO J, V17, P3342, DOI 10.1093/emboj/17.12.3342; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Offer H, 2001, ONCOGENE, V20, P581, DOI 10.1038/sj.onc.1204120; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Prives C, 1999, J PATHOL, V187, P112; Reis AM, 2000, CANCER RES, V60, P1571; Rodin SN, 1998, INT J MOL MED, V1, P191; Sage E, 1996, P NATL ACAD SCI USA, V93, P176, DOI 10.1073/pnas.93.1.176; Saller E, 1999, EMBO J, V18, P4424, DOI 10.1093/emboj/18.16.4424; SCHARER E, 1992, NUCLEIC ACIDS RES, V20, P1539, DOI 10.1093/nar/20.7.1539; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Smith PD, 1999, ONCOGENE, V18, P2451, DOI 10.1038/sj.onc.1202565; Storici F, 2001, NAT BIOTECHNOL, V19, P773, DOI 10.1038/90837; Suzuki A, 2000, CELL DEATH DIFFER, V7, P721, DOI 10.1038/sj.cdd.4400706; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Takeuchi S, 1998, CANCER RES, V58, P641; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Thornborrow EC, 1999, J BIOL CHEM, V274, P33747, DOI 10.1074/jbc.274.47.33747; van Oosten M, 2000, P NATL ACAD SCI USA, V97, P11268, DOI 10.1073/pnas.200226697; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Wieczorek AM, 1996, NAT MED, V2, P1143, DOI 10.1038/nm1096-1143; Wijnhoven SWP, 2000, ONCOGENE, V19, P5034, DOI 10.1038/sj.onc.1203844; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhao RB, 2000, GENE DEV, V14, P981	66	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2002	21	37					5704	5715		10.1038/sj.onc.1205779	http://dx.doi.org/10.1038/sj.onc.1205779			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	584JL	12173040				2022-12-17	WOS:000177463400005
J	Masciarelli, S; Mattioli, B; Galletti, R; Samoggia, P; Chichiarelli, S; Mearini, G; Mattia, E				Masciarelli, S; Mattioli, B; Galletti, R; Samoggia, P; Chichiarelli, S; Mearini, G; Mattia, E			Antisense to Epstein Barr virus-encoded LMP1 does not affect the transcription of viral and cellular proliferation-related genes, but induces phenotypic effects on EBV-transformed B lymphocytes	ONCOGENE			English	Article						EBV; LMP1; antisense oligodeoxynucleotides; EBV transforming genes; anti-apoptotic genes; B cell phenotype	LATENT MEMBRANE-PROTEIN; HUMAN EPITHELIAL-CELLS; GROWTH TRANSFORMATION; NUCLEAR PROTEIN-2; BCL-2 EXPRESSION; INDUCTION; LYMPHOMA; TUMORIGENICITY; IDENTIFICATION; INHIBITION	It is generally accepted that Epstein-Barr virus (EBV) latent genes EBNA-2, EBNA-3A, -3C, EBNA-LP and LMP1 are essential for growth transformation and immortalization of B lymphocytes. Among these genes, LMP1 plays a key role in the survival and dissemination of the infected B cells by inducing anti-apoptotic genes and surface expression of several activation antigens and adhesion molecules. We have previously shown that antisense oligodeoxynucleotides directed to LMP1 mRNA, effectively suppress LMP1 gene expression and substantially reduce B95.8 cell proliferation. In this study, we have used antisense LMP1 oligomers to investigate whether LMP1 suppression might influence the expression of latent EBV genes with oncogenic potential, anti-apoptotic genes, or affect the phenotype of EBV-infected B95.8 cells. Our data show that LMP1 suppression does not affect the transcription of EBNA-2, EBNA-3A, -3B and -3C genes, or that of bcl-2 and mcl-1 anti-apoptotic genes. In contrast, consistent modifications in the expression of CD39, CD54, CD23, CD11 and CD10 molecules were observed in B95.8 cells after treatment with antisense LMP1. Our findings support the possibility for using LMP1 antisense oligomers as therapeutics in EBV-associated tumors.	Univ Roma La Sapienza, Fac Med & Surg, Dept Publ Hlth Sci, Microbiol Sect, I-00185 Rome, Italy; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Ist Super Sanita, Dept Hematol Oncol, I-00161 Rome, Italy	Sapienza University Rome; Sapienza University Rome; Istituto Superiore di Sanita (ISS)	Mattia, E (corresponding author), Univ Roma La Sapienza, Fac Med & Surg, Dept Publ Hlth Sci, Microbiol Sect, Piazzale Aldo Moro 5, I-00185 Rome, Italy.		Chichiarelli, Silvia/F-1226-2011	Galletti, Roberta/0000-0001-8299-7649; MASCIARELLI, SILVIA/0000-0002-6738-6281; Chichiarelli, Silvia/0000-0002-5682-0353				BAICHWAL VR, 1988, ONCOGENE, V2, P461; COHEN JI, 1989, P NATL ACAD SCI USA, V86, P9558, DOI 10.1073/pnas.86.23.9558; D'Souza B, 2000, J VIROL, V74, P6652, DOI 10.1128/JVI.74.14.6652-6658.2000; FAHRAEUS R, 1990, NATURE, V345, P447, DOI 10.1038/345447a0; Farrell Paul J., 1995, Trends in Microbiology, V3, P105, DOI 10.1016/S0966-842X(00)88891-5; HAMMERSCHMIDT W, 1989, NATURE, V340, P393, DOI 10.1038/340393a0; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HU LF, 1993, ONCOGENE, V8, P1575; KAYE KM, 1993, P NATL ACAD SCI USA, V90, P9150, DOI 10.1073/pnas.90.19.9150; KEMPKES B, 1995, EMBO J, V14, P88, DOI 10.1002/j.1460-2075.1995.tb06978.x; Kenney JL, 1998, BLOOD, V92, P1721, DOI 10.1182/blood.V92.5.1721.417a08_1721_1727; KINTNER C, 1981, NATURE, V294, P458, DOI 10.1038/294458a0; Kulwichit W, 1998, P NATL ACAD SCI USA, V95, P11963, DOI 10.1073/pnas.95.20.11963; MARTIN JM, 1993, J VIROL, V67, P5269, DOI 10.1128/JVI.67.9.5269-5278.1993; Mattia E, 1997, ONCOGENE, V15, P489, DOI 10.1038/sj.onc.1201183; MILLER G, 1990, VIROLOGY, P1921; Nicholson LJ, 1997, ONCOGENE, V15, P275, DOI 10.1038/sj.onc.1201187; Noguchi T, 2001, BRIT J HAEMATOL, V114, P84, DOI 10.1046/j.1365-2141.2001.02887.x; PATARROYO M, 1986, INT J CANCER, V38, P539, DOI 10.1002/ijc.2910380414; ROWE M, 1994, J VIROL, V68, P5602, DOI 10.1128/JVI.68.9.5602-5612.1994; THORLEYLAWSON DA, 1985, J IMMUNOL, V134, P3007; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG D, 1988, J VIROL, V62, P4173, DOI 10.1128/JVI.62.11.4173-4184.1988; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; Wang S, 1996, CANCER RES, V56, P4610	26	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 13	2002	21	26					4166	4170		10.1038/sj.onc.1205515	http://dx.doi.org/10.1038/sj.onc.1205515			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	562FD	12037673				2022-12-17	WOS:000176186000011
J	Rovida, E; Baccarini, M; Olivotto, M; Dello Sbarba, P				Rovida, E; Baccarini, M; Olivotto, M; Dello Sbarba, P			Opposite effects of different doses of MCSF on ERK phosphorylation and cell proliferation in macrophages	ONCOGENE			English	Article						macrophage; proliferation; MAPK; fes; MCSF	PROTEIN PHOSPHATASE 2A; MAP-KINASE; TRANSFORMING ACTIVITY; TYROSINE KINASE; V-RAF; GROWTH; ACTIVATION; SPECIFICITY; FAMILY; PATHWAYS	We had previously shown that murine macrophages expressing v-Fes, the oncogenically activated counterpart of the c-Fes cytoplasmic tyrosine kinase, proliferate independently of Macrophage Colony-Stimulating Factor (MCSF) and that the Extracellular signal-Regulated Kinase (ERK) pathway mediates the mitogenic effect of v-Fes. In this study, the response of c-fes- and v-fes-overexpressing cells to MCSF was investigated. A critical modulation of the activation of Mitogen-activated ERK Kinase (MEK) and ERK based on the MCSF dose was characterized. ERK activation was increased by MCSF doses capable to elicit a mitogenic response (2-5 U/ml). On the contrary, MCSF doses as low as 0.05 U/ml markedly reduced ERK phosphorylation and nuclear content and moderately but significantly reduced cell proliferation. The reduction of MEK and ERK phosphorylation was very rapid, suggesting the involvement of cytosolic phosphatases. Among these, phospho-tyrosine protein phosphatases and phosphoserine/threonine protein phosphatase-2A were found involved. These findings represent the first observation that different doses of the same growth factor, MCSF in particular, can exert opposite effects on cell proliferation by switching on or off ERK signaling.	Univ Florence, Dipartimento Patol & Oncol Sperimentali, Dept Expt Pathol & Oncol, I-50134 Florence, Italy; Univ Vienna, Inst Microbiol & Genet, Vienna Bioctr, A-1090 Vienna, Austria	University of Florence; University of Vienna; Vienna Biocenter (VBC)	Dello Sbarba, P (corresponding author), Univ Florence, Dipartimento Patol & Oncol Sperimentali, Dept Expt Pathol & Oncol, Viale GB Morgagni 50, I-50134 Florence, Italy.	persio@unifi.it	Baccarini, Manuela/B-6481-2014; Dello Sbarba, Persio/AAX-9887-2020; Rovida, Elisabetta/F-3565-2015	Baccarini, Manuela/0000-0002-3033-391X; Rovida, Elisabetta/0000-0002-5949-3239				ALESSI DR, 1995, CURR BIOL, V5, P283, DOI 10.1016/S0960-9822(95)00059-5; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARECES LB, 1994, MOL CELL BIOL, V14, P4606, DOI 10.1128/MCB.14.7.4606; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; BUSCHER D, 1993, ONCOGENE, V8, P3323; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; CHEN J, 1994, J BIOL CHEM, V269, P7957; CHEN J, 1992, SCIENCE, V257, P1261, DOI 10.1126/science.1325671; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Favre B, 1997, J BIOL CHEM, V272, P13856, DOI 10.1074/jbc.272.21.13856; FELDMAN RA, 1989, J VIROL, V63, P5469, DOI 10.1128/JVI.63.12.5469-5474.1989; FELDMAN RA, 1990, ONCOGENE RES, V5, P187; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; Jaworowski A, 1999, J BIOL CHEM, V274, P15127, DOI 10.1074/jbc.274.21.15127; Jaworowski A, 1996, BIOCHEM J, V320, P1011, DOI 10.1042/bj3201011; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289; KRAUTWALD S, 1995, ONCOGENE, V10, P1187; KRAUTWALD S, 1993, BIOCHEM BIOPH RES CO, V192, P720, DOI 10.1006/bbrc.1993.1474; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MORGAN C, 1987, J CELL PHYSIOL, V130, P420, DOI 10.1002/jcp.1041300316; Rovida E, 2000, BLOOD, V95, P3959; Smithgall TE, 1998, CRIT REV ONCOGENESIS, V9, P43, DOI 10.1615/CritRevOncog.v9.i1.40; Valledor AF, 2000, J BIOL CHEM, V275, P7403, DOI 10.1074/jbc.275.10.7403; Wilson NJ, 1999, BIOCHEM J, V339, P517, DOI 10.1042/0264-6021:3390517; YEUNG YG, 1992, J BIOL CHEM, V267, P23447	28	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3670	3676		10.1038/sj.onc.1205409	http://dx.doi.org/10.1038/sj.onc.1205409			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032835				2022-12-17	WOS:000175676000002
J	Hollmann, CA; Kittrell, FS; Medina, D; Butel, JS				Hollmann, CA; Kittrell, FS; Medina, D; Butel, JS			Wnt-1 and int-2 mammary oncogene effects on the beta-catenin pathway in immortalized mouse mammary epithelial cells are not sufficient for tumorigenesis	ONCOGENE			English	Article						mammary oncogenes; wnt-1; int-2; mammary epithelial cells; mammary tumorigenesis; mouse model for breast cancer; signal transduction pathways	FIBROBLAST-GROWTH-FACTOR; GENE-PRODUCT ACTS; E-CADHERIN; IN-VIVO; PROVIRAL ACTIVATION; TRANSGENIC MICE; CELLULAR GENE; TUMOR VIRUS; CYCLIN D1; C-MYC	Development of strategies for prevention of breast cancer development requires an understanding of the effects of mammary oncogenes on mammary cells at early stages in neoplastic transformation. As mammary oncogenes wnt-1 and int-2 affect different signal transduction pathways, we investigated their effects on established mouse mammary epithelial cell lines (MMECLs) reflecting early stages in tumorigenesis. Normal interactions between beta -catenin and E-cadherin were abrogated in all three immortalized MMECLs and the cells lacked beta -catenin-mediated transactivation activity, detectable using a reporter assay, suggesting that alterations in cell adhesion may be very early events in mammary tumorigenesis. Immortalized FSK4 and EL12 cells and hyperplastic TM3 cells were stably transfected with expression vectors encoding wnt-1 or int-2 or the control vector, and drug-selected pooled cells from each tine were confirmed by reverse transcription-polymerase chain reaction to express the transfected oncogene; this expression persisted in the cells analysed in vitro and in vivo. Resultant phenotypic changes depended both on the oncogene and the target mammary cell line. In FSK4 cells, expression of wnt-1 or int-2 resulted in proliferative changes in vitro, including reduced contact inhibition, increased beta -catenin expression, and decreased p53 transcriptional activity, but neither oncogene conferred upon those cells the ability to produce tumors in vivo. EL12 cells were highly refractory to the effects of both oncogenes, with the only measurable changes being increased E-cadherin levels induced by both oncogenes and increased proliferation of the int-2-transfected cells in the absence of serum. Parental TM3 cells were phenotypically similar to wnt-1- or int-2-transfected FSK4 cells and displayed an increased rate of proliferation in vitro and markedly increased tumorigenicity in vivo following transfection with int-2 but not with wnt-1. These results suggest that wnt-1 signaling is redundant in the hyperplastic TM3 cells and indicate that wnt-1-induced effects in the immortalized FSK4 and EL12 cells were not sufficient to mediate a tumorigenic phenotype. This study showed that the wnt-1 and int-2 oncogenes have similar but distinguishable effects on immortalized MMECLs and that the genetic background of the mammary cells greatly influences the consequences of oncogene expression at early stages of cell transformation.	Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Butel, JS (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, Mail Stop BCM 385,1 Baylor Plaza, Houston, TX 77030 USA.	jbutel@bcm.tmc.edu		Butel, Janet/0000-0002-6876-3245	NCI NIH HHS [CA25215] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA025215] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Bonnette SG, 1999, CARCINOGENESIS, V20, P1715, DOI 10.1093/carcin/20.9.1715; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; COLEMANKRNACIK S, 1994, MOL ENDOCRINOL, V8, P218, DOI 10.1210/me.8.2.218; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DIXON M, 1989, MOL CELL BIOL, V9, P4896, DOI 10.1128/MCB.9.11.4896; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELYAZIDI I, 1995, ANTICANCER RES, V15, P783; Fioravanti L, 1997, INT J CANCER, V74, P620, DOI 10.1002/(SICI)1097-0215(19971219)74:6<620::AID-IJC11>3.0.CO;2-9; Galzie Z, 1997, BIOCHEM CELL BIOL, V75, P669, DOI 10.1139/bcb-75-6-669; GAVIN BJ, 1992, MOL CELL BIOL, V12, P2418, DOI 10.1128/MCB.12.5.2418; Hajitou A, 1998, ONCOGENE, V17, P2059, DOI 10.1038/sj.onc.1202126; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; Hollmann CA, 2000, IN VITRO CELL DEV-AN, V36, P74; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Jackson D, 1997, J CELL SCI, V110, P1261; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; Jansen LAM, 1996, CARCINOGENESIS, V17, P1527, DOI 10.1093/carcin/17.7.1527; JERRY DJ, 1993, CANCER RES, V53, P3374; Jiang WG, 1996, BRIT J SURG, V83, P437, DOI 10.1002/bjs.1800830404; KERN FG, 1994, BREAST CANCER RES TR, V31, P153, DOI 10.1007/BF00666149; KITTRELL FS, 1992, CANCER RES, V52, P1924; KLINT P, 1999, FRONT BIOSCI, V4, P165; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhl M, 2000, TRENDS GENET, V16, P279, DOI 10.1016/s0168-9525(00)02028-x; KWAN H, 1992, MOL CELL BIOL, V12, P147, DOI 10.1128/MCB.12.1.147; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; McLeskey SW, 1996, BREAST CANCER RES TR, V39, P103, DOI 10.1007/BF01806082; Medina D, 1998, MOL CARCINOGEN, V22, P199, DOI 10.1002/(SICI)1098-2744(199807)22:3<199::AID-MC8>3.0.CO;2-G; MEDINA D, 1993, CANCER RES, V53, P668; MEDINA D, 1993, CARCINOGENESIS, V14, P25, DOI 10.1093/carcin/14.1.25; MEDINA D, 1993, CANCER RES, V53, P663; MEDINA D, 1973, METHOD CANCER RES, V7, P353; MERLO GR, 1990, CELL GROWTH DIFFER, V1, P463; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; Naylor S, 2000, J CELL SCI, V113, P2129; NUSSE R, 1984, NATURE, V307, P131, DOI 10.1038/307131a0; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; OZBUN MA, 1993, CANCER RES, V53, P1646; Papkoff J, 1997, J BIOL CHEM, V272, P4536; PETERS G, 1984, NATURE, V309, P273, DOI 10.1038/309273a0; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; Polakis P, 2000, GENE DEV, V14, P1837; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; Schroeder JA, 2000, ONCOGENE, V19, P3193, DOI 10.1038/sj.onc.1203652; Shaulian E, 1997, ONCOGENE, V15, P2717, DOI 10.1038/sj.onc.1201453; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Uitenbroek DG., 1997, SISA BINOMIAL; VENESIO T, 1992, CELL GROWTH DIFFER, V3, P63; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEBERHALL SJ, 1994, DIFFERENTIATION, V57, P205, DOI 10.1046/j.1432-0436.1994.5730205.x; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x	63	12	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 15	2001	20	52					7645	7657		10.1038/sj.onc.1204980	http://dx.doi.org/10.1038/sj.onc.1204980			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	491TC	11753642				2022-12-17	WOS:000172124100007
J	Kim, KC; Kim, TS; Kang, KH; Choi, KH				Kim, KC; Kim, TS; Kang, KH; Choi, KH			Amphiphysin IIb-1, a novel splicing variant of amphiphysin II, regulates p73 beta function through protein-protein interactions	ONCOGENE			English	Article						p73; amphiphysin IIb-1; SH3 domain; NLS; yeast two-hybrid; splicing variants	KINASE C-ABL; TYROSINE KINASE; DNA-DAMAGE; APOPTOTIC RESPONSE; ADENOVIRUS TYPE-5; INDUCE APOPTOSIS; MAMMALIAN-CELLS; 3-HYBRID SYSTEM; E4ORF6 PROTEINS; BREAST-CANCER	p73 is a nuclear protein that is similar in structure and function to p53. Notably, the C-terminal region of p73 has a regulatory function, through interactions with a positive or negative regulator. In this study, we use the yeast two-hybrid technique to identify a novel p73 beta binding protein, designated amphiphysin IIb-1. Amphiphysin IIb-1 is one of the splicing variants of amphiphysin II, and has a shorter protein product than amphiphysin IIb, which has been previously reported. We confirmed that amphiphysin IIb-1 binds full-length p73 beta, both in vitro and in vivo. This association is mediated via the SH3 domain of amphiphysin IIb-1 and C-terminal amino acids 321-376 of p73 beta. Double immunofluorescence patterns revealed that p73 beta is relocalized to the cytoplasm in the presence of amphiphysin IIb-1. Overexpression of amphiphysin IIb-1 was found to significantly inhibit the transcriptional activity of p73 beta in a dose-dependent manner. In addition, the cell death function of p73 beta was inhibited by amphiphysin IIb-1. These findings offer a new insight into the regulation mechanism of p73 beta, and suggest that amphiphysin IIb-1 modulates p73 beta function by direct binding.	Chung Ang Univ, Coll Nat Sci, Dept Biol, Mol Biol Lab,Dongjak Ku, Seoul 156756, South Korea	Chung Ang University	Choi, KH (corresponding author), Chung Ang Univ, Coll Nat Sci, Dept Biol, Mol Biol Lab,Dongjak Ku, Heuksuk Dong, Seoul 156756, South Korea.							Agami R, 1999, NATURE, V399, P809; BAUER F, 1993, MOL CELL BIOL, V13, P5070, DOI 10.1128/MCB.13.8.5070; Butler MH, 1997, J CELL BIOL, V137, P1355, DOI 10.1083/jcb.137.6.1355; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dobbelstein M, 1999, ONCOGENE, V18, P2101, DOI 10.1038/sj.onc.1202512; Elliott K, 1999, ONCOGENE, V18, P3564, DOI 10.1038/sj.onc.1202670; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Ge K, 2000, GENOMICS, V67, P210, DOI 10.1006/geno.2000.6216; Gong JG, 1999, NATURE, V399, P806; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; HORVATH A, 1994, YEAST, V10, P1305, DOI 10.1002/yea.320101007; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kadlec L, 1997, P NATL ACAD SCI USA, V94, P12390, DOI 10.1073/pnas.94.23.12390; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim IS, 2000, J BIOL CHEM, V275, P23139, DOI 10.1074/jbc.M909256199; Kleihues P, 1997, AM J PATHOL, V150, P1; LEDOUARIN B, 1995, NUCLEIC ACIDS RES, V23, P876, DOI 10.1093/nar/23.5.876; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Licitra EJ, 1996, P NATL ACAD SCI USA, V93, P12817, DOI 10.1073/pnas.93.23.12817; MARTIN MC, 1998, MOL CELL BIOL, V18, P6316; Moll UM, 1996, MOL CELL BIOL, V16, P1126; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; Ostermeyer AG, 1996, P NATL ACAD SCI USA, V93, P15190, DOI 10.1073/pnas.93.26.15190; Ozaki T, 1999, CANCER RES, V59, P5902; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; Roth J, 1998, J VIROL, V72, P8510, DOI 10.1128/JVI.72.11.8510-8516.1998; Sakamuro D, 1996, NAT GENET, V14, P69, DOI 10.1038/ng0996-69; Steegenga WT, 1999, MOL CELL BIOL, V19, P3885; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Tirode F, 1997, J BIOL CHEM, V272, P22995, DOI 10.1074/jbc.272.37.22995; Tsutsui K, 1997, BIOCHEM BIOPH RES CO, V236, P178, DOI 10.1006/bbrc.1997.6927; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Wienzek S, 2000, J VIROL, V74, P193, DOI 10.1128/JVI.74.1.193-202.2000; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	44	12	12	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6689	6699		10.1038/sj.onc.1204839	http://dx.doi.org/10.1038/sj.onc.1204839			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709703				2022-12-17	WOS:000171551600005
J	Kim, SW; Kim, HJ; Jung, DJ; Lee, SK; Kim, YS; Kim, JH; Kim, TS; Lee, JW				Kim, SW; Kim, HJ; Jung, DJ; Lee, SK; Kim, YS; Kim, JH; Kim, TS; Lee, JW			Retinoid-dependent antagonism of serum response factor transactivation mediated by transcriptional coactivator proteins	ONCOGENE			English	Article						SRF; retinoids; transcription; coactivator; nuclear receptors	NUCLEAR HORMONE-RECEPTOR; THYROID-HORMONE; BINDING DOMAIN; CO-REPRESSOR; EXPRESSION; ELEMENT; GENE; ACTIVATION; INTERACTS; PROMOTER	Transcriptional coactivators SRC-1 and p300 specifically interact with liganded-nuclear receptors and also modulate other transcription factors, including serum response factor (SRF). Here, we report that retinoids repress transactivation by SRF and specific interactions exist between the DNA binding domains of SRF and retinoic acid and retinoid X receptors. We further demonstrate that the repression may involve retinoid-dependent competition for a limiting amount of SRC-I and p300 between SRF and retinoid receptors. We propose that the well-defined anti-proliferative action of retinoids could, at least in part, result from this novel transrepressive action on the mitogenic transcription factor SRF.	Pohang Univ Sci & Technol, Ctr Ligand & Transcript, Pohang 790784, South Korea; Chonnam Natl Univ, Coll Pharm, Kwangju 500757, South Korea; Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 506303, South Korea	Pohang University of Science & Technology (POSTECH); Chonnam National University; Salk Institute; Gwangju Institute of Science & Technology (GIST)	Lee, JW (corresponding author), Pohang Univ Sci & Technol, Ctr Ligand & Transcript, Pohang 790784, South Korea.		Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208; Kim, Seung-Whan/0000-0001-6983-0481				Arsenian S, 1998, EMBO J, V17, P6289, DOI 10.1093/emboj/17.21.6289; Belaguli NS, 1997, J BIOL CHEM, V272, P18222, DOI 10.1074/jbc.272.29.18222; BUSHEL P, 1995, ONCOGENE, V10, P1361; CATALA F, 1995, MOL CELL BIOL, V15, P4585; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kim HJ, 1998, J BIOL CHEM, V273, P28564, DOI 10.1074/jbc.273.44.28564; KIM JH, 1994, J BIOL CHEM, V269, P13740; Lee JW, 2001, CELL MOL LIFE SCI, V58, P289, DOI 10.1007/PL00000856; LEE JW, 1992, MOL ENDOCRINOL, V6, P1867, DOI 10.1210/me.6.11.1867; Lee SK, 2000, J BIOL CHEM, V275, P12470, DOI 10.1074/jbc.275.17.12470; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; Moore DD, 1995, GLOB MOB SURV; Poser S, 2000, EMBO J, V19, P4955, DOI 10.1093/emboj/19.18.4955; Ramirez S, 1997, J BIOL CHEM, V272, P31016, DOI 10.1074/jbc.272.49.31016; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Slack J L, 1999, Curr Opin Hematol, V6, P236, DOI 10.1097/00062752-199907000-00007; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5	27	12	12	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 4	2001	20	45					6638	6642		10.1038/sj.onc.1204695	http://dx.doi.org/10.1038/sj.onc.1204695			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	479KU	11641790				2022-12-17	WOS:000171404200018
J	Schmidt, M; Koller, R; Haviernik, P; Bies, J; Maciag, K; Wolff, L				Schmidt, M; Koller, R; Haviernik, P; Bies, J; Maciag, K; Wolff, L			Deregulated c-Myb expression in murine myeloid leukemias prevents the up-regulation of p15(INK4b) normally associated with differentiation	ONCOGENE			English	Article						c-Myb; p15(INK4b); myeloid leukemia	CELL-CYCLE INHIBITORS; TERMINAL DIFFERENTIATION; GENE FAMILY; BALB/C MICE; APOPTOSIS; INACTIVATION; METHYLATION; P16(INK4A); INDUCTION; PROTEIN	Deregulated expression of the proto-oncogene c-myb, which results from provirus integration, is thought to be responsible for transformation in a set of murine leukemia virus (MuLV)-induced myeloid leukemias (MML). We reported recently that this transcription factor promotes proliferation by directly transactivating c-myc and inhibits cell death through its up-regulation of Bcl-2 (Schmidt et al., 2000). To understand more about how these cells become transformed we looked at how they deal with cellular pathways inducing growth arrest. Specifically, we were interested in the expression of the tumor suppressor gene Cdkn2b (p15(INK4b)) in MML because this gene is expressed during myeloid differentiation and its inactivation by methylation has been shown to be important for the development of human acute myeloid leukemia. mRNA levels for p15(INK4b) and another INK4 gene p16(INK4b) were examined in monocytic Myb tumors and were compared with expression of the same genes in c-myc transformed monocytic tumors that do not express c-Myb. The Cdkn2a (p16(INK4b)) gene was generally not expressed in either tumor type, an observation explained by methylation or deletion in the promoter region. Although Cdkn2b (p15(INK4b)) mRNA was expressed in the Myc tumors, many transcripts were aberrant in size and contained only exon 1. Surprisingly, in the majority of the Myb tumors there was no p15(INK4b) transcription and neither deletion nor methylation could explain this result. Additional experiments demonstrated that, in the presence of constitutive c-Myb expression, the induction of p15(INK4b) mRNA that accompanies differentiation of MI cells to monocytes does not occur. Therefore, the transcriptional regulator c-Myb appears to prevent activation of a growth arrest pathway that normally accompanies monocyte maturation.	NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA; Canc Res Inst, Mol Virol Lab, Bratislava, Slovakia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Slovak Academy of Sciences	Wolff, L (corresponding author), NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA.	LWOLFF@helix.nih.gov		/0000-0003-0803-4312				Amanullah A, 2000, BLOOD, V96, P475; Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; Batova A, 1997, CANCER RES, V57, P832; Bies J, 1996, ONCOGENE, V12, P355; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; Cameron EE, 1999, BLOOD, V94, P2445, DOI 10.1182/blood.V94.7.2445.419k19_2445_2451; COGSWELL JP, 1993, MOL CELL BIOL, V13, P2858, DOI 10.1128/MCB.13.5.2858; DellaRagione F, 1997, LEUKEMIA LYMPHOMA, V25, P23, DOI 10.3109/10428199709042493; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; GODA SK, 1995, NUCLEIC ACIDS RES, V23, P3357, DOI 10.1093/nar/23.16.3357; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Herman JG, 1996, CANCER RES, V56, P722; HIRAMA T, 1995, BLOOD, V86, P841; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; Latres E, 2000, EMBO J, V19, P3496, DOI 10.1093/emboj/19.13.3496; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; NASONBURCHENAL K, 1993, P NATL ACAD SCI USA, V90, P1619, DOI 10.1073/pnas.90.4.1619; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; QUELLE DE, 1995, ONCOGENE, V11, P635; Ratajczak MZ, 1998, BLOOD, V91, P1934, DOI 10.1182/blood.V91.6.1934.1934_1934_1946; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Schwaller J, 1997, LEUKEMIA, V11, P54, DOI 10.1038/sj.leu.2400522; SELVAKUMARAN M, 1992, MOL CELL BIOL, V12, P2493, DOI 10.1128/MCB.12.6.2493; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; Siebert R, 1996, LEUKEMIA LYMPHOMA, V23, P505, DOI 10.3109/10428199609054859; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; Teofili L, 1998, EXP HEMATOL, V26, P1133; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; Wolff L, 1996, CURR TOP MICROBIOL, V211, P191; WOLFF L, 1991, J VIROL, V65, P3607, DOI 10.1128/JVI.65.7.3607-3616.1991; WOLFF L, 1988, J IMMUNOL, V141, P681; Wolff L, 1996, CRIT REV ONCOGENESIS, V7, P245, DOI 10.1615/CritRevOncog.v7.i3-4.60; Zhang B, 2000, J MOL BIOL, V299, P1121, DOI 10.1006/jmbi.2000.3803; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; ZOBEL A, 1992, BIOCHEM BIOPH RES CO, V186, P715, DOI 10.1016/0006-291X(92)90805-U	45	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2001	20	43					6205	6214		10.1038/sj.onc.1204821	http://dx.doi.org/10.1038/sj.onc.1204821			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	476BL	11593429				2022-12-17	WOS:000171206300012
J	Sigal, A; Matas, D; Almog, N; Goldfinger, N; Rotter, V				Sigal, A; Matas, D; Almog, N; Goldfinger, N; Rotter, V			The C-terminus of mutant p53 is necessary for its ability to interfere with growth arrest or apoptosis	ONCOGENE			English	Article						mutant p53; gain of function; apoptosis; growth arrest; G(2)	WILD-TYPE P53; DNA-BINDING FUNCTION; GAIN-OF-FUNCTION; P53-REGULATED GENE-EXPRESSION; ALTERNATIVELY SPLICED FORM; CELL-CYCLE CONTROL; FUNCTION MUTATIONS; TYROSINE KINASE; MYELOID CELLS; PROTEIN	The ability to suppress wild type p53-independent apoptosis may play an important role in the oncogenicity of p53 mutant proteins. However, structural elements necessary for this activity are unknown. Furthermore, it is unclear whether this mutant p53 mediated inhibition is specific to the apoptotic pathway or a more general suppression of the cellular response to stress. We observed that an unmodified C-terminus was required for the suppression of apoptosis by the p53 135(Ala to Val) oncogenic p53 mutant. It was also required for the novel activity of G(2) arrest suppression, the predominant response at low levels of genotoxic stress. These observations are consistent with a model whereby mutant p53 suppressive activity is not specific to the apoptotic pathway, but rather increases the threshold of genotoxic stress needed for a DNA damage response to occur. Furthermore, these observations indicate that it may be possible to selectively kill mutant p53 expressing cells based on the lower sensitivity of their growth arrest response.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	varda.rotter@weizmann.ac.il	Sigal, Alex/GWC-7488-2022	Sigal, Alex/0000-0001-8571-2004				Agami R, 1999, NATURE, V399, P809; Almog N, 1997, MOL CELL BIOL, V17, P713, DOI 10.1128/MCB.17.2.713; Almog N, 2000, ONCOGENE, V19, P3395, DOI 10.1038/sj.onc.1203673; ALONIGRINSTEIN R, 1995, EMBO J, V14, P1392, DOI 10.1002/j.1460-2075.1995.tb07125.x; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; ARAI N, 1986, MOL CELL BIOL, V6, P3232, DOI 10.1128/MCB.6.9.3232; Blagosklonny MV, 2000, J CLIN INVEST, V105, P533, DOI 10.1172/JCI8625; Blagosklonny MV, 2000, CANCER RES, V60, P3425; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chene P, 1998, J MOL BIOL, V281, P205, DOI 10.1006/jmbi.1998.1897; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; DARZYNKIEWICZ Z, 1994, CELL BIOL LAB HDB, V1, P261; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P427; Davison TS, 1999, J BIOL CHEM, V274, P18709, DOI 10.1074/jbc.274.26.18709; Delia D, 1997, ONCOGENE, V14, P2137, DOI 10.1038/sj.onc.1201050; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Goi K, 1997, CANCER RES, V57, P1895; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HSIAO M, 1994, AM J PATHOL, V145, P702; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1993, NUCLEIC ACIDS RES, V21, P3167, DOI 10.1093/nar/21.14.3167; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Hussain SP, 1998, CANCER RES, V58, P4023; Iwamoto KS, 1996, CANCER RES, V56, P3862; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lanyi A, 1998, ONCOGENE, V16, P3169, DOI 10.1038/sj.onc.1201857; Lassus P, 1999, ONCOGENE, V18, P4699, DOI 10.1038/sj.onc.1202841; Lassus P, 1996, EMBO J, V15, P4566, DOI 10.1002/j.1460-2075.1996.tb00834.x; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Marston NJ, 1998, ONCOGENE, V16, P3123, DOI 10.1038/sj.onc.1201856; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Peled A, 1996, CANCER RES, V56, P2148; POWELL SN, 1995, CANCER RES, V55, P1643; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Selivanova G, 1998, SEMIN CANCER BIOL, V8, P369, DOI 10.1006/scbi.1998.0099; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHAULSKY G, 1991, CANCER RES, V51, P5232; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Sigal A, 2000, CANCER RES, V60, P6788; SRIVASTAVA S, 1993, CANCER RES, V53, P4452; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; WOLF D, 1984, CELL, V38, P119, DOI 10.1016/0092-8674(84)90532-4; Wolkowicz R, 1998, CANCER DETECT PREV, V22, P1, DOI 10.1046/j.1525-1500.1998.00003.x; WOLKOWICZ R, 1995, P NATL ACAD SCI USA, V92, P6842, DOI 10.1073/pnas.92.15.6842; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhao RB, 2000, GENE DEV, V14, P981; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	61	12	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2001	20	35					4891	4898		10.1038/sj.onc.1204724	http://dx.doi.org/10.1038/sj.onc.1204724			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	459VH	11521201				2022-12-17	WOS:000170271800014
J	Bensaad, K; Rouillard, D; Soussi, T				Bensaad, K; Rouillard, D; Soussi, T			Regulation of the cell cycle by p53 after DNA damage in an amphibian cell line	ONCOGENE			English	Article						p53; DNA damage; Xenopus laevis; cell cycle	XENOPUS-LAEVIS P53; WILD-TYPE P53; HUMAN CANCER; PROTEIN; BINDING; MUTATIONS; GENE; TRANSACTIVATION; MDM2; PHOSPHORYLATION	In mammalian cells, the p53 protein is a kev regulator of the cell cycle following DNA damage. In the present study, we investigated the function of p53 in the A6 amphibian cell line. Using various specific Xenopus p53 monoclonal antibodies, we showed that Xenopus p53 accumulates after DNA damage, including gamma and UV irradiation or treatment with adriamycin, Such accumulation is accompanied by an increase in the apparent molecular weight of the protein. This change was shown to be the result of a phosphorylation event that occurs after DNA damage. Accumulation of Xenopus p53 is parallel to a drastic change in the cell cycle distribution. Brief exposure to adriamycin or gamma irradiation induces reversible growth arrest, whereas long-term exposure to adriamycin leads to apoptosis, Taken together, these results indicate that p53 has a similar behaviour in frog cells and mammalian cells, and that it conserves two activities, cell cycle arrest and apoptosis.	Inst Curie, Lab Genotoxicol Tumeurs, F-75005 Paris, France; Inst Curie, Serv Cytometrie, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Soussi, T (corresponding author), Inst Curie, Lab Genotoxicol Tumeurs, 26 Rue Ulm, F-75005 Paris, France.			soussi, thierry/0000-0001-8184-3293				Amariglio F, 1997, ONCOGENE, V15, P2191, DOI 10.1038/sj.onc.1201395; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BISBEE CA, 1977, SCIENCE, V195, P785, DOI 10.1126/science.65013; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; DEQUIEDT F, 1995, VIROLOGY, V209, P676, DOI 10.1006/viro.1995.1303; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Hansen S, 1996, J BIOL CHEM, V271, P3917; HARDYBESSARD AC, 1998, ONCOGENE, V16, P883; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; Mayr B, 2000, RES VET SCI, V68, P63, DOI 10.1053/rvsc.1999.0339; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; NIGRO JM, 1992, MOL CELL BIOL, V12, P1357, DOI 10.1128/MCB.12.3.1357; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; ORY K, 1994, EMBO J, V13, P3496, DOI 10.1002/j.1460-2075.1994.tb06656.x; RAFFERTY KA, 1969, BIOL AMPHIBIAN TUMOR, P52; RIDGWAY PJ, 1994, J VIROL, V68, P7178, DOI 10.1128/JVI.68.11.7178-7187.1994; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Soussi T, 2000, HUM MUTAT, V15, P105, DOI 10.1002/(SICI)1098-1004(200001)15:1<105::AID-HUMU19>3.0.CO;2-G; SOUSSI T, 1987, ONCOGENE, V1, P71; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; SOUSSI T, 1989, J VIROL, V63, P3894, DOI 10.1128/JVI.63.9.3894-3901.1989; Tchang F, 1999, EXP CELL RES, V251, P46, DOI 10.1006/excr.1999.4570; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; Veldhoen N, 1998, ONCOGENE, V16, P249, DOI 10.1038/sj.onc.1201489; WANG Y, 1995, ONCOGENE, V10, P779; WILSON GD, 1985, CYTOMETRY, V6, P641, DOI 10.1002/cyto.990060621; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343	37	12	12	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 28	2001	20	29					3766	3775		10.1038/sj.onc.1204492	http://dx.doi.org/10.1038/sj.onc.1204492			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	446CE	11439340				2022-12-17	WOS:000169494700002
J	Naka, M; Ozaki, T; Takada, N; Takahashi, M; Shishikura, T; Sakiyama, S; Tada, M; Todo, S; Nakagawara, A				Naka, M; Ozaki, T; Takada, N; Takahashi, M; Shishikura, T; Sakiyama, S; Tada, M; Todo, S; Nakagawara, A			Functional characterization of naturally occurring mutants (P405R and P425L) of p73 alpha and p73 beta found in neuroblastoma and lung cancer	ONCOGENE			English	Article						growth suppression; missense mutation; p73; transcriptional activity	KINASE C-ABL; APOPTOTIC RESPONSE; TERMINAL REGION; P73 FUNCTION; P53; INDUCTION; VARIANTS; IDENTIFICATION; CELLS	The novel candidate tumor suppressor p73, a structural and functional homolog of p53, activates various p53 responsive promoters and induces tumor cell apoptosis, Although p73 is infrequently mutated in human cancers, we ha, e previously found two types of p73 mutation with amino acid substitution (P405R and P425L) in primary neuroblastoma and lung cancer. Here we report generations of the p73 mutants with either P405R or P425L substitution and functional analysis of these naturally occurring mutants, Indirect immunofluorescence staining revealed that nuclear accumulation of p73 alpha or p73 beta was not affected by these mutations. The P425L substitution reduced the ability of p73a to transactivate various p53 responsive promoters (p21(Waf1), Mdm2, and Bax), Moreover, this down-regulation was correlated with the reduced capability of p73 alpha (P425L) to suppress cell growth in p53-deficient SAOS-2 cells. In contrast, p73 beta (P425L) was as effective as wild-type p73 beta in transactivation and growth inhibition. On the other hand, the P405R substitution had no significant effect on both the transcriptional activity and the growth-suppressive ability of p73 alpha or p73 beta. These results suggested that, at least, one of the naturally occurring p73 mutants, p73 alpha (P425L), was a functionally defective mutant of p73.	Chiba Canc Ctr, Res Inst, Div Biochem, Chiba 2608717, Japan; Inst Canc Res, Div Cell Biol, Ciba 2608717, Japan; Hokkaido Univ, Sch Med, Dept Surg 1, Sapporo, Hokkaido 0608638, Japan	Chiba Cancer Center; Hokkaido University	Nakagawara, A (corresponding author), Chiba Canc Ctr, Res Inst, Div Biochem, 666-2 Nitona, Chiba 2608717, Japan.							Agami R, 1999, NATURE, V399, P809; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dickman S, 1997, SCIENCE, V277, P1605, DOI 10.1126/science.277.5332.1605; Fang L, 1999, J CELL BIOL, V147, P823, DOI 10.1083/jcb.147.4.823; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; Gong JG, 1999, NATURE, V399, P806; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Ichimiya S, 1999, ONCOGENE, V18, P1061, DOI 10.1038/sj.onc.1202390; Ikawa S, 1999, CELL DEATH DIFFER, V6, P1154, DOI 10.1038/sj.cdd.4400631; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, ONCOGENE, V18, P7701, DOI 10.1038/sj.onc.1202955; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kim AL, 1999, J BIOL CHEM, V274, P34924, DOI 10.1074/jbc.274.49.34924; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Ozaki T, 1999, CANCER RES, V59, P5902; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Takada N, 1999, CANCER RES, V59, P2810; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zeng XY, 1999, MOL CELL BIOL, V19, P3257	27	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 14	2001	20	27					3568	3572		10.1038/sj.onc.1204470	http://dx.doi.org/10.1038/sj.onc.1204470			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	445VB	11429704				2022-12-17	WOS:000169478300013
J	Niitsu, N; Hayashi, Y; Honma, Y				Niitsu, N; Hayashi, Y; Honma, Y			Downregulation of MLL-CBP fusion gene expression is associated with differentiation of SN-1 cells with t(11;16)(q23;p13)	ONCOGENE			English	Article						differentiation; MLL-CBP; t(11;16)(q23;p13); RXR agonist, butyrate	RETINOID-X-RECEPTOR; ACUTE MYELOID-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; ACUTE MYELOGENOUS LEUKEMIA; NUCLEAR-PROTEIN CBP; HISTONE ACETYLTRANSFERASE; BUTYRIC-ACID; SODIUM-BUTYRATE; TRANSCRIPTIONAL ACTIVATION; MYELOMONOCYTIC LEUKEMIA	The translocation t(11;16)(q23;p13) has only been documented in patients with acute leukemia or myelodysplasia secondary to therapy with drugs targeting DNA topoisomerase II. We have established a myeloid cell line (SN-1) with the MLL-CBP fusion gene from an acute leukemia patient with t(11;16)(q23;p13), Although SN-1 cells were not induced to differentiate by all-tr mw retinoic acid (ATRA) and 1 alpha ,25-dihydroxyvitamin D-3 (VD3), retinoid Ii receptor (RXR) agonists, such as 9-cis retinoic acid and Ro48-2250, effectively induced differentiation of the cells. Downregulation of the expression of the MLL-CBP fusion gene occurred during the differentiation of SN-1 cells, When SN-1 cells were treated with MLL-CBP antisense oligonucleotide, the cells were induced to differentiate by ATRA or VD3, suggesting that the MLL-CBP fusion gene dominant-negatively suppresses ATRA- or VD3-induced differentiation. Moreover, suboptimal concentrations of sodium butyrate, a histone deacetylase inhibitor, had a cooperative effect with ATRA or VD3 in inducing the differentiation of SN-1 cells, The downregulation of the expression of MLL-CBP mRNA was accompanied by the induction of differentiation. These findings suggest that RXR agonists or a clinically applicable combination of ATRA and butyrate derivatives might be useful for differentiation therapy in leukemia patients with the MLL-CBP fusion gene.	Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan; Toho Univ, Sch Med, Dept Internal Med 1, Tokyo 153, Japan; Univ Tokyo, Fac Med, Dept Pediat, Tokyo 113, Japan	Toho University; University of Tokyo	Honma, Y (corresponding author), Saitama Canc Ctr, Res Inst, Ina, Saitama 3620806, Japan.							Apfel CM, 1995, J BIOL CHEM, V270, P30765, DOI 10.1074/jbc.270.51.30765; AVIRAM A, 1994, INT J CANCER, V56, P906, DOI 10.1002/ijc.2910560625; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Bischoff ED, 1999, J NATL CANCER I, V91, P2118, DOI 10.1093/jnci/91.24.2118; Borrow J, 1996, NAT GENET, V14, P33, DOI 10.1038/ng0996-33; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHOMIENNE C, 1990, BLOOD, V76, P1710; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; Giles RH, 1997, LEUKEMIA, V11, P2087, DOI 10.1038/sj.leu.2400882; Harrison CJ, 1998, LEUKEMIA, V12, P811, DOI 10.1038/sj.leu.2401017; Hayashi Y, 2000, CANCER RES, V60, P1139; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HONMA Y, 1983, EUR J CANCER CLIN ON, V19, P251, DOI 10.1016/0277-5379(83)90424-8; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Ida K, 1997, BLOOD, V90, P4699, DOI 10.1182/blood.V90.12.4699.4699_4699_4704; Iijima T, 1999, CHEM PHARM BULL, V47, P398; Joh T, 1999, ONCOGENE, V18, P1125, DOI 10.1038/sj.onc.1202400; KAGECHIKA H, 1988, J MED CHEM, V31, P2182, DOI 10.1021/jm00119a021; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kasukabe T, 1997, BRIT J CANCER, V75, P850, DOI 10.1038/bjc.1997.151; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Makishima M, 1996, BLOOD, V87, P3384, DOI 10.1182/blood.V87.8.3384.bloodjournal8783384; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; MILLER AA, 1987, EUR J CANCER CLIN ON, V23, P1283, DOI 10.1016/0277-5379(87)90109-X; Miller VA, 1997, J CLIN ONCOL, V15, P790, DOI 10.1200/JCO.1997.15.2.790; Niitsu N, 1997, CELL GROWTH DIFFER, V8, P319; NOVOGRODSKY A, 1983, CANCER-AM CANCER SOC, V51, P9, DOI 10.1002/1097-0142(19830101)51:1<9::AID-CNCR2820510104>3.0.CO;2-4; NUDELMAN A, 1992, J MED CHEM, V35, P687, DOI 10.1021/jm00082a009; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; PETKOVICH M, 1987, NATURE, V330, P444, DOI 10.1038/330444a0; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; PRASAD KN, 1980, LIFE SCI, V27, P1351, DOI 10.1016/0024-3205(80)90397-5; PUI CH, 1994, J CLIN ONCOL, V12, P909, DOI 10.1200/JCO.1994.12.5.909; Rowley JD, 1997, BLOOD, V90, P535; Rowley JD, 1998, ANNU REV GENET, V32, P495, DOI 10.1146/annurev.genet.32.1.495; Rubnitz JE, 1997, PEDIATRICS, V100, P101, DOI 10.1542/peds.100.1.101; RUBNITZ JE, 1994, BLOOD, V84, P1747; Satake N, 1997, GENE CHROMOSOME CANC, V20, P60, DOI 10.1002/(SICI)1098-2264(199709)20:1<60::AID-GCC9>3.3.CO;2-O; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Sobulo OM, 1997, P NATL ACAD SCI USA, V94, P8732, DOI 10.1073/pnas.94.16.8732; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Taki T, 1997, BLOOD, V89, P3945, DOI 10.1182/blood.V89.11.3945; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; WARRELL RP, 1991, NEW ENGL J MED, V324, P1385, DOI 10.1056/NEJM199105163242002; Wolffe AP, 1997, NATURE, V387, P16, DOI 10.1038/387016a0; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yokoyama A, 1996, BLOOD, V88, P3555, DOI 10.1182/blood.V88.9.3555.bloodjournal8893555; YOSHIDA M, 1988, EXP CELL RES, V177, P122, DOI 10.1016/0014-4827(88)90030-4	54	12	15	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2001	20	3					375	384		10.1038/sj.onc.1204081	http://dx.doi.org/10.1038/sj.onc.1204081			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	392KV	11313967				2022-12-17	WOS:000166411000012
J	Klockow, B; Ahmadian, MR; Block, C; Wittinghofer, A				Klockow, B; Ahmadian, MR; Block, C; Wittinghofer, A			Oncogenic insertional mutations in the P-loop of Ras are overactive in MAP kinase signaling	ONCOGENE			English	Article						Ras; GTPase; oncogene; MAP kinase pathway	GTPASE-ACTIVATING PROTEINS; H-RAS; BINDING-PROTEINS; TRIPHOSPHATE CONFORMATION; STRUCTURAL DIFFERENCES; ESCHERICHIA-COLI; PC12 CELLS; IN-VITRO; P21; DOMAIN	Mutations of Ras with three extra amino acids inserted into the phosphate-binding (P) loop have been investigated both in vitro and in vivo. Such mutants have originally been detected as oncogenes both in the ras and the TC21 genes. Biochemical experiments reveal the molecular basis of their oncogenic potential: the mutants show a strongly attenuated binding affinity for nucleotides, most notably for GDP, leading to a preference for GTP binding. Furthermore, both the intrinsic as web as the GAP-stimulated GTP hydrolysis are drastically diminished. The binding interaction with GAP is reduced, whereas binding to the Ras-binding domain of the downstream effector c-Raf1 is not altered appreciably. Microinjection into PC12 cells shows the mutants to be as potent to induce neurite outgrowth as conventional oncogenic Ras mutants. Unexpectedly, their ability to stimulate the MAP kinase pathway as measured by a reporter gene assay in RK13 cells is much higher than that of the normal oncogenic mutant G12V. This characteristic was attributed to an increased stimulation of c-Raf1 kinase activity by the insertional Ras mutants.	Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany	Max Planck Society	Wittinghofer, A (corresponding author), Max Planck Inst Mol Physiol, Otto Hahn Str 11, D-44227 Dortmund, Germany.							Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Block C, 1996, NAT STRUCT BIOL, V3, P244, DOI 10.1038/nsb0396-244; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; Bollag G, 1996, J BIOL CHEM, V271, P32491, DOI 10.1074/jbc.271.51.32491; BOS JL, 1989, CANCER RES, V49, P4682; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHIPPERFIELD RG, 1985, MOL CELL BIOL, V5, P1809, DOI 10.1128/MCB.5.8.1809; Daub M, 1998, MOL CELL BIOL, V18, P6698, DOI 10.1128/MCB.18.11.6698; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; ENOMOTO T, 1990, CANCER RES, V50, P6139; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FRANKEN SM, 1993, BIOCHEMISTRY-US, V32, P8411, DOI 10.1021/bi00084a005; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOODY RS, 1991, TRENDS BIOCHEM SCI, V16, P327, DOI 10.1016/0968-0004(91)90134-H; GUERRERO I, 1987, MUTAT RES, V185, P293, DOI 10.1016/0165-1110(87)90021-2; Herrmann C, 1996, J BIOL CHEM, V271, P6794, DOI 10.1074/jbc.271.12.6794; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HIGINBOTHAM KG, 1994, ONCOGENE, V9, P2455; HUANG Y, 1995, ONCOGENE, V11, P1255; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1993, J BIOL CHEM, V268, P923; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; McCormick F, 1996, CURR OPIN BIOTECH, V7, P449, DOI 10.1016/S0958-1669(96)80123-6; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NEAL SE, 1988, J BIOL CHEM, V263, P19718; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PICARD V, 1994, NUCLEIC ACIDS RES, V22, P2587, DOI 10.1093/nar/22.13.2587; REINSTEIN J, 1991, J BIOL CHEM, V266, P17700; RENSLAND H, 1995, BIOCHEMISTRY-US, V34, P593, DOI 10.1021/bi00002a026; RENSLAND H, 1991, BIOCHEMISTRY-US, V30, P11181, DOI 10.1021/bi00110a023; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Schmidt G, 1996, ONCOGENE, V12, P87; SCHMIDT G, 1996, THESIS RUHR U BOCHUM; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; TONG L, 1989, NATURE, V337, P90, DOI 10.1038/337090a0; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VISVANATHAN KV, 1988, ONCOGENE RES, V3, P77; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; WIEST JS, 1994, ONCOGENE, V9, P2449; Zhang J, 1998, BIOCHEMISTRY-US, V37, P14881, DOI 10.1021/bi9811157; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	64	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 9	2000	19	47					5367	5376		10.1038/sj.onc.1203909	http://dx.doi.org/10.1038/sj.onc.1203909			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	373RH	11103938				2022-12-17	WOS:000165302300008
J	Narayan, S; Wilson, SH				Narayan, S; Wilson, SH			Kinetic analysis of Sp1-mediated transcriptional activation of the human DNA polymerase beta promoter	ONCOGENE			English	Article						Sp1; beta-pol promoter; in vitro transcription; kinetic analysis	PROTEIN-PROTEIN INTERACTIONS; BOX-BINDING-PROTEINS; TATA-LESS PROMOTER; PREINITIATION COMPLEX; FUNCTIONAL-ANALYSIS; II TRANSCRIPTION; TFIID COMPLEX; SP1; INITIATOR; CLONING	In the present studies, we have examined the effect of Spl on the activation of the human DNA polymerase beta (beta-pol), a TATA-less promoter. A HeLa cell nuclear extract (NE) based in vitro runoff transcription system of core beta-pol promoter human DNA (p beta P8) three-step kinetic model of transcription initiation were used to describe the kinetic effect of Spl. The results showed that distal Spl-binding sites in the core beta-pol promoter are important for transcriptional activation of the p beta P8 promoter. A detailed kinetic analysis showed that Spl stimulates the activity of the p beta PS promoter through distal Spl-binding sites by increasing the amount of recruitment, instead of stimulating the apparent rate of RPc assembly (k(1)), There was no significant effect of Sp1 on the apparent rate of open complex (RP0) formation (k(2)) Or on the apparent rate of promoter clearance (k(3)) Of the p beta P8 promoter. These studies define the kinetic mechanisms by which Spl may regulate the rate of transcript formation of the p beta P8 promoter, and these results may have implications for Spl regulation of TATA-less promoters.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Univ Texas, Med Branch, Sealy Ctr Oncol & Hematol, Galveston, TX 77555 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Narayan, S (corresponding author), Univ Florida, UF Shands Canc Ctr, POB 100232, Gainesville, FL 32610 USA.		Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293	NCI NIH HHS [CA77721] Funding Source: Medline; NIEHS NIH HHS [ES06492] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050159, R01ES006492, ZIAES050159] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; CHOY B, 1993, NATURE, V366, P531, DOI 10.1038/366531a0; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOODRICH JA, 1994, CELL, V77, P145, DOI 10.1016/0092-8674(94)90242-9; Goodrich JA, 1996, CELL, V84, P825, DOI 10.1016/S0092-8674(00)81061-2; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HE F, 1996, BIOCHEMISTRY-US, V35, P1776; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIEBERMAN PM, 1994, GENE DEV, V8, P995, DOI 10.1101/gad.8.9.995; MAJELLO B, 1994, NUCLEIC ACIDS RES, V22, P4914, DOI 10.1093/nar/22.23.4914; MAXON ME, 1994, GENE DEV, V8, P515, DOI 10.1101/gad.8.5.515; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; NARAYAN S, 1994, J BIOL CHEM, V269, P12755; NARAYAN S, 1995, BIOCHEMISTRY-US, V34, P73, DOI 10.1021/bi00001a009; Narayan S, 2000, BIOCHEMISTRY-US, V39, P818, DOI 10.1021/bi9912701; Narayan S, 1996, J BIOL CHEM, V271, P18508, DOI 10.1074/jbc.271.31.18508; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; VANDYKE MW, 1988, SCIENCE, V241, P1335, DOI 10.1126/science.3413495; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; Weis L, 1997, MOL CELL BIOL, V17, P2973, DOI 10.1128/MCB.17.6.2973; WIDEN SG, 1988, J BIOL CHEM, V263, P16992; Yean D, 1996, NUCLEIC ACIDS RES, V24, P2723, DOI 10.1093/nar/24.14.2723; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2	44	12	13	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 28	2000	19	41					4729	4735		10.1038/sj.onc.1203823	http://dx.doi.org/10.1038/sj.onc.1203823			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	357YB	11032023				2022-12-17	WOS:000089528800007
J	Facchinetti, V; Lopa, R; Spreafico, F; Bolognese, F; Mantovani, R; Tavner, F; Watson, R; Introna, M; Golay, J				Facchinetti, V; Lopa, R; Spreafico, F; Bolognese, F; Mantovani, R; Tavner, F; Watson, R; Introna, M; Golay, J			Isolation and characterization of the human A-myb promoter: regulation by NF-Y and Sp1	ONCOGENE			English	Article						myb; promoter; Sp1; NF-Y	CELL-CYCLE REGULATION; TRANSCRIPTION FACTOR; B-MYB; GENE-EXPRESSION; IN-VIVO; C-MYB; BURKITTS-LYMPHOMA; MUSCLE CELLS; CLASS-II; BINDING	The A-myb transcription factor shows a restricted tissue distribution and is cell cycle regulated. Furthermore its deregulation has profound effects on the growth and/or differentiation of the cells in which it is normally expressed. We have therefore characterized its promoter. A 12 kb genomic clone was isolated that comprises the first exon, part of the first intron as well as upstream regulatory sequences. Multiple transcription start sites have been identified which operate in both B lymphocytes and epithelial cells and the upsteam region was shown to have promoter, activity. The boundaries of the minimal promoter region (-183-14), of a positive upstream (-538-183) and a negative downstream regulatory region (NRE) (+83+374) have been defined. The NRE is promoter- and orientation-independent but position specific. The A-myb minimal promoter is GC-rich, does not contain any TATA box but has a functional CCAAT box. The! CCAAT box and minimal promoter is highly conserved in the corresponding murine sequence, The CCAAT box efficiently binds the NF-Y complex and its mutation decreases basal promoter activity by 50%, Two Sp1 binding sites are present upstream from the CCAAT box which can bind Sp1 and contribute to A-myb promoter activity by 70 and 30%, respectively. The two Sp1 sites and CCAAT box together contribute to over 80% of A-myb basal promoter activity and are therefore the major regulatory elements. Finally, we show that the promoter is cell cycle regulated and that the SP1 and CCAAT elements are required for S phase induction.	Mario Negri Inst Pharmacol Res, Dept Immunol & Cell Biol, Lab Mol Immunohaematol, I-20157 Milan, Italy; Univ Milan, Dept Genet & Biol Microorganisms, I-20133 Milan, Italy; St Marys Hosp, Sch Med, Ludwig Inst Canc Res, London W2 1PG, England	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Milan; Imperial College London; Ludwig Institute for Cancer Research	Introna, M (corresponding author), Mario Negri Inst Pharmacol Res, Dept Immunol & Cell Biol, Lab Mol Immunohaematol, Via Eritrea 62, I-20157 Milan, Italy.		Golay, Josee/AAA-4085-2022; Introna, Martino/AAA-5823-2019	Golay, Josee/0000-0002-7932-909X; Introna, Martino/0000-0001-6216-0892				Birnbaum MJ, 1995, BIOCHEMISTRY-US, V34, P16503, DOI 10.1021/bi00050a034; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; Blackwood EM, 1998, SCIENCE, V281, P60, DOI 10.1126/science.281.5373.60; Bolognese F, 1999, ONCOGENE, V18, P1845, DOI 10.1038/sj.onc.1202494; Busslinger M, 1996, P NATL ACAD SCI USA, V93, P6129, DOI 10.1073/pnas.93.12.6129; DATTA AK, 1995, NUCLEIC ACIDS RES, V23, P4530, DOI 10.1093/nar/23.21.4530; DeRocco SE, 1997, P NATL ACAD SCI USA, V94, P3240, DOI 10.1073/pnas.94.7.3240; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; FOOS G, 1994, ONCOGENE, V9, P2481; Golay J, 1996, BLOOD, V87, P1900; Golay J, 1997, LEUKEMIA LYMPHOMA, V26, P271, DOI 10.3109/10428199709051776; GOLAY J, 1994, ONCOGENE, V9, P2469; GOLAY J, 1994, J IMMUNOL, V153, P543; Golay J, 1998, J IMMUNOL, V160, P2786; GONDA TJ, 1987, J VIROL, V61, P2754, DOI 10.1128/JVI.61.9.2754-2763.1987; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Huet X, 1996, MOL CELL BIOL, V16, P3789; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Latham KE, 1996, ONCOGENE, V13, P1161; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1992, EMBO J, V11, P3315, DOI 10.1002/j.1460-2075.1992.tb05410.x; Marhamati DJ, 1997, MOL CELL BIOL, V17, P2448, DOI 10.1128/MCB.17.5.2448; METTUS RV, 1994, ONCOGENE, V9, P3077; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; NOMURA N, 1988, NUCLEIC ACIDS RES, V16, P11075, DOI 10.1093/nar/16.23.11075; Noti JD, 1996, MOL CELL BIOL, V16, P2940; Oh IH, 1997, J BIOL CHEM, V272, P21432, DOI 10.1074/jbc.272.34.21432; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Roder K, 1997, J BIOL CHEM, V272, P21616, DOI 10.1074/jbc.272.34.21616; Sala A, 1999, ONCOGENE, V18, P1333, DOI 10.1038/sj.onc.1202421; Saville MK, 1998, ADV CANCER RES, V72, P109; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; Smith CL, 1997, J BIOL CHEM, V272, P27493, DOI 10.1074/jbc.272.44.27493; Sundseth R, 1997, MOL PHARMACOL, V51, P963, DOI 10.1124/mol.51.6.963; TAKAHASHI T, 1995, FEBS LETT, V358, P89, DOI 10.1016/0014-5793(94)01402-M; Toscani A, 1997, NATURE, V386, P713, DOI 10.1038/386713a0; TRAUTH K, 1994, EMBO J, V13, P5994, DOI 10.1002/j.1460-2075.1994.tb06945.x; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; vanGinkel PR, 1997, J BIOL CHEM, V272, P18367, DOI 10.1074/jbc.272.29.18367; Wells J, 1996, MOL CELL BIOL, V16, P634; WRIGHT KL, 1995, J BIOL CHEM, V270, P20978, DOI 10.1074/jbc.270.36.20978; Ying GG, 1997, J BIOL CHEM, V272, P24921, DOI 10.1074/jbc.272.40.24921; Young Wise, 1993, Journal of Emergency Medicine, V11, P13; Ziebold U, 1997, ONCOGENE, V15, P1011, DOI 10.1038/sj.onc.1201282; Zwicker J, 1997, TRENDS GENET, V13, P3, DOI 10.1016/S0168-9525(96)30112-1; ZWICKER J, 1995, NUCLEIC ACIDS RES, V23, P3822, DOI 10.1093/nar/23.19.3822; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	53	12	13	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 10	2000	19	34					3931	3940		10.1038/sj.onc.1203730	http://dx.doi.org/10.1038/sj.onc.1203730			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341WQ	10951586				2022-12-17	WOS:000088614300012
J	McPherson, RA; Taylor, MM; Hershey, ED; Sturgill, TW				McPherson, RA; Taylor, MM; Hershey, ED; Sturgill, TW			A different function for a critical tryptophan in c-Raf and Hck	ONCOGENE			English	Article						Raf; Ras; Src; kinase	PROTEIN-KINASE-C; SRC FAMILY; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; IN-VITRO; ACTIVATION; CELLS; C-RAF-1; PATHWAY; VIVO	The similarity of the catalytic domains of Raf and Src family members suggests that functions of homologous residues may be similar in both kinase families. A tryptophan residue, W260, in the WEI region of the Src family kinase Hck has an important role in regulating ATP binding. We tested the hypothesis that the tryptophan, W342, in the WEI region of c-Raf may have a similar role to the W260 of Hck. Mutation of W260 to A in Hck activates kinase activity, but me found that mutation of W342 to A in c-Raf inactivates the kinase activity. Mutating W342 to aspartate (D), lysine (K) or histidine (H) also inactivated c-Raf whether assayed as a purified immunoprecipitate or when recruited to the plasma membrane. A constitutively active c-Raf can be generated by mutating two regulatory tyrosines to aspartate. When placed into this active c-Raf mutant, mutation of W342 to D, K or H enabled phosphorylation and activation of the c-Raf substrate MEK at the plasma membrane but not in an immunoprecipitation assay. We conclude that (1) Tryptophan has a different role in the WEI regions of c-Raf and Hck, (2) W342 is not directly involved in MEK binding as both positive and negative residues at 342 are permissive for MEK activation at the membrane in a constitutively active c-Raf mutant, (3) Factors at the membrane are capable of potentiating activation of c-Raf containing mutated W342 in a hyperactivated c-Raf, but not in a wild type c-Raf and (4) There is a stringent structural requirement for W at residue 342 in c-Raf.	Univ Virginia, Hlth Sci Ctr, Dept Clin Pharmacol, Ctr Cell Signaling, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Sci Ctr, Howard Hughes Med Inst, Charlottesville, VA 22908 USA	University of Virginia; Howard Hughes Medical Institute; University of Virginia	McPherson, RA (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Clin Pharmacol, Ctr Cell Signaling, Box 577, Charlottesville, VA 22908 USA.							Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Dent P, 1997, CELL SIGNAL, V9, P539, DOI 10.1016/S0898-6568(97)00048-X; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Hagemann D, 1999, ONCOGENE, V18, P1391, DOI 10.1038/sj.onc.1202431; Jelinek T, 1996, MOL CELL BIOL, V16, P1027; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARK GE, 1984, SCIENCE, V224, P285, DOI 10.1126/science.6324342; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McPherson RA, 1999, ONCOGENE, V18, P3862, DOI 10.1038/sj.onc.1202730; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; Rizzo MA, 1999, J BIOL CHEM, V274, P1131, DOI 10.1074/jbc.274.2.1131; Rosario M, 1999, EMBO J, V18, P1270, DOI 10.1093/emboj/18.5.1270; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Shapiro PS, 1998, J BIOL CHEM, V273, P1788, DOI 10.1074/jbc.273.3.1788; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Xia K, 1999, MOL CELL BIOL, V19, P4819; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; Ziogas A, 1998, J BIOL CHEM, V273, P24108, DOI 10.1074/jbc.273.37.24108	25	12	12	0	1	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 27	2000	19	32					3616	3622		10.1038/sj.onc.1203678	http://dx.doi.org/10.1038/sj.onc.1203678			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	341AF	10951567				2022-12-17	WOS:000088568300007
J	Umemori, H; Hayashi, T; Inoue, T; Nakanishi, S; Mikoshiba, K; Yamamoto, T				Umemori, H; Hayashi, T; Inoue, T; Nakanishi, S; Mikoshiba, K; Yamamoto, T			Involvement of protein tyrosine phosphatases in activation of the trimeric G protein G(q/11)	ONCOGENE			English	Article						tyrosine phosphorylation; tyrosine phosphatase; metabotropic glutamate receptor; G protein; G alpha(q/11); IP3	METABOTROPIC GLUTAMATE RECEPTORS; HETEROTRIMERIC G-PROTEINS; SIGNAL TRANSDUCTION; PHENYLARSINE OXIDE; RAT-1 FIBROBLASTS; ALPHA-SUBUNIT; PHOSPHORYLATION; KINASES; TRANSFORMATION; CELLS	A variety of receptors coupled to the heterotrimeric guanine nucleotide-binding protein G(q/11) stimulate intracellular Ca2+ release through inositol (1,4,5)-trisphosphate (IP3) formation. We previously reported that tyrosine phosphorylation of the alpha subunit of the G(q/11) protein by protein tyrosine kinases (PTKs) regulates the activation of G(q/11) protein. Here we show that protein tyrosine phosphatases (PTPs) are also essential for G(q/11) protein activation. We find that G(q/11) protein-coupled receptor-mediated formation of IP3 is blocked by PTP inhibitors as well as PTK inhibitors. These inhibitors act prior to G(q/11) protein activation. Tyrosine phosphorylation of the alpha subunit of G(q/11) appears to inhibit its interaction with receptors. Thus, PTP is required for controlling the level of tyrosine phosphorylation of the alpha subunit of G(q/11) to promote its interaction with receptors. Therefore, we conclude that PTKs and PTPs co-operate to proceed activation cycle of the G(q/11) protein through tyrosine phosphorylation and de-phosphorylation of the alpha subunit of G(q/11).	Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan; Univ Tokyo, Inst Med Sci, Dept Mol Neurobiol, Tokyo 1088639, Japan; Kyoto Univ, Fac Med, Dept Sci Biol, Kyoto 6068501, Japan	University of Tokyo; University of Tokyo; Kyoto University	Yamamoto, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Oncol, Tokyo 1088639, Japan.		Inoue, Takafumi/AAM-9533-2020; Mikoshiba, Katsuhiko/N-7943-2015	Inoue, Takafumi/0000-0002-2728-0060; Umemori, Hisashi/0000-0001-7198-2062; Hayashi, Takashi/0000-0003-3591-2109				ARAMORI I, 1992, NEURON, V8, P757, DOI 10.1016/0896-6273(92)90096-V; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BLUML K, 1994, J BIOL CHEM, V269, P18870; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; Fusaki N, 1996, J IMMUNOL, V156, P1369; GREENWALT DE, 1994, BRIT J HAEMATOL, V88, P830, DOI 10.1111/j.1365-2141.1994.tb05124.x; Hamm HE, 1996, CURR OPIN CELL BIOL, V8, P189, DOI 10.1016/S0955-0674(96)80065-2; Helgadottir A, 1997, ARTERIOSCL THROM VAS, V17, P287, DOI 10.1161/01.ATV.17.2.287; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Liu WW, 1996, P NATL ACAD SCI USA, V93, P8258, DOI 10.1073/pnas.93.16.8258; MATTINGLY RR, 1992, J BIOL CHEM, V267, P7470; NAKANISHI S, 1994, NEURON, V13, P1031, DOI 10.1016/0896-6273(94)90043-4; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OKUMA Y, 1992, J BIOL CHEM, V267, P14826; PIN JP, 1995, CURR OPIN NEUROBIOL, V5, P342, DOI 10.1016/0959-4388(95)80047-6; QIAN NX, 1993, P NATL ACAD SCI USA, V90, P4077, DOI 10.1073/pnas.90.9.4077; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Umemori H, 1997, SCIENCE, V276, P1878, DOI 10.1126/science.276.5320.1878; WANG YT, 1994, NATURE, V369, P233, DOI 10.1038/369233a0; YANAGA F, 1995, FEBS LETT, V368, P377, DOI 10.1016/0014-5793(95)00670-5; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	25	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7399	7402		10.1038/sj.onc.1203152	http://dx.doi.org/10.1038/sj.onc.1203152			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602498				2022-12-17	WOS:000084119400028
J	Kieran, MW; Katz, S; Vail, B; Zon, LI; Mayer, BJ				Kieran, MW; Katz, S; Vail, B; Zon, LI; Mayer, BJ			Concentration-dependent positive and negative regulation of a MAP kinase by a MAP kinase kinase	ONCOGENE			English	Article						MAP kinase; stress-activated kinase; JNK	ACTIVATED PROTEIN-KINASE; SIGNAL-TRANSDUCTION PATHWAY; PHEROMONE RESPONSE PATHWAY; HIGH-AFFINITY INTERACTION; JUN NH2-TERMINAL KINASE; C-JUN; INFLAMMATORY CYTOKINES; NUCLEAR TRANSLOCATION; DUAL PHOSPHORYLATION; STRUCTURAL BASIS	There are at least three distinct MAP kinase signaling modules in mammalian cells, distinguished by the family of kinases (Erk, SAPK/JNK, or p38) that is ultimately activated. Many input signals activate multiple MAP kinase cascades, and the mechanisms that control the specificity of signal output are not well understood. We show that SEK1/MKK4, a MAP kinase kinase proposed to activate SAPK/JNK, is a very potent inhibitor of p54 SAPK beta/JNK3 both in vitro and irt vivo if present at equimolar or higher ratios. In contrast SEK can activate SAPK when present in substoichiometric amounts, but this activation is slow, consistent with the rate-limiting step in activation being the dissociation of an inactive SEK:SAPK complex. The N-terminal unique region of SEK is both necessary and partially sufficient for inhibition of SAPK, and is also necessary for activation of SAPK by SEK in vitro. We have also used the p38 MAP kinase and its activator MKK6 to examine the regulatory relationships among different kinases involved in stress responses. We show using purified kinases that inhibitory activity is specific for the combination of SEK and SAPK: SEK can activate but not inhibit p38, and MKK6 can activate but not inhibit SAPK beta and p38. These results reveal a potential mechanism for regulating stress-activated kinases, adding to a growing body of evidence suggesting that MAP kinases are controlled by relatively stable interactions with their activators.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Dept Microbiol & Mol Genet, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Div Hematol Oncol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute	Mayer, BJ (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,Dept Microbiol & Mol Genet, 320 Longwood Ave, Boston, MA 02115 USA.			Kieran, Mark/0000-0003-2184-7692				Bardwell L, 1996, TRENDS BIOCHEM SCI, V21, P373, DOI 10.1016/S0968-0004(96)30032-7; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; CHOI KY, 1994, CELL, V78, P499; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; Cuenda A, 1996, EMBO J, V15, P4156, DOI 10.1002/j.1460-2075.1996.tb00790.x; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Fukuda M, 1997, EMBO J, V16, P1901, DOI 10.1093/emboj/16.8.1901; Ganiatsas S, 1998, P NATL ACAD SCI USA, V95, P6881, DOI 10.1073/pnas.95.12.6881; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; Khokhlatchev AV, 1998, CELL, V93, P605, DOI 10.1016/S0092-8674(00)81189-7; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; LEE LR, 1994, MOL ENDOCRINOL, V8, P746, DOI 10.1210/me.8.6.746; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARCUS S, 1994, P NATL ACAD SCI USA, V91, P7762, DOI 10.1073/pnas.91.16.7762; Mendelson KG, 1996, P NATL ACAD SCI USA, V93, P12908, DOI 10.1073/pnas.93.23.12908; Moriguchi T, 1996, J BIOL CHEM, V271, P13675, DOI 10.1074/jbc.271.23.13675; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Moriguchi T, 1996, J BIOL CHEM, V271, P26981, DOI 10.1074/jbc.271.43.26981; Nishina H, 1997, NATURE, V385, P350, DOI 10.1038/385350a0; Paul A, 1997, CELL SIGNAL, V9, P403, DOI 10.1016/S0898-6568(97)00042-9; Pelech SL, 1996, CURR BIOL, V6, P551, DOI 10.1016/S0960-9822(02)00540-7; PRINTEN JA, 1994, GENETICS, V138, P609; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; SETH A, 1992, J BIOL CHEM, V267, P24796; Shim J, 1996, NATURE, V381, P804, DOI 10.1038/381804a0; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Stein B, 1996, J BIOL CHEM, V271, P11427, DOI 10.1074/jbc.271.19.11427; TANAKA M, 1995, MOL CELL BIOL, V15, P6829; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wu ZG, 1997, MOL CELL BIOL, V17, P7407, DOI 10.1128/MCB.17.12.7407; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yao ZB, 1997, J BIOL CHEM, V272, P32378, DOI 10.1074/jbc.272.51.32378; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	52	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6647	6657		10.1038/sj.onc.1203057	http://dx.doi.org/10.1038/sj.onc.1203057			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597270				2022-12-17	WOS:000083792000004
J	Sherman, L; Sleeman, JP; Hennigan, RF; Herrlich, P; Ratner, N				Sherman, L; Sleeman, JP; Hennigan, RF; Herrlich, P; Ratner, N			Overexpression of activated neu/erbB2 initiates immortalization and malignant transformation of immature Schwann cells in vitro	ONCOGENE			English	Article						Schwann cells; neu; erbB2; transformation; immortalization	EPIDERMAL GROWTH-FACTOR; NEU DIFFERENTIATION FACTOR; TYROSINE KINASE-ACTIVITY; HUMAN BREAST-CANCER; NERVOUS-SYSTEM; WALLERIAN DEGENERATION; INCREASED EXPRESSION; SIGNAL-TRANSDUCTION; PERIPHERAL-NERVE; MULTISTEP NATURE	The neu/erbB2 protooncogene is overexpressed in numerous human cancers and is mutationally activated in N-ethyl-N-nitrosourea (ENU)-induced rodent tumors of the Schwann cell lineage. We investigated whether expression of activated neu in Schwann cells is sufficient to initiate their immortalization and transformation. Clones of embryonic dorsal root ganglia cells infected with a retrovirus bearing activated neu (NID cells) were selected based on their expression of Schwann cell-specific markers. Compared to embryonic Schwann cells infected,vith a virus encoding empty vector, we found that NID cells have altered shapes and disorganized cytoskeletons, grow in the absence of growth factors required for normal Schwann cell survival and proliferation, and can be repeatedly passaged. Furthermore, NID cells are invasive in an in vitro matrix invasion assay and form metastatic tumors when injected into syngeneic animals. The neu-induced growth and invasive phenotypes could be reversed by drugs that inhibit Ras and Src activity. Interestingly, later stage Schwann cells infected with activated neu failed to become immortalized. These findings indicate that constitutive activation of erbB2 is sufficient to initiate the immortalization and transformation of immature Schwann cells, and support the notion that Schwann cells have particular developmental stages during which they are susceptible to immortalizing and transforming events.	Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45267 USA; Forschungszentrum Karlsruhe, Inst Genet, D-76021 Karlsruhe, Germany	University System of Ohio; University of Cincinnati; Helmholtz Association; Karlsruhe Institute of Technology	Sherman, L (corresponding author), Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, 231 Bethesda Ave, Cincinnati, OH 45267 USA.		Sleeman, Jonathan P/H-2515-2013	Sleeman, Jonathan P/0000-0003-1718-7687; RATNER, NANCY/0000-0001-5030-9354	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028840] Funding Source: NIH RePORTER; NINDS NIH HHS [NS10297, NS28840] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARGMANN CI, 1988, EMBO J, V7, P2043, DOI 10.1002/j.1460-2075.1988.tb03044.x; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; BRADBURY JM, 1993, ONCOGENE, V8, P1551; Carroll SL, 1997, J NEUROSCI, V17, P1642; COHEN JA, 1992, J NEUROSCI RES, V31, P622, DOI 10.1002/jnr.490310406; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; DIMARCO E, 1990, MOL CELL BIOL, V10, P3247, DOI 10.1128/MCB.10.6.3247; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; DOUGALL WC, 1994, ONCOGENE, V9, P2109; DRUCKREY H, 1973, Z KREBSFORSCH KLIN O, V79, P282, DOI 10.1007/BF00304022; FUKAZAWA H, 1991, BIOCHEM PHARMACOL, V42, P1661; GOLDMAN R, 1990, BIOCHEMISTRY-US, V29, P11024, DOI 10.1021/bi00502a002; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Grinspan JB, 1996, J NEUROSCI, V16, P6107; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; JANES PW, 1994, ONCOGENE, V9, P3601; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; JIN JJ, 1993, CELL GROWTH DIFFER, V4, P227; Kim HA, 1997, J NEUROSCI RES, V49, P236; Kim HA, 1997, MOL CELL BIOL, V17, P862, DOI 10.1128/MCB.17.2.862; KLEITMAN N, 1991, CULTURING NERVE CELL, P251; Lamb RF, 1997, MOL CELL BIOL, V17, P963, DOI 10.1128/MCB.17.2.963; LEVI ADO, 1995, J NEUROSCI, V15, P1329; LUTTRELL DK, 1994, P NATL ACAD SCI USA, V91, P83, DOI 10.1073/pnas.91.1.83; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MORRISSEY TK, 1995, P NATL ACAD SCI USA, V92, P1431, DOI 10.1073/pnas.92.5.1431; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P271; Namba M, 1996, CRIT REV ONCOGENESIS, V7, P19, DOI 10.1615/CritRevOncog.v7.i1-2.20; NEWBOLD RF, 1993, TOXICOL LETT, V67, P211, DOI 10.1016/0378-4274(93)90057-5; NIKITIN AY, 1991, P NATL ACAD SCI USA, V88, P9939, DOI 10.1073/pnas.88.22.9939; Nikitin AY, 1996, ONCOGENE, V12, P1309; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; PENG WW, 1982, SCIENCE, V215, P1102, DOI 10.1126/science.7063842; PERANTONI AO, 1987, P NATL ACAD SCI USA, V84, P6317, DOI 10.1073/pnas.84.17.6317; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; RAJEWSKY MF, 1983, RECENT RES CANCER, V84, P63; RHIM JS, 1990, CANCER RES, V50, pS5653; SALZER JL, 1980, J CELL BIOL, V84, P739, DOI 10.1083/jcb.84.3.739; SCHUBERT D, 1974, NATURE, V249, P224, DOI 10.1038/249224a0; Sherman L, 1997, ONCOGENE, V15, P2505, DOI 10.1038/sj.onc.1201418; Sobko A, 1998, EMBO J, V17, P4723, DOI 10.1093/emboj/17.16.4723; Stancovski I, 1994, Cancer Treat Res, V71, P161; TOMOZAWA Y, 1978, P NATL ACAD SCI USA, V75, P6305, DOI 10.1073/pnas.75.12.6305; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Tzahar E, 1998, BBA-REV CANCER, V1377, pM25, DOI 10.1016/S0304-419X(97)00032-2; UEHARA Y, 1989, BIOCHEM BIOPH RES CO, V163, P803, DOI 10.1016/0006-291X(89)92293-6; Vartanian T, 1997, J CELL BIOL, V137, P211, DOI 10.1083/jcb.137.1.211; VOGELSTEIN B, 1993, TRENDS GENET, V9, P138, DOI 10.1016/0168-9525(93)90209-Z; WADA T, 1990, CELL, V61, P1339, DOI 10.1016/0092-8674(90)90697-D; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0	57	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 18	1999	18	48					6692	6699		10.1038/sj.onc.1203055	http://dx.doi.org/10.1038/sj.onc.1203055			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	257QA	10597275				2022-12-17	WOS:000083792000009
J	Maroulakou, IG; Shibata, MA; Anver, M; Jorcyk, CL; Liu, ML; Roche, N; Roberts, AB; Tsarfaty, I; Reseau, J; Ward, J; Green, JE				Maroulakou, IG; Shibata, MA; Anver, M; Jorcyk, CL; Liu, ML; Roche, N; Roberts, AB; Tsarfaty, I; Reseau, J; Ward, J; Green, JE			Heterotopic endochondrial ossification with mixed tumor formation in C3(1)/Tag transgenic mice is associated with elevated TGF-beta1 and BMP-2 expression	ONCOGENE			English	Article						heterotopic bone; endochondrial ossification; mixed tumors; transgenic mice; transforming growth factor-beta; bone morphogenetic protein-2	LARGE T-ANTIGEN; BONE-FORMATION; TRANSFORMING GROWTH-FACTOR-BETA-1; SV40-TRANSFORMED CELLS; P53 MUTATIONS; PROGRESSION; GROWTH; GENE; OVEREXPRESSION; TUMORIGENESIS	Transgenic mice which express the simian virus 40 large T-antigen (Tag) under the regulatory control of the hormone responsive rat C3(1) gene develop unusual lesions of heterotopic bone growth associated with mixed tumor formation arising from eccrine sweat glands found only in the foot pads of mice, ischiocavernosus muscle adjacent to bulbourethral glands and occasionally the salivary and mammary glands. These lesions are very similar to mixed tumors arising in several types of human cancers. Based upon electron microscopic examination and immunocytochemical analyses of cellular differentiation markers, the mixed proliferative lesions in this transgenic mouse model begin with the Tag-induced proliferation of epithelial and myoepithelial cells. The proliferation of these two types of cells results in hyperplasia and adenomatous transformation of the epithelial component, whereas the proliferating myoepithelial cells undergo metaplasia to form chondrocytes which deposit extracellular matrix, including collagen fibers. Cartilage develops focally between areas of epithelial proliferation and subsequently ossifies through process of endochondrial bone formation, The metaplasia of myoepithelial cells to chondrocytes appears to require the inductive interaction of factors produced by the closely associated proliferating epithelial cells, including members of the TGF-beta superfamily, We demonstrate that TGF-beta1 protein accumulates in the extracellular matrix of the lesions, whereas RNA in situ hybridization reveals that BMP-2, another strong inducer of heterotopic bone formation, is overexpressed by the proliferating epithelial cells during the development of ectopic bone. The formation of sarcomatous tumors within the mixed tumors appears to be androgen-dependent and more frequent in mice lacking a normal allele of p53. This process of cartilage and bone induction may mimic epithelial-mesenchymal interactions which occur during embryonic bone formation. These transgenic mice may provide new insights into the processes of ectopic endochondrial bone formation associated with mixed tumor formation and serve as a useful model for human heterotopic bone disease.	NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA; NCI, Frederick Canc Res & Dev Ctr, Pathol Histol Lab, SAIC, Frederick, MD 21702 USA; Sackler Sch Med, Tel Aviv, Israel; NCI, Frederick Canc Res & Dev Ctr, ABL, Frederick, MD 21702 USA; NCI, OLAS, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Tel Aviv University; Sackler Faculty of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Green, JE (corresponding author), NCI, Lab Cell Regulat & Carcinogenesis, Bethesda, MD 20892 USA.		Shibata, Masa-Aki/L-1624-2019	Shibata, Masa-Aki/0000-0002-3350-7305; Tsarfaty, Ilan/0000-0002-5230-7093	OFFICE OF THE DIRECTOR, NCI [N01CO056000] Funding Source: NIH RePORTER; NCI NIH HHS [N01CO56000] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JM, 1991, SCIENCE, V254, P1161, DOI 10.1126/science.1957168; ASHLEY DJB, 1990, EVANS HISTOLOGICAL A, P611; BLECHER SR, 1986, J INVEST DERMATOL, V87, P720, DOI 10.1111/1523-1747.ep12456718; BRINKMANN V, 1995, J CELL BIOL, V131, P1573, DOI 10.1083/jcb.131.6.1573; CAMPBELL JT, 1992, CALCIFIED TISSUE INT, V50, P283, DOI 10.1007/BF00296294; CAPLAN AI, 1994, CLIN PLAST SURG, V21, P429; CHEN JD, 1992, ONCOGENE, V7, P1167; COHEN RB, 1993, J BONE JOINT SURG AM, V75A, P215, DOI 10.2106/00004623-199302000-00008; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DOBASHI Y, 1993, DIAGN MOL PATHOL, V2, P257; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; Duneas N, 1998, GROWTH FACTORS, V15, P259, DOI 10.3109/08977199809017482; ERLEBACHER A, 1995, CELL, V80, P371, DOI 10.1016/0092-8674(95)90487-5; GNEPP DR, 1993, PATHOL ANNU, V28, P279; HANAHAN D, 1988, ANNU REV GENET, V22, P479, DOI 10.1146/annurev.ge.22.120188.002403; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Huggins CB, 1931, ARCH SURG-CHICAGO, V22, P377, DOI 10.1001/archsurg.1931.01160030026002; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JACOBSON ES, 1973, J ORAL SURG, V31, P539; JAENISCH R, 1988, SCIENCE, V240, P1468, DOI 10.1126/science.3287623; JUBB KVF, 1993, PATHOLOGY DOMESTIC A, V1, P315; KAPLAN FS, 1994, J BONE JOINT SURG AM, V76A, P425, DOI 10.2106/00004623-199403000-00013; KAPLAN FS, 1993, J BONE JOINT SURG AM, V75A, P220, DOI 10.2106/00004623-199302000-00009; KURKI P, 1986, EXP CELL RES, V166, P209, DOI 10.1016/0014-4827(86)90520-3; Kurosumi K, 1970, Arch Histol Jpn, V31, P455; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1994, J LAB CLIN MED, V123, P817; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; Liu ML, 1998, ONCOGENE, V17, P2403, DOI 10.1038/sj.onc.1202456; LUDLOW JW, 1993, FASEB J, V7, P866, DOI 10.1096/fasebj.7.10.8344486; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Maroulakou IG, 1997, MOL CARCINOGEN, V20, P168, DOI 10.1002/(SICI)1098-2744(199710)20:2<168::AID-MC3>3.0.CO;2-J; MCKUSICK VA, 1992, MENDELIAN INHERITANC, P13510; MERLINO G, 1994, CANCER INVEST, V12, P203, DOI 10.3109/07357909409024875; Michiels L, 1993, Cancer Treat Res, V62, P7; MIETZ JA, 1992, EMBO J, V11, P5013, DOI 10.1002/j.1460-2075.1992.tb05608.x; MOULTON JE, 1978, TUMORS DOMESTIC ANIM, P350; Olmsted EA, 1998, CLIN ORTHOP RELAT R, P81; PERZIN KH, 1980, CANCER, V45, P2593, DOI 10.1002/1097-0142(19800515)45:10<2593::AID-CNCR2820451019>3.0.CO;2-S; PRAKASH UBS, 1989, MAYO CLIN PROC, V64, P1091, DOI 10.1016/S0025-6196(12)64978-7; PULLEY LT, 1973, AM J VET RES, V34, P1513; REDONO C, 1982, CANCER, V48, P1690, DOI 10.1002/1097-0142(19820415)49:8<1690::AID-CNCR2820490825>3.0.CO;2-O; Ripamonti U, 1997, J BONE MINER RES, V12, P1584, DOI 10.1359/jbmr.1997.12.10.1584; Rosen V, 1996, ANN NY ACAD SCI, V785, P59, DOI 10.1111/j.1749-6632.1996.tb56244.x; ROSEN V, 1992, TRENDS GENET, V8, P97, DOI 10.1016/0168-9525(92)90063-A; RUSSO CL, 1994, MED PEDIATR ONCOL, V23, P354, DOI 10.1002/mpo.2950230407; SCHOLZ RB, 1992, PEDIATR HEMAT ONCOL, V9, P125, DOI 10.3109/08880019209018328; SCHRECK RR, 1992, PEDIATR HEMAT ONCOL, V9, pR9, DOI 10.3109/08880019209018322; Schulick AH, 1998, P NATL ACAD SCI USA, V95, P6983, DOI 10.1073/pnas.95.12.6983; Shafritz AB, 1996, NEW ENGL J MED, V335, P555, DOI 10.1056/NEJM199608223350804; SHAFRITZ AB, 1998, CLIN ORTHOP RELAT R, V346, P46; SHI SR, 1991, J HISTOCHEM CYTOCHEM, V39, P741, DOI 10.1177/39.6.1709656; Shibata MA, 1996, CANCER RES, V56, P2998; Shibata MA, 1998, CARCINOGENESIS, V19, P195, DOI 10.1093/carcin/19.1.195; Shibata MA, 1996, CANCER RES, V56, P4894; SMITHSORENSEN B, 1993, HUM MUTAT, V2, P274, DOI 10.1002/humu.1380020407; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; TSARFATY I, 1992, SCIENCE, V257, P1258, DOI 10.1126/science.1387731; WADAYAMA B, 1993, BRIT J CANCER, V68, P1134, DOI 10.1038/bjc.1993.493; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WOZNEY JM, 1993, MOL BASIS MORPHOGENE, P221	62	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	1999	18	39					5435	5447		10.1038/sj.onc.1202926	http://dx.doi.org/10.1038/sj.onc.1202926			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238PL	10498897				2022-12-17	WOS:000082718600008
J	Yageta, M; Tsunoda, H; Yamanaka, T; Nakajima, T; Tomooka, Y; Tsuchida, N; Oda, K				Yageta, M; Tsunoda, H; Yamanaka, T; Nakajima, T; Tomooka, Y; Tsuchida, N; Oda, K			The adenovirus E1A domains required for induction of DNA rereplication in G(2)/M arrested cells coincide with those required for apoptosis	ONCOGENE			English	Article						adenovirus E1A; Id; apoptosis; cyclin D1 promoter; DNA rereplication	CYCLIN D1; RETINOBLASTOMA PROTEIN; E1A-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR; NUCLEAR ANTIGEN; ID PROTEINS; P53; EXPRESSION; GADD45; PCNA	Induction of apoptosis by adenovirus E1A in rodent cells is stimulated by wild type (wt) p53 but completely suppressed by mutated p53, The suppression is overcome by coexpression with Id proteins (Ids), The cells expressing E1A and Ids undergo apoptosis after accumulation in S phase, suggesting that S phase events are perturbed by E1A and Ids. The E1A domains required for induction of apoptosis, analysed by transfection with expression vectors for E1A, Ids and their mutants, followed by flow cytometry, reside in N-terminal (positions 17-38), CR1 and CR2 regions. Interaction of E1A with Ids requires the N-terminal and CR1 regions. The cyclin D1 promoter activity in S phase was reduced severely by E1A and this reduction is caused through CR1 and CR2 regions required for interaction with pRB. Analysis of DNA synthesis in G(2)/M arrested cells indicated that E1A is capable of inducing >4N cells and this E1A-mediated DNA rereplication is enhanced by coexpression with Id-1H, The E1A domains required for induction of DNA rereplication coincide with those required for apoptosis.	Sci Univ Tokyo, Dept Biol Sci & Technol, Noda, Chiba 278, Japan; Tokyo Med & Dent Univ, Fac Dent, Dept Mol Cellular Oncol & Microbiol, Bunkyo Ku, Tokyo 113, Japan	Tokyo University of Science; Tokyo Medical & Dental University (TMDU)	Oda, K (corresponding author), Sci Univ Tokyo, Dept Biol Sci & Technol, 2641 Yamazaki, Noda, Chiba 278, Japan.		Sakurai-Yageta, Mika/U-1842-2019	Sakurai-Yageta, Mika/0000-0001-5606-3324				Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cox LS, 1997, TRENDS CELL BIOL, V7, P493, DOI 10.1016/S0962-8924(97)01170-7; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Di Leonardo A, 1997, CANCER RES, V57, P1013; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Florio M, 1998, MOL CELL BIOL, V18, P5435, DOI 10.1128/MCB.18.9.5435; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HALL PA, 1995, ONCOGENE, V10, P2427; ISHII T, 1993, EXP CELL RES, V208, P407, DOI 10.1006/excr.1993.1262; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KIMURA G, 1975, INT J CANCER, V15, P694, DOI 10.1002/ijc.2910150419; Kranenburg O, 1996, EMBO J, V15, P46, DOI 10.1002/j.1460-2075.1996.tb00332.x; Lahti JM, 1997, J BIOL CHEM, V272, P10859; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MATSUOKA S, 1994, J BIOL CHEM, V269, P11030; MULLER H, 1994, P NATL ACAD SCI USA, V91, P2945, DOI 10.1073/pnas.91.8.2945; MYMRYK JS, 1994, ONCOGENE, V9, P1187; Nakajima T, 1998, P NATL ACAD SCI USA, V95, P10590, DOI 10.1073/pnas.95.18.10590; NAKAJIMA T, 1995, ONCOGENE, V10, P651; Norton JD, 1998, TRENDS CELL BIOL, V8, P58, DOI 10.1016/S0962-8924(97)01183-5; Notterman D, 1998, ONCOGENE, V17, P2743, DOI 10.1038/sj.onc.1202210; PHILIPP A, 1994, MOL CELL BIOL, V14, P4032, DOI 10.1128/MCB.14.6.4032; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Shikama N, 1997, TRENDS CELL BIOL, V7, P230, DOI 10.1016/S0962-8924(97)01048-9; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SoferLevi Y, 1996, ONCOGENE, V13, P2431; Tanaka K, 1998, J BIOL CHEM, V273, P25922, DOI 10.1074/jbc.273.40.25922; Tsunoda H, 1999, BIOCHEM BIOPH RES CO, V255, P722, DOI 10.1006/bbrc.1999.0143; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; Xu J, 1999, MOL CELL BIOL, V19, P12; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	38	12	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 26	1999	18	34					4767	4776		10.1038/sj.onc.1203063	http://dx.doi.org/10.1038/sj.onc.1203063			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229GH	10490810				2022-12-17	WOS:000082184800001
J	Pham, CD; Vuyyuru, VB; Yang, YD; Bai, WL; Singh, B				Pham, CD; Vuyyuru, VB; Yang, YD; Bai, WL; Singh, B			Evidence for an important role of serine 16 and its phosphorylation in the stabilization of c-Mos	ONCOGENE			English	Article						mos oncogene; protein phosphorylation; enzyme regulation	PROTEIN-KINASE ACTIVITY; MURINE SARCOMA-VIRUS; V-MOS; NUCLEOTIDE-SEQUENCE; OOCYTE MATURATION; MAP KINASE; XENOPUS-OOCYTES; CELL-CYCLE; GENE; TRANSFORMATION	The c-Mos serine/threonine protein kinase is an essential component of cytostatic factor (CSF), which is required for metaphase Il arrest of eggs in vertebrates. Previously, we showed that c-Mos residue Ser-16 is phosphorylated in the ts110 Mo-MuSV-encoded Gag-Mos fusion protein, Here we provide evidence that Mos is phosphorylated at Ser-16 in transfected COS-1 cells. To investigate the role of this phosphorylation, Ser-16 was substituted with alanine or glutamic acid in full-length v-Mos (an Env-Mos fusion protein that contains 31 additional amino acids at the amino terminus of c-Mos), its mouse c-Mos equivalent version (v-Mos residues 32-374, hereafter referred to as Mos), and mouse c-Mos, Constructs expressing mutant versions of Mos,were transfected into COS-l and NIH3T3 cells in a transient and stable manner, respectively, Synthesis and proteolysis of Mos were evaluated by pulse-chase analysis of S-35-methionine-labeled proteins. Our findings indicate that the S16A mutant of Mos was highly unstable. It accumulated to approximately 10% of the level of wild-type Mos or its S16E mutant. In addition, the S16A mutation but not the S16E mutation inhibited Mos interaction with a cellular protein, p35, suggesting that phosphorylation at Ser-16 may promote Riles interaction with p35, As expected from its destabilizing effect, the S16A mutation caused a dramatic decrease in the cellular transforming activity of Mos (determined by soft-agar colony-formation assay with the stably transfected NIH3T3 cells), which is known to correlate with its CSF function. Efficient ubiquitin-mediated proteolysis of c-Mos requires proline as the second residue from the amino-terminus. In contrast to Mos, neither the stability nor protein kinase activity of v-Mos (in which c-Mos residue Pro-2 becomes Pro-33) was affected by the S16A mutation. To provide further proof that, similar to c-Mos, the S16A mutant is recognized by the proteolysis system through Pro-2, we show that the effect of the S16A mutation is reversed by the Pro-2-Ala mutation. Thus, our results indicate that Ser-16 has an important role in the regulation of c-Mos and that phosphorylation at Ser-16 mag inhibit proteolysis of c-Mos.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Singh, B (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Box 172,1515 Holcombe Blvd, Houston, TX 77030 USA.		Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NCI NIH HHS [CA16672, R01 CA45125] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; BAI WL, 1991, ONCOGENE, V6, P1715; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CHEN MZ, 1995, MOL CELL BIOL, V15, P4727; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; Huang CYF, 1996, EMBO J, V15, P2169, DOI 10.1002/j.1460-2075.1996.tb00570.x; LIU H, 1999, IN PRESS ONCOGENE, V18; LIU JX, 1990, ONCOGENE, V5, P171; Matten WT, 1996, DEV BIOL, V179, P485, DOI 10.1006/dbio.1996.0277; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; OKAZAKI K, 1991, JPN J CANCER RES, V82, P250, DOI 10.1111/j.1349-7006.1991.tb01837.x; PHAM CD, 1995, ONCOGENE, V10, P1683; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; Roy LM, 1996, ONCOGENE, V12, P2203; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; Sambrook J., 1989, MOL CLONING; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1988, ONCOGENE, V3, P79; Singh B, 1997, Prog Cell Cycle Res, V3, P251; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yang YD, 1996, MOL CELL BIOL, V16, P800; Yang YD, 1998, J BIOL CHEM, V273, P15946, DOI 10.1074/jbc.273.26.15946; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604	29	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	1999	18	30					4287	4294		10.1038/sj.onc.1202804	http://dx.doi.org/10.1038/sj.onc.1202804			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	221NG	10439036				2022-12-17	WOS:000081732700001
J	Gibbons, DL; MacDonald, D; McCarthy, KP; Cleary, HJ; Plumb, M; Wright, EG; Greaves, MF				Gibbons, DL; MacDonald, D; McCarthy, KP; Cleary, HJ; Plumb, M; Wright, EG; Greaves, MF			An E mu-BCL-2 transgene facilitates leukaemogenesis by ionizing radiation	ONCOGENE			English	Article						apoptosis; leukaemogenesis; BCL-2; irradiation	IMMUNOGLOBULIN HEAVY-CHAIN; MYELOID-LEUKEMIA; CELL-SURVIVAL; PROGENITOR CELLS; PRE-B; MICE; GENE; BCL-2; P53; IRRADIATION	Clonogenic murine B cell precursors are normally ultrasensiti ve to apoptosis following genotoxic exposure in vitro but can be protected by expression of an E mu-BCL-2 transgene. Such exposures are likely to be mutagenic. This in turn suggests that a level of in vivo genotoxic exposure that usually has minimal pathological consequences might become leukaemogenic when damaged cells fail to abort by apoptosis. If this were to be the case, then the cell type that becomes leukaemic and the chromosomal/molecular changes that occur would also be of considerable interest. We tested this possibility by exposing E mu-BCL-2 and wild-type mice of differing ages to a single dose of X-irradiation of 1-4 Gy, Young (similar to 4-6 weeks) transgenic mice developed leukaemia at a high rate following exposure to 2 Gy but adult mice (4-6 months) did not. Exposure to 4 Gy produced leukaemia in both young and adult transgenic mice but at a higher frequency in the former. Leukaemic cell populations showed clonal rearrangements of the IGH gene but in most cases analysed had immunophenotypic features of an early B lympho-myeloid progenitor population which has not previously been recorded in radiation leukaemogenesis. Molecular cytogenetic analysis of leukaemic cells by banded karyotype and FISH revealed a consistent double abnormality: trisomy 15 plus an interstitial deletion of chromosome 4 that was confirmed by LOH analysis.	Inst Canc Res, Leukaemia Res Fund Ctr, Chester Beatty Labs, London SW3 6JB, England; MRC, Radiat & Genome Stabil Unit, Harwell OX11 0RD, Oxon, England; Cheltenham Gen Hosp, Dept Histol, Cheltenham GL53 7AN, Glos, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Gloucestershire Hospitals NHS Foundation Trust; Cheltenham General Hospital	Greaves, MF (corresponding author), Inst Canc Res, Leukaemia Res Fund Ctr, Chester Beatty Labs, 237 Fulham Rd, London SW3 6JB, England.			Gibbons, Deena/0000-0002-7953-3576				Alexander BJ, 1995, LEUKEMIA, V9, P2009; Boice J. D., 1996, LEUKEMIA, P195; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Doll R, 1997, BRIT J RADIOL, V70, P130, DOI 10.1259/bjr.70.830.9135438; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fennelly J, 1997, LEUKEMIA, V11, P807, DOI 10.1038/sj.leu.2400674; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FORD AM, 1988, EMBO J, V7, P2393, DOI 10.1002/j.1460-2075.1988.tb03084.x; FORD AM, 1992, P NATL ACAD SCI USA, V89, P3424, DOI 10.1073/pnas.89.8.3424; GREAVES MF, 1986, SCIENCE, V234, P697, DOI 10.1126/science.3535067; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; GRIFFITHS SD, 1994, J EXP MED, V179, P1789, DOI 10.1084/jem.179.6.1789; Griffiths SD, 1997, ONCOGENE, V14, P523, DOI 10.1038/sj.onc.1200871; GRIFFITHS SD, 1994, INT J RADIAT BIOL, V66, P197, DOI 10.1080/09553009414551101; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JI WZ, 1995, CANCER RES, V55, P2876; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Koyama M, 1997, INT IMMUNOL, V9, P1767, DOI 10.1093/intimm/9.11.1767; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LIU YF, 1994, P NATL ACAD SCI USA, V91, P8910, DOI 10.1073/pnas.91.19.8910; MAJOR IR, 1978, NATURE, V272, P455, DOI 10.1038/272455a0; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; MCDONNELL TJ, 1991, NATURE, V349, P254, DOI 10.1038/349254a0; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MERINO R, 1994, EMBO J, V13, P683, DOI 10.1002/j.1460-2075.1994.tb06307.x; Nishii K, 1998, CELL DEATH DIFFER, V5, P77, DOI 10.1038/sj.cdd.4400317; NUNEZ G, 1994, IMMUNOL TODAY, V15, P582, DOI 10.1016/0167-5699(94)90221-6; OSMOND DG, 1993, IMMUNOL TODAY, V14, P34, DOI 10.1016/0167-5699(93)90322-C; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PURDIE CA, 1994, ONCOGENE, V9, P603; Santos J, 1996, ONCOGENE, V12, P669; STRASSER A, 1993, ONCOGENE, V8, P1; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; Strasser A, 1996, EMBO J, V15, P3823, DOI 10.1002/j.1460-2075.1996.tb00756.x; UPTON AC, 1958, CANCER RES, V18, P842; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WIENER F, 1978, NATURE, V275, P658, DOI 10.1038/275658a0; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Zhuang SM, 1998, ONCOGENE, V16, P803, DOI 10.1038/sj.onc.1201600	40	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 1	1999	18	26					3870	3877		10.1038/sj.onc.1202721	http://dx.doi.org/10.1038/sj.onc.1202721			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	211QK	10445850				2022-12-17	WOS:000081171700008
J	Klefstrom, J; Kovanen, PE; Somersalo, K; Hueber, AO; Littlewood, T; Evan, GI; Greenberg, AH; Saksela, E; Timonen, T; Alitalo, K				Klefstrom, J; Kovanen, PE; Somersalo, K; Hueber, AO; Littlewood, T; Evan, GI; Greenberg, AH; Saksela, E; Timonen, T; Alitalo, K			c-Myc and E1A induced cellular sensitivity to activated NK cells involves cytotoxic granules as death effectors	ONCOGENE			English	Article						apoptosis; c-Myc; E1A; NK cells; cytotoxicity	NATURAL-KILLER-CELLS; TUMOR-NECROSIS-FACTOR; WILD-TYPE P53; GRANZYME-B; CYTOLYTIC SUSCEPTIBILITY; ONCOGENE EXPRESSION; DEPENDENT APOPTOSIS; MELANOMA-CELLS; CYTO-TOXICITY; TARGET-CELLS	The contact of natural killer (NK) cells with foreign cells and with certain virus-infected or tumor cells triggers the cytolytic machinery of NK cells. This triggering leads to exocytosis of the cytotoxic NK cell granules. The oncoproteins c-Myc and E1A render cells vulnerable to NK cell mediated cytolysis yet the mechanisms of sensitization are not well understood. In a model where foreign cells (rat fibroblasts) were cocultured with human IL-2 activated NK cells, we observed that NK cells were capable of efficiently killing their targets only if the cells overexpressed the oncogene c-Myc or E1A. Both the parental and the oncogene expressing fibroblasts similarly triggered phosphoinositide hydrolysis in the bound NK cells, demonstrating that NK cells were cytolytically activated in contact with both resistant parental and oncogene expressing sensitive target fibroblasts. The cell death was independent of mild-type p53 and was not inhibited by an anti-apoptotic protein E1B19K. These results provided evidence that c-Myc and E1A activated the NK cell induced cytolysis at a post-triggering stage of NK cell-target cell interaction. In consistence, the c-Myc and E1A overexpressing fibroblasts were more sensitive to the cytolytic effects of isolated NK cell-derived granules than parental cells. The data indicate that oncogenes activate the cytotoxicity of NK cell granules. This mechanism can have a role in directing the cytolytic action of NK cells towards the virus-infected and cancer cells.	Imperial Canc Res Fund, Biochem Cell Nucleus Lab, London WC2A 3PX, England; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Haartman Inst, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Manitoba, Manitoba Inst Cell Biol, Dept Pediat, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Dept Immunol, Winnipeg, MB R3E 0V9, Canada	Cancer Research UK; University of Helsinki; University of Helsinki; University of Manitoba; University of Manitoba	Klefstrom, J (corresponding author), Imperial Canc Res Fund, Biochem Cell Nucleus Lab, POB 123,44 Lincolns Inn Fields, London WC2A 3PX, England.		Anne-Odile, Hueber/P-9860-2019; Alitalo, Kari K/J-5013-2014; Anne-Odile, Hueber/G-4352-2013	Anne-Odile, Hueber/0000-0003-3816-2446; Alitalo, Kari K/0000-0002-7331-0902; Anne-Odile, Hueber/0000-0003-3816-2446				ARASE H, 1995, J EXP MED, V181, P1235, DOI 10.1084/jem.181.3.1235; ATKINSON EA, 1990, J LEUKOCYTE BIOL, V47, P39, DOI 10.1002/jlb.47.1.39; AVERSA G, 1993, J EXP MED, V177, P1575, DOI 10.1084/jem.177.6.1575; BERKE G, 1994, ANNU REV IMMUNOL, V12, P735, DOI 10.1146/annurev.immunol.12.1.735; BRUTKIEWICZ RR, 1995, J VIROL, V69, P3967, DOI 10.1128/JVI.69.7.3967-3971.1995; CHEN MJ, 1987, NATURE, V330, P581, DOI 10.1038/330581a0; CHOW DA, 1990, CELL IMMUNOL, V127, P172, DOI 10.1016/0008-8749(90)90123-9; CHOW SC, 1990, IMMUNOLOGY, V70, P106; Cook JL, 1996, ONCOGENE, V13, P833; COOK JL, 1989, J IMMUNOL, V142, P4527; CUOMO L, 1993, INT J CANCER, V53, P1008; DARMON AJ, 1995, NATURE, V377, P446, DOI 10.1038/377446a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fearnhead HO, 1997, GENE DEV, V11, P1266, DOI 10.1101/gad.11.10.1266; GRIFFITHS GM, 1995, CURR OPIN IMMUNOL, V7, P343, DOI 10.1016/0952-7915(95)80108-1; GUMPERZ JE, 1995, NATURE, V378, P245, DOI 10.1038/378245a0; Helander TS, 1996, NATURE, V382, P265, DOI 10.1038/382265a0; Hueber AO, 1997, SCIENCE, V278, P1305, DOI 10.1126/science.278.5341.1305; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; Jans DA, 1996, J BIOL CHEM, V271, P30781, DOI 10.1074/jbc.271.48.30781; KHALIL N, 1990, J IMMUNOL, V145, P1286; Klefstrom J, 1997, EMBO J, V16, P7382, DOI 10.1093/emboj/16.24.7382; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; LACAVA A, 1994, INT J CANCER, V58, P123, DOI 10.1002/ijc.2910580120; Lanier LL, 1997, IMMUNITY, V6, P371, DOI 10.1016/S1074-7613(00)80280-0; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; LJUNGGREN HG, 1990, IMMUNOL TODAY, V11, P237, DOI 10.1016/0167-5699(90)90097-S; PELTENBURG LTC, 1992, EUR J IMMUNOL, V22, P2737, DOI 10.1002/eji.1830221040; RAULET DH, 1995, CELL, V82, P697, DOI 10.1016/0092-8674(95)90466-2; SHAULIAN E, 1995, ONCOGENE, V10, P671; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; Shi LF, 1996, P NATL ACAD SCI USA, V93, P11002, DOI 10.1073/pnas.93.20.11002; Shi LF, 1997, J EXP MED, V185, P855, DOI 10.1084/jem.185.5.855; STAHLS AK, 1989, SCAND J IMMUNOL, V29, P211, DOI 10.1111/j.1365-3083.1989.tb01118.x; Sutton VR, 1997, J IMMUNOL, V158, P5783; TIMONEN T, 1980, J IMMUNOL METHODS, V36, P285, DOI 10.1016/0022-1759(80)90133-7; VERSTEEG R, 1989, J IMMUNOL, V143, P4331; WAGNER AJ, 1994, GENE DEV, V8, P2817, DOI 10.1101/gad.8.23.2817; WALKER TA, 1991, P NATL ACAD SCI USA, V88, P6491, DOI 10.1073/pnas.88.15.6491; WRIGHT SC, 1987, J IMMUNOL, V138, P1791	44	12	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	1999	18	13					2181	2188		10.1038/sj.onc.1202546	http://dx.doi.org/10.1038/sj.onc.1202546			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	182YE	10327064				2022-12-17	WOS:000079525100002
J	Jouanneau, J; Moens, G; Thiery, JP				Jouanneau, J; Moens, G; Thiery, JP			The community effect in FGF-1 mediated tumor progression of a rat bladder carcinoma does not involve a direct paracrine signaling	ONCOGENE			English	Article						dominant-negative FGFR mutant; community effect; tumor heterogeneity; tumor cell interactions	FIBROBLAST GROWTH-FACTOR; TISSUE-CULTURE; ATHYMIC MICE; CELL-LINE; IN-VIVO; EXPRESSION; RECEPTORS; TUMORIGENICITY; TRANSFORMATION; ORGANIZATION	A community effect was found to occur between heterogeneous tumor cell populations leading to an overall increased tumorigenicity without a clonal dominance of the more tumorigenic clone. In the rat bladder carcinoma cell line NET-II, this effect appears mediated by the Fibroblast Growth Factor-1 (FGF-1) through either a direct or an indirect signaling pathway. Neovascularization induced by FGF-1 was found not to be responsible for the community effect. The present study shows that the community effect does not involve a direct FGF-1 signaling since tumor cells expressing a dominant-negative FGF receptor mutant were still responding to the highly tumorigenic FGF-1 expressing cells. Tumors arising from inoculates of the FGF-1 producing NET-II cells mixed with non tumorigenic epithelial MDCK cells contain only the tumorigenic cells indicating that MDCK cells may exerce a helper effect for the growth of the tumor not dependant on their own growth. Therefore the helper function of MDCK cells must be distinguished from a community effect where the contribution of low tumorigenic cells not only provides an in vivo growth advantage to few highly tumorigenic cells but become themselves highly tumorigenic indicating that the community effect may require cell-cell specific cooperativity independent from an helper effect.	UMR 144 CNRS, F-75248 Paris 05, France; Inst Curie, F-75248 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Jouanneau, J (corresponding author), UMR 144 CNRS, 26 Rue Ulm, F-75248 Paris 05, France.		Thiery, Jean Paul/M-9387-2019; Thiery, Jean Paul/H-1550-2011	Thiery, Jean Paul/0000-0003-0478-5020				AABO K, 1995, EUR J CANCER, V31A, P222, DOI 10.1016/0959-8049(94)00434-7; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BELLUSCI S, 1994, ONCOGENE, V9, P1091; BOYER B, 1989, J CELL BIOL, V109, P1495, DOI 10.1083/jcb.109.4.1495; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; COLBEREGARAPIN F, 1981, J MOL BIOL, V105, P1; DeBoth NJ, 1997, INT J CANCER, V72, P1137, DOI 10.1002/(SICI)1097-0215(19970917)72:6<1137::AID-IJC32>3.0.CO;2-Z; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIDMAN R, 1992, INT J CANCER, V51, P740, DOI 10.1002/ijc.2910510513; GARTNER MFRM, 1992, INT J CANCER, V51, P788, DOI 10.1002/ijc.2910510520; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gregoire M, 1995, CANCER METAST REV, V14, P339, DOI 10.1007/BF00690602; GURDON JB, 1993, CELL, V75, P831, DOI 10.1016/0092-8674(93)90526-V; HENNIGAN TW, 1994, SURG ONCOL, V3, P275, DOI 10.1016/0960-7404(94)90029-9; JOUANNEAU J, 1991, P NATL ACAD SCI USA, V88, P2893, DOI 10.1073/pnas.88.7.2893; Jouanneau J, 1997, ONCOGENE, V14, P671, DOI 10.1038/sj.onc.1200883; JOUANNEAU J, 1994, P NATL ACAD SCI USA, V91, P286, DOI 10.1073/pnas.91.1.286; LI Y, 1994, MOL CELL BIOL, V14, P7660, DOI 10.1128/MCB.14.11.7660; Loizidou MC, 1996, BRIT J SURG, V83, P24, DOI 10.1002/bjs.1800830107; MEHTA RR, 1993, BREAST CANCER RES TR, V25, P65, DOI 10.1007/BF00662402; Nakajima M, 1993, Hum Cell, V6, P7; PAWELETZ N, 1994, CRIT REV ONCOGENESIS, V5, P69, DOI 10.1615/CritRevOncog.v5.i1.40; RAK JW, 1993, IN VITRO CELL DEV-AN, V29A, P742; SAVAGNER P, 1994, MOL BIOL CELL, V5, P851, DOI 10.1091/mbc.5.8.851; Schor S L, 1995, EXS, V74, P273; SHI E, 1993, MOL CELL BIOL, V13, P3907, DOI 10.1128/MCB.13.7.3907; TOYOSHIMA K, 1971, JNCI-J NATL CANCER I, V47, P979; ULRICH A, 1990, CELL, V61, P203; VALLES AM, 1990, P NATL ACAD SCI USA, V87, P1124, DOI 10.1073/pnas.87.3.1124; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WILSON PA, 1994, CURR BIOL, V4, P676, DOI 10.1016/S0960-9822(00)00152-4	33	12	18	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 14	1999	18	2					327	333		10.1038/sj.onc.1202285	http://dx.doi.org/10.1038/sj.onc.1202285			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HL	9927189				2022-12-17	WOS:000078166500005
J	Menjo, M; Kaneko, Y; Ogata, E; Ikeda, K; Nakanishi, M				Menjo, M; Kaneko, Y; Ogata, E; Ikeda, K; Nakanishi, M			Critical role for p27(Kip1) in cell cycle arrest after androgen depletion in mouse mammary carcinoma cells (SC-3)	ONCOGENE			English	Article						androgen; cancer; endocrine therapy; cell cycle; p27(Kip1) Cdk inhibitor	HUMAN BREAST-CANCER; DEPENDENT KINASE-ACTIVITY; GROWTH-FACTOR; INHIBITOR P27(KIP1); ESTROGEN-RECEPTOR; G1 PHASE; EXPRESSION; D1; ACTIVATION; PROGRESSION	The molecular mechanisms underlying androgen-regulated cancer growth and the frequent development of refractoriness to endocrine therapy remain unknown. In this study functional and quantitative alterations in cell cycle regulators after androgen depletion were examined in androgen-dependent mouse mammary carcinoma cells (SC-3) as a model system to clarify the initial response of cancer cells to anti-androgen therapy. FAGS analysis of SC-3 cells cultured with or without 10(-7) M testosterone revealed that suppression of cell growth after hormone withdrawal was due to G1 arrest. Although cyclin D1/Cdk4 activity decreased along with a reduced level of cyclin D1 protein, this was a later event (48-72 h) than the G1 arrest (24 h). Taken together with the results that constitutive expression of cyclin D1 in SC-3 cells did not overcome the growth suppression following androgen depletion, the existence of an alternative pathway(s) causing G1 arrest was suggested. Cyclin E/Cdk2 and cyclin A/Cdk2 activities decreased significantly at 24 h without apparent changes in the amounts of Cdk2, cyclin E or cyclin A. Among various Cdk inhibitors (CKIs) examined, p27(Kip1) was upregulated at both mRNA and protein levels at 24 h after androgen depletion. In addition, immunoprecipitation-Western analysis showed that the amount of p27(Kip1) associated with Cdk2 complexes increased as early as 24 h. These results suggest that p27(Kip1) CKI is a critical target in the initial response of cancer cells to androgen depletion and plays a key role in Cdk2 inactivation through association with the kinase complex, leading to cell cycle arrest.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; Japanese Fdn Canc Res, Inst Canc, Tokyo 170, Japan	Japanese Foundation for Cancer Research	Nakanishi, M (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, 36-3 Gengo, Aichi 4748522, Japan.							Altucci L, 1996, ONCOGENE, V12, P2315; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CATALONA WJ, 1994, NEW ENGL J MED, V331, P996; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Goldhirsch A, 1996, SEMIN ONCOL, V23, P494; HENDERSON BE, 1993, SCIENCE, V259, P633, DOI 10.1126/science.8381558; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Liu Y, 1996, CANCER RES, V56, P31; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Lu S, 1997, CANCER RES, V57, P4511; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; MATSUSHIME H, 1994, MOL CELL BIOL, V14, P2066, DOI 10.1128/MCB.14.3.2066; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MINESITA T, 1965, CANCER RES, V25, P1168; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Neuman E, 1997, MOL CELL BIOL, V17, P5338, DOI 10.1128/MCB.17.9.5338; NOGUCHI S, 1987, CANCER RES, V47, P263; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; PlanasSilva MD, 1997, MOL CELL BIOL, V17, P4059, DOI 10.1128/MCB.17.7.4059; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WATTS CKW, 1995, MOL ENDOCRINOL, V9, P1804, DOI 10.1210/me.9.12.1804; Zwijsen RML, 1997, CELL, V88, P405, DOI 10.1016/S0092-8674(00)81879-6	41	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 19	1998	17	20					2619	2627		10.1038/sj.onc.1202193	http://dx.doi.org/10.1038/sj.onc.1202193			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	139YN	9840925				2022-12-17	WOS:000077058900009
J	Kim, JH; Hui, P; Yue, DX; Aycock, J; Leclerc, C; Bjoring, AR; Perkins, AS				Kim, JH; Hui, P; Yue, DX; Aycock, J; Leclerc, C; Bjoring, AR; Perkins, AS			Identification of candidate target genes for EVI-1, a zinc finger oncoprotein, using a novel selection strategy	ONCOGENE			English	Article						myeloid leukemia; transcription factor; target gene	MYELOID-TRANSFORMING GENE; ACUTE MYELOGENOUS LEUKEMIAS; DNA-BINDING PROTEINS; TRANSCRIPTIONAL REGULATION; CONSENSUS SEQUENCE; CELL-LINES; EXPRESSION; PROTOONCOGENE; ACTIVATION; RECEPTOR	We have sought to identify and isolate target genes for the zinc finger protein, EVI-1, which has been implicated in the genesis of myelogenous leukemia both in mouse and human. We have approached this with a two-step selection: we first selected for genomic fragments of mouse DNA that bind to the protein with high affinity; second, we employed cDNA hybrid selection to identify gene sequences contained within these fragments. We show that we have constructed a sublibrary of genomic fragments that contains a significant fraction of the EVI-1-binding sites in the mouse genome, Our data has allowed us to estimate that there are approximately 4300 binding sites per haploid genome in the mouse. We further demonstrate that by using cDNA hybrid selection, it is relatively straightforward to isolate cDNAs that correspond to genes embedded in the EVI-1-binding sublibrary. Several of these are novel, but are represented in databases of anonymous human or mouse cDNAs (expressed sequence tags), One selected gene is Itpr2, encoding the inositol trisphosphate type two receptor, which is transcriptionally regulated during myelopoiesis. Finally, using a chimeric EVI-1-VP16-fusion protein under the control of a tetracycline-regulated system, we have shown that this chimeric activator can directly regulate Itpr2.	Yale Univ, Dept Pathol, New Haven, CT 06520 USA	Yale University	Perkins, AS (corresponding author), Yale Univ, Dept Pathol, POB 208023, New Haven, CT 06520 USA.							Bartholomew C, 1997, ONCOGENE, V14, P569, DOI 10.1038/sj.onc.1200864; BRADFORD PG, 1992, J BIOL CHEM, V267, P20959; BRAUN BS, 1995, MOL CELL BIOL, V15, P4623; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DELWEL R, 1993, MOL CELL BIOL, V13, P4291, DOI 10.1128/MCB.13.7.4291; DILLON N, 1993, TRENDS GENET, V9, P134, DOI 10.1016/0168-9525(93)90208-Y; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FICHELSON S, 1992, LEUKEMIA, V6, P93; FUNABIKI T, 1994, ONCOGENE, V9, P1575; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Hoyt PR, 1997, MECH DEVELOP, V65, P55, DOI 10.1016/S0925-4773(97)00057-9; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KINZLER KW, 1989, NUCLEIC ACIDS RES, V17, P3645, DOI 10.1093/nar/17.10.3645; KREIDER BL, 1993, P NATL ACAD SCI USA, V90, P6454, DOI 10.1073/pnas.90.14.6454; LEVY ER, 1994, BLOOD, V83, P1348; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MATSUGI T, 1995, ONCOGENE, V11, P191; MCENTEE K, 1980, P NATL ACAD SCI-BIOL, V77, P857, DOI 10.1073/pnas.77.2.857; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; MITANI K, 1994, EMBO J, V13, P504, DOI 10.1002/j.1460-2075.1994.tb06288.x; MOHLER JD, 1977, GENETICS, V85, P259; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1995, ONCOGENE, V10, P1961; MORISHITA K, 1992, P NATL ACAD SCI USA, V89, P3937, DOI 10.1073/pnas.89.9.3937; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; NUCIFORA G, 1994, P NATL ACAD SCI USA, V91, P4004, DOI 10.1073/pnas.91.9.4004; PARIMOO S, 1993, METHODS MOL GENETICS, V1, P23; Peeters P, 1997, CANCER RES, V57, P564; PERKINS AS, 1991, MOL CELL BIOL, V11, P2665, DOI 10.1128/MCB.11.5.2665; PERKINS AS, 1991, DEVELOPMENT, V111, P479; Perkins AS, 1996, J BIOL CHEM, V271, P1104, DOI 10.1074/jbc.271.2.1104; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SHOCKETT P, 1995, P NATL ACAD SCI USA, V92, P6522, DOI 10.1073/pnas.92.14.6522; SOMPAYRAC L, 1990, P NATL ACAD SCI USA, V87, P3274, DOI 10.1073/pnas.87.9.3274; SUDHOF TC, 1991, EMBO J, V10, P3199, DOI 10.1002/j.1460-2075.1991.tb04882.x; SUGIYAMA T, 1994, FEBS LETT, V349, P191, DOI 10.1016/0014-5793(94)00662-8; Summers MD, 1987, TEXAS AGR EXPT STATI; SUZUKAWA K, 1994, BLOOD, V84, P2681; TANAKA T, 1994, J BIOL CHEM, V269, P24020; TSANG SY, 1990, MOL CELL BIOL, V10, P711, DOI 10.1128/MCB.10.2.711; WANG Z, 1991, P NATL ACAD SCI USA, V88, P11505, DOI 10.1073/pnas.88.24.11505	49	12	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 24	1998	17	12					1527	1538		10.1038/sj.onc.1202331	http://dx.doi.org/10.1038/sj.onc.1202331			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	122UM	9794230				2022-12-17	WOS:000076089900005
J	Kelley, LL; Hicks, GG; Hsieh, FF; Prasher, JM; Green, WF; Miller, MD; Eide, EJ; Ruley, HE				Kelley, LL; Hicks, GG; Hsieh, FF; Prasher, JM; Green, WF; Miller, MD; Eide, EJ; Ruley, HE			Endogenous p53 regulation and function in early stage Friend virus-induced tumor progression differs from that following DNA damage	ONCOGENE			English	Article						p53; p21; activation; differentiation; erythroleukemia	WILD-TYPE P53; P53-MEDIATED G(1) ARREST; CELL-CYCLE ARREST; ERYTHROPOIETIN RECEPTOR; ERYTHROLEUKEMIA-CELLS; TRANSCRIPTION FACTOR; TRANSGENIC MICE; GROWTH ARREST; GLOBIN GENE; E7 GENE	Erythroleukemia induced by the anemia strain of Friend virus occurs in two stages, The first stage results in rapid expansion of pre-leukemic proerythroblasts (FVA cells) dependent on erythropoietin (Epo) for differentiation and survival in vitro. The second stage is characterized by emergence of erythroleukemic clones (MEL cells) which typically bear activation of the ets-oncogene, PU.1/spi.1, and loss of functional p53. We developed a Friend virus-sensitive, p53-deficient mouse model to investigate the biological advantage conferred by p53-loss during tumor progression. Here we report p53 was not required for cell survival or growth arrest during differentiation of FVA cells, nor was p53 required for induction of apoptosis upon Epo withdrawal. However, we detected induction of the p21(Cip1) cyclin-dependent kinase inhibitor gene during differentiation, which was markedly enhanced in the presence of p53. p53-dependent expression of p21(Cip1) occurred in the absence of an increase in p53 mRNA and protein levels and was specific for p21(Cip1) since expression of gadd45, mdm-2, cyclin G and bax were unaffected by p53. In contrast, treatment of FVA cells with DNA damaging agents led to rapid accumulation of p53 protein resulting in transcription of multiple p53-regulated genes, leading to either apoptosis or growth arrest, depending on the agent used. These data demonstrate that p53-dependent activities during differentiation of preleukemic erythroblasts are distinct from those observed in response to genotoxic agents. We propose that enhancement of p53-dependent gene expression during differentiation may represent a tumor suppressor function which is necessary to monitor differentiation of preleukemic cells and which is selected against during tumor progression.	Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84132 USA; Univ Utah, Sch Med, Dept Oncol Sci, Salt Lake City, UT 84132 USA; Vanderbilt Univ, Dept Microbiol & Immunol, Nashville, TN 37212 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Vanderbilt University	Kelley, LL (corresponding author), Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT 84132 USA.			Hicks, Geoffrey/0000-0003-4688-2312	NCI NIH HHS [R01CA69169, 5P30CA42014] Funding Source: Medline; NIDDK NIH HHS [P50DK49219] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA069169, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049219] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BONDURANT MC, 1985, MOL CELL BIOL, V5, P675, DOI 10.1128/MCB.5.4.675; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CANMAN CE, 1995, GENE DEV, V9, P600, DOI 10.1101/gad.9.5.600; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GOTTLIEB E, 1994, EMBO J, V13, P1368, DOI 10.1002/j.1460-2075.1994.tb06390.x; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HARPER JW, 1993, CELL, V75, P805; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HOWES KA, 1994, GENE DEV, V8, P1300, DOI 10.1101/gad.8.11.1300; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; KASTAN MB, 1991, CANCER RES, V51, P6304; KELLEY LL, 1992, J CELL PHYSIOL, V151, P487, DOI 10.1002/jcp.1041510307; KELLEY LL, 1994, MOL CELL BIOL, V14, P4183, DOI 10.1128/MCB.14.6.4183; KELLEY LL, 1993, BLOOD, V82, P2340; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1992, EUR J BIOCHEM, V210, P649, DOI 10.1111/j.1432-1033.1992.tb17466.x; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; KOURY MJ, 1984, J CELL PHYSIOL, V121, P526, DOI 10.1002/jcp.1041210311; KOURY ST, 1988, EXP HEMATOL, V16, P758; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LI JP, 1995, J VIROL, V69, P1714, DOI 10.1128/JVI.69.3.1714-1719.1995; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MORGENBESSER SD, 1994, NATURE, V371, P72, DOI 10.1038/371072a0; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; PAN HC, 1994, GENE DEV, V8, P1285, DOI 10.1101/gad.8.11.1285; PAPATHANASIOU MA, 1991, MOL CELL BIOL, V11, P1009, DOI 10.1128/MCB.11.2.1009; Poluha W, 1996, MOL CELL BIOL, V16, P1335; Ruley H. Earl, 1996, P37; SAWYER ST, 1987, METHOD ENZYMOL, V147, P340; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; WEINBERG WC, 1995, ONCOGENE, V10, P2271; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	53	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 3	1998	17	9					1119	1130		10.1038/sj.onc.1202037	http://dx.doi.org/10.1038/sj.onc.1202037			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	114FL	9764822				2022-12-17	WOS:000075598400007
J	Rose, DW; Xiao, S; Pillay, TS; Kolch, W; Olefsky, JM				Rose, DW; Xiao, S; Pillay, TS; Kolch, W; Olefsky, JM			Prolonged vs transient roles for early cell cycle signaling components	ONCOGENE			English	Article						insulin IGF-I; DNA synthesis; microinjection	INSULIN-RECEPTOR SUBSTRATE-1; EPIDERMAL GROWTH-FACTOR; NUCLEOTIDE-RELEASING-FACTOR; PHOSPHOTYROSINE PHOSPHATASE SYP; PROTEIN-TYROSINE-PHOSPHATASE; SRC HOMOLOGY-2 DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; SH2 DOMAIN; FACTOR-I; C-FOS	Both p21ras and phosphatidylinositol 3-kinase (PI 3-k) are critical elements in signaling pathways mediating insulin/IGF-I induced cell cycle progression. For example, microinjection of antibodies, peptides, or recombinant proteins which block the interaction of the SH2 domains of the PI 3-k p85 alpha subunit with tyrosine phosphorylated intracellular targets blocks insulin mediated DNA synthesis. We report here that this inhibitory phenotype is observed whether the injections are made into quiescent cells (the standard approach), or at any time point during G(1) phase subsequent to stimulation. This observation is not true, however, for the major substrate of the insulin/IGF-I receptor (IRS-1) despite the well known interaction of p85 with IRS-1, Antibodies to IRS-1 are inhibitory only when injected during the first 15 min of G(1) phase, as are antibodies to another major IRS-1 binding protein, the tyrosine phosphatase SHP2. We also have microinjected reagents which target proteins involved in the formation of rasGTP and which mediate some of the downstream effects of ras activation. Reagents which target the formation of rasGTP (Shc and dominant negative ras protein) inhibit DNA synthesis only at points early in G(1), as do reagents which target components of the MAP kinase pathway. Injection of antibodies to p21ras itself, or a recombinant Raf-l protein domain which binds to the effector region of ras in a GTP-dependent manner, results in the inhibition of cell cycle progression throughout G(1) phase. The results point to a continuous requirement for both PI 3-k and ras activity until cellular commitment to DNA synthesis, although some of the molecules which are both upstream and downstream of these activities are only required transiently. Our results are also consistent with a Raf-l independent ras activity late in G(1), as well as IRS-1 independent effects of PI 3-kinase.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; Vet Adm Med Ctr, San Diego, CA 92161 USA; Haematologikum, GSF, Whittier Diabet Res Program, D-81377 Munich, Germany; Haematologikum, GSF, Inst Klin Mol Biol & Tumorgenet, D-81377 Munich, Germany	University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Rose, DW (corresponding author), Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA.		Admin, SBI/HGB-2738-2022; Kolch, Walter/ABF-2102-2021	pillay, tahir/0000-0002-9982-9710; Kolch, Walter/0000-0001-5777-5016	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033651, R37DK033651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK33651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adachi M, 1996, CELL, V85, P15; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; FENG GS, 1994, ONCOGENE, V9, P1545; HARUTA T, 1995, J BIOL CHEM, V270, P27991; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; HUNTER T, 1995, CELL, V83, P1, DOI 10.1016/0092-8674(95)90225-2; JHUN BH, 1994, J BIOL CHEM, V269, P5699; JHUN BH, 1994, MOL CELL BIOL, V14, P7466, DOI 10.1128/MCB.14.11.7466; KAPLAN JB, 1994, ONCOL RES, V6, P611; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Klippel A, 1996, MOL CELL BIOL, V16, P4117; KODAKI T, 1995, BIOCHEM SOC T, V23, pS195, DOI 10.1042/bst023195s; KODAKI T, 1994, CURR BIOL, V4, P798, DOI 10.1016/S0960-9822(00)00177-9; KOLCH W, 1990, ONCOGENE, V5, P713; Kolch W, 1996, ONCOGENE, V13, P1305; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANGLOIS WJ, 1994, ENDOCRINOLOGY, V135, P2412, DOI 10.1210/en.135.6.2412; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MYERS MG, 1995, J BIOL CHEM, V270, P11715, DOI 10.1074/jbc.270.20.11715; MYERS MG, 1994, J BIOL CHEM, V269, P28783; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; Peeper DS, 1997, NATURE, V386, P177, DOI 10.1038/386177a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PICCIONE E, 1993, BIOCHEMISTRY-US, V32, P3197, DOI 10.1021/bi00064a001; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; PUMIGLIA K, 1995, MOL CELL BIOL, V15, P398, DOI 10.1128/MCB.15.1.398; QUON MJ, 1995, MOL CELL BIOL, V15, P5403; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; ROSE DW, 1992, J CELL BIOL, V119, P1405, DOI 10.1083/jcb.119.6.1405; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUGIMOTO S, 1994, J BIOL CHEM, V269, P13614; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	62	12	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	1998	17	7					889	899		10.1038/sj.onc.1201997	http://dx.doi.org/10.1038/sj.onc.1201997			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111QH	9780005				2022-12-17	WOS:000075448800010
J	Lu, XL; Qu, CK; Shi, ZQ; Feng, GS				Lu, XL; Qu, CK; Shi, ZQ; Feng, GS			Downregulation of platelet-derived growth factor receptor-beta in Shp-2 mutant fibroblast cell lines	ONCOGENE			English	Article						phosphatase; kinase; SH2 domain; signal transduction	SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; PROTEIN-TYROSINE-PHOSPHATASE; FACTOR-ALPHA-RECEPTOR; MOTH-EATEN MICE; SIGNAL-TRANSDUCTION; DNA-SYNTHESIS; SH3 DOMAINS; SYP; SH-PTP2; ACTIVATION	The SH2-containing tyrosine phosphatase Shp-2 appears to function downstream of a variety of growth factor receptors and might play a positive role in cell proliferation, Here we report that expression of the beta subunit of platelet-derived growth factor receptor (PDGFR-beta) was specifically downregulated in mutant fibroblasts lacking a functional Shp-2, while the levels of PDGFR-alpha EGFR and IGFIR were not changed, PDGF-stimulated DNA synthesis and extracellular signal regulated kinase (Erk) activation was severely suppressed in mutant cells, RasGAP, that responds to activation of PDGFR-beta but not PDGFR-alpha, was not phosphorylated on tyrosine in mutant cells upon PDGF-treatment, Northern blot analysis failed to detect PDGFR-beta mRNA in mutant cells. The transcription initiation from the PDGFR-beta gene promoter was not significantly changed, but the half-life of its mRNA was shortened in Shp-2 mutant cells. These observations indicate that Shp-2 not only participates in transmission of signals from growth factor receptors but also plays a specific role in the control of the PDGFR-beta expression. We propose that this is an important mechanism for the positive control of cell proliferation by Shp-2.	Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Med, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Walther Canc Inst, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Walther Cancer Institute	Feng, GS (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.				NIGMS NIH HHS [R29GM53660] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053660] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arrandale JM, 1996, J BIOL CHEM, V271, P21353, DOI 10.1074/jbc.271.35.21353; AUSUBEL FM, 1994, CURRENT PROTOCOLS, V1; BAZENET CE, 1994, ONCOGENE, V9, P517; Bazenet CE, 1996, MOL CELL BIOL, V16, P6926; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DAMBROSIO D, 1995, SCIENCE, V268, P293, DOI 10.1126/science.7716523; FENG GS, 1994, ONCOGENE, V9, P1545; FENG GS, 1994, TRENDS GENET, V10, P54, DOI 10.1016/0168-9525(94)90149-X; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HEIDARAN MA, 1993, J BIOL CHEM, V268, P9287; KAZLAUSKAS A, 1993, P NATL ACAD SCI USA, V90, P6939, DOI 10.1073/pnas.90.15.6939; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KOZLOWSKI M, 1993, J EXP MED, V178, P2157, DOI 10.1084/jem.178.6.2157; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; Lih CJ, 1996, P NATL ACAD SCI USA, V93, P4617, DOI 10.1073/pnas.93.10.4617; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Neel B G, 1993, Semin Cell Biol, V4, P419, DOI 10.1006/scel.1993.1050; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PaasinenSohns A, 1997, ONCOGENE, V15, P1953, DOI 10.1038/sj.onc.1201366; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Qu CK, 1997, MOL CELL BIOL, V17, P5499, DOI 10.1128/MCB.17.9.5499; Roche S, 1996, EMBO J, V15, P4940, DOI 10.1002/j.1460-2075.1996.tb00874.x; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; SHI ZQ, 1998, IN PRESS J BIOL CHEM; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; SORIANO P, 1994, GENE DEV, V8, P1888, DOI 10.1101/gad.8.16.1888; TANG TL, 1995, CELL, V80, P473, DOI 10.1016/0092-8674(95)90498-0; TSUI HW, 1993, NAT GENET, V4, P124, DOI 10.1038/ng0693-124; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WASILENKO WJ, 1990, MOL CELL BIOL, V10, P1254, DOI 10.1128/MCB.10.3.1254; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3864, DOI 10.1128/MCB.8.9.3864; XIAO S, 1994, J BIOL CHEM, V269, P21244; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; ZHANG QX, 1995, BBA-MOL CELL RES, V1266, P9, DOI 10.1016/0167-4889(94)00232-4	40	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 30	1998	17	4					441	448		10.1038/sj.onc.1201988	http://dx.doi.org/10.1038/sj.onc.1201988			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	104XY	9696037				2022-12-17	WOS:000075043000006
J	Trink, B; Pai, SI; Spunt, SL; Raman, V; Cairns, P; Jen, J; Gabrielson, E; Sukumar, S; Sidransky, D				Trink, B; Pai, SI; Spunt, SL; Raman, V; Cairns, P; Jen, J; Gabrielson, E; Sukumar, S; Sidransky, D			Absence of TSG101 transcript abnormalities in human cancers	ONCOGENE			English	Article						breast cancer; Wilms' tumor; TSG101; RT-PCR	FHIT GENE; EXPRESSION; 3P14.2	The human TSG101 gene was cloned and mapped to chromosome 11p15, a site suspected to contain a tumor suppressor gene involved in a variety of human cancers. Subsequent investigation described the presence of abnormally spliced transcripts and point mutations of TSG101 in breast cancer, Thus, we performed RT-PCR amplification of the entire open reading frame of TSG101 to test for aberrant transcripts in various human tumor cell lines derived from breast, bladder, head and neck, and lung cancer. In addition, we performed RT-PCR on cDNA from primary human breast and Wilms' tumor tissue. We found a single band of the expected size in 10 of 11 breast cancers and 6 of 6 Wilms' tumor samples after the first round of PCR, The remaining breast cancer sample displayed a barely visible smaller band. However, aberrant bands appeared in most cases after performing nested PCR casting doubt on the physiologic relevance of these spliced variants, We then searched for small intragenic mutations by complete sequence analysis of TSG101 in breast cancer cell lines and tumors, as well as in Wilms' tumors and normal fetal and adult kidney, No point mutations were found in any of the samples, including four breast tumors with chormosomal loss at 11p15, We found no consistent evidence of aberrant splicing or point mutations in breast cancer or Wilms' tumor suggesting that TSG101 is not a primary target of inactivation in human cancer.	Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Ctr Oncol, Breast Canc Program, Baltimore, MD 21205 USA; Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Sidransky, D (corresponding author), Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Div Head & Neck Canc Res, Baltimore, MD 21205 USA.			Pai, Sara/0000-0002-6341-9971; Spunt, Sheri/0000-0002-1669-2676				BRATTSAND G, 1993, LEUKEMIA, V7, P569; Feinberg AP, 1996, MED PEDIATR ONCOL, V27, P484; Haber D, 1997, NAT GENET, V16, P320, DOI 10.1038/ng0897-320; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Lee MP, 1997, CANCER RES, V57, P3131; Li LM, 1996, CELL, V85, P319, DOI 10.1016/S0092-8674(00)81111-3; Li LM, 1997, CELL, V88, P143, DOI 10.1016/S0092-8674(00)81866-8; Liu B, 1996, NAT MED, V2, P169, DOI 10.1038/nm0296-169; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; ROOS G, 1993, LEUKEMIA, V7, P1538; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Steiner P, 1997, NAT GENET, V16, P332, DOI 10.1038/ng0897-332; Thiagalingam S, 1996, CANCER RES, V56, P2936; Todd S, 1997, CANCER RES, V57, P1344; WINQVIST R, 1995, CANCER RES, V55, P2660	16	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 28	1998	16	21					2815	2818		10.1038/sj.onc.1201795	http://dx.doi.org/10.1038/sj.onc.1201795			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZQ013	9652749				2022-12-17	WOS:000073812200014
J	Kim, JH; Shirouzu, M; Kataoka, T; Bowtell, D; Yokoyama, S				Kim, JH; Shirouzu, M; Kataoka, T; Bowtell, D; Yokoyama, S			Activation of Ras and its downstream extracellular signal-regulated protein kinases by the CDC25 homology domain of mouse Son-of-sevenless 1 (mSos1)	ONCOGENE			English	Article						Son-of-sevenless (Sos); Dbl-homology (DH) domain; Ras; ERK; guanine nucleotide exchange factor; Pleckstrin homology (PH) domain	NUCLEOTIDE EXCHANGE FACTOR; TYROSINE KINASE; PLECKSTRIN; GRB2; RECEPTOR; PATHWAY; BINDING; SOS1; TRANSDUCTION; ASSOCIATION	A fragment consisting of residues 584-1071 of the mouse Son-of-sevenless 1 (mSos1) protein was found to be sufficient for stimulation of the guanine nucleotide exchange of Ras in vitro, which defines the CDC25 homology (CDC25H) domain of mSos1, Furthermore, we found that the CDC25H-domain fragment activated the extracellular signal-regulated protein kinases (ERKs), and was mainly membrane localized, when expressed in unstimulated human embryonic kidney 293 cells, Then, we examined the roles of other mSos1 domains in autoinhibition of the CDC25H-domain functions in unstimulated cellular environments. First, longer fragments that have the CDC25H domain and the following proline-rich Grb2-binding domain exhibited negligible membrane localization, and accordingly much lower ERK-activation activities, under serum-starved conditions. On the other hand, the preceding Pleckstrin-homology (PH) domain affects neither the ERK-activation activity nor the membrane-localization activity of the CDC25H domain. By contrast, the cells expressing a fragment containing the Dbl homology (DH) domain in addition to the PH and CDC25H domains exhibited remarkably low ERK activities under serum-starved conditions. This autoinhibitory effect of the DH domain on the CDC25H-domain function was shown to be relieved when cells were stimulated with epidermal growth factor. The DH-domain extention affected neither the irt vitro guanine nucleotide exchange activity nor the membrane-localization activity of the CDC25H domain. Therefore, one of the roles of the DH domain is to exert an autoinhibition over the CDC25H-domain function on the cell membrane, in the absence, but not in the presence, of extracellular stimuli.	Inst Phys & Chem Res, Cellular Signaling Lab, Wako, Saitama 35101, Japan; Univ Tokyo, Grad Sch Sci, Dept Biophys & Biochem, Bunkyo Ku, Tokyo 113, Japan; Kobe Univ, Sch Med, Dept Physiol 2, Chuo Ku, Kobe, Hyogo 650, Japan; Peter MacCallum Canc Inst, Melbourne, Vic 3000, Australia	RIKEN; University of Tokyo; Kobe University; Peter Maccallum Cancer Center	Yokoyama, S (corresponding author), Inst Phys & Chem Res, Cellular Signaling Lab, 2-1 Hirosawa, Wako, Saitama 35101, Japan.		Yokoyama, Shigeyuki/N-6911-2015; Bowtell, David/H-1007-2016; Shirouzu, Mikako/A-6521-2016	Yokoyama, Shigeyuki/0000-0003-3133-7338; Bowtell, David/0000-0001-9089-7525; 				Akasaka K, 1996, J BIOL CHEM, V271, P5353, DOI 10.1074/jbc.271.10.5353; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARONHEIM A, 1994, CELL, V78, P949, DOI 10.1016/0092-8674(94)90271-2; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P7100; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; Buchsbaum R, 1996, MOL CELL BIOL, V16, P4888; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Byrne JL, 1996, ONCOGENE, V13, P2055; CEN H, 1993, MOL CELL BIOL, V13, P7718, DOI 10.1128/MCB.13.12.7718; CHARDIN P, 1993, SCIENCE, V260, P1388; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; Garreau H, 1996, BIOL CELL, V86, P93, DOI 10.1016/0248-4900(96)84771-X; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; Hu YL, 1996, ONCOGENE, V12, P1865; KARLOVICH CA, 1995, SCIENCE, V268, P576, DOI 10.1126/science.7725106; KIMURA M, 1994, BBA-GENE STRUCT EXPR, V1219, P653, DOI 10.1016/0167-4781(94)90224-0; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MAHADEVAN D, 1995, BIOCHEMISTRY-US, V34, P9111, DOI 10.1021/bi00028a021; MCCOLLAM L, 1995, J BIOL CHEM, V270, P15954, DOI 10.1074/jbc.270.27.15954; PORFIRI E, 1994, J BIOL CHEM, V269, P22672; QUILLIAM LA, 1994, P NATL ACAD SCI USA, V91, P8512, DOI 10.1073/pnas.91.18.8512; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; WHELHAM MJ, 1994, J BIOL CHEM, V269, P21165; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	36	12	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 21	1998	16	20					2597	2607		10.1038/sj.onc.1201822	http://dx.doi.org/10.1038/sj.onc.1201822			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZN934	9632136				2022-12-17	WOS:000073698200004
J	Bull, EK; Chakrabarty, S; Brodsky, I; Haines, DS				Bull, EK; Chakrabarty, S; Brodsky, I; Haines, DS			mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells	ONCOGENE			English	Article						mdm2-P2 transcripts; p53 functional assay	NON-HODGKINS-LYMPHOMAS; WILD-TYPE P53; GENE; EXPRESSION; PROTEIN; ACTIVATION; INDUCTION; APOPTOSIS; OVEREXPRESSION; ONCOGENE	The mdm2-P2 promoter is a transcriptional target of the p53 tumor suppressor. The aim of this study was to determine if there is an association between the level of these transcripts and the status of the p53 gene in human leukemic cells, A correlation between mdm2-P2 transcript levels and p53 gene status was observed in all cell lines examined. Primary malignant cells from 10 leukemic patients were also analysed for both mdm2-P2 levels and p53 gene status, All five patients with detectable mdm2-P2 transcripts possessed wild-type p53 alleles, However, only two of five patients with undetectable mdm2-P2 transcripts possessed mutant p53, mdm2-P2 levels were also determined in primary leukemic cells from 14 additional cases both before and after in vitro exposure to cisplatin. The p53 gene was found to be wild-type in all cases where mdm2-P2 levels were induced by cisplatin, There were four cases where no, or only modest, increases in mdm2-P2 levels were detected after cisplatin exposure, Two of these patients were found to harbor mutant p53 while one other possessed leukemic cells with elevated levels of mdm2 protein, These results show that induction of mdm2-P2 transcripts can be used to predict the presence of transcriptionally active p53 in primary leukemic cells.	Allegheny Univ Hlth Sci, Barry Ashbee Leukemia Res Labs, Philadelphia, PA 19102 USA	Drexel University	Haines, DS (corresponding author), Allegheny Univ Hlth Sci, Barry Ashbee Leukemia Res Labs, MS412,Broad & Vine St, Philadelphia, PA 19102 USA.							BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bischoff JR, 1996, SCIENCE, V274, P373, DOI 10.1126/science.274.5286.373; Bourdon JC, 1997, ONCOGENE, V14, P85, DOI 10.1038/sj.onc.1200804; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Bukholm IK, 1997, J PATHOL, V181, P140, DOI 10.1002/(SICI)1096-9896(199702)181:2<140::AID-PATH745>3.0.CO;2-A; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; Chilosi M, 1996, BLOOD, V88, P4012, DOI 10.1182/blood.V88.10.4012.bloodjournal88104012; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DEVENTE JE, 1995, J CLIN INVEST, V96, P1874, DOI 10.1172/JCI118233; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Gottlieb E, 1997, EMBO J, V16, P1381, DOI 10.1093/emboj/16.6.1381; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; HAINES DS, 1994, MOL CELL BIOL, V14, P1171, DOI 10.1128/MCB.14.2.1171; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Landers JE, 1997, CANCER RES, V57, P3562; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li ML, 1996, CELL GROWTH DIFFER, V7, P13; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; MAESTRO R, 1995, BLOOD, V85, P3239, DOI 10.1182/blood.V85.11.3239.bloodjournal85113239; Marks DI, 1996, BRIT J HAEMATOL, V92, P890, DOI 10.1046/j.1365-2141.1996.439978.x; Marks DI, 1997, J CLIN ONCOL, V15, P1158, DOI 10.1200/JCO.1997.15.3.1158; MARTINEZ JC, 1995, J PATHOL, V177, P27, DOI 10.1002/path.1711770106; MIYASHITA T, 1995, CELL, V80, P293; MOSNER J, 1994, ONCOGENE, V9, P3321; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PERRY ME, 1993, P NATL ACAD SCI USA, V90, P11623, DOI 10.1073/pnas.90.24.11623; Velculescu VE, 1996, CLIN CHEM, V42, P858; WATANABE T, 1994, BLOOD, V84, P3158; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584	40	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 30	1998	16	17					2249	2257		10.1038/sj.onc.1201757	http://dx.doi.org/10.1038/sj.onc.1201757			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZK226	9619834				2022-12-17	WOS:000073298000010
J	Kherrouche, Z; Beuscart, A; Huguet, C; Flourens, A; Moreau-Gachelin, F; Stehelin, D; Coll, J				Kherrouche, Z; Beuscart, A; Huguet, C; Flourens, A; Moreau-Gachelin, F; Stehelin, D; Coll, J			Isolation and characterization of a chicken homologue of the Spi-1/PU.1 transcription factor	ONCOGENE			English	Article						Spi-1/PU.1; ets genes; transcription factor; chicken; in-situ-hybridization	PUTATIVE ONCOGENE SPI-1; ETS GENE FAMILY; FACTOR PU.1; CHAIN GENE; C-MYB; HEMATOPOIETIC-CELLS; BINDING-SITE; PROMOTER; EXPRESSION; ENHANCER	Spi-1/PU.1 is a member of the Ets family of transcription factors important in regulation of hematopoiesis. We have isolated a chicken cDNA homologuous to the mammalian Spi-1/PU.1 gene with an open reading frame of 250 amino acids (aa). The chicken Spi-1/PU.1 protein is 14 aa and 16 aa shorter than its human and mouse counterparts but is extremely well conserved with 78.8% and 75.2% identity respectively. The carboxy terminal DNA binding region, or ETS binding domain, is 100% identical to that of human and mouse. Some differences with the mammalian homologues are seen in the N-terminal part of the protein and in the PEST connecting domain. However, the differences are mainly conservative and all the features underlying functional aspects seem preserved. The major discrepancy lies in a 12 aa deletion in an already poorly conserved part of the PEST sequence. Spi-1/PU.1 transcripts were detected at high levels in spleen and Fabricius bursa of chick embryos by Northern blot and in situ hybridization. Our results show that the chicken Spi-1/PU.1 protein behaves like a bonafide Spi-1/PU.1 transcription factor in its DNA binding and transactivating properties.	Univ Lille 1, Inst Pasteur, CNRS, UMR 319,Inst Biol Lille, F-59021 Lille, France; Inst Curie, INSERM, U248, F-75231 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Coll, J (corresponding author), Univ Lille 1, Inst Pasteur, CNRS, UMR 319,Inst Biol Lille, 1 Rue Calmette,BP 441, F-59021 Lille, France.		KHERROUCHE, Zoulika/HHN-0213-2022; Coll, Jean-Luc/G-2520-2013; KHERROUCHE, Zoulika/L-6549-2019	Coll, Jean-Luc/0000-0002-2453-3552; 				AHNE B, 1994, J BIOL CHEM, V269, P17794; ANSIEAU S, 1993, GENOMICS, V18, P537, DOI 10.1016/S0888-7543(11)80010-8; Carey JO, 1996, BLOOD, V87, P4316, DOI 10.1182/blood.V87.10.4316.bloodjournal87104316; CARVALHO M, 1993, J VIROL, V67, P6586, DOI 10.1128/JVI.67.11.6586-6595.1993; CHEN HM, 1995, ONCOGENE, V11, P1549; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLL J, 1983, EXP CELL RES, V149, P151, DOI 10.1016/0014-4827(83)90388-9; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DELGADO MD, 1994, ONCOGENE, V9, P1723; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; GRAF T, 1992, CELL, V70, P201, DOI 10.1016/0092-8674(92)90096-U; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; Heydemann A, 1996, MOL CELL BIOL, V16, P1676; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KISTLER B, 1995, ONCOGENE, V11, P1095; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; KOLMER JA, 1945, APPROVED LAB TECHNIC, P71; KOMINATO Y, 1995, MOL CELL BIOL, V15, P59; LAUDET V, 1993, BIOCHEM BIOPH RES CO, V190, P8, DOI 10.1006/bbrc.1993.1002; LAUTENBERGER JA, 1992, ONCOGENE, V7, P1713; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; Mao C, 1996, ONCOGENE, V12, P863; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; Oelgeschlager M, 1996, MOL CELL BIOL, V16, P4717; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; Pongubala JMR, 1997, P NATL ACAD SCI USA, V94, P127, DOI 10.1073/pnas.94.1.127; PONGUBALA JMR, 1993, SCIENCE, V259, P1622, DOI 10.1126/science.8456286; QUANG CT, 1995, ONCOGENE, V11, P1229; QUEVA C, 1992, DEVELOPMENT, V114, P125; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; RAY D, 1992, MOL CELL BIOL, V12, P4297, DOI 10.1128/MCB.12.10.4297; RAYGALLET D, 1995, ONCOGENE, V11, P303; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; RIVERA RR, 1993, MOL CELL BIOL, V13, P7163, DOI 10.1128/MCB.13.11.7163; ROSMARIN AG, 1995, J BIOL CHEM, V270, P23627, DOI 10.1074/jbc.270.40.23627; Sambrook J, 1989, MOL CLONING LAB MANU; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; Tondravi MM, 1997, NATURE, V386, P81, DOI 10.1038/386081a0; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x	52	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 12	1998	16	10					1357	1367		10.1038/sj.onc.1201650	http://dx.doi.org/10.1038/sj.onc.1201650			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA978	9546438				2022-12-17	WOS:000072422000015
J	Braspenning, J; Marchini, A; Albarani, V; Levy, L; Ciccolini, F; Cremonesi, C; Ralston, R; Gissmann, L; Tommasino, M				Braspenning, J; Marchini, A; Albarani, V; Levy, L; Ciccolini, F; Cremonesi, C; Ralston, R; Gissmann, L; Tommasino, M			The CXXC Zn binding motifs of the human papillomavirus type 16 E7 oncoprotein are not required for its in vitro transforming activity in rodent cells	ONCOGENE			English	Article						human papillomavirus type 16 E7 protein; E7-E1A243 chimeric protein; CXXC motifs; cellular transformation; E7 homodimerization	RETINOBLASTOMA GENE-PRODUCT; ADENOVIRUS E1A PROTEINS; CERVICAL-CARCINOMA; ZINC-BINDING; IN-VIVO; IDENTIFICATION; DIMERIZATION; COMPLEXES; DOMAINS; REGION	The conserved region 3 (CR3) of the E7 protein of human papillomaviruses contains two CXXC motifs involved in zinc binding and in the homodimerization of the molecule, Studies have suggested that the intact CXXC motifs in the CR3 of HPV16 and HPV18 E7 are required for the in vitro transforming activity of these proteins, CR3 also contains a low affinity pRb binding site and is involved in the disruption of the E2F/Rb1 complex, E7 is structurally and functionally related to Adenovirus E1A protein, which also has two CXXC motifs in CR3. However, the Ad E1A transforming activity appears to be independent of the presence of such domains, In fact, this viral protein exists in vivo as two different forms of 289 and 243 amino acids, The shorter Ad E1A form (Ad E1A243), where both CXXC motifs are deleted by internal splicing, retains its in vitro transforming activity, We have investigated if the HPV16 E7 CR3 can be functionally replaced by the Ad E1A243 CR3, which lacks both CXXC motifs, A chimeric protein (E7/E1A243) containing the CR1 and CR2 of HPV16 E7 fused to the CR3 of Ad E1A 243 was constructed. The E7/E1A243 while not able to homodimerize in the S. cerevisiae two-hybrid system retains several of the properties of the parental proteins, HPV16 E7 and Ad E1A, It associates with the 'pocket' proteins, induces growth in soft agar of NIH3T3 cells and immortalizes rat embryo fibroblasts, These data suggest that the CXXC motifs in CR3 of E7 do not play a direct role in the transforming properties of this viral protein but probably are important for maintaining the correct protein configuration.	Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany; Chiron Corp, Dept Virol, Emeryville, CA 94608 USA; GeneMed Inc, The Woodlands, TX USA	Helmholtz Association; German Cancer Research Center (DKFZ); Novartis	Tommasino, M (corresponding author), Deutsch Krebsforschungszentrum, D-6900 Heidelberg, Germany.		Gissmann, Lutz/H-4688-2011; Marchini, Antonio/ABD-3328-2020; Ralston, Robert O/A-6924-2009; Marchini, Antonio/AAG-7151-2019	Marchini, Antonio/0000-0003-3157-4552; Ciccolini, Francesca/0000-0002-7276-7361				BARBOSA MS, 1989, J VIROL, V63, P1404, DOI 10.1128/JVI.63.3.1404-1407.1989; CHOO KB, 1987, VIROLOGY, V161, P259, DOI 10.1016/0042-6822(87)90195-4; CLEMENS KE, 1995, VIROLOGY, V214, P289, DOI 10.1006/viro.1995.9926; CULLEN AP, 1991, J VIROL, V65, P606, DOI 10.1128/JVI.65.2.606-612.1991; DAVIES R, 1993, J VIROL, V67, P2521, DOI 10.1128/JVI.67.5.2521-2528.1993; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FATTAEY AR, 1993, MOL CELL BIOL, V13, P7267, DOI 10.1128/MCB.13.12.7267; HARLOW E, 1985, J VIROL, V55, P533, DOI 10.1128/JVI.55.3.533-546.1985; HAUSEN HZ, 1991, VIROLOGY, V184, P9, DOI 10.1016/0042-6822(91)90816-T; HU TH, 1995, INT J ONCOL, V6, P167; HUANG PS, 1993, MOL CELL BIOL, V13, P953, DOI 10.1128/MCB.13.2.953; IKEDA MA, 1993, MOL CELL BIOL, V13, P7029, DOI 10.1128/MCB.13.11.7029; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; PATRICK DR, 1994, J BIOL CHEM, V269, P6842; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; SCHWARZ E, 1985, NATURE, V314, P111, DOI 10.1038/314111a0; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; VOUSDEN KH, 1989, ONCOGENE, V4, P153; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, J VIROL, V62, P257, DOI 10.1128/JVI.62.1.257-265.1988; WU EW, 1993, J VIROL, V67, P2402, DOI 10.1128/JVI.67.4.2402-2407.1993; ZERFASS K, 1995, J GEN VIROL, V76, P1815, DOI 10.1099/0022-1317-76-7-1815; Zwerschke W, 1996, ONCOGENE, V12, P213	26	12	15	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	1998	16	8					1085	1089		10.1038/sj.onc.1201617	http://dx.doi.org/10.1038/sj.onc.1201617			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519882	Bronze			2022-12-17	WOS:000072335900014
J	Burke, TF; Cocke, KS; Lemke, SJ; Angleton, E; Becker, GW; Beckmann, RP				Burke, TF; Cocke, KS; Lemke, SJ; Angleton, E; Becker, GW; Beckmann, RP			Identification of a BRCA1-associated kinase with potential biological relevance	ONCOGENE			English	Article						breast cancer; BRCA1; phosphorylation	CANCER SUSCEPTIBILITY GENE; OVARIAN-CANCER; BREAST-CANCER; TRANSCRIPTIONAL ACTIVATION; SUBCELLULAR-LOCALIZATION; BRCA1 EXPRESSION; MUTATIONS; TUMOR; FAMILIES; CELLS	A biochemical approach was used to identify proteins which interact with human BRCA1, Through this work, a kinase activity which co-purifies with BRCA1 has been identified, This kinase activity, which phosphorylates BRCA1 in vitro, was originally identified in Sf9 insect cells but is also present in cells of human origin including breast and ovarian carcinoma cell lines, The BRCA1 kinase activity in vitro is associated with a fragment of BRCA1 encompassing amino acids 329-435, This peptide is also phosphorylated in various human cell lines, A computer-assisted sequence analysis revealed that this peptide was a potential substrate for phosphorylation by PKA, PKC, or CKII, However, phosphorylation by these kinases could not be demonstrated in vitro indicating the presence of another kinase activity, Phosphorylation in vitro requires a minimal domain of BRCA1 encompassing amino acids 379-408, Notably, deletion of this minimal domain abolishes growth suppression by BRCA1 indicating that this domain, as well as phosphorylation within this domain, may be important for BRCA1 function.	Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Canc Res Div, Indianapolis, IN 46285 USA; Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Div Biotechnol, Indianapolis, IN 46285 USA	Eli Lilly; Eli Lilly	Beckmann, RP (corresponding author), Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Canc Res Div, Indianapolis, IN 46285 USA.							Bienstock RJ, 1996, CANCER RES, V56, P2539; BOYD J, 1995, NAT GENET, V9, P335, DOI 10.1038/ng0495-335; CASTILLA LH, 1994, NAT GENET, V8, P387, DOI 10.1038/ng1294-387; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen YM, 1996, CANCER RES, V56, P3168; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; FRIEDMAN LS, 1994, NAT GENET, V8, P399, DOI 10.1038/ng1294-399; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Gudas JM, 1996, CELL GROWTH DIFFER, V7, P717; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; HOSKING L, 1995, NAT GENET, V9, P343, DOI 10.1038/ng0495-343; Jensen RA, 1996, NAT GENET, V12, P303, DOI 10.1038/ng0396-303; LANE TF, 1995, GENE DEV, V9, P2712, DOI 10.1101/gad.9.21.2712; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; OBrien K, 1997, GENE, V184, P115, DOI 10.1016/S0378-1119(96)00583-5; Rao VN, 1996, ONCOGENE, V12, P523; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; SHATTUCKEIDENS D, 1995, JAMA-J AM MED ASSOC, V273, P535, DOI 10.1001/jama.273.7.535; SIMARD J, 1994, NAT GENET, V8, P392, DOI 10.1038/ng1294-392; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; Szabo CI, 1996, HUM MOL GENET, V5, P1289, DOI 10.1093/hmg/5.9.1289; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; Thomas JE, 1996, J BIOL CHEM, V271, P28630, DOI 10.1074/jbc.271.45.28630; THOMAS JE, 1997, IN PRESS CELL GROWTH; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vaughn JP, 1996, CELL GROWTH DIFFER, V7, P711; VOGELSTEIN B, 1994, CELL, V79, P1, DOI 10.1016/0092-8674(94)90393-X	32	12	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 26	1998	16	8					1031	1040		10.1038/sj.onc.1201623	http://dx.doi.org/10.1038/sj.onc.1201623			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA169	9519877				2022-12-17	WOS:000072335900009
J	Qi, XM; Simonson, M; Distelhorst, CW				Qi, XM; Simonson, M; Distelhorst, CW			Bcl-2 inhibits c-fos induction by calcium	ONCOGENE			English	Article						Bcl-2; calcium; c-fos; thapsigargin	PROGRAMMED CELL-DEATH; GENE-EXPRESSION; APOPTOSIS; THAPSIGARGIN; PROTEIN; FAMILY; CA2+; BCL-X(L); PATHWAY; NUCLEAR	Transient elevation of cytosolic Ca2+ induces the expression of a variety of genes involved in cell growth and transformation, including the early response gene c-fos. Previously, we reported that Bcl-2 inhibits the transient elevation of cytosolic Ca2+ induced by thapsigargin (TG), a selective inhibitor of the endoplasmic reticulum-associated Ca2+-ATPase. Therefore, to determine if the effect of Bcl-2 on cytosolic Ca2+ elevation modulates Ca2+ signaling, we investigated the induction of c-fos by TG in WEHI7.2 mouse lymphoma cells, control transfectants (WEHI7.2-neo), and transfectants that stably express a high level of Bcl-2 (W.Hb12 and W.Hb15). TG induced 20-fold elevation of c-fos mRNA in WEHI7.2 and WEHI7.2-neo cells, but c-fos mRNA induction by TG was only fivefold in W.Hb12 and W.Hb15 cells, In contrast, phorbol 12-myristate acetate induced marked c-fos mRNA elevation in both WEHI7.2 and W.Hb12 cells, indicating that the inhibitory effect of Bcl-2 is selective for induction of c-fos by Ca2+. To measure c-fos promoter activity, WEHI7.2 and W.Hb12 cells were transiently transfected with a c-fos promoter-luciferase reporter plasmid, TG induced c-fos promoter activity in WEHI7.2 cells, but not in W.Hb12 cells. In WEHI7.2 cells, the signal for c-fos induction by TG was cytosolic Ca2+ elevation, as the increase in both c-fos mRNA level and promoter activity were prevented by lowering extracellular Ca2+ concentration, a condition that inhibits cytosolic Ca2+ elevation by reducing the TG-mobilizable Ca2+ pool, In summary, the findings indicate that Bcl-2 regulates Ca2+ signaling.	CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,DEPT PHARMACOL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NCI NIH HHS [R01 CA42755-11] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042755] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAFFY G, 1993, J BIOL CHEM, V268, P6511; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4573; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; COLOTTA F, 1992, J BIOL CHEM, V267, P18278; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.iy.13.040195.002501; CURRAN T, 1987, ONCOGENE, V2, P79; FLOMERFELT FA, 1994, J CELL BIOL, V127, P1729, DOI 10.1083/jcb.127.6.1729; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; HENGARTNER MO, 1992, NATURE, V356, P494, DOI 10.1038/356494a0; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MAGNELLI L, 1994, BIOCHEM BIOPH RES CO, V204, P84, DOI 10.1006/bbrc.1994.2429; Marin MC, 1996, ONCOGENE, V12, P2259; McCormick TS, 1997, J BIOL CHEM, V272, P6087, DOI 10.1074/jbc.272.9.6087; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Muchmore SW, 1996, NATURE, V381, P335, DOI 10.1038/381335a0; Murphy AN, 1996, P NATL ACAD SCI USA, V93, P9893, DOI 10.1073/pnas.93.18.9893; Preston GA, 1996, MOL CELL BIOL, V16, P211; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; SCHONTHAL A, 1991, P NATL ACAD SCI USA, V88, P7096, DOI 10.1073/pnas.88.16.7096; Simonson MS, 1996, J BIOL CHEM, V271, P77, DOI 10.1074/jbc.271.1.77; SMEYNE RJ, 1993, NATURE, V363, P166, DOI 10.1038/363166a0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; WERLEN G, 1993, J BIOL CHEM, V268, P16596; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	32	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 4	1997	15	23					2849	2853		10.1038/sj.onc.1201463	http://dx.doi.org/10.1038/sj.onc.1201463			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YJ803	9419976				2022-12-17	WOS:A1997YJ80300011
J	Ishino, M; Ohba, T; Inazawa, J; Sasaki, H; Ariyama, Y; Sasaki, T				Ishino, M; Ohba, T; Inazawa, J; Sasaki, H; Ariyama, Y; Sasaki, T			Identification of an Efs isoform that lacks the SH3 domain and chromosomal mapping of human Efs	ONCOGENE			English	Article						Efs; Src homology; FAK; tyrosine phosphorylation; chromosomal mapping	PROTEIN-TYROSINE KINASE; FOCAL ADHESION KINASE; BINDING; SRC; GRB2; CRK; HYBRIDIZATION; EXPRESSION; P130(CAS); PEPTIDES	Efs was originally found by expression cloning of a mouse embryo cDNA library through its Fyn-SH3 binding capacity (Ishino et al., Oncogene 11, 2331-2338, 1995), Efs has characteristic regions important in intracellular signal transduction; these are an SH3 domain, a cluster of putative ligands for SH2 domains and proline-rich sequences with SH3-binding consensus, In this paper, we report cDNA cloning of human Efs and a variant of it from a hippocampal cDNA library, The human Efs gene was mapped to chromosome 14q11.2-q12 by fluorescence in situ hybridization. We identified two forms of human Efs, designated hEfs1 and hEfs2, hEfs1 represents the human counterpart of original mouse embryo Efs (mEfs1), hEfs2, the newly identified form, is identical to hEfs1, except for its lack of the SH3 domain, hEfs1 and mEfs1 are 80% identical in their amino acid sequences and 100% identical within the SH3 domain. Reverse transcription polymerase chain reaction analysis of adult mouse tissue RNA indicated expression of Efs2 and of Efs1 in various tissues, Evidence suggesting the presence of the Efs2 protein in human tissue was obtained by immunoprecipitation followed by immunoblotting with two different anti-Efs antibodies. Possible functions of Efs2 are discussed.	SAPPORO MED UNIV, CANC RES INST, DEPT BIOCHEM, CHUO KU, SAPPORO, HOKKAIDO 060, JAPAN; KYOTO PREFECTURAL UNIV MED, DEPT HYG, KAMIGYO KU, KYOTO 602, JAPAN	Sapporo Medical University; Kyoto Prefectural University of Medicine								AKASHI M, 1994, BLOOD, V83, P3182; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; INAZAWA J, 1993, GENOMICS, V17, P153, DOI 10.1006/geno.1993.1297; Ishino M, 1995, ONCOGENE, V11, P2331; Law SF, 1996, MOL CELL BIOL, V16, P3327; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	24	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 2	1997	15	14					1741	1745		10.1038/sj.onc.1201346	http://dx.doi.org/10.1038/sj.onc.1201346			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XY631	9349509				2022-12-17	WOS:A1997XY63100015
J	Mattia, E; Chichiarelli, S; Hickish, T; Gaeta, A; Mancini, C; Cunningham, D; vanRenswoude, J				Mattia, E; Chichiarelli, S; Hickish, T; Gaeta, A; Mancini, C; Cunningham, D; vanRenswoude, J			Inhibition of in vitro proliferation of Epstein Barr Virus infected B cells by an antisense oligodeoxynucleotide targeted against EBV latent membrane protein LMP1	ONCOGENE			English	Article						EBV; LMP1 expression; antisense oligodeoxynucleotides	HODGKINS-DISEASE; GENE-EXPRESSION; DIFFERENTIATION; TRANSFORMATION		UNIV ROMA LA SAPIENZA,FAC MED & SURG,DEPT EXPT MED & PATHOL,ROME,ITALY; ROYAL MARSDEN HOSP,LYMPHOMA UNIT,SUTTON,SURREY,ENGLAND	Sapienza University Rome; Royal Marsden NHS Foundation Trust	Mattia, E (corresponding author), UNIV ROMA LA SAPIENZA,FAC MED & SURG,INST MICROBIOL,ROME,ITALY.		Chichiarelli, Silvia/F-1226-2011	Hickish, Tamas/0000-0001-6770-7279; Cunningham, David/0000-0001-5158-1069; Chichiarelli, Silvia/0000-0002-5682-0353				BROCKSMITH D, 1991, J PATHOL, V165, P11, DOI 10.1002/path.1711650104; BROOKS L, 1992, J VIROL, V66, P2689, DOI 10.1128/JVI.66.5.2689-2697.1992; CHEUNG RK, 1993, INT IMMUNOL, V5, P707, DOI 10.1093/intimm/5.7.707; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DAWSON CW, 1990, NATURE, V344, P777, DOI 10.1038/344777a0; DEACON EM, 1993, J EXP MED, V177, P339, DOI 10.1084/jem.177.2.339; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HERBST H, 1990, AM J PATHOL, V137, P13; HERBST H, 1992, BLOOD, V80, P484; HUDSON GS, 1985, J VIROL, V53, P528, DOI 10.1128/JVI.53.2.528-535.1985; JOSKE DJL, 1992, BLOOD, V80, P2610; KHAN G, 1993, CANCER-AM CANCER SOC, V71, P3124, DOI 10.1002/1097-0142(19930515)71:10<3124::AID-CNCR2820711038>3.0.CO;2-J; MANFREDINI R, 1993, J EXP MED, V178, P381, DOI 10.1084/jem.178.2.381; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; MILLER G, 1990, VIROLOGY, P1921; PALLESEN G, 1991, LANCET, V337, P320, DOI 10.1016/0140-6736(91)90943-J; ROTH G, 1994, BLOOD, V84, P582, DOI 10.1182/blood.V84.2.582.bloodjournal842582; ROWE M, 1987, J GEN VIROL, V68, P1575, DOI 10.1099/0022-1317-68-6-1575; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG D, 1985, CELL, V43, P831, DOI 10.1016/0092-8674(85)90256-9; WANG F, 1990, J VIROL, V64, P2309, DOI 10.1128/JVI.64.5.2309-2318.1990; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028; WILSON JB, 1990, CELL, V61, P1315, DOI 10.1016/0092-8674(90)90695-B	23	12	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 24	1997	15	4					489	493		10.1038/sj.onc.1201183	http://dx.doi.org/10.1038/sj.onc.1201183			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM238	9242386	Bronze			2022-12-17	WOS:A1997XM23800014
J	Cairns, LA; Crotta, S; Minuzzo, M; RicciardiCastagnoli, P; Pozzi, L; Ottolenghi, S				Cairns, LA; Crotta, S; Minuzzo, M; RicciardiCastagnoli, P; Pozzi, L; Ottolenghi, S			Immortalization of neuro-endocrine cells from adrenal tumors arising in SV40 T-transgenic mice	ONCOGENE			English	Article						pheochromocytoma; transgenic mice; adrenal medullary tumor; ret	INTENSELY FLUORESCENT CELLS; NERVE GROWTH-FACTOR; RET PROTOONCOGENE; CHROMAFFIN CELLS; CREST DERIVATIVES; EXPRESSION; GENE; DIFFERENTIATION; RAT; GLUCOCORTICOIDS	Pheochromocytomas are adrenal medullary tumors which arise from the transformation of neural crest-derived cells. In the course of studies of mice transgenic for an SV40 T-gene ectopically expressed in the adrenal medulla, we observed the occurrence of large, mainly bilateral tumors in a high proportion of transgenic animals. From these tumors we established immortalized cell lines which grow in vitro at 32 degrees C (the permissive temperature for the tsA58 T-protein encoded by the transgene), but not at 38 degrees C. These cells demonstrate characteristics of both neuronal (160 kd neurofilament) and endocrine (chromogranins) cells. The expression of Mash-1 and ret supports their initial characterization as early bipotential neuro-endocrine progenitors.	CNR,CTR STUDIO FARMACOL CELLULARE & MOL,I-20133 MILAN,ITALY; UNIV ROME,SEZ BIOL CELLULARE,DIP BIOPATHOL UMANA,ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Cairns, LA (corresponding author), UNIV MILAN,DIP GENET & BIOL MICROORGANISMI,MILAN,ITALY.			Crotta, Stefania/0000-0003-4676-8616				Anderson D J, 1993, Curr Opin Neurobiol, V3, P8, DOI 10.1016/0959-4388(93)90028-W; ANDERSON DJ, 1989, TRENDS GENET, V5, P74; BABINET C, 1989, GENOME, V31, P938, DOI 10.1139/g89-165; BIRREN SJ, 1990, NEURON, V4, P189, DOI 10.1016/0896-6273(90)90094-V; BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; CAIRNS LA, 1994, EMBO J, V13, P4577, DOI 10.1002/j.1460-2075.1994.tb06779.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLAUDE P, 1988, NEURON, V1, P783, DOI 10.1016/0896-6273(88)90126-2; DOUPE AJ, 1985, J NEUROSCI, V5, P2143; DOUPE AJ, 1985, J NEUROSCI, V5, P2119; EIDEN LE, 1987, NEUROSCIENCE, V21, P1019, DOI 10.1016/0306-4522(87)90056-X; ERANKO O, 1972, HISTOCHEM J, V4, P49, DOI 10.1007/BF01005268; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GROVES AK, 1995, DEVELOPMENT, V121, P887; GUILLEMOT F, 1993, MECH DEVELOP, V42, P171, DOI 10.1016/0925-4773(93)90006-J; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; IKEDA I, 1990, ONCOGENE, V5, P1291; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Jing SQ, 1996, CELL, V85, P1113, DOI 10.1016/S0092-8674(00)81311-2; JOHNSON JE, 1990, NATURE, V346, P858, DOI 10.1038/346858a0; LANDIS SC, 1981, TRENDS NEUROSCI, V4, P172, DOI 10.1016/0166-2236(81)90056-4; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; POSSENTI R, 1989, EMBO J, V8, P2217, DOI 10.1002/j.1460-2075.1989.tb08345.x; ROBINSON MO, 1994, P NATL ACAD SCI USA, V91, P12798, DOI 10.1073/pnas.91.26.12798; SANTORO M, 1990, ONCOGENE, V5, P1595; SHALNIK DG, 1991, MOL CELL BIOL, V11, P4518; STEMPLE DL, 1988, NEURON, V1, P517, DOI 10.1016/0896-6273(88)90182-1; TAKAHASHI M, 1987, MOL CELL BIOL, V7, P1378, DOI 10.1128/MCB.7.4.1378; Treanor JJS, 1996, NATURE, V382, P80, DOI 10.1038/382080a0; Trupp M, 1996, NATURE, V381, P785, DOI 10.1038/381785a0; UNSICKER K, 1978, P NATL ACAD SCI USA, V75, P3498, DOI 10.1073/pnas.75.7.3498; UNSICKER K, 1989, INT J DEV NEUROSCI, V7, P413, DOI 10.1016/0736-5748(89)90002-6; VANHEYNINGEN V, 1994, NATURE, V367, P319, DOI 10.1038/367319a0; WHITE LA, 1994, J NEUROSCI, V14, P6744; YOMOGIDA K, 1994, DEVELOPMENT, V120, P1759	40	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3093	3098		10.1038/sj.onc.1201137	http://dx.doi.org/10.1038/sj.onc.1201137			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223673				2022-12-17	WOS:A1997XG10000012
J	Berkowitz, EA; Hecht, CP; Azizkhan, JC; Chen, XR; Lee, DC				Berkowitz, EA; Hecht, CP; Azizkhan, JC; Chen, XR; Lee, DC			Transcription factor AP2 is required for expression of the rat transforming growth factor-alpha gene	ONCOGENE			English	Article						TGF alpha promoter; AP2; DNase I footprinting; electrophoretic mobility shift assay; TATA binding protein	MAMMARY EPITHELIAL-CELLS; TRANSGENIC MICE; TGF-ALPHA; FACTOR AP-2; C-MYC; MESSENGER-RNA; PHORBOL ESTER; PROMOTER; ACTIVATION; INDUCTION	DNase I footprinting of the rat TGF alpha promoter in the presence of crude cell nuclear extract revealed three sites of protein-DNA interaction (Fp-A, Fp-B, Fp-C) in the region from -222 to +73. Mutation of specific sites within the Fp-A and Fp-B regions reduced expression of a TGF alpha promoter-reporter gene (TGF alpha LUC) from 50-90% in transiently transfected CHO cells, indicating the importance of protein/DNA interactions at these sites. Since Fp-A contained a perfect AP2 consensus sequence (5'-GCCNNNGGC-3') as its center, we investigated the possibility that AP2 binding is important for TGF alpha promoter activity, A double-stranded oligonucleotide spanning Fp-A displayed a distinct mobility shift in the presence of nuclear extract that was inhibited by an excess of known functional AP2-binding sequence. Moreover, a similar mobility shift occurred in the presence of purified AP2 protein, and the further addition of AP2 antibody produced a supershifted complex. More refined DNase I footprinting of a smaller, oligonucleotide probe in the presence of purified AP2 protein revealed a protected region that included the putative AP2 binding site, Additionally, co-transfection of an AP2 expression vector increased TGF alpha LUC expression 25-foId in Drosophila Schneider cells. These various findings corroborate a role for AP2 in TGF alpha promoter activity. The Fp-B region contains a T-5 motif that has been previously suggested to function as an atypical TATA box. An Fp-B oligonucleotide displayed a specific gel mobility shift in the presence of a TATA binding protein (TBP)-TFIIA complex, and the further addition of TBP antibody produced a supershift. These resdts confirm that protein binding within Fp-B is functionally important, and they also indicate that the T-5 motif functions as a TBP binding site.	UNIV N CAROLINA,SCH MED,LINEBERGER CANC RES CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599; ROSWELL PK CANC INST,DEPT EXPT THERAPEUT,BUFFALO,NY 14263	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Roswell Park Cancer Institute			Van Dyke, Michael W./AAY-6751-2020; Imhof, Axel/O-8905-2018	Van Dyke, Michael W./0000-0003-0306-4002; Imhof, Axel/0000-0003-2993-8249	NCI NIH HHS [CA 43973] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUER R, 1994, NUCLEIC ACIDS RES, V22, P1413, DOI 10.1093/nar/22.8.1413; Berkowitz EA, 1996, ONCOGENE, V12, P1991; Berkowitz EA, 1996, CELL GROWTH DIFFER, V7, P1271; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BUETTNER R, 1993, MOL CELL BIOL, V13, P4174, DOI 10.1128/MCB.13.7.4174; CHEN XR, 1992, ONCOGENE, V7, P1805; CHEN XR, 1994, ONCOGENE, V9, P3179; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1988, MOL ENDOCRINOL, V2, P1202, DOI 10.1210/mend-2-12-1202; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Fenton SE, 1996, J BIOL CHEM, V271, P30870, DOI 10.1074/jbc.271.48.30870; GODWIN AK, 1990, ONCOGENE, V5, P1231; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; Johnson AC, 1996, J BIOL CHEM, V271, P3033; KANNAN F, 1994, GENE DEV, V8, P1258, DOI 10.1101/gad.8.11.1258; LEE DC, 1995, PHARMACOL REV, V47, P51; LEE LW, 1991, CANCER RES, V51, P5238; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LIU C, 1988, CANCER RES, V48, P850; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MARTINEZ E, 1994, EMBO J, V13, P3155; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1991, GENE DEV, V5, P1212; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; MURAKAMI H, 1993, CANCER RES, V53, P1719; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RAYMOND VW, 1989, CANCER RES, V49, P3608; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; ROY AL, 1993, NATURE, V365, P355, DOI 10.1038/365355a0; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schorle H, 1996, NATURE, V381, P235, DOI 10.1038/381235a0; SHIN TH, 1994, MOL ENDOCRINOL, V8, P704, DOI 10.1210/me.8.6.704; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; SHIN TH, 1995, MOL CELL BIOL, V15, P4694; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; TWARDZIK DR, 1982, SCIENCE, V216, P894, DOI 10.1126/science.6177040; TWARDZIK DR, 1983, VIROLOGY, V124, P201, DOI 10.1016/0042-6822(83)90307-0; WILEY SR, 1992, P NATL ACAD SCI USA, V89, P5813; WILLIAMS T, 1991, GENE DEV, V5, P670, DOI 10.1101/gad.5.4.670; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; Zhang JA, 1996, NATURE, V381, P238, DOI 10.1038/381238a0; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964; ZHOU Q, 1993, GENE DEV, V7, P180, DOI 10.1101/gad.7.2.180	55	12	12	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 8	1997	14	18					2229	2238		10.1038/sj.onc.1201051	http://dx.doi.org/10.1038/sj.onc.1201051			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WX938	9174059				2022-12-17	WOS:A1997WX93800012
J	Araujo, JC; Doniger, J; Stoppler, H; Sadie, MR; Rosenthal, LJ				Araujo, JC; Doniger, J; Stoppler, H; Sadie, MR; Rosenthal, LJ			Cell lines containing and expressing the human herpesvirus 6A ts gene are protected from both H-ras and BPV-1 transformation	ONCOGENE			English	Article						transformation suppression; cellular oncogene promoter suppressor; viral oncogene promoter suppressor; retroviral mediated gene transfer	IMMUNODEFICIENCY-VIRUS TYPE-1; LONG TERMINAL REPEAT; BOVINE PAPILLOMAVIRUS; BINDING PROTEIN; REGION; DNA; INHIBITION; ELEMENTS; RNA; REPLICATION	Human herpesvirus 6A (HHV-6A) strain U1102 was previously shown to contain a 1473 bp transformation suppressor gene (ts) (Araujo et al,, 1995), Ts inhibited transformation of NIH3T3 cells by H-vas and transcription of the H-uas and human immunodeficiency type 1 (HIV-1) promoters in transient transfection experiments. In the current study, stable NIH3T3 cell lines expressing ts protein were established by transfection with pRc-ts containing the ts gene under the control of the Rous sarcoma virus (RSV) long terminal repeat (LTR) and a neomycin selectable marker. Selected cell lines contained approximately one to two copies per cell of intact ts sequences, expressed ts protein and grew at approximately the same rate as parental NIH3T3 cells. These cell lines were protected from H-ras transformation while parental and NIH3T3 cells containing the ts gene cloned in the antisense orientation were not. Expression of the chloramphenicol acetyl transferase (CAT) gene under the control of the EJ-H-ras promoter was also suppressed in the ts cell lines but not when the CAT gene was under the control of the murine osteosarcoma virus LTR or human cytomegalovirus immediate early promoter. When NIH3T3 cell lines expressing ts protein were established by infection with the retrovirus, LNCts, the cells expressed ts protein and were protected from H-ras transformation, Furthermore, bovine papillomavirus type 1 (BPV-1) transformation was also suppressed in cells cotransfected with BPV-1 plus ts and in ts expressing cell lines transfected with BPV-1. The BPV-1 p89 and p2443 promoters were down-regulated in 3T3-ts lines. Because the human papillomavirus type 16 (HPV-16) p97 promoter has similarity to the BPV-1 p89 promoter, the ability of ts to suppress p97 was also tested. Like the H-ras and BPV-1 promoters, HPV-16 p97 was downregulated in 3T3-ts lines. The data indicate the utility of ts against H-ras, BPV-1 and HPV-16 promoters and their respective oncogenes.	GEORGETOWN UNIV, MED CTR, DEPT MICROBIOL & IMMUNOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC CTR, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, DEPT PATHOL, WASHINGTON, DC 20007 USA; US FDA, CTR BIOL EVALUAT & RES, DIV TRANSFUS TRANSMITTED DIS, ROCKVILLE, MD 20852 USA	Georgetown University; Georgetown University; Georgetown University; US Food & Drug Administration (FDA)								ANTONI BA, 1991, J VIROL, V65, P396, DOI 10.1128/JVI.65.1.396-404.1991; ARAUJO JC, 1995, J VIROL, V69, P4933, DOI 10.1128/JVI.69.8.4933-4940.1995; BATCHU RB, 1994, CANCER LETT, V86, P23, DOI 10.1016/0304-3835(94)90176-7; BATCHU RB, 1995, FEBS LETT, V367, P267, DOI 10.1016/0014-5793(95)00584-V; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIORINI JA, 1994, J VIROL, V68, P797, DOI 10.1128/JVI.68.2.797-804.1994; DONIGER J, 1987, J BIOL CHEM, V262, P3813; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; HERMONAT PL, 1991, CANCER RES, V51, P3373; HERMONAT PL, 1989, VIROLOGY, V172, P253, DOI 10.1016/0042-6822(89)90127-X; HERMONAT PL, 1994, CANCER RES, V54, P2278; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; LANS MS, 1994, J BIOL CHEM, V269, P14170; LOWY DR, 1980, NATURE, V287, P72, DOI 10.1038/287072a0; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; OELZE I, 1994, J VIROL, V68, P1229, DOI 10.1128/JVI.68.2.1229-1233.1994; RITTNER K, 1992, J GEN VIROL, V73, P2977, DOI 10.1099/0022-1317-73-11-2977; ROUNSEVILLE MP, 1992, J VIROL, V66, P1688, DOI 10.1128/JVI.66.3.1688-1694.1992; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHILLER JT, 1984, P NATL ACAD SCI-BIOL, V81, P7880, DOI 10.1073/pnas.81.24.7880; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPALHOLZ BA, 1987, J VIROL, V61, P2128, DOI 10.1128/JVI.61.7.2128-2137.1987; SPALHOLZ BA, 1991, J VIROL, V65, P743, DOI 10.1128/JVI.65.2.743-753.1991; THOMSON BJ, 1994, VIROLOGY, V204, P304, DOI 10.1006/viro.1994.1535; THOMSON BJ, 1991, NATURE, V351, P78, DOI 10.1038/351078a0; WU F, 1991, GENE DEV, V5, P2128, DOI 10.1101/gad.5.11.2128	28	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	1997	14	8					937	943		10.1038/sj.onc.1200899	http://dx.doi.org/10.1038/sj.onc.1200899			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WK344	9050993				2022-12-17	WOS:A1997WK34400007
J	Francastel, C; AugeryBourget, Y; Prenant, M; Walters, M; Martin, DIK; RobertLezenes, J				Francastel, C; AugeryBourget, Y; Prenant, M; Walters, M; Martin, DIK; RobertLezenes, J			c-Jun inhibits NF-E2 transcriptional activity in association with p18/maf in Friend erythroleukemia cells	ONCOGENE			English	Article						c-Jun; NF-E2; transactivation; globin regulation; erythroleukemia	PORPHOBILINOGEN DEAMINASE GENE; LEUCINE ZIPPER PROTEIN; LOCUS-CONTROL REGION; SMALL MAF PROTEINS; ERYTHROID-CELLS; TRANSGENIC MICE; DIFFERENTIATION; EXPRESSION; FOS; ENHANCER	We have reported previously that antisense c-jun overcomes a block of Friend erythroleukemia cells to differentiation suggesting that the factor c-Jun may be an important negative regulator of erythroid differentiation, The recently described erythroid transcription factor NF-E2 plays an important role in the regulation of the transcription of globin genes and recognizes a sequence containing an AP-1 site, NF-E2 is a complex of two bZip proteins, p45 and p18/Maf. In order to determine whether c-Jun can interact with NF-E2/AP-1 sites to regulate transcriptional activation from them, we have compared the activity of AP-1 and NF-E2 in transient transcriptional assays, in erythroid and nonerythroid cells in the presence of c-jan sense and antisense expression vectors. In non-erythroid cells, c-Jun activates and NF-E2p18 inhibits both AP-1 and NF-E2 activities, suggesting that NF-E2/AP-1 sites function as AP-1 binding sites in these cells, In contrast, NF-E2p18 is a positive regulator of NF-E2 activity in erythroid cells. c-Jun alone is also a positive regulator of NF-E2 activity in erythroid cells but in association with NF-E2p18 inhibits this activity, Moreover antisense c-jun increases endogenous NF-E2 activity in erythroid cells. These results suggest that c-Jun could act as a repressor of NF-E2 transcriptional activity by forming inactive c-Jun/NF-E2p18 heterocomplexes which interfer with the transcription of globin genes in Friend erythroleukemia cells.	HOP PAUL BROUSSE,INSERM U268,F-94800 VILLEJUIF,FRANCE; FRED HUTCHINSON CANC RES CTR,SEATTLE,WA 98104	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Fred Hutchinson Cancer Center			Francastel, Claire/AAI-4798-2021	Francastel, Claire/0000-0002-6353-4320				ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; CATERINA JJ, 1991, P NATL ACAD SCI USA, V88, P1626, DOI 10.1073/pnas.88.5.1626; CHARNAY P, 1984, CELL, V55, P17; CHEN ZX, 1982, P NATL ACAD SCI-BIOL, V79, P471, DOI 10.1073/pnas.79.2.471; FRANCASTEL C, 1992, LEUKEMIA, V6, P935; FRANCASTEL C, 1994, ONCOGENE, V9, P1957; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; IGARASHI K, 1995, J BIOL CHEM, V270, P7615, DOI 10.1074/jbc.270.13.7615; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KERPPOLA TK, 1994, ONCOGENE, V9, P675; LIU DP, 1992, P NATL ACAD SCI USA, V89, P3899, DOI 10.1073/pnas.89.9.3899; LU SJ, 1994, P NATL ACAD SCI USA, V91, P8398, DOI 10.1073/pnas.91.18.8398; MIGNOTTE V, 1989, NUCLEIC ACIDS RES, V17, P37, DOI 10.1093/nar/17.1.37; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; NEY PA, 1990, NUCLEIC ACIDS RES, V18, P6011, DOI 10.1093/nar/18.20.6011; NEY PA, 1990, GENE DEV, V4, P993, DOI 10.1101/gad.4.6.993; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; PROFOUSJUCHELKA HR, 1983, MOL CELL BIOL, V3, P229, DOI 10.1128/MCB.3.2.229; ROBERTLEZENES J, 1988, CANCER RES, V48, P3972; TALBOT D, 1991, EMBO J, V10, P1391, DOI 10.1002/j.1460-2075.1991.tb07659.x; WALTERS M, 1992, P NATL ACAD SCI USA, V89, P10444, DOI 10.1073/pnas.89.21.10444	26	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 20	1997	14	7					873	877		10.1038/sj.onc.1200902	http://dx.doi.org/10.1038/sj.onc.1200902			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WJ112	9047395				2022-12-17	WOS:A1997WJ11200014
J	Uren, A; Yu, JC; Karcaaltincaba, M; Pierce, JH; Heidaran, MA				Uren, A; Yu, JC; Karcaaltincaba, M; Pierce, JH; Heidaran, MA			Oncogenic activation of the alpha PDGFR defines a domain that negatively regulates receptor dimerization	ONCOGENE			English	Article						PDGFR; dimerization; tyrosine kinase; transformation	GROWTH-FACTOR RECEPTORS; FMS PROTO-ONCOGENE; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; LIGAND-BINDING; MONOCLONAL-ANTIBODY; POINT MUTATION; BB BINDING; AA; EXPRESSION	The alpha platelet derived growth factor receptor (alpha PDGFR) extracellular Immunoglobulin (Ig) like domains 1-3 contain major determinants for ligand interaction. We now report that a deletion of Ig-like loop 3, but not Ig-like loop 1 or 2, of the alpha PDGFR causes ligandindependent transformation in NIH3T3 cells. Biochemical analyses of alpha PDGFR mutants lacking Ig-like loop 3 indicate that cellular transformation is mediated by ligand-independent activation of the alpha PDGFR tyrosine kinase activity as determined by receptor autophosphorylation both in vivo and in vitro. Moreover, crosslinking analysis of alpha PDGFR mutants expressed ectopically in NIH3T3 cells indicate that deletion within extracellular domain 3 leads to ligand-independent receptor dimerization. All of these findings suggest that the Ig-like loop 3 of the alpha PDGFR contains the major determinants which inhibit receptor dimerization in the quiescent cells and that the ligand binding induces receptor activation by neutralizing the inhibitory effect of this domain.	NCI,CELLULAR & MOL BIOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Karcaaltincaba, Musturay/A-3866-2016	Karcaaltincaba, Musturay/0000-0002-3384-0909				BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BLECHMAN JM, 1995, CELL, V80, P103, DOI 10.1016/0092-8674(95)90455-7; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; FLEMING TP, 1992, ONCOGENE, V7, P1355; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HEIDARAN MA, 1990, J BIOL CHEM, V265, P18741; HEIDARAN MA, 1992, J BIOL CHEM, V267, P2884; HEIDARAN MA, 1990, ONCOGENE, V5, P1265; HEIDARAN MA, 1991, J BIOL CHEM, V266, P20232; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HURWITZ DR, 1991, J BIOL CHEM, V266, P22035; LAROCHELLE WJ, 1993, CELL GROWTH DIFFER, V4, P547; MAHADEVAN D, 1995, J BIOL CHEM, V270, P27595, DOI 10.1074/jbc.270.46.27595; MATSUI T, 1989, SCIENCE, V243, P800, DOI 10.1126/science.2536956; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; YU JC, 1994, J BIOL CHEM, V269, P10668	25	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN 16	1997	14	2					157	162		10.1038/sj.onc.1200810	http://dx.doi.org/10.1038/sj.onc.1200810			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WC818	9010217				2022-12-17	WOS:A1997WC81800003
J	Gopalkrishnan, RV; Dolle, P; Mattei, MG; LaThangue, NB; Kedinger, C				Gopalkrishnan, RV; Dolle, P; Mattei, MG; LaThangue, NB; Kedinger, C			Genomic structure and developmental expression of the mouse cell cycle regulatory transcription factor DP1	ONCOGENE			English	Article						DP1; E2F; cell cycle; genomic structure; mouse chromosome; in situ hybridisation	E2F FAMILY; FACTOR DRTF1/E2F; IN-VIVO; RETINOBLASTOMA PROTEIN; DEPENDENT KINASES; SUPPRESSOR GENES; MAMMALIAN-CELLS; BINDING PROTEIN; MEMBER; DNA	The E2F/DP family of transcription factors play an important role in the control of cell cycle progression. By direct regulatory interactions with the retinoblastoma family of proteins, they integrate extracellular growth promoting signals impinging on the cyclin and cyclin dependent kinase complex during the G(1) phase, with cell cycle progression. This is accomplished by direct transcriptional activation of genes required for nucleotide biosynthesis and DNA replication in the S phase, In addition, these transcription factors also play a role in the control of genes involved in regulating G(1) and S phase progression including, autoregulatory control, as in the case of E2F1 itself, In this report, we describe the characterisation of the genomic locus encoding DP1, a member of this family, The DP1 gene has a TATA-less promoter and transcription initiates at multiple sites. Using transient transfection assays we have delineated sequences in the upstream region which have promoter or enhancer activity. The DP1 gene was localised to mouse chromosome 8 by metaphase chromosome analysis, We describe a dynamic pattern of DP1 expression using in situ hybridisation on cryostat sections of mouse embryos at various stages of development and a variable level of expression by Northern blot analysis of RNA from various adult tissues.	INST GENET & BIOL MOL & CELLULAIRE,F-67404 ILLKIRCH GRAFFENS,FRANCE; FAC MED TIMONE,INSERM U406,F-13385 MARSEILLE,FRANCE; UNIV GLASGOW,INST BIOMED & LIFE SCI,DIV BIOCHEM & MOL BIOL,GLASGOW G12 8QQ,LANARK,SCOTLAND	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; University of Glasgow			Dolle, Pascal/A-8037-2010	Dolle, Pascal/0000-0002-9294-9090				ADAMS PD, 1995, SEMIN CANCER BIOL, V6, P99, DOI 10.1006/scbi.1995.0013; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BANDARA LR, 1993, EMBO J, V12, P4317, DOI 10.1002/j.1460-2075.1993.tb06116.x; BANDARA LR, 1994, EMBO J, V13, P3104, DOI 10.1002/j.1460-2075.1994.tb06609.x; BANERJI J, 1981, CELL, V27, P299, DOI 10.1016/0092-8674(81)90413-X; BATES S, 1995, SEMIN CANCER BIOL, V6, P73, DOI 10.1006/scbi.1995.0010; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BOCCO JL, 1993, ONCOGENE, V8, P2977; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; BUCK V, 1995, ONCOGENE, V11, P31; CHITTENDEN T, 1993, MOL CELL BIOL, V13, P3975, DOI 10.1128/MCB.13.7.3975; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; Decimo D, 1996, GENE PROBES PRACTICA, P183; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; DRAETTA GF, 1994, CURR OPIN CELL BIOL, V6, P842, DOI 10.1016/0955-0674(94)90054-X; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GIRLING R, 1993, NATURE, V362, P83, DOI 10.1038/362083a0; GIRLING R, 1994, MOL BIOL CELL, V5, P1081, DOI 10.1091/mbc.5.10.1081; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRANA X, 1995, ONCOGENE, V11, P211; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERBER B, 1994, ONCOGENE, V9, P1295; HIEBERT SW, 1995, MOL CELL BIOL, V15, P6864; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; HINDS PW, 1994, CURR OPIN GENET DEV, V4, P135, DOI 10.1016/0959-437X(94)90102-3; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; HUBER HE, 1993, P NATL ACAD SCI USA, V90, P3525, DOI 10.1073/pnas.90.8.3525; ITOH A, 1995, CELL MOL BIOL RES, V41, P147; IVEYHOYLE M, 1993, MOL CELL BIOL, V13, P7802, DOI 10.1128/MCB.13.12.7802; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; JOOSS K, 1995, ONCOGENE, V10, P1529; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KREK W, 1993, SCIENCE, V262, P1557, DOI 10.1126/science.8248803; KREK W, 1994, CELL, V78, P161, DOI 10.1016/0092-8674(94)90582-7; LAM EWF, 1995, GENE, V160, P277, DOI 10.1016/0378-1119(95)00184-8; LAM EWF, 1994, CURR OPIN CELL BIOL, V6, P859; LATHANGUE NB, 1994, CURR OPIN CELL BIOL, V6, P443, DOI 10.1016/0955-0674(94)90038-8; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LI Y, 1994, MOL CELL BIOL, V14, P1861, DOI 10.1128/MCB.14.3.1861; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; LUCIBELLO FC, 1995, EMBO J, V14, P132, DOI 10.1002/j.1460-2075.1995.tb06983.x; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MIRONOV VN, 1995, NUCLEIC ACIDS RES, V23, P3359, DOI 10.1093/nar/23.16.3359; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NEUMAN E, 1995, MOL CELL BIOL, V15, P4660; ORMONDROYD E, 1995, ONCOGENE, V11, P1437; OSWALD F, 1994, ONCOGENE, V9, P2029; PASTEAU S, 1995, ONCOGENE, V11, P1475; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; SAITO M, 1995, GENOMICS, V25, P130, DOI 10.1016/0888-7543(95)80118-6; Sambrook J, 1989, MOL CLONING LAB MANU; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHMID P, 1989, SCIENCE, V243, P226, DOI 10.1126/science.2911736; SCHWARZ JK, 1993, EMBO J, V12, P1013, DOI 10.1002/j.1460-2075.1993.tb05742.x; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SINGH P, 1995, NATURE, V374, P562, DOI 10.1038/374562a0; Tevosian SG, 1996, CELL GROWTH DIFFER, V7, P43; WEBSTER NJG, 1989, EMBO J, V8, P1441, DOI 10.1002/j.1460-2075.1989.tb03526.x; WU CL, 1995, MOL CELL BIOL, V15, P2536; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; ZHANG YH, 1995, ONCOGENE, V10, P2085; Zwicker J, 1996, SCIENCE, V271, P1595, DOI 10.1126/science.271.5255.1595; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	69	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 19	1996	13	12					2671	2680						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VZ654	9000141				2022-12-17	WOS:A1996VZ65400017
J	McLure, KG; Lee, PWK				McLure, KG; Lee, PWK			A PAb240(+) conformation of wild type p53 binds DNA	ONCOGENE			English	Article						p53 conformation; DNA binding; PAb 240; dominant negative	2 CELLULAR PROTEINS; MUTANT P53; OLIGOMERIZATION DOMAIN; COMPLEXES; SITE; MODULATION; MUTATIONS	It is generally accepted that wild type (growth suppressing) p53 is capable of binding to a consensus DNA sequence and is in a conformation recognizable by antibody PAb246 (for murine p53), but not by antibody PAb240. Conversely, mutant forms of p53 incapable of DNA binding often assume conformations that display the PAb240, but not the PAb246 epitope, Exposure of these tao epitopes on p53 is therefore believed to be mutually exclusive, We show that mild type p53 translated in vitro in rabbit reticulocyte lysate (RRL) has a PAb240 epitope that is not always cryptic, even on p53 that is bound sequence-specifically to DNA (presumably as a tetramer), All of the DNA-bound, PAb240(+) p53 concurrently displays the PAb246 epitope, and both epitopes can be occupied by antibody while p53 is bound to DNA, This novel 'dual positive' conformation also exists in the absence of DNA and suggests that p53 is not necessarily inactive when the PAb240 epitope is displayed, When the C-terminal 58 amino acids of p53 containing the dimer/tetramerization domains are replaced with a heterologous dimerization domain, the resultant dimeric p53 manifests only the PAb246(+)/PAb240(-) conformation while bound to DNA, Thus, the C-terminal 58 amino acids of p53 are required for the PAb246(+)/PAb240(+) phenotype, possibly due to tetramerization, This novel (dual positive' p53 conformation exists in an excess of wild type p53 that has the PAb246(-)/PAb240(+) 'mutant' conformation, suggesting that the 'mutant' conformation is not dominant negative in and of itself.	UNIV CALGARY,HLTH SCI CTR,CANC BIOL RES GRP,CALGARY,AB T2N 4N1,CANADA; UNIV CALGARY,HLTH SCI CTR,DEPT MICROBIOL & INFECT DIS,CALGARY,AB T2N 4N1,CANADA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba								CHEN JY, 1993, ONCOGENE, V8, P2159; CHEN YM, 1994, MOL CELL BIOL, V14, P6764, DOI 10.1128/MCB.14.10.6764; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CHODOSH LA, 1991, CURRENT PROTOCOLS MO; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; COOK A, 1990, BRIT J CANCER, V61, P553; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FREIDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319; FRIEND S, 1994, SCIENCE, V265, P334, DOI 10.1126/science.8023155; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1995, ONCOGENE, V10, P27; HAINAUT P, 1994, ONCOGENE, V9, P299; HAINAUT P, 1992, EMBO J, V11, P3515; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; HALL AR, 1995, ONCOGENE, V10, P561; HARLOW E, 1988, ANTIBODIES LABORATOR, P309; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILNER J, 1990, J MOL BIOL, V216, P481, DOI 10.1016/0022-2836(90)90371-R; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; MILNER J, 1995, TRENDS BIOCHEM SCI, V20, P49, DOI 10.1016/S0968-0004(00)88954-9; PRIVES C, 1994, CELL, V78, P543, DOI 10.1016/0092-8674(94)90519-3; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; WANG Y, 1995, MOL CELL BIOL, V15, P2157; WOLKOWICZ R, 1995, ONCOGENE, V10, P1167; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485	32	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1297	1303						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808704				2022-12-17	WOS:A1996VJ20200021
J	Patel, G; Tantravahi, R; Oh, IH; Reddy, EP				Patel, G; Tantravahi, R; Oh, IH; Reddy, EP			Transcriptional activation potential of normal and tumor-associated myb isoforms does not correlate with their ability to block GCSF-induced terminal differentiation of murine myeloid precursor cells	ONCOGENE			English	Article						c-myb; ABPL tumor myb; transactivation; myeloid cell differentiation	COLONY-STIMULATING FACTOR; C-MYB; V-MYB; GRANULOCYTIC DIFFERENTIATION; HEMATOPOIETIC-CELLS; FUNCTIONAL DOMAINS; VIRAL INTEGRATION; GENE-EXPRESSION; LEUKEMIA-VIRUS; MIM-1 GENE	The myb gene has been shown to be an important regulator of hematopoietic cell proliferation, differentiation and apoptosis, Activation of the myb gene into an oncogenic form has involved structural alterations to the coding sequences, Thus, the v-myb gene encoded by the Avian Myeloblastosis Virus, is truncated at both the 5' and 3' ends, Additionally, tumor cells containing rearrangements in the myb locus, such as the ABPL tumors or NFS60 tumor cell line have recently been shown to display a heterogeneity of structure, In this study, we examined the growth and differentiation properties of clonal cell lines derived from 32Dcl3 which harbor myb transgenes derived from v-myb, and the ABPL-1, ABPL-2, ABPL-4 and NFS-60 cell Lines, Retroviral vectors containing the appropriate myb cDNAs were produced, transfected into packaging cell lines, and the viruses were used to generate the 32D derivative cell clones, Abrogation of IL-3 dependence was never observed in any cell line, Expression of c-my6, ABPL1-myb and ABPL-2-myb isoforms in 32D cells resulted in a block to their ability to terminally differentiate into granulocytes at the pro-myelocytic stage, However, expression of ABPL-4-myb or NFS60-myb in these cells failed:to result in a similar effect, These cells differentiated into granulocytes in the presence of G-CSF, albeit more slowly than control 32Dcl3 cells, We also examined the ability of various Myb-isoforms to transactivate transcription of reporter genes containing Myb-binding elements in their promoter/enhancer sequences, to determine whether the phenotypic effects produced by these various isoforms correlate with their ability to transactivate transcription, Our results show that while v-myb and c-myb transactivated transcription equally well, the MFS60-myb exhibited the highest levels of transcriptional transactivation. The ABPL-1, ABPL-2 and ABPL-4-myb isoforms showed very low levels of transcriptional transactivation potential with the same reporter genes. These results suggest that the ability of various Myb-isoforms to transactivate transcription does not by itself correlate with their ability to induce a block to G-CSF-induced terminal differentiation of myeloid precursor cells.	TEMPLE UNIV,SCH MED,FELS INST CANC RES & MOL BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University			Reddy, E. Premkumar/F-6233-2011		NCI NIH HHS [CA52009] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA052009] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BALUDA MA, 1994, ONCOGENE, V9, P2761; BIES J, 1995, CELL GROWTH DIFFER, V6, P59; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; CRAIG RW, 1984, CANCER RES, V44, P442; CUDDIHY AE, 1993, MOL CELL BIOL, V13, P3505, DOI 10.1128/MCB.13.6.3505; DUDEK H, 1989, ONCOGENE, V4, P1489; DUDEK H, 1989, ONCOGENE, V4, P1061; DUDEK H, 1992, P NATL ACAD SCI USA, V89, P1291, DOI 10.1073/pnas.89.4.1291; GERWITZ AM, 1988, SCIENCE, V242, P1303; GONDA TJ, 1989, EMBO J, V8, P1777, DOI 10.1002/j.1460-2075.1989.tb03571.x; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; Harlow E LD, 1988, ANTIBODIES LAB MANUA; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1988, J VIROL, V62, P1981, DOI 10.1128/JVI.62.6.1981-1988.1988; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LEAVITT J, 1984, MOL CELL BIOL, V4, P1961, DOI 10.1128/MCB.4.10.1961; MAGLI MC, 1987, P NATL ACAD SCI USA, V84, P789, DOI 10.1073/pnas.84.3.789; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORISHITA K, 1992, MOL CELL BIOL, V12, P183, DOI 10.1128/MCB.12.1.183; MORISHITA K, 1988, CELL, V54, P831, DOI 10.1016/S0092-8674(88)91175-0; MUCENSKI ML, 1988, MOL CELL BIOL, V8, P301, DOI 10.1128/MCB.8.1.301; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1987, CELL, V51, P41, DOI 10.1016/0092-8674(87)90008-0; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PATEL G, 1993, MOL CELL BIOL, V13, P2269, DOI 10.1128/MCB.13.4.2269; PRESS RD, 1994, MOL CELL BIOL, V14, P2278, DOI 10.1128/MCB.14.4.2278; PRESS RD, 1995, ONCOGENE, V11, P525; ROVERA G, 1987, ONCOGENE, V1, P29; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V84, P3171; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; SHENONG GLC, 1989, MOL CELL BIOL, V9, P5456, DOI 10.1128/MCB.9.12.5456; SHENONG GLC, 1984, SCIENCE, V226, P1077, DOI 10.1126/science.6093260; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SHENONG GLC, 1987, J VIROL, V61, P3721, DOI 10.1128/JVI.61.12.3721-3725.1987; SIU G, 1992, MOL CELL BIOL, V12, P1592, DOI 10.1128/MCB.12.4.1592; TANTRAVAHI R, 1996, IN PRESS ONCOGENE; VALTIERI M, 1987, J IMMUNOL, V138, P3829; WEINSTEIN Y, 1986, P NATL ACAD SCI USA, V83, P5010, DOI 10.1073/pnas.83.14.5010; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2194, DOI 10.1073/pnas.79.7.2194; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4	51	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 19	1996	13	6					1197	1208						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VJ202	8808694				2022-12-17	WOS:A1996VJ20200011
J	Zhao, JQ; Schmieg, FI; Logsdon, N; Freedman, D; Simmons, DT; Molloy, GR				Zhao, JQ; Schmieg, FI; Logsdon, N; Freedman, D; Simmons, DT; Molloy, GR			p53 binds to a novel recognition sequence in the proximal promoter of the rat muscle creatine kinase gene and activates its transcription	ONCOGENE			English	Article						p53; creatine kinase genes; energy metabolism; in vitro transactivation	WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; CELL NUCLEAR ANTIGEN; DNA-BINDING; RESPONSIVE ELEMENT; INDUCED APOPTOSIS; MDM2 EXPRESSION; MICE DEFICIENT; BRAIN; IDENTIFICATION	The rat muscle creatine kinase (CKM) gene promoter is unusual since it is one of the few cellular promoters containing a p53 response element which is located proximally (bp -168 to -57) to the transcription start site. We have previously shown that p53wt transactivates transcription in vivo of rat CKM, in CV-1 monkey kidney cells, through this 112 bp promoter-proximal fragment which contains at least five degenerate p53-binding elements. In this report, we employed the gel-shift assay and demonstrated that recombinant, immunoaffinity-purified mouse p53wt binds to this 112 bp CKM sequence and activates the in vitro transcription of the proximal CKM promoter by nuclear extracts from CV-1 cells. Also, a competitor plasmid containing this 112 bp CKM fragment interferred with the in vivo transactivation of CKM by p53. This CKM fragment, when cloned upstream of the rat br ain creatine kinase (CKB) promoter, mediated the p53 transactivation of CKB. Analyses of p53 wt and a series of missense mutants (altered in conserved region II of p53) showed that binding of p53 to the CKM promoter was required but was not sufficient for transactivation. The results are discussed in relation to the possible role of p53wt in the expression of CKM in cell types which may not express the myogenic transcription factors.	UNIV DELAWARE,DEPT BIOL,NEWARK,DE 19716	University of Delaware					NCI NIH HHS [CA 55234] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R55CA055234] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AOYAMA N, 1992, P NATL ACAD SCI USA, V89, P5403, DOI 10.1073/pnas.89.12.5403; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; CHIN KV, 1992, SCIENCE, V250, P1576; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; EDMONDOSN EG, 1993, J BIOL CHEM, V268, P755; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARMER G, 1992, NATURE, V358, P83, DOI 10.1038/358083a0; FOORD O, 1993, MOL CELL BIOL, V13, P1378, DOI 10.1128/MCB.13.3.1378; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GASDAR AF, 1981, CANCER RES, V41, P2773; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; HAMES BD, 1993, IRL PRESS, V136; HARPER JW, 1993, CELL, V75, P805; HEMMER W, 1993, DEV NEUROSCI-BASEL, V15, P249, DOI 10.1159/000111342; HEMMER W, 1994, EUR J NEUROSCI, V6, P538, DOI 10.1111/j.1460-9568.1994.tb00298.x; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOBSON GM, 1990, MOL CELL BIOL, V10, P6533, DOI 10.1128/MCB.10.12.6533; HORLICK RA, 1989, MOL CELL BIOL, V9, P2396, DOI 10.1128/MCB.9.6.2396; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JUVEN T, 1993, ONCOGENE, V8, P3411; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; KERN SE, 1991, SCIENCE, V252, P1707; KLEY N, 1992, NUCLEIC ACIDS RES, V17, P3645; KLEY SE, 1992, SCIENCE, V17, P3645; KUZHIKANDATHIL EV, 1994, J NEUROSCI RES, V39, P70, DOI 10.1002/jnr.490390110; LIN D, 1992, P NATL ACAD SCI USA, V89, P9210, DOI 10.1073/pnas.89.19.9210; LIU X, 1993, MOL CELL BIOL, V13, P3219; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MANOS P, 1993, DEV NEUROSCI-BASEL, V15, P271, DOI 10.1159/000111344; MANOS P, 1991, J NEUROCHEM, V56, P2101, DOI 10.1111/j.1471-4159.1991.tb03472.x; MARGULIES L, 1993, J BIOL CHEM, V268, P15096; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; MAXWELL SA, 1993, ONCOGENE, V8, P3421; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MITCHELL MT, 1990, J BIOL CHEM, V265, P8259; MIYASHITA T, 1995, CELL, V80, P293; MOLLOY GR, 1992, J NEUROCHEM, V59, P1925, DOI 10.1111/j.1471-4159.1992.tb11028.x; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OBEROSLER P, 1993, EMBO J, V12, P2389, DOI 10.1002/j.1460-2075.1993.tb05893.x; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; PIETENPOL JA, 1993, NATURE, V365, P17, DOI 10.1038/365017a0; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; SCHMIEG FI, 1993, ONCOGENE, V8, P2043; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SHAW P, 1992, P NATL ACAD SCI USA, V89, P4495, DOI 10.1073/pnas.89.10.4495; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; TRUANT R, 1993, J BIOL CHEM, V268, P2284; UEBA T, 1994, P NATL ACAD SCI USA, V91, P9009, DOI 10.1073/pnas.91.19.9009; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VANDEURSEN J, 1993, CELL, V74, P621, DOI 10.1016/0092-8674(93)90510-W; WALLIMANN T, 1994, MOL CELL BIOCHEM, V133, P193, DOI 10.1007/BF01267955; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; WILSON CD, 1993, J NEUROSCI RES, V35, P92, DOI 10.1002/jnr.490350111; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZAUBERMAN A, 1993, EMBO J, V12, P2799, DOI 10.1002/j.1460-2075.1993.tb05941.x; ZHAO JQ, 1994, MOL CELL BIOL, V14, P8483, DOI 10.1128/MCB.14.12.8483	79	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL 18	1996	13	2					293	302						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710368				2022-12-17	WOS:A1996VA25200008
J	Shiio, Y; Sawada, JI; Handa, H; Yamamoto, T; Inoue, JI				Shiio, Y; Sawada, JI; Handa, H; Yamamoto, T; Inoue, JI			Activation of the retinoblastoma gene expression by Bcl-3: Implication for muscle cell differentiation	ONCOGENE			English	Article						Bcl-3; E4TF1; GABP; muscle differentiation; Rb	NF-KAPPA-B; CANDIDATE PROTOONCOGENE BCL-3; EMBRYONAL CARCINOMA-CELLS; BETA INTERFERON GENE; NEGATIVE REGULATION; DNA-BINDING; ONCOPROTEIN BCL-3; MOLECULAR-CLONING; PROMOTER REGION; C-MYC	The retinoblastoma (Rb) protein is a master regulator of cell cycle. Accumulating evidence suggests that elevation of Rb expression is a key event in differentiation of various cell types. However the mechanism of regulation of Rb expression is poorly understood. Here we report that the candidate oncoprotein Bcl-3, previously characterized as a member of the I kappa B family, activates transcription of the Rb gene, whose promoter has no typical kappa B sites. A target element for Bcl-3 that matches the consensus for the E4TF1/GABP transcription factor was identified. Bcl-3 was shown to promote tetramer formation of E4TF1. During muscle cell differentiation, increased bcl-3 expression was observed before the induction of the Rb mRNA. Transient expression of Bcl-3 in myoblasts was shown to induce expression of the endogenous Rb. Furthermore, expression of the antisense bcl-3 RNA in myoblasts suppressed induction of Rb and myogenic differentiation. These results suggest that Bcl-3 is an upstream regulator of Rb expression during differentiation of muscle cells.	UNIV TOKYO,INST MED SCI,DEPT ONCOL,MINATO KU,TOKYO 108,JAPAN; TOKYO INST TECHNOL,FAC BIOSCI & BIOTECHNOL,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN	University of Tokyo; Tokyo Institute of Technology								BERNARDS R, 1989, P NATL ACAD SCI USA, V86, P6474, DOI 10.1073/pnas.86.17.6474; BHATIA K, 1991, ONCOGENE, V6, P1569; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BOLWIG GM, 1992, NUCLEIC ACIDS RES, V20, P6555, DOI 10.1093/nar/20.24.6555; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; COPPOLA JA, 1990, ONCOGENE, V5, P1731; DUPRIEZ VJ, 1993, P NATL ACAD SCI USA, V90, P8224, DOI 10.1073/pnas.90.17.8224; ENDO T, 1992, J BIOCHEM-TOKYO, V112, P427, DOI 10.1093/oxfordjournals.jbchem.a123916; FRANZOSO G, 1992, NATURE, V359, P339, DOI 10.1038/359339a0; FUJITA T, 1993, GENE DEV, V7, P1354, DOI 10.1101/gad.7.7b.1354; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HATADA EN, 1992, P NATL ACAD SCI USA, V89, P2489, DOI 10.1073/pnas.89.6.2489; HAUPT Y, 1995, ONCOGENE, V10, P1563; HONG FD, 1989, P NATL ACAD SCI USA, V86, P5502, DOI 10.1073/pnas.86.14.5502; INOUE J, 1993, ONCOGENE, V8, P2067; ISHIDA T, 1993, BIOCHEM BIOPH RES CO, V191, P831, DOI 10.1006/bbrc.1993.1292; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; KANEIISHII C, 1989, NUCLEIC ACIDS RES, V17, P1521, DOI 10.1093/nar/17.4.1521; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; MIYAZAKI J, 1986, P NATL ACAD SCI USA, V83, P9537, DOI 10.1073/pnas.83.24.9537; MOSCA JD, 1986, MOL CELL BIOL, V6, P2279, DOI 10.1128/MCB.6.6.2279; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; OHNO H, 1990, CELL, V60, P991, DOI 10.1016/0092-8674(90)90347-H; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; RICHON VM, 1992, CELL GROWTH DIFFER, V3, P413; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAKAI T, 1991, NATURE, V353, P83, DOI 10.1038/353083a0; SAWADA J, 1994, EMBO J, V13, P1396, DOI 10.1002/j.1460-2075.1994.tb06393.x; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; SHIIO Y, 1992, P NATL ACAD SCI USA, V89, P5206, DOI 10.1073/pnas.89.12.5206; SHIROKI K, 1988, J VIROL, V62, P325, DOI 10.1128/JVI.62.1.325-330.1988; SLACK RS, 1993, ONCOGENE, V8, P1585; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TRIEZENBERG SJ, 1988, GENE DEV, V2, P730, DOI 10.1101/gad.2.6.730; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0; UCHIUMI F, 1992, MOL CELL BIOL, V12, P3784, DOI 10.1128/MCB.12.9.3784; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VIRBASIUS JV, 1993, GENE DEV, V7, P380, DOI 10.1101/gad.7.3.380; WATANABE H, 1993, MOL CELL BIOL, V13, P1385, DOI 10.1128/MCB.13.3.1385; WATANABE H, 1988, MOL CELL BIOL, V8, P1290, DOI 10.1128/MCB.8.3.1290; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; ZACKSENHAUS E, 1993, ONCOGENE, V8, P2343; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	52	12	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1837	1845						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649843				2022-12-17	WOS:A1996UK49800001
J	Kubota, S; Siomi, H; Hatanaka, M; Pomerantz, RJ				Kubota, S; Siomi, H; Hatanaka, M; Pomerantz, RJ			Cis trans-activation of the interleukin-9 receptor gene in an HTLV-I-transformed human lymphocytic cell	ONCOGENE			English	Article						interleukin-9; receptor; T-lymphocyte; long terminal repeat; HTLV-I; HIV-1	VIRUS TYPE-I; NF-KAPPA-B; LEUKEMIA-ASSOCIATED ANTIGEN; STIMULATING FACTOR GENE; TRANSCRIPTIONAL ACTIVATOR; TRANSACTIVATOR TAX; MOLECULAR-CLONING; T-CELLS; EXPRESSION; PROTEIN	The MT-2 cell-line, which had been established through in vitro cell to cell transmission of human T-cell leukemia virus type T (HTLV-I) among human primary lymphocytes, was shown to possess multiple copies of integrated proviruses, including defective proviral genomes. By analysing a genomic clone, we identified the integration site of a single HTLV-I long terminal repeat (LTR) in the interleukin-9 (IL-9) receptor (IL-9R) gene. The integrated HTLV-I-LTR was shown to be functional as a promoter and the integration site was located in an intron upstream of the first coding exon of the IL-9R gene. Upon analysis of total cellular RNA, specific expression of HTLV-I-LTR IL-9R chimeric mRNAs in MT-2 cells was demonstrated. Cloning and characterization of these cDNAs have identified HTLV-I-IL-9R chimeric splicing, using either intact or alternative splice sites within the IL-9R gene. The potential roles of multiple interactions between IL-9, IL-9R and HTLV-I in the monoclonal expansion and transformation of MT-2 cells are explored.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT MED,DIV INFECT DIS,SECT MOL RETROVIROL,PHILADELPHIA,PA 19107; KYOTO UNIV,INST VIRUS RES,SAKYO KU,KYOTO 60601,JAPAN	Jefferson University; Kyoto University			Siomi, Haruhiko/A-7020-2015	Siomi, Haruhiko/0000-0001-8690-3822	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036552] Funding Source: NIH RePORTER; NIAID NIH HHS [AI36552] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHMED YF, 1991, CELL, V64, P727, DOI 10.1016/0092-8674(91)90502-P; CHANG MS, 1994, BLOOD, V83, P3199; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Coffin J. M., 1990, VIROLOGY, P1437; DEROSSI A, 1985, VIROLOGY, V143, P640, DOI 10.1016/0042-6822(85)90405-2; Derse David, 1994, AIDS Research and Human Retroviruses, V10, pS120; DITTMER J, 1993, J VIROL, V67, P6087, DOI 10.1128/JVI.67.10.6087-6095.1993; DUYAO MP, 1992, J BIOL CHEM, V267, P16288; FAN N, 1992, J CLIN MICROBIOL, V30, P905, DOI 10.1128/JCM.30.4.905-910.1992; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; HAERTLE T, 1985, J BIOL CHEM, V229, P563; HARADA S, 1985, SCIENCE, V229, P563, DOI 10.1126/science.2992081; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI H, 1992, ONCOGENE, V7, P1737; HOUSSIAU FA, 1992, J IMMUNOL, V148, P3147; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; IINO T, 1986, J GEN VIROL, V67, P1373, DOI 10.1099/0022-1317-67-7-1373; KELLEHER K, 1991, BLOOD, V77, P1436; KOBAYASHI N, 1984, EMBO J, V3, P1399; Krainer AR, 1988, TRANSCRIPTION SPLICI, P131; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; MERZ H, 1991, BLOOD, V78, P1311; MIURA S, 1991, MOL CELL BIOL, V11, P1313, DOI 10.1128/MCB.11.3.1313; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MORI K, 1987, J GEN VIROL, V68, P499, DOI 10.1099/0022-1317-68-2-499; MORI N, 1994, BLOOD, V84, P1688; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; OSAME M, 1986, LANCET, V1, P1031; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RENAULD JC, 1993, ADV IMMUNOL, V54, P79, DOI 10.1016/S0065-2776(08)60533-7; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; SABE H, 1988, INT J CANCER, V41, P880, DOI 10.1002/ijc.2910410619; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281, DOI 10.1128/MCB.10.3.1281; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SODROSKI J, 1985, SCIENCE, V228, P1430, DOI 10.1126/science.2990028; SUZUKI T, 1993, ONCOGENE, V8, P2391; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TAKEUCHI K, 1985, J GEN VIROL, V66, P1825, DOI 10.1099/0022-1317-66-8-1825; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; UYTTENHOVE C, 1991, J EXP MED, V173, P519, DOI 10.1084/jem.173.2.519; YAMAOKA S, 1992, ONCOGENE, V7, P433; YAMASHITA I, 1994, BLOOD, V84, P1573	47	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 4	1996	12	7					1441	1447						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UF076	8622860				2022-12-17	WOS:A1996UF07600008
J	Fraser, SD; WilkesJohnston, J; Browder, LW				Fraser, SD; WilkesJohnston, J; Browder, LW			Effects of c-myc first exons and 5' synthetic hairpins on RNA translation in oocytes and early embryos of Xenopus laevis	ONCOGENE			English	Article						myc; translation; secondary structure; Xenopus	YEAST SACCHAROMYCES-CEREVISIAE; MESSENGER-RNA; SECONDARY STRUCTURE; ORNITHINE DECARBOXYLASE; INITIATION-FACTORS; NONCODING REGION; PROTO-ONCOGENE; EXPRESSION; GENE; INHIBITION	Mammalian c-myc transcripts have long G/C-rich 5' untranslated regions (UTRs) that may fold into secondary structural elements that may impede translation. We have examined the effects of different c-myc first exons, which produce most of the 5' UTR of c-myc transcripts, on translation in Xenopus oocytes and embryos, by placing these structures upstream of a chloramphenicol acetyltransferase (CAT) reporter. Our results demonstrate that the human c-myc first exon inhibits reporter translation in both oocytes and embryos. Unlike their mammalian counterparts, Xenopus c-mycI first exons initiated at either promoter 1 or promoter 2 do not impede translation. We conclude that translation inhibition reported in a previous investigation (Lazarus, 1992. Oncogene, 7:1037) utilizing Xenopus c-mycI 5' non-coding elements was due to the inclusion of non-relevant non-transcribed sequences. Previous investigators have reported that inhibition of translation in Xenopus oocytes by 5' secondary structure is alleviated after fertilization (Lazarus et al., 1988. Oncogene 3:517; Fu et al., 1991. Science 251:807). We repeated the experiments of Fu et al., examining the effects on translation by a highly stable synthetic hairpin. The hairpin severly restricted translation in both oocytes and embryos, indicating that highly stable 5' secondary structure is equally inhibitory in oocytes and embryos.	UNIV CALGARY, DEPT BIOL SCI, CALGARY, AB T2N 1N4, CANADA	University of Calgary								BAIM SB, 1988, MOL CELL BIOL, V8, P1591, DOI 10.1128/MCB.8.4.1591; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BETTANY AJE, 1989, YEAST, V5, P187, DOI 10.1002/yea.320050308; BUTNICK NZ, 1985, MOL CELL BIOL, V5, P3009, DOI 10.1128/MCB.5.11.3009; CIGAN AM, 1988, MOL CELL BIOL, V8, P2964, DOI 10.1128/MCB.8.7.2964; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; EDERY I, 1995, MOL CELL BIOL, V15, P3363; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; FU L, 1991, THESIS U CALGARY CAL; FU LN, 1991, SCIENCE, V251, P807, DOI 10.1126/science.1990443; GALILI G, 1988, J BIOL CHEM, V263, P5764; GRENS A, 1990, J BIOL CHEM, V265, P11810; HITCHCOCK MJM, 1980, ANAL BIOCHEM, V109, P338, DOI 10.1016/0003-2697(80)90657-0; JARAMILLO M, 1990, BIOCHIM BIOPHYS ACTA, V1050, P134, DOI 10.1016/0167-4781(90)90154-T; Kay BK, 1991, METHODS CELL BIOL, V36; KING MW, 1986, MOL CELL BIOL, V6, P4499, DOI 10.1128/MCB.6.12.4499; KING MW, 1991, NUCLEIC ACIDS RES, V19, P5777, DOI 10.1093/nar/19.20.5777; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LASO MRV, 1993, J BIOL CHEM, V268, P6453; LAZARUS P, 1992, ONCOGENE, V7, P1037; LAZARUS P, 1988, ONCOGENE, V3, P517; MANZELLA JM, 1991, J BIOL CHEM, V266, P2383; MANZELLA JM, 1990, J BIOL CHEM, V265, P11817; MELTON DA, 1987, METHOD ENZYMOL, V152, P288; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NILSEN TW, 1984, MOL CELL BIOL, V4, P2235, DOI 10.1128/MCB.4.10.2235; OLIVEIRA CC, 1993, MOL MICROBIOL, V9, P521, DOI 10.1111/j.1365-2958.1993.tb01713.x; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PRINCIPAUD E, 1991, NUCLEIC ACIDS RES, V19, P3081, DOI 10.1093/nar/19.11.3081; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; SAGLIOCCO FA, 1993, J BIOL CHEM, V268, P26522; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; TCHANG F, 1991, FEBS LETT, V291, P177, DOI 10.1016/0014-5793(91)81277-F; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; VRIZ S, 1989, EMBO J, V8, P4091, DOI 10.1002/j.1460-2075.1989.tb08593.x; XU W, 1994, THESIS U CALGARY CAL; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	43	12	16	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 21	1996	12	6					1223	1230						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UC067	8649824				2022-12-17	WOS:A1996UC06700007
J	KIKUCHIYANOSHITA, R; TANAKA, K; MURAOKA, M; KONISHI, M; KAWASHIMA, I; TAKAMOTO, S; HIRAI, H; MIYAKI, M				KIKUCHIYANOSHITA, R; TANAKA, K; MURAOKA, M; KONISHI, M; KAWASHIMA, I; TAKAMOTO, S; HIRAI, H; MIYAKI, M			MALIGNANT TRANSFORMATION OF RAT EMBRYO FIBROBLASTS BY COTRANSFECTION WITH 11 HUMAN MUTANT P53 CDNAS AND ACTIVATED H-RAS GENE	ONCOGENE			English	Article						MUTANT P53 CDNAS; H-RAS GENE; REF; TRANSFORMATION; METASTASIS	FAMILIAL ADENOMATOUS POLYPOSIS; WILD-TYPE P53; TUMOR-ANTIGEN; CELLS; CARCINOMAS; ALLELES; DNA; IMMORTALIZATION; AMPLIFICATION; EXPRESSION	Eleven different missense and one nonsense mutant-type p53 cDNAs, which have been frequently detected in human colorectal carcinomas, were constructed and examined for their ability to cooperate with activated human H-ras genes, pSK2 and pHs49, in transfection of rat embryo fibroblasts (REF), Each missense mutant-type p53 cDNA with either of the two activated H-ras genes transformed REF with a different frequency of transformation depending on the different kind of mutation, whereas wild-type p53 (with ras), nonsense mutant-type p53 (with pas), as well as mutant-type p53 (alone) and ras (alone), did not transform REF, Six transformed REF cell lines were established from cotransfection with missense mutant-type p53 cDNA and ras gene; all of them exhibiting exogenous human p53 DNA, RNA, protein, and H-ras DNA and RNA, All six transformed cell lines showed both tumorigenicity and lung metastatic potential in nude mice, They also exhibited 92 kilodalton gelatinase activity, which was not detected in parental REF, These results suggest that missense mutations in p53 gene have a role in malignant transformation as well as metastatic potential.	TOKYO METROPOLITAN INST MED SCI,DEPT BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN INST MED SCI,DEPT TUMOR IMMUNOL,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN KOMAGOME HOSP,DEPT TRANSFUS MED,BUNKYO KU,TOKYO 113,JAPAN; UNIV TOKYO,DEPT INTERNAL MED 3,BUNKYO KU,TOKYO 113,JAPAN	Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Institute of Medical Science; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; University of Tokyo								ADDISON C, 1990, ONCOGENE, V5, P423; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BERNHARD EJ, 1990, CANCER RES, V550, P3872; BRISTOW RG, 1994, ONCOGENE, V9, P1527; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; DONEHOWER LA, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181, DOI 10.1016/0304-419X(93)90004-V; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; HIDDEMANN W, 1984, CYTOMETRY, V5, P445, DOI 10.1002/cyto.990050502; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; IINO H, 1994, CANCER, V73, P1324, DOI 10.1002/1097-0142(19940301)73:5<1324::AID-CNCR2820730503>3.0.CO;2-W; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3801; KONISHI M, 1993, JPN J CANCER RES, V84, P893, DOI 10.1111/j.1349-7006.1993.tb02063.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; MIYAKI M, 1990, CANCER RES, V50, P7166; MIYAKI M, 1995, CRIT REV ONCOL HEMAT, V19, P1, DOI 10.1016/1040-8428(94)00129-H; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; POLLACK R, 1974, P NATL ACAD SCI USA, V71, P4792, DOI 10.1073/pnas.71.12.4792; PONTA H, 1994, EUR J CANCER, V30A, P1995, DOI 10.1016/0959-8049(94)00393-J; ROVINSKI B, 1988, ONCOGENE, V2, P445; SEKIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P4771, DOI 10.1073/pnas.81.15.4771; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SLINGERLAND JM, 1991, J CELL PHYSIOL, V148, P391, DOI 10.1002/jcp.1041480309; TAKAMOTO S, 1991, CYTOMETRY RES, V1, P77; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0; ZAMBETTI GP, 1993, FASEB J, V7, P855, DOI 10.1096/fasebj.7.10.8344485; ZHANG JY, 1992, CANCER RES, V52, P6682	35	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	OCT 5	1995	11	7					1339	1345						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RY967	7478555				2022-12-17	WOS:A1995RY96700015
J	INOUE, H; TAVOLONI, N; HANAFUSA, H				INOUE, H; TAVOLONI, N; HANAFUSA, H			SUPPRESSION OF V-SRC TRANSFORMATION IN PRIMARY RAT EMBRYO FIBROBLASTS	ONCOGENE			English	Article						TYROSINE KINASE; FIBRONECTIN; FIBRONECTIN RECEPTOR; CELL FUSION; ANCHORAGE INDEPENDENT GROWTH; PAXILLIN	HUMAN PAPILLOMAVIRUS TYPE-16; MONOCLONAL-ANTIBODIES; FIBRONECTIN RECEPTOR; CELL-TRANSFORMATION; SURFACE PROTEIN; FOCAL ADHESIONS; ONCOGENE; GENES; IDENTIFICATION; HYBRIDS	To understand the mechanism for resistance of primary cultures of rat embryo fibroblasts (REFs) to oncogene-induced transformation, we studied the transforming ability of a recombinant retrovirus, ZSV, containing v-src and neo genes in REFs and in the rat cell line F2408. The susceptibility of REFs to p60(v-src) transformation was markedly reduced when compared with that of F2408 cells, despite high levels of expression of functional p60(v-src) tyrosine kinase in the two systems, In hybrid cells obtained by somatic cell fusion between F2408 cells transformed by v-src and uninfected REFs, the transformed phenotype was suppressed despite persistent expression of p60(v-src) tyrosine kinase, On the other hand, hybrid cells between v-src transformed F2408 cells and uninfected F2408 cells retained the transformed phenotypes, These results indicate that primary cells possess an intracellular function(s) that cause suppression of the transformed phenotype induced by the v-src gene, In ZSV-infected REFs, tyrosine phosphorylation of cellular proteins, including p125 focal adhesion kinase, p70 paxillin and p130 was similar to that in the ZSV-infected F2408 cells, indicating that tyrosine phosphorylation of these proteins is not sufficient for the expression of transformed phenotype, On the other hand, cellular fibronectin and one of integrin receptors were downregulated in the ZSV-transformed F2408 cells but not in ZSV-infected REFs, suggesting that fibronectin and/or its receptor might play a role in suppressing v-src transformation in primary rat cells.	ROCKEFELLER UNIV,MOLEC ONCOL LAB,NEW YORK,NY 10021	Rockefeller University					NCI NIH HHS [CA44356] Funding Source: Medline; NIDDK NIH HHS [DK24346] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALI IU, 1977, CELL, V11, P115, DOI 10.1016/0092-8674(77)90322-1; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CRAIG RW, 1985, P NATL ACAD SCI USA, V82, P2062, DOI 10.1073/pnas.82.7.2062; DYSON PJ, 1982, CELL, V30, P491, DOI 10.1016/0092-8674(82)90246-X; FREEMAN AE, 1973, P NATL ACAD SCI USA, V70, P2417; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; GILMER TM, 1985, MOL CELL BIOL, V5, P1707, DOI 10.1128/MCB.5.7.1707; HARRIS H, 1988, CANCER RES, V48, P3302; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1982, J CELL BIOL, V95, P369, DOI 10.1083/jcb.95.2.369; INOUE H, 1983, VIROLOGY, V125, P242, DOI 10.1016/0042-6822(83)90078-8; INOUE H, 1992, VIROLOGY, V187, P343, DOI 10.1016/0042-6822(92)90325-J; INOUE H, 1993, VIROLOGY, V195, P757, DOI 10.1006/viro.1993.1426; INOUE H, 1991, J MED VIROL, V35, P246, DOI 10.1002/jmv.1890350407; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MACAULEY A, 1988, J VIROL, V62, P4712, DOI 10.1128/JVI.62.12.4712-4721.1988; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MIYASAKA M, 1991, J VIROL, V65, P479, DOI 10.1128/JVI.65.1.479-482.1991; NIGG EA, 1986, VIROLOGY, V151, P50, DOI 10.1016/0042-6822(86)90103-0; NODA M, 1987, ONCOGENES CANCER, P261; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SABE H, 1992, MOL CELL BIOL, V12, P4706, DOI 10.1128/MCB.12.10.4706; SAGER R, 1985, ADV CANCER RES, V44, P43, DOI 10.1016/S0065-230X(08)60025-1; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; STEEL DM, 1989, J CELL SCI, V93, P515; TAVOLONI N, 1994, J CELL BIOL, V126, P475, DOI 10.1083/jcb.126.2.475; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; WAYNER EA, 1988, J CELL BIOL, V107, P1881, DOI 10.1083/jcb.107.5.1881; WAYNER EA, 1987, J CELL BIOL, V105, P1873, DOI 10.1083/jcb.105.4.1873; WILLINGHAM MC, 1977, CELL, V10, P375, DOI 10.1016/0092-8674(77)90024-1; WULF E, 1979, P NATL ACAD SCI USA, V76, P4498, DOI 10.1073/pnas.76.9.4498; YAMADA KM, 1983, ANNU REV BIOCHEM, V52, P761, DOI 10.1146/annurev.bi.52.070183.003553; YAMADA KM, 1976, P NATL ACAD SCI USA, V73, P1217, DOI 10.1073/pnas.73.4.1217; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P	46	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					231	238						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624140				2022-12-17	WOS:A1995RK95700003
J	STEEGENGA, WT; SHVARTS, A; VANLAAR, T; VANDEREB, AJ; JOCHEMSEN, AG				STEEGENGA, WT; SHVARTS, A; VANLAAR, T; VANDEREB, AJ; JOCHEMSEN, AG			ALTERED PHOSPHORYLATION AND OLIGOMERIZATION OF P53 IN ADENOVIRUS TYPE 12-TRANSFORMED CELLS	ONCOGENE			English	Article						P53; ADENOVIRUS; PHOSPHORYLATION; COMPLEXATION; STABILIZATION	CASEIN KINASE-II; LARGE-T-ANTIGEN; WILD-TYPE P53; TUMOR-SUPPRESSOR PROTEIN; PRIMARY RAT-CELLS; TRANSFORMED-CELLS; SV40-TRANSFORMED CELLS; GENE AMPLIFICATION; E1B PROTEINS; CYCLE	Loss of function of the tumor-suppressor protein p53 is, in general, either caused by mutation, inducing a conformational change, or by binding to inactivating cellular (e.g. MDM2) or viral (e.g, SV40 large T) proteins. In adenovirus type 12 (Ad12)-transformed cells, p53 is stabilized without detectable binding to the Ad12 E1B/54 kDa protein and still present in a wild-type conformation but contains a mutant-like activity in cellular transformation, In this study we examined whether the changed characteristics of p53 in Ad12-transformed cells are correlated with changes in phosphorylation or complex formation of the protein, By making tryptic phosphopeptide maps we found a significant increase in the phosphorylation of the N-terminus of p53. Furthermore, expression of E1A was found to be essential for the altered phosphorylation, while expression of only Ad12 E1B/54 kDa is sufficient to increase the protein half-life. Additionally, we observed p53 to be present in increased molecular weight complexes in Ad12-transformed cells. We conclude that both the phosphorylation and oligomerization of p53 is changed as a result of Ad12 transformation.	LEIDEN UNIV, SYLVIUS LABS, MOLEC CARCINOGENESIS LAB, 2300 RA LEIDEN, NETHERLANDS	Leiden University; Leiden University - Excl LUMC								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BERNARDS R, 1982, VIROLOGY, V120, P422, DOI 10.1016/0042-6822(82)90042-3; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BRAITHWAITE AW, 1991, ONCOGENE, V6, P781; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FISCELLA M, 1993, ONCOGENE, V8, P1519; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GARVIN AJ, 1993, AM J PATHOL, V142, P375; HERRMANN CPE, 1991, ONCOGENE, V6, P877; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JOCHEMSEN AG, 1987, EMBO J, V6, P3399, DOI 10.1002/j.1460-2075.1987.tb02663.x; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KRAISS S, 1992, BIOCHIM BIOPHYS ACTA, V1119, P11, DOI 10.1016/0167-4838(92)90227-5; KRAISS S, 1991, EXP CELL RES, V192, P157, DOI 10.1016/0014-4827(91)90170-Y; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LIN WC, 1993, SCIENCE, V260, P953, DOI 10.1126/science.8493533; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MILNE DM, 1992, NUCLEIC ACIDS RES, V20, P5565, DOI 10.1093/nar/20.21.5565; MILNE DM, 1992, ONCOGENE, V7, P1361; MILNE DM, 1994, J BIOL CHEM, V269, P9253; MILNER J, 1990, EMBO J, V9, P2885, DOI 10.1002/j.1460-2075.1990.tb07478.x; NISHIZAWA M, 1992, EMBO J, V11, P2433, DOI 10.1002/j.1460-2075.1992.tb05308.x; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEIDTMANN KH, 1991, MOL CELL BIOL, V11, P1996, DOI 10.1128/MCB.11.4.1996; SCHEIDTMANN KH, 1990, J VIROL, V64, P672, DOI 10.1128/JVI.64.2.672-679.1990; SLINGERLAND JM, 1993, EMBO J, V12, P1029, DOI 10.1002/j.1460-2075.1993.tb05744.x; SOUSSI T, 1990, ONCOGENE, V5, P945; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; TACK LC, 1992, J VIROL, V66, P1312, DOI 10.1128/JVI.66.3.1312-1320.1992; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; VAESSEN RTMJ, 1986, EMBO J, V5, P335, DOI 10.1002/j.1460-2075.1986.tb04217.x; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VANDENHEUVEL SJL, 1993, J VIROL, V67, P5226, DOI 10.1128/JVI.67.9.5226-5234.1993; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0; ZANTEMA A, 1985, MOL CELL BIOL, V5, P3084, DOI 10.1128/MCB.5.11.3084	53	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	1995	11	1					49	57						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RJ295	7624131				2022-12-17	WOS:A1995RJ29500007
J	CHEN, PC; LIN, HH; WEISSMAN, BE				CHEN, PC; LIN, HH; WEISSMAN, BE			A FUNCTIONAL-ANALYSIS OF TUMOR-SUPPRESSOR ACTIVITY FOR PERIPHERAL NEUROEPITHELIOMAS BY MONOCHROMOSOME TRANSFER	ONCOGENE			English	Article						TUMOR SUPPRESSOR GENES; MICROCELL HYBRIDIZATION; PNET	NORMAL HUMAN CHROMOSOME-11; DINUCLEOTIDE REPEAT POLYMORPHISMS; HUMAN NEUROBLASTOMA-CELLS; POLYMERASE CHAIN-REACTION; HUMAN CANCER; TUMORIGENICITY; LINE; GROWTH; AMPLIFICATION; EXPRESSION	The microcell hybridization technique provides a powerful method for the identification and characterization of tumor suppressor genes. By introducing chromosomes from a normal human cell into a tumor cell, several studies have presented functional evidence for the presence of tumor suppressor activity. In order to map the location(s) of functional tumor suppressor gene(s) for peripheral neuroepithelioma (PNET) cells, we have used the microcell hybridization technique to transfer three individual human chromosomes into three different PNET cell lines, A673, SK-N-MC and TC32. We could not isolate microcell hybrids from one of the cell lines as the transferred chromosome tended to fragment upon transfer. Introduction of chromosome 13 into the remaining two cell lines caused a marked inhibition of in vitro and in vivo growth. Chromosome 11 appeared to harbor a functional tumor suppressor gene while transfer of chromosome 17 caused a suppression of growth in culture, presumably due to the presence of the p53 tumor suppressor gene. Thus, each cell line showed a different response to the introduction off normal genetic information suggesting diverse genetic abnormalities among these tumors of similar histological or origin.	UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PEDIAT,CYTOGENET LAB,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL CANCER INSTITUTE [R01CA044470] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44470] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AURIAS A, 1983, NEW ENGL J MED, V309, P496; BADER SA, 1991, CELL GROWTH DIFFER, V2, P245; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BANERJEE A, 1992, CANCER RES, V52, P6297; BENEDICT WF, 1984, CANCER RES, V44, P3471; BIEDLER JL, 1973, CANCER RES, V33, P2643; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; CAHILL TC, 1990, PRENATAL DIAG, V10, P795, DOI 10.1002/pd.1970101206; CHEN PC, 1994, MOL CELL BIOL, V14, P534, DOI 10.1128/MCB.14.1.534; DAVIDOFF AM, 1992, ONCOGENE, V7, P127; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; EGE T, 1974, EXP CELL RES, V87, P378, DOI 10.1016/0014-4827(74)90494-7; FOURNIER REK, 1977, P NATL ACAD SCI USA, V74, P319, DOI 10.1073/pnas.74.1.319; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GIARD DJ, 1974, J NATL CANCER I, V51, P1417; GORMAN PA, 1991, CANCER GENET CYTOGEN, V51, P13, DOI 10.1016/0165-4608(91)90003-D; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRIFFIN CA, 1988, CANCER RES, V48, P175; HALL JM, 1992, AM J HUM GENET, V50, P1235; HARRIS H, 1969, NATURE, V223, P363, DOI 10.1038/223363a0; HORN GT, 1989, NUCLEIC ACIDS RES, V17, P2140, DOI 10.1093/nar/17.5.2140; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; KOI M, 1989, MOL CARCINOGEN, V2, P12, DOI 10.1002/mc.2940020103; KUGOH HM, 1990, ONCOGENE, V5, P1637; NEGRINI M, 1994, CANCER RES, V54, P1331; NEGRINI M, 1992, ONCOGENE, V7, P2013; OSHIMURA M, 1990, J CELL BIOCHEM, V42, P135, DOI 10.1002/jcb.240420304; PASQUALE SR, 1988, CANCER RES, V48, P2715; SAXON PJ, 1985, MOL CELL BIOL, V5, P140, DOI 10.1128/MCB.5.1.140; SCHOTT DR, 1994, CANCER RES, V54, P1393; SHIMIZU M, 1990, ONCOGENE, V5, P185; STANBRIDGE EJ, 1981, ISRAEL J MED SCI, V17, P563; STANBRIDGE EJ, 1992, CANCER SURV, V12, P5; STANBRIDGE EJ, 1976, NATURE, V260, P17, DOI 10.1038/260017a0; TURCCAREL C, 1983, NEW ENGL J MED, V309, P497; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4636, DOI 10.1093/nar/18.15.4636-a; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4036, DOI 10.1093/nar/18.13.4036; WEBER JL, 1989, AM J HUM GENET, V44, P388; WEBER JL, 1990, NUCLEIC ACIDS RES, V18, P4640, DOI 10.1093/nar/18.15.4640-a; WEISSMAN BE, 1983, JNCI-J NATL CANCER I, V70, P667; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; WEISSMAN BE, 1990, CANCER SURV, V9, P475; WHANGPENG J, 1984, CANCER GENET CYTOGEN, V21, P185; YAMADA H, 1990, ONCOGENE, V5, P1141; YANDELL DW, 1989, AM J HUM GENET, V45, P547	47	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					577	586						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845683				2022-12-17	WOS:A1995QF64800019
J	ANANT, S; AXENOVICH, SA; MADDEN, SL; RAUSCHER, FJ; SUBRAMANIAN, KN				ANANT, S; AXENOVICH, SA; MADDEN, SL; RAUSCHER, FJ; SUBRAMANIAN, KN			NOVEL REPLICATION INHIBITORY FUNCTION OF THE DEVELOPMENTAL REGULATOR TRANSCRIPTION REPRESSOR PROTEIN WT1 ENCODED BY THE WILMS-TUMOR GENE	ONCOGENE			English	Article							ZINC FINGER PROTEIN; SIMIAN-VIRUS 40; SV40 T-ANTIGEN; RETINOBLASTOMA SUSCEPTIBILITY GENE; DNA-BINDING DOMAIN; FACTOR-A-CHAIN; TRANSCRIPTIONAL ACTIVATOR; CELL-GROWTH; EGR FAMILY; SV40-TRANSFORMED CELLS	The tumor suppressor/developmental regulator protein WT1 encoded by the Wilms' tumor gene is a zinc finger-containing transcription factor which binds to the G + C-rich motif 5'-GCGGGGGCG-3' and represses transcription. Alternatively spliced variants of WT1 (termed + KTS) having an insertion in the zinc finger region are defective for binding to and hence for repression of transcription from promoters containing this motif. Due to the known interactions of two other tumor suppressor proteins with the simian virus 40 (SV40) oncoprotein large tumor antigen (TAg) [which in one case (p53) results in inhibition of the replication initiation activity of TAg], and because of the presence of G+C-rich sequences in the SV40 origin region, we tested the effect of WT1 on TAg- and SV40 origin-dependent DNA replication. WT1 and its alternatively spliced variants were found to be potent inhibitors of replication. Inhibition of replication by WT1 required portions of the N-terminal transcription repression domain and the C-terminal DNA binding domain, while other WT1 sequences needed for transcriptional regulation were dispensable. WT1 neither inhibited the synthesis of TAg nor formed a stable complex with it. Studies of the requirement of cis-active origin sequences in vivo and protein-DNA interactions in vitro indicated that WT1 and its alternatively spliced variants might inhibit replication by their novel binding to the GC box promoter motifs of the SV40 21 bp repeat replication-auxiliary sequence.	UNIV ILLINOIS, COLL MED, DEPT GENET, CHICAGO, IL 60612 USA; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; The Wistar Institute					NCI NIH HHS [CA 52009, CA 47983] Funding Source: Medline; NCRR NIH HHS [S07 RR 05369] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA047983, P01CA052009] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005369] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANANT S, 1992, METHOD ENZYMOL, V216, P20; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; BERGSMA DJ, 1982, P NATL ACAD SCI-BIOL, V79, P381, DOI 10.1073/pnas.79.2.381; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOROWIEC JA, 1990, CELL, V60, P181, DOI 10.1016/0092-8674(90)90730-3; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHANDRASEKHARAPPA SC, 1987, J VIROL, V61, P2973, DOI 10.1128/JVI.61.10.2973-2980.1987; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELUCIA AL, 1986, J VIROL, V57, P138, DOI 10.1128/JVI.57.1.138-144.1986; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FRIEDMAN PN, 1990, P NATL ACAD SCI USA, V87, P9275, DOI 10.1073/pnas.87.23.9275; GANNON JV, 1987, NATURE, V329, P456, DOI 10.1038/329456a0; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUNARI F, 1990, EMBO J, V9, P559, DOI 10.1002/j.1460-2075.1990.tb08143.x; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARLOW E, 1988, ANTIBODIES LABORATOR; HERTZ GZ, 1986, MOL CELL BIOL, V6, P3513, DOI 10.1128/MCB.6.10.3513; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOANG AT, 1992, MOL CELL BIOL, V12, P3087, DOI 10.1128/MCB.12.7.3087; HUANG HC, 1990, GENE DEV, V4, P287, DOI 10.1101/gad.4.2.287; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; KRIWACKI RW, 1992, P NATL ACAD SCI USA, V89, P9759, DOI 10.1073/pnas.89.20.9759; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEE NG, 1991, ONCOGENE, V6, P1161; LEECHEN GJ, 1986, MOL CELL BIOL, V6, P3086, DOI 10.1128/MCB.6.9.3086; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LINZER DIH, 1979, CELL, V17, P43, DOI 10.1016/0092-8674(79)90293-9; MADDEN SL, 1993, ONCOGENE, V8, P1713; MADDEN SL, 1993, ANN NY ACAD SCI, V684, P75, DOI 10.1111/j.1749-6632.1993.tb32272.x; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MAHESWARAN S, 1993, P NATL ACAD SCI USA, V90, P5100, DOI 10.1073/pnas.90.11.5100; MERCER WE, 1991, P NATL ACAD SCI USA, V88, P1958, DOI 10.1073/pnas.88.5.1958; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORRIS JF, 1991, ONCOGENE, V6, P2339; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; NEVINS JR, 1992, SCIENCE, V258, P424; PATWARDHAN S, 1991, ONCOGENE, V6, P917; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLETIER J, 1991, CELL, V67, P437, DOI 10.1016/0092-8674(91)90194-4; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Roswell D. F., 1978, METHOD ENZYMOL, V57, P409, DOI [10.1016/0076-6879(78)57038-9, DOI 10.1016/0076-6879(78)57038-9]; Sambrook J., 1989, MOL CLONING LAB MANU; SHALLOWAY D, 1980, CELL, V20, P411, DOI 10.1016/0092-8674(80)90627-3; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STURZBECHER HW, 1988, ONCOGENE, V3, P405; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SZYMANSKI P, 1990, J VIROL, V64, P1360, DOI 10.1128/JVI.64.3.1360-1365.1990; TEGTMEYER P, 1983, J VIROL, V46, P151, DOI 10.1128/JVI.46.1.151-161.1983; TRIFILLIS P, 1990, J VIROL, V64, P1345, DOI 10.1128/JVI.64.3.1345-1347.1990; VERRIJZER CP, 1990, EMBO J, V9, P1883, DOI 10.1002/j.1460-2075.1990.tb08314.x; WANG EH, 1989, CELL, V57, P379, DOI 10.1016/0092-8674(89)90913-6; WANG ZY, 1992, J BIOL CHEM, V267, P21999; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	73	12	12	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	1994	9	11					3113	3126						14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PM658	7936634				2022-12-17	WOS:A1994PM65800003
J	KONDO, M; SUZUKI, H; UEDA, R; TAKAGI, K; TAKAHASHI, T; TAKAHASHI, T				KONDO, M; SUZUKI, H; UEDA, R; TAKAGI, K; TAKAHASHI, T; TAKAHASHI, T			PARENTAL ORIGIN OF 11P15 DELETIONS IN HUMAN LUNG-CANCER	ONCOGENE			English	Note							SHORT ARM; WILMS-TUMOR; CHROMOSOME-11; GENES; CARCINOGENESIS; ABNORMALITIES; RELAXATION; CARCINOMAS; ALLELE	Frequent occurrence of 11p deletions has been reported for diverse types of human cancers including lung cancers and Wilms' tumors. In contrast to the well documented identification of preferential retention of the paternal allele in Wihms' tumors, no data have hitherto been available for cancers of adults. Taking advantage of the paternal allele-specific expression of IGF2 in the normal lung, we examined 79 lung cancer cases to investigate allelic loss at 11p15 and the parental origin of the retained alleles. While 11 of 36 (31%) informative lung cancer cases exhibited 11p15 deletions, only seven of these (64%) retained the paternal allele in tumors (P = 0.274), showing a contrast to the strong paternal bias in childhood tumors. Our strategy eliminates the need for parental DNAs for the determination and should be applicable to other adulthood tumors carrying 11P deletions such as breast and bladder cancers.	AICHI CANC CTR, RES INST, CHEMOTHERAPY LAB, CHIKUSA KU, NAGOYA 464, AICHI, JAPAN; AICHI CANC CTR, RES INST, IMMUNOL LAB, CHIKUSA KU, NAGOYA 464, AICHI, JAPAN; NAGOYA UNIV, SCH MED, DEPT INTERNAL MED 2, SHOWA KU, NAGOYA, AICHI 466, JAPAN	Aichi Cancer Center; Aichi Cancer Center; Nagoya University			Takahashi, Takashi/I-7262-2014; Kondo, Masashi/I-7378-2014	Takahashi, Takashi/0000-0003-0615-7001; 				FEARON ER, 1985, NATURE, V318, P377, DOI 10.1038/318377a0; FEINBERG AP, 1993, NAT GENET, V4, P110, DOI 10.1038/ng0693-110; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HENRY I, 1989, P NATL ACAD SCI USA, V86, P3247, DOI 10.1073/pnas.86.9.3247; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; LEE JH, 1989, CANCER RES, V49, P1220; LUDWIG CU, 1991, INT J CANCER, V49, P661, DOI 10.1002/ijc.2910490506; MINNA JD, 1991, BRIS MYER C, V12, P63; Minna JD, 1989, CANCER PRINCIPLES PR, P591; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; SAPIENZA C, 1991, BIOCHIM BIOPHYS ACTA, V1072, P51, DOI 10.1016/0304-419X(91)90006-7; SHIRAISHI M, 1987, JPN J CANCER RES, V78, P1302; SUZUKI H, 1994, NAT GENET, V6, P332, DOI 10.1038/ng0494-332; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; THEILLET C, 1986, CANCER RES, V46, P4776; WESTON A, 1989, P NATL ACAD SCI USA, V86, P5099, DOI 10.1073/pnas.86.13.5099; WILKINS RJ, 1988, LANCET, V1, P329	19	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT	1994	9	10					3063	3065						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PG822	7916149				2022-12-17	WOS:A1994PG82200038
J	SHALABY, F; SCHUH, AC; BREITMAN, ML				SHALABY, F; SCHUH, AC; BREITMAN, ML			2 DISTINCT TARGET-CELLS FOR V-JUN MEDIATED WOUND TUMORIGENESIS	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; DNA-BINDING ACTIVITY; C-JUN; TRANSGENIC MICE; PROTO-ONCOGENE; FOS JUN; GLUCOCORTICOID RECEPTOR; FUNCTIONAL ANTAGONISM; ENHANCER ELEMENTS; ACTIVATION	Transgenic mice expressing v-jun under the control of the H-2K promoter develop dermal fibrosarcomas and rhabdomyosarcomas via a multistep process following wounding. To assess the relative roles that wounding and the H-2K promoter play in this process, we compared the phenotype of H-2K-v-jun mice with that of animals expressing v-jun under the control of the metallothionein I (MTI) promoter. MT-v-jun animals also develop wound-induced neoplasms by a multistage process. Both early and late features of tumorigenesis in MT-v-jun mice are different, however, from what is observed in H-2K-v-jun animals. First, the acute hyperplastic response that is characteristic of H-2K-v-jun granulation tissue is not observed in MT-v-jun wounds. Second, the myogenic components that are readily detected in the majority of late stage H-2K neoplasms are never observed in their MT counterparts. Moreover, analysis of wound tumours arising in animals expressing both MT-v-jun and H-2K-v-jun reveals that the two transgenes are not expressed in identical malignant cell populations. These results imply that mesenchymal granulation tissue is heterogeneous in composition and that the different cellular phenotypes of MT-v-jun and H-2K-v-jun malignancies result from oncogenic activation of wound-derived cells which differ in their differentiation potential. Thus, whereas the wounding component of multistage tumorigenesis is attributable to the action of v-jun, the transcriptional regulatory elements which drive its expression determine the nature of the target cells which give rise to wound-induced neoplasms.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,DIV MOLEC & DEV BIOL,TORONTO M5G 1X5,ON,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto								ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BLACK EJ, 1991, ONCOGENE, V6, P1949; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; Clark RA, 1988, WOUND REPAIR MOL CEL, P3, DOI [10.1007/978-1-4615-1795-5_1, DOI 10.1007/978-1-4615-1795-5_1]; DAVID-WATINE B, 1990, IMMUNOL TODAY, V11, P286, DOI 10.1016/0167-5699(90)90114-O; GARRITY PA, 1990, MOL CELL BIOL, V10, P5646, DOI 10.1128/MCB.10.11.5646; GLANVILLE N, 1981, NATURE, V292, P267, DOI 10.1038/292267a0; GROSSI M, 1991, ONCOGENE, V6, P1767; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; Hogan B., 1986, MANIPULATING MOUSE E; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOVACS EJ, 1991, IMMUNOL TODAY, V12, P17, DOI 10.1016/0167-5699(91)90107-5; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MACGREGOR PF, 1990, ONCOGENE, V5, P451; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MORGAN IM, 1993, ONCOGENE, V8, P1135; OEHLER T, 1993, ONCOGENE, V8, P1141; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RUTHER U, 1987, NATURE, V325, P412, DOI 10.1038/325412a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1990, ONCOGENE, V5, P427; SCHUH AC, 1992, ONCOGENE, V7, P667; SCHUH AC, 1990, NATURE, V346, P756, DOI 10.1038/346756a0; SCHUH AC, 1993, CELL GROWTH DIFFER, V4, P177; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; SU HY, 1991, ONCOGENE, V6, P1759; VANHAMME L, 1993, CANCER RES, V53, P615; WANG ZQ, 1991, EMBO J, V10, P2437, DOI 10.1002/j.1460-2075.1991.tb07783.x; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	45	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1994	9	9					2579	2588						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PC054	8058321				2022-12-17	WOS:A1994PC05400017
J	BREIT, TM; WOLVERSTETTERO, ILM; VANDONGEN, JJM				BREIT, TM; WOLVERSTETTERO, ILM; VANDONGEN, JJM			LINEAGE-SPECIFIC DEMETHYLATION OF TAL-1 GENE BREAKPOINT REGION DETERMINES THE FREQUENCY OF TAL-1 DELETIONS IN ALPHA-BETA LINEAGE T-CELLS	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; SITE-SPECIFIC DELETIONS; LOOP-HELIX PROTEIN; V(D)J RECOMBINATION; METHYLATION STATUS; CHAIN GENE; SCL GENE; CHROMOSOME-TRANSLOCATION; CHROMATIN STRUCTURE; DNA METHYLATION	tal-1 deletions are caused by a site specific recombination, which exclusively occurs in 12-26% of T-cell acute lymphoblastic leukemias (T-ALL). In a previous study on a large series of T-ALL we demonstrated an apparent preferential occurrence of tal-1 deletions in CD3(-) and CD3(+) alpha beta lineage T-ALL with TcR-delta gene deletions on one or both alleles. In the present study we investigated whether accessibility of the tal-1 deletion breakpoint regions influences the preferential occurrence in specific T-ALL subgroups. Because DNA methylation is assumed to determine accessibility of DNA for recombination, the methylation status of the tal-1 deletion type 1 breakpoint regions (sildb and taldb1) was studied. Although the sildb were completely demethylated in all T-ALL, preferential (de)methylation configurations of the taldb1 were observed in the analysed 119 T-ALL. Most TcR-alpha beta(+) T-ALL contained completely demethylated taldb1 (77%), whereas in most TcR-gamma delta(+) T-ALL partial or complete methylation occurred (42% and 47%, respectively). In T-ALL subgroups defined by different TcR-delta gene configurations also preferential taldb1 (de)methylation patterns were seen, which was most prominent in T-ALL with both TcR-delta genes deleted (84% complete demethylation). The previously observed preferential occurrence of tal-1 deletion type 1 in TcR-alpha beta(+) vs CD3(-) T-ALL and in T-ALL with both vs one TcR-delta genes deleted, disappeared when we retricted to T-ALL with completely demethylated taldb1. Moreover, all T-ALL with a tal-1 deletion type 1 (n = 15) contained completely demethylated taldb1. We therefore conclude that complete demethylation of taldb1 is a prerequisite for tal-1 deletions type I and that the differences in tal-1 deletion frequencies observed in the various T-ALL subgroups are caused by differences in the (de)methylation status of taldb1 in these subgroups.	ERASMUS UNIV ROTTERDAM,HOSP DIJKZIGT,DEPT IMMUNOL,3015 GE ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam; Erasmus MC			van Dongen, Jacques J.M./F-8537-2015	van Dongen, Jacques J.M./0000-0001-7686-0021; van Dongen, Jacques J.M./0000-0002-3650-7087				ADRIAANSEN HJ, 1991, LEUKEMIA, V5, P744; AKIRA S, 1987, SCIENCE, V238, P1134, DOI 10.1126/science.3120312; ALT FW, 1982, P NATL ACAD SCI-BIOL, V79, P4118, DOI 10.1073/pnas.79.13.4118; ALT FW, 1987, SCIENCE, V238, P1079, DOI 10.1126/science.3317825; ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; APLAN PD, 1992, J EXP MED, V176, P1303, DOI 10.1084/jem.176.5.1303; APLAN PD, 1992, BLOOD, V79, P1327; APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; APLAN PD, 1991, MOL CELL BIOL, V11, P5462, DOI 10.1128/MCB.11.11.5462; BASH RO, 1993, BLOOD, V81, P2110; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BERNARD O, 1991, ONCOGENE, V6, P1477; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BLACKWELL TK, 1989, J BIOL CHEM, V264, P10327; BORIES JC, 1991, BLOOD, V78, P2053, DOI 10.1182/blood.V78.8.2053.bloodjournal7882053; BREIT TM, 1993, J EXP MED, V177, P965, DOI 10.1084/jem.177.4.965; BREIT TM, 1993, BLOOD, V82, P3063; BREIT TM, 1993, LEUKEMIA, V7, P2004; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; BURGER C, 1990, EUR J IMMUNOL, V20, P2285, DOI 10.1002/eji.1830201018; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; DEVILLARTAY JP, 1988, NATURE, V335, P170, DOI 10.1038/335170a0; ENGLER P, 1991, J IMMUNOL, V146, P2826; ENGLER P, 1991, CELL, V65, P939, DOI 10.1016/0092-8674(91)90546-B; ENGLER P, 1993, MOL CELL BIOL, V13, P571, DOI 10.1128/MCB.13.1.571; FITZGERALD TJ, 1991, BLOOD, V78, P2686; HESSE JE, 1989, GENE DEV, V3, P1053, DOI 10.1101/gad.3.7.1053; HOCKETT RD, 1988, P NATL ACAD SCI USA, V85, P9694, DOI 10.1073/pnas.85.24.9694; HSIEH CL, 1992, J BIOL CHEM, V267, P15613; ISOBE M, 1988, P NATL ACAD SCI USA, V85, P3933, DOI 10.1073/pnas.85.11.3933; JONSSON OG, 1991, J CLIN INVEST, V87, P2029, DOI 10.1172/JCI115232; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LITZ CE, 1992, LEUKEMIA, V6, P35; MACINTYRE EA, 1992, BLOOD, V80, P1511; MARTIN D, 1991, J EXP MED, V173, P639, DOI 10.1084/jem.173.3.639; MINOWADA J, 1988, Cancer Reviews, V10, P1; OETTINGER MA, 1992, TRENDS GENET, V8, P413, DOI 10.1016/0168-9525(92)90323-V; OHYASHIKI JH, 1992, CANCER RES, V52, P6598; OHYASHIKI JH, 1993, LEUKEMIA, V7, P801; SATAYANARANA K, 1988, P NATL ACAD SCI USA, V85, P8166; SCHATZ DG, 1992, ANNU REV IMMUNOL, V10, P359, DOI 10.1146/annurev.iy.10.040192.002043; SCHLISSEL MS, 1991, J EXP MED, V173, P711, DOI 10.1084/jem.173.3.711; SHIEH CL, 1992, EMBO J, V11, P315; TAUCHI T, 1991, CANCER RES, V51, P2917; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TSUKAMOTO N, 1992, EXP HEMATOL, V20, P1061; VANDONGEN JJM, 1990, THYMUS, V16, P207; VANDONGEN JJM, 1991, CLIN CHIM ACTA, V198, P1; WAALWIJK C, 1978, NUCLEIC ACIDS RES, V5, P3231, DOI 10.1093/nar/5.9.3231	55	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1847	1853						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208530				2022-12-17	WOS:A1994NR68500006
J	MAYO, MW; STEELMAN, LS; MCCUBREY, JA				MAYO, MW; STEELMAN, LS; MCCUBREY, JA			PHORBOL ESTERS SUPPORT THE PROLIFERATION OF A HEMATOPOIETIC-CELL LINE BY UP-REGULATING C-JUN EXPRESSION	ONCOGENE			English	Article							PROTEIN-KINASE-C; TRANSCRIPTION FACTOR AP-1; EARLY GENE-EXPRESSION; MESSENGER-RNA; METALLOTHIONEIN GENE; GROWTH-FACTORS; FOS; ONCOGENE; INDUCTION; DNA	FD/PMA, a derivative of the interleukin-3 (IL-3) dependent FDC-P1 cell line, proliferates in response to either phorbol esters (phorbol 12-myristate 13-acetate, PMA) or IL-3. Analysis of immediate-early gene expression revealed that FD/PMA cells contained elevated levels of c-jun transcripts when grown in the presence of phorbol esters. Upregulation of c-jun mRNA was specific since other jun family members (namely jun-B and jun-D) displayed similar patterns of gene expression as observed in the parental cell line. The accumulation of c-jun RNA was due to increased c-jun transcription and not the result of altered message stability, Furthermore, elevated c-jun expression resulted in increased AP-1 binding activity in FD/PMA cells, Antisense c-jun oligonucleotides suppressed proliferation of FD/PMA cells by 80% and resulted in a significant reduction in both AP-1 binding activity and c-jun message levels. Collectively, these results demonstrate that FD/PMA cells require elevated levels of c-jun expression for PMA-responsive proliferation and indicate that tumor promoters have the ability to abrogate IL-3 dependency by elevating AP-1 activity.	E CAROLINA UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,GREENVILLE,NC 27858	University of North Carolina; East Carolina University				McCubrey, James/0000-0001-6027-3156	NATIONAL CANCER INSTITUTE [R01CA051025] Funding Source: NIH RePORTER; NCI NIH HHS [NCI RO1CA51025] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BERNSTEIN LR, 1989, SCIENCE, V244, P566, DOI 10.1126/science.2541502; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; Bravo R., 1990, GROWTH FACTORS DIFFE, P324; BUTTKE TM, 1993, J IMMUNOL METHODS, V157, P233, DOI 10.1016/0022-1759(93)90092-L; CARTER TH, 1987, MECHANISMS ENV CARCI, V1, P47; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CORNELIUS P, 1990, J BIOL CHEM, V265, P20506; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FAVOLORO J, 1980, METHOD ENZYMOL, V65, P718; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HERRMANN F, 1992, CYTOKINES HEMATOLOGY, V2; IMBRA RJ, 1987, MOL CELL BIOL, V7, P1358, DOI 10.1128/MCB.7.4.1358; KALB VF, 1977, ANAL BIOCHEM, V82, P362, DOI 10.1016/0003-2697(77)90173-7; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MCCUBREY J, 1989, ONCOGENE RES, V4, P97; MCCUBREY JA, 1991, ONCOGENE RES, V6, P1; MCCUBREY JA, 1990, BLOOD, V76, P63; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; WAYS DK, 1991, BLOOD, V78, P2633; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YANG-YEN H-F, 1990, New Biologist, V2, P351	46	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1994	9	7					1999	2008						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NR685	8208545				2022-12-17	WOS:A1994NR68500024
J	KOSHIMIZU, U; TSUJIMURA, T; ISOZAKI, K; NOMURA, S; FURITSU, T; KANAKURA, Y; KITAMURA, Y; NISHIMUNE, Y				KOSHIMIZU, U; TSUJIMURA, T; ISOZAKI, K; NOMURA, S; FURITSU, T; KANAKURA, Y; KITAMURA, Y; NISHIMUNE, Y			W-N MUTATION OF C-KIT RECEPTOR AFFECTS ITS POSTTRANSLATIONAL PROCESSING AND EXTRACELLULAR EXPRESSION	ONCOGENE			English	Article							CULTURED MAST-CELLS; INTRACELLULAR-TRANSPORT; PROTO-ONCOGENE; INSULIN-RECEPTOR; TYROSINE KINASE; V-KIT; MOUSE; LOCUS; MICE; DOMAIN	The W locus of mice encodes the c-kit receptor tyrosine kinase. Recently, we characterized a novel mutant allele, W-n, and demonstrated that the c-kit protein synthesized in W-n/W-n cultured mast cells (CMC) was reduced in size and not expressed on their surface (Tsujimura et al., 1993). In this study, we further examined biochemical nature of the mutant form of c-kit protein, by using W-n/W-n CMC and 293T cells transfected with W-n-type c-kit cDNA (c-kit(Wn)). The c-kit product synthesized in W-n/W-n CMC was truncated almost all cytoplasmic domain and was less glycosylated. In c-kif(Wn)-tranfected cells, both glycosylation and extracellular expression of c-kit protein was also impaired, however, no truncation was detected. These results indicate that W-n-mutant form of c-kit product is insufficient in maturation, which is associated with impairments in the transport to the plasma membrane, and retention of the mutant protein in endoplasmic reticulum is suggested. This is the first demonstration of the c-kit mutation affecting posttranslational processing its product.	OSAKA UNIV,RES INST MICROBIAL DIS,OSAKA,JAPAN; OSAKA UNIV,SCH MED,DEPT PATHOL,OSAKA,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED,OSAKA,JAPAN	Osaka University; Osaka University; Osaka University								ACCILI D, 1989, EMBO J, V8, P2509, DOI 10.1002/j.1460-2075.1989.tb08388.x; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; Besmer P, 1991, CURR OPIN CELL BIOL, V3, P939, DOI 10.1016/0955-0674(91)90111-B; BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; DOYLE C, 1985, J CELL BIOL, V100, P704, DOI 10.1083/jcb.100.3.704; DOYLE C, 1986, J CELL BIOL, V103, P1193, DOI 10.1083/jcb.103.4.1193; ESSER V, 1988, J BIOL CHEM, V263, P13276; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; GEISSLER EN, 1981, GENETICS, V97, P337; GO S, 1980, J HERED, V71, P41, DOI 10.1093/oxfordjournals.jhered.a109308; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GREEN MC, 1990, GENETIC VARIANTS STR, P383; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYASHI SI, 1991, NUCLEIC ACIDS RES, V19, P1267, DOI 10.1093/nar/19.6.1267; HOBBS HH, 1990, ANNU REV GENET, V24, P133, DOI 10.1146/annurev.ge.24.120190.001025; HURTLEY SM, 1993, TRENDS BIOCHEM SCI, V18, P3, DOI 10.1016/0968-0004(93)90078-2; ISHIHARA K, 1992, P NATL ACAD SCI USA, V89, P633, DOI 10.1073/pnas.89.2.633; KADOWAKI T, 1991, J BIOL CHEM, V266, P21224; KITAMURA Y, 1978, BLOOD, V52, P447; KITAMURA Y, 1979, BLOOD, V53, P492; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215; LEV S, 1993, MOL CELL BIOL, V13, P2224, DOI 10.1128/MCB.13.4.2224; LOBELL RB, 1993, J BIOL CHEM, V268, P1207; LODISH HF, 1988, J BIOL CHEM, V263, P2107; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; MCCULLOCH EA, 1964, SCIENCE, V144, P844, DOI 10.1126/science.144.3620.844; MIURA O, 1989, J BIOL CHEM, V264, P18213; NAKAHATA T, 1982, BLOOD, V60, P352; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NELSON WJ, 1992, SCIENCE, V258, P948, DOI 10.1126/science.1439806; NISHIKAWA S, 1991, EMBO J, V10, P2111, DOI 10.1002/j.1460-2075.1991.tb07744.x; NOCKA K, 1990, EMBO J, V9, P1805, DOI 10.1002/j.1460-2075.1990.tb08305.x; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; PREFFER SR, 1987, ANN REV BIOCH, V56, P829; QIU F, 1988, EMBO J, V7, P1003, DOI 10.1002/j.1460-2075.1988.tb02907.x; REITH AD, 1990, GENE DEV, V4, P390, DOI 10.1101/gad.4.3.390; REITH AD, 1991, GENOME ANAL, V3, P105; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; ROUSSEL MF, 1988, CELL, V55, P979, DOI 10.1016/0092-8674(88)90243-7; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; RUSSELL ES, 1968, ARCH BIOCHEM BIOPHYS, V125, P594, DOI 10.1016/0003-9861(68)90617-6; SAKAMAKI K, 1989, BIOL REPROD, V41, P1097, DOI 10.1095/biolreprod41.6.1097; SEVERINSSON L, 1989, EUR J BIOCHEM, V182, P679, DOI 10.1111/j.1432-1033.1989.tb14879.x; Silvers W.K., 1979, COAT COLORS MICE, P206; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAN JC, 1990, SCIENCE, V247, P209, DOI 10.1126/science.1688471; TONO T, 1992, BLOOD, V80, P1448; TSUJIMURA T, 1993, BLOOD, V81, P2530; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; WILLIAMS DB, 1988, J BIOL CHEM, V263, P4549; WILLIAMS DE, 1992, DEV BIOL, V151, P368, DOI 10.1016/0012-1606(92)90176-H; WILLIAMS DE, 1990, CELL, V63, P167, DOI 10.1016/0092-8674(90)90297-R; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YARDEN Y, 1987, EMBO J, V6, P3341, DOI 10.1002/j.1460-2075.1987.tb02655.x; YEE NS, 1993, J BIOL CHEM, V268, P14189	56	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1994	9	1					157	162						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	7508100				2022-12-17	WOS:A1994MW24700019
J	PAPKOFF, J				PAPKOFF, J			IDENTIFICATION AND BIOCHEMICAL-CHARACTERIZATION OF SECRETED WNT-1 PROTEIN FROM P19 EMBRYONAL CARCINOMA-CELLS INDUCED TO DIFFERENTIATE ALONG THE NEUROECTODERMAL LINEAGE	ONCOGENE			English	Note							MOUSE MAMMARY ONCOGENE; INT-1 PROTOONCOGENE; XENOPUS EMBRYOS; EXPRESSION; DROSOPHILA; PRODUCTS; WINGLESS; REGION; AXIS; RNA	Previous studies have described Wnt-1 protein synthesized by cell lines transfected with Wnt-1 cDNA. This report presents the first identification and biochemical characterization of native Wnt-1 protein, from P19 embryonal carcinoma cells undergoing neuroectodermal differentiation. The data demonstrate that P19 cells efficiently process and secrete glycosylated Wnt-1 protein species of 40kD and 42kD. Similar to recombinant Wnt-1 proteins, native Wnt-1 proteins are associated with the cell surface upon secretion and can be released by suramin treatment of the cells. Non-reducing gel analysis showed that Wnt-1 proteins are secreted as monomers.			PAPKOFF, J (corresponding author), SUGEN INC, 515 GALVESTON DR, REDWOOD CITY, CA 94063 USA.							ARIAS AM, 1988, DEVELOPMENT, V103, P157; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; KITAJEWSKI J, 1992, MOL CELL BIOL, V12, P784, DOI 10.1128/MCB.12.2.784; MASON JO, 1992, MOL BIOL CELL, V3, P521, DOI 10.1091/mbc.3.5.521; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMAHON AP, 1989, CELL, V58, P1075, DOI 10.1016/0092-8674(89)90506-0; MORATA G, 1977, DEV BIOL, V56, P227, DOI 10.1016/0012-1606(77)90266-4; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; SCHUURING E, 1989, MOL CELL BIOL, V9, P1357, DOI 10.1128/MCB.9.3.1357; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; STARNAUD R, 1989, ONCOGENE, V4, P1077; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; THOMAS KR, 1991, CELL, V67, P969, DOI 10.1016/0092-8674(91)90369-A; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7	23	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					313	317						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302595				2022-12-17	WOS:A1994MW24700038
J	VERDERAME, MF; VARMUS, HE				VERDERAME, MF; VARMUS, HE			HIGHLY CONSERVED AMINO-ACIDS IN THE SH2 AND CATALYTIC DOMAINS OF V-SRC ARE ALTERED IN NATURALLY-OCCURRING, TRANSFORMATION-DEFECTIVE ALLELES	ONCOGENE			English	Article							TERMINAL REGULATORY DOMAIN; TYROSINE PROTEIN-KINASES; C-ABL; ONCOGENIC ACTIVATION; CELL-TRANSFORMATION; CRYSTAL-STRUCTURE; PHOSPHOLIPASE-C; POINT MUTATIONS; SARCOMA-VIRUS; PP60C-SRC	We have identified 11 novel point mutations that abolish the transforming capacity of the oncogene v-src. These transformation-defective alleles were originally identified in morphologically flat subclones of rat cells transformed by wild type v-src. Nine of the mutations affect amino acid residues that are highly conserved in the catalytic domain of pp60(v-src) and completely abolish kinase activity. The other 2 mutations alter conserved residues in the SH2 domain (Phe-172 replaced with Val in one case [F172V] and Leu-186 replaced with Phe in the other [L186F]), drastically reducing, but not eliminating, kinase activity. The enzymatic and transforming functions of one of the SH2 mutants, L186F are host dependent; the mutant protein is active in chicken cells, but inactive in rat cells, as previously observed for some other SH2 mutants. These results are interpreted in relation to the recently described three-dimensional structures of SH2 domains and of the catalytic domain of a protein kinase. In addition, they support a role for the SH2 domain in the regulation of kinase activity.	UNIV CALIF SAN FRANCISCO, DEPT MICROBIOL & IMMUNOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	VERDERAME, MF (corresponding author), PENN STATE UNIV, COLL MED, DEPT MICROBIOL & IMMUNOL, HERSHEY, PA 17033 USA.			Verderame, Michael F./0000-0001-7046-0879	NATIONAL CANCER INSTITUTE [R01CA052791, R35CA039832] Funding Source: NIH RePORTER; NCI NIH HHS [CA52791, CA39832] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; COOPER JA, 1984, J BIOL CHEM, V259, P7835; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; DECLUE JE, 1989, J VIROL, V63, P542, DOI 10.1128/JVI.63.2.542-554.1989; DECLUE JE, 1987, P NATL ACAD SCI USA, V84, P9064, DOI 10.1073/pnas.84.24.9064; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hanks SK, 1991, CURR OPIN STRUC BIOL, V1, P369, DOI 10.1016/0959-440X(91)90035-R; HIRAI H, 1990, P NATL ACAD SCI USA, V87, P8592, DOI 10.1073/pnas.87.21.8592; HIRAI H, 1990, GENE DEV, V4, P2342, DOI 10.1101/gad.4.12b.2342; HIRAI H, 1990, MOL CELL BIOL, V10, P1307, DOI 10.1128/MCB.10.4.1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LIEBL EC, 1992, J VIROL, V66, P4315, DOI 10.1128/JVI.66.7.4315-4324.1992; LIEBL EC, 1993, VIROLOGY, V195, P265, DOI 10.1006/viro.1993.1371; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; OBRIEN MC, 1990, MOL CELL BIOL, V10, P2855, DOI 10.1128/MCB.10.6.2855; OPPERMANN H, 1981, VIROLOGY, V108, P47, DOI 10.1016/0042-6822(81)90526-2; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PARSONS JT, 1989, CURR TOP MICROBIOL, V147, P79; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1990, ONCOGENE, V5, P1437; ROUSSEL RR, 1991, P NATL ACAD SCI USA, V88, P10696, DOI 10.1073/pnas.88.23.10696; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; VARMUS HE, 1981, VIROLOGY, V108, P28, DOI 10.1016/0042-6822(81)90525-0; VERDERAME MF, 1989, J VIROL, V63, P338, DOI 10.1128/JVI.63.1.338-348.1989; WAGES DS, 1992, J VIROL, V66, P1866, DOI 10.1128/JVI.66.4.1866-1874.1992; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WYKE JA, 1987, BIOCHIM BIOPHYS ACTA, V907, P47, DOI 10.1016/0304-419X(87)90018-7	40	12	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1994	9	1					175	182						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW247	8302576				2022-12-17	WOS:A1994MW24700021
J	BARKER, PE; SAVELYEVA, L; SCHWAB, M				BARKER, PE; SAVELYEVA, L; SCHWAB, M			TRANSLOCATION JUNCTIONS CLUSTER AT THE DISTAL SHORT ARM OF CHROMOSOME-1 (1P36.1-2) IN HUMAN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article							HUMAN NEURO-BLASTOMA; INSITU HYBRIDIZATION; LINKAGE MAP; HETEROZYGOSITY; DELETIONS; FEATURES; CANCER; LINES; DNA	Human neuroblastoma cells show at high frequency structural changes of the distal short arm of chromosome 1 (1p). The commonly altered region has been identified in previous loss-of-heterozygosity (LOH) studies to involve deletion of 1p36.1-2. These bands are also the site of constitutional alterations in patients with neuroblastoma. In an approach to define the 1p36.1-2 alterations in more detail we here employ four neuroblastoma cell lines to map translocation breaks involving 1p36.1-2 by fluorescence in situ hybridization (FISH). A chromosomal interval flanked by loci DIS96 and DIS98 contained translocation junctions in each of four lines. This analysis identifies in 1p a restricted genomic region as involved in chromosomal rearrangement in different neuroblastomas. The specificity of neuroblastoma translocation junctions at the molecular level implicates this genomic region in tumor development.	GERMAN CANC RES CTR,DEPT CYTOGENET,D-69120 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								BARKER PE, 1993, METHODS MOL GENETICS, V2, P129; BARKER PE, 1993, HUMAN NEUROBLASTOMA, P209; BERTHOLD F, 1990, NEUROBLASTOMA TUMOR, P1; BIEGEL JA, 1993, AM J HUM GENET, V52, P176; BRODEUR GM, 1981, CANCER RES, V41, P4678; BRODEUR GM, 1989, CANCER GENET CYTOGEN, V41, P153, DOI 10.1016/0165-4608(89)90243-4; BUROKER N, 1987, HUM GENET, V77, P175, DOI 10.1007/BF00272388; COLLINS A, 1992, P NATL ACAD SCI USA, V2, P4589; DRACOPOLI NC, 1991, GENOMICS, V9, P686, DOI 10.1016/0888-7543(91)90362-I; ENGELSTEIN M, 1993, GENOMICS, V15, P251, DOI 10.1006/geno.1993.1054; FONG CT, 1989, P NATL ACAD SCI USA, V86, P3753, DOI 10.1073/pnas.86.10.3753; FONG CT, 1992, CANCER RES, V52, P1780; GOLDSTEIN AM, 1993, AM J HUM GENET, V52, P537; HAINSWORTH PJ, 1992, BRIT J CANCER, V66, P131, DOI 10.1038/bjc.1992.229; HARNETT PR, 1991, CANCER GENET CYTOGEN, V54, P109, DOI 10.1016/0165-4608(91)90037-U; HEIM S, 1992, RECENT ADV HISTOPATH, V15, P37; LAMB J, 1989, CYTOGENET CELL GENET, V51, P1029; LAUREYS G, 1990, GENE CHROMOSOME CANC, V2, P252, DOI 10.1002/gcc.2870020315; LEISTER I, 1990, CANCER RES, V50, P7232; LICHTER P, 1991, GENET ANAL-BIOMOL E, V8, P24, DOI 10.1016/1050-3862(91)90005-C; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; MARTINSSON T, 1989, GENE CHROMOSOME CANC, V1, P67, DOI 10.1002/gcc.2870010111; MOLEY JF, 1992, CANCER RES, V52, P770; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; PINKEL D, 1986, P NATL ACAD SCI USA, V83, P2934, DOI 10.1073/pnas.83.9.2934; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1991, ADV NEUROBLASTOMA RE, P1; SRIVATSAN ES, 1993, GENE CHROMOSOME CANC, V7, P32, DOI 10.1002/gcc.2870070106; TAKAYAMA H, 1992, ONCOGENE, V7, P1185; TRASK BJ, 1991, TRENDS GENET, V7, P149, DOI 10.1016/0168-9525(91)90378-4; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WEITH A, 1989, GENE CHROMOSOME CANC, V1, P159, DOI 10.1002/gcc.2870010209; WONG Z, 1987, ANN HUM GENET, V51, P269, DOI 10.1111/j.1469-1809.1987.tb01062.x	33	12	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1993	8	12					3353	3358						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MG782	8247537				2022-12-17	WOS:A1993MG78200019
J	MIN, SY; MASCARENHAS, NT; TAPAROWSKY, EJ				MIN, SY; MASCARENHAS, NT; TAPAROWSKY, EJ			FUNCTIONAL-ANALYSIS OF THE CARBOXY-TERMINAL TRANSFORMING REGION OF V-MYC - BINDING TO MAX IS NECESSARY, BUT NOT SUFFICIENT, FOR CELLULAR-TRANSFORMATION	ONCOGENE			English	Article							AVIAN MYELOCYTOMATOSIS VIRUS; HUMAN C-MYC; LARGE-T-ANTIGEN; DNA-BINDING; LEUCINE ZIPPER; N-MYC; TRANSCRIPTIONAL ACTIVATION; MULTISTEP TRANSFORMATION; ERYTHROLEUKEMIA-CELLS; DIMERIZATION DOMAINS	To understand the mechanism by which the Myc protein contributes to cell growth and development, our laboratory is studying functions of the avian myelocytomatosis virus 29 (MC29) Gag-Myc protein (v-Myc) in the mouse fibroblast cell line C3H10T1/2. Previously, we identified two specific regions in v-Myc which are required for co-transformation with activated H-ras. One maps to the amino-terminal portion of v-Myc (amino acids 1-137) and has the potential to activate transcription of a basal promoter. The second region spans the carboxy-terminal region of v-Myc (amino acids 244-410), contains a basic/helix-loop-helix/leucine zipper motif and specifies the nuclear location of the protein. In this study, we have generated a series of deletion mutations within the MC29 gag-myc gene to define precisely the carboxy-terminal transforming region using the co-transformation of C3H10T1/2 celts as an assay. v-Myc proteins encoded by selected deletion mutations were also examined for their intracellular location, the ability to interact with the Max protein and the potential to bind specifically to DNA. Our results demonstrate that integrity of both the basic/helix-loop-helix and the leucine zipper motifs of v-Myc is required for co-transforming activity, but that the major nuclear localization signal sequence of v-Myc can be deleted without compromising the ability of v-Myc to cooperate with activated H-Ras p21 to transform C3H10T1/2 celts. In addition, while the binding of v-Myc to Max is necessary for ras/myc co-transformation, it is not sufficient, and also requires the integrity of Myc sequences specifying site-specific DNA binding.	PURDUE UNIV,DEPT BIOL SCI,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus				Min, Soyoung/0000-0001-7511-1520	NATIONAL CANCER INSTITUTE [R01CA042835, R23CA042835] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; AMATI B, 1993, CELL, V72, P233, DOI 10.1016/0092-8674(93)90663-B; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BECKMANN H, 1991, GENE DEV, V5, P1057, DOI 10.1101/gad.5.6.1057; BENVENISTY N, 1992, GENE DEV, V6, P2513, DOI 10.1101/gad.6.12b.2513; BERBERICH SJ, 1992, GENE DEV, V6, P166, DOI 10.1101/gad.6.2.166; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLACKWOOD EM, 1992, GENE DEV, V6, P166; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DANG CV, 1989, J BIOL CHEM, V264, P18019; DAVENPORT EA, 1992, EXP CELL RES, V202, P532, DOI 10.1016/0014-4827(92)90108-K; DAVENPORT EA, 1988, ANTICANCER RES, V8, P959; DAVIS LJ, 1993, ONCOGENE, V8, P125; DEAN M, 1986, J BIOL CHEM, V261, P9161; DEPINHO R, 1987, J CELL BIOCHEM, V33, P257, DOI 10.1002/jcb.240330404; EILERS M, 1991, EMBO J, V10, P133, DOI 10.1002/j.1460-2075.1991.tb07929.x; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FARINA SF, 1992, J VIROL, V66, P2698, DOI 10.1128/JVI.66.5.2698-2708.1992; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HANN SR, 1985, NATURE, V310, P592; HEANEY ML, 1986, J VIROL, V60, P167, DOI 10.1128/JVI.60.1.167-176.1986; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KATO GJ, 1992, GENE DEV, V6, P81, DOI 10.1101/gad.6.1.81; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KERKHOFF E, 1991, ONCOGENE, V6, P93; KERKHOFF E, 1991, P NATL ACAD SCI USA, V88, P4323, DOI 10.1073/pnas.88.10.4323; KITCHENER G, 1980, P NATL ACAD SCI-BIOL, V77, P1637, DOI 10.1073/pnas.77.3.1637; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN H, 1991, MOL CELL BIOL, V11, P267, DOI 10.1128/MCB.11.1.267; MAKELA TP, 1992, SCIENCE, V256, P373, DOI 10.1126/science.256.5055.373; MIN SY, 1992, ONCOGENE, V7, P1531; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; REDDY CD, 1992, ONCOGENE, V7, P2085; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; Sambrook J., 1989, MOL CLONING LAB MANU; SHEINESS D, 1978, J VIROL, V28, P600, DOI 10.1128/JVI.28.2.600-610.1978; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; TAPAROWSKY EJ, 1987, CANCER RES, V47, P4125; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; VENNSTROM B, 1982, J VIROL, V42, P773, DOI 10.1128/JVI.42.3.773-779.1982; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P2146, DOI 10.1073/pnas.80.8.2146; WEINBERG RA, 1989, ONCOGENES MOL ORIGIN, P307; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WICKSTROM EL, 1988, P NATL ACAD SCI USA, V85, P1028, DOI 10.1073/pnas.85.4.1028	57	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2691	2701						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378081				2022-12-17	WOS:A1993LX34300010
J	LEIBOVITCH, SA; GUILLIER, M; LENORMAND, JL; LEIBOVITCH, MP				LEIBOVITCH, SA; GUILLIER, M; LENORMAND, JL; LEIBOVITCH, MP			P34(CD2) PROTEIN IS COMPLEXED WITH THE C-MOS PROTEIN IN RAT SKELETAL-MUSCLE	ONCOGENE			English	Article							CELL-CYCLE; ONCOGENE PRODUCT; XENOPUS OOCYTES; KINASE-ACTIVITY; CDC2 KINASE; GERM-CELLS; MEIOSIS-II; EXPRESSION; PROTOONCOGENE; EGGS	We have used fractionation of subcellular components of the skeletal muscle followed by Western blot analyses to study the localization of the c-mos protein in adult rat muscle. We find that p43c-mos is predominantly located in the KCl supernatant fraction. We show that immunoprecipitates of p43c-mos phosphorylate in vitro two polypeptides of about 34 kDa and 80 kDa respectively. Muscle fractionation and immunodetection studies showed that the p34 protein associated with p43c-mos is the cdc2 protein. p43c-mos is coprecipitated with p34cdc2 when using either anti PSTAIR antibody, antibody directed against the conserved COOH terminal region of the p34cdc2 and by binding to beads that contain crosslinked p13suc1, a protein known to bind p34cdc2. Likewise p34cdc2 coprecipitated with p43c-mos when using anti mos antibody. However p43c-mos is not present in histone H1 kinase active p34cdc2 complex precipitated with anti p34cdc2 COOH-terminal peptide antibody. In adult muscle tissue tubulin is not complexed with p34cdc2 and p43c-mos as previously observed in c-mos and v-mos transformed cells. Gel filtration and crosslinking experiments show that a 170 kDa complex contains c-mos and p34cdc2 proteins. In addition during postnatal development of skeletal muscle we observe modifications in the migration pattern of p34cdc2 correlated with the accumulation of p43c-mos. Our findings raise the possibility of a p43c-mos-p34cdc2 complex could play a role in the differentiation process and maintenance of myotubes in Go.			LEIBOVITCH, SA (corresponding author), INST GUSTAVE ROUSSY,ONCOL MOLEC LAB,CNRS,URA126,UA 1158,39 RUE CAMILLE DESMOULINS,F-94805 VILLEJUIF,FRANCE.		Lenormand, Jean-Luc/ABF-3850-2021; Lenormand, Jean-Luc/M-6644-2014	Lenormand, Jean-Luc/0000-0002-2766-9180				BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1992, ONCOGENE, V7, P1757; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DOUCET JP, 1991, J BIOL CHEM, V266, P17613; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, ONCOGENE, V2, P533; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DUNN SMJ, 1989, J BIOL CHEM, V264, P11053; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HERZOG NK, 1989, ONCOGENE, V4, P1307; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; KURUTA N, 1989, EMBO J, V8, P457; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEIBOVITCH SA, 1990, ONCOGENE, V5, P1149; LEIBOVITCH SA, 1991, ONCOGENE, V6, P1617; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LORCA T, 1992, EMBO J, V11, P2381, DOI 10.1002/j.1460-2075.1992.tb05302.x; LORCA T, 1991, EMBO J, V10, P2082; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PIERCE GN, 1985, J BIOL CHEM, V260, P6862; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINSET C, 1991, EMBO J, V10, P2411, DOI 10.1002/j.1460-2075.1991.tb07780.x; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHMIDT M, 1988, MOL CELL BIOL, V8, P923, DOI 10.1128/MCB.8.2.923; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TUANA BS, 1988, MOL CELL BIOCHEM, V80, P133; WATANABE N, 1989, NATURE, V342, P505, DOI 10.1038/342505a0; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; ZHOU RP, 1992, MOL CELL BIOL, V12, P3583, DOI 10.1128/MCB.12.8.3583; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	38	12	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2361	2369						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	8395677				2022-12-17	WOS:A1993LT36800006
J	HILBERT, DM; PUMPHREY, JG; TROPPMAIR, J; RAPP, UR; RUDIKOFF, S				HILBERT, DM; PUMPHREY, JG; TROPPMAIR, J; RAPP, UR; RUDIKOFF, S			SUSCEPTIBILITY AND RESISTANCE TO J3V1 RETROVIRUS-INDUCED MURINE PLASMACYTOMAGENESIS IN RECONSTITUTED SEVERE COMBINED IMMUNODEFICIENT MICE	ONCOGENE			English	Article							MOUSE PLASMACYTOMAS; BALB/C MICE; B-CELLS; V-MYC; INDUCTION; GENETICS; LOCALIZATION; EXPRESSION; MACROPHAGE; MUTATION	To date much is known about the genetics of susceptibility and resistance to plasmacytoma induction in mice, however little is known about the cellular aspects of these phenotypes. The complexity of plasmacytomagenesis allows for susceptibility and resistance to reflect differences in B cells, T cells, accessory cells and/or stromal elements contributing to the disease process. Alternatively, these phenotypes may result from differential abilities to affect events critical to plasmacytomagenesis, such as myc deregulation. To address these possibilities, the v-myc-raf-containing retrovirus, J3V1, was used to induce plasmacytomas (PCTs) in severe combined immunodeficient (SCID) mice reconstituted with susceptible (Balb/c) and/or resistant (DBA/2) cells. The results demonstrate that Balb/c bone marrow (BM)-reconstituted SCID mice yielded PCTs of donor origin, while DBA/2 BM-reconstituted mice did not. Mice reconstituted with both DBA/2 BM and Balb/c peripheral lymphocytes, as well as those reconstituted with Balb/c peripheral lymphocytes alone, also yielded only Balb/c PCTs. These results indicate that: (1) a microenvironment supportive of plasmacytomagenesis is insufficient to allow PCT development among resistant cells; (2) DBA/ 2 BM-derived cells do not suppress plasmacytomagenesis by target cell elimination or microenvironment destruction; (3) resistance is not solely attributable to the inability of DBA/2 B cells to deregulate myc; and (4) potential PCT targets reside in a number of lymphoid tissues. Taken together, these results demonstrate that a major aspect of resistance/susceptibility to plasmacytomagenesis is dictated by the genotype of the target B cell.	NCI,FREDERICK CANC RES CTR,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	HILBERT, DM (corresponding author), NCI,GENET LAB,BETHESDA,MD 20892, USA.							ANDERSON PN, 1969, NATURE, V222, P994, DOI 10.1038/222994a0; AUSTYN JM, 1981, EUR J IMMUNOL, V1, P801; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; CANCRO M, 1976, J EXP MED, V144, P1554, DOI 10.1084/jem.144.6.1554; CLYNES R, 1989, P NATL ACAD SCI USA, V85, P6067; Coffman R L, 1982, Immunol Rev, V69, P5; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; CREWS S, 1981, CELL, V25, P59, DOI 10.1016/0092-8674(81)90231-2; DORSHKIND K, 1984, J IMMUNOL, V132, P1804; ECKHARDT L, 1989, IMMUNOGENETICS, V11, P275; HAVRAN WL, 1987, NATURE, V330, P170, DOI 10.1038/330170a0; HAYAKAWA K, 1985, J EXP MED, V161, P1554, DOI 10.1084/jem.161.6.1554; HAYAKAWA K, 1986, EUR J IMMUNOL, V16, P1313, DOI 10.1002/eji.1830161021; HO MK, 1982, J IMMUNOL, V128, P2281; JOLLEY ME, 1984, J IMMUNOL METHODS, V67, P21, DOI 10.1016/0022-1759(84)90082-6; KURIE JM, 1990, ONCOGENE, V5, P577; LARGAESPADA D, 1990, CURR TOP MICROBIOL, V166, P91; MERWIN RM, 1959, P SOC EXP BIOL MED, V101, P437; MERWIN RM, 1963, J NAT CANC, V31, P998; OHNO S, 1979, CELL, V18, P1001, DOI 10.1016/0092-8674(79)90212-5; POTTER M, 1988, Genomics, V2, P257, DOI 10.1016/0888-7543(88)90010-9; POTTER M, 1983, J NATL CANCER I, V71, P391; POTTER M, 1975, J NATL CANCER I, V54, P1413, DOI 10.1093/jnci/54.6.1413; POTTER M, 1984, J EXP MED, V160, P435, DOI 10.1084/jem.160.2.435; POTTER M, 1962, NATURE, V193, P1086, DOI 10.1038/1931086a0; POTTER M, 1984, CANCER SURV, V3, P247; POTTER M, 1981, J IMMUNOL, V127, P1591; POTTER M, 1960, J NATL CANCER I, V25, P847, DOI 10.1093/jnci/25.4.847; POTTER M, 1967, METHOD CANCER RES, V2, P105; POTTER M, 1982, CANCER COMPREHENSIVE, P139; RAPP UR, 1985, J VIROL, V55, P23, DOI 10.1128/JVI.55.1.23-33.1985; REEVES RH, 1987, CYTOGENET CELL GENET, V44, P76, DOI 10.1159/000132347; SCHEID MP, 1979, IMMUNOGENETICS, V9, P423, DOI 10.1007/BF01570435; SHENONG GLC, 1982, CELL, V31, P443, DOI 10.1016/0092-8674(82)90137-4; SILVA S, 1991, INT J CANCER, V49, P224, DOI 10.1002/ijc.2910490214; SPRENT J, 1991, J EXP MED, V174, P717, DOI 10.1084/jem.174.3.717; SPRINGER TA, 1979, EUR J IMMUNOL, V9, P311; TROPPMAIR J, 1989, P NATL ACAD SCI USA, V86, P9941, DOI 10.1073/pnas.86.24.9941; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; VENNSTROM B, 1981, J VIROL, V39, P625	40	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1993	8	7					1993	2000						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LG682	7685514				2022-12-17	WOS:A1993LG68200032
J	HAO, MM; FINLAY, CA; LOZANO, G				HAO, MM; FINLAY, CA; LOZANO, G			A FUNCTIONALLY INACTIVE P53 LI-FRAUMENI SYNDROME MUTANT	ONCOGENE			English	Article							WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-LOCALIZATION; PROTEINS BIND; GENE-PRODUCT; T-ANTIGEN; DNA; MUTATIONS; CANCER; CELLS	Germline mutations in the tumor-suppressor p53 have been recently identified in Li-Fraumeni syndrome patients. We analysed the function of one of these mutations, an arg-to-trp substitution at amino acid 245 in the murine p53 gene. This p53LFS mutant could not, unlike wild-type p53, suppress foci formation of rat embryo-fibroblasts. Like other p53 mutants it cooperated with activated ras to transform rat embryo fibroblasts. Overexpression of p53LFS thus resulted in a phenotype similar to other mutant p53s. The p53LFS protein was also transcriptionally inactive in contrast to previous studies using a p53LFS/GAL4 fusion protein. To better understand the functional domain disrupted in p53LFS, we developed a dimerization assay and showed that p53LFS still dimerized. In addition, p53LFS retained its ability to bind SV40 large T antigen and not hsc70, both characteristics of wild-type p53. Using immunofluorescence, we localized p53LFS to the nucleus. From these results we conclude that p53LFS represents an unusual p53 mutant in that it retains many characteristics of wild-type p53, however activities critical for growth suppression are lost.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC GENET,HOUSTON,TX 77030; PRINCETON UNIV,DEPT BIOL,PRINCETON,NJ 08544	University of Texas System; UTMD Anderson Cancer Center; Princeton University					NCI NIH HHS [CA47296] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047296, R01CA047296] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARGONETTI J, 1991, CELL, V65, P1083, DOI 10.1016/0092-8674(91)90560-L; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FIELDS S, 1990, SCIENCE, V249, P1046, DOI 10.1126/science.2144363; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KERN SE, 1991, ONCOGENE, V6, P131; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KRAISS S, 1988, J VIROL, V62, P4737, DOI 10.1128/JVI.62.12.4737-4744.1988; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LEVINE AJ, 1990, VIROLOGY, V177, P419, DOI 10.1016/0042-6822(90)90505-L; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MILNER J, 1991, MOL CELL BIOL, V11, P12, DOI 10.1128/MCB.11.1.12; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1991, MOL CELL BIOL, V11, P6067, DOI 10.1128/MCB.11.12.6067; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; SOUSSI T, 1990, ONCOGENE, V5, P945; SRIVASTAVA S, 1990, NATURE, V348, P747, DOI 10.1038/348747a0; STENGER JE, 1992, MOL CARCINOGEN, V5, P102, DOI 10.1002/mc.2940050204; TAN TH, 1986, J VIROL, V59, P574, DOI 10.1128/JVI.59.3.574-583.1986; UNGER T, 1992, EMBO J, V11, P1383, DOI 10.1002/j.1460-2075.1992.tb05183.x; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; ZAMBETTI GP, 1992, GENE DEV, V6, P1143, DOI 10.1101/gad.6.7.1143	40	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1993	8	2					299	306						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN006	8426739				2022-12-17	WOS:A1993KN00600008
J	CROWE, AJ; HAYMAN, MJ				CROWE, AJ; HAYMAN, MJ			POSTTRANSLATIONAL MODIFICATIONS OF THE ENV-SEA ONCOGENE PRODUCT - THE ROLE OF PROTEOLYTIC PROCESSING IN TRANSFORMATION	ONCOGENE			English	Article							AVIAN ERYTHROBLASTOSIS VIRUS; GROWTH-FACTOR RECEPTOR; HUMAN-IMMUNODEFICIENCY-VIRUS; TYROSINE KINASE-ACTIVITY; CELL-SURFACE EXPRESSION; MET PROTO-ONCOGENE; C-MET; INSULIN-RECEPTOR; MAMMALIAN-CELLS; RETROVIRUS S13	The transforming gene product of the S13 avian erythroblastosis virus, env-sea, is a member of the growth factor receptor class of tyrosine kinases. The env-sea precursor protein gp155env-sea is proteolytically processed into the mature cleavage products gp85env-sea and gp70env-sea which are subsequently terminally glycosylated. Previous studies have shown that the abnormal glycosylation of gp155env-sea which takes place in the presence of the inhibitor castanospermine inhibits the proteolytic cleavage of gp155env-sea and blocks its transforming ability. To define a role for proteolytic processing of env-sea in transformation, we have introduced mutations at the protease recognition site which efficiently block cleavage without affecting the biosynthesis or transport of the resulting uncleaved protein. We show here that an uncleaved but fully glycosylated sea-encoded protein retains the ability to transform chicken embryo fibroblasts, indicating that proteolytic processing is not essential for transformation by the env-sea tyrosine kinase.	SUNY STONY BROOK,DEPT MICROBIOL,STONY BROOK,NY 11794	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NCI NIH HHS [CA42573, CA28146, 5T32 CA09176] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009176, P01CA028146, R01CA042573] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BENEDICT SH, 1985, VIROLOGY, V145, P154, DOI 10.1016/0042-6822(85)90210-7; BEUG H, 1985, VIROLOGY, V145, P141, DOI 10.1016/0042-6822(85)90209-0; BEUG H, 1984, CELL, V36, P963, DOI 10.1016/0092-8674(84)90046-1; BEUG H, 1982, J CELL PHYSL S, V1, P195; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; BRADAC J, 1986, VIROLOGY, V150, P491, DOI 10.1016/0042-6822(86)90313-2; CHAN AML, 1988, ONCOGENE, V2, P593; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; CROWE AJ, 1991, J VIROL, V65, P2533, DOI 10.1128/JVI.65.5.2533-2538.1991; DEAN M, 1985, NATURE, V318, P385, DOI 10.1038/318385a0; EINFELD D, 1988, P NATL ACAD SCI USA, V85, P8688, DOI 10.1073/pnas.85.22.8688; GEYER H, 1988, J BIOL CHEM, V263, P11760; GIORDANO S, 1989, ONCOGENE, V4, P1383; HARDWICK JM, 1986, J CELL BIOL, V103, P829, DOI 10.1083/jcb.103.3.829; HAYMAN M, 1978, VIROLOGY, V85, P475, DOI 10.1016/0042-6822(78)90454-3; HAYMAN MJ, 1986, VIROLOGY, V150, P270, DOI 10.1016/0042-6822(86)90287-4; HAYMAN MJ, 1985, P NATL ACAD SCI USA, V82, P8237, DOI 10.1073/pnas.82.23.8237; HEDO JA, 1983, J BIOL CHEM, V258, P20; HUNTER E, 1989, CURR TOP MICROBIOL, V157, P188; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KNIGHT J, 1988, GENE DEV, V2, P247, DOI 10.1101/gad.2.2.247; KNIGHT J, 1988, ONCOGENE, V2, P317; KNIGHT J, 1990, VIROLOGY, V178, P232, DOI 10.1016/0042-6822(90)90398-B; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIPSICK JS, 1986, J VIROL, V59, P267, DOI 10.1128/JVI.59.2.267-275.1986; MONDINO A, 1991, MOL CELL BIOL, V11, P6084, DOI 10.1128/MCB.11.12.6084; NALDINI L, 1991, ONCOGENE, V6, P501; NALDINI L, 1991, IN PRESS EMBO J; NICHOLS EJ, 1985, MOL CELL BIOL, V5, P3467, DOI 10.1128/MCB.5.12.3467; PEREZ LG, 1987, J VIROL, V61, P1609, DOI 10.1128/JVI.61.5.1609-1614.1987; PINTER A, 1984, J VIROL, V49, P452, DOI 10.1128/JVI.49.2.452-458.1984; RODRIGUES GA, 1991, MOL CELL BIOL, V11, P2962, DOI 10.1128/MCB.11.6.2962; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; SCHMIDT JA, 1985, EMBO J, V4, P105, DOI 10.1002/j.1460-2075.1985.tb02323.x; SCHWALLER M, 1989, VIROLOGY, V172, P367; SMITH DR, 1989, P NATL ACAD SCI USA, V86, P5291, DOI 10.1073/pnas.86.14.5291; STOKER AW, 1988, J VIROL, V62, P1008, DOI 10.1128/JVI.62.3.1008-1015.1988; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Vogt PK, 1969, FUNDAMENTAL TECHNIQU, P198; WEISS CD, 1990, J VIROL, V64, P5674, DOI 10.1128/JVI.64.11.5674-5677.1990; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YOSHIMASA Y, 1988, SCIENCE, V240, P784, DOI 10.1126/science.3283938; YOSHIMASA Y, 1990, J BIOL CHEM, V265, P17230	45	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					181	189						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423995				2022-12-17	WOS:A1993KN00500022
J	SHIN, S; STEFFEN, DL				SHIN, S; STEFFEN, DL			FREQUENT ACTIVATION OF THE LCK GENE BY PROMOTER INSERTION AND ABERRANT SPLICING IN MURINE LEUKEMIA VIRUS-INDUCED RAT LYMPHOMAS	ONCOGENE			English	Article							TYROSINE-PROTEIN-KINASE; INBRED MOUSE STRAINS; SIGNAL TRANSDUCTION; CD4 RECEPTOR; P56LCK; SITES; MICE; RNA	We have analysed DNA and RNA from 36 T-cell lymphomas induced in Fischer rats by Moloney murine leukemia virus for alterations affecting the structure or expression of the lck gene. At least five primary tumors (14%) have a proviral insertion upstream of lck. In at least four of the tumors, proviral insertion increases lck mRNA levels an average of eight-fold. Overexpression of lck results from transcription initiating in the viral promoter and extending into lck sequences. Three different structures of hybrid transcript were detected. In all three, the hybrid RNAs are spliced to a normal lck splice acceptor in the first exon of lck, resulting in removal of three out of frame ATG codons which would be expected to increase the translation efficiency of the hybrid message. In one tumor, the viral splice donor is used, in one tumor, proviral insertion generates a splice donor sequence one base pair downstream of the long terminal repeat boundary, and in two tumors, a cryptic splice donor in the upstream lck sequences is used. The significance of these unusual splicing patterns and of the higher frequency of proviral insertions adjacent to lck in rats relative to mice is discussed.	BAYLOR COLL MED,DIV MOLEC VIROL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine					NCI NIH HHS [CA30674] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA030674] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; ADLER HT, 1988, J VIROL, V62, P4113, DOI 10.1128/JVI.62.11.4113-4122.1988; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BERGER SL, 1987, METHOD ENZYMOL, V152, P215; BILOFSKY HS, 1986, NUCLEIC ACIDS RES, V14, P1, DOI 10.1093/nar/14.1.1; CHANG KS, 1984, MOL CELL BIOL, V4, P2498, DOI 10.1128/MCB.4.11.2498; CLOYD MW, 1980, J EXP MED, V151, P542, DOI 10.1084/jem.151.3.542; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GISSELBRECHT S, 1981, INT J CANCER, V27, P531, DOI 10.1002/ijc.2910270417; GREEN N, 1980, J EXP MED, V152, P2498; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; JACKSON IJ, 1991, NUCLEIC ACIDS RES, V19, P3795; KRETZ KA, 1989, NUCLEIC ACIDS RES, V17, P5864, DOI 10.1093/nar/17.14.5864; LAWRENCE CB, 1989, EUGENE SOFTWARE PACK; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LI JP, 1991, J VIROL, V65, P2408, DOI 10.1128/JVI.65.5.2408-2414.1991; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MUCENSKI ML, 1987, J VIROL, V61, P2929, DOI 10.1128/JVI.61.9.2929-2933.1987; MUCENSKI ML, 1988, J VIROL, V62, P839, DOI 10.1128/JVI.62.3.839-846.1988; MUCENSKI ML, 1987, ONCOGENE RES, V2, P33; MUCENSKI ML, 1986, MOL CELL BIOL, V6, P4236, DOI 10.1128/MCB.6.12.4236; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SELDEN RF, 1987, CURRENT PROTOCOLS MO; SITBON M, 1985, VIROLOGY, V140, P144, DOI 10.1016/0042-6822(85)90453-2; STEFFEN D, 1984, P NATL ACAD SCI-BIOL, V81, P2097, DOI 10.1073/pnas.81.7.2097; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VIJAYA S, 1987, J VIROL, V61, P1164, DOI 10.1128/JVI.61.4.1164-1170.1987; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	32	12	14	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1993	8	1					141	149						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN005	8423992				2022-12-17	WOS:A1993KN00500017
J	THE, SM; XIE, XL; SMYTH, F; PAPAS, TS; WATSON, DK; SCHULZ, RA				THE, SM; XIE, XL; SMYTH, F; PAPAS, TS; WATSON, DK; SCHULZ, RA			MOLECULAR CHARACTERIZATION AND STRUCTURAL ORGANIZATION OF D-ELG, AN ETS PROTO-ONCOGENE-RELATED GENE OF DROSOPHILA	ONCOGENE			English	Article							PUTATIVE 2ND-CELL-DERIVED ONCOGENE; AVIAN LEUKEMIA RETROVIRUS-E26; LONG TERMINAL REPEAT; DNA-BINDING; C-ETS; C-ETS-1 PROTOONCOGENE; V-ETS; DEVELOPMENTAL EXPRESSION; TRANSCRIPTION FACTORS; TRANSFORMING GENE	We have continued the molecular analysis of D-elg, a member of the Drosophila ets gene family. Based on the characterization of cDNA and genomic sequences, the D-elg gene contains five exons and four introns and produces a mRNA with an open reading frame of 464 amino acids. Consistent with this analysis, in vitro translation of a near full-length D-elg cRNA yields a protein with a molecular weight of approximately 56 kDa. D-elg shows significant homology to other ets proteins in the amino-terminal A domain and strong homology in the carboxy-terminal ETS domain. The D-elg protein is most similar to the alpha-subunit of the mouse GA-binding protein.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030; NCI,MOLEC ONCOL LAB,FREDERICK,MD 21702	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ANDERSON KV, 1985, CELL, V42, P779, DOI 10.1016/0092-8674(85)90274-0; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BURDETT LA, 1992, NUCLEIC ACIDS RES, V20, P371, DOI 10.1093/nar/20.2.371; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; CHEN JH, 1990, ONCOGENE RES, V5, P277; CHEN JH, 1988, ONCOGENE RES, V2, P371; CHEN T, 1992, DEV BIOL, V151, P176, DOI 10.1016/0012-1606(92)90225-6; CHEN ZQ, 1988, DEV BIOL, V125, P432, DOI 10.1016/0012-1606(88)90224-2; CHEN ZQ, 1990, SCIENCE, V250, P1416, DOI 10.1126/science.2255913; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FISHER RJ, 1991, ONCOGENE, V6, P2249; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; JANKNECHT R, 1989, NUCLEIC ACIDS RES, V17, P4455, DOI 10.1093/nar/17.12.4455; JORCYK CL, 1991, ONCOGENE, V6, P523; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEWIN B, 1991, CELL, V64, P303, DOI 10.1016/0092-8674(91)90640-K; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; PRIBYL LJ, 1991, ONCOGENE, V6, P1175; PRIBYL LJ, 1988, DEV BIOL, V127, P45, DOI 10.1016/0012-1606(88)90187-X; RAO VN, 1992, ONCOGENE, V7, P65; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; REDDY ESP, 1991, ONCOGENE, V6, P2285; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIKERT J, 1992, ONCOGENE, V7, P249; SCHULZ RA, 1989, DEV BIOL, V131, P515, DOI 10.1016/S0012-1606(89)80022-3; SETH A, 1990, ONCOGENE, V5, P1761; SETH A, 1992, CELL GROWTH DIFFER, V30, P327; STIEGLER P, 1990, NUCLEIC ACIDS RES, V18, P5298, DOI 10.1093/nar/18.17.5298; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TOMLINSON A, 1988, CELL, V55, P771, DOI 10.1016/0092-8674(88)90133-X; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; VANDAAL A, 1992, MOL BIOL CELL, V3, P593, DOI 10.1091/mbc.3.6.593; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON D K, 1990, Critical Reviews in Oncogenesis, V1, P409; WATSON DK, 1988, VIROLOGY, V164, P99, DOI 10.1016/0042-6822(88)90624-1; WATSON DK, 1990, ONCOGENE, V5, P1521; WATSON DK, 1988, P NATL ACAD SCI USA, V85, P7862, DOI 10.1073/pnas.85.21.7862; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WATSON DK, 1992, IN PRESS CELL GROWTH; WOLFF CM, 1991, CELL GROWTH DIFFER, V2, P447; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481	60	12	13	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1992	7	12					2471	2478						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KA856	1461651				2022-12-17	WOS:A1992KA85600012
J	JEFFERS, M; PELLICER, A				JEFFERS, M; PELLICER, A			MULTIPLE INTRAGENIC ELEMENTS REGULATE THE EXPRESSION OF THE MURINE N-RAS GENE	ONCOGENE			English	Article							ADENOSINE-DEAMINASE GENE; RNA POLYMERASE-II; C-MYC GENE; TRANSCRIPTIONAL ARREST; SEQUENCE REQUIREMENTS; PREMATURE TERMINATION; TRANSFORMING GENES; RIBONUCLEIC-ACID; MAMMALIAN-CELLS; SARCOMA-VIRUSES	We have identified two separate regions within the murine N-ras transcription unit which may participate in the regulation of N-ras gene expression. One of these regions, localized to the first half of intron 1, contains a site of premature transcriptional arrest. We propose that premature transcription termination, which has been identified as an important control mechanism for several genes, may also play a role in the regulation of the N-ras gene. In addition, we have identified a positively acting region within the N-ras transcription unit. This region, localized to the end of intron 1/beginning of exon 1, was found to greatly increase expression from the N-ras promoter.	NYU MED CTR,DEPT PATHOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CANC CTR,NEW YORK,NY 10016	New York University; New York University			MARTINEZ, ANTONIO PELLICER/C-4832-2015	Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R37CA036327, R01CA036327, R01CA050434] Funding Source: NIH RePORTER; NCI NIH HHS [CA36327, CA50434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1991, J CELL BIOCH SG, V15, P268; BESMOND C, 1987, CURRENT PROTOCOLS MO, V1; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHANG HY, 1987, ONCOGENE RES, V1, P129; CHEN Z, 1990, MOL CELL BIOL, V10, P4555, DOI 10.1128/MCB.10.9.4555; CHEN Z, 1991, MOL CELL BIOL, V11, P6248, DOI 10.1128/MCB.11.12.6248; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI T, 1991, MOL CELL BIOL, V11, P3070, DOI 10.1128/MCB.11.6.3070; CHUNG S, 1989, MOL CELL BIOL, V9, P2075, DOI 10.1128/MCB.9.5.2075; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DONIGER J, 1988, NUCLEIC ACIDS RES, V16, P969, DOI 10.1093/nar/16.3.969; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FUJITA J, 1985, P NATL ACAD SCI USA, V82, P3849, DOI 10.1073/pnas.82.11.3849; GEROSA MA, 1989, J NATL CANCER I, V81, P63, DOI 10.1093/jnci/81.1.63; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG M, 1987, CURRENT PROTOCOLS MO, V1; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALL A, 1985, NUCLEIC ACIDS RES, V13, P5255, DOI 10.1093/nar/13.14.5255; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAWLEY DK, 1985, J BIOL CHEM, V260, P8163; HONKAWA H, 1987, MOL CELL BIOL, V7, P2933, DOI 10.1128/MCB.7.8.2933; INGOLIA DE, 1986, MOL CELL BIOL, V6, P4458, DOI 10.1128/MCB.6.12.4458; INNIS JW, 1991, MOL CELL BIOL, V11, P5398, DOI 10.1128/MCB.11.11.5398; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; LATTIER DL, 1989, NUCLEIC ACIDS RES, V17, P1061, DOI 10.1093/nar/17.3.1061; LEE PC, 1973, DEV BIOL, V31, P227, DOI 10.1016/0012-1606(73)90259-5; LEON J, 1987, MOL CELL BIOL, V7, P1535, DOI 10.1128/MCB.7.4.1535; LONDON L, 1991, MOL CELL BIOL, V11, P4599, DOI 10.1128/MCB.11.9.4599; LOWNDES NF, 1989, MOL CELL BIOL, V9, P3758, DOI 10.1128/MCB.9.9.3758; MANGUES R, 1992, IN PRESS ONCOGENE; MCKAY IA, 1986, EMBO J, V5, P2617, DOI 10.1002/j.1460-2075.1986.tb04542.x; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MICOLAIEW N, 1991, ONCOGENE, V6, P721; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; PACIUCCI R, 1991, MOL CELL BIOL, V11, P1334, DOI 10.1128/MCB.11.3.1334; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; PULCIANI S, 1985, MOL CELL BIOL, V5, P2836, DOI 10.1128/MCB.5.10.2836; RAMAMURTHY V, 1990, MOL CELL BIOL, V10, P1484, DOI 10.1128/MCB.10.4.1484; ROEDER RG, 1974, J BIOL CHEM, V249, P241; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; SPENCER CA, 1990, ONCOGENE, V5, P777; SPENCER CA, 1990, GENE DEV, V4, P75, DOI 10.1101/gad.4.1.75; THORN JT, 1991, ONCOGENE, V65, P1843; WINTER E, 1986, MOL CELL BIOL, V6, P2562, DOI 10.1128/MCB.6.7.2562; YAMAMOTO F, 1988, ONCOGENE RES, V3, P125; YANG JQ, 1986, EMBO J, V5, P3553, DOI 10.1002/j.1460-2075.1986.tb04682.x	60	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2115	2123						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1437142				2022-12-17	WOS:A1992JW66500003
J	MOLL, J; EIBEL, H; BOTTERI, F; SANSIG, G; REGNIER, C; VANDERPUTTEN, H				MOLL, J; EIBEL, H; BOTTERI, F; SANSIG, G; REGNIER, C; VANDERPUTTEN, H			TRANSGENES ENCODING MUTANT SIMIAN-VIRUS 40 LARGE T-ANTIGENS UNMASK PHENOTYPIC AND FUNCTIONAL CONSTRAINTS IN THYMIC EPITHELIAL-CELLS	ONCOGENE			English	Article							RETINOBLASTOMA SUSCEPTIBILITY GENE; SV40 LARGE-T; HEMATOPOIETIC GROWTH-FACTORS; LARGE TUMOR-ANTIGEN; PROGENITOR CELLS; THYMOCYTE DEVELOPMENT; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANES; HYDROPHOBIC REGION; MESSENGER-RNA	Transgenes encoding simian virus 40 (SV40) T antigen (Tag) can cause hyperplastic or tumorigenic lesions of desired but also of unforeseen cellular origin. Unexpectedly the human growth hormone-releasing factor (GRF) gene promoter directs expression of SV40 Tag specifically in thymic epithelial (TE) cells. Expression starts in the neonate, in which GRF-Tag+ cells display strict numerical and spatial constraints. Tag supersedes mechanisms that constrain these features and GRF-Tag mice develop thymic hyperplasia. To characterize GRF-Tag+ TE cells and their putative normal counterparts we compared phenotypic and functional effects caused by transgenes encoding mutant large T antigens. This strategy is applicable to any situation in which T antigen is used to alter development. One large Tag mutant (K1 + 5080) does not cause thymic hyperplasia. GRF-Tag (K1 + 5080)+ TE cells display strict temporal and spatial constraints throughout life. TE cells expressing other mutant large T antigens that cause thymic hyperplasia do not obey these rules and reveal that phenotypically distinct GRF-Tag+ TE-cell stages exist in vivo. Analysis of conditional immortal GRF-Tag(tsA58)+ TE cells expressing a temperature-sensitive large Tag shows that large Tag blocks differentiation in these cells. Phenotype and functions in these cells are regulated by cellular differentiation and interleukin 4 (IL-4).	CIBA GEIGY AG,DEPT BIOTECHNOL,DIV PHARMA,K681447,CH-4002 BASEL,SWITZERLAND; MAX PLANCK INST IMMUNBIOL,W-7800 FREIBURG,GERMANY; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Novartis; Max Planck Society; Friedrich Miescher Institute for Biomedical Research				Regnier, Catherine/0000-0002-4386-1324				BALL RK, 1984, EMBO J, V3, P1485, DOI 10.1002/j.1460-2075.1984.tb02000.x; BARTEK J, 1992, ONCOGENE, V7, P101; BAUVOIS B, 1989, J IMMUNOL, V143, P1077; BERRIH S, 1985, J HISTOCHEM CYTOCHEM, V33, P655, DOI 10.1177/33.7.3891843; BOSCH FX, 1988, J CELL BIOL, V106, P1635, DOI 10.1083/jcb.106.5.1635; BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; BOYD RL, 1991, IMMUNOL TODAY, V12, P71, DOI 10.1016/0167-5699(91)90161-L; Brekelmans P, 1990, Semin Immunol, V2, P13; BROMBACHER F, 1989, EMBO J, V8, P3719, DOI 10.1002/j.1460-2075.1989.tb08547.x; BROXMEYER HE, 1991, EXP HEMATOL, V19, P143; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CARDING SR, 1991, IMMUNOL TODAY, V12, P239, DOI 10.1016/0167-5699(91)90037-T; CARTER WG, 1991, CELL, V65, P599, DOI 10.1016/0092-8674(91)90092-D; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; CRISPE IN, 1987, J IMMUNOL, V138, P2013; DARGEMONT C, 1989, SCIENCE, V246, P803, DOI 10.1126/science.2683083; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; ERICKSON HP, 1989, ANNU REV CELL BIOL, V5, P71, DOI 10.1146/annurev.cb.05.110189.000443; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; EZINE S, 1991, INT IMMUNOL, V3, P237; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FUCHS E, 1988, TRENDS GENET, V4, P277, DOI 10.1016/0168-9525(88)90169-2; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GODFREY DI, 1990, IMMUNOLOGY, V70, P66; GUTIERREZ JC, 1991, P NATL ACAD SCI USA, V88, P642, DOI 10.1073/pnas.88.2.642; HRONIS TS, 1984, CANCER RES, V44, P5797; JAT PS, 1989, MOL CELL BIOL, V9, P1672, DOI 10.1128/MCB.9.4.1672; Jenkinson E J, 1990, Semin Immunol, V2, P51; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; KAMPINGA J, 1990, J IMMUNOL, V145, P1659; KANARIOU M, 1989, CLIN EXP IMMUNOL, V78, P263; KENDALL MD, 1989, THYMUS, V13, P157; KRAAL G, 1986, J EXP MED, V163, P981, DOI 10.1084/jem.163.4.981; KUEHN R, 1991, Science (Washington D C), V254, P707; LEWIS DB, 1991, J EXP MED, V173, P89, DOI 10.1084/jem.173.1.89; LOBACH DF, 1987, J CLIN IMMUNOL, V7, P81, DOI 10.1007/BF00916002; LOEWENTHAL J, 1988, J IMMUNOL, V140, P456; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARTINEZ J, 1991, GENE DEV, V5, P51; MATSUSHIME H, 1991, BLOOD, V78, P616; MCNIECE IK, 1991, J IMMUNOL, V146, P3785; MCNIECE IK, 1991, EXP HEMATOL, V19, P226; MILLNER J, 1990, ONCOGENE, V5, P1683; MIYAMAINABA M, 1988, J EXP MED, V168, P811, DOI 10.1084/jem.168.2.811; MOLL J, 1992, IN PRESS EUR J IMMUN; MONROE JG, 1988, CLIN IMMUNOL IMMUNOP, V49, P292, DOI 10.1016/0090-1229(88)90119-5; MURPHY ED, 1971, P AM ASSOC CANC RES, V12, P45; NAGAMINE J, 1991, J IMMUNOL, V147, P1147; OKADA S, 1991, BLOOD, V78, P1706; PALACIOS R, 1989, EMBO J, V8, P4053, DOI 10.1002/j.1460-2075.1989.tb08589.x; PALACIOS R, 1987, EMBO J, V6, P91, DOI 10.1002/j.1460-2075.1987.tb04723.x; PALACIOS R, 1990, J EXP MED, V172, P219, DOI 10.1084/jem.172.1.219; PALACIOS R, 1991, EUR J IMMUNOL, V21, P109, DOI 10.1002/eji.1830210117; PAUL WE, 1991, BLOOD, V77, P1859; PEDEN KWC, 1989, VIROLOGY, V168, P13, DOI 10.1016/0042-6822(89)90398-X; PLANTEFABER LC, 1989, CELL, V56, P281, DOI 10.1016/0092-8674(89)90902-1; PLUM J, 1990, J IMMUNOL, V145, P1066; POTTEN CS, 1990, DEVELOPMENT, V110, P1001; RENNICK D, 1989, BLOOD, V73, P1828; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RUOSLAHTI E, 1989, CANCER CELL-MON REV, V1, P119; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAMARIDIS J, 1991, EUR J IMMUNOL, V21, P453, DOI 10.1002/eji.1830210230; Sambrook J., 1989, MOL CLONING LAB MANU; SHAULSKY G, 1991, ONCOGENE, V6, P2055; SHAULSKY G, 1990, ONCOGENE, V5, P1707; SHORES EW, 1991, EUR J IMMUNOL, V21, P1657, DOI 10.1002/eji.1830210711; SHORES EW, 1991, EUR J IMMUNOL, V21, P973, DOI 10.1002/eji.1830210417; Shortman K, 1990, Semin Immunol, V2, P3; SMALL M, 1989, IMMUNOLOGY, V68, P371; SPRANGRUDE CJ, 1990, J IMMUNOLY, V145, P3661; STANLEY ER, 1990, GENETICS OF PATTERN FORMATION AND GROWTH CONTROL, P165; STUDA T, 1991, J IMMUNOL, V146, P3068; TACK LC, 1989, J VIROL, V63, P3362, DOI 10.1128/JVI.63.8.3362-3367.1989; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; TRUEB B, 1985, J CELL BIOL, V100, P638, DOI 10.1083/jcb.100.2.638; VANEWIJK W, 1991, ANNU REV IMMUNOL, V9, P591, DOI 10.1146/annurev.iy.09.040191.003111; VANVLIET E, 1985, EUR J IMMUNOL, V15, P675, DOI 10.1002/eji.1830150707; WELHAM MJ, 1991, MOL CELL BIOL, V11, P2901, DOI 10.1128/MCB.11.5.2901; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WU L, 1991, J EXP MED, V174, P1617, DOI 10.1084/jem.174.6.1617; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	87	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2175	2187						13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1279498				2022-12-17	WOS:A1992JW66500010
J	REDDY, MVR; DESAI, M; JEYAPAUL, J; PRASAD, DDK; SESHAMMA, T; PALMERI, D; KHAN, SA				REDDY, MVR; DESAI, M; JEYAPAUL, J; PRASAD, DDK; SESHAMMA, T; PALMERI, D; KHAN, SA			FUNCTIONAL-ANALYSIS OF THE N-TERMINAL DOMAIN OF TAT PROTEIN OF THE HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1	ONCOGENE			English	Article							ACTIVATION-RESPONSIVE REGION; RNA-BINDING PROTEIN; CELL-FREE SYSTEM; HIV-1 TAT; TRANS-ACTIVATION; MUTATIONAL ANALYSIS; TRANSCRIPTIONAL ACTIVATION; GENE-EXPRESSION; NUCLEAR-PROTEIN; BASIC DOMAIN	The Tat protein of human immunodeficiency virus type 1 (HIV-1) is a potent trans-activator of the viral long terminal repeat (LTR). The N-terminal region of Tat is rich in proline and acidic residues analogous to the activation domains of other transcription factors such as GAL4 and CTF/NF-1. Several basic residues are also present in this region. To investigate the role of these structural features in the Tat-mediated trans-activation, we have chemically synthesized and evaluated Tat analogs with alanine or glutamine replacing one or more of these amino acid residues. Our data show that substitution of Glu-2, His-13, or all the proline in the Pro-Xaa3-Pro triad drastically reduced activity. In contrast, changes at Arg-7, Lys-12 and any one proline residue in the triad moderately reduced, and substitution of Lys-19 showed tittle effect on, activity. These results show that the native structure of the N-terminal 19 amino acid sequence is essential for Tat function. and that the overall topology of this domain and not the acidic residues alone appears necessary for trans-activation.	WISTAR INST,3601 SPRUCE ST,PHILADELPHIA,PA 19104	The Wistar Institute					NIAID NIH HHS [AI27422, AI25380] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027422, P01AI025380] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BERKHOUT B, 1990, CELL, V62, P757, DOI 10.1016/0092-8674(90)90120-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; BRADDOCK M, 1989, CELL, V58, P269, DOI 10.1016/0092-8674(89)90841-6; BRAKE DA, 1990, J VIROL, V64, P962, DOI 10.1128/JVI.64.2.962-965.1990; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CULLEN BR, 1991, FASEB J, V5, P2361, DOI 10.1096/fasebj.5.10.1712325; CULLEN BR, 1990, CELL, V63, P655, DOI 10.1016/0092-8674(90)90129-3; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; FRANKEL AD, 1988, SCIENCE, V240, P70, DOI 10.1126/science.2832944; FRANKEL AD, 1988, CELL, V55, P1189, DOI 10.1016/0092-8674(88)90263-2; FRANKEL AD, 1989, P NATL ACAD SCI USA, V86, P7397, DOI 10.1073/pnas.86.19.7397; GARCIA JA, 1989, EMBO J, V8, P765, DOI 10.1002/j.1460-2075.1989.tb03437.x; GARCIA JA, 1988, EMBO J, V7, P3143, DOI 10.1002/j.1460-2075.1988.tb03181.x; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; GATIGNOL A, 1989, P NATL ACAD SCI USA, V86, P7828, DOI 10.1073/pnas.86.20.7828; GAYNOR R, 1989, P NATL ACAD SCI USA, V86, P4858, DOI 10.1073/pnas.86.13.4858; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; HAUBER J, 1988, J VIROL, V62, P673, DOI 10.1128/JVI.62.3.673-679.1988; HAUBER J, 1989, J VIROL, V63, P1181, DOI 10.1128/JVI.63.3.1181-1187.1989; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; JEYAPAUL J, 1990, P NATL ACAD SCI USA, V87, P7030, DOI 10.1073/pnas.87.18.7030; JEYAPAUL J, 1991, ONCOGENE, V6, P1507; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; LASPIA MF, 1989, CELL, V59, P283, DOI 10.1016/0092-8674(89)90290-0; LATCHMAN DS, 1990, BIOCHEM J, V270, P281, DOI 10.1042/bj2700281; LORET EP, 1991, BIOCHEMISTRY-US, V30, P6013, DOI 10.1021/bi00238a027; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MEYERS G, 1989, HUMAN RETROVIRUS AID, P11; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAPPAPORT J, 1989, New Biologist, V1, P101; RICE AP, 1990, J VIROL, V64, P1864, DOI 10.1128/JVI.64.4.1864-1868.1990; RICE AP, 1990, J VIROL, V64, P6018, DOI 10.1128/JVI.64.12.6018-6026.1990; ROBSON B, 1986, INTRO PROTEIN PROTEI; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; ROY S, 1990, GENE DEV, V4, P1365, DOI 10.1101/gad.4.8.1365; RUBEN S, 1989, J VIROL, V63, P1; SELBY MJ, 1990, CELL, V62, P769, DOI 10.1016/0092-8674(90)90121-T; SUBRAMANIAN T, 1991, EMBO J, V10, P2311, DOI 10.1002/j.1460-2075.1991.tb07768.x; TILEY LS, 1990, VIROLOGY, V178, P560, DOI 10.1016/0042-6822(90)90354-T; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; VARMUS H, 1988, GENE DEV, V2, P1055, DOI 10.1101/gad.2.9.1055	46	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1743	1748						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1501886				2022-12-17	WOS:A1992JJ37600010
J	QURESHI, SA; RIM, M; ALEXANDROPOULOS, K; BERG, K; SUKHATME, VP; FOSTER, DA				QURESHI, SA; RIM, M; ALEXANDROPOULOS, K; BERG, K; SUKHATME, VP; FOSTER, DA			SUSTAINED INDUCTION OF EGR-1 BY V-SRC CORRELATES WITH A LACK OF FOS-MEDIATED REPRESSION OF THE EGR-1 PROMOTER	ONCOGENE			English	Article								Serum stimulation of quiescent fibroblasts leads to a transient induction of the transcription factor egr-1. However, the induction of egr-1 by v-src was found to be sustained rather than transient. The proto-oncogene fos has been reported to be co-regulated with egr-1 and to repress serum-induced egr-1 expression. We found that c-fos prevents v-src-induced gene expression regulated by the egr-1 promoter. Thus, the sustained induction of egr-1 by v-src could be explained by a lack of c-fos induction by v-src. Consistent with this hypothesis, egr-1 and c-fos were co-induced by serum, but not by v-src, in Balb/c 3T3 cells, v-src did not induce c-fos expression in these cells. We propose that sustained expression of egr-1 induced by v-src in Balb/c 3T3 cells is due to a lack of c-fos down-regulation of egr-1.	CUNY HUNTER COLL, INST BIOMOLEC STRUCT & FUNCT, 695 PARK AVE, NEW YORK, NY 10021 USA; CUNY HUNTER COLL, DEPT BIOL RES, NEW YORK, NY 10021 USA; UNIV CHICAGO, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA	City University of New York (CUNY) System; Hunter College (CUNY); City University of New York (CUNY) System; Hunter College (CUNY); Howard Hughes Medical Institute; University of Chicago; University of Chicago			Sukhatme, Vikas/W-2776-2019		NATIONAL CANCER INSTITUTE [R01CA046677, R29CA046677] Funding Source: NIH RePORTER; NCI NIH HHS [CA46677] Funding Source: Medline; NCRR NIH HHS [RRO-3037-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; Battey, 1986, BASIC METHODS MOL BI; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHRISTY B, 1989, MOL CELL BIOL, V9, P4889, DOI 10.1128/MCB.9.11.4889; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1990, ONCOGENE, V5, P929; CURRAN T, 1987, ONCOGENE, V2, P79; CURRAN T, 1988, ONCOGENE HDB, P305; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GRAY GM, 1988, J BIOL CHEM, V263, P10714; HATCH CL, 1987, ANAL BIOCHEM, V162, P283, DOI 10.1016/0003-2697(87)90038-8; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; JAHNER D, 1991, ONCOGENE, V6, P1259; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KRIEGLER M, 1984, CELL, V38, P483, DOI 10.1016/0092-8674(84)90503-8; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PATWARDHAN S, 1991, ONCOGENE, V6, P917; QURESHI SA, 1991, MOL CELL BIOL, V11, P102, DOI 10.1128/MCB.11.1.102; QURESHI SA, 1991, J BIOL CHEM, V266, P10802; QURESHI SA, 1991, ONCOGENE, V6, P995; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; RIVERA V M, 1990, New Biologist, V2, P751; RIVERA VM, 1990, GENE DEV, V4, P255, DOI 10.1101/gad.4.2.255; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEYFERT VL, 1989, MOL CELL BIOL, V9, P2083, DOI 10.1128/MCB.9.5.2083; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; VOGT PK, 1988, ONCOGENE, V3, P3; WELHAM MJ, 1990, ONCOGENE, V5, P161; WILSON T, 1988, EMBO J, V7, P4193, DOI 10.1002/j.1460-2075.1988.tb03316.x	48	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					121	125						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1741159				2022-12-17	WOS:A1992HC22700016
J	DEGROOT, RP; MEIJER, I; VANDENBRINK, S; MUMMERY, C; KRUIJER, W				DEGROOT, RP; MEIJER, I; VANDENBRINK, S; MUMMERY, C; KRUIJER, W			DIFFERENTIAL REGULATION OF JUNB AND JUND BY ADENOVIRUS TYPE-5 AND TYPE-12 E1A-PROTEINS	ONCOGENE			English	Note							EMBRYONAL CARCINOMA-CELLS; CELLULAR TRANSCRIPTION FACTOR; C-HA-RAS; PROTO-ONCOGENE; RESPONSE ELEMENT; TRANS-ACTIVATION; MESSENGER-RNAS; FACTOR FAMILY; E1A PRODUCTS; GENE FAMILY	The genes of the Jun family encode components of the TPA-inducible transcription factor AP-1. These genes are induced by a wide variety of extracellular stimuli, such as growth factors, phorbol esters and activators of protein kinase A. We have previously shown that the adenovirus type 5 E1A protein (E1A5) induces c-jun and junB expression in a number of different cell types. In this paper we show that the third member of the Jun family junD, is also strongly induced by E1A5. Multiple sequences in the junB and junD promoters are responsible for the effects of E1A5. By contrast, adenovirus type 12 E1A (E1A12), like retinoic acid (RA), strongly induces c-jun expression, while expression of junB and junD is not altered. Interestingly, E1A12 expression leads to complete differentiation of P19 EC cells, comparable to the effect of RA on these cells, while E1A5-expressing cells are only partially differentiated.	NETHERLANDS INST DEV BIOL,HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS; LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,2300 RA LEIDEN,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Leiden University; Leiden University - Excl LUMC				Mummery, Christine/0000-0002-4549-6535				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BERK AJ, 1979, CELL, V17, P935, DOI 10.1016/0092-8674(79)90333-7; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BORRELLI E, 1984, NATURE, V312, P608, DOI 10.1038/312608a0; BUCKBINDER L, 1989, EMBO J, V8, P4239, DOI 10.1002/j.1460-2075.1989.tb08609.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P1585, DOI 10.1093/nar/19.7.1585; DEGROOT RP, 1991, EMBO J, V10, P2523, DOI 10.1002/j.1460-2075.1991.tb07792.x; DEGROOT RP, 1991, NUCLEIC ACIDS RES, V19, P775, DOI 10.1093/nar/19.4.775; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; FRISCH SM, 1990, ONCOGENE, V5, P75; HARDY S, 1988, P NATL ACAD SCI USA, V85, P4171, DOI 10.1073/pnas.85.12.4171; HEN R, 1985, SCIENCE, V230, P1391, DOI 10.1126/science.2999984; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; Imler J L, 1989, Prog Growth Factor Res, V1, P69, DOI 10.1016/0955-2235(89)90001-X; JALINOT P, 1988, P NATL ACAD SCI USA, V85, P2484, DOI 10.1073/pnas.85.8.2484; JONES N, 1979, P NATL ACAD SCI USA, V79, P3655; KAO HT, 1983, MOL CELL BIOL, V3, P2058, DOI 10.1128/MCB.3.11.2058; KITABAYASHI I, 1991, NUCLEIC ACIDS RES, V19, P649, DOI 10.1093/nar/19.3.649; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P592; LEFF T, 1984, P NATL ACAD SCI-BIOL, V81, P4381, DOI 10.1073/pnas.81.14.4381; LEZA MA, 1988, J VIROL, V62, P3003, DOI 10.1128/JVI.62.8.3003-3013.1988; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MEIJER I, 1991, ONCOGENE, V6, P911; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; MULLER U, 1989, GENE DEV, V3, P1991, DOI 10.1101/gad.3.12a.1991; MUMMERY CL, 1986, EXP CELL RES, V165, P229, DOI 10.1016/0014-4827(86)90547-1; MUMMERY CL, 1985, DEV BIOL, V109, P402, DOI 10.1016/0012-1606(85)90466-X; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; REES AR, 1979, NATURE, V281, P309, DOI 10.1038/281309a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1987, P NATL ACAD SCI USA, V84, P6430, DOI 10.1073/pnas.84.18.6430; SASSONECORSI P, 1988, P NATL ACAD SCI USA, V85, P7192, DOI 10.1073/pnas.85.19.7192; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VELCICH A, 1989, ONCOGENE, V4, P707; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; YAMAGUCHIIWAI Y, 1990, P NATL ACAD SCI USA, V87, P8670, DOI 10.1073/pnas.87.21.8670; YANG-YEN H-F, 1990, New Biologist, V2, P351; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	55	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2357	2361						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1837351				2022-12-17	WOS:A1991GX73500027
J	ROUX, P; VERRIER, B; KLEIN, B; NICCOLINO, M; MARTY, L; ALEXANDRE, C; PIECHACZYK, M				ROUX, P; VERRIER, B; KLEIN, B; NICCOLINO, M; MARTY, L; ALEXANDRE, C; PIECHACZYK, M			RETROVIRUS-MEDIATED GENE-TRANSFER OF A HUMAN C-FOS CDNA INTO MOUSE BONE-MARROW STROMAL CELLS	ONCOGENE			English	Note							STEM-CELLS; PROTO-ONCOGENE; T-ANTIGEN; V-FOS; EXPRESSION; PROTEINS; TRANSCRIPTION; CONSTRUCTION; SEQUENCE; SIGNALS	A cDNA encoding a complete human c-fos protein was isolated and inserted into two different murine MoMuLV-derived recombinant retroviruses allowing expression of c-fos protein in different cell types. One c-fos-expressing retrovirus, chosen for its ability to express high levels of proteins in fibroblast-like cells, was shown to potentiate long-term cultures of mouse bone marrow stromal cells in vitro and therefore constitutes a potential tool for immortalizing such cells. Moreover, when tested in an in vitro differentiation assay, stromal cells constitutively expressing c-fos favor the granulocyte differentiation of hematopoietic precursors. Interestingly, retroviruses expressing v-src and v-abl oncogenes, included as controls in our experiments, do not produce any detectable effects, whereas those expressing polyoma virus middle T antigen facilitate long-term growth in vitro of stromal cells that favor the macrophage differentiation pathway of bone marrow stem cells. Our observation supports the idea that constitutive expression of some oncogenes, including c-fos and polyoma virus middle T antigen, may influence cytokine production by bone marrow stromal cells.	UNIV MONTPELLIER 2,CNRS,UA 1191,PL E BATAILLON,F-34095 MONTPELLIER 05,FRANCE; FAC ALEXIS CARREL,IMMUNOVIROL MOLEC LAB,CNRS,UMR 005,F-69372 LYONS 07,FRANCE; CTR VAL AURELLE PAUL LAMARQUE,BIOCHIM LAB,F-34994 MONTPELLIER 05,FRANCE; ECOLE NATL SUPER LYON,CNRS BIOMERIEUX,UMR 103,LYONS 07,FRANCE; INSERM,U191,ZOLAD,F-34000 MONTPELLIER,FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier			Roux, Pierre/D-8833-2017; PIECHACZYK, Marc/E-7896-2013; verrier, bernard/J-4094-2017	PIECHACZYK, Marc/0000-0003-1367-2597; verrier, bernard/0000-0002-8478-7095				BORELLI E, 1984, NATURE, V312, P608; BOULTER CA, 1987, NUCLEIC ACIDS RES, V15, P7194, DOI 10.1093/nar/15.17.7194; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; Curran T, 1988, ONCOGENE HDB, P307; FORT P, 1987, NUCLEIC ACIDS RES, V15, P5567; FRANZA BR, 1987, ONCOGENE, V1, P213; GORMAN CM, 1985, CELL, V42, P519, DOI 10.1016/0092-8674(85)90109-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUILD BC, 1988, J VIROL, V62, P3795, DOI 10.1128/JVI.62.10.3795-3801.1988; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAT PS, 1986, MOL CELL BIOL, V6, P1204, DOI 10.1128/MCB.6.4.1204; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; LAMB NJC, 1990, CELL, V61, P485, DOI 10.1016/0092-8674(90)90530-R; LINNEY E, 1984, NATURE, V308, P470, DOI 10.1038/308470a0; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; METCALF D, 1987, EMBO J, V6, P3703, DOI 10.1002/j.1460-2075.1987.tb02704.x; METCALF D, 1984, HEMOPOIETIC COLONIES; MOLDERS H, 1987, ONCOGENE, V1, P337; MULLER R, 1986, EMBO J, V5, P311, DOI 10.1002/j.1460-2075.1986.tb04214.x; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROUX P, 1990, CELL, V63, P341, DOI 10.1016/0092-8674(90)90167-D; RUTHER U, 1989, ONCOGENE, V4, P861; SALMON SE, 1979, CANCER RES, V39, P1133; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VELCICH A, 1985, CELL, V40, P705, DOI 10.1016/0092-8674(85)90219-3; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WARNER NL, 1969, J NATL CANCER I, V43, P963; WEISS R, 1985, RNA TUMOR VIRUSES, V2, P893; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; WILLIAMS DA, 1984, NATURE, V310, P476, DOI 10.1038/310476a0; WILLIAMS DA, 1988, MOL CELL BIOL, V8, P3664; WILLIAMS RL, 1989, CELL, V57, P1053, DOI 10.1016/0092-8674(89)90343-7	34	12	14	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1991	6	11					2155	2160						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX119	1658710				2022-12-17	WOS:A1991GX11900029
J	DUIGOU, GJ; SU, ZZ; BABISS, LE; DRISCOLL, B; FUNG, YKT; FISHER, PB				DUIGOU, GJ; SU, ZZ; BABISS, LE; DRISCOLL, B; FUNG, YKT; FISHER, PB			ANALYSIS OF VIRAL AND CELLULAR GENE-EXPRESSION DURING PROGRESSION AND SUPPRESSION OF THE TRANSFORMED PHENOTYPE IN TYPE 5 ADENOVIRUS-TRANSFORMED RAT EMBRYO CELLS	ONCOGENE			English	Article							PROTEIN-KINASE-C; ANCHORAGE-INDEPENDENT GROWTH; RETINOBLASTOMA GENE; TUMOR PROMOTERS; MOLECULAR-CLONING; NEOPLASTIC TRANSFORMATION; CHEMICAL CARCINOGENS; FIBROBLAST CELLS; THYROID-HORMONE; VIRUS GENOME	Transformation of secondary Sprague-Dawley rat embryo (RE) cells with type 5 adenovirus (Ad5) results in morphologically transformed cells which can undergo a series of sequential changes resulting in enhanced expression of the transformed phenotype, a process termed progression. Selection for a progressed phenotype often occurs after growth in agar or tumor formation in nude mice, and this process is reversible following treatment of cells with 5-azacytidine. In the present study we have analyzed a series of clonal populations of Ad5-transformed RE cells representing different stages in a defined progression lineage. Progression was not associated with alterations in the steady-state levels of mRNA produced by the viral transforming genes, E1A and E1B, or the cellular gene, c-myc. In addition, the tumor-promoting agent 12-O-tetradecanoyl-phorbol-13-acetate (TPA), which induces expression of a progressed phenotype in Ad5-transformed RE cells, did not significantly alter the RNA transcription rates of the Ad5 E1A or E1B genes, the TPA-inducible gene TPA-S1 or the TPA-responsive genes Pro1 or protein kinase C. TPA did, however, increase by 1 h the steady-state level of c-fos mRNA, but this effect was similar in both progressed and unprogressed cells. Progression also did not involve a change in the RNA transcription rate of a number of cellular and viral genes, including actin, c-Ha-ras, c-myc, v-fos, erbB, TGF-alpha, TGF-beta, Pro-2, transin, TPA-R1, v-myb and c-mos, or other adenovirus genes in addition to E1A and E1B, including E2A and E4. Immunoblotting analysis using E1B polyclonal antiserum further indicated that progression was not associated with changes in the levels of an M(r) 21 000 polypeptide encoded by E1B. Similarly, immunoprecipitation analysis with an Ad2 E1A monoclonal antibody indicated similar levels of the M(r) 55 000 and 48 000 E1A polypeptides, as well as co-precipitated proteins of M(r) 300 000, 107 000 and 105 000 [which is the retinoblastoma (Rb) protein], in E11 and E11-NMT cells. Immunoprecipitation of cell lysates with a monoclonal antibody specific for the M(r) 105 000 Rb protein further demonstrated that progression also was not associated with a change in the level or state of phosphorylation of the Rb protein. However, transfection of a human Rb gene (also containing a neomycin resistance gene) into Ad5-transformed RE cells was more inhibitory, with respect to formation of G418-resistant colonies, in unprogressed than in progressed Ad5-transformed RE cells. These findings suggest that progression of the transformed phenotype in Ad5-transformed RE cells does not involve the altered expression of virus-encoded transforming genes. Moreover, progression of these cells is not associated with an alteration of genes previously shown to be associated with enhanced expression of the transformed cell phenotype in other progression model cell culture systems. It appears that regulation of the progression phenotype in Ad5-transformed RE cells is controlled by a cellular-encoded gene(s) which remains to be identified. This gene(s) modulates the stage of progression in these cells without directly altering expression of viral genes or the Rb tumor-suppressor gene, which is associated with expression of the transformed phenotype.	COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES,DEPT PATHOL,CTR CANC,650 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES, DEPT UROL, CTR CANC, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, INST CANC RES, DEPT NEUROL SURG, CTR CANC, NEW YORK, NY 10032 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; CHILDRENS HOSP, DEPT OPHTHALMOL, LOS ANGELES, CA 90054 USA; UNIV SO CALIF, LOS ANGELES, CA 90054 USA	Columbia University; Columbia University; Columbia University; Rockefeller University; Children's Hospital Los Angeles; University of Southern California					NCI NIH HHS [CA35675, CA43208, CA44754] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA044754, R29CA044754, R01CA035675, R01CA043208] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANTEQUERA F, 1990, CELL, V62, P503, DOI 10.1016/0092-8674(90)90015-7; BABISS LE, 1983, J VIROL, V46, P454, DOI 10.1128/JVI.46.2.454-465.1983; BABISS LE, 1985, SCIENCE, V228, P1099, DOI 10.1126/science.2581317; BABISS LE, 1984, J VIROL, V49, P731, DOI 10.1128/JVI.49.3.731-740.1984; BABISS LE, 1983, P NATL ACAD SCI-BIOL, V80, P1352, DOI 10.1073/pnas.80.5.1352; BABISS LE, 1986, P NATL ACAD SCI USA, V83, P2167, DOI 10.1073/pnas.83.7.2167; BABISS LE, 1985, CANCER RES, V45, P6017; BARRETT JC, 1978, P NATL ACAD SCI USA, V75, P3297, DOI 10.1073/pnas.75.7.3297; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BOYLAN JF, 1990, ANTICANCER RES, V10, P717; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; COLBURN NH, 1979, NATURE, V281, P589, DOI 10.1038/281589a0; COLBURN NH, 1987, J CELL BIOCHEM, V34, P129, DOI 10.1002/jcb.240340207; CURRAN T, 1983, MOL CELL BIOL, V3, P914, DOI 10.1128/MCB.3.5.914; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DERYNCK R, 1985, NATURE, V316, P701, DOI 10.1038/316701a0; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; DORSCHHASLER K, 1980, J VIROL, V34, P305; DUIGOU GJ, 1990, MOL CELL BIOL, V10, P2027, DOI 10.1128/MCB.10.5.2027; DUIGOU GJ, 1989, ANN NY ACAD SCI, V567, P302, DOI 10.1111/j.1749-6632.1989.tb16487.x; DYSON N, 1989, CELL, V30, P491; FISHER PB, 1983, P NATL ACAD SCI-BIOL, V80, P196, DOI 10.1073/pnas.80.1.196; FISHER PB, 1979, CELL, V18, P695, DOI 10.1016/0092-8674(79)90124-7; FISHER PB, 1982, P NATL ACAD SCI-BIOL, V79, P3527, DOI 10.1073/pnas.79.11.3527; FISHER PB, 1978, P NATL ACAD SCI USA, V75, P2311, DOI 10.1073/pnas.75.5.2311; FISHER PB, 1979, NATURE, V281, P591, DOI 10.1038/281591a0; FISHER PB, 1979, CANCER RES, V39, P3051; Fisher PB, 1984, TUMOR PROMOTION COCA, P57; FRIEDMAN JM, 1986, MOL CELL BIOL, V6, P3791, DOI 10.1128/MCB.6.11.3791; FUNG YKT, 1991, IN PRESS SCIENCE; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; HEPPNER GH, 1984, CANCER RES, V44, P2259; HERBST RS, 1988, J VIROL, V62, P4634, DOI 10.1128/JVI.62.12.4634-4643.1988; HOFER E, 1981, CELL, V23, P585, DOI 10.1016/0092-8674(81)90154-9; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; HSIAO WLW, 1989, MOL CELL BIOL, V9, P2641, DOI 10.1128/MCB.9.6.2641; JOHNSON MD, 1987, MOL CELL BIOL, V7, P2821, DOI 10.1128/MCB.7.8.2821; JOHNSON MD, 1987, ENVIRON HEALTH PERSP, V76, P89, DOI 10.2307/3430469; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; LERMAN MI, 1986, INT J CANCER, V37, P293, DOI 10.1002/ijc.2910370219; MARSHALL CJ, 1991, CELL, V64, P313, DOI 10.1016/0092-8674(91)90641-B; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MIHARA K, 1989, SCIENCE, V246, P1300, DOI 10.1126/science.2588006; MONTELL C, 1984, CELL, V36, P951, DOI 10.1016/0092-8674(84)90045-X; NICOLSON GL, 1987, CANCER RES, V47, P1473; NOWELL PC, 1986, CANCER RES, V46, P2203; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SANCHEZLOPEZ R, 1988, J BIOL CHEM, V263, P11892; SARNOW P, 1982, CELL, V28, P387, DOI 10.1016/0092-8674(82)90356-7; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SU ZZ, 1990, MOL CARCINOGEN, V3, P309, DOI 10.1002/mc.2940030512; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; TIMMERS HTM, 1988, ONCOGENE RES, V3, P67; VANDENHEUVEL SJL, 1990, EMBO J, V9, P2621, DOI 10.1002/j.1460-2075.1990.tb07444.x; VANDEREB AJ, 1989, CURR TOP MICROBIOL, V144, P197; VARLEY JM, 1989, ONCOGENE, V4, P725; VENNSTROM B, 1980, J VIROL, V36, P575; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	69	12	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1991	6	10					1813	1824						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1923506				2022-12-17	WOS:A1991GX11800014
J	BONHAM, L; KWOK, J; CHISHOLM, O; SYMONDS, G				BONHAM, L; KWOK, J; CHISHOLM, O; SYMONDS, G			INDUCIBLE TRANSFORMATION OF FIBROBLASTS USING A METALLOTHIONEIN-V-MYC GENE CONSTRUCT	ONCOGENE			English	Note							MAMMARY-TUMOR VIRUS; LEUKEMIA-VIRUS; FUSION GENE; CELLS; INVITRO; ONCOGENE; GROWTH; IDENTIFICATION; TRANSFECTION; EXPRESSION	An inducible oncogene construct has been engineered by coupling the MC29 v-myc oncogene to the sheep metallothionein promoter. Transfection of this plasmid, which also contains the neomycin resistance gene, into Rat-1 cells, has resulted in the isolation of independent clones resistant to G418. Certain of these clones were found to exhibit inducible transformation in response to ZnSO4. Transformation was graded with increasing ZnSO4 levels and was reversible when ZnSO4 was removed from the media. By analyzing v-myc mRNA levels, the inducible alterations in cellular morphology and growth were found to be associated with increased v-myc expression. The metallothionein promoter exhibited negligible constitutive expression of v-myc and none of the clones isolated exhibited spontaneous transformation. Our results show that the use of a metallothionein promoter v-myc construct facilitates the study of inducible fibroblast transformation.			BONHAM, L (corresponding author), CHILDRENS MED RES FDN,POB 61,CAMPERDOWN,NSW 2050,AUSTRALIA.		Chisholm, Orin/L-4206-2016	Chisholm, Orin/0000-0002-9749-4160				ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; BIRCHENALLROBERTS MC, 1989, ONCOGENE, V4, P731; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; Bishop JM, 1985, RNA TUMOR VIRUSES, P249; BONHAM L, 1987, J VIROL, V61, P3072, DOI 10.1128/JVI.61.10.3072-3081.1987; BRIGHTMAN BK, 1988, J IMMUNOL, V141, P2844; BRIGHTMAN BK, 1986, J VIROL, V60, P68, DOI 10.1128/JVI.60.1.68-81.1986; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHISHOLM O, 1988, NUCLEIC ACIDS RES, V16, P2352, DOI 10.1093/nar/16.5.2352; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; EILERS M, 1989, NATURE, V340, P66, DOI 10.1038/340066a0; FREEMAN AE, 1973, P NATL ACAD SCI USA, V70, P2415, DOI 10.1073/pnas.70.8.2415; FRYKBERG L, 1987, ONCOGENE, V1, P415; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; JAKOBOVITS EB, 1984, CELL, V38, P757, DOI 10.1016/0092-8674(84)90271-X; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; OSTROWSKI MC, 1984, EMBO J, V3, P1891, DOI 10.1002/j.1460-2075.1984.tb02064.x; PALMITER RD, 1982, NATURE, V300, P611, DOI 10.1038/300611a0; PAPKOFF J, 1984, J VIROL, V52, P420, DOI 10.1128/JVI.52.2.420-430.1984; PETERSON MG, 1986, EUR J BIOCHEM, V160, P579, DOI 10.1111/j.1432-1033.1986.tb10077.x; Prehn R T, 1976, Adv Cancer Res, V23, P203, DOI 10.1016/S0065-230X(08)60547-3; REYNOLDS VL, 1987, ONCOGENE, V1, P323; STAPLETON P, 1991, ONCOGENE, V6, P807; SYMONDS G, 1989, ONCOGENE, V4, P285; TOWNES TM, 1985, MOL CELL BIOL, V5, P1977, DOI 10.1128/MCB.5.8.1977; WEINBERG RA, 1989, CANCER RES, V49, P3713; WURM FM, 1986, P NATL ACAD SCI USA, V83, P5414, DOI 10.1073/pnas.83.15.5414	27	12	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1073	1077						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	2067845				2022-12-17	WOS:A1991GU62200026
J	HARADA, S; YANAGI, K				HARADA, S; YANAGI, K			AMINO-ACID-SEQUENCE HOMOLOGY OF EPSTEIN-BARR-VIRUS NUCLEAR ANTIGEN-2 TO ADENOVIRUS E1A, HUMAN PAPILLOMA VIRUS-16 E7 AND SV40 LARGE T-ANTIGEN IN THE FUNCTIONAL DOMAINS FOR GROWTH TRANSFORMATION	ONCOGENE			English	Note							RETINOBLASTOMA GENE-PRODUCT; SEPARATE DOMAINS; PHOSPHORYLATION; ACTIVATION; PROTEINS; BINDING				HARADA, S (corresponding author), NATL INST HLTH,DEPT VIROL & RICKETTSIOL,2-10-35 KAMIOSAKI,SHINAGAWA KU,TOKYO 141,JAPAN.							BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BARBOSA MS, 1990, EMBO J, V9, P153, DOI 10.1002/j.1460-2075.1990.tb08091.x; Dayhoff M., 1978, ATLAS PROTEIN SEQ ST, V5, P345; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; GRASSER FA, 1988, VIROLOGY, V165, P13, DOI 10.1016/0042-6822(88)90653-8; GREEN MR, 1989, CELL, V56, P1, DOI 10.1016/0092-8674(89)90975-6; KIEFF E, 1990, VIROLOGY, P1889; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; LUSCHER B, 1989, EMBO J, V8, P111; MILLER G, 1990, VIROLOGY, P1921; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0	14	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1991	6	3					461	462						2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1849247				2022-12-17	WOS:A1991FT34400017
J	SENECA, S; PUNYAMMALEE, B; BAILLY, M; GHYSDAEL, J; CRABEEL, M				SENECA, S; PUNYAMMALEE, B; BAILLY, M; GHYSDAEL, J; CRABEEL, M			ETS1, WHEN FUSED TO THE GAL4 DNA-BINDING DOMAIN, EFFICIENTLY ENHANCES GALACTOSE PROMOTOR DEPENDENT GENE-EXPRESSION IN YEAST	ONCOGENE			English	Article							UPSTREAM ACTIVATING SEQUENCES; ONCOGENE C-ETS; SACCHAROMYCES-CEREVISIAE; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATOR; V-ETS; REGULATORY PROTEIN; TRANSFORMING GENE; LEUKEMIA VIRUSES; E26 RETROVIRUS	Ets1, the translation product of the c-ets1 proto-oncogene and the related Ets2 protein, act as sequence-specific transcriptional factors in transient transfection experiments in animal cells. We report here that in S. cerevisiae, expression of a lacZ test gene placed under the control of the GAL1 promoter is stimulated efficiently by a fusion protein in which the chicken Ets1 sequence starting from amino acid 37, is linked to the DNA binding domain of the yeast GAL4 transcriptional activator. This suggests that Ets1 contains one or more intrinsic transcription activation domain(s). However, the GAL4 integral Ets1 fusion protein was unable to restore growth of a gal4 deletion mutant on galactose, implying that the fusion product cannot substitute for GAL4 enhancement on all GAL genes.	VRIJE UNIV BRUSSELS, CERIA COOVI, EMILE GRYSONLAAN 1, B-1070 BRUSSELS, BELGIUM; INST PASTEUR, CNRS, UA 041160, INSERM, U186, F-59019 LILLE, FRANCE	Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			GHYSDAEL, Jacques/F-3377-2013	Seneca, Sara/0000-0002-0853-9890				BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, IN PRESS EMBO J; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRAM RJ, 1986, EMBO J, V5, P603, DOI 10.1002/j.1460-2075.1986.tb04253.x; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1988, ONCOGENE RES, V2, P371; CHEVALLIER MR, 1980, GENE, V11, P11, DOI 10.1016/0378-1119(80)90082-7; CRABEEL M, 1983, EMBO J, V2, P205, DOI 10.1002/j.1460-2075.1983.tb01406.x; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FINLEY RL, 1989, MOL CELL BIOL, V9, P4282, DOI 10.1128/MCB.9.10.4282; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GHYSDAEL J, 1986, EMBO J, V5, P2251, DOI 10.1002/j.1460-2075.1986.tb04492.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON M, 1990, Yeast, V6, pS16; JOHNSTON SA, 1982, P NATL ACAD SCI-BIOL, V79, P6971, DOI 10.1073/pnas.79.22.6971; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MYLIN LM, 1989, GENE DEV, V3, P1157, DOI 10.1101/gad.3.8.1157; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; TAJIMA M, 1986, MOL CELL BIOL, V6, P246, DOI 10.1128/MCB.6.1.246; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1	51	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1991	6	3					357	360						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1901401				2022-12-17	WOS:A1991FT34400002
J	KRAFT, AS; WAGNER, F; HOUSEY, GM				KRAFT, AS; WAGNER, F; HOUSEY, GM			OVEREXPRESSION OF PROTEIN-KINASE-C BETA-1 IS NOT SUFFICIENT TO INDUCE FACTOR INDEPENDENCE IN THE INTERLEUKIN-3-DEPENDENT MYELOID CELL-LINE FDC-P1	ONCOGENE			English	Note									PROGEN PHARMACEUT INC,DEPT BIOCHEM & MOLEC BIOPHYS,TARRYTOWN,NY		KRAFT, AS (corresponding author), UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294, USA.							BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COWAN NJ, 1981, P NATL ACAD SCI-BIOL, V78, P4877, DOI 10.1073/pnas.78.8.4877; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; FARRAR WL, 1985, NATURE, V315, P235, DOI 10.1038/315235a0; FARRAR WL, 1985, NATURE, V315, P233, DOI 10.1038/315233a0; HAPEL AJ, 1986, LYMPHOKINE RES, V5, P249; HASEGAWASASAKI H, 1988, J BIOL CHEM, V263, P12970; HOGANS BB, 1988, J CELL PHYSIOL, V137, P346, DOI 10.1002/jcp.1041370219; HOUSEY GM, 1987, P NATL ACAD SCI USA, V84, P1065, DOI 10.1073/pnas.84.4.1065; HOUSEY GM, 1988, CELL, V52, P343, DOI 10.1016/S0092-8674(88)80027-8; KRAFT AS, 1988, J BIOL CHEM, V263, P8437; KRAFT AS, 1987, ONCOGENE, V1, P111; KRAFT AS, 1986, P NATL ACAD SCI USA, V83, P1334, DOI 10.1073/pnas.83.5.1334; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; KRAFT AS, 1983, J BIOL CHEM, V258, P9178; KRAUSS RS, 1989, ONCOGENE, V4, P991; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; LOPEZRIVAS A, 1987, P NATL ACAD SCI USA, V84, P5768, DOI 10.1073/pnas.84.16.5768; MILLS GB, 1988, CELL, V55, P91, DOI 10.1016/0092-8674(88)90012-8; NAIR APK, 1989, MOL CELL BIOL, V9, P1183, DOI 10.1128/MCB.9.3.1183; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OVERELL RW, 1987, MOL CELL BIOL, V7, P3394, DOI 10.1128/MCB.7.10.3394; PERSONS DA, 1988, CELL, V52, P447, DOI 10.1016/S0092-8674(88)80037-0; RAMSDELL JS, 1986, J BIOL CHEM, V261, P7073; STABEL S, 1987, J CELL PHYSIOL, V130, P111, DOI 10.1002/jcp.1041300116; STOCKING C, 1988, CELL, V53, P869, DOI 10.1016/S0092-8674(88)90329-7; TALLANT EA, 1987, BIOCHIM BIOPHYS ACTA, V929, P40, DOI 10.1016/0167-4889(87)90239-4; TIGGES MA, 1989, SCIENCE, V243, P781, DOI 10.1126/science.2492678; VALGE VE, 1988, CELL, V55, P101, DOI 10.1016/0092-8674(88)90013-X; WATSON JD, 1987, J IMMUNOL, V139, P123; WHETTON AD, 1986, J CELL SCI, V84, P93; WHETTON AD, 1986, EMBO J, V5, P3281, DOI 10.1002/j.1460-2075.1986.tb04640.x; WHETTON AD, 1988, P NATL ACAD SCI USA, V85, P3284, DOI 10.1073/pnas.85.10.3284	34	12	15	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1243	1246						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2392326				2022-12-17	WOS:A1990DX36100018
J	HAN, JW; GAUT, J; BURSTEIN, E; SADOWSKI, H; YOUNG, D; MACARA, IG				HAN, JW; GAUT, J; BURSTEIN, E; SADOWSKI, H; YOUNG, D; MACARA, IG			THE ONCOGENIC PROTEIN P60V-SRC HAS COMPETENCE ACTIVITY BUT DOES NOT ACTIVATE PHOSPHATIDYLINOSITOL TURNOVER OR PROTEIN KINASE-C IN BALB/C 3T3 CELLS	ONCOGENE			English	Article									UNIV ROCHESTER,MED CTR,DEPT MED,ROCHESTER,NY 14642	University of Rochester	HAN, JW (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOPHYS,ENVIRONM HLTH SCI CTR,601 ELMWOOD AVE,ROCHESTER,NY 14642, USA.				NATIONAL CANCER INSTITUTE [R01CA038888, R01CA047650] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016177] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38888, CA 47650] Funding Source: Medline; NIDDK NIH HHS [DK-16177] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERT KA, 1987, P NATL ACAD SCI USA, V84, P7046, DOI 10.1073/pnas.84.20.7046; ANTONIADES HN, 1975, P NATL ACAD SCI USA, V72, P2635, DOI 10.1073/pnas.72.7.2635; BERRIDGE MJ, 1982, BIOCHEM J, V206, P587, DOI 10.1042/bj2060587; BLACKSHEAR PJ, 1986, J BIOL CHEM, V261, P1459; CHIARUGI V, 1987, ONCOGENE, V2, P37; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; ESCOBEDO JA, 1988, J BIOL CHEM, V263, P1482; FALETTO DL, 1985, CELL, V43, P315, DOI 10.1016/0092-8674(85)90037-6; FUKAMI K, 1988, P NATL ACAD SCI USA, V85, P9057, DOI 10.1073/pnas.85.23.9057; GRAY GM, 1988, J BIOL CHEM, V263, P10714; HASEGAWASASAKI H, 1985, BIOCHEM J, V232, P99, DOI 10.1042/bj2320099; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; LEVENSON RM, 1986, ANAL BIOCHEM, V158, P294, DOI 10.1016/0003-2697(86)90553-1; MACARA IG, 1985, AM J PHYSIOL, V248, pC3, DOI 10.1152/ajpcell.1985.248.1.C3; MACARA IG, 1984, P NATL ACAD SCI-BIOL, V81, P2728, DOI 10.1073/pnas.81.9.2728; MACARA IG, 1986, J BIOL CHEM, V261, P9321; MARTINS TJ, 1989, J CELL BIOL, V108, P683, DOI 10.1083/jcb.108.2.683; MATUOKA K, 1988, SCIENCE, V239, P640, DOI 10.1126/science.2829356; MAYTIN EV, 1983, J BIOL CHEM, V258, P2718; OLASHAW NE, 1986, P NATL ACAD SCI USA, V83, P3834, DOI 10.1073/pnas.83.11.3834; PLEDGER WJ, 1978, P NATL ACAD SCI USA, V75, P2839, DOI 10.1073/pnas.75.6.2839; PREISS J, 1986, J BIOL CHEM, V261, P8597; REDDY S, 1988, MOL CELL BIOL, V8, P704, DOI 10.1128/MCB.8.2.704; RODRIGUEZPENA A, 1986, EMBO J, V5, P77, DOI 10.1002/j.1460-2075.1986.tb04180.x; SAGARA J, 1986, CANCER RES, V46, P5291; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SNYDER MA, 1983, CELL, V32, P891, DOI 10.1016/0092-8674(83)90074-0; STILES CD, 1979, P NATL ACAD SCI USA, V76, P1279, DOI 10.1073/pnas.76.3.1279; SUGIMOTO Y, 1985, MOL CELL BIOL, V5, P3194, DOI 10.1128/MCB.5.11.3194; SUGIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P2117, DOI 10.1073/pnas.81.7.2117; THOM RE, 1987, FEBS LETT, V222, P104, DOI 10.1016/0014-5793(87)80200-4; WOLFMAN A, 1987, J BIOL CHEM, V262, P16546; YOUNG DA, 1983, METHOD ENZYMOL, V91, P190	36	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					467	474						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2158036				2022-12-17	WOS:A1990DB85300003
J	MCCAFFERY, RE; COGGINS, LW; DOHERTY, I; KENNEDY, I; OPREY, M; MCCOLL, L; CAMPO, MS				MCCAFFERY, RE; COGGINS, LW; DOHERTY, I; KENNEDY, I; OPREY, M; MCCOLL, L; CAMPO, MS			MULTIPLE HARVEY-RAS GENES IN THE BOVINE GENOME	ONCOGENE			English	Article									BEATSON INST CANC RES, GARSCUBE ESTATE, GLASGOW G61 1BD, SCOTLAND	Beatson Institute								ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BISHOP JM, 1985, TRENDS GENET, V1, P245, DOI 10.1016/0168-9525(85)90094-0; BROWN K, 1988, MOL CARCINOGEN, V1, P161, DOI 10.1002/mc.2940010304; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CHANG EH, 1982, P NATL ACAD SCI-BIOL, V79, P4848, DOI 10.1073/pnas.79.16.4848; CHATTOPADHYAY SK, 1982, NATURE, V296, P361, DOI 10.1038/296361a0; Coggins LW, 1987, ELECTRON MICROS, P1; COOPER GM, 1982, SCIENCE, V217, P801, DOI 10.1126/science.6285471; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HESS JF, 1984, SCIENCE, V226, P67, DOI 10.1126/science.6474190; HUNTER T, 1984, JNCI-J NATL CANCER I, V73, P773; LEUNG DW, 1984, BIO-TECHNOL, V2, P458, DOI 10.1038/nbt0584-458; Maniatis T., 1982, MOL CLONING; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; NEIL JC, 1984, NATURE, V308, P814, DOI 10.1038/308814a0; OBRIEN SJ, 1983, NATURE, V302, P839, DOI 10.1038/302839a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RIMM DL, 1980, GENE, V12, P301, DOI 10.1016/0378-1119(80)90113-4; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANTOS E, 1982, NATURE, V298, P343, DOI 10.1038/298343a0; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2	29	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1989	4	12					1441	1448						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CB659	2687766				2022-12-17	WOS:A1989CB65900004
J	BAKKUS, MHC; BRAKELVANPEER, KMJ; ADRIAANSEN, HJ; WIERENGAWOLF, AF; VANDENAKKER, TW; DICKEEVINGER, MJ; BENNER, R				BAKKUS, MHC; BRAKELVANPEER, KMJ; ADRIAANSEN, HJ; WIERENGAWOLF, AF; VANDENAKKER, TW; DICKEEVINGER, MJ; BENNER, R			DETECTION OF ONCOGENE EXPRESSION BY FLUORESCENT INSITU HYBRIDIZATION IN COMBINATION WITH IMMUNOFLUORESCENT STAINING OF CELL-SURFACE MARKERS	ONCOGENE			English	Article									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,DEPT HEMATOL,HOUSTON,TX 77030; ACAD HOSP ROTTERDAM DIJKZIGT,ROTTERDAM,NETHERLANDS	University of Texas System; UTMD Anderson Cancer Center; Erasmus University Rotterdam; Erasmus MC	BAKKUS, MHC (corresponding author), ERASMUS UNIV,DEPT IMMUNOL,POB 1738,3000 DR ROTTERDAM,NETHERLANDS.							ANGERER LM, 1981, NUCLEIC ACIDS RES, V9, P2819, DOI 10.1093/nar/9.12.2819; BAUMAN JGJ, 1988, CYTOMETRY, V9, P517, DOI 10.1002/cyto.990090602; BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x; BHATT B, 1988, NUCLEIC ACIDS RES, V16, P3951, DOI 10.1093/nar/16.9.3951; BRAHIC M, 1984, P NATL ACAD SCI USA, V81, P5455; BRESSER J, 1987, GENE ANAL TECH, V4, P89, DOI 10.1016/0735-0651(87)90002-1; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COGHLAN JP, 1985, ANAL BIOCHEM, V149, P1, DOI 10.1016/0003-2697(85)90472-5; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COX KH, 1984, DEV BIOL, V101, P485, DOI 10.1016/0012-1606(84)90162-3; DALLAFAVERA R, 1983, SCIENCE, V219, P963, DOI 10.1126/science.6401867; DIRKS RW, 1989, J HISTOCHEM CYTOCHEM, V37, P7, DOI 10.1177/37.1.2642295; EVINGERHODGES MJ, 1988, LEUKEMIA, V2, P45; FERRARI S, 1985, CANCER RES, V7, P833; GALLAGHER R, 1979, BLOOD, V54, P713; GARSON JA, 1987, NUCLEIC ACIDS RES, V15, P4761, DOI 10.1093/nar/15.12.4761; HAYASHI S, 1978, J HISTOCHEM CYTOCHEM, V26, P677, DOI 10.1177/26.8.99471; HOEFLER H, 1986, HISTOCHEM J, V18, P597, DOI 10.1007/BF01675295; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; HOPMAN AHN, 1986, HISTOCHEMISTRY, V85, P1, DOI 10.1007/BF00508646; LAWRENCE JB, 1985, NUCLEIC ACIDS RES, V13, P1777; LAWRENCE JB, 1988, CELL, V52, P51; LOZIO CB, 1975, BLOOD, V45, P321; Maniatis T., 1982, MOL CLONING; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NILSSON K, 1970, CLIN EXP IMMUNOL, V7, P477; PAIETTA E, 1987, BLOOD, V70, P1151; SHIVERS BD, 1986, J HISTOCHEM CYTOCHEM, V34, P39, DOI 10.1177/34.1.3510246; SINGER RH, 1986, BIOTECHNIQUES, V4, P230; VANDONGEN JJM, 1987, APPLICATION MONOCLON, P87; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	32	12	15	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1255	1262						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2677919				2022-12-17	WOS:A1989AU50800014
J	VEILLETTE, A; OSHAUGHNESSY, J; HORAK, ID; ISRAEL, MA; YEE, D; ROSEN, N; FUJITA, DJ; KUNG, HJ; BIEDLER, JL; BOLEN, JB				VEILLETTE, A; OSHAUGHNESSY, J; HORAK, ID; ISRAEL, MA; YEE, D; ROSEN, N; FUJITA, DJ; KUNG, HJ; BIEDLER, JL; BOLEN, JB			COORDINATE ALTERATION OF PP60C-SRC ABUNDANCE AND C-SRC RNA EXPRESSION IN HUMAN NEURO-BLASTOMA VARIANTS	ONCOGENE			English	Article									NCI,TUMOR VIRUS BIOL LAB,BLDG 41,ROOM D-824,BETHESDA,MD 20892; NCI,PEDIAT BRANCH,BETHESDA,MD 20892; NCI,MED BRANCH,BETHESDA,MD 20892; UNIV CALGARY,DEPT BIOCHEM,CALGARY T2N 4N1,ALBERTA,CANADA; CASE WESTERN RESERVE UNIV,DEPT MICROBIOL & MOLEC BIOL,CLEVELAND,OH 44106; MEM SLOAN KETTERING CANC CTR,CELLULAR & BIOCHEM GENET LAB,NEW YORK,NY 10021	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Calgary; Case Western Reserve University; Memorial Sloan Kettering Cancer Center			Rosen, Neal/ABF-2677-2020; Kung, Hsing-Jien/C-7651-2013					AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BERNAL S, 1983, CANCER RES, V43, P1256; BIEDLER JL, 1976, J NATL CANCER I, V57, P683, DOI 10.1093/jnci/57.3.683; BIEDLER JL, 1973, CANCER RES, V33, P2643; BOLEN JB, 1985, P NATL ACAD SCI USA, V82, P7275, DOI 10.1073/pnas.82.21.7275; BOLEN JB, 1987, ONCOGENE RES, V1, P149; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; ISRAEL MA, 1986, AM J PEDIAT HEMATOL, V8, P163; KAWAKAMI T, 1986, MOL CELL BIOL, V6, P4195, DOI 10.1128/MCB.6.12.4195; LEBEAU JM, 1987, MOL CELL BIOL, V7, P4115, DOI 10.1128/MCB.7.11.4115; LEVY BT, 1984, DEV BIOL, V104, P9, DOI 10.1016/0012-1606(84)90031-9; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MELLSTROM K, 1987, MOL CELL BIOL, V7, P4178, DOI 10.1128/MCB.7.12.4178; OSHAUGHNESSY J, 1987, ONCOGENE RES, V2, P1; RETTIG WJ, 1987, CANCER RES, V47, P1383; ROSEN N, 1986, J BIOL CHEM, V261, P3754; ROSS RA, 1983, J NATL CANCER I, V71, P741; ROSS RA, 1980, ADV NEUROBLASTOMA RE, P151; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SEEGER RC, 1977, CANCER RES, V37, P1364; SEMBA K, 1986, P NATL ACAD SCI USA, V81, P4940; SORGE JP, 1985, AM J PATHOL, V119, P151; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; STREBHARDT K, 1987, P NATL ACAD SCI USA, V84, P8778, DOI 10.1073/pnas.84.24.8778; TANAKA A, 1987, MOL CELL BIOL, V7, P1978, DOI 10.1128/MCB.7.5.1978; TUMILOWICZ JJ, 1970, CANCER RES, V30, P2110; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1987, ONCOGENE RES, V1, P357; WESTON JA, 1982, EMBRYONIC DEV B, P113; WIESTLER OD, 1988, MOL CELL BIOL, V8, P502, DOI 10.1128/MCB.8.1.502; YANG XM, 1988, ONCOGENE, V3, P237	38	12	12	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1989	4	4					421	427						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	U5677	2470006				2022-12-17	WOS:A1989U567700005
J	GREEN, PL; KAEHLER, DA; MCKEARN, J; RISSER, R				GREEN, PL; KAEHLER, DA; MCKEARN, J; RISSER, R			SUBSTITUTION OF THE LTR OF ABELSON MURINE LEUKEMIA-VIRUS DOES NOT ALTER THE CELL TYPE OF VIRALLY INDUCED-TUMORS	ONCOGENE			English	Article									UNIV WISCONSIN, MCARDLE LAB CANC RES, MADISON, WI 53706 USA; DUPONT CO, GLENOLDEN, PA 19036 USA	University of Wisconsin System; University of Wisconsin Madison; DuPont					NATIONAL CANCER INSTITUTE [T32CA009135, R01CA041302] Funding Source: NIH RePORTER; NCI NIH HHS [CA-41302, CA-09135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGOLD PJ, 1987, J VIROL, V61, P1193, DOI 10.1128/JVI.61.4.1193-1202.1987; BESMER P, 1983, NATURE, V303, P825, DOI 10.1038/303825a0; BOSZE Z, 1986, EMBO J, V5, P1615, DOI 10.1002/j.1460-2075.1986.tb04404.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHATIS PA, 1984, J VIROL, V52, P248, DOI 10.1128/JVI.52.1.248-254.1984; CHATIS PA, 1983, P NATL ACAD SCI-BIOL, V80, P4408, DOI 10.1073/pnas.80.14.4408; COOK WD, 1985, MOL CELL BIOL, V5, P390, DOI 10.1128/MCB.5.2.390; COOK WD, 1982, P NATL ACAD SCI-BIOL, V79, P2917, DOI 10.1073/pnas.79.9.2917; DALE B, 1981, MOL CELL BIOL, V1, P731, DOI 10.1128/MCB.1.8.731; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DESGROSEILLERS L, 1984, J VIROL, V52, P945, DOI 10.1128/JVI.52.3.945-952.1984; DESGROSEILLERS L, 1983, P NATL ACAD SCI-BIOL, V80, P4203, DOI 10.1073/pnas.80.14.4203; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREEN PL, 1987, J VIROL, V61, P2192, DOI 10.1128/JVI.61.7.2192-2197.1987; GREEN PL, 1985, J IMMUNOL, V134, P1268; GREEN PL, 1987, P NATL ACAD SCI USA, V84, P5932, DOI 10.1073/pnas.84.16.5932; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; HOLLAND CA, 1987, P NATL ACAD SCI USA, V84, P8662, DOI 10.1073/pnas.84.23.8662; HOPKINS N, 1981, P NATL ACAD SCI-BIOL, V78, P7555, DOI 10.1073/pnas.78.12.7555; HOROWITZ JM, 1987, J VIROL, V61, P701, DOI 10.1128/JVI.61.3.701-707.1987; HOROWITZ JM, 1982, J VIROL, V44, P950, DOI 10.1128/JVI.44.3.950-957.1982; ISHIMOTO A, 1985, VIROLOGY, V141, P30, DOI 10.1016/0042-6822(85)90180-1; JAHNER D, 1980, NATURE, V287, P456, DOI 10.1038/287456a0; KESSLER SW, 1975, J IMMUNOL, V115, P1617; KIPREOS ET, 1987, P NATL ACAD SCI USA, V84, P1345, DOI 10.1073/pnas.84.5.1345; KOCH W, 1983, J VIROL, V45, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENZ J, 1984, NATURE, V308, P467, DOI 10.1038/308467a0; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; MCKEARN JP, 1985, EUR J IMMUNOL, V15, P295, DOI 10.1002/eji.1830150316; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; OLIFF AI, 1980, J VIROL, V33, P475, DOI 10.1128/JVI.33.1.475-486.1980; POTTER M, 1973, SCIENCE, V182, P592, DOI 10.1126/science.182.4112.592; QUEEN C, 1983, CELL, V33, P741, DOI 10.1016/0092-8674(83)90016-8; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; RISSER R, 1985, J VIROL, V55, P547, DOI 10.1128/JVI.55.3.547-553.1985; RISSER R, 1978, J EXP MED, V148, P714, DOI 10.1084/jem.148.3.714; ROSENBERG N, 1976, J EXP MED, V143, P1453, DOI 10.1084/jem.143.6.1453; ROSENBERG NE, 1980, J VIROL, V36, P766, DOI 10.1128/JVI.36.3.766-774.1980; ROWE WP, 1970, VIROLOGY, V42, P1136, DOI 10.1016/0042-6822(70)90362-4; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SHIELDS A, 1979, CELL, V18, P955, DOI 10.1016/0092-8674(79)90208-3; SHINNICK TM, 1981, NATURE, V293, P543, DOI 10.1038/293543a0; SHORT MK, 1987, J VIROL, V61, P1067, DOI 10.1128/JVI.61.4.1067-1072.1987; SKLAR MD, 1975, NATURE, V253, P550, DOI 10.1038/253550a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPECK NA, 1987, MOL CELL BIOL, V7, P1101, DOI 10.1128/MCB.7.3.1101; STOCKING C, 1985, P NATL ACAD SCI USA, V82, P5746, DOI 10.1073/pnas.82.17.5746; WANG JYJ, 1982, J BIOL CHEM, V257, P13181; WANG JYJ, 1984, CELL, V36, P349; WEISS R, 1985, RNA TUMOR VIRUSES MO, P928; WHITLOCK CA, 1983, MOL CELL BIOL, V3, P596, DOI 10.1128/MCB.3.4.596; WHITLOCK CA, 1981, J VIROL, V40, P577, DOI 10.1128/JVI.40.2.577-584.1981; WITTE ON, 1981, J VIROL, V39, P870, DOI 10.1128/JVI.39.3.870-878.1981; WITTE ON, 1980, NATURE, V283, P826, DOI 10.1038/283826a0; YEN L, 1987, J VIROL, V61, P693, DOI 10.1128/JVI.61.3.693-700.1987	63	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1988	2	6					585	592						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	N8415	2838788				2022-12-17	WOS:A1988N841500009
J	KNOWLES, MA; EYDMANN, ME; PROCTOR, A; PADUA, RA; ROBERTS, J				KNOWLES, MA; EYDMANN, ME; PROCTOR, A; PADUA, RA; ROBERTS, J			N-METHYL-N-NITROSOUREA-INDUCED TRANSFORMATION OF RAT UROTHELIAL CELLS-INVITRO IS NOT MEDIATED BY ACTIVATION OF RAS ONCOGENES	ONCOGENE			English	Article											KNOWLES, MA (corresponding author), MARIE CURIE RES INST,OXTED RH8 0TL,SURREY,ENGLAND.		Padua, Rose Ann/GVT-5961-2022; PADUA, Rose Ann/E-8621-2019	PADUA, Rose Ann/0000-0001-9964-7864; Knowles, Margaret/0000-0002-9363-8657				BALMAIN A, 1983, NATURE, V303, P72, DOI 10.1038/303072a0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BARBACID M, 1986, CARCINOGENESIS, V7, P1037, DOI 10.1093/carcin/7.7.1037; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BOS JL, 1986, NUCLEIC ACIDS RES, V14, P1209, DOI 10.1093/nar/14.3.1209; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; COOK PJ, 1969, INT J CANCER, V4, P93, DOI 10.1002/ijc.2910040113; COOPER CS, 1986, EMBO J, V5, P2623, DOI 10.1002/j.1460-2075.1986.tb04543.x; ELLIS RW, 1980, J VIROL, V36, P408, DOI 10.1128/JVI.36.2.408-420.1980; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; EVA A, 1983, SCIENCE, V220, P955, DOI 10.1126/science.6302839; FUJITA J, 1984, NATURE, V309, P464, DOI 10.1038/309464a0; GARTE SJ, 1985, CARCINOGENESIS, V6, P1709, DOI 10.1093/carcin/6.12.1709; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GUERRERO I, 1984, SCIENCE, V225, P1159, DOI 10.1126/science.6474169; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HARPER JR, 1986, MOL CELL BIOL, V6, P3144, DOI 10.1128/MCB.6.9.3144; KNOWLES MA, 1986, CARCINOGENESIS, V7, P2059, DOI 10.1093/carcin/7.12.2059; KNOWLES MA, 1986, IN VITRO MODELS CANC, P127; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; PARADA LF, 1982, NATURE, V297, P474, DOI 10.1038/297474a0; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; SEGAL A, 1982, CHEM-BIOL INTERACT, V40, P209, DOI 10.1016/0009-2797(82)90102-8; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; SUMMERHAYES IC, 1986, INT J CANCER, V37, P233, DOI 10.1002/ijc.2910370211; TAHIRA T, 1986, MOL CELL BIOL, V6, P1349, DOI 10.1128/MCB.6.4.1349; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; WHITNEY FR, 1984, J BIOL CHEM, V259, P10481; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	30	12	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1987	1	2					143	148						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	3325878				2022-12-17	WOS:A1987J635200006
J	Koorman, T; Jansen, KA; Khalil, A; Haughton, PD; Visser, D; Ratze, MAK; Haakma, WE; Sakalauskaite, G; van Diest, PJ; de Rooij, J; Derksen, PWB				Koorman, Thijs; Jansen, Karin A.; Khalil, Antoine; Haughton, Peter D.; Visser, Daan; Ratze, Max A. K.; Haakma, Wisse E.; Sakalauskaite, Gabriele; van Diest, Paul J.; de Rooij, Johan; Derksen, Patrick W. B.			Spatial collagen stiffening promotes collective breast cancer cell invasion by reinforcing extracellular matrix alignment	ONCOGENE			English	Article							LYSYL OXIDASE; MOLECULAR ROLE; 2 LOXL2; METASTASIS; STIFFNESS; LOCALIZATION; TRANSMISSION; PROTEOLYSIS; REPRESSION; MIGRATION	The tumor micro-environment often contains stiff and irregular-bundled collagen fibers that are used by tumor cells to disseminate. It is still unclear how and to what extent, extracellular matrix (ECM) stiffness versus ECM bundle size and alignment dictate cancer cell invasion. Here, we have uncoupled Collagen-I bundling from stiffness by introducing inter-collagen crosslinks, combined with temperature induced aggregation of collagen bundling. Using organotypic models from mouse invasive ductal and invasive lobular breast cancers, we show that increased collagen bundling in 3D induces a generic increase in breast cancer invasion that is independent of migration mode. However, systemic collagen stiffening using advanced glycation end product (AGE) crosslinking prevents collective invasion, while leaving single cell invasion unaffected. Collective invasion into collagen matrices by ductal breast cancer cells depends on Lysyl oxidase-like 3 (Loxl3), a factor produced by tumor cells that reinforces local collagen stiffness. Finally, we present clinical evidence that collectively invading cancer cells at the invasive front of ductal breast carcinoma upregulate LOXL3. By uncoupling the mechanical, chemical, and structural cues that control invasion of breast cancer in three dimensions, our data reveal that spatial control over stiffness and bundling underlie collective dissemination of ductal-type breast cancers.	[Koorman, Thijs; Jansen, Karin A.; Haughton, Peter D.; Visser, Daan; Ratze, Max A. K.; Haakma, Wisse E.; Sakalauskaite, Gabriele; van Diest, Paul J.; Derksen, Patrick W. B.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Khalil, Antoine; de Rooij, Johan] Univ Med Ctr Utrecht, Ctr Mol Med, Mol Canc Res, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Derksen, PWB (corresponding author), Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands.; de Rooij, J (corresponding author), Univ Med Ctr Utrecht, Ctr Mol Med, Mol Canc Res, Utrecht, Netherlands.	J.deRooij-3@umcutrecht.nl; p.w.b.derksen@umcutrecht.nl	; Derksen, Patrick/C-6643-2008	Haakma, Wisse/0000-0002-1362-4790; de rooij, johan/0000-0001-6101-7875; Khalil, Antoine A./0000-0003-3469-0778; Derksen, Patrick/0000-0003-0732-7762; Koorman, Thijs/0000-0002-6064-3353	Netherlands Organization for Scientific Research [NWO-TOP 02007]; Dutch Cancer Society [KWF-2017-10456]; European Union [731957]; COST (European Cooperation in Science and Technology) [CA19138]	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Dutch Cancer Society(KWF Kankerbestrijding); European Union(European Commission); COST (European Cooperation in Science and Technology)(European Cooperation in Science and Technology (COST))	The authors thank Tina Vermonden and Mies van Steenbergen for help with and use of the rheometer, and Holger Rehmann and Richard van Schaik for purifying the GFP-CNA35 probe. We are indebted to Federica Burla for sharing the pore size determining program in Python, and Nico Jansen for help with rewriting the collagen alignment program to an ImageJ plugin. Lilian Sluimer and Jeroen Vermeulen are thanked for their help on quality control and statistics of the clinical datasets, and the Tissue Facility (Pathology Department UMCU) for immunohistochemistry on tissue sections. We are also grateful to Nalan Liv and Tineke Veenendaal for electron microscopy. We thank Jacco van Rheenen for the parental PyMT organoids and Martijn Gloerich for comments and conceptual input. This work was financially supported by grants from The Netherlands Organization for Scientific Research (NWO-TOP 02007), Dutch Cancer Society grants (KWF-2017-10456), and the European Union's Horizon 2020 FET Proactive program under the grant agreement No. 731957 (MECHANO-CONTROL). This article is also based upon work from COST Action (CA19138), supported by COST (European Cooperation in Science and Technology).	Acerbi I, 2015, INTEGR BIOL-UK, V7, P1120, DOI 10.1039/c5ib00040h; Ahmad S, 2018, SEMIN CANCER BIOL, V49, P44, DOI 10.1016/j.semcancer.2017.07.001; Ahmadzadeh H, 2017, P NATL ACAD SCI USA, V114, pE1617, DOI 10.1073/pnas.1617037114; Baker AM, 2013, ONCOGENE, V32, P1863, DOI 10.1038/onc.2012.202; Balcioglu HE, 2016, SCI REP-UK, V6, DOI 10.1038/srep22580; Blank MAB, 2017, ULTRASOUND MED BIOL, V43, P387, DOI 10.1016/j.ultrasmedbio.2016.09.002; Canesin G, 2015, ONCOGENE, V34, P951, DOI 10.1038/onc.2014.23; Cheung KJ, 2013, CELL, V155, P1639, DOI 10.1016/j.cell.2013.11.029; Chiue H, 2015, BIOCHEM BIOPH RES CO, V461, P445, DOI 10.1016/j.bbrc.2015.04.011; Christgen M, 2016, PATHOL RES PRACT, V212, P583, DOI 10.1016/j.prp.2016.05.002; Condeelis J, 2003, NAT REV CANCER, V3, P921, DOI 10.1038/nrc1231; Conklin MW, 2011, AM J PATHOL, V178, P1221, DOI 10.1016/j.ajpath.2010.11.076; Cuevas EP, 2014, BIOL OPEN, V3, P129, DOI 10.1242/bio.20146841; Derksen PWB, 2011, DIS MODEL MECH, V4, P347, DOI 10.1242/dmm.006395; Drifka CR, 2016, ONCOTARGET, V7, P76197, DOI 10.18632/oncotarget.12772; Dupont S, 2016, EXP CELL RES, V343, P42, DOI 10.1016/j.yexcr.2015.10.034; Ewald AJ, 2012, J CELL SCI, V125, P2638, DOI 10.1242/jcs.096875; Fan HJ, 2020, GENE DEV, V34, P1359, DOI 10.1101/gad.339796.120; Feldker N, 2020, EMBO J, V39, DOI 10.15252/embj.2019103209; Fiorino S, 2018, FUTURE ONCOL, V14, P1601, DOI 10.2217/fon-2017-0510; Hynes RO., 2012, COLD SPRING HARB PER, V4, pA004903, DOI [10.1101/cshperspect.a004903, DOI 10.1101/CSHPERSPECT.A004903]; Jansen KA, 2018, BIOPHYS J, V114, P2665, DOI 10.1016/j.bpj.2018.04.043; Kai F, 2019, DEV CELL, V49, P332, DOI 10.1016/j.devcel.2019.03.026; Keating M, 2017, ACTA BIOMATER, V57, P304, DOI 10.1016/j.actbio.2017.05.008; Kirschmann DA, 2002, CANCER RES, V62, P4478; Kraft-Sheleg O, 2016, DEV CELL, V36, P550, DOI 10.1016/j.devcel.2016.02.009; Krajina BA, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe1969; Kushner MH, 2020, EMBO REP, V21, DOI 10.15252/embr.201948741; Laurentino TD, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20143587; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Lopez JI, 2011, INTEGR BIOL-UK, V3, P910, DOI 10.1039/c1ib00043h; Ma XY, 2013, BIOPHYS J, V104, P1410, DOI 10.1016/j.bpj.2013.02.017; Millanes-Romero A, 2013, MOL CELL, V52, P746, DOI 10.1016/j.molcel.2013.10.015; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586-019-1526-3; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pickup MW, 2014, EMBO REP, V15, P1243, DOI 10.15252/embr.201439246; Salvador F, 2017, CANCER RES, V77, P5846, DOI 10.1158/0008-5472.CAN-16-3152; Schackmann RCJ, 2011, J CLIN INVEST, V121, P3176, DOI 10.1172/JCI41695; Sflomos G, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202013180; Sharma A, 2016, PHYS REV E, V94, DOI 10.1103/PhysRevE.94.042407; Staneva R, 2018, MOL BIOL CELL, V29, P2979, DOI 10.1091/mbc.E18-01-0068; Tasdemir N, 2018, CANCER RES, V78, P6209, DOI 10.1158/0008-5472.CAN-18-1416; Vallet SD, 2019, ESSAYS BIOCHEM, V63, P349, DOI 10.1042/EBC20180050; van de Ven RAH, 2015, DIS MODEL MECH, V8, P373, DOI 10.1242/dmm.018648; Vlug E, 2014, ARCH IMMUNOL THER EX, V62, P7, DOI 10.1007/s00005-013-0251-0; Vlug EJ, 2013, CELL ONCOL, V36, P375, DOI 10.1007/s13402-013-0143-7; Wada KI, 2011, DEVELOPMENT, V138, P3907, DOI 10.1242/dev.070987; Wang HL, 2014, BIOPHYS J, V107, P2592, DOI 10.1016/j.bpj.2014.09.044; Weiler SME, 2020, CANCER LETT, V473, P164, DOI 10.1016/j.canlet.2019.12.044; Wolf K, 2013, J CELL BIOL, V201, P1069, DOI 10.1083/jcb.201210152; Wrenn ED, 2020, CELL, V183, P395, DOI 10.1016/j.cell.2020.08.045; Yang YL, 2009, BIOPHYS J, V97, P2051, DOI 10.1016/j.bpj.2009.07.035; Zemke NR, 2019, GENE DEV, V33, P828, DOI 10.1101/gad.324814.119	56	11	11	13	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2022	41	17					2458	2469		10.1038/s41388-022-02258-1	http://dx.doi.org/10.1038/s41388-022-02258-1		MAR 2022	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0R6YF	35292774	Green Published, hybrid			2022-12-17	WOS:000769296900001
J	Chen, BB; Jiang, W; Huang, Y; Zhang, J; Yu, P; Wu, LR; Peng, H				Chen, Binbin; Jiang, Wei; Huang, Ying; Zhang, Jian; Yu, Peng; Wu, Lirong; Peng, Hao			N-7-methylguanosine tRNA modification promotes tumorigenesis and chemoresistance through WNT/beta-catenin pathway in nasopharyngeal carcinoma	ONCOGENE			English	Article							TO-MESENCHYMAL TRANSITION; STAGING SYSTEM; CANCER; TRANSLATION; METHYLATION; METASTASIS; EXPRESSION; WNT; WDR4	Treatment selections are very limited for patients with advanced nasopharyngeal carcinoma (NPC) experiencing disease progression. Uncovering mechanisms underlying NPC progression is crucial for the development of novel treatments. Here we show that N-7-methylguanosine (m(7)G) tRNA modification enzyme METTL1 and its partner WDR4 are significantly elevated in NPC and are associated with poor prognosis. Loss-of-function and gain-of-function assays demonstrated that METTL1/WDR4 promotes NPC growth and metastasis in vitro and in vivo. Mechanistically, ARNT was identified as an upstream transcription factor regulating METTL1 expression in NPC. METTL1 depletion resulted in decreased m(7)G tRNA modification and expression, which led to impaired codon recognition during mRNA translation, therefore reducing the translation efficiencies of mRNAs with higher m(7)G codons. METTL1 upregulated the WNT/beta-catenin signaling pathway and promoted NPC cell epithelial-mesenchymal transition (EMT) and chemoresistance to cisplatin and docetaxel in vitro and in vivo. Overexpression of WNT3A bypassed the requirement of METTL1 for EMT and chemoresistance. This work uncovers novel insights into tRNA modification-mediated mRNA translation regulation and highlights the critical function of tRNA modification in cancer progression.	[Chen, Binbin; Peng, Hao] Sun Yat Sen Univ, Affiliated Hosp 1, Precis Med Inst, Ctr Translat Med, Guangzhou 510080, Guangdong, Peoples R China; [Chen, Binbin] Sun Yat Sen Univ, Dept Clin Nutr, Canc Ctr, State Key Lab Oncol South China,Collaborat Innova, Guangzhou 510060, Peoples R China; [Jiang, Wei] Guilin Med Univ, Affiliated Hosp, Dept Radiat Oncol, Guilin 541001, Peoples R China; [Huang, Ying] Sun Yat Sen Univ, Dept Radiat Oncol, Canc Ctr, State Key Lab Oncol South China,Collaborat Innova, Guangzhou 510060, Peoples R China; [Zhang, Jian; Yu, Peng] Guangzhou Inst Resp Dis, Dept Radiat Oncol, Affiliated Canc Hosp, Guangzhou 510095, Peoples R China; [Zhang, Jian; Yu, Peng] Inst Guangzhou Med Univ, State Key Lab Resp Dis, Guangzhou Inst Resp Dis, Guangzhou 510095, Peoples R China; [Wu, Lirong] Nanjing Med Univ, Dept Radiat Oncol, Jiangsu Canc Hosp, Nanjing 210009, Peoples R China; [Wu, Lirong] Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing 210009, Peoples R China; [Wu, Lirong] Nanjing Med Univ, Affiliated Canc Hosp, Nanjing 210009, Peoples R China	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Guilin Medical University; State Key Lab Oncology South China; Sun Yat Sen University; State Key Laboratory of Respiratory Disease; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University	Peng, H (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 1, Precis Med Inst, Ctr Translat Med, Guangzhou 510080, Guangdong, Peoples R China.; Wu, LR (corresponding author), Nanjing Med Univ, Dept Radiat Oncol, Jiangsu Canc Hosp, Nanjing 210009, Peoples R China.; Wu, LR (corresponding author), Nanjing Med Univ, Jiangsu Inst Canc Res, Nanjing 210009, Peoples R China.; Wu, LR (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Nanjing 210009, Peoples R China.	wulirong126@126.com; pengh67@mail.sysu.edu.cn			National Natural Science Foundation of China [82002981, 82003232, 82003212]; China Postdoctoral Science Foundation [2020M673003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We sincerely thank professor Jun Ma (Department of Radiation Oncology, Sun Yat-sen University Cancer Center) for kindly donate the NPC cell lines and nasopharyngeal normal cell lines. We sincerely thank Drs. Weidong Ji and Shuibin Lin for kindly sharing us with the plasmids for METTL1 overexpression and depletion. We thank all the patients who generously donate the tissues. The work was funded by National Natural Science Foundation of China (82002981, 82003232 and 82003212) and China Postdoctoral Science Foundation (2020M673003).	Alexandrov A, 2002, RNA, V8, P1253, DOI 10.1017/S1355838202024019; Bernaudo S, 2016, ONCOGENE, V35, P4828, DOI 10.1038/onc.2016.65; Blanco S, 2014, EMBO J, V33, P2020, DOI 10.15252/embj.201489282; Boccaletto P, 2018, NUCLEIC ACIDS RES, V46, pD202, DOI 10.1093/nar/gkx966; Boccaletto P, 2018, NUCLEIC ACIDS RES, V46, pD303, DOI 10.1093/nar/gkx1030; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chang GQ, 2020, CANCER CELL, V38, P857, DOI 10.1016/j.ccell.2020.10.004; Chen G, 2020, MOL CARCINOGEN, V59, P897, DOI 10.1002/mc.23201; Chen X, 2018, EUR J MED GENET, V61, P468, DOI 10.1016/j.ejmg.2018.03.007; Chen XY, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1033-z; Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0; Chou HJ, 2017, MOL CELL, V68, P978, DOI 10.1016/j.molcel.2017.11.002; Dai ZH, 2021, MOL CELL, V81, P3339, DOI 10.1016/j.molcel.2021.07.003; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Frye M, 2018, SCIENCE, V361, P1346, DOI 10.1126/science.aau1646; Torres AG, 2014, TRENDS MOL MED, V20, P306, DOI 10.1016/j.molmed.2014.01.008; Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189; Guy MP, 2015, HUM MUTAT, V36, P1176, DOI 10.1002/humu.22897; Han X, 2021, SEMIN CANCER BIOL, V75, P97, DOI 10.1016/j.semcancer.2020.11.007; Hong XH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01149-x; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huo FC, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12921; Kim SW, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp1235; Kirchner S, 2015, NAT REV GENET, V16, P98, DOI 10.1038/nrg3861; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Leick KM, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1665978; Lin S., 2009, NAT PROTOC, V4, P44; Lin SB, 2018, MOL CELL, V71, P244, DOI 10.1016/j.molcel.2018.06.001; Lin SB, 2016, MOL CELL, V62, P335, DOI 10.1016/j.molcel.2016.03.021; Liu FG, 2016, CELL, V167, P816, DOI 10.1016/j.cell.2016.09.038; Liu J, 2019, TRENDS CELL BIOL, V29, P487, DOI 10.1016/j.tcb.2019.02.008; Liu L, 2020, MOL THER, V28, P2177, DOI 10.1016/j.ymthe.2020.06.024; Liu Y, 2020, LIFE SCI, V249, DOI 10.1016/j.lfs.2020.117480; Ma JY, 2021, MOL THER, V29, P3422, DOI 10.1016/j.ymthe.2021.08.005; Mao YP, 2008, CLIN CANCER RES, V14, P7497, DOI 10.1158/1078-0432.CCR-08-0271; Mao YP, 2009, INT J RADIAT ONCOL, V73, P1326, DOI 10.1016/j.ijrobp.2008.07.062; Michaud J, 2000, GENOMICS, V68, P71, DOI 10.1006/geno.2000.6258; Najmabadi H, 2011, NATURE, V478, P57, DOI 10.1038/nature10423; Nelson WJ, 2004, SCIENCE, V303, P1483, DOI 10.1126/science.1094291; Okamoto M, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004639; Orellana EA, 2021, MOL CELL, V81, P3323, DOI 10.1016/j.molcel.2021.06.031; Pan JJ, 2016, CANCER-AM CANCER SOC, V122, P546, DOI 10.1002/cncr.29795; Pan T, 2018, CELL RES, V28, P395, DOI 10.1038/s41422-018-0013-y; Peng H, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0997-7; Persson CU, 2020, EXP CELL RES, V388, DOI 10.1016/j.yexcr.2020.111845; Pinello N, 2018, CANCER BIOL MED, V15, P323, DOI 10.20892/j.issn.2095-3941.2018.0365; Polakis P, 2000, GENE DEV, V14, P1837; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ren XY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14053; Schimmel P, 2018, NAT REV MOL CELL BIO, V19, P45, DOI 10.1038/nrm.2017.77; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Shaheen R, 2016, HUM GENET, V135, P707, DOI 10.1007/s00439-016-1665-7; Shaheen R, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0779-x; Shen CQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01190-w; Song P, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01244-z; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Terashima J, 2016, CELL BIOL INT, V40, P1187, DOI 10.1002/cbin.10656; Tian QH, 2019, J MOL MED, V97, P1535, DOI 10.1007/s00109-019-01830-9; Trimouille A, 2018, CLIN GENET, V93, P374, DOI 10.1111/cge.13074; Wu LR, 2017, ORAL ONCOL, V69, P26, DOI 10.1016/j.oraloncology.2017.03.015; Zhang J, 2020, AGING-US, V12, P5423, DOI 10.18632/aging.102968; Zhang PP, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1224-3; Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064	64	11	11	5	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 8	2022	41	15					2239	2253		10.1038/s41388-022-02250-9	http://dx.doi.org/10.1038/s41388-022-02250-9		FEB 2022	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	0J8DX	35217794				2022-12-17	WOS:000761868000003
J	Xia, Q; Jia, J; Hu, CP; Lu, JY; Li, JJ; Xu, HY; Fang, JC; Feng, DJ; Wang, LW; Chen, Y				Xia, Qing; Jia, Jing; Hu, Chupeng; Lu, Jinying; Li, Jiajin; Xu, Haiyan; Fang, Jianchen; Feng, Dongju; Wang, Liwei; Chen, Yun			Tumor-associated macrophages promote PD-L1 expression in tumor cells by regulating PKM2 nuclear translocation in pancreatic ductal adenocarcinoma	ONCOGENE			English	Article							PYRUVATE-KINASE M2; CANCER-IMMUNOTHERAPY; CARCINOMA CELLS; PATHWAY; METABOLISM	In many types of cancer, tumor cells prefer to use glycolysis as a major energy acquisition method. Here, we found that the (18)fluoro-deoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT)-based markers were positively associated with the expression of programmed cell death ligand 1 (PD-L1), pyruvate kinase M2 (PKM2), both of which indicate poor prognosis in patients with pancreatic ductal adenocarcinoma (PDAC). However, the regulatory mechanism of PD-L1 remains elusive. In this study, we confirmed that transforming growth factor-beta1 (TGF-beta 1) secreted by tumor-associated macrophages (TAMs) was a key factor contributing to the expression of PD-L1 in PDAC cells by inducing the nuclear translocation of PKM2. Using co-immunoprecipitation and chromatin immunoprecipitation assays, we demonstrated that the interaction between PKM2 and signal transducer and activator of transcription 1 (STAT1) was enhanced by TGF-beta 1 stimulation, which facilitated the transactivation of PD-L1 by the binding of PKM2 and STAT1 to its promoter. In vivo, PKM2 knockdown decreased PD-L1 expression in PDAC cells and inhibited tumor growth partly by promoting natural killer cell activation and function, and the combination of PD-1/PD-L1 blockade with PKM2 knockdown limited tumor growth. In conclusion, PKM2 significantly contributes to TAM-induced PD-L1 overexpression and immunosuppression, providing a novel target for immunotherapies for PDAC.	[Xia, Qing] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Oncol, Shanghai 200127, Peoples R China; [Jia, Jing] Nanjing Med Univ, Med Ctr Digest Dis, Affiliated Hosp 2, Nanjing 210011, Jiangsu, Peoples R China; [Hu, Chupeng; Lu, Jinying; Chen, Yun] Nanjing Med Univ, Jiangsu Canc Hosp, Res Ctr Clin Oncol, Jiangsu Inst Canc Res,Affiliated Canc Hosp, Nanjing 210018, Jiangsu, Peoples R China; [Hu, Chupeng; Lu, Jinying; Feng, Dongju; Chen, Yun] Nanjing Med Univ, Dept Immunol, Key Lab Human Funct Genom Jiangsu Prov, Nanjing 211166, Jiangsu, Peoples R China; [Hu, Chupeng; Lu, Jinying; Chen, Yun] Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China; [Li, Jiajin] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Nucl Med, Shanghai 200127, Peoples R China; [Xu, Haiyan; Wang, Liwei] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogenes & Rela, Shanghai 200127, Peoples R China; [Fang, Jianchen] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Pathol, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Chen, Y (corresponding author), Nanjing Med Univ, Jiangsu Canc Hosp, Res Ctr Clin Oncol, Jiangsu Inst Canc Res,Affiliated Canc Hosp, Nanjing 210018, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Dept Immunol, Key Lab Human Funct Genom Jiangsu Prov, Nanjing 211166, Jiangsu, Peoples R China.; Chen, Y (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Personalized Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing 211166, Jiangsu, Peoples R China.; Wang, LW (corresponding author), Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Shanghai Canc Inst,State Key Lab Oncogenes & Rela, Shanghai 200127, Peoples R China.	liweiwang@shsmu.edu.cn; chenyun@njmu.edu.cn		chen, yun/0000-0002-4118-362X; Li, Jiajin/0000-0003-1300-6025	National Natural Science Foundation of China [82071767, 81772602, 91742105, 91942309, 82073195, 8210102291, 81874048]; Jiangsu Provincial key research development program of China [BE2018750]; Key Laboratory of Emergency and Trauma, Ministry of Education [KLET-201913]; Innovation Group Project of Shanghai Municipal Health Commission [2019CXJQ03]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Jiangsu Provincial key research development program of China; Key Laboratory of Emergency and Trauma, Ministry of Education; Innovation Group Project of Shanghai Municipal Health Commission	This work was supported by project grants from The National Natural Science Foundation of China (82071767, 81772602, 91742105, and 91942309 to Y.C.; 82073195 to Q.X.; 8210102291 to C.P.H., and 81874048 to L.W.W.), Jiangsu Provincial key research development program of China (BE2018750 to Y.C.), Key Laboratory of Emergency and Trauma, Ministry of Education (KLET-201913 to Y.C.), and Innovation Group Project of Shanghai Municipal Health Commission (2019CXJQ03 to L.W.W.).	Adamska A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071338; Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561; Balachandran VP, 2019, GASTROENTEROLOGY, V156, P2056, DOI 10.1053/j.gastro.2018.12.038; Brooks J, 2018, CANCER RES, V78, P475, DOI 10.1158/0008-5472.CAN-17-2415; Chang CH, 2015, CELL, V162, P1229, DOI 10.1016/j.cell.2015.08.016; Chen BF, 2020, BIOMATERIALS, V255, DOI 10.1016/j.biomaterials.2020.120187; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Cortese N, 2020, CANCER IMMUNOL RES, V8, P493, DOI 10.1158/2326-6066.CIR-19-0403; David JM, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1349589; Deng WJ, 2018, CELL REP, V24, P366, DOI 10.1016/j.celrep.2018.06.026; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Feng MY, 2017, CANCER LETT, V407, P57, DOI 10.1016/j.canlet.2017.08.006; Gao XL, 2013, J BIOL CHEM, V288, P15971, DOI 10.1074/jbc.M112.448753; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Garrido F, 2001, ADV CANCER RES, V83, P117, DOI 10.1016/S0065-230X(01)83005-0; Giehl K, 2000, ONCOGENE, V19, P4531, DOI 10.1038/sj.onc.1203806; Gong J, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0316-z; Hsu J, 2018, J CLIN INVEST, V128, P4654, DOI 10.1172/JCI99317; Hussain SM, 2021, CELL ONCOL, V44, P673, DOI 10.1007/s13402-021-00594-0; Ijichi H, 2004, ONCOGENE, V23, P1043, DOI 10.1038/sj.onc.1207222; Jiang XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0928-4; Joergensen MT, 2010, PANCREAS, V39, P243, DOI 10.1097/MPA.0b013e3181bae8ab; Kumar Y, 2007, PANCREAS, V35, P114, DOI 10.1097/mpa.0b013e3180537237; Li TE, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.589997; Long L, 2020, J CANCER, V11, P4442, DOI 10.7150/jca.42610; Mohammad GH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151635; Murray PJ, 2007, J IMMUNOL, V178, P2623, DOI 10.4049/jimmunol.178.5.2623; Nomi T, 2007, CLIN CANCER RES, V13, P2151, DOI 10.1158/1078-0432.CCR-06-2746; Ohaegbulam KC, 2015, TRENDS MOL MED, V21, P24, DOI 10.1016/j.molmed.2014.10.009; Palsson-McDermott EM, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01300; Pan Y, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1581529; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Roemer MGM, 2016, CANCER IMMUNOL RES, V4, P910, DOI 10.1158/2326-6066.CIR-16-0201; Ruscetti M, 2020, CELL, V181, P424, DOI 10.1016/j.cell.2020.03.008; Shifrin N, 2014, SEMIN IMMUNOL, V26, P138, DOI 10.1016/j.smim.2014.02.007; Smahel M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061331; Subramanian G, 2004, CANCER RES, V64, P5200, DOI 10.1158/0008-5472.CAN-04-0018; Van Audenaerde JRM, 2018, PHARMACOL THERAPEUT, V189, P31, DOI 10.1016/j.pharmthera.2018.04.003; Wartenberg M, 2018, CLIN CANCER RES, V24, P4444, DOI 10.1158/1078-0432.CCR-17-3401; Wong N, 2015, CANCER LETT, V356, P184, DOI 10.1016/j.canlet.2014.01.031; Yan L, 2019, CANCERS, V11, DOI 10.3390/cancers11101460; Yang S, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.607209; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Zhang C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01295; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-01968-5, 10.1038/s41467-017-00321-0]; Zhang Z, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0317-8	47	11	12	1	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 4	2022	41	6					865	877		10.1038/s41388-021-02133-5	http://dx.doi.org/10.1038/s41388-021-02133-5		DEC 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YT5VS	34862460	Green Published, hybrid			2022-12-17	WOS:000725939000001
J	Yu, CN; Luo, D; Yu, J; Zhang, M; Zheng, XB; Xu, GC; Wang, JX; Wang, HL; Xu, YF; Jiang, K; Xu, J; Ma, XL; Jing, J; Shi, HB				Yu, Chune; Luo, Dan; Yu, Jing; Zhang, Min; Zheng, Xiaobo; Xu, Guangchao; Wang, Jiaxin; Wang, Huiling; Xu, Yufei; Jiang, Ke; Xu, Jie; Ma, Xuelei; Jing, Jing; Shi, Hubing			Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer	ONCOGENE			English	Article							LUNG; BRAF; ACTIVATION; TRAMETINIB; MUTATIONS	Targeting the KRAS pathway is a promising but challenging approach for colorectal cancer therapy. Despite showing potent efficacy in BRAF-mutated melanoma, MEK inhibitors appeared to be tolerated by colorectal cancer cells due to their intrinsic compensatory signaling. Here, we performed genome-wide CRISPR/Cas9 screening in the presence of MEK inhibitor to identify genes that are synthetically lethal with MEK inhibition in CRC models harboring KRAS mutations. Several genes were identified as potential functional drivers, which were significantly enriched in the GRB7-mediated RTK pathway. Loss-of-function and gain-of-function assays validated that GRB7 potently rendered CRC cells primary resistance to MEK inhibitors through the RTK pathway. Mass spectrum analysis of GRB7 immunoprecipitates revealed that PLK1 was the predominant interacting kinase of GRB7. Inhibition of PLK1 suppressed downstream signaling of RTK, including FAK, STAT3, AKT, and 4EBP1. The combination of PLK1 and MEK inhibitors synergistically inhibited CRC cell proliferation and induced apoptosis in vitro and in vivo. In conclusion, we identified GRB7-PLK1 as a pivotal axis mediating RTKs, resulting in MEK inhibitor tolerance. PLK1 is therefore a promising target for synergizing MEK inhibitors in the clinical treatment of CRC patients harboring KRAS mutations.	[Yu, Chune; Yu, Jing; Zhang, Min; Zheng, Xiaobo; Wang, Jiaxin; Wang, Huiling; Xu, Yufei; Jing, Jing; Shi, Hubing] Sichuan Univ, West China Hosp, Clin Res Ctr Breast, Lab Integrat Med,State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China; [Yu, Chune; Yu, Jing; Zhang, Min; Zheng, Xiaobo; Wang, Jiaxin; Wang, Huiling; Xu, Yufei; Jing, Jing; Shi, Hubing] Collaborat Innovat Ctr, Chengdu 610041, Sichuan, Peoples R China; [Luo, Dan] Chengdu Med Coll, Sch Basic Med Sci, Dept Immunol, Chengdu 610500, Sichuan, Peoples R China; [Xu, Guangchao] Zunyi Med Univ, Dept Plast Surg, Affiliated Hosp, Zunyi 563000, Guizhou, Peoples R China; [Jiang, Ke] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Dept Head & Neck, State Key Lab Oncol South China,Canc Ctr, Guangzhou 510000, Peoples R China; [Xu, Jie] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Gastroenterol & Hepatol, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China; [Ma, Xuelei] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy,State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China	Sichuan University; Chengdu Medical College; Zunyi Medical University; State Key Lab Oncology South China; Sun Yat Sen University; Shanghai Jiao Tong University; Sichuan University	Jing, J; Shi, HB (corresponding author), Sichuan Univ, West China Hosp, Clin Res Ctr Breast, Lab Integrat Med,State Key Lab Biotherapy, Chengdu 610041, Sichuan, Peoples R China.; Jing, J; Shi, HB (corresponding author), Collaborat Innovat Ctr, Chengdu 610041, Sichuan, Peoples R China.	jj_zcy@vip.163.com; shihb@scu.edu.cn	yu, jing/GZL-0747-2022	yu, chune/0000-0002-5625-2843; Shi, Hubing/0000-0002-2926-3440; Xu, Guangchao/0000-0002-3806-2245	National Natural Science Foundation of China [81773752, 81902793, 81803574, 82172634, 31801143]; National Key Research and Development Program of China [2016YFC0906000, 2016YFC0906003]; Key Program of the Science and Technology Bureau of Sichuan [2021YFSY0007]; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University [ZYYC20013]; Western Medical Talent Training and Disciplinary Development Fund from Hengrui Pharma; China Postdoctoral Science Foundation [2019M653430]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key Research and Development Program of China; Key Program of the Science and Technology Bureau of Sichuan; 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University; Western Medical Talent Training and Disciplinary Development Fund from Hengrui Pharma; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	We are also grateful to Li Chai and Yan Wang (Core Facility of West China Hospital) for their technical assistance. This work was funded by the National Natural Science Foundation of China (Nos. 81773752, 81902793, 81803574, 82172634, 31801143), the National Key Research and Development Program of China (No. 2016YFC0906000 [2016YFC0906003]), Key Program of the Science and Technology Bureau of Sichuan (No. 2021YFSY0007), 1.3.5 project for disciplines of excellence, West China Hospital, Sichuan University (No. ZYYC20013), Western Medical Talent Training and Disciplinary Development Fund from Hengrui Pharma, and China Postdoctoral Science Foundation (2019M653430).	Amodio V, 2020, CANCER DISCOV, V10, P1129, DOI 10.1158/2159-8290.CD-20-0187; Ascierto PA, 2013, LANCET ONCOL, V14, P249, DOI 10.1016/S1470-2045(13)70024-X; Babagana M, 2020, MOL CARCINOGEN, V59, P5, DOI 10.1002/mc.23123; Chan DW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052578; Chu PY, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050435; Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226; Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471; Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Fedele C, 2018, CANCER DISCOV, V8, P1237, DOI 10.1158/2159-8290.CD-18-0444; Fiala O, 2016, TUMOR BIOL, V37, P6823, DOI 10.1007/s13277-015-4523-7; Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015; Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239; Housden BE, 2016, NAT BIOTECHNOL, V34, P621, DOI 10.1038/nbt.3599; Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X; Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006; Joung J, 2017, NAT PROTOC, V12, P828, DOI 10.1038/nprot.2017.016; Kirouac DC, 2017, NPJ SYST BIOL APPL, V3, DOI 10.1038/s41540-017-0016-1; Kitai H, 2016, CANCER DISCOV, V6, P754, DOI 10.1158/2159-8290.CD-15-1377; Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033; Li XL, 2019, CANCER RES, V79, P5088, DOI 10.1158/0008-5472.CAN-19-0325; Liang JB, 2020, CANCER RES, V80, P510, DOI 10.1158/0008-5472.CAN-18-3374; Liu YH, 2019, EPIGENET CHROMATIN, V12, DOI 10.1186/s13072-019-0285-6; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600; Misale S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007947; Moore AR, 2020, NAT REV DRUG DISCOV, V19, P533, DOI 10.1038/s41573-020-0068-6; Neumann J, 2009, PATHOL RES PRACT, V205, P858, DOI 10.1016/j.prp.2009.07.010; Peng X, 2020, SOFT MATTER, V16, P54, DOI 10.1039/c9sm01847f; Ryan MB, 2020, CLIN CANCER RES, V26, P1633, DOI 10.1158/1078-0432.CCR-19-3523; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sparano JA, 2011, CLIN CANCER RES, V17, P7194, DOI 10.1158/1078-0432.CCR-10-3357; Sudhan DR, 2020, CANCER CELL, V37, P183, DOI 10.1016/j.ccell.2019.12.013; Sulahian R, 2019, CELL REP, V29, P118, DOI 10.1016/j.celrep.2019.08.090; Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045; Sustic T, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0600-z; Sveen A, 2020, NAT REV CLIN ONCOL, V17, P11, DOI 10.1038/s41571-019-0241-1; Szlachta K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06676-2; Tsai NP, 2010, J CELL BIOL, V188, P325, DOI 10.1083/jcb.200910083; Van Schaeybroeck S, 2014, CELL REP, V7, P1940, DOI 10.1016/j.celrep.2014.05.032; Wang YJ, 2010, CLIN CANCER RES, V16, P2529, DOI 10.1158/1078-0432.CCR-10-0018; Wei L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12606-7; Ye JW, 2019, J PHARM ANAL, V9, P217, DOI 10.1016/j.jpha.2019.05.004; Yu Chune, 2020, Mol Biomed, V1, P12, DOI 10.1186/s43556-020-00013-0; Yu CE, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00990	45	11	11	4	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 5	2022	41	2					191	203		10.1038/s41388-021-02077-w	http://dx.doi.org/10.1038/s41388-021-02077-w		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC1XK	34718347	hybrid, Green Published			2022-12-17	WOS:000712941800002
J	Chen, Z; Yu, DL; Owonikoko, TK; Ramalingam, SS; Sun, SY				Chen, Zhen; Yu, Danlei; Owonikoko, Taofeek K.; Ramalingam, Suresh S.; Sun, Shi-Yong			Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib	ONCOGENE			English	Article							FATTY-ACID SYNTHESIS; THERAPEUTIC-EFFICACY; ACQUIRED-RESISTANCE; LIPID-METABOLISM; INHIBITION; AZD9291; GROWTH; BIM	Emergence of acquired resistance to osimertinib (AZD9291), the first-approved third-generation EGFR inhibitor that selectively and irreversibly inhibits the activating EGFR mutations and the resistant T790M mutation, is a giant and urgent clinical challenge. Fully understanding the biology underlying the response of EGFR mutant non-small cell lung cancer (NSCLC) to osimertinib is the foundation for development of mechanism-driven strategies to overcome acquired resistance to osimertinib or other third-generation EGFR inhibitors. This study focused on tackling this important issue by elucidating the critical role of sterol regulatory element-binding protein 1 (SREBP1) degradation in conferring the response of EGFR mutant NSCLC cells to osimertinib and by validating the strategy via directly targeting SREBP1 for overcoming osimertinib acquired resistance. Osimertinib facilitated degradation of the mature form of SREBP1 (mSREBP1) in a GSK3/FBXW7-dependent manner and reduced protein levels of its regulated genes in EGFR-mutant NSCLC cells/tumors accompanied with suppression of lipogenesis. Once resistant, EGFR-mutant NSCLC cell lines possessed elevated levels of mSREBP1, which were resistant to osimertinib modulation. Both genetic and pharmacological inhibition of SREBP1 sensitized osimertinib-resistant cells and tumors to osimertinib primarily through enhancing Bim-dependent induction of apoptosis, whereas enforced expression of ectopic SREBP1 in sensitive EGFR-mutant NSCLC cells compromised osimertinib's cell-killing effects. Collectively, we have demonstrated a novel connection between osimertinib and SREBP1 degradation and its impact on the response of EGFR mutant NSCLC cells to osimertinib and suggested an effective strategy for overcoming acquired resistance to osimertinib, and possibly other EGFR inhibitors, via targeting SREBP1.	[Chen, Zhen; Yu, Danlei; Ramalingam, Suresh S.; Sun, Shi-Yong] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA; [Chen, Zhen; Yu, Danlei; Ramalingam, Suresh S.; Sun, Shi-Yong] Winship Canc Inst, Atlanta, GA 30322 USA; [Owonikoko, Taofeek K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA; [Owonikoko, Taofeek K.] Hillman Canc Ctr, Pittsburgh, PA USA	Emory University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Sun, SY (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.; Sun, SY (corresponding author), Winship Canc Inst, Atlanta, GA 30322 USA.	ssun@emory.edu	Owonikoko, Taofeek/C-3012-2011	Owonikoko, Taofeek/0000-0002-7724-7728; Sun, Shi-Yong/0000-0002-0117-8826	NIH/NCI [R01 CA223220, R01 CA245386, UG1 CA233259, P50 CA217691]; Emory University Winship Cancer Institute lung cancer pilot funds	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Emory University Winship Cancer Institute lung cancer pilot funds	We are thankful to Dr. Dongsheng Wang and Mr. Guojing Zhang in our department for helping us with animal experiments, to Dr. Teng Wang and Dr. Dong Hua (Affiliated Hospital of Jiangnan University) for providing us with clinical samples, to Dr. Peng Zhang (Longgang E.N.T. Hospital & Shenzhen Key Laboratory of E.N.T.) for staining the patients' samples, and to Drs. Deliang Guo and Wenyi Wei for providing some shRNAs. We are also grateful to Dr. Anthea Hammond in our department for editing the manuscript. This work was supported by the NIH/NCI R01 CA223220 (to S-YS), R01 CA245386 (to S-YS), UG1 CA233259 (to SSR) and lung cancer SPORE P50 CA217691 DRP award (to S-YS) and Emory University Winship Cancer Institute lung cancer pilot funds (to S-YS). DY is a visiting medical student participating in the Xiangya-Emory Visiting Medical Student Program. SSR, TKO, and S-YS are Georgia Research Alliance Distinguished Cancer Scientists.	Ali A, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708313; Cheng X, 2018, CURR TOP MED CHEM, V18, P484, DOI 10.2174/1568026618666180523104541; Geng F, 2016, CLIN CANCER RES, V22, P5337, DOI 10.1158/1078-0432.CCR-15-2973; Guo DL, 2014, CURR PHARM DESIGN, V20, P2619, DOI 10.2174/13816128113199990486; Guo DL, 2011, CANCER DISCOV, V1, P442, DOI 10.1158/2159-8290.CD-11-0102; Guo DL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000446; Hagiwara A, 2012, CELL METAB, V15, P725, DOI 10.1016/j.cmet.2012.03.015; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Li JJ, 2016, ONCOTARGET, V7, P52392, DOI 10.18632/oncotarget.10721; Li S, 2016, ONCOGENE, V35, P642, DOI 10.1038/onc.2015.123; Li YT, 2020, CANCER-AM CANCER SOC, V126, P1339, DOI 10.1002/cncr.32655; Malvezzi M, 2017, ANN ONCOL, V28, P1117, DOI 10.1093/annonc/mdx033; Salvador MM, 2017, CRIT REV ONCOL HEMAT, V112, P31, DOI 10.1016/j.critrevonc.2017.02.001; Oh WJ, 2011, CELL CYCLE, V10, P2305, DOI 10.4161/cc.10.14.16586; Polonio-Alcala E, 2020, CANCERS, V12, DOI 10.3390/cancers12051283; Recondo G, 2018, NAT REV CLIN ONCOL, V15, P694, DOI 10.1038/s41571-018-0081-4; Rohrig F, 2016, NAT REV CANCER, V16, P732, DOI 10.1038/nrc.2016.89; Shi PY, 2017, CLIN CANCER RES, V23, P6567, DOI 10.1158/1078-0432.CCR-17-1574; Siegel RL, 2018, CA-CANCER J CLIN, V68, P7, DOI 10.3322/caac.21442; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Sun SY, 1997, CANCER RES, V57, P4931; Takada M, 2017, CANCER RES, V77, P4881, DOI 10.1158/0008-5472.CAN-17-1240; Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052; Yao WL, 2015, CANCER LETT, V364, P70, DOI 10.1016/j.canlet.2015.04.028; Yu DL, 2020, AM J CANCER RES, V10, P3316; Yue SH, 2014, CELL METAB, V19, P393, DOI 10.1016/j.cmet.2014.01.019; Zang HJ, 2020, MOL ONCOL, V14, P882, DOI 10.1002/1878-0261.12645; Zhao W, 2021, CANCER LETT, V519, P141, DOI 10.1016/j.canlet.2021.07.007; Zhou J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1057-7	29	11	11	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 9	2021	40	49					6653	6665		10.1038/s41388-021-02057-0	http://dx.doi.org/10.1038/s41388-021-02057-0		OCT 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XM1GJ	34635799	Green Accepted			2022-12-17	WOS:000706082100001
J	Su, JC; Wu, GD; Ye, Y; Zhang, JL; Zeng, LX; Huang, XD; Zheng, YF; Bai, RH; Zhuang, LS; Li, M; Pan, L; Deng, JG; Li, R; Deng, S; Zhang, SP; Zuo, ZX; Liu, ZX; Lin, JZ; Lin, DX; Zheng, J				Su, Jiachun; Wu, Guandi; Ye, Ying; Zhang, Jialiang; Zeng, Lingxing; Huang, Xudong; Zheng, Yanfen; Bai, Ruihong; Zhuang, Lisha; Li, Mei; Pan, Ling; Deng, Junge; Li, Rui; Deng, Shuang; Zhang, Shaoping; Zuo, Zhixiang; Liu, Zexian; Lin, Junzhong; Lin, Dongxin; Zheng, Jian			NSUN2-mediated RNA 5-methylcytosine promotes esophageal squamous cell carcinoma progression via LIN28B-dependent GRB2 mRNA stabilization	ONCOGENE			English	Article							POOR-PROGNOSIS; GENE-EXPRESSION; MISU NSUN2; METHYLTRANSFERASE; METHYLATION; PROLIFERATION; BINDING; TRANSFORMATION; METASTASIS; INHIBITION	5-Methylcytosine (m(5)C) is a posttranscriptional RNA modification participating in many critical bioprocesses, but its functions in human cancer remain unclear. Here, by detecting the transcriptome-wide m(5)C profiling in esophageal squamous cell carcinoma (ESCC), we showed increased m(5)C methylation in ESCC tumors due to the overexpressed m(5)C methyltransferase NSUN2. Aberrant expression of NSUN2 was positively regulated by E2F Transcription Factor 1 (E2F1). High NSUN2 levels predicted poor survival of ESCC patients. Moreover, silencing NSUN2 suppressed ESCC tumorigenesis and progression in Nsun2 knockout mouse models. Mechanistically, NSUN2 induced m(5)C modification of growth factor receptor-bound protein 2 (GRB2) and stabilized its mRNA, which was mediated by a novel m(5)C mediator, protein lin-28 homolog B (LIN28B). Elevated GRB2 levels increased the activation of PI3K/AKT and ERK/MAPK signalling. These results demonstrate that NSUN2 enhances the initiation and progression of ESCC via m(5)C-LIN28B dependent stabilization of GRB2 transcript, providing a promising epitranscriptomic-targeted therapeutic strategy for ESCC.	[Su, Jiachun; Wu, Guandi; Ye, Ying; Zhang, Jialiang; Zeng, Lingxing; Huang, Xudong; Zheng, Yanfen; Bai, Ruihong; Li, Mei; Pan, Ling; Deng, Junge; Li, Rui; Deng, Shuang; Zhang, Shaoping; Zuo, Zhixiang; Liu, Zexian; Lin, Junzhong; Lin, Dongxin; Zheng, Jian] Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China; [Su, Jiachun; Wu, Guandi; Ye, Ying; Zhang, Jialiang; Zeng, Lingxing; Huang, Xudong; Zheng, Yanfen; Bai, Ruihong; Li, Mei; Pan, Ling; Deng, Junge; Li, Rui; Deng, Shuang; Zhang, Shaoping; Zuo, Zhixiang; Liu, Zexian; Lin, Junzhong; Lin, Dongxin; Zheng, Jian] Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China; [Zhuang, Lisha] Sun Yat Sen Univ Canc Ctr, Dept Pathol, Guangzhou, Peoples R China; [Lin, Junzhong] Sun Yat Sen Univ Canc Ctr, Dept Surg, Guangzhou, Peoples R China; [Lin, Dongxin] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr,Dept Etiol & Carcinogenesis, Beijing, Peoples R China; [Lin, Dongxin; Zheng, Jian] Nanjing Med Univ, Collaborat Innovat Ctr Canc Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Peoples R China	State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Nanjing Medical University	Lin, JZ; Lin, DX; Zheng, J (corresponding author), Sun Yat Sen Univ Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China.; Lin, JZ; Lin, DX; Zheng, J (corresponding author), Sun Yat Sen Univ Canc Ctr, Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China.; Lin, JZ (corresponding author), Sun Yat Sen Univ Canc Ctr, Dept Surg, Guangzhou, Peoples R China.; Lin, DX (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr,Dept Etiol & Carcinogenesis, Beijing, Peoples R China.; Lin, DX; Zheng, J (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Canc Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Peoples R China.	linjzh@sysucc.org.cn; lindx@sysucc.org.cn; zhengjian@sysucc.org.cn	Zhang, Jialiang/HDN-0467-2022; Zuo, Zhixiang/M-4441-2016	Zuo, Zhixiang/0000-0002-2492-2689; Zeng, Lingxing/0000-0002-0846-8762; Su, Jiachun/0000-0002-8445-4901; Zheng, Jian/0000-0001-9831-7038	Program for Guangdong Introducing Innovative and Entrepreneurial Teams [2017ZT07S096]; Natural Science Foundation of China [U1601229]; National Young Top-notch Talent Support Program; Sun Yat-sen University Intramural Funds	Program for Guangdong Introducing Innovative and Entrepreneurial Teams; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Young Top-notch Talent Support Program; Sun Yat-sen University Intramural Funds	We thank Dr. Bin Shen (Department of Histology and Embryology, Nanjing Medical University, Nanjing, China) for his generous donation of Nsun2 +/- C57BL/6J mice. This study was supported by the Program for Guangdong Introducing Innovative and Entrepreneurial Teams (2017ZT07S096 to DL), Natural Science Foundation of China (U1601229 to DL), National Young Top-notch Talent Support Program (to JZ) and Sun Yat-sen University Intramural Funds (to DL and to JZ).	Amort T, 2017, GENOME BIOL, V18, DOI 10.1186/s13059-016-1139-1; Blanco S, 2016, NATURE, V534, P335, DOI 10.1038/nature18282; Blanco S, 2014, EMBO J, V33, P2020, DOI 10.15252/embj.201489282; Bourgeois G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0133321; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Budkina KS, 2020, BIOCHEMISTRY-MOSCOW+, V85, P1, DOI 10.1134/S0006297920140011; Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000; Chen X, 2019, NAT CELL BIOL, V21, P978, DOI 10.1038/s41556-019-0361-y; CHENG J, 2018, NAT COMMUN, V9; David R, 2017, PLANT CELL, V29, P445, DOI 10.1105/tpc.16.00751; Delaunay S, 2019, NAT CELL BIOL, V21, P552, DOI 10.1038/s41556-019-0319-0; Flores JV, 2017, STEM CELL REP, V8, P112, DOI 10.1016/j.stemcr.2016.11.014; Frye M, 2006, CURR BIOL, V16, P971, DOI 10.1016/j.cub.2006.04.027; Frye M, 2010, CANCER LETT, V289, P71, DOI 10.1016/j.canlet.2009.08.004; Giubellino A, 2007, CANCER RES, V67, P6012, DOI 10.1158/0008-5472.CAN-07-0022; Hamano R, 2012, BRIT J CANCER, V106, P1415, DOI 10.1038/bjc.2012.90; Huang HL, 2018, NAT CELL BIOL, V20, P285, DOI 10.1038/s41556-018-0045-z; Hussain S, 2013, CELL REP, V4, P255, DOI 10.1016/j.celrep.2013.06.029; Ijaz M, 2017, PROTEIN PEPTIDE LETT, V24, P1084, DOI 10.2174/0929866525666171123213148; Keskin T, 2020, CELL REP, V30, P4567, DOI 10.1016/j.celrep.2019.12.053; Khan MA, 2012, AM J HUM GENET, V90, P856, DOI 10.1016/j.ajhg.2012.03.023; Khoddami V, 2013, NAT BIOTECHNOL, V31, P458, DOI 10.1038/nbt.2566; Khosronezhad N, 2015, J ASSIST REPROD GEN, V32, P807, DOI 10.1007/s10815-015-0443-0; Li B, 2016, CLIN CANCER RES, V22, P1243, DOI 10.1158/1078-0432.CCR-15-1196; Li LY, 2015, J PROTEOMICS, V117, P145, DOI 10.1016/j.jprot.2015.01.016; Li LY, 2014, INT J CLIN EXP PATHO, V7, P3132; Lu LG, 2018, CANCER INVEST, V36, P246, DOI 10.1080/07357907.2018.1466896; Luo YH, 2016, CIRC RES, V118, P944, DOI 10.1161/CIRCRESAHA.115.307674; Madison BB, 2013, GENE DEV, V27, P2233, DOI 10.1101/gad.224659.113; Motorin Y, 2010, NUCLEIC ACIDS RES, V38, P1415, DOI 10.1093/nar/gkp1117; Nan P, 2020, CARCINOGENESIS, V41, P1263, DOI 10.1093/carcin/bgz200; Nicolau-Neto Pedro, 2018, Oncotarget, V9, P16634, DOI 10.18632/oncotarget.24621; Ohanian M, 2018, LANCET HAEMATOL, V5, pE136, DOI 10.1016/S2352-3026(18)30021-8; Piovesan D, 2016, NUCLEIC ACIDS RES, V44, pW367, DOI 10.1093/nar/gkw315; Roundtree IA, 2017, CELL, V169, P1187, DOI 10.1016/j.cell.2017.05.045; Sajini AA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10020-7; Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Schumann U, 2020, BMC BIOL, V18, DOI 10.1186/s12915-020-00769-5; Selmi T, 2021, NUCLEIC ACIDS RES, V49, DOI 10.1093/nar/gkaa1193; Shi QZ, 2018, CELL PHYSIOL BIOCHEM, V46, P2187, DOI 10.1159/000489548; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smyth EC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.48; Song MQ, 2018, MOL CANCER THER, V17, P1540, DOI 10.1158/1535-7163.MCT-17-0823; Squires JE, 2012, NUCLEIC ACIDS RES, V40, P5023, DOI 10.1093/nar/gks144; Trixl L, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1510; Van Haute L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12039; Veschi V, 2017, CANCER CELL, V31, P50, DOI 10.1016/j.ccell.2016.12.002; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang WG, 2016, WIRES RNA, V7, P838, DOI 10.1002/wrna.1380; Wang XC, 2018, BIOMED PHARMACOTHER, V104, P383, DOI 10.1016/j.biopha.2018.05.064; Wang Y, 2014, NAT CELL BIOL, V16, P191, DOI 10.1038/ncb2902; Yang JC, 2017, FUTURE ONCOL, V13, P1981, DOI 10.2217/fon-2017-0084; Yang X, 2017, CELL RES, V27, P606, DOI 10.1038/cr.2017.55; Yang Y, 2019, MOL CELL, V75, P1188, DOI 10.1016/j.molcel.2019.06.033; Zhang JP, 2019, BLOOD, V134, P171, DOI 10.1182/blood.2019001043	57	11	11	6	21	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 30	2021	40	39					5814	5828		10.1038/s41388-021-01978-0	http://dx.doi.org/10.1038/s41388-021-01978-0		AUG 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UZ8WB	34345012	Green Published, hybrid			2022-12-17	WOS:000681523500001
J	Hagiwara, M; Fushimi, A; Yamashita, N; Bhattacharya, A; Rajabi, H; Long, MD; Yasumizu, Y; Oya, M; Liu, S; Kufe, D				Hagiwara, Masayuki; Fushimi, Atsushi; Yamashita, Nami; Bhattacharya, Atrayee; Rajabi, Hasan; Long, Mark D.; Yasumizu, Yota; Oya, Mototsugu; Liu, Song; Kufe, Donald			MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells	ONCOGENE			English	Article							TRANSCRIPTIONAL REPRESSION; PLURIPOTENCY; EXPRESSION; SUBUNIT; BAF180; STRESS; REPAIR; GENES; NANOG	The polybromo-associated PBAF (SWI/SNF) chromatin remodeling complex, which includes PBRM1, ARID2, and BRD7, regulates cell differentiation and genomic integrity. MUC1-C is an oncogenic protein that drives lineage plasticity in prostate cancer (PC) progression. The present work demonstrates that MUC1-C induces PBRM1, ARID2, and BRD7 expression by the previously unrecognized E2F1-mediated activation of their respective promoters. The functional significance of the MUC1-C -> PBAF pathway is supported by demonstrating involvement of MUC1-C in associating with nuclear PBAF and driving the NRF2 antioxidant gene transcriptome in PC cells. Mechanistically, MUC1-C forms a complex with NRF2 and PBRM1 on the NRF2 target SLC7A11 gene that encodes the xCT cystine-glutamate antiporter, increases chromatin accessibility and induces SLC7A11/xCT expression. We also show that MUC1-C and PBRM1 are necessary for induction of other NRF2 target genes, including G6PD and PGD that regulate the pentose phosphate pathway. Our results further demonstrate that MUC1-C integrates activation of PBRM1 with the regulation of antioxidant genes, ROS levels, pluripotency factor expression and the cancer stem cell (CSC) state. These findings reveal a role for MUC1-C in regulating PBAF, redox balance and lineage plasticity of PC CSC progression. Our findings also uncover involvement of MUC1-C in integrating the PBAF and BAF pathways in cancer.	[Hagiwara, Masayuki; Fushimi, Atsushi; Yamashita, Nami; Bhattacharya, Atrayee; Rajabi, Hasan; Kufe, Donald] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA; [Long, Mark D.; Liu, Song] Roswell Park Comprehens Canc Ctr, Dept Biostat & Bioinformat, Buffalo, NY USA; [Yasumizu, Yota; Oya, Mototsugu] Keio Univ, Sch Med, Dept Urol, Tokyo, Japan	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Keio University	Kufe, D (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA.	donald_kufe@dfci.harvard.edu	Bhattacharya, Atrayee/AAJ-9314-2021	Bhattacharya, Atrayee/0000-0002-3322-6175; Long, Mark/0000-0003-1120-8176	National Cancer Institute of the National Institutes of Health [CA97098, CA166480, CA233084, CA232979]	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under grant numbers CA97098, CA166480 and CA233084 awarded to DK and CA232979 awarded to SL.	Ahmad R, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0608-9; Brownlee PM, 2014, CELL REP, V6, P973, DOI 10.1016/j.celrep.2014.02.012; Buenrostro Jason D, 2015, Curr Protoc Mol Biol, V109, DOI 10.1002/0471142727.mb2129s109; de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022; Guerrero-Martinez JA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20217-3; Hagiwara M, 2021, CANCER RES, V81, P1111, DOI 10.1158/0008-5472.CAN-20-2588; Harte MT, 2010, CANCER RES, V70, P2538, DOI 10.1158/0008-5472.CAN-09-2089; Hasegawa M, 2015, CLIN CANCER RES, V21, P2338, DOI 10.1158/1078-0432.CCR-14-3000; Hata T, 2019, CANCER RES, V79, P5711, DOI 10.1158/0008-5472.CAN-19-1034; Hata T, 2019, MOL CANCER THER, V18, P1744, DOI 10.1158/1535-7163.MCT-19-0156; Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001; Hiraki M, 2017, ONCOGENE, V36, P2791, DOI 10.1038/onc.2016.439; Hodges C, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026930; Hopson S, 2017, ACS CHEM BIOL, V12, P2482, DOI 10.1021/acschembio.7b00541; Huang Lei, 2010, Genes Cancer, V1, P239; Jeter CR, 2015, STEM CELLS, V33, P2381, DOI 10.1002/stem.2007; Kadoch C, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500447; Kakarougkas A, 2014, MOL CELL, V55, P723, DOI 10.1016/j.molcel.2014.06.028; Kent LN, 2019, NAT REV CANCER, V19, P326, DOI 10.1038/s41568-019-0143-7; Kidder BL, 2009, STEM CELLS, V27, P317, DOI 10.1634/stemcells.2008-0710; King HW, 2017, ELIFE, V6, DOI 10.7554/eLife.22631; Kufe DW, 2020, CARCINOGENESIS, V41, P1173, DOI 10.1093/carcin/bgaa082; Li W, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.137112; Lim JKM, 2019, P NATL ACAD SCI USA, V116, P9433, DOI 10.1073/pnas.1821323116; Liu XD, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15959-6; Lu X, 2014, ONCOGENE, V33, P2655, DOI 10.1038/onc.2013.209; Malhotra D, 2010, NUCLEIC ACIDS RES, V38, P5718, DOI 10.1093/nar/gkq212; Miao D, 2018, SCIENCE, V359, P801, DOI 10.1126/science.aan5951; Pan D, 2018, SCIENCE, V359, P770, DOI 10.1126/science.aao1710; Pan J, 2019, NAT GENET, V51, P618, DOI 10.1038/s41588-019-0363-5; Papamichos-Chronakis M, 2013, NAT REV GENET, V14, P62, DOI 10.1038/nrg3345; Porter EG, 2019, ISCIENCE, V15, P196, DOI 10.1016/j.isci.2019.04.027; Rajabi H, 2018, ONCOGENE, V37, P2079, DOI 10.1038/s41388-017-0096-9; Rajabi H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07850-0; Schick S, 2019, NAT GENET, V51, P1399, DOI 10.1038/s41588-019-0477-9; Somyajit K, 2017, SCIENCE, V358, P797, DOI 10.1126/science.aao3172; Tanabe A, 2020, CANCERS, V12, DOI 10.3390/cancers12102780; Vitale I, 2017, MOL CELL, V66, P306, DOI 10.1016/j.molcel.2017.04.006; Wu Q, 2017, EPIGENOMICS-UK, V9, P919, DOI 10.2217/epi-2017-0034; Yamamoto M, 2019, CANCER RES, V79, P2031, DOI 10.1158/0008-5472.CAN-18-3259; Yan ZJ, 2005, GENE DEV, V19, P1662, DOI 10.1101/gad.1323805; Yasumizu Y, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14219-6; Yin L, 2012, BLOOD, V119, P810, DOI 10.1182/blood-2011-07-369686; Zhang XL, 2014, STEM CELL REP, V3, P460, DOI 10.1016/j.stemcr.2014.07.004	44	11	11	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 29	2021	40	30					4930	4940		10.1038/s41388-021-01899-y	http://dx.doi.org/10.1038/s41388-021-01899-y		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TS1QO	34163028	Green Published, hybrid			2022-12-17	WOS:000664853000006
J	Chen, J; Na, RS; Xiao, C; Wang, X; Wang, YP; Yan, DW; Song, GH; Liu, XI; Chen, JY; Lu, HJ; Chen, CY; Tang, HM; Zhuang, GH; Fan, GJ; Peng, ZH				Chen, Jian; Na, Risi; Xiao, Chao; Wang, Xiao; Wang, Yupeng; Yan, Dongwang; Song, Guohe; Liu, Xueni; Chen, Jiayi; Lu, Huijun; Chen, Chunyan; Tang, Huamei; Zhuang, Guohong; Fan, Guangjian; Peng, Zhihai			The loss of SHMT2 mediates 5-fluorouracil chemoresistance in colorectal cancer by upregulating autophagy	ONCOGENE			English	Article							GLYCINE; METABOLISM; METASTASIS; SERINE; CELLS; PKM2; RISK; GENE	5-Fluorouracil (5-FU)-based chemotherapy is the first-line treatment for colorectal cancer (CRC) but is hampered by chemoresistance. Despite its impact on patient survival, the mechanism underlying chemoresistance against 5-FU remains poorly understood. Here, we identified serine hydroxymethyltransferase-2 (SHMT2) as a critical regulator of 5-FU chemoresistance in CRC. SHMT2 inhibits autophagy by binding cytosolic p53 instead of metabolism. SHMT2 prevents cytosolic p53 degradation by inhibiting the binding of p53 and HDM2. Under 5-FU treatment, SHMT2 depletion promotes autophagy and inhibits apoptosis. Autophagy inhibitors decrease low SHMT2-induced 5-FU resistance in vitro and in vivo. Finally, the lethality of 5-FU treatment to CRC cells was enhanced by treatment with the autophagy inhibitor chloroquine in patient-derived and CRC cell xenograft models. Taken together, our findings indicate that autophagy induced by low SHMT2 levels mediates 5-FU resistance in CRC. These results reveal the SHMT2-p53 interaction as a novel therapeutic target and provide a potential opportunity to reduce chemoresistance.	[Chen, Jian] Tongji Univ, Shanghai Pulm Hosp, Sch Med, Dept Thorac Surg, Shanghai, Peoples R China; [Na, Risi; Tang, Huamei; Peng, Zhihai] Xiamen Univ, Sch Med, Xiang An Hosp, Dept Gen Surg, Xiamen, Peoples R China; [Xiao, Chao] Fu Dan Univ, Sch Med, Hua Shan Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Wang, Xiao] Sun Yat Sen Univ, Dept Gastrointestinal Surg, Affiliated Hosp 5, Zhuhai, Peoples R China; [Wang, Yupeng; Song, Guohe] Fu Dan Univ, Sch Med, Zhong Shan Hosp, Dept Gen Surg, Shanghai, Peoples R China; [Yan, Dongwang; Liu, Xueni; Chen, Jiayi; Fan, Guangjian] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Translat Med Ctr, Shanghai, Peoples R China; [Lu, Huijun] Guigang City Peoples Hosp, Dept Pathol, Guigang, Guangxi, Peoples R China; [Chen, Chunyan] Shanghai Jiao Tong Univ Affiliated Peoples Hosp 6, Dept Pathol, Shanghai, Peoples R China; [Tang, Huamei; Zhuang, Guohong; Peng, Zhihai] Xiamen Univ, Organ Transplantat Inst, Sch Med, Fujian Prov Key Lab Organ & Tissue Regenerat, Xiamen, Peoples R China	Tongji University; Xiamen University; Fudan University; Sun Yat Sen University; Fudan University; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Xiamen University	Tang, HM; Peng, ZH (corresponding author), Xiamen Univ, Sch Med, Xiang An Hosp, Dept Gen Surg, Xiamen, Peoples R China.; Fan, GJ (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Translat Med Ctr, Shanghai, Peoples R China.; Tang, HM; Zhuang, GH; Peng, ZH (corresponding author), Xiamen Univ, Organ Transplantat Inst, Sch Med, Fujian Prov Key Lab Organ & Tissue Regenerat, Xiamen, Peoples R China.	tanghuamei2014@163.com; zhgh@xmu.edu.cn; ytfan@126.com; pengzhihai1958@163.com	Chen, Jiayi/GZM-5106-2022		National Natural Science Foundation of China [81530044, 81802343, 81871931, 81602069, 81220108021, 81702337, 81602616]; Medical Guidance Project of Shanghai Science and Technology Commission [17411968200, 19QA1407100]; Natural Science Foundation of Shanghai Municipality [16ZR1427700, 16CR2008A]; National Science and Technology Major Project of China [2017ZX10203206]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Medical Guidance Project of Shanghai Science and Technology Commission; Natural Science Foundation of Shanghai Municipality(Natural Science Foundation of Shanghai); National Science and Technology Major Project of China	We acknowledge the National Natural Science Foundation of China (81530044, 81802343, 81871931, 81602069, 81220108021, 81702337, 81602616), the Medical Guidance Project of Shanghai Science and Technology Commission (17411968200, 19QA1407100), and the Natural Science Foundation of Shanghai Municipality (16ZR1427700). Shanghai 3-year action plan to promote the clinical skills and clinical innovation capacity of municipal hospitals (No. 16CR2008A). National Science and Technology Major Project of China Grant 2017ZX10203206.	Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Anderson DJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008305; Annavajhala M.K., 2021, NATURE; Apel A, 2008, CANCER RES, V68, P1485, DOI 10.1158/0008-5472.CAN-07-0562; Bao XR, 2016, ELIFE, V5, DOI 10.7554/eLife.10575; Chaachouay H, 2011, RADIOTHER ONCOL, V99, P287, DOI 10.1016/j.radonc.2011.06.002; Chen DT, 2012, J GASTROINTEST SURG, V16, P905, DOI 10.1007/s11605-011-1815-0; Chen SN, 2016, TUMOR BIOL, V37, P2321, DOI 10.1007/s13277-015-3800-9; Chowdhury RM, 2018, J STOMATOL ORAL MAXI, V119, P37, DOI 10.1016/j.jormas.2017.11.001; DALLE PP, 2016, NAT COMMUN, V7, DOI [10.1038/ncomms13254, DOI 10.1038/NC0MMS13254]; Fan GJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20208-x; Golden EB, 2014, NEUROSURG FOCUS, V37, DOI 10.3171/2014.9.FOCUS14504; Green DR, 2009, NATURE, V458, P1127, DOI 10.1038/nature07986; Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002; Harris I, 2012, CELL RES, V22, P447, DOI 10.1038/cr.2011.203; HASHIZUME O, 2015, SCI REP-UK, V5; Hong Y, 2010, CLIN EXP METASTAS, V27, P83, DOI 10.1007/s10585-010-9305-4; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431; Kelemen Linda E., 2012, Frontiers in Genetics, V3, P33, DOI 10.3389/fgene.2012.00033; Kim D, 2015, NATURE, V520, P363, DOI 10.1038/nature14363; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Lee GY, 2014, CANCER RES, V74, P3114, DOI 10.1158/0008-5472.CAN-13-2683; Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Long M, 2017, TRENDS ENDOCRIN MET, V28, P818, DOI 10.1016/j.tem.2017.09.001; Lorente J, 2018, BIOL REV, V93, P152, DOI 10.1111/brv.12337; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453; Morscher RJ, 2018, NATURE, V554, P128, DOI 10.1038/nature25460; Ning SL, 2018, GASTROENT RES PRACT, V2018, DOI 10.1155/2018/4369253; Nyfeler B, 2016, AUTOPHAGY, V12, P1206, DOI 10.1080/15548627.2016.1170265; Piffoux M, 2021, BRIT J CANCER, V124, P333, DOI 10.1038/s41416-020-01039-5; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; Ron-Harel N, 2016, CELL METAB, V24, P104, DOI 10.1016/j.cmet.2016.06.007; Ryan BM, 2014, INT J CANCER, V134, P1399, DOI 10.1002/ijc.28457; Saha S, 2018, BIOMED PHARMACOTHER, V104, P485, DOI 10.1016/j.biopha.2018.05.007; Santana-Codina N, 2017, ANNU REV CANC BIOL, V1, P19, DOI 10.1146/annurev-cancerbio-041816-122338; Sanz-Pamplona R, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-46; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005; Son SM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16886-2; Song GH, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0427-7; Sui X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.350; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Thandi RS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17310-5; Walden M, 2019, NATURE, V570, P194, DOI 10.1038/s41586-019-1232-1; WEI Z, 2018, NAT COMMUN, V9; Woo CC, 2016, ONCOTARGET, V7, P53005, DOI 10.18632/oncotarget.10415; Xiao C, 2018, CANCER SCI, V109, P1075, DOI 10.1111/cas.13516; Xu MY, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1007071; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yang X, 2018, CANCER RES, V78, P372, DOI 10.1158/0008-5472.CAN-17-1912; Zhao EH, 2016, CELL REP, V14, P506, DOI 10.1016/j.celrep.2015.12.053; Zheng H, 2013, CELL REP, V5, P180, DOI 10.1016/j.celrep.2013.08.025	55	11	11	6	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	2021	40	23					3974	3988		10.1038/s41388-021-01815-4	http://dx.doi.org/10.1038/s41388-021-01815-4		MAY 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SQ8GV	33990700	hybrid, Green Published			2022-12-17	WOS:000650652500001
J	Tian, BQ; Liu, JD; Zhang, NS; Song, YM; Xu, YY; Xie, MY; Wang, BW; Hua, H; Shen, Y; Li, YK; Yang, M				Tian, Baoqing; Liu, Jiandong; Zhang, Nasha; Song, Yemei; Xu, Yeyang; Xie, Mengyu; Wang, Bowen; Hua, Hui; Shen, Yue; Li, Yankang; Yang, Ming			Oncogenic SNORD12B activates the AKT-mTOR-4EBP1 signaling in esophageal squamous cell carcinoma via nucleus partitioning of PP-1 alpha	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; SMALL NUCLEOLAR RNAS; SUSCEPTIBILITY LOCI; NONCODING RNAS; CANCER; RISK; EXPRESSION; PROTEIN; SNORNA; PROLIFERATION	Esophageal cancer is a complex malignancy and the sixth leading cause of cancer death worldwide. In Eastern Asia including China, about 90% of all incident cases have esophageal squamous cell carcinoma (ESCC). Mounting evidence elucidates that aberrant expression of various non-coding RNAs (ncRNAs) contributes to ESCC progression, but it remains unclear how small nucleolar RNAs (snoRNAs) are involved in ESCC development. We systemically screened clinically relevant snoRNAs in ESCC via integrative analyses of The Cancer Genome Atlas (TCGA) data and validation in ESCC tissues. We found that snoRNA SNORD12B was one of the most evidently upregulated snoRNAs in ESCC specimens and its high expression was significantly associated with poor prognosis of patients. SNORD12B profoundly promoted proliferation, migration, invasion, and metastasis of ESCC cells in vitro and in vivo, indicating its oncogene nature. In particular, SNORD12B could interact with PP-1 alpha, one of the three catalytic subunits of serine/threonine protein phosphatase 1, which is a major phosphatase that directly dephosphorylates AKT to suppress its activation. Interestingly, high levels of SNORD12B in ESCC cells could break interactions between 14-3-3 zeta and PP-1 alpha, abolish the retention of PP-1 alpha in the cytosol by 14-3-3 zeta and relocate PP-1 alpha from the cytosol to the nucleus. This led to sequestered PP-1 alpha in the nucleus, enhanced phosphorylation of AKT in the cytosol, activated AKT-mTOR-4EBP1 signaling, and, thus, ESCC progression. These insights would improve our understanding of how snoRNAs contribute to tumorigenesis and highlight the potential of snoRNAs as future therapeutic targets against cancers.	[Tian, Baoqing; Liu, Jiandong; Zhang, Nasha; Song, Yemei; Hua, Hui; Yang, Ming] Shandong First Med Univ, Shandong Canc Hosp & Inst, Canc Res Ctr, Shandong Prov Key Lab Radiat Oncol, Jinan, Shandong, Peoples R China; [Tian, Baoqing; Liu, Jiandong; Zhang, Nasha; Song, Yemei; Hua, Hui; Yang, Ming] Shandong Acad Med Sci, Jinan, Shandong, Peoples R China; [Xu, Yeyang; Xie, Mengyu; Wang, Bowen; Shen, Yue; Li, Yankang] Shandong Univ, Cheeloo Coll Med, Jinan, Shandong, Peoples R China	Shandong First Medical University & Shandong Academy of Medical Sciences; Shandong First Medical University & Shandong Academy of Medical Sciences; University of Jinan; Shandong University	Yang, M (corresponding author), Shandong First Med Univ, Shandong Canc Hosp & Inst, Canc Res Ctr, Shandong Prov Key Lab Radiat Oncol, Jinan, Shandong, Peoples R China.; Yang, M (corresponding author), Shandong Acad Med Sci, Jinan, Shandong, Peoples R China.	aaryoung@yeah.net	Yang, Ming/G-4705-2012	Yang, Ming/0000-0002-7722-7487	National Natural Science Foundation of China [31671300, 31871306]; Taishan Scholars Program of Shandong Province [tsqn20161060]; Program of Science and Technology for the youth innovation team in universities of Shandong Province [2020KJL001]; Medical and Health Science and Technology Development Plan of Shandong Province [2019WS202]; Youth Foundation Programs of Shandong Academy of Medical Sciences [2018-28]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Taishan Scholars Program of Shandong Province; Program of Science and Technology for the youth innovation team in universities of Shandong Province; Medical and Health Science and Technology Development Plan of Shandong Province; Youth Foundation Programs of Shandong Academy of Medical Sciences	This work was supported by the National Natural Science Foundation of China (31671300, 31871306); Taishan Scholars Program of Shandong Province (tsqn20161060); Program of Science and Technology for the youth innovation team in universities of Shandong Province (2020KJL001); Medical and Health Science and Technology Development Plan of Shandong Province (2019WS202); Youth Foundation Programs of Shandong Academy of Medical Sciences (2018-28). The authors would like to thank the many individuals who participated in the study.	Abnet CC, 2018, GASTROENTEROLOGY, V154, P360, DOI 10.1053/j.gastro.2017.08.023; Abnet CC, 2012, HUM MOL GENET, V21, P2132, DOI 10.1093/hmg/dds029; Abnet CC, 2010, NAT GENET, V42, P764, DOI 10.1038/ng.649; Baillat D, 2005, CELL, V123, P265, DOI 10.1016/j.cell.2005.08.019; Brameier M, 2011, NUCLEIC ACIDS RES, V39, P675, DOI 10.1093/nar/gkq776; Bratkovic T, 2014, BBA-GENE REGUL MECH, V1839, P438, DOI 10.1016/j.bbagrm.2014.04.009; Cao PB, 2018, GASTROENTEROLOGY, V155, P542, DOI 10.1053/j.gastro.2018.04.020; Chang J, 2018, NAT GENET, V50, P338, DOI 10.1038/s41588-018-0045-8; Chen YS, 2020, THERANOSTICS, V10, P4983, DOI 10.7150/thno.43046; Cui R, 2009, GASTROENTEROLOGY, V137, P1768, DOI 10.1053/j.gastro.2009.07.070; Dupuis-Sandoval F, 2015, WIRES RNA, V6, P381, DOI 10.1002/wrna.1284; Ender C, 2008, MOL CELL, V32, P519, DOI 10.1016/j.molcel.2008.10.017; Falaleeva M, 2016, P NATL ACAD SCI USA, V113, pE1625, DOI 10.1073/pnas.1519292113; Fan RH, 2018, ONCOL LETT, V15, P6497, DOI 10.3892/ol.2018.8087; Fong LY, 2020, P NATL ACAD SCI USA, V117, P6075, DOI 10.1073/pnas.1920333117; Gong J, 2017, CELL REP, V21, P1968, DOI 10.1016/j.celrep.2017.10.070; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Huang CL, 2017, NUCLEIC ACIDS RES, V45, P8647, DOI 10.1093/nar/gkx651; Islami F, 2004, BRIT J CANCER, V90, P1402, DOI 10.1038/sj.bjc.6601737; Jerome M, 2014, ARCH BIOCHEM BIOPHYS, V558, P28, DOI 10.1016/j.abb.2014.06.012; Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265; Li JG, 2014, GUT, V63, P1700, DOI 10.1136/gutjnl-2013-305806; Li YK, 2020, CARCINOGENESIS, V41, P1195, DOI 10.1093/carcin/bgaa069; Liu J., 2020, NAT COMMUN, V11; Luo AP, 2019, ONCOGENE, V38, P4990, DOI 10.1038/s41388-019-0771-0; Matera AG, 2007, NAT REV MOL CELL BIO, V8, P209, DOI 10.1038/nrm2124; Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]; Schubert T, 2012, MOL CELL, V48, P434, DOI 10.1016/j.molcel.2012.08.021; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Siprashvili Z, 2016, NAT GENET, V48, P53, DOI 10.1038/ng.3452; SUDO K, 2019, JAMA NETW OPEN, V2; Tan DSW, 2017, NAT MED, V23, P1167, DOI 10.1038/nm.4401; Tanaka F, 2010, GUT, V59, P1457, DOI 10.1136/gut.2009.205724; Tran GD, 2005, INT J CANCER, V113, P456, DOI 10.1002/ijc.20616; Wang LD, 2010, NAT GENET, V42, P759, DOI 10.1038/ng.648; Wang XY, 2015, J BIOL CHEM, V290, P3925, DOI 10.1074/jbc.M114.596866; Wu C, 2014, NAT GENET, V46, P1001, DOI 10.1038/ng.3064; Wu C, 2012, NAT GENET, V44, P1090, DOI 10.1038/ng.2411; Wu C, 2011, NAT GENET, V43, P679, DOI 10.1038/ng.849; Wu M, 2009, INT J CANCER, V124, P1907, DOI 10.1002/ijc.24142; Xiao L, 2010, CELL DEATH DIFFER, V17, P1448, DOI 10.1038/cdd.2010.16; Xu L, 2016, CLIN CANCER RES, V22, P773, DOI 10.1158/1078-0432.CCR-15-0737; You BH, 2019, P NATL ACAD SCI USA, V116, P24620, DOI 10.1073/pnas.1912126116; Yuan JP, 2020, ONCOGENE, V39, P6664, DOI 10.1038/s41388-020-01460-3; Zhang HF, 2019, CLIN CANCER RES, V25, P1989, DOI 10.1158/1078-0432.CCR-18-0773; Zhang NS, 2020, THERANOSTICS, V10, P9378, DOI 10.7150/thno.48247; Zhang NS, 2020, BIOCHEM PHARMACOL, V172, DOI 10.1016/j.bcp.2019.113772; Zhang XD, 2018, NUCLEIC ACIDS RES, V46, P1793, DOI 10.1093/nar/gkx1259; Zhou FB, 2017, NAT CELL BIOL, V19, P844, DOI 10.1038/ncb3563	50	11	12	3	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 27	2021	40	21					3734	3747		10.1038/s41388-021-01809-2	http://dx.doi.org/10.1038/s41388-021-01809-2		MAY 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SI8ZW	33941854				2022-12-17	WOS:000646512300001
J	Liu, YB; Li, XZ; Zhang, H; Zhang, MM; Wei, YL				Liu, Yanbin; Li, Xingzhi; Zhang, Hui; Zhang, Mingming; Wei, Yanli			HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer	ONCOGENE			English	Article							MESSENGER-RNA; 3'-UNTRANSLATED REGION; EXPRESSION; PROTEIN; IDENTIFICATION; CYCLOOXYGENASE-2; INHIBITOR; LIGANDS; TARGET; BINDS	Despite the well-established role of CMTM6 in the stabilization of cell surface PD-L1 in cancer cells, the mechanisms underlying CMTM6 expression and regulation are still largely unknown. Here we unexpectedly find a strikingly positive correlation between CMTM6 and Hu-Antigen R (HuR) expression in most types of cancer. Mechanistically, we elucidate HuR stabilizes CMTM6 mRNA via direct association with AU-rich elements (AREs) in its 3'UTR and predominantly upregulates CMTM6, which is readily abolished by HuR-specific inhibitor, MS-444. Phenotypically, we notice abundant cell surface PD-L1 in HuR-high cancer cells, which significantly inhibits immune activation of co-cultured T cells as indicated by IL-2 production. Treatment with MS-444 completely relieves immune suppression imposed by HuR-overexpression and further stimulates immune responses. Ectopic HuR accelerates allograft tumor progression in vivo, which is greatly compromised by simultaneous administration with MS-444. Our study uncovers a novel mechanism in control of CMTM6 and therefore PD-L1 expression, and suggests the potential of combining HuR inhibitor with PD-1/PD-L1 antibodies for cancer immunotherapy.	[Liu, Yanbin; Zhang, Hui] Jining Med Univ, Inst Immunol & Mol Med, Jining, Peoples R China; [Liu, Yanbin] BioBox Sci Inc, Guangzhou, Peoples R China; [Li, Xingzhi] Longgang Dist Peoples Hosp Shenzhen, Dept Urol Surg, Shenzhen, Peoples R China; [Zhang, Mingming; Wei, Yanli] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Biochem, Guangzhou, Peoples R China	Jining Medical University; Sun Yat Sen University	Liu, YB (corresponding author), Jining Med Univ, Inst Immunol & Mol Med, Jining, Peoples R China.; Liu, YB (corresponding author), BioBox Sci Inc, Guangzhou, Peoples R China.	yanbliu@hotmail.com			National Natural Science Foundation of China [81672796]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by National Natural Science Foundation of China, No. 81672796 to YBL.	Allegri L, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43894-0; Blanco FF, 2016, ONCOTARGET, V7, P74043, DOI 10.18632/oncotarget.12189; Brennan SE, 2009, CANCER RES, V69, P5168, DOI 10.1158/0008-5472.CAN-08-4238; Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643; Casey SC, 2016, SCIENCE, V352, P227, DOI 10.1126/science.aac9935; Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8; Chen L, 2020, CANCER IMMUNOL RES, V8, P179, DOI 10.1158/2326-6066.CIR-19-0394; Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241; Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI12973; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fialcowitz-White EJ, 2007, J BIOL CHEM, V282, P20948, DOI 10.1074/jbc.M701751200; Filippova N, 2011, MOL CANCER RES, V9, P648, DOI 10.1158/1541-7786.MCR-10-0325; Gao F, 2019, BIOCHEM BIOPHYS REP, V20, DOI 10.1016/j.bbrep.2019.100690; GRAUS F, 1987, ACTA NEUROL SCAND, V75, P249, DOI 10.1111/j.1600-0404.1987.tb07928.x; Graus F, 1986, Neurologia, V1, P11; Green MR, 2010, BLOOD, V116, P3268, DOI 10.1182/blood-2010-05-282780; Guan XD, 2018, EBIOMEDICINE, V35, P233, DOI 10.1016/j.ebiom.2018.08.012; Kang MJ, 2008, GASTROENTEROLOGY, V135, P2030, DOI 10.1053/j.gastro.2008.08.009; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Lai KKY, 2017, GASTROENTEROLOGY, V152, P1477, DOI 10.1053/j.gastro.2017.01.021; Lal S, 2017, MOL CANCER RES, V15, P696, DOI 10.1158/1541-7786.MCR-16-0361; Lang M, 2017, CANCER RES, V77, P2424, DOI 10.1158/0008-5472.CAN-15-1726; Liu JZ, 2007, BLOOD, V110, P296, DOI 10.1182/blood-2006-10-051482; Loflin P, 2001, FEBS LETT, V509, P267, DOI 10.1016/S0014-5793(01)03176-3; Meisner NC, 2007, NAT CHEM BIOL, V3, P508, DOI 10.1038/nchembio.2007.14; Mezzadra R, 2017, NATURE, V549, P106, DOI 10.1038/nature23669; Mrena J, 2005, CLIN CANCER RES, V11, P7362, DOI 10.1158/1078-0432.CCR-05-0764; Muralidharan R, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07787-4; Nabors LB, 2001, CANCER RES, V61, P2154; Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916; Peng WD, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00427-17; Poggio M, 2019, CELL, V177, P414, DOI 10.1016/j.cell.2019.02.016; Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172; Spolski R, 2018, NAT REV IMMUNOL, V18, P648, DOI 10.1038/s41577-018-0046-y; Sun C, 2018, IMMUNITY, V48, P434, DOI 10.1016/j.immuni.2018.03.014; Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247; Twa DDW, 2014, BLOOD, V123, P2062, DOI 10.1182/blood-2013-10-535443; Wang JP, 2019, CANCER BIOL THER, V20, P979, DOI 10.1080/15384047.2019.1591673; Wang XJ, 2019, NATURE, V571, P127, DOI 10.1038/s41586-019-1340-y; Wang ZH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138780; Wu XQ, 2015, ACS CHEM BIOL, V10, P1476, DOI 10.1021/cb500851u; Young LE, 2009, GASTROENTEROLOGY, V136, P1669, DOI 10.1053/j.gastro.2009.01.010	44	11	11	1	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 25	2021	40	12					2230	2242		10.1038/s41388-021-01689-6	http://dx.doi.org/10.1038/s41388-021-01689-6		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YL8NI	33649535	hybrid, Green Published			2022-12-17	WOS:000623739900006
J	You, BS; Sun, Y; Luo, J; Wang, KL; Liu, Q; Fang, RZ; Liu, BM; Chou, FJ; Wang, RH; Meng, JL; Huang, CP; Yeh, SY; Chang, CS; Xu, WH				You, Bosen; Sun, Yin; Luo, Jie; Wang, Keliang; Liu, Qing; Fang, Ruizhe; Liu, Bingmei; Chou, Fuju; Wang, Ronghao; Meng, Jialin; Huang, Chi-Ping; Yeh, Shuyuan; Chang, Chawnshang; Xu, Wanhai			Androgen receptor promotes renal cell carcinoma (RCC) vasculogenic mimicry (VM) via altering TWIST1 nonsense-mediated decay through lncRNA-TANAR	ONCOGENE			English	Article							MESSENGER-RNA DECAY; LONG NONCODING RNAS; GASTRIC-CANCER; METASTASIS; PATTERNS; UPF1	While the androgen receptor (AR) may influence the progression of clear cell renal cell carcinoma (ccRCC), its role to impact vasculogenic mimicry (VM) to alter the ccRCC progression and metastasis remains obscure. Here, we demonstrated that elevated AR expression was positively correlated with tumor-originated vasculogenesis in ccRCC patients. Consistently, in vitro research revealed AR promoted VM formation in ccRCC cell lines via modulating lncRNA-TANAR/TWIST1 signals. Mechanism dissection showed that AR could increase lncRNA-TANAR (TANAR) expression through binding to the androgen response elements (AREs) located in its promoter region. Moreover, we found that TANAR could impede nonsense-mediated mRNA decay (NMD) of TWIST1 mRNA by direct interaction with TWIST1 5'UTR. A preclinical study using in vivo mouse model with orthotopic xenografts of ccRCC cells further confirmed the in vitro data. Together, these results illustrated that AR-mediated TANAR signals might play a crucial role in ccRCC VM formation and metastasis, and targeting this newly identified AR/TANAR/TWIST1 signaling may help in the development of a novel anti-angiogenesis therapy to better suppress the ccRCC progression.	[You, Bosen; Wang, Keliang; Fang, Ruizhe; Xu, Wanhai] Harbin Med Univ, Affiliated Hosp 4, Dept Urol, Harbin 150001, Peoples R China; [You, Bosen; Liu, Qing] Harbin Med Univ, Affiliated Hosp 2, Dept Urol, Harbin 150001, Peoples R China; [You, Bosen; Sun, Yin; Luo, Jie; Wang, Keliang; Liu, Qing; Fang, Ruizhe; Chou, Fuju; Wang, Ronghao; Meng, Jialin; Yeh, Shuyuan; Chang, Chawnshang] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14646 USA; [You, Bosen; Sun, Yin; Luo, Jie; Wang, Keliang; Liu, Qing; Fang, Ruizhe; Chou, Fuju; Wang, Ronghao; Meng, Jialin; Yeh, Shuyuan; Chang, Chawnshang] Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14646 USA; [You, Bosen; Sun, Yin; Luo, Jie; Wang, Keliang; Liu, Qing; Fang, Ruizhe; Chou, Fuju; Wang, Ronghao; Meng, Jialin; Yeh, Shuyuan; Chang, Chawnshang] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14646 USA; [Liu, Bingmei] Heilongjiang Prov Hosp, Dept Pathol & Cutaneous Oncol, Harbin 150001, Peoples R China; [Huang, Chi-Ping; Chang, Chawnshang] China Med Univ Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan; [Huang, Chi-Ping; Chang, Chawnshang] China Med Univ Hosp, Dept Urol, Taichung 404, Taiwan	Harbin Medical University; Harbin Medical University; University of Rochester; University of Rochester; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan	Xu, WH (corresponding author), Harbin Med Univ, Affiliated Hosp 4, Dept Urol, Harbin 150001, Peoples R China.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14646 USA.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, George Whipple Lab Canc Res, Dept Pathol, Rochester, NY 14646 USA.; Chang, CS (corresponding author), Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY 14646 USA.; Chang, CS (corresponding author), China Med Univ Hosp, Sex Hormone Res Ctr, Taichung 404, Taiwan.; Chang, CS (corresponding author), China Med Univ Hosp, Dept Urol, Taichung 404, Taiwan.	chang@urmc.rochester.edu; xuwanhai@hrbmu.edu.cn	liu, qingqing/HHD-0360-2022; Meng, Jialin/L-8480-2019; Wang, Ronghao/AAV-9769-2021; You, Bosen/AHC-2523-2022	Meng, Jialin/0000-0002-4622-833X; you, bosen/0000-0002-9037-2136; Chang, Chawnshang/0000-0001-8510-3516	NIH [CA155477]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by NIH grant (CA155477).	Adelaiye-Ogala R, 2018, CANCER RES, V78, P2886, DOI 10.1158/0008-5472.CAN-17-3386; Bai J, 2018, J UROLOGY, V199, pE1200; Bao ZQ, 2018, INT J CLIN EXP PATHO, V11, P3656; Cao LM, 2017, ELIFE, V6, DOI 10.7554/eLife.30433; Cui YF, 2015, ONCOTARGET, V6, P11087, DOI 10.18632/oncotarget.3571; Delgado-Bellido D, 2019, CELL DEATH DIFFER, V26, P348, DOI 10.1038/s41418-018-0125-4; Engreitz JM, 2016, NAT REV MOL CELL BIO, V17, P756, DOI 10.1038/nrm.2016.126; Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937; Flippot R, 2019, NAT REV UROL, V16, P484, DOI 10.1038/s41585-019-0195-1; Franks TM, 2010, CELL, V143, P938, DOI 10.1016/j.cell.2010.11.043; Gong CG, 2011, NATURE, V470, P284, DOI 10.1038/nature09701; Gong WC, 2016, ONCOTARGET, V7, P70152, DOI 10.18632/oncotarget.12161; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Guo JQ, 2018, MOL THER-NUCL ACIDS, V10, P170, DOI 10.1016/j.omtn.2017.11.011; Han SH, 2020, MOL ONCOL, V14, P1074, DOI 10.1002/1878-0261.12631; Hendrix MJC, 2016, PHARMACOL THERAPEUT, V159, P83, DOI 10.1016/j.pharmthera.2016.01.006; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; Higgins JPT, 2003, AM J PATHOL, V162, P925, DOI 10.1016/S0002-9440(10)63887-4; Hu ZY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15943; Huang QB, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00701-6; Imamachi N, 2017, GENOME RES, V27, P407, DOI 10.1101/gr.206060.116; Karam R, 2008, ONCOGENE, V27, P4255, DOI 10.1038/onc.2008.62; Khatiwada P, 2020, PEERJ, V8, DOI 10.7717/peerj.8921; Knoll M, 2015, NAT REV ENDOCRINOL, V11, P151, DOI 10.1038/nrendo.2014.229; Kotecha RR, 2019, NAT REV CLIN ONCOL, V16, P621, DOI 10.1038/s41571-019-0209-1; Li R.-H., 2018, CELL DEATH DIS, V9, P1, DOI DOI 10.1038/s41419-017-0012-9; Lopez D, 2009, ARCH BIOCHEM BIOPHYS, V482, P77, DOI 10.1016/j.abb.2008.11.016; Lucca I, 2015, NAT REV UROL, V12, P585, DOI 10.1038/nrurol.2015.232; Luo J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09784-9; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Melero R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10585; Meng J, 2019, ONCOGENE, V38, P228, DOI 10.1038/s41388-018-0428-4; Motzer RJ, 2013, NEW ENGL J MED, V369, P722, DOI 10.1056/NEJMoa1303989; Popp MW, 2018, CURR OPIN GENET DEV, V48, P44, DOI 10.1016/j.gde.2017.10.007; Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004; Rasti A, 2018, CLIN EXP MED, V18, P177, DOI 10.1007/s10238-017-0481-2; Serova M, 2016, ONCOTARGET, V7, P38467, DOI 10.18632/oncotarget.9542; Shang ZQ, 2019, NUCLEIC ACIDS RES, V47, P4211, DOI 10.1093/nar/gkz108; Sun T, 2011, HEPATOLOGY, V54, P1690, DOI 10.1002/hep.24543; Tao W, 2018, BIOCHEM BIOPH RES CO, V504, P629, DOI 10.1016/j.bbrc.2018.08.122; Vartanian AA, 2009, CAN J UROL, V16, P4726; Velez DO, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01556-7; Wang CF, 2019, P NATL ACAD SCI USA, V116, P14620, DOI 10.1073/pnas.1903432116; Wang KF, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1330-x; Wang L, 2015, ONCOTARGET, V6, P11492, DOI 10.18632/oncotarget.3416; Xia Y, 2019, INT J CANCER, V144, P2227, DOI 10.1002/ijc.31958; Xiao T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0902-5; Xie XN, 2019, CLIN SCI, V133, P1457, DOI 10.1042/CS20181061; Yang J, 2017, ONCOTARGET, V8, P47801, DOI 10.18632/oncotarget.17999; Yochum ZA, 2019, ONCOGENE, V38, P656, DOI 10.1038/s41388-018-0482-y; Yochum ZA, 2017, MOL CANCER RES, V15, P1764, DOI 10.1158/1541-7786.MCR-17-0298; Zerbino DR, 2018, NUCLEIC ACIDS RES, V46, pD754, DOI 10.1093/nar/gkx1098; Zhai W, 2017, CELL DEATH DIFFER, V24, P1502, DOI 10.1038/cdd.2017.74; Zhang JX, 2017, ONCOTARGETS THER, V10, P2923, DOI 10.2147/OTT.S135477; Zhang YH, 2013, J SURG ONCOL, V108, P414, DOI 10.1002/jso.23402; Zhao HJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146505; Zhuang JL, 2017, THERANOSTICS, V7, P3053, DOI 10.7150/thno.19542; Zund D, 2013, NAT STRUCT MOL BIOL, V20, P936, DOI 10.1038/nsmb.2635	59	11	11	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1674	1689		10.1038/s41388-020-01616-1	http://dx.doi.org/10.1038/s41388-020-01616-1		JAN 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33510354	hybrid, Green Published, Green Submitted			2022-12-17	WOS:000612563100003
J	Lin, SH; Zhang, XC; Huang, GH; Cheng, L; Lv, J; Zheng, DW; Lin, SM; Wang, SN; Wu, QT; Long, YG; Li, BH; Wei, W; Liu, PT; Pei, DQ; Li, YQ; Wen, ZS; Cui, SZ; Li, P; Sun, XF; Wu, YL; Yao, Y				Lin, Shouheng; Zhang, Xuchao; Huang, Guohua; Cheng, Lin; Lv, Jiang; Zheng, Diwei; Lin, Simiao; Wang, Suna; Wu, Qiting; Long, Youguo; Li, Baiheng; Wei, Wei; Liu, Pentao; Pei, Duanqing; Li, Yangqiu; Wen, Zhesheng; Cui, Shuzhong; Li, Peng; Sun, Xiaofang; Wu, Yilong; Yao, Yao			Myeloid-derived suppressor cells promote lung cancer metastasis by CCL11 to activate ERK and AKT signaling and induce epithelial-mesenchymal transition in tumor cells	ONCOGENE			English	Article							CORRELATE; EOTAXIN-1; MICROENVIRONMENT; EXPRESSION; PATHWAYS; MARKER; STAGE	Myeloid-derived suppressor cells (MDSCs) suppress antitumor immune activities and facilitate cancer progression. Although the concept of immunosuppressive MDSCs is well established, the mechanism that MDSCs regulate non-small cell lung cancer (NSCLC) progression through the paracrine signals is still lacking. Here, we reported that the infiltration of MDSCs within NSCLC tissues was associated with the progression of cancer status, and was positively correlated with the Patient-derived xenograft model establishment, and poor patient prognosis. Intratumoral MDSCs directly promoted NSCLC metastasis and highly expressed chemokines that promote NSCLC cells invasion, including CCL11. CCL11 was capable of activating the AKT and ERK signaling pathways to promote NSCLC metastasis through the epithelial-mesenchymal transition (EMT) process. Moreover, high expression of CCL11 was associated with a poor prognosis in lung cancer as well as other types of cancer. Our findings underscore that MDSCs produce CCL11 to promote NSCLC metastasis via activation of ERK and AKT signaling and induction of EMT, suggesting that the MDSCs-CCL11-ERK/AKT-EMT axis contains potential targets for NSCLC metastasis treatment.	[Lin, Shouheng; Sun, Xiaofang] Guangzhou Med Univ, Affiliated Hosp 3, Key Lab Major Obstetr Dis Guangdong Prov, Key Lab Reprod & Genet Guangdong Higher Educ Inst, Guangzhou, Guangdong, Peoples R China; [Lin, Shouheng; Cheng, Lin; Lv, Jiang; Zheng, Diwei; Lin, Simiao; Wang, Suna; Wu, Qiting; Long, Youguo; Pei, Duanqing; Li, Peng; Yao, Yao] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, State Key Lab Resp Dis, Guangdong Prov Key Lab Stem Cell & Regenerat Med, Guangzhou, Peoples R China; [Lin, Shouheng; Cheng, Lin; Pei, Duanqing; Li, Peng; Sun, Xiaofang] Bioland Lab, Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou, Peoples R China; [Zhang, Xuchao; Wu, Yilong] Guangdong Acad Med Sci, Guangdong Prov Key Lab Translat Med Lung Canc, Guangdong Lung Canc Inst, Med Res Ctr, Guangzhou, Peoples R China; [Huang, Guohua] Southern Med Univ, Nanfang Hosp, Dept Resp Med, Guangzhou, Peoples R China; [Li, Baiheng] Hunan Zhaotai Biopharmaceut Co Ltd, Changsha, Peoples R China; [Wei, Wei] Guangdong Cord Blood Bank, Guangzhou, Guangdong, Peoples R China; [Liu, Pentao] Univ Hong Kong, Li Ka Shing Fac Med, Stem Cell & Regenerat Med Ctr, Sch Biomed Sci, Hong Kong, Peoples R China; [Li, Yangqiu] Jinan Univ, Med Coll, Inst Hematol, Guangzhou, Peoples R China; [Wen, Zhesheng] Sun Yat Sen Univ, Dept Thorac Oncol, Canc Ctr, Guangzhou, Peoples R China; [Cui, Shuzhong] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Guangzhou, Peoples R China	Guangzhou Medical University; Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS; State Key Laboratory of Respiratory Disease; Guangzhou Regenerative Medicine & Health Guangdong Laboratory (Bioisland Laboratory); Guangdong Academy of Medical Sciences & Guangdong General Hospital; Southern Medical University - China; University of Hong Kong; Jinan University; Sun Yat Sen University; Guangzhou Medical University	Sun, XF (corresponding author), Guangzhou Med Univ, Affiliated Hosp 3, Key Lab Major Obstetr Dis Guangdong Prov, Key Lab Reprod & Genet Guangdong Higher Educ Inst, Guangzhou, Guangdong, Peoples R China.; Yao, Y (corresponding author), Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, State Key Lab Resp Dis, Guangdong Prov Key Lab Stem Cell & Regenerat Med, Guangzhou, Peoples R China.; Sun, XF (corresponding author), Bioland Lab, Guangzhou Regenerat Med & Hlth Guangdong Lab, Guangzhou, Peoples R China.; Wu, YL (corresponding author), Guangdong Acad Med Sci, Guangdong Prov Key Lab Translat Med Lung Canc, Guangdong Lung Canc Inst, Med Res Ctr, Guangzhou, Peoples R China.	xiaofangsun@gzhmu.edu.cn; syylwu@live.cn; yao_yao@gibh.ac.cn	zhang, xu/GYE-3558-2022; zhang, xian/GYA-0290-2022; Zhang, xiaoyu/GXA-3206-2022; zhang, xu/GRX-9733-2022; Wu, Yi-Long/AAB-9137-2022; Wu, Yi-Long/GRJ-9238-2022; Li, Peng/AER-7520-2022	Wu, Yi-Long/0000-0002-3611-0258; lin, shouheng/0000-0002-6248-5926	Strategic Priority Research Program of the Chinese Academy of Sciences [XDB19030205]; National Key Research and Development Plan [2017YFE0131600, 2019YFA0111500]; National Natural Science Foundation of China [81961128003, 81972672, 31872800, 81773301, 82003054]; China Postdoctoral Science Foundation [2018M640771]; Guangdong Provincial Significant New Drugs Development [2019B020202003]; Guangdong Basic and Applied Basic Research Foundation [2019A1515110084, 2019A1515010062, 2020A1515011516]; Guangdong Special Support Program [2017TX04R102]; Science and Technology Planning Project of Guangdong Province [2017B030314056]; Natural Science Foundation of Guangdong Province [2020A0505100062]; Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer [2017B030314120]; Guangzhou City Science and Technology Key Topics Project [201904020025]; Guangzhou Science and Technology Plan Project [201907010042, 201904010473]; Foundation of Guangzhou Science and Information Technology of Guangzhou Key Project [201803040009]; Guangzhou Regenerative Medicine and Health Guangdong Laboratory Frontier Research Program [2018GZR110105003]; Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory [2018GZR0201002]; Research Program of the Hefei Institute of Stem Cell and Regenerative Medicine [2019YF001]; Science and Technology Program of Guangzhou [202002020083]	Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); National Key Research and Development Plan; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Guangdong Provincial Significant New Drugs Development; Guangdong Basic and Applied Basic Research Foundation; Guangdong Special Support Program; Science and Technology Planning Project of Guangdong Province; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer; Guangzhou City Science and Technology Key Topics Project; Guangzhou Science and Technology Plan Project; Foundation of Guangzhou Science and Information Technology of Guangzhou Key Project; Guangzhou Regenerative Medicine and Health Guangdong Laboratory Frontier Research Program; Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory; Research Program of the Hefei Institute of Stem Cell and Regenerative Medicine; Science and Technology Program of Guangzhou	We thank the cancer patients who donated their tissues. This work was supported by Strategic Priority Research Program of the Chinese Academy of Sciences (XDB19030205); and National Key Research and Development Plan (2017YFE0131600, 2019YFA0111500); and National Natural Science Foundation of China (81961128003; 81972672; 31872800; 81773301; 82003054); and China Postdoctoral Science Foundation (2018M640771); and Guangdong Provincial Significant New Drugs Development (2019B020202003); and Guangdong Basic and Applied Basic Research Foundation (2019A1515110084, 2019A1515010062, 2020A1515011516); and Guangdong Special Support Program (2017TX04R102); and Science and Technology Planning Project of Guangdong Province (2017B030314056); and Natural Science Foundation of Guangdong Province (2020A0505100062); and Guangdong Provincial Key Lab of Translational Medicine in Lung Cancer (2017B030314120); and Guangzhou City Science and Technology Key Topics Project (201904020025); and Guangzhou Science and Technology Plan Project (201907010042, 201904010473) and Foundation of Guangzhou Science and Information Technology of Guangzhou Key Project (201803040009); and Guangzhou Regenerative Medicine and Health Guangdong Laboratory Frontier Research Program (2018GZR110105003); and Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2018GZR0201002); and Research Program of the Hefei Institute of Stem Cell and Regenerative Medicine (2019YF001); and Science and Technology Program of Guangzhou (202002020083).	Agarwal M, 2013, PROSTATE, V73, P573, DOI 10.1002/pros.22597; Alzahrani AS, 2019, SEMIN CANCER BIOL, V59, P125, DOI 10.1016/j.semcancer.2019.07.009; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Blank S, 2017, ONCOTARGET, V8, P47518, DOI 10.18632/oncotarget.17671; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; Diaz-Montero CM, 2009, CANCER IMMUNOL IMMUN, V58, P49, DOI 10.1007/s00262-008-0523-4; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Huang A, 2013, CANCER IMMUNOL IMMUN, V62, P1439, DOI 10.1007/s00262-013-1450-6; Ichikawa M, 2011, MOL CANCER RES, V9, P133, DOI 10.1158/1541-7786.MCR-10-0394; John T, 2011, CLIN CANCER RES, V17, P134, DOI 10.1158/1078-0432.CCR-10-2224; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kim D, 2015, NAT METHODS, V12, P357, DOI [10.1038/NMETH.3317, 10.1038/nmeth.3317]; Lai YX, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0470-7; Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037; Levina V, 2009, CLIN CANCER RES, V15, P2647, DOI 10.1158/1078-0432.CCR-08-2024; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Lin SH, 2018, MABS-AUSTIN, V10, P1301, DOI 10.1080/19420862.2018.1518948; Lin SH, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01713; Lindau D, 2012, IMMUNOLOGY, V137, P589, DOI 10.1111/imm.12036; Liu H, 2019, NEOPLASMA, V66, P487, DOI 10.4149/neo_2018_181029N805; Mao YM, 2013, CANCER RES, V73, P3877, DOI 10.1158/0008-5472.CAN-12-4115; Marvel D, 2015, J CLIN INVEST, V125, P3356, DOI 10.1172/JCI80005; Mendoza MC, 2011, TRENDS BIOCHEM SCI, V36, P320, DOI 10.1016/j.tibs.2011.03.006; Meyer C, 2014, CANCER IMMUNOL IMMUN, V63, P247, DOI 10.1007/s00262-013-1508-5; Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565; Miyagaki T, 2011, CANCER RES, V71, P2056, DOI 10.1158/0008-5472.CAN-10-3764; Miyagaki T, 2010, J INVEST DERMATOL, V130, P2304, DOI 10.1038/jid.2010.128; NAGY A, 2018, SCI REP UK, V8; Oh K, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3473; Ouzounova M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14979; Peranzoni E, 2010, CURR OPIN IMMUNOL, V22, P238, DOI 10.1016/j.coi.2010.01.021; Rodriguez PC, 2004, CANCER RES, V64, P5839, DOI 10.1158/0008-5472.CAN-04-0465; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Sun HL, 2012, WORLD J GASTROENTERO, V18, P3303, DOI 10.3748/wjg.v18.i25.3303; Tian M, 2016, ONCOTARGET, V7, P32617, DOI 10.18632/oncotarget.8958; Tian W, 2016, ONCOL REP, V35, P2171, DOI 10.3892/or.2016.4561; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Wang DZ, 2017, CANCER RES, V77, P3655, DOI 10.1158/0008-5472.CAN-16-3199; Wang L, 2013, J IMMUNOL, V190, P794, DOI 10.4049/jimmunol.1202088; Watanabe-Takano H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127888; Xu WF, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1118-y; Xu WT, 2015, CELL ADHES MIGR, V9, P317, DOI 10.1080/19336918.2015.1016686; Yang ZZ, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-0843-1; Ye W, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0156-y; Zajkowska M, 2020, CANCERS, V12, DOI 10.3390/cancers12061383; Zhang GB, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.977164; Zhao F, 2012, IMMUNOLOGY, V136, P176, DOI 10.1111/j.1365-2567.2012.03566.x; Zhu F, 2014, ONCOL REP, V31, P2049, DOI 10.3892/or.2014.3060; Zohny SF, 2010, MED ONCOL, V27, P1246, DOI 10.1007/s12032-009-9366-x	49	11	12	4	20	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2021	40	8					1476	1489		10.1038/s41388-020-01605-4	http://dx.doi.org/10.1038/s41388-020-01605-4		JAN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QM6NM	33452453				2022-12-17	WOS:000607998600011
J	Zhang, Z; Zhang, J; Diao, LX; Han, L				Zhang, Zhao; Zhang, Jian; Diao, Lixia; Han, Leng			Small non-coding RNAs in human cancer: function, clinical utility, and characterization	ONCOGENE			English	Review							POLYMERASE-III TRANSCRIPTION; SMALL NUCLEOLAR RNAS; MICRORNA SIGNATURES; BREAST-CANCER; EXPRESSION; ATLAS; PIRNA; IDENTIFICATION; METASTASIS; CARCINOMA	Small non-coding RNAs (sncRNAs) play critical roles in multiple regulatory processes, including transcription, post-transcription, and translation. Emerging evidence reveals the critical roles of sncRNAs in cancer development and their potential role as biomarkers and/or therapeutic targets. In this paper, we review recent research on four sncRNA species with functional significance in cancer: small nucleolar RNAs, transfer RNA, small nuclear RNAs, and piwi-interacting RNAs. We introduce their functional roles in tumorigenesis and discuss the potential utility of sncRNAs as prognostic and diagnostic biomarkers and therapeutic targets. We further summarize approaches to characterize sncRNAs in a high-throughput manner, including the specific library construction and computational framework. Our review provides a perspective of the functions, clinical utility, and characterization of sncRNAs in cancer.	[Zhang, Zhao; Zhang, Jian; Han, Leng] Univ Texas Hlth Sci Ctr Houston, Dept Biochem & Mol Biol, McGovern Med Sch, Houston, TX 77030 USA; [Diao, Lixia] Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center	Zhang, Z; Han, L (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Biochem & Mol Biol, McGovern Med Sch, Houston, TX 77030 USA.; Diao, LX (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Bioinformat & Computat Biol, Houston, TX 77030 USA.	zzzczeus@163.com; ldiao@mdanderson.org; leng.han@uth.tmc.edu	Han, Leng/HCH-3491-2022; ZHANG, Jian/E-7203-2010	Han, Leng/0000-0002-7380-2640; zhang, zhao/0000-0002-3757-8469; ZHANG, Jian/0000-0001-8870-515X	Cancer Prevention Research Institute of Texas (CPRIT) [RR150085, RP190570]; UTHealth Innovation for the Cancer Prevention Research Training Program Postdoctoral Fellowship (Cancer Prevention and Research Institute of Texas) [RP160015]	Cancer Prevention Research Institute of Texas (CPRIT); UTHealth Innovation for the Cancer Prevention Research Training Program Postdoctoral Fellowship (Cancer Prevention and Research Institute of Texas)	We regret that the space limitations have prevented us from including all the relevant literature. This work was supported by the Cancer Prevention Research Institute of Texas (CPRIT; RR150085 and RP190570) to the CPRIT Scholar in Cancer Research (LH). This work was also supported by UTHealth Innovation for the Cancer Prevention Research Training Program Postdoctoral Fellowship (Cancer Prevention and Research Institute of Texas grant # RP160015). We thank LeeAnn Chastain for editorial assistance.	Andersen PR, 2017, NATURE, V549, P54, DOI 10.1038/nature23482; Bachellerie JP, 2002, BIOCHIMIE, V84, P775, DOI 10.1016/S0300-9084(02)01402-5; Balaratnam S, 2018, NUCLEIC ACIDS RES, V46, P10635, DOI 10.1093/nar/gky728; Beggs JD, 2005, BIOCHEM SOC T, V33, P433, DOI 10.1042/BST0330433; Campbell PJ, 2020, NATURE, V578, P82, DOI 10.1038/s41586-020-1969-6; Cao PB, 2018, GASTROENTEROLOGY, V155, P542, DOI 10.1053/j.gastro.2018.04.020; Chalbatani GM, 2019, PRACT LAB MED, V13, DOI 10.1016/j.plabm.2018.e00113; Chan PP, 2016, NUCLEIC ACIDS RES, V44, pD184, DOI 10.1093/nar/gkv1309; Chen WJ, 2015, CURR BIOL, V25, pR181, DOI 10.1016/j.cub.2014.11.059; Cheng CJ, 2015, NATURE, V518, P107, DOI 10.1038/nature13905; Cheng J, 2011, CLIN CHIM ACTA, V412, P1621, DOI 10.1016/j.cca.2011.05.015; Cheng Z, 2017, ONCOTARGET, V8, P112867, DOI 10.18632/oncotarget.22842; Chu A, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkv808; Chu HY, 2015, CANCER LETT, V356, P561, DOI 10.1016/j.canlet.2014.10.004; Clarke CJ, 2016, CURR BIOL, V26, P755, DOI 10.1016/j.cub.2016.01.045; Cui L, 2017, GASTROENTEROLOGY, V153, P292, DOI 10.1053/j.gastro.2017.03.050; Dever TE, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a013706; Dong XH, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01627; Dudda JC, 2013, IMMUNITY, V38, P742, DOI 10.1016/j.immuni.2012.12.006; Dupuis-Sandoval F, 2015, WIRES RNA, V6, P381, DOI 10.1002/wrna.1284; Dvinge H, 2019, GENOME RES, V29, P1591, DOI 10.1101/gr.246678.118; Erber L, 2020, RNA BIOL, V17, P23, DOI 10.1080/15476286.2019.1664250; Fang XL, 2017, J MOL CELL BIOL, V9, P243, DOI 10.1093/jmcb/mjw048; Felton-Edkins ZA, 2003, EMBO J, V22, P2422, DOI 10.1093/emboj/cdg240; Gao L, 2015, INT J CANCER, V136, pE623, DOI 10.1002/ijc.29169; Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3; Girard A, 2006, NATURE, V442, P199, DOI 10.1038/nature04917; Gomez-Roman N, 2003, NATURE, V421, P290, DOI 10.1038/nature01327; Gong J, 2017, CELL REP, V21, P1968, DOI 10.1016/j.celrep.2017.10.070; Goodarzi H, 2016, CELL, V165, P1416, DOI 10.1016/j.cell.2016.05.046; Grady WM, 2010, GUT, V59, P706, DOI 10.1136/gut.2009.200022; Grewal SS, 2015, BBA-GENE REGUL MECH, V1849, P898, DOI 10.1016/j.bbagrm.2014.12.005; Hernandez-Alias X, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20199275; Hoffmann A, 2018, BIOINFORMATICS, V34, P1116, DOI 10.1093/bioinformatics/btx756; INOUE D, 2019, BLOOD S, V134, DOI DOI 10.1182/blood-2019-124616; Isakova A, 2020, P NATL ACAD SCI USA, V117, P25634, DOI 10.1073/pnas.2002277117; Jorjani H, 2016, NUCLEIC ACIDS RES, V44, P5068, DOI 10.1093/nar/gkw386; Kassavetis GA, 2001, EMBO J, V20, P2823, DOI 10.1093/emboj/20.11.2823; Kiss T, 2010, MOL CELL, V37, P597, DOI 10.1016/j.molcel.2010.01.032; Korsunsky I, 2017, J INVEST MED, V65, P1068, DOI 10.1136/jim-2017-000457; Kosmyna B., 2020, BIORXIV, DOI [10.1101/2020.01.24.917260, DOI 10.1101/2020.01.24.917260]; Lee YJ, 2016, BIOMATERIALS, V101, P143, DOI 10.1016/j.biomaterials.2016.05.052; Li YP, 2015, MOL MED, V21, P381, DOI 10.2119/molmed.2014.00203; Liang JN, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00587; Liu YM, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01228-z; Liu YM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1052-9; Mannoor K, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-104; Martinez VD, 2015, SCI REP-UK, V5, DOI 10.1038/srep10423; Moyano M, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0133-5; Murillo OD, 2019, CELL, V177, P463, DOI 10.1016/j.cell.2019.02.018; Oh JM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13993-7; Olson P, 2009, GENE DEV, V23, P2152, DOI 10.1101/gad.1820109; Pan T, 2018, CELL RES, V28, P395, DOI 10.1038/s41422-018-0013-y; Paranjape T, 2009, GUT, V58, P1546, DOI 10.1136/gut.2009.179531; Pavon-Eternod M, 2009, NUCLEIC ACIDS RES, V37, P7268, DOI 10.1093/nar/gkp787; Pedroza-Torres A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01404; Peng Y, 2016, SIGNAL TRANSDUCT TAR, V1, DOI 10.1038/sigtrans.2015.4; Romano G, 2017, CARCINOGENESIS, V38, P485, DOI 10.1093/carcin/bgx026; Santos M, 2019, TRENDS MOL MED, V25, P853, DOI 10.1016/j.molmed.2019.05.011; Schorn AJ, 2017, CELL, V170, P61, DOI 10.1016/j.cell.2017.06.013; Shigematsu M, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkx005; Shuai SM, 2019, NATURE, V574, P712, DOI 10.1038/s41586-019-1651-z; Siprashvili Z, 2016, NAT GENET, V48, P53, DOI 10.1038/ng.3452; Su H, 2014, ONCOGENE, V33, P1348, DOI 10.1038/onc.2013.89; Suzuki HI, 2015, ONCOGENE, V34, P3085, DOI 10.1038/onc.2014.254; Suzuki H, 2019, NATURE, V574, P707, DOI 10.1038/s41586-019-1650-0; Taft RJ, 2009, RNA, V15, P1233, DOI 10.1261/rna.1528909; Tan LP, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0940-3; Vickers KC, 2015, TRENDS BIOCHEM SCI, V40, P4, DOI 10.1016/j.tibs.2014.10.009; Vinson V., 2015, SCIENCE, V349, p1178.3, DOI [10.1126/science.349.6253.1178-c, DOI 10.1126/science.349.6253.1178-c, DOI 10.1126/SCIENCE.349.6253.1178-C]; Wang XY, 2016, SCI REP-UK, V6, DOI 10.1038/srep28260; Warashina M, 2001, RNA, V13, P277, DOI [10.1016/B978-008043408-7/50037-X, DOI 10.1016/B978-008043408-7/50037-X]; Weinstein JN, 2013, NAT GENET, V45, P1113, DOI 10.1038/ng.2764; Wong CM, 2018, NAT REV GASTRO HEPAT, V15, P137, DOI 10.1038/nrgastro.2017.169; Xiang Y, 2018, TRENDS CANCER, V4, P823, DOI 10.1016/j.trecan.2018.09.009; Xing Y, 2006, NUCLEIC ACIDS RES, V34, P3150, DOI 10.1093/nar/gkl396; Yang QY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11312-8; Yang Y, 2018, ONCOL LETT, V15, P368, DOI 10.3892/ol.2017.7338; Zhang Z, 2020, RNA BIOL, V17, P1674, DOI 10.1080/15476286.2019.1657744; Zhang Z, 2018, COMMUN BIOL, V1, DOI 10.1038/s42003-018-0239-8; Zheng D, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0170-5; Zheng GQ, 2015, NAT METHODS, V12, P835, DOI [10.1038/NMETH.3478, 10.1038/nmeth.3478]; Zheng TS, 2010, INT J CANCER, V126, P2, DOI 10.1002/ijc.24782; Zhou FB, 2017, NAT CELL BIOL, V19, P844, DOI 10.1038/ncb3563	84	11	11	6	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 4	2021	40	9					1570	1577		10.1038/s41388-020-01630-3	http://dx.doi.org/10.1038/s41388-020-01630-3		JAN 2021	8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QR9UA	33452456				2022-12-17	WOS:000607998600002
J	Ochiiwa, H; Ailiken, G; Yokoyama, M; Yamagata, K; Nagano, H; Yoshimura, C; Muraoka, H; Ishida, K; Haruma, T; Nakayama, A; Hashimoto, N; Murata, K; Nishimura, M; Kawashima, Y; Ohara, O; Ohkubo, S; Tanaka, T				Ochiiwa, Hiroaki; Ailiken, Guzhanuer; Yokoyama, Masataka; Yamagata, Kazuyuki; Nagano, Hidekazu; Yoshimura, Chihoko; Muraoka, Hiromi; Ishida, Keiji; Haruma, Tomonori; Nakayama, Akitoshi; Hashimoto, Naoko; Murata, Kazutaka; Nishimura, Motoi; Kawashima, Yusuke; Ohara, Osamu; Ohkubo, Shuichi; Tanaka, Tomoaki			TAS4464, a NEDD8-activating enzyme inhibitor, activates both intrinsic and extrinsic apoptotic pathways via c-Myc-mediated regulation in acute myeloid leukemia	ONCOGENE			English	Article							PEVONEDISTAT TAK-924/MLN4924; PHASE-I; CULLIN; NEDD8; FLIP; MLN4924; PROTEIN; CHEMORESISTANCE; TRANSCRIPTION; EXPRESSION	TAS4464, a potent, selective small molecule NEDD8-activating enzyme (NAE) inhibitor, leads to inactivation of cullin-RING E3 ubiquitin ligases (CRLs) and consequent accumulations of its substrate proteins. Here, we investigated the antitumor properties and action mechanism of TAS4464 in acute myeloid leukemia (AML). TAS4464 induced apoptotic cell death in various AML cell lines. TAS4464 treatments resulted in the activation of both the caspase-9-mediated intrinsic apoptotic pathway and caspase-8-mediated extrinsic apoptotic pathway in AML cells; combined treatment with inhibitors of these caspases markedly diminished TAS4464-induced apoptosis. In each apoptotic pathway, TAS4464 induced the mRNA transcription of the intrinsic proapoptotic factor NOXA and decreased that of the extrinsic antiapoptotic factor c-FLIP. RNA-sequencing analysis showed that the signaling pathway of the CRL substrate c-Myc was enriched after TAS4464 treatment. Chromatin immunoprecipitation (ChIP) assay revealed that TAS4464-induced c-Myc bound to the PMAIP1 (encoding NOXA) and CFLAR (encoding c-FLIP) promoter regions, and siRNA-mediated c-Myc knockdown neutralized both TAS4464-mediated NOXA induction and c-FLIP downregulation. TAS4464 activated both caspase-8 and caspase-9 along with an increase in NOXA and a decrease in c-FLIP, resulting in complete tumor remission in a human AML xenograft model. These findings suggest that NAE inhibition leads to anti-AML activity via a novel c-Myc-dependent apoptosis induction mechanism.	[Ochiiwa, Hiroaki; Yoshimura, Chihoko; Muraoka, Hiromi; Ishida, Keiji; Haruma, Tomonori; Ohkubo, Shuichi] Taiho Pharmaceut Co Ltd, Discovery & Preclin Res Div, 3 Okubo, Tsukuba, Ibaraki 3002611, Japan; [Ailiken, Guzhanuer; Yokoyama, Masataka; Yamagata, Kazuyuki; Nagano, Hidekazu; Nakayama, Akitoshi; Hashimoto, Naoko; Murata, Kazutaka; Tanaka, Tomoaki] Chiba Univ, Grad Sch Med, Dept Mol Diag, Chiba 2608670, Japan; [Nishimura, Motoi] Chiba Univ Hosp, Div Lab Med Clin Genet & Prote, Chiba 2608670, Japan; [Kawashima, Yusuke; Ohara, Osamu] Kazusa DNA Res Inst, Dept Appl Genom, Kisarazu, Chiba 2920818, Japan	Taiho Pharmaceutical; Chiba University; Chiba University; Kazusa DNA Research Institute	Ohkubo, S (corresponding author), Taiho Pharmaceut Co Ltd, Discovery & Preclin Res Div, 3 Okubo, Tsukuba, Ibaraki 3002611, Japan.; Tanaka, T (corresponding author), Chiba Univ, Grad Sch Med, Dept Mol Diag, Chiba 2608670, Japan.	s-ohkubo@taiho.co.jp; tomoaki@restaff.chiba-u.jp	Ohara, Osamu/G-5448-2015	Ohara, Osamu/0000-0002-3328-9571; YAMAGATA, Kazuyuki/0000-0002-5804-6090	Taiho Pharmaceutical Co., Ltd., Japan; Fostering Joint International Research [19KK0407]; Naito Foundation; Novartis Foundation (Japan); Cell Science Research Foundation; Princess Takamatsu Cancer Research Fund; Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care; Hamaguchi biochemistry Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Yamaguchi endocrine Foundation; Donated Fund of Next Generation Hormone Academy for Human Health Longevity; Takeda Science Foundation;  [19H03708];  [20K08397];  [20K07561];  [18K08464];  [19K07635];  [18K07439]	Taiho Pharmaceutical Co., Ltd., Japan; Fostering Joint International Research; Naito Foundation(Naito Memorial Foundation); Novartis Foundation (Japan)(Novartis); Cell Science Research Foundation(Cell Science Research Foundation, Japan); Princess Takamatsu Cancer Research Fund; Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care; Hamaguchi biochemistry Foundation; Mochida Memorial Foundation for Medical and Pharmaceutical Research; Yamaguchi endocrine Foundation; Donated Fund of Next Generation Hormone Academy for Human Health Longevity; Takeda Science Foundation(Takeda Science Foundation (TSF)); ; ; ; ; ; 	This study was funded by Taiho Pharmaceutical Co., Ltd., Japan, and was supported by Grants-in-Aid for Scientific Research-KAKENHI-, Scientific Research [(B) #19H03708, (C) #20K08397, (C) #20K07561, (C) #18K08464, (C) #19K07635, (C) #18K07439], and Fostering Joint International Research [(A) #19KK0407]. This work was partly supported by the Takeda Science Foundation, the Naito Foundation, the Novartis Foundation (Japan), the Cell Science Research Foundation, the Princess Takamatsu Cancer Research Fund, the Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care, the Hamaguchi biochemistry Foundation, the Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Yamaguchi endocrine Foundation and the Donated Fund of Next Generation Hormone Academy for Human Health & Longevity.	Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bhatia S, 2016, INVEST NEW DRUG, V34, P439, DOI 10.1007/s10637-016-0348-5; Bogenberger J, 2017, ONCOTARGET, V8, P107206, DOI 10.18632/oncotarget.22284; Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7; Conti S, 2016, CELL SIGNAL, V28, P1262, DOI 10.1016/j.cellsig.2016.06.003; DiNardo CD, 2019, BLOOD, V133, P7, DOI 10.1182/blood-2018-08-868752; Enchev RI, 2015, NAT REV MOL CELL BIO, V16, P30, DOI 10.1038/nrm3919; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; Hoffman B, 2008, ONCOGENE, V27, P6462, DOI 10.1038/onc.2008.312; Hori T, 1999, ONCOGENE, V18, P6829, DOI 10.1038/sj.onc.1203093; Kamitani T, 1997, J BIOL CHEM, V272, P28557, DOI 10.1074/jbc.272.45.28557; Kawashima Y, 2019, J PROTEOME RES, V18, P301, DOI 10.1021/acs.jproteome.8b00609; Kiechle FL, 2002, CLIN CHIM ACTA, V326, P27, DOI 10.1016/S0009-8981(02)00297-8; Knorr KLB, 2015, CELL DEATH DIFFER, V22, P2133, DOI 10.1038/cdd.2015.74; Konopleva M, 2002, BRIT J HAEMATOL, V118, P521, DOI 10.1046/j.1365-2141.2002.03637.x; Krueger A, 2001, MOL CELL BIOL, V21, P8247, DOI 10.1128/MCB.21.24.8247-8254.2001; Kumar C Chandra, 2011, Genes Cancer, V2, P95, DOI 10.1177/1947601911408076; Li LH, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju083; Li XX, 2019, ONCOTARGETS THER, V12, P3295, DOI 10.2147/OTT.S194549; Lockhart AC, 2019, INVEST NEW DRUG, V37, P87, DOI 10.1007/s10637-018-0610-0; McLornan D, 2013, BRIT J HAEMATOL, V160, P188, DOI 10.1111/bjh.12108; Mehta SV, 2013, NEOPLASMA, V60, P666, DOI 10.4149/neo_2013_085; Muraoka H, 2019, CANCER SCI, V110, P3802, DOI 10.1111/cas.14209; Pan Yongfu, 2012, Int J Biochem Mol Biol, V3, P273; Pan ZQ, 2004, ONCOGENE, V23, P1985, DOI 10.1038/sj.onc.1207414; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Phesse TJ, 2014, CELL DEATH DIFFER, V21, P956, DOI 10.1038/cdd.2014.15; Read MA, 2000, MOL CELL BIOL, V20, P2326, DOI 10.1128/MCB.20.7.2326-2333.2000; Ricci MS, 2004, MOL CELL BIOL, V24, P8541, DOI 10.1128/MCB.24.19.8541-8555.2004; Sarantopoulos J, 2016, CLIN CANCER RES, V22, P847, DOI 10.1158/1078-0432.CCR-15-1338; Shah JJ, 2016, CLIN CANCER RES, V22, P34, DOI 10.1158/1078-0432.CCR-15-1237; Soucy Teresa A, 2010, Genes Cancer, V1, P708, DOI 10.1177/1947601910382898; Soucy TA, 2009, CLIN CANCER RES, V15, P3912, DOI 10.1158/1078-0432.CCR-09-0343; Stennicke HR, 1998, BBA-PROTEIN STRUCT M, V1387, P17, DOI 10.1016/S0167-4838(98)00133-2; Sweet K, 2014, CURR HEMATOL MALIG R, V9, P109, DOI 10.1007/s11899-014-0199-0; Swords RT, 2015, BRIT J HAEMATOL, V169, P534, DOI 10.1111/bjh.13323; Tanaka T, 2020, DRYAD DIGITAL REPOSI, DOI [10.5061/dryad.hqbzkh1f6, DOI 10.5061/DRYAD.HQBZKH1F6]; Wirth M, 2014, NUCLEIC ACIDS RES, V42, P10433, DOI 10.1093/nar/gku763; Xie P, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.195; Xie P, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4733; Yoshimura C, 2019, MOL CANCER THER, V18, P1205, DOI 10.1158/1535-7163.MCT-18-0644; Zhao LQ, 2011, MOL CANCER THER, V10, P2415, DOI 10.1158/1535-7163.MCT-11-0401; Zhou LS, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0979-1	43	11	11	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1217	1230		10.1038/s41388-020-01586-4	http://dx.doi.org/10.1038/s41388-020-01586-4		JAN 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420360	Green Published, hybrid			2022-12-17	WOS:000607346000017
J	Roggero, CM; Jin, LJ; Cao, SB; Sonavane, R; Kopplin, NG; Ta, HQ; Ekoue, DN; Witwer, M; Ma, SH; Liu, H; Ma, TF; Gioeli, D; Raj, GV; Dong, Y				Roggero, Carlos M.; Jin, Lianjin; Cao, Subing; Sonavane, Rajni; Kopplin, Noa G.; Ta, Huy Q.; Ekoue, Dede N.; Witwer, Michael; Ma, Shihong; Liu, Hong; Ma, Tianfang; Gioeli, Daniel; Raj, Ganesh V.; Dong, Yan			A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells	ONCOGENE			English	Article							SPLICE VARIANTS; RESISTANCE; ENZALUTAMIDE; ABIRATERONE; AR-V7; AR; BINDING; GROWTH; INHIBITION; EXPRESSION	Expression of the androgen receptor splice variant 7 (AR-V7) is frequently detected in castrate resistant prostate cancer and associated with resistance to AR-targeted therapies. While we have previously noted that homodimerization is required for the transcriptional activity of AR-V7 and that AR-V7 can also form heterodimers with the full-length AR (AR-FL), there are still many gaps of knowledge in AR-V7 stepwise activation. In the present study, we show that neither AR-V7 homodimerization nor AR-V7/AR-FL heterodimerization requires cofactors or DNA binding. AR-V7 can enter the nucleus as a monomer and drive a transcriptional program and DNA-damage repair as a homodimer. While forming a heterodimer with AR-FL to induce nuclear localization of unliganded AR-FL, AR-V7 does not need to interact with AR-FL to drive gene transcription or DNA-damage repair in prostate cancer cells that co-express AR-V7 and AR-FL. These data indicate that AR-V7 can function independently of its interaction with AR-FL in the true castrate state or "absence of ligand", providing support for the utility of targeting AR-V7 in improving outcomes of patients with castrate resistant prostate cancer.	[Roggero, Carlos M.; Sonavane, Rajni; Kopplin, Noa G.; Ekoue, Dede N.; Witwer, Michael; Ma, Shihong; Raj, Ganesh V.] UT SouthWestern Med Ctr Dallas, Dept Urol, Dallas, TX USA; [Jin, Lianjin; Cao, Subing; Ma, Tianfang; Dong, Yan] Tulane Univ, Sch Med, Tulane Canc Ctr, Dept Struct & Cellular Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA; [Ta, Huy Q.; Gioeli, Daniel] Univ Virginia, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA USA; [Liu, Hong] Tulane Univ, Sch Med, Dept Biochem & Mol Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA; [Raj, Ganesh V.] UT Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA	Tulane University; University of Virginia; Tulane University	Raj, GV (corresponding author), UT SouthWestern Med Ctr Dallas, Dept Urol, Dallas, TX USA.; Dong, Y (corresponding author), Tulane Univ, Sch Med, Tulane Canc Ctr, Dept Struct & Cellular Biol, 1430 Tulane Ave, New Orleans, LA 70112 USA.; Raj, GV (corresponding author), UT Southwestern Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA.	ganesh.raj@utsouthwestern.edu; ydong@tulane.edu		Ma, Tianfang/0000-0003-4161-882X	Department of Defense [W81XWH-19-1-0363, W81XWH-17-10674, W81XWH-15-1-0439, W81XWH-16-1-0317]; Prostate Cancer Foundation Challenge Award; Mimi and John Cole Foundation; Charles Y. Pak grant; National Institutes of Health [R01CA188609, R01 CA178338]	Department of Defense(United States Department of Defense); Prostate Cancer Foundation Challenge Award; Mimi and John Cole Foundation; Charles Y. Pak grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded by grants from the Department of Defense (W81XWH-19-1-0363, W81XWH-17-10674), Prostate Cancer Foundation Challenge Award, Mimi and John Cole Foundation and Charles Y. Pak grant to GVR, from the National Institutes of Health (R01CA188609) and the Department of Defense (W81XWH-15-1-0439 and W81XWH-16-1-0317) to YD, and from the National Institutes of Health (R01 CA178338) to DG. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.	Anders Simon, 2010, Genome Biol, V11, pR106, DOI 10.1186/gb-2010-11-10-r106; Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815; Bai SS, 2019, ONCOGENE, V38, P4977, DOI 10.1038/s41388-019-0768-8; Cai CM, 2011, ENDOCR-RELAT CANCER, V18, pR175, DOI 10.1530/ERC-10-0339; Cai L, 2018, MOL CELL, V72, P341, DOI 10.1016/j.molcel.2018.08.029; Cao B, 2014, ONCOTARGET, V5, P1646, DOI 10.18632/oncotarget.1802; Cao SB, 2019, ONCOGENE, V38, P7060, DOI 10.1038/s41388-019-0947-7; Cao SB, 2016, ENDOCR-RELAT CANCER, V23, pT199, DOI 10.1530/ERC-16-0298; Cato L, 2019, CANCER CELL, V35, P401, DOI 10.1016/j.ccell.2019.01.008; Chan SC, 2015, NUCLEIC ACIDS RES, V43, P5880, DOI 10.1093/nar/gkv262; Chan SC, 2012, J BIOL CHEM, V287, P19736, DOI 10.1074/jbc.M112.352930; Chen Z, 2018, P NATL ACAD SCI USA, V115, P6810, DOI 10.1073/pnas.1718811115; Davis ID, 2019, NEW ENGL J MED, V381, P121, DOI 10.1056/NEJMoa1903835; de Bono J, 2017, NEW ENGL J MED, V377, P1694; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dong Y, 2004, CANCER RES, V64, P19, DOI 10.1158/0008-5472.CAN-03-2789; Dong Y, 2005, MOL CANCER THER, V4, P1047, DOI 10.1158/1535-7163.MCT-05-0124; Dubbink HJ, 2004, MOL ENDOCRINOL, V18, P2132, DOI 10.1210/me.2003-0375; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; He YD, 2018, NUCLEIC ACIDS RES, V46, P1895, DOI 10.1093/nar/gkx1306; Hornberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019059; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Hussain M, 2018, NEW ENGL J MED, V378, P2465, DOI 10.1056/NEJMoa1800536; Kohli M, 2017, CLIN CANCER RES, V23, P4704, DOI 10.1158/1078-0432.CCR-17-0017; Kounatidou E, 2019, NUCLEIC ACIDS RES, V47, P5634, DOI 10.1093/nar/gkz286; Krause WC, 2014, INT J BIOCHEM CELL B, V54, P49, DOI 10.1016/j.biocel.2014.06.013; Li B, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-323; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Loriot Y, 2017, CANCER-AM CANCER SOC, V123, P253, DOI 10.1002/cncr.30336; Lu J, 2015, J UROLOGY, V193, P690, DOI 10.1016/j.juro.2014.08.043; Magani F, 2018, MOL SYST BIOL, V14, DOI 10.15252/msb.20188202; Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728; Nadiminty N, 2013, MOL CANCER THER, V12, P1629, DOI 10.1158/1535-7163.MCT-13-0027; Nyquist MD, 2013, P NATL ACAD SCI USA, V110, P17492, DOI 10.1073/pnas.1308587110; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Sartor O, 2018, NEW ENGL J MED, V378, P645, DOI 10.1056/NEJMra1701695; Scher HI, 2016, JAMA ONCOL, V2, P1441, DOI 10.1001/jamaoncol.2016.1828; Shaffer PL, 2004, P NATL ACAD SCI USA, V101, P4758, DOI 10.1073/pnas.0401123101; Shafi AA, 2015, ONCOTARGET, V6, P31997, DOI 10.18632/oncotarget.5585; Sharp A, 2019, EUR UROL, V76, P676, DOI 10.1016/j.eururo.2019.04.006; Sharp A, 2019, J CLIN INVEST, V129, P192, DOI 10.1172/JCI122819; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Ta HQ, 2020, ELIFE, V9, DOI 10.7554/eLife.51378; Todenhofer T, 2017, J UROLOGY, V197, P135, DOI 10.1016/j.juro.2016.06.094; Uo T, 2017, ONCOGENE, V36, P1440, DOI 10.1038/onc.2016.313; van Royen ME, 2012, J CELL SCI, V125, P1970, DOI 10.1242/jcs.096792; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Welti J, 2016, EUR UROL, V70, P599, DOI 10.1016/j.eururo.2016.03.049; Xu D, 2015, CANCER RES, V75, P3663, DOI 10.1158/0008-5472.CAN-15-0381; Yin Y, 2017, CANCER RES, V77, P4745, DOI 10.1158/0008-5472.CAN-17-0164; Yuan X, 2014, ONCOGENE, V33, P2815, DOI 10.1038/onc.2013.235; Zhan Y, 2017, MOL CANCER RES, V15, P59, DOI 10.1158/1541-7786.MCR-16-0236	54	11	11	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2021	40	6					1106	1117		10.1038/s41388-020-01585-5	http://dx.doi.org/10.1038/s41388-020-01585-5		DEC 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QG0OL	33323969	Green Accepted			2022-12-17	WOS:000599126500002
J	Buckup, M; Rice, MA; Hsu, EC; Garcia-Marques, F; Liu, SQ; Aslan, M; Bermudez, A; Huang, JT; Pitteri, SJ; Stoyanova, T				Buckup, Mark; Rice, Meghan A.; Hsu, En-Chi; Garcia-Marques, Fernando; Liu, Shiqin; Aslan, Merve; Bermudez, Abel; Huang, Jiaoti; Pitteri, Sharon J.; Stoyanova, Tanya			Plectin is a regulator of prostate cancer growth and metastasis	ONCOGENE			English	Article							ABIRATERONE ACETATE; SURVIVAL ANALYSIS; DOUBLE-BLIND; CLUSTERIN; ENZALUTAMIDE; MEN; NEUROENDOCRINE; EXPRESSION; INHIBITOR; INTEGRITY	Prostate cancer is responsible for over 30,000 US deaths annually, attributed largely to incurable metastatic disease. Here, we demonstrate that high levels of plectin are associated with localized and metastatic human prostate cancer when compared to benign prostate tissues. Knock-down of plectin inhibits prostate cancer cell growth and colony formation in vitro, and growth of prostate cancer xenografts in vivo. Plectin knock-down further impairs aggressive and invasive cellular behavior assessed by migration, invasion, and wound healing in vitro. Consistently, plectin knock-down cells have impaired metastatic colonization to distant sites including liver, lung, kidney, bone, and genitourinary system. Plectin knock-down inhibited number of metastases per organ, as well as decreased overall metastatic burden. To gain insights into the role of plectin in prostate cancer growth and metastasis, we performed proteomic analysis of prostate cancer plectin knock-down xenograft tissues. Gene set enrichment analysis shows an increase in levels of proteins involved with extracellular matrix and laminin interactions, and a decrease in levels of proteins regulating amino acid metabolism, cytoskeletal proteins, and cellular response to stress. Collectively these findings demonstrate that plectin is an important regulator of prostate cancer cell growth and metastasis.	[Buckup, Mark; Rice, Meghan A.; Hsu, En-Chi; Garcia-Marques, Fernando; Liu, Shiqin; Aslan, Merve; Bermudez, Abel; Pitteri, Sharon J.; Stoyanova, Tanya] Stanford Univ, Dept Radiol, Canary Ctr Stanford Canc Early Detect, Palo Alto, CA 94304 USA; [Huang, Jiaoti] Duke Univ, Dept Pathol, Durham, NC 27706 USA	Stanford University; Duke University	Stoyanova, T (corresponding author), Stanford Univ, Dept Radiol, Canary Ctr Stanford Canc Early Detect, Palo Alto, CA 94304 USA.	stanya@stanford.edu	Hsu, En-Chi/AAH-4589-2021	Hsu, En-Chi/0000-0002-5671-6169; Garcia-Marques, Fernando/0000-0002-2105-2905; Buckup, Mark/0000-0001-6938-3474; Rice, Meghan/0000-0003-4578-0461	Canary Foundation; National Institutes of Health/National Cancer Institute (NCI) [R37CA240822, R01CA244281, R03CA230819]; CDMRP [W81XWH1810141]	Canary Foundation; National Institutes of Health/National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CDMRP(United States Department of Defense)	TS is supported by the Canary Foundation, the National Institutes of Health/National Cancer Institute (NCI) R37CA240822, R01CA244281 and R03CA230819. MAR is supported by the CDMRP through Award No. W81XWH1810141.	Andra K, 1997, GENE DEV, V11, P3143, DOI 10.1101/gad.11.23.3143; Bausch D, 2011, CLIN CANCER RES, V17, P302, DOI 10.1158/1078-0432.CCR-10-0999; Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095; Bekelman JE, 2018, J ONCOL PRACT, V14, P618, DOI 10.1200/JOP.18.00434; Bubendorf L, 2000, HUM PATHOL, V31, P578, DOI 10.1053/hp.2000.6698; Burch TC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065005; Burgstaller G, 2010, MOL BIOL CELL, V21, P3362, DOI 10.1091/mbc.E10-02-0094; Damber JE, 2008, LANCET, V371, P1710, DOI 10.1016/S0140-6736(08)60729-1; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de Wit R, 2019, NEW ENGL J MED, V381, P2506, DOI 10.1056/NEJMoa1911206; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; Drake CG, 2014, ONCOLOGY-NY, V28, P974; Evans CP, 2016, EUR UROL, V70, P675, DOI 10.1016/j.eururo.2016.03.017; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Gatto L, 2012, BIOINFORMATICS, V28, P288, DOI 10.1093/bioinformatics/btr645; Graff JN, 2015, EXPERT OPIN PHARMACO, V16, P749, DOI 10.1517/14656566.2015.1016911; Hsu EC, 2020, P NATL ACAD SCI USA, V117, P2032, DOI 10.1073/pnas.1905384117; Huang JT, 2005, AM J PATHOL, V166, P1807, DOI 10.1016/S0002-9440(10)62490-X; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Katada K, 2012, J PROTEOMICS, V75, P1803, DOI 10.1016/j.jprot.2011.12.018; Kim N, 2012, ALCOHOL CLIN EXP RES, V36, P72, DOI 10.1111/j.1530-0277.2011.01588.x; Knott SRV, 2018, NATURE, V554, P378, DOI 10.1038/nature25465; Koster J, 2004, MOL BIOL CELL, V15, P1211, DOI 10.1091/mbc.E03-09-0697; Kyriakopoulos CE, 2018, J CLIN ONCOL, V36, P1080, DOI 10.1200/JCO.2017.75.3657; Litjens SHM, 2006, TRENDS CELL BIOL, V16, P376, DOI 10.1016/j.tcb.2006.05.004; Mi HY, 2019, NAT PROTOC, V14, P703, DOI 10.1038/s41596-019-0128-8; Navarro P, 2014, J PROTEOME RES, V13, P1234, DOI 10.1021/pr4006958; Osmanagic-Myers S, 2004, J BIOL CHEM, V279, P18701, DOI 10.1074/jbc.M312382200; Osmanagic-Myers S, 2006, J CELL BIOL, V174, P557, DOI 10.1083/jcb.200605172; Osmanagic-Myers S, 2015, J CELL SCI, V128, P4138, DOI 10.1242/jcs.172056; Peng M, 2019, CANCER MANAG RES, V11, P2405, DOI 10.2147/CMAR.S196273; Porporato PE, 2016, CELL MOL LIFE SCI, V73, P1349, DOI 10.1007/s00018-015-2100-2; Raymond AC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51004-3; Rice MA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00801; Rice MA, 2019, MOL CANCER THER, V18, P1230, DOI 10.1158/1535-7163.MCT-18-0804; Ryan CJ, 2015, LANCET ONCOL, V16, P152, DOI 10.1016/S1470-2045(14)71205-7; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Ryan CJ, 2010, J CLIN ONCOL, V28, P1481, DOI 10.1200/JCO.2009.24.1281; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Scaltriti M, 2004, CANCER RES, V64, P6174, DOI 10.1158/0008-5472.CAN-04-0920; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Sevik J, 2004, EUR J BIOCHEM, V271, P1873, DOI [10.1111/j.1432-1033.2004.04095.x, DOI 10.1111/J.1432-1033.2004.04095.X]; Shapiro B, 2015, ONCOTARGET, V6, P34389, DOI 10.18632/oncotarget.5360; Shin SJ, 2013, P NATL ACAD SCI USA, V110, P19414, DOI 10.1073/pnas.1309720110; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252; Song JG, 2015, STRUCTURE, V23, P558, DOI 10.1016/j.str.2015.01.011; Stoyanova T, 2016, P NATL ACAD SCI USA, V113, pE6457, DOI 10.1073/pnas.1614529113; Strmiska V, 2019, BBA-REV CANCER, V1871, P248, DOI 10.1016/j.bbcan.2019.01.001; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/NMETH.3901, 10.1038/nmeth.3901]; Wang C, 2015, ONCOTARGET, V6, P2903, DOI 10.18632/oncotarget.3093; Wang J, 2010, CANCER RES, V70, P10182, DOI 10.1158/0008-5472.CAN-10-2414; Wiche G, 1998, J CELL SCI, V111, P2477; Wiche Gerhard, 2011, Bioarchitecture, V1, P14; Winter L, 2013, ACTA NEUROPATHOL, V125, P77, DOI 10.1007/s00401-012-1026-0; Yoneyama MS, 2014, EUR J CELL BIOL, V93, P157, DOI 10.1016/j.ejcb.2014.03.002; Zhou WM, 2014, ONCOL LETT, V8, P1175, DOI 10.3892/ol.2014.2287; Zhu Y, 2018, EBIOMEDICINE, V30, P148, DOI 10.1016/j.ebiom.2018.03.032	59	11	11	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					663	676		10.1038/s41388-020-01557-9	http://dx.doi.org/10.1038/s41388-020-01557-9		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33219316	Green Accepted			2022-12-17	WOS:000591146100001
J	Noh, K; Bach, DH; Choi, HJ; Kim, MS; Wu, SY; Pradeep, S; Ivan, C; Cho, MS; Bayraktar, E; Rodriguez-Aguayo, C; Dasari, SK; Stur, E; Mangala, LS; Lopez-Berestein, G; Sood, AK				Noh, Kyunghee; Duc-Hiep Bach; Choi, Hyun-Jin; Kim, Mark S.; Wu, Sherry Y.; Pradeep, Sunila; Ivan, Cristina; Cho, Min-Soon; Bayraktar, Emine; Rodriguez-Aguayo, Cristian; Dasari, Santosh K.; Stur, Elaine; Mangala, Lingegowda S.; Lopez-Berestein, Gabriel; Sood, Anil K.			The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis	ONCOGENE			English	Article							OVARIAN-CANCER METASTASIS; PLASMINOGEN-ACTIVATOR; SRC KINASES; KAPPA-B; EXPRESSION; PHOSPHORYLATION; PROTECTS; CELLS; FAK	Paxillin (PXN), a key component of the focal adhesion complex, has been associated with cancer progression, but the underlying mechanisms are poorly understood. The purpose of this study was to elucidate mechanisms by which PXN affects cancer growth and progression, which we addressed using cancer patient data, cell lines, and orthotopic mouse models. We demonstrated a previously unrecognized mechanism whereby nuclear PXN enhances angiogenesis by transcriptionally regulating SRC expression. SRC, in turn, increases PLAT expression through NF-kappa B activation; PLAT promotes angiogenesis via LRP1 in endothelial cells. PXN silencing in ovarian cancer mouse models reduced angiogenesis, tumor growth, and metastasis. These findings provide a new understanding of the role of PXN in regulating tumor angiogenesis and growth.	[Noh, Kyunghee; Duc-Hiep Bach; Choi, Hyun-Jin; Kim, Mark S.; Wu, Sherry Y.; Pradeep, Sunila; Bayraktar, Emine; Dasari, Santosh K.; Stur, Elaine; Mangala, Lingegowda S.; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA; [Noh, Kyunghee] Korea Res Inst Biosci & Biotechnol, 125 Gwahak Ro, Daejeon, South Korea; [Choi, Hyun-Jin] Chung Ang Univ, Dept Obstet & Gynecol, Coll Med, Seoul, South Korea; [Ivan, Cristina; Rodriguez-Aguayo, Cristian; Mangala, Lingegowda S.; Lopez-Berestein, Gabriel; Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 77030 USA; [Ivan, Cristina; Rodriguez-Aguayo, Cristian; Lopez-Berestein, Gabriel] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Cho, Min-Soon] Univ Texas MD Anderson Canc Ctr, Dept Benign Hematol, Houston, TX 77030 USA; [Sood, Anil K.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chung Ang University; Chung Ang University Hospital; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, Houston, TX 77030 USA.; Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Ctr RNA Interference & Noncoding RNA, Houston, TX 77030 USA.; Sood, AK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.	asood@mdanderson.org	Sood, Anoop Kumar/A-7344-2013; dasari, santosh kumar/V-3867-2019; Bach, Duc-Hiep/V-5276-2017	Sood, Anoop Kumar/0000-0001-5702-4108; dasari, santosh kumar/0000-0003-3078-3424; Bach, Duc-Hiep/0000-0002-9826-3137; RODRIGUEZ-AGUAYO, CRISTIAN/0000-0002-7880-7723; Ivan, Cristina/0000-0002-4848-0168; Bayraktar, Emine/0000-0002-5189-1507	National Institutes of Health [P30 CA016672, P50 CA217685, P50 CA098258, R35 CA209904]; Frank McGraw Memorial Chair in Cancer Research; Ovarian Cancer Research Fund Alliance (OCRFA); Ovarian Cancer Research Alliance (OCRA) [FP00006137]; KRIBB Research Initiative Program; Blanton-Davis Ovarian Cancer Research Program; American Cancer Society Research Professor Award; Judy's Mission	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Frank McGraw Memorial Chair in Cancer Research; Ovarian Cancer Research Fund Alliance (OCRFA); Ovarian Cancer Research Alliance (OCRA); KRIBB Research Initiative Program; Blanton-Davis Ovarian Cancer Research Program; American Cancer Society Research Professor Award(American Cancer Society); Judy's Mission	Portions of this work were supported by the National Institutes of Health (P30 CA016672, P50 CA217685, P50 CA098258, and R35 CA209904), the Blanton-Davis Ovarian Cancer Research Program, American Cancer Society Research Professor Award, Judy's Mission, and the Frank McGraw Memorial Chair in Cancer Research. SP is supported by the Ovarian Cancer Research Fund Alliance (OCRFA). ES is supported by Ovarian Cancer Research Alliance (OCRA number FP00006137). KHN is supported by the KRIBB Research Initiative Program. We thank Dr. Bryan F. Tutt (Department of Scientific Publications) and Nicholas B. Jennings for kindly reviewing this manuscript.	Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Byers LA, 2009, CLIN CANCER RES, V15, P6852, DOI 10.1158/1078-0432.CCR-09-0767; Chen DL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-277; Deakin Nicholas O, 2012, Genes Cancer, V3, P362, DOI 10.1177/1947601912458582; Diaz VM, 2002, GASTROENTEROLOGY, V122, P806, DOI 10.1053/gast.2002.31885; Dong JM, 2009, BIOCHEM J, V418, P173, DOI 10.1042/BJ20080170; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hou XY, 2007, NEUROSCI LETT, V420, P235, DOI 10.1016/j.neulet.2007.03.048; Hu KB, 2008, J AM SOC NEPHROL, V19, P503, DOI 10.1681/ASN.2007030300; Hu W, 2014, CANCER RES, V74, P3282, DOI 10.1158/0008-5472.CAN-13-2066; Ip CKM, 2014, ONCOTARGET, V5, P9133; Kenny HA, 2014, J CLIN INVEST, V124, P4614, DOI 10.1172/JCI74778; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kratimenos P, 2017, PEDIATR HEMAT ONCOL, V34, P221, DOI 10.1080/08880018.2017.1360969; Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530; Li BZ, 2008, J INT MED RES, V36, P273, DOI 10.1177/147323000803600209; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Mackinnon AC, 2011, J CLIN PATHOL, V64, P16, DOI 10.1136/jcp.2010.075853; Lopez-Colome AM, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0418-y; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Noh KH, 2020, METABOLISM, V110, DOI 10.1016/j.metabol.2020.154302; Ohki M, 2010, BLOOD, V115, P4302, DOI 10.1182/blood-2009-08-236851; Panetti TS, 2002, FRONT BIOSCI-LANDMRK, V7, pD143, DOI 10.2741/panetti; Phung CD, 2020, J CONTROL RELEASE, V324, P413, DOI 10.1016/j.jconrel.2020.05.029; Playford MP, 2004, ONCOGENE, V23, P7928, DOI 10.1038/sj.onc.1208080; Rupaimoole R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6202; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Schlessinger J, 2000, CELL, V100, P293, DOI 10.1016/S0092-8674(00)80664-9; Sen A, 2012, J CLIN INVEST, V122, P2469, DOI 10.1172/JCI62044; Shi JN, 2010, J ORAL PATHOL MED, V39, P548, DOI 10.1111/j.1600-0714.2009.00859.x; Ulfhammer E, 2006, J THROMB HAEMOST, V4, P1781, DOI 10.1111/j.1538-7836.2006.02035.x; Wu SY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11169; Zhou J, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1265-1	34	11	11	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 14	2021	40	2					384	395		10.1038/s41388-020-01517-3	http://dx.doi.org/10.1038/s41388-020-01517-3		NOV 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PS4WP	33149280	Green Accepted			2022-12-17	WOS:000585762500001
J	Gupta, R; Janostiak, R; Wajapeyee, N				Gupta, Romi; Janostiak, Radoslav; Wajapeyee, Narendra			Transcriptional regulators and alterations that drive melanoma initiation and progression	ONCOGENE			English	Review							TERT PROMOTER MUTATIONS; MALIGNANT-MELANOMA; MITF; EXPRESSION; LANDSCAPE; GENE; PROTEIN; BRN-2; BRAF; P53	Although melanoma is the least frequent type of skin cancer, it accounts for the majority of skin cancer-related deaths. Large-scale sequencing efforts have led to the classification of melanoma into four major subtypes (i.e., BRAF-mutant, NRAS-mutant, NF1-deficient, and triple wild-type). These sequencing studies have also revealed that melanoma genomes are some of the most mutated genomes of all cancers and therefore have a high neoantigen load. These findings have resulted in the development and clinical use of targeted therapies against the oncogenic BRAF -> MEK -> ERK pathway and immune checkpoint inhibitors for the treatment of metastatic melanoma. Although some patients with metastatic melanoma benefit immensely from these transformative therapies, others either become resistant or do not respond at all. These clinical challenges have intensified the search for new drug targets and drugs that can benefit patients who are either intrinsically resistant or have acquired resistance to targeted therapies and immunotherapies. Numerous signaling pathways and oncogenic drivers can cause changes in mRNA transcription that in turn drive melanoma initiation and progression. Transcriptional regulation of mRNA expression is necessary to maintain cell identity and cellular plasticity via the regulation of transcription factor expression and function, promoter/enhancer activities, chromatin regulators, and three-dimensional genome organization. Transcriptional deregulation can arise due to genetic and/or non-genetic alterations in the genome. Specifically, these deregulated transcriptional programs can become liabilities for melanoma cells due to their acquired dependencies on these programs for survival, which can be harnessed to develop new therapies for melanoma. In this article, we present an overview of the mechanisms that result in the transcriptional deregulation of mRNA expression in melanoma cells and assess how these changes facilitate melanoma initiation and progression. We also describe how these deregulated transcriptional pathways represent new opportunities for the development of unconventional and potentially impactful treatments for metastatic melanoma.	[Gupta, Romi; Wajapeyee, Narendra] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; [Janostiak, Radoslav] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona 08028, Spain	University of Alabama System; University of Alabama Birmingham; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona	Gupta, R; Wajapeyee, N (corresponding author), Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.	romigup@uab.edu; nwajapey@uab.edu	Janostiak, Radoslav/ABE-5349-2020	Janostiak, Radoslav/0000-0002-6602-9389; Wajapeyee, Narendra/0000-0003-3306-349X; Gupta, Romi/0000-0001-5108-5962	NCI NIH HHS [R01 CA200919, R01 CA196566, R21 CA191364] Funding Source: Medline; U.S. Department of Health &amp; Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER) [R01CA200919, R01CA196566, R03CA221926] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); U.S. Department of Health &amp; Human Services | NIH | Office of Extramural Research, National Institutes of Health (OER)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Akdemir KC, 2020, NAT GENET, V52, P294, DOI 10.1038/s41588-019-0564-y; Ally A, 2017, CELL, V169, P1327, DOI 10.1016/j.cell.2017.05.046; ANGUS J, 1995, ONCOGENE, V11, P691; Arrowsmith CH, 2019, NAT STRUCT MOL BIOL, V26, P863, DOI 10.1038/s41594-019-0290-2; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Chaoui A, 2015, HUM MOL GENET, V24, P4933, DOI 10.1093/hmg/ddv215; Chi P, 2010, NAT REV CANCER, V10, P457, DOI 10.1038/nrc2876; Corces MR, 2018, SCIENCE, V362, P420, DOI 10.1126/science.aav1898; Dai C, 2010, TRENDS MOL MED, V16, P528, DOI 10.1016/j.molmed.2010.09.002; Dekker J, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a019356; Dixon JR, 2012, NATURE, V485, P376, DOI 10.1038/nature11082; Donaldson-Collier MC, 2019, NAT GENET, V51, P517, DOI 10.1038/s41588-018-0338-y; EISEN T, 1995, ONCOGENE, V11, P2157; Ernst J, 2017, NAT PROTOC, V12, P2478, DOI 10.1038/nprot.2017.124; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Fujimoto A, 2016, NAT GENET, V48, P500, DOI 10.1038/ng.3547; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Goodall J, 2004, MOL CELL BIOL, V24, P2923, DOI 10.1128/MCB.24.7.2923-2931.2004; Greenberg MVC, 2019, NAT REV MOL CELL BIO, V20, P590, DOI 10.1038/s41580-019-0159-6; Han SJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02354-x; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751; Herbert K, 2019, GENE DEV, V33, P310, DOI 10.1101/gad.314633.118; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Italiano A, 2018, LANCET ONCOL, V19, P649, DOI 10.1016/S1470-2045(18)30145-1; Jain AK, 2017, J MOL BIOL, V429, P2003, DOI 10.1016/j.jmb.2016.11.020; Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688; Kato S, 2020, CANCER DISCOV, V10, P980, DOI 10.1158/2159-8290.CD-19-0532; Kinsler VA, 2017, BRIT J DERMATOL, V176, P1131, DOI 10.1111/bjd.15301; Kundaje A, 2015, NATURE, V518, P317, DOI 10.1038/nature14248; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Li YH, 2016, P NATL ACAD SCI USA, V113, P14402, DOI 10.1073/pnas.1611106113; Lian CG, 2012, CELL, V150, P1135, DOI 10.1016/j.cell.2012.07.033; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Mansky KC, 2002, J BIOL CHEM, V277, P11077, DOI 10.1074/jbc.M111696200; Maric H, 2019, MELANOMA RES, V29, P596, DOI 10.1097/CMR.0000000000000612; Micevic G, 2016, CELL REP, V14, P2180, DOI 10.1016/j.celrep.2016.02.010; Miller AJ, 2005, J BIOL CHEM, V280, P146, DOI 10.1074/jbc.M411757200; Misteli T, 2007, CELL, V128, P787, DOI 10.1016/j.cell.2007.01.028; Murakami H, 2005, PIGM CELL RES, V18, P265, DOI 10.1111/j.1600-0749.2005.00234.x; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Musselman CA, 2012, NAT STRUCT MOL BIOL, V19, P1218, DOI 10.1038/nsmb.2436; Nacev BA, 2019, NATURE, V567, P473, DOI 10.1038/s41586-019-1038-1; Nora EP, 2012, NATURE, V485, P381, DOI 10.1038/nature11049; Pan W, 2017, IMMUNITY, V47, P284, DOI 10.1016/j.immuni.2017.07.020; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Phillips JE, 2009, CELL, V137, P1194, DOI 10.1016/j.cell.2009.06.001; Pierce CJ, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00247-1; Polak P, 2015, NATURE, V518, P360, DOI 10.1038/nature14221; Pusch C, 1998, HUM GENET, V103, P115, DOI 10.1007/s004390050793; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Sen N, 2011, MOL CELL, V44, P621, DOI 10.1016/j.molcel.2011.08.044; Shah S., 2019, ONCOTARGET, V10, P3745, DOI [10.18632/oncotarget.26959, DOI 10.18632/ONCOTARGET.26959]; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Simmons JL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11366-y; Souroullas GP, 2016, NAT MED, V22, P632, DOI 10.1038/nm.4092; Taberlay PC, 2016, GENOME RES, V26, P719, DOI 10.1101/gr.201517.115; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Takeda K, 2000, HUM MOL GENET, V9, P125, DOI 10.1093/hmg/9.1.125; Talantov D, 2005, CLIN CANCER RES, V11, P7234, DOI 10.1158/1078-0432.CCR-05-0683; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; Villicana C, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-18; Weinhold N, 2014, NAT GENET, V46, P1160, DOI 10.1038/ng.3101; Whetstine JR, 2006, CELL, V125, P467, DOI 10.1016/j.cell.2006.03.028; Wu H, 2011, GENE DEV, V25, P2436, DOI 10.1101/gad.179184.111; Wu M, 2000, GENE DEV, V14, P301; Yan ZJ, 2005, GENE DEV, V19, P1662, DOI 10.1101/gad.1323805; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2010, CANCER RES, V70, P4709, DOI 10.1158/0008-5472.CAN-09-4524; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Zingg D, 2018, CANCER CELL, V34, P69, DOI 10.1016/j.ccell.2018.06.001; Zingg D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7051	77	11	12	1	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 26	2020	39	48					7093	7105		10.1038/s41388-020-01490-x	http://dx.doi.org/10.1038/s41388-020-01490-x		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PE1YE	33024276	Green Published, hybrid			2022-12-17	WOS:000575700700002
J	Gan, T; Stevens, AT; Xiong, XP; Wen, YA; Farmer, TN; Li, AT; Stevens, PD; Golshani, S; Weiss, HL; Evers, BM; Gao, TY				Gan, Tong; Stevens, Ashley T.; Xiong, Xiaopeng; Wen, Yang-An; Farmer, Trevor N.; Li, Austin T.; Stevens, Payton D.; Golshani, Sanam; Weiss, Heidi L.; Mark Evers, B.; Gao, Tianyan			Inhibition of protein tyrosine phosphatase receptor type F suppresses Wnt signaling in colorectal cancer	ONCOGENE			English	Article							TUMOR-GROWTH; STEM-CELLS; EXPRESSION; LAR; PTPRF; GENES; CLATHRIN; COMPLEX; LRP6	Wnt signaling dysregulation promotes tumorigenesis in colorectal cancer (CRC). We investigated the role of PTPRF, a receptor-type tyrosine phosphatase, in regulating Wnt signaling in CRC. Knockdown of PTPRF decreased cell proliferation in patient-derived primary colon cancer cells and established CRC cell lines. In addition, the rate of proliferation as well as colony formation ability were significantly decreased in tumor organoids grown in 3D, whereas the number of differentiated tumor organoids were markedly increased. Consistently, knockdown of PTPRF resulted in a decrease in the expression of genes associated with cancer stem cells downstream of Wnt/beta-catenin signaling. Treating PTPRF knockdown cells with GSK3 inhibitor rescued the expression of Wnt target genes suggesting that PTPRF functions upstream of the beta-catenin destruction complex. PTPRF was found to interact with LRP6 and silencing PTPRF largely decreased the activation of LRP6. Interestingly, this PTPRF-mediated activation of Wnt signaling was blocked in cells treated with clathrin endocytosis inhibitor. Furthermore, knockdown of PTPRF inhibited xenograft tumor growth in vivo and decreased the expression of Wnt target genes. Taken together, our studies identify a novel role of PTPRF as an oncogenic protein phosphatase in supporting the activation of Wnt signaling in CRC.	[Gan, Tong; Mark Evers, B.] Univ Kentucky, Dept Surg, Lexington, KY 40536 USA; [Gan, Tong; Stevens, Ashley T.; Xiong, Xiaopeng; Wen, Yang-An; Farmer, Trevor N.; Stevens, Payton D.; Golshani, Sanam; Weiss, Heidi L.; Mark Evers, B.; Gao, Tianyan] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA; [Stevens, Ashley T.; Stevens, Payton D.; Gao, Tianyan] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; [Li, Austin T.] Paul Laurence Dunbar High Sch, Lexington, KY USA; [Stevens, Payton D.] Van Andel Res Inst, Ctr Canc & Cell Biol, Grand Rapids, MI 49503 USA	University of Kentucky; University of Kentucky; University of Kentucky; Van Andel Institute	Gao, TY (corresponding author), Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA.; Gao, TY (corresponding author), Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA.	tianyan.gao@uky.edu		, Ashley Skaggs/0000-0001-6732-1640	National Science Foundation Graduate Research Fellowship Award [1839289]; Biospecimen Procurement and Translational Pathology and Biostatistics and Bioinformatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center at the University of Kentucky [P30CA177558];  [R01CA133429];  [R01CA208343];  [T32CA160003];  [F31CA196219]	National Science Foundation Graduate Research Fellowship Award(National Science Foundation (NSF)); Biospecimen Procurement and Translational Pathology and Biostatistics and Bioinformatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center at the University of Kentucky; ; ; ; 	This work was supported by funding grants R01CA133429 (TG), R01CA208343 (BME and TG), T32CA160003 (BME), and F31CA196219 (PDS). This material is based upon work supported by the National Science Foundation Graduate Research Fellowship Award (#1839289). The studies were conducted with support provided by the Biospecimen Procurement and Translational Pathology and Biostatistics and Bioinformatics Shared Resource Facilities of the University of Kentucky Markey Cancer Center (P30CA177558) at the University of Kentucky.	Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Barlan K, 2017, DEV CELL, V40, P467, DOI 10.1016/j.devcel.2017.02.003; Barr AJ, 2009, CELL, V136, P352, DOI 10.1016/j.cell.2008.11.038; Bera R, 2014, HEPATOLOGY, V59, P2238, DOI 10.1002/hep.27030; Bujko M, 2015, ONCOL LETT, V9, P2463, DOI 10.3892/ol.2015.3107; Chen MY, 2009, BIOCHEMISTRY-US, V48, P10267, DOI 10.1021/bi9009677; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; DaSilva JO, 2013, PROSTATE, V73, P801, DOI 10.1002/pros.22624; Du WW, 2013, J CELL SCI, V126, P1440, DOI 10.1242/jcs.118299; Flanagan DJ, 2019, CANCER RES, V79, P5901, DOI 10.1158/0008-5472.CAN-19-1362; Flanagan DJ, 2019, CANCER RES, V79, P970, DOI 10.1158/0008-5472.CAN-18-2095; Hagemann AIH, 2014, J CELL SCI, V127, P3970, DOI 10.1242/jcs.148767; HARDER KW, 1995, GENOMICS, V27, P552, DOI 10.1006/geno.1995.1092; Johnson KG, 2003, PHYSIOL REV, V83, P1, DOI 10.1152/physrev.00016.2002; Julien SG, 2011, NAT REV CANCER, V11, P35, DOI 10.1038/nrc2980; Kim I, 2013, J CELL BIOL, V200, P419, DOI 10.1083/jcb.201206096; Komiya Yuko, 2008, Organogenesis, V4, P68; Konishi N, 2003, BRIT J CANCER, V88, P1223, DOI 10.1038/sj.bjc.6600876; Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418; LeVea CM, 2000, BREAST CANCER RES TR, V64, P221, DOI 10.1023/A:1006410509740; Li X, 2014, GASTROENTEROLOGY, V146, P1301, DOI 10.1053/j.gastro.2014.02.003; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Mana G, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13546; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470; Nunes-Xavier CE, 2013, BBA-REV CANCER, V1836, P211, DOI 10.1016/j.bbcan.2013.06.001; Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016; O'Connell JB, 2004, AM J SURG, V187, P343, DOI 10.1016/j.amjsurg.2003.12.020; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Saito-Diaz K, 2018, DEV CELL, V44, P566, DOI 10.1016/j.devcel.2018.02.013; Schatoff EM, 2017, CURR COLORECT CANC R, V13, P101, DOI 10.1007/s11888-017-0354-9; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smith RA, 2018, CA-CANCER J CLIN, V68, P297, DOI 10.3322/caac.21446; Soulieres D, 2015, J THORAC ONCOL, V10, P1364, DOI 10.1097/JTO.0000000000000624; Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898; Stevens PD, 2018, CANCER RES, V78, P4839, DOI 10.1158/0008-5472.CAN-17-3629; Stewart K, 2013, DEVELOPMENT, V140, P3413, DOI 10.1242/dev.094532; STREULI M, 1992, EMBO J, V11, P897, DOI 10.1002/j.1460-2075.1992.tb05128.x; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tian XX, 2018, ONCOTARGETS THER, V11, P7795, DOI 10.2147/OTT.S178152; Vermeulen L, 2013, SCIENCE, V342, P995, DOI 10.1126/science.1243148; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Virshup DM, 2009, MOL CELL, V33, P537, DOI 10.1016/j.molcel.2009.02.015; Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Wen YA, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0330-6; Wen YA, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.21; Wu DQ, 2010, TRENDS BIOCHEM SCI, V35, P161, DOI 10.1016/j.tibs.2009.10.002; Yamamoto H, 2006, DEV CELL, V11, P213, DOI 10.1016/j.devcel.2006.07.003; Yang T, 1999, MOL CARCINOGEN, V25, P139, DOI 10.1002/(SICI)1098-2744(199906)25:2<139::AID-MC9>3.3.CO;2-K	50	11	11	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6789	6801		10.1038/s41388-020-01472-z	http://dx.doi.org/10.1038/s41388-020-01472-z		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32973331	Green Accepted			2022-12-17	WOS:000572607300001
J	Zhu, J; Li, X; Su, P; Xue, M; Zang, YF; Ding, YL				Zhu, Jian; Li, Xin; Su, Peng; Xue, Min; Zang, Yifeng; Ding, Yinlu			The ubiquitin ligase RNF181 stabilizes ER alpha and modulates breast cancer progression	ONCOGENE			English	Article							ESTROGEN-RECEPTOR-ALPHA; SHARPIN; IDENTIFICATION; COACTIVATOR; EXPRESSION; RESISTANCE; COMPONENT; P300	ER alpha positive breast cancer accounts for 70% of breast malignancies. Compared with ER alpha negative types, ER alpha positive breast cancer could be effective controlled by endocrine therapy. However, more than half of the patients will develop endocrine resistance, making it an important clinical issue for breast cancer therapy. Endocrine resistance might be caused by multiple alternations, including the components of ER alpha signaling, during tumor progression. Thus, it is urgent and necessary to uncover the molecular mechanisms that controls ER alpha expression and stability to improve breast cancer therapeutics. In our current study, we identifies that the ubiquitin ligase RNF181 stabilizes ER alpha and facilitates breast cancer progression. The expression of RNF181 is correlated with ER alpha level in human breast tumors and relates to poor survival in endocrine-treated patients. RNF181 depletion inhibits breast cancer progression in vivo and in vitro, reduces ER alpha protein level and its target gene expression, such as PS2 and GREB1. Unbiased RNA sequencing analysis indicates RNF181 is necessary for ER alpha signature gene expression in whole genomic level. Immuno-precipitation assays indicate that RNF181 associates with ER alpha and promotes its stability possibly via inducing ER alpha K63-linked poly-ubiquitination. In conclusion, our data implicate a non-genomic mechanism by RNF181 via stabilizing ER alpha protein controls ER alpha target gene expression linked to breast cancer progression.	[Zhu, Jian; Zang, Yifeng; Ding, Yinlu] Shandong Univ, Second Hosp, Dept Gen Surg, Cheeloo Coll Med, Jinan 250033, Peoples R China; [Li, Xin; Xue, Min] Xinxiang Med Univ, Xinxiang Key Lab Tumor Migrat Invas & Precis Med, Sch Lab Med, Henan Collaborat Innovat Ctr Mol Diag & Lab Med, Xinxiang 453003, Henan, Peoples R China; [Su, Peng] Shandong Univ, Qilu Hosp, Dept Pathol, Cheeloo Coll Med, Jinan 250033, Peoples R China	Shandong University; Xinxiang Medical University; Shandong University	Zhu, J; Ding, YL (corresponding author), Shandong Univ, Second Hosp, Dept Gen Surg, Cheeloo Coll Med, Jinan 250033, Peoples R China.	zhujian1204@yahoo.com; dingyinlu@126.com	zhu, jian/D-7361-2017	zhu, jian/0000-0003-3596-4339	National Natural Science Foundation of China [U1604190]; Key R&D programs in Shandong Province [2019gsf108229]; KI-SDU joint research program for 2020	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key R&D programs in Shandong Province; KI-SDU joint research program for 2020	The project was supported from Joint Fund of the National Natural Science Foundation of China (No.U1604190, JZ), The KI-SDU joint research program for 2020, and the Key R&D programs in Shandong Province (2019gsf108229, YD).	Abdel-Magid AF, 2017, ACS MED CHEM LETT, V8, P1129, DOI 10.1021/acsmedchemlett.7b00424; Ali S, 2000, J MAMMARY GLAND BIOL, V5, P271, DOI 10.1023/A:1009594727358; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brophy TM, 2008, BIOCHEM BIOPH RES CO, V369, P1088, DOI 10.1016/j.bbrc.2008.02.142; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cai ZJ, 2021, SCI CHINA LIFE SCI, V64, P1017, DOI 10.1007/s11427-019-9816-1; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Eisenhaber B, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-3-209; Fan P, 2019, CANCER DRUG RESIST, V2, P198, DOI 10.20517/cdr.2019.13; GREENE GL, 1986, SCIENCE, V231, P1150, DOI 10.1126/science.3753802; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Haque MM, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00573; Ikeda F, 2011, NATURE, V471, P637, DOI 10.1038/nature09814; Jackisch C, 2019, LANCET ONCOL, V20, P1185, DOI 10.1016/S1470-2045(19)30500-5; Jin HW, 2016, J PROTEOMICS, V136, P77, DOI 10.1016/j.jprot.2015.12.012; Lei JT, 2019, BREAST, V48, pS26, DOI 10.1016/S0960-9776(19)31118-X; Liu ZH, 2018, J CELL MOL MED, V22, P4161, DOI 10.1111/jcmm.13694; Metzger MB, 2012, J CELL SCI, V125, P531, DOI 10.1242/jcs.091777; Musgrove EA, 2009, NAT REV CANCER, V9, P631, DOI 10.1038/nrc2713; Onitilo AA, 2009, CLIN MED RES, V7, P4, DOI 10.3121/cmr.2009.825; Pedersen SM, 2016, MOL CELL BIOL, V36, P794, DOI 10.1128/MCB.00876-15; Raab M, 2010, PROTEOMICS, V10, P2790, DOI 10.1002/pmic.200900621; Ranganathan P, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00708; Renaud J, 2005, J MED CHEM, V48, P364, DOI 10.1021/jm040858p; Renaud J, 2003, J MED CHEM, V46, P2945, DOI 10.1021/jm030086h; Shaaban AM, 2002, AM J PATHOL, V160, P597, DOI 10.1016/S0002-9440(10)64879-1; Tokunaga F, 2011, NATURE, V471, P633, DOI 10.1038/nature09815; Vaz-Luis I, 2014, J CLIN ONCOL, V32, P2142, DOI 10.1200/JCO.2013.53.1608; Wang CG, 2001, J BIOL CHEM, V276, P18375, DOI 10.1074/jbc.M100800200; Wang SL, 2017, BBA-MOL BASIS DIS, V1863, P1615, DOI 10.1016/j.bbadis.2017.02.011; Xue M, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0139-x; Yang HJ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0672-z; Yang HJ, 2017, NEOPLASIA, V19, P84, DOI 10.1016/j.neo.2016.12.002; Zhu J, 2014, ONCOGENE, V33, P4340, DOI 10.1038/onc.2013.573; Zhuang T, 2017, ONCOTARGET, V8, P77137, DOI 10.18632/oncotarget.20368	35	11	11	2	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 29	2020	39	44					6776	6788		10.1038/s41388-020-01464-z	http://dx.doi.org/10.1038/s41388-020-01464-z		SEP 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	OH9QS	32973333	Green Published, hybrid			2022-12-17	WOS:000572607300003
J	Cho, C; Mukherjee, R; Peck, AR; Sun, YG; McBrearty, N; Katlinski, KV; Gui, J; Govindaraju, PK; Pure, E; Rui, H; Fuchs, SY				Cho, Christina; Mukherjee, Riddhita; Peck, Amy R.; Sun, Yunguang; McBrearty, Noreen; Katlinski, Kanstantsin V.; Gui, Jun; Govindaraju, Priya K.; Pure, Ellen; Rui, Hallgeir; Fuchs, Serge Y.			Cancer-associated fibroblasts downregulate type I interferon receptor to stimulate intratumoral stromagenesis	ONCOGENE			English	Article							ACTIVATION PROTEIN; TGF-BETA; TUMOR STROMA; GROWTH; FAP; IMMUNOTHERAPY; EXPRESSION; PROMOTES; IMMUNITY; CELLS	Activation of cancer-associated fibroblasts (CAFs) and ensuing desmoplasia play an important role in the growth and progression of solid tumors. Here we demonstrate that, within colon and pancreatic ductal adenocarcinoma tumors, efficient stromagenesis relies on downregulation of the IFNAR1 chain of the type I interferon (IFN1) receptor. Expression of the fibroblast activation protein (FAP) and accumulation of the extracellular matrix (ECM) was notably impaired in tumors grown in theIfnar1(S526A)(SA) knock-in mice, which are deficient in IFNAR1 downregulation. Primary fibroblasts from these mice exhibited elevated levels of Smad7, a negative regulator of the transforming growth factor-beta (TGF beta) pathway. Knockdown of Smad7 alleviated deficient ECM production in SA fibroblasts in response to TGF beta. Analysis of human colorectal cancers revealed an inverse correlation between IFNAR1 and FAP levels. Whereas growth of tumors in SA mice was stimulated by co-injection of wild type but not SA fibroblasts, genetic ablation of IFNAR1 in fibroblasts also accelerated tumor growth. We discuss how inactivation of IFNAR1 in CAFs acts to stimulate stromagenesis and tumor growth.	[Cho, Christina; Mukherjee, Riddhita; McBrearty, Noreen; Katlinski, Kanstantsin V.; Gui, Jun; Govindaraju, Priya K.; Pure, Ellen; Fuchs, Serge Y.] Univ Penn, Sch Vet Med, Dept Biomed Sci, Philadelphia, PA 19104 USA; [Peck, Amy R.; Sun, Yunguang; Rui, Hallgeir] Med Coll Wisconsin, Dept Pathol, Milwaukee, WI 53226 USA	University of Pennsylvania; Medical College of Wisconsin	Fuchs, SY (corresponding author), Univ Penn, Sch Vet Med, Dept Biomed Sci, Philadelphia, PA 19104 USA.	syfuchs@upenn.edu		McBrearty, Noreen/0000-0002-2597-9441; Gui, Jun/0000-0002-8022-1203; Cho, Christina/0000-0001-5482-9533	NIH/NCI [CA092900, CA240814, P01 CA217805];  [T32 CA115299];  [T32 CA009140]	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; 	This work was supported by the by the NIH/NCI R01 grants CA092900 (to SYF), CA240814 (to SYF and HR), and P01 CA217805 (to EP). Additional support from T32 CA115299 (to NM) and T32 CA009140 (to KVK) is also greatly appreciated. We would like to thank Dr. Ben Z. Stanger and Jinyang Li for generously gifting mouse PDA cells and advising us in the generation of PDAC subcutaneous tumors. We also thank Drs. Xin-Hua Feng and Yi Yu and for generously gifting the pLKO.1 plasmids, and providing the protocols for generating the aforementioned lentiviruses.	Alexander J, 2016, CURR OPIN CELL BIOL, V42, P80, DOI 10.1016/j.ceb.2016.05.002; Beacham DA, 2005, SEMIN CANCER BIOL, V15, P329, DOI 10.1016/j.semcancer.2005.05.003; Bhattacharya S, 2014, EMBO MOL MED, V6, P384, DOI 10.1002/emmm.201303236; Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710; Calon A, 2014, SEMIN CANCER BIOL, V25, P15, DOI 10.1016/j.semcancer.2013.12.008; Castello-Cros Remedios, 2009, V522, P275, DOI 10.1007/978-1-59745-413-1_19; Chen H, 2009, EXP MOL PATHOL, V87, P189, DOI 10.1016/j.yexmp.2009.09.001; Erdogan B, 2017, BIOCHEM SOC T, V45, P229, DOI 10.1042/BST20160387; Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110; Fish EN, 2014, MOL CANCER RES, V12, P1691, DOI 10.1158/1541-7786.MCR-14-0450; Fuchs SY, 2013, J INTERF CYTOK RES, V33, P211, DOI 10.1089/jir.2012.0117; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Gui J, 2020, NAT CANCER, V1, P603, DOI 10.1038/s43018-020-0064-0; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Henry LR, 2007, CLIN CANCER RES, V13, P1736, DOI 10.1158/1078-0432.CCR-06-1746; HuangFu WC, 2012, ONCOGENE, V31, P161, DOI 10.1038/onc.2011.221; Katlinskaya YV, 2016, CELL REP, V15, P171, DOI 10.1016/j.celrep.2016.03.006; Katlinski KV, 2017, CANCER CELL, V31, P194, DOI 10.1016/j.ccell.2017.01.004; Kato T, 2018, CLIN CANCER RES, V24, P4820, DOI 10.1158/1078-0432.CCR-18-0205; Li JY, 2018, IMMUNITY, V49, P178, DOI 10.1016/j.immuni.2018.06.006; Lieberman A, 2019, CANCER RES, V79, P3928, DOI 10.1158/0008-5472.CAN-19-0056; Lo A, 2015, CANCER RES, V75, P2800, DOI 10.1158/0008-5472.CAN-14-3041; Ohlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024; Ortiz A, 2019, CANCER CELL, V35, P33, DOI 10.1016/j.ccell.2018.12.001; Peck AR, 2016, MODERN PATHOL, V29, P1143, DOI 10.1038/modpathol.2016.112; Piehler J, 2012, IMMUNOL REV, V250, P317, DOI 10.1111/imr.12001; Pure E, 2016, CANCER IMMUNOL RES, V4, P269, DOI 10.1158/2326-6066.CIR-16-0011; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Valkenburg KC, 2018, NAT REV CLIN ONCOL, V15, P366, DOI 10.1038/s41571-018-0007-1; Wang LCS, 2014, CANCER IMMUNOL RES, V2, P154, DOI 10.1158/2326-6066.CIR-13-0027; Webber J P, 2015, Oncogene, V34, P290, DOI 10.1038/onc.2013.560; Webber J, 2010, CANCER RES, V70, P9621, DOI 10.1158/0008-5472.CAN-10-1722; Wikberg ML, 2013, TUMOR BIOL, V34, P1013, DOI 10.1007/s13277-012-0638-2; Yu Y, 2017, P NATL ACAD SCI USA, V114, P10113, DOI 10.1073/pnas.1705755114; Zhang RS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1435-2; Zheng H, 2011, BLOOD, V118, P4003, DOI 10.1182/blood-2011-06-359745	39	11	11	4	16	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6129	6137		10.1038/s41388-020-01424-7	http://dx.doi.org/10.1038/s41388-020-01424-7		AUG 2020	9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32807917	Green Accepted			2022-12-17	WOS:000560274700001
J	Sabbagh, Q; Andre-Gregoire, G; Guevel, L; Gavard, J				Sabbagh, Quentin; Andre-Gregoire, Gwennan; Guevel, Laetitia; Gavard, Julie			Vesiclemia: counting on extracellular vesicles for glioblastoma patients	ONCOGENE			English	Review							CELL-DERIVED EXOSOMES; STEM-CELLS; TEMOZOLOMIDE RESISTANCE; GLIOMA-CELLS; RNA; MICROVESICLES; RECEPTOR; MEDIATE; GROWTH; IDENTIFICATION	Although rare, glioblastoma is a devastating tumor of the central nervous system characterized by a poor survival and an extremely dark prognosis, making its diagnosis, treatment, and monitoring highly challenging. Numerous studies have highlighted extracellular vesicles (EVs) as key players of tumor growth, invasiveness, and resistance, as they carry oncogenic material. Moreover, EVs have been shown to communicate locally in a paracrine way but also at remote throughout the organism. Indeed, recent reports demonstrated the presence of brain tumor-derived EVs into body fluids such as plasma and cerebrospinal fluid. Fluid-associated EVs have indeed been suspected to reflect quantitative and qualitative information about the status and fate of the tumor and can potentially act as a resource for noninvasive biomarkers that might assist in diagnosis, treatment, and follow-up of glioblastoma patients. Here, we coined the name vesiclemia to define the concentration of plasmatic EVs, an intuitive term to be directly transposed in the clinical jargon.	[Sabbagh, Quentin; Andre-Gregoire, Gwennan; Guevel, Laetitia; Gavard, Julie] Univ Nantes, CNRS, INSERM, CRCINA, Nantes, France; [Sabbagh, Quentin; Andre-Gregoire, Gwennan; Guevel, Laetitia; Gavard, Julie] SIRIC Iliad, Nantes, France; [Andre-Gregoire, Gwennan; Gavard, Julie] ICO, Integrated Ctr Oncol, St Herblain, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; UNICANCER; Institut de Cancerologie de l'Ouest (ICO)	Gavard, J (corresponding author), Univ Nantes, CNRS, INSERM, CRCINA, Nantes, France.; Gavard, J (corresponding author), SIRIC Iliad, Nantes, France.; Gavard, J (corresponding author), ICO, Integrated Ctr Oncol, St Herblain, France.	julie.gavard@inserm.fr	Sabbagh, Quentin/ABD-1358-2020; Gavard, Julie/I-5487-2012; Andre-Gregoire, Gwennan/K-9284-2015	Sabbagh, Quentin/0000-0003-4600-5387; Gavard, Julie/0000-0002-7985-9007; Guevel, Laetitia/0000-0002-0320-2615; Andre-Gregoire, Gwennan/0000-0002-9167-8727	Fondation pour la Recherche Medicale [DEQ20180339184]; Fondation ARC contre le Cancer [PJA20171206146, PJA20191209477, PGA1 RF20190208474]; INCa PLBIO [2019-151, 2019-291]; Ligue nationale contre le cancer comite de Loire-Atlantique; Ligue nationale contre le cancer comite de Maine et Loire; Ligue nationale contre le cancer comite de Vendee; Ligue nationale contre le cancer comite de Ille-et-Vilaine; SIRIC ILIAD [INCa-DGOS-Inserm_12558]; Region Pays de la Loire et Nantes Metropole under Connect Talent Grant; ITMO Cancer (Plan Cancer 2014-2019)	Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Fondation ARC contre le Cancer; INCa PLBIO; Ligue nationale contre le cancer comite de Loire-Atlantique; Ligue nationale contre le cancer comite de Maine et Loire; Ligue nationale contre le cancer comite de Vendee; Ligue nationale contre le cancer comite de Ille-et-Vilaine; SIRIC ILIAD; Region Pays de la Loire et Nantes Metropole under Connect Talent Grant; ITMO Cancer (Plan Cancer 2014-2019)	We thank SOAP team members (Nantes, France). The research from the team was funded by Fondation pour la Recherche Medicale (Equipe labellisee DEQ20180339184), Fondation ARC contre le Cancer (PJA20171206146, PJA20191209477, PGA1 RF20190208474), INCa PLBIO (2019-151, 2019-291), Ligue nationale contre le cancer comites de Loire-Atlantique, Maine et Loire, Vendee, Ille-et-Vilaine, SIRIC ILIAD (INCa-DGOS-Inserm_12558) and Region Pays de la Loire et Nantes Metropole under Connect Talent Grant. QS received Master internship fellowship from ITMO Cancer (Plan Cancer 2014-2019).	Akers JC, 2013, J NEURO-ONCOL, V113, P1, DOI 10.1007/s11060-013-1084-8; Al-Nedawi K, 2008, NAT CELL BIOL, V10, P619, DOI 10.1038/ncb1725; An JH, 2009, J PROTEOME RES, V8, P2873, DOI 10.1021/pr900020q; Andre-Gregoire G, 2018, BIOCHIMIE, V155, P11, DOI 10.1016/j.biochi.2018.02.007; Andre-Gregoire G, 2017, CELL ADHES MIGR, V11, P164, DOI 10.1080/19336918.2016.1247145; Bebawy M, 2009, LEUKEMIA, V23, P1643, DOI 10.1038/leu.2009.76; Bellingham SA, 2012, NUCLEIC ACIDS RES, V40, P10937, DOI 10.1093/nar/gks832; Berenguer J, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1446660; Bondy ML, 2008, CANCER-AM CANCER SOC, V113, P1953, DOI 10.1002/cncr.23741; Bronisz A, 2014, CANCER RES, V74, P738, DOI 10.1158/0008-5472.CAN-13-2650; Chandran VI, 2019, CLIN CANCER RES, V25, P3115, DOI 10.1158/1078-0432.CCR-18-2946; Chinot OL, 2014, NEW ENGL J MED, V370, P709, DOI 10.1056/NEJMoa1308345; Colangelo NW, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-019-0494-4; Cosset EC, 2012, INT J CANCER, V131, P601, DOI 10.1002/ijc.26415; de Vrij J, 2015, INT J CANCER, V137, P1630, DOI 10.1002/ijc.29521; Domenis R, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169932; Dusoswa SA, 2019, J EXTRACELL VESICLES, V8, DOI 10.1080/20013078.2019.1648995; Ebrahimkhani S, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0071-0; Escola JM, 1998, J BIOL CHEM, V273, P20121, DOI 10.1074/jbc.273.32.20121; Evans SM, 2016, J NEURO-ONCOL, V127, P391, DOI 10.1007/s11060-015-2051-3; Figueroa J, 2017, CANCER RES, V77, P5808, DOI 10.1158/0008-5472.CAN-16-2524; Figueroa JM, 2017, NEURO-ONCOLOGY, V19, P1494, DOI 10.1093/neuonc/nox085; Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721; FU L, 2019, EBIOMEDICINE, V42, DOI DOI 10.1590/1678-4685-GMB-2018-0234; Gandham S, 2020, TRENDS BIOTECHNOL, V38, P1066, DOI 10.1016/j.tibtech.2020.05.012; Gardiner C, 2016, J EXTRACELL VESICLES, V5, DOI 10.3402/jev.v5.32945; Garnier D, 2018, NEURO-ONCOLOGY, V20, P236, DOI 10.1093/neuonc/nox142; Ghiaseddin Ashley, 2015, CNS Oncol, V4, P157, DOI 10.2217/cns.15.8; Gimple RC, 2019, GENE DEV, V33, P591, DOI 10.1101/gad.324301.119; Godlewski J, 2017, STEM CELL REP, V8, P1497, DOI 10.1016/j.stemcr.2017.04.024; Guo XF, 2019, INT J CANCER, V144, P3111, DOI 10.1002/ijc.32052; Hallal S, 2019, MOL NEUROBIOL, V56, P4566, DOI 10.1007/s12035-018-1385-1; Hallal S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21134754; Himes BT, 2020, NEURO-ONCOLOGY, V22, P967, DOI 10.1093/neuonc/noaa029; Jain KK, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00419; Jeppesen DK, 2019, CELL, V177, P428, DOI 10.1016/j.cell.2019.02.029; Kucharzewska P, 2013, P NATL ACAD SCI USA, V110, P7312, DOI 10.1073/pnas.1220998110; Lan FM, 2018, CELL ONCOL, V41, P25, DOI 10.1007/s13402-017-0355-3; Lathia JD, 2015, GENE DEV, V29, P1203, DOI 10.1101/gad.261982.115; Laulagnier K, 2004, BIOCHEM J, V380, P161, DOI 10.1042/BJ20031594; Li DK, 2019, ONCOGENE, V38, P6898, DOI 10.1038/s41388-019-0903-6; Linos E, 2007, JNCI-J NATL CANCER I, V99, P1544, DOI 10.1093/jnci/djm170; Lu-Emerson C, 2015, J CLIN ONCOL, V33, P1197, DOI 10.1200/JCO.2014.55.9575; Lucero R, 2020, CELL REP, V30, P2065, DOI 10.1016/j.celrep.2020.01.073; Manda SV, 2018, J NEUROSURG, V128, P1091, DOI 10.3171/2016.11.JNS161187; Nolte-'t Hoen ENM, 2012, NUCLEIC ACIDS RES, V40, P9272, DOI 10.1093/nar/gks658; Osti D, 2019, CLIN CANCER RES, V25, P266, DOI 10.1158/1078-0432.CCR-18-1941; Oushy S, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0477; Pace KR, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163982; PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942; Pavlyukov MS, 2018, CANCER CELL, V34, P119, DOI 10.1016/j.ccell.2018.05.012; Ramakrishnan V, 2020, EBIOMEDICINE, V55, DOI 10.1016/j.ebiom.2020.102736; Saugstad JA, 2017, J EXTRACELL VESICLES, V6, P1, DOI 10.1080/20013078.2017.1317577; Shao HL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7999; Simon T, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0878-x; Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800; Skotland T., 2020, ADV DRUG DELIV REV S, pS0169; Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Subra C, 2007, BIOCHIMIE, V89, P205, DOI 10.1016/j.biochi.2006.10.014; Tan SK, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0822-0; Thery C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750; Treps L, 2016, ONCOGENE, V35, P2615, DOI 10.1038/onc.2015.317; Treps L, 2017, J EXTRACELL VESICLES, V6, DOI 10.1080/20013078.2017.1359479; van der Vos KE, 2016, NEURO-ONCOLOGY, V18, P58, DOI 10.1093/neuonc/nov244; Van Deun J, 2017, NAT METHODS, V14, P228, DOI 10.1038/nmeth.4185; Van Deun J, 2014, J EXTRACELL VESICLES, V3, DOI 10.3402/jev.v3.24858; van Niel G, 2018, NAT REV MOL CELL BIO, V19, P213, DOI 10.1038/nrm.2017.125; Vijapura C, 2017, RADIOGRAPHICS, V37, P258, DOI 10.1148/rg.2017160057; Weaver AM, 2020, CANCER RES, V80, P379, DOI 10.1158/0008-5472.CAN-19-2782; Williams C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1442985; Wubbolts R, 2003, J BIOL CHEM, V278, P10963, DOI 10.1074/jbc.M207550200; Yang JK, 2017, J NEURO-ONCOL, V131, P255, DOI 10.1007/s11060-016-2308-5; Yekula A, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2019.1689784; Yu TF, 2018, CANCER LETT, V433, P210, DOI 10.1016/j.canlet.2018.06.041; Yue X, 2019, MOL THER, V27, P1939, DOI 10.1016/j.ymthe.2019.07.011; Zhang CZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-229; Zhang HY, 2019, NAT PROTOC, V14, P1027, DOI 10.1038/s41596-019-0126-x; Zhang HY, 2018, NAT CELL BIOL, V20, P332, DOI 10.1038/s41556-018-0040-4; Zhang ZOA, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1336-3	80	11	12	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6043	6052		10.1038/s41388-020-01420-x	http://dx.doi.org/10.1038/s41388-020-01420-x		AUG 2020	10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32801336				2022-12-17	WOS:000559718800003
J	Du, RJ; Huang, CT; Chen, HY; Liu, KD; Xiang, P; Yao, N; Yang, L; Zhou, LT; Wu, Q; Zheng, YQ; Xin, MX; Dong, ZG; Li, X				Du, Ruijuan; Huang, Chuntian; Chen, Hanyong; Liu, Kangdong; Xiang, Pu; Yao, Ning; Yang, Lu; Zhou, Liting; Wu, Qiong; Zheng, Yaqiu; Xin, Mingxia; Dong, Zigang; Li, Xiang			SDCBP/MDA-9/syntenin phosphorylation by AURKA promotes esophageal squamous cell carcinoma progression through the EGFR-PI3K-Akt signaling pathway	ONCOGENE			English	Article							AURORA-A; MDA-9/SYNTENIN; PROTEIN; SYNTENIN; OVEREXPRESSION; PROLIFERATION; ACTIVATION; MIGRATION; SPECIFICITY; INHIBITION	SDCBP is an adapter protein containing two tandem PDZ domains mediating cell adhesion. The role and underlying molecular mechanism of SDCBP in ESCC remain obscure. Here, we report that SDCBP is frequently overexpressed in ESCC tissues and cells compared to normal controls and that its overexpression is correlated with late clinical stage and predicts poor prognosis in ESCC patients. Functionally, high expression of SDCBP is positively related to ESCC progression both in vitro and in vivo. Furthermore, mechanistic studies show that SDCBP activates the EGFR-PI3K-Akt signaling pathway by binding to EGFR and preventing EGFR internalization. Moreover, we provide evidence that AURKA binds to SDCBP and phosphorylates it at the Ser131 and Thr200 sites to inhibit ubiquitination-mediated SDCBP degradation. More importantly, the sites at which AURKA phosphorylates SDCBP are crucial for the EGFR signaling-mediated oncogenic function of SDCBP. Taken together, we propose that SDCBP phosphorylation by AURKA prevents SDCBP degradation and promotes ESCC tumor growth through the EGFR-PI3K-Akt signaling pathway. Our findings unveil a new AURKA-SDCBP-EGFR axis that is involved in ESCC progression and provide a promising therapeutic target for ESCC treatment in the clinic.	[Du, Ruijuan; Huang, Chuntian; Liu, Kangdong; Zhou, Liting; Wu, Qiong; Dong, Zigang; Li, Xiang] Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China; [Du, Ruijuan; Huang, Chuntian; Liu, Kangdong; Yao, Ning; Yang, Lu; Zhou, Liting; Wu, Qiong; Zheng, Yaqiu; Xin, Mingxia; Dong, Zigang; Li, Xiang] China US Henan Hormel Canc Inst, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China; [Chen, Hanyong] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Liu, Kangdong; Dong, Zigang; Li, Xiang] Collaborat Innovat Ctr Henan Prov Canc Chemopreve, Zhengzhou, Peoples R China; [Liu, Kangdong; Dong, Zigang; Li, Xiang] Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Henan, Peoples R China; [Xiang, Pu] Zhengzhou Univ, Dept Hematol, Affiliated Canc Hosp, Zhengzhou 450008, Henan, Peoples R China; [Xiang, Pu] Henan Canc Hosp, Zhengzhou 450008, Henan, Peoples R China	Zhengzhou University; University of Minnesota System; Zhengzhou University; Zhengzhou University; Zhengzhou University	Dong, ZG; Li, X (corresponding author), Zhengzhou Univ, Sch Basic Med Sci, Dept Pathophysiol, Zhengzhou 450001, Henan, Peoples R China.; Dong, ZG; Li, X (corresponding author), China US Henan Hormel Canc Inst, 127 Dongming Rd, Zhengzhou 450008, Henan, Peoples R China.; Dong, ZG; Li, X (corresponding author), Collaborat Innovat Ctr Henan Prov Canc Chemopreve, Zhengzhou, Peoples R China.; Dong, ZG; Li, X (corresponding author), Zhengzhou Univ, State Key Lab Esophageal Canc Prevent & Treatment, Zhengzhou, Henan, Peoples R China.	dongzg@zzu.edu.cn; lixiang@zzu.edu.cn			National Natural Science Foundation of China [81802795, 31301144]; Key Scientific Research Project Plan of Colleges and Universities in Henan Province [18A310034]; Science and Technology Project of Henan Province [182102310324, 202102310206]; Training plan for Young Backbone Teachers of Zhengzhou University [2018ZDGGJS037]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Scientific Research Project Plan of Colleges and Universities in Henan Province; Science and Technology Project of Henan Province; Training plan for Young Backbone Teachers of Zhengzhou University	This study was supported by the National Natural Science Foundation of China (Nos. 81802795 and 31301144); the Key Scientific Research Project Plan of Colleges and Universities in Henan Province (No. 18A310034); the Science and Technology Project of Henan Province (Nos. 182102310324 and 202102310206); and the Training plan for Young Backbone Teachers of Zhengzhou University (No. 2018ZDGGJS037).	Baietti MF, 2012, NAT CELL BIOL, V14, P677, DOI 10.1038/ncb2502; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boukerche H, 2005, CANCER RES, V65, P10901, DOI 10.1158/0008-5472.CAN-05-1614; Boukerche H, 2010, ONCOGENE, V29, P3054, DOI 10.1038/onc.2010.65; Boukerche H, 2008, P NATL ACAD SCI USA, V105, P15914, DOI 10.1073/pnas.0808171105; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Choi Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep36818; Cui L, 2016, ONCOTARGET, V7, P82634, DOI 10.18632/oncotarget.13020; Das SK, 2012, FRONT BIOSCI-LANDMRK, V17, P1, DOI 10.2741/3911; Dasgupta S, 2013, CLIN CANCER RES, V19, P4621, DOI 10.1158/1078-0432.CCR-13-0585; Dutertre S, 2002, ONCOGENE, V21, P6175, DOI 10.1038/sj.onc.1205775; Egea-Jimenez AL, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12101; Fancelli D, 2006, J MED CHEM, V49, P7247, DOI 10.1021/jm060897w; Ferrari S, 2005, BIOCHEM J, V390, P293, DOI 10.1042/BJ20050343; Gangemi R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029989; Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076; Guan Z, 2007, CANCER RES, V67, P10436, DOI 10.1158/0008-5472.CAN-07-1379; Humphrey SJ, 2015, TRENDS ENDOCRIN MET, V26, P676, DOI 10.1016/j.tem.2015.09.013; Kamran M, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2016.80; Kang BS, 2003, STRUCTURE, V11, P845, DOI 10.1016/S0969-2126(03)00125-4; Kang BS, 2003, STRUCTURE, V11, P459, DOI 10.1016/S0969-2126(03)00052-2; Kegelman TP, 2017, P NATL ACAD SCI USA, V114, P370, DOI 10.1073/pnas.1616100114; Kegelman TP, 2014, NEURO-ONCOLOGY, V16, P50, DOI 10.1093/neuonc/not157; Koo TH, 2002, ONCOGENE, V21, P4080, DOI 10.1038/sj.onc.1205514; Liu JH, 2018, EUR J MED CHEM, V154, P354, DOI 10.1016/j.ejmech.2018.05.015; Lopez-Saez JF, 1998, HISTOL HISTOPATHOL, V13, P1197, DOI 10.14670/HH-13.1197; Luyten A, 2008, MOL BIOL CELL, V19, P1594, DOI 10.1091/mbc.E07-08-0832; Macindoe G, 2010, NUCLEIC ACIDS RES, V38, pW445, DOI 10.1093/nar/gkq311; Melhado Rachel E, 2010, Cancers (Basel), V2, P1379, DOI 10.3390/cancers2031379; Mori H, 1999, MUTAT RES-FUND MOL M, V428, P291, DOI 10.1016/S1383-5742(99)00055-1; Ohno K, 2004, MOL CELL NEUROSCI, V26, P518, DOI 10.1016/j.mcn.2004.04.007; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Oyesanya Regina A, 2014, Oncoscience, V1, P725; Qian XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060046; Qina L, 2009, CANCER LETT, V275, P77, DOI 10.1016/j.canlet.2008.10.011; Radivojac P, 2008, BIOINFORMATICS, V24, pI241, DOI 10.1093/bioinformatics/btn267; Rajesh S, 2011, J BIOL CHEM, V286, P39606, DOI 10.1074/jbc.M111.262402; Sala-Valdes M, 2012, J CELL SCI, V125, P1235, DOI 10.1242/jcs.094912; Talukdar S, 2018, P NATL ACAD SCI USA, V115, P5768, DOI 10.1073/pnas.1721650115; Tanaka E, 2005, CLIN CANCER RES, V11, P1827, DOI 10.1158/1078-0432.CCR-04-1627; Tong T, 2004, CLIN CANCER RES, V10, P7304, DOI 10.1158/1078-0432.CCR-04-0806; Wang J, 2017, J CELL SCI, V130, P1078, DOI 10.1242/jcs.196790; Wang J, 2017, BMC BIOL, V15, DOI 10.1186/s12915-016-0335-5; Wang LK, 2016, ONCOTARGET, V7, P386, DOI 10.18632/oncotarget.6299; Wang XX, 2012, MOL CANCER RES, V10, P588, DOI 10.1158/1541-7786.MCR-11-0416; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; Yang SB, 2007, ONCOL REP, V17, P1083; Yao JE, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-95; Yoshida GJ, 2018, P NATL ACAD SCI USA, V115, pE7652, DOI 10.1073/pnas.1810152115; Zeng HM, 2018, LANCET GLOB HEALTH, V6, pE555, DOI 10.1016/S2214-109X(18)30127-X; Zhong D, 2012, ASIAN PAC J CANCER P, V13, P2897, DOI 10.7314/APJCP.2012.13.6.2897; Zimmermann P, 2001, MOL BIOL CELL, V12, P339, DOI 10.1091/mbc.12.2.339	52	11	11	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	2020	39	31					5405	5419		10.1038/s41388-020-1369-2	http://dx.doi.org/10.1038/s41388-020-1369-2		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MT1TS	32572158				2022-12-17	WOS:000542723000003
J	Jiang, K; Liu, P; Xu, HZ; Liang, DP; Fang, K; Du, S; Cheng, W; Ye, LG; Liu, T; Zhang, XH; Gong, P; Shao, SJ; Wang, YF; Meng, SS				Jiang, Ke; Liu, Peng; Xu, Huizhe; Liang, Dapeng; Fang, Kun; Du, Sha; Cheng, Wei; Ye, Leiguang; Liu, Tong; Zhang, Xiaohong; Gong, Peng; Shao, Shujuan; Wang, Yifei; Meng, Songshu			SASH1 suppresses triple-negative breast cancer cell invasion through YAP-ARHGAP42-actin axis	ONCOGENE			English	Article							HIPPO PATHWAY; ACTIN CYTOSKELETON; YAP; GENE; COMPLEX; GROWTH; PHOSPHORYLATION; METASTASIS; INHIBITION; EXPRESSION	Triple-negative breast cancer (TNBC) is extremely aggressive and lacks effective therapy. SAM and SH3 domain containing1 (SASH1) has been implicated in TNBC as a candidate tumor suppressor; however, the mechanisms of action of SASH1 in TNBC remain underexplored. Here, we show that SASH1 was significantly downregulated in TNBC patients samples compared with other subtypes of breast cancer. Ectopic SASH1 expression inhibited, while depletion of SASH1 enhanced, the invasive phenotype of TNBC cells, accompanied by deregulated expression of MMP2 and MMP9. The functional effects of SASH1 depletion were confirmed in the chicken chorioallantoic membrane and mouse xenograft models. Mechanistically, SASH1 knockdown downregulated the phosphorylation levels of the Hippo kinase LATS1 and its effector YAP (Yes associated protein), thereby upregulating YAP accumulation together with its downstream target CYR61. Consistently, forced SASH1 expression exhibited opposite effects. Pharmacological inhibition of YAP or knockdown of YAP reversed the enhanced cell invasion of TNBC cells following SASH1 depletion. Furthermore, SASH1-induced YAP signaling was LATS1-dependent, which in reverse enhanced phosphorylation of SASH1. The SASH1 S407A mutant (phosphorylation deficient) failed to rescue the altered YAP signaling by SASH1 knockdown. Notably, SASH1 depletion upregulated ARHGAP42 levels via YAP-TEAD and the YAP-ARHGAP42-actin axis contributed to SASH1-regulated TNBC cell invasion. Therefore, our findings uncover a new mechanism for the tumor-suppressive activity of SASH1 in TNBC, which may serve as a novel target for therapeutic intervention.	[Jiang, Ke; Xu, Huizhe; Liang, Dapeng; Fang, Kun; Du, Sha; Cheng, Wei; Zhang, Xiaohong; Meng, Songshu] Dalian Med Univ, Inst Canc Stem Cell, Canc Ctr, Dalian 116044, Peoples R China; [Liu, Peng; Gong, Peng] Shenzhen Univ, Gen Hosp, Dept Gen Surg, Shenzhen 518055, Peoples R China; [Liu, Peng; Gong, Peng] Shenzhen Univ, Sch Med, Carson Int Canc Res Ctr, Shenzhen 518055, Peoples R China; [Ye, Leiguang] Harbin Med Univ, Canc Hosp, Dept Oncol, Harbin 150000, Peoples R China; [Liu, Tong] Harbin Med Univ, Canc Hosp, Dept Breast Surg, Harbin 150000, Peoples R China; [Shao, Shujuan] Dalian Med Univ, Key Lab Prote, Dalian 116044, Peoples R China; [Wang, Yifei] Dalian Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Dalian 116027, Peoples R China	Dalian Medical University; Shenzhen University; Shenzhen University; Harbin Medical University; Harbin Medical University; Dalian Medical University; Dalian Medical University	Meng, SS (corresponding author), Dalian Med Univ, Inst Canc Stem Cell, Canc Ctr, Dalian 116044, Peoples R China.; Shao, SJ (corresponding author), Dalian Med Univ, Key Lab Prote, Dalian 116044, Peoples R China.; Wang, YF (corresponding author), Dalian Med Univ, Affiliated Hosp 2, Dept Obstet & Gynecol, Dalian 116027, Peoples R China.	shaoshujuan2006@126.com; yly2000.312@163.com; ssmeng@dmu.edu.cn	chegn, maizy/GVU-3127-2022	Jiang, Ke/0000-0001-7959-7716	National Natural Science Foundation of China [81572707, 81772973, 81973646, 81402071]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank professors Bin Zhao, Huadong Pei, Shian Wu, Zengqiang Yuan and Alexander Hergovich for providing plasmids. The authors gratefully acknowledge the financial support from the National Natural Science Foundation of China (81572707 and 81772973 to SM, 81973646 to PG, 81402071 to DL).	BUBB MR, 1994, J BIOL CHEM, V269, P14869; Burgess JT, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.364; Burgess JT, 2016, ONCOTARGET, V7, P72807, DOI 10.18632/oncotarget.12020; Calses PC, 2019, TRENDS CANCER, V5, P297, DOI 10.1016/j.trecan.2019.04.001; Citron F, 2017, CLIN CANCER RES, V23, P3769, DOI 10.1158/1078-0432.CCR-16-2814; Cordenonsi M, 2011, CELL, V147, P759, DOI 10.1016/j.cell.2011.09.048; Coumans Joelle V F, 2018, Biophys Rev, V10, P1323, DOI 10.1007/s12551-018-0445-0; Das Thakur M, 2010, CURR BIOL, V20, P657, DOI 10.1016/j.cub.2010.02.035; Fang Q, 2018, ONCOTARGET, V9, P2475, DOI 10.18632/oncotarget.23504; Franke FC, 2019, CELL MOL GASTROENTER, V7, P33, DOI 10.1016/j.jcmgh.2018.08.007; Gong XC, 2017, ONCOTARGETS THER, V10, P271, DOI 10.2147/OTT.S119244; Hiemer SE, 2014, J BIOL CHEM, V289, P13461, DOI 10.1074/jbc.M113.529115; Jagannathan R, 2016, MOL CELL BIOL, V36, P2526, DOI 10.1128/MCB.00136-16; Jiang K, 2016, ONCOTARGET, V7, P25652, DOI 10.18632/oncotarget.8357; Kim T, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10186; Kumar MA, 2018, MOL CELL BIOCHEM, V442, P1, DOI 10.1007/s11010-017-3187-6; Lin SY, 2013, J BUON, V18, P891; Liu M, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0806-3; Liu X, 2018, CELL SIGNAL, V51, P243, DOI 10.1016/j.cellsig.2018.08.011; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Luo WF, 2017, J CELL SCI, V130, P2382, DOI 10.1242/jcs.197434; Ma SH, 2019, ANNU REV BIOCHEM, V88, P577, DOI 10.1146/annurev-biochem-013118-111829; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Martini M, 2011, INT J BIOCHEM CELL B, V43, P1630, DOI 10.1016/j.biocel.2011.07.012; Meng ZP, 2016, GENE DEV, V30, P1, DOI 10.1101/gad.274027.115; Porazinski S, 2015, NATURE, V521, P217, DOI 10.1038/nature14215; Qiao YT, 2017, CELL REP, V19, P1495, DOI 10.1016/j.celrep.2017.04.075; Rimkus C, 2006, BRIT J CANCER, V95, P1419, DOI 10.1038/sj.bjc.6603452; Shi PG, 2015, ACTA BIOCH BIOPH SIN, V47, P53, DOI 10.1093/abbs/gmu114; Shoji K, 2012, BIOCHEM BIOPH RES CO, V424, P52, DOI 10.1016/j.bbrc.2012.06.063; Stubblefield K, 2017, EXP CELL RES, V359, P384, DOI 10.1016/j.yexcr.2017.08.022; Sulaiman A, 2018, MOL ONCOL, V12, P423, DOI 10.1002/1878-0261.12167; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sun CY, 2017, INT J BIOCHEM CELL B, V89, P95, DOI 10.1016/j.biocel.2017.06.006; Yao Chuanbo, 2017, Yichuan, V39, P617, DOI 10.16288/j.yczz.17-100; Yu FX, 2014, EMBO J, V33, P942, DOI 10.1002/embj.201488329; Zeller C, 2003, ONCOGENE, V22, P2972, DOI 10.1038/sj.onc.1206474; Zhang ZZ, 2014, ACS MED CHEM LETT, V5, P993, DOI 10.1021/ml500160m; Zheng YG, 2019, DEV CELL, V50, P264, DOI 10.1016/j.devcel.2019.06.003; Zhou X, 2015, J CLIN INVEST, V125, P2123, DOI 10.1172/JCI79573	40	11	11	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 2	2020	39	27					5015	5030		10.1038/s41388-020-1356-7	http://dx.doi.org/10.1038/s41388-020-1356-7		JUN 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ME5NL	32523092				2022-12-17	WOS:000539515400002
J	Zhou, YH; Zhang, JL; Li, H; Huang, TT; Wong, CC; Wu, F; Wu, M; Weng, NQ; Liu, LP; Cheng, ASL; Yu, J; Wong, N; Lo, KW; Tang, PMK; Kang, W; To, KF				Zhou, Yuhang; Zhang, Jinglin; Li, Hui; Huang, Tingting; Wong, Chi Chun; Wu, Feng; Wu, Man; Weng, Nuoqing; Liu, Liping; Cheng, Alfred S. L.; Yu, Jun; Wong, Nathalie; Lo, Kwok Wai; Tang, Patrick M. K.; Kang, Wei; To, Ka Fai			AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis	ONCOGENE			English	Article							HIPPO PATHWAY; CANCER PROGRESSION; FAMILY PROTEINS; ANGIOMOTIN; ACTIVATION; REVEALS	Hippo signaling functions to limit cellular growth, but the aberrant nuclear accumulation of its downstream YAP1 leads to carcinogenesis. YAP1/TEAD complex activates the oncogenic downstream transcription, such as CTGF and c-Myc. How YAP1 is protected in the cytoplasm from ubiquitin-mediated degradation remains elusive. In this study, a member of Angiomotin (Motin) family, AMOTL1 (Angiomotin Like 1), was screened out as the only one to promote YAP1 nuclear accumulation by several clinical cohorts, which was further confirmed by the cellular functional assays. The interaction between YAP1 and AMOTL1 was suggested by co-immunoprecipitation and immunofluorescent staining. The clinical significance of the AMOTL1-YAP1-CTGF axis in gastric cancer (GC) was analyzed by multiple clinical cohorts. Moreover, the therapeutic effect of targeting the oncogenic axis was appraised by drug-sensitivity tests and xenograft-formation assays. The upregulation of AMOTL1 is associated with unfavorable clinical outcomes of GC, and knocking down AMOTL1 impairs its oncogenic properties. The cytoplasmic interaction between AMOTL1 and YAP1 protects each other from ubiquitin-mediated degradation. AMOTL1 promotes YAP1 translocation into the nuclei to activate the downstream expression, such as CTGF. Knocking down AMOTL1, YAP1, and CTGF enhances the therapeutic efficacies of the first-line anticancer drugs. Taken together, AMOTL1 plays an oncogenic role in gastric carcinogenesis through interacting with YAP1 and promoting its nuclear accumulation. A combination of AMOTL1, YAP1, and CTGF expression might serve as a surrogate of Hippo activation status. The co-activation of the AMOTL1/YAP1-CTGF axis is associated with poor clinical outcomes of GC patients, and targeting this oncogenic axis may enhance the chemotherapeutic effects.	[Zhou, Yuhang; Zhang, Jinglin; Li, Hui; Huang, Tingting; Wu, Feng; Wu, Man; Wong, Nathalie; Lo, Kwok Wai; Tang, Patrick M. K.; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Translat Oncol, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China; [Zhou, Yuhang; Zhang, Jinglin; Huang, Tingting; Wong, Chi Chun; Yu, Jun; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China; [Zhou, Yuhang; Zhang, Jinglin; Huang, Tingting; Wong, Nathalie; Lo, Kwok Wai; Kang, Wei; To, Ka Fai] Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China; [Weng, Nuoqing; Cheng, Alfred S. L.; Yu, Jun] Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China; [Liu, Liping] Jinan Univ, Clin Med Coll 2, Shenzhen Peoples Hosp, Dept Hepatobiliary & Pancreat Surg, Shenzhen, Guangdong, Peoples R China; [Cheng, Alfred S. L.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China; [Yu, Jun] Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Sun Yat Sen University; Jinan University; Chinese University of Hong Kong; Chinese University of Hong Kong	Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, State Key Lab Translat Oncol, Dept Anat & Cellular Pathol, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Inst Digest Dis, State Key Lab Digest Dis, Hong Kong, Peoples R China.; Kang, W; To, KF (corresponding author), Chinese Univ Hong Kong, Sir YK Pao Canc Ctr, Li Ka Shing Inst Hlth Sci, Hong Kong, Peoples R China.	weikang@cuhk.edu.hk; kfto@cuhk.edu.hk	Tang, Patrick MK/AAJ-8461-2021; huang, ting/GRR-3141-2022; KANG, Wei/C-5451-2016	Tang, Patrick MK/0000-0002-3194-3736; KANG, Wei/0000-0002-4651-677X	Research Grants Council of the Hong Kong Special Administrative Region, China [CUHK 14100019, 14118518]; Innovation and Technology Fund of Hong Kong [ITS/068/18, PiH/009/19, PiH/010/19, InP/008/19, InP/009/19]; CUHK Direct Grant for Research from The Chinese University of Hong Kong [2018.002]	Research Grants Council of the Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council); Innovation and Technology Fund of Hong Kong; CUHK Direct Grant for Research from The Chinese University of Hong Kong	The paper is under support of the Research Grants Council of the Hong Kong Special Administrative Region, China [Project No.: CUHK 14100019 and 14118518 (for GRF projects)], Innovation and Technology Fund of Hong Kong (Project No.: (ITS/068/18, PiH/009/19, PiH/010/19, InP/008/19, and InP/009/19)), and CUHK Direct Grant for Research (2018.002) from The Chinese University of Hong Kong.	Aase K, 2007, GENE DEV, V21, P2055, DOI 10.1101/gad.432007; Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Cheng TY, 2014, WORLD J GASTROENTERO, V20, P1694, DOI 10.3748/wjg.v20.i7.1694; Couderc C, 2016, NEOPLASIA, V18, P10, DOI 10.1016/j.neo.2015.11.010; Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839; Hong SA, 2017, APMIS, V125, P996, DOI 10.1111/apm.12750; Hsu YL, 2015, ONCOGENE, V34, P4056, DOI 10.1038/onc.2014.333; Huang HZ, 2007, DEVELOPMENT, V134, P979, DOI 10.1242/dev.02782; Huang TT, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1466-y; Hultin S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4743; Jiang CG, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-122; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Kang W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0134-0; Kang W, 2017, J THORAC DIS, V9, P1748, DOI 10.21037/jtd.2017.06.26; Kang W, 2016, WORLD J GASTROENTERO, V22, P1279, DOI 10.3748/wjg.v22.i3.1279; Kang W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0323-3; Kang W, 2011, CLIN CANCER RES, V17, P2130, DOI 10.1158/1078-0432.CCR-10-2467; Li ZQ, 2012, J BIOL CHEM, V287, P13005, DOI 10.1074/jbc.M112.347419; Lim B, 2014, CARCINOGENESIS, V35, P1020, DOI 10.1093/carcin/bgt409; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Lu TT, 2018, CANCER LETT, V423, P36, DOI 10.1016/j.canlet.2018.02.015; Paramasivam M, 2011, MOL BIOL CELL, V22, P3725, DOI 10.1091/mbc.E11-04-0300; Perra A, 2014, J HEPATOL, V61, P1088, DOI 10.1016/j.jhep.2014.06.033; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Shi Z, 2017, ONCOGENE, V36, P4362, DOI 10.1038/onc.2017.24; Trautmann M, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201809889; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Wang WQ, 2011, J BIOL CHEM, V286, P4364, DOI 10.1074/jbc.C110.205401; Wang Y, 2017, ONCOGENE, V36, P534, DOI 10.1038/onc.2016.224; Weiler SME, 2017, GASTROENTEROLOGY, V152, P2037, DOI 10.1053/j.gastro.2017.02.018; Yi CL, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004060; Yu MX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0515-z; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zheng YJ, 2009, CIRC RES, V105, P260, DOI 10.1161/CIRCRESAHA.109.195156; Zhou Y, 2017, ONCOGENE, V36, P6518, DOI 10.1038/onc.2017.257; Zhou YH, 2018, CANCER LETT, V426, P73, DOI 10.1016/j.canlet.2018.04.004; Zhou YH, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0647-2; Zhou YH, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17010138	40	11	11	2	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	22					4375	4389		10.1038/s41388-020-1293-5	http://dx.doi.org/10.1038/s41388-020-1293-5		APR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LR9IT	32313226	Green Published, hybrid			2022-12-17	WOS:000527509300001
J	Zhang, X; Huang, ZN; Guo, YY; Xiao, T; Tang, L; Zhao, S; Wu, LS; Su, J; Zeng, WQ; Huang, HB; Li, Z; Tao, J; Zhou, JD; Chen, X; Peng, C				Zhang, Xu; Huang, Zunnan; Guo, Yeye; Xiao, Ta; Tang, Ling; Zhao, Shuang; Wu, Lisha; Su, Juan; Zeng, Weiqi; Huang, Hongbin; Li, Zheng; Tao, Juan; Zhou, Jianda; Chen, Xiang; Peng, Cong			The phosphorylation of CD147 by Fyn plays a critical role for melanoma cells growth and metastasis	ONCOGENE			English	Article							GNT-V; PROLIFERATION; INVASION; MATRIX-METALLOPROTEINASE-9; METALLOPROTEINASES; PROGRESSION; EXPRESSION; ADHESION; 3-KINASE; DOMAINS	CD147, also known as extracellular matrix metalloproteinase inducer (EMMPRIN), is a transmembrane glycoprotein that is highly expressed in tumor cells, particularly melanoma cells, and plays critical roles in tumor cell metastasis through the regulation of matrix metalloprotease (MMP) expression. In this study, we identified Fyn as a novel interacting protein of CD147. Fyn is a member of the Src family of nonreceptor tyrosine kinases that regulates diverse physiological processes, such as T lymphocyte differentiation, through the TCR signaling pathway. Our findings demonstrated that Fyn directly phosphorylates CD147 at Y140 and Y183. Two phosphospecific antibodies against Y140 and Y183 were developed to validate the phosphorylation of CD147 by Fyn. Moreover, the CD147-FF (Y140F/Y183F) mutation impaired the interaction between CD147 and GnT-V, leading to decreased CD147 glycosylation and membrane recruitment. In addition, CD147-FF significantly blocked MMP-9 expression as well as cell migration. Moreover, we found that Fyn is overexpressed in clinical melanoma tissues as well as in melanoma cell lines. Knockdown of Fyn expression markedly attenuated the malignant phenotype of melanoma cells in vitro and in vivo through downregulation of CD147 phosphorylation, indicating that Fyn/CD147 is a potential target molecule in melanoma treatment. Finally, through virtual screening, we identified amodiaquine as a potential inhibitor targeting the Fyn/CD147 axis. Amodiaquine treatment dramatically inhibited the phosphorylation of CD147 by Fyn, thus attenuating melanoma cell growth and invasion in vitro and in vivo, suggesting that amodiaquine is a promising inhibitor for melanoma treatment.	[Zhang, Xu; Guo, Yeye; Xiao, Ta; Tang, Ling; Zhao, Shuang; Wu, Lisha; Su, Juan; Zeng, Weiqi; Chen, Xiang; Peng, Cong] Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha, Hunan, Peoples R China; [Zhang, Xu; Guo, Yeye; Xiao, Ta; Tang, Ling; Zhao, Shuang; Wu, Lisha; Su, Juan; Zeng, Weiqi; Chen, Xiang; Peng, Cong] Cent South Univ, Xiangya Hosp, Hunan Key Lab Skin Canc & Psoriasis, Changsha, Hunan, Peoples R China; [Zhang, Xu; Guo, Yeye; Xiao, Ta; Tang, Ling; Zhao, Shuang; Wu, Lisha; Su, Juan; Zeng, Weiqi; Chen, Xiang; Peng, Cong] Cent South Univ, Xiangya Hosp, Hunan Engn Res Ctr Skin Hlth & Dis, Changsha, Hunan, Peoples R China; [Huang, Zunnan; Huang, Hongbin] Guangdong Med Univ, Res Platform Serv Management Ctr, Key Lab Big Data Min & Precis Drug Design, Dongguan 523808, Guangdong, Peoples R China; [Li, Zheng] Cent South Univ, Xiangya Hosp, Chinese Minist Hlth, Key Lab Carcinogenesis, Changsha, Hunan, Peoples R China; [Tao, Juan] Huazhong Univ Sci & Technol, Tongji Med Coll, Affiliated Union Hosp, Dept Dermatol, Wuhan, Peoples R China; [Zhou, Jianda] Cent South Univ, Xiangya Hosp 3, Dept Plast Surg, Changsha, Peoples R China	Central South University; Central South University; Central South University; Guangdong Medical University; Central South University; Huazhong University of Science & Technology; Central South University	Chen, X; Peng, C (corresponding author), Cent South Univ, Xiangya Hosp, Dept Dermatol, Changsha, Hunan, Peoples R China.; Chen, X; Peng, C (corresponding author), Cent South Univ, Xiangya Hosp, Hunan Key Lab Skin Canc & Psoriasis, Changsha, Hunan, Peoples R China.; Chen, X; Peng, C (corresponding author), Cent South Univ, Xiangya Hosp, Hunan Engn Res Ctr Skin Hlth & Dis, Changsha, Hunan, Peoples R China.	chenxiangck@126.com; pengcongxy@csu.edu.cn	zhao, shuangling/HCI-6255-2022; wu, Xianrui/AAM-6540-2021; Wu, Lisha/ABG-2923-2021; Huang, Zunnan/M-5214-2019	wu, Xianrui/0000-0003-4803-5934; Wu, Lisha/0000-0003-2847-1982; Huang, Zunnan/0000-0002-5821-703X	Major Projects of International Cooperation and Exchanges NSFC [81620108024]; National Natural Science Foundation [81572679, 81773341, 31770774, 81572677, 81830096]; Strategy-Oriented Special Project of Central South University in China [ZLXD2017003]; Provincial Major Project of basic or Applied Research in Natural Science, Guangdong Provincial, Education Department [2016KZDXM038]; China Postdoctoral Science Foundation [2019M652808]	Major Projects of International Cooperation and Exchanges NSFC; National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Strategy-Oriented Special Project of Central South University in China; Provincial Major Project of basic or Applied Research in Natural Science, Guangdong Provincial, Education Department; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was financially supported by the Major Projects of International Cooperation and Exchanges NSFC Grant No. 81620108024; Grant No. 81572679, 81773341, 31770774, 81572677, 81830096 from the National Natural Science Foundation; the Strategy-Oriented Special Project of Central South University in China (ZLXD2017003); the Provincial Major Project of basic or Applied Research in Natural Science, Guangdong Provincial, Education Department (2016KZDXM038) and the China Postdoctoral Science Foundation (2019M652808).	Baillat G, 2008, BBA-MOL CELL RES, V1783, P2323, DOI 10.1016/j.bbamcr.2008.08.008; Cotignola J, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-10; Cui J, 2018, J PATHOL, V245, P41, DOI 10.1002/path.5054; Elias D, 2015, PHARMACOL RES, V100, P250, DOI 10.1016/j.phrs.2015.08.010; Fan JH, 2012, GLYCOCONJUGATE J, V29, P323, DOI 10.1007/s10719-012-9414-1; Gruszewska Ewa, 2013, Pol Merkur Lekarski, V34, P58; Huang BB, 2014, INT J ONCOL, V44, P849, DOI 10.3892/ijo.2014.2248; Huang BB, 2013, ONCOL REP, V29, P2392, DOI 10.3892/or.2013.2373; Huang W, 2013, BIOCHEM J, V449, P437, DOI 10.1042/BJ20120343; Kanekura T, 2002, INT J CANCER, V99, P520, DOI 10.1002/ijc.10390; Kanekura T, 2010, J DERMATOL SCI, V57, P149, DOI 10.1016/j.jdermsci.2009.12.008; Kato N, 2009, J AM SOC NEPHROL, V20, P1565, DOI 10.1681/ASN.2008090957; Kuphal S, 2009, J PATHOL, V219, P400, DOI 10.1002/path.2617; Lang V, 1999, J IMMUNOL, V162, P7224; Li B, 2016, MOL MED REP, V13, P469, DOI 10.3892/mmr.2015.4492; Li JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep35210; Li K, 2018, ANN RHEUM DIS, V77, P935, DOI 10.1136/annrheumdis-2017-212658; Liang XQ, 2004, J BIOL CHEM, V279, P8133, DOI 10.1074/jbc.M311180200; Liao CG, 2011, MOL CELL BIOL, V31, P2591, DOI 10.1128/MCB.05160-11; Long TT, 2013, CANCER LETT, V339, P93, DOI 10.1016/j.canlet.2013.07.019; Mauris J, 2014, J CELL SCI, V127, P3141, DOI 10.1242/jcs.148510; Mehner C, 2014, ONCOTARGET, V5, P2736, DOI 10.18632/oncotarget.1932; Miyamoto Y, 2016, DATA BRIEF, V7, P1098, DOI 10.1016/j.dib.2016.03.096; Moro N, 2014, EUR J CELL BIOL, V93, P23, DOI 10.1016/j.ejcb.2014.01.002; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; Rey MCW, 2011, AM J DERMATOPATH, V33, P413, DOI 10.1097/DAD.0b013e3181e2e8d6; Saito YD, 2010, CANCER-AM CANCER SOC, V116, P1629, DOI 10.1002/cncr.24879; Salmond RJ, 2009, IMMUNOL REV, V228, P9, DOI 10.1111/j.1600-065X.2008.00745.x; Schaeuble K, 2011, J IMMUNOL, V187, P5645, DOI 10.4049/jimmunol.1101850; Su J, 2016, ONCOTARGET, V7, P64778, DOI 10.18632/oncotarget.11415; Su J, 2009, CANCER LETT, V273, P140, DOI 10.1016/j.canlet.2008.07.034; Susa M, 1996, BIOCHEM BIOPH RES CO, V220, P729, DOI 10.1006/bbrc.1996.0472; Tang Y, 2018, BIOCHEM BIOPH RES CO, V503, P3142, DOI 10.1016/j.bbrc.2018.08.107; Villanueva J, 2008, CURR ONCOL REP, V10, P439, DOI 10.1007/s11912-008-0067-y; Vultur Adina, 2013, Cancer Cell, V23, P706, DOI 10.1016/j.ccr.2013.05.001; Watanabe A, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003086; Wu JB, 2015, INT J CLIN EXP PATHO, V8, P9901; Yadav V, 2011, MOL CARCINOGEN, V50, P346, DOI 10.1002/mc.20716; Yu XL, 2006, INT J BIOCHEM CELL B, V38, P1939, DOI 10.1016/j.biocel.2006.05.008; Zeng W, 2014, CURR MOL MED, V14, P163, DOI 10.2174/15665240113136660077; Zhang J, 2014, MOL MED REP, V10, P1084, DOI 10.3892/mmr.2014.2277; Zhou J, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-25	42	11	12	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4183	4197		10.1038/s41388-020-1287-3	http://dx.doi.org/10.1038/s41388-020-1287-3		APR 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32291412				2022-12-17	WOS:000526237900005
J	Lartigue, L; Merle, C; Lagarde, P; Delespaul, L; Lesluyes, T; Le Guellec, S; Perot, G; Leroy, L; Coindre, JM; Chibon, F				Lartigue, Lydia; Merle, Candice; Lagarde, Pauline; Delespaul, Lucile; Lesluyes, Tom; Le Guellec, Sophie; Perot, Gaelle; Leroy, Laura; Coindre, Jean-Michel; Chibon, Frederic			Genome remodeling upon mesenchymal tumor cell fusion contributes to tumor progression and metastatic spread	ONCOGENE			English	Article							MALIGNANT FIBROUS HISTIOCYTOMAS; CHROMOSOME INSTABILITY; CANCER; ANEUPLOIDY; MODEL; MECHANISMS; SARCOMAS; DNA; CONSEQUENCES; ONCOGENESIS	Cell fusion in tumor progression mostly refers to the merging of a cancer cell with a cell that has migration and immune escape capabilities such as macrophages. Here we show that spontaneous hybrids made from the fusion of transformed mesenchymal cells with partners from the same lineage undergo nonrecurrent large-scale genomic rearrangements, leading to the creation of highly aneuploid cells with novel phenotypic traits, including metastatic spreading capabilities. Moreover, in contrast to their parents, hybrids were the only cells able to recapitulate in vivo all features of human pleomorphic sarcomas, a rare and genetically complex mesenchymal tumor. Hybrid tumors not only displayed specific mesenchymal markers, but also combined a complex genetic profile with a highly metastatic behavior, like their human counterparts. Finally, we provide evidence that patient-derived pleomorphic sarcoma cells are inclined to spontaneous cell fusion. The resulting hybrids also gain in aggressiveness, exhibiting superior growth capacity in mouse models. Altogether, these results indicate that cell fusion has the potential to promote cancer progression by increasing growth and/or metastatic capacities, regardless of the nature of the companion cell. Moreover, such events likely occur upon sarcoma development, paving the way for better understanding of the biology, and aggressiveness of these tumors.	[Lartigue, Lydia; Lagarde, Pauline; Coindre, Jean-Michel; Chibon, Frederic] INSERM, U1218, 229 Cours Argonne, F-33076 Bordeaux, France; [Lartigue, Lydia; Lagarde, Pauline; Coindre, Jean-Michel] Bordeaux Univ, 146 Rue Leo Saignat, F-33000 Bordeaux, France; [Merle, Candice; Delespaul, Lucile; Lesluyes, Tom; Le Guellec, Sophie; Perot, Gaelle; Leroy, Laura; Chibon, Frederic] CRCT, INSERM, U1037, F-31037 Toulouse, France; [Merle, Candice] Univ Toulouse 3 Paul Sabatier, 118 Route Narbonne, F-31062 Toulouse 9, France; [Lagarde, Pauline; Coindre, Jean-Michel; Chibon, Frederic] Bergonie Inst, Dept Biopathol, 229 Cours Argonne, F-33076 Bordeaux, France; [Le Guellec, Sophie; Perot, Gaelle; Leroy, Laura; Chibon, Frederic] Inst Claudius Regaud, IUCT Oncopole, Dept Pathol, Toulouse, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; UNICANCER; Institut Bergonie; UNICANCER; Institut Claudius Regaud	Chibon, F (corresponding author), INSERM, U1218, 229 Cours Argonne, F-33076 Bordeaux, France.; Chibon, F (corresponding author), CRCT, INSERM, U1037, F-31037 Toulouse, France.; Chibon, F (corresponding author), Bergonie Inst, Dept Biopathol, 229 Cours Argonne, F-33076 Bordeaux, France.; Chibon, F (corresponding author), Inst Claudius Regaud, IUCT Oncopole, Dept Pathol, Toulouse, France.	frederic.chibon@inserm.fr	Lesluyes, Tom/GSD-4621-2022; Delespaul, Lucile/AAZ-1073-2021; Lesluyes, Tom/AAB-6229-2019; Pérot, Gaëlle/W-8038-2019; leroy, laura/ABE-2798-2021	Lesluyes, Tom/0000-0003-2251-5884; Lesluyes, Tom/0000-0003-2251-5884; Leroy, Laura/0000-0002-6804-2245; Delespaul, Lucile/0000-0002-9509-6425	Fondation ARC pour la recherche contre le cancer; "Fondation pour la recherche medicale" (FRM); association "Phil'Anthrope"; association "Pour Corentin"	Fondation ARC pour la recherche contre le cancer; "Fondation pour la recherche medicale" (FRM)(Fondation pour la Recherche Medicale); association "Phil'Anthrope"; association "Pour Corentin"	This work was supported by the "Fondation ARC pour la recherche contre le cancer", "the Fondation pour la recherche medicale" (FRM), and the associations "Phil'Anthrope" and "Pour Corentin".	Aichel O, 1911, ZELLVERSCHMELZUNG QU; Berndt Benjamin, 2013, Critical Reviews in Oncogenesis, V18, P97; Broncy L, 2018, J LAB PRECIS MED, V3; Chakraborty A, 2004, BONE MARROW TRANSPL, V34, P183, DOI 10.1038/sj.bmt.1704547; Chibon F, 2003, CANCER GENET CYTOGEN, V141, P75, DOI 10.1016/S0165-4608(02)00664-7; Chibon F, 2002, CANCER GENET CYTOGEN, V139, P24, DOI 10.1016/S0165-4608(02)00614-3; Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174; Cooke MS, 2003, FASEB J, V17, P1195, DOI 10.1096/fj.02-0752rev; Davoli T, 2013, CELL, V155, P948, DOI 10.1016/j.cell.2013.10.011; Delespaul L, 2019, ONCOGENE; Dittmar T, 2015, INT J MOL SCI, V16, P30362, DOI 10.3390/ijms161226240; Dittmar T, 2011, CLIN EXP METASTAS, V28, P75, DOI 10.1007/s10585-010-9359-3; Dodd Rebecca D, 2015, Methods Mol Biol, V1267, P283, DOI 10.1007/978-1-4939-2297-0_13; Dodd RD, 2010, DIS MODEL MECH, V3, P557, DOI 10.1242/dmm.005223; Duelli D, 2003, CANCER CELL, V3, P445, DOI 10.1016/S1535-6108(03)00114-4; Duelli DM, 2005, J CELL BIOL, V171, P493, DOI 10.1083/jcb.200507069; Duelli DM, 2007, CURR BIOL, V17, P431, DOI 10.1016/j.cub.2007.01.049; Durrieu-Gaillard S, 2018, CELL CYCLE, V17, P605, DOI 10.1080/15384101.2017.1405881; Gao RL, 2016, NAT GENET, V48, P1119, DOI 10.1038/ng.3641; Garvin S, 2018, J CANCER RES CLIN, V144, P1253, DOI 10.1007/s00432-018-2646-0; Gast CE, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aat7828; Gibault L, 2011, J PATHOL, V223, P64, DOI 10.1002/path.2787; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Goldenberg DM, 2012, EXPERT OPIN BIOL TH, V12, pS133, DOI 10.1517/14712598.2012.671807; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Guillou L, 2010, VIRCHOWS ARCH, V456, P201, DOI 10.1007/s00428-009-0853-4; Gupta PB, 2005, COLD SH Q B, V70, P291, DOI 10.1101/sqb.2005.70.033; Hahn WC, 2002, MOL CELL BIOL, V22, P2111, DOI 10.1128/MCB.22.7.2111-2123.2002; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Han ZY, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10421; Haurie V, 2010, P NATL ACAD SCI USA, V107, P4176, DOI 10.1073/pnas.0914980107; Hernando E, 2007, NAT MED, V13, P748, DOI 10.1038/nm1560; Jemaa M, 2017, ONCOTARGET, V8, P16669, DOI 10.18632/oncotarget.14291; Jiang EH, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/5013592; JOHNSON RT, 1970, NATURE, V226, P717, DOI 10.1038/226717a0; KERBEL RS, 1983, MOL CELL BIOL, V3, P523, DOI 10.1128/MCB.3.4.523; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Laberge GS, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020170; LaBerge GS, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168581; Lagarde P., 2015, AUSTIN J GENET GENOM, V2, P1014; Lagarde P, 2013, J CLIN ONCOL, V31, P608, DOI 10.1200/JCO.2012.46.0147; Lagarde P, 2012, CLIN CANCER RES, V18, P826, DOI 10.1158/1078-0432.CCR-11-1610; Lartigue L, 2015, EUR J CANCER, V51, P75, DOI 10.1016/j.ejca.2014.10.014; Lazar AJ, 2017, CELL, V171, P950, DOI 10.1016/j.cell.2017.10.014; Lazebnik Y, 2014, CELL CYCLE, V13, P2323, DOI 10.4161/cc.29704; Lazova R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066731; Lu X, 2009, CANCER RES, V69, P8536, DOI 10.1158/0008-5472.CAN-09-2159; Magdalou I, 2014, SEMIN CELL DEV BIOL, V30, P154, DOI 10.1016/j.semcdb.2014.04.035; Mairal A, 1999, CANCER GENET CYTOGEN, V111, P134, DOI 10.1016/S0165-4608(98)00227-1; Massague J, 2017, MOL ONCOL, V11, P3, DOI 10.1002/1878-0261.12024; Melzer C, 2019, CANCERS, V11, DOI 10.3390/cancers11020185; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Mohr M, 2015, METHODS MOL BIOL, P21, DOI 10.1007/978-1-4939-2703-6_2; Notta F, 2016, NATURE, V538, P378, DOI 10.1038/nature19823; Pachmayr E, 2017, VISC MED, V33, P11, DOI 10.1159/000454696; Powell AE, 2011, CANCER RES, V71, P1497, DOI 10.1158/0008-5472.CAN-10-3223; Rachkovsky M, 1998, CLIN EXP METASTAS, V16, P299; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; RAO PN, 1970, NATURE, V225, P159, DOI 10.1038/225159a0; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Riggi N, 2018, ANNU REV PATHOL-MECH, V13, P117, DOI 10.1146/annurev-pathol-020117-044127; Rizvi AZ, 2006, P NATL ACAD SCI USA, V103, P6321, DOI 10.1073/pnas.0508593103; Searles Stephen C, 2018, Oncotarget, V9, P6156, DOI 10.18632/oncotarget.23715; Seyfried Thomas N., 2013, Critical Reviews in Oncogenesis, V18, P43; Shabo I, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1935-0; Steele CD, 2019, CANCER CELL, V35, P441, DOI 10.1016/j.ccell.2019.02.002; Terada N, 2002, NATURE, V416, P542, DOI 10.1038/nature730; Turajlic S, 2019, NAT REV GENET, V20, P404, DOI 10.1038/s41576-019-0114-6; Turajlic S, 2018, CELL, V173, P581, DOI 10.1016/j.cell.2018.03.057; van de Vijver MJ, 2009, GENE EXPRESSION SIGN, DOI [10.1056/NEJMoa021967, DOI 10.1056/NEJMOA021967]; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Wang RX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042653; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Xue JG, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1780-1; Yilmaz Y, 2005, BONE MARROW TRANSPL, V35, P1021, DOI 10.1038/sj.bmt.1704939; Zhang S, 2014, ONCOGENE, V33, P116, DOI 10.1038/onc.2013.96; Zhou XF, 2015, AM J PATHOL, V185, P2049, DOI 10.1016/j.ajpath.2015.03.014	79	11	11	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2020	39	21					4198	4211		10.1038/s41388-020-1276-6	http://dx.doi.org/10.1038/s41388-020-1276-6		APR 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LQ2DH	32242148				2022-12-17	WOS:000522996500002
J	Diaz-Valdivia, NI; Diaz, J; Contreras, P; Campos, A; Rojas-Celis, V; Burgos-Ravanal, RA; Lobos-Gonzalez, L; Torres, VA; Perez, VI; Frei, B; Leyton, L; Quest, AFG				Diaz-Valdivia, Natalia I.; Diaz, Jorge; Contreras, Pamela; Campos, America; Rojas-Celis, Victoria; Burgos-Ravanal, Renato A.; Lobos-Gonzalez, Lorena; Torres, Vicente A.; Perez, Viviana I.; Frei, Balz; Leyton, Lisette; Quest, Andrew F. G.			The non-receptor tyrosine phosphatase type 14 blocks caveolin-1-enhanced cancer cell metastasis	ONCOGENE			English	Article							FOCAL ADHESION DYNAMICS; MESENCHYMAL TRANSITION; SRC KINASE; PHOSPHORYLATION; GROWTH; MIGRATION; CAVEOLIN; BETA; PEZ; IDENTIFICATION	Caveolin-1 (CAV1) enhanced migration, invasion, and metastasis of cancer cells is inhibited by co-expression of the glycoprotein E-cadherin. Although the two proteins form a multiprotein complex that includes beta-catenin, it remained unclear how this would contribute to blocking the metastasis promoting function of CAV1. Here, we characterized by mass spectrometry the protein composition of CAV1 immunoprecipitates from B16F10 murine melanoma cells expressing or not E-cadherin. The novel protein tyrosine phosphatase PTPN14 was identified by mass spectrometry analysis exclusively in co-immunoprecipitates of CAV1 with E-cadherin. Interestingly, PTPN14 is implicated in controlling metastasis, but only few known PTPN14 substrates exist. We corroborated by western blotting experiments that PTPN14 and CAV1 co-inmunoprecipitated in the presence of E-cadherin in B16F10 melanoma and other cancer cells. Moreover, the CAV1(Y14F) mutant protein was shown to co-immunoprecipitate with PTPN14 even in the absence of E-cadherin, and overexpression of PTPN14 reduced CAV1 phosphorylation on tyrosine-14, as well as suppressed CAV1-enhanced cell migration, invasion and Rac-1 activation in B16F10, metastatic colon [HT29(US)] and breast cancer (MDA-MB-231) cell lines. Finally, PTPN14 overexpression in B16F10 cells reduced the ability of CAV1 to induce metastasis in vivo. In summary, we identify here CAV1 as a novel substrate for PTPN14 and show that overexpression of this phosphatase suffices to reduce CAV1-induced metastasis.	[Diaz-Valdivia, Natalia I.; Diaz, Jorge; Contreras, Pamela; Campos, America; Rojas-Celis, Victoria; Burgos-Ravanal, Renato A.; Lobos-Gonzalez, Lorena; Leyton, Lisette; Quest, Andrew F. G.] Univ Chile, Fac Med, Cellular Commun Lab, Ctr Studies Exercise Metab & Canc CEMC,Adv Ctr Ch, Santiago, Chile; [Diaz, Jorge; Torres, Vicente A.] Univ Chile, Inst Res Dent Sci, Fac Dent, Santiago, Chile; [Campos, America; Lobos-Gonzalez, Lorena] Fdn Ciencia & Vida, Santiago, Chile; [Perez, Viviana I.; Frei, Balz] Oregon State Univ, Dept Biochem & Biophys, Linus Pauling Inst, Corvallis, OR 97331 USA	Universidad de Chile; Universidad de Chile; Oregon State University	Leyton, L; Quest, AFG (corresponding author), Univ Chile, Fac Med, Cellular Commun Lab, Ctr Studies Exercise Metab & Canc CEMC,Adv Ctr Ch, Santiago, Chile.	lleyton@med.uchile.cl; aquest@med.uchile.cl	Díaz-Valdivia, Natalia/Z-1893-2019	Díaz-Valdivia, Natalia/0000-0002-8063-2598; Lobos-Gonzalez, Lorena/0000-0002-4957-9864; Torres, Vicente A/0000-0002-5973-7248	CONICYT-FONDAP [15130011]; FONDECYT [1130250, 1170925, 1150744, 1140907, 11140204]; American federation for Aging Research (AFAR); Faculty Development Funds from Linus Pauling Institute; CONICYT; BASAL CCTE-PFB16 CONICYT;  [Anillo ACT 1111]	CONICYT-FONDAP(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDAP); FONDECYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)CONICYT FONDECYT); American federation for Aging Research (AFAR); Faculty Development Funds from Linus Pauling Institute; CONICYT(Comision Nacional de Investigacion Cientifica y Tecnologica (CONICYT)); BASAL CCTE-PFB16 CONICYT; 	This work was supported by CONICYT-FONDAP 15130011 (AFGQ), FONDECYT 1130250, 1170925 (AFGQ), Anillo ACT 1111 (AFGQ), FONDECYT 1150744 (LL), FONDECYT 1140907 (VAT), American federation for Aging Research (AFAR), Faculty Development Funds from Linus Pauling Institute (VIP) and CONICYT PhD fellowships (NDV, JD, AC), FONDECYT 11140204 (LLG), BASAL CCTE-PFB16 CONICYT (LLG).	Barr AJ, 2009, CELL, V136, P352, DOI 10.1016/j.cell.2008.11.038; Belle L, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005547; Bender FC, 2000, CANCER RES, V60, P5870; Cao HM, 2004, EXP CELL RES, V294, P159, DOI 10.1016/j.yexcr.2003.11.010; Cao HM, 2002, J BIOL CHEM, V277, P8771, DOI 10.1074/jbc.C100661200; Cao XQ, 2008, J BIOL CHEM, V283, P31401, DOI 10.1074/jbc.M804002200; Chiang WF, 2008, ORAL ONCOL, V44, P325, DOI 10.1016/j.oraloncology.2007.03.004; del Pozo MA, 2005, NAT CELL BIOL, V7, P901, DOI 10.1038/ncb1293; Diaz Jorge, 2014, Commun Integr Biol, V7, DOI 10.4161/19420889.2014.972850; Diaz J, 2014, J CELL SCI, V127, P2401, DOI 10.1242/jcs.141689; Diaz-Valdivia N, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1477-5; Diaz-Valdivia NI, 2017, ONCOTARGET, V8, P111943, DOI 10.18632/oncotarget.22955; Galvagni F, 2007, BIOCHEMISTRY-US, V46, P3998, DOI 10.1021/bi061400n; Goetz JG, 2008, J CELL BIOL, V180, P1261, DOI 10.1083/jcb.200709019; Grande-Garcia A, 2007, J CELL BIOL, V177, P683, DOI 10.1083/jcb.200701006; Hu HL, 2005, CURR BIOL, V15, P815, DOI 10.1016/j.cub.2005.03.049; Jo A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091582; Joshi B, 2008, CANCER RES, V68, P8210, DOI 10.1158/0008-5472.CAN-08-0343; Khusial PR, 2010, ONCOTARGET, V1, P198; Kimura A, 2002, J BIOL CHEM, V277, P30153, DOI 10.1074/jbc.M203375200; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Labrecque L, 2004, J BIOL CHEM, V279, P52132, DOI 10.1074/jbc.M409617200; Lee H, 2006, BIOCHEMISTRY-US, V45, P234, DOI 10.1021/bi051560j; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Li SW, 1996, J BIOL CHEM, V271, P3863; Liu X, 2013, ONCOGENE, V32, P1266, DOI 10.1038/onc.2012.147; Lobos-Gonzalez L, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12085; Mastick CC, 1997, J BIOL CHEM, V272, P20706, DOI 10.1074/jbc.272.33.20706; MASTICK CC, 1995, J CELL BIOL, V129, P1523, DOI 10.1083/jcb.129.6.1523; Ogata M, 1999, J BIOL CHEM, V274, P12905, DOI 10.1074/jbc.274.18.12905; Ogata M, 1999, J BIOL CHEM, V274, P20717, DOI 10.1074/jbc.274.29.20717; Orlichenko L, 2006, J BIOL CHEM, V281, P4570, DOI 10.1074/jbc.M512088200; Ortiz R, 2016, ONCOTARGET, V7, P40571, DOI 10.18632/oncotarget.9738; Parat MO, 2003, MOL BIOL CELL, V14, P3156, DOI 10.1091/mbc.e02-11-0761; Poernbacher I, 2012, CURR BIOL, V22, P389, DOI 10.1016/j.cub.2012.01.019; Radel C, 2005, AM J PHYSIOL-HEART C, V288, pH936, DOI 10.1152/ajpheart.00519.2004; Rizzo V, 2003, AM J PHYSIOL-HEART C, V285, pH1720, DOI 10.1152/ajpheart.00344.2002; Rodriguez DA, 2009, MOL BIOL CELL, V20, P2297, DOI 10.1091/mbc.E08-09-0939; SMITH AL, 1995, BIOCHEM BIOPH RES CO, V209, P959, DOI 10.1006/bbrc.1995.1591; Sun YF, 2014, SCI REP-UK, V4, DOI 10.1038/srep06527; Tomono T, 2017, J PHARM SCI-US, V106, P2642, DOI 10.1016/j.xphs.2017.03.011; Torres VA, 2007, MOL CELL BIOL, V27, P7703, DOI 10.1128/MCB.01991-06; Torres VA, 2006, J CELL SCI, V119, P1812, DOI 10.1242/jcs.02894; Urra H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033085; Vaisar T, 2007, J CLIN INVEST, V117, P746, DOI 10.1172/JCI26206; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Wadham C, 2003, MOL BIOL CELL, V14, P2520, DOI 10.1091/mbc.E02-09-0577; Wilson KE, 2014, J BIOL CHEM, V289, P23693, DOI 10.1074/jbc.M113.534701; Wyatt L, 2007, J CELL BIOL, V178, P1223, DOI 10.1083/jcb.200705035; Zhang P, 2013, ONCOGENE, V32, P2087, DOI 10.1038/onc.2012.220	51	11	11	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3693	3709		10.1038/s41388-020-1242-3	http://dx.doi.org/10.1038/s41388-020-1242-3		MAR 2020	17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32152405	Green Published, hybrid			2022-12-17	WOS:000518734000001
J	Lucia, K; Wu, YH; Garcia, JM; Barlier, A; Buchfelder, M; Saeger, W; Renner, U; Stalla, GK; Theodoropoulou, M				Lucia, Kristin; Wu, Yonghe; Garcia, Jose Monteserin; Barlier, Anne; Buchfelder, Michael; Saeger, Wolfgang; Renner, Ulrich; Stalla, Guenter K.; Theodoropoulou, Marily			Hypoxia and the hypoxia inducible factor 1 alpha activate protein kinase A by repressing RII beta subunit transcription	ONCOGENE			English	Article							REGULATORY SUBUNIT; CATALYTIC SUBUNIT; GENE-EXPRESSION; DNA-BINDING; DIFFERENTIAL EXPRESSION; GROWTH-HORMONE; LUNG-CANCER; CELL-GROWTH; I-ALPHA; PHOSPHORYLATION	Overactivation of the cAMP signal transduction pathway plays a central role in the pathogenesis of endocrine tumors. Genetic aberrations leading to increased intracellular cAMP or directly affecting PKA subunit expression have been identified in inherited and sporadic endocrine tumors, but are rare indicating the presence of nongenomic pathological PKA activation. In the present study, we examined the impact of hypoxia on PKA activation using human growth hormone (GH)-secreting pituitary tumors as a model of an endocrine disease displaying PKA-CREB overactivation. We show that hypoxia activates PKA and enhances CREB transcriptional activity and subsequently GH oversecretion. This is due to a previously uncharacterized ability of HIF-1 alpha to suppress the transcription of the PKA regulatory subunit 2B (PRKAR2B) by sequestering Sp1 from the PRKAR2B promoter. The present study reveals a novel mechanism through which the transcription factor HIF-1 alpha transduces environmental signals directly onto PKA activity, without affecting intracellular cAMP concentrations. By identifying a point of interaction between the cellular microenvironment and intracellular enzyme activation, neoplastic, and nonneoplastic diseases involving overactivated PKA pathway may be more efficiently targeted.	[Lucia, Kristin; Garcia, Jose Monteserin; Renner, Ulrich; Stalla, Guenter K.; Theodoropoulou, Marily] Max Planck Inst Psychiat, Dept Endocrinol, Munich, Germany; [Lucia, Kristin; Stalla, Guenter K.; Theodoropoulou, Marily] Ludwig Maximilians Univ Munchen, Med Klin & Poliklin 4, Munich, Germany; [Lucia, Kristin; Wu, Yonghe] Deutsch Krebsforschungszentrum, Div Mol Genet, Heidelberg, Germany; [Barlier, Anne] Ctr Rech Neurobiol & Neurophysiol Marseille, Marseille, France; [Buchfelder, Michael] Klinikum Univ Erlangen, Dept Neurosurg, Erlangen, Germany; [Saeger, Wolfgang] Univ Hamburg, Dept Neuropathol, Hamburg, Germany; [Lucia, Kristin] Charite, Dept Neurosurg, Berlin, Germany	Max Planck Society; University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); UDICE-French Research Universities; Aix-Marseille Universite; University of Erlangen Nuremberg; University of Hamburg; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Theodoropoulou, M (corresponding author), Max Planck Inst Psychiat, Dept Endocrinol, Munich, Germany.; Theodoropoulou, M (corresponding author), Ludwig Maximilians Univ Munchen, Med Klin & Poliklin 4, Munich, Germany.	marily.theodoropoulou@med.uni-muechen.de	Barlier, Anne/G-2398-2015; Theodoropoulou, Marily/S-9546-2017; Wu, Yonghe/N-2269-2019; Monteserin-Garcia, Jose Luis/AAC-7052-2020	Theodoropoulou, Marily/0000-0002-7378-4374; Wu, Yonghe/0000-0001-9667-8198; Monteserin-Garcia, Jose Luis/0000-0002-4508-6771; Barlier, Anne/0000-0002-3740-6173	Projekt DEAL	Projekt DEAL	Open access funding provided by Projekt DEAL.	ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; Amieux PS, 1997, J BIOL CHEM, V272, P3993, DOI 10.1074/jbc.272.7.3993; ARZT E, 1993, ENDOCRINOLOGY, V132, P459, DOI 10.1210/en.132.1.459; Barlier A, 1998, J CLIN ENDOCR METAB, V83, P1604, DOI 10.1210/jc.83.5.1604; Barry S, 2019, ONCOGENE, V38, P5381, DOI 10.1038/s41388-019-0779-5; Basso F, 2014, HORM METAB RES, V46, P883, DOI 10.1055/s-0034-1389951; BERTHERAT J, 1995, MOL ENDOCRINOL, V9, P777, DOI 10.1210/me.9.7.777; Bertout JA, 2008, NAT REV CANCER, V8, P967, DOI 10.1038/nrc2540; Beuschlein F, 2014, NEW ENGL J MED, V370, P1019, DOI 10.1056/NEJMoa1310359; BODNER M, 1988, CELL, V55, P505, DOI 10.1016/0092-8674(88)90037-2; Brandon EP, 1998, J NEUROSCI, V18, P3639; Bullen JW, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf0583; Canettieri G, 2003, NAT STRUCT BIOL, V10, P175, DOI 10.1038/nsb895; Carlucci A, 2008, EMBO J, V27, P1073, DOI 10.1038/emboj.2008.33; Cheong HI, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.90240; Elliott MR, 2003, J IMMUNOL, V171, P3636, DOI 10.4049/jimmunol.171.7.3636; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ezzat S, 2005, MOL ENDOCRINOL, V19, P1004, DOI 10.1210/me.2004-0432; Finger EC, 2015, P NATL ACAD SCI USA, V112, P4441, DOI 10.1073/pnas.1418164112; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HANDSCHIN JC, 1979, FEBS LETT, V106, P301, DOI 10.1016/0014-5793(79)80519-0; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hayward BE, 2001, J CLIN INVEST, V107, pR31, DOI 10.1172/JCI11887; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; Katznelson L, 2014, J CLIN ENDOCR METAB, V99, P3933, DOI 10.1210/jc.2014-2700; Kietzmann T, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00011; Kim C, 2007, CELL, V130, P1032, DOI 10.1016/j.cell.2007.07.018; Kirschner LS, 2000, NAT GENET, V26, P89, DOI 10.1038/79238; Kitagawa K, 2007, FEBS J, V274, P3210, DOI 10.1111/j.1742-4658.2007.05890.x; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; KURTEN RC, 1992, MOL ENDOCRINOL, V6, P536, DOI 10.1210/me.6.4.536; MCCORMICK A, 1990, NATURE, V345, P829, DOI 10.1038/345829a0; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; Melmed S, 2009, J CLIN INVEST, V119, P3189, DOI 10.1172/JCI39375; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Michel G, 2002, BBA-GENE STRUCT EXPR, V1578, P73, DOI 10.1016/S0167-4781(02)00484-0; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Nesterova M, 1996, EUR J BIOCHEM, V235, P486, DOI 10.1111/j.1432-1033.1996.00486.x; Pagotto U, 2000, CANCER RES, V60, P6794; Prabu SK, 2006, J BIOL CHEM, V281, P2061, DOI 10.1074/jbc.M507741200; Pullamsetti SS, 2013, ONCOGENE, V32, P1121, DOI 10.1038/onc.2012.136; Ronchi CL, 2016, EUR J ENDOCRINOL, V174, P363, DOI 10.1530/EJE-15-1064; Ryan HE, 2000, CANCER RES, V60, P4010; Sandrini F, 2002, GENE CHROMOSOME CANC, V35, P182, DOI 10.1002/gcc.10112; Sandrini F, 2002, J Med Genet, V39, pe78, DOI 10.1136/jmg.39.12.e78; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2017, EMBO J, V36, P252, DOI 10.15252/embj.201695204; Semenza GL, 2013, J CLIN INVEST, V123, P3664, DOI 10.1172/JCI67230; Shaikh D, 2012, CELL SIGNAL, V24, P2396, DOI 10.1016/j.cellsig.2012.08.007; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; STALLA GK, 1989, ENDOCRINOLOGY, V125, P699, DOI 10.1210/endo-125-2-699; STRUTHERS RS, 1991, NATURE, V350, P622, DOI 10.1038/350622a0; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Taylor SS, 2004, BBA-PROTEINS PROTEOM, V1697, P259, DOI 10.1016/j.bbapap.2003.11.029; Taylor SS, 2012, NAT REV MOL CELL BIO, V13, P646, DOI 10.1038/nrm3432; Theodoropoulou M, 2004, ENDOCR-RELAT CANCER, V11, P333, DOI 10.1677/erc.0.0110333; Theodoropoulou M, 2006, CANCER RES, V66, P1576, DOI 10.1158/0008-5472.CAN-05-1189; Toffoli S, 2007, BBA-MOL CELL RES, V1773, P1558, DOI 10.1016/j.bbamcr.2007.06.002; TORTORA G, 1994, ONCOGENE, V9, P3233; Tsigginou A, 2012, ENDOCR-RELAT CANCER, V19, P457, DOI 10.1530/ERC-11-0328; Turner HE, 2000, J CLIN ENDOCR METAB, V85, P1159, DOI 10.1210/jc.85.3.1159; Valimaki N, 2015, J CLIN ENDOCR METAB, V100, P3918, DOI 10.1210/jc.2015-3129; Vitali E, 2014, MOL CELL ENDOCRINOL, V383, P193, DOI 10.1016/j.mce.2013.12.006; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; Zhong H, 1999, CANCER RES, V59, P5830	71	11	11	2	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2020	39	16					3367	3380		10.1038/s41388-020-1223-6	http://dx.doi.org/10.1038/s41388-020-1223-6		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF9OJ	32111982	hybrid, Green Published			2022-12-17	WOS:000517049100001
J	Crupi, MJF; Maritan, SM; Reyes-Alvarez, E; Lian, EY; Hyndman, BD; Rekab, AN; Moodley, S; Antonescu, CN; Mulligan, LM				Crupi, Mathieu J. F.; Maritan, Sarah M.; Reyes-Alvarez, Eduardo; Lian, Eric Y.; Hyndman, Brandy D.; Rekab, Aisha N.; Moodley, Serisha; Antonescu, Costin N.; Mulligan, Lois M.			GGA3-mediated recycling of the RET receptor tyrosine kinase contributes to cell migration and invasion	ONCOGENE			English	Article							AKT PHOSPHORYLATION; ISOFORMS; CLATHRIN; ROLES; ARF6; TRAFFICKING; ACTIVATION; BINDING; GGA3; INTERNALIZATION	The RET receptor tyrosine kinase plays important roles in regulating cellular proliferation, migration, and survival in the normal development of neural crest derived tissues. However, aberrant activation of RET, through oncogenic mutations or overexpression, can contribute to tumourigenesis, regional invasion, and metastasis of several human cancers. RET is expressed as two main isoforms with unique C-terminal sequences that differ in protein interactions and subcellular trafficking in response to RET activation, and which also have distinct oncogenic potentials. The long isoform, termed RET51, is internalized from the membrane in response to stimulation by its ligand, GDNF, but is known to recycle back to the surface via RAB11 endosomes. However, the mechanisms regulating this process and its cellular effects have not been defined. Here, we show that recycling of RET51 requires a multicomponent complex that includes the endosomal-sorting protein GGA3, which mediates GDNF-dependent slow recycling of RET51 receptors to the plasma membrane. Our data show that the GRB2 adapter associates with RET51 through interactions with its C-terminal sequences, facilitating recruitment of active ARF6 and GGA3 interaction, and that depletion of GGA3 or ARF6 reduced RET51 recycling. Further, GGA3 knockdown accelerated RET51 degradation and also attenuated RET-mediated AKT activation. Finally, we showed that recycling of RET51 to the cell surface through association with GGA3 and ARF6 contributes to RET51-dependent cell motility, migration, and invasion. Our data establish RET recycling as a mechanism coordinating location and duration of RET signals in order to direct cell movement and invasion.	[Crupi, Mathieu J. F.; Maritan, Sarah M.; Reyes-Alvarez, Eduardo; Lian, Eric Y.; Hyndman, Brandy D.; Rekab, Aisha N.; Moodley, Serisha; Mulligan, Lois M.] Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada; [Crupi, Mathieu J. F.; Maritan, Sarah M.; Reyes-Alvarez, Eduardo; Lian, Eric Y.; Hyndman, Brandy D.; Rekab, Aisha N.; Moodley, Serisha; Mulligan, Lois M.] Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada; [Antonescu, Costin N.] Ryerson Univ, Dept Chem & Biol, Toronto, ON M5B 2K3, Canada	Queens University - Canada; McMaster University; Queens University - Canada; Toronto Metropolitan University	Mulligan, LM (corresponding author), Queens Univ, Canc Res Inst, Div Canc Biol & Genet, Kingston, ON K7L 3N6, Canada.; Mulligan, LM (corresponding author), Queens Univ, Dept Pathol & Mol Med, Kingston, ON K7L 3N6, Canada.	mulligal@queensu.ca	Mulligan, Lois/D-1893-2010	Mulligan, Lois/0000-0002-9308-8245; Maritan, Sarah/0000-0002-9703-7429; Antonescu, Costin/0000-0001-9192-6340; /0000-0003-4096-0922; Reyes-Alvarez, Eduardo/0000-0003-3093-3859	Canadian Institutes of Health Research (CIHR) [MOP-142303, PJT-156355]; Queen Elizabeth II Graduate Scholarship in Science and Technology; Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research; Ontario Graduate Scholarships; Mitacs Globalink Research Graduate Fellowship; Queen's Research Opportunities Fund; CIHR Post-doctoral Fellowships; Master's CIHR award; CONACyT; Journal of Cell Science Travelling Fellowship from The Company of Biologists	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Queen Elizabeth II Graduate Scholarship in Science and Technology; Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research; Ontario Graduate Scholarships(Ontario Graduate Scholarship); Mitacs Globalink Research Graduate Fellowship; Queen's Research Opportunities Fund; CIHR Post-doctoral Fellowships(Canadian Institutes of Health Research (CIHR)); Master's CIHR award; CONACyT(Consejo Nacional de Ciencia y Tecnologia (CONACyT)); Journal of Cell Science Travelling Fellowship from The Company of Biologists	This work was supported by operating grants from the Canadian Institutes of Health Research (CIHR) (MOP-142303, LMM; PJT-156355, CNA), a Queen Elizabeth II Graduate Scholarship in Science and Technology (MJFC), studentships from the Terry Fox Research Institute Training Program in Transdisciplinary Cancer Research (MJFC, SMM, ER-A, EYL, ANR), and by Ontario Graduate Scholarships (SMM, EYL), a Mitacs Globalink Research Graduate Fellowship (ER-A), Queen's Research Opportunities Fund and CIHR Post-doctoral Fellowships (SM), a Master's CIHR award (SMM), CONACyT (ER-A), as well as a Journal of Cell Science Travelling Fellowship from The Company of Biologists (MJFC).	AGARD DA, 1983, NATURE, V302, P676, DOI 10.1038/302676a0; Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bhinge K, 2017, ONCOTARGET, V8, P27155, DOI 10.18632/oncotarget.15676; Crupi MJF, 2015, TRAFFIC, V16, P1155, DOI 10.1111/tra.12315; Crupi Mathieu J. F., 2014, METHOD MOL BIOL, P91; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Doray B, 2002, SCIENCE, V297, P1700, DOI 10.1126/science.1075327; Frankel EB, 2018, SEMIN CELL DEV BIOL, V74, P4, DOI 10.1016/j.semcdb.2017.08.020; Garay C, 2015, MOL BIOL CELL, V26, P3504, DOI 10.1091/mbc.E14-09-1412; Goh LK, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a017459; Gong XW, 2018, EMBO J, V37, DOI 10.15252/embj.201898994; Gorelik R, 2014, NAT PROTOC, V9, P1931, DOI 10.1038/nprot.2014.131; Haines E, 2014, J BIOL CHEM, V289, P5687, DOI 10.1074/jbc.M113.516047; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Haugsten EM, 2014, TRAFFIC, V15, P665, DOI 10.1111/tra.12168; Hu ZZ, 2013, EXP CELL RES, V319, P1932, DOI 10.1016/j.yexcr.2013.05.028; Hung MC, 2016, CANCER CELL, V30, P374, DOI 10.1016/j.ccell.2016.08.014; Hyndman BD, 2017, J CELL SCI, V130, P3282, DOI 10.1242/jcs.203885; Le Hir H, 2000, ONCOLOGY-BASEL, V58, P311, DOI 10.1159/000012118; Li R, 2017, LIFE SCI, V182, P80, DOI 10.1016/j.lfs.2017.06.008; Li XZ, 2015, MOL BIOL CELL, V26, P4412, DOI 10.1091/mbc.E15-02-0087; Lian EY, 2017, ENDOCR-RELAT CANCER, V24, P53, DOI 10.1530/ERC-16-0393; Liang C, 2017, CANCER LETT, V388, P303, DOI 10.1016/j.canlet.2016.12.014; Lucarelli S, 2017, METHODS MOL BIOL, V1652, P191, DOI 10.1007/978-1-4939-7219-7_15; Maritan SM, 2017, JOVE-J VIS EXP, DOI 10.3791/55544; Matsumoto Y, 2017, HEAD NECK-J SCI SPEC, V39, P476, DOI 10.1002/hed.24626; Mulligan LM, 2018, ENDOCR RELAT CANCER, V25, pT189, DOI 10.1530/ERC-18-0141; Mulligan LM, 2019, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01873; Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680; Mutch LJ, 2014, TRAFFIC, V15, P648, DOI 10.1111/tra.12165; Oka S, 2014, ONCOLOGY-BASEL, V86, P263, DOI 10.1159/000360089; Orth JD, 2002, P NATL ACAD SCI USA, V99, P167, DOI 10.1073/pnas.012607899; Parachoniak CA, 2011, DEV CELL, V20, P751, DOI 10.1016/j.devcel.2011.05.007; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Pinilla-Macua I, 2016, P NATL ACAD SCI USA, V113, P2122, DOI 10.1073/pnas.1520301113; Plaza-Menacho I, 2016, CELL REP, V17, P3319, DOI 10.1016/j.celrep.2016.11.061; Puertollano R, 2004, NAT CELL BIOL, V6, P244, DOI 10.1038/ncb1106; Rainero E, 2012, J CELL BIOL, V196, P277, DOI 10.1083/jcb.201109112; Ratcliffe CDH, 2016, TRAFFIC, V17, P670, DOI 10.1111/tra.12390; Ren XF, 2010, EMBO J, V29, P1045, DOI 10.1038/emboj.2010.6; Richardson DS, 2006, ONCOGENE, V25, P3206, DOI 10.1038/sj.onc.1209349; Richardson DS, 2012, MOL BIOL CELL, V23, P3838, DOI 10.1091/mbc.E12-02-0114; Schmid SL, 2017, J CELL BIOL, V216, P2623, DOI 10.1083/jcb.201705017; Sorkin A, 2015, RECEPTOR TYROSINE KI; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; TAHIRA T, 1990, ONCOGENE, V5, P97; Tsui-Pierchala BA, 2002, J BIOL CHEM, V277, P34618, DOI 10.1074/jbc.M203580200; Wandinger-Ness A, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a022616; Yamauchi Yohei, 2017, Advances in Biological Regulation, V63, P115, DOI 10.1016/j.jbior.2016.10.004; Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017	51	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1361	1377		10.1038/s41388-019-1068-z	http://dx.doi.org/10.1038/s41388-019-1068-z			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31645646				2022-12-17	WOS:000526714600014
J	Waisertreiger, I; Popovich, K; Block, M; Anderson, KR; Barlow, JH				Waisertreiger, Irina; Popovich, Katherine; Block, Maya; Anderson, Krista R.; Barlow, Jacqueline H.			Visualizing locus-specific sister chromatid exchange reveals differential patterns of replication stress-induced fragile site breakage	ONCOGENE			English	Article							DNA SECONDARY STRUCTURES; HOMOLOGOUS RECOMBINATION; REPAIR PATHWAYS; COMMON; INSTABILITY; GENE; APHIDICOLIN; CANCER; CHROMOSOMES; INHIBITION	Chromosomal fragile sites are genomic loci sensitive to replication stress which accumulate high levels of DNA damage, and are frequently mutated in cancers. Fragile site damage is thought to arise from the aberrant repair of spontaneous replication stress, however successful fragile site repair cannot be calculated using existing techniques. Here, we report a new assay measuring recombination-mediated repair at endogenous genomic loci by combining a sister chromatid exchange (SCE) assay with fluorescent in situ hybridization (SCE-FISH). Using SCE-FISH, we find that endogenous and exogenous replication stress generated unrepaired breaks and SCEs at fragile sites. We also find that distinct sources of replication stress induce distinct patterns of breakage: ATR inhibition induces more breaks at early replicating fragile sites (ERFS), while ERFS and late-replicating common fragile sites (CFS) are equally fragile in response to aphidicolin. Furthermore, SCEs were suppressed at fragile sites near centromeres in response to replication stress, suggesting that genomic location influences DNA repair pathway choice. SCE-FISH also measured successful recombination in human primary lymphocytes, and identificed the proto-oncogene BCL2 as a replication stress-induced fragile site. These findings demonstrate that SCE-FISH frequency at fragile sites is a sensitive indicator of replication stress, and that large-scale genome organization influences DNA repair pathway choice.	[Waisertreiger, Irina; Popovich, Katherine; Block, Maya; Anderson, Krista R.; Barlow, Jacqueline H.] Univ Calif Davis, Dept Microbiol & Mol Genet, Davis, CA 95616 USA; [Barlow, Jacqueline H.] Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Barlow, JH (corresponding author), Univ Calif Davis, Dept Microbiol & Mol Genet, Davis, CA 95616 USA.; Barlow, JH (corresponding author), Univ Calif Davis, Genome Ctr, Davis, CA 95616 USA.	jhbarlow@ucdavis.edu			NIHK22 grant from the NCI [K22CA188106]; NIH [S100D018223]	NIHK22 grant from the NCI; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Dr. Neil Hunter, Jack McTiernan, and all members of the Barlow and Hunter labs for helpful discussions and suggestions. This work was supported by a NIHK22 grant to JHB from the NCI (K22CA188106) and NIH S100D018223.	Alzu A, 2012, CELL, V151, P835, DOI 10.1016/j.cell.2012.09.041; Arlt MF, 2004, MOL CELL BIOL, V24, P6701, DOI 10.1128/mcb.24.15.6701-6709.2004; Baranovskiy AG, 2014, NUCLEIC ACIDS RES, V42, P14013, DOI 10.1093/nar/gku1209; Barlow JH, 2013, CELL, V152, P620, DOI 10.1016/j.cell.2013.01.006; Berti M, 2016, NAT STRUCT MOL BIOL, V23, P103, DOI 10.1038/nsmb.3163; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Deans B, 2003, CANCER RES, V63, P8181; Dillon LW, 2013, HUM MOL GENET, V22, P1443, DOI 10.1093/hmg/dds561; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; Flynn RL, 2011, TRENDS BIOCHEM SCI, V36, P133, DOI 10.1016/j.tibs.2010.09.005; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Garsed DW, 2014, CANCER CELL, V26, P653, DOI 10.1016/j.ccell.2014.09.010; Gascoigne KE, 2013, CHROMOSOME RES, V21, P407, DOI 10.1007/s10577-013-9368-6; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Glover TW, 2017, NAT REV CANCER, V17, P489, DOI 10.1038/nrc.2017.52; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; Helmrich A, 2006, GENOME RES, V16, P1222, DOI 10.1101/gr.5335506; Helmrich A, 2011, MOL CELL, V44, P966, DOI 10.1016/j.molcel.2011.10.013; Jaco I, 2008, J CELL BIOL, V181, P885, DOI 10.1083/jcb.200803042; Jiang YW, 2009, HUM MOL GENET, V18, P4501, DOI 10.1093/hmg/ddp410; LAMBIE EJ, 1988, CELL, V52, P863, DOI 10.1016/0092-8674(88)90428-X; Leon-Ortiz AM, 2014, DNA REPAIR, V19, P152, DOI 10.1016/j.dnarep.2014.03.016; Letessier A, 2011, NATURE, V470, P120, DOI 10.1038/nature09745; Lopez-Contreras AJ, 2015, GENE DEV, V29, P690, DOI 10.1101/gad.256958.114; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Marotta M, 2017, SCI REP-UK, V7, DOI 10.1038/srep41921; McClintock B, 1941, GENETICS, V26, P234; Mortusewicz O, 2013, EMBO J, V32, P493, DOI 10.1038/emboj.2013.20; Nagaraju G, 2009, MOL CELL BIOL, V29, P4283, DOI 10.1128/MCB.01406-08; Orii KE, 2006, P NATL ACAD SCI USA, V103, P10017, DOI 10.1073/pnas.0602436103; Ozeri-Galai E, 2011, MOL CELL, V43, P122, DOI 10.1016/j.molcel.2011.05.019; Paeschke K, 2011, CELL, V145, P678, DOI 10.1016/j.cell.2011.04.015; PORFIRIO B, 1985, MUTAT RES, V144, P257, DOI 10.1016/0165-7992(85)90061-2; Richardson C, 1998, GENE DEV, V12, P3831, DOI 10.1101/gad.12.24.3831; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; Rozier L, 2004, ONCOGENE, V23, P6872, DOI 10.1038/sj.onc.1207809; Schwartz M, 2005, GENE DEV, V19, P2715, DOI 10.1101/gad.340905; Serra H, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003971; Shiraishi T, 2001, P NATL ACAD SCI USA, V98, P5722, DOI 10.1073/pnas.091095898; Somyajit K, 2015, NUCLEIC ACIDS RES, V43, P9835, DOI 10.1093/nar/gkv880; Sozzi G, 1996, CELL, V85, P17, DOI 10.1016/S0092-8674(00)81078-8; Takata M, 2001, MOL CELL BIOL, V21, P2858, DOI 10.1128/MCB.21.8.2858-2866.2001; Talbert PB, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000326; Termolino P, 2016, CHROMOSOMA, V125, P301, DOI 10.1007/s00412-016-0574-9; Vincenten N, 2015, ELIFE, V4, DOI 10.7554/eLife.10850; Ying SM, 2013, NAT CELL BIOL, V15, P1001, DOI 10.1038/ncb2773; Yonetani Y, 2005, NUCLEIC ACIDS RES, V33, P4544, DOI 10.1093/nar/gki766; Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897; Zhou Y, 2015, ANAL BIOCHEM, V479, P48, DOI 10.1016/j.ab.2015.03.025; Zlotorynski E, 2003, MOL CELL BIOL, V23, P7143, DOI 10.1128/MCB.23.20.7143-7151.2003	52	11	11	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1260	1272		10.1038/s41388-019-1054-5	http://dx.doi.org/10.1038/s41388-019-1054-5			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636383	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000526714600007
J	Mani, C; Tripathi, K; Luan, S; Clark, DW; Andrews, JF; Vindigni, A; Thomas, G; Palle, K				Mani, Chinnadurai; Tripathi, Kaushlendra; Luan, Shan; Clark, David W.; Andrews, Joel F.; Vindigni, Alessandro; Thomas, Gary; Palle, Komaraiah			The multifunctional protein PACS-1 is required for HDAC2-and HDAC3-dependent chromatin maturation and genomic stability	ONCOGENE			English	Article							HISTONE DEACETYLASE 3; REPLICATION STRESS; DNA-REPLICATION; DELETION; HDAC3; CELLS; 11Q13; ROLES; ACETYLATION; TRAFFICKING	Phosphofurin acidic cluster sorting protein-1 (PACS-1) is a multifunctional membrane traffic regulator that plays important roles in organ homeostasis and disease. In this study, we elucidate a novel nuclear function for PACS-1 in maintaining chromosomal integrity. PACS-1 progressively accumulates in the nucleus during cell cycle progression, where it interacts with class I histone deacetylases 2 and 3 (HDAC2 and HDAC3) to regulate chromatin dynamics by maintaining the acetylation status of histones. PACS-1 knockdown results in the proteasome-mediated degradation of HDAC2 and HDAC3, compromised chromatin maturation, as indicated by elevated levels of histones H3K9 and H4K16 acetylation, and, consequently, increased replication stress-induced DNA damage and genomic instability.	[Mani, Chinnadurai; Palle, Komaraiah] Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA; [Mani, Chinnadurai; Tripathi, Kaushlendra; Clark, David W.; Andrews, Joel F.; Palle, Komaraiah] Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA; [Luan, Shan; Thomas, Gary] Univ Pittsburgh, Sch Med, Dept Microbiol & Mol Genet, Pittsburgh, PA 15219 USA; [Luan, Shan; Thomas, Gary] Univ Pittsburgh, Canc Inst, Pittsburgh, PA 15239 USA; [Luan, Shan; Thomas, Gary] Univ Pittsburgh, Sch Med, 5117 Ctr Ave, Pittsburgh, PA 15213 USA; [Vindigni, Alessandro] St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; [Palle, Komaraiah] Texas Tech Univ, Hlth Sci Ctr, Dept Surg, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; University of South Alabama; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Saint Louis University; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Palle, K (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA.; Palle, K (corresponding author), Univ S Alabama, Mitchell Canc Inst, Dept Oncol Sci, Mobile, AL 36604 USA.; Palle, K (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Surg, Lubbock, TX 79430 USA.	komaraiah.palle@ttuhsc.edu			Abraham Mitchell Cancer Research Scholar Endowment grant; NIH [DK114855, DK112844, R01GM108648, R01GM098956, R01CA219187]; DOD BRCP [BC151728]	Abraham Mitchell Cancer Research Scholar Endowment grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD BRCP(United States Department of Defense)	We thank Steve McClellan, Mitchell Cancer Institute for flow cytometry. This work is supported by grants from Abraham Mitchell Cancer Research Scholar Endowment grant, and partly by NIH grants R01GM098956 and R01CA219187 to KP, the NIH grants DK114855 and DK112844 to GT, the NIH grant R01GM108648 and DOD BRCP Breakthrough Award BC151728 to AV.	Atkins KM, 2014, CELL REP, V8, P1545, DOI 10.1016/j.celrep.2014.07.049; Bhaskara S, 2008, MOL CELL, V30, P61, DOI 10.1016/j.molcel.2008.02.030; Bhaskara S, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-27; Bhaskara S, 2010, CANCER CELL, V18, P436, DOI 10.1016/j.ccr.2010.10.022; Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Clark DW, 2015, ONCOTARGET, V6, P28816, DOI 10.18632/oncotarget.5006; Conti C, 2010, CANCER RES, V70, P4470, DOI 10.1158/0008-5472.CAN-09-3028; Crump CM, 2001, EMBO J, V20, P2191, DOI 10.1093/emboj/20.9.2191; Crump CM, 2003, J VIROL, V77, P11105, DOI 10.1128/JVI.77.20.11105-11113.2003; De Souza C, 2015, RECENT PAT ANTI-CANC, V10, P145; Feng D, 2011, SCIENCE, V331, P1315, DOI 10.1126/science.1198125; Gaillard H, 2015, NAT REV CANCER, V15, P276, DOI 10.1038/nrc3916; Gilbert N, 2005, INT REV CYTOL, V242, P283; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Godman CA, 2008, CANCER BIOL THER, V7, P1570, DOI 10.4161/cbt.7.10.6561; Hagelkruys A, 2014, DEVELOPMENT, V141, P604, DOI 10.1242/dev.100487; Hayakawa T, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/129383; Hinners I, 2003, EMBO REP, V4, P1182, DOI 10.1038/sj.embor.7400018; Jenkins PM, 2009, J NEUROSCI, V29, P10541, DOI 10.1523/JNEUROSCI.1590-09.2009; Johnson CA, 2002, J BIOL CHEM, V277, P9590, DOI 10.1074/jbc.M107942200; Khurana S, 2015, GENES-BASEL, V6, P858, DOI 10.3390/genes6030858; Lande-Diner L, 2009, MOL CELL, V34, P767, DOI 10.1016/j.molcel.2009.05.027; Leman AR, 2013, GENES-BASEL, V4, P1, DOI 10.3390/genes4010001; Ma PP, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003377; Mendonca MS, 2004, GENE CHROMOSOME CANC, V39, P277, DOI 10.1002/gcc.20007; Mullican SE, 2011, GENE DEV, V25, P2480, DOI 10.1101/gad.175950.111; Peterson CL, 2004, CURR BIOL, V14, pR546, DOI 10.1016/j.cub.2004.07.007; Piguet V, 2000, NAT CELL BIOL, V2, P163, DOI 10.1038/35004038; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; Schmidt V, 2007, J BIOL CHEM, V282, P32956, DOI 10.1074/jbc.M705073200; Scott GK, 2003, EMBO J, V22, P6234, DOI 10.1093/emboj/cdg596; Scott GK, 2006, EMBO J, V25, P4423, DOI 10.1038/sj.emboj.7601336; Senese S, 2007, MOL CELL BIOL, V27, P4784, DOI 10.1128/MCB.00494-07; Seto E, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a018713; Sirbu BM, 2011, GENE DEV, V25, P1320, DOI 10.1101/gad.2053211; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Srivatsan ES, 2002, ONCOGENE, V21, P5631, DOI 10.1038/sj.onc.1205698; Srivatsan ES, 2000, GENE CHROMOSOME CANC, V29, P157, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1024>3.0.CO;2-P; Stengel KR, 2015, ANTIOXID REDOX SIGN, V23, P51, DOI 10.1089/ars.2014.5915; Stern D, 2017, CLIN GENET, V92, P221, DOI 10.1111/cge.12956; Summers AR, 2013, J CLIN INVEST, V123, P3112, DOI 10.1172/JCI60806; Thomas G, 2017, J CELL SCI, V130, P1865, DOI 10.1242/jcs.199463; Tripathi K, 2016, ONCOTARGET, V7, P12537, DOI 10.18632/oncotarget.7247; Tripathi K, 2015, ONCOTARGET, V6, P5237, DOI 10.18632/oncotarget.3026; Tripathi K, 2014, J BIOL CHEM, V289, P31513, DOI 10.1074/jbc.M114.606483; Wagner FF, 2015, CHEM SCI, V6, P804, DOI 10.1039/c4sc02130d; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Wells CE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068915; Yoon HG, 2003, EMBO J, V22, P1336, DOI 10.1093/emboj/cdg120; Zainabadi K, 2014, GENOMICS, V103, P276, DOI 10.1016/j.ygeno.2014.01.001; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004	53	11	11	2	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	12					2583	2596		10.1038/s41388-020-1167-x	http://dx.doi.org/10.1038/s41388-020-1167-x		JAN 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KW4HU	31988453	Green Accepted			2022-12-17	WOS:000509655100006
J	Rabinovich, S; Silberman, A; Adler, L; Agron, S; Levin-Zaidman, S; Bahat, A; Porat, Z; Ben-Zeev, E; Geva, I; Itkin, M; Malitsky, S; Buchaklian, A; Helbling, D; Dimmock, D; Erez, A				Rabinovich, Shiran; Silberman, Alon; Adler, Lital; Agron, Shani; Levin-Zaidman, Smadar; Bahat, Amir; Porat, Ziv; Ben-Zeev, Efrat; Geva, Inbal; Itkin, Maxim; Malitsky, Sergey; Buchaklian, Adam; Helbling, Daniel; Dimmock, David; Erez, Ayelet			The mitochondrial carrier Citrin plays a role in regulating cellular energy during carcinogenesis	ONCOGENE			English	Article							DEFICIENCY; CANCER; EXPERIENCE; ASPARTATE	Citrin, encoded by SLC25A13 gene, is an inner mitochondrial transporter that is part of the malate-aspartate shuttle, which regulates the NAD+/NADH ratio between the cytosol and mitochondria. Citrullinemia type II (CTLN-II) is an inherited disorder caused by germline mutations in SLC25A13, manifesting clinically in growth failure that can be alleviated by dietary restriction of carbohydrates. The association of citrin with glycolysis and NAD+/NADH ratio led us to hypothesize that it may play a role in carcinogenesis. Indeed, we find that citrin is upregulated in multiple cancer types and is essential for supplementing NAD+ for glycolysis and NADH for oxidative phosphorylation. Consequently, citrin deficiency associates with autophagy, whereas its overexpression in cancer cells increases energy production and cancer invasion. Furthermore, based on the human deleterious mutations in citrin, we found a potential inhibitor of citrin that restricts cancerous phenotypes in cells. Collectively, our findings suggest that targeting citrin may be of benefit for cancer therapy.	[Rabinovich, Shiran; Silberman, Alon; Adler, Lital; Agron, Shani; Bahat, Amir; Erez, Ayelet] Weizmann Inst Sci, Dept Biol Regulat, Rehovot, Israel; [Levin-Zaidman, Smadar] Weizmann Inst Sci, Dept Chem Res Support, Rehovot, Israel; [Porat, Ziv] Weizmann Inst Sci, Dept Cell Sorting, Rehovot, Israel; [Ben-Zeev, Efrat; Geva, Inbal] Weizmann Inst Sci, Grand Israel Natl Ctr Personalized Med, Rehovot, Israel; [Itkin, Maxim; Malitsky, Sergey] Weizmann Inst Sci, Dept Life Sci Core Facil, Rehovot, Israel; [Buchaklian, Adam; Helbling, Daniel; Dimmock, David] Med Coll Wisconsin, Human & Mol Genet & Biochem Ctr, Milwaukee, WI 53226 USA; [Dimmock, David] Rady Childrens Inst Genom Med, San Diego, CA USA	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Medical College of Wisconsin	Erez, A (corresponding author), Weizmann Inst Sci, Dept Biol Regulat, Rehovot, Israel.	ayelet.erez@weizmann.ac.il	Itkin, Maxim/AFU-5181-2022; Itkin, Maxim/ABB-9183-2020; Malitsky, Sergey/ABC-2545-2020; Porat, Ziv/K-1672-2012	Itkin, Maxim/0000-0003-1348-2814; Malitsky, Sergey/0000-0003-4619-7219; Porat, Ziv/0000-0003-3059-181X	European research program [CIG618113, ERC614204]; Israel Science Foundation [1343/13, 1952/13]; Minerva grant [711730]; Adelis Foundation; Henry S. and Anne S. Reich Research Fund; Dukler Fund for Cancer Research; Paul Sparr Foundation; Saul and Theresa Esman Foundation; estate of Fannie Sherr; Weizmann Institute	European research program(European Commission); Israel Science Foundation(Israel Science Foundation); Minerva grant; Adelis Foundation; Henry S. and Anne S. Reich Research Fund; Dukler Fund for Cancer Research; Paul Sparr Foundation; Saul and Theresa Esman Foundation; estate of Fannie Sherr; Weizmann Institute	We acknowledge and thank the Weizmann Institute for providing financial and infrastructural support. We thank Tomer Shlomi and his student Won Dong-Lee, Gad Asher, Zvulun Elazar and his student Adi Abada, Yoav Shaul, Irit Sagi, Ron Rotkopf, and Sivan Galai for the intellectual and technical assistance. AE is incumbent of the Leah Omenn Career Development Chair and is supported by research grants from the European research program (CIG618113, ERC614204), the Israel Science Foundation (1343/13; 1952/13), and from the Minerva grant award (711730). AE received additional support from the Adelis Foundation, the Henry S. and Anne S. Reich Research Fund, the Dukler Fund for Cancer Research, the Paul Sparr Foundation, the Saul and Theresa Esman Foundation, from Joseph Piko Baruch, and from the estate of Fannie Sherr. The authors declare applying for a patent for citrin inhibition as cancer therapy.	Amoedo ND, 2016, BBA-MOL CELL RES, V1863, P2394, DOI 10.1016/j.bbamcr.2016.04.011; Bartolome Fernando, 2015, Methods Mol Biol, V1264, P263, DOI 10.1007/978-1-4939-2257-4_23; Cahoy JD, 2008, J NEUROSCI, V28, P264, DOI 10.1523/JNEUROSCI.4178-07.2008; Chang KW, 2011, MOL GENET METAB, V103, P293, DOI 10.1016/j.ymgme.2011.03.013; Chung HY, 2017, J CANCER PREV, V22, P127, DOI 10.15430/JCP.2017.22.3.127; Corbet C, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03525-0; Dimmock D, 2009, MOL GENET METAB, V96, P44, DOI 10.1016/j.ymgme.2008.10.007; Dimmock D, 2007, PEDIATRICS, V119, pE773, DOI 10.1542/peds.2006-1950; Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549; Erez A, 2015, NAT REV CANCER, V15, P440, DOI 10.1038/nrc3949; Fass E, 2006, J BIOL CHEM, V281, P36303, DOI 10.1074/jbc.M607031200; Fiermonte G, 2011, MOL GENET METAB, V104, P501, DOI 10.1016/j.ymgme.2011.08.022; Garcia-Bermudez J, 2018, NAT CELL BIOL, V20, P775, DOI 10.1038/s41556-018-0118-z; Gaude E, 2018, MOL CELL, V69, P581, DOI 10.1016/j.molcel.2018.01.034; Hollinshead KER, 2016, WIRES SYST BIOL MED, V8, P272, DOI 10.1002/wsbm.1334; Kimura N, 2013, TRANSPL P, V45, P3432, DOI 10.1016/j.transproceed.2013.06.016; Kluza J, 2012, CANCER RES, V72, P5035, DOI 10.1158/0008-5472.CAN-12-0979; Komatsu M, 2010, FEBS LETT, V584, P1374, DOI 10.1016/j.febslet.2010.02.017; Malitsky S, 2016, NEW PHYTOL, V210, P88, DOI 10.1111/nph.13852; Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043; Rabinovich S, 2015, NATURE, V527, P379, DOI 10.1038/nature15529; Revollo JR, 2007, CURR OPIN GASTROEN, V23, P164, DOI 10.1097/MOG.0b013e32801b3c8f; ROBINSON BH, 1985, AM J HUM GENET, V37, P938; Saheki T, 2010, MOL GENET METAB, V100, pS59, DOI 10.1016/j.ymgme.2010.02.014; Salem M, 2017, JOVE-J VIS EXP, V1, P124; Satrustegui J, 2007, PHYSIOL REV, V87, P29, DOI 10.1152/physrev.00005.2006; Shaul YD, 2016, NUCLEIC ACIDS RES, V44, pD560, DOI 10.1093/nar/gkv1337; Shinohara M, 2010, J BIOL CHEM, V285, P4481, DOI 10.1074/jbc.M109.071779; Song YZ, 2011, INT J MOL MED, V28, P33, DOI 10.3892/ijmm.2011.653; Sullivan LB, 2018, NAT CELL BIOL, V20, P782, DOI 10.1038/s41556-018-0125-0; Takeuchi S, 2015, PEDIATRICS, V136, pE530, DOI 10.1542/peds.2014-4172; Torrano V, 2016, NAT CELL BIOL, V18, P645, DOI 10.1038/ncb3357; van Niekerk G, 2018, CELL ONCOL, V41, P343, DOI 10.1007/s13402-018-0383-7; Xian ZY, 2015, TUMOR BIOL, V36, P8093, DOI 10.1007/s13277-015-3540-x; Hung YP, 2011, CELL METAB, V14, P545, DOI 10.1016/j.cmet.2011.08.012; Zheng L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7001	36	11	11	2	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	1					164	175		10.1038/s41388-019-0976-2	http://dx.doi.org/10.1038/s41388-019-0976-2			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG3NM	31462712				2022-12-17	WOS:000509849200011
J	Tsompana, M; Gluck, C; Sethi, I; Joshi, I; Bard, J; Nowak, NJ; Sinha, S; Buck, MJ				Tsompana, Maria; Gluck, Christian; Sethi, Isha; Joshi, Ishita; Bard, Jonathan; Nowak, Norma J.; Sinha, Satrajit; Buck, Michael J.			Reactivation of super-enhancers by KLF4 in human Head and Neck Squamous Cell Carcinoma	ONCOGENE			English	Article							PLURIPOTENT STEM-CELLS; CHIP-SEQ; GENOMIC CHARACTERIZATION; HOMEOBOX GENES; HOX GENES; EXPRESSION; CANCER; TRANSCRIPTION; P63; DISCOVERY	Head and neck squamous cell carcinoma (HNSCC) is a disease of significant morbidity and mortality and rarely diagnosed in early stages. Despite extensive genetic and genomic characterization, targeted therapeutics and diagnostic markers of HNSCC are lacking due to the inherent heterogeneity and complexity of the disease. Herein, we have generated the global histone mark based epigenomic and transcriptomic cartogram of SCC25, a representative cell type of mesenchymal HNSCC and its normal oral keratinocyte counterpart. Examination of genomic regions marked by differential chromatin states and associated with misregulated gene expression led us to identify SCC25 enriched regulatory sequences and transcription factors (TF) motifs. These findings were further strengthened by ATAC-seq based open chromatin and TF footprint analysis which unearthed Kruppel-like Factor 4 (KLF4) as a potential key regulator of the SCC25 cistrome. We reaffirm the results obtained from in silico and chromatin studies in SCC25 by ChIP-seq of KLF4 and identify Delta Np63 as a co-oncogenic driver of the cancer-specific gene expression milieu. Taken together, our results lead us to propose a model where elevated KLF4 levels sustains the oncogenic state of HNSCC by reactivating repressed chromatin domains at key downstream genes, often by targeting super-enhancers.	[Tsompana, Maria; Gluck, Christian; Sethi, Isha; Joshi, Ishita; Bard, Jonathan; Nowak, Norma J.; Sinha, Satrajit; Buck, Michael J.] SUNY Buffalo, Ctr Excellence Bioinformat & Life Sci, Dept Biochem, Buffalo, NY 14260 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Sinha, S; Buck, MJ (corresponding author), SUNY Buffalo, Ctr Excellence Bioinformat & Life Sci, Dept Biochem, Buffalo, NY 14260 USA.	ssinha2@buffalo.edu; mjbuck@buffalo.edu	Gluck, Christian/HHC-5073-2022	Bard, Jonathan/0000-0001-7433-0086; Tsompana, Maria/0000-0001-7546-3198	Community Foundation for Greater Buffalo	Community Foundation for Greater Buffalo	We thank University at Buffalo Genomics and Bioinformatics Core facility for Next-generation sequencing and analysis support. These studies were supported, in part, by grants from the Community Foundation for Greater Buffalo to NJN.	Alorabi M, 2016, CRIT REV ONCOL HEMAT, V99, P170, DOI 10.1016/j.critrevonc.2015.12.006; Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Andrews S., 2010, FASTQC QUALITY CONTR; [Anonymous], PIC SET COMM LIN TOO; Bailey TL, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks433; Bailey TL, 2009, NUCLEIC ACIDS RES, V37, pW202, DOI 10.1093/nar/gkp335; Bishop JA, 2012, MODERN PATHOL, V25, P405, DOI 10.1038/modpathol.2011.173; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; Botchkarev VA, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a015248; Boudreau NJ, 2004, J BIOL CHEM, V279, P4862, DOI 10.1074/jbc.M305190200; Buenrostro JD, 2013, NAT METHODS, V10, P1213, DOI [10.1038/NMETH.2688, 10.1038/nmeth.2688]; Buganim Y, 2013, NAT REV GENET, V14, P427, DOI 10.1038/nrg3473; Candi E, 2015, CELL DEATH DIFFER, V22, P12, DOI 10.1038/cdd.2014.113; Care A, 1996, MOL CELL BIOL, V16, P4842; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chen YJ, 2008, CANCER BIOL THER, V7, P777, DOI 10.4161/cbt.7.5.5768; Cui Rutao, 2005, Biochem Biophys Res Commun, V336, P339; Destro MFDS, 2010, INT J ONCOL, V36, P141, DOI 10.3892/ijo_00000485; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Ernst J, 2012, NAT METHODS, V9, P215, DOI 10.1038/nmeth.1906; Evans PM, 2008, ACTA BIOCH BIOPH SIN, V40, P554, DOI 10.1111/j.1745-7270.2008.00439.x; Evans PM, 2007, J BIOL CHEM, V282, P33994, DOI 10.1074/jbc.M701847200; Feng JX, 2012, NAT PROTOC, V7, P1728, DOI 10.1038/nprot.2012.101; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Foster KW, 2005, ONCOGENE, V24, P1491, DOI 10.1038/sj.onc.1208307; Foster KW, 1999, CELL GROWTH DIFFER, V10, P423; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; Hassan NMM, 2006, ONCOL RES, V16, P217, DOI 10.3727/000000006783981080; He HH, 2014, NAT METHODS, V11, P73, DOI [10.1038/NEMTH.2762, 10.1038/nmeth.2762]; Huang CC, 2005, CANCER BIOL THER, V4, P1401, DOI 10.4161/cbt.4.12.2355; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Iglesias-Bartolome R, 2013, CANCER DISCOV, V3, P722, DOI 10.1158/2159-8290.CD-13-0239; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jiang W, 2008, CANCER BIOL THER, V7, P783, DOI 10.4161/cbt.7.5.6110; Jimenez L, 2015, ARCH PATHOL LAB MED, V139, P1349, DOI 10.5858/arpa.2014-0471-OA; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2086, DOI 10.1073/pnas.89.6.2086; Kaichi S, 2010, CARDIOVASC RES, V88, P314, DOI 10.1093/cvr/cvq189; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Kheradpour P, 2014, NUCLEIC ACIDS RES, V42, P2976, DOI 10.1093/nar/gkt1249; Lai WKM, 2012, BIOINFORMATICS, V28, P1021, DOI 10.1093/bioinformatics/bts063; Landt SG, 2012, GENOME RES, V22, P1813, DOI 10.1101/gr.136184.111; Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/nmeth.1923, 10.1038/NMETH.1923]; Lawrence MS, 2015, NATURE, V517, P576, DOI 10.1038/nature14129; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li QH, 2011, ANN APPL STAT, V5, P1752, DOI 10.1214/11-AOAS466; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Lui VWY, 2013, CANCER DISCOV, V3, P761, DOI 10.1158/2159-8290.CD-13-0103; Machanick P, 2011, BIOINFORMATICS, V27, P1696, DOI 10.1093/bioinformatics/btr189; Mao ZB, 2003, ONCOGENE, V22, P4434, DOI 10.1038/sj.onc.1206508; Marcinkiewicz KM, 2014, J CELL PHYSIOL, V229, P1405, DOI 10.1002/jcp.24577; Marcinkiewicz KM, 2014, EXP CELL RES, V320, P128, DOI 10.1016/j.yexcr.2013.09.011; Marinov GK, 2014, G3-GENES GENOM GENET, V4, P209, DOI 10.1534/g3.113.008680; Molinolo AA, 2007, CLIN CANCER RES, V13, P4964, DOI 10.1158/1078-0432.CCR-07-1041; Nakatake Y, 2006, MOL CELL BIOL, V26, P7772, DOI 10.1128/MCB.00468-06; Nichols AC, 2012, ARCH OTOLARYNGOL, V138, P732, DOI 10.1001/archoto.2012.1558; Pandya AY, 2004, CLIN CANCER RES, V10, P2709, DOI 10.1158/1078-0432.CCR-03-0484; Pickering CR, 2013, CANCER DISCOV, V3, P770, DOI 10.1158/2159-8290.CD-12-0537; Pique-Regi R, 2011, GENOME RES, V21, P447, DOI 10.1101/gr.112623.110; Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033; Rahman M, 2015, BIOINFORMATICS, V31, P3666, DOI 10.1093/bioinformatics/btv377; Ramirez F, 2014, NUCLEIC ACIDS RES, V42, pW187, DOI 10.1093/nar/gku365; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Segre JA, 1999, NAT GENET, V22, P356, DOI 10.1038/11926; Sethi I, 2017, NUCLEIC ACIDS RES, V45, P8208, DOI 10.1093/nar/gkx416; Sethi I, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1793-9; Sethi I, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1042; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Tai SK, 2011, CANCER SCI, V102, P895, DOI 10.1111/j.1349-7006.2011.01859.x; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Tetreault MP, 2010, GASTROENTEROLOGY, V139, P2124, DOI 10.1053/j.gastro.2010.08.048; Thomas-Chollier M, 2012, NAT PROTOC, V7, P1551, DOI 10.1038/nprot.2012.088; Tomov ML, 2016, SCI REP-UK, V6, DOI 10.1038/srep37637; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Walter V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056823; Yamatoji M, 2010, ONCOL REP, V23, P61, DOI 10.3892/or_00000606; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	80	11	12	2	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					262	277		10.1038/s41388-019-0990-4	http://dx.doi.org/10.1038/s41388-019-0990-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477832				2022-12-17	WOS:000507766400002
J	Wang, DM; Cheng, XH; Li, Y; Guo, MW; Zhao, WJ; Qiu, J; Zheng, Y; Meng, MY; Ping, XD; Chen, X; Wang, S; Luo, J; Luo, QQ; Ma, XR; Xu, LY				Wang, Dongmei; Cheng, Xinghua; Li, Yu; Guo, Mingwei; Zhao, Wenjun; Qiu, Jin; Zheng, Ying; Meng, Meiyao; Ping, Xiaodan; Chen, Xin; Wang, Shu; Luo, Jian; Luo, Qingquan; Ma, Xinran; Xu, Lingyan			C/EBP delta-Slug-Lox1 axis promotes metastasis of lung adenocarcinoma via oxLDL uptake	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; FATTY-ACID SYNTHASE; TRANSCRIPTIONAL REGULATION; C/EBP-DELTA; STEM-CELLS; CANCER; RECEPTOR; BINDING; LOX-1; METABOLISM	Cancer cells undergo significant lipid metabolic reprogramming to ensure sufficient energy supply for survival and progression. However, how cancer cells integrate lipid metabolic signaling with cancer progression is not well understood. In the present study, we demonstrated that C/EBP delta, a critical lipid metabolic regulator, is a TGF-beta 1 downstream gene and promotes lung adenocarcinoma metastasis. Importantly, C/EBP delta caused significant oscillations in both lipid metabolic and epithelial to mesenchymal transition (EMT) gene networks. Mechanistically, we demonstrated that C/EBP delta recruited oncogene NCOA3 to transcriptionally activate Slug, a canonical EMT transcription factor, which in turn induced oxLDL receptor-1 (Lox1) expression and enhanced oxLDL uptake to promote cancer metastasis, which could be blocked with LOX1 neutralizing antibody. In summary, our results unveiled a previously unappreciated interplay between lipid metabolic and metastatic program, as well as the existence of a pivotal C/EBP delta-Slug-Lox1 transcription axis to promote oxLDL levels and cancer metastasis.	[Wang, Dongmei; Li, Yu; Guo, Mingwei; Zhao, Wenjun; Qiu, Jin; Zheng, Ying; Meng, Meiyao; Ping, Xiaodan; Chen, Xin; Luo, Jian; Ma, Xinran; Xu, Lingyan] East China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, 500 Dong Chuan Rd, Shanghai 200241, Peoples R China; [Wang, Dongmei; Li, Yu; Guo, Mingwei; Zhao, Wenjun; Qiu, Jin; Zheng, Ying; Meng, Meiyao; Ping, Xiaodan; Chen, Xin; Luo, Jian; Ma, Xinran; Xu, Lingyan] East China Normal Univ, Sch Life Sci, 500 Dong Chuan Rd, Shanghai 200241, Peoples R China; [Cheng, Xinghua; Luo, Qingquan] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Pulm Tumor Med Ctr, Dept Oncol, 241 West Huai Hai Rd, Shanghai 200030, Peoples R China; [Wang, Shu; Ma, Xinran; Xu, Lingyan] Shanghai Jiao Tong Univ, Rui Jin Hosp, Shanghai Clin Ctr Endocrine & Metab Dis, Sch Med,Dept Endocrinol & Metab, 197 Rui Jin 2nd Rd, Shanghai 200025, Peoples R China	East China Normal University; East China Normal University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Ma, XR; Xu, LY (corresponding author), East China Normal Univ, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, 500 Dong Chuan Rd, Shanghai 200241, Peoples R China.; Ma, XR; Xu, LY (corresponding author), East China Normal Univ, Sch Life Sci, 500 Dong Chuan Rd, Shanghai 200241, Peoples R China.; Ma, XR; Xu, LY (corresponding author), Shanghai Jiao Tong Univ, Rui Jin Hosp, Shanghai Clin Ctr Endocrine & Metab Dis, Sch Med,Dept Endocrinol & Metab, 197 Rui Jin 2nd Rd, Shanghai 200025, Peoples R China.	xrma@bio.ecnu.edu.cn; lyxu@ecnu.edu.cn			National Natural Science Foundation of China [31770840, 31800989, 81902980, 81502480]; Shanghai Pujiang Program [17PJ1402600, 17PJ1402700]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [TP2017042]; Shanghai Young Top Notch Talents; China Postdoctoral Science Foundation [2017M611499]; ECNU public platform for Innovation [011]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Pujiang Program(Shanghai Pujiang Program); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Young Top Notch Talents; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); ECNU public platform for Innovation	We are thankful to Dr Yan Lu (Zhongshan Hospital, Shanghai) and Zhenfei Li (SIBS, Shanghai) for reading the paper and for discussions throughout the project. This project is supported by funds from the National Natural Science Foundation of China (31770840 to XM, 31800989 to LX, 81902980 to DW, and 81502480 to XC), Shanghai Pujiang Program (17PJ1402600 to XM and 17PJ1402700 to LX), the Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning (TP2017042 to XM), Shanghai Young Top Notch Talents (to XM), the China Postdoctoral Science Foundation (2017M611499 to DW), and ECNU public platform for Innovation (011).	Ackerman D, 2014, TRENDS CELL BIOL, V24, P472, DOI 10.1016/j.tcb.2014.06.001; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Perez-Mancera PA, 2007, HUM MOL GENET, V16, P2972, DOI 10.1093/hmg/ddm278; Balamurugan K, 2019, ONCOGENE, V38, P3765, DOI 10.1038/s41388-018-0516-5; Balamurugan K, 2013, INT J BIOL SCI, V9, P917, DOI 10.7150/ijbs.7224; Balzan S, 2018, LIFE SCI, V198, P79, DOI 10.1016/j.lfs.2018.02.024; Currie E, 2013, CELL METAB, V18, P153, DOI 10.1016/j.cmet.2013.05.017; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Deshmukh A, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0555-x; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Garcia MR, 2017, CELL METAB, V26, P842, DOI 10.1016/j.cmet.2017.09.018; Gonzalez-Chavarria I, 2018, CANCER LETT, V414, P34, DOI 10.1016/j.canlet.2017.10.035; Hou SD, 2017, AM J PATHOL, V187, P954, DOI 10.1016/j.ajpath.2017.01.009; HUNT JE, 1993, P NATL ACAD SCI USA, V90, P2141, DOI 10.1073/pnas.90.6.2141; Kobayashi K, 2003, J LIPID RES, V44, P716, DOI 10.1194/jlr.M200329-JLR200; Li Z, 2017, CELL METAB, V25, P228, DOI 10.1016/j.cmet.2017.01.016; Lin HP, 2016, CANCER RES, V76, P6924, DOI 10.1158/0008-5472.CAN-16-1597; Louet JF, 2006, P NATL ACAD SCI USA, V103, P17868, DOI 10.1073/pnas.0608711103; Lu JJ, 2011, ANTIOXID REDOX SIGN, V15, P2301, DOI 10.1089/ars.2010.3792; Lue HW, 2017, GENE DEV, V31, P2067, DOI 10.1101/gad.305292.117; MACDOUGALD OA, 1995, ANNU REV BIOCHEM, V64, P345, DOI 10.1146/annurev.bi.64.070195.002021; Mendoza-Villanueva D, 2016, ONCOGENE, V35, P6166, DOI 10.1038/onc.2016.156; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Mittal V, 2018, ANNU REV PATHOL-MECH, V13, P395, DOI 10.1146/annurev-pathol-020117-043854; Nishimura S, 2004, OSTEOARTHR CARTILAGE, V12, P568, DOI 10.1016/j.joca.2004.04.005; Noto A, 2017, ONCOGENE, V36, P4573, DOI [10.1038/onc.2017.75, 10.1038/onc.2017.212]; Pascual G, 2017, NATURE, V541, P41, DOI 10.1038/nature20791; Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/BJ20020508; Rosen ED, 2000, GENE DEV, V14, P1293; Samet JM, 2009, CLIN CANCER RES, V15, P5626, DOI 10.1158/1078-0432.CCR-09-0376; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; Schoors S, 2015, NATURE, V520, P192, DOI 10.1038/nature14362; Schug ZT, 2015, CANCER CELL, V27, P57, DOI 10.1016/j.ccell.2014.12.002; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Tregnago C, 2016, LEUKEMIA, V30, P1887, DOI 10.1038/leu.2016.98; Wang JY, 2013, MOL CELL, V51, P211, DOI 10.1016/j.molcel.2013.05.013; Wang WJ, 2017, CLIN CANCER RES, V23, P503, DOI 10.1158/1078-0432.CCR-15-1169; Wang YW, 2014, J INVEST DERMATOL, V134, P2016, DOI 10.1038/jid.2014.84; Ye HB, 2016, CELL STEM CELL, V19, P23, DOI 10.1016/j.stem.2016.06.001; Ye X, 2015, NATURE, V525, P256, DOI 10.1038/nature14897	41	11	11	2	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	4					833	848		10.1038/s41388-019-1015-z	http://dx.doi.org/10.1038/s41388-019-1015-z			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KF4EJ	31562393				2022-12-17	WOS:000509197200007
J	Wang, JY; Nagy, N; Masucci, MG				Wang, Jiayu; Nagy, Noemi; Masucci, Maria G.			The Epstein-Barr virus nuclear antigen-1 upregulates the cellular antioxidant defense to enable B-cell growth transformation and immortalization	ONCOGENE			English	Article							PROMOTES GENOMIC INSTABILITY; BASE-EXCISION-REPAIR; DNA-DAMAGE; OXIDATIVE STRESS; CANCER; MTH1; PATHWAY; ESTABLISHMENT; TRANSCRIPTION; INHIBITION	Epstein-Barr virus (EBV) immortalizes human B-lymphocytes and is implicated in the pathogenesis of lymphoid and epithelial cell malignancies. The EBV nuclear antigen (EBNA)-1 induces the accumulation of reactive oxygen species (ROS), which enables B-cell immortalization but causes oxidative DNA damage and triggers antiproliferative DNA damage responses. By comparing pairs of EBV-negative and -positive tumor cell lines we found that, while associated with the accumulation of oxidized nucleotides, EBV carriage promotes the concomitant activation of oxo-dNTP sanitization and purging pathways, including upregulation of the nucleoside triphosphatase mut-T homolog 1 (MTH1) and the DNA glycosylases 8-oxoguanine-glycosylase-1 (OGG1) and mut-Y homolog (MUTYH). Expression of EBNA1 was reversibly associated with transcriptional activation of this cellular response. DNA damage and apoptosis were preferentially induced in EBNA1-positive cell lines by treatment with MTH1 inhibitors, suggesting that virus carriage is linked to enhanced vulnerability to oxidative stress. MTH1, OGG1, and MUTYH were upregulated upon EBV infection in primary B-cells and treatment with MTH1 inhibitors prevented B-cell immortalization. These findings highlight an important role of the cellular antioxidant response in sustaining EBV infection, and suggests that targeting this cellular defense may offer a novel approach to antiviral therapy and could reduce the burden of EBV associated cancer.	[Wang, Jiayu; Nagy, Noemi; Masucci, Maria G.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden	Karolinska Institutet	Masucci, MG (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden.	maria.masucci@ki.se	Wang, jiayu/ABB-6772-2020	Masucci, Maria/0000-0002-5541-2809; Nagy, Noemi/0000-0002-7800-3493	Swedish Cancer Society; Swedish Medical Research Council; Karolinska Institutet, Stockholm, Sweden	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Karolinska Institutet, Stockholm, Sweden	This study was supported by grants awarded by the Swedish Cancer Society, the Swedish Medical Research Council and the Karolinska Institutet, Stockholm, Sweden. We are grateful to Drs Martin Row, Alan Chang, and Georg Klein for the generous gift of cell lines and reagents and to Dr Teresa Frisan and members of the Masucci group for helpful discussion and careful revision of the manuscript.	BARRANCO SC, 1983, CANCER RES, V43, P1703; Borrego S, 2013, INT J MOL SCI, V14, P3467, DOI 10.3390/ijms14023467; Bottero V, 2013, J VIROL, V87, P1733, DOI 10.1128/JVI.02958-12; Brautigam L, 2016, CANCER RES, V76, P2366, DOI 10.1158/0008-5472.CAN-15-2380; Carter RJ, 2016, MOL CELL BIOL, V36, P1426, DOI 10.1128/MCB.00030-16; Cerimele F, 2005, P NATL ACAD SCI USA, V102, P175, DOI 10.1073/pnas.0408381102; Chen X, 2016, ONCOGENE, V35, P3807, DOI 10.1038/onc.2015.450; Chen XS, 2014, SEMIN CANCER BIOL, V26, P43, DOI 10.1016/j.semcancer.2014.01.006; Chlichlia K, 2010, CHEM-BIOL INTERACT, V188, P359, DOI 10.1016/j.cbi.2010.06.005; Chodosh J, 1998, J INFECT DIS, V177, P1194, DOI 10.1086/515290; Coppotelli G, 2013, NUCLEIC ACIDS RES, V41, P2950, DOI 10.1093/nar/gkt032; Delia D, 2017, INT J HEMATOL, V106, P328, DOI 10.1007/s12185-017-2300-7; Frappier L, 2015, CURR TOP MICROBIOL, V391, P3, DOI 10.1007/978-3-319-22834-1_1; Gad H, 2014, NATURE, V508, P215, DOI 10.1038/nature13181; Grande BM, 2019, BLOOD, V133, P1313, DOI 10.1182/blood-2018-09-871418; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; Gruhne B, 2009, ONCOGENE, V28, P3997, DOI 10.1038/onc.2009.258; Gruhne B, 2009, SEMIN CANCER BIOL, V19, P394, DOI 10.1016/j.semcancer.2009.07.005; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; Guerreiro-Cacais AO, 2007, J VIROL, V81, P1390, DOI 10.1128/JVI.01999-06; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harris IS, 2015, CANCER CELL, V27, P211, DOI 10.1016/j.ccell.2014.11.019; Huber KVM, 2014, NATURE, V508, P222, DOI 10.1038/nature13194; Ivanov AV, 2013, VIRUSES-BASEL, V5, P439, DOI 10.3390/v5020439; Kamranvar SA, 2007, ONCOGENE, V26, P5115, DOI 10.1038/sj.onc.1210324; Kamranvar SA, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9080217; Kang MS, 2001, P NATL ACAD SCI USA, V98, P15233, DOI 10.1073/pnas.211556598; KASAI H, 1984, NUCLEIC ACIDS RES, V12, P2137, DOI 10.1093/nar/12.4.2137; Kawamura T, 2016, SCI REP-UK, V6, DOI 10.1038/srep26521; Kettle JG, 2016, J MED CHEM, V59, P2346, DOI 10.1021/acs.jmedchem.5b01760; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Lenoir G M, 1985, IARC Sci Publ, P309; Li Q, 2013, ASIAN PAC J CANCER P, V14, P5145, DOI 10.7314/APJCP.2013.14.9.5145; Lin CT, 1997, AM J PATHOL, V150, P1745; LIN CT, 1993, LAB INVEST, V68, P716; Lunn RM, 2017, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0266; Markkanen E, 2017, DNA REPAIR, V59, P82, DOI 10.1016/j.dnarep.2017.09.007; MENEZES J, 1975, BIOMEDICINE, V22, P276; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; Molesworth SJ, 2000, J VIROL, V74, P6324, DOI 10.1128/JVI.74.14.6324-6332.2000; Moloney JN, 2018, SEMIN CELL DEV BIOL, V80, P50, DOI 10.1016/j.semcdb.2017.05.023; Nakabeppu Y, 2014, INT J MOL SCI, V15, P12543, DOI 10.3390/ijms150712543; Nikitin PA, 2010, CELL HOST MICROBE, V8, P510, DOI 10.1016/j.chom.2010.11.004; Ogrunc M, 2014, CELL DEATH DIFFER, V21, P998, DOI 10.1038/cdd.2014.16; Samaranayake GJ, 2017, CANCERS, V9, DOI 10.3390/cancers9050047; SHIMIZU N, 1994, J VIROL, V68, P6069, DOI 10.1128/JVI.68.9.6069-6073.1994; Sompallae R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012052; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; Wang JY, 2016, J INVEST DERMATOL, V136, P2277, DOI 10.1016/j.jid.2016.06.625; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452	50	11	11	2	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					603	616		10.1038/s41388-019-1003-3	http://dx.doi.org/10.1038/s41388-019-1003-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31511648	Green Published, hybrid			2022-12-17	WOS:000509718300009
J	Wang, MD; Nagle, RB; Knudsen, BS; Cress, AE; Rogers, GC				Wang, Mengdie; Nagle, Raymond B.; Knudsen, Beatrice S.; Cress, Anne E.; Rogers, Gregory C.			Centrosome loss results in an unstable genome and malignant prostate tumors	ONCOGENE			English	Article							CHROMOSOMAL INSTABILITY; CENTRIOLE DUPLICATION; C-MYC; CANCER; AMPLIFICATION; EXPRESSION; CELLS; DIFFERENTIATION; TUMORIGENESIS; PROGRESSION	Localized, nonindolent prostate cancer (PCa) is characterized by large-scale genomic rearrangements, aneuploidy, chromothripsis, and other forms of chromosomal instability (CIN), yet how this occurs remains unclear. A well-established mechanism of CIN is the overproduction of centrosomes, which promotes tumorigenesis in various mouse models. Therefore, we developed a single-cell assay for quantifying centrosomes in human prostate tissue. Surprisingly, centrosome loss-which has not been described in human cancer-was associated with PCa progression. By chemically or genetically inducing centrosome loss in nontumorigenic prostate epithelial cells, mitotic errors ensued, producing aneuploid, and multinucleated cells. Strikingly, transient or chronic centrosome loss transformed prostate epithelial cells, which produced highly proliferative and poorly differentiated malignant tumors in mice. Our findings suggest that centrosome loss could create a cellular crisis with oncogenic potential in prostate epithelial cells.	[Wang, Mengdie; Cress, Anne E.; Rogers, Gregory C.] Univ Arizona, Canc Ctr, Dept Cellular & Mol Med, Tucson, AZ 85724 USA; [Nagle, Raymond B.] Univ Arizona, Canc Ctr, Dept Pathol, Tucson, AZ 85724 USA; [Knudsen, Beatrice S.] Cedars Sinai Med Ctr, Dept Pathol & Lab Med, Los Angeles, CA 90048 USA	University of Arizona; University of Arizona; Cedars Sinai Medical Center	Cress, AE; Rogers, GC (corresponding author), Univ Arizona, Canc Ctr, Dept Cellular & Mol Med, Tucson, AZ 85724 USA.	cress@email.arizona.edu; gcrogers@email.arizona.edu		Cress, Anne/0000-0001-6194-0061	DoD PCa Research Program [W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH-14-2-0186, W81XWH-15-2-0062]; NIH [NCI P30 CA23074, R01GM110166, R01GM126035, R01CA159406]; Tim and Diane Bowden Cancer Biology Research Fellowship	DoD PCa Research Program(United States Department of Defense); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Tim and Diane Bowden Cancer Biology Research Fellowship	We thank K. Oegema for providing centrinone and CRISPR constructs, D. Pellman for histone-H2B construct, V. Bautch for centrin1 construct, W. Hahn for PrEC cells, C. Miranti for iPEC37 cells, and N. Ellis and J. DeLuca for technical advice. Tissue samples were obtained from the PCa Biorepository Network (PCBN) (DoD PCa Research Program Award No W81XWH-14-2-0182, W81XWH-14-2-0183, W81XWH-14-2-0185, W81XWH-14-2-0186, and W81XWH-15-2-0062). This work was supported by NIH grants NCI P30 CA23074, R01GM110166, and R01GM126035 to GCR, R01CA159406 to AEC and Tim and Diane Bowden Cancer Biology Research Fellowship to MW.	Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025; Armenia J, 2018, NAT GENET, V50, P645, DOI 10.1038/s41588-018-0078-z; Baca SC, 2013, CELL, V153, P666, DOI 10.1016/j.cell.2013.03.021; Barbieri CE, 2012, NAT GENET, V44, P685, DOI 10.1038/ng.2279; Bazzi H, 2014, P NATL ACAD SCI USA, V111, pE1491, DOI 10.1073/pnas.1400568111; Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Berger R, 2004, CANCER RES, V64, P8867, DOI 10.1158/0008-5472.CAN-04-2938; Bettencourt-Dias M, 2005, CURR BIOL, V15, P2199, DOI 10.1016/j.cub.2005.11.042; Bettencourt-Dias M, 2007, NAT REV MOL CELL BIO, V8, P451, DOI 10.1038/nrm2180; Boutros PC, 2015, NAT GENET, V47, P736, DOI 10.1038/ng.3315; Cangemi R, 2008, ONCOGENE, V27, P2877, DOI 10.1038/sj.onc.1210953; Chan JY, 2011, INT J BIOL SCI, V7, P1122, DOI 10.7150/ijbs.7.1122; Chatterjee SJ, 2014, BREAST CANCER-TARGET, V6, P15, DOI 10.2147/BCTT.S43764; Coelho PA, 2015, OPEN BIOL, V5, DOI 10.1098/rsob.150209; Conduit PT, 2015, NAT REV MOL CELL BIO, V16, P611, DOI 10.1038/nrm4062; Cosenza MR, 2017, CELL REP, V20, P1906, DOI 10.1016/j.celrep.2017.08.005; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Denu RA, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2083-x; Edick MJ, 2007, MOL BIOL CELL, V18, P2481, DOI 10.1091/mbc.E06-04-0261; Espiritu SMG, 2018, CELL, V173, P1003, DOI 10.1016/j.cell.2018.03.029; Fraser M, 2017, NATURE, V541, P359, DOI 10.1038/nature20788; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gmyrek GA, 2001, AM J PATHOL, V159, P579, DOI 10.1016/S0002-9440(10)61729-4; Godinho SA, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0467; Godinho SA, 2014, NATURE, V510, P167, DOI 10.1038/nature13277; Gregan J, 2011, TRENDS CELL BIOL, V21, P374, DOI 10.1016/j.tcb.2011.01.003; Habedanck R, 2005, NAT CELL BIOL, V7, P1140, DOI 10.1038/ncb1320; Khodjakov A, 2001, J CELL BIOL, V153, P237, DOI 10.1083/jcb.153.1.237; Kushner EJ, 2014, J CELL BIOL, V206, P257, DOI 10.1083/jcb.201311013; Lambrus BG, 2015, J CELL BIOL, V210, P63, DOI 10.1083/jcb.201502089; Lawo S, 2012, NAT CELL BIOL, V14, P1148, DOI 10.1038/ncb2591; Levine MS, 2017, DEV CELL, V40, P313, DOI 10.1016/j.devcel.2016.12.022; Lipponen P, 2001, EUR J CANCER, V37, P849, DOI 10.1016/S0959-8049(00)00448-2; Malhas AN, 2014, ADV EXP MED BIOL, V773, P523, DOI 10.1007/978-1-4899-8032-8_24; Meunier S, 2016, TRENDS CELL BIOL, V26, P80, DOI 10.1016/j.tcb.2015.09.001; Nigg EA, 2018, NAT REV MOL CELL BIO, V19, P297, DOI 10.1038/nrm.2017.127; Ouyang XS, 2001, BBA-MOL CELL RES, V1541, P212, DOI 10.1016/S0167-4889(01)00157-4; PETEIN M, 1991, AM J CLIN PATHOL, V96, P628, DOI 10.1093/ajcp/96.5.628; Pihan GA, 2001, CANCER RES, V61, P2212; Pimenta-Marques A, 2016, SCIENCE, V353, DOI 10.1126/science.aaf4866; Rickman DS, 2012, P NATL ACAD SCI USA, V109, P9083, DOI 10.1073/pnas.1112570109; Robinson DR, 2017, NATURE, V548, P297, DOI 10.1038/nature23306; Rubin MA, 2001, HUM PATHOL, V32, P690, DOI 10.1053/hupa.2001.25902; Sercin O, 2016, NAT CELL BIOL, V18, P100, DOI 10.1038/ncb3270; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Sir JH, 2013, J CELL BIOL, V203, P747, DOI 10.1083/jcb.201309038; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; van Bokhoven A, 2001, PROSTATE, V47, P36; Vitre B, 2015, P NATL ACAD SCI USA, V112, pE6321, DOI 10.1073/pnas.1519388112; Wang M, 2019, MOL BIOL CELL, DOI [10.1091/mcb.E18-10-0651, DOI 10.1091/MCB.E18-10-0651]; Wang MD, 2017, J CELL SCI, V130, P104, DOI 10.1242/jcs.188177; Werner S, 2017, J CELL SCI, V130, P3789, DOI 10.1242/jcs.203505; Wong YL, 2015, SCIENCE, V348, P1155, DOI 10.1126/science.aaa5111; Wu YM, 2018, CELL, V173, P1770, DOI 10.1016/j.cell.2018.04.034; Xue JZ, 2013, DEV CELL, V27, P47, DOI 10.1016/j.devcel.2013.08.002; Zeng W, 2015, INT J CLIN EXP PATHO, V8, P1878	59	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	2					399	413		10.1038/s41388-019-0995-z	http://dx.doi.org/10.1038/s41388-019-0995-z			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KD3JY	31477840	Green Accepted			2022-12-17	WOS:000507766400011
J	Powers, MP				Powers, Martin P.			The ever-changing world of gene fusions in cancer: a secondary gene fusion and progression	ONCOGENE			English	Editorial Material									[Powers, Martin P.] Neogen Labs, Aliso Viejo, CA 92656 USA		Powers, MP (corresponding author), Neogen Labs, Aliso Viejo, CA 92656 USA.	m.p.powers@gmail.com		Powers, Martin/0000-0002-0445-120X				Capper D, 2018, NATURE, V555, P469, DOI 10.1038/nature26000; Cocco E, 2018, NAT REV CLIN ONCOL, V15, P731, DOI 10.1038/s41571-018-0113-0; Dupain C, 2019, ONCOGENE, DOI [10.1038/s43188-019-0914-3, DOI 10.1038/S43188-019-0914-3]; Dupain C, 2019, MOL THER, V27, P200, DOI 10.1016/j.ymthe.2018.10.022; Kwa M, 2017, NAT REV CLIN ONCOL, V14, P595, DOI 10.1038/nrclinonc.2017.74; Nikiforov YE, 2002, ENDOCR PATHOL, V13, P3, DOI 10.1385/EP:13:1:03; Powers M, 2011, CANCER BIOMARK, V9, P475, DOI 10.3233/CBM-2011-0170; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Wang YH, 2017, CURR GENOMICS, V18, P378, DOI 10.2174/1389202918666170329110349; Weinberg BA, 2019, CLIN ADV HEMATOL ONC, V17, P109; Wong S, 2004, ANNU REV IMMUNOL, V22, P247, DOI 10.1146/annurev.immunol.22.012703.104753	11	11	11	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2019	38	47					7197	7199		10.1038/s41388-019-1057-2	http://dx.doi.org/10.1038/s41388-019-1057-2			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JP0UL	31616060	Bronze			2022-12-17	WOS:000497989400001
J	Ki, DH; Oppel, F; Durbin, AD; Look, AT				Ki, Dong Hyuk; Oppel, Felix; Durbin, Adam D.; Look, A. Thomas			Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors	ONCOGENE			English	Article							PHASE-II; NUCLEAR EXPORT; SOFT-TISSUE; CAMPTOTHECIN; INITIATION; ZEBRAFISH; PATHWAYS; MODELS; TRANSLATION; REPRESSION	Malignant peripheral nerve sheath tumors (MPNSTs) are soft-tissue sarcomas that frequently arise in patients with neurofibromatosis type 1 (NF1). Most of these tumors are unresectable at diagnosis and minimally responsive to conventional treatment, lending urgency to the identification of new pathway dependencies and drugs with potent antitumor activities. We therefore examined a series of candidate agents for their ability to induce apoptosis in MPNST cells arising in nf1/tp53-deficient zebrafish. In this study, we found that DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors were the most effective single agents in eliminating MPNST cells without prohibitive toxicity. In addition, three members of these classes of drugs, either AZD2014 or INK128 in combination with irinotecan, acted synergistically to induce apoptosis both in vitro and in vivo. In mechanistic studies, irinotecan not only induces apoptosis by eliciting a DNA damage response, but also acts synergistically with AZD2014 to potentiate the hypophosphorylation of 4E-BP1, a downstream target of mTORC1. Profound hypophosphorylation of 4E-BP1 induced by this drug combination causes an arrest of protein synthesis, which potently induces tumor cell apoptosis. Our findings provide a compelling rationale for further in vivo evaluation of the combination of DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors against these aggressive nerve sheath tumors.	[Ki, Dong Hyuk; Oppel, Felix; Durbin, Adam D.; Look, A. Thomas] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Ki, Dong Hyuk; Oppel, Felix; Durbin, Adam D.; Look, A. Thomas] Boston Childrens Hosp, Div Pediat Hematol Oncol, Boston, MA 02115 USA; [Durbin, Adam D.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute	Look, AT (corresponding author), Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.	Thomas_Look@dfci.harvard.edu		Ki, Dong Hyuk/0000-0002-1571-7077; Look, A. Thomas/0000-0001-7851-8617; Durbin, Adam/0000-0002-5472-9847	Boston Children's Hospital Neurofibromatosis program; Department of Defense [W81XWH-12-1-0125]; Drug Discovery Initiative Award; NF1 Research Consortium Fund; Children's Tumor Foundation; NF Research Initiative at Boston Children's Hospital; German Cancer Aid; Mildred-Scheel-Postdoctoral program of the Mildred-Scheel Foundation; Alex's Lemonade Stand Young Investigator Award; American Society of Clinical Oncology Young Investigator Award; Rally Foundation for Childhood Cancer Research Young Investigator Award;  [DRSG-24-18]	Boston Children's Hospital Neurofibromatosis program; Department of Defense(United States Department of Defense); Drug Discovery Initiative Award; NF1 Research Consortium Fund; Children's Tumor Foundation; NF Research Initiative at Boston Children's Hospital; German Cancer Aid(Deutsche Krebshilfe); Mildred-Scheel-Postdoctoral program of the Mildred-Scheel Foundation; Alex's Lemonade Stand Young Investigator Award; American Society of Clinical Oncology Young Investigator Award; Rally Foundation for Childhood Cancer Research Young Investigator Award; 	We thank Dr. Donna Neuberg for biostatistical advice regarding the sample size, statistical power, and most appropriate statistical tests. We are grateful to Hillary Layden and Grace Thurston for their expert assistance with zebrafish husbandry and to Drs. Karen Cichowski and Nancy Ratner for providing human MPNST cell lines. This work was supported by the Latsis family fellowship from the Boston Children's Hospital Neurofibromatosis program, a grant from the Department of Defense (grant number W81XWH-12-1-0125), a Drug Discovery Initiative Award, the NF1 Research Consortium Fund, and Children's Tumor Foundation Young Investigator Award to DHK supported by the NF Research Initiative at Boston Children's Hospital made possible by an anonymous gift. FO acknowledges the German Cancer Aid for their generous funding within the Mildred-Scheel-Postdoctoral program of the Mildred-Scheel Foundation. ADD is a Damon-Runyon Sohn Pediatric Fellow (grant number DRSG-24-18), and acknowledges grant support from the Alex's Lemonade Stand Young Investigator Award, the American Society of Clinical Oncology Young Investigator Award and the Rally Foundation for Childhood Cancer Research Young Investigator Award.	Barbazuk WB, 2000, GENOME RES, V10, P1351, DOI 10.1101/gr.144700; Beauchamp RL, 2015, ONCOTARGET, V6, P16981, DOI 10.18632/oncotarget.4858; BLAIR SC, 1994, AM J CLIN ONCOL-CANC, V17, P480, DOI 10.1097/00000421-199412000-00005; Brohl AS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15183-1; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Cam M, 2014, J BIOL CHEM, V289, P4083, DOI 10.1074/jbc.M113.530303; Charest Mathieu, 2017, J Nucl Med Technol, DOI 10.2967/jnmt.117.199927; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Chugh R, 2009, J CLIN ONCOL, V27, P3148, DOI 10.1200/JCO.2008.20.5054; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Cubitt Christopher L., 2013, Sarcoma, V2013, P365723, DOI 10.1155/2013/365723; De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561; Dickson MA, 2016, ANN ONCOL, V27, P1855, DOI 10.1093/annonc/mdw281; Durbin AD, 2016, ADV EXP MED BIOL, V916, P495, DOI 10.1007/978-3-319-30654-4_22; Endo M, 2013, CLIN CANCER RES, V19, P450, DOI 10.1158/1078-0432.CCR-12-1067; EricksonMiller CL, 1997, CANCER CHEMOTH PHARM, V39, P467, DOI 10.1007/s002800050600; Etchin J, 2013, BRIT J HAEMATOL, V161, P117, DOI 10.1111/bjh.12231; Evans DGR, 2011, EUR J HUM GENET, V19, P1187, DOI 10.1038/ejhg.2011.113; Ferner RE, 2007, LANCET NEUROL, V6, P340, DOI 10.1016/S1474-4422(07)70075-3; Ferrari Andrea, 2007, Paediatr Drugs, V9, P239, DOI 10.2165/00148581-200709040-00005; Gilbert DC, 2012, BRIT J CANCER, V106, P18, DOI 10.1038/bjc.2011.498; Goodsell DS, 1999, STEM CELLS, V17, P235, DOI 10.1002/stem.170235; Gupta G, 2008, NEUROSURG CLIN N AM, V19, P533, DOI 10.1016/j.nec.2008.07.004; Hagel C, 2007, J NEURO-ONCOL, V82, P187, DOI 10.1007/s11060-006-9266-2; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jessen WJ, 2013, J CLIN INVEST, V123, P340, DOI 10.1172/JCI60578; Kebudi R, 2013, PEDIATR HEMAT ONCOL, V30, P170, DOI 10.3109/08880018.2013.767868; Ki DH, 2017, ONCOGENE, V36, P1058, DOI 10.1038/onc.2016.269; Kim AeRang, 2017, Sarcoma, V2017, P7429697, DOI 10.1155/2017/7429697; Kim J, 2016, NATURE, V538, P114, DOI 10.1038/nature19771; Kroep JR, 2011, ANN ONCOL, V22, P207, DOI 10.1093/annonc/mdq338; Lansiaux A, 2007, MOL PHARMACOL, V72, P311, DOI 10.1124/mol.107.034637; Lee W, 2014, NAT GENET, V46, P1227, DOI 10.1038/ng.3095; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; MADER S, 1995, MOL CELL BIOL, V15, P4990; Maki RG, 2009, J CLIN ONCOL, V27, P3133, DOI 10.1200/JCO.2008.20.4495; Malone CF, 2014, CANCER DISCOV, V4, P1062, DOI 10.1158/2159-8290.CD-14-0159; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Nair JS, 2017, CLIN CANCER RES, V23, P4301, DOI 10.1158/1078-0432.CCR-16-2632; Nkere UU, 1997, EUR J CARDIO-THORAC, V12, P144, DOI 10.1016/S1010-7940(97)00085-7; Schuetze SM, 2016, CANCER-AM CANCER SOC, V122, P868, DOI 10.1002/cncr.29858; Shin J, 2012, DIS MODEL MECH, V5, P881, DOI 10.1242/dmm.009779; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Stucky CCH, 2012, ANN SURG ONCOL, V19, P878, DOI 10.1245/s10434-011-1978-7; Tee AR, 2000, ONCOGENE, V19, P3021, DOI 10.1038/sj.onc.1203622; Thompson J, 1998, BBA-GENE STRUCT EXPR, V1400, P301, DOI 10.1016/S0167-4781(98)00143-2; Duong TA, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-18; Valentin T, 2016, EUR J CANCER, V56, P77, DOI 10.1016/j.ejca.2015.12.015; Varin J, 2016, ONCOTARGET, V7, P35753, DOI 10.18632/oncotarget.7099; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wang Jun, 2014, Cancer Cell Microenviron, V1; Watson AL, 2014, ONCOTARGET, V5, P1502, DOI 10.18632/oncotarget.1609; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE; White RM, 2008, CELL STEM CELL, V2, P183, DOI 10.1016/j.stem.2007.11.002; Zhao CJ, 2011, CARCINOGENESIS, V32, P1143, DOI 10.1093/carcin/bgr076	56	11	11	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2019	38	39					6585	6598		10.1038/s41388-019-0965-5	http://dx.doi.org/10.1038/s41388-019-0965-5			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JA5AQ	31444410	hybrid			2022-12-17	WOS:000487856000002
J	Nguyen, T; Duchesne, L; Narayana, GHNS; Boggetto, N; Fernig, DD; Murade, CU; Ladoux, B; Mege, RM				Thao Nguyen; Duchesne, Laurence; Narayana, Gautham Hari Narayana Sankara; Boggetto, Nicole; Fernig, David D.; Murade, Chandrashekhar Uttamrao; Ladoux, Benoit; Mege, Rene-Marc			Enhanced cell-cell contact stability and decreased N-cadherin-mediated migration upon fibroblast growth factor receptor-N-cadherin cross talk	ONCOGENE			English	Article							P120 CATENIN; NEURITE OUTGROWTH; ADHESION MOLECULE; LIGAND-BINDING; TYROSINE PHOSPHORYLATION; MORPHOGENETIC MOVEMENT; NEURONAL MIGRATION; BREAST-CANCER; FGF RECEPTOR; EXPRESSION	N-cadherin adhesion has been reported to enhance cancer and neuronal cell migration either by mediating actomyosin-based force transduction or initiating fibroblast growth factor receptor (FGFR)-dependent biochemical signalling. Here we show that FGFR1 reduces N-cadherin-mediated cell migration. Both proteins are co-stabilised at cell-cell contacts through direct interaction. As a consequence, cell adhesion is strengthened, limiting the migration of cells on N-cadherin. Both the inhibition of migration and the stabilisation of cell adhesions require the FGFR activity stimulated by N-cadherin engagement. FGFR1 stabilises N-cadherin at the cell membrane through a pathway involving Src and p120. Moreover, FGFR1 stimulates the anchoring of N-cadherin to actin. We found that the migratory behaviour of cells depends on an optimum balance between FGFR-regulated N-cadherin adhesion and actin dynamics Based on these findings we propose a positive feed-back loop between N-cadherin and FGFR at adhesion sites limiting N-cadherin-based single-cell migration.	[Thao Nguyen; Narayana, Gautham Hari Narayana Sankara; Boggetto, Nicole; Murade, Chandrashekhar Uttamrao; Ladoux, Benoit; Mege, Rene-Marc] Univ Paris Diderot, Inst Jacques Monod, CNRS, 15 Rue Helene Brion, F-75205 Paris 13, France; [Duchesne, Laurence] Univ Rennes, CNRS, UMR 6290, IGDR, F-35000 Rennes, France; [Fernig, David D.] Univ Liverpool, Dept Biochem, Inst Integrated Biol, Liverpool L69 7ZB, Merseyside, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Rennes 1; University of Liverpool	Mege, RM (corresponding author), Univ Paris Diderot, Inst Jacques Monod, CNRS, 15 Rue Helene Brion, F-75205 Paris 13, France.	rene-marc.mege@ijm.fr	Fernig, David G/A-3590-2008	Fernig, David G/0000-0003-4875-4293; Mege, Rene-Marc/0000-0001-8128-5543; Sankara Narayana, Gautham Hari Narayana/0000-0002-2534-5836; Ladoux, Benoit/0000-0003-2086-1556; Duchesne, Laurence/0000-0003-1985-6266	CNRS; ARC foundation [PJA 20151203185]; Human Frontier Science Program (HFSP) [RPG0040/2012]; European Research Council under the European Union's Seventh Framework Program (FP7/2007-2013)/ERC grant [617233]; Agence Nationale de la Recherche [ANR 2010 Blan1515]; NUS-USPC exchange program; HFSP [RPG0040/2012]; Fondation pour la Recherche Medicale and Labex WhoAmI; Region Ile de France [E539]; Ligue contre le Cancer [R03/75-79]; Fondation pour la Recherche Medicale [FDT20150532600]; Association pour la Recherche contre le Cancer (Fondation ARC) [P2009 CDD POST-DOC]; DDF by North West Cancer; Cancer and Polio Research Fund; ImagoSeine core facility of the Institut Jacques Monod, member of IBiSA and France-BioImaging [ANR-10-INBS-04]	CNRS(Centre National de la Recherche Scientifique (CNRS)); ARC foundation(Australian Research Council); Human Frontier Science Program (HFSP)(Human Frontier Science Program); European Research Council under the European Union's Seventh Framework Program (FP7/2007-2013)/ERC grant; Agence Nationale de la Recherche(French National Research Agency (ANR)); NUS-USPC exchange program; HFSP(Human Frontier Science Program); Fondation pour la Recherche Medicale and Labex WhoAmI; Region Ile de France(Region Ile-de-France); Ligue contre le Cancer(Ligue nationale contre le cancer); Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Association pour la Recherche contre le Cancer (Fondation ARC); DDF by North West Cancer; Cancer and Polio Research Fund; ImagoSeine core facility of the Institut Jacques Monod, member of IBiSA and France-BioImaging	This work was supported by grants from the CNRS, ARC foundation (contract number: PJA 20151203185), Human Frontier Science Program (HFSP grant RPG0040/2012), European Research Council under the European Union's Seventh Framework Program (FP7/2007-2013)/ERC grant agreements no 617233 (BL), Agence Nationale de la Recherche (ANR 2010 Blan1515) and NUS-USPC exchange program. TN was supported by a HFSP grant RPG0040/2012, then by Fondation pour la Recherche Medicale and Labex WhoAmI. We would like also to thank all present and past members of the Cell Adhesion & Mechanics lab at the Institute Jacques Monod for constant support and exchange. We thank Region Ile de France (E539) and Ligue contre le Cancer (R03/75-79) for the acquisition of the equipment. We thank CUM and M. Yao for held with magnetic tweezer experiment. CUM was supported by Fondation pour la Recherche Medicale (FDT20150532600), LD by the Association pour la Recherche contre le Cancer (Fondation ARC, P2009 CDD POST-DOC) and DDF by North West Cancer and the Cancer and Polio Research Fund. We thank O. Thoumine and R. Horwitz for their kind gift of NcadAAA and FGFR1 encoding plasmids, respectively. We acknowledge the ImagoSeine core facility of the Institut Jacques Monod, member of IBiSA and France-BioImaging (ANR-10-INBS-04) infrastructures.	Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Bard L, 2008, J NEUROSCI, V28, P5879, DOI 10.1523/JNEUROSCI.5331-07.2008; BIXBY JL, 1990, J CELL BIOL, V110, P1253, DOI 10.1083/jcb.110.4.1253; Boscher C, 2008, CELL SIGNAL, V20, P1061, DOI 10.1016/j.cellsig.2008.01.008; Brittis PA, 1996, MOL CELL NEUROSCI, V8, P120, DOI 10.1006/mcne.1996.0051; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Carmeliet P., 2000, ANN NY ACAD SCI, V902, P62; Chen XY, 2003, J CELL BIOL, V163, P547, DOI 10.1083/jcb.200305137; Chu WC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073878; Chu YS, 2006, J BIOL CHEM, V281, P2901, DOI 10.1074/jbc.M506185200; Ciruna B, 2001, DEV CELL, V1, P37, DOI 10.1016/S1534-5807(01)00017-X; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; Debiais F, 2001, J CELL BIOCHEM, V81, P68, DOI 10.1002/1097-4644(20010401)81:1<68::AID-JCB1024>3.0.CO;2-S; del Valle-Perez B, 2011, J CELL SCI, V124, P2298, DOI 10.1242/jcs.082693; DENG CX, 1994, GENE DEV, V8, P3045, DOI 10.1101/gad.8.24.3045; Derycke LDM, 2004, INT J DEV BIOL, V48, P463, DOI 10.1387/ijdb.041793ld; Franco SJ, 2011, NEURON, V69, P482, DOI 10.1016/j.neuron.2011.01.003; Gavard J, 2004, J BIOL CHEM, V279, P36795, DOI 10.1074/jbc.M401705200; Giannone G, 2009, TRENDS CELL BIOL, V19, P475, DOI 10.1016/j.tcb.2009.07.001; Giannotta M, 2013, DEV CELL, V26, P441, DOI 10.1016/j.devcel.2013.08.020; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; Hazan RB, 2000, J CELL BIOL, V148, P779, DOI 10.1083/jcb.148.4.779; Huttenlocher A, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005074; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jossin Y, 2011, NAT NEUROSCI, V14, P697, DOI 10.1038/nn.2816; Kadowaki M, 2007, DEV BIOL, V304, P22, DOI 10.1016/j.ydbio.2006.12.014; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kawauchi T, 2010, NEURON, V67, P588, DOI 10.1016/j.neuron.2010.07.007; KE YQ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P307, DOI 10.1016/0167-4781(92)90029-Y; Kolijn K, 2015, ONCOTARGET, V6, P24488, DOI 10.18632/oncotarget.4177; Kontaridis MI, 2002, MOL CELL BIOL, V22, P3875, DOI 10.1128/MCB.22.11.3875-3891.2002; Kourtidis A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129964; Kourtidis A, 2013, PROG MOL BIOL TRANSL, V116, P409, DOI 10.1016/B978-0-12-394311-8.00018-2; Lebreton G, 2016, DEV DYNAM, V245, P372, DOI 10.1002/dvdy.24345; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; LETOURNEAU PC, 1990, DEV BIOL, V138, P430, DOI 10.1016/0012-1606(90)90209-2; Li G, 2001, CANCER RES, V61, P3819; Luccardini C, 2013, J NEUROSCI, V33, P18149, DOI 10.1523/JNEUROSCI.0593-13.2013; Mariner DJ, 2004, J CELL SCI, V117, P1339, DOI 10.1242/jcs.01001; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; MATSUNAGA M, 1988, NATURE, V334, P62, DOI 10.1038/334062a0; Mayor R, 2016, NAT REV MOL CELL BIO, V17, P97, DOI 10.1038/nrm.2015.14; McCrea PD, 2015, CURR TOP DEV BIOL, V112, P129, DOI 10.1016/bs.ctdb.2014.11.018; McIntosh I, 2000, CELL STRUCT FUNCT, V25, P85, DOI 10.1247/csf.25.85; Mege RM, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a028738; Meng WX, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a002899; Nagi C, 2005, BREAST CANCER RES TR, V94, P225, DOI 10.1007/s10549-005-7727-5; Nakashima T, 2003, BRIT J CANCER, V88, P1727, DOI 10.1038/sj.bjc.6600955; Nanes BA, 2012, J CELL BIOL, V199, P365, DOI 10.1083/jcb.201205029; Oas RG, 2013, MOL BIOL CELL, V24, P704, DOI 10.1091/mbc.E12-06-0471; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Peterson SJ, 2015, CELL, V160, P313, DOI 10.1016/j.cell.2014.11.043; Peyton SR, 2005, J CELL PHYSIOL, V204, P198, DOI 10.1002/jcp.20274; Plestant C, 2014, J CELL SCI, V127, P1660, DOI 10.1242/jcs.131284; Porta R, 2017, CRIT REV ONCOL HEMAT, V113, P256, DOI 10.1016/j.critrevonc.2017.02.018; Prasad M, 2011, METHODS MOL BIOL, V769, P277, DOI 10.1007/978-1-61779-207-6_19; Redies C, 1996, DEV BIOL, V180, P413, DOI 10.1006/dbio.1996.0315; Ren MQ, 2011, CANCER RES, V71, P7312, DOI 10.1158/0008-5472.CAN-11-1109; Rieger-Christ KM, 2004, ONCOGENE, V23, P4745, DOI 10.1038/sj.onc.1207629; Scarpa E, 2015, DEV CELL, V34, P421, DOI 10.1016/j.devcel.2015.06.012; Strale PO, 2015, J CELL BIOL, V210, P333, DOI 10.1083/jcb.201410111; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Suzuki SC, 2008, DEV GROWTH DIFFER, V50, pS119, DOI 10.1111/j.1440-169X.2008.01002.x; Taeger J, 2011, MOL CANCER THER, V10, P2157, DOI 10.1158/1535-7163.MCT-11-0312; Takehara T, 2015, SCI REP-UK, V5, DOI 10.1038/srep14722; Nguyen T, 2016, EUR J CELL BIOL, V95, P415, DOI 10.1016/j.ejcb.2016.05.002; Thoreson MA, 2000, J CELL BIOL, V148, P189, DOI 10.1083/jcb.148.1.189; Thoumine O, 2006, MOL BIOL CELL, V17, P862, DOI 10.1091/mbc.E05-04-0335; Treubert-Zimmermann U, 2002, J NEUROSCI, V22, P7617; Trolice MP, 1997, ENDOCRINOLOGY, V138, P107, DOI 10.1210/en.138.1.107; Utton MA, 2001, J NEUROCHEM, V76, P1421, DOI 10.1046/j.1471-4159.2001.00140.x; van Roy F, 2008, CELL MOL LIFE SCI, V65, P3756, DOI 10.1007/s00018-008-8281-1; van Roy F, 2014, NAT REV CANCER, V14, P121, DOI 10.1038/nrc3647; Wesche J, 2011, BIOCHEM J, V437, P199, DOI 10.1042/BJ20101603; Wheelock MJ, 2001, J MAMMARY GLAND BIOL, V6, P275, DOI 10.1023/A:1011319507155; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; YAMAGUCHI TP, 1994, GENE DEV, V8, P3032, DOI 10.1101/gad.8.24.3032; ZHAN X, 1994, J BIOL CHEM, V269, P20221	81	11	11	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 29	2019	38	35					6283	6300		10.1038/s41388-019-0875-6	http://dx.doi.org/10.1038/s41388-019-0875-6			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IU9RZ	31312021	Green Submitted			2022-12-17	WOS:000483919400004
J	Fadhlullah, SFB; Halim, NBA; Yeo, JYT; Ho, RLY; Um, P; Ang, BT; Tang, C; Ng, WH; Virshup, DM; Ho, IAW				Fadhlullah, Siti Farah Bte; Halim, Nurashikin Bte Abdul; Yeo, Jacqueline Y. T.; Ho, Rachel L. Y.; Um, Phoebe; Ang, Beng Ti; Tang, Carol; Ng, Wai H.; Virshup, David M.; Ho, Ivy A. W.			Pathogenic mutations in neurofibromin identifies a leucine-rich domain regulating glioma cell invasiveness	ONCOGENE			English	Article							NF1 TUMOR-SUPPRESSOR; EPITHELIAL-MESENCHYMAL TRANSITION; INTEGRATED GENOMIC ANALYSIS; PATIENT SURVIVAL; PROTEIN-KINASE; UP-REGULATION; GLIOBLASTOMA; CANCER; EXPRESSION; SUBTYPES	Glioblastoma (GBM) is the most aggressive tumor of the brain. NF1, a tumor suppressor gene and RAS-GTPase, is one of the highly mutated genes in GBM. Dysregulated NF1 expression promotes cell invasion, proliferation, and tumorigenesis. Loss of NF1 expression in glioblastoma is associated with increased aggressiveness of the tumor. Here, we show that NF1-loss in patient-derived glioma cells using shRNA increases self-renewal, heightens cell invasion, and promotes mesenchymal subtype and epithelial mesenchymal transition-specific gene expression that enhances tumorigenesis. The neurofibromin protein contains at least four major domains, with the GAP-related domain being the most well-studied. In this study, we report that the leucine-rich domain (LRD) of neurofibromin inhibits invasion of human glioblastoma cells without affecting their proliferation. Moreover, under conditions tested, the NF1-LRD fails to hydrolyze Ras-GTP to Ras-GDP, suggesting that its suppressive function is independent of Ras signaling. We further demonstrate that rare variants within the NF1-LRD domain found in a subset of the patients are pathogenic and reduce NF1-LRD's invasion suppressive function. Taken together, our results show, for the first time, that NF1-LRD inhibits glioma invasion, and provides evidence of a previously unrecognized function of NF1-LRD in glioma biology.	[Fadhlullah, Siti Farah Bte; Halim, Nurashikin Bte Abdul; Yeo, Jacqueline Y. T.; Ho, Rachel L. Y.; Um, Phoebe; Ho, Ivy A. W.] Natl Neurosci Inst, Mol Neurotherapeut Lab, Singapore 308433, Singapore; [Um, Phoebe] Univ Penn, Philadelphia, PA 19104 USA; [Ang, Beng Ti; Ng, Wai H.] Natl Neurosci Inst, Dept Neurosurg, Singapore 308433, Singapore; [Ang, Beng Ti; Ho, Ivy A. W.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 119228, Singapore; [Ang, Beng Ti] ASTAR, Singapore Inst Clin Sci, Singapore 117609, Singapore; [Ang, Beng Ti; Ho, Ivy A. W.] Duke NUS Med Sch, Singapore 169857, Singapore; [Tang, Carol] Natl Neurosci Inst, Dept Res, Singapore 308433, Singapore; [Tang, Carol; Virshup, David M.] Duke NUS Med Sch, Program Canc & Stem Cell Biol, Singapore 169857, Singapore; [Tang, Carol] Natl Canc Ctr, Div Cellular & Mol Res, Singapore 169610, Singapore; [Virshup, David M.] Duke Univ, Dept Pediat, Sch Med, Durham, NC 27703 USA; [Fadhlullah, Siti Farah Bte] Lucence Diagnost Pte Ltd, Singapore, Singapore	National Neuroscience Institute (NNI); University of Pennsylvania; National Neuroscience Institute (NNI); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Institute for Clinical Sciences (SICS); National University of Singapore; National Neuroscience Institute (NNI); National University of Singapore; National Cancer Centre Singapore (NCCS); Duke University	Ho, IAW (corresponding author), Natl Neurosci Inst, Mol Neurotherapeut Lab, Singapore 308433, Singapore.; Ho, IAW (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 119228, Singapore.; Ho, IAW (corresponding author), Duke NUS Med Sch, Singapore 169857, Singapore.	ivy_aw_ho@nni.com.sg	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X; Ho, Ivy/0000-0002-2948-3726; Tang, Carol/0000-0002-1835-5083	NCC Research Fund and Oncology Academic Program [NCCRF-OACPCCS-YR2014-AUG-3]; National Medical Research Council [NMRC/OFIRG/0039/2017]; Singapore Ministry of Health's National Medical Research Council under its Translational and Clinical Research (TCR) Flagship Program-Tier 1 [NMRC/TCR/016-NNI/2016]	NCC Research Fund and Oncology Academic Program; National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Singapore Ministry of Health's National Medical Research Council under its Translational and Clinical Research (TCR) Flagship Program-Tier 1	This project is funded by grants from NCC Research Fund and Oncology Academic Program (NCCRF-OACPCCS-YR2014-AUG-3), National Medical Research Council (NMRC/OFIRG/0039/2017), and institutional center grant to IAWH. This work is also partially supported by the Singapore Ministry of Health's National Medical Research Council under its Translational and Clinical Research (TCR) Flagship Program-Tier 1 (Project No. NMRC/TCR/016-NNI/2016) awarded to BTA and CT.	Ambrosini G, 2008, MOL CANCER THER, V7, P890, DOI 10.1158/1535-7163.MCT-07-0518; Arima Y, 2010, EXP DERMATOL, V19, pE136, DOI 10.1111/j.1600-0625.2009.01017.x; Bayo P, 2015, MOL ONCOL, V9, P1704, DOI 10.1016/j.molonc.2015.05.006; Berezovsky AD, 2014, NEOPLASIA, V16, DOI 10.1016/j.neo.2014.03.006; Boissan M, 2010, CANCER RES, V70, P7710, DOI 10.1158/0008-5472.CAN-10-1887; Bonneau F, 2009, PROTEIN EXPRES PURIF, V65, P30, DOI 10.1016/j.pep.2008.12.001; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Brown DV, 2015, ONCOTARGET, V6, P6267, DOI 10.18632/oncotarget.3365; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheng GZ, 2008, CANCER RES, V68, P957, DOI 10.1158/0008-5472.CAN-07-5067; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Chong YK, 2009, STEM CELLS, V27, P29, DOI 10.1634/stemcells.2008-0009; Chow RD, 2017, NAT NEUROSCI, V20, P1329, DOI 10.1038/nn.4620; Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8; Cui Y, 2019, HUM MUTAT, V40, P187, DOI 10.1002/humu.23681; D'Angelo I, 2006, EMBO REP, V7, P174, DOI 10.1038/sj.embor.7400602; de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dodd RD, 2013, MOL CANCER THER, V12, P1906, DOI 10.1158/1535-7163.MCT-13-0189; Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943; Elston MS, 2009, J CLIN ENDOCR METAB, V94, P1436, DOI 10.1210/jc.2008-2075; Feng LP, 2004, FEBS LETT, V557, P275, DOI 10.1016/S0014-5793(03)01507-2; Foong Charlene Shu Fen, 2011, Front Biosci (Schol Ed), V3, P698, DOI 10.2741/s181; Fortier AM, 2013, J BIOL CHEM, V288, P11555, DOI 10.1074/jbc.M112.428920; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Guo JM, 2017, AM J CANCER RES, V7, P923; Herting CJ, 2017, GLIA, V65, P1914, DOI 10.1002/glia.23203; Ho IAW, 2009, STEM CELLS, V27, P1366, DOI 10.1002/stem.50; Holen I, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3201; Holzel M, 2010, CELL, V142, P218, DOI 10.1016/j.cell.2010.06.004; Hsueh YP, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-33; Johnson DR, 2012, J NEURO-ONCOL, V107, P359, DOI 10.1007/s11060-011-0749-4; Joseph NM, 2008, CANCER CELL, V13, P129, DOI 10.1016/j.ccr.2008.01.003; Kahen Elliot John, 2018, Oncotarget, V9, P22571, DOI 10.18632/oncotarget.25181; Kim D, 2001, FASEB J, V15, P1953, DOI 10.1096/fj.01-0198com; Koh LWH, 2013, ANTIOXID REDOX SIGN, V19, P2261, DOI 10.1089/ars.2012.4999; Kweh F, 2009, MOL CARCINOGEN, V48, P1005, DOI 10.1002/mc.20552; Kwiatkowska A, 2011, BBA-MOL CELL RES, V1813, P655, DOI 10.1016/j.bbamcr.2011.01.020; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lee JK, 2014, ONCOTARGETS THER, V7, P1933, DOI 10.2147/OTT.S36582; Lin YL, 2007, J CELL BIOL, V177, P829, DOI 10.1083/jcb.200608121; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Llaguno SRA, 2015, CANCER CELL, V28, P429, DOI 10.1016/j.ccell.2015.09.007; Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313; Maki RG, 2009, J CLIN ONCOL, V27, P3133, DOI 10.1200/JCO.2008.20.4495; McGillicuddy LT, 2009, CANCER CELL, V16, P44, DOI 10.1016/j.ccr.2009.05.009; Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Ng FSL, 2012, CLIN CANCER RES, V18, P4122, DOI 10.1158/1078-0432.CCR-11-3064; Nissan MH, 2014, CANCER RES, V74, P2340, DOI 10.1158/0008-5472.CAN-13-2625; Ozawa T, 2014, CANCER CELL, V26, P288, DOI 10.1016/j.ccr.2014.06.005; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Patrakitkomjorn S, 2008, J BIOL CHEM, V283, P9399, DOI 10.1074/jbc.M708206200; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Pu PY, 2006, J NEURO-ONCOL, V76, P1, DOI 10.1007/s11060-005-3029-3; Qian Y, 2004, AM J PHYSIOL-CELL PH, V286, pC153, DOI 10.1152/ajpcell.00142.2003; Ratner N, 2015, NAT REV CANCER, V15, P290, DOI 10.1038/nrc3911; Scheffzek K, 2012, FEBS LETT, V586, P2662, DOI 10.1016/j.febslet.2012.06.006; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308; Sintupisut N, 2013, NUCLEIC ACIDS RES, V41, P8803, DOI 10.1093/nar/gkt656; Stowe IB, 2012, GENE DEV, V26, P1421, DOI 10.1101/gad.190876.112; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; Tokuo H, 2001, FEBS LETT, V494, P48, DOI 10.1016/S0014-5793(01)02309-2; Tuominen VJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2615; Vallee B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047283; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Wang HF, 2011, J CLIN INVEST, V121, P4820, DOI 10.1172/JCI45677; Wang KZQ, 2006, J CELL SCI, V119, P1579, DOI 10.1242/jcs.02889; Welti S, 2007, J MOL BIOL, V366, P551, DOI 10.1016/j.jmb.2006.11.055; Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470; Yamaguchi N, 2015, SCI REP-UK, V5, DOI 10.1038/srep07656; Yulyana Y, 2013, STEM CELLS DEV, V22, P1870, DOI 10.1089/scd.2012.0529; Zhu Y, 2001, EXP CELL RES, V264, P19, DOI 10.1006/excr.2000.5138	75	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2019	38	27					5367	5380		10.1038/s41388-019-0809-3	http://dx.doi.org/10.1038/s41388-019-0809-3			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IG5KR	30967630	hybrid, Green Published			2022-12-17	WOS:000473842500003
J	Yamaguchi, T; Hayashi, M; Ida, L; Yamamoto, M; Lu, C; Kajino, T; Cheng, JL; Nakatochi, M; Isomura, H; Yamazaki, M; Suzuki, M; Fujimoto, T; Takahashi, T				Yamaguchi, Tomoya; Hayashi, Miyu; Ida, Lisa; Yamamoto, Masatoshi; Lu, Can; Kajino, Taisuke; Cheng, Jinglei; Nakatochi, Masahiro; Isomura, Hisanori; Yamazaki, Masaya; Suzuki, Motoshi; Fujimoto, Toyoshi; Takahashi, Takashi			ROR1-CAVIN3 interaction required for caveolae-dependent endocytosis and pro-survival signaling in lung adenocarcinoma	ONCOGENE			English	Article							PLASMA-MEMBRANE; PROTEINS; NKX2-1/TTF-1; ONCOGENE; ROR1	The receptor tyrosine kinase-like orphan receptor 1 (ROR1) is a transcriptional target of the lineage-survival oncogene NKX2-1/TTF-1 in lung adenocarcinomas. In addition to its kinase-dependent role, ROR1 functions as a scaffold protein to facilitate interaction between caveolin-1 (CAV1) and CAVIN1, and consequently maintains caveolae formation, which in turn sustains pro-survival signaling toward AKT from multiple receptor tyrosine kinases (RTKs), including epidermal growth factor receptor (EGFR), MET (proto-oncogene, receptor tyrosine kinase), and IGF-IR (insulin-like growth factor receptor 1). Therefore, ROR1 is an attractive target for overcoming EGFR-TKI resistance due to various mechanisms such as EGFR T790M double mutation and bypass signaling from other RTKs. Here, we report that ROR1 possesses a novel scaffold function indispensable for efficient caveolae-dependent endocytosis. CAVIN3 was found to bind with ROR1 at a site distinct from sites for CAV1 and CAVIN1, a novel function required for proper CAVIN3 subcellular localization and caveolae-dependent endocytosis, but not caveolae formation itself. Furthermore, evidence of a mechanistic link between ROR1-CAVIN3 interaction and consequential caveolae trafficking, which was found to utilize a binding site distinct from those for ROR1 interactions with CAV1 and CAVIN1, with RTK-mediated pro-survival signaling towards AKT in early endosomes in lung adenocarcinoma cells was also obtained. The present findings warrant future study to enable development of novel therapeutic strategies for inhibiting the multifaceted scaffold functions of ROR1 in order to reduce the intolerable death toll from this devastating cancer.	[Yamaguchi, Tomoya; Hayashi, Miyu; Ida, Lisa; Lu, Can; Kajino, Taisuke; Isomura, Hisanori; Suzuki, Motoshi; Takahashi, Takashi] Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Nagoya, Aichi 4668550, Japan; [Yamaguchi, Tomoya; Yamamoto, Masatoshi; Yamazaki, Masaya] Kumamoto Univ, Grad Sch Med Sci, Dept Canc Biol, Kumamoto 8608556, Japan; [Yamaguchi, Tomoya; Yamamoto, Masatoshi] Kumamoto Univ, Ctr Metab Regulat Hlth Aging, Kumamoto 8608556, Japan; [Kajino, Taisuke; Isomura, Hisanori] Aichi Canc Ctr, Res Inst, Div Mol Therapeut, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan; [Cheng, Jinglei; Fujimoto, Toyoshi] Nagoya Univ, Grad Sch Med, Dept Anat & Mol Cell Biol, Nagoya, Aichi 4668550, Japan; [Nakatochi, Masahiro] Nagoya Univ Hosp, Ctr Adv Med & Clin Res, Nagoya, Aichi 4668550, Japan; [Takahashi, Takashi] Aichi Canc Ctr, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan	Nagoya University; Kumamoto University; Kumamoto University; Aichi Cancer Center; Nagoya University; Nagoya University; Aichi Cancer Center	Takahashi, T (corresponding author), Nagoya Univ, Grad Sch Med, Ctr Neurol Dis & Canc, Div Mol Carcinogenesis, Nagoya, Aichi 4668550, Japan.; Takahashi, T (corresponding author), Aichi Canc Ctr, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	tak@aichi-cc.jp	Takahashi, Takashi/I-7262-2014; Fujimoto, Toyoshi/ABH-9058-2020; Nakatochi, Masahiro/Q-1247-2015; Yamaguchi, Tomoya/AAN-7524-2020	Takahashi, Takashi/0000-0003-0615-7001; Fujimoto, Toyoshi/0000-0002-3601-7977; Nakatochi, Masahiro/0000-0002-1838-4837; Yamaguchi, Tomoya/0000-0001-6933-543X; Yamazaki, Masaya/0000-0003-4151-4983	Japan Society for the Promotion of Science (JSPS); Project for Cancer Research and Therapeutic Evolution (P-CREATE) program of the Japan Agency for Medical Research and Development (AMED); Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan	Japan Society for the Promotion of Science (JSPS)(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Project for Cancer Research and Therapeutic Evolution (P-CREATE) program of the Japan Agency for Medical Research and Development (AMED); Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Yukako Shimada and Naoe Hotta for their technical support, and Kiyoshi Yanagisawa for the valuable discussion regarding this study. We are also grateful for the expert assistance from N Tsurumaki for image analysis. This work was supported in part by grants-in-aid for Scientific Research (A) and (C) from the Japan Society for the Promotion of Science (JSPS), the Project for Cancer Research and Therapeutic Evolution (P-CREATE) program of the Japan Agency for Medical Research and Development (AMED), and a grant-in-aid for Scientific Research on Innovative Areas from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan.	Briand N, 2011, BIOCHIMIE, V93, P71, DOI 10.1016/j.biochi.2010.03.022; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Chaudhary N, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001832; Cheng JPX, 2016, TRENDS CELL BIOL, V26, P177, DOI 10.1016/j.tcb.2015.10.010; Choudhury A, 2006, NAT CELL BIOL, V8, P317, DOI 10.1038/ncb1380; Di Guglielmo GM, 2003, NAT CELL BIOL, V5, P410, DOI 10.1038/ncb975; Echarri A, 2015, J CELL SCI, V128, P2747, DOI 10.1242/jcs.153940; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Gambin Y, 2014, ELIFE, V3, DOI 10.7554/eLife.01434; Hansen CG, 2010, TRENDS CELL BIOL, V20, P177, DOI 10.1016/j.tcb.2010.01.005; Hansen CG, 2009, NAT CELL BIOL, V11, P807, DOI 10.1038/ncb1887; Hernandez VJ, 2013, ELIFE, V2, DOI 10.7554/eLife.00905; Ida L, 2016, CANCER SCI, V107, P155, DOI 10.1111/cas.12858; Kirkham M, 2005, BBA-MOL CELL RES, V1746, P349, DOI 10.1016/j.bbamcr.2005.11.005; Kovtun O, 2015, J CELL SCI, V128, P1269, DOI 10.1242/jcs.167866; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lievens S, 2006, NAT METHODS, V3, P971, DOI 10.1038/nmeth1206-971; Liu LB, 2008, J BIOL CHEM, V283, P4314, DOI 10.1074/jbc.M707890200; McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151; McMahon KA, 2009, EMBO J, V28, P1001, DOI 10.1038/emboj.2009.46; Mohan J, 2015, J CELL SCI, V128, P979, DOI 10.1242/jcs.161463; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Nichols B, 2003, J CELL SCI, V116, P4707, DOI 10.1242/jcs.00840; Palfy M, 2012, TRENDS CELL BIOL, V22, P447, DOI 10.1016/j.tcb.2012.06.004; Parton RG, 2007, NAT REV MOL CELL BIO, V8, P185, DOI 10.1038/nrm2122; Parton RG, 2013, NAT REV MOL CELL BIO, V14, P98, DOI 10.1038/nrm3512; Pelkmans L, 2002, TRAFFIC, V3, P311, DOI 10.1034/j.1600-0854.2002.30501.x; Schermelleh L, 2010, J CELL BIOL, V190, P165, DOI 10.1083/jcb.201002018; Shvets E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7867; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Xu XL, 2001, CANCER RES, V61, P7943; Yamaguchi T, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10060; Yamaguchi T, 2013, CANCER CELL, V23, P718, DOI 10.1016/j.ccr.2013.04.002; Yamaguchi T, 2012, CANCER CELL, V21, P348, DOI 10.1016/j.ccr.2012.02.008; Zochbauer-Muller S, 2005, ONCOGENE, V24, P6249, DOI 10.1038/sj.onc.1208775	36	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 27	2019	38	26					5142	5157		10.1038/s41388-019-0785-7	http://dx.doi.org/10.1038/s41388-019-0785-7			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IF4AX	30894682				2022-12-17	WOS:000473025300003
J	Seoane, M; Buhs, S; Iglesias, P; Strauss, J; Puller, AC; Muller, J; Gerull, H; Feldhaus, S; Alawi, M; Brandner, JM; Eggert, D; Du, JY; Thomale, J; Wild, PJ; Zimmermann, M; Sternsdorf, T; Schumacher, U; Nollau, P; Fisher, DE; Horstmann, MA				Seoane, Marcos; Buhs, Sophia; Iglesias, Pablo; Strauss, Julia; Puller, Ann-Christin; Mueller, Juergen; Gerull, Helwe; Feldhaus, Susanne; Alawi, Malik; Brandner, Johanna M.; Eggert, Dennis; Du, Jinyan; Thomale, Juergen; Wild, Peter J.; Zimmermann, Martin; Sternsdorf, Thomas; Schumacher, Udo; Nollau, Peter; Fisher, David E.; Horstmann, Martin A.			Lineage-specific control of TFIIH by MITF determines transcriptional homeostasis and DNA repair	ONCOGENE			English	Article							NUCLEOTIDE EXCISION-REPAIR; CELL-CYCLE ARREST; XERODERMA-PIGMENTOSUM; MASTER REGULATOR; MELANOMA; MICROPHTHALMIA; MELANOCYTES; ACTIVATION; MYC; EXPRESSION	The melanocytic lineage, which is prominently exposed to ultraviolet radiation (UVR) and radiation-independent oxidative damage, requires specific DNA-damage response mechanisms to maintain genomic and transcriptional homeostasis. The coordinate lineage-specific regulation of intricately intertwined DNA repair and transcription is incompletely understood. Here we demonstrate that the Microphthalmia-associated transcription factor (MITF) directly controls general transcription and UVR-induced nucleotide excision repair by transactivation of GTF2H1 as a core element of TFIIH. Thus, MITF ensures the rapid resumption of transcription after completion of strand repair and maintains transcriptional output, which is indispensable for survival of the melanocytic lineage including melanoma in vitro and in vivo. Moreover, MITF controls c-MYC implicated in general transcription by transactivation of far upstream binding protein 2 (FUBP2/KSHRP), which induces c-MYC pulse regulation through TFIIH, and experimental depletion of MITF results in consecutive loss of CDK7 in the TFIIH-CAK subcomplex. Targeted for proteasomal degradation, CDK7 is dependent on transactivation by MITF or c-MYC to maintain a steady state. The dependence of TFIIH-CAK on sequence-specific MITF and c-MYC constitutes a previously unrecognized mechanism feeding into super-enhancer-driven or other oncogenic transcriptional circuitries, which supports the concept of a transcription-directed therapeutic intervention in melanoma.	[Seoane, Marcos; Buhs, Sophia; Iglesias, Pablo; Strauss, Julia; Puller, Ann-Christin; Mueller, Juergen; Gerull, Helwe; Sternsdorf, Thomas; Nollau, Peter; Horstmann, Martin A.] Childrens Canc Ctr Hamburg, Res Inst, D-20246 Hamburg, Germany; [Seoane, Marcos; Buhs, Sophia; Iglesias, Pablo; Strauss, Julia; Puller, Ann-Christin; Mueller, Juergen; Gerull, Helwe; Sternsdorf, Thomas; Nollau, Peter; Horstmann, Martin A.] Univ Med Ctr Hamburg, Dept Pediat Hematol & Oncol, D-20246 Hamburg, Germany; [Feldhaus, Susanne; Schumacher, Udo] Univ Med Ctr Hamburg, Inst Anat & Expt Morphol, D-20246 Hamburg, Germany; [Alawi, Malik] Univ Med Ctr Hamburg, Bioinformat Serv Facil, D-20246 Hamburg, Germany; [Alawi, Malik; Eggert, Dennis] Leibniz Inst Expt Virol, Heinrich Pette Inst, D-20251 Hamburg, Germany; [Brandner, Johanna M.] Univ Med Ctr Hamburg, Dept Dermatol, D-20246 Hamburg, Germany; [Eggert, Dennis] Max Planck Inst Struct & Dynam Matter, D-22761 Hamburg, Germany; [Du, Jinyan] Harvard Med Sch, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Thomale, Juergen] Univ Duisburg Essen, Inst Cell Biol, D-45122 Essen, Germany; [Wild, Peter J.] Univ Hosp Zurich, Inst Surg Pathol, CH-8091 Zurich, Switzerland; [Zimmermann, Martin] Med Sch Hannover, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany; [Fisher, David E.] Harvard Med Sch, Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Dept Dermatol, Boston, MA 02115 USA; [Du, Jinyan] Merrimack Pharmaceut, Cambridge, MA 02139 USA	University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf; Heinrich Pette Institute; University of Hamburg; University Medical Center Hamburg-Eppendorf; Max Planck Society; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Duisburg Essen; University of Zurich; University Zurich Hospital; Hannover Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Horstmann, MA (corresponding author), Childrens Canc Ctr Hamburg, Res Inst, D-20246 Hamburg, Germany.; Horstmann, MA (corresponding author), Univ Med Ctr Hamburg, Dept Pediat Hematol & Oncol, D-20246 Hamburg, Germany.	horstman@uke.de	Fisher, David/AAH-2878-2019; , Malik/AAB-7437-2021	, Malik/0000-0002-5993-7709; Iglesias Vazquez, Pablo/0000-0003-2506-5313; Wild, Peter Johannes/0000-0002-1017-3744	Deutsche Forschungsgemeinschaft (DFG) [Ho2176/3-1/2]; Fordergemeinschaft Kinderkrebs-Zentrum Hamburg; Rudiger Colditz Stiftung; NATIONAL CANCER INSTITUTE [R01CA222871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR043369] Funding Source: NIH RePORTER	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Fordergemeinschaft Kinderkrebs-Zentrum Hamburg; Rudiger Colditz Stiftung; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	Deutsche Forschungsgemeinschaft (DFG) grants to M.A.H. (Ho2176/3-1/2), Fordergemeinschaft Kinderkrebs-Zentrum Hamburg and the Rudiger Colditz Stiftung. We gratefully acknowledge help from members of the Grundhoff lab for technical support and members of the microscopy and imaging group, both at the Heinrich-Pette-Institute, Hamburg. We also thank Ewa Wladykowski, Christine Knies, and Tobias Gosau for technical assistance.	Anders S, 2015, BIOINFORMATICS, V31, P166, DOI 10.1093/bioinformatics/btu638; Beerens N, 2005, J BIOL CHEM, V280, P4722, DOI 10.1074/jbc.M409147200; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Bushnell DA, 1996, J BIOL CHEM, V271, P20170, DOI 10.1074/jbc.271.33.20170; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Chen J, 2003, NATURE, V424, P228, DOI 10.1038/nature01746; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; Coin F, 2008, MOL CELL, V31, P9, DOI 10.1016/j.molcel.2008.04.024; Compe E, 2012, NAT REV MOL CELL BIO, V13, P343, DOI 10.1038/nrm3350; Cui RT, 2007, CELL, V128, P853, DOI 10.1016/j.cell.2006.12.045; Davis IJ, 2006, CANCER CELL, V9, P473, DOI 10.1016/j.ccr.2006.04.021; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Development Core Team, 2013, R LANG ENV STAT COMP; DRAPKIN R, 1994, NATURE, V368, P769, DOI 10.1038/368769a0; Drapkin R, 1996, P NATL ACAD SCI USA, V93, P6488, DOI 10.1073/pnas.93.13.6488; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Eliades P, 2018, J INVEST DERMATOL, V138, P1582, DOI 10.1016/j.jid.2017.09.056; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; Ganuza M, 2012, EMBO J, V31, P2498, DOI 10.1038/emboj.2012.94; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Garrett S, 2001, MOL CELL BIOL, V21, P88, DOI 10.1128/MCB.21.1.88-99.2001; Gervais V, 2004, NAT STRUCT MOL BIOL, V11, P616, DOI 10.1038/nsmb782; Hachiya A, 2001, J INVEST DERMATOL, V116, P578, DOI 10.1046/j.1523-1747.2001.01290.x; Hanawalt PC, 2002, ONCOGENE, V21, P8949, DOI 10.1038/sj.onc.1206096; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Iben S, 2002, CELL, V109, P297, DOI 10.1016/S0092-8674(02)00729-8; James L, 2002, P NATL ACAD SCI USA, V99, P10429, DOI 10.1073/pnas.162369299; Jao CY, 2008, P NATL ACAD SCI USA, V105, P15779, DOI 10.1073/pnas.0808480105; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; King R, 1999, AM J PATHOL, V155, P731, DOI 10.1016/S0002-9440(10)65172-3; Kraemer KH, 2007, NEUROSCIENCE, V145, P1388, DOI 10.1016/j.neuroscience.2006.12.020; Kwiatkowski N, 2014, NATURE, V511, P616, DOI 10.1038/nature13393; Larochelle S, 2012, NAT STRUCT MOL BIOL, V19, P1108, DOI 10.1038/nsmb.2399; Levy C, 2006, TRENDS MOL MED, V12, P406, DOI 10.1016/j.molmed.2006.07.008; Liedert B, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl051; Limsirichaikul S, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp023; Liu JH, 2006, EMBO J, V25, P2119, DOI 10.1038/sj.emboj.7601101; Loercher AE, 2005, J CELL BIOL, V168, P35, DOI 10.1083/jcb.200410115; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Loven J, 2012, CELL, V151, P476, DOI 10.1016/j.cell.2012.10.012; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Miller AJ, 2004, CANCER RES, V64, P509, DOI 10.1158/0008-5472.CAN-03-2440; Muller J, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6712; Price ER, 1998, J BIOL CHEM, V273, P33042, DOI 10.1074/jbc.273.49.33042; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Singleton KR, 2017, CELL REP, V21, P2796, DOI 10.1016/j.celrep.2017.11.022; Steingrimsson E, 2004, ANNU REV GENET, V38, P365, DOI 10.1146/annurev.genet.38.072902.092717; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wellbrock C, 2015, PIGM CELL MELANOMA R, V28, P390, DOI 10.1111/pcmr.12370; Xia M, 2017, CELL REP, V20, P1794, DOI 10.1016/j.celrep.2017.07.056; Yokoi M, 2000, J BIOL CHEM, V275, P9870, DOI 10.1074/jbc.275.13.9870; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258; 2004, CANC CELL, V6, P565	57	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3616	3635		10.1038/s41388-018-0661-x	http://dx.doi.org/10.1038/s41388-018-0661-x			20	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30651597	Green Published, hybrid			2022-12-17	WOS:000467379600005
J	Yang, XY; Shen, H; Buckley, B; Chen, YM; Yang, N; Mussell, AL; Chernov, M; Kobzik, L; Frangou, C; Han, SX; Zhang, JM				Yang, Xinyuan; Shen, He; Buckley, Brian; Chen, Yanmin; Yang, Nuo; Mussell, Ashley L.; Chernov, Mikhail; Kobzik, Lester; Frangou, Costa; Han, Su-Xia; Zhang, Jianmin			NTRK1 is a positive regulator of YAP oncogenic function	ONCOGENE			English	Article							NERVE GROWTH-FACTOR; HIPPO PATHWAY; CANCER; PROLIFERATION; INHIBITORS; MOLECULE; COMPLEX; YAP/TAZ; CELLS	Multiple cancer signalling networks take part in regulatory crosstalks with the Hippo tumour suppressor pathway through the transcriptional cofactor Yes-associated protein (YAP). Nevertheless, how YAP is controlled by pathway crosstalks in tumourigenesis remains poorly understood. Here, we performed a targeted kinase inhibitor screen in human cancer cells to identify novel Hippo pathway regulators. Notably, we identified the nerve growth factor (NGF) receptor tyrosine kinase (NTRK1), a molecule not previously associated with Hippo signalling. NTRK1 inhibition decreased YAP-driven transcription, cancer cell proliferation and migration. Furthermore, using a complementary functional genomics approach and mouse xenograft models, we show that NTRK1 regulates YAP oncogenic activity in vivo. Mechanistically, NTRK1 inhibition was found to induce large suppressor kinase 1 (LATS1) phosphorylation and to control YAP subcellular localization. Taken together, these results provide compelling evidence of crosstalks between the NGF-NTRK1 and Hippo cancer pathways.	[Yang, Xinyuan; Han, Su-Xia] Xi An Jiao Tong Univ, Dept Oncol, Affiliated Hosp 1, Coll Med, Xian 710061, Shaanxi, Peoples R China; [Yang, Xinyuan; Shen, He; Chen, Yanmin; Mussell, Ashley L.; Zhang, Jianmin] Roswell Pk Canc Inst, Dept Canc Genet & Genom, Buffalo, NY 14263 USA; [Buckley, Brian; Chernov, Mikhail] Roswell Pk Canc Inst, Small Mol Core, Buffalo, NY 14263 USA; [Yang, Nuo] SUNY Buffalo, Dept Anesthesiol, Jacobs Sch Med & Biomed Sci, Buffalo, NY 14214 USA; [Kobzik, Lester; Frangou, Costa] Harvard TH Chan Sch Publ Hlth, Mol & Integrat Physiol Sci, 665 Huntington Ave, Boston, MA 02115 USA	Xi'an Jiaotong University; Roswell Park Cancer Institute; Roswell Park Cancer Institute; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; Harvard University; Harvard T.H. Chan School of Public Health	Han, SX (corresponding author), Xi An Jiao Tong Univ, Dept Oncol, Affiliated Hosp 1, Coll Med, Xian 710061, Shaanxi, Peoples R China.; Zhang, JM (corresponding author), Roswell Pk Canc Inst, Dept Canc Genet & Genom, Buffalo, NY 14263 USA.	shan87@mail.xjtu.edu.cn; Jianmin.zhang@roswellpark.org	Zhang, Jianmin/AAN-2931-2020	Han, Suxia/0000-0002-1513-7427	National Natural Science Foundation of China [81672921]; Innovation Capacity Support Plan of Shaanxi Province [2018TD-002]; Roswell Park Cancer Institute; National Cancer Institute (NCI) [P30 CA016056, R01 CA207]; Roswell Park Alliance Foundation; American Cancer Society [RSG-14-214-01-TBE]; NATIONAL CANCER INSTITUTE [P30CA016056, R01CA207504] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Capacity Support Plan of Shaanxi Province; Roswell Park Cancer Institute; National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Roswell Park Alliance Foundation; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr. Haber who kindly provided us 293AD cells and Dr. Camargo who kindly provided us the CTGF promoter luciferase reporter construct. Also, we thank the Small Molecule Screen, Flow and Image Cytometry, Laboratory Animal and Experimental Tumour Models Shared Resources/Facilities of RPCI. This work was supported by the National Natural Science Foundation of China 81672921; Innovation Capacity Support Plan of Shaanxi Province, Grant/Award Number: 2018TD-002 (to SH). This work was supported by the Roswell Park Cancer Institute and National Cancer Institute (NCI) Grant #P30 CA016056, Roswell Park Alliance Foundation, National Cancer Institute (NCI) R01 CA207504 and the American Cancer Society Research Scholar Grant RSG-14-214-01-TBE (to JZ).	Aloe L, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0395-y; Arash EH, 2017, EMBO REP, V18, P420, DOI 10.15252/embr.201642455; Arkin MR, 2004, NAT REV DRUG DISCOV, V3, P301, DOI 10.1038/nrd1343; Benito-Gutierrez E, 2006, MOL CELL NEUROSCI, V31, P179, DOI 10.1016/j.mcn.2005.09.007; Descamps S, 2001, CANCER RES, V61, P4337; Descamps S, 2001, J BIOL CHEM, V276, P17864, DOI 10.1074/jbc.M010499200; Fiore M, 2009, REV NEUROSCIENCE, V20, P133; Gibault F, 2017, CHEMMEDCHEM, V12, P954, DOI 10.1002/cmdc.201700063; Harvey K, 2007, NAT REV CANCER, V7, P182, DOI 10.1038/nrc2070; Harvey KF, 2013, NAT REV CANCER, V13, P246, DOI 10.1038/nrc3458; Johnson R, 2014, NAT REV DRUG DISCOV, V13, P63, DOI 10.1038/nrd4161; Lange AM, 2018, CANCERS, V10, DOI 10.3390/cancers10040105; Li YW, 2016, CELL CYCLE, V15, P2497, DOI 10.1080/15384101.2016.1207836; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Mello SS, 2017, CANCER CELL, V32, P460, DOI 10.1016/j.ccell.2017.09.007; Mohseni M, 2014, NAT CELL BIOL, V16, P108, DOI 10.1038/ncb2884; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; Niederhauser O, 2000, J NEUROSCI RES, V61, P263, DOI 10.1002/1097-4547(20000801)61:3<263::AID-JNR4>3.0.CO;2-M; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Song SM, 2018, MOL CANCER THER, V17, P443, DOI 10.1158/1535-7163.MCT-17-0560; Wilson KE, 2014, J BIOL CHEM, V289, P23693, DOI 10.1074/jbc.M113.534701; Yu FX, 2015, CELL, V163, P811, DOI 10.1016/j.cell.2015.10.044; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang JM, 2008, CANCER RES, V68, P2789, DOI 10.1158/0008-5472.CAN-07-6205; Zhang JM, 2009, NAT CELL BIOL, V11, P1444, DOI 10.1038/ncb1993; Zhang Y, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05856-2; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907	30	11	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 11	2019	38	15					2778	2787		10.1038/s41388-018-0609-1	http://dx.doi.org/10.1038/s41388-018-0609-1			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HS8LQ	30542115	Green Accepted			2022-12-17	WOS:000464121600008
J	Fan, ZY; Yang, J; Zhang, D; Zhang, XL; Ma, X; Kang, L; Liu, Y; Yan, X; Ji, QB; Wang, JL; Li, Y; Zhang, SJ; Zhu, X; Hu, Y; Xu, XJ; Ye, QN; Jiao, SC				Fan, Zhongyi; Yang, Jing; Zhang, Dong; Zhang, Xuelin; Ma, Xiaoyan; Kang, Lei; Liu, Ying; Yan, Xiang; Ji, Quanbo; Wang, Jinliang; Li, Ying; Zhang, Sujie; Zhu, Xiang; Hu, Yi; Xu, Xiaojie; Ye, Qinong; Jiao, Shunchang			The risk variant rs884225 within EGFR impairs miR-103a-3p's anti-tumourigenic function in non-small cell lung cancer	ONCOGENE			English	Article							GROWTH-FACTOR-RECEPTOR; TYROSINE KINASE INHIBITORS; GENE COPY NUMBER; AMERICAN SOCIETY; EXPRESSION; POLYMORPHISM; STATISTICS; MUTATIONS; PROLIFERATION; PROGRESSION	Epidermal growth factor receptor (EGFR) status is the major determinant of non-small cell lung cancer (NSCLC) therapy selection. Studies have hinted that EGFR antibodies or tyrosine kinase inhibitors were beneficial in patients with EGFR mutation-negative but EGFR-overexpressing of NSCLC. However, the mechanisms underlying EGFR amplification and overexpression in NSCLC remain largely unknown. Here, we report that rs884225, a single nucleotide polymorphism in the EGFR 3'-terminal untranslated region, was significantly associated with EGFR expression level and contributed to NSCLC susceptibility. Mechanistically, the rs884225 C allele enhanced EGFR expression by altering the miR-103a-3p binding site, thus impairing miR-103a-3p's anti-tumourigenic function. As a tumour suppressor gene, miR-103a-3p expression correlated with overall and recurrence-free survival in NSCLC patients. Furthermore, miR-103a-3p inhibited growth and metastasis via effects on the KRAS pathway and epithelial-to-mesenchymal transition in EGFR wild-type NSCLC cell lines, respectively, which substantially reduced EGFR expression and activity. Thus, rs884225 may be a biomarker for NSCLC susceptibility, and miR-103a-3p may be a potential therapeutic target in NSCLC.	[Fan, Zhongyi; Yan, Xiang; Ji, Quanbo; Wang, Jinliang; Li, Ying; Zhang, Sujie; Hu, Yi; Jiao, Shunchang] Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China; [Yang, Jing; Zhang, Dong] Peoples Liberat Army Gen Hosp, Dept Nanlou Oncol, Beijing, Peoples R China; [Zhang, Xuelin] Peoples Liberat Army Gen Hosp, Dept Nanlou Respirat, Beijing, Peoples R China; [Ma, Xiaoyan] Changchun Univ Chinese Med, Sch Chinese Med, Dept Cardiovasc Dis, Changchun, Jilin, Peoples R China; [Kang, Lei] Peking Univ, Dept Nucl Med, Hosp 1, Beijing, Peoples R China; [Liu, Ying] Peoples Liberat Army Gen Hosp, Dept Ophthalmol, Beijing, Peoples R China; [Zhu, Xiang; Xu, Xiaojie; Ye, Qinong] Beijing Inst Biotechnol, Dept Med Mol Biol, Beijing, Peoples R China	Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; Chinese People's Liberation Army General Hospital; Changchun University of Chinese Medicine; Peking University; Chinese People's Liberation Army General Hospital	Jiao, SC (corresponding author), Peoples Liberat Army Gen Hosp, Dept Oncol, Beijing, Peoples R China.; Xu, XJ; Ye, QN (corresponding author), Beijing Inst Biotechnol, Dept Med Mol Biol, Beijing, Peoples R China.	miraclexxj@126.com; yeqn66@yahoo.com; jiaosc301@163.com	yan, Xiang/ABI-1846-2020; wang, jinliang/AAA-2799-2021	yan, Xiang/0000-0002-3683-474X; wang, jinliang/0000-0001-6427-3487; Jiao, Shunchang/0000-0002-9120-5233; Kang, Lei/0000-0001-8729-4547	National Natural Science Foundation of China [81702936, 81672602, 81822037, 81472589, 81630067]; Scientific Research Project of Health Care [15BJZ43]; Natural Science Foundation of Beijing [7172199]; Logistics Scientific Research Project [BWS16J010]; Postdoctoral Science Foundation of China [2017M613389, 2018T111142, 2017T100809]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Scientific Research Project of Health Care; Natural Science Foundation of Beijing(Beijing Natural Science Foundation); Logistics Scientific Research Project; Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation)	This work was supported by the National Natural Science Foundation of China (81702936, 81672602, 81822037, 81472589 and 81630067), Scientific Research Project of Health Care (15BJZ43), the Natural Science Foundation of Beijing (7172199), Logistics Scientific Research Project (BWS16J010) and General Financial Grant from the Postdoctoral Science Foundation of China (2017M613389, 2018T111142 and 2017T100809). The PLA General Hospital and Beijing Institute of Biotechnology made equal contributions to this work.	Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Barlesi F, 2013, J CLIN ONCOL, V31, p486s; Baumgart A, 2010, CANCER RES, V70, P5368, DOI 10.1158/0008-5472.CAN-09-3763; Bradley JD, 2015, LANCET ONCOL, V16, P187, DOI 10.1016/S1470-2045(14)71207-0; Burstein HJ, 2017, J CLIN ONCOL, V35, P1341, DOI 10.1200/JCO.2016.71.5292; Cappuzzo F, 2010, LANCET ONCOL, V11, P521, DOI 10.1016/S1470-2045(10)70112-1; Cavalleri T, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0176680; Chang JTH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0168284; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Chiyomaru T, 2015, INT J ONCOL, V46, P487, DOI 10.3892/ijo.2014.2752; Chu HY, 2013, MUTAGENESIS, V28, P49, DOI 10.1093/mutage/ges051; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Datta D, 2003, CHEST, V123, P2096, DOI 10.1378/chest.123.6.2096; Duan L, 2003, J BIOL CHEM, V278, P28950, DOI 10.1074/jbc.M304474200; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Goldstraw P, 2011, LANCET, V378, P1727, DOI 10.1016/S0140-6736(10)62101-0; Grandis JR, 2004, PHARMACOL THERAPEUT, V102, P37, DOI 10.1016/j.pharmthera.2004.01.002; Hart S, 2004, CANCER RES, V64, P1943, DOI 10.1158/0008-5472.CAN-03-3720; Hirsch FR, 2005, J CLIN ONCOL, V23, P6838, DOI 10.1200/JCO.2005.01.2823; Izar B, 2014, J THORAC ONCOL, V9, P1363, DOI 10.1097/JTO.0000000000000266; Jiang XM, 2016, ONCOTARGET, V7, P36733, DOI 10.18632/oncotarget.9166; Jokinen E, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-612; Lee Y, 2012, CLIN CANCER RES, V18, P1760, DOI 10.1158/1078-0432.CCR-11-2582; Li YW, 2010, CANCER RES, V70, P1486, DOI 10.1158/0008-5472.CAN-09-2792; Liang JL, 2015, CELL PROLIFERAT, V48, P78, DOI 10.1111/cpr.12159; Lin YX, 2014, AM J CANCER RES, V4, P411; Liu WQ, 2005, CANCER RES, V65, P46; Liu XM, 2017, ONCOTARGET, V8, P50209, DOI 10.18632/oncotarget.16854; Merrick DT, 2006, CLIN CANCER RES, V12, P2281, DOI 10.1158/1078-0432.CCR-05-2291; Milas L, 2004, INT J RADIAT ONCOL, V58, P966, DOI 10.1016/j.ijrobp.2003.08.035; Morgillo F, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000060; Nomura M, 2007, PLOS MED, V4, P715, DOI 10.1371/journal.pmed.0040125; Ohe Y, 2008, CLIN CANCER RES, V14, P4206, DOI 10.1158/1078-0432.CCR-07-5143; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Patel JD, 2014, J CLIN ONCOL, V32, P129, DOI 10.1200/JCO.2013.53.7076; Pirker R, 2012, LANCET ONCOL, V13, P33, DOI 10.1016/S1470-2045(11)70318-7; Qin Q, 2016, J CELL MOL MED, V20, P1974, DOI 10.1111/jcmm.12889; Rizvi NA, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.tps8123; Ruan YF, 2016, SCI REP-UK, V6, DOI 10.1038/srep23368; RUSCH V, 1993, CANCER RES, V53, P2379; Santos GD, 2011, ANNU REV PATHOL-MECH, V6, P49, DOI 10.1146/annurev-pathol-011110-130206; Shelton JG, 2005, CELL CYCLE, V4, P822, DOI 10.4161/cc.4.6.1724; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; van Meerbeeck JP, 2011, LANCET, V378, P1741, DOI 10.1016/S0140-6736(11)60165-7; Wang F, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-90; Weber DG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0114483; Xu NQ, 2016, ONCOTARGET, V7, P3884, DOI 10.18632/oncotarget.6461; Yu MJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0677-9; Yuan ZQ, 2009, CANCER RES, V69, P7811, DOI 10.1158/0008-5472.CAN-09-0986; Zhong ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep30919; Zhou SJ, 2015, CELL PHYSIOL BIOCHEM, V36, P166, DOI 10.1159/000374061	52	11	11	2	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2291	2304		10.1038/s41388-018-0576-6	http://dx.doi.org/10.1038/s41388-018-0576-6			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30470824				2022-12-17	WOS:000462588000005
J	He, YF; Hooker, E; Yu, EJ; Cunha, GR; Liao, L; Xu, JM; Earl, A; Wu, HQ; Gonzalgo, ML; Sun, ZJ				He, Yongfeng; Hooker, Erika; Yu, Eun-Jeong; Cunha, Gerald R.; Liao, Lan; Xu, Jianming; Earl, Andrew; Wu, Huiqing; Gonzalgo, Michael L.; Sun, Zijie			Androgen signaling is essential for development of prostate cancer initiated from prostatic basal cells	ONCOGENE			English	Article							EPITHELIAL STEM-CELLS; BETA-CATENIN; MURINE PROSTATE; P53 HOMOLOG; RECEPTOR; ORIGIN; P63; REGENERATION; ACTIVATION; POLYPOSIS	Emerging evidence has shown that both prostatic basal and luminal cells are able to initiate oncogenic transformation. However, despite the diversity of tumor-initiating cells, most prostate cancer cells express the androgen receptor (AR) and depend on androgens for their growth and expansion, implicating an essential role of androgen signaling in prostate tumorigenesis. Prostatic basal cells express p63 and are able to differentiate into luminal, neuroendocrine, and basal cells. Here, we directly assessed the essential role of androgen signaling in prostatic p63-expressing cell initiated oncogenic transformation and tumor formation. Using novel and relevant mouse models, we demonstrated that, with stabilized beta-catenin expression, prostatic p63-expressing cells possess the ability to initiate oncogenic transformation and, in the presence of androgens, they further transdifferentiate into luminal-like tumor cells and develop adenocarcinomas. Castration prior to activating stabilized beta-catenin sensitizes p63-expressing cells and increases their sensitivity to androgens, resulting in aggressive and fast growing tumor phenotypes. These findings are consistent with what have been observed in human prostate cancers, demonstrating an essential role for androgen signaling in prostate cancer initiation and progression. This study also provides fresh insight into developing new therapeutic strategies for better treating prostate cancer patients.	[He, Yongfeng; Hooker, Erika; Yu, Eun-Jeong; Earl, Andrew; Sun, Zijie] Beckman Res Inst & Canc Ctr, Dept Canc Biol, Duarte, CA 91010 USA; [He, Yongfeng; Hooker, Erika; Yu, Eun-Jeong; Sun, Zijie] Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA; [Cunha, Gerald R.] Univ Calif San Francisco, Dept Urol, Sch Med, San Francisco, CA 94143 USA; [Liao, Lan; Xu, Jianming] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Wu, Huiqing] Beckman Res Inst & Canc Ctr, Dept Pathol, Duarte, CA 91010 USA; [Gonzalgo, Michael L.] Univ Miami, Dept Urol, Sylvester Comprehens Canc Ctr, Sch Med, Miami, FL 33136 USA	Stanford University; University of California System; University of California San Francisco; Baylor College of Medicine; University of Miami	Sun, ZJ (corresponding author), Beckman Res Inst & Canc Ctr, Dept Canc Biol, Duarte, CA 91010 USA.; Sun, ZJ (corresponding author), Stanford Univ, Sch Med, Dept Urol, Stanford, CA 94305 USA.	zjsun@coh.org	He, Yongfeng/AAR-8257-2020	Hooker, Erika/0000-0002-4515-4041; Earl, Andrew/0000-0002-5732-954X	NIH [R01CA070297, R01CA151623, R01CA166894, R21CA190021, R01DK104941, R01CA193455, R01CA112403]; NATIONAL CANCER INSTITUTE [R01CA151623, R01CA112403, R01CA193455, R01CA166894, R01CA070297, R21CA190021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK104941] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by NIH grants R01CA070297 (Z.S.), R01CA151623 (Z.S.), R01CA166894 (Z.S.), R21CA190021 (Z.S.), R01DK104941 (Z.S.), R01CA193455 (J.X.), and R01CA112403 (J.X.).	Balk SP, 2002, UROLOGY, V60, P132, DOI 10.1016/S0090-4295(02)01593-5; Beliakoff J, 2008, MOL CELL BIOL, V28, P282, DOI 10.1128/MCB.00771-07; Bierie B, 2003, ONCOGENE, V22, P3875, DOI 10.1038/sj.onc.1206426; Bruxvoort KJ, 2007, CANCER RES, V67, P2490, DOI 10.1158/0008-5472.CAN-06-3028; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Gelmann EP, 2002, J CLIN ONCOL, V20, P3001, DOI 10.1200/JCO.2002.10.018; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Harada N, 1999, EMBO J, V18, P5931, DOI 10.1093/emboj/18.21.5931; Ittmann M, 2013, CANCER RES, V73, P2718, DOI 10.1158/0008-5472.CAN-12-4213; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Lawson DA, 2007, J CLIN INVEST, V117, P2044, DOI 10.1172/JCI32810; Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107; Lee DK, 2014, INT J BIOL SCI, V10, P1007, DOI 10.7150/ijbs.9997; Lee SH, 2016, ONCOGENE, V35, P702, DOI 10.1038/onc.2015.117; Lee SH, 2015, STEM CELLS, V33, P3356, DOI 10.1002/stem.2096; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Murillo-Garzon V, 2017, NAT REV UROL, V14, P683, DOI 10.1038/nrurol.2017.144; Muzumdar MD, 2007, GENESIS, V45, P593, DOI 10.1002/dvg.20335; Peng Y, 2011, J BIOL CHEM, V286, P40331, DOI 10.1074/jbc.M111.302059; Pignon JC, 2013, P NATL ACAD SCI USA, V110, P8105, DOI 10.1073/pnas.1221216110; Placencio VR, 2008, CANCER RES, V68, P4709, DOI 10.1158/0008-5472.CAN-07-6289; Sartor O, 2002, UROLOGY, V60, P138; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; SUGIMURA Y, 1986, BIOL REPROD, V34, P973, DOI 10.1095/biolreprod34.5.973; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Truica CI, 2000, CANCER RES, V60, P4709; Truica CI, 2001, AACR ANN M P, V42, P693; Tsujimura A, 2002, J CELL BIOL, V157, P1257, DOI 10.1083/jcb.200202067; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Wang YZ, 2001, DIFFERENTIATION, V68, P270, DOI 10.1046/j.1432-0436.2001.680414.x; Wang ZA, 2011, ONCOGENE, V30, P1261, DOI 10.1038/onc.2010.530; Wang ZA, 2013, NAT CELL BIOL, V15, P274, DOI 10.1038/ncb2697; Weischenfeldt J, 2013, CANCER CELL, V23, P159, DOI 10.1016/j.ccr.2013.01.002; Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yu X, 2011, ONCOGENE, V30, P1868, DOI 10.1038/onc.2010.560; Zhu CF, 2011, J BIOL CHEM, V286, P33478, DOI 10.1074/jbc.M111.269894	46	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2337	2350		10.1038/s41388-018-0583-7	http://dx.doi.org/10.1038/s41388-018-0583-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30510232	Green Accepted, Green Submitted			2022-12-17	WOS:000462588000008
J	Guo, H; Zeng, DF; Zhang, H; Bell, T; Yao, J; Liu, Y; Huang, SJ; Li, CJ; Lorence, E; Zhou, SH; Gong, TJ; Jiang, CY; Ahmed, M; Yao, YX; Nomie, KJ; Zhang, L; Wang, M				Guo, Hui; Zeng, Dongfeng; Zhang, Hui; Bell, Taylor; Yao, Jun; Liu, Yang; Huang, Shengjian; Li, Carrie J.; Lorence, Elizabeth; Zhou, Shouhao; Gong, Tiejun; Jiang, Changying; Ahmed, Makhdum; Yao, Yixin; Nomie, Krystle J.; Zhang, Liang; Wang, Michael			( Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma )	ONCOGENE			English	Article							IBRUTINIB RESISTANCE; FOLLICULAR LYMPHOMA; DNA-DAMAGE; OPEN-LABEL; PHASE-I; IDELALISIB; CUDC-907; HDAC; APOPTOSIS; PATHWAY	The dysregulation of PI3K signaling has been implicated as an underlying mechanism associated with resistance to Bruton's tyrosine kinase inhibition by ibrutinib in both chronic lymphocytic leukemia and mantle cell lymphoma (MCL). Ibrutinib resistance has become a major unmet clinical need, and the development of therapeutics to overcome ibrutinib resistance will greatly improve the poor outcomes of ibrutinib-exposed MCL patients. CUDC-907 inhibits both PI3K and HDAC functionality to exert synergistic or additive effects. Therefore, the activity of CUDC-907 was examined in MCL cell lines and patient primary cells, including ibrutinib-resistant MCL cells. The efficacy of CUDC-907 was further examined in an ibrutinib-resistant MCL patient-derived xenograft (PDX) mouse model. The molecular mechanisms by which CUDC-907 dually inhibits PI3K and histone deacetylation were assessed using reverse protein array, immunoblotting, and chromatin immunoprecipitation (ChIP) coupled with sequencing. We showed evidence that CUDC-907 treatment increased histone acetylation in MCL cells. We found that CUDC-907 caused decreased proliferation and increased apoptosis in MCL in vitro and in vivo MCL models. In addition, CUDC-907 was effective in inducing lethality in ibrutinib-resistant MCL cells. Lastly, CUDC-907 treatment increased histone acetylation in MCL cells. Overall, these studies suggest that CUDC-907 may be a promising therapeutic option for relapsed or resistant MCL.	[Guo, Hui; Zeng, Dongfeng; Zhang, Hui; Bell, Taylor; Liu, Yang; Huang, Shengjian; Li, Carrie J.; Lorence, Elizabeth; Jiang, Changying; Ahmed, Makhdum; Yao, Yixin; Nomie, Krystle J.; Zhang, Liang; Wang, Michael] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Zeng, Dongfeng] Third Mil Med Univ, Xinqiao Hosp, Dept Hematol, Chongqing 430000, Peoples R China; [Yao, Jun] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Zhou, Shouhao] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA; [Gong, Tiejun] First Hosp Harbin, Inst Hematol & Oncol, Harbin 150010, Heilongjiang, Peoples R China; [Wang, Michael] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Army Medical University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Wang, M (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA.; Wang, M (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.	miwang@mdanderson.org	Jiang, Changying/AAL-3711-2020	Yao, Yixin/0000-0002-8439-6043; Jiang, Changying/0000-0003-3778-4438; dongfeng, zeng/0000-0002-0460-7593; Guo, Hui/0000-0003-3901-6336	NIH [P30 CA016672, R21 CA202104]; Gary Rogers Foundation; Kinder Foundation; Pharmacyclics, an AbbVie Company; NCI [CA016672]; NATIONAL CANCER INSTITUTE [P30CA016672, R21CA202104] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Gary Rogers Foundation; Kinder Foundation; Pharmacyclics, an AbbVie Company; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the NIH-funded Cancer Center Support Grant (CCSG) P30 CA016672 and the R21 CA202104 (Michael Wang, PI). This study was also partially supported by the generous philanthropic support to the MD Anderson B Cell Lymphoma Moon Shot Project and philanthropy funds from The Gary Rogers Foundation and the Kinder Foundation. Pharmacyclics, an AbbVie Company, also provided funds for this laboratory work. The reagent CUDC-907 was provided by Curis, Inc. The laboratory research was not supported by Curis, Inc. Ibrutinib was provided by Pharmacyclics, an AbbVie Company. Cell line authentication was performed by the MD Anderson Cancer Center Characterized Cell Line Core Facility, funded by grant NCI # CA016672.	Ahn IE, 2017, BLOOD, V129, P1469, DOI 10.1182/blood-2016-06-719294; Ali D, 2017, STEM CELLS DEV, V26, P353, DOI 10.1089/scd.2016.0183; Bolden JE, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.9; Cheah CY, 2016, J CLIN ONCOL, V34, P1256, DOI 10.1200/JCO.2015.63.5904; Cheah CY, 2015, BLOOD, V125, P3357, DOI 10.1182/blood-2015-03-633156; Cheng S, 2015, LEUKEMIA, V29, P895, DOI 10.1038/leu.2014.263; Chiron D, 2014, CANCER DISCOV, V4, P1022, DOI 10.1158/2159-8290.CD-14-0098; Dreyling M, 2016, LANCET, V387, P770, DOI 10.1016/S0140-6736(15)00667-4; Dudakovic A, 2013, J BIOL CHEM, V288, P28783, DOI 10.1074/jbc.M113.489732; Ghosh K, 2018, J DERMATOL SCI, V89, P226, DOI 10.1016/j.jdermsci.2017.12.006; Giles F, 2006, CLIN CANCER RES, V12, P4628, DOI 10.1158/1078-0432.CCR-06-0511; Gopal AK, 2017, BLOOD, V129, P3037, DOI 10.1182/blood-2016-12-757740; Gopal AK, 2014, NEW ENGL J MED, V370, P1008, DOI 10.1056/NEJMoa1314583; Goy A, 2016, HEMATOL ONCOL CLIN N, V30, P1345, DOI 10.1016/j.hoc.2016.07.014; Graf SA, 2016, EXPERT OPIN PHARMACO, V17, P265, DOI 10.1517/14656566.2016.1135130; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; Lee EJ, 2011, BIOCHEM BIOPH RES CO, V414, P384, DOI 10.1016/j.bbrc.2011.09.083; Lee JH, 2010, P NATL ACAD SCI USA, V107, P14639, DOI 10.1073/pnas.1008522107; Lemoine M, 2010, DISCOV MED, V10, P462; Lim HJ, 2016, ANTICANCER RES, V36, P5765, DOI 10.21873/anticanres.11160; Martin P, 2016, LANCET, V388, P535, DOI 10.1016/S0140-6736(16)30451-2; Martin P, 2016, LANCET, V387, P728, DOI 10.1016/S0140-6736(15)01040-5; Medina DJ, 2012, HAEMATOL-HEMATOL J, V97, P1255, DOI 10.3324/haematol.2011.040659; Oki Y, 2017, HAEMATOLOGICA, V102, P1923, DOI 10.3324/haematol.2017.172882; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Qian DZ, 2006, CLIN CANCER RES, V12, P634, DOI 10.1158/1078-0432.CCR-05-1132; Rahal R, 2014, NAT MED, V20, P87, DOI 10.1038/nm.3435; Rahmani M, 2009, BLOOD, V114, P4507, DOI 10.1182/blood-2008-09-177881; Salles G, 2017, HAEMATOLOGICA, V102, pE156, DOI 10.3324/haematol.2016.151738; Scuto A, 2008, BLOOD, V111, P5093, DOI 10.1182/blood-2007-10-117762; Sun KM, 2017, MOL CANCER THER, V16, P285, DOI 10.1158/1535-7163.MCT-16-0390; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang CH, 2014, FEBS LETT, V588, P4654, DOI 10.1016/j.febslet.2014.10.037; Woyach JA, 2017, J CLIN ONCOL, V35, P1437, DOI 10.1200/JCO.2016.70.2282; Yoshioka T, 2013, GYNECOL ONCOL, V129, P425, DOI 10.1016/j.ygyno.2013.02.008; Younes A, 2016, LANCET ONCOL, V17, P622, DOI 10.1016/S1470-2045(15)00584-7; Zhang L, 2017, CLIN CANCER RES, V23, P4212, DOI 10.1158/1078-0432.CCR-16-2703; Zhang XC, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-168; Zhao XH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14920	39	11	11	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1802	1814		10.1038/s41388-018-0550-3	http://dx.doi.org/10.1038/s41388-018-0550-3			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30361685				2022-12-17	WOS:000461164400002
J	Zhang, BY; Lyu, JF; Liu, YF; Wu, CJ; Yang, EJ; Pardeshi, L; Tan, KL; Wong, KH; Chen, Q; Xu, XL; Deng, CX; Shim, JS				Zhang, Baoyuan; Lyu, Junfang; Liu, Yifan; Wu, Changjie; Yang, Eun Ju; Pardeshi, Lakhansing; Tan, Kaeling; Wong, Koon Ho; Chen, Qiang; Xu, Xiaoling; Deng, Chu-Xia; Shim, Joong Sup			BRCA1 deficiency sensitizes breast cancer cells to bromodomain and extra-terminal domain (BET) inhibition	ONCOGENE			English	Article							THIOREDOXIN-INTERACTING PROTEIN; UP-REGULATED PROTEIN-1; DNA-DAMAGE; CYCLE; GENE; MYC; SUPPRESSION; EXPRESSION; RESISTANCE; APOPTOSIS	BRCA1 is a tumor suppressor frequently mutated in breast and ovarian cancer, serving it as a target for therapeutic exploitation. Here, we show that BRCA1 has a synthetic lethality interaction with an epigenetics regulator, bromodomain and extra-terminal domain (BET). BET inhibition led to gene expression changes reversing MYC-dependent transcription repression of a redox regulator, thioredoxin-interacting protein (TXNIP), via switching the promoter occupant from MYC to MondoA:MLX complex. Reversing the MYC-TXNIP axis inhibited thioredoxin activity and elevated cellular oxidative stress, causing DNA damages that are detrimental to BRCA1-deficient breast cancer cells. Tumor xenograft models and breast cancer clinical data analyses further demonstrated an in vivo synthetic lethality interaction and clinical association between BET/TXNIP and BRCA1 deficiency in the survival of breast cancer patients.	[Zhang, Baoyuan; Lyu, Junfang; Liu, Yifan; Wu, Changjie; Yang, Eun Ju; Pardeshi, Lakhansing; Tan, Kaeling; Wong, Koon Ho; Chen, Qiang; Xu, Xiaoling; Deng, Chu-Xia; Shim, Joong Sup] Univ Macau, Fac Hlth Sci, Ave Univ, Taipa 999078, Macau, Peoples R China	University of Macau	Shim, JS (corresponding author), Univ Macau, Fac Hlth Sci, Ave Univ, Taipa 999078, Macau, Peoples R China.	jsshim@umac.mo	Wong, Koon Ho/P-3685-2018; wong, chris/GSN-0962-2022; Wong, Koon/AAH-3021-2020; LIU, Yifan/AAV-1994-2020	Wong, Koon Ho/0000-0002-9264-5118; Wong, Koon/0000-0002-9264-5118; Pardeshi, Lakhansing/0000-0003-0702-5465; Tan, Kaeling/0000-0002-3347-7628	Multi-Year Research Grant of the University of Macau [MYRG2015-00181-FHS, MYRG2017-00176-FHS]; Science and Technology Development Fund (FDCT) of Macau SAR [FDCT/024/2015/A1]	Multi-Year Research Grant of the University of Macau; Science and Technology Development Fund (FDCT) of Macau SAR	We thank to the members of the Genomics and Bioinformatics Core of FHS at UM for experimental and technical supports for the RNA-sequencing and data analyses and to Jacky Chan and William Pang from ICTO at UM for supporting the High Performance Computing cluster. We are also grateful to the members of FHS Animal Facility at UM for arranging and maintaining experimental animals for this study. This work was supported by the Multi-Year Research Grant of the University of Macau (MYRG2015-00181-FHS and MYRG2017-00176-FHS to J.S.S) and the Science and Technology Development Fund (FDCT) of Macau SAR (FDCT/024/2015/A1 to J.S.S).	Bae I, 2004, CANCER RES, V64, P7893, DOI 10.1158/0008-5472.CAN-04-1119; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bruna A, 2016, CELL, V167, P260, DOI 10.1016/j.cell.2016.08.041; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Cadenas C, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2599; CHEN KS, 1994, BBA-GENE STRUCT EXPR, V1219, P26, DOI 10.1016/0167-4781(94)90242-9; Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Deng CX, 2006, NUCLEIC ACIDS RES, V34, P1416, DOI 10.1093/nar/gkl010; Deng CX, 2000, BIOESSAYS, V22, P728; Fabregat A, 2016, NUCLEIC ACIDS RES, V44, pD481, DOI 10.1093/nar/gkv1351; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Fujisawa T, 2017, NAT REV MOL CELL BIO, V18, P246, DOI 10.1038/nrm.2016.143; Gorrini C, 2013, J EXP MED, V210, P1529, DOI 10.1084/jem.20121337; Greenup R, 2013, ANN SURG ONCOL, V20, P3254, DOI 10.1245/s10434-013-3205-1; Jeon JH, 2005, CANCER RES, V65, P4485, DOI 10.1158/0008-5472.CAN-04-2271; Jin HO, 2011, ONCOGENE, V30, P3792, DOI 10.1038/onc.2011.102; Junn E, 2000, J IMMUNOL, V164, P6287, DOI 10.4049/jimmunol.164.12.6287; Kalinin A, 2001, J CELL SCI, V114, P3069; Karakashev S, 2017, CELL REP, V21, P3398, DOI 10.1016/j.celrep.2017.11.095; Ladurner AG, 2003, MOL CELL, V11, P365, DOI 10.1016/S1097-2765(03)00035-2; Leroy G, 2008, MOL CELL, V30, P51, DOI 10.1016/j.molcel.2008.01.018; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Morrison JA, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-62; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Nishiyama A, 1999, J BIOL CHEM, V274, P21645, DOI 10.1074/jbc.274.31.21645; Nishizawa K, 2011, CARCINOGENESIS, V32, P1459, DOI 10.1093/carcin/bgr137; O'Shea JM, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014258; Olive PL, 2006, NAT PROTOC, V1, P23, DOI 10.1038/nprot.2006.5; Patwari P, 2006, J BIOL CHEM, V281, P21884, DOI 10.1074/jbc.M600427200; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Schafer M, 2011, J INVEST DERMATOL, V131, P1409, DOI 10.1038/jid.2011.119; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Shen LL, 2015, P NATL ACAD SCI USA, V112, P5425, DOI 10.1073/pnas.1501555112; Shibanuma M, 2011, FREE RADICAL RES, V45, P672, DOI 10.3109/10715762.2011.564169; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Sun CY, 2018, CANCER CELL, V33, P401, DOI 10.1016/j.ccell.2018.01.019; Tome ME, 2005, BLOOD, V106, P3594, DOI 10.1182/blood-2005-02-0487; Tomlinson GE, 1998, CANCER RES, V58, P3237; Tonissen KF, 2009, MOL NUTR FOOD RES, V53, P87, DOI 10.1002/mnfr.200700492; Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016; Vazquez-Ortiz G, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3682; Vermeij WP, 2011, J INVEST DERMATOL, V131, P1435, DOI 10.1038/jid.2010.433; Wilde BR, 2015, BRIT J CANCER, V113, P1529, DOI 10.1038/bjc.2015.360; Woolston CM, 2013, REDOX BIOL, V1, P285, DOI 10.1016/j.redox.2013.04.006; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yang L, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal1645; Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983	54	11	11	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2018	37	49					6341	6356		10.1038/s41388-018-0408-8	http://dx.doi.org/10.1038/s41388-018-0408-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HD3AP	30042414				2022-12-17	WOS:000452384400005
J	Dhar, SK; Bakthavatchalu, V; Dhar, B; Chen, J; Tadahide, I; Zhu, HN; Gao, TY; St Clair, DK				Dhar, Sanjit K.; Bakthavatchalu, Vasudevan; Dhar, Bithika; Chen, Jing; Tadahide, Izumi; Zhu, Haining; Gao, Tianyan; St Clair, Daret K.			DNA polymerase gamma (Pol gamma) deficiency triggers a selective mTORC2 prosurvival autophagy response via mitochondria-mediated ROS signaling	ONCOGENE			English	Article							MANGANESE SUPEROXIDE-DISMUTASE; KAPPA-B; SURVIVAL; IDENTIFICATION; TUMORIGENESIS; MECHANISMS; PROTEIN; DAMAGE; CELLS	Autophagy is a highly regulated evolutionarily conserved metabolic process induced by stress and energy deprivation. Here, we show that DNA polymerase gamma (Pol gamma) deficiency activates a selective prosurvival autophagic response via mitochondria-mediated reactive oxygen species (ROS) signaling and the mammalian target of rapamycin complex 2 (mTORC2) activities. In keratinocytes, Pol gamma deficiency causes metabolic adaptation that triggers cytosolic sensing of energy demand for survival. Knockdown of Pol gamma causes mitochondrial stress, decreases mitochondrial energy production, increases glycolysis, increases the expression of autophagy-associated genes, and enhances AKT phosphorylation and cell proliferation. Deficiency of Pol gamma preferentially activates mTORC2 formation to increase autophagy and cell proliferation, and knocking down Rictor abrogates these responses. Overexpression of Rictor, but not Raptor, reactivates autophagy in Pol gamma-deficient cells. Importantly, inhibition of ROS by a mitochondria-selective ROS scavenger abolishes autophagy and cell proliferation. These results identify Rictor as a critical link between mitochondrial stress, ROS, and autophagy. They represent a major shift in our understanding of the prosurvival role of the mTOR complexes and highlight mitochondria-mediated ROS as a prosurvival autophagy regulator during cancer development.	[Dhar, Sanjit K.; Dhar, Bithika; Tadahide, Izumi; St Clair, Daret K.] Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA; [Bakthavatchalu, Vasudevan] MIT, Div Comparat Med, Cambridge, MA 02139 USA; [Chen, Jing; Zhu, Haining; Gao, Tianyan] Univ Kentucky, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA	University of Kentucky; Massachusetts Institute of Technology (MIT); University of Kentucky	St Clair, DK (corresponding author), Univ Kentucky, Dept Toxicol & Canc Biol, Lexington, KY 40536 USA.	dstcl00@uky.edu	Zhu, Haining/A-6076-2008	Zhu, Haining/0000-0001-5498-6694	National Institutes of Health [CA 49797, CA 73599]; NCI Cancer Center Support Grant [P30 CA177558]; NATIONAL CANCER INSTITUTE [R01CA214638, P30CA177558, R01CA073599, R01CA049797, R01CA133429] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported, in part, by National Institutes of Health Grants CA 49797 and CA 73599 to Daret K. St. Clair, and the NCI Cancer Center Support Grant P30 CA177558 to B. Mark Evers.	Abada A, 2014, EMBO REP, V15, P839, DOI 10.15252/embr.201439076; Alvarez B, 2003, AMINO ACIDS, V25, P295, DOI 10.1007/s00726-003-0018-8; Aoki H, 2008, AUTOPHAGY, V4, P467, DOI 10.4161/auto.5668; Bakthavatchalu V, 2012, ONCOGENE, V31, P2129, DOI 10.1038/onc.2011.407; Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; BOLDEN A, 1977, J BIOL CHEM, V252, P3351; Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788; Copeland William C, 2003, ScientificWorldJournal, V3, P34; Dangi A, 2016, J CELL PHYSIOL, V231, P94, DOI 10.1002/jcp.25055; Dhar SK, 2010, J BIOL CHEM, V285, P9835, DOI 10.1074/jbc.M109.060715; Dhar SK, 2014, ANTIOXID REDOX SIGN, V20, P1550, DOI 10.1089/ars.2012.4984; Dhar SK, 2004, J BIOL CHEM, V279, P28209, DOI 10.1074/jbc.M403553200; Doria A, 2013, NEW ENGL J MED, V368, P1845, DOI [10.1056/NEJMra1205406, 10.1056/NEJMc1303158]; Duan HY, 2015, EXP CELL RES, V335, P99, DOI 10.1016/j.yexcr.2015.05.003; Fan QW, 2011, AUTOPHAGY, V7, P536, DOI 10.4161/auto.7.5.14779; Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392; Hance N, 2005, HUM MOL GENET, V14, P1775, DOI 10.1093/hmg/ddi184; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; He CC, 2009, ANNU REV GENET, V43, P67, DOI 10.1146/annurev-genet-102808-114910; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P2316, DOI 10.1073/pnas.76.5.2316; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455; Kovalenko O.A., 2009, CURR PROTOC HUM GENE, V62; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Longley Matthew J, 2002, Methods Mol Biol, V197, P245, DOI 10.1385/1-59259-284-8:245; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; MacMillan-Crow LA, 1999, ARCH BIOCHEM BIOPHYS, V366, P82, DOI 10.1006/abbi.1999.1202; Maglio DHG, 2005, PHOTODERMATOL PHOTO, V21, P311, DOI 10.1111/j.1600-0781.2005.00185.x; Matsuda-Lennikov M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0079795; Matsuzawa Y, 2015, AUTOPHAGY, V11, P1052, DOI 10.1080/15548627.2015.1055439; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Petersson AS, 2001, J MASS SPECTROM, V36, P616, DOI 10.1002/jms.161; Pua HH, 2009, J IMMUNOL, V182, P4046, DOI 10.4049/jimmunol.0801143; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rodriguez-Rocha H, 2011, MUTAT RES-FUND MOL M, V711, P158, DOI 10.1016/j.mrfmmm.2011.03.007; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; Szczesny B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075201; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606; Wang P, 2013, MOL CELL BIOCHEM, V372, P161, DOI 10.1007/s11010-012-1457-x; Wang RC, 2012, SCIENCE, V338, P956, DOI 10.1126/science.1225967; Wu SY, 2010, PHOTOCHEM PHOTOBIOL, V86, P389, DOI 10.1111/j.1751-1097.2009.00682.x	46	11	11	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 29	2018	37	48					6225	6242		10.1038/s41388-018-0404-z	http://dx.doi.org/10.1038/s41388-018-0404-z			18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC2HE	30038268	hybrid, Green Accepted, Green Published			2022-12-17	WOS:000451622100003
J	Serandour, AA; Mohammed, H; Miremadi, A; Mulder, KW; Carroll, JS				Serandour, A. A.; Mohammed, H.; Miremadi, A.; Mulder, K. W.; Carroll, J. S.			TRPS1 regulates oestrogen receptor binding and histone acetylation at enhancers	ONCOGENE			English	Article							BREAST-CANCER; THERAPY; FOXA1; TRANSCRIPTION; INTEGRATION; INHIBITORS; COMPLEXES; PROTEINS; REVEALS; TARGET	The chromatin state is finely tuned to regulate function and specificity for transcription factors such as oestrogen receptor alpha (ER), which contributes to cell growth in breast cancer. ER transcriptional potential is mediated, in large part, by the specific associated proteins and co-factors that interact with it. Despite the identification and characterisation of several ER coregulators, a complete and systematic view of ER-regulating chromatin modifiers is lacking. By exploiting a focused siRNA screen that investigated the requirement for a library of 330 chromatin regulators in ER-mediated cell growth, we find that the NuRD and coREST histone deacetylation complexes are critical for breast cancer cell proliferation. Further, by proteomic and genomics approaches, we discover the transcription factor TRPS1 to be a key interactor of the NuRD and coREST complexes. Interestingly, TRPS1 gene amplification occurs in 28% of human breast tumours and is associated with poor prognosis. We propose that TRPS1 is required to repress spurious binding of ER, where it contributes to the removal of histone acetylation. Our data suggest that TRPS1 is an important ER-associated transcriptional repressor that regulates cell proliferation, chromatin acetylation and ER binding at the chromatin of cis-regulatory elements.	[Serandour, A. A.; Mohammed, H.; Miremadi, A.; Mulder, K. W.; Carroll, J. S.] Univ Cambridge, Cambridge Inst, Canc Res UK, Robinson Way, Cambridge CB2 0RE, England; [Serandour, A. A.] Univ Nantes, CRCINA, INSERM, CNRS,Univ Angers, Nantes, France; [Serandour, A. A.] Ecole Cent Nantes, Nantes, France; [Mohammed, H.] Oregon Hlth & Sci Univ, Knight Canc Early Detect Adv Res Ctr, Portland, OR 97201 USA; [Mulder, K. W.] Radboud Univ Nijmegen, Fac Sci, Radboud Inst Mol Life Sci, Dept Mol Dev Biol, Nijmegen, Netherlands	Cancer Research UK; CRUK Cambridge Institute; University of Cambridge; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Nantes Universite; Universite d'Angers; Nantes Universite; Ecole Centrale de Nantes; Oregon Health & Science University; Radboud University Nijmegen	Mulder, KW; Carroll, JS (corresponding author), Univ Cambridge, Cambridge Inst, Canc Res UK, Robinson Way, Cambridge CB2 0RE, England.; Mulder, KW (corresponding author), Radboud Univ Nijmegen, Fac Sci, Radboud Inst Mol Life Sci, Dept Mol Dev Biol, Nijmegen, Netherlands.	k.mulder@science.ru.nl; jason.carroll@cruk.cam.ac.uk	Serandour, Aurelien/AAG-7036-2019	Serandour, Aurelien/0000-0001-5253-9567; Carroll, Jason/0000-0003-3643-0080	ERC; Komen Scholar Award; University of Cambridge; Cancer Research UK; Hutchison Whampoa Limited	ERC(European Research Council (ERC)European Commission); Komen Scholar Award; University of Cambridge(University of Cambridge); Cancer Research UK(Cancer Research UK); Hutchison Whampoa Limited	We would like to thank Clive D'Santos and Chris Taylor from the CRUK CI Proteomics core, James Hadfield and the other members of the Genomics core, and Suraj Menon from the Bioinformatics core. Jason Carroll is supported by an ERC Consolidator grant and a Komen Scholar Award. We would like to acknowledge the support of the University of Cambridge, Cancer Research UK and Hutchison Whampoa Limited.	Alluri PG, 2014, CELL RES, V24, P899, DOI 10.1038/cr.2014.90; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; Cerase A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0733-y; Chen Jie Qing, 2011, Hormones & Cancer, V2, P132, DOI 10.1007/s12672-011-0067-5; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013; DiRenzo J, 2000, MOL CELL BIOL, V20, P7541, DOI 10.1128/MCB.20.20.7541-7549.2000; Eeckhoute J, 2007, CANCER RES, V67, P6477, DOI 10.1158/0008-5472.CAN-07-0746; Fortunati N, 2010, MOL CELL ENDOCRINOL, V314, P17, DOI 10.1016/j.mce.2009.09.011; Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751; Hohmann AF, 2014, TRENDS GENET, V30, P356, DOI 10.1016/j.tig.2014.05.001; Hurtado A, 2011, NAT GENET, V43, P27, DOI 10.1038/ng.730; Johnston SRD, 2003, NAT REV CANCER, V3, P821, DOI 10.1038/nrc1211; Jozwik KM, 2016, CELL REP, V17, P2715, DOI 10.1016/j.celrep.2016.11.028; Jozwik KM, 2012, NAT REV CANCER, V12, P381, DOI 10.1038/nrc3263; Kawai H, 2002, ONCOGENE, V21, P7730, DOI 10.1038/sj.onc.1205971; Kurihara I, 2007, PLOS GENET, V3, P1053, DOI 10.1371/journal.pgen.0030102; Ladd B, 2016, ONCOTARGET, V7, P54120, DOI 10.18632/oncotarget.10852; Mohammed H, 2016, NAT PROTOC, V11, P316, DOI 10.1038/nprot.2016.020; Mohammed H, 2013, CELL REP, V3, P342, DOI 10.1016/j.celrep.2013.01.010; Mulder KW, 2012, NAT CELL BIOL, V14, P753, DOI 10.1038/ncb2520; Nagarajan S, 2014, CELL REP, V8, P459, DOI 10.1016/j.celrep.2014.06.016; Perdomo J, 2002, EUR J BIOCHEM, V269, P5885, DOI 10.1046/j.1432-1033.2002.03313.x; Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736; Plass C, 2013, NAT REV GENET, V14, P765, DOI 10.1038/nrg3554; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Ross-Innes CS, 2012, NATURE, V481, P389, DOI 10.1038/nature10730; Ross-Innes CS, 2010, GENE DEV, V24, P171, DOI 10.1101/gad.552910; Sanchez-Garcia F, 2014, CELL, V159, P1461, DOI 10.1016/j.cell.2014.10.048; Schmidt D, 2009, METHODS, V48, P240, DOI 10.1016/j.ymeth.2009.03.001; Serandour AA, 2011, GENOME RES, V21, P555, DOI 10.1101/gr.111534.110; Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508; Theodorou V, 2013, GENOME RES, V23, P12, DOI 10.1101/gr.139469.112; Thomas C, 2015, TRENDS ENDOCRIN MET, V26, P453, DOI 10.1016/j.tem.2015.08.002; Thomas C, 2011, NAT REV CANCER, V11, P597, DOI 10.1038/nrc3093; Toska E, 2017, SCIENCE, V355, P1324, DOI 10.1126/science.aah6893; Wang S, 2013, NAT PROTOC, V8, P2502, DOI 10.1038/nprot.2013.150; Wu LL, 2014, ONCOTARGET, V5, P7677, DOI 10.18632/oncotarget.2291; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	39	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 27	2018	37	39					5281	5291		10.1038/s41388-018-0312-2	http://dx.doi.org/10.1038/s41388-018-0312-2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV0NW	29895970	Green Submitted, Green Accepted			2022-12-17	WOS:000445759700003
J	Vorhagen, S; Kleefisch, D; Persa, OD; Graband, A; Schwickert, A; Saynisch, M; Leitges, M; Niessen, CM; Iden, S				Vorhagen, Susanne; Kleefisch, Dominik; Persa, Oana-Diana; Graband, Annika; Schwickert, Alexandra; Saynisch, Michael; Leitges, Michael; Niessen, Carien M.; Iden, Sandra			Shared and independent functions of aPKC lambda and Par3 in skin tumorigenesis	ONCOGENE			English	Article							POLARITY PROTEIN PAR3; NF-KAPPA-B; CELL POLARITY; EPIDERMAL HOMEOSTASIS; BREAST-CANCER; CARCINOGENESIS; STAT3; DIFFERENTIATION; COMPLEX; TUMORS	The polarity proteins Par3 and aPKC are key regulators of processes altered in cancer. Par3/aPKC are thought to dynamically interact with Par6 but increasing evidence suggests that aPKC and Par3 also exert complex-independent functions. Whereas aPKC. serves as tumor promotor, Par3 can either promote or suppress tumorigenesis. Here we asked whether and how Par3 and aPKC lambda genetically interact to control two-stage skin carcinogenesis. Epidermal loss of Par3, aPKC lambda, or both, strongly reduced tumor multiplicity and increased latency but inhibited invasion to similar extents, indicating that Par3 and aPKC lambda function as a complex to promote tumorigenesis. Molecularly, Par3/aPKC lambda cooperate to promote Akt, ERK and NF-kappa B signaling during tumor initiation to sustain growth, whereas aPKC lambda dominates in promoting survival. In the inflammatory tumorigenesis phase Par3/aPKC lambda cooperate to drive Stat3 activation and hyperproliferation. Unexpectedly, the reduced inflammatory signaling did not alter carcinogen-induced immune cell numbers but reduced IL-4 Receptor-positive stromal macrophage numbers in all mutant mice, suggesting that epidermal aPKC lambda and Par3 promote a tumor-permissive environment. Importantly, aPKC lambda also serves a distinct, carcinogen-independent role in controlling skin immune cell homeostasis. Collectively, our data demonstrates that Par3 and aPKC lambda cooperate to promote skin tumor initiation and progression, likely through sustaining growth, survival, and inflammatory signaling.	[Vorhagen, Susanne; Persa, Oana-Diana; Schwickert, Alexandra; Niessen, Carien M.] Univ Cologne, Dept Dermatol, Cologne, Germany; [Vorhagen, Susanne; Kleefisch, Dominik; Persa, Oana-Diana; Graband, Annika; Schwickert, Alexandra; Saynisch, Michael; Niessen, Carien M.; Iden, Sandra] Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany; [Vorhagen, Susanne; Kleefisch, Dominik; Graband, Annika; Schwickert, Alexandra; Saynisch, Michael; Niessen, Carien M.; Iden, Sandra] Univ Cologne, CMMC, Cologne, Germany; [Leitges, Michael] Univ Oslo, Biotechnol Ctr Oslo, N-0316 Oslo, Norway	University of Cologne; University of Cologne; University of Cologne; University of Oslo	Niessen, CM (corresponding author), Univ Cologne, Dept Dermatol, Cologne, Germany.; Niessen, CM; Iden, S (corresponding author), Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany.; Niessen, CM; Iden, S (corresponding author), Univ Cologne, CMMC, Cologne, Germany.	carien.niessen@uni-koeln.de; sandra.iden@uk-koeln.de	Leitges, Michael/AAN-1953-2021; Iden, Sandra/ABB-2698-2021	Iden, Sandra/0000-0003-2333-9827; Niessen, Carien M./0000-0002-4892-9391; Leitges, Michael/0000-0003-4203-6995	joint German Research Foundation (DFG) grant [NIE-1234/4-1, ID79/1-1]; Koln Fortune grant [197/2013]; DFG [ID79/2-1, CRC829/A10, CRC829/A01 + A05, NIE-1234/6-1]; German Cancer Society;  [DFG-SFB832]	joint German Research Foundation (DFG) grant(German Research Foundation (DFG)); Koln Fortune grant; DFG(German Research Foundation (DFG)); German Cancer Society; 	We thank Martim Dias Gomes for mouse line maintenance, Julia Stinn, Emmi Wachsmuth, Soriba Letzian, and Annika Schmitz for technical assistance, and the UoC animal facilities and CECAD histology unit for important services. We acknowledge Walter Birchmeier and Shigeo Ohno for sharing mouse lines, and thank the Niessen, Iden, Wickstrom, and Bazzi laboratories for helpful discussions. This project was funded by a joint German Research Foundation (DFG) grant (NIE-1234/4-1 and ID79/1-1 to C.N. and S. I.), a DFG-SFB832 grant to CMN (A3) and a Koln Fortune grant to S. I. (#197/2013). Work in the Iden laboratory is also supported by the DFG (ID79/2-1, CRC829/A10). Work in the Niessen laboratory is supported by the DFG (CRC829/A01 + A05, NIE-1234/6-1) and the German Cancer Society.	Abel EL, 2009, NAT PROTOC, V4, P1350, DOI 10.1038/nprot.2009.120; Ali NJA, 2016, J INVEST DERMATOL, V136, P2406, DOI 10.1016/j.jid.2016.07.011; Bandyopadhyay G, 2004, MOL ENDOCRINOL, V18, P373, DOI 10.1210/me.2003-0087; Bonastre E, 2015, CANCER RES, V75, P1287, DOI 10.1158/0008-5472.CAN-14-2444; Campanale JP, 2017, J CELL SCI, V130, P1201, DOI 10.1242/jcs.188599; Chan KS, 2008, ONCOGENE, V27, P1087, DOI 10.1038/sj.onc.1210726; Chan KS, 2004, J CLIN INVEST, V114, P720, DOI 10.1172/JCI200421032; Fang LH, 2007, CELL RES, V17, P100, DOI 10.1038/sj.cr.7310145; Forteza R, 2016, MOL BIOL CELL, V27, P2186, DOI 10.1091/mbc.E16-02-0086; Geng H, 2009, EMBO REP, V10, P381, DOI 10.1038/embor.2009.10; Godde NJ, 2014, EXP CELL RES, V328, P249, DOI 10.1016/j.yexcr.2014.08.036; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Guyer RA, 2015, J BIOL CHEM, V290, P8457, DOI 10.1074/jbc.M114.621011; Hirose T, 2006, DEVELOPMENT, V133, P1389, DOI 10.1242/dev.02294; Hirose T, 2002, J CELL SCI, V115, P2485; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Iden S, 2006, EMBO REP, V7, P1239, DOI 10.1038/sj.embor.7400819; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Ishiguro H, 2009, P NATL ACAD SCI USA, V106, P16369, DOI 10.1073/pnas.0907044106; Ishiuchi T, 2011, NAT CELL BIOL, V13, P860, DOI 10.1038/ncb2274; Kern F, 2011, BRIT J CANCER, V104, P229, DOI 10.1038/sj.bjc.6606009; Kim C, 2014, EMBO MOL MED, V6, P970, DOI 10.15252/emmm.201303541; Kojima Y, 2008, HUM PATHOL, V39, P824, DOI 10.1016/j.humpath.2007.11.001; Lechler T, 2007, J CELL BIOL, V176, P147, DOI 10.1083/jcb.200609109; McCaffrey LM, 2012, CANCER CELL, V22, P601, DOI 10.1016/j.ccr.2012.10.003; McCreery MQ, 2015, NAT MED, V21, P1514, DOI 10.1038/nm.3979; Nakamura H, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2929-2; Nassar D, 2015, NAT MED, V21, P946, DOI 10.1038/nm.3878; Niessen MT, 2013, J CELL BIOL, V202, P887, DOI 10.1083/jcb.201307001; Nolan ME, 2008, CANCER RES, V68, P8201, DOI 10.1158/0008-5472.CAN-07-6567; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Segrelles C, 2007, CANCER RES, V67, P10879, DOI 10.1158/0008-5472.CAN-07-2564; Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643; Tervonen TA, 2011, ADV CANCER RES, V111, P97, DOI 10.1016/B978-0-12-385524-4.00003-9; Tran CS, 2014, CELL HOST MICROBE, V15, P636, DOI 10.1016/j.chom.2014.04.007; Williams SE, 2011, NATURE, V470, P353, DOI 10.1038/nature09793; Xue B, 2013, NAT CELL BIOL, V15, P189, DOI 10.1038/ncb2663; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012	40	11	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 13	2018	37	37					5136	5146		10.1038/s41388-018-0313-1	http://dx.doi.org/10.1038/s41388-018-0313-1			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT3LT	29789715	Green Published, hybrid			2022-12-17	WOS:000444405300009
J	Oh, YT; Qian, GQ; Deng, JS; Sun, SY				Oh, You-Take; Qian, Guoqing; Deng, Jiusheng; Sun, Shi-Yong			Monocyte chemotactic protein-induced protein-1 enhances DR5 degradation and negatively regulates DR5 activation-induced apoptosis through its deubiquitinase function	ONCOGENE			English	Article							BREAST-CANCER CELLS; ENDOPLASMIC-RETICULUM STRESS; RECEPTOR 5 EXPRESSION; DEATH RECEPTORS; OXIDATIVE STRESS; TRAIL RESISTANCE; AUTOPHAGY; MCPIP1; ENDOCYTOSIS; COACTIVATION	Monocyte chemotactic protein-induced protein-1 (MCPIP1; also called Regnase-1) encoded by the ZC3H12A gene critically regulates inflammatory responses and immune homeostasis primarily by RNase-dependent and - independent mechanisms. However, the relationship of MCPIP1 with apoptosis and cancer and the underlying mechanisms are largely unclear. The current study has demonstrated a previously uncovered connection between MCPIP1 and the negative regulation of death receptor 5 (DR5; also known as TRAIL-R2 or killer/DR5), a cell surface receptor for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which is produced endogenously by various immune cells such as T cells. Our findings have revealed that MCPIP1 decreases both total cellular and cell surface DR5, primarily through modulating DUB-mediated protein autophagic/lysosomal degradation. Suppression of MCPIP1 by gene knockdown induces the formation of death-induced signaling complex (DISC) and enhances TRAIL or DR5 activation-induced apoptosis in cancer cells. Moreover, we demonstrated an inverse correlation between MCPIP1 expression and DR5 expression/cell sensitivity to DR5 activation-induced apoptosis in cancer cells. Our findings warrant future investigation of the roles of negative regulation of DR5 by MCPIP1 in cancer and in T-cell immunity.	[Oh, You-Take; Qian, Guoqing; Deng, Jiusheng; Sun, Shi-Yong] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA	Emory University	Sun, SY (corresponding author), Emory Univ, Sch Med, Dept Hematol & Med Oncol, Winship Canc Inst, Atlanta, GA 30322 USA.	ssun@emory.edu	Qian, Guoqing/ABH-1307-2021	Qian, Guoqing/0000-0003-1804-7993	Halpern Research Scholar award	Halpern Research Scholar award	We are thankful to Drs. M. Fu and J. Liu for generously providing us with MCPIP1 expression plasmids and MCPIP1-inducible cell line. We are also grateful to Dr. A. Hammond for editing the manuscript. This study was supported by Halpern Research Scholar award (to S-YS). S-YS is a Georgia Research Alliance Distinguished Cancer Scientist and Halpern Research Scholar.	Akazawa Y, 2009, GASTROENTEROLOGY, V136, P2365; Anel A, 2007, FRONT BIOSCI-LANDMRK, V12, P2074, DOI 10.2741/2212; Austin CD, 2006, P NATL ACAD SCI USA, V103, P10283, DOI 10.1073/pnas.0604044103; Bellail AC, 2009, REV RECENT CLIN TRIA, V4, P34, DOI 10.2174/157488709787047530; Chen L, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.234; Dhandapani L, 2011, CANCER RES, V71, P5245, DOI 10.1158/0008-5472.CAN-10-4180; Di X, 2013, ONCOTARGET, V4, P1349, DOI 10.18632/oncotarget.1174; Falschlehner C, 2009, ADV EXP MED BIOL, V647, P195, DOI 10.1007/978-0-387-89520-8_14; Falschlehner C, 2009, IMMUNOLOGY, V127, P145, DOI 10.1111/j.1365-2567.2009.03058.x; Fu L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-315; Gonzalvez F, 2010, ONCOGENE, V29, P4752, DOI 10.1038/onc.2010.221; Janku F, 2011, NAT REV CLIN ONCOL, V8, P528, DOI 10.1038/nrclinonc.2011.71; Jura J, 2012, BBA-MOL CELL RES, V1823, P1905, DOI 10.1016/j.bbamcr.2012.06.029; Kolattukudy PE, 2012, CIRC RES, V110, P174, DOI 10.1161/CIRCRESAHA.111.243212; Liang JA, 2010, J EXP MED, V207, P2959, DOI 10.1084/jem.20092641; Lim B, 2015, EXPERT OPIN THER TAR, V19, P1171, DOI 10.1517/14728222.2015.1049838; Liu HJ, 2016, PART FIBRE TOXICOL, V13, DOI 10.1186/s12989-016-0167-z; Lu WB, 2016, CANCER RES, V76, P1429, DOI 10.1158/0008-5472.CAN-15-1115; Matsushita K, 2009, NATURE, V458, P1185, DOI 10.1038/nature07924; Mellman I, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a016949; Oh YT, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08424-w; Oh YT, 2012, J BIOL CHEM, V287, P257, DOI 10.1074/jbc.M111.304006; Oh YT, 2010, J BIOL CHEM, V285, P41310, DOI 10.1074/jbc.M110.153775; Qi DF, 2011, J BIOL CHEM, V286, P41692, DOI 10.1074/jbc.M111.276006; Shanker A, 2007, ADV EXP MED BIOL, V601, P163; Shin GC, 2016, AUTOPHAGY, V12, P2451, DOI 10.1080/15548627.2016.1239002; Skalniak A, 2014, ONCOL REP, V31, P2385, DOI 10.3892/or.2014.3076; Smyth MJ, 2003, IMMUNITY, V18, P1, DOI 10.1016/S1074-7613(02)00502-2; Song JJ, 2010, CELL SIGNAL, V22, P553, DOI 10.1016/j.cellsig.2009.11.012; Sun SY, 2007, J BIOL CHEM, V282, P18800, DOI 10.1074/jbc.M611438200; Suzuki HI, 2011, MOL CELL, V44, P424, DOI 10.1016/j.molcel.2011.09.012; Twomey JD, 2015, DRUG RESIST UPDATE, V19, P13, DOI 10.1016/j.drup.2015.02.001; Uehata T, 2013, CELL, V153, P1036, DOI 10.1016/j.cell.2013.04.034; Wang KK, 2011, J MOL CELL BIOL, V3, P360, DOI 10.1093/jmcb/mjr021; Xu JW, 2012, PROTEIN CELL, V3, P903, DOI 10.1007/s13238-012-2075-9; Yang A, 2010, CURR OPIN CELL BIOL, V22, P837, DOI 10.1016/j.ceb.2010.08.001; Yao WL, 2015, CANCER LETT, V364, P70, DOI 10.1016/j.canlet.2015.04.028; Younce CW, 2010, BIOCHEM J, V426, P43, DOI 10.1042/BJ20090976; Zhang YQ, 2009, CANCER BIOL THER, V8, P917, DOI 10.4161/cbt.8.10.8141; Zhang YQ, 2008, MOL CANCER RES, V6, P1861, DOI 10.1158/1541-7786.MCR-08-0313; Zhou LM, 2006, CIRC RES, V98, P1177, DOI 10.1161/01.RES.0000220106.64661.71	41	11	11	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	25					3415	3425		10.1038/s41388-018-0200-9	http://dx.doi.org/10.1038/s41388-018-0200-9			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TC	29551769				2022-12-17	WOS:000436411300007
J	Yao, K; Lee, SY; Peng, C; Lim, DY; Yamamoto, H; Ryu, J; Lim, TG; Chen, HY; Jin, GG; Zhao, ZJ; Han, YP; Ma, WY; Bode, AM; Dong, ZG				Yao, Ke; Lee, Sung-Young; Peng, Cong; Lim, Do Young; Yamamoto, Hiroyuki; Ryu, Joohyun; Lim, Tae-Gyu; Chen, Hanyong; Jin, Guoguo; Zhao, Zhenjiang; Han, Yaping; Ma, Wei-Ya; Bode, Ann M.; Dong, Zigang			RSK2 is required for TRAF6 phosphorylation-mediated colon inflammation	ONCOGENE			English	Article							INNATE IMMUNITY; UBIQUITIN; ACTIVATION; RECEPTOR; KINASES; FAMILY; RESPONSES; DOMAIN; CELLS	Inflammation is a complex biological host reaction to tissue damage, infection and trauma. Extensive study of the inflammatory response has led to the identification of several protein kinases that are essential for signaling and could be potential therapeutic targets. The RSK family of kinases has multiple cellular functions. In our study, we found that RSK2 is a mediator for inflammation signaling and interacts with TRAF6. In vitro kinase assay results indicated that RSK2 strongly phosphorylates TRAF6 at serines 46, 47 and 48. Ectopic overexpression of TRAF6 or knocking down RSK2 expression confirmed that RSK2 is a positive regulator of TRAF6 K63 ubiquitination. TRAF6 is also required for RSK2 ubiquitination. TRAF6 bridges the TNF receptor superfamily and intracellular signaling for the induction of proinflammatory cytokines. We developed a colon inflammation model using RSK2 wild type (WT) and knockout (KO) mice. As expected, F4/80 and CD3 infiltration were significantly upregulated in WT mice compared to RSK2 KO mice. Furthermore, inflammation signaling, including Ikk alpha/beta, p38 and JNKs, was dramatically upregulated in WT mice. Colon tissue immunoprecipitation results further confirmed that TRAF6 K63 ubiquitination was lower in RSK2 KO mice. Overall, these results indicate that phosphorylation of TRAF6 (S46, 47, 48) by RSK2 is required for TRAF6 K63 ubiquitination and inflammation signaling.	[Yao, Ke; Lee, Sung-Young; Peng, Cong; Lim, Do Young; Yamamoto, Hiroyuki; Ryu, Joohyun; Lim, Tae-Gyu; Chen, Hanyong; Jin, Guoguo; Zhao, Zhenjiang; Han, Yaping; Ma, Wei-Ya; Bode, Ann M.; Dong, Zigang] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Yao, Ke; Jin, Guoguo; Zhao, Zhenjiang; Han, Yaping; Dong, Zigang] China US Henan Hormel Canc Inst, Zhengzhou, Henan, Peoples R China; [Peng, Cong] Cent S Univ, Xiangya Hosp, Dept Dermatol, Changsha, Hunan, Peoples R China; [Zhao, Zhenjiang] Henan Luoyang Orthoped Hosp, Zhengzhou, Henan, Peoples R China	University of Minnesota System; Central South University	Dong, ZG (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.; Dong, ZG (corresponding author), China US Henan Hormel Canc Inst, Zhengzhou, Henan, Peoples R China.	zgdong@hi.umn.edu	Lim, Tae-Gyu/AAO-8475-2020	Lim, Tae-Gyu/0000-0001-6930-9565	Hormel Foundation; National Institutes of Health [CA166011, CA187027, CA196639]; NSF of Henan Province China [162300410337]; NATIONAL CANCER INSTITUTE [R01CA196639, R01CA187027, R01CA166011] Funding Source: NIH RePORTER	Hormel Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF of Henan Province China; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Simin Zhao and Todd Schuster for supporting experiments, Nicki Brickman and Dr. Tia Rai for assistance in submitting our manuscript (The Hormel Institute, University of Minnesota). This work was funded by The Hormel Foundation, National Institutes of Health grants CA166011, CA187027, CA196639 and NSF of Henan Province China No. 162300410337.	Adhikari A, 2007, ONCOGENE, V26, P3214, DOI 10.1038/sj.onc.1210413; Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Bekes M, 2009, CELL, V137, P604, DOI 10.1016/j.cell.2009.04.052; Broom OJ, 2009, CLIN EXP IMMUNOL, V158, P272, DOI 10.1111/j.1365-2249.2009.04033.x; Chen ZJJ, 2012, IMMUNOL REV, V246, P95, DOI 10.1111/j.1600-065X.2012.01108.x; Cho YY, 2007, CANCER RES, V67, P8104, DOI 10.1158/0008-5472.CAN-06-4668; Cho YY, 2007, J BIOL CHEM, V282, P8380, DOI 10.1074/jbc.M611322200; Cho YY, 2009, CANCER RES, V69, P4398, DOI 10.1158/0008-5472.CAN-08-4959; Choo Yeun Su, 2009, J Vis Exp, DOI 10.3791/1293; Corn JE, 2014, NAT STRUCT MOL BIOL, V21, P297, DOI 10.1038/nsmb.2808; Davidson LA, 2015, CANCER RES, V75, P5392, DOI 10.1158/0008-5472.CAN-15-1706; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Hinz M, 2010, MOL CELL, V40, P63, DOI 10.1016/j.molcel.2010.09.008; Huang GH, 2009, CYTOKINE, V48, P161, DOI 10.1016/j.cyto.2009.08.002; Hunter T, 2007, MOL CELL, V28, P730, DOI 10.1016/j.molcel.2007.11.019; Jiao S, 2015, NAT IMMUNOL, V16, P246, DOI 10.1038/ni.3097; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kulathu Y, 2012, NAT REV MOL CELL BIO, V13, P508, DOI 10.1038/nrm3394; Lamothe B, 2007, J BIOL CHEM, V282, P4102, DOI 10.1074/jbc.M609503200; Lin HH, 2005, J EXP MED, V201, P1615, DOI 10.1084/jem.20042307; Liu AG, 2012, J BIOL CHEM, V287, P16132, DOI 10.1074/jbc.M111.310102; Liu KD, 2011, J BIOL CHEM, V286, P2057, DOI 10.1074/jbc.M110.147306; Malakhova M, 2008, NAT STRUCT MOL BIOL, V15, P112, DOI 10.1038/nsmb1347; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ricciotti E, 2011, ARTERIOSCL THROM VAS, V31, P986, DOI 10.1161/ATVBAHA.110.207449; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Wang YB, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000253; Wertz IE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003350; Wu H, 2003, BIOESSAYS, V25, P1096, DOI 10.1002/bies.10352; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Yang WL, 2010, CELL CYCLE, V9, P486, DOI 10.4161/cc.9.3.10508; Yang WL, 2009, SCIENCE, V325, P1134, DOI 10.1126/science.1175065; Yin Q, 2009, NAT STRUCT MOL BIOL, V16, P658, DOI 10.1038/nsmb.1605; Zhang JM, 2007, INT ANESTHESIOL CLIN, V45, P27, DOI 10.1097/AIA.0b013e318034194e; Zhang XF, 2013, CELL RES, V23, P366, DOI 10.1038/cr.2013.21; Zhao W, 2012, J IMMUNOL, V188, P2567, DOI 10.4049/jimmunol.1103255; Zhou FF, 2012, J BIOL CHEM, V287, P11002, DOI 10.1074/jbc.M111.328187; Zhu F, 2011, CANCER RES, V71, P393, DOI 10.1158/0008-5472.CAN-10-2012; Zinngrebe J, 2014, EMBO REP, V15, P28, DOI 10.1002/embr.201338025	47	11	12	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	2018	37	26					3501	3513		10.1038/s41388-018-0167-6	http://dx.doi.org/10.1038/s41388-018-0167-6			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GK7TM	29563609	Green Accepted			2022-12-17	WOS:000436412500003
J	Dubuisson, L; Lormieres, F; Fochi, S; Turpin, J; Pasquier, A; Douceron, E; Oliva, A; Bazarbachi, A; Lallemand-Breitenbach, V; De The, H; Journo, C; Mahieux, R				Dubuisson, Louise; Lormieres, Florence; Fochi, Stefania; Turpin, Jocelyn; Pasquier, Amandine; Douceron, Estelle; Oliva, Anais; Bazarbachi, Ali; Lallemand-Breitenbach, Valerie; De The, Hugues; Journo, Chloe; Mahieux, Renaud			Stability of HTLV-2 antisense protein is controlled by PML nuclear bodies in a SUMO-dependent manner	ONCOGENE			English	Article							T-CELL LEUKEMIA; KAPPA-B ACTIVATION; VIRUS TYPE-1; IN-VIVO; HBZ; TRANSFORMATION; TRANSCRIPTION; CONJUGATION; PATHWAYS; THERAPY	Since the identification of the antisense protein of HTLV-2 (APH-2) and the demonstration that APH-2 mRNA is expressed in vivo in most HTLV-2 carriers, much effort has been dedicated to the elucidation of similarities and/or differences between APH-2 and HBZ, the antisense protein of HTLV-1. Similar to HBZ, APH-2 negatively regulates HTLV-2 transcription. However, it does not promote cell proliferation. In contrast to HBZ, APH-2 half-life is very short. Here, we show that APH-2 is addressed to PML nuclear bodies in T-cells, as well as in different cell types. Covalent SUMOylation of APH-2 is readily detected, indicating that APH-2 might be addressed to the PML nuclear bodies in a SUMO-dependent manner. We further show that silencing of PML increases expression of APH-2, while expression of HBZ is unaffected. On the other hand, SUMO-1 overexpression leads to a specific loss of APH-2 expression that is restored upon proteasome inhibition. Furthermore, the carboxy-terminal LAGLL motif of APH-2 is responsible for both the targeting of the protein to PML nuclear bodies and its short half-life. Taken together, these observations indicate that natural APH-2 targeting to PML nuclear bodies induces proteasomal degradation of the viral protein in a SUMO-dependent manner. Hence, this study deciphers the molecular and cellular bases of APH-2 short half-life in comparison to HBZ and highlights key differences in the post-translational mechanisms that control the expression of both proteins.	[Dubuisson, Louise; Lormieres, Florence; Turpin, Jocelyn; Pasquier, Amandine; Douceron, Estelle; Oliva, Anais; Journo, Chloe; Mahieux, Renaud] Univ Claude Bernard Lyon 1, Ecole Normale Super Lyon, Int Ctr Res Infectiol,Univ Lyon, Retroviral Oncogenesis Lab,INSERM U1111,CNRS,UMR5, F-69007 Lyon, France; [Dubuisson, Louise; Lormieres, Florence; Turpin, Jocelyn; Pasquier, Amandine; Douceron, Estelle; Oliva, Anais; Journo, Chloe; Mahieux, Renaud] Equipe Labellisee Ligue Natl Canc, Lyon, France; [Fochi, Stefania] Univ Verona, Dept Neurosci Biomed & Movement Sci, Verona, Italy; [Bazarbachi, Ali] Amer Univ Beirut, Dept Internal Med, Fac Med, Beirut, Lebanon; [Bazarbachi, Ali] Amer Univ Beirut, Dept Anat Cell Biol & Physiol Sci, Beirut, Lebanon; [Lallemand-Breitenbach, Valerie; De The, Hugues] Univ Paris Diderot, Coll France, Paris Sorbonne, Inserm U944,CNRS 7212, Lettre 11 Pl Marcelin Berthelot, F-75231 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; University of Verona; American University of Beirut; American University of Beirut; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universite Paris Cite	Journo, C; Mahieux, R (corresponding author), Univ Claude Bernard Lyon 1, Ecole Normale Super Lyon, Int Ctr Res Infectiol,Univ Lyon, Retroviral Oncogenesis Lab,INSERM U1111,CNRS,UMR5, F-69007 Lyon, France.; Journo, C; Mahieux, R (corresponding author), Equipe Labellisee Ligue Natl Canc, Lyon, France.	chloe.journo@ens-lyon.fr; renaud.mahieux@ens-lyon.fr		Bazarbachi, Ali/0000-0002-7171-4997; Lallemand, Valerie/0000-0001-9852-204X; Lormieres, Florence/0000-0002-7603-1394; mahieux, renaud/0000-0002-5129-6804; Journo, Chloe/0000-0002-0973-0777; Turpin, Jocelyn/0000-0001-5177-2471	ENS Lyon; ANR; Fondation ARC pour la Recherche sur le Cancer; Ministere de la Recherche; ARC; La Ligue Contre le Cancer "programme Equipe Labellisee"; INSERM	ENS Lyon; ANR(French National Research Agency (ANR)); Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ministere de la Recherche(Ministry of Science and Innovation, Spain (MICINN)Ministry of Research, France); ARC(Australian Research Council); La Ligue Contre le Cancer "programme Equipe Labellisee"; INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	We thank the microscopy facility team of the Lyon SFR Biosciences. R.M., C.J., and F.L. are supported by ENS Lyon. L.D. is supported by ANR. J.T. was supported by the Fondation ARC pour la Recherche sur le Cancer. E.D. was supported by the Ministere de la Recherche. This work was supported by ARC and La Ligue Contre le Cancer "programme Equipe Labellisee" and INSERM.	Bruhn RMR, 2017, CLIN VIROLOGY, P771; Cachat A, 2013, J VIROL, V87, P13386, DOI 10.1128/JVI.02758-13; Ciminale V, 2014, FRONT MICROBIOL, V5, DOI 10.3389/fmicb.2014.00398; Currer R, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00406; Dassouki Z, 2015, BLOOD, V125, P474, DOI 10.1182/blood-2014-04-572750; Douceron E, 2012, J INFECT DIS, V205, P82, DOI 10.1093/infdis/jir708; El Hajj H, 2010, J EXP MED, V207, P2785, DOI 10.1084/jem.20101095; Everett RD, 2013, NAT REV MICROBIOL, V11, P400, DOI 10.1038/nrmicro3015; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Giam CZ, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8060161; Halin M, 2009, BLOOD, V114, P2427, DOI 10.1182/blood-2008-09-179879; Hivin P, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-14; Ivanschitz L, 2015, P NATL ACAD SCI USA, V112, P14278, DOI 10.1073/pnas.1507540112; Jean M, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9040067; Journo C, 2013, J VIROL, V87, P1123, DOI 10.1128/JVI.01792-12; Journo C, 2009, FUTURE MICROBIOL, V4, P425, DOI 10.2217/FMB.09.13; Kadamb R, 2013, EUR J CELL BIOL, V92, P237, DOI 10.1016/j.ejcb.2013.09.001; Kfoury Y, 2012, ADV CANCER RES, V113, P85, DOI 10.1016/B978-0-12-394280-7.00003-8; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Komatsu T, 2016, VIRUSES-BASEL, V8, DOI 10.3390/v8100290; Lowrey AJ, 2017, CELL COMMUN SIGNAL, V15, DOI 10.1186/s12964-017-0183-0; Mesnard JM, 2015, VIRUSES-BASEL, V7, P6490, DOI 10.3390/v7122952; Nasr R, 2006, BLOOD, V107, P4021, DOI 10.1182/blood-2005-09-3572; Nicot Christophe, 2015, J Cancer Sci, V2, DOI 10.13188/2377-9292.1000009; Panfil AR, 2016, J VIROL, V90, P3760, DOI 10.1128/JVI.03113-15; Pene S, 2014, J VIROL, V88, P10655, DOI 10.1128/JVI.01827-14; Regad T, 2001, EMBO J, V20, P3495, DOI 10.1093/emboj/20.13.3495; Sahin U, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5187; Satou Y, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001274; Shiio Y, 2006, MOL CELL BIOL, V26, P1386, DOI 10.1128/MCB.26.4.1386-1397.2006; Shirinian M, 2015, J VIROL, V89, P8092, DOI 10.1128/JVI.00918-15; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; Wang TG, 2000, AIDS RES HUM RETROV, V16, P1661, DOI 10.1089/08892220050193119; Watanabe T, 2017, BLOOD, V129, P1071, DOI 10.1182/blood-2016-09-692574; Xie L, 2005, J VIROL, V79, P14536, DOI 10.1128/JVI.79.23.14536-14545.2005; Yamano Y, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00389; Yin H, 2012, J VIROL, V86, P8412, DOI 10.1128/JVI.00717-12; Zhao TJ, 2012, FRONT MICROBIOL, V3, DOI 10.3389/fmicb.2012.00247	38	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	21					2806	2816		10.1038/s41388-018-0163-x	http://dx.doi.org/10.1038/s41388-018-0163-x			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GG8EE	29507418				2022-12-17	WOS:000432929800004
J	Zhang, HY; Wang, QY; Gu, JZ; Yin, Y; Liang, SH; Wu, LD; Xu, H; Zhao, C; Gu, YC				Zhang, Huiyuan; Wang, Qinyi; Gu, Junzhong; Yin, Le; Liang, Shenghui; Wu, Lida; Xu, Hao; Zhao, Chao; Gu, Yuchun			Elevated mitochondrial SLC25A29 in cancer modulates metabolic status by increasing mitochondria-derived nitric oxide	ONCOGENE			English	Article							TRANSPORTER FAMILY SLC25; SYNTHASE; RESPIRATION; IDENTIFICATION; GLYCOLYSIS; PATHWAY; KINASE; OXYGEN	Warburg effect has been recognized as a hallmark of cancer cells for many years, but its modulation mechanism remains a great focus. Our current study found a member of solute carrier family 25 (SLC25A29), the main arginine transporter on mitochondria, significantly elevated in various cancer cells. Knockout of SLC25A29 by CRISPR/Cas9 inhibited proliferation and migration of cancer cells both in vitro and in vivo. SLC25A29-knockout cells also showed an altered metabolic status with enhanced mitochondrial respiration and reduced glycolysis. All of above impacts could be reversed after rescuing SLC25A29 expression in SLC25A29-knockout cells. Arginine is transported into mitochondria partly for nitric oxide (NO) synthesis. Deletion of SLC25A29 resulted in severe decrease of NO production, indicating that the mitochondria is a significant source of NO. SLC25A29-knockout cells dramatically altered the variation of metabolic processes, whereas addition of arginine failed to reverse the effect, highlighting the necessity of transporting arginine into mitochondria by SLC25A29. In conclusion, aberrant elevated SLC25A29 in cancer functioned to transport more arginine into mitochondria, improved mitochondria-derived NO levels, thus modulated metabolic status to facilitate increased cancer progression.	[Zhang, Huiyuan; Wang, Qinyi; Gu, Junzhong; Yin, Le; Liang, Shenghui; Wu, Lida; Xu, Hao; Gu, Yuchun] Peking Univ, Inst Mol Med, Lab Mol Pharmacol, Beijing, Peoples R China; [Zhao, Chao] Univ Cambridge, WT MRC Cambridge Stem Cell Inst, Dept Clin Neurosci, Cambridge, England; [Gu, Yuchun] Aston Univ, Translat & Regenerat Med Ctr, Aston Med Res Inst, Birmingham, W Midlands, England	Peking University; University of Cambridge; Aston University	Gu, YC (corresponding author), Peking Univ, Inst Mol Med, Lab Mol Pharmacol, Beijing, Peoples R China.; Gu, YC (corresponding author), Aston Univ, Translat & Regenerat Med Ctr, Aston Med Res Inst, Birmingham, W Midlands, England.	ycgu@pku.edu.cn	wu, lida/ABD-8498-2020	wu, lida/0000-0001-7059-0788; gu, yuchun/0000-0002-7558-0447	973 Project [2013CB531206, 2012CB517803]; NSF [81170236, 31127001]	973 Project(National Basic Research Program of China); NSF(National Science Foundation (NSF))	This work is supported by the research grants held by Yuchun Gu (973 Project Number 2013CB531206, 973 Project Number 2012CB517803, and NSF Number 81170236 and Number 31127001).	Almeida A, 2004, NAT CELL BIOL, V6, P45, DOI 10.1038/ncb1080; Berkers CR, 2013, CELL METAB, V18, P617, DOI 10.1016/j.cmet.2013.06.019; Brix B, 2012, J NEUROSCI, V32, P9727, DOI 10.1523/JNEUROSCI.0879-12.2012; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; Brown GC, 2007, CARDIOVASC RES, V75, P283, DOI 10.1016/j.cardiores.2007.03.022; Brune B, 2007, CARDIOVASC RES, V75, P275, DOI 10.1016/j.cardiores.2007.03.005; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Camacho JA, 2009, PEDIATR RES, V66, P35, DOI 10.1203/PDR.0b013e3181a283c1; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chang CF, 2015, FREE RADICAL BIO MED, V79, P324, DOI 10.1016/j.freeradbiomed.2014.11.012; Cidad P, 2004, BIOCHEM J, V384, P629, DOI 10.1042/BJ20040886; Conacci-Sorrell Maralice, 2014, Cold Spring Harb Perspect Med, V4, pa014357, DOI 10.1101/cshperspect.a014357; Contractor T, 2012, CANCER RES, V72, P560, DOI 10.1158/0008-5472.CAN-11-1215; Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217; Dedkova EN, 2009, J PHYSIOL-LONDON, V587, P851, DOI 10.1113/jphysiol.2008.165423; Finocchietto PV, 2009, EXP BIOL MED, V234, P1020, DOI 10.3181/0902-MR-81; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Ghafourifar P, 2005, METHOD ENZYMOL, V396, P424, DOI 10.1016/S0076-6879(05)96036-9; Ghafourifar P, 2005, TRENDS PHARMACOL SCI, V26, P190, DOI 10.1016/j.tips.2005.02.005; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hill BG, 2012, BIOL CHEM, V393, P1485, DOI 10.1515/hsz-2012-0198; Jobgen WS, 2006, J NUTR BIOCHEM, V17, P571, DOI 10.1016/j.jnutbio.2005.12.001; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Lacza Z, 2009, FRONT BIOSCI, V14, P4436, DOI 10.2741/3539; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Moncada S, 2006, J NEUROCHEM, V97, P1676, DOI 10.1111/j.1471-4159.2006.03988.x; Monne M, 2015, AMINO ACIDS, V47, P1763, DOI 10.1007/s00726-015-1990-5; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Palmieri F, 2004, PFLUG ARCH EUR J PHY, V447, P689, DOI 10.1007/s00424-003-1099-7; Palmieri F, 2013, MOL ASPECTS MED, V34, P465, DOI 10.1016/j.mam.2012.05.005; Persichini T, 2005, NEUROSCI LETT, V384, P254, DOI 10.1016/j.neulet.2005.04.085; Porcelli V, 2014, J BIOL CHEM, V289, P13374, DOI 10.1074/jbc.M114.547448; Quintero M, 2006, CANCER RES, V66, P770, DOI 10.1158/0008-5472.CAN-05-0333; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Sekoguchi E, 2003, J BIOL CHEM, V278, P38796, DOI 10.1074/jbc.M306372200; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Switzer CH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3319; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wu GY, 1998, BIOCHEM J, V336, P1, DOI 10.1042/bj3360001; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhong H, 1999, CANCER RES, V59, P5830	48	11	11	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	19					2545	2558		10.1038/s41388-018-0139-x	http://dx.doi.org/10.1038/s41388-018-0139-x			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GF3RN	29459713				2022-12-17	WOS:000431873400007
J	Deryugina, EI; Zajac, E; Zilberberg, L; Muramatsu, T; Joshi, G; Dabovic, B; Rifkin, D; Quigley, JP				Deryugina, Elena I.; Zajac, Ewa; Zilberberg, Lior; Muramatsu, Tomoki; Joshi, Grishma; Dabovic, Branka; Rifkin, Daniel; Quigley, James P.			LTBP3 promotes early metastatic events during cancer cell dissemination	ONCOGENE			English	Article							BETA BINDING-PROTEIN; TGF-BETA; VASCULAR INTRAVASATION; TUMOR ANGIOGENESIS; SIGNALING PATHWAY; GROWTH; MECHANISMS; MUTATIONS; DOMAIN; EXPRESSION	Latent transforming growth factor beta(TGF beta)-binding proteins (LTBPs) are important for the secretion, activation, and function of mature TGF beta, especially so in cancer cell physiology. However, specific roles of the LTBPs remain understudied in the context of the primary tumor microenvironment. Herein, we investigated the role of LTBP3 in the distinct processes involved in cancer metastasis. By using three human tumor cell lines of different tissue origin (epidermoid HEp-3 and prostate PC-3 carcinomas and HT-1080 fibrosarcoma) and several metastasis models conducted in both mammalian and avian settings, we show that LTBP3 is involved in the early dissemination of primary cancer cells, namely in the intravasation step of the metastatic cascade. Knockdown of LTBP3 in all tested cell lines led to significant inhibition of tumor cell intravasation, but did not affect primary tumor growth. LTBP3 was dispensable in the late steps of carcinoma cell metastasis that follow tumor cell intravasation, including vascular arrest, extravasation, and tissue colonization. However, LTBP3 depletion diminished the angiogenesis-inducing potential of HEp-3 cells in vivo, which was restorable by exogenous delivery of LTBP3 protein. A similar compensatory approach rescued the dampened intravasation of LTBP3-deficient HEp3 cells, suggesting that LTBP3 regulates the induction of the intravasation-supporting angiogenic vasculature within developing primary tumors. Using our recently developed microtumor model, we confirmed that LTBP3 loss resulted in the development of intratumoral vessels with an abnormal microarchitecture incompatible with efficient intravasation of HEp-3 carcinoma cells. Collectively, these findings demonstrate that LTBP3 represents a novel oncotarget that has distinctive functions in the regulation of angiogenesis-dependent tumor cell intravasation, a critical process during early cancer dissemination. Our experimental data are also consistent with the survival prognostic value of LTBP3 expression in early-stage head and neck squamous cell carcinomas, further indicating a specific role for LTBP3 in cancer progression toward metastatic disease.	[Deryugina, Elena I.; Zajac, Ewa; Muramatsu, Tomoki; Quigley, James P.] Scripps Res Inst, La Jolla, CA 92037 USA; [Zilberberg, Lior; Joshi, Grishma; Dabovic, Branka; Rifkin, Daniel] NYU, Sch Med, New York, NY USA	Scripps Research Institute; New York University	Deryugina, EI (corresponding author), Scripps Res Inst, La Jolla, CA 92037 USA.	deryugin@scripps.edu			National Institutes of Health [R01CA157792, R01CA105412, R01CA034282]; NATIONAL CANCER INSTITUTE [R01CA157792, R01CA105412, R01CA034282] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by grants R01CA157792 (E.I.D.), R01CA105412 (J.P.Q.), and R01CA034282 (D.R.) from the National Institutes of Health. This is manuscript no. 29589 from TSRI.	Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810; Bachman KE, 2005, CURR OPIN ONCOL, V17, P49, DOI 10.1097/01.cco.0000143682.45316.ae; Bos PD, 2009, NATURE, V459, P1005, DOI 10.1038/nature08021; Chandramouli A, 2011, J MAMMARY GLAND BIOL, V16, P67, DOI 10.1007/s10911-011-9215-3; Chen H, 2017, ONCOGENE, V36, P4415, DOI 10.1038/onc.2017.73; Chen Y, 2002, FEBS LETT, V517, P277, DOI 10.1016/S0014-5793(02)02648-0; Chung AS, 2011, ANNU REV CELL DEV BI, V27, P563, DOI 10.1146/annurev-cellbio-092910-154002; Conn EM, 2009, AM J PATHOL, V175, P1638, DOI 10.2353/ajpath.2009.090384; Connolly EC, 2012, INT J BIOL SCI, V8, P964, DOI 10.7150/ijbs.4564; Dabovic B, 2015, J CELL PHYSIOL, V230, P226, DOI 10.1002/jcp.24704; Dell Ralph B, 2002, ILAR J, V43, P207; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Deryugina EI, 2005, CANCER RES, V65, P10959, DOI 10.1158/0008-5472.CAN-05-2228; Deryugina EI, 2008, METHOD ENZYMOL, V444, P21, DOI 10.1016/S0076-6879(08)02802-4; Deryugina EI, 2017, CELL REP, V19, P601, DOI 10.1016/j.celrep.2017.03.064; Deryugina EI, 2016, METHODS MOL BIOL, V1430, P283, DOI 10.1007/978-1-4939-3628-1_19; Deryugina EI, 2015, MATRIX BIOL, V44-46, P94, DOI 10.1016/j.matbio.2015.04.004; Deryugina EI, 2008, HISTOCHEM CELL BIOL, V130, P1119, DOI 10.1007/s00418-008-0536-2; Dongre A, 2017, CANCER RES, V77, P3982, DOI 10.1158/0008-5472.CAN-16-3292; EKLOV S, 1993, CANCER RES, V53, P3193; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Fontana L, 2005, FASEB J, V19, P1798, DOI 10.1096/fj.05-4134com; Gleizes PE, 1996, J BIOL CHEM, V271, P29891, DOI 10.1074/jbc.271.47.29891; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HENRIKSEN R, 1995, LAB INVEST, V73, P213; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Inoue T, 2014, HUM MOL GENET, V23, P5672, DOI 10.1093/hmg/ddu283; Isogai M, 2003, MOL PLANT MICROBE IN, V16, P188, DOI 10.1094/MPMI.2003.16.3.188; Jilani SM, 2003, J HISTOCHEM CYTOCHEM, V51, P597, DOI 10.1177/002215540305100505; Juncker-Jensen A, 2013, CANCER RES, V73, P4196, DOI 10.1158/0008-5472.CAN-12-4495; Kim J, 1998, CELL, V94, P353, DOI 10.1016/S0092-8674(00)81478-6; Lack J, 2003, J MOL BIOL, V334, P281, DOI 10.1016/j.jmb.2003.09.053; Lebrun Jean-Jacques, 2012, ISRN Mol Biol, V2012, P381428, DOI 10.5402/2012/381428; Lindsay ME, 2012, NAT GENET, V44, P922, DOI 10.1038/ng.2349; Loeys BL, 2005, NAT GENET, V37, P275, DOI 10.1038/ng1511; Massague J, 2017, MOL ONCOL, V11, P3, DOI 10.1002/1878-0261.12024; Minder P, 2015, NEOPLASIA, V17, P634, DOI 10.1016/j.neo.2015.08.002; Miyazono Kohei, 1992, Journal of Dermatology (Tokyo), V19, P644; Moustakas A, 2014, BBA-GEN SUBJECTS, V1840, P2621, DOI 10.1016/j.bbagen.2014.02.004; Naba A, 2014, ELIFE, V3, DOI 10.7554/eLife.01308; Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Penttinen C, 2002, J CELL SCI, V115, P3457; Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369; Roth-Eichhorn S, 2001, SCAND J GASTROENTERO, V36, P1204; Saharinen J, 2000, MOL BIOL CELL, V11, P2691, DOI 10.1091/mbc.11.8.2691; Schepers D, 2015, EUR J HUM GENET, V23, P224, DOI 10.1038/ejhg.2014.61; Shi ML, 2011, NATURE, V474, P343, DOI 10.1038/nature10152; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Tanaka T, 2012, CANCER SCI, V103, P455, DOI 10.1111/j.1349-7006.2011.02174.x; Vehvilainen P, 2011, HUM PATHOL, V42, P269, DOI 10.1016/j.humpath.2010.07.005; Vincent-Chong VK, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174865; Wakefield LM, 2013, NAT REV CANCER, V13, P328, DOI 10.1038/nrc3500; Wan FQ, 2017, ONCOL RES, V25, P503, DOI 10.3727/096504016X14755368915591; Weinberg RA, 2008, CARCINOGENESIS, V29, P1092, DOI 10.1093/carcin/bgn104; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yoshinaga K, 2008, P NATL ACAD SCI USA, V105, P18758, DOI 10.1073/pnas.0805411105	59	11	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1815	1829		10.1038/s41388-017-0075-1	http://dx.doi.org/10.1038/s41388-017-0075-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29348457	Green Accepted			2022-12-17	WOS:000429303300001
J	Gong, L; Pan, X; Lim, CB; de Polo, A; Little, JB; Yuan, ZM				Gong, Lu; Pan, Xiao; Lim, Chuan-Bian; de Polo, Anna; Little, John B.; Yuan, Zhi-Min			A functional interplay between Delta 133p53 and Delta Np63 in promoting glycolytic metabolism to fuel cancer cell proliferation	ONCOGENE			English	Article							PLURIPOTENT STEM-CELLS; P53 ISOFORM; RESPONSE ELEMENTS; BREAST-CANCER; DNA-DAMAGE; SENESCENCE; EXPRESSION; DEATH; APOPTOSIS; P53-BETA	Although Delta Np63 is known to promote cancer cell proliferation, the underlying mechanism behind its oncogenic function remains elusive. We report here a functional interplay between Delta Np63 and Delta 133p53. These two proteins are co-overexpressed in a subset of human cancers and cooperate to promote cell proliferation. Mechanistically, Delta 133p53 binds to Delta Np63 and utilizes its transactivation domain to upregulate GLUT1, GLUT4, and PGM expression driving glycolysis. While increased glycolysis provides cancer cells with anabolic metabolism critical for proliferation and survival, it can be harnessed for selective cancer cell killing. Indeed, we show that tumors overexpressing both Delta Np63 and Delta 133p53 exhibit heightened sensitivity to vitamin C that accumulate to a lethal level due to accelerated uptake via overexpressed GLUT1. These observations offer a new therapeutic avenue that could be exploited for clinical applications.	[Gong, Lu; Lim, Chuan-Bian; de Polo, Anna; Yuan, Zhi-Min] Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Gong, Lu; Lim, Chuan-Bian; de Polo, Anna; Little, John B.; Yuan, Zhi-Min] John B Little Ctr Radiat Sci, Boston, MA 02115 USA; [Pan, Xiao] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China; [Pan, Xiao] Zhejiang Univ, Sch Med, Inst Translat Med, Hangzhou, Zhejiang, Peoples R China	Harvard University; Harvard T.H. Chan School of Public Health; Zhejiang University; Zhejiang University	Yuan, ZM (corresponding author), Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.; Yuan, ZM (corresponding author), John B Little Ctr Radiat Sci, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Gong, Lu/X-2715-2019; Gong, Lu/AAM-3697-2021	Gong, Lu/0000-0001-9151-0767; de Polo, Anna/0000-0002-5607-8048	Morningside Foundation; National Cancer Institute at the National Institute of Health [R01CA85679, R01CA167814, R01CA125144]; Zhu Fund	Morningside Foundation; National Cancer Institute at the National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Zhu Fund	This work was supported in part by the Morningside Foundation, the Zhu Fund and grants from the National Cancer Institute at the National Institute of Health (R01CA85679, R01CA167814, and R01CA125144).	Aoubala M, 2011, CELL DEATH DIFFER, V18, P248, DOI 10.1038/cdd.2010.91; Arsic N, 2015, STEM CELL REP, V4, P531, DOI 10.1016/j.stemcr.2015.02.001; Barbareschi M, 2001, AM J SURG PATHOL, V25, P1054, DOI 10.1097/00000478-200108000-00010; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bernard H, 2013, ONCOGENE, V32, P2150, DOI 10.1038/onc.2012.242; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Candi E, 2007, CELL CYCLE, V6, P274, DOI 10.4161/cc.6.3.3797; Chen J, 2009, GENE DEV, V23, P278, DOI 10.1101/gad.1761609; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Gong L, 2016, SCI REP-UK, V6, DOI 10.1038/srep37281; Gong L, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1033587; Gong L, 2016, J MOL CELL BIOL, V8, P88, DOI 10.1093/jmcb/mjv069; Gong L, 2015, CELL RES, V25, P351, DOI 10.1038/cr.2015.22; Green DR, 2006, CELL, V126, P30, DOI 10.1016/j.cell.2006.06.032; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Hainaut P, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026179; Hofstetter G, 2011, BRIT J CANCER, V105, P1593, DOI 10.1038/bjc.2011.433; Horikawa I, 2017, CELL DEATH DIFFER, V24, P1017, DOI 10.1038/cdd.2017.48; Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348; Ji WS, 2015, INT J CLIN EXP PATHO, V8, P10468; Joruiz SM, 2016, COLD SPRING HARBOR P, V6, DOI [10.1101/cshperspect.a02, DOI 10.1101/CSHPERSPECT.A02]; Khoury Marie P, 2011, Genes Cancer, V2, P453, DOI 10.1177/1947601911408893; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Liu J, 2015, CANCER LETT, V356, P197, DOI 10.1016/j.canlet.2013.12.025; Marcel V, 2010, ONCOGENE, V29, P2691, DOI 10.1038/onc.2010.26; Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776; Mondal AM, 2013, J CLIN INVEST, V123, P5247, DOI 10.1172/JCI70355; Moore HC, 2010, ONCOGENE, V29, P6475, DOI 10.1038/onc.2010.381; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Roth I, 2016, ONCOGENE, V35, P4981, DOI 10.1038/onc.2016.45; Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846; Shen L, 2012, CLIN CANCER RES, V18, P1561, DOI 10.1158/1078-0432.CCR-11-3040; Tannapfel A, 2001, J PATHOL, V195, P163, DOI 10.1002/path.947; Turnquist C, 2016, CELL DEATH DIFFER, V23, P1515, DOI 10.1038/cdd.2016.37; Yang XP, 2011, CANCER RES, V71, P3688, DOI 10.1158/0008-5472.CAN-10-3445; Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004	36	11	11	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	16					2150	2164		10.1038/s41388-017-0117-8	http://dx.doi.org/10.1038/s41388-017-0117-8			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GD5ZV	29371679				2022-12-17	WOS:000430589000006
J	Hu, TX; Chong, YT; Qin, HY; Kitamura, E; Chang, CS; Silva, J; Ren, MQ; Cowell, JK				Hu, Tianxiang; Chong, Yating; Qin, Haiyan; Kitamura, Eiko; Chang, Chang-Sheng; Silva, Jeane; Ren, Mingqiang; Cowell, John K.			The miR-17/92 cluster is involved in the molecular etiology of the SCLL syndrome driven by the BCR-FGFR1 chimeric kinase	ONCOGENE			English	Article							8P11 MYELOPROLIFERATIVE SYNDROME; T-CELL LYMPHOMA; MYELOID-LEUKEMIA; MICRORNAS; CANCER; GENE; ACTIVATION; FGFR1; OVEREXPRESSION; ASSOCIATION	MicroRNAs (miRNAs) have pathogenic roles in the development of a variety of leukemias. Here we identify miRNAs that have important roles in the development of B lymphomas resulting from the expression of the chimeric BCR-FGFR1 kinase. The miR-17/92 cluster was particularly implicated and forced expression resulted in increased cell proliferation, while inhibiting its function using miRNA sponges reduced cell growth and induced apoptosis. Cells treated with the potent BGJ389 FGFR1 inhibitor led to miR-17/92 downregulation, suggesting regulation by FGFR1. Transient luciferase reporter assays and qRT-PCR detection of endogenous miR-17/92 expression in stable transduced cell lines demonstrated that BCR-FGFR1 can regulate miR-17/92 expression. This positive association of miR-17/92 with BCR-FGFR1 was also confirmed in primary mouse SCLL tissues and primary human CLL samples. miR-17/92 promotes cell proliferation and survival by targeting CDKN1A and PTEN in B-lymphoma cell lines and primary tumors. An inverse correlation in expression levels was seen between miR-17/92 and both CDKN1A and PTEN in two cohorts of CLL patients. Finally, in vivo engraftment studies demonstrated that manipulation of miR-17/92 was sufficient to affect BCR-FGFR1-driven leukemogenesis. Overall, our results define miR-17/92 as a downstream effector of FGFR1 in BCR-FGFR1-driven B-cell lymphoblastic leukemia.	[Hu, Tianxiang; Chong, Yating; Qin, Haiyan; Kitamura, Eiko; Chang, Chang-Sheng; Silva, Jeane; Ren, Mingqiang; Cowell, John K.] Augusta Univ, Georgia Canc Ctr, Augusta, GA 30912 USA; [Cowell, John K.] Uniformed Serv Univ Hlth Sci, Consortium Hlth & Mil Performance, Dept Mil & Emergency Med, Bethesda, MD 20814 USA	University System of Georgia; Augusta University; Uniformed Services University of the Health Sciences - USA	Cowell, JK (corresponding author), Augusta Univ, Georgia Canc Ctr, Augusta, GA 30912 USA.; Cowell, JK (corresponding author), Uniformed Serv Univ Hlth Sci, Consortium Hlth & Mil Performance, Dept Mil & Emergency Med, Bethesda, MD 20814 USA.	jcowell@augusta.edu	Hu, TianXiang/Q-2099-2019	Hu, TianXiang/0000-0002-5127-9211; Silva, PhD, MPA, EdS, EdD, MB(ASCP)CM, Jeane/0000-0003-3368-3963	National Institutes of Health [CA076167]; NATIONAL CANCER INSTITUTE [R01CA076167] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grant CA076167 from the National Institutes of Health.	Agerstam H, 2010, BLOOD, V116, P2103, DOI 10.1182/blood-2009-05-217182; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Cowell JK, 2016, BRIT J HAEMATOL, V175, P542, DOI 10.1111/bjh.13877; Demiroglu A, 2001, BLOOD, V98, P3778, DOI 10.1182/blood.V98.13.3778; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Eekels JJM, 2012, GENE THER, V19, P1058, DOI 10.1038/gt.2011.191; Gao J, 2013, J CHEM-NY, V2013, DOI 10.1155/2013/719179; Guasch G, 2004, BLOOD, V103, P309, DOI 10.1182/blood-2003-05-1690; Hong LX, 2010, CANCER RES, V70, P8547, DOI 10.1158/0008-5472.CAN-10-1938; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Jackson CC, 2010, HUM PATHOL, V41, P461, DOI 10.1016/j.humpath.2009.11.003; Jiang X, 2016, CANCER RES, V76, P4470, DOI 10.1158/0008-5472.CAN-15-2949; Jiang X, 2012, CANCER CELL, V22, P524, DOI 10.1016/j.ccr.2012.08.028; Kim Kang Ho, 2015, Curr Protoc Mol Biol, V111, DOI 10.1002/0471142727.mb2806s111; Kluiver J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029275; Kumar KR, 2015, AM J CLIN PATHOL, V143, P738, DOI 10.1309/AJCPUD6W1JLQQMNA; Lai NS, 2014, J CLIN NEUROSCI, V21, P755, DOI 10.1016/j.jocn.2013.06.024; Macdonald D, 2002, ACTA HAEMATOL-BASEL, V107, P101, DOI 10.1159/000046639; Marcucci G, 2011, BLOOD, V117, P1121, DOI 10.1182/blood-2010-09-191312; Maura F, 2015, LEUKEMIA LYMPHOMA, V56, P3150, DOI 10.3109/10428194.2015.1028051; Mavrakis KJ, 2011, NAT GENET, V43, P673, DOI 10.1038/ng.858; Mayr C, 2009, CELL, V138, P673, DOI 10.1016/j.cell.2009.06.016; Mi SL, 2010, P NATL ACAD SCI USA, V107, P3710, DOI 10.1073/pnas.0914900107; Mihailovich M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9725; Mogilyansky E, 2013, CELL DEATH DIFFER, V20, P1603, DOI 10.1038/cdd.2013.125; Morabito F, 2013, CLIN CANCER RES, V19, P5890, DOI 10.1158/1078-0432.CCR-13-0622; Mu P, 2009, GENE DEV, V23, P2806, DOI 10.1101/gad.1872909; Olive V, 2009, GENE DEV, V23, P2839, DOI 10.1101/gad.1861409; Ornitz DM, 2015, WIRES DEV BIOL, V4, P215, DOI 10.1002/wdev.176; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Pan YY, 2014, CURR PHARM DESIGN, V20, P5260, DOI 10.2174/1381612820666140128211724; Petrocca F, 2008, CANCER RES, V68, P8191, DOI 10.1158/0008-5472.CAN-08-1768; Psathas JN, 2013, BLOOD, V122, P4220, DOI 10.1182/blood-2012-12-473090; Qin HY, 2016, HAEMATOLOGICA, V101, pE91, DOI 10.3324/haematol.2015.137695; Ren MQ, 2016, INT J CANCER, V139, P836, DOI 10.1002/ijc.30100; Ren MQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038265; Ren MQ, 2011, CANCER RES, V71, P7312, DOI 10.1158/0008-5472.CAN-11-1109; Ren MQ, 2011, BLOOD, V117, P6837, DOI 10.1182/blood-2010-07-295725; Ren MQ, 2009, BLOOD, V114, P1576, DOI 10.1182/blood-2009-03-212704; Roumiantsev S, 2004, CANCER CELL, V5, P287, DOI 10.1016/S1535-6108(04)00053-4; Teng Y, 2014, ONCOGENE, V33, P203, DOI 10.1038/onc.2012.565; Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780; Veronese A, 2010, CANCER RES, V70, P3140, DOI 10.1158/0008-5472.CAN-09-4456; Volinia S, 2010, GENOME RES, V20, P589, DOI 10.1101/gr.098046.109; Wu Q, 2016, ONCOTARGET, V7, P49733, DOI 10.18632/oncotarget.10438; Xiao FQ, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-195; Xie BY, 2013, BIOINFORMATICS, V29, P638, DOI 10.1093/bioinformatics/btt014; Xu SL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7764; Yang ZH, 2013, J BIOL CHEM, V288, P28893, DOI 10.1074/jbc.M113.502682; Zhou L, 2016, ONCOTARGET, V7, P51943, DOI 10.18632/oncotarget.10460	50	11	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	14					1926	1938		10.1038/s41388-017-0091-1	http://dx.doi.org/10.1038/s41388-017-0091-1			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GB8CU	29367757	Green Accepted			2022-12-17	WOS:000429303300009
J	Li, Y; Sun, H; Zhang, C; Liu, J; Zhang, H; Fan, F; Everley, RA; Ning, X; Sun, Y; Hu, J; Liu, J; Zhang, J; Ye, W; Qiu, X; Dai, S; Liu, B; Xu, H; Fu, S; Gygi, SP; Zhou, C				Li, Y.; Sun, H.; Zhang, C.; Liu, J.; Zhang, H.; Fan, F.; Everley, R. A.; Ning, X.; Sun, Y.; Hu, J.; Liu, J.; Zhang, J.; Ye, W.; Qiu, X.; Dai, S.; Liu, B.; Xu, H.; Fu, S.; Gygi, S. P.; Zhou, C.			Identification of translationally controlled tumor protein in promotion of DNA homologous recombination repair in cancer cells by affinity proteomics	ONCOGENE			English	Article							DAMAGE RESPONSE; ATM ACTIVATION; THERAPEUTIC TARGET; TCTP; MECHANISM; ALPHA; SERTRALINE; INHIBITION; INTERACTS; PATHWAYS	Translationally controlled tumor protein (TCTP) has been implicated in the regulation of apoptosis, DNA repair and drug resistance. However, the underlying molecular mechanisms are poorly defined. To better understand the molecular mechanisms underlying TCTP involved in cellular processes, we performed an affinity purification-based proteomic profiling to identify proteins interacting with TCTP in human cervical cancer HeLa cells. We found that a group of proteins involved in DNA repair are enriched in the potential TCTP interactome. Silencing TCTP by short hairpin RNA in breast carcinoma MCF-7 cells leads to the declined repair efficiency for DNA double-strand breaks on the GFP-Pem1 reporter gene by homologous recombination, the persistent activation and the prolonged retention of gamma H2AX and Rad51 foci following ionizing radiation. Reciprocal immunoprecipitations indicated that TCTP forms complexes with Rad51 in vivo, and the stability maintenance of Rad51 requires TCTP in MCF-7 cells under normal cell culture conditions. Moreover, inactivation of TCTP by sertraline treatment enhances UVC irradiation-induced apoptosis in MCF-7 cells, and causes sensitization to DNA-damaging drug etoposide and DNA repair inhibitor olaparib. Thus, we have identified an important role of TCTP in promoting DNA double-stand break repair via facilitating DNA homologous recombination processes and highlighted the great potential of TCTP as a drug target to enhance conventional chemotherapy for cancer patients with high levels of TCTP expression.	[Li, Y.; Sun, H.; Liu, J.; Zhang, H.; Fan, F.; Ning, X.; Sun, Y.; Hu, J.; Fu, S.; Zhou, C.] Harbin Med Univ, Lab Med Genet, 157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China; [Zhang, C.; Liu, J.; Zhang, J.; Ye, W.; Qiu, X.] Harbin Med Univ, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China; [Everley, R. A.; Gygi, S. P.] Harvard Med Sch, Dept Cell Biol, Boston, MA USA; [Dai, S.; Liu, B.] Harbin Med Univ, Tumor Hosp, Harbin, Heilongjiang, Peoples R China; [Xu, H.] Dalian Med Univ, Affiliated Hosp 1, Dept Clin Lab, Dalian, Peoples R China	Harbin Medical University; Harbin Medical University; Harvard University; Harvard Medical School; Harbin Medical University; Dalian Medical University	Zhou, C (corresponding author), Harbin Med Univ, Lab Med Genet, 157 Baojian Rd, Harbin 150081, Heilongjiang, Peoples R China.	Chunshuizhou@163.com			National Natural Science Foundation of China [81272582, 31600662]; National Institutes of Health, USA	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Professor Vera Gorbunova of the University of Rochester for providing the GFP-Pem1 reporter plasmid and CMV-HA-I-Sce I expression plasmid for detection of HR. We also thank Drs Bo Zhai, Willi Haas of SPG lab for their assistance and advice, and Dr Noah Dephoure's critical comments on manuscript writing. YL, HS, JL, HZ and CZ are supported by Grant No. 81272582 from the National Natural Science Foundation of China, HX is supported by Grant No. 31600662 from the National Natural Science Foundation of China. RAE and SPG are supported by National Institutes of Health, USA.	Acunzo J, 2014, CANCER TREAT REV, V40, P760, DOI 10.1016/j.ctrv.2014.02.007; Aglipay JA, 2006, J BIOL CHEM, V281, P9710, DOI 10.1074/jbc.M510332200; Amson R, 2013, TRENDS CELL BIOL, V23, P37, DOI 10.1016/j.tcb.2012.10.002; Amson R, 2012, NAT MED, V18, P91, DOI 10.1038/nm.2546; Batchelor E, 2009, NAT REV CANCER, V9, P371, DOI 10.1038/nrc2604; Baylot V, 2012, MOL THER, V20, P2244, DOI 10.1038/mt.2012.155; Bouwmeester T, 2004, NAT CELL BIOL, V6, P97, DOI 10.1038/ncb1086; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Cucchi U, 2010, ANTICANCER RES, V30, P4973; Filippo JS, 2008, ANNU REV BIOCHEM, V77, P229, DOI 10.1146/annurev.biochem.77.061306.125255; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Gachet Y, 1999, J CELL SCI, V112, P1257; Gnanasekar M, 2009, BIOCHEM BIOPH RES CO, V386, P333, DOI 10.1016/j.bbrc.2009.06.028; Gunaratne J, 2011, J BIOL CHEM, V286, P18093, DOI 10.1074/jbc.M111.221184; Hong ST, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3986; Hurov KE, 2010, GENE DEV, V24, P1939, DOI 10.1101/gad.1934210; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Jorge RE, 2016, JAMA PSYCHIAT, V73, P1041, DOI 10.1001/jamapsychiatry.2016.2189; Jung J, 2004, J BIOL CHEM, V279, P49868, DOI 10.1074/jbc.M400895200; Katsogiannou M, 2014, MOL CELL PROTEOMICS, V13, P3585, DOI 10.1074/mcp.M114.041228; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Li F, 2001, J BIOL CHEM, V276, P47542, DOI 10.1074/jbc.M108954200; Li TY, 2016, ONCOTARGET, V7, P11838, DOI 10.18632/oncotarget.7864; Lieber MR, 2008, J BIOL CHEM, V283, P1, DOI 10.1074/jbc.R700039200; Lieber MR, 2010, ANNU REV BIOCHEM, V79, P181, DOI 10.1146/annurev.biochem.052308.093131; Liu JM, 2001, ONCOGENE, V20, P336, DOI 10.1038/sj.onc.1204098; Low LH, 2015, J BIOL CHEM, V290, P7141, DOI 10.1074/jbc.M114.613687; Lu GQ, 2016, P NATL ACAD SCI USA, V113, P1256, DOI 10.1073/pnas.1521597113; Lucibello M, 2015, ONCOTARGET, V6, P5275, DOI 10.18632/oncotarget.2971; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Mao ZY, 2012, P NATL ACAD SCI USA, V109, P11800, DOI 10.1073/pnas.1200583109; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; Rho SB, 2011, FEBS LETT, V585, P29, DOI 10.1016/j.febslet.2010.11.014; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Seo EJ, 2016, ONCOTARGET, V7, P16818, DOI 10.18632/oncotarget.7605; Simsek D, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002080; Sinha P, 2000, ELECTROPHORESIS, V21, P3048, DOI 10.1002/1522-2683(20000801)21:14<3048::AID-ELPS3048>3.0.CO;2-W; Susini L, 2008, CELL DEATH DIFFER, V15, P1211, DOI 10.1038/cdd.2008.18; Suwaki N, 2011, SEMIN CELL DEV BIOL, V22, P898, DOI 10.1016/j.semcdb.2011.07.019; Tkach JM, 2012, NAT CELL BIOL, V14, P966, DOI 10.1038/ncb2549; Tuynder M, 2004, P NATL ACAD SCI USA, V101, P15364, DOI 10.1073/pnas.0406776101; Wang LF, 2016, NEUROPSYCH DIS TREAT, V12, P1127, DOI 10.2147/NDT.S106562; Woodhouse BC, 2008, DNA REPAIR, V7, P932, DOI 10.1016/j.dnarep.2008.03.017; Xu H, 2015, J PROTEOME RES, V14, P2480, DOI 10.1021/acs.jproteome.5b00004; Yang Y, 2005, ONCOGENE, V24, P4778, DOI 10.1038/sj.onc.1208666; You ZS, 2005, MOL CELL BIOL, V25, P5363, DOI 10.1128/MCB.25.13.5363-5379.2005; Zhang D, 2002, J BIOL CHEM, V277, P37430, DOI 10.1074/jbc.M207413200; Zhang J, 2012, P NATL ACAD SCI USA, V109, pE926, DOI 10.1073/pnas.1106300109; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	51	11	12	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 14	2017	36	50					6839	6849		10.1038/onc.2017.289	http://dx.doi.org/10.1038/onc.2017.289			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FQ0JM	28846114	hybrid, Green Published			2022-12-17	WOS:000418041800001
J	Ando, S; Malivindi, R; Catalano, S; Rizza, P; Barone, I; Panza, S; Rovito, D; Emprou, C; Bornert, JM; Laverny, G; Metzger, D				Ando, S.; Malivindi, R.; Catalano, S.; Rizza, P.; Barone, I.; Panza, S.; Rovito, D.; Emprou, C.; Bornert, J-M; Laverny, G.; Metzger, D.			Conditional expression of Ki-Ras(G12V) in the mammary epithelium of transgenic mice induces estrogen receptor alpha (ER alpha)-positive adenocarcinoma	ONCOGENE			English	Article							SITE-SPECIFIC RECOMBINATION; BREAST-CANCER; MOUSE MODEL; GENE-EXPRESSION; RAS ACTIVATION; TUMOR-GROWTH; K-RAS; MYC; INHIBITION; ONCOGENE	Appropriate 'in vivo' models are crucial for studying breast cancer biology and evaluating the efficacy of therapeutic agents. Thus we engineered a novel transgenic mouse line expressing the human Ki-Ras bearing an activating mutation (Ki-Ras(G12V)) selectively in the mammary epithelium after lactation. These mice develop invasive ductal adenocarcinomas with 100% incidence within 3-9 months after Ki-Ras(G12V) induction. Immunophenotyping revealed that the mammary tumors express luminal markers, are positive for estrogen and progesterone receptors, negative for HER2 and have a low proliferation index. Moreover, cell lines derived from such tumors are estrogen-responsive and, when transplanted into nude mice, form tumors that respond to the antiestrogen ICI 182780. In conclusion, the mammary tumors of these transgenic mice and the derived cell lines exhibit key features of the major form of human breast cancer, that is, luminal A subtype and thus have a high potential for breast cancer research and treatment.	[Ando, S.; Malivindi, R.; Catalano, S.; Rizza, P.; Barone, I.; Panza, S.; Rovito, D.] Univ Calabria, Dept Pharm Hlth & Nutr Sci, Edificio Polifunz,Via P Bucci, I-87036 Arcavacata Di Renda, CS, Italy; [Ando, S.] Univ Calabria, Ctr Sanit, Arcavacata Di Renda, CS, Italy; [Rovito, D.; Emprou, C.; Bornert, J-M; Laverny, G.; Metzger, D.] Univ Strasbourg, Dept Funct Genom & Canc, U964, CNRS,INSERM,IGBMC,UMR 7104, F-67404 Illkirch Graffenstaden, France	University of Calabria; University of Calabria; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Ando, S (corresponding author), Univ Calabria, Dept Pharm Hlth & Nutr Sci, Edificio Polifunz,Via P Bucci, I-87036 Arcavacata Di Renda, CS, Italy.; Metzger, D (corresponding author), Univ Strasbourg, Dept Funct Genom & Canc, U964, CNRS,INSERM,IGBMC,UMR 7104, F-67404 Illkirch Graffenstaden, France.	sebastiano.ando@unical.it; metzger@igbmc.fr	Rovito, Daniela/AEN-0314-2022; Malivindi, Rocco/ABB-8562-2021; Emprou, Camille/F-3854-2019; Laverny, Gilles/G-5412-2017	Rovito, Daniela/0000-0001-5390-5477; Emprou, Camille/0000-0002-0185-3668; MALIVINDI, Rocco/0000-0002-8313-2492; Metzger, Daniel/0000-0002-5555-046X; Laverny, Gilles/0000-0002-2666-6877; CATALANO, Stefania/0000-0002-6352-9628; BARONE, Ines/0000-0002-9769-1615	PRIN [2015B7M39T]; Fondazione Italiana per la Ricerca sul Cancro (AIRC) [11595]; PROGRAMMA 'FUTURO IN RICERCA' [RBFR12FI27]; AIRC Fellowships [19552]; EMBO ASTF [182010]; European Social Fund operational programme of the Calabria region; Faculte de Medecine, Universite de Strasbourg; Centre National pour la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (INSERM); Universite de Strasbourg; French state funds through the Agence Nationale de la Recherche [ANR-10-LABX-0030-INRT, ANR-10-IDEX-0002-02]; MFAG [16899]	PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Fondazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); PROGRAMMA 'FUTURO IN RICERCA'; AIRC Fellowships(Fondazione AIRC per la ricerca sul cancro); EMBO ASTF(European Molecular Biology Organization (EMBO)); European Social Fund operational programme of the Calabria region; Faculte de Medecine, Universite de Strasbourg; Centre National pour la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); Universite de Strasbourg; French state funds through the Agence Nationale de la Recherche(French National Research Agency (ANR)); MFAG	We thank Dr Watson and Dr Whitelaw for BLG-Cre mice, Merck Research Laboratories for the MMTV-Ki-Ras<SUP>(G12V)</SUP> plasmid and Catherine Tomasetto and Fabien Alpy for helpful discussions. We also thank Neil E Hubbard and Judith Walls (Center for Comparative Medicine, University of California, Davis, CA, USA), the staff of the mouse and genetic engineering facilities from ICS and IGBMC and Elise Grelet for their excellent assistance. This work was supported by: PRIN2015 #2015B7M39T (to SA), Fondazione Italiana per la Ricerca sul Cancro (AIRC) grants: IG no. 11595 (to SA), MFAG no. 16899 (to IB), PROGRAMMA 'FUTURO IN RICERCA' Anno 2012 no. RBFR12FI27 (to IB), AIRC Fellowships for abroad no. 19552 (to DR), EMBO ASTF no. 182010 (to RM), European Social Fund operational programme of the Calabria region (to SP), Faculte de Medecine, Universite de Strasbourg (to CE) and by the Centre National pour la Recherche Scientifique (CNRS), the Institut National de la Sante et de la Recherche Medicale (INSERM), the Universite de Strasbourg and French state funds through the Agence Nationale de la Recherche ANR-10-LABX-0030-INRT under the frame programme Investissements d'Avenir labelled ANR-10-IDEX-0002-02.	Andrechek ER, 2000, P NATL ACAD SCI USA, V97, P3444, DOI 10.1073/pnas.050408497; Barone I, 2012, ENDOCRINOLOGY, V153, P5157, DOI 10.1210/en.2012-1561; Barone I, 2009, CANCER RES, V69, P4724, DOI 10.1158/0008-5472.CAN-08-4194; Cardiff RD, 2000, ONCOGENE, V19, P968, DOI 10.1038/sj.onc.1203277; Catalano S, 2016, MINI-REV MED CHEM, V16, P691, DOI 10.2174/1389557516666160321113041; Catalano S, 2013, INT J CANCER, V132, P2237, DOI 10.1002/ijc.27915; Catalano S, 2009, MOL ENDOCRINOL, V23, P1634, DOI 10.1210/me.2009-0039; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Chen M, 2013, ONCOL LETT, V6, P118, DOI 10.3892/ol.2013.1324; Dabydeen SA, 2014, ENDOCR-RELAT CANCER, V21, pR195, DOI 10.1530/ERC-13-0512; DATI C, 1991, INT J CANCER, V47, P833, DOI 10.1002/ijc.2910470607; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Feil R, 1996, P NATL ACAD SCI USA, V93, P10887, DOI 10.1073/pnas.93.20.10887; Giordano C, 2016, SCI REP-UK, V6, DOI 10.1038/srep21782; Giordano C, 2016, ONCOTARGET, V7, P1262, DOI 10.18632/oncotarget.6014; Grande F, 2016, FUTURE MED CHEM, V8, P93, DOI 10.4155/fmc.15.176; Green JE, 2000, ONCOGENE, V19, P1020, DOI 10.1038/sj.onc.1203280; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Habashy HO, 2012, HISTOPATHOLOGY, V60, P854, DOI 10.1111/j.1365-2559.2011.03912.x; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Howe LR, 2011, CANCER PREV RES, V4, P1149, DOI 10.1158/1940-6207.CAPR-11-0334; Imai T, 2000, GENESIS, V26, P147, DOI 10.1002/(SICI)1526-968X(200002)26:2<147::AID-GENE15>3.0.CO;2-3; Indra AK, 1999, NUCLEIC ACIDS RES, V27, P4324, DOI 10.1093/nar/27.22.4324; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Klinakis A, 2009, P NATL ACAD SCI USA, V106, P2359, DOI 10.1073/pnas.0810221106; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; LAKSO M, 1992, P NATL ACAD SCI USA, V89, P6232, DOI 10.1073/pnas.89.14.6232; Loboda A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-26; Malaney S, 2001, J MAMMARY GLAND BIOL, V6, P101, DOI 10.1023/A:1009572700317; Mauro L, 2007, CANCER RES, V67, P3412, DOI 10.1158/0008-5472.CAN-06-2890; McGlynn LM, 2013, EUR J CANCER, V49, P1176, DOI 10.1016/j.ejca.2012.11.020; Metzger D, 2001, METHODS, V24, P71, DOI 10.1006/meth.2001.1159; NANDI S, 1995, P NATL ACAD SCI USA, V92, P3650, DOI 10.1073/pnas.92.9.3650; O'Hagan Ronan C, 2011, Genes Cancer, V2, P335, DOI 10.1177/1947601911408080; Omer CA, 2000, CANCER RES, V60, P2680; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Podsypanina K, 2008, P NATL ACAD SCI USA, V105, P5242, DOI 10.1073/pnas.0801197105; Reddy Haritha K D L, 2010, Genes Cancer, V1, P69, DOI 10.1177/1947601909358105; SANDGREN EP, 1995, CANCER RES, V55, P3915; Santen RJ, 2009, ENDOCR REV, V30, P343, DOI 10.1210/er.2008-0016; SCHOENENBERGER CA, 1988, EMBO J, V7, P169, DOI 10.1002/j.1460-2075.1988.tb02797.x; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Selbert S, 1998, TRANSGENIC RES, V7, P387, DOI 10.1023/A:1008848304391; Shen Q, 2005, MUTAT RES-FUND MOL M, V576, P93, DOI 10.1016/j.mrfmmm.2004.10.013; Singh AP, 2004, CANCER RES, V64, P622, DOI 10.1158/0008-5472.CAN-03-2636; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920	51	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 16	2017	36	46					6420	6431		10.1038/onc.2017.252	http://dx.doi.org/10.1038/onc.2017.252			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FM9WN	28745321	Green Submitted			2022-12-17	WOS:000415622900006
J	Forsberg, J; Zhivotovsky, B; Olsson, M				Forsberg, J.; Zhivotovsky, B.; Olsson, M.			Caspase-2: an orphan enzyme out of the shadows	ONCOGENE			English	Review							CELL-DEATH; MITOTIC CATASTROPHE; METABOLIC-REGULATION; TUMOR SUPPRESSION; DNA-DAMAGE; APOPTOSIS; PIDDOSOME; INSTABILITY; ACTIVATION; PROTEIN	Caspase-2 has been embodied as an initiator or executioner protease in diverse apoptotic scenarios. However, accumulating evidence is challenging this view, pertaining to its true role. The enzyme's catalytic activity is currently implicated in various functions required for correct cell proliferation, such as counteracting genomic instability, as well as suppressing tumorigenesis. Here, apart from summarizing the latest observations in caspase-2-related research, we make an attempt to reconcile these findings and discuss their implications for future directions.	[Forsberg, J.; Zhivotovsky, B.; Olsson, M.] Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden; [Zhivotovsky, B.] Lomonosov Moscow State Univ, Fac Fundamental Med, Moscow, Russia	Karolinska Institutet; Lomonosov Moscow State University	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden.	Boris.Zhivotovsky@ki.se	Zhivotovsky, Boris/A-4346-2014; Olsson, Magnus/E-3140-2012	Zhivotovsky, Boris/0000-0002-2238-3482; Olsson, Magnus/0000-0002-6370-8423	Swedish Cancer Society; Stockholm Cancer Society; Swedish Childhood Cancer Foundation; Swedish Research Council; Russian Science Foundation [14-25-00056-II]; Russian President Fund [NSH-7082.2016]; Russian Science Foundation [17-25-00012] Funding Source: Russian Science Foundation	Swedish Cancer Society(Swedish Cancer Society); Stockholm Cancer Society; Swedish Childhood Cancer Foundation(European Commission); Swedish Research Council(Swedish Research CouncilEuropean Commission); Russian Science Foundation(Russian Science Foundation (RSF)); Russian President Fund; Russian Science Foundation(Russian Science Foundation (RSF))	The work in the authors' laboratories is supported by grants from the Swedish and Stockholm Cancer Societies, the Swedish Childhood Cancer Foundation, the Swedish Research Council. BZ was supported by the Russian Science Foundation (14-25-00056-II) and the Russian President Fund (grant number NSH-7082.2016).	Albertini V, 2006, NUCLEIC ACIDS RES, V34, P1721, DOI 10.1093/nar/gkl063; Andersen JL, 2009, EMBO J, V28, P3216, DOI 10.1038/emboj.2009.253; Bataller M, 2008, MOL CANCER THER, V7, P2988, DOI 10.1158/1535-7163.MCT-08-0420; Biffi G, 2017, NATURE, V542, P34, DOI 10.1038/nature21117; BLUME SW, 1991, J CLIN INVEST, V88, P1613, DOI 10.1172/JCI115474; Bouchier-Hayes L, 2012, CELL DEATH DIFFER, V19, P51, DOI 10.1038/cdd.2011.157; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Dawar S, 2017, ONCOGENE, V36, P2704, DOI 10.1038/onc.2016.423; Dawar S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.406; Dey P, 2017, NATURE, V542, P119, DOI 10.1038/nature21052; Dorstyn L, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.342; Dorstyn L, 2012, CELL DEATH DIFFER, V19, P1288, DOI 10.1038/cdd.2012.36; Fava LL, 2017, GENE DEV, V31, P34, DOI 10.1101/gad.289728.116; Fava LL, 2012, J CELL SCI, V125, P5911, DOI 10.1242/jcs.115105; Gitenay D, 2014, ONCOTARGET, V5, P5845, DOI 10.18632/oncotarget.2286; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Guha M, 2010, ONCOGENE, V29, P1280, DOI 10.1038/onc.2009.428; Heng HH, 2013, CANCER METAST REV, V32, P325, DOI 10.1007/s10555-013-9427-7; Ho LH, 2008, ONCOGENE, V27, P3393, DOI 10.1038/sj.onc.1211005; Ho LH, 2009, P NATL ACAD SCI USA, V106, P5336, DOI 10.1073/pnas.0811928106; Imreh G, 2011, J CELL SCI, V124, P2951, DOI 10.1242/jcs.081612; Kim IR, 2009, APOPTOSIS, V14, P1039, DOI 10.1007/s10495-009-0375-1; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; Lee JK, 2016, ANNU REV PATHOL-MECH, V11, P283, DOI 10.1146/annurev-pathol-012615-044446; Liu J, 2017, MITOCHONDRIAL DNA B, V2, P1, DOI 10.1080/23802359.2016.1186511; Lopez-Garcia C, 2017, CANCER CELL, V31, P79, DOI 10.1016/j.ccell.2016.11.001; Manzl C, 2012, CELL DEATH DIFFER, V19, P1722, DOI 10.1038/cdd.2012.54; Manzl C, 2009, J CELL BIOL, V185, P291, DOI 10.1083/jcb.200811105; Mccoy F, 2013, MOL CELL, V52, P325, DOI 10.1016/j.molcel.2013.08.043; McCoy F, 2013, J BIOL CHEM, V288, P8838, DOI 10.1074/jbc.M112.437186; Mendelsohn AR, 2002, P NATL ACAD SCI USA, V99, P6871, DOI 10.1073/pnas.072290599; Nutt LK, 2005, CELL, V123, P89, DOI 10.1016/j.cell.2005.07.032; Ohashi A, 2016, MOL CELL ONCOL, V3, DOI 10.1080/23723556.2015.1088503; Ohashi A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8668; Oliver TG, 2011, MOL CELL, V43, P57, DOI 10.1016/j.molcel.2011.06.012; Olsson M, 2015, ONCOGENE, V34, P1877, DOI 10.1038/onc.2014.139; Parsons MJ, 2013, CELL DEATH DIFFER, V20, P1174, DOI 10.1038/cdd.2013.38; Peintner L, 2015, CELL DEATH DIFFER, V22, P1803, DOI 10.1038/cdd.2015.31; Puccini J, 2013, CELL DEATH DIFFER, V20, P1133, DOI 10.1038/cdd.2013.87; Puccini J, 2013, P NATL ACAD SCI USA, V110, P19920, DOI 10.1073/pnas.1311947110; Ren KQ, 2012, J BIOL CHEM, V287, P14792, DOI 10.1074/jbc.M112.347625; Ribe EM, 2012, BIOCHEM J, V444, P591, DOI 10.1042/BJ20111588; Shalini S, 2015, ONCOGENE, V34, P4995, DOI 10.1038/onc.2014.413; Terry MR, 2015, CELL DEATH DIFFER, V22, P719, DOI 10.1038/cdd.2014.159; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Tiwari M, 2014, AUTOPHAGY, V10, P1054, DOI 10.4161/auto.28528; Vakifahmetoglu H, 2006, ONCOGENE, V25, P5683, DOI 10.1038/sj.onc.1209569; Vitale I GM, 2017, MOL CELL ON IN PRESS; Yang ZNJ, 2011, MOL CANCER THER, V10, P1533, DOI 10.1158/1535-7163.MCT-11-0047; Yao Y, 2014, J CARCINOG MUTAGEN, V5; Zhivotovsky B, 2004, NAT REV MOL CELL BIO, V5, P752, DOI 10.1038/nrm1443	52	11	11	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 28	2017	36	39					5441	5444		10.1038/onc.2017.169	http://dx.doi.org/10.1038/onc.2017.169			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FI4RG	28581521				2022-12-17	WOS:000411960500001
J	Hernandez-Perez, S; Cabrera, E; Salido, E; Lim, M; Reid, L; Lakhani, SR; Khanna, KK; Saunus, JM; Freire, R				Hernandez-Perez, S.; Cabrera, E.; Salido, E.; Lim, M.; Reid, L.; Lakhani, S. R.; Khanna, K. K.; Saunus, J. M.; Freire, R.			DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer	ONCOGENE			English	Article							DNA-REPLICATION; DEUBIQUITINATING ENZYMES; SUMO DEUBIQUITINASE; STEM-CELLS; CDT1; P53; STABILIZATION; EXPRESSION; STABILITY; TRANSFORMATION	Correct control of DNA replication is crucial to maintain genomic stability in dividing cells. Inappropriate re-licensing of replicated origins is associated with chromosomal instability (CIN), a hallmark of cancer progression that at the same time provides potential opportunities for therapeutic intervention. Geminin is a critical inhibitor of the DNA replication licensing factor Cdt1. To properly achieve its functions, Geminin levels are tightly regulated through the cell cycle by ubiquitin-dependent proteasomal degradation, but the de-ubiquitinating enzymes ( DUBs) involved had not been identified. Here we report that DUB3 and USP7 control human Geminin. Overexpression of either DUB3 or USP7 increases Geminin levels through reduced ubiquitination. Conversely, depletion of DUB3 or USP7 reduces Geminin levels, and DUB3 knockdown increases re-replication events, analogous to the effect of Geminin depletion. In exploring potential clinical implications, we found that USP7 and Geminin are strongly correlated in a cohort of invasive breast cancers (P < 1.01E - 08). As expected, Geminin expression is highly prognostic. Interestingly, we found a non-monotonic relationship between USP7 and breast cancer-specific survival, with both very low or high levels of USP7 associated with poor outcome, independent of estrogen receptor status. Altogether, our data identify DUB3 and USP7 as factors that regulate DNA replication by controlling Geminin protein stability, and suggest that USP7 may be involved in Geminin dysregulation during breast cancer progression.	[Hernandez-Perez, S.; Cabrera, E.; Salido, E.; Freire, R.] Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, Ofra S-N, San Cristobal la Laguna 38320, Tenerife, Spain; [Lim, M.; Reid, L.; Lakhani, S. R.; Saunus, J. M.] Univ Queensland, UQ Ctr Clin Res, Herston, Qld, Australia; [Lim, M.; Reid, L.; Saunus, J. M.] QIMR Berghofer Med Res Inst, Herston, Qld, Australia; [Lakhani, S. R.] Royal Brisbane & Womens Hosp, Pathol Queensland, Herston, Qld, Australia; [Lakhani, S. R.] Univ Queensland, Sch Med, Herston, Qld, Australia; [Khanna, K. K.] QIMR Berghofer Inst Med Res, Signal Transduct Lab, Brisbane, Qld, Australia	Universidad de la Laguna; University of Queensland; QIMR Berghofer Medical Research Institute; Royal Brisbane & Women's Hospital; University of Queensland; QIMR Berghofer Medical Research Institute	Freire, R (corresponding author), Hosp Univ Canarias, Inst Tecnol Biomed, Unidad Invest, Ofra S-N, San Cristobal la Laguna 38320, Tenerife, Spain.; Saunus, JM (corresponding author), Univ Queensland, UQ Ctr Clin Res, Herston, Qld, Australia.	j.saunus@uq.edu.au; rfreire@ull.edu.es	Cabrera, Elisa/GPX-3455-2022; Freire, Raimundo/Q-7660-2019; Saunus, Jodi/AAE-5291-2020; Lakhani, Sunil R/I-1970-2018; Saunus, Jodi M/C-6657-2011; Salido, Eduardo/I-2232-2015	Freire, Raimundo/0000-0003-4473-8894; Saunus, Jodi/0000-0002-4604-4709; Lakhani, Sunil R/0000-0003-4067-2760; Saunus, Jodi M/0000-0002-4604-4709; Lim, Malcolm/0000-0003-3691-4368; Salido, Eduardo/0000-0001-9599-9854; Khanna, Kum Kum/0000-0001-8650-5381	Instituto de Salud Carlos III [BA15/00092]; Spanish Ministry of Economy and Competitiveness [SAF2013-49149-R, BFU2014-51672-REDC]; Fundacion CajaCanarias [AP2015/008]; Australian National Health and Medical Research (NHMRC program grant) [APP1017028]	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Spanish Ministry of Economy and Competitiveness(Spanish Government); Fundacion CajaCanarias; Australian National Health and Medical Research (NHMRC program grant)(National Health and Medical Research Council (NHMRC) of Australia)	We are grateful to V Smits for critical reading of the manuscript, J Moreira, E Lam, M van Vugt for sending cell lines and A Bravo for logistic help. This work was supported by grants from Instituto de Salud Carlos III (BA15/00092), the Spanish Ministry of Economy and Competitiveness (SAF2013-49149-R, BFU2014-51672-REDC), Fundacion CajaCanarias (AP2015/008) to RF and the Australian National Health and Medical Research (NHMRC program grant to SRL and KKK (APP1017028)).	Al-Ejeh F, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.41; Alonso-de Vega I, 2014, CELL CYCLE, V13, P3921, DOI 10.4161/15384101.2014.973324; Ballabeni A, 2004, EMBO J, V23, P3122, DOI 10.1038/sj.emboj.7600314; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Blow JJ, 2008, NAT REV CANCER, V8, P799, DOI 10.1038/nrc2500; Cabrera E, 2017, ONCOGENE, V36, P678, DOI 10.1038/onc.2016.239; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Chen H, 2013, MOL CELL BIOL, V33, P1139, DOI 10.1128/MCB.01191-12; Duncker BP, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-214; Epping MT, 2011, NAT CELL BIOL, V13, P102, DOI 10.1038/ncb2142; Faustrup H, 2009, J CELL BIOL, V184, P13, DOI 10.1083/jcb.200807137; Field S, 2016, INT J CANCER, V138, P1959, DOI 10.1002/ijc.29946; Fujita M, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-22; Gonzalez MA, 2004, J PATHOL, V204, P121, DOI 10.1002/path.1625; Hernandez-Perez S, 2016, MOL ONCOL, V10, P1196, DOI 10.1016/j.molonc.2016.05.008; Hills SA, 2014, CURR BIOL, V24, pR435, DOI 10.1016/j.cub.2014.04.012; Hu M, 2006, PLOS BIOL, V4, P228, DOI 10.1371/journal.pbio.0040027; Hussain S, 2009, CELL CYCLE, V8, P1688, DOI 10.4161/cc.8.11.8739; Jagannathan M, 2014, MOL CELL BIOL, V34, P132, DOI 10.1128/MCB.00639-13; Perez-Castro AJ, 2012, J CELL SCI, V125, P1152, DOI 10.1242/jcs.091124; Jones RM, 2013, ONCOGENE, V32, P3744, DOI 10.1038/onc.2012.387; Junankar S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7548; Kessler BM, 2014, EXPERT OPIN THER PAT, V24, P597, DOI 10.1517/13543776.2014.882320; Lecona E, 2016, NAT STRUCT MOL BIOL, V23, P270, DOI 10.1038/nsmb.3185; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Macheret M, 2015, ANNU REV PATHOL-MECH, V10, P425, DOI 10.1146/annurev-pathol-012414-040424; Maire V, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0063712, 10.1371/journal.pone.0077372]; Martin Y, 2015, ONCOGENE, V34, P1058, DOI 10.1038/onc.2014.38; McClurg UL, 2015, ONCOTARGET, V6, P9657, DOI 10.18632/oncotarget.3922; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Mihaylov IS, 2002, MOL CELL BIOL, V22, P1868, DOI 10.1128/MCB.22.6.1868-1880.2002; Nicholson B, 2011, CELL BIOCHEM BIOPHYS, V60, P61, DOI 10.1007/s12013-011-9185-5; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Pereg Y, 2010, NAT CELL BIOL, V12, P400, DOI 10.1038/ncb2041; Petropoulou C, 2008, FRONT BIOSCI, V13, P4485, DOI 10.2741/3018; Qian J, 2015, ONCOGENE, V34, P4791, DOI 10.1038/onc.2014.394; Rajan SS, 2014, BREAST CANCER RES TR, V143, P91, DOI 10.1007/s10549-013-2786-5; Refolio E, 2011, J CELL SCI, V124, P2488, DOI 10.1242/jcs.081711; Rialland M, 2002, J CELL SCI, V115, P1435; Rivlin N, 2014, P NATL ACAD SCI USA, V111, P7006, DOI 10.1073/pnas.1320428111; Delgado-Diaz MR, 2014, MOL ONCOL, V8, P884, DOI 10.1016/j.molonc.2014.03.003; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Smits VAJ, 2016, BIOESSAYS, V38, P863, DOI 10.1002/bies.201600096; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Srihari S, 2015, BIOL DIRECT, V10, DOI 10.1186/s13062-015-0086-1; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Wang Q, 2016, J CLIN INVEST, V126, P2205, DOI 10.1172/JCI85747; Yagi T, 2016, BREAST CANCER-TOKYO, V23, P224, DOI 10.1007/s12282-014-0556-9; Zhang P, 2014, NAT CELL BIOL, V16, P864, DOI 10.1038/ncb3013; Zhu WG, 2004, MOL CELL BIOL, V24, P7140, DOI 10.1128/MCB.24.16.7140-7150.2004; Zlatanou A, 2016, ONCOGENE, V35, P965, DOI 10.1038/onc.2015.149	51	11	11	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2017	36	33					4802	4809		10.1038/onc.2017.21	http://dx.doi.org/10.1038/onc.2017.21			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FD7JM	28288134				2022-12-17	WOS:000407702400012
J	Mertz, TM; Baranovskiy, AG; Wang, J; Tahirov, TH; Shcherbakova, PV				Mertz, T. M.; Baranovskiy, A. G.; Wang, J.; Tahirov, T. H.; Shcherbakova, P. V.			Nucleotide selectivity defect and mutator phenotype conferred by a colon cancer-associated DNA polymerase delta mutation in human cells	ONCOGENE			English	Article							MICROSATELLITE INSTABILITY; MISMATCH REPAIR; GERMLINE MUTATIONS; COLORECTAL-CANCER; HPRT LOCUS; REPLICATION; EPSILON; LINES; GENE; POLE	Mutations in the POLD1 and POLE genes encoding DNA polymerases delta (Pol delta) and epsilon (Pol epsilon) cause hereditary colorectal cancer (CRC) and have been found in many sporadic colorectal and endometrial tumors. Much attention has been focused on POLE exonuclease domain mutations, which occur frequently in hypermutated DNA mismatch repair (MMR)-proficient tumors and appear to be responsible for the bulk of genomic instability in these tumors. In contrast, somatic POLD1 mutations are seen less frequently and typically occur in MMR-deficient tumors. Their functional significance is often unclear. Here we demonstrate that expression of the cancer-associated POLD1-R689W allele is strongly mutagenic in human cells. The mutation rate increased synergistically when the POLD1-R689W expression was combined with a MMR defect, indicating that the mutator effect of POLD1-R689W results from a high rate of replication errors. Purified human Pol delta-R689W has normal exonuclease activity, but the nucleotide selectivity of the enzyme is severely impaired, providing a mechanistic explanation for the increased mutation rate in the POLD1-R689W-expressing cells. The vast majority of mutations induced by the POLD1-R689W are GC -> TA transversions and GC -> AT transitions, with transversions showing a strong strand bias and a remarkable preference for polypurine/polypyrimidine sequences. The mutational specificity of the Pol delta variant matches that of the hypermutated CRC cell line, HCT15, in which this variant was first identified. The results provide compelling evidence for the pathogenic role of the POLD1-R689W mutation in the development of the human tumor and emphasize the need to experimentally determine the significance of Pold variants present in sporadic tumors.	[Mertz, T. M.; Baranovskiy, A. G.; Wang, J.; Tahirov, T. H.; Shcherbakova, P. V.] Univ Nebraska, Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, 600 S 42nd St, Omaha, NE 68198 USA; [Mertz, T. M.] Washington State Univ, Sch Mol Biosci, Coll Vet Med, Pullman, WA 99164 USA	University of Nebraska System; University of Nebraska Medical Center; Washington State University	Shcherbakova, PV (corresponding author), Univ Nebraska, Med Ctr, Fred & Pamela Buffett Canc Ctr, Eppley Inst Res Canc & Allied Dis, 600 S 42nd St, Omaha, NE 68198 USA.	pshcherb@unmc.edu		Tahirov, Tahir/0000-0002-1238-0069	National Institutes of Health [ES015869, GM101167, CA140988]; Nebraska Department of Health and Human Services [LB506]; University of Nebraska Medical Center Graduate Studies Research Fellowship; Cancer Biology Training Grant from the National Cancer Institute [T32CA009476]; NATIONAL CANCER INSTITUTE [T32CA009476, R01CA140988] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM106397, R01GM101167] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska Department of Health and Human Services; University of Nebraska Medical Center Graduate Studies Research Fellowship; Cancer Biology Training Grant from the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Rob Lewis and Mike Brattain for cell lines, and Elizabeth Moore and Krista Brown for technical assistance. This work was supported by the National Institutes of Health grants ES015869 to PVS, GM101167 to THT and CA140988 to JW and by Nebraska Department of Health and Human Services grants LB506 to PVS and THT. TMM was supported by a University of Nebraska Medical Center Graduate Studies Research Fellowship and by the Cancer Biology Training Grant T32CA009476 from the National Cancer Institute.	Abaan OD, 2013, CANCER RES, V73, P4372, DOI 10.1158/0008-5472.CAN-12-3342; Agbor AA, 2013, DNA REPAIR, V12, P954, DOI 10.1016/j.dnarep.2013.08.012; Briggs S, 2013, J PATHOL, V230, P148, DOI 10.1002/path.4185; Church DN, 2013, HUM MOL GENET, V22, P2820, DOI 10.1093/hmg/ddt131; Daee DL, 2010, P NATL ACAD SCI USA, V107, P157, DOI 10.1073/pnas.0907526106; Flohr T, 1999, INT J CANCER, V80, P919, DOI 10.1002/(SICI)1097-0215(19990315)80:6<919::AID-IJC19>3.0.CO;2-U; Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113; Ghodgaonkar MM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5990; Giannakis M, 2016, CELL REP, V17, P1206, DOI 10.1016/j.celrep.2016.10.009; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; Herr AJ, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002282; Imai K, 2008, CARCINOGENESIS, V29, P673, DOI 10.1093/carcin/bgm228; Kane DP, 2014, CANCER RES, V74, P1895, DOI 10.1158/0008-5472.CAN-13-2892; Keohavong Phouthone, 2005, Methods Mol Biol, V291, P161, DOI 10.1385/1-59259-840-4:161; KOI M, 1994, CANCER RES, V54, P4308; Li L, 2005, GENETICS, V170, P569, DOI 10.1534/genetics.104.040295; Liu XQ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.221697; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; Masuda Y, 2007, NUCLEIC ACIDS RES, V35, P6904, DOI 10.1093/nar/gkm822; McElhinny SAN, 2007, J BIOL CHEM, V282, P2324, DOI 10.1074/jbc.M609591200; Mertz TM, 2015, P NATL ACAD SCI USA, V112, pE2467, DOI 10.1073/pnas.1422934112; Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Ohzeki S, 1997, CARCINOGENESIS, V18, P1127, DOI 10.1093/carcin/18.6.1127; Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503; Peltomaki P, 2004, DIS MARKERS, V20, P269, DOI 10.1155/2004/305058; Preston BD, 2010, SEMIN CANCER BIOL, V20, P281, DOI 10.1016/j.semcancer.2010.10.009; Seshagiri S, 2013, NAT GENET, V45, P121, DOI 10.1038/ng.2540; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; SHCHERBAKOVA PV, 1993, MUTAGENESIS, V8, P417, DOI 10.1093/mutage/8.5.417; Shinbrot E, 2014, GENOME RES, V24, P1740, DOI 10.1101/gr.174789.114; Shlien A, 2015, NAT GENET, V47, P257, DOI 10.1038/ng.3202; TIBBETTS LM, 1977, CANCER, V40, P2651, DOI 10.1002/1097-0142(197711)40:5+<2651::AID-CNCR2820400939>3.0.CO;2-V; Valle L, 2014, HUM MOL GENET, V23, P3506, DOI 10.1093/hmg/ddu058; Venkatesan RN, 2006, J BIOL CHEM, V281, P4486, DOI 10.1074/jbc.M510245200; Wong A, 2016, GYNECOL ONCOL, V141, P113, DOI 10.1016/j.ygyno.2015.12.031; Yoshida R, 2011, EUR J HUM GENET, V19, P320, DOI 10.1038/ejhg.2010.216	37	11	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 3	2017	36	31					4427	4433		10.1038/onc.2017.22	http://dx.doi.org/10.1038/onc.2017.22			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FC4JL	28368425	Green Accepted			2022-12-17	WOS:000406806000005
J	Yang, H; Kircher, DA; Kim, KH; Grossmann, AH; VanBrocklin, MW; Holmen, SL; Robinson, JP				Yang, H.; Kircher, D. A.; Kim, K. H.; Grossmann, A. H.; VanBrocklin, M. W.; Holmen, S. L.; Robinson, J. P.			Activated MEK cooperates with Cdkn2a and Pten loss to promote the development and maintenance of melanoma	ONCOGENE			English	Article							BRAF V600E MUTATION; ACQUIRED-RESISTANCE; METASTATIC MELANOMA; RAF INHIBITION; INK4A/ARF LOSS; OPEN-LABEL; B-RAF; VEMURAFENIB; BRAF(V600E); MULTICENTER	The development of targeted inhibitors, vemurafenib and dabrafenib, has led to improved clinical outcome for melanoma patients with BRAF(V600E) mutations. Although the initial response to these inhibitors can be dramatic, sometimes causing complete tumor regression, the majority of melanomas eventually become resistant. Mitogen-activated protein kinase kinase (MEK) mutations are found in primary melanomas and frequently reported in BRAF melanomas that develop resistance to targeted therapy; however, melanoma is a molecularly heterogeneous cancer, and which mutations are drivers and which are passengers remains to be determined. In this study, we demonstrate that in BRAFV600E melanoma cell lines, activating MEK mutations drive resistance and contribute to suboptimal growth of melanoma cells following the withdrawal of BRAF inhibition. In this manner, the cells are drug-addicted, suggesting that melanoma cells evolve a 'just right' level of mitogen-activated protein kinase signaling and the additive effects of MEK and BRAF mutations are counterproductive. We also used a novel mouse model of melanoma to demonstrate that several of these MEK mutants promote the development, growth and maintenance of melanoma in vivo in the context of Cdkn2a and Pten loss. By utilizing a genetic approach to control mutant MEK expression in vivo, we were able to induce tumor regression and significantly increase survival; however, after a long latency, all tumors subsequently became resistant. These data suggest that resistance to BRAF or MEK inhibitors is probably inevitable, and novel therapeutic approaches are needed to target dormant tumors.	[Yang, H.; Kim, K. H.; Robinson, J. P.] Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA; [Kircher, D. A.; VanBrocklin, M. W.; Holmen, S. L.] Univ Utah, Hlth Sci Ctr, Huntsman Canc Inst, Salt Lake City, UT USA; [Kircher, D. A.; Holmen, S. L.] Univ Utah, Hlth Sci Ctr, Dept Oncol Sci, Salt Lake City, UT USA; [Grossmann, A. H.] Univ Utah, Hlth Sci Ctr, Dept Pathol, Salt Lake City, UT 84132 USA; [Grossmann, A. H.] ARUP Labs, Salt Lake City, UT USA; [VanBrocklin, M. W.; Holmen, S. L.] Univ Utah, Hlth Sci Ctr, Dept Surg, Salt Lake City, UT USA	University of Minnesota System; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; ARUP Laboratories; Utah System of Higher Education; University of Utah	Robinson, JP (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	jrobinson@hi.umn.edu		YANG, HANA/0000-0002-7008-6837; Kircher, David/0000-0003-4122-0336; KIM, KWAN HYUN/0000-0003-4975-2839; Robinson, James/0000-0002-6585-0116	Hormel Institute; National Cancer Institute [R01 CA121118]; NATIONAL CANCER INSTITUTE [R01CA121118] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS073870, R01NS075155] Funding Source: NIH RePORTER	Hormel Institute; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank the members of the Holmen labs as well as W. Pavan, M. McMahon, M. Bosenberg, R. DePinho and L. Chin for providing mouse strains, reagents and advice. This work was largely supported by The Hormel Institute. We thank our lab technicians Selena Hataye and Anne Holtz for their assistance with our experiments and in preparing reagents. We also thank the Huntsman Cancer Institute and Hormel Vivarium staff for assistance. This work was also supported by Award Number R01 CA121118 from the National Cancer Institute (to SLH).	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Bromberg-White JL, 2004, J VIROL, V78, P4914, DOI 10.1128/JVI.78.9.4914-4916.2004; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cho JH, 2015, CELL REP, V13, P898, DOI 10.1016/j.celrep.2015.09.057; Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148; Cui RT, 2007, CELL, V128, P853, DOI 10.1016/j.cell.2006.12.045; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Ferguson B, 2010, PIGM CELL MELANOMA R, V23, P771, DOI 10.1111/j.1755-148X.2010.00752.x; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Gowrishankar K, 2012, J INVEST DERMATOL, V132, P1850, DOI 10.1038/jid.2012.63; Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Huang TG, 2013, J HEMATOL ONCOL, V6, DOI 10.1186/1756-8722-6-30; Jang S, 2013, LANCET ONCOL, V14, pE60, DOI 10.1016/S1470-2045(12)70539-9; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Johnson DB, 2015, EUR J CANCER, V51, P2792, DOI 10.1016/j.ejca.2015.08.022; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kemper K, 2015, EMBO MOL MED, V7, P1104, DOI 10.15252/emmm.201404914; Kunz M, 2013, EXP DERMATOL, V22, P10, DOI 10.1111/exd.12054; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Livingstone E, 2014, CHIN CLIN ONCOL, V3, DOI 10.3978/j.issn.2304-3865.2014.03.03; Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037; McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Narita Y, 2014, MOL CANCER THER, V13, P823, DOI 10.1158/1535-7163.MCT-13-0667; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nikolaev SI, 2012, NAT GENET, V44, P133, DOI 10.1038/ng.1026; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Robinson JP, 2011, ONCOGENE, V30, P1341, DOI 10.1038/onc.2010.513; Robinson JP, 2010, ONCOGENE, V29, P335, DOI 10.1038/onc.2009.333; Shin Clifford H, 2015, Genes Cancer, V6, P9; Shull AY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043369; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121; Trunzer K, 2013, J CLIN ONCOL, V31, P1767, DOI 10.1200/JCO.2012.44.7888; Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617; VanBrocklin MW, 2012, NEURO-ONCOLOGY, V14, P34, DOI 10.1093/neuonc/nor184; VanBrocklin MW, 2010, PIGM CELL MELANOMA R, V23, P531, DOI 10.1111/j.1755-148X.2010.00717.x; VanBrocklin MW, 2009, CANCER RES, V69, P1985, DOI 10.1158/0008-5472.CAN-08-3934; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Young MR, 2006, GENE, V379, P1, DOI 10.1016/j.gene.2006.05.001	46	11	11	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 6	2017	36	27					3842	3851		10.1038/onc.2016.526	http://dx.doi.org/10.1038/onc.2016.526			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EZ6SM	28263969	Green Published, Green Accepted, hybrid			2022-12-17	WOS:000404848200005
J	van Attekum, MHA; Terpstra, S; Slinger, E; von Lindern, M; Moerland, PD; Jongejan, A; Kater, AP; Eldering, E				van Attekum, M. H. A.; Terpstra, S.; Slinger, E.; von Lindern, M.; Moerland, P. D.; Jongejan, A.; Kater, A. P.; Eldering, E.			Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia	ONCOGENE			English	Article							GLYCOGEN-SYNTHASE KINASE-3; IN-VIVO; B-CELLS; PROTEIN-SYNTHESIS; MAMMALIAN TARGET; UP-REGULATION; CLL CELLS; T-CELLS; APOPTOSIS; EXPRESSION	Protective interactions with bystander cells in micro-environmental niches, such as lymph nodes (LNs), contribute to survival and therapy resistance of chronic lymphocytic leukemia (CLL) cells. This is caused by a shift in expression of B-cell lymphoma 2 (BCL-2) family members. Pro-survival proteins B-cell lymphoma-extra large (BCL-XL), BCL-2-related protein A1 (BFL-1) and myeloid leukemia cell differentiation protein 1 (MCL-1) are upregulated by LN-residing T cells through CD40L interaction, presumably via nuclear factor (NF)-kappa B signaling. Macrophages (M phi s) also reside in the LN, and are assumed to provide important supportive functions for CLL cells. However, if and how M phi s are able to induce survival is incompletely known. We first established that M phi s induced survival because of an exclusive upregulation of MCL-1. Next, we investigated the mechanism underlying MCL-1 induction by M phi s in comparison with CD40L. Genome-wide expression profiling of in vitro M phi-and CD40L-stimulated CLL cells indicated activation of the phosphoinositide 3-kinase (PI3K)-V-Akt murine thymoma viral oncogene homolog (AKT)-mammalian target of rapamycin (mTOR) pathway, which was confirmed in ex vivo CLL LN material. Inhibition of PI3K-AKT-mTOR signaling abrogated MCL-1 upregulation and survival by M phi s, as well as CD40 stimulation. MCL-1 can be regulated at multiple levels, and we established that AKT leads to increased MCL-1 translation, but does not affect MCL-1 transcription or protein stabilization. Furthermore, among M phi-secreted factors that could activate AKT, we found that induction of MCL-1 and survival critically depended on C-C motif chemokine receptor-1 (CCR1). In conclusion, this study indicates that two distinct micro-environmental factors, CD40L and M phi s, signal via CCR1 to induce AKT activation resulting in translational stabilization of MCL-1, and hence can contribute to CLL cell survival.	[van Attekum, M. H. A.; Terpstra, S.; Slinger, E.; Kater, A. P.] Univ Amsterdam, Acad Med Ctr, Dept Hematol, Amsterdam, Netherlands; [van Attekum, M. H. A.; Terpstra, S.; Slinger, E.; Eldering, E.] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Meibergdreef 9, NL-1105 AZ Amsterdam, Noord Holland, Netherlands; [von Lindern, M.] Sanquin Res, Dept Hematopoiesis, Amsterdam, Netherlands; [Moerland, P. D.; Jongejan, A.] Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol Biostat & Bioinformat, Amsterdam, Netherlands; [Kater, A. P.; Eldering, E.] Lymphoma & Myeloma Ctr Amsterdam LYMMCARE, Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Eldering, E (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Meibergdreef 9, NL-1105 AZ Amsterdam, Noord Holland, Netherlands.	e.eldering@amc.nl	Moerland, Perry/AAG-1425-2020; von Lindern, Marieke/AAH-2350-2020	Moerland, Perry/0000-0002-2357-3659; von Lindern, Marieke/0000-0001-6162-6320	Dutch Cancer Foundation (Dutch Cancer Society Clinical Fellowship) [UVA 2011-5097]	Dutch Cancer Foundation (Dutch Cancer Society Clinical Fellowship)	We thank Richard Volckmann for his help with the analysis of the microarray data, Jannie Borst for providing the BFL-1 antibody and Steven Pals for providing us with the CLL LN slides. APK is a Dutch Cancer Foundation fellow. This work was supported by the Dutch Cancer Foundation (Dutch Cancer Society Clinical Fellowship UVA 2011-5097).	Allen JC, 2011, BLOOD, V117, P2414, DOI 10.1182/blood-2010-08-301176; Awan FT, 2009, BLOOD, V113, P535, DOI 10.1182/blood-2008-08-173450; Balakrishnan K, 2010, BLOOD, V116, P1083, DOI 10.1182/blood-2009-10-246199; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Ballou LM, 2007, J BIOL CHEM, V282, P24463, DOI 10.1074/jbc.M704741200; Baudot AD, 2009, ONCOGENE, V28, P3261, DOI 10.1038/onc.2009.179; Buggins AGS, 2010, CANCER RES, V70, P7523, DOI 10.1158/0008-5472.CAN-10-1634; Burger JA, 2000, BLOOD, V96, P2655; Burger JA, 2011, HEMATOL-AM SOC HEMAT, P96, DOI 10.1182/asheducation-2011.1.96; Castillo JJ, 2012, EXPERT OPIN INV DRUG, V21, P15, DOI 10.1517/13543784.2012.640318; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Delgado-Martin C, 2011, J BIOL CHEM, V286, P37222, DOI 10.1074/jbc.M111.294116; Fox CJ, 2003, GENE DEV, V17, P1841, DOI 10.1101/gad.1105003; Hallaert DYH, 2008, BLOOD, V112, P5141, DOI 10.1182/blood-2008-03-146704; Hanna BS, 2016, LEUKEMIA, V30, P570, DOI 10.1038/leu.2015.305; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Johansson Staffan, 1997, Frontiers in Bioscience (online), V2, pD126; Kitada S, 1998, BLOOD, V91, P3379, DOI 10.1182/blood.V91.9.3379; Kitada S, 1999, BRIT J HAEMATOL, V106, P995, DOI 10.1046/j.1365-2141.1999.01642.x; Longo PG, 2008, BLOOD, V111, P846, DOI 10.1182/blood-2007-05-089037; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Martelli AM, 2011, LEUKEMIA, V25, P1064, DOI 10.1038/leu.2011.46; Martinez A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123352; Masek T, 2011, METHODS MOL BIOL, V703, P293, DOI 10.1007/978-1-59745-248-9_20; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; Mills JR, 2008, P NATL ACAD SCI USA, V105, P10853, DOI 10.1073/pnas.0804821105; Mojsa B, 2014, CELLS-BASEL, V3, P418, DOI 10.3390/cells3020418; Nishio M, 2005, BLOOD, V106, P1012, DOI 10.1182/blood-2004-03-0889; Olsson A, 2007, BRIT J CANCER, V97, P769, DOI 10.1038/sj.bjc.6603951; Pascutti MF, 2013, BLOOD, V122, P3010, DOI 10.1182/blood-2012-11-467670; Pepper C, 2008, BLOOD, V112, P3807, DOI 10.1182/blood-2008-05-157131; Pradelli LA, 2010, ONCOGENE, V29, P1641, DOI 10.1038/onc.2009.448; Prevot D, 2003, BIOL CELL, V95, P141, DOI 10.1016/S0248-4900(03)00031-5; Saxena A, 2004, AM J HEMATOL, V75, P22, DOI 10.1002/ajh.10453; Smit LA, 2007, BLOOD, V109, P1660, DOI 10.1182/blood-2006-05-021683; Su CC, 2007, J IMMUNOL, V179, P4589, DOI 10.4049/jimmunol.179.7.4589; Takai S, 2007, MOL CELL ENDOCRINOL, V267, P46, DOI 10.1016/j.mce.2006.12.036; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Tromp JM, 2010, ONCOGENE, V29, P5071, DOI 10.1038/onc.2010.248; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; van Attekum MHA, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.20; Vary TC, 2007, J NUTR, V137, P1835, DOI 10.1093/jn/137.8.1835; Vogler M, 2008, CELL DEATH DIFFER, V15, P820, DOI 10.1038/cdd.2008.25; Vogler M, 2009, BLOOD, V113, P4403, DOI 10.1182/blood-2008-08-173310; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Yamada KM, 2002, NAT CELL BIOL, V4, pE75, DOI 10.1038/ncb0402-e75	46	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 29	2017	36	26					3651	3660		10.1038/onc.2016.515	http://dx.doi.org/10.1038/onc.2016.515			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY9WM	28192408	hybrid, Green Published			2022-12-17	WOS:000404349700001
J	Modi, DA; Tagare, RD; Karthikeyan, S; Russo, A; Dean, M; Davis, DA; Lantvit, DD; Burdette, JE				Modi, D. A.; Tagare, R. D.; Karthikeyan, S.; Russo, A.; Dean, M.; Davis, D. A.; Lantvit, D. D.; Burdette, J. E.			PAX2 function, regulation and targeting in fallopiantube-derived high-grade serous ovarian cancer	ONCOGENE			English	Article							TUBE EPITHELIAL-CELLS; GENE-EXPRESSION; BRCT-DOMAIN; DNA-DAMAGE; STATHMIN 1; TRANSFORMATION; MODEL; PTIP; P53; CARCINOGENESIS	The fallopian tube epithelium (FTE) is one of the progenitor populations for high-grade serous ovarian cancer (HGSC). Loss of PAX2 is the earliest known molecular aberration in the FTE occurring in serous carcinogenesis followed by a mutation in p53. Pathological studies report consistent loss of PAX2 in benign lesions as well as serous tumors. In the current study, the combined loss of PAX2 and expression of the R273H p53 mutant protein in murine oviductal epithelial (MOE) cells enhanced proliferation and growth in soft agar in vitro but was insufficient to drive tumorigenesis in vivo. A serially passaged model was generated to investigate the role of aging, but was also insufficient to drive tumorigenesis. These models recapitulate early benign lesions and suggest that a latency period exists between loss of PAX2, p53 mutation and tumor formation. Stathmin and fut8 were identified as downstream targets regulated by loss of PAX2 and mutation of p53 in MOE cells. Re-expression of PAX2 in PAX2-null human HGSC cells reduced cell survival via apoptosis. Phosphatase and tensin homolog (PTEN)(shRNA) negatively regulated PAX2 expression and stable re-expression of PAX2 in MOE: PTENshRNA cells significantly reduced proliferation and peritoneal tumor formation in athymic nude mice. PAX2 was determined to be a direct transcriptional target that was activated by wild-type p53, whereas mutant p53 inhibited PAX2 transcription in MOE cells. A small molecule screen using the proximal PAX2 promoter driving luciferase identified four small molecules that were able to enhance PAX2 mRNA expression in MOE cells. PAX2 re-expression in HGSC cells and PTEN-deficient oviductal tumors may have the potential to induce apoptosis. In summary, mutant p53 and PTEN loss negatively regulated PAX2 and PAX2 re-expression in HGSC cells induced cell death.	[Modi, D. A.; Tagare, R. D.; Karthikeyan, S.; Russo, A.; Dean, M.; Davis, D. A.; Lantvit, D. D.; Burdette, J. E.] Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Ctr Biomol Sci, M-C 870,Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Burdette, JE (corresponding author), Univ Illinois, Coll Pharm, Dept Med Chem & Pharmacognosy, Ctr Biomol Sci, M-C 870,Mol Biol Res Bldg,900 S Ashland Ave, Chicago, IL 60607 USA.	joannab@uic.edu		Karthikeyan, Subbulakshmi/0000-0003-0815-164X; Dean, Matthew/0000-0001-5014-9311	American Cancer Society (ACS) [RSG-12-230-01]; NIH [R21 CA208610-01]; Office of the Director, National Institutes of Health (OD); National Center for Complementary & Integrative Health (NCCIH) [T32AT007533]; Tell Every Amazing Lady About Ovarian Cancer; NATIONAL CANCER INSTITUTE [R21CA208610] Funding Source: NIH RePORTER; National Center for Complementary & Integrative Health [T32AT007533] Funding Source: NIH RePORTER	American Cancer Society (ACS)(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Office of the Director, National Institutes of Health (OD)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Center for Complementary & Integrative Health (NCCIH); Tell Every Amazing Lady About Ovarian Cancer; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Center for Complementary & Integrative Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by American Cancer Society (ACS) grant RSG-12-230-01 (J.E.B.), NIH R21 CA208610-01 (J.E.B.), the Office of the Director, National Institutes of Health (OD) & National Center for Complementary & Integrative Health (NCCIH; T32AT007533; M.D.) and Tell Every Amazing Lady About Ovarian Cancer, T.E.A.L. (J.E.B). We thank Dr Barbara Vanderhyden (University of Ottawa) for kindly providing MOE and MOSE cells, Dr Kwong Wong (University of Texas, M.D. Anderson Cancer Center) for the NEO and PAX2 plasmids, Dr Gregory Dressler (University of Michigan) for the PAX2-Luc plasmid, Dr Kiira Ratia (University of Illinois at Chicago, High Throughput Screen Core) for providing compounds for screening.	Al-Hujaily EM, 2015, CANCER PREV RES, V8, P1163, DOI 10.1158/1940-6207.CAPR-15-0121-T; Alli E, 2002, CANCER RES, V62, P6864; Auersperg N, 2011, INT J GYNECOL PATHOL, V30, P12, DOI 10.1097/PGP.0b013e3181f45f3e; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Cai Y, 2002, J BIOL CHEM, V277, P1217, DOI 10.1074/jbc.M109663200; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chen EY, 2010, J PATHOL, V222, P110, DOI 10.1002/path.2739; Chen WL, 2016, BMC CANCER, V16, DOI 10.1186/s12885-015-1988-0; Dressler GR, 1999, INT J DEV BIOL, V43, P463; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; Eddie SL, 2015, ONCOTARGET, V6, P20500, DOI 10.18632/oncotarget.3985; Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207; Endsley MP, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00154; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Hilliard TS, 2013, INT J MOL SCI, V14, P4762, DOI 10.3390/ijms14034762; Jazaeri AA, 2011, NEOPLASIA, V13, P899, DOI 10.1593/neo.11138; Karst AM, 2011, GYNECOL ONCOL, V123, P5, DOI 10.1016/j.ygyno.2011.05.021; Karst AM, 2011, P NATL ACAD SCI USA, V108, P7547, DOI 10.1073/pnas.1017300108; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Kim JS, 2005, IMMUNOLOGY, V115, P375, DOI 10.1111/j.1365-2567.2005.02156.x; Kindelberger DW, 2007, AM J SURG PATHOL, V31, P161, DOI 10.1097/01.pas.0000213335.40358.47; King SM, 2013, CARCINOGENESIS, V34, P1125, DOI 10.1093/carcin/bgt003; King SM, 2011, ENDOCR-RELAT CANCER, V18, P627, DOI 10.1530/ERC-11-0107; Lechner MS, 2000, NUCLEIC ACIDS RES, V28, P2741, DOI 10.1093/nar/28.14.2741; Levanon K, 2010, ONCOGENE, V29, P1103, DOI 10.1038/onc.2009.402; Lin Y, 2008, CURR CANCER DRUG TAR, V8, P634, DOI 10.2174/156800908786241050; Medeiros F, 2006, AM J SURG PATHOL, V30, P230, DOI 10.1097/01.pas.0000180854.28831.77; Mehra Karishma, 2011, Front Biosci (Elite Ed), V3, P625, DOI 10.2741/e275; Mitra AK, 2015, GYNECOL ONCOL, V138, P372, DOI 10.1016/j.ygyno.2015.05.040; Monte NM, 2010, CANCER RES, V70, P6225, DOI 10.1158/0008-5472.CAN-10-0149; Ning G, 2014, J PATHOL, V234, P478, DOI 10.1002/path.4417; Novak M, 2015, GYNECOL ONCOL, V139, P104, DOI 10.1016/j.ygyno.2015.07.100; Patel SR, 2007, DEV CELL, V13, P580, DOI 10.1016/j.devcel.2007.09.004; Patel SR, 2004, DEV BIOL, V267, P505, DOI 10.1016/j.ydbio.2003.11.002; Perets R, 2013, CANCER CELL, V24, P751, DOI 10.1016/j.ccr.2013.10.013; Piek JMJ, 2001, J PATHOL, V195, P451, DOI 10.1002/path.1000; Quartuccio SM, 2015, INT J CANCER, V137, P1528, DOI 10.1002/ijc.29528; Quick CM, 2012, MODERN PATHOL, V25, P449, DOI 10.1038/modpathol.2011.175; Rana S, 2008, EXPERT REV ANTICANC, V8, P1461, DOI 10.1586/14737140.8.9.1461; Rodgers LH, 2016, ONCOTARGET, V7, P32785, DOI 10.18632/oncotarget.9051; Roh MH, 2010, MODERN PATHOL, V23, P1316, DOI 10.1038/modpathol.2010.119; Saifudeen Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044869; Shaw PA, 2009, MODERN PATHOL, V22, P1133, DOI 10.1038/modpathol.2009.89; Sherman-Baust CA, 2014, J PATHOL, V233, P228, DOI 10.1002/path.4353; Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI [10.3322/caac.21708, 10.3322/caac.21332, 10.3322/caac.21590]; Song HJ, 2013, INT J MOL SCI, V14, P6090, DOI 10.3390/ijms14036090; Stayner CK, 1998, J BIOL CHEM, V273, P25472, DOI 10.1074/jbc.273.39.25472; Sukerkar PA, 2011, BIOCONJUGATE CHEM, V22, P2304, DOI 10.1021/bc2003555; Vasudevan D, 2015, CANCER RES, V75, P5299, DOI 10.1158/0008-5472.CAN-15-1582; Wu JX, 2009, J BIOL CHEM, V284, P18078, DOI 10.1074/jbc.M109.002527; Yamamoto Y, 2016, J PATHOL, V238, P519, DOI 10.1002/path.4649; Zhang SL, 2015, CANCER RES, V75, P3842, DOI 10.1158/0008-5472.CAN-13-1079	52	11	11	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					3015	3024		10.1038/onc.2016.455	http://dx.doi.org/10.1038/onc.2016.455			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	27991925	Green Accepted			2022-12-17	WOS:000402000400009
J	Wang, L; Ren, J; Li, G; Moorman, JP; Yao, ZQ; Ning, S				Wang, L.; Ren, J.; Li, G.; Moorman, J. P.; Yao, Z. Q.; Ning, S.			LMP1 signaling pathway activates IRF4 in latent EBV infection and a positive circuit between PI3K and Src is required	ONCOGENE			English	Article							EPSTEIN-BARR-VIRUS; PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; NF-KAPPA-B; CHRONIC LYMPHOCYTIC-LEUKEMIA; MEMBRANE-PROTEIN 1; MULTIPLE-MYELOMA; CELL-SURVIVAL; REGULATORY FACTOR-4; FAMILY-MEMBER; TARGET GENES	Interferon (IFN) regulatory factors (IRFs) have crucial roles in immune regulation and oncogenesis. We have recently shown that IRF4 is activated through c-Src-mediated tyrosine phosphorylation in virus-transformed cells. However, the intracellular signaling pathway triggering Src activation of IRF4 remains unknown. In this study, we provide evidence that Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) promotes IRF4 phosphorylation and markedly stimulates IRF4 transcriptional activity, and that Src mediates LMP1 activation of IRF4. As to more precise mechanism, we show that LMP1 physically interacts with c-Src, and the phosphatidylinositol 3 kinase (PI3K) subunit P85 mediates their interaction. Depletion of P85 by P85-specific short hairpin RNAs disrupts their interaction and diminishes IRF4 phosphorylation in EBV-transformed cells. Furthermore, we show that Src is upstream of PI3K for activation of both IRF4 and Akt. In turn, inhibition of PI3K kinase activity by the PI3K-speicfic inhibitor LY294002 impairs Src activity. Our results show that LMP1 signaling is responsible for IRF4 activation, and further characterize the IRF4 regulatory network that is a promising therapeutic target for specific hematological malignancies.	[Wang, L.; Ren, J.; Li, G.; Moorman, J. P.; Yao, Z. Q.; Ning, S.] East Tennessee State Univ, Div Infect Dis, Dept Internal Med, Quillen Coll Med, Johnson City, TN 37614 USA; [Wang, L.; Ren, J.; Li, G.; Moorman, J. P.; Yao, Z. Q.; Ning, S.] East Tennessee State Univ, Ctr Excellence Inflammat Infect Dis & Immun, Quillen Coll Med, Johnson City, TN 37614 USA; [Moorman, J. P.; Yao, Z. Q.] James H Quillen VA Med Ctr, Hepatitis HCV HIV Program, Johnson City, TN USA	East Tennessee State University; East Tennessee State University	Ning, S (corresponding author), East Tennessee State Univ, Div Infect Inflammatory & Immunol Dis, Dept Internal Med, Quillen Coll Med, Johnson City, TN 37614 USA.	nings1@etsu.edu	Ning, Shunbin/I-3961-2019; Ning, Shunbin/AAC-6895-2021	Ning, Shunbin/0000-0001-5484-5779; 	NIH NIDDK grant [R01DK093526]; NIH NIAID grant [R01AI114748]; American Society of Hematology Scholar Award; NIH grant [C06RR0306551]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI114748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK093526] Funding Source: NIH RePORTER	NIH NIDDK grant; NIH NIAID grant(CGIAR); American Society of Hematology Scholar Award; NIH grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by an NIH NIDDK grant to ZQY/JPM (R01DK093526), an NIH NIAID grant to ZQY/JPM (R01AI114748), the American Society of Hematology Scholar Award to SN, and in part by the NIH grant C06RR0306551. We thank Dr Bill Sugden for providing pSV2-LMP1 and its deletion mutant pSV2-LMP1.(12-20). This publication is the result of work supported with resources and the use of facilities at the James H Quillen Veterans Affairs Medical Center. The contents in this publication do not represent the views of the Department of Veterans Affairs or the United States Government.	Alvarez RH, 2006, CANCER-AM CANCER SOC, V107, P1918, DOI 10.1002/cncr.22215; Arron JR, 2001, J BIOL CHEM, V276, P30011, DOI 10.1074/jbc.M100414200; Banerjee S, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003314; Biswas PS, 2010, IMMUNOL REV, V233, P79, DOI 10.1111/j.0105-2896.2009.00864.x; Bloss T, 1999, J GEN VIROL, V80, P3227, DOI 10.1099/0022-1317-80-12-3227; Boshoff C, 2002, NAT REV CANCER, V2, P373, DOI 10.1038/nrc797; Cahir-McFarland ED, 2004, J VIROL, V78, P4108, DOI 10.1128/JVI.78.8.4108-4119.2004; Carbone A, 2008, ONCOLOGIST, V13, P577, DOI 10.1634/theoncologist.2008-0036; Chang CC, 2002, BLOOD, V100, P4671, DOI 10.1182/blood-2002-01-0104; Davies CC, 2005, MOL CELL BIOL, V25, P9806, DOI 10.1128/MCB.25.22.9806-9819.2005; Dawson CW, 2012, SEMIN CANCER BIOL, V22, P144, DOI 10.1016/j.semcancer.2012.01.004; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Deregibus MC, 2003, J BIOL CHEM, V278, P18008, DOI 10.1074/jbc.M300711200; Feldman AL, 2009, LEUKEMIA, V23, P574, DOI 10.1038/leu.2008.320; Fukuda M, 2004, J VIROL, V78, P1697, DOI 10.1128/JVI.78.4.1697-1705.2004; Grandvaux N, 2002, J VIROL, V76, P5532, DOI 10.1128/JVI.76.11.5532-5539.2002; Gu TL, 2010, LEUKEMIA, V24, P861, DOI 10.1038/leu.2009.293; Hatton O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042610; Havelange V, 2011, BLOOD, V118, P2827, DOI 10.1182/blood-2011-04-350579; Huye LE, 2007, MOL CELL BIOL, V27, P2910, DOI 10.1128/MCB.02256-06; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Kieser A., 2007, SIGNAL TRANSDUCTION, V7, P20, DOI [10.1002/sita.200600116, DOI 10.1002/SITA.200600116]; Kieser A, 2015, CURR TOP MICROBIOL, V391, P119, DOI 10.1007/978-3-319-22834-1_4; Li HP, 2003, J BIOMED SCI, V10, P490, DOI 10.1159/000072376; Mamane Y, 2002, J INTERF CYTOK RES, V22, P135, DOI 10.1089/107999002753452746; Martin HJ, 2007, J VIROL, V81, P9748, DOI 10.1128/JVI.01122-07; Middeldorp JM, 2008, SEMIN CANCER BIOL, V18, P388, DOI 10.1016/j.semcancer.2008.10.004; Ning S, 2011, GENES IMMUN, V12, P399, DOI 10.1038/gene.2011.21; Ning S, 2013, J ONCOBIOMARKERS, V1, P6; Ning SB, 2008, MOL CELL BIOL, V28, P6536, DOI 10.1128/MCB.00785-08; Pagano JS, 2004, SEMIN CANCER BIOL, V14, P453, DOI 10.1016/j.semcancer.2004.06.009; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Portis T, 2004, ONCOGENE, V23, P8619, DOI 10.1038/sj.onc.1207905; Ramos JC, 2007, BLOOD, V109, P3060, DOI 10.1182/blood-2006-07-036368; Rui LX, 2011, NAT IMMUNOL, V12, P933, DOI 10.1038/ni.2094; Saddawi-Konefka R, 2010, J NEUROIMMUNE PHARM, V5, P387, DOI 10.1007/s11481-010-9204-0; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; Shaffer AL, 2009, CLIN CANCER RES, V15, P2954, DOI 10.1158/1078-0432.CCR-08-1845; Sharma S, 2002, J IMMUNOL, V169, P3120, DOI 10.4049/jimmunol.169.6.3120; So T, 2011, J IMMUNOL, V186, P3547, DOI 10.4049/jimmunol.1003156; Soni V, 2007, ADV EXP MED BIOL, V597, P173; Spender LC, 2006, J GEN VIROL, V87, P2859, DOI 10.1099/vir.0.82128-0; St-Germain JR, 2009, P NATL ACAD SCI USA, V106, P20127, DOI 10.1073/pnas.0910957106; Stunz LL, 2014, CRIT REV IMMUNOL, V34, P177, DOI 10.1615/CritRevImmunol.2014010041; Sundram U, 2003, MODERN PATHOL, V16, P802, DOI 10.1097/01.MP.0000081726.49886.CF; Swart R, 2000, J VIROL, V74, P10838, DOI 10.1128/JVI.74.22.10838-10845.2000; Thornburg NJ, 2006, ONCOGENE, V25, P288, DOI 10.1038/sj.onc.1209023; Wang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106788; Wang L, 2013, J VIROL, V87, P9672, DOI 10.1128/JVI.01435-13; Wang L, 2011, J VIROL, V85, P8328, DOI 10.1128/JVI.00570-11; Wong BR, 1999, MOL CELL, V4, P1041, DOI 10.1016/S1097-2765(00)80232-4; Xu DS, 2008, J VIROL, V82, P6251, DOI 10.1128/JVI.00163-08; Zhang BC, 2012, CELL, V148, P739, DOI 10.1016/j.cell.2011.12.031; Zhang LW, 2004, J VIROL, V78, P12987, DOI 10.1128/JVI.78.23.12987-12995.2004	55	11	11	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 20	2017	36	16					2265	2274		10.1038/onc.2016.380	http://dx.doi.org/10.1038/onc.2016.380			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DM	27819673	Green Accepted, Green Submitted			2022-12-17	WOS:000399782700007
J	Chandrasinghe, P; Stebbing, J; Warusavitarne, J				Chandrasinghe, P.; Stebbing, J.; Warusavitarne, J.			The MACC1-SPON2 axis: a new biomarker and therapeutic target in colorectal cancer	ONCOGENE			English	Editorial Material							MACC1; METASTASIS; PATHWAY; KRAS	this issue of the Journal, Schmid et al identify Spondin 2 (SPON2) as a prominent downstream signaling target of metastasisassociated in colon cancer 1 (MACC1) in colorectal cancer (CRC). It is shown that SPON2 mediates MACC1- induced CRC cell proliferation, invasion and metastasis in vitro and in vivo, while its high expression correlates with adverse disease free survival in clinical samples. Therefore, not only does this study shed further light into the complexity of colorectal carcinogenesis, but it also puts forward a potential novel prognostic biomarker to predict high-risk tumors before they metastasize. The MACC1/SPON2 axis may also have utility beyond an indicator of tumor aggressiveness and lends itself as a promising therapeutic target for colorectal and potentially other solid tumors.	[Chandrasinghe, P.; Warusavitarne, J.] St Marks Hosp, Dept Surg, London, England; [Chandrasinghe, P.; Warusavitarne, J.] Imperial Coll, London, England; [Stebbing, J.] Imperial Coll, Hammersmith Hosp, London, England	Imperial College London; Imperial College London; Imperial College London	Stebbing, J (corresponding author), Imperial Coll London, Surg & Canc, Hammersmith Hosp Campus, London W12 0NN, England.	j.stebbing@imperial.ac.uk		Chandrasinghe, Pramodh/0000-0002-3485-961X; Stebbing, Justin/0000-0002-1117-6947	DKFZ Postdoctoral Fellowship; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish	DKFZ Postdoctoral Fellowship; National Institute for Health Research(National Institute for Health Research (NIHR))	We thank Iris Augustin, Fillip Port, Katharina Kober and Lucie Wolf for carefully reading the manuscript and contributing valuable ideas. T.Z. was supported by a DKFZ Postdoctoral Fellowship. We apologize to all colleagues whose work was not cited due to space constrains.	de Haas S, 2014, ANGIOGENESIS, V17, P909, DOI 10.1007/s10456-014-9438-1; De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6; Gao SW, 2016, JAMA ONCOL, V2, P37, DOI 10.1001/jamaoncol.2015.3413; Ilm K, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0316-2; Jackson SE, 2015, INT J CANCER, V137, P262, DOI 10.1002/ijc.28940; Lievre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191; Lin L, 2015, ONCOGENE, V34, P2700, DOI 10.1038/onc.2014.204; Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889; Warusavitarne J, 2006, INT J COLORECTAL DIS, V21, P625, DOI 10.1007/s00384-005-0071-8; Zhang Q, 2015, ONCOTARGET, V6, P15095, DOI 10.18632/oncotarget.3822; Zhang YC, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0044465, 10.1155/2012/583417]; Zhen TT, 2014, ONCOTARGET, V5, P3756, DOI 10.18632/oncotarget.1993	12	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1474	1475		10.1038/onc.2016.322	http://dx.doi.org/10.1038/onc.2016.322			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27669439				2022-12-17	WOS:000397458100002
J	Haase, G; Gavert, N; Brabletz, T; Ben-Ze'ev, A				Haase, G.; Gavert, N.; Brabletz, T.; Ben-Ze'ev, A.			A point mutation in the extracellular domain of L1 blocks its capacity to confer metastasis in colon cancer cells via CD10	ONCOGENE			English	Article							ADHESION MOLECULE L1; NEUTRAL ENDOPEPTIDASE; LIVER METASTASIS; EXPRESSION; BINDING; GENE; OUTGROWTH; TARGET; CAM; ENKEPHALINASE	The neural L1 transmembrane cell adhesion receptor of the immunoglobulin-like family is a target gene of Wnt-beta-catenin signaling in human colorectal cancer (CRC) cells and is expressed at the invasive edge of the tumor tissue. L1 overexpression in cultured CRC cells confers enhanced proliferation, motility and liver metastasis. We have analyzed the mechanisms of L1-mediated signaling in CRC cells by using various point mutations in the L1 ectodomain that are known to cause severe genetically inherited mental retardation disorders in patients. We found that all such L1 ectodomain mutations abolish the ability of L1 to confer metastatic properties in CRC cells. Using gene array analysis, we identified L1-mutation-specific gene expression signatures for the L1/H210Q and L1/D598N mutations. We identified CD10, a metalloprotease (neprilysin, neutral endopeptidase) and a gene that is specifically induced in CRC cells by L1 in an L1/H210Q mutation-specific manner. CD10 expression was required for the L1-mediated induction of cell proliferation, motility and metastasis, as suppression of CD10 levels in L1-expressing CRC cells abolished the L1 effects on CRC progression. The signaling from L1 to CD10 was mediated through the L1-ezrin-NF-.B pathway. In human CRC tissue L1 and CD10 were localized in partially overlapping regions in the more invasive areas of the tumor tissue. The results suggest that CD10 is a necessary component conferring the L1 effects in CRC cells. The identification of gene expression patterns of L1-domain-specific point mutations may provide novel markers and targets for interfering with L1-mediated CRC progression.	[Haase, G.; Brabletz, T.; Ben-Ze'ev, A.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; [Brabletz, T.] Univ Erlangen Nuernberg, Dept Expt Med, Erlangen, Germany	Weizmann Institute of Science; University of Erlangen Nuremberg	Ben-Ze'ev, A (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	avri.ben-zeev@weizmann.ac.il		Gavert, Nancy/0000-0003-1639-4684; ben-ze'ev, avri/0000-0001-6113-3921	Israel Science Foundation (ISF); Israel Cancer Research Fund (ICRF)	Israel Science Foundation (ISF)(Israel Science Foundation); Israel Cancer Research Fund (ICRF)	We thank Drs N Iwata, M Shtutman, F Rathjen and V Lemmon for providing reagents. This study was supported by grants from the Israel Science Foundation (ISF) and from the Israel Cancer Research Fund (ICRF). A B-Z is the incumbent of the Lunenfeld-Kunin professorial chair in genetics and cell biology.	Beer S, 1999, J CELL SCI, V112, P2667; Ben-Shmuel A, 2013, ONCOGENE, V32, P3220, DOI 10.1038/onc.2012.340; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; CHANG S, 1987, J CELL BIOL, V104, P355, DOI 10.1083/jcb.104.2.355; Cohen NR, 1998, CURR BIOL, V8, P26, DOI 10.1016/S0960-9822(98)70017-X; Conacci-Sorrell ME, 2002, GENE DEV, V16, P2058, DOI 10.1101/gad.227502; De Angelis E, 2002, HUM MOL GENET, V11, P1, DOI 10.1093/hmg/11.1.1; De Angelis E, 1999, EMBO J, V18, P4744, DOI 10.1093/emboj/18.17.4744; ERDOS EG, 1989, FASEB J, V3, P145, DOI 10.1096/fasebj.3.2.2521610; Felding-Habermann B, 1997, J CELL BIOL, V139, P1567, DOI 10.1083/jcb.139.6.1567; FRIEDLANDER DR, 1994, J CELL BIOL, V125, P669, DOI 10.1083/jcb.125.3.669; Gavert N, 2005, J CELL BIOL, V168, P633, DOI 10.1083/jcb.200408051; Gavert N, 2007, CANCER RES, V67, P7703, DOI 10.1158/0008-5472.CAN-07-0991; Gavert N, 2013, CANCER RES, V73, P5754, DOI 10.1158/0008-5472.CAN-13-0576; Gavert N, 2010, J CELL SCI, V123, P2134, DOI 10.1242/jcs.069542; Grumet M, 1991, Curr Opin Neurobiol, V1, P370, DOI 10.1016/0959-4388(91)90055-C; Haspel J, 2003, FRONT BIOSCI-LANDMRK, V8, pS1210, DOI 10.2741/1108; HLAVIN ML, 1991, GENOMICS, V11, P416, DOI 10.1016/0888-7543(91)90150-D; JOUET M, 1994, NAT GENET, V7, P402, DOI 10.1038/ng0794-402; Kamiguchi H, 1998, MOL CELL NEUROSCI, V12, P48, DOI 10.1006/mcne.1998.0702; Koga Y, 2008, HISTOPATHOLOGY, V52, P569, DOI 10.1111/j.1365-2559.2008.02996.x; LEMMON V, 1989, NEURON, V2, P1597, DOI 10.1016/0896-6273(89)90048-2; Maguer-Satta V, 2011, STEM CELLS, V29, P389, DOI 10.1002/stem.592; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; Ogawa H, 2002, HUM PATHOL, V33, P806, DOI 10.1053/hupa.2002.125773; Ohji Y, 2007, ONCOL REP, V17, P525; Oleszewski M, 1999, J BIOL CHEM, V274, P24602, DOI 10.1074/jbc.274.35.24602; RATHJEN FG, 1987, J CELL BIOL, V104, P343, DOI 10.1083/jcb.104.2.343; Schmid RS, 2008, CURR OPIN NEUROBIOL, V18, P245, DOI 10.1016/j.conb.2008.07.015; Shapiro B, 2015, ONCOTARGET, V6, P34389, DOI 10.18632/oncotarget.5360; Silletti S, 2004, J BIOL CHEM, V279, P28880, DOI 10.1074/jbc.M404075200; WONG EV, 1995, TRENDS NEUROSCI, V18, P168, DOI 10.1016/0166-2236(95)93896-6; Yao T, 2002, PATHOLOGY, V34, P556, DOI 10.1080/0031302021000035965-4	33	11	11	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1597	1606		10.1038/onc.2016.329	http://dx.doi.org/10.1038/onc.2016.329			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27641335				2022-12-17	WOS:000397458100013
J	Wang, Y; Hong, X; Wang, J; Yin, Y; Zhang, Y; Zhou, Y; Piao, HI; Liang, Z; Zhang, L; Li, G; Xu, G; Kwiatkowski, DJ; Liu, Y				Wang, Y.; Hong, X.; Wang, J.; Yin, Y.; Zhang, Y.; Zhou, Y.; Piao, H-I; Liang, Z.; Zhang, L.; Li, G.; Xu, G.; Kwiatkowski, D. J.; Liu, Y.			Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth	ONCOGENE			English	Article							TSC2 GAP ACTIVITY; RHEB GTPASE; CELL-PROLIFERATION; MAMMALIAN TARGET; MTOR; ACTIVATION; KINASE; MUTATIONS; AMPK; IDENTIFICATION	Rheb is a Ras family GTPase, which binds to and activates mammalian target of rapamycin complex 1 (mTORC1) when GTP loaded. Recently, cancer genome sequencing efforts have identified recurrent Rheb Tyr35Asn mutations in kidney and endometrial carcinoma. Here we show that Rheb-Y35N causes not only constitutive mTORC1 activation, but sustained activation of the MEK-ERK pathway in a TSC1/TSC2/TBC1D7 protein complex and mTORC1-independent manner, contributing to intrinsic resistance to rapamycin. Rheb-Y35N transforms NIH3T3 cells, resulting in aggressive tumor formation in xenograft nude mice, which could be suppressed by combined treatment with rapamycin and an extracellular signal-regulated kinase (ERK) inhibitor. Furthermore, Rheb-Y35N inhibits AMPKa activation in response to nutrient depletion or 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), leading to attenuated phosphorylation of BRAF-S729 and retained mitogen-activated protein kinase (MAPK) activation. Finally, we demonstrate that Rheb-WT can bind AMPK to facilitate AMPK activation, whereas Rheb-Y35N competitively binds AMPK, impairing AMPK phosphorylation. In summary, our findings indicate that Rheb-Y35N is a dominantly active tumor driver that activates both mTORC1 and MAPK to promote tumor growth, suggesting a combination of mTORC1 and MAPK inhibitors may be of therapeutic value in patients whose cancers sustain this mutation.	[Wang, Y.; Yin, Y.; Piao, H-I; Liu, Y.] Chinese Acad Sci, Sci Res Ctr Translat Med, Dalian Inst Chem Phys, Dept Biotechnol, 457 Zhongshan Rd,Rm 114, Dalian 116023, Liaoning, Peoples R China; [Wang, Y.; Wang, J.] Dalian Univ, Sch Life Sci, Dalian, Peoples R China; [Hong, X.] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China; [Hong, X.] Peking Union Med Coll, Beijing, Peoples R China; [Zhang, Y.; Li, G.] Chinese Acad Sci, Dalian Inst Chem Phys, Dept Biotechnol, State Key Lab Mol React Dynam,Lab Mol Modelling &, Dalian, Peoples R China; [Zhou, Y.; Piao, H-I; Liang, Z.; Zhang, L.; Xu, G.; Liu, Y.] Chinese Acad Sci, Dalian Inst Chem Phys, Key Lab Separat Sci Analyt Chem, Dalian, Peoples R China; [Kwiatkowski, D. J.; Liu, Y.] Harvard Med Sch, Brigham & Women Hosp, Div Pulm & Crit Care Med, Boston, MA USA	Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; Dalian University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; Chinese Academy of Sciences; Dalian Institute of Chemical Physics, CAS; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Liu, Y (corresponding author), Chinese Acad Sci, Sci Res Ctr Translat Med, Dalian Inst Chem Phys, Dept Biotechnol, 457 Zhongshan Rd,Rm 114, Dalian 116023, Liaoning, Peoples R China.; Kwiatkowski, DJ (corresponding author), Harvard Med Sch Thorn Bldg, Brigham & Womens Hosp, Div Pulm & Crit Care, RM 826c,20 Shattuck St, Boston, MA 02115 USA.	dk@rics.bwh.harvard.edu; yliuqq@dicp.ac.cn	Xu, Guowang/L-6910-2014	Xu, Guowang/0000-0003-4298-3554	NIH [NCI 1P01CA120964]; NATIONAL CANCER INSTITUTE [P01CA120964] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NIH NCI 1P01CA120964. We thank Nathanael Gray, Heidi Greulich and John Blenis for the gift of reagents.	Aspuria PJ, 2004, CELL SIGNAL, V16, P1105, DOI 10.1016/j.cellsig.2004.03.019; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Choudhary S, 2007, MOL CANCER THER, V6, P1099, DOI 10.1158/1535-7163.MCT-06-0586; Eom M, 2008, PATHOL INT, V58, P226, DOI 10.1111/j.1440-1827.2008.02215.x; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Ghosh AP, 2015, ONCOTARGET, V6, P17895, DOI 10.18632/oncotarget.4963; Goorden SMI, 2011, MOL CELL BIOL, V31, P1672, DOI 10.1128/MCB.00985-10; Grabiner BC, 2014, CANCER DISCOV, V4, P554, DOI 10.1158/2159-8290.CD-13-0929; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hodges AK, 2001, HUM MOL GENET, V10, P2899, DOI 10.1093/hmg/10.25.2899; Holz MK, 2005, J BIOL CHEM, V280, P26089, DOI 10.1074/jbc.M504045200; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jeon MT, 2015, BIOMED REP, V3, P137, DOI 10.3892/br.2014.397; Jiang H, 2008, ONCOGENE, V27, P5729, DOI 10.1038/onc.2008.180; Kim SY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.95; Lacher MD, 2010, ONCOGENE, V29, P6543, DOI 10.1038/onc.2010.393; Lafourcade CA, 2013, J NEUROSCI, V33, P2419, DOI 10.1523/JNEUROSCI.1840-12.2013; Langendorf CG, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10912; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Li Y, 2004, MOL CELL BIOL, V24, P7965, DOI 10.1128/MCB.24.18.7965-7975.2004; Long X, 2005, CURR BIOL, V15, P702, DOI 10.1016/j.cub.2005.02.053; Lu ZH, 2010, CANCER RES, V70, P3287, DOI 10.1158/0008-5472.CAN-09-3467; Martin TD, 2014, MOL CELL, V53, P209, DOI 10.1016/j.molcel.2013.12.004; Mavrakis KJ, 2008, GENE DEV, V22, P2178, DOI 10.1101/gad.1690808; Mazhab-Jafari MT, 2012, STRUCTURE, V20, P1528, DOI 10.1016/j.str.2012.06.013; Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070; Pierce BG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024657; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Shen CH, 2013, MOL CELL, V52, P161, DOI 10.1016/j.molcel.2013.08.044; Tabancay AP, 2003, J BIOL CHEM, V278, P39921, DOI 10.1074/jbc.M306553200; Wang YN, 2008, J MOL CELL CARDIOL, V45, P812, DOI 10.1016/j.yjmcc.2008.07.016; Yan LJ, 2006, J BIOL CHEM, V281, P19793, DOI 10.1074/jbc.C600028200; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026; Zhou XM, 2009, P NATL ACAD SCI USA, V106, P8923, DOI 10.1073/pnas.0903621106	37	11	12	3	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 9	2017	36	6					756	765		10.1038/onc.2016.246	http://dx.doi.org/10.1038/onc.2016.246			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IX	27399332				2022-12-17	WOS:000394168200003
J	Zhang, Z; Liu, X; Feng, B; Liu, N; Wu, Q; Han, Y; Nie, Y; Wu, K; Shi, Y; Fan, D				Zhang, Z.; Liu, X.; Feng, B.; Liu, N.; Wu, Q.; Han, Y.; Nie, Y.; Wu, K.; Shi, Y.; Fan, D.			STIM1, a direct target of microRNA-185, promotes tumor metastasis and is associated with poor prognosis in colorectal cancer (vol 34, pg 4808, 2014)	ONCOGENE			English	Correction																		Zhang Z, 2015, ONCOGENE, V34, P4808, DOI 10.1038/onc.2014.404	1	11	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2016	35	46					6043	6043		10.1038/onc.2016.140	http://dx.doi.org/10.1038/onc.2016.140			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED0CA	27375024	Green Published, hybrid			2022-12-17	WOS:000388509400011
J	Fremin, C; Guegan, JP; Plutoni, C; Mahaffey, J; Philips, MR; Emery, G; Meloche, S				Fremin, C.; Guegan, J-P; Plutoni, C.; Mahaffey, J.; Philips, M. R.; Emery, G.; Meloche, S.			ERK1/2-induced phosphorylation of R-Ras GTPases stimulates their oncogenic potential	ONCOGENE			English	Article							P21(RAS) S-NITROSYLATION; GENE-EXPRESSION; BCL-XL; K-RAS; TC21; PROTEIN; PHOSPHOPROTEOMICS; OVEREXPRESSION; TRANSFORMATION; M-RAS/R-RAS3	The Ras-related (R-Ras) isoforms TC21, R-Ras and M-Ras are members of the Ras superfamily of small GTPases. R-Ras family proteins are frequently overexpressed in human cancers, and expression of activated mutants of these GTPases is sufficient to induce cell transformation. Unlike Ras, few activating mutations of R-Ras proteins have been reported in human cancer, and very little is known about the regulation of their activity. In this study, we report that TC21 and R-Ras are phosphorylated on a conserved serine, Ser186 and Ser201, respectively, in intact cells. This residue is located in the C-terminal hypervariable region of the proteins and is not conserved in M-Ras. We show that the MAP kinases ERK1/2 phosphorylate TC21 and R-Ras on this C-terminal serine residue both in vitro and in vivo. Phosphorylation of R-Ras proteins does not affect their subcellular localization or stability but rather stimulates their activation. Phosphorylation-defective mutants of R-Ras and TC21 are compromised in their ability to promote cancer cell adhesion and migration/invasion, respectively. Importantly, we show that phosphorylation of TC21 and R-Ras potentiates their tumorigenic activity in immunodeficient mice. Our results identify a novel regulatory mechanism of the small GTPases TC21 and R-Ras that controls their oncogenic potential.	[Fremin, C.; Guegan, J-P; Plutoni, C.; Emery, G.; Meloche, S.] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ, Canada; [Mahaffey, J.; Philips, M. R.] NYU, Dept Med, Perlmutter Canc Inst, 550 1St Ave, New York, NY 10016 USA; [Mahaffey, J.; Philips, M. R.] NYU, Dept Cell Biol & Pharmacol, Perlmutter Canc Inst, 550 1St Ave, New York, NY 10016 USA; [Emery, G.; Meloche, S.] Univ Montreal, Program Mol Biol, Montreal, PQ, Canada; [Emery, G.] Univ Montreal, Dept Pathol & Cell Biol, Montreal, PQ, Canada; [Meloche, S.] Univ Montreal, Dept Pharmacol, Montreal, PQ, Canada	Universite de Montreal; New York University; New York University; Universite de Montreal; Universite de Montreal; Universite de Montreal	Meloche, S (corresponding author), Inst Res Immunol & Canc, 2950 Chemin Polytech, Montreal, PQ H3C 3J7, Canada.	sylvain.meloche@umontreal.ca		Mark, Philips/0000-0002-1179-8156; Guegan, Jean-Philippe/0000-0002-3993-0956; Emery, Gregory/0000-0002-6874-6875	Cole Foundation; Association pour la Recherche centre le Cancer (ARC); Fonds de la recherche en sante du Quebec (FRSQ); Fondation pour la Recherche Medicale (FRM); Canadian Institutes of Health Research; NATIONAL CANCER INSTITUTE [R01CA116034] Funding Source: NIH RePORTER	Cole Foundation; Association pour la Recherche centre le Cancer (ARC); Fonds de la recherche en sante du Quebec (FRSQ)(Fonds de la Recherche en Sante du Quebec); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank B Alarcon (CBMSO, Madrid) for pGex-4T3-TC21 and pEGFP-TC21 plasmids. CF is a recipient of fellowships from the Cole Foundation, the Association pour la Recherche centre le Cancer (ARC) and the Fonds de la recherche en sante du Quebec (FRSQ). JPG is a recipient of fellowships from the Fondation pour la Recherche Medicale (FRM), the Cole Foundation and the Fonds de la recherche en sante du Quebec (FRSQ). SM and GE hold the Canada Research Chairs in Cellular Signaling and Vesicle Transport and Cell Signaling, respectively. This work was supported by grants from the Canadian Institutes of Health Research to SM and GE.	Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255; Arora S, 2005, MOL CARCINOGEN, V42, P97, DOI 10.1002/mc.20048; Barcelo C, 2014, CANCER RES, V74, P1190, DOI 10.1158/0008-5472.CAN-13-1750; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; Castro AF, 2012, J CELL BIOCHEM, V113, P1253, DOI 10.1002/jcb.23458; Clark GJ, 1996, ONCOGENE, V12, P169; Courcelles M, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.25; COX AD, 1994, ONCOGENE, V9, P3281; Delgado P, 2009, NAT IMMUNOL, V10, P880, DOI 10.1038/ni.1749; Ehrhardt A, 2002, EXP HEMATOL, V30, P1089, DOI 10.1016/S0301-472X(02)00904-9; Fremin C, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-8; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Grosstessner-Hain K, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.008540; Guo X, 2006, ONCOGENE, V25, P4241, DOI 10.1038/sj.onc.1209452; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; Heo JY, 2004, BIOCHEMISTRY-US, V43, P2314, DOI 10.1021/bi035275g; Humphrey SJ, 2013, CELL METAB, V17, P1009, DOI 10.1016/j.cmet.2013.04.010; Kim JY, 2013, P NATL ACAD SCI USA, V110, P12414, DOI 10.1073/pnas.1220674110; Larive RM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4881; Lee JH, 2011, INT J DERMATOL, V50, P956, DOI 10.1111/j.1365-4632.2010.04846.x; Louahed J, 1999, BLOOD, V94, P1701, DOI 10.1182/blood.V94.5.1701.417k29_1701_1710; LOWE DG, 1987, MOL CELL BIOL, V7, P2845, DOI 10.1128/MCB.7.8.2845; Luo HR, 2010, INT J ONCOL, V37, P853, DOI 10.3892/ijo_00000736; Macha MA, 2010, J ORAL PATHOL MED, V39, P477, DOI 10.1111/j.1600-0714.2009.00854.x; Nishigaki M, 2005, CANCER RES, V65, P2115, DOI 10.1158/0008-5472.CAN-04-3340; Quilliam LA, 1999, J BIOL CHEM, V274, P23850, DOI 10.1074/jbc.274.34.23850; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Robitaille AM, 2013, SCIENCE, V339, P1320, DOI 10.1126/science.1228771; Sandri C, 2012, CELL RES, V22, P1479, DOI 10.1038/cr.2012.110; Sasaki AT, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001518; Sawada J, 2012, CANCER CELL, V22, P235, DOI 10.1016/j.ccr.2012.06.013; Sung PJ, 2013, P NATL ACAD SCI USA, V110, P20593, DOI 10.1073/pnas.1306431110; Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660; Williams JG, 2003, P NATL ACAD SCI USA, V100, P6376, DOI 10.1073/pnas.1037299100; Yang MH, 2012, P NATL ACAD SCI USA, V109, P10843, DOI 10.1073/pnas.1201487109	35	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 27	2016	35	43					5692	5698		10.1038/onc.2016.122	http://dx.doi.org/10.1038/onc.2016.122			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EA9XP	27086924				2022-12-17	WOS:000386998300012
J	Bieging-Rolett, KT; Johnson, TM; Brady, CA; Beaudry, VG; Pathak, N; Han, S; Attardi, LD				Bieging-Rolett, K. T.; Johnson, T. M.; Brady, C. A.; Beaudry, V. G.; Pathak, N.; Han, S.; Attardi, L. D.			p19(Arf) is required for the cellular response to chronic DNA damage	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; GENOMIC INSTABILITY; TUMOR SUPPRESSION; LIFE-SPAN; ARF; P53; CELLS; ACTIVATION; ARREST; CHECKPOINT	The p53 tumor suppressor is a stress sensor, driving cell cycle arrest or apoptosis in response to DNA damage or oncogenic signals. p53 activation by oncogenic signals relies on the p19(Arf) tumor suppressor, while p53 activation downstream of acute DNA damage is reported to be p19(Arf)-independent. Accordingly, p19(Arf)-deficient mouse embryo fibroblasts (MEFs) arrest in response to acute DNA damage. However, p19(Arf) is required for replicative senescence, a condition associated with an activated DNA damage response, as p19(Arf) -/- MEFs do not senesce after serial passage. A possible explanation for these seemingly disparate roles for p19(Arf) is that acute and chronic DNA damage responses are mechanistically distinct. Replicative senescence may result from chronic, low-dose DNA damage responses in which p19(Arf) has a specific role. We therefore examined the role of p19(Arf) in cellular responses to chronic, low-dose DNA-damaging agent treatment by maintaining MEFs in low oxygen and administering 0.5 G y gamma-irradiation daily or 150 mu M hydroxyurea, a replication stress inducer. In contrast to their response to acute DNA damage, p19(Arf) -/- MEFs exposed to chronic DNA damage do not senesce, revealing a selective role for p19(Arf) in senescence upon low-level, chronic DNA damage. We show further that p53 pathway activation in p19(Arf) -/- MEFs exposed to chronic DNA damage is attenuated relative to wild-type MEFs, suggesting a role for p19(Arf) in fine-tuning p53 activity. However, combined Nutlin3a and chronic DNA-damaging agent treatment is insufficient to promote senescence in p19(Arf) -/- MEFs, suggesting that the role of p19(Ar)f in the chronic DNA damage response may be partially p53-independent. These data suggest the importance of p19(Arf) for the cellular response to the low-level DNA damage incurred in culture or upon oncogene expression, providing new insight into how p19(Arf) serves as a tumor suppressor. Moreover, our study helps reconcile reports suggesting crucial roles for both p19(Arf) and DNA damage-signaling pathways in tumor suppression.	[Bieging-Rolett, K. T.; Johnson, T. M.; Brady, C. A.; Beaudry, V. G.; Pathak, N.; Han, S.; Attardi, L. D.] Stanford Univ, Dept Radiat Oncol, Sch Med, Div Radiat & Canc Biol, Stanford, CA 94305 USA; [Attardi, L. D.] Stanford Univ, Dept Genet, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Attardi, LD (corresponding author), Stanford Univ, Sch Med, Div Radiat & Canc Biol, Dept Radiat Oncol,CCSR South, Room 1255,269 Campus Dr, Stanford, CA 94305 USA.	attardi@stanford.edu		han, shuo/0000-0003-1181-351X	American Cancer Society postdoctoral fellowship [122767-PF-12-195-01-TBG]; American Cancer Society [RSG-06-065-01-MGO]; Leukemia and Lymphoma Society [LLS-1012-09]; National Institutes of Health [CA140875]; NATIONAL CANCER INSTITUTE [R35CA197591, R01CA140875] Funding Source: NIH RePORTER	American Cancer Society postdoctoral fellowship(American Cancer Society); American Cancer Society(American Cancer Society); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Charles Sherr for the kind gift of the p19<SUP>Arf</SUP> antibody and Nitin Raj and Margot Bowen for critical reading of the manuscript. KBR was funded by an American Cancer Society postdoctoral fellowship 122767-PF-12-195-01-TBG. This work was supported by funding from the American Cancer Society (RSG-06-065-01-MGO), the Leukemia and Lymphoma Society (LLS-1012-09), and the National Institutes of Health (CA140875) to LDA.	Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bester AC, 2011, CELL, V145, P435, DOI 10.1016/j.cell.2011.03.044; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Borel F, 2002, J CELL SCI, V115, P2829; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Carlos AR, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3697; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Christensen C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6348; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Di Micco R, 2008, CELL CYCLE, V7, P3601, DOI 10.4161/cc.7.22.7152; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Evangelou K, 2013, CELL DEATH DIFFER, V20, P1485, DOI 10.1038/cdd.2013.76; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hinkal G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006654; Kamijo T, 1999, CANCER RES, V59, P2464; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Kotsinas A, 2014, CELL CYCLE, V13, P1227, DOI 10.4161/cc.28654; Kuo ML, 2008, CELL CYCLE, V7, P3378, DOI 10.4161/cc.7.21.6930; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lessard F, 2010, MOL CELL, V38, P539, DOI 10.1016/j.molcel.2010.03.015; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Monasor A, 2013, CELL CYCLE, V12, P1948, DOI 10.4161/cc.25017; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Sherr CJ, 2000, CELL, V102, P407, DOI 10.1016/S0092-8674(00)00046-5; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; Tanaka S, 2002, GENE DEV, V16, P2639, DOI 10.1101/gad.1011002; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Valente LJ, 2013, CELL REP, V3, P1339, DOI 10.1016/j.celrep.2013.04.012; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Velimezi G, 2013, NAT CELL BIOL, V15, P967, DOI 10.1038/ncb2795; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991	44	11	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33					4414	4421		10.1038/onc.2015.490	http://dx.doi.org/10.1038/onc.2015.490			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	26725325	Green Accepted			2022-12-17	WOS:000382152100013
J	Wang, YC; Wang, SA; Chen, PH; Hsu, TI; Yang, WB; Chuang, YP; Su, WC; Liaw, HJ; Chang, WC; Hung, JJ				Wang, Y-C; Wang, S-A; Chen, P-H; Hsu, T-I; Yang, W-B; Chuang, Y-P; Su, W-C; Liaw, H-J; Chang, W-C; Hung, J-J			Variants of ubiquitin-specific peptidase 24 play a crucial role in lung cancer malignancy	ONCOGENE			English	Article							SINGLE-NUCLEOTIDE POLYMORPHISMS; HEPATOCELLULAR-CARCINOMA; DNA METHYLATION; RNA; METASTASIS; USP24; MDM2; STABILITY; SUV39H1; DISEASE	Ubiquitin is a critical modifier regulating the degradation and function of its target proteins during posttranslational modification. Here we found that ubiquitin-specific peptidase 24 (USP24) is highly expressed in cell lines with enhanced malignancy and in late-stage lung cancer clinical samples. Studying single-nucleotide polymorphisms (SNPs) of USP24 using genomic DNA of lung cancer patients revealed an increase in SNP 7656C/T. When using RNA specimens instead of the genomic DNA of lung cancer patients, we found significant increases in the ratios of variants 930C/T and 7656T/C, suggesting that variants at these two sites are not only caused by the SNP of DNA but also by the RNA editing. USP24-930T and USP24-7656C increase USP24 expression levels by increasing RNA stability. Knocking down USP24 increased Suv39h1 level through a decrease in mouse double-minute 2 homolog levels, thus enhancing lysine-9 methylation of histone H3, and resulting in the prevention of lung cancer malignancy. In conclusion, as USP24 variant analysis revealed a higher ratio of variants in blood specimens of lung cancer patients than that in normal individuals, USP24-930T and USP24-7656C might be useful as diagnostic markers for cancer detection.	[Wang, Y-C; Hung, J-J] Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan, Taiwan; [Wang, S-A; Hsu, T-I; Yang, W-B; Hung, J-J] Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, Coll Biosci & Biotechnol, Tainan, Taiwan; [Chen, P-H; Chuang, Y-P] Natl Cheng Kung Univ, Dept Pharmacol, Tainan, Taiwan; [Hsu, T-I; Hung, J-J] Natl Cheng Kung Univ, Ctr Infect Dis & Signal Transduct, Tainan, Taiwan; [Hsu, T-I] Taipei Med Univ, PhD Program Neural Regenerat Med, Taipei, Taiwan; [Su, W-C] Natl Cheng Kung Univ, Dept Internal Med, Coll Med & Hosp, Tainan, Taiwan; [Liaw, H-J] Natl Cheng Kung Univ, Dept Life Sci, Coll Biosci Biotechnol, Tainan, Taiwan; [Chang, W-C; Hung, J-J] Taipei Med Univ, Grad Inst Med Sci, Coll Med, Taipei, Taiwan	National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; National Cheng Kung University; Taipei Medical University; National Cheng Kung University; National Cheng Kung University; Taipei Medical University	Hung, JJ (corresponding author), Natl Cheng Kung Univ, Inst Bioinformat & Biosignal Transduct, 1 Univ Rd, Tainan 701, Taiwan.	petehung@mail.ncku.edu.tw	Liaw, Hungjiun/G-7034-2014; Hsu, Tsung-I/AAK-9942-2020; Yang, Wen-Bin/AAO-3593-2021	Liaw, Hungjiun/0000-0002-3481-709X; Hsu, Tsung-I/0000-0002-7524-7740; Yang, Wen-Bin/0000-0002-6497-4176; Wang, Shao-an/0000-0002-5473-4195; Su, Wu-Chou/0000-0003-2953-4105; Wang, Yi-Chang/0000-0001-9346-5234	National Cheng Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers; Ministry of Science and Technology, Taiwan [MOST 103-2320-B-006-035-MY3, MOST 103-2321-B-006-023-MY3]; National Research Program for Biopharmaceuticals of National Science Council, Taiwan	National Cheng Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers; Ministry of Science and Technology, Taiwan(Ministry of Science and Technology, Taiwan); National Research Program for Biopharmaceuticals of National Science Council, Taiwan	This work was supported by the National Cheng Kung University project of the Program for Promoting Academic Excellence and Developing World Class Research Centers, together with grants MOST 103-2320-B-006-035-MY3 and MOST 103-2321-B-006-023-MY3 obtained from the Ministry of Science and Technology, Taiwan. In addition, we thank the Taiwan Lung Cancer Tissue/Specimen and Information Resource Center at National Health Research Institute (NHRI), Taiwan for blood samples' support. This Center was supported by grants from National Research Program for Biopharmaceuticals of National Science Council, Taiwan.	Avesson L, 2014, BBA-REV CANCER, V1845, P308, DOI 10.1016/j.bbcan.2014.03.001; Blanc V, 2010, WIRES SYST BIOL MED, V2, P594, DOI 10.1002/wsbm.82; Blons H, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-25; Bosch-Presegue L, 2011, MOL CELL, V42, P210, DOI 10.1016/j.molcel.2011.02.034; Chiba T, 2015, INT J CANCER, V136, P289, DOI 10.1002/ijc.28985; Das TK, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.34; Dominissini D, 2011, CARCINOGENESIS, V32, P1569, DOI 10.1093/carcin/bgr124; Dong C, 2013, ONCOGENE, V32, P1351, DOI 10.1038/onc.2012.169; Torres AG, 2014, FEBS LETT, V588, P4279, DOI 10.1016/j.febslet.2014.09.025; Garg AV, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003699; Guo WH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117075; Heideker J, 2015, BIOCHEM J, V467, P191, DOI 10.1042/bj4670191; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Katono K, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121460; Khanal P, 2013, FASEB J, V27, P4606, DOI 10.1096/fj.13-236851; Kramer K, 2014, TISSUE ANTIGENS, V84, P370, DOI 10.1111/tan.12411; Li SM, 2014, J BIOL CHEM, V289, P34152, DOI 10.1074/jbc.M113.546077; Li YH, 2006, HUM MUTAT, V27, P1017, DOI 10.1002/humu.20382; Liu CC, 2014, NUCLEIC ACIDS RES, V42, P9543, DOI 10.1093/nar/gku675; Nagahara A, 2010, BIOCHEM BIOPH RES CO, V391, P1641, DOI 10.1016/j.bbrc.2009.12.105; Nicoloso MS, 2010, CANCER RES, V70, P2789, DOI 10.1158/0008-5472.CAN-09-3541; Ranaweera RS, 2013, J BIOL CHEM, V288, P18939, DOI 10.1074/jbc.M113.454470; Rebbani K, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0340-2; Schmid F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-49; Sharma S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7881; Shi Dingding, 2012, Genes Cancer, V3, P240, DOI 10.1177/1947601912455199; Strock CJ, 2006, CANCER RES, V66, P7509, DOI 10.1158/0008-5472.CAN-05-3048; Tomaselli S, 2014, CELL TISSUE RES, V356, P527, DOI 10.1007/s00441-014-1863-3; Vage J, 2008, BMC GENET, V9, DOI 10.1186/1471-2156-9-10; Villegas J, 2002, NUCLEIC ACIDS RES, V30, P1895, DOI 10.1093/nar/30.9.1895; Wang YQ, 2015, AUTOPHAGY, V11, P595, DOI 10.1080/15548627.2015.1034408; Whibley C, 2009, NAT REV CANCER, V9, P95, DOI 10.1038/nrc2584; Wu PC, 2014, CANCER RES, V74, P7333, DOI 10.1158/0008-5472.CAN-13-3572; Wu YR, 2010, CLIN CHIM ACTA, V411, P955, DOI 10.1016/j.cca.2010.03.013; Xu C, 2015, ONCOGENE, V34, P342, DOI 10.1038/onc.2013.557; Yanagisawa T, 2003, THEOR APPL GENET, V107, P84, DOI 10.1007/s00122-003-1235-y; Yang Y, 2015, ONCOGENE, V34, P104, DOI 10.1038/onc.2013.522; Zhang L, 2015, CELL REP, V10, P140, DOI 10.1016/j.celrep.2014.12.024; Zhang L, 2012, CELL CYCLE, V11, P4378, DOI 10.4161/cc.22688; Zhao B, 2012, EUR NEUROL, V68, P181, DOI 10.1159/000339641; Zhao GY, 2015, TUMOR BIOL, V36, P1721, DOI 10.1007/s13277-014-2773-4; Zou Q, 2014, NAT IMMUNOL, V15, P562, DOI 10.1038/ni.2885	42	11	11	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 14	2016	35	28					3669	3680		10.1038/onc.2015.432	http://dx.doi.org/10.1038/onc.2015.432			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UQ	26568301				2022-12-17	WOS:000379622800006
J	Malaterre, J; Pereira, L; Putoczki, T; Millen, R; Paquet-Fifield, S; Germann, M; Liu, J; Cheasley, D; Sampurno, S; Stacker, SA; Achen, MG; Ward, RL; Waring, P; Mantamadiotis, T; Ernst, M; Ramsay, RG				Malaterre, J.; Pereira, L.; Putoczki, T.; Millen, R.; Paquet-Fifield, S.; Germann, M.; Liu, J.; Cheasley, D.; Sampurno, S.; Stacker, S. A.; Achen, M. G.; Ward, R. L.; Waring, P.; Mantamadiotis, T.; Ernst, M.; Ramsay, R. G.			Intestinal-specific activatable Myb initiates colon tumorigenesis in mice	ONCOGENE			English	Article							ADENOID CYSTIC CARCINOMA; C-MYB; COLORECTAL-CANCER; STEM-CELLS; MOUSE MODEL; VASCULAR-PERMEABILITY; EXPRESSION; GROWTH; P27(KIP1); GENES	Transcription factor Myb is overexpressed in most colorectal cancers (CRC). Patients with CRC expressing the highest Myb are more likely to relapse. We previously showed that mono-allelic loss of Myb in an Adenomatous polyposis coli (APC)-driven CRC mouse model (Apc(Min/+)) significantly improves survival. Here we directly investigated the association of Myb with poor prognosis and how Myb co-operates with tumor suppressor genes (TSGs) (Apc) and cell cycle regulator, p27. Here we generated the first intestinal-specific, inducible transgenic model; a MybER transgene encoding a tamoxifen-inducible fusion protein between Myb and the estrogen receptor-a ligand-binding domain driven by the intestinal-specific promoter, Gpa33. This was to mimic human CRC with constitutive Myb activity in a highly tractable mouse model. We confirmed that the transgene was faithfully expressed and inducible in intestinal stem cells (ISCs) before embarking on carcinogenesis studies. Activation of the MybER did not change colon homeostasis unless one p27 allele was lost. We then established that MybER activation during CRC initiation using a pro-carcinogen treatment, azoxymethane (AOM), augmented most measured aspects of ISC gene expression and function and accelerated tumorigenesis in mice. CRC-associated symptoms of patients including intestinal bleeding and anaemia were faithfully mimicked in AOM-treated MybER transgenic mice and implicated hypoxia and vessel leakage identifying an additional pathogenic role for Myb. Collectively, the results suggest that Myb expands the ISC pool within which CRC is initiated while co-operating with TSG loss. Myb further exacerbates CRC pathology partly explaining why high MYB is a predictor of worse patient outcome.	[Malaterre, J.; Pereira, L.; Millen, R.; Paquet-Fifield, S.; Germann, M.; Cheasley, D.; Sampurno, S.; Stacker, S. A.; Achen, M. G.; Ramsay, R. G.] Peter MacCallum Canc Ctr, Differentiat & Transcript Lab, Melbourne, Vic, Australia; [Malaterre, J.; Millen, R.; Cheasley, D.; Stacker, S. A.; Achen, M. G.; Ramsay, R. G.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Putoczki, T.; Cheasley, D.] Walter & Elisa Hall Inst Med Res, Melbourne, Vic, Australia; [Millen, R.; Liu, J.; Ward, R. L.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Waring, P.; Mantamadiotis, T.; Ramsay, R. G.] UNSW Med, Prince Wales Clin Sch, Sydney, NSW, Australia; [Waring, P.; Mantamadiotis, T.; Ramsay, R. G.] UNSW Med, Lowy Canc Res Ctr, Sydney, NSW, Australia	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne	Ramsay, RG (corresponding author), Peter MacCallum Canc Ctr, Differentiat & Transcript Lab, East Melbourne, Vic 3002, Australia.	rob.ramsay@petermac.org	Ernst, Matthias/D-5111-2012; Ramsay, Robert G/C-3291-2015; Paquet-Fifield, Sophie/AAL-6410-2021; Mantamadiotis, Theo/W-9010-2019; Mantamadiotis, Theo/AAM-1346-2020; Ward, Robyn/I-2313-2013	Ernst, Matthias/0000-0002-6399-1177; Ramsay, Robert G/0000-0001-5003-0433; Mantamadiotis, Theo/0000-0003-3971-5380; Ward, Robyn/0000-0002-6877-8906; Achen, Marc/0000-0002-3791-803X; Germann, Markus/0000-0001-8306-6918; Cheasley, Dane/0000-0002-1170-4690; Stacker, Steven/0000-0003-4096-9273	NHMRC	NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	The authors thank the Peter MacCallum Histology and Microscopy departments and animal facility as well as the NHMRC Senior Research Fellowship Scheme (RR, ME) and Program Grant scheme (RGR, JM and ME).	Altemani A, 2013, HISTOPATHOLOGY, V62, P531, DOI 10.1111/j.1365-2559.2013.04352.x; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Bates DO, 2002, VASC PHARMACOL, V39, P225, DOI 10.1016/S1537-1891(03)00011-9; Bell D, 2011, CANCER BIOL THER, V12, P569, DOI 10.4161/cbt.12.7.17008; Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1; Cheasley D, 2011, STEM CELLS, V29, P2042, DOI 10.1002/stem.761; CHENG H, 1974, AM J ANAT, V141, P503, DOI 10.1002/aja.1001410405; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Ciznadija D, 2009, CELL DEATH DIFFER, V16, P1530, DOI 10.1038/cdd.2009.94; Coletta PL, 2004, BLOOD, V103, P1050, DOI 10.1182/blood-2003-03-0707; CORBETT TH, 1975, CANCER RES, V35, P2434; Cross RS, 2015, CLIN TRANSL IMMUNOL, V4, DOI 10.1038/cti.2014.29; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Flentjar N, 2007, GASTROENTEROLOGY, V132, P1410, DOI 10.1053/j.gastro.2007.02.054; Gottschalk AR, 2001, CANCER RES, V61, P2105; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Ho AS, 2013, NAT GENET, V45, P791, DOI 10.1038/ng.2643; Holstein von SL, 2013, OPHTHALMOLOGY; Hugo H, 2006, GENE CHROMOSOME CANC, V45, P1143, DOI 10.1002/gcc.20378; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Kim SY, 2008, ORAL ONCOL, V44, P383, DOI 10.1016/j.oraloncology.2007.05.004; Lin SA, 2011, J GASTROENTEROL, V46, P1039, DOI 10.1007/s00535-011-0424-8; Lutwyche JK, 2006, BIOCHEM BIOPH RES CO, V344, P1300, DOI 10.1016/j.bbrc.2006.04.045; Malaterre J, 2007, P NATL ACAD SCI USA, V104, P3829, DOI 10.1073/pnas.0610055104; Mitani Y, 2010, CLIN CANCER RES, V16, P4722, DOI 10.1158/1078-0432.CCR-10-0463; MOSER AR, 1995, EUR J CANCER, V31A, P1061, DOI 10.1016/0959-8049(95)00181-H; Nagy JA, 2008, ANGIOGENESIS, V11, P109, DOI 10.1007/s10456-008-9099-z; Ouyang DL, 2005, AM J GASTROENTEROL, V100, P1393, DOI 10.1111/j.1572-0241.2005.41427.x; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Philipp-Staheli J, 2001, EXP CELL RES, V264, P148, DOI 10.1006/excr.2000.5143; POTTEN CS, 1974, CELL TISSUE KINET, V7, P271, DOI 10.1111/j.1365-2184.1974.tb00907.x; POTTEN CS, 1977, NATURE, V269, P518, DOI 10.1038/269518a0; Ramsay RG, 2005, DNA CELL BIOL, V24, P21, DOI 10.1089/dna.2005.24.21; Ramsay RG, 2003, EXPERT OPIN THER TAR, V7, P235; RAMSAY RG, 1989, ONCOGENE RES, V4, P259; Ramsay RG, 2008, NAT REV CANCER, V8, P523, DOI 10.1038/nrc2439; Roeb E, 2013, INTERNIST, V54, P242, DOI 10.1007/s00108-012-3184-5; Rothenberg ME, 2012, GASTROENTEROLOGY, V142, P1195, DOI 10.1053/j.gastro.2012.02.006; Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050; Stenman G, 2013, HEAD NECK PATHOL, V7, pS12, DOI 10.1007/s12105-013-0462-z; Stephens PJ, 2013, J CLIN INVEST, V123, P2965, DOI 10.1172/JCI67201; Takeda N, 2011, SCIENCE, V334, P1420, DOI 10.1126/science.1213214; Thompson MA, 1997, ONCOGENE, V14, P1715, DOI 10.1038/sj.onc.1201007; Tsihlias J, 1999, ANNU REV MED, V50, P401; Tsutsui S, 2005, CANCER-AM CANCER SOC, V104, P2048, DOI 10.1002/cncr.21471; Umar Shahid, 2010, Curr Gastroenterol Rep, V12, P340, DOI 10.1007/s11894-010-0130-3; van Es JH, 2012, NAT CELL BIOL, V14, P1099, DOI 10.1038/ncb2581; Vernon SW, 1997, JNCI-J NATL CANCER I, V89, P1406, DOI 10.1093/jnci/89.19.1406; Waldron T, 2012, LEUKEMIA, V26, P644, DOI 10.1038/leu.2011.264; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Williams BB, 2008, CANCER IMMUNOL IMMUN, V57, P1635, DOI 10.1007/s00262-008-0497-2; Xu HL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012112; You SJ, 2006, INT J EXP PATHOL, V87, P227, DOI 10.1111/j.1365-2613.2006.00477.x; Ziskin JL, 2013, GUT, V62, P1012, DOI 10.1136/gutjnl-2011-301195	54	11	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 12	2016	35	19					2475	2484		10.1038/onc.2015.305	http://dx.doi.org/10.1038/onc.2015.305			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DM2GQ	26300002	Green Published, hybrid			2022-12-17	WOS:000376165500006
J	Kharat, SS; Tripathi, V; Damodaran, AP; Priyadarshini, R; Chandra, S; Tikoo, S; Nandhakumar, R; Srivastava, V; Priya, S; Hussain, M; Kaur, S; Fishman, JB; Sengupta, S				Kharat, S. S.; Tripathi, V.; Damodaran, A. P.; Priyadarshini, R.; Chandra, S.; Tikoo, S.; Nandhakumar, R.; Srivastava, V.; Priya, S.; Hussain, M.; Kaur, S.; Fishman, J. B.; Sengupta, S.			Mitotic phosphorylation of Bloom helicase at Thr182 is required for its proteasomal degradation and maintenance of chromosomal stability	ONCOGENE			English	Article							BLM HELICASE; CELL-CYCLE; HOMOLOGOUS RECOMBINATION; REPLICATION STRESS; UBIQUITIN LIGASE; RECQ HELICASES; DNA-DAMAGE; MULTISITE PHOSPHORYLATION; SYNDROME PROTEIN; F-BOX	Mutations in Bloom helicase (BLM) lead to Bloom Syndrome (BS). BS is characterized by multiple clinical manifestations including predisposition to a wide spectrum of cancers. Studies have revealed the mechanism of BLM recruitment after stalled replication and its role during the repair of DNA damage. We now provide evidence that BLM undergoes K48-linked ubiquitylation and subsequent degradation during mitosis due to the E3 ligase, Fbw7 alpha. Fbw7 alpha carries out its function after GSK3 beta- and CDK2/cyclin A2-dependent phosphorylation events on Thr171 and Ser175 of BLM which lies within a well-defined phosphodegron, a sequence which is conserved in all primates. Phosphorylation on BLM Thr171 and Ser175 depends on prior phosphorylation at Thr182 by Chk1/Chk2. Thr182 phosphorylation not only controls BLM ubiquitylation and degradation during mitosis but is also a determinant for its localization on the ultrafine bridges. Consequently lack of Thr182 phosphorylation leads to multiple manifestations of chromosomal instability including increased levels of DNA damage, lagging chromatin, micronuclei formation, breaks and quadriradials. Hence Thr182 phosphorylation on BLM has two functions-it regulates BLM turnover during mitosis and also helps to maintain the chromosomal stability.	[Kharat, S. S.; Tripathi, V.; Damodaran, A. P.; Priyadarshini, R.; Chandra, S.; Tikoo, S.; Nandhakumar, R.; Srivastava, V.; Priya, S.; Hussain, M.; Kaur, S.; Sengupta, S.] Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India; [Fishman, J. B.] 21st Century Biochem, 260 Cedar Hill St, Marlborough, MA USA	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Sengupta, S (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Marg, New Delhi 110067, India.	sagar@nii.ac.in	Tripathi, Vivek/O-9164-2018; Tikoo, Shweta/AAX-1902-2021; Sengupta, Sagar/AGR-1063-2022; Kharat, Suhas/V-2129-2019; Hussain, Mansoor/GQI-2915-2022	Tripathi, Vivek/0000-0002-4453-0105; Tikoo, Shweta/0000-0001-5850-8075; Sengupta, Sagar/0000-0002-6365-1770; Kharat, Suhas/0000-0003-2283-7429; Hussain, Mansoor/0000-0003-4260-2256	National Institute of Immunology core funds, Department of Biotechnology (DBT), India [BT/PR3148/AGR/36/706/2011]; Science and Engineering Research Board, India [SR/SO/BB-0124/2013]; Indo-French Centre for the Promotion of Advanced Research (IFCPAR) [IFC/4603-A/2011/1250]; Council of Scientific and Industrial Research (CSIR), India [37(1541)/12/EMR-II]	National Institute of Immunology core funds, Department of Biotechnology (DBT), India; Science and Engineering Research Board, India; Indo-French Centre for the Promotion of Advanced Research (IFCPAR)(Indo-French Centre for the Promotion of Advanced Research (IFCPAR/CEFIPRA)); Council of Scientific and Industrial Research (CSIR), India(Council of Scientific & Industrial Research (CSIR) - India)	We acknowledge Bruce Clurman, Markus Welcker, Jonathan Grim, Ian Hickson, Stephen Elledge, Thanos Halazonetis, Jerry Shay, Nathan Ellis, Bert Vogelstein for plasmids and cells, Simon Gemble for help with SCEs and UFB staining, Priyanka Modi for transfection experiments, Jyoti Kumari for lentivirus-mediated stable line generation and Richa Mudgal for bioinformatic analysis. SS acknowledges National Institute of Immunology core funds, Department of Biotechnology (DBT), India (BT/PR3148/AGR/36/706/2011); Science and Engineering Research Board, India (SR/SO/BB-0124/2013); Indo-French Centre for the Promotion of Advanced Research (IFCPAR) (IFC/4603-A/2011/1250) and Council of Scientific and Industrial Research (CSIR), India [37(1541)/12/EMR-II] for financial assistance.	Ababou M, 2000, ONCOGENE, V19, P5955, DOI 10.1038/sj.onc.1204003; Aguilera A, 2013, ANNU REV GENET, V47, P1, DOI 10.1146/annurev-genet-111212-133232; Bachrati CZ, 2003, BIOCHEM J, V374, P577, DOI 10.1042/BJ20030491; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; Bayart E, 2006, CELL CYCLE, V5, P1681, DOI 10.4161/cc.5.15.3122; Beamish H, 2002, J BIOL CHEM, V277, P30515, DOI 10.1074/jbc.M203801200; Bendris N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022879; Bohm S, 2014, DNA REPAIR, V22, P123, DOI 10.1016/j.dnarep.2014.07.007; Bugreev DV, 2007, GENE DEV, V21, P3085, DOI 10.1101/gad.1609007; Busino L, 2004, ONCOGENE, V23, P2050, DOI 10.1038/sj.onc.1207394; Chan KL, 2009, NAT CELL BIOL, V11, P753, DOI 10.1038/ncb1882; Chan KL, 2007, EMBO J, V26, P3397, DOI 10.1038/sj.emboj.7601777; Chandra S, 2013, J CELL SCI, V126, P3782, DOI 10.1242/jcs.124719; Chu WK, 2009, NAT REV CANCER, V9, P644, DOI 10.1038/nrc2682; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Dai XP, 2014, ONCOTARGET, V5, P3307, DOI 10.18632/oncotarget.1939; Davies SL, 2007, NAT STRUCT MOL BIOL, V14, P677, DOI 10.1038/nsmb1267; Davies SL, 2004, MOL CELL BIOL, V24, P1279, DOI 10.1128/MCB.24.3.1279-1291.2004; De Boer L, 2008, ONCOGENE, V27, P4261, DOI 10.1038/onc.2008.74; Dutertre S, 2000, ONCOGENE, V19, P2731, DOI 10.1038/sj.onc.1203595; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; Franchitto A, 2002, J CELL BIOL, V157, P19, DOI 10.1083/jcb.200110009; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Kaur S, 2010, MOL CANCER RES, V8, P1234, DOI 10.1158/1541-7786.MCR-10-0233; Ke YW, 2011, EMBO J, V30, P3309, DOI 10.1038/emboj.2011.226; Kimura T, 2003, CANCER SCI, V94, P431, DOI 10.1111/j.1349-7006.2003.tb01460.x; Leng M, 2006, P NATL ACAD SCI USA, V103, P11485, DOI 10.1073/pnas.0601828103; Melixetian M, 2009, NAT CELL BIOL, V11, P1247, DOI 10.1038/ncb1969; Naim V, 2009, NAT CELL BIOL, V11, P761, DOI 10.1038/ncb1883; Nash P, 2001, NATURE, V414, P514, DOI 10.1038/35107009; Nimonkar AV, 2008, P NATL ACAD SCI USA, V105, P16906, DOI 10.1073/pnas.0809380105; Nimonkar AV, 2011, GENE DEV, V25, P350, DOI 10.1101/gad.2003811; Orlicky S, 2003, CELL, V112, P243, DOI 10.1016/S0092-8674(03)00034-5; Perez-Benavente B, 2013, ONCOGENE, V32, P2189, DOI 10.1038/onc.2012.235; Petsalaki E, 2014, J CELL SCI, V127, P3902, DOI 10.1242/jcs.155176; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reavie L, 2013, CANCER CELL, V23, P362, DOI 10.1016/j.ccr.2013.01.025; ROSIN MP, 1985, HUM GENET, V71, P187, DOI 10.1007/BF00284570; Rouzeau S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033905; Sanz MM, 2000, CYTOGENET CELL GENET, V91, P217, DOI 10.1159/000056848; Schmitt E, 2006, J CELL SCI, V119, P4269, DOI 10.1242/jcs.03200; Spruck CH, 2002, CANCER RES, V62, P4535; Srivastava V, 2009, J CELL SCI, V122, P3093, DOI 10.1242/jcs.051813; Suhasini AN, 2011, EMBO J, V30, P692, DOI 10.1038/emboj.2010.362; Swaney DL, 2013, NAT METHODS, V10, P676, DOI [10.1038/NMETH.2519, 10.1038/nmeth.2519]; Takeishi S, 2013, CANCER CELL, V23, P347, DOI 10.1016/j.ccr.2013.01.026; Tan MJ, 2011, DEV CELL, V21, P1062, DOI 10.1016/j.devcel.2011.09.014; Tikoo S, 2013, EMBO J, V32, P1778, DOI 10.1038/emboj.2013.117; Tikoo Shweta, 2010, Genome Integr, V1, P14, DOI 10.1186/2041-9414-1-14; Tripathi V, 2008, CARCINOGENESIS, V29, P52, DOI 10.1093/carcin/bgm238; Tripathi V, 2007, J CELL BIOL, V178, P9, DOI 10.1083/jcb.200610051; Wang JD, 2013, MOL CELL, V52, P667, DOI 10.1016/j.molcel.2013.10.012; Wang ZW, 2014, NAT REV CANCER, V14, P233, DOI 10.1038/nrc3700; Welcker M, 2003, MOL CELL, V12, P381, DOI 10.1016/S1097-2765(03)00287-9; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290	57	11	12	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 25	2016	35	8					1025	1038		10.1038/onc.2015.157	http://dx.doi.org/10.1038/onc.2015.157			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DE7NF	26028025				2022-12-17	WOS:000370823300008
J	Satija, YK; Das, S				Satija, Y. K.; Das, S.			Tyr99 phosphorylation determines the regulatory milieu of tumor suppressor p73	ONCOGENE			English	Article							KINASE C-ABL; DNA-DAMAGE; P53 FAMILY; APOPTOTIC RESPONSE; INDUCE APOPTOSIS; DOWN-REGULATION; E3 LIGASE; CANCER; PROTEIN; GENE	p73 is a member of the p53 tumor suppressor family, which mediates genotoxic stress response by triggering cell cycle arrest and apoptosis. Similar to p53, p73 is maintained at very low levels, but it gets rapidly induced upon genotoxic stress. Mounting evidences demonstrate that p73 is primarily regulated posttranslationally. However, the molecular mechanisms which determine its stability and activity discerningly under normal and stress conditions are still not well understood. Here, we employed a proteomics approach to identify differential interactors of p73 under normal and genotoxic stress conditions. We report here that TRIM28, an E3 ligase, interacts with p73 and targets it for proteasomal degradation under normal conditions. Genotoxic stress-induced phosphorylation of p73 at tyrosine 99 residue by c-abl kinase leads to abrogation of this interaction thereby promoting p73 stabilization. Furthermore, the phosphorylated form of p73 specifically interacts with MED15, which serves as a transcriptional coactivator and leads to activation of proarrest, proapoptotic and anti-metastatic genes. RNAi-mediated abrogation of TRIM28 expression facilitates p73-mediated tumor suppression in mouse tumor models, whereas disruption of MED15 expression abrogates p73 tumor suppressor and anti-metastatic functions. These findings provide new insights into the pivotal role of Tyr99 phosphorylation in determining p73 levels and functions.	[Satija, Y. K.; Das, S.] Natl Inst Immunol, Mol Oncol Lab, Aruna Asaf Ali Marg, New Delhi 110067, India	Department of Biotechnology (DBT) India; National Institute of Immunology (NII)	Das, S (corresponding author), Natl Inst Immunol, Mol Oncol Lab, Aruna Asaf Ali Marg, New Delhi 110067, India.	sdas@nii.ac.in		Das, Sanjeev/0000-0002-3594-1033	Department of Biotechnology, Government of India [BT/PR7200/BRB/10/1155/2012]; NII Core Fund; Council for Scientific and Industrial Research, Government of India	Department of Biotechnology, Government of India(Department of Biotechnology (DBT) India); NII Core Fund; Council for Scientific and Industrial Research, Government of India(Council of Scientific & Industrial Research (CSIR) - India)	We thank the members of the Molecular Oncology Lab for helpful discussions. This work was supported by a grant from the Department of Biotechnology, Government of India (BT/PR7200/BRB/10/1155/2012). We also acknowledge the financial support received from NII Core Fund. YKS was supported by a fellowship from the Council for Scientific and Industrial Research, Government of India.	Agami R, 1999, NATURE, V399, P809; Allton K, 2009, P NATL ACAD SCI USA, V106, P11612, DOI 10.1073/pnas.0813177106; Beer DG, 2002, NAT MED, V8, P816, DOI 10.1038/nm733; Beitzinger M, 2008, EMBO J, V27, P792, DOI 10.1038/emboj.2008.13; Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004; Das S, 2006, CANCER BIOL THER, V5, P210, DOI 10.4161/cbt.5.2.2402; Dotsch V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004887; Gong JG, 1999, NATURE, V399, P806; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Ishikawa H, 2006, FEBS LETT, V580, P4784, DOI 10.1016/j.febslet.2006.07.066; Jiang WG, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-71; Jing C, 2002, JNCI-J NATL CANCER I, V94, P482; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kato Y, 2002, NATURE, V418, P641, DOI 10.1038/nature00969; Lapi E, 2006, ONCOGENE, V25, P3628, DOI 10.1038/sj.onc.1209401; Levy D, 2007, CELL DEATH DIFFER, V14, P743, DOI 10.1038/sj.cdd.4402063; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Liang QM, 2011, J IMMUNOL, V187, P4754, DOI 10.4049/jimmunol.1101704; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2008, CELL DEATH DIFFER, V15, P1103, DOI 10.1038/cdd.2008.60; Meroni G, 2005, BIOESSAYS, V27, P1147, DOI 10.1002/bies.20304; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Noon AT, 2010, NAT CELL BIOL, V12, P177, DOI 10.1038/ncb2017; Oberst A, 2005, BIOCHEM BIOPH RES CO, V331, P707, DOI 10.1016/j.bbrc.2005.03.158; Ozaki T, 2005, CANCER SCI, V96, P729, DOI 10.1111/j.1349-7006.2005.00116.x; Peschiaroli A, 2009, ONCOGENE, V28, P3157, DOI 10.1038/onc.2009.177; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Sasaki Y, 2012, CANCER BIOL THER, V13, P1512, DOI 10.4161/cbt.22280; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Steder M, 2013, CANCER CELL, V24, P512, DOI 10.1016/j.ccr.2013.08.023; Strano S, 2005, MOL CELL, V18, P447, DOI 10.1016/j.molcel.2005.04.008; Suzuki F, 2005, ONCOL REP, V14, P1493; Takai N, 2005, MOL CANCER RES, V3, P261, DOI 10.1158/1541-7786.MCR-04-0110; Tanikawa C, 2012, NEOPLASIA, V14, P141, DOI 10.1593/neo.111700; Wang CG, 2005, EMBO J, V24, P3279, DOI 10.1038/sj.emboj.7600791; Wezensky SJ, 2010, GENE, V452, P22, DOI 10.1016/j.gene.2009.12.003; Yang FJ, 2006, NATURE, V442, P700, DOI 10.1038/nature04942; Yokoe T, 2010, ANN SURG ONCOL, V17, P821, DOI 10.1245/s10434-009-0795-8; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhang JM, 2004, ONCOGENE, V23, P2241, DOI 10.1038/sj.onc.1207328; Zhang S, 2011, ONCOGENE, V30, P4941, DOI 10.1038/onc.2011.199; Zhang X, 2007, HEAD NECK-J SCI SPEC, V29, P236, DOI 10.1002/hed.20511; Zhu JH, 1998, CANCER RES, V58, P5061; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	51	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2016	35	4					513	527		10.1038/onc.2015.111	http://dx.doi.org/10.1038/onc.2015.111			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DC2OT	25893286				2022-12-17	WOS:000369056700011
J	Kim, HJ; Kim, SH; Yu, EJ; Seo, WY; Kim, JH				Kim, H. J.; Kim, S-H; Yu, E. J.; Seo, W-Y; Kim, J. H.			A positive role of DBC1 in PEA3-mediated progression of estrogen receptor-negative breast cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR PEA3; DNA-BINDING; MATRIX METALLOPROTEINASE-1; ACTIVATOR PEA3; ACETYLATION; EXPRESSION; SUMOYLATION; DOMAIN; CELLS; SIRT1	Deleted in Breast Cancer 1 (DBC1), a negative regulator of deacetylase SIRT1, has been shown to act as an estrogen receptor a (ER) coactivator that has a key role in ER transcription complex assembly and estrogen-dependent breast cancer cell proliferation. However, little is known about its physiological role and mechanism of action in ER-negative breast cancer cells. Here we report that DBC1 functions as a coactivator for the oncogenic ETS transcription factor PEA3 to promote ER-negative breast cancer progression. DBC1 is required for the expression of PEA3 target genes and for recruitment of PEA3 and RNA polymerase II to PEA3 target promoters. We also demonstrated that acetylation of PEA3 stimulates its DNA binding and association with DBC1 by disrupting the intramolecular interaction of PEA3. The molecular mechanism underlying DBC1 function in PEA3-mediated transcription involves inhibition of SIRT1 interaction with PEA3 and of SIRT1-mediated deacetylation of PEA3. Moreover, DBC1 depletion inhibited the tumorigenic properties of ER-negative breast cancer cells in vitro and in vivo. Importantly, increased DBC1 expression correlated with shorter relapse-free survival of ER-negative breast cancer patients. Our results firmly established DBC1 as a critical coactivator of PEA3 and as a key player in PEA3-mediated breast cancer progression.	[Kim, H. J.; Kim, S-H; Yu, E. J.; Seo, W-Y; Kim, J. H.] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Seoul 135710, South Korea; [Kim, H. J.; Yu, E. J.; Seo, W-Y; Kim, J. H.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Biomed Sci,Samsung Biomed Res Inst, Seoul, South Korea; [Kim, S-H] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul 135710, South Korea	Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan University (SKKU); Samsung Medical Center	Kim, JH (corresponding author), Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Dept Hlth Sci & Technol, Samsung Canc Ctr, 50 Irwon Dong, Seoul 135710, South Korea.	jeongkim@skku.edu			Samsung Biomedical Research Institute (SBRI) [SMX1132501]; National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning [NRF-2013R1A1A2059697]	Samsung Biomedical Research Institute (SBRI); National Research Foundation of Korea (NRF) - Ministry of Science, ICT and Future Planning	We thank Jason W Chin (MRC Laboratory for Molecular Biology, Cambridge, UK) for providing vectors and Yoon-La Choi (Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea) for providing the tissue microarray slides of primary invasive breast carcinoma specimens. This work was supported by Samsung Biomedical Research Institute (SBRI) grant (SMX1132501) and Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT and Future Planning (NRF-2013R1A1A2059697) to JHK.	Baert JL, 1997, INT J CANCER, V70, P590, DOI 10.1002/(SICI)1097-0215(19970304)70:5<590::AID-IJC17>3.0.CO;2-H; Barcellos-Hoff MH, 2013, CLIN CANCER RES, V19, P541, DOI 10.1158/1078-0432.CCR-12-2241; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Bohn OL, 2010, INT J CLIN EXP PATHO, V3, P139; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; Chini CCS, 2010, J BIOL CHEM, V285, P40830, DOI 10.1074/jbc.M110.153270; Choi YL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-507; Cojoc Monica, 2013, Onco Targets Ther, V6, P1347, DOI 10.2147/OTT.S36109; Eck SM, 2009, MOL CANCER RES, V7, P1033, DOI 10.1158/1541-7786.MCR-09-0015; Fu JJ, 2009, J BIOL CHEM, V284, P6832, DOI 10.1074/jbc.M808988200; Goel A, 2003, MOL CELL BIOL, V23, P6243, DOI 10.1128/MCB.23.17.6243-6254.2003; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; Gu SM, 2011, ACTA BIOCH BIOPH SIN, V43, P771, DOI 10.1093/abbs/gmr070; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guo BQ, 2011, NUCLEIC ACIDS RES, V39, P6403, DOI 10.1093/nar/gkr267; Guo BQ, 2009, MOL CELL BIOL, V29, P3204, DOI 10.1128/MCB.01128-08; Hiraike H, 2011, EXP THER MED, V2, P1105, DOI 10.3892/etm.2011.333; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500; Kim JH, 2008, MOL CELL, V31, P510, DOI 10.1016/j.molcel.2008.08.001; Kim SH, 2012, HISTOL HISTOPATHOL, V27, P49, DOI 10.14670/HH-27.49; Lee H, 2011, HUM PATHOL, V42, P204, DOI 10.1016/j.humpath.2010.05.023; Myers E, 2006, BRIT J CANCER, V95, P1404, DOI 10.1038/sj.bjc.6603427; Neumann H, 2009, MOL CELL, V36, P153, DOI 10.1016/j.molcel.2009.07.027; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; OHagan RC, 1996, ONCOGENE, V13, P1323; Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0; Seo WY, 2013, NUCLEIC ACIDS RES, V41, P8526, DOI 10.1093/nar/gkt644; Sharrocks AD, 2001, NAT REV MOL CELL BIO, V2, P827, DOI 10.1038/35099076; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Sun YB, 2002, J BIOL CHEM, V277, P1544, DOI 10.1074/jbc.M100567200; Wollenick K, 2012, NUCLEIC ACIDS RES, V40, P1928, DOI 10.1093/nar/gkr978; Yu EJ, 2013, ONCOGENE, V32, P4160, DOI 10.1038/onc.2012.420; Yu EJ, 2011, NUCLEIC ACIDS RES, V39, P6932, DOI 10.1093/nar/gkr347; Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515	37	11	11	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 20	2015	34	34					4500	4508		10.1038/onc.2014.381	http://dx.doi.org/10.1038/onc.2014.381			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CP9BR	25417701				2022-12-17	WOS:000360189200009
J	Cheng, Y; Ho, RLKY; Chan, KC; Kan, R; Tung, E; Lung, HL; Yau, WL; Cheung, AKL; Ko, JMY; Zhang, ZF; Luo, DZ; Feng, ZB; Chen, S; Guan, XY; Kwong, D; Stanbridge, EJ; Lung, ML				Cheng, Y.; Ho, R. L. K. Y.; Chan, K. C.; Kan, R.; Tung, E.; Lung, H. L.; Yau, W. L.; Cheung, A. K. L.; Ko, J. M. Y.; Zhang, Z. F.; Luo, D. Z.; Feng, Z. B.; Chen, S.; Guan, X. Y.; Kwong, D.; Stanbridge, E. J.; Lung, M. L.			Anti-angiogenic pathway associations of the 3p21.3 mapped BLU gene in nasopharyngeal carcinoma	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; ENDOTHELIAL-GROWTH-FACTOR; EPIGENETIC INACTIVATION; CHROMOSOME 3P21.3; LUNG-CANCER; THROMBOSPONDIN-1; EXPRESSION; VEGF; P53; HYPERMETHYLATION	Zinc-finger, MYND-type containing 10 (ZMYND10), or more commonly called BLU, expression is frequently downregulated in nasopharyngeal carcinoma (NPC) and many other tumors due to promoter hypermethylation. Functional evidence shows that the BLU gene inhibits tumor growth in animal assays, but the detailed molecular mechanism responsible for this is still not well understood. In current studies, we find that 93.5% of early-stage primary NPC tumors show downregulated BLU expression. Using a PCR array, overexpression of the BLU gene was correlated to the angiogenesis network in NPC cells. Moreover, expression changes of the MMP family, VEGF and TSP1, were often detected in different stages of NPC, suggesting the possibility that BLU may be directly involved in the microenvironment and anti-angiogenic activity in NPC development. Compared with vector-alone control cells, BLU stable transfectants, derived from poorly-differentiated NPC HONE1 cells, suppress VEGF165, VEGF189 and TSP1 expression at both the RNA and protein levels, and significantly reduce the secreted VEGF protein in these cells, reflecting an unknown regulatory mechanism mediated by the BLU gene in NPC. Cells expressing BLU inhibited cellular invasion, migration and tube formation. These in vitro results were further confirmed by in vivo tumor suppression and a matrigel plug angiogenesis assay in nude mice. Tube-forming ability was clearly inhibited, when the BLU gene is expressed in these cells. Up to 70-90% of injected tumor cells expressing increased exogenous BLU underwent cell death in animal assays. Overexpressed BLU only inhibited VEGF165 expression in differentiated squamous NPC HK1 cells, but also showed an anti-angiogenic effect in the animal assay, revealing a complicated mechanism regulating angiogenesis and the microenvironment in different NPC cell lines. Results of these studies indicate that alteration of BLU gene expression influences anti-angiogenesis pathways and is important for the development of NPC.	[Cheng, Y.; Ho, R. L. K. Y.; Chan, K. C.; Kan, R.; Tung, E.; Lung, H. L.; Cheung, A. K. L.; Ko, J. M. Y.; Guan, X. Y.; Kwong, D.; Lung, M. L.] Univ Hong Kong, Ctr Nasopharyngeal Carcinoma Res, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Yau, W. L.] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Zhang, Z. F.; Luo, D. Z.; Feng, Z. B.; Chen, S.] Guangxi Med Univ, Dept Pathol, Guangxi, Peoples R China; [Stanbridge, E. J.] Univ Calif Irvine, Dept Microbiol & Mol Genet, Irvine, CA 92717 USA	University of Hong Kong; Chinese University of Hong Kong; Guangxi Medical University; University of California System; University of California Irvine	Cheng, Y (corresponding author), Univ Hong Kong, Dept Clin Oncol, Ctr Nasopharyngeal Carcinoma Res, Li Ka Shing Fac Medicne, L6-02 Lab Bldg,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	yuecheng@hotmail.com; mlilung@hku.hk	Ko, Josephine/U-2972-2019; Cheng, Yue/Z-4456-2019; Lung, Maria Li/C-4495-2009; /A-3639-2009	Ko, Josephine/0000-0002-7997-331X; Lung, Maria Li/0000-0003-2559-3626; /0000-0003-1874-9805	General Research Fund [HKU762912M]; Research Grants Council of Hong Kong Special Administrative Region, China	General Research Fund; Research Grants Council of Hong Kong Special Administrative Region, China(Hong Kong Research Grants Council)	We thank Dr Didier Trono for plasmid 12254, pWPI, and Dr Jack Lawler for plasmid 12993, pGEM2 hTSP-1, Addgene, USA. We also thank the Tissue Bank of NPC Area of Excellence Scheme for NPC samples. This work was supported by the General Research Fund (Project number: HKU762912M to Yue Cheng), Research Grants Council of Hong Kong Special Administrative Region, China.	Abe M, 2005, CANCER RES, V65, P828; Agathanggelou A, 2003, ONCOGENE, V22, P1580, DOI 10.1038/sj.onc.1206243; Ancelin M, 2004, LAB INVEST, V84, P502, DOI 10.1038/labinvest.3700053; Ancelin M, 2002, P NATL ACAD SCI USA, V99, P6023, DOI 10.1073/pnas.082110999; Bauvois B, 2012, BBA-REV CANCER, V1825, P29, DOI 10.1016/j.bbcan.2011.10.001; Bornstein P, 2009, J CELL COMMUN SIGNAL, V3, P189, DOI 10.1007/s12079-009-0060-8; Chan KC, 2011, INT J CANCER, V129, P1826, DOI 10.1002/ijc.25855; Cheng Y, 1998, P NATL ACAD SCI USA, V95, P3042, DOI 10.1073/pnas.95.6.3042; Cheng Y, 2000, GENE CHROMOSOME CANC, V28, P82, DOI 10.1002/(SICI)1098-2264(200005)28:1<82::AID-GCC10>3.0.CO;2-8; Cheng Y, 2013, BMC CELL BIOL, V14, DOI 10.1186/1471-2121-14-44; DAMERON KM, 1994, SCIENCE, V265, P1582, DOI 10.1126/science.7521539; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; do Outeiro-Bernstein MAF, 2002, MATRIX BIOL, V21, P311, DOI 10.1016/S0945-053X(02)00010-0; Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767; Herve MA, 2005, EXP CELL RES, V309, P24, DOI 10.1016/j.yexcr.2005.05.022; Hesson L, 2004, ONCOGENE, V23, P2408, DOI 10.1038/sj.onc.1207407; Hesson LB, 2007, ONCOGENE, V26, P7283, DOI 10.1038/sj.onc.1210547; Heusinkveld M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-216; Hui EP, 2002, CLIN CANCER RES, V8, P2595; Ji W, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013442; Kaur S, 2010, J BIOL CHEM, V285, P38923, DOI 10.1074/jbc.M110.172304; Koo BH, 2010, AM J PATHOL, V176, P1494, DOI 10.2353/ajpath.2010.090655; Krishna SM, 2006, VIRUS RES, V115, P85, DOI 10.1016/j.virusres.2005.07.010; Lai HC, 2007, GYNECOL ONCOL, V104, P629, DOI 10.1016/j.ygyno.2006.10.003; Law EWL, 2012, ONCOGENE, V31, P728, DOI 10.1038/onc.2011.272; Lawler PR, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006627; Lee YJ, 2010, CANCER RES, V70, P948, DOI 10.1158/0008-5472.CAN-09-3094; Lerman MI, 2000, CANCER RES, V60, P6116; Linderholm B, 2000, INT J CANCER, V89, P51, DOI 10.1002/(SICI)1097-0215(20000120)89:1<51::AID-IJC9>3.3.CO;2-#; Liu XQ, 2003, INT J CANCER, V106, P60, DOI 10.1002/ijc.11166; Lo PHY, 2010, CANCER RES, V70, P5567, DOI 10.1158/0008-5472.CAN-09-4510; Lo PHY, 2006, CANCER LETT, V234, P184, DOI 10.1016/j.canlet.2005.03.036; Lung HL, 2012, TUMOR SUPPRESSOR GEN, P53; Lung HL, 2008, INT J CANCER, V123, P401, DOI 10.1002/ijc.23528; Lung HL, 2012, SEMIN CANCER BIOL, V22, P87, DOI 10.1016/j.semcancer.2011.11.002; Mane DR, 2013, APPL IMMUNOHISTO M M, V21, P431, DOI 10.1097/PAI.0b013e31827c00e1; Marsit CJ, 2005, INT J CANCER, V114, P219, DOI 10.1002/ijc.20714; Miyata Y, 2013, INT J MOL SCI, V14, P12249, DOI 10.3390/ijms140612249; Nucera C, 2010, P NATL ACAD SCI USA, V107, P10649, DOI 10.1073/pnas.1004934107; Park ST, 2013, BIOCHEM BIOPH RES CO, V435, P153, DOI 10.1016/j.bbrc.2013.04.061; Peng XW, 2010, ANTI-CANCER DRUG, V21, P381, DOI 10.1097/CAD.0b013e3283363980; Qiu GH, 2004, ONCOGENE, V23, P4793, DOI 10.1038/sj.onc.1207632; Raza A, 2010, AM J HEMATOL, V85, P593, DOI 10.1002/ajh.21745; Sargiannidou I, 2001, EXP BIOL MED, V226, P726, DOI 10.1177/153537020222600803; SUN Y, 1992, P NATL ACAD SCI USA, V89, P6516, DOI 10.1073/pnas.89.14.6516; Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944; Trudel D, 2003, CANCER RES, V63, P8511; Tuszynski GP, 1996, BIOESSAYS, V18, P71, DOI 10.1002/bies.950180113; Wilgus TA, 2012, J INVEST DERMATOL, V132, P493, DOI 10.1038/jid.2011.343; Yang EV, 2006, CANCER RES, V66, P10357, DOI 10.1158/0008-5472.CAN-06-2496; Yang YJ, 2012, J CANCER RES CLIN, V138, P729, DOI 10.1007/s00432-012-1151-0; Yau WL, 2006, INT J CANCER, V119, P2821, DOI 10.1002/ijc.22232; Yoo HJ, 2013, INT J BIOCHEM CELL B, V45, P1236, DOI 10.1016/j.biocel.2013.04.001; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zaslavsky A, 2010, BLOOD, V115, P4605, DOI 10.1182/blood-2009-09-242065; Zhang XN, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-267	56	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4219	4228		10.1038/onc.2014.353	http://dx.doi.org/10.1038/onc.2014.353			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25347745	Green Published, hybrid			2022-12-17	WOS:000359199800008
J	Kazami, T; Nie, H; Satoh, M; Kuga, T; Matsushita, K; Kawasaki, N; Tomonaga, T; Nomura, F				Kazami, T.; Nie, H.; Satoh, M.; Kuga, T.; Matsushita, K.; Kawasaki, N.; Tomonaga, T.; Nomura, F.			Nuclear accumulation of annexin A2 contributes to chromosomal instability by coilin-mediated centromere damage	ONCOGENE			English	Article							PRIMARY COLORECTAL-CANCER; EARLY PROTEIN VMW110; MITOTIC CHECKPOINT; DNA-REPLICATION; BREAST-CANCER; HUMAN-CELLS; ANEUPLOIDY; OVEREXPRESSION; EXPRESSION; SEGREGATION	Most human cancers show chromosomal instability (CIN), but the precise mechanisms remain uncertain. Annexin A2 is frequently overexpressed in human cancers, and its relationship to tumorigenesis is poorly understood. We found that annexin A2 is overexpressed in the nuclei of CIN cells compared with cells with microsatellite instability (MIN). Ectopic annexin A2 expression in MIN cells results in a high level of aneuploidy and induces lagging chromosomes; suppression of annexin A2 in CIN cells reduces such CIN signatures with apoptosis of highly aneuploid cells. Ectopic expression of annexin A2 in MIN cells reduces the expression of centromere proteins. Conversely, annexin A2-knockdown in CIN cells increases the expression of centromere proteins. Moreover, the endogenous expression levels of centromere proteins in CIN cells were greatly reduced compared with MIN cell lines. The reduced expression of centromere proteins likely occurred due to aberrant centromere localization of coilin, a major component of the Cajal bodies. These results suggest that nuclear accumulation of annexin A2 has a crucial role in CIN by disrupting centromere function.	[Kazami, T.; Nie, H.; Satoh, M.; Matsushita, K.; Kawasaki, N.; Tomonaga, T.; Nomura, F.] Chiba Univ, Dept Mol Diag F8, Grad Sch Med, Chuo Ku, Chiba, Japan; [Kuga, T.; Kawasaki, N.; Tomonaga, T.] Natl Inst Biomed Innovat, Lab Proteome Res, Ibaraki, Osaka 5670085, Japan	Chiba University; National Institute of Health Sciences - Japan	Tomonaga, T (corresponding author), Natl Inst Biomed Innovat, Lab Proteome Res, 7-6-8 Saito Asagi, Ibaraki, Osaka 5670085, Japan.	tomonaga@nibio.go.jp	Kuga, Takahisa/AAX-9334-2020; Matsushita, Kazuyuki/AAJ-5380-2020	Matsushita, Kazuyuki/0000-0001-6742-0761	Ministry of Education, Science, Sports and Culture of Japan; Grants-in-Aid for Scientific Research [26460081] Funding Source: KAKEN	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Masumi Ishibashi and Nobuko Tanaka for technical assistance. This work was supported by Grants-in-Aid from the Ministry of Education, Science, Sports and Culture of Japan.	Bakhoum SF, 2009, CURR BIOL, V19, P1937, DOI 10.1016/j.cub.2009.09.055; Bakhoum SF, 2009, NAT CELL BIOL, V11, P27, DOI 10.1038/ncb1809; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Bayani J, 2007, SEMIN CANCER BIOL, V17, P5, DOI 10.1016/j.semcancer.2006.10.006; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Chuthapisith S, 2007, INT J ONCOL, V30, P1545; Duncan R, 2008, BRIT J CANCER, V98, P426, DOI 10.1038/sj.bjc.6604128; Eberhard DA, 2001, J CELL SCI, V114, P3155; Esposito I, 2006, J PATHOL, V208, P673, DOI 10.1002/path.1935; Everett RD, 1999, EMBO J, V18, P1526, DOI 10.1093/emboj/18.6.1526; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Green RA, 2003, J CELL BIOL, V163, P949, DOI 10.1083/jcb.200307070; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Kalitsis P, 1998, P NATL ACAD SCI USA, V95, P1136, DOI 10.1073/pnas.95.3.1136; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Kuga T, 2014, ONCOGENESIS, V3, DOI 10.1038/oncsis.2014.6; KUMBLE KD, 1992, J CELL SCI, V101, P35; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Liu Jie, 2003, BMC Biochem, V4, P10, DOI 10.1186/1471-2091-4-10; Lomonte P, 1999, J VIROL, V73, P9456, DOI 10.1128/JVI.73.11.9456-9467.1999; Morency E, 2007, J CELL BIOL, V177, P757, DOI 10.1083/jcb.200612107; Nishimori T, 2006, PROTEOMICS, V6, P1011, DOI 10.1002/pmic.200500262; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; Sawyers CL, 2001, SCIENCE, V294, P1834; Seimiya M, 2008, HEPATOLOGY, V48, P519, DOI 10.1002/hep.22364; Sharma MR, 2006, EXP MOL PATHOL, V81, P146, DOI 10.1016/j.yexmp.2006.03.003; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; Takano S, 2008, ANN SURG ONCOL, V15, P3157, DOI 10.1245/s10434-008-0061-5; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Tomas A, 2004, J CELL BIOL, V165, P813, DOI 10.1083/jcb.200311054; Tomonaga T, 2007, HISTOL HISTOPATHOL, V22, P191, DOI 10.14670/HH-22.191; Tomonaga T, 2005, CANCER RES, V65, P4683, DOI 10.1158/0008-5472.CAN-04-3613; Tomonaga T, 2004, CLIN CANCER RES, V10, P2007, DOI 10.1158/1078-0432.CCR-03-0321; Tomonaga T, 2003, CANCER RES, V63, P3511; VISHWANATHA JK, 1993, J CELL SCI, V105, P533; Wang JL, 2004, BBA-GEN SUBJECTS, V1673, P75, DOI 10.1016/j.bbagen.2004.03.013; Wang TL, 2004, P NATL ACAD SCI USA, V101, P3089, DOI 10.1073/pnas.0308716101; Zhang NG, 2008, P NATL ACAD SCI USA, V105, P13033, DOI 10.1073/pnas.0801610105; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	48	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2015	34	32					4177	4189		10.1038/onc.2014.345	http://dx.doi.org/10.1038/onc.2014.345			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CO5LE	25347736				2022-12-17	WOS:000359199800004
J	Stebbing, J; Zhang, H; Xu, Y; Lit, LC; Green, AR; Grothey, A; Lombardo, Y; Periyasamy, M; Blighe, K; Zhang, W; Shaw, JA; Ellis, IO; Lenz, HJ; Giamas, G				Stebbing, J.; Zhang, H.; Xu, Y.; Lit, L. C.; Green, A. R.; Grothey, A.; Lombardo, Y.; Periyasamy, M.; Blighe, K.; Zhang, W.; Shaw, J. A.; Ellis, I. O.; Lenz, H. J.; Giamas, G.			KSR1 regulates BRCA1 degradation and inhibits breast cancer growth	ONCOGENE			English	Article							KINASE SUPPRESSOR; IN-VIVO; SIGNAL-TRANSDUCTION; UBIQUITIN LIGASE; RAS-1 PROTECTS; GENE ENCODES; DNA-DAMAGE; C-ELEGANS; ACTIVATION; EXPRESSION	Kinase suppressor of Ras-1 (KSR1) facilitates signal transduction in Ras-dependent cancers, including pancreatic and lung carcinomas but its role in breast cancer has not been well studied. Here, we demonstrate for the first time it functions as a tumor suppressor in breast cancer in contrast to data in other tumors. Breast cancer patients (n>1000) with high KSR1 showed better disease-free and overall survival, results also supported by Oncomine analyses, microarray data (n = 2878) and genomic data from paired tumor and cell-free DNA samples revealing loss of heterozygosity. KSR1 expression is associated with high breast cancer 1, early onset (BRCA1), high BRCA1-associated ring domain 1 (BARD1) and checkpoint kinase 1 (Chk1) levels. Phospho-profiling of major components of the canonical Ras-RAF-mitogen-activated protein kinases pathway showed no significant changes after KSR1 overexpression or silencing. Moreover, KSR1 stably transfected cells formed fewer and smaller size colonies compared to the parental ones, while in vivo mouse model also demonstrated that the growth of xenograft tumors overexpressing KSR1 was inhibited. The tumor suppressive action of KSR1 is BRCA1 dependent shown by 3D-matrigel and soft agar assays. KSR1 stabilizes BRCA1 protein levels by reducing BRCA1 ubiquitination through increasing BARD1 abundance. These data link these proteins in a continuum with clinical relevance and position KSR1 in the major oncoprotein pathways in breast tumorigenesis.	[Stebbing, J.; Zhang, H.; Xu, Y.; Lit, L. C.; Grothey, A.; Lombardo, Y.; Periyasamy, M.; Giamas, G.] Univ London Imperial Coll Sci Technol & Med, Ctr Translat & Expt Med, Dept Surg & Canc, Div Canc, London W12 0NN, England; [Lit, L. C.; Ellis, I. O.] Univ Malaya, Fac Med, Dept Physiol, Kuala Lumpur, Malaysia; [Green, A. R.] Nottingham Univ Hosp NHS Trust, Queens Med Ctr, Dept Cellular Pathol, Nottingham, England; [Blighe, K.; Shaw, J. A.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester, Leics, England; [Zhang, W.; Lenz, H. J.] Univ So Calif, Keck Sch Med, Norris Comprehens Canc Ctr, Div Med Oncol, Los Angeles, CA 90033 USA	Imperial College London; Universiti Malaya; Nottingham University Hospital NHS Trust; University of Nottingham; University of Leicester; University of Southern California	Giamas, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Translat & Expt Med, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus,Cane Rd, London W12 0NN, England.	g.giamas@imperial.ac.uk	Periyasamy, Manikandan/AAL-6211-2020; Zhang, Hua/AAV-2344-2020; LIT, LEI CHENG/B-8875-2010; Green, Andrew/AAF-1991-2020; periyasamy, manikandan/AAB-7924-2020; Giamas, Georgios/AAP-3487-2021; Lit, Lei Cheng/AAS-9778-2021	Zhang, Hua/0000-0001-7704-4712; LIT, LEI CHENG/0000-0002-3210-4491; Lit, Lei Cheng/0000-0002-3210-4491; Giamas, Georgios/0000-0002-4417-2707; Shaw, Jacqui/0000-0003-4227-503X; Green, Andrew/0000-0002-0488-5913; Stebbing, Justin/0000-0002-1117-6947; Periyasamy, Manikandan/0000-0001-7626-2531; Blighe, Kevin/0000-0002-6322-6571; Ellis, Ian/0000-0001-5292-8474	Imperial Biomedical Research Centre; Experimental Cancer Medicine Centre; National Institute for Health Research; Pink Ribbon Foundation; China Scholarship Council; Action Against Cancer; Breast Cancer Campaign; Cancer Research UK; Cancer Research UK [13462, 14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish	Imperial Biomedical Research Centre; Experimental Cancer Medicine Centre; National Institute for Health Research(National Institute for Health Research (NIHR)); Pink Ribbon Foundation; China Scholarship Council(China Scholarship Council); Action Against Cancer; Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	We would like to thank Chun Fui Lai, Aleksandra Filipovic, Monica Faronato and Dongyun Yang for their technical assistance and Pritesh Trivedi for performing the immunohistochemistry staining. This work was supported by the Imperial Biomedical Research Centre, the Experimental Cancer Medicine Centre, the National Institute for Health Research, the Pink Ribbon Foundation, China Scholarship Council, Action Against Cancer, Breast Cancer Campaign and Cancer Research UK. We thank Richard and Evelina Girling and the 'kinase group' for their support.	Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Choudhury AD, 2004, J BIOL CHEM, V279, P33909, DOI 10.1074/jbc.M403646200; Dalton LW, 2000, MODERN PATHOL, V13, P730, DOI 10.1038/modpathol.3880126; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Finak G, 2008, NAT MED, V14, P518, DOI 10.1038/nm1764; Fusello AM, 2006, J IMMUNOL, V177, P6152, DOI 10.4049/jimmunol.177.9.6152; Giamas G, 2011, NAT MED, V17, P715, DOI 10.1038/nm.2351; Goettel JA, 2011, EXP CELL RES, V317, P452, DOI 10.1016/j.yexcr.2010.11.018; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hayami R, 2005, CANCER RES, V65, P6; Hiraike H, 2010, BRIT J CANCER, V102, P1061, DOI 10.1038/sj.bjc.6605577; Hu JC, 2011, P NATL ACAD SCI USA, V108, P6067, DOI 10.1073/pnas.1102554108; Irminger-Finger I, 2006, NAT REV CANCER, V6, P382, DOI 10.1038/nrc1878; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kim HS, 2006, CANCER RES, V66, P4561, DOI 10.1158/0008-5472.CAN-05-3629; Kim M, 2005, CANCER RES, V65, P3986, DOI 10.1158/0008-5472.CAN-03-2334; Kolesnick R, 2004, J CLIN INVEST, V114, P1233, DOI 10.1172/JCI200423441; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Kortum RL, 2004, MOL CELL BIOL, V24, P4407, DOI 10.1128/MCB.24.10.4407-4416.2004; Lombardo Y, 2012, P NATL ACAD SCI USA, V109, P16558, DOI 10.1073/pnas.1206268109; Lozano J, 2003, CANCER RES, V63, P4232; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; McKay MM, 2011, CURR BIOL, V21, P563, DOI 10.1016/j.cub.2011.02.033; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Nguyen A, 2002, MOL CELL BIOL, V22, P3035, DOI 10.1128/MCB.22.9.3035-3045.2002; Rajakulendran T, 2009, NATURE, V461, P542, DOI 10.1038/nature08314; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Salerno M, 2005, MOL CELL BIOL, V25, P1379, DOI 10.1128/MCB.25.4.1379-1388.2005; Shaw JA, 2012, GENOME RES, V22, P220, DOI 10.1101/gr.123497.111; Stebbing J, 2010, CLIN EVID, V2010, P1; Stebbing J, 2012, BREAST CANCER RES TR, V132, P537, DOI 10.1007/s10549-011-1622-z; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Wallace MD, 2012, GENETICS, V192, P385, DOI 10.1534/genetics.112.142802; Witzel F, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00475; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xing HR, 2003, NAT MED, V9, P1266, DOI 10.1038/nm927; Yan F, 2004, J CLIN INVEST, V114, P1272, DOI 10.1172/JCI200421022; Zafrullah M, 2009, BIOCHEM BIOPH RES CO, V390, P434, DOI 10.1016/j.bbrc.2009.09.048; Zhang H, 2013, BRIT J CANCER, V109, P2675, DOI 10.1038/bjc.2013.628; Zhang H, 2010, BREAST CANCER RES TR, V121, P41, DOI 10.1007/s10549-009-0450-x; Zhang H, 2013, BIOCHEM SOC T, V41, P1078, DOI 10.1042/BST20130042; Zhang H, 2012, CELL SIGNAL, V24, P1173, DOI 10.1016/j.cellsig.2012.01.017; Zhang JJ, 2008, CANCER BIOL THER, V7, P1492, DOI 10.4161/cbt.7.9.6472; Zhang Y, 2011, NAT MED, V17, P341, DOI 10.1038/nm.2296	52	11	11	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 16	2015	34	16					2103	2114		10.1038/onc.2014.129	http://dx.doi.org/10.1038/onc.2014.129			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CG3IL	24909178	Green Submitted			2022-12-17	WOS:000353173400010
J	Azzi, S; Smith, SS; Dwyer, J; Leclair, HM; Alexia, C; Hebda, JK; Dupin, N; Bidere, N; Gavard, J				Azzi, S.; Smith, S. S.; Dwyer, J.; Leclair, H. M.; Alexia, C.; Hebda, J. K.; Dupin, N.; Bidere, N.; Gavard, J.			YGLF motif in the Kaposi sarcoma herpes virus G-protein-coupled receptor adjusts NF-kappa B activation and paracrine actions	ONCOGENE			English	Article						KSHV; vGPCR; NF-kappa B; trafficking; B-lymphocytes; HIV malignancies	PRIMARY EFFUSION LYMPHOMA; ENDOTHELIAL-CELLS; IN-VIVO; MULTIPLE PATHWAYS; KSHV VFLIP; VGPCR; CONTRIBUTES; PROGRESSION; EXPRESSION; NEOPLASIA	Kaposi sarcoma (KS) and primary effusion lymphoma (PEL) are two pathologies associated with KS herpes virus (KSHV/HHV-8) infection. KSHV genome contains several oncogenes, among which, the viral G-protein-coupled receptor (vGPCR open reading frame 74) has emerged as a major factor in KS pathogenicity. Indeed, vGPCR is a constitutively active receptor, whose expression is sufficient to drive cell transformation in vitro and tumour development in mice. However, neither the role of vGPCR in KSHV-infected B-lymphocytes nor the molecular basis for its constitutive activation is well understood. Here, we show that vGPCR expression contributes to nuclear factor-kappa B (NF-kappa B)-dependent cellular survival in both PEL cells and primary B cells from HIV-negative KS patients. We further identified within vGPCR an AP2 consensus binding motif, Y(326)GLF, that directs its localization between the plasma membrane and clathrin-coated vesicles. The introduction of a mutation in this site (Y(326)A) increased NF-kappa B activity and proinflammatory cytokines production. This correlated with exacerbated morphological rearrangement, migration and proliferation of non-infected monocytes. Collectively, our work raises the possibility that KSHV-infected B-lymphocytes use vGPCR to impact ultimately the immune response and communication within the tumour microenvironment in KSHV-associated pathologies.	[Azzi, S.; Smith, S. S.; Dwyer, J.; Leclair, H. M.; Hebda, J. K.; Gavard, J.] CNRS, UMR8104, Paris, France; [Azzi, S.; Smith, S. S.; Dwyer, J.; Leclair, H. M.; Hebda, J. K.; Gavard, J.] INSERM, U1016, Paris, France; [Azzi, S.; Smith, S. S.; Dwyer, J.; Leclair, H. M.; Hebda, J. K.; Dupin, N.; Gavard, J.] Univ Paris 05, Sorbonne Paris Cite, F-75014 Paris, France; [Alexia, C.; Bidere, N.] Hop Paul Brousse, INSERM, U1014, Villejuif, France; [Alexia, C.] Univ Paris 11, Orsay, France; [Alexia, C.] Equipe Labellisee Ligue Contre Canc, Villejuif, France; [Dupin, N.] Hop Cochin Tarnier, AP HP, Serv Dermatol, Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Paul-Brousse - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite	Gavard, J (corresponding author), Univ Paris 05, Inst Cochin, CNRS, UMR8104,INSERM U1016, 22 Rue Mech,Room 306, F-75014 Paris, France.	julie.gavard@inserm.fr	Bidère, Nicolas/K-8887-2015; Gavard, Julie/I-5487-2012; Gavard, Julie/I-5487-2012	Bidère, Nicolas/0000-0001-9177-0008; Gavard, Julie/0000-0002-7985-9007; Dupin, Nicolas/0000-0002-6237-4951; Gavard, Julie/0000-0003-3107-2026; Leclair, Heloise/0000-0002-9517-9079	ANR JCJC; Fondation ARC; Fondation pour la Recherche Medicale; Ligue nationale contre le cancer comite de Paris; Marie Curie International Reintegration Grant within The Seventh Framework Program; Canceropole Ile-de-France; ANRS; Universite Paris Descartes;  [INCA_6508]	ANR JCJC(French National Research Agency (ANR)); Fondation ARC; Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Ligue nationale contre le cancer comite de Paris; Marie Curie International Reintegration Grant within The Seventh Framework Program; Canceropole Ile-de-France(Region Ile-de-France); ANRS(ANRSFrench National Research Agency (ANR)); Universite Paris Descartes; 	We thank the members of JG laboratory for comments on the manuscript. We are grateful to Dr A Benmerah (Institut Necker, Paris, France) for the EPS15 constructs and helpful discussion and to C Catherinet (INSA, Rennes, France) for technical support. This research was funded by: ANR JCJC, Fondation ARC, Fondation pour la Recherche Medicale, INCA_6508, Ligue nationale contre le cancer comite de Paris and a Marie Curie International Reintegration Grant within The Seventh Framework Program. SA, SSS and JD are supported by postdoctoral fellowships from Fondation ARC, Canceropole Ile-de-France and ANRS, respectively. JKH is supported by a doctoral fellowship from Universite Paris Descartes.	An J, 2004, LEUKEMIA, V18, P1699, DOI 10.1038/sj.leu.2403460; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Ballon G, 2011, J CLIN INVEST, V121, P1141, DOI 10.1172/JCI44417; Benmerah A, 1999, J CELL SCI, V112, P1303; BOSHOFF C, 1995, LANCET, V345, P1043; Boshoff C, 2011, J CLIN INVEST, V121, P838, DOI 10.1172/JCI46499; Cannon M, 2003, J VIROL, V77, P57, DOI 10.1128/JVI.77.1.57-67.2003; Cannon ML, 2004, ONCOGENE, V23, P514, DOI 10.1038/sj.onc.1207021; Caselli E, 2007, BLOOD, V109, P2718, DOI 10.1182/blood-2006-03-012500; Cesarman E, 1996, AM J PATHOL, V149, P53; Chang HH, 2013, CELL HOST MICROBE, V13, P429, DOI 10.1016/j.chom.2013.03.009; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen YB, 2007, ONCOLOGIST, V12, P569, DOI 10.1634/theoncologist.12-5-569; Chugh P, 2005, P NATL ACAD SCI USA, V102, P12885, DOI 10.1073/pnas.0408577102; Couty JP, 2001, J BIOL CHEM, V276, P33805, DOI 10.1074/jbc.M104631200; de Oliveira DE, 2010, TRENDS MICROBIOL, V18, P248, DOI 10.1016/j.tim.2010.04.001; Dwyer J, 2011, ONCOGENE, V30, P190, DOI 10.1038/onc.2010.411; Dwyer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045562; Field N, 2003, J CELL SCI, V116, P3721, DOI 10.1242/jcs.00691; Grossmann C, 2006, J VIROL, V80, P7179, DOI 10.1128/JVI.01603-05; Guasparri I, 2004, J EXP MED, V199, P993, DOI 10.1084/jem.20031467; Hassman LM, 2011, J CLIN INVEST, V121, P752, DOI 10.1172/JCI44185; Keller SA, 2006, BLOOD, V107, P3295, DOI 10.1182/blood-2005-07-2730; Lagos D, 2008, CELL HOST MICROBE, V4, P470, DOI 10.1016/j.chom.2008.09.012; Lanternier F, 2008, AIDS, V22, P1163, DOI 10.1097/QAD.0b013e3283031a8a; Liu F, 2012, IMMUNOL REV, V246, P239, DOI 10.1111/j.1600-065X.2012.01107.x; Liu L, 2002, J BIOL CHEM, V277, P13745, DOI 10.1074/jbc.M110480200; Lodi S, 2010, JNCI-J NATL CANCER I, V102, P784, DOI 10.1093/jnci/djq134; Martin D, 2008, ONCOGENE, V27, P1844, DOI [10.1038/sj.onc.1210817, 10.1038/onc.2009.351]; Martin D, 2011, CANCER CELL, V19, P805, DOI 10.1016/j.ccr.2011.05.005; Matta H, 2004, P NATL ACAD SCI USA, V101, P9399, DOI 10.1073/pnas.0308016101; Mesri EA, 1996, J EXP MED, V183, P2385, DOI 10.1084/jem.183.5.2385; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2004, BLOOD, V104, P2903, DOI 10.1182/blood-2003-12-4436; Montaner S, 2013, ANNU REV PHARMACOL, V53, P331, DOI 10.1146/annurev-pharmtox-010510-100608; Myoung J, 2011, J CLIN INVEST, V121, P1130, DOI 10.1172/JCI43755; Rosenkilde MM, 2000, J BIOL CHEM, V275, P26309, DOI 10.1074/jbc.M003800200; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Sin SH, 2013, BLOOD, V121, P2952, DOI 10.1182/blood-2012-03-415620; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Sodhi A, 2004, P NATL ACAD SCI USA, V101, P4821, DOI 10.1073/pnas.0400835101; Tan WF, 2006, J BIOL CHEM, V281, P39542, DOI 10.1074/jbc.M609062200; Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843; WHITBY D, 1995, LANCET, V346, P799, DOI 10.1016/S0140-6736(95)91619-9; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445	48	11	11	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2014	33	49					5609	5618		10.1038/onc.2013.503	http://dx.doi.org/10.1038/onc.2013.503			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW1ZW	24292677	Green Published			2022-12-17	WOS:000346088700005
J	Fernandez, S; Genis, L; Torres-Aleman, I				Fernandez, S.; Genis, L.; Torres-Aleman, I.			A phosphatase-independent gain-of-function mutation in PTEN triggers aberrant cell growth in astrocytes through an autocrine IGF-1 loop	ONCOGENE			English	Article						glioma; PTEN; IGF-1; gain-of-function; PKA	FACTOR-KAPPA-B; CENTRAL-NERVOUS-SYSTEM; FACTOR-I RECEPTOR; SOMATIC MUTATIONS; RESPONSE ELEMENT; HUMAN GLIOMAS; PHOSPHORYLATION; CANCER; P53; EXPRESSION	Loss-of-function mutations in the phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome10) contribute to aberrant cell growth in part through upregulation of the mitogenic IGF-1/PI3K/Akt pathway. In turn, this pathway exerts a homeostatic feedback over PTEN. Using mutagenesis analysis to explore a possible impact of this mutual control on astrocyte growth, we found that truncation of the C-terminal region of PTEN (Delta 51) associates with a marked increase in NF kappa B activity, a transcription factor overactivated in astrocyte tumors. Whereas mutations of PTEN are considered to lead to a loss-of-function, PTEN Delta 51, a truncation that comprises a region frequently mutated in human gliomas, displayed a neomorphic (gain-of-function) activity that was independent of its phosphatase activity. This gain-of-function of PTEN Delta 51 includes stimulation of IGF-1 synthesis through protein kinase A activation of the IGF-1 promoter. Increased IGF-1 originates an autocrine loop that activates Akt and NF kappa B. Constitutive activation of NF kappa B in PTEN Delta 51-expressing astrocytes leads to aberrant cell growth; astrocytes expressing this mutant PTEN generate colonies in vitro and tumors in vivo. Mutations converting a tumor suppressor such as PTEN into a tumor promoter through a gain-of-function involving IGF-1 production may further our understanding of the role played by this growth factor in glioma growth and help us define druggable targets for personalized therapy.	[Torres-Aleman, I.] Inst Cajal, CSIC, Dept Syst Neurosci, Madrid 28002, Spain; CIBERNED, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Cajal (IC); CIBERNED	Torres-Aleman, I (corresponding author), Inst Cajal, Neuroendocrinol Lab, Madrid 28002, Spain.	torres@cajal.csic.es	Fernandez, Silvia/Z-4848-2019; Torres-Aleman, Ignacio/A-1613-2008	Torres-Aleman, Ignacio/0000-0001-8107-7947	Spanish Ministry of Science [SAF2007-60051, SAF2010-17036]; CIBERNED	Spanish Ministry of Science(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); CIBERNED(Instituto de Salud Carlos III)	We are thankful to L. Guinea and M. Garcia for excellent technical support. This work was funded by Spanish Ministry of Science (SAF2007-60051 andSAF2010-17036) and by CIBERNED.	ANTONIADES HN, 1992, INT J CANCER, V50, P215, DOI 10.1002/ijc.2910500210; Bartkova J, 2010, ONCOGENE, V29, P5095, DOI 10.1038/onc.2010.249; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; BASERGA R, 1995, CANCER RES, V55, P249; Bredel M, 2011, NEW ENGL J MED, V364, P627, DOI 10.1056/NEJMoa1006312; Carnero A, 2008, CURR CANCER DRUG TAR, V8, P187, DOI 10.2174/156800908784293659; Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311; Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009; Chen TC, 1998, LAB INVEST, V78, P165; Duerr EM, 1998, ONCOGENE, V16, P2259, DOI 10.1038/sj.onc.1201756; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Feinman R, 1999, BLOOD, V93, P3044; Fernandez AM, 2007, J NEUROSCI, V27, P8745, DOI 10.1523/JNEUROSCI.1002-07.2007; Fernandez S, 2008, BBA-MOL CELL RES, V1783, P803, DOI 10.1016/j.bbamcr.2007.10.020; Forbes SA, 2008, CURR PROTOC HUM GENE, V39, pD945; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Franco C, 2012, MOL NEURODEGENER, V7, DOI 10.1186/1750-1326-7-51; Glick RP, 1997, J NEURO-ONCOL, V35, P315, DOI 10.1023/A:1005876819455; Green A, 2010, NEW ENGL J MED, V362, P369, DOI 10.1056/NEJMc0910063; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Jacques TS, 2010, EMBO J, V29, P222, DOI 10.1038/emboj.2009.327; Jenkins LMM, 2012, CARCINOGENESIS, V33, P1441, DOI 10.1093/carcin/bgs145; Johnson RF, 2012, TRENDS BIOCHEM SCI, V37, P317, DOI 10.1016/j.tibs.2012.04.002; KACHRA Z, 1994, ENDOCRINOLOGY, V135, P1722, DOI 10.1210/en.135.5.1722; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li Z, 2005, NAT CELL BIOL, V7, P399, DOI 10.1038/ncb1236; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Maier D, 1999, CANCER RES, V59, P5479; Maillet A, 2012, ANTIOXID REDOX SIGN, V16, P1285, DOI 10.1089/ars.2011.4434; MCCARTHY TL, 1995, ENDOCRINOLOGY, V136, P3901, DOI 10.1210/en.136.9.3901; Nowsheen S, 2009, MUTAT RES-GEN TOX EN, V674, P131, DOI 10.1016/j.mrgentox.2008.09.010; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Pons S, 2000, J BIOL CHEM, V275, P38620, DOI 10.1074/jbc.M004531200; Rahdar M, 2009, P NATL ACAD SCI USA, V106, P480, DOI 10.1073/pnas.0811212106; Rasheed BKA, 1997, CANCER RES, V57, P4187; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; SANDBERG AC, 1988, NEUROSCI LETT, V93, P114, DOI 10.1016/0304-3940(88)90022-5; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shono T, 2001, CANCER RES, V61, P4375; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; Tang YF, 2006, CANCER RES, V66, P736, DOI 10.1158/0008-5472.CAN-05-1557; Taniguchi CM, 2006, P NATL ACAD SCI USA, V103, P12093, DOI 10.1073/pnas.0604628103; Thomas MJ, 1996, J BIOL CHEM, V271, P21835, DOI 10.1074/jbc.271.36.21835; Vasudevan KM, 2004, MOL CELL BIOL, V24, P1007, DOI 10.1128/MCB.24.3.1007-1021.2004; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang Y, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-277; Werner Haim, 2009, Archives of Physiology and Biochemistry, V115, P58, DOI 10.1080/13813450902783106; Zumkeller W, 2001, J CLIN PATHOL-MOL PA, V54, P227, DOI 10.1136/mp.54.4.227	52	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4114	4122		10.1038/onc.2013.376	http://dx.doi.org/10.1038/onc.2013.376			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24056966				2022-12-17	WOS:000340595700002
J	de Giorgio, A; Castellano, L; Krell, J; Stebbing, J				de Giorgio, A.; Castellano, L.; Krell, J.; Stebbing, J.			Crosstalk-induced loss of miR-126 promotes angiogenesis	ONCOGENE			English	Editorial Material							ENDOTHELIAL GROWTH-FACTOR; EXPRESSION; MICRORNAS	A molecular environment that promotes vascularization around human carcinomas can materialise rapidly, and has been termed the angiogenic switch. Turning this switch toward a proangiogenic state involves an altered interplay between tumor cells and multiple components of the surrounding stroma. The regulatory landscape of these interactions in cervical cancer is now investigated by Huang et al. in this issue of Oncogene, who demonstrate that the microRNA miR-126 is downregulated during cancer progression, particularly in stromal cells. Such a reduction of miR-126 is shown to free at least one target, the proangiogenic adrenomedullin, from repression, enhancing vascular growth especially at the in situ to invasive carcinoma transition. The study implicates the temporal, spatial and progressive nature of tumor-stroma interactions during carcinogenesis, while in turn suggesting therapeutic strategies.	[de Giorgio, A.; Castellano, L.; Krell, J.; Stebbing, J.] Univ London Imperial Coll Sci Technol & Med, Div Oncol, Dept Surg & Canc, Imperial Ctr Translat & Expt Med, London W12 0NN, England	Imperial College London	Stebbing, J (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Oncol, Dept Surg & Canc, Imperial Ctr Translat & Expt Med, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	j.stebbing@imperial.ac.uk	Castellano, Leandro/AAE-1366-2021	Stebbing, Justin/0000-0002-1117-6947; Castellano, Leandro/0000-0002-3059-4829	National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish; Department of Health [NIHR-RP-011-053] Funding Source: Medline	National Institute for Health Research(National Institute for Health Research (NIHR)); Department of Health		Anand S, 2011, CURR OPIN HEMATOL, V18, P171, DOI 10.1097/MOH.0b013e328345a180; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Fish JE, 2008, DEV CELL, V15, P272, DOI 10.1016/j.devcel.2008.07.008; GUIDI AJ, 1995, J NATL CANCER I, V87, P1237, DOI 10.1093/jnci/87.16.1237; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harris TA, 2008, P NATL ACAD SCI USA, V105, P1516, DOI 10.1073/pnas.0707493105; Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3; Huang T- H, 2013, ONCOGENE UNPUB; Ribatti D, 2005, PEPTIDES, V26, P1670, DOI 10.1016/j.peptides.2005.02.017; Urbich C, 2008, CARDIOVASC RES, V79, P581, DOI 10.1093/cvr/cvn156; Wang SS, 2008, DEV CELL, V15, P261, DOI 10.1016/j.devcel.2008.07.002; Zhu N, 2011, MOL CELL BIOCHEM, V351, P157, DOI 10.1007/s11010-011-0723-7	13	11	11	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 10	2014	33	28					3634	3635		10.1038/onc.2013.317	http://dx.doi.org/10.1038/onc.2013.317			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AL2GC	24013227				2022-12-17	WOS:000338942900002
J	Bi, X; Feng, D; Korczeniewska, J; Alper, N; Hu, G; Barnes, BJ				Bi, X.; Feng, D.; Korczeniewska, J.; Alper, N.; Hu, G.; Barnes, B. J.			Deletion of Irf5 protects hematopoietic stem cells from DNA damage-induced apoptosis and suppresses gamma-irradiation-induced thymic lymphomagenesis	ONCOGENE			English	Article						IRF5; thymic lymphoma; gamma-irradiation; apoptosis; stem cells	INTERFERON REGULATORY FACTOR; PRISTANE-INDUCED LUPUS; TUMOR-SUPPRESSOR; GENE-EXPRESSION; IRF5(-/-) MICE; PUMA; P53; DEATH; INDUCTION; TUMORIGENESIS	Repeated low-dose gamma-irradiation (IR) induces thymic lymphoma in mice because of oncogenic mutations propagating from a primitive hematopoietic stem/progenitor cell (HSC) in the bone marrow. It is well known that IR-induced thymic lymphomagenesis is markedly enhanced by p53 deficiency, yet data also indicate that p53-dependent apoptosis can actively drive tumor formation in this model. The latter was recently expounded on by findings from Puma-deficient mice, indicating that loss of this proapoptotic p53 target gene results in protection from IR-induced lymphomagenesis rather than enhanced susceptibility to. Similar to Puma, the transcription factor interferon regulatory factor 5 (Irf5) has been reported as a p53 target gene and is required for DNA damage-induced apoptosis. To date, no studies have been performed to elucidate the in vivo role of IRF5 in tumorigenesis. Given its essential role in DNA damage-induced apoptosis, we explored the tumor suppressor function of IRF5 in IR-induced thymic lymphomagenesis. Somewhat surprisingly, we found that thymic lymphoma development was significantly suppressed in Irf5(-/-) mice as compared with wild-type littermates. Suppression was due, in part, to reduced thymocyte and HSC apoptosis, resulting in reduced compensatory proliferation, and reduced replication stress-associated DNA damage. The observed effects were independent of p53 or Puma as these proteins were upregulated in Irf5(-/-) mice in response to IR. This study demonstrates an important new role for IRF5 in maintaining HSC homeostasis after IR and supports the non-redundant functions of IRF5, p53 and PUMA in DNA damage-induced lymphomagenesis. We propose that IRF5 may be an attractive target for developing therapeutic agents to ameliorate radiation-induced bone marrow injury.	[Bi, X.; Feng, D.; Korczeniewska, J.; Barnes, B. J.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07103 USA; [Bi, X.; Feng, D.; Korczeniewska, J.; Alper, N.; Hu, G.; Barnes, B. J.] Univ Med & Dent New Jersey, New Jersey Med Sch, Univ Hosp, Ctr Canc, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Barnes, BJ (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Univ Hosp,Canc Ctr, G1224,205 South Orange Ave, Newark, NJ 07103 USA.	barnesbe@umdnj.edu			New Jersey Medical School-University Hospital Cancer Center; UMDNJ Foundation; New Jersey Commission on Cancer Research (NJCCR)	New Jersey Medical School-University Hospital Cancer Center; UMDNJ Foundation; New Jersey Commission on Cancer Research (NJCCR)	We gratefully acknowledge Dr David Lagunoff for pathology assistance and Dr Lisong Yang for technical assistance. This work was supported in part by funds from the New Jersey Medical School-University Hospital Cancer Center, the UMDNJ Foundation and the New Jersey Commission on Cancer Research (NJCCR).	Barnes BJ, 2003, CANCER RES, V63, P6424; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Bi XH, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3053; Botcheva K, 2011, CELL CYCLE, V10, P4237, DOI 10.4161/cc.10.24.18383; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Erlacher M, 2006, J EXP MED, V203, P2939, DOI 10.1084/jem.20061552; Feng D, 2012, EUR J IMMUNOL, V42, P1477, DOI 10.1002/eji.201141642; Feng D, 2010, J IMMUNOL, V185, P6003, DOI 10.4049/jimmunol.1000482; Fresquet V, 2012, BRIT J HAEMATOL, V158, P712, DOI 10.1111/j.1365-2141.2012.09226.x; Garrison SP, 2008, MOL CELL BIOL, V28, P5391, DOI 10.1128/MCB.00907-07; Hu GD, 2005, CANCER RES, V65, P7403, DOI 10.1158/0008-5472.CAN-05-0583; Hu GD, 2009, J BIOL CHEM, V284, P2767, DOI 10.1074/jbc.M804744200; KAPLAN HENRY S., 1964, NAT CANCER INST MONOGR, V14, P207; KAPLAN HS, 1952, J NATL CANCER I, V13, P185; Kelly PN, 2010, CELL DEATH DIFFER, V17, P1655, DOI 10.1038/cdd.2010.43; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kim HJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011439; Kominami R, 2006, CANCER SCI, V97, P575, DOI 10.1111/j.1349-7006.2006.00218.x; Labi V, 2010, GENE DEV, V24, P1602, DOI 10.1101/gad.1940210; Liu C, 2011, LEUKEMIA, V25, P1516, DOI 10.1038/leu.2011.113; MAUCH P, 1995, INT J RADIAT ONCOL, V31, P1319, DOI 10.1016/0360-3016(94)00430-S; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; Michalak EM, 2009, CELL DEATH DIFFER, V16, P684, DOI 10.1038/cdd.2008.195; Michalak EM, 2010, GENE DEV, V24, P1608, DOI 10.1101/gad.1940110; Mori T, 2002, ONCOGENE, V21, P2914, DOI 10.1038/sj.onc.1205459; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Purtha WE, 2012, P NATL ACAD SCI USA, V109, pE898, DOI 10.1073/pnas.1118155109; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Schoenemeyer A, 2005, J BIOL CHEM, V280, P17005, DOI 10.1074/jbc.M412584200; Stankovic T, 2004, BLOOD, V103, P291, DOI 10.1182/blood-2003-04-1161; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang Y, 2006, BLOOD, V107, P358, DOI 10.1182/blood-2005-04-1418; Watkins AJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044997; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Xu DS, 2011, J BIOL CHEM, V286, P18261, DOI 10.1074/jbc.M110.210542; Yanai H, 2007, P NATL ACAD SCI USA, V104, P3402, DOI 10.1073/pnas.0611559104; Yang LS, 2012, J IMMUNOL, V189, P3741, DOI 10.4049/jimmunol.1201162; Yang L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005500; Yu H, 2010, BLOOD, V115, P3472, DOI 10.1182/blood-2009-10-248278	40	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 19	2014	33	25					3288	3297		10.1038/onc.2013.295	http://dx.doi.org/10.1038/onc.2013.295			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK5DA	23912454				2022-12-17	WOS:000338443400008
J	Ory, V; Tassi, E; Cavalli, LR; Sharif, GM; Saenz, F; Baker, T; Schmidt, MO; Mueller, SC; Furth, PA; Wellstein, A; Riegel, AT				Ory, V.; Tassi, E.; Cavalli, L. R.; Sharif, G. M.; Saenz, F.; Baker, T.; Schmidt, M. O.; Mueller, S. C.; Furth, P. A.; Wellstein, A.; Riegel, A. T.			The nuclear coactivator amplified in breast cancer 1 maintains tumor-initiating cells during development of ductal carcinoma in situ	ONCOGENE			English	Article						AIB1; DCIS; tumor-initiating cells; coactivator; xenografts	MAMMARY TUMORIGENESIS; MOLECULAR MARKERS; EPITHELIAL ACINI; SRC FAMILY; STEM-CELLS; RECEPTOR; AIB1; GENE; MICE; PROGRESSION	The key molecular events required for the formation of ductal carcinoma in situ (DCIS) and its progression to invasive breast carcinoma have not been defined. Here, we show that the nuclear receptor coactivator amplified in breast cancer 1 (AIB1) is expressed at low levels in normal breast but is highly expressed in DCIS lesions. This is of significance since reduction of AIB1 in human MCFDCIS cells restored a more normal three-dimensional mammary acinar structure. Reduction of AIB1 in MCFDCIS cells, both before DCIS development or in existing MCFDCIS lesions in vivo, inhibited tumor growth and led to smaller, necrotic lesions. AIB1 reduction in MCFDCIS cells was correlated with significant reduction in the CD24-/CD44+ breast cancer-initiating cell (BCIC) population, and a decrease in myoepithelial progenitor cells in the DCIS lesions in vitro and in vivo. The loss of AIB1 in MCFDCIS cells was also accompanied by a loss of expression of NOTCH 2, 3 and 4, JAG2, HES1, GATA3, human epidermal growth factor receptor 2 (HER2) and HER3 in vivo. These signaling molecules have been associated with differentiation of breast epithelial progenitor cells. These data indicate that AIB1 has a central role in the initiation and maintenance of DCIS and that reduction of AIB1 causes loss of BCIC, loss of components of the NOTCH, HER2 and HER3 signaling pathways and fewer DCIS myoepithelial progenitor cells in vivo. We propose that increased expression of AIB1, through the maintenance of BCIC, facilitates formation of DCIS, a necessary step before development of invasive disease.	[Ory, V.; Tassi, E.; Cavalli, L. R.; Sharif, G. M.; Saenz, F.; Baker, T.; Schmidt, M. O.; Mueller, S. C.; Furth, P. A.; Wellstein, A.; Riegel, A. T.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, Washington, DC 20057 USA	Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, Dept Oncol, E307 Res Bldg,3970 Reservoir Rd NW, Washington, DC 20057 USA.	ariege01@georgetown.edu	Schmidt, Marcel/AAV-8054-2021; Cavalli, Luciane R/J-6100-2012; Saenz, Francisco/ABE-7477-2020	Schmidt, Marcel/0000-0002-3991-2766; Saenz, Francisco/0000-0003-4738-4710; Wellstein, Anton/0000-0002-0570-4950; Cavalli, Luciane Regina/0000-0001-5619-9037	Department of Defense Breast Cancer Research Program [BC098103]; NIH/NCI [CA113477]; National Cancer Institute [P30CA051008]; NATIONAL CANCER INSTITUTE [R01CA113477, R01CA112176, T32CA009686, P30CA051008] Funding Source: NIH RePORTER	Department of Defense Breast Cancer Research Program(United States Department of Defense); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the Department of Defense Breast Cancer Research Program BC098103 (VO) and by NIH/NCI Grants CA113477 (ATR). This project was also supported by Award Number P30CA051008 from the National Cancer Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Defense.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Al-Otaiby M, 2012, AM J PATHOL, V180, P1474, DOI 10.1016/j.ajpath.2011.12.032; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Balko JM, 2012, P NATL ACAD SCI USA, V109, P221, DOI 10.1073/pnas.1115802109; Bouras T, 2008, CELL STEM CELL, V3, P429, DOI 10.1016/j.stem.2008.08.001; Cavalli LR, 2008, CANCER GENET CYTOGEN, V186, P120, DOI 10.1016/j.cancergencyto.2008.06.011; Cavalli LR, 2008, CANCER GENET CYTOGEN, V187, P19, DOI 10.1016/j.cancergencyto.2008.07.004; Chien CD, 2011, J BIOL CHEM, V286, P26813, DOI 10.1074/jbc.M110.216200; Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409; Cody HS, 2007, ANN SURG ONCOL, V14, P2179, DOI 10.1245/s10434-006-9300-9; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Espina V, 2011, NAT REV CANCER, V11, P618, DOI 10.1038/nrc2950-c2; Fereshteh MP, 2008, CANCER RES, V68, P3697, DOI 10.1158/0008-5472.CAN-07-6702; Hu M, 2008, CANCER CELL, V13, P394, DOI 10.1016/j.ccr.2008.03.007; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Korkaya H, 2007, BIODRUGS, V21, P299, DOI 10.2165/00063030-200721050-00002; Korkaya H, 2009, CLIN CANCER RES, V15, P1845, DOI 10.1158/1078-0432.CCR-08-3087; Kuang SQ, 2005, CANCER RES, V65, P7993, DOI 10.1158/0008-5472.CAN-05-1179; Lahusen T, 2009, BREAST CANCER RES TR, V116, P225, DOI 10.1007/s10549-009-0405-2; Lauritsen KJ, 2002, ONCOGENE, V21, P7147, DOI 10.1038/sj.onc.1205943; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Long WW, 2010, MOL CELL, V37, P321, DOI 10.1016/j.molcel.2010.01.004; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Miller FR, 2000, J MAMMARY GLAND BIOL, V5, P379, DOI 10.1023/A:1009577811584; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nakles RE, 2011, MOL ENDOCRINOL, V25, P549, DOI 10.1210/me.2010-0114; Nofech-Mozes S, 2005, ADV ANAT PATHOL, V12, P256, DOI 10.1097/01.pap.0000184177.65919.5e; Oh A, 2004, CANCER RES, V64, P8299, DOI 10.1158/0008-5472.CAN-04-0354; Porter D, 2003, MOL CANCER RES, V1, P362; Pradeep CR, 2012, ONCOGENE, V31, P907, DOI 10.1038/onc.2011.279; Qutob MS, 2002, MOL CELL BIOL, V22, P6611, DOI 10.1128/MCB.22.18.6611-6626.2002; RADFORD DM, 1995, CANCER RES, V55, P5180; Rosenfield SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047876; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Stingl J, 2005, J MAMMARY GLAND BIOL, V10, P49, DOI 10.1007/s10911-005-2540-7; STRATTON MR, 1995, J PATHOL, V175, P195, DOI 10.1002/path.1711750207; Sung YM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007445; Torres-Arzayus MI, 2010, CANCER RES, V70, P4102, DOI 10.1158/0008-5472.CAN-09-4080; Torres-Arzayus MI, 2004, CANCER CELL, V6, P263, DOI 10.1016/j.ccr.2004.06.027; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; York B, 2010, J BIOL CHEM, V285, P38743, DOI 10.1074/jbc.R110.193367	44	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3033	3042		10.1038/onc.2013.263	http://dx.doi.org/10.1038/onc.2013.263			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23851504	Green Accepted			2022-12-17	WOS:000337232200010
J	Kong, F; Zhang, J; Li, Y; Hao, X; Ren, X; Li, H; Zhou, P				Kong, F.; Zhang, J.; Li, Y.; Hao, X.; Ren, X.; Li, H.; Zhou, P.			Engineering a single ubiquitin ligase for the selective degradation of all activated ErbB receptor tyrosine kinases	ONCOGENE			English	Article						ubiquitin; ErbB; breast cancer; protein knockout; proteolysis; receptor tyrosine kinase	PHASE-II TRIAL; BREAST-CANCER; BETA-CATENIN; GROWTH; TRASTUZUMAB; TARGET; HER-2; GENE; PROLIFERATION; DESTRUCTION	Interrogating specific cellular activities often entails the dissection of posttranslational modifications or functional redundancy conferred by protein families, which demands more sophisticated research tools than simply eliminating a specific gene product by gene targeting or RNA interference. We have developed a novel methodology that involves engineering a single SCF beta TrCP-based ubiquitin ligase that is capable of not only simultaneously targeting the entire family of ErbB receptor tyrosine kinases for ubiquitination and degradation, but also selectively recruiting only activated ErbBs. The engineered SCF beta TrCP ubiquitin ligase effectively blocked ErbB signaling and attenuated oncogenicity in breast cancer cells, yet had little effect on the survival and growth of non-cancerous breast epithelial cells. Therefore, engineering ubiquitin ligases offers a simple research tool to dissect the specific traits of tumorigenic protein families, and provides a rapid and feasible means to expand the dimensionality of drug discovery by assessing protein families or posttranslational modifications as potential drug targets.	[Kong, F.; Zhang, J.; Li, Y.; Zhou, P.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA; [Kong, F.; Hao, X.; Ren, X.; Li, H.] Tianjin Med Univ, Canc Inst & Hosp, Dept Biotherapy, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China	Cornell University; Tianjin Medical University	Li, H (corresponding author), Tianjin Med Univ, Canc Inst & Hosp, Dept Biotherapy, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.	lihui_0105@yahoo.com; pez2001@med.cornell.edu			National Institutes of Health [CA92792]; Irma T. Hirschl Career Scientist Award; New York Academy of Medicine; Natural Science Foundation of China [30901754]; Innovation Funding for Graduates of Tianjin Medical University; 211 Project for Higher Education [2010GSI01]; NATIONAL CANCER INSTITUTE [R01CA098210, R33CA092792, R21CA092792, R01CA159925] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Irma T. Hirschl Career Scientist Award; New York Academy of Medicine; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Funding for Graduates of Tianjin Medical University; 211 Project for Higher Education; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Bruce Mayer (University of Connecticut) for Shc plasmids, Alexandra Grassian for helpful discussions, and Jeffrey Hannah and Jennifer Lee for critical reading of the manuscript. This work is supported by National Institutes of Health Grant CA92792, the Irma T. Hirschl Career Scientist Award and the Speakers Fund from the New York Academy of Medicine to P.Z., and the Natural Science Foundation of China (No. 30901754) and Innovation Funding for Graduates of Tianjin Medical University, third Phase of the 211 Project for Higher Education (No. 2010GSI01).	Burstein HJ, 2001, J CLIN ONCOL, V19, P2722, DOI 10.1200/JCO.2001.19.10.2722; Carraway KL, 2010, SEMIN CELL DEV BIOL, V21, P936, DOI 10.1016/j.semcdb.2010.09.006; Castaneda CA, 2010, CANCER METAST REV, V29, P751, DOI 10.1007/s10555-010-9261-0; Chen W, 2004, CANCER RES, V64, P3949, DOI 10.1158/0008-5472.CAN-03-3906; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; Chen XA, 2006, MOL CELL, V22, P489, DOI 10.1016/j.molcel.2006.04.021; Cohen J Craig, 2004, BMC Dev Biol, V4, P4; Colomer R, 2000, CLIN CANCER RES, V6, P2356; Cong F, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-10; Faltus T, 2004, NEOPLASIA, V6, P786, DOI 10.1593/neo.04313; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Gasparini G, 2007, BREAST CANCER RES TR, V101, P355, DOI 10.1007/s10549-006-9306-9; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hannah J, 2011, CELL RES, V21, P1152, DOI 10.1038/cr.2011.89; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Klapper LN, 2000, CANCER RES, V60, P3384; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Liu J, 2004, BIOCHEM BIOPH RES CO, V313, P1023, DOI 10.1016/j.bbrc.2003.12.035; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Palmieri D, 2006, BREAST CANCER RES TR, V100, P127, DOI 10.1007/s10549-006-9244-6; Panigada M, 2002, J EXP MED, V195, P1585, DOI 10.1084/jem.20020047; Persons DA, 1998, BLOOD CELL MOL DIS, V24, P167, DOI 10.1006/bcmd.1998.0184; Rabindran SK, 2005, CANCER LETT, V227, P9, DOI 10.1016/j.canlet.2004.11.015; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Sarikas A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-220; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Sithanandam G, 2008, CANCER GENE THER, V15, P413, DOI 10.1038/cgt.2008.15; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Su YY, 2003, P NATL ACAD SCI USA, V100, P12729, DOI 10.1073/pnas.2133261100; Suenaga A, 2009, BIOPHYS J, V96, P2278, DOI 10.1016/j.bpj.2008.11.018; Worster DT, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001986; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang JX, 2003, P NATL ACAD SCI USA, V100, P14127, DOI 10.1073/pnas.2233012100; Zhou PB, 2000, MOL CELL, V6, P751, DOI 10.1016/S1097-2765(00)00074-5; Zhou PB, 2005, CURR OPIN CHEM BIOL, V9, P51, DOI 10.1016/j.cbpa.2004.10.012; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	46	11	11	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					986	995		10.1038/onc.2013.33	http://dx.doi.org/10.1038/onc.2013.33			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23416973	Green Accepted			2022-12-17	WOS:000331933200006
J	Kuchenreuther, MJ; Weber, JD				Kuchenreuther, M. J.; Weber, J. D.			The ARF tumor-suppressor controls Drosha translation to prevent Ras-driven transformation	ONCOGENE			English	Article						ARF; Drosha; translation; tumor suppression; rRNA	RIBOSOMAL-RNA; PROTEIN; P53; EXPRESSION; P19(ARF); COMPLEX; DICER; MDM2; BIOGENESIS; MICRORNAS	ARF is a multifunctional tumor suppressor that acts as both a sensor of oncogenic stimuli and as a key regulator of ribosome biogenesis. Recently, our group established the DEAD-box RNA helicase and microRNA (miRNA) microprocessor accessory subunit, DDX5, as a critical target of basal ARF function. To identify other molecular targets of ARF, we focused on known interacting proteins of DDX5 in the microprocessor complex. Drosha, the catalytic core of the microprocessor complex, has a critical role in the maturation of specific non-coding RNAs, including miRNAs and ribosomal RNAs (rRNAs). Here, we report that chronic or acute loss of Arf enhanced Drosha protein expression. This induction did not involve Drosha mRNA transcription or protein stability but rather relied on the increased translation of existing Drosha mRNAs. Enhanced Drosha expression did not alter global miRNA production but rather modified expression of a subset of miRNAs in the absence of Arf. Elevated Drosha protein levels were required to maintain the increased rRNA synthesis and cellular proliferation observed in the absence of Arf. Arf-deficient cells transformed by oncogenic RasV12 were dependent on increased Drosha expression as Drosha knockdown was sufficient to inhibit Ras-dependent cellular transformation. Thus, we propose that ARF regulates Drosha mRNA translation to prevent aberrant cell proliferation and Ras-dependent transformation.	[Kuchenreuther, M. J.; Weber, J. D.] Washington Univ, Sch Med, BRIGHT Inst, St Louis, MO 63110 USA; [Kuchenreuther, M. J.; Weber, J. D.] Washington Univ, Sch Med, Dept Internal Med, Div Mol Oncol, St Louis, MO 63110 USA; [Weber, J. D.] Washington Univ, Sch Med, Dept Cell Biol, Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	Weber, JD (corresponding author), Washington Univ, Sch Med, Dept Internal Med, BRIGHT Inst,Div Mol Oncol, 660 South Euclid Ave,Campus 8069, St Louis, MO 63110 USA.	jweber@dom.wustl.edu		Weber, Jason/0000-0002-1069-6983	Siteman Cancer Center, Cancer Biology Pathway Training Grant [T32 CA113275]; National Institutes of Health [R01 CA120436]; Department of Defense Era of Hope Scholar Award [BC075004]; NATIONAL CANCER INSTITUTE [R01CA120436, T32CA113275] Funding Source: NIH RePORTER	Siteman Cancer Center, Cancer Biology Pathway Training Grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Era of Hope Scholar Award(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Weber lab for their technical input and suggestions. The Children's Discovery Institute and the Genome Institute at Washington University provided lentiviral knockdown constructs. MJK was supported by the Siteman Cancer Center, Cancer Biology Pathway Training Grant (T32 CA113275). Grants from the National Institutes of Health (R01 CA120436) and Department of Defense Era of Hope Scholar Award (BC075004) to JDW supported this work.	Apicelli AJ, 2008, MOL CELL BIOL, V28, P1068, DOI 10.1128/MCB.00484-07; Ayrault O, 2004, ONCOGENE, V23, P8097, DOI 10.1038/sj.onc.1207968; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Diederichs S, 2007, CELL, V131, P1097, DOI 10.1016/j.cell.2007.10.032; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Han J, 2009, CELL, V136, P75, DOI 10.1016/j.cell.2008.10.053; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kawagishi H, 2010, CANCER RES, V70, P4749, DOI 10.1158/0008-5472.CAN-10-0368; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lessard F, 2010, MOL CELL, V38, P539, DOI 10.1016/j.molcel.2010.03.015; Lin RJ, 2010, CANCER RES, V70, P7841, DOI 10.1158/0008-5472.CAN-10-0970; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Miceli AP, 2012, MOL CELL BIOL, V32, P348, DOI 10.1128/MCB.06030-11; Muralidhar B, 2011, J PATHOL, V224, P496, DOI 10.1002/path.2898; Olanich ME, 2011, ONCOGENE, V30, P77, DOI 10.1038/onc.2010.404; Oskowitz AZ, 2011, INT J BIOCHEM CELL B, V43, P1563, DOI 10.1016/j.biocel.2011.07.005; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Sand M, 2010, CANCER INVEST, V28, P649, DOI 10.3109/07357901003630918; Saporita AJ, 2011, CANCER RES, V71, P6708, DOI 10.1158/0008-5472.CAN-11-1472; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Shiohama A, 2007, EXP CELL RES, V313, P4196, DOI 10.1016/j.yexcr.2007.07.020; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Sugito N, 2006, CLIN CANCER RES, V12, P7322, DOI 10.1158/1078-0432.CCR-06-0515; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wu HJ, 2000, J BIOL CHEM, V275, P36957, DOI 10.1074/jbc.M005494200; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	41	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					300	307		10.1038/onc.2012.601	http://dx.doi.org/10.1038/onc.2012.601			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318441	Green Accepted			2022-12-17	WOS:000330214000004
J	van de Kooij, B; Rooswinkel, RW; Kok, F; Herrebout, M; de Vries, E; Paauwe, M; Janssen, GMC; van Veelen, PA; Borst, J				van de Kooij, B.; Rooswinkel, R. W.; Kok, F.; Herrebout, M.; de Vries, E.; Paauwe, M.; Janssen, G. M. C.; van Veelen, P. A.; Borst, J.			Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B	ONCOGENE			English	Article						apoptosis; Bcl-2 family; Bcl-B; ubiquitination	E3 UBIQUITIN LIGASE; MASS-SPECTROMETRY; LEUKEMIC-CELLS; PROTEIN; FAMILY; MCL-1; DEATH; ABT-737; RESISTANCE; EXPRESSION	Anti-apoptotic Bcl-2 family members can contribute to tumorigenesis and may convey resistance to anti-cancer regimens. Therefore, they are important targets for novel therapeutics, particularly Bcl-2 homology (BH) 3 mimetics. Bcl-B (BCL-2-like protein-10) is a relatively understudied member of the Bcl-2 protein family. Its physiological function is unknown, but it has been proven to have an anti-apoptotic activity and to act as a tumor promoter in mice. In human, high Bcl-B protein expression levels correlate with poor prognosis in various carcinomas and predict treatment resistance in acute myeloid leukemia. We here report that protein expression level and anti-apoptotic activity of Bcl-B are dictated by its ubiquitination. We demonstrate that Bcl-B is polyubiquitinated at steady state, in a unique loop between the BH1 and BH2 domains. Mutagenesis identified lysine (K) 128 as an acceptor site for polyubiquitin chains, and K119 and K120, but not K181, as potential ubiquitination sites. Mass spectrometry confirmed K128 as a ubiquitination site and defined the polyubiquitin chains as K48-linked, which was confirmed by linkage-specific antibodies. Accordingly, Bcl-B proved to be an instable protein that is subject to ubiquitin-dependent proteasomal degradation at steady state. At equal mRNA expression, protein expression of a lysineless, nonubiquitinated Bcl-B mutant was fivefold higher than that of wild-type Bcl-B, demonstrating that ubiquitination is a key determinant for Bcl-B protein expression levels. Ubiquitination controlled the anti-apoptotic capacity of Bcl-B, in response to a variety of conventional and novel anti-cancer drugs. Certain anti-cancer drugs, known to reduce Mcl-1 protein levels, likewise downregulated Bcl-B. Together, these data demonstrate that polyubiquitination and proteasomal turnover dictate the expression level and anti-apoptotic capacity of Bcl-B.	[van de Kooij, B.; Rooswinkel, R. W.; Kok, F.; Herrebout, M.; de Vries, E.; Paauwe, M.; Borst, J.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; [Janssen, G. M. C.; van Veelen, P. A.] Leiden Univ, Med Ctr, Dept Immunohematol, Leiden, Netherlands; [Janssen, G. M. C.; van Veelen, P. A.] Leiden Univ, Med Ctr, Blood Bank, Leiden, Netherlands	Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Borst, J (corresponding author), Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.borst@nki.nl	Paauwe, Madelon/C-8244-2018	Borst, Jannie/0000-0002-8043-5009; van Veelen, Peter/0000-0002-7898-9408	Netherlands Organization for Scientific Research [ECHO 700.57.008]; Dutch Cancer Society [NKI 2008-4110]; Netherlands Proteomics Center	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Proteomics Center	We thank Lennert Janssen, Drs Ricky Johnstone, Henning Walczak and Huib Ovaa for kindly providing reagents, and Drs Abdel Aouacheria and Mark Hinds for advise on the Bcl-B protein structure. This work was supported by grant ECHO 700.57.008 from the Netherlands Organization for Scientific Research and grant NKI 2008-4110 from the Dutch Cancer Society, awarded to JB, and GMCJ was supported by the Netherlands Proteomics Center.	Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Aouacheria A, 2001, ONCOGENE, V20, P5846, DOI 10.1038/sj.onc.1204740; Beverly LJ, 2009, ONCOGENE, V28, P1274, DOI 10.1038/onc.2008.466; Beverly LJ, 2012, P NATL ACAD SCI USA, V109, P119, DOI 10.1073/pnas.1119167109; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Cluzeau T, 2012, ONCOTARGET, V3, P490; El Oualid F, 2010, ANGEW CHEM INT EDIT, V49, P10149, DOI 10.1002/anie.201005995; Fan GF, 2010, BLOOD, V115, P3559, DOI 10.1182/blood-2009-08-236760; Fernandez-Fuentes N, 2007, NUCLEIC ACIDS RES, V35, pW363, DOI 10.1093/nar/gkm341; Gandhi L, 2011, J CLIN ONCOL, V29, P909, DOI 10.1200/JCO.2010.31.6208; Goetze S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000236; Guillemin Y, 2011, MOL BIOL EVOL, V28, P3271, DOI 10.1093/molbev/msr152; Hao ZY, 2012, J EXP MED, V209, P173, DOI 10.1084/jem.20111363; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Ke N, 2001, J BIOL CHEM, V276, P12481, DOI 10.1074/jbc.C000871200; Kirkpatrick DS, 2005, NAT CELL BIOL, V7, P750, DOI 10.1038/ncb0805-750; Knoops L, 2007, BLOOD, V110, P1116, DOI 10.1182/blood-2007-01-067579; Krajewska M, 2008, CLIN CANCER RES, V14, P3011, DOI 10.1158/1078-0432.CCR-07-1955; Lee RM, 2001, BBA-GENE STRUCT EXPR, V1520, P187, DOI 10.1016/S0167-4781(01)00268-8; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Meiring HD, 2002, J SEP SCI, V25, P557, DOI 10.1002/1615-9314(20020601)25:9<557::AID-JSSC557>3.0.CO;2-F; Merino D, 2012, BLOOD, V119, P5807, DOI 10.1182/blood-2011-12-400929; Nemunaitis J, 2013, CANCER CHEMOTH PHARM, V71, P35, DOI 10.1007/s00280-012-1963-2; Newton K, 2008, CELL, V134, P668, DOI 10.1016/j.cell.2008.07.039; Nielsen ML, 2008, NAT METHODS, V5, P459, DOI 10.1038/nmeth0608-459; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pepper C, 2008, BLOOD, V112, P3807, DOI 10.1182/blood-2008-05-157131; Rautureau GJP, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.178; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; Rocha N, 2009, J CELL BIOL, V185, P1209, DOI 10.1083/jcb.200811005; Rooswinkel RW, CELL DEATH DIS, V3, pe366; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Stewart DP, 2010, MOL CELL BIOL, V30, P3099, DOI 10.1128/MCB.01266-09; Sutherland BW, 2008, J MASS SPECTROM, V43, P699, DOI 10.1002/jms.1415; Tait SWG, 2007, J CELL BIOL, V179, P1453, DOI 10.1083/jcb.200707063; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tothova E, 2002, NEOPLASMA, V49, P141; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; van Lummel M, 2012, J BIOL CHEM, V287, P9514, DOI 10.1074/jbc.M111.313940; Verbrugge I, 2008, ONCOGENE, V27, P574, DOI 10.1038/sj.onc.1210696; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Whitecross KF, 2009, BLOOD, V113, P1982, DOI 10.1182/blood-2008-05-156851; Wiggins CM, 2011, J CELL SCI, V124, P969, DOI 10.1242/jcs.058438; Yecies D, 2010, BLOOD, V115, P3304, DOI 10.1182/blood-2009-07-233304; Zhai DY, 2008, J BIOL CHEM, V283, P9580, DOI 10.1074/jbc.M708426200; Zhai DY, 2003, BIOCHEM J, V376, P229, DOI 10.1042/BJ20030374; Zhang H, 2001, HUM MOL GENET, V10, P2329, DOI 10.1093/hmg/10.21.2329; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	52	11	11	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2013	32	48					5439	5448		10.1038/onc.2013.99	http://dx.doi.org/10.1038/onc.2013.99			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263BE	23563182	Green Published			2022-12-17	WOS:000327780800001
J	Eissmann, M; Melzer, IM; Fernandez, SBM; Michel, G; de Angelis, MH; Hoefler, G; Finkenwirth, P; Jauch, A; Schoell, B; Grez, M; Schmidt, M; Bartholomae, CC; Newrzela, S; Haetscher, N; Rieger, MA; Zachskorn, C; Mittelbronn, M; Zornig, M				Eissmann, M.; Melzer, I. M.; Fernandez, S. B. M.; Michel, G.; de Angelis, M. Hrabe; Hoefler, G.; Finkenwirth, P.; Jauch, A.; Schoell, B.; Grez, M.; Schmidt, M.; Bartholomae, C. C.; Newrzela, S.; Haetscher, N.; Rieger, M. A.; Zachskorn, C.; Mittelbronn, M.; Zoernig, M.			Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms	ONCOGENE			English	Article						AVEN; apoptosis; T-ALL; acute lymphoblastic leukemia; p53; transgenic mice	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACTIVATION; APOPTOSOME; MOUSE	AVEN has been identified as an inhibitor of apoptosis, which binds to the adaptor protein, APAF-1, and thereby prevents apoptosome formation and mitochondrial apoptosis. Recent data have demonstrated high expression levels of AVEN messenger RNA in acute leukemias as well as a positive correlation between AVEN mRNA overexpression and poor prognosis in childhood acute lymphoblastic leukemia. On the basis of these data, we investigated the potential involvement of AVEN in tumorigenesis. First, we confirmed the overexpression of AVEN in T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) patient samples. We then established a transgenic mouse model with T-cell-specific overexpression of AVEN, with which we demonstrated the oncogenic cooperation of AVEN with heterozygous loss of p53. Finally, we used a subcutaneous xenograft mouse model to show that AVEN knockdown in the T-ALL cell lines, MOLT-4 and CCRF-CEM, and in the acute myeloblastic leukemia cell line, Kasumi-1, leads to a halt in tumor growth owing to the increased apoptosis and decreased proliferation of tumor cells. Collectively, our data demonstrate that the anti-apoptotic molecule, AVEN, functions as an oncoprotein in hematopoietic neoplasms.	[Eissmann, M.; Melzer, I. M.; Fernandez, S. B. M.; Finkenwirth, P.; Grez, M.; Haetscher, N.; Rieger, M. A.; Zoernig, M.] Chemotherapeut Forschungsinst Georg Speyer Haus, D-60596 Frankfurt, Germany; [Michel, G.; de Angelis, M. Hrabe] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Inst Expt Genet, German Mouse Clin, Neuherberg, Germany; [de Angelis, M. Hrabe] Tech Univ Munich, Chair Expt Genet, Freising Weihenstephan, Germany; [Hoefler, G.] Med Univ Graz, Inst Pathol, Graz, Austria; [Jauch, A.; Schoell, B.] Univ Heidelberg Hosp, Inst Human Genet, Heidelberg, Germany; [Schmidt, M.; Bartholomae, C. C.] German Canc Res Ctr, Natl Ctr Tumor Dis Heidelberg NCT, Heidelberg, Germany; [Newrzela, S.] Goethe Univ Hosp, Senckenberg Inst Pathol, Frankfurt, Germany; [Zachskorn, C.; Mittelbronn, M.] Edinger Inst, Inst Neurol, Frankfurt, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Technical University of Munich; Medical University of Graz; Ruprecht Karls University Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Zornig, M (corresponding author), Chemotherapeut Forschungsinst Georg Speyer Haus, Paul Ehrlich Str 42-44, D-60596 Frankfurt, Germany.	zoernig@em.uni-frankfurt.de	de Angelis, Martin Hrabe/F-5531-2012; Rieger, Michael A/L-8324-2017; Hoefler, Gerald/H-1796-2016	de Angelis, Martin Hrabe/0000-0002-7898-2353; Rieger, Michael A/0000-0002-4158-5872; Mittelbronn, Michel/0000-0002-2998-052X; Hoefler, Gerald/0000-0002-9056-3063	German Cancer Aid Foundation [108659]; German National Genome Research Network (NGFN project) [N1KR-S12T23]; SFB 'Lipotox' of the Austrian Science foundation FWF [W30]; LOEWE Center for Cell and Gene Therapy Frankfurt [HMWK III L 4-518/17.004 (2010)]; German Federal Ministry of Health (BMG); Ministry of Higher Education, Research and the Arts of the state of Hessen (HMWK)	German Cancer Aid Foundation; German National Genome Research Network (NGFN project); SFB 'Lipotox' of the Austrian Science foundation FWF; LOEWE Center for Cell and Gene Therapy Frankfurt; German Federal Ministry of Health (BMG); Ministry of Higher Education, Research and the Arts of the state of Hessen (HMWK)	The authors would like to thank Susanne Bosser for excellent technical support. This work was supported by grants from the German Cancer Aid Foundation (no. 108659; MZ), the German National Genome Research Network (NGFN project N1KR-S12T23, MZ) and the SFB 'Lipotox' of the Austrian Science foundation FWF (no. W30; GH). MZ, IMM and MAR are thankful for the support by the LOEWE Center for Cell and Gene Therapy Frankfurt (HMWK III L 4-518/17.004 (2010)). The Georg-Speyer-Haus is funded jointly by the German Federal Ministry of Health (BMG) and the Ministry of Higher Education, Research and the Arts of the state of Hessen (HMWK).	ASOU H, 1991, BLOOD, V77, P2031; Bao Q, 2007, CELL DEATH DIFFER, V14, P56, DOI 10.1038/sj.cdd.4402028; Bratton SB, 2010, J CELL SCI, V123, P3209, DOI 10.1242/jcs.073643; Brenner D, 2009, CURR OPIN CELL BIOL, V21, P871, DOI 10.1016/j.ceb.2009.09.004; Burkhardt B, 2010, BRIT J HAEMATOL, V149, P653, DOI 10.1111/j.1365-2141.2009.08006.x; Chau BN, 2000, MOL CELL, V6, P31, DOI 10.1016/S1097-2765(00)00005-8; Choi J, 2006, LEUKEMIA RES, V30, P1019, DOI 10.1016/j.leukres.2005.11.001; Cleaver AL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-105; de Leval L, 2009, CRIT REV ONCOL HEMAT, V72, P125, DOI 10.1016/j.critrevonc.2009.01.002; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Esmaili AM, 2010, CELL CYCLE, V9, P3913, DOI 10.4161/cc.9.19.13138; Guo JY, 2008, CURR BIOL, V18, P933, DOI 10.1016/j.cub.2008.05.045; Hajra KM, 2004, APOPTOSIS, V9, P691, DOI 10.1023/B:APPT.0000045786.98031.1d; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Imada K, 2003, INT J HEMATOL, V77, P336, DOI 10.1007/BF02982640; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Ledgerwood EC, 2009, CLIN CANCER RES, V15, P420, DOI 10.1158/1078-0432.CCR-08-1172; Ozoren N, 2003, SEMIN CANCER BIOL, V13, P135, DOI 10.1016/S1044-579X(02)00131-1; Paolini S, 2011, SEMIN DIAGN PATHOL, V28, P124, DOI 10.1053/j.semdp.2011.02.008; Paydas S, 2003, ANN ONCOL, V14, P1045, DOI 10.1093/annonc/mdg277; Riccardi C, 2006, NAT PROTOC, V1, P1458, DOI 10.1038/nprot.2006.238; Riz I, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-181; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Swerdlow SH., 2017, WHO CLASSIFICATION T; Vangestel C, 2009, CANCER BIOTHER RADIO, V24, P395, DOI 10.1089/cbr.2008.0598; Xu GW, 2007, CELL RES, V17, P759, DOI 10.1038/cr.2007.52	28	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2013	32	20					2586	2591		10.1038/onc.2012.263	http://dx.doi.org/10.1038/onc.2012.263			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	148UY	22751129				2022-12-17	WOS:000319274300010
J	Qiu, W; Liu, H; Sebastini, A; Sun, Q; Wang, H; Zhang, L; Yu, J				Qiu, W.; Liu, H.; Sebastini, A.; Sun, Q.; Wang, H.; Zhang, L.; Yu, J.			An apoptosis-independent role of SMAC in tumor suppression	ONCOGENE			English	Article						SMAC; cIAP; NF-kappa B; proliferation; colon cancer	NF-KAPPA-B; DRUG-INDUCED APOPTOSIS; TNF-ALPHA; INTESTINAL TUMORIGENESIS; STEM-CELLS; CANCER; PUMA; SMAC/DIABLO; INFLAMMATION; ACTIVATION	Reduced expression of the pro-apoptotic protein SMAC (second mitochondria-derived activator of caspase) has been reported to correlate with cancer progression, while its significance and underlying mechanisms are poorly understood. In this study, we investigated the role of SMAC in intestinal tumorigenesis using both human samples and animal models. Decreased SMAC expression was found to correlate with increased cIAP2 expression and higher grades of human colon cancer. In mice, SMAC deficiency significantly increased the incidence and size of colon tumors induced by azoxymethane (AOM)/dextran sulfate sodium salt (DSS), and highly enriched beta-catenin hot spot mutations. SMAC deficiency also significantly increased the incidence of spontaneous intestinal polyps in APC(Min/+) mice. Loss of SMAC in mice led to elevated levels of cIAP1 and cIAP2, increased proliferation and activation of the NF-kappa B p65 subunit in normal and tumor tissues. Unexpectedly, SMAC deficiency had little effect on the incidence of precursor lesions, or apoptosis induced by AOM or DSS, or in established tumors in mice. Furthermore, SMAC knockout enhanced TNF alpha-mediated NF-kappa B activation via cIAP2 in HCT 116 colon cancer cells. These results demonstrate an essential and apoptosis-independent function of SMAC in tumor suppression and provide new insights into the biology and targeting of colon cancer.	[Qiu, W.; Liu, H.; Sebastini, A.; Sun, Q.; Wang, H.; Zhang, L.; Yu, J.] Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; [Qiu, W.; Sun, Q.; Yu, J.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA; [Wang, H.] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA; [Zhang, L.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Yu, J (corresponding author), Univ Pittsburgh, Pittsburgh Canc Inst, Hillman Canc Ctr, UPCI Res Pavil,Suite 2-26 H,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	yuj2@upmc.edu	Zhang, Lin/A-7389-2009; Yu, Jian/A-8301-2009	Zhang, Lin/0000-0003-0018-3903; Yu, Jian/0000-0002-4021-1000; Wang, Hong/0000-0003-0477-2908	NIH [CA129829, UO1-DK085570, CA106348, CA121105]; American Cancer Society [RGS-10-124-01-CCE, RSG-07-156-01-CNE]; FAMRI;  [P30CA047904]; NATIONAL CANCER INSTITUTE [R01CA106348, R01CA121105, P30CA047904, R01CA129829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085570] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); FAMRI; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Monica E Buchanan, Matthew F Brown and other members of Zhang and Yu labs for helpful discussion and critical reading, and Laurice A Vance-Carr for editorial assistance. This work is supported in part by NIH grants CA129829, UO1-DK085570, American Cancer Society grant RGS-10-124-01-CCE and FAMRI (JY), NIH grants CA106348, CA121105, and American Cancer Society grant RSG-07-156-01-CNE (LZ). This project used the UPCI shared glassware, animal, and cell and tissue imaging facilities that were supported in part by award P30CA047904.	Bank A, 2008, CANCER RES, V68, P276, DOI 10.1158/0008-5472.CAN-07-5242; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Conze DB, 2005, MOL CELL BIOL, V25, P3348, DOI 10.1128/MCB.25.8.3348-3356.2005; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Endo K, 2009, ONCOL REP, V21, P351, DOI 10.3892/or_00000229; Fingleton B, 2007, CANCER RES, V67, P4800, DOI 10.1158/0008-5472.CAN-06-4473; Fulda S, 2002, NAT MED, V8, P808, DOI 10.1038/nm735; Gaither A, 2007, CANCER RES, V67, P11493, DOI 10.1158/0008-5472.CAN-07-5173; Geserick P, 2009, J CELL BIOL, V187, P1037, DOI 10.1083/jcb.200904158; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Guillen-Ahlers H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009070; Gyrd-Hansen M, 2010, NAT REV CANCER, V10, P561, DOI 10.1038/nrc2889; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hirose Y, 1996, JPN J CANCER RES, V87, P575, DOI 10.1111/j.1349-7006.1996.tb00262.x; Kohli M, 2004, P NATL ACAD SCI USA, V101, P16897, DOI 10.1073/pnas.0403405101; Krajewska M, 2003, CLIN CANCER RES, V9, P4914; LaCasse EC, 2008, ONCOGENE, V27, P6252, DOI 10.1038/onc.2008.302; Leibowitz Brian, 2010, Cancer Biol Ther, V9, P417, DOI 10.4161/cbt.9.6.11392; Leibowitz BJ, 2011, MOL CANCER RES, V9, P616, DOI 10.1158/1541-7786.MCR-11-0052; Mace PD, 2010, J MOL BIOL, V400, P8, DOI 10.1016/j.jmb.2010.04.055; Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105; Martinez-Ruiz G, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-48; Okada H, 2002, MOL CELL BIOL, V22, P3509, DOI 10.1128/MCB.22.10.3509-3517.2002; Petersen SL, 2010, P NATL ACAD SCI USA, V107, P11936, DOI 10.1073/pnas.1005667107; Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]; Qiu W, 2008, CELL STEM CELL, V2, P576, DOI 10.1016/j.stem.2008.03.009; Qiu W, 2011, J CLIN INVEST, V121, P1722, DOI 10.1172/JCI42917; Qiu W, 2010, P NATL ACAD SCI USA, V107, P20027, DOI 10.1073/pnas.1010430107; Qiu W, 2009, CANCER RES, V69, P4999, DOI 10.1158/0008-5472.CAN-09-0262; Quante M, 2008, PHYSIOLOGY, V23, P350, DOI 10.1152/physiol.00031.2008; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Stevens RG, 2007, CANCER LETT, V252, P171, DOI 10.1016/j.canlet.2006.11.009; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Sun QH, 2011, CLIN CANCER RES, V17, P2361, DOI 10.1158/1078-0432.CCR-10-2262; Takahashi M, 2000, CARCINOGENESIS, V21, P1117, DOI 10.1093/carcin/21.6.1117; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Vlantis K, 2011, J CLIN INVEST, V121, P2781, DOI 10.1172/JCI45349; Wang L, 2008, CELL, V133, P693, DOI 10.1016/j.cell.2008.03.036; Wang P, 2009, CELL DEATH DIFFER, V16, P1192, DOI 10.1038/cdd.2009.51; Wu B, 2007, GUT, V56, P645, DOI 10.1136/gut.2006.101683; Xu Y, 2011, CLIN CANCER RES, V17, P5412, DOI 10.1158/1078-0432.CCR-11-0426; Yu J, 2007, ONCOGENE, V26, P4189, DOI 10.1038/sj.onc.1210196; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2004, CURR OPIN ONCOL, V16, P19, DOI 10.1097/00001622-200401000-00005; Yue W, 2007, CLIN CANCER RES, V13, P4336, DOI 10.1158/1078-0432.CCR-07-0015	50	11	13	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2013	32	19					2380	2389		10.1038/onc.2012.265	http://dx.doi.org/10.1038/onc.2012.265			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	140ZL	22751125	Green Accepted			2022-12-17	WOS:000318694900002
J	Ozenne, P; Dayde, D; Brambilla, E; Eymin, B; Gazzeri, S				Ozenne, P.; Dayde, D.; Brambilla, E.; Eymin, B.; Gazzeri, S.			p14(ARF) inhibits the growth of lung adenocarcinoma cells harbouring an EGFR L858R mutation by activating a STAT3-dependent pro-apoptotic signalling pathway	ONCOGENE			English	Article						p14(ARF); mutant EGFR; STAT3; apoptosis; lung cancer	RECEPTOR GENE-MUTATIONS; P53 OVEREXPRESSION; TRANSCRIPTIONAL CONTROL; STAT3 ACTIVATION; CANCER; EXPRESSION; GEFITINIB; PROGNOSIS; PROTEIN; MECHANISMS	Epidermal growth factor receptor (EGFR) stimulates proliferative and survival signals. Activating mutations of EGFR are involved in the aetiology and maintenance of the malignant phenotype of lung tumours. We previously described the frequent association of these mutations with the decreased expression of the p14(ARF) tumour suppressor, another common feature of lung cancer. Based on these data, we postulated that p14(ARF) could protect cells against untimely or excessive mitotic signals induced by mutant EGFR. In this study, we demonstrate that p14(ARF) promotes apoptosis in lung tumour cells harbouring the EGFR L858R mutation through the accumulation of phosphorylated signal transducer and activator of transcription 3 (STAT3) on Tyr 705 residue, which leads to BcI-2 downregulation. Using siRNA against PTP-RT, the phosphatase that specifically targets Tyr 705 residue, we show that accumulation of pSTAT3-Tyr705 promotes EGFR L858R mutant cell death, thereby confirming the existence of a STAT3-dependent pro-apoptotic pathway in these cells. Finally, we show that the expression of the EGFR L858R mutant represses p14(ARF) expression and inhibits STAT3/BcI-2 signalling. These results identify a novel link between the p14(ARF) and EGFR pathways and suggest that EGFR L858R counteracts the pro-apoptotic function of p14(ARF) by downregulating its expression to promote carcinogenesis. Oncogene (2013) 32, 1050-1058; doi:10.1038/onc.2012.107; published online 26 March 2012	[Ozenne, P.; Dayde, D.; Brambilla, E.; Eymin, B.; Gazzeri, S.] Inst Albert Bonniot, INSERM, Equipe Bases Mol Progress Canc Poumon, Ctr Rech,U823, F-38042 Grenoble 09, Isere, France; [Ozenne, P.; Dayde, D.; Brambilla, E.; Eymin, B.; Gazzeri, S.] Univ Grenoble 1, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gazzeri, S (corresponding author), Inst Albert Bonniot, INSERM, Equipe Bases Mol Progress Canc Poumon, Ctr Rech,U823, BP170, F-38042 Grenoble 09, Isere, France.	Sylvie.Gazzeri@ujf-grenoble.fr	eymin, beatrice/U-4670-2019; gazzeri, sylvie/U-4669-2019; Eymin, Beatrice/M-1962-2013; gazzeri, sylvie/M-1961-2013	eymin, beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839; Eymin, Beatrice/0000-0002-7311-3810; gazzeri, sylvie/0000-0001-5817-1839	Institut National de la Sante et de la Recherche Medicale [U823]; Association pour la Recherche sur le Cancer; la Fondation de France; AGIR a Dom; Fond de dotation pour la recherche en sante respiratoire	Institut National de la Sante et de la Recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); la Fondation de France(Fondation de France); AGIR a Dom; Fond de dotation pour la recherche en sante respiratoire	We thank Professor A Gazdar for providing us with the H1975 and H3255 cellular models and Dr P Hainaut for the pcDNA3.1-EGFR-L858R expression vector. We also thank Celine Barrial-Lampreia and Pascal Perron for their technical assistance. This work was supported by Institut National de la Sante et de la Recherche Medicale U823, Association pour la Recherche sur le Cancer and la Fondation de France. PO is supported by AGIR a Dom. DD is supported by the Fond de dotation pour la recherche en sante respiratoire 2010.	Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Chapman RS, 1999, GENE DEV, V13, P2604, DOI 10.1101/gad.13.19.2604; Eymin B, 2003, ONCOGENE, V22, P1822, DOI 10.1038/sj.onc.1206303; Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871; Gazzeri S, 1998, CANCER RES, V58, P3926; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Haura EB, 2005, NAT CLIN PRACT ONCOL, V2, P315, DOI 10.1038/ncponc0195; Haura EB, 2005, CLIN CANCER RES, V11, P8288, DOI 10.1158/1078-0432.CCR-05-0827; Hirsch FR, 2003, J CLIN ONCOL, V21, P3798, DOI 10.1200/JCO.2003.11.069; Hsu HS, 2004, CLIN CANCER RES, V10, P4734, DOI 10.1158/1078-0432.CCR-03-0704; Ichiba M, 1998, J BIOL CHEM, V273, P6132, DOI 10.1074/jbc.273.11.6132; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Leduc C, 2006, ONCOGENE, V25, P4147, DOI 10.1038/sj.onc.1209446; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Mounawar M, 2007, CANCER RES, V67, P5667, DOI 10.1158/0008-5472.CAN-06-4229; Mukohara T, 2003, LUNG CANCER, V41, P123, DOI 10.1016/S0169-5002(03)00225-3; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; Narimatsu M, 2001, MOL CELL BIOL, V21, P6615, DOI 10.1128/MCB.21.19.6615-6625.2001; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Ohsaki Y, 2000, ONCOL REP, V7, P603; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Ozenne P, 2010, INT J CANCER, V127, P2239, DOI 10.1002/ijc.25511; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Van Den Broeck A, 2008, CLIN CANCER RES, V14, P7237, DOI 10.1158/1078-0432.CCR-08-0869; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Xiao H, 2003, J BIOL CHEM, V278, P11197, DOI 10.1074/jbc.M210816200; Yarden Y, 2001, EUR J CANCER, V37, pS3; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422	40	11	11	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 21	2013	32	8					1050	1058		10.1038/onc.2012.107	http://dx.doi.org/10.1038/onc.2012.107			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22450744	Bronze			2022-12-17	WOS:000316523200012
J	Balogh, K; Asa, SL; Zheng, L; Cassol, C; Cheng, S; Ezzat, S				Balogh, K.; Asa, S. L.; Zheng, L.; Cassol, C.; Cheng, S.; Ezzat, S.			The insulin resistance Grb14 adaptor protein promotes thyroid cancer ret signaling and progression	ONCOGENE			English	Article						Grb14; RET; thyroid cancer; cancer progression	TYROSINE KINASE; EXPRESSION; ENDOCRINE; ASSOCIATION; FAMILY; GROWTH; ROLES	The growth factor receptor-bound protein (Grb) 14 is an adaptor molecule of the Grb7/10/14 family with characteristic Between Plekstrin and SH2 (BPS) domains serving to avidly bind tyrosine kinases. Grb14 inhibits insulin receptor (IR) catalytic activity through interaction with the BPS domain and impedes peptide substrate binding. Members of this Grb family have also been shown to interact with other kinases through their SH2 domain. Here we examined the functional role of Grb14 in thyroid cancer using loss- and gain-of-function approaches. Stable knockdown of Grb14 in thyroid cancer cells facilitated IR signaling. In contrast, RET phosphorylation was diminished in concert with reduced activation of Akt and signal transducer and activator of transcription 3 (STAT3). Loss of Grb14 also resulted in diminished cell proliferation and invasion both in vitro and in mouse flank xenografts. In complementary studies, forced expression of Grb14 interrupted IR signaling but facilitated RET activation, STAT3 and Akt phosphorylation. Consistent with these findings Grb14 overexpression enhanced cell invasion and resulted in striking metastases in an orthotopic thyroid cancer mouse xenograft model. Primary human thyroid cancer microarrays revealed a positive correlation between Grb14 expression and invasive behavior. Our findings uncover a new role for Grb14 in finely tuning receptor signaling and modulating thyroid cancer progression. Oncogene (2012) 31, 4012-4021; doi:10.1038/onc.2011.569; published online 12 December 2011	[Balogh, K.; Zheng, L.; Cheng, S.; Ezzat, S.] Univ Hlth Network, Ontario Canc Inst, Dept Med, Toronto, ON M5G 2M9, Canada; [Asa, S. L.; Cassol, C.] Univ Hlth Network, Ontario Canc Inst, Princess Margaret Hosp, Pathol & Endocrine Oncol Site Grp, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Ezzat, S (corresponding author), Univ Hlth Network, Ontario Canc Inst, Dept Med, 610 Univ Ave,8-327, Toronto, ON M5G 2M9, Canada.	shereen.ezzat@utoronto.ca		Cassol, Clarissa/0000-0001-7536-6806; Asa, Sylvia/0000-0001-8418-5054	Canadian Institutes of Health Research (CIHR) [MOP-86493]; Princess Margaret Hospital Foundation; Ontario Ministry of Health and Long Term Care (OMOHLTC)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Princess Margaret Hospital Foundation; Ontario Ministry of Health and Long Term Care (OMOHLTC)(Ministry of Health and Long-Term Care, Ontario)	We thank Kelvin So for his technical assistance. This work was supported by the Canadian Institutes of Health Research (CIHR)(Grant MOP-86493), the Princess Margaret Hospital Foundation and the Ontario Ministry of Health and Long Term Care (OMOHLTC).	Asa SL, 2001, MODERN PATHOL, V14, P246, DOI 10.1038/modpathol.3880293; AVANTAGGIATO V, 1994, CELL GROWTH DIFFER, V5, P305; Bai T, 2008, CARCINOGENESIS, V29, P473, DOI 10.1093/carcin/bgm221; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Briese J, 2010, ANTICANCER RES, V30, P1681; Buckwalter TLF, 2002, ONCOGENE, V21, P8166, DOI 10.1038/sj.onc.1205938; Cheng S, 2011, CLIN CANCER RES, V17, P2385, DOI 10.1158/1078-0432.CCR-10-2837; Cheng S, 2009, ENDOCR-RELAT CANCER, V16, P455, DOI 10.1677/ERC-09-0002; Cooney GJ, 2004, EMBO J, V23, P582, DOI 10.1038/sj.emboj.7600082; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; de Groot JWB, 2006, ENDOCR REV, V27, P535, DOI 10.1210/er.2006-0017; Durbec P, 1996, NATURE, V381, P789, DOI 10.1038/381789a0; Engelmann D, 2009, ENDOCR-RELAT CANCER, V16, P211, DOI 10.1677/ERC-08-0158; Ezzat S, 2005, J CLIN INVEST, V115, P1021, DOI 10.1172/JCI22486; Ezzat S, 2002, J CLIN INVEST, V109, P69, DOI 10.1172/JCI200214036; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Hwang JH, 2003, MOL ENDOCRINOL, V17, P1155, DOI 10.1210/me.2002-0401; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kondo T, 2006, NAT REV CANCER, V6, P292, DOI 10.1038/nrc1836; Liu W, 2007, ONCOGENE, V26, P2747, DOI 10.1038/sj.onc.1210077; Marchini S, 2008, CLIN CANCER RES, V14, P7850, DOI 10.1158/1078-0432.CCR-08-0523; MARGOLIS B, 1994, PROG BIOPHYS MOL BIO, V62, P223, DOI 10.1016/0079-6107(94)90013-2; Nouaille S, 2006, EMBO REP, V7, P512, DOI 10.1038/sj.embor.7400668; O-Sullivan I, 2008, CANCER RES, V68, P2463, DOI 10.1158/0008-5472.CAN-07-5685; Pandey A, 1996, J BIOL CHEM, V271, P10607, DOI 10.1074/jbc.271.18.10607; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Reilly JF, 2000, J BIOL CHEM, V275, P7771, DOI 10.1074/jbc.275.11.7771; Saji M, 2010, MOL CELL ENDOCRINOL, V321, P20, DOI 10.1016/j.mce.2009.10.016; Wang YJ, 2010, CLIN CANCER RES, V16, P2529, DOI 10.1158/1078-0432.CCR-10-0018; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	30	11	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP	2012	31	36					4012	4021		10.1038/onc.2011.569	http://dx.doi.org/10.1038/onc.2011.569			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22158039	Bronze, Green Accepted			2022-12-17	WOS:000308688800002
J	Martin, L; Rainey, M; Santocanale, C; Gardner, LB				Martin, L.; Rainey, M.; Santocanale, C.; Gardner, L. B.			Hypoxic activation of ATR and the suppression of the initiation of DNA replication through cdc6 degradation	ONCOGENE			English	Article						hypoxia; ATR; cdc6; DNA replication; APC/C-Cdh1	MINICHROMOSOME MAINTENANCE PROTEINS; INHIBITS REPLICON INITIATION; CELL-CYCLE; S-PHASE; PREREPLICATION COMPLEXES; CDC25A PHOSPHATASE; DAMAGE RESPONSE; INDUCED ARREST; CHECKPOINT; PHOSPHORYLATION	Many severely hypoxic cells fail to initiate DNA replication, but the mechanism underlying this observation is unknown. Specifically, although the ataxia-telangiectasia-rad3 related (ATR) kinase has been shown to be activated in hypoxic cells, several studies have not been able to document down-stream consequences of ATR activation in these cells. By clearly defining the DNA replication initiation checkpoint in hypoxic cells, we now demonstrate that ATR is responsible for activating this checkpoint. We show that the hypoxic activation of ATR leads to the phosphorylation-dependent degradation of the cdc25a phosphatase. Downregulation of cdc25a protein by ATR in hypoxic cells decreases CDK2 phosphorylation and activity, which results in the degradation of cdc6 by APC/C-Cdh1. These events do not occur in hypoxic cells when ATR is depleted, and the initiation of DNA replication is maintained. We therefore present a novel mechanism of cdc6 regulation in which ATR can have a central role in inhibiting the initiation of DNA replication by the regulation of cdc6 by APC/C-Cdh1. This model provides insight into the biology and therapy of hypoxic tumors. Oncogene (2012) 31, 4076-4084; doi: 10.1038/onc.2011.585; published online 19 December 2011	[Gardner, L. B.] NYU, Sch Med, NYU Canc Inst, Div Hematol & Med Oncol,Dept Pharmacol, New York, NY 10016 USA; [Martin, L.; Gardner, L. B.] NYU, Sch Med, Dept Med, New York, NY 10016 USA; [Rainey, M.; Santocanale, C.] NUI Galway, Ctr Chromosome Biol, Galway, Ireland	New York University; New York University; Ollscoil na Gaillimhe-University of Galway	Gardner, LB (corresponding author), NYU, Sch Med, NYU Canc Inst, Div Hematol & Med Oncol,Dept Pharmacol, 550 1st Ave, New York, NY 10016 USA.	Lawrence.gardner@nyumc.org		Gardner, Lawrence/0000-0003-0191-0172; Rainey, Michael/0000-0001-9777-873X; Santocanale, Corrado/0000-0003-1337-5656	Feldstein Foundation;  [DK08164]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007151] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081641] Funding Source: NIH RePORTER	Feldstein Foundation; ; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We appreciate the kind gifts of reagents from John Dillfey and Stephen Elledge. Luca Busino, Michele Pagano, Vincenzo D'Angiolella provided reagents and helpful advice. This work was supported in part by DK08164 and the Feldstein Foundation. LBG is the Saul J Farber Assistant Professor of Medicine.	Benmaamar R, 2005, CELL CYCLE, V4, P1230, DOI 10.4161/cc.4.9.2048; Borlado LR, 2008, CARCINOGENESIS, V29, P237, DOI 10.1093/carcin/bgm268; Brown EJ, 2000, GENE DEV, V14, P397; Busino L, 2003, NATURE, V426, P87, DOI 10.1038/nature02082; Cook JG, 2002, P NATL ACAD SCI USA, V99, P1347, DOI 10.1073/pnas.032677499; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; Cortez D, 2004, P NATL ACAD SCI USA, V101, P10078, DOI 10.1073/pnas.0403410101; Costanzo V, 2003, MOL CELL, V11, P203, DOI 10.1016/S1097-2765(02)00799-2; de Oliveira PEQ, 2009, CELL CYCLE, V8, P3157; Gardner LB, 2008, CELL CYCLE, V7, P1916, DOI 10.4161/cc.7.13.6203; Gardner LB, 2003, MOL CELL BIOL, V23, P9032, DOI 10.1128/MCB.23.24.9032-9045.2003; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; Green SL, 2001, MOL CELL BIOL, V21, P1196, DOI 10.1128/MCB.21.4.1196-1206.2001; Green SL, 1998, CANCER J SCI AM, V4, P218; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Hall JR, 2007, MOL BIOL CELL, V18, P3340, DOI 10.1091/mbc.E07-02-0173; Hammer S, 2007, CELL CYCLE, V6, P1919, DOI 10.4161/cc.6.15.4515; Hammond EM, 2004, DNA REPAIR, V3, P1117, DOI 10.1016/j.dnarep.2004.03.035; Hammond EM, 2004, CANCER RES, V64, P6556, DOI 10.1158/0008-5472.CAN-04-1520; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hateboer G, 1998, MOL CELL BIOL, V18, P6679, DOI 10.1128/MCB.18.11.6679; Heffernan TP, 2007, J BIOL CHEM, V282, P9458, DOI 10.1074/jbc.M611292200; Heffernan TP, 2002, MOL CELL BIOL, V22, P8552, DOI 10.1128/MCB.22.24.8552-8561.2002; Jiang W, 1999, EMBO J, V18, P5703, DOI 10.1093/emboj/18.20.5703; KAUFMANN WK, 1980, BIOCHIM BIOPHYS ACTA, V608, P191, DOI 10.1016/0005-2787(80)90147-1; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Lau E, 2006, EMBO REP, V7, P425, DOI 10.1038/sj.embor.7400624; Machida YJ, 2007, GENE DEV, V21, P184, DOI 10.1101/gad.1495007; Mailand N, 2000, SCIENCE, V288, P1425, DOI 10.1126/science.288.5470.1425; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Martin L, 2010, J BIOL CHEM, V285, P31944, DOI 10.1074/jbc.M110.153148; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Montagnoli A, 2006, J BIOL CHEM, V281, P10281, DOI 10.1074/jbc.M512921200; Olcina M, 2010, CLIN CANCER RES, V16, P5624, DOI 10.1158/1078-0432.CCR-10-0286; Olive PL, 2002, RADIAT RES, V158, P159, DOI 10.1667/0033-7587(2002)158[0159:TROOIS]2.0.CO;2; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Schmaltz C, 1998, MOL CELL BIOL, V18, P2845, DOI 10.1128/MCB.18.5.2845; Sivaprasad U, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-8; Sotillo E, 2009, J BIOL CHEM, V284, P14126, DOI 10.1074/jbc.M900687200; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Vassin VM, 2004, MOL CELL BIOL, V24, P1930, DOI 10.1128/MCB.24.5.1930-1943.2004; VAUPEL P, 1991, CANCER RES, V51, P3316; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	47	11	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2012	31	36					4076	4084		10.1038/onc.2011.585	http://dx.doi.org/10.1038/onc.2011.585			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	004NQ	22179839	Green Accepted			2022-12-17	WOS:000308688800008
J	Sharma, SS; Ma, L; Bagui, TK; Forinash, KD; Pledger, WJ				Sharma, S. S.; Ma, L.; Bagui, T. K.; Forinash, K. D.; Pledger, W. J.			A p27(Kip1) mutant that does not inhibit CDK activity promotes centrosome amplification and micronucleation	ONCOGENE			English	Article						p27(Kip1); cyclin F; micronuclei; centrosome amplification	CYCLIN-DEPENDENT-KINASE; CELL-CYCLE; MITOTIC CATASTROPHE; LACKING P27(KIP1); MICE LACKING; P27; DEGRADATION; PHOSPHORYLATION; TRANSCRIPTION; DUPLICATION	Mitotic catastrophe occurs when cells enter mitosis with damaged DNA or excess centrosomes. Cells overexpressing the centrosome protein CP110 or depleted of cyclin F, which targets CP110 for destruction, have more than two centrosomes and undergo mitotic catastrophe. Our studies show centrosome reduplication and mitotic catastrophe in osteosarcoma cells inducibly expressing a p27(Kip1) mutant (termed p27K) that binds cyclins but not cyclin-dependent kinases (CDKs). p27K inhibited cell proliferation but not CDK activity or cell cycle progression. It did not induce apoptosis; however, cells expressing p27K had more than two centrosomes and, indicative of mitotic catastrophe, irregularly shaped nuclei or multiple micronuclei. p27K interacted with cyclin F in vivo (as did endogenous p27(Kip1)) and displaced cyclin F from CP110. Depletion of CP110 rescued p27K-expressing cells from centrosome reduplication and mitotic catastrophe. Collectively, our data show that p27(Kip1) can perturb mitosis and suggest that it does so by sequestering cyclin F, which prevents its interaction with and the subsequent degradation of CP110, ultimately resulting in centrosome reduplication, mitotic catastrophe and abrogation of cell proliferation. Oncogene (2012) 31, 3989 3998; doi: 10.1038/onc.2011.550; published online 12 December 2011	[Pledger, W. J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Gonzmart Res Lab,Sarcoma Program, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Pledger, WJ (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12902 Magnolia Dr, Tampa, FL 33612 USA.	jack.pledger@moffitt.org			Team Science Grant [09KT-03-23121]; Cortner Couch Chair; Amandalee Weiss Foundation; V Foundation; Bankhead-Coley Post-doctoral Grant [IBD08-34209]; NATIONAL CANCER INSTITUTE [P30CA076292] Funding Source: NIH RePORTER	Team Science Grant; Cortner Couch Chair; Amandalee Weiss Foundation; V Foundation; Bankhead-Coley Post-doctoral Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Sources of Support: Team Science Grant no. 09KT-03-23121, the Cortner Couch Chair, the Amandalee Weiss Foundation and the V Foundation (WJP), and Bankhead-Coley Post-doctoral Grant no. IBD08-34209 (SSS).	Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Bagui TK, 2009, CELL CYCLE, V8, P115, DOI 10.4161/cc.8.1.7527; Bagui TK, 2000, MOL CELL BIOL, V20, P8748, DOI 10.1128/MCB.20.23.8748-8757.2000; Bai C, 1996, CELL, V86, P263, DOI 10.1016/S0092-8674(00)80098-7; BAI C, 1994, EMBO J, V13, P6087, DOI 10.1002/j.1460-2075.1994.tb06955.x; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2006, GENE DEV, V20, P47, DOI 10.1101/gad.1384406; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Caruso R, 2011, ULTRASTRUCT PATHOL, V35, P66, DOI 10.3109/01913123.2010.543753; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chen ZH, 2002, DEV CELL, V3, P339, DOI 10.1016/S1534-5807(02)00258-7; D'Angiolella V, 2010, NATURE, V466, P138, DOI 10.1038/nature09140; Dodson H, 2007, CELL CYCLE, V6, P364, DOI 10.4161/cc.6.3.3834; Duensing A, 2006, ONCOGENE, V25, P2943, DOI 10.1038/sj.onc.1209310; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fukasawa K, 2008, BBA-REV CANCER, V1786, P15, DOI 10.1016/j.bbcan.2008.04.002; Gao H, 2004, P NATL ACAD SCI USA, V101, P17204, DOI 10.1073/pnas.0407693101; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Khattar E, 2010, J BIOL CHEM, V285, P4554, DOI 10.1074/jbc.M109.029280; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Kong M, 2000, EMBO J, V19, P1378, DOI 10.1093/emboj/19.6.1378; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Korzeniewski N, 2010, MOL BIOL CELL, V21, P3942, DOI 10.1091/mbc.E09-12-1049; Larrea MD, 2009, CELL CYCLE, V8, P3455, DOI 10.4161/cc.8.21.9789; Loda M, 1997, NAT MED, V3, P231, DOI 10.1038/nm0297-231; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; Nallamshetty S, 2005, FEBS LETT, V579, P6529, DOI 10.1016/j.febslet.2005.10.028; Nguyen L, 2006, GENE DEV, V20, P1511, DOI 10.1101/gad.377106; Portugal J, 2010, CURR PHARM DESIGN, V16, P69, DOI 10.2174/138161210789941801; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Schmidt TI, 2009, CURR BIOL, V19, P1005, DOI 10.1016/j.cub.2009.05.016; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Singhal S, 2003, CANCER BIOL THER, V2, P291, DOI 10.4161/cbt.2.3.399; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Sugihara E, 2006, CANCER RES, V66, P4020, DOI 10.1158/0008-5472.CAN-05-3250; Tetzlaff MT, 2004, MOL CELL BIOL, V24, P2487, DOI 10.1128/MCB.24.6.2487-2498.2004; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Winston JT, 1999, CURR BIOL, V9, P1180, DOI 10.1016/S0960-9822(00)80021-4; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Wu FY, 2006, CANCER RES, V66, P2162, DOI 10.1158/0008-5472.CAN-05-3304	58	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2012	31	35					3989	3998		10.1038/onc.2011.550	http://dx.doi.org/10.1038/onc.2011.550			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	999VJ	22158041	hybrid, Green Published			2022-12-17	WOS:000308342800007
J	Piccione, EC; Lieu, TJ; Gentile, CF; Williams, TR; Connolly, AJ; Godwin, AK; Koong, AC; Wong, AJ				Piccione, E. C.; Lieu, T. J.; Gentile, C. F.; Williams, T. R.; Connolly, A. J.; Godwin, A. K.; Koong, A. C.; Wong, A. J.			A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors	ONCOGENE			English	Article						EGFR; GRP78; ER stress; unfolded protein response; transcription	UNFOLDED PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM STRESS; GLUCOSE-REGULATED PROTEINS; HUMAN-BRAIN TUMORS; CELL LUNG-CANCER; EGF-RECEPTOR; ER STRESS; NUCLEAR-LOCALIZATION; MALIGNANT GLIOMAS; OXIDATIVE STRESS	The epidermal growth factor receptor (EGFR) is essential to multiple physiological and neoplastic processes via signaling by its tyrosine kinase domain and subsequent activation of transcription factors. EGFR overexpression and alteration, including point mutations and structural variants, contribute to oncogenesis in many tumor types. In this study, we identified an in-frame splice variant of the EGFR called mini-LEEK (mLEEK) that is more broadly expressed than the EGFR and is overexpressed in several cancers. Unlike previously characterized EGFR variants, mLEEK lacks the extracytoplasmic, transmembrane and tyrosine kinase domains. mLEEK localizes in the nucleus and functions as a transcription factor to regulate target genes involved in the cellular response to endoplasmic reticulum (ER) stress, including the master regulator of the unfolded protein response (UPR) pathways, molecular chaperone GRP78/Bip. We demonstrated that mLEEK regulates GRP78 transcription through direct interaction with a cis-regulatory element within the gene promoter. Several UPR pathways were interrogated and mLEEK expression was found to attenuate the induction of all pathways upon ER stress. Conversely, knockdown of mLEEK resulted in caspase-mediated cell death and sensitization to ER stress. These findings indicate that mLEEK levels determine cellular responses to unfavorable conditions that cause ER stress. This information, along with the overexpression of mLEEK in tumors, suggests unique strategies for therapeutic intervention. Furthermore, the identification of mLEEK expands the known mechanisms by which the EGFR gene contributes to oncogenesis and represents the first link between two previously disparate areas in cancer cell biology: EGFR signaling and the UPR.	[Piccione, E. C.; Lieu, T. J.; Gentile, C. F.; Williams, T. R.; Wong, A. J.] Stanford Univ, Sch Med, Dept Neurosurg, Stanford, CA 94305 USA; [Piccione, E. C.; Lieu, T. J.; Gentile, C. F.; Williams, T. R.; Wong, A. J.] Stanford Univ, Sch Med, Canc Biol Program, Stanford, CA 94305 USA; [Connolly, A. J.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Godwin, A. K.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA; [Koong, A. C.] Stanford Univ, Sch Med, Dept Radiat Oncol, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University; University of Kansas; University of Kansas Medical Center; Stanford University	Wong, AJ (corresponding author), Stanford Univ, Sch Med, Dept Neurosurg, 1201 Welch Rd,MSLS P105, Stanford, CA 94305 USA.	ajwong@stanford.edu		Piccione, Emilio/0000-0001-7754-7395; Koong, Albert/0000-0001-9824-1643; Lieu, Tiffany/0000-0001-7430-4064	NIH from NINDS [F31 NS056581, R01 CA69495, R01 CA096539, R01 CA124832]; Ovarian SPORE at FCCC [P50 CA083638]; National Brain Tumor Foundation; California Breast Cancer Program [15IB-0080]; NATIONAL CANCER INSTITUTE [R01CA140323, R01CA124832, P50CA083638, R01CA069495, T32CA009302, R01CA096539] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F31NS056581] Funding Source: NIH RePORTER	NIH from NINDS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Ovarian SPORE at FCCC; National Brain Tumor Foundation; California Breast Cancer Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank R Nitta, G Li, S Mitra, C Del Vecchio and M Holgado-Madruga for comments. We thank K Mori, K Kokame, R Prywes and G Nolan for reagents. This work was supported by the NIH under Ruth L Kirschstein National Research Service Award F31 NS056581 from the NINDS to ECP, the Ovarian SPORE at FCCC (P50 CA083638) to AKG and AJW, NIH Grants R01 CA69495, R01 CA096539 and R01 CA124832, as well as a research grant from the National Brain Tumor Foundation and Grant 15IB-0080 from the California Breast Cancer Program to AJW.	Allen TD, 2000, J CELL SCI, V113, P1651; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Cai Y, 2007, NAT STRUCT MOL BIOL, V14, P872, DOI 10.1038/nsmb1276; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; CHANG SC, 1989, MOL CELL BIOL, V9, P2153, DOI 10.1128/MCB.9.5.2153; Demeter J, 2007, NUCLEIC ACIDS RES, V35, pD766, DOI 10.1093/nar/gkl1019; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309; Eley G, 1998, GENE CHROMOSOME CANC, V23, P248, DOI 10.1002/(SICI)1098-2264(199811)23:3<248::AID-GCC7>3.0.CO;2-1; Feldman DE, 2005, MOL CANCER RES, V3, P597, DOI 10.1158/1541-7786.MCR-05-0221; Fu Y, 2006, CANCER BIOL THER, V5, P741, DOI 10.4161/cbt.5.7.2970; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; HALEY J, 1987, ONCOGENE RES, V1, P375; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Holgado-Madruga M, 2003, MOL CELL BIOL, V23, P4471, DOI 10.1128/MCB.23.13.4471-4484.2003; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Kandul NP, 2009, BMC GENET, V10, DOI 10.1186/1471-2156-10-67; Kim J, 2005, CANCER RES, V65, P8242, DOI 10.1158/0008-5472.CAN-05-0942; Kokame K, 2001, J BIOL CHEM, V276, P9199, DOI 10.1074/jbc.M010486200; Koumenis C, 2007, METHOD ENZYMOL, V435, P275, DOI 10.1016/S0076-6879(07)35014-3; Kudo T, 2008, CELL DEATH DIFFER, V15, P364, DOI 10.1038/sj.cdd.4402276; Lawson B, 1998, J CELL PHYSIOL, V174, P170, DOI 10.1002/(SICI)1097-4652(199802)174:2<170::AID-JCP4>3.3.CO;2-A; Lee AH, 2003, MOL CELL BIOL, V23, P7448, DOI 10.1128/MCB.23.21.7448-7459.2003; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2005, METHODS, V35, P373, DOI 10.1016/j.ymeth.2004.10.010; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; LIBERMANN TA, 1984, CANCER RES, V44, P753; Lin JH, 2007, SCIENCE, V318, P944, DOI 10.1126/science.1146361; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; LIU ES, 1991, NUCLEIC ACIDS RES, V19, P5425, DOI 10.1093/nar/19.19.5425; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lo HW, 2005, CANCER RES, V65, P338; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; MALDEN LT, 1988, CANCER RES, V48, P2711; Malhotra JD, 2007, SEMIN CELL DEV BIOL, V18, P716, DOI 10.1016/j.semcdb.2007.09.003; Moenner M, 2007, CANCER RES, V67, P10631, DOI 10.1158/0008-5472.CAN-07-1705; Moscatello DK, 1998, J BIOL CHEM, V273, P200, DOI 10.1074/jbc.273.1.200; Moscatello DK, 1996, ONCOGENE, V13, P85; Mu TW, 2008, CELL, V134, P769, DOI 10.1016/j.cell.2008.06.037; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Pedersen MW, 2005, J CELL BIOCHEM, V96, P412, DOI 10.1002/jcb.20554; Pedersen MW, 2001, ANN ONCOL, V12, P745, DOI 10.1023/A:1011177318162; Pedersen MW, 2001, BRIT J CANCER, V85, P1211, DOI 10.1054/bjoc.2001.2053; Pines G, 2010, ONCOGENE, V29, P5850, DOI 10.1038/onc.2010.313; Psyrri A, 2005, CLIN CANCER RES, V11, P5856, DOI 10.1158/1078-0432.CCR-05-0420; Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Roy M, 2008, RNA, V14, P2261, DOI 10.1261/rna.1024908; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Suzuki T, 2007, ARCH BIOCHEM BIOPHYS, V468, P1, DOI 10.1016/j.abb.2007.09.004; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Wang YN, 2010, J BIOL CHEM, V285, P38720, DOI 10.1074/jbc.M110.158659; Weihua Z, 2008, CANCER CELL, V13, P385, DOI 10.1016/j.ccr.2008.03.015; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; WONG AJ, 1987, P NATL ACAD SCI USA, V84, P6899, DOI 10.1073/pnas.84.19.6899; Wouters BG, 2008, NAT REV CANCER, V8, P851, DOI 10.1038/nrc2501; Xie W, 1997, ANTICANCER RES, V17, P2627; YAMAZAKI H, 1988, MOL CELL BIOL, V8, P1816, DOI 10.1128/MCB.8.4.1816; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	68	11	11	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN	2012	31	24					2953	2967		10.1038/onc.2011.465	http://dx.doi.org/10.1038/onc.2011.465			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	960LD	21986942	Green Accepted			2022-12-17	WOS:000305388400005
J	Peric, D; Chvalova, K; Rousselet, G				Peric, D.; Chvalova, K.; Rousselet, G.			Identification of microprocessor-dependent cancer cells allows screening for growth-sustaining micro-RNAs	ONCOGENE			English	Article						microprocessor; growth arrest; drosha; DGCR8; PTEN; micro-RNA	TUMOR-SUPPRESSOR; STABLE EXPRESSION; BREAST-CANCER; IN-VIVO; COMPLEX; DGCR8; GENE; TRANSFORMATION; BIOGENESIS; LET-7	Micro-RNAs are deregulated in cancer cells, and some are either tumor suppressive or oncogenic. In addition, a link has been established between decreased expression of micro-RNAs and transformation, and several proteins of the RNA interference pathway have been shown to be haploinsufficient tumor suppressors. Oncogenic microRNAs (oncomiRs) could represent new therapeutic targets, and their identification is therefore crucial. However, structural and functional redundancy between micro-RNAs hampers approaches relying on individual micro-RNA inhibition. We reasoned that in cancer cells that depend on oncomiRs, impairing the micro-RNA pathway could lead to growth perturbation rather than increased tumorigenesis. Identifying such cells could allow functional analyses of individual micro-RNAs by complementation of the phenotypes observed upon global micro-RNA inhibition. Therefore, we developed episomal vectors coding for small hairpin RNAs targeting either Drosha or DGCR8, the two components of the microprocessor, the nuclear micro-RNA maturation complex. We identified cancer cell lines in which both vectors induced colony growth arrest. We then screened for individual micro-RNAs complementing this growth arrest, and identified miR-19a, miR-19b, miR-20a and miR-27b as major growth-sustaining micro-RNAs. However, the effect of miR-19a and miR-19b was only transient. In addition, embryonic stem cell-derived micro-RNAs with miR-20a seeds were much less efficient than miR-20a in sustaining cancer cell growth, a finding that contrasted with results obtained in stem cells. Finally, we showed that the tumor suppressor phosphatase and tensin homologue deleted on chromosome 10, a shared target of miR-19 and miR-20, was functionally involved in the growth arrest induced by microprocessor inhibition. We conclude that our approach allowed to identify microprocessor-dependent cancer cells, which could be used to screen for growth-sustaining micro-RNAs. This complementation screen unveiled functional differences between homologous micro-RNAs. Phenotypic characterization of the complemented cells will allow precise functional studies of these micro-RNAs. Oncogene (2012) 31, 2039-2048; doi:10.1038/onc.2011.391; published online 12 September 2011	[Peric, D.; Chvalova, K.; Rousselet, G.] CEA, DSV, IRCM, LGR, F-92265 Fontenay Aux Roses, France	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Rousselet, G (corresponding author), CEA, DSV, IRCM, LGR, Bat 5 P 219,18 Route Panorama, F-92265 Fontenay Aux Roses, France.	germain.rousselet@cea.fr	Rousselet, Germain/E-3525-2018	Rousselet, Germain/0000-0002-1710-1639	Angulo laboratory; Electricite De France [V3-104]	Angulo laboratory; Electricite De France	We thank V Neuville for assistance with the in vivo experiments, B Vogelstein and B Bugler for the HCT116 cell lines, J Lebeau for the A549, T-47D, ZR751, MDA-MB-157 and MDA-MB-231 cell lines, and DSF Biard for the pEBP and pEBH vectors and advice for their use. We also thank M Mangeney, C Pique and all members of the Angulo laboratory for helpful discussions and support. This work was supported by the Electricite De France grant no. V3-104 to G.R.	Alimonti A, 2010, NAT GENET, V42, P454, DOI 10.1038/ng.556; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Biard DSF, 2007, NUCLEIC ACIDS RES, V35, P3535, DOI 10.1093/nar/gkm195; Biard DSF, 2005, MOL CANCER RES, V3, P519, DOI 10.1158/1541-7786.MCR-05-0044; Boehler C, 2011, P NATL ACAD SCI USA, V108, P2783, DOI 10.1073/pnas.1016574108; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Chong MMW, 2008, J EXP MED, V205, P2449, DOI [10.1084/jem.20071219090508c, 10.1084/jem.20081219]; Cole KA, 2008, MOL CANCER RES, V6, P735, DOI 10.1158/1541-7786.MCR-07-2102; Colmont C, 2001, AM J PHYSIOL-CELL PH, V280, pC614, DOI 10.1152/ajpcell.2001.280.3.C614; Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Desaint S, 2004, J BIOL CHEM, V279, P31157, DOI 10.1074/jbc.M401888200; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Esquela-Kerscher A, 2008, CELL CYCLE, V7, P759, DOI 10.4161/cc.7.6.5834; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Han J, 2009, CELL, V136, P75, DOI 10.1016/j.cell.2008.10.053; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Hand NJ, 2009, HEPATOLOGY, V49, P618, DOI 10.1002/hep.22656; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Ivey KN, 2010, CELL STEM CELL, V7, P36, DOI 10.1016/j.stem.2010.06.012; Kadener S, 2009, RNA, V15, P537, DOI 10.1261/rna.1319309; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kuchenbauer F, 2011, BLOOD, DOI 10.1182; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Landthaler M, 2004, CURR BIOL, V14, P2162, DOI 10.1016/j.cub.2004.11.001; Le May N, 2010, MOL CELL, V38, P54, DOI 10.1016/j.molcel.2010.03.004; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Mayr C, 2007, SCIENCE, V315, P1576, DOI 10.1126/science.1137999; Medina PP, 2010, NATURE, V467, P86, DOI 10.1038/nature09284; Melo SA, 2010, CANCER CELL, V18, P303, DOI 10.1016/j.ccr.2010.09.007; Melo SA, 2009, NAT GENET, V41, P365, DOI 10.1038/ng.317; Miska EA, 2007, PLOS GENET, V3, P2395, DOI 10.1371/journal.pgen.0030215; Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Qi JL, 2009, CELL CYCLE, V8, P3729, DOI 10.4161/cc.8.22.10033; RUNNEBAUM IB, 1991, P NATL ACAD SCI USA, V88, P10657, DOI 10.1073/pnas.88.23.10657; Shenoy A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006971; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Triboulet R, 2009, RNA, V15, P1005, DOI 10.1261/rna.1591709; Wang YM, 2007, NAT GENET, V39, P380, DOI 10.1038/ng1969; Wang Y, 2008, NAT GENET, V40, P1478, DOI 10.1038/ng.250; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Weng LP, 1999, CANCER RES, V59, P5808	56	11	11	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2012	31	16					2039	2048		10.1038/onc.2011.391	http://dx.doi.org/10.1038/onc.2011.391			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	928TP	21909134				2022-12-17	WOS:000303008600005
J	Lee, KM; Choi, WI; Koh, DI; Kim, YJ; Jeon, BN; Yoon, JH; Lee, CE; Kim, SH; Oh, J; Hur, MW				Lee, K. M.; Choi, W. I.; Koh, D. I.; Kim, Y. J.; Jeon, B. N.; Yoon, J. H.; Lee, C. E.; Kim, S. H.; Oh, J.; Hur, M. W.			The proto-oncoprotein KR-POK represses transcriptional activation of CDKN1A by MIZ-1 through competitive binding	ONCOGENE			English	Article						MIZ-1; Kr-pok; CDKN1A; p21; competition; cell proliferation	ACUTE PROMYELOCYTIC LEUKEMIA; INTERACTION MOTIF; P53 PATHWAY; STEM-CELLS; GENE; DOMAIN; P21CIP1; BCL-6; SP1; P21	The BTB/POZ family of proteins has been implicated in multiple biological processes, including tumourigenesis, DNA damage responses and cell cycle progression and development. MIZ-1 (Myc-interacting zinc-finger protein 1) is known to activate transcription of CDKN1A. We recently found that a kidney cancer-related POK transcription factor, KR-POK, is highly expressed in kidney, brain and bone marrow cancer tissues and is a potential proto-oncoprotein. Mouse Kr-pok represses transcription of the CDKN1A by acting on the proximal promoter. The BiFC/FRET assay, co-immunoprecipitation and glutathione S-transferase-fusion protein pull-down assay indicate that MIZ-1 and Kr-pok interact via their POZ domains. Oligoucleotide pull-down assays and chromatin immunoprecipitation assays revealed that MIZ-1 binds to the proximal GC-box#3 (bp, -55 to -63) and the MIZ-1-binding elements, MRE-A (bp, -90 to -64) and MRE-B (bp, -27 to -17). Interestingly, MIZ-1 also binds to the distal p53-binding elements. Kr-pok binds to the proximal GC-box#1 (bp, -95 to -100) and #3 (bp, -55 to -63) relatively strongly. It also shows weak binding to the MREs and the distal p53-binding elements. Kr-pok competes with MIZ-1 in binding to these elements and represses transcription by inhibiting MIZ-1/p300 recruitment, which decreases the acetylation of histones H3 and H4. Our data indicate that Kr-pok stimulates cell proliferation by interfering with the function of MIZ-1 in CDKN1A gene transcription using a mechanism that is radically different from other MIZ-1-interacting proteins, such as B-cell lymphoma 6, c-Myc and Gfi-1. Oncogene (2012) 31, 1442-1458; doi:10.1038/onc.2011.331; published online 1 August 2011	[Lee, K. M.; Choi, W. I.; Koh, D. I.; Kim, Y. J.; Jeon, B. N.; Yoon, J. H.; Hur, M. W.] Yonsei Univ, Brain Korea Project Med Sci 21, Dept Biochem & Mol Biol, Severance Biomed Res Inst,Sch Med, Seoul 120752, South Korea; [Lee, C. E.; Kim, S. H.; Oh, J.] Sungkyunkwan Univ, Dept Biol Sci, Suwon, South Korea	Yonsei University; Sungkyunkwan University (SKKU)	Hur, MW (corresponding author), Yonsei Univ, Brain Korea Project Med Sci 21, Dept Biochem & Mol Biol, Severance Biomed Res Inst,Sch Med, 134 ShinChon Dong, Seoul 120752, South Korea.	mwhur2@yuhs.ac		Hur, Man-Wook/0000-0002-3416-1334; CHOI, WONIL/0000-0002-4837-0436	Basic Science Research Grant [314-2008-1-E00030]; MRC from the National Research Foundation of Korea [R13-2002-054-05002-0]; Yonsei University School of Medicine	Basic Science Research Grant; MRC from the National Research Foundation of Korea(National Research Foundation of Korea); Yonsei University School of Medicine	This work was mainly funded by a Basic Science Research Grant (314-2008-1-E00030 to M-W Hur and C-E Lee), and MRC (R13-2002-054-05002-0) from the National Research Foundation of Korea, and also by a Faculty Research Grant from Yonsei University School of Medicine.	ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Aravind L, 1999, J MOL BIOL, V285, P1353, DOI 10.1006/jmbi.1998.2394; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; Basu S, 2009, P NATL ACAD SCI USA, V106, P1433, DOI 10.1073/pnas.0804863106; Chang CC, 1996, P NATL ACAD SCI USA, V93, P6947, DOI 10.1073/pnas.93.14.6947; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Choi WI, 2008, J BIOL CHEM, V283, P29341, DOI 10.1074/jbc.M802477200; Choi WI, 2009, J BIOL CHEM, V284, P12633, DOI 10.1074/jbc.M809794200; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARKAS G, 1994, NATURE, V371, P806, DOI 10.1038/371806a0; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gartel AL, 2009, BIOFACTORS, V35, P161, DOI 10.1002/biof.26; He X, 2010, ANNU REV IMMUNOL, V28, P295, DOI 10.1146/annurev.immunol.25.022106.141715; Huynh KD, 2000, GENE DEV, V14, P1810; Issa JPJ, 1997, CANCER RES, V57, P1678; Jeon BN, 2009, J BIOL CHEM, V284, P17935, DOI 10.1074/jbc.M809559200; Jeon BN, 2008, J BIOL CHEM, V283, P33199, DOI 10.1074/jbc.M802935200; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kim MH, 2007, CELL PHYSIOL BIOCHEM, V20, P703, DOI 10.1159/000110431; Koh DI, 2009, J BIOL CHEM, V284, P19856, DOI 10.1074/jbc.M109.025817; KOONIN EV, 1992, TRENDS BIOCHEM SCI, V17, P213, DOI 10.1016/0968-0004(92)90379-N; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu Q, 2010, ONCOGENE, V29, P2843, DOI 10.1038/onc.2010.48; Maeda T, 2005, NATURE, V433, P278, DOI 10.1038/nature03203; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ogryzko VV, 1997, MOL CELL BIOL, V17, P4877, DOI 10.1128/MCB.17.8.4877; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; Phan RT, 2005, NAT IMMUNOL, V6, P1054, DOI 10.1038/ni1245; Piluso D, 2002, J BIOL CHEM, V277, P46799, DOI 10.1074/jbc.M206226200; Seoane J, 2002, NATURE, V419, P729, DOI 10.1038/nature01119; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Weber A, 2008, EMBO J, V27, P1563, DOI 10.1038/emboj.2008.85; Willenbring H, 2008, CANCER CELL, V14, P59, DOI 10.1016/j.ccr.2008.05.004; Yamochi T, 1999, ONCOGENE, V18, P487, DOI 10.1038/sj.onc.1202334; Zhan FH, 2007, BLOOD, V109, P1692, DOI 10.1182/blood-2006-07-037077	44	11	11	1	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR	2012	31	11					1442	1458		10.1038/onc.2011.331	http://dx.doi.org/10.1038/onc.2011.331			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	912FL	21804610				2022-12-17	WOS:000301780000011
J	Li, Z; Li, W; Song, L; Zhu, W				Li, Z.; Li, W.; Song, L.; Zhu, W.			Cilia, adenomatous polyposis coli and associated diseases	ONCOGENE			English	Review						cilia; adenomatous polyposis coli; familial adenomatous polyposis; mutation	TUMOR-SUPPRESSOR APC; BETA-CATENIN; SOMATIC MUTATIONS; GENE; PROTEIN; IDENTIFICATION; DROSOPHILA; DELETION; COMPLEX; PHENOTYPE	Cilium is a conservative cell organelle, found in many types of cell surfaces. Cilia are tail-like prominence protruding out of the cell surface, capable of locomotion and acting as the cell's signal transduction sensory organs with their complex structures and ingenious function. Studies have shown that ciliary pathological changes and defects are related to the development of many diseases, including renal cysts, infertility, organ reversal, obesity and so on. The inactivation and mutation of cilia-related proteins can cause tumors, such as neoplasms, intestinal cancer, myeloma, rhabdomyosarcoma and adenocarcinoma. Adenomatous polyposis coli (APC) is a kind of multifunctional protein encoded by the APC gene that participates in many vital activities of organisms. The mutation of APC can lead to familial adenomatous polyposis, and also has a role in the development of human tumors, such as gastric cancer, esophageal cancer and breast carcinoma. Recent studies indicate that the abnormal mutation of APC may lead to some diseases caused by abnormal growth of cilia. Herein, the development of studies on cilia, APC and associated diseases are summarized in brief. Oncogene (2012) 31, 1475-1483; doi:10.1038/onc.2011.351; published online 22 August 2011	[Li, Z.; Li, W.; Song, L.; Zhu, W.] Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Educ Minist, Taiyuan 030006, Shanxi, Peoples R China	Shanxi University	Li, Z (corresponding author), Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Educ Minist, 92 Wucheng, Taiyuan 030006, Shanxi, Peoples R China.	lzy@sxu.edu.cn			National Natural Science Foundation of China [31040018]; Shanxi scholarship council of China	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanxi scholarship council of China	This project was supported by grants of National Natural Science Foundation of China (No. 31040018), and the research project was supported by Shanxi scholarship council of China (2010-2012). We wish to thank Dr Enmin Zou of the Department of Biological Sciences of Nicolls State University, USA, for improving the readability of the manuscript.	AFZELIUS BA, 1985, CRC CR REV BIOCH MOL, V19, P63, DOI 10.3109/10409238509086788; Ahmed Y, 1998, CELL, V93, P1171, DOI 10.1016/S0092-8674(00)81461-0; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Banizs B, 2005, DEVELOPMENT, V132, P5329, DOI 10.1242/dev.02153; Benzing T, 2007, J AM SOC NEPHROL, V18, P1389, DOI 10.1681/ASN.2006121355; Beroud C, 1996, NUCLEIC ACIDS RES, V24, P121, DOI 10.1093/nar/24.1.121; Bertario L, 2003, J CLIN ONCOL, V21, P1698, DOI 10.1200/JCO.2003.09.118; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Bisgrove BW, 2006, DEVELOPMENT, V133, P4131, DOI 10.1242/dev.02595; Brault V, 2001, DEVELOPMENT, V128, P1253; CASPARI R, 1995, HUM MOL GENET, V4, P337, DOI 10.1093/hmg/4.3.337; Chodhari R, 2004, Paediatr Respir Rev, V5, P69, DOI 10.1016/j.prrv.2003.09.005; Cobas M, 2004, J EXP MED, V199, P221, DOI 10.1084/jem.20031615; D'Angelo Anna, 2009, Pathogenetics, V2, P3, DOI 10.1186/1755-8417-2-3; Davenport JR, 2005, AM J PHYSIOL-RENAL, V289, pF1159, DOI 10.1152/ajprenal.00118.2005; Debinski HS, 1996, GASTROENTEROLOGY, V110, P1028, DOI 10.1053/gast.1996.v110.pm8612989; Eley L, 2005, CURR OPIN GENET DEV, V15, P308, DOI 10.1016/j.gde.2005.04.008; Escudier E, 2009, PAEDIATR RESPIR REV, V10, P51, DOI 10.1016/j.prrv.2009.02.001; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fodde R, 2002, EUR J CANCER, V38, P867, DOI 10.1016/S0959-8049(02)00040-0; Freese JL, 2010, NEUROBIOL DIS, V38, P148, DOI 10.1016/j.nbd.2009.09.003; Galiatsatos P, 2006, AM J GASTROENTEROL, V101, P385, DOI 10.1111/j.1572-0241.2006.00375.x; Garcia EBG, 2009, LANCET ONCOL, V10, P727, DOI 10.1016/S1470-2045(09)70167-6; Gerdes JM, 2007, NAT GENET, V39, P1350, DOI 10.1038/ng.2007.12; Giardiello FM, 1997, GUT, V40, P521, DOI 10.1136/gut.40.4.521; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hemmer PH, 2004, ARCH SURG-CHICAGO, V139, P223, DOI 10.1001/archsurg.139.2.223; HERRERA L, 1986, AM J MED GENET, V25, P473, DOI 10.1002/ajmg.1320250309; Hong DH, 2003, INVEST OPHTH VIS SCI, V44, P2413, DOI 10.1167/iovs.02-1206; Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169; Ishidate T, 2000, ONCOGENE, V19, P365, DOI 10.1038/sj.onc.1203309; Jimbo T, 2002, NAT CELL BIOL, V4, P323, DOI 10.1038/ncb779; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Klysik M, 2008, PATHOL RES PRACT, V204, P77, DOI 10.1016/j.prp.2007.10.013; Kulaga HM, 2004, NAT GENET, V36, P994, DOI 10.1038/ng1418; Lancaster MA, 2009, CURR OPIN GENET DEV, V19, P220, DOI 10.1016/j.gde.2009.04.008; Laurence J.Z., 1866, OPHTHALMIC REV, V2, P32; Mans DA, 2008, BBA-REV CANCER, V1786, P114, DOI 10.1016/j.bbcan.2008.02.002; Matsumine A, 1996, SCIENCE, V272, P1020, DOI 10.1126/science.272.5264.1020; Michaud EJ, 2006, CANCER RES, V66, P6463, DOI 10.1158/0008-5472.CAN-06-0462; Mimori-Kiyosue Y, 2000, J CELL BIOL, V148, P505, DOI 10.1083/jcb.148.3.505; Miyaki M, 2008, INT J CANCER, V122, P2491, DOI 10.1002/ijc.23390; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Mykytyn K, 2003, AM J HUM GENET, V72, P429, DOI 10.1086/346172; Narayan Satya, 2003, Mol Cancer, V2, P41, DOI 10.1186/1476-4598-2-41; Noone PG, 2004, AM J RESP CRIT CARE, V169, P459, DOI 10.1164/rccm.200303-365OC; Ou GS, 2005, NATURE, V436, P583, DOI 10.1038/nature03818; Pan JM, 2005, LAB INVEST, V85, P452, DOI 10.1038/labinvest.3700253; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; Robert A, 2007, J CELL SCI, V120, P628, DOI 10.1242/jcs.03366; Rubinfeld B, 1997, CANCER RES, V57, P4624; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Rubinfeld B, 1993, SCIENCE, V289, P1194; Saadi-Kheddouci S, 2001, ONCOGENE, V20, P5972, DOI 10.1038/sj.onc.1204825; Schneider L, 2005, CURR BIOL, V15, P1861, DOI 10.1016/j.cub.2005.09.012; Signoron S, 2007, CLIN CANCER RES, V13, P5034, DOI 10.1158/1078-0432.CCR-07-0336; Sloboda RD, 2005, J CELL BIOCHEM, V94, P266, DOI 10.1002/jcb.20323; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Tanaka Y, 2005, NATURE, V435, P172, DOI 10.1038/nature03494; Thliveris A, 1996, GENOMICS, V34, P268, DOI 10.1006/geno.1996.0285; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Wilson PD, 2004, NEW ENGL J MED, V350, P151, DOI 10.1056/NEJMra022161	68	11	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	12					1475	1483		10.1038/onc.2011.351	http://dx.doi.org/10.1038/onc.2011.351			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	916VT	21860414				2022-12-17	WOS:000302132000001
J	Ma, W; Lin, Y; Xuan, W; Iversen, PL; Smith, LJ; Benchimol, S				Ma, W.; Lin, Y.; Xuan, W.; Iversen, P. L.; Smith, L. J.; Benchimol, S.			Inhibition of p53 expression by peptide-conjugated phosphorodiamidate morpholino oligomers sensitizes human cancer cells to chemotherapeutic drugs	ONCOGENE			English	Article						p53 tumor suppressor protein; morpholino antisense oligomers; chemosensitivity	LI-FRAUMENI-SYNDROME; WILD-TYPE P53; MUTANT P53; MONOCLONAL-ANTIBODIES; PENETRATING PEPTIDES; ANTICANCER AGENTS; BREAST-CANCER; APOPTOSIS; ISOFORMS; DOMAIN	The p53 tumor suppressor gene encodes a transcription factor that is commonly mutated in cancer. Tumors arise when premalignant cells are unable to undergo p53-dependent apoptosis, cell cycle arrest or DNA repair. The p53-signaling pathway affects not only tumor development, but also the response of tumors to chemotherapeutic drugs. In this study, we use cell penetrating peptide conjugates of phosphorodiamidate morpholino oligomers (PPMOs) to inhibit p53 expression. We examine the functional properties of endogenous p53 isoforms that are produced upon PPMO-mediated inhibition of p53 translation and splicing, and report that loss of N-terminal or C-terminal sequences interferes with the transcriptional activity of p53. Importantly, we report that PPMO-mediated inhibition of p53 expression sensitizes human cancer cells with wild-type p53 to chemotherapeutic drugs. Oncogene (2012) 31, 1024-1033; doi:10.1038/onc.2011.300; published online 18 July 2011	[Ma, W.; Lin, Y.; Xuan, W.; Benchimol, S.] York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada; [Iversen, P. L.] AVI BioPharma Inc, Corvallis, OR USA; [Smith, L. J.] Eleos Inc, Omaha, NE USA	York University - Canada	Benchimol, S (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.	benchimo@yorku.ca	Iversen, Patrick L/D-8854-2019; Iversen, Patrick L./L-5454-2019	Iversen, Patrick L/0000-0003-0106-9790; Iversen, Patrick L./0000-0003-0106-9790; Benchimol, Samuel/0000-0003-3433-890X	Eleos Inc; Canada Research Chair	Eleos Inc; Canada Research Chair(Natural Resources CanadaCanadian Forest ServiceCanada Research Chairs)	This work was supported by a grant from Eleos Inc to SB. SB is supported by a Canada Research Chair.	Abes R, 2008, J PEPT SCI, V14, P455, DOI 10.1002/psc.979; Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; Bertheau P, 2008, PATHOBIOLOGY, V75, P132, DOI 10.1159/000123851; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Fei PW, 2002, CANCER RES, V62, P7316; Flaman JM, 1996, ONCOGENE, V12, P813; Fujita K, 2009, NAT CELL BIOL, V11, P1135, DOI 10.1038/ncb1928; Ghosh A, 2004, MOL CELL BIOL, V24, P7987, DOI 10.1128/MCB.24.18.7987-7997.2004; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; Harms KL, 2006, CELL DEATH DIFFER, V13, P890, DOI 10.1038/sj.cdd.4401904; HORIKAWA I, 1995, HUM MOL GENET, V4, P313, DOI 10.1093/hmg/4.2.313; Iversen PL, 2001, CURR OPIN MOL THER, V3, P235; Kim E, 2009, BIOCHEM PHARMACOL, V77, P11, DOI 10.1016/j.bcp.2008.08.030; Koonin EV, 2005, CELL CYCLE, V4, P686, DOI 10.4161/cc.4.5.1691; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lim LY, 2009, BRIT J CANCER, V101, P1606, DOI 10.1038/sj.bjc.6605335; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; McGill G, 1999, J CLIN INVEST, V104, P223, DOI 10.1172/JCI7861; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Nakamura S, 2000, MOL CELL BIOL, V20, P9391, DOI 10.1128/MCB.20.24.9391-9398.2000; Nelson MH, 2005, BIOCONJUGATE CHEM, V16, P959, DOI 10.1021/bc0501045; OConnor PM, 1997, CANCER RES, V57, P4285; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; ROVINSKI B, 1987, MOL CELL BIOL, V7, P847, DOI 10.1128/MCB.7.2.847; Stambolsky P, 2010, CANCER CELL, V17, P273, DOI 10.1016/j.ccr.2009.11.025; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; WANG C, 1989, LEUKEMIA, V3, P699; Wu RP, 2007, NUCLEIC ACIDS RES, V35, P5182, DOI 10.1093/nar/gkm478; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	41	11	11	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2012	31	8					1024	1033		10.1038/onc.2011.300	http://dx.doi.org/10.1038/onc.2011.300			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	898BG	21765469				2022-12-17	WOS:000300709700008
J	Spassov, DS; Wong, CH; Harris, G; McDonough, S; Phojanakong, P; Wang, D; Hann, B; Bazarov, AV; Yaswen, P; Khanafshar, E; Moasser, MM				Spassov, D. S.; Wong, C. H.; Harris, G.; McDonough, S.; Phojanakong, P.; Wang, D.; Hann, B.; Bazarov, A. V.; Yaswen, P.; Khanafshar, E.; Moasser, M. M.			A tumor-suppressing function in the epithelial adhesion protein Trask	ONCOGENE			English	Article						Trask; CDCP1; SIMA135; 3p21.3; metastasis	DOMAIN-CONTAINING PROTEIN-1; CUB-DOMAIN; SUBSTRATE TRASK; LUNG METASTASIS; FAK INHIBITOR; CANCER-CELLS; KINASE; EXPRESSION; CDCP1; ADENOCARCINOMA	Trask/CDCP1 is a transmembrane glycoprotein widely expressed in epithelial tissues whose functions are just beginning to be understood, but include a role as an anti-adhesive effector of Src kinases. Early studies looking at RNA transcript levels seemed to suggest overexpression in some cancers, but immunostaining studies are now providing more accurate analyses of its expression. In an immuno-histochemical survey of human cancer specimens, we find that Trask expression is retained, reduced or sometimes lost in some tumors compared with their normal epithelial tissue counterparts. A survey of human cancer cell lines also show a similar wide variation in the expression of Trask, including some cell types with the loss of Trask expression, and additional cell types that have lost the physiological detachment-induced phosphorylation of Trask. Three experimental models were established to interrogate the role of Trask in tumor progression, including two gain-of-function models with tet-inducible expression of Trask in tumor cells lacking Trask expression, and one loss-of-function model to suppress Trask expression in tumor cells with abundant Trask expression. The induction of Trask expression and phosphorylation in MCF-7 cells and in 3T3v-src cells was associated with a reduction in tumor metastases while the shRNA-induced knockdown of Trask in L3.6pl cancer cells was associated with increased tumor metastases. The results from these three models are consistent with a tumor-suppressing role for Trask. These data identify Trask as one of several potential candidates for functionally relevant tumor suppressors on the 3p21.3 region of the genome frequently lost in human cancers. Oncogene (2012) 31, 419-431; doi: 10.1038/onc.2011.246; published online 27 June 2011	[Spassov, D. S.; Wong, C. H.; Harris, G.; McDonough, S.; Moasser, M. M.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Spassov, D. S.; Wong, C. H.; Phojanakong, P.; Wang, D.; Hann, B.; Moasser, M. M.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Bazarov, A. V.; Yaswen, P.] Univ Calif Berkeley, Lawrence Berkeley Natl Lab, Div Life Sci, Berkeley, CA 94720 USA; [Khanafshar, E.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California San Francisco	Moasser, MM (corresponding author), Univ Calif San Francisco, Dept Med, UCSF Box 1387,2340 Sutter St,Rm N-144, San Francisco, CA 94143 USA.	mmoasser@medicine.ucsf.edu	Spassov, Danislav S/GQA-4368-2022	Spassov, Danislav S/0000-0002-6680-877X	National Institutes of Health [CA113952]; Susan G Komen for the Cure; California Breast Cancer Research Program Postdoctoral Fellowship; NATIONAL CANCER INSTITUTE [R01CA113952] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); California Breast Cancer Research Program Postdoctoral Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by the National Institutes of Health CA113952 (MMM). DS is funded by a Susan G Komen for the Cure Postdoctoral Fellowship. CHW is funded by a California Breast Cancer Research Program Postdoctoral Fellowship. We wish to thank Michael McManus and the UCSF Sandler Lentiviral RNAi core facility. We acknowledge the use of core facilities of the UCSF Helen Diller Family Comprehensive Cancer Center, including the Preclinical Therapeutics Core, the immunohistochemistry core and the mouse pathology core.	Abdel-Ghany M, 2002, J BIOL CHEM, V277, P34391, DOI 10.1074/jbc.M205307200; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; Brakebusch C, 2002, J CLIN INVEST, V109, P999, DOI 10.1172/JCI200215468; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; Chen JS, 2010, CLIN EXP METASTAS, V27, P71, DOI 10.1007/s10585-010-9306-3; Conze T, 2003, ANN NY ACAD SCI, V996, P222, DOI 10.1111/j.1749-6632.2003.tb03249.x; Felding-Habermann B, 2003, CLIN EXP METASTAS, V20, P203, DOI 10.1023/A:1022983000355; Hanada M, 2005, CLIN EXP METASTAS, V22, P485, DOI 10.1007/s10585-005-3733-6; Hirohashi S, 2003, CANCER SCI, V94, P575, DOI 10.1111/j.1349-7006.2003.tb01485.x; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Ikeda JI, 2006, J PATHOL, V210, P75, DOI 10.1002/path.2026; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Ji Lin, 2005, Future Oncol, V1, P79, DOI 10.1517/14796694.1.1.79; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Mamat S, 2010, ONCOL REP, V23, P1221, DOI 10.3892/or_00000753; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Perry SE, 2007, FEBS LETT, V581, P1137, DOI 10.1016/j.febslet.2007.02.025; Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045; Provenzano PP, 2008, AM J PATHOL, V173, P1551, DOI 10.2353/ajpath.2008.080308; Ramsay AG, 2007, CANCER METAST REV, V26, P567, DOI 10.1007/s10555-007-9078-7; Rathinam R, 2010, CANCER METAST REV, V29, P223, DOI 10.1007/s10555-010-9211-x; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Spassov DS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019154; Spassov DS, 2011, MOL CELL BIOL, V31, P766, DOI 10.1128/MCB.00841-10; Spassov DS, 2009, AM J PATHOL, V174, P1756, DOI 10.2353/ajpath.2009.080890; Spiegelberg BD, 2007, CURR OPIN GENET DEV, V17, P40, DOI 10.1016/j.gde.2006.12.002; Srinivasan Divya Mani, 2005, Curr Opin Investig Drugs, V6, P1246; Sun HH, 2010, CANCER BIOL THER, V10, P38, DOI 10.4161/cbt.10.1.11993; Tang J, 2008, CELL MOL LIFE SCI, V65, P2933, DOI 10.1007/s00018-008-8315-8; Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224; Trimmer C, 2010, CANCER RES, V70, P7489, DOI 10.1158/0008-5472.CAN-10-0900; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; van Nimwegen MJ, 2005, CANCER RES, V65, P4698, DOI 10.1158/0008-5472.CAN-04-4126; Walsh C, 2010, CANCER BIOL THER, V9, P778, DOI 10.4161/cbt.9.10.11433; Wistuba II, 2000, CANCER RES, V60, P1949; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533	41	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2012	31	4					419	431		10.1038/onc.2011.246	http://dx.doi.org/10.1038/onc.2011.246			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	891LU	21706059	Green Submitted, Green Accepted			2022-12-17	WOS:000300219300002
J	Furu, M; Kajita, Y; Nagayama, S; Ishibe, T; Shima, Y; Nishijo, K; Uejima, D; Takahashi, R; Aoyama, T; Nakayama, T; Nakamura, T; Nakashima, Y; Ikegawa, M; Imoto, S; Katagiri, T; Nakamura, Y; Toguchida, J				Furu, M.; Kajita, Y.; Nagayama, S.; Ishibe, T.; Shima, Y.; Nishijo, K.; Uejima, D.; Takahashi, R.; Aoyama, T.; Nakayama, T.; Nakamura, T.; Nakashima, Y.; Ikegawa, M.; Imoto, S.; Katagiri, T.; Nakamura, Y.; Toguchida, J.			Identification of AFAP1L1 as a prognostic marker for spindle cell sarcomas	ONCOGENE			English	Article						AFAP1L1; spindle cell sarcoma; metastasis; prognostic marker	ACTIN-FILAMENT INTEGRITY; SOFT-TISSUE SARCOMAS; MESENCHYMAL STEM-CELLS; GENE-EXPRESSION; SYNOVIAL SARCOMAS; MATRIX METALLOPROTEINASES; MUTATION SPECTRUM; ADAPTER PROTEIN; AFAP-110; CANCER	Spindle cell sarcomas consist of tumors with different biological features, of which distant metastasis is the most ominous sign for a poor prognosis. However, metastasis is difficult to predict on the basis of current histopathological analyses. We have identified actin filament-associated protein 1-like 1 (AFAP1L1) as a candidate for a metastasis-predicting marker from the gene expression profiles of 65 spindle cell sarcomas. A multivariate analysis determined that AFAP1L1 was an independent factor for predicting the occurrence of distant metastasis (P = 0.0001), which was further confirmed in another set of 41 tumors by a quantitative mRNA expression analysis. Immunohistochemical staining using paraffin-embedded tumor tissues revealed that the metastasis-free rate was significantly better in tumors negative for AFAP1L1 (P = 0.0093 by log-rank test). Knocking down the AFAP1L1 gene in sarcoma cells resulted in inhibition of the cell invasion, and forced expression of AFAP1L1 in immortalized human mesenchymal stem cells induced anchorage-independent growth and increased cell invasiveness with high activity levels of matrix metallo-peptidase. Furthermore, tumor growth in vivo was accelerated in AFAP1L1-transduced sarcoma cell lines. These results suggest that AFAP1L1 has a role in the progression of spindle cell sarcomas and is a prognostic biomarker. Oncogene (2011) 30, 4015-4025; doi:10.1038/onc.2011.108; published online 25 April 2011	[Toguchida, J.] Kyoto Univ, Inst Frontier Med Sci, Dept Tissue Regenerat, Sakyo Ku, Kyoto 6068507, Japan; [Furu, M.; Ishibe, T.; Shima, Y.; Nishijo, K.; Nakayama, T.; Nakamura, T.; Toguchida, J.] Kyoto Univ, Dept Orthopaed Surg, Grad Sch Med, Kyoto 6068507, Japan; [Kajita, Y.] Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto 6068507, Japan; [Nagayama, S.; Takahashi, R.] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto 6068507, Japan; [Uejima, D.; Aoyama, T.] Kansai Med Univ, Dept Orthopaed Surg, Osaka, Japan; [Nakashima, Y.] Kyoto Univ Hosp, Dept Diagnost Pathol, Kyoto 606, Japan; [Ikegawa, M.] Kyoto Prefectural Univ Med, Dept Genom Med Sci, Grad Sch Med Sci, Kyoto, Japan; [Imoto, S.] Univ Tokyo, Lab DNA Informat Anal, Ctr Human Genome, Inst Med Sci, Kyoto, Japan; [Katagiri, T.; Nakamura, Y.] Univ Tokyo, Mol Med Lab, Ctr Human Genome, Inst Med Sci, Kyoto, Japan; [Toguchida, J.] Kyoto Univ, Ctr iPS Cell Res & Applicat, Kyoto 6068507, Japan	Kyoto University; Kyoto University; Kyoto University; Kyoto University; Kansai Medical University; Kyoto University; Kyoto Prefectural University of Medicine; University of Tokyo; University of Tokyo; Kyoto University	Toguchida, J (corresponding author), Kyoto Univ, Inst Frontier Med Sci, Dept Tissue Regenerat, Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	togjun@frontier.kyoto-u.ac.jp	Katagiri, Toyomasa/I-7344-2012; Ikegawa, Masaya/AAG-5327-2020		Ministry of Education, Culture, Sports, Science and Technology; Grants-in-Aid for Scientific Research [21390420] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Drs H Sonobe, A Kawai, S Tanaka, O Larsson, A Ogose, and H Kanda for providing cell lines, and T Tsunoda and S Miyano for data analyses. This work was supported by Grants-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology.	Aoyama T, 2004, J BIOL CHEM, V279, P28789, DOI 10.1074/jbc.M401273200; Baisden JM, 2001, ONCOGENE, V20, P6607, DOI 10.1038/sj.onc.1204802; Baisden JM, 2001, ONCOGENE, V20, P6435, DOI 10.1038/sj.onc.1204784; Barretina J, 2010, NAT GENET, V42, P715, DOI 10.1038/ng.619; Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174; CLARK J, 1994, NAT GENET, V7, P502, DOI 10.1038/ng0894-502; Dorfleutner A, 2007, J CELL PHYSIOL, V213, P740, DOI 10.1002/jcp.21143; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fletcher CDM, 2001, J CLIN ONCOL, V19, P3045, DOI 10.1200/JCO.2001.19.12.3045; Fletcher CDM., 2002, WHO CLASSIFICATION T; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; Francis P, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-73; Gatesman A, 2004, MOL CELL BIOL, V24, P7578, DOI 10.1128/MCB.24.17.7578-7597.2004; Guappone AC, 1997, MOL CELL BIOCHEM, V175, P243, DOI 10.1023/A:1006840104666; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Ishibe T, 2005, CLIN CANCER RES, V11, P2702, DOI 10.1158/1078-0432.CCR-04-2057; Ishibe T, 2008, CLIN ORTHOP RELAT R, V466, P2147, DOI 10.1007/s11999-008-0343-z; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Kohno Y, 2006, J BIOL CHEM, V281, P38941, DOI 10.1074/jbc.M608389200; Lee YF, 2004, CANCER RES, V64, P7201, DOI 10.1158/0008-5472.CAN-04-1673; Lodyga M, 2009, ONCOGENE, V28, P937, DOI 10.1038/onc.2008.447; Matushansky I, 2007, J CLIN INVEST, V117, P3248, DOI 10.1172/JCI31377; Nagayama S, 2005, ONCOGENE, V24, P6201, DOI 10.1038/sj.onc.1208780; Nagayama S, 2002, CANCER RES, V62, P5859; Nakayama R, 2007, MODERN PATHOL, V20, P749, DOI 10.1038/modpathol.3800794; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Ottaiano A, 2005, ANTICANCER RES, V25, P4519; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Qian Y, 2004, J CELL BIOCHEM, V91, P602, DOI 10.1002/jcb.10725; Qian Y, 1998, ONCOGENE, V16, P2185, DOI 10.1038/sj.onc.1201753; Qian Y, 2000, EXP CELL RES, V255, P102, DOI 10.1006/excr.1999.4795; Shibata KR, 2007, STEM CELLS, V25, P2371, DOI 10.1634/stemcells.2007-0225; Shima Y, 2007, BIOCHEM BIOPH RES CO, V353, P60, DOI 10.1016/j.bbrc.2006.11.137; St-Pierre Y, 2004, EXPERT OPIN THER TAR, V8, P473, DOI 10.1517/14728222.8.5.473; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; TOGUCHIDA J, 1992, CANCER RES, V52, P6194; Toguchida J, 2009, CANCER SCI, V100, P1573, DOI 10.1111/j.1349-7006.2009.01232.x; WADAYAMA B, 1994, CANCER RES, V54, P3042; Xu J, 2007, J BIOL CHEM, V282, P16401, DOI 10.1074/jbc.M701684200; Zhang J, 2007, J CLIN INVEST, V117, P2962, DOI 10.1172/JCI30710	40	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2011	30	38					4015	4025		10.1038/onc.2011.108	http://dx.doi.org/10.1038/onc.2011.108			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	823KR	21516130	Green Submitted			2022-12-17	WOS:000295121600003
J	Cheng, F; Liu, J; Teh, C; Chong, SW; Korzh, V; Jiang, YJ; Deng, LW				Cheng, F.; Liu, J.; Teh, C.; Chong, S-W; Korzh, V.; Jiang, Y-J; Deng, L-W			Camptothecin-induced downregulation of MLL5 contributes to the activation of tumor suppressor p53	ONCOGENE			English	Article						MLL5; camptothecin; p53; p53 tetramer; Serine 392	HISTONE METHYLTRANSFERASE COMPLEX; TOPOISOMERASE-I INHIBITORS; DNA-DAMAGE; CELL-CYCLE; INDUCED PHOSPHORYLATION; H3K4 METHYLATION; PROTEIN-KINASE; DEGRADATION; ATR; TETRAMERIZATION	Mixed lineage leukemia 5 (MLL5) has been implicated in multiple aspects of cell physiology, such as hematopoiesis, cell cycle control and chromatin regulatory network. In this study, we present evidence that MLL5 is involved in the camptothecin (CPT)-induced p53 activation. CPT promoted the degradation of MLL5 protein in a time-and dose-dependent manner in actively replicating cells. The downregulation of MLL5 led to phosphorylation of p53 at Ser392, which was abrogated by exogenous overexpression of MLL5. In MLL5-knockdown cells, p53 protein was stabilized and bound to DNA with higher affinity, leading to activation of downstream genes. Co-immunoprecipitation showed that MLL5 preferentially interacted with the tetramerized form of p53, and knockdown of MLL5 promoted chromatin accumulation of p53 tetramers, suggesting that the association of MLL5 with p53 may prevent the p53 tetramers from binding to the chromatin target sites. The role of MLL5 in CPT-induced p53 activation was conserved in developing zebrafish, where CPT downregulated zebrafish Mll5 protein, and the microinjection of zebrafish mll5 mRNA substantially blocked the CPT-induced apoptosis. In summary, our study proposed MLL5 as a novel component in the regulation of p53 homeostasis and a new cellular determinant of CPT. Oncogene (2011) 30, 3599-3611; doi:10.1038/onc.2011.71; published online 21 March 2011	[Cheng, F.; Liu, J.; Deng, L-W] Natl Univ Singapore, Natl Univ Hlth Syst, Dept Biochem, Yong Loo Lin Sch Med, Singapore 117597, Singapore; [Teh, C.; Korzh, V.] ASTAR, Inst Mol & Cell Biol, Canc & Dev Cell Biol Div, Singapore, Singapore; [Chong, S-W; Jiang, Y-J] ASTAR, Inst Mol & Cell Biol, Genes & Dev Div, Singapore, Singapore; [Jiang, Y-J] Natl Hlth Res Inst, Div Mol & Genom Med, Miaoli Cty, Taiwan	National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National Health Research Institutes - Taiwan	Deng, LW (corresponding author), Natl Univ Singapore, Natl Univ Hlth Syst, Dept Biochem, Yong Loo Lin Sch Med, 8 Med Dr, Singapore 117597, Singapore.	lih_wen_deng@nuhs.edu.sg	Xie, Huangming/B-2260-2012; Jiang, Yun-Jin/E-3995-2010; Korzh, Vladimir P/H-1596-2011	Jiang, Yun-Jin/0000-0003-0499-7306; Korzh, Vladimir P/0000-0002-6580-7986; Deng, Lih-Wen/0000-0002-4985-7844	BMRC-A*STAR [R-183-000-164-305]; NMRC-A*STAR [R-183-000-220-275]; Ministry of Education [Tier2, R-183-000-195-112]; A*STAR-IMCB; Ministry of Education, Singapore	BMRC-A*STAR(Agency for Science Technology & Research (A*STAR)); NMRC-A*STAR; Ministry of Education; A*STAR-IMCB(Agency for Science Technology & Research (A*STAR)); Ministry of Education, Singapore(Ministry of Education, Singapore)	We are grateful to Dr Thilo Hagen and Dr Qiang Yu for their valuable suggestions. We thank Dr Bert Vogelstein for HCT116 p53<SUP>+/+</SUP> and HCT116 p53 / cells and Dr Victor Yu for pXJ-HA-p53 plasmid. This work was supported in part by BMRC-A*STAR, R-183-000-164-305; NMRC-A*STAR, R-183-000-220-275; and Ministry of Education Academic Research Fund Tier2, R-183-000-195-112 to LWD, and A*STAR-IMCB funding to YJJ and VK Both FC and JL are recipients of research scholarships from Ministry of Education, Singapore.	Bartek J, 2001, CURR OPIN CELL BIOL, V13, P738, DOI 10.1016/S0955-0674(00)00280-5; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang F, 2008, INT J BIOCHEM CELL B, V40, P2472, DOI 10.1016/j.biocel.2008.04.012; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Claudio PP, 2006, J CELL PHYSIOL, V208, P602, DOI 10.1002/jcp.20698; Cuddihy AR, 1999, ONCOGENE, V18, P2690, DOI 10.1038/sj.onc.1202620; Dambacher S, 2010, HEREDITY, V105, P24, DOI 10.1038/hdy.2010.49; Deng LW, 2004, P NATL ACAD SCI USA, V101, P757, DOI 10.1073/pnas.2036345100; Desai SD, 2001, CANCER RES, V61, P5926; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Dul BE, 2007, J BIOL CHEM, V282, P18397, DOI 10.1074/jbc.M700729200; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Emerling BM, 2002, ONCOGENE, V21, P4849, DOI 10.1038/sj.onc.1205615; ENG WK, 1988, MOL PHARMACOL, V34, P755; Foo RSY, 2007, P NATL ACAD SCI USA, V104, P20826, DOI 10.1073/pnas.0710017104; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; Fujiki R, 2009, NATURE, V459, P455, DOI 10.1038/nature07954; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Houser S, 2001, BIOCHEM BIOPH RES CO, V289, P998, DOI 10.1006/bbrc.2001.6073; Huang CS, 1999, J BIOL CHEM, V274, P12229, DOI 10.1074/jbc.274.18.12229; Huang TT, 2000, J BIOL CHEM, V275, P9501, DOI 10.1074/jbc.275.13.9501; Hughes CM, 2004, MOL CELL, V13, P587, DOI 10.1016/S1097-2765(04)00081-4; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; Kim T, 2009, CELL, V137, P259, DOI 10.1016/j.cell.2009.02.045; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Langheinrich U, 2002, CURR BIOL, V12, P2023, DOI 10.1016/S0960-9822(02)01319-2; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Li TK, 2001, ANNU REV PHARMACOL, V41, P53, DOI 10.1146/annurev.pharmtox.41.1.53; Liu H, 2010, NATURE, V467, P343, DOI 10.1038/nature09350; Liu J, 2010, J BIOL CHEM, V285, P20904, DOI 10.1074/jbc.M109.098558; Liu L, 1999, MOL CELL BIOL, V19, P1202; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; NITISS J, 1988, P NATL ACAD SCI USA, V85, P7501, DOI 10.1073/pnas.85.20.7501; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; Pommier Y, 1999, DRUG RESIST UPDATE, V2, P307, DOI 10.1054/drup.1999.0102; Pommier Y, 2006, NAT REV CANCER, V6, P789, DOI 10.1038/nrc1977; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sarkaria JN, 1999, CANCER RES, V59, P4375; Scheel H, 2003, TRENDS CELL BIOL, V13, P285, DOI 10.1016/S0962-8924(03)00102-8; Sebastian S, 2009, P NATL ACAD SCI USA, V106, P4719, DOI 10.1073/pnas.0807136106; Shao RG, 1999, EMBO J, V18, P1397, DOI 10.1093/emboj/18.5.1397; Staker BL, 2002, P NATL ACAD SCI USA, V99, P15387, DOI 10.1073/pnas.242259599; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE; Wysocka J, 2005, CELL, V121, P859, DOI 10.1016/j.cell.2005.03.036; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Yokoyama A, 2004, MOL CELL BIOL, V24, P5639, DOI 10.1128/MCB.24.13.5639-5649.2004; Zhao H, 2008, CELL CYCLE, V7, P3048, DOI 10.4161/cc.7.19.6750	57	11	12	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	33					3599	3611		10.1038/onc.2011.71	http://dx.doi.org/10.1038/onc.2011.71			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21423215				2022-12-17	WOS:000294005100004
J	Maas, C; de Vries, E; Tait, SWG; Borst, J				Maas, C.; de Vries, E.; Tait, S. W. G.; Borst, J.			Bid can mediate a pro-apoptotic response to etoposide and ionizing radiation without cleavage in its unstructured loop and in the absence of p53	ONCOGENE			English	Article						Bid; apoptosis; DNA damage; p53	BH3-ONLY PROTEINS PUMA; CYTOCHROME-C RELEASE; DNA-DAMAGE; LYMPHOID-CELLS; MITOCHONDRIA; TRANSLOCATION; ACTIVATION; NOXA; DRUG; LIFE	BH3-only protein Bid is a key player in death receptor-induced apoptosis, because it provides the link with the mitochondrial route for caspase activation. In this pathway, Bid is activated upon cleavage by caspase-8. Its BH3 domain-containing carboxy-terminal fragment subsequently provokes mitochondrial outer membrane permeabilization by Bak/Bax activation. Bid has also been implicated in the apoptotic response to ionizing radiation (IR) and the topoisomerase inhibitor etoposide, anti-cancer regimens that cause double-strand (ds) DNA breaks. We confirm the existence of this pathway and show that it is p53-independent. However, the degree of Bid participation in the apoptotic response to dsDNA breaks depends on the nature of cell transformation. We used Bid-deficient mouse embryonic fibroblast (MEF) lines that were reconstituted with Bid to control the cellular background and demonstrated that the Bid-dependent apoptotic pathway induced by IR and etoposide operates in MEFs that are transformed by SV40, but is not evident in E1A/Ras-transformed MEFs. The Bid-dependent apoptotic response in p53-deficient SV40-transformed MEFs contributed to clonogenic execution of the cells, implying relevance for treatment outcome. In these cells, Bid acted in a conventional manner in that it required its BH3 domain to mediate apoptosis in response to IR and etoposide, and triggered apoptotic execution by indirect activation of Bak/Bax, mitochondrial permeabilization and caspase-9 activation. However, the mechanism of Bid activation was unconventional, because elimination of all known or suspected cleavage sites for caspases or other proteolytic enzymes and even complete elimination of its unstructured cleavage loop left Bid's pro-apoptotic role in the response to IR and etoposide unaffected. Oncogene (2011) 30, 3636-3647; doi:10.1038/onc.2011.75; published online 21 March 2011	[Maas, C.; de Vries, E.; Tait, S. W. G.; Borst, J.] Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute	Borst, J (corresponding author), Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.borst@nki.nl		Tait, Stephen/0000-0001-7697-132X; Borst, Jannie/0000-0002-8043-5009	Dutch Cancer Society [NKI 2008-4110]	Dutch Cancer Society(KWF Kankerbestrijding)	This work was supported by grant NKI 2008-4110 from the Dutch Cancer Society. We thank Dr Atan Gross for MEF cell lines, Rogier Rooswinkel for data analysis, Inge Verbrugge, Bert van de Kooij and Rogier Rooswinkel for discussions and critical reading of the manuscript, and personnel of the flow cytometry facility of the Netherlands Cancer Institute for experimental assistance.	Anguissola S, 2009, MOL PHARMACOL, V76, P998, DOI 10.1124/mol.109.058156; Brown JM, 1999, CANCER RES, V59, P1391; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908; Chou JJ, 1999, CELL, V96, P615, DOI 10.1016/S0092-8674(00)80572-3; Cirman T, 2004, J BIOL CHEM, V279, P3578, DOI 10.1074/jbc.M308347200; Erlacher M, 2005, BLOOD, V106, P4131, DOI 10.1182/blood-2005-04-1595; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Gross A, 2006, CELL CYCLE, V5, P582, DOI 10.4161/cc.5.6.2575; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kaufmann T, 2007, CELL, V129, P423, DOI 10.1016/j.cell.2007.03.017; Kohler B, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002844; Krajewska M, 2002, NEOPLASIA, V4, P129, DOI 10.1038/sj.neo.7900222; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; Letai A, 2002, CANCER CELL, V2, P183, DOI 10.1016/S1535-6108(02)00127-7; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mandic A, 2002, MOL CELL BIOL, V22, P3003, DOI 10.1128/MCB.22.9.3003-3013.2002; McDonnell JM, 1999, CELL, V96, P625, DOI 10.1016/S0092-8674(00)80573-5; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; Oberkovitz G, 2007, CELL DEATH DIFFER, V14, P1628, DOI 10.1038/sj.cdd.4402181; Ploner C, 2008, ONCOGENE, V27, pS84, DOI 10.1038/onc.2009.46; Ren DC, 2010, SCIENCE, V330, P1390, DOI 10.1126/science.1190217; Sarig R, 2003, J BIOL CHEM, V278, P10707, DOI 10.1074/jbc.M210296200; Sax JK, 2002, NAT CELL BIOL, V4, P842, DOI 10.1038/ncb866; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Shelton SN, 2009, J BIOL CHEM, V284, P11247, DOI 10.1074/jbc.M809392200; Simmen T, 2005, EMBO J, V24, P717, DOI 10.1038/sj.emboj.7600559; Slee EA, 2000, CELL DEATH DIFFER, V7, P556, DOI 10.1038/sj.cdd.4400689; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; Tait SWG, 2007, J CELL BIOL, V179, P1453, DOI 10.1083/jcb.200707063; Tan KO, 1999, J BIOL CHEM, V274, P23687, DOI 10.1074/jbc.274.34.23687; Valentijn AJ, 2004, J BIOL CHEM, V279, P32848, DOI 10.1074/jbc.M313375200; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wang XD, 2001, GENE DEV, V15, P2922; Ward MW, 2006, J BIOL CHEM, V281, P5837, DOI 10.1074/jbc.M511562200; Werner AB, 2004, J BIOL CHEM, V279, P28771, DOI 10.1074/jbc.M400268200; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zha JP, 2000, SCIENCE, V290, P1761, DOI 10.1126/science.290.5497.1761; Zinkel SS, 2007, CELL, V130, P9, DOI 10.1016/j.cell.2007.06.035; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	42	11	13	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	33					3636	3647		10.1038/onc.2011.75	http://dx.doi.org/10.1038/onc.2011.75			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808UL	21423217	Green Published, hybrid			2022-12-17	WOS:000294005100007
J	Zhang, Y; Wang, C				Zhang, Y.; Wang, C.			Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells	ONCOGENE			English	Article						fusion transcription factor; rhabdomyosarcoma; skeletal muscle; transcription; matricellular protein; CCN3	GROWTH-FACTOR CTGF/CCN2; CCN FAMILY; DNA-BINDING; FUSION PROTEIN; MYOGENIC DIFFERENTIATION; IN-VIVO; PAX3; EXPRESSION; IDENTIFICATION; HOMEODOMAIN	The CCN (Cy61, CTGF and NOV) family of proteins is a group of matricellular biomolecules involved in both physiological and pathological processes. Elevated expression of the CCN3 (also known as NOV, Nephroblastoma overexpressed) gene has been detected in clinical samples of the skeletal muscle cancer rhabdomyosarcoma, with the highest expression found in the alveolar subtype (aRMS). Over 80% of aRMSs are characterized by a chromosomal translocation-derived fusion transcription factor PAX3-FKHR. In this study, we linked elevated CCN3 levels in aRMS cells to PAX3-FKHR expression. We found reduced CCN3 levels in aRMS cells following small interfering RNA knockdown of PAX3-FKHR, and increased CCN3 levels in C2 myoblasts following ectopic expression of PAX3-FKHR. Promoter, electrophoretic mobility shift assay and chromatin immunoprecipitation analyses confirmed that the CCN3 gene was a direct target for PAX3-FKHR transcriptional activation through a paired-domain DNA sequence in the first intron of the CCN3 gene. To determine the function of CCN3, we showed that knockdown and ectopic expression of CCN3 decreased survival and increased differentiation in aRMS cells, respectively. In addition, we found that exogenously supplied CCN3 protein promoted aRMS cell adhesion, migration and Matrigel invasion. Taken together, data from this study have (1) provided a mechanistic basis for the CCN3 overexpression in aRMS cells, and (2) identified CCN3 as an autocrine/paracrine factor that contributes to the aggressive behavior of aRMS cells, perhaps through a positive feedback loop. Thus, CCN3 may be an attractive target for therapeutic intervention in aRMS. Oncogene (2011) 30, 3549-3562; doi:10.1038/onc.2011.69; published online 21 March 2011	[Zhang, Y.; Wang, C.] Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Wang, C (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, 801 S Paulina St,RM 530CB, Chicago, IL 60612 USA.	chiayeng@uic.edu			NIH [CA074904]; NATIONAL CANCER INSTITUTE [R01CA074907, R29CA074907, R01CA074904] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Lester Lau (University of Illinois at Chicago) for providing antibody against mouse CCN3 protein, and Mr Jian Zhou for his technical assistance in protein and RNA analysis. We thank Dr Peter Tontonoz (Pathology and Laboratory Medicine, UCLA) for assisting in microarray analysis confirming the molecular link between CCN3 and PAX3-FKHR, and Drs Reed Graves and Peter Tontonoz for their valuable suggestions in the preparation of this manuscript. This work is supported by NIH Grant (CA074904) to C.W.	Anderson J, 2001, AM J PATHOL, V159, P1089, DOI 10.1016/S0002-9440(10)61784-1; Apuzzo S, 2004, J BIOL CHEM, V279, P33601, DOI 10.1074/jbc.M402949200; Armoni M, 2002, J CLIN ENDOCR METAB, V87, P5312, DOI 10.1210/jc.2002-020318; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Ayalon D., 2001, Growth Hormone and IGF Research, V11, P289, DOI 10.1054/ghir.2001.0244; BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Begum S, 2005, ONCOGENE, V24, P1860, DOI 10.1038/sj.onc.1208315; Benini S, 2005, ONCOGENE, V24, P4349, DOI 10.1038/sj.onc.1208620; Bernasconi M, 1996, P NATL ACAD SCI USA, V93, P13164, DOI 10.1073/pnas.93.23.13164; Bohlig L, 2008, CELL CYCLE, V7, P1254, DOI 10.4161/cc.7.9.5812; Calhabeua F, 2006, EXP CELL RES, V312, P1876, DOI 10.1016/j.yexcr.2006.02.027; Cao Y, 2000, J BIOL CHEM, V275, P9854, DOI 10.1074/jbc.275.13.9854; CHALEPAKIS G, 1994, P NATL ACAD SCI USA, V91, P12745, DOI 10.1073/pnas.91.26.12745; CHALEPAKIS G, 1995, GENE, V162, P267, DOI 10.1016/0378-1119(95)00345-7; Croci S, 2004, CANCER RES, V64, P1730, DOI 10.1158/0008-5472.CAN-3502-02; Croci S, 2007, PATHOL ONCOL RES, V13, P336, DOI 10.1007/BF02940313; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; Diomedi-Camassei F, 2004, J PEDIATR SURG, V39, P1673, DOI 10.1016/j.jpedsurg.2004.07.014; Durbin AD, 2009, J CLIN INVEST, V119, P1558, DOI 10.1172/JCI37958; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; Epstein JA, 1996, P NATL ACAD SCI USA, V93, P4213, DOI 10.1073/pnas.93.9.4213; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Gupta N, 2001, J CLIN PATHOL-MOL PA, V54, P293, DOI 10.1136/mp.54.5.293; Holbourn KP, 2008, TRENDS BIOCHEM SCI, V33, P461, DOI 10.1016/j.tibs.2008.07.006; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Katsube K, 2009, DEV GROWTH DIFFER, V51, P55, DOI 10.1111/j.1440-169X.2009.01077.x; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Khan J, 1999, P NATL ACAD SCI USA, V96, P13264, DOI 10.1073/pnas.96.23.13264; Lafont J, 2005, CELL COMMUN ADHES, V12, P41, DOI 10.1080/15419060500383069; Lam PYP, 1999, MOL CELL BIOL, V19, P594; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Laurent M, 2003, FASEB J, V17, P1919, DOI 10.1096/fj.02-1023fje; Leu SJ, 2003, J BIOL CHEM, V278, P33801, DOI 10.1074/jbc.M305862200; Leu SJ, 2002, J BIOL CHEM, V277, P46248, DOI 10.1074/jbc.M209288200; Lin CG, 2005, J BIOL CHEM, V280, P8229, DOI 10.1074/jbc.M404903200; Lin CG, 2003, J BIOL CHEM, V278, P24200, DOI 10.1074/jbc.M302028200; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; Mercado GE, 2008, GENE CHROMOSOME CANC, V47, P510, DOI 10.1002/gcc.20554; Natarajan D, 2000, DEV DYNAM, V219, P417, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1058>3.0.CO;2-2; Oberlin O, 2008, J CLIN ONCOL, V26, P2384, DOI 10.1200/JCO.2007.14.7207; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P103, DOI 10.1136/mp.54.2.103; Perbal B, 2001, B CANCER, V88, P645; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Perbal B, 2006, ADV EXP MED BIOL, V587, P23; Perbal B, 2009, J CELL COMMUN SIGNAL, V3, P153, DOI 10.1007/s12079-009-0051-9; Perbal B, 2008, J CELL COMMUN SIGNAL, V2, P57, DOI 10.1007/s12079-008-0033-3; Perbal B, 2008, J CELL COMMUN SIGNAL, V2, P3, DOI 10.1007/s12079-008-0028-0; Phelan SA, 1998, J BIOL CHEM, V273, P19153, DOI 10.1074/jbc.273.30.19153; Planque N, 2006, J CELL BIOCHEM, V99, P105, DOI 10.1002/jcb.20887; Ren YX, 2008, CANCER RES, V68, P6587, DOI 10.1158/0008-5472.CAN-08-0859; Rikhof B, 2009, J PATHOL, V217, P469, DOI 10.1002/path.2499; Scheidler S, 1996, P NATL ACAD SCI USA, V93, P9805, DOI 10.1073/pnas.93.18.9805; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Taniguchi E, 2008, ONCOGENE, V27, P6550, DOI 10.1038/onc.2008.255; TURCCAREL C, 1986, CANCER GENET CYTOGEN, V19, P361, DOI 10.1016/0165-4608(86)90069-5; Underhill DA, 1997, J BIOL CHEM, V272, P14175, DOI 10.1074/jbc.272.22.14175; Vallacchi V, 2008, CANCER RES, V68, P715, DOI 10.1158/0008-5472.CAN-07-2103; Wang W, 2005, INT J ONCOL, V27, P1087; Wang-Wuu S, 1988, Cancer Res, V48, P983; Williamson D, 2007, CANCER RES, V67, P57, DOI 10.1158/0008-5472.CAN-06-1650; XU WG, 1995, CELL, V80, P639, DOI 10.1016/0092-8674(95)90518-9; Yeger H, 2007, J CELL COMMUN SIGNAL, V1, P159, DOI 10.1007/s12079-008-0022-6; YUN K, 1992, LAB INVEST, V67, P653; ZHAN SL, 1994, J CLIN INVEST, V94, P445, DOI 10.1172/JCI117344; Zhang L, 2007, ONCOGENE, V26, P1595, DOI 10.1038/sj.onc.1209958; Zhang YB, 2009, INT J CLIN EXP PATHO, V2, P370	68	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2011	30	32					3549	3562		10.1038/onc.2011.69	http://dx.doi.org/10.1038/onc.2011.69			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	806CR	21423212	hybrid, Green Accepted			2022-12-17	WOS:000293782300007
J	Li, Q; He, Y; Wei, L; Wu, X; Wu, D; Lin, S; Wang, Z; Ye, Z; Lin, SC				Li, Q.; He, Y.; Wei, L.; Wu, X.; Wu, D.; Lin, S.; Wang, Z.; Ye, Z.; Lin, S-C			AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation	ONCOGENE			English	Article						AXIN; PML; p53; PML-nuclear body	TUMOR-SUPPRESSOR; RAR-ALPHA; PML; HIPK2; GENE; PHOSPHORYLATION; IDENTIFICATION; GROWTH; DAXX; TRANSLOCATION	The PML protein is best known for its role as a tumor suppressor for acute promyelocytic leukemia. Both PML and the key Wnt signaling regulator AXIN regulate p53-dependent apoptosis in response to DNA damage. However, how the two major tumor suppressors coordinate with each other is unknown, and the molecular components orchestrating the PML-induced apoptosis remain enigmatic. Here we show that AXIN interacts with PML in vivo, and further that AXIN, PML and p53 form a ternary complex. Exposure to genotoxic signals including UV and doxorubicin induces AXIN to enter into the nucleus where it colocalizes with PML in the nuclear bodies. Domain-mapping experiments revealed that the C-terminal region (aa 597-832) of AXIN is responsible for its interaction with PML. AXIN fails to activate p53 in PML-/- cells, and conversely, PML is unable to activate p53 in AXIN-null SNU475 cells. Consistently, knockdown with respective siRNAs revealed that AXIN and PML depend on each other to elevate p53-Ser-46 phosphorylation and to induce apoptosis after treatment with genotoxins. Moreover, we found that dominant-negative mutants of PML blocked AXIN-induced p53 activation, and that AXIN promotes PML sumoylation, a modification necessary for PML functions. Our finding has thus provided a new avenue for understanding the mechanism by which PML activates p53 and exerts its role as a tumor suppressor. Oncogene (2011) 30, 1194-1204; doi:10.1038/onc.2010.499; published online 8 November 2010	[Li, Q.; He, Y.; Wei, L.; Wu, X.; Wu, D.; Lin, S.; Wang, Z.; Ye, Z.; Lin, S-C] Xiamen Univ, Key Lab, Fujian Lab Canc Biol, Sch Life Sci,Minist Educ Cell Biol & Tumor Cell, Xiamen 361005, Fujian, Peoples R China	Xiamen University	Lin, SC (corresponding author), Xiamen Univ, Key Lab, Fujian Lab Canc Biol, Sch Life Sci,Minist Educ Cell Biol & Tumor Cell, 422 Siming S Rd, Xiamen 361005, Fujian, Peoples R China.	linsc@xmu.edu.cn	Lin, Shu-Yong/B-7726-2012; Wu, Di/D-3595-2017; Lin, SC/G-4666-2010	Lin, Shu-Yong/0000-0002-4419-1713; Wu, Di/0000-0002-5895-2237; 	MOST [2009CB522200, 2006AA02A303, 2007CB914602]; National Natural Science Foundation of China [30730025, 30921005, 30500273, 30770454, 30970613]; Natural Science Foundation of Fujian Province [2008J0109, 2009J06021]; program for NCET	MOST; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Fujian Province(Natural Science Foundation of Fujian Province); program for NCET(Program for New Century Excellent Talents in University (NCET))	We thank Dr PP Pandolfi for the gift of the wild-type MEF cells and PML <SUP>/</SUP> MEF cells, Dr Qiao Wu for the RARE luciferase reporter. This work was supported by grants from MOST (nos. 2009CB522200 and 2006AA02A303). This work was also supported by grants from National Natural Science Foundation of China (nos. 30730025, 30921005, 30500273, 30770454, 30970613), the National Basic Research Program of MOST (no. 2007CB914602), the Natural Science Foundation of Fujian Province (nos. 2008J0109 and 2009J06021) and the program for NCET.	ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; Bernardi R, 2008, ONCOGENE, V27, P6299, DOI 10.1038/onc.2008.305; Bruno S, 2003, BLOOD, V101, P3514, DOI 10.1182/blood-2002-11-3335; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Eskiw CH, 2004, J BIOL CHEM, V279, P9577, DOI 10.1074/jbc.M312580200; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Gresko E, 2009, ONCOGENE, V28, P698, DOI 10.1038/onc.2008.420; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Gurrieri C, 2004, JNCI-J NATL CANCER I, V96, P269, DOI 10.1093/jnci/djh043; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Jin LH, 2003, INT J CANCER, V107, P696, DOI 10.1002/ijc.11435; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Le XF, 1996, J BIOL CHEM, V271, P130, DOI 10.1074/jbc.271.1.130; Li QX, 2007, CANCER RES, V67, P66, DOI 10.1158/0008-5472.CAN-06-1671; Li QX, 2009, NAT CELL BIOL, V11, P1128, DOI 10.1038/ncb1927; Martic TN, 2010, PATHOL ONCOL RES, V16, P75, DOI 10.1007/s12253-009-9190-9; Moller A, 2003, CANCER RES, V63, P4310; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Rui YN, 2004, EMBO J, V23, P4583, DOI 10.1038/sj.emboj.7600475; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Salomoni P, 2008, CELL RES, V18, P620, DOI 10.1038/cr.2008.58; Salomoni P, 2006, TRENDS CELL BIOL, V16, P97, DOI 10.1016/j.tcb.2005.12.002; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Shima Y, 2008, MOL CELL BIOL, V28, P7126, DOI 10.1128/MCB.00897-08; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Wu Q, 2009, J BIOL CHEM, V284, P8738, DOI 10.1074/jbc.M807590200; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	45	11	12	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	10					1194	1204		10.1038/onc.2010.499	http://dx.doi.org/10.1038/onc.2010.499			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	732QD	21057547				2022-12-17	WOS:000288202400006
J	Lui, VWY; Yau, DMS; Cheung, CSF; Wong, SCC; Chan, AKC; Zhou, Q; Wong, EL; Lau, CPY; Lam, EKY; Hui, EP; Hong, B; Hui, CWC; Chan, ASK; Ng, PKS; Ng, YK; Lo, KW; Tsang, CM; Tsui, SKW; Tsao, SW; Chan, ATC				Lui, V. W. Y.; Yau, D. M-S; Cheung, C. S-F; Wong, S. C. C.; Chan, A. K-C; Zhou, Q.; Wong, EY-L; Lau, C. P. Y.; Lam, E. K. Y.; Hui, E. P.; Hong, B.; Hui, C. W. C.; Chan, A. S-K; Ng, P. K. S.; Ng, Y-K; Lo, K-W; Tsang, C. M.; Tsui, S. K. W.; Tsao, S-W; Chan, A. T. C.			FGF8b oncogene mediates proliferation and invasion of Epstein-Barr virus-associated nasopharyngeal carcinoma cells: implication for viral-mediated FGF8b upregulation	ONCOGENE			English	Article						FGF8b; NPC; LMP1; NF-kappa B	INDUCED GROWTH-FACTOR; ANDROGEN RECEPTORS; FGF-8 ISOFORMS; FIBROBLAST-GROWTH-FACTOR-8 EXPRESSION; ESOPHAGEAL ADENOCARCINOMA; OVER-EXPRESSION; PROSTATE-CANCER; PROGRESSION; ACTIVATION; SURVIVAL	The fibroblast growth factor 8b (FGF8b) oncogene is known to be primarily involved in the tumorigenesis and progression of hormone-related cancers. Its role in other epithelial cancers has not been investigated, except for esophageal cancer, in which FGF8b overexpression was mainly found in tumor biopsies of male patients. These observations were consistent with previous findings in these cancer types that the male sex-hormone androgen is responsible for FGF8b expression. Nasopharyngeal carcinoma (NPC) is a highly metastatic cancer of head and neck commonly found in Asia. It is etiologically associated with Epstein-Barr Virus (EBV) infection, inflammatory tumor microenvironment and relatively higher male predominance. Here, we reported for the first time that FGF8b is overexpressed in this EBV-associated non-hormone-related cancer of the head and neck, NPC. More importantly, overexpression of FGF8b mRNA and protein was detected in a large majority of NPC tumors from both male and female genders, in addition to multiple NPC cell lines. We hypothesized that FGF8b overexpression may contribute to NPC tumorigenesis. Using EBV-associated NPC cell lines, we demonstrated that specific knockdown of FGF8b by small interfering RNA inhibited cell proliferation, migration and invasion, whereas exogenous FGF8b stimulated these multiple phenotypes. Further mechanistic investigation revealed that in addition to NF-kappa B signaling (a major inflammatory signaling pathway known to be activated in NPC), an important EBV oncoprotein, the latent membrane protein 1 (LMP1), was found to be a direct inducer of FGF8b overexpression in NPC cells, whereas androgen (testosterone) has minimal effect on FGF8b expression in EBV-associated NPC cells. In summary, our study has identified LMP1 as the first viral oncogene capable of directly inducing FGF8b (an important cellular oncogene) expression in human cancer cells. This novel mechanism of viral-mediated FGF8 upregulation may implicate a new role of oncoviruses in human carcinogenesis. Oncogene (2011) 30, 1518-1530; doi: 10.1038/onc.2010.529; published online 29 November 2010	[Lui, V. W. Y.; Yau, D. M-S; Cheung, C. S-F; Wong, S. C. C.; Zhou, Q.; Wong, EY-L; Lau, C. P. Y.; Lam, E. K. Y.; Hui, E. P.; Hong, B.; Hui, C. W. C.; Chan, A. S-K; Chan, A. T. C.] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, State Key Lab Oncol S China,Sir YK Pao Ctr Canc, Hong Kong, Hong Kong, Peoples R China; [Chan, A. K-C] Queen Elizabeth Hosp, Dept Pathol, Hong Kong, Hong Kong, Peoples R China; [Ng, P. K. S.; Tsui, S. K. W.] Chinese Univ Hong Kong, Sch Biomed Sci, Hong Kong, Hong Kong, Peoples R China; [Ng, Y-K] Chinese Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China; [Lo, K-W] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Tsang, C. M.; Tsao, S-W] Univ Hong Kong, Dept Anat, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Chinese University of Hong Kong; Chinese University of Hong Kong; Chinese University of Hong Kong; University of Hong Kong	Chan, ATC (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Oncol, State Key Lab Oncol S China,Sir YK Pao Ctr Canc, Hong Kong, Hong Kong, Peoples R China.	vivian@clo.cuhk.edu.hk; anthony@clo.cuhk.edu.hk	Hui, Edwin/ABC-1818-2021; Tsui, Stephen Kwok-Wing/E-4385-2015; Hong, Bo/ABA-3687-2021; Ng, Yuen-Keng/ABC-3906-2020; Lui, Vivian W. Y./I-5458-2016; Chan, Anthony Tak Cheung/R-3940-2018	Tsui, Stephen Kwok-Wing/0000-0003-0686-4259; Hong, Bo/0000-0001-8117-5029; Ng, Yuen-Keng/0000-0003-4491-5221; Lui, Vivian W. Y./0000-0001-6918-1573; Chan, Anthony Tak Cheung/0000-0002-6912-8091; Lo, Kwok Wai/0000-0002-3488-6124; WONG, Sze Chuen Cesar/0000-0003-0058-140X	Clinical Oncology, CUHK	Clinical Oncology, CUHK(Chinese University of Hong Kong)	Financial support by research fund, Clinical Oncology, CUHK (VWYL). We thank Drs Q Tao and GT Chung for experimental assistance.	Anderson KE, 2006, CANC EPIDEMIOLOGY PR, P721; Armstrong K, 2006, PROSTATE, V66, P1223, DOI 10.1002/pros.20376; Awan AK, 2007, EJSO-EUR J SURG ONC, V33, P561, DOI 10.1016/j.ejso.2006.12.001; Bhattacharyya N, 2004, AM J OTOLARYNG, V25, P94, DOI 10.1016/j.amjoto.2003.11.005; BLOT WJ, 1993, JAMA-J AM MED ASSOC, V270, P1320, DOI 10.1001/jama.270.11.1320; Blunt AG, 1997, J BIOL CHEM, V272, P3733, DOI 10.1074/jbc.272.6.3733; Castellano I, 2010, BREAST CANCER RES TR, V124, P607, DOI 10.1007/s10549-010-0761-y; Chan ATC, 2002, ANN ONCOL, V13, P1007, DOI 10.1093/annonc/mdf179; Chou J, 2008, HEAD NECK-J SCI SPEC, V30, P946, DOI 10.1002/hed.20833; Crossley PH, 1996, NATURE, V380, P66, DOI 10.1038/380066a0; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; Cui D, 2001, Lin Chuang Er Bi Yan Hou Ke Za Zhi, V15, P202; Daphna-Iken D, 1998, ONCOGENE, V17, P2711, DOI 10.1038/sj.onc.1202212; Dawson CW, 2003, J BIOL CHEM, V278, P3694, DOI 10.1074/jbc.M209840200; Dorkin TJ, 1999, ONCOGENE, V18, P2755, DOI 10.1038/sj.onc.1202624; Gemel J, 1996, GENOMICS, V35, P253, DOI 10.1006/geno.1996.0349; Gnanapragasam V, 2003, BRIT J CANCER, V88, P1432, DOI 10.1038/sj.bjc.6600875; Gnanapragasam VJ, 2002, ONCOGENE, V21, P5069, DOI 10.1038/sj.onc.1205663; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; Hong B, 2009, INVEST NEW DRUGS; Zheng H, 2007, CELL MOL IMMUNOL, V4, P185; Ishibe T, 2005, CLIN CANCER RES, V11, P2702, DOI 10.1158/1078-0432.CCR-04-2057; Kuo Wen-Rei, 1994, Journal of the Formosan Medical Association, V93, P569; Leung HY, 1996, ONCOGENE, V12, P1833; Liao Wei, 2001, Zhonghua Zhongliu Zazhi, V23, P199; Lo AKF, 2006, NEOPLASIA, V8, P173, DOI 10.1593/neo.05625; Lo KW, 2002, SEMIN CANCER BIOL, V12, P451, DOI 10.1016/S1044579X02000883; Lui VWY, 2009, CARCINOGENESIS, V30, P2085, DOI 10.1093/carcin/bgp253; Lui VWY, 2009, INT J CANCER, V125, P1884, DOI 10.1002/ijc.24567; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MACARTHUR CA, 1995, CELL GROWTH DIFFER, V6, P817; MACARTHUR CA, 1995, J VIROL, V69, P2501, DOI 10.1128/JVI.69.4.2501-2507.1995; Marsh SK, 1999, ONCOGENE, V18, P1053, DOI 10.1038/sj.onc.1202392; Mattila MA, 2007, CYTOKINE GROWTH F R, V18, P257, DOI 10.1016/j.cytogfr.2007.04.010; Ohshima K, 1998, CANCER LETT, V122, P43, DOI 10.1016/S0304-3835(97)00368-6; Olsen SK, 2006, GENE DEV, V20, P185, DOI 10.1101/gad.1365406; Park S, 2010, ANN ONCOL, V21, P488, DOI 10.1093/annonc/mdp510; Rudra-Ganguly N, 1998, ONCOGENE, V16, P1487, DOI 10.1038/sj.onc.1201652; Ruohola JK, 2001, CANCER RES, V61, P4229; Shi W, 2006, INT J CANCER, V119, P2467, DOI 10.1002/ijc.22107; SKINNER DW, 1991, ANN OTO RHINOL LARYN, V100, P544, DOI 10.1177/000348949110000705; Song ZG, 2000, CANCER RES, V60, P6730; Song ZG, 2002, CANCER RES, V62, P5096; Spano JP, 2003, EUR J CANCER, V39, P2121, DOI 10.1016/S0959-8049(03)00367-8; Tanaka A, 1998, CANCER RES, V58, P2053; TANAKA A, 1995, FEBS LETT, V363, P226, DOI 10.1016/0014-5793(95)00324-3; Tanaka A, 2002, VIRCHOWS ARCH, V441, P380, DOI 10.1007/s00428-002-0687-9; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; Tanaka S, 2001, DIGEST DIS SCI, V46, P1016, DOI 10.1023/A:1010753826788; Thaver V, 2009, CELL BIOCHEM FUNCT, V27, P205, DOI 10.1002/cbf.1557; Thornburg NJ, 2003, CANCER RES, V63, P8293; Tsao SW, 2002, SEMIN CANCER BIOL, V12, P473, DOI 10.1016/S1044579X02000901; Tucker AS, 1999, DEVELOPMENT, V126, P51; Valta MP, 2008, INT J CANCER, V123, P22, DOI 10.1002/ijc.23422; Valve EM, 2001, LAB INVEST, V81, P815, DOI 10.1038/labinvest.3780291; Wong JHT, 2010, CANCER LETT, V287, P23, DOI 10.1016/j.canlet.2009.05.022; Wong SCC, 2002, J PATHOL, V196, P145, DOI 10.1002/path.1035; Wong SCC, 2001, J PATHOL, V194, P35, DOI 10.1002/path.838; YAMASHITA Y, 1989, JPN J SURG, V19, P195, DOI 10.1007/BF02471585; Zhong C, 2006, CANCER RES, V66, P2188, DOI 10.1158/0008-5472.CAN-05-3440	60	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2011	30	13					1518	1530		10.1038/onc.2010.529	http://dx.doi.org/10.1038/onc.2010.529			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	743DU	21119603				2022-12-17	WOS:000288998300003
J	Giglio, S; Mancini, F; Pellegrino, M; Di Conza, G; Puxeddu, E; Sacchi, A; Pontecorvi, A; Moretti, F				Giglio, S.; Mancini, F.; Pellegrino, M.; Di Conza, G.; Puxeddu, E.; Sacchi, A.; Pontecorvi, A.; Moretti, F.			Regulation of MDM4 (MDMX) function by p76(MDM2): a new facet in the control of p53 activity	ONCOGENE			English	Article						p53; MDM4; MDM2; p76(MDM2); p90(MDM2)	DEGRADATION; HDMX; PHOSPHORYLATION; UBIQUITINATION; TRANSCRIPTS; STABILITY; REVEALS; ABILITY; ATM	Under basal growth conditions, p53 function is tightly controlled by the members of MDM family, MDM2 and MDM4. The Mdm2 gene codes, in addition to the full-length p90(MDM2), for a short protein, p76(MDM2) that lacks the p53-binding domain. Despite this property and at variance with p90(MDM2), this protein acts positively toward p53, although the molecular mechanism remains elusive. Here, we report that p76(MDM2) antagonizes MDM4 inhibitory function. We show that p76(MDM2) possesses intrinsic ubiquitinating and degrading activity, and through these activities controls MDM4 levels. Furthermore, the presence of p76(MDM2) decreases the association of MDM4 with p53 and p90(MDM2), and antagonizes p53 degradation by the heterodimer MDM4/ p90(MDM2). The p76(MDM2)-mediated regulation of MDM4 occurs in the cytoplasm, under basal growth conditions. Conversely, upon DNA damage, phosphorylation of MDM4Ser403 dissociates p76(MDM2) and prevents MDM4 degradation. The overall negative control of MDM4 by p76(MDM2) reflects on p53 function as p76(MDM2) impairs MDM4-mediated inhibition of p53 activity. In agreement with the positive role of p76(MDM2) toward p53, the p76(MDM2)/p90(MDM2) ratio significantly decreases in a group of thyroid tumor samples compared with normal counterparts. Overall, these findings reveal a new mechanism in the control of p53 basal activity that may account for the distinct sensitivity of tissues to stress signals depending on the balance among MDM proteins. Moreover, these data suggest an onco-suppressive function for a product of the Mdm2 gene. Oncogene (2010) 29, 5935-5945; doi:10.1038/onc.2010.324; published online 9 August 2010	[Giglio, S.; Mancini, F.; Pellegrino, M.; Di Conza, G.; Moretti, F.] CNR, Inst Neurobiol & Mol Med, Fdn Santa Lucia, I-6400143 Rome, Italy; [Giglio, S.; Mancini, F.; Pontecorvi, A.] Catholic Univ, Inst Med Pathol, Rome, Italy; [Di Conza, G.] Univ Messina, Dept Expt Clin Med & Pharmacol, Messina, Italy; [Puxeddu, E.] Univ Perugia, Dept Internal Med, I-06100 Perugia, Italy; [Sacchi, A.] Regina Elena Inst Canc Res, Lab Mol Oncogenesis, Rome, Italy	Consiglio Nazionale delle Ricerche (CNR); IRCCS Santa Lucia; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; University of Messina; University of Perugia; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Moretti, F (corresponding author), CNR, Inst Neurobiol & Mol Med, Fdn Santa Lucia, Via Fosso di Fiorano, I-6400143 Rome, Italy.	moretti@inmm.cnr.it	Mancini, Francesca/AAZ-1672-2021; Moretti, Fabiola/I-5647-2013; Puxeddu, Efisio/I-8188-2012; Pellegrino, Marsha/K-4500-2016; Di Conza, Giusy/GPP-1438-2022; mancini, francesca/K-6062-2016	Mancini, Francesca/0000-0002-2459-8815; Moretti, Fabiola/0000-0002-2691-1254; Pellegrino, Marsha/0000-0002-9002-3622; mancini, francesca/0000-0002-2459-8815; Di Conza, Giusy/0000-0003-1353-5867	Associazione Italiana Ricerca sul Cancro (AIRC), Ministero della Sanita	Associazione Italiana Ricerca sul Cancro (AIRC), Ministero della Sanita(Fondazione AIRC per la ricerca sul cancro)	The work was supported by research grants from Associazione Italiana Ricerca sul Cancro (AIRC), Ministero della Sanita. We are grateful to Dr Lozano for Mdm2<SUP>-/-</SUP> p53<SUP>-/-</SUP> MEFs, to Dr JC Marine for Mdm4<SUP>-/-</SUP> Mdm2<SUP>-/-</SUP> p53<SUP>-/-</SUP> MEFs and to Dr Jochemsen for phosphorylation-defective human MDM4S403A coding plasmid. We are also especially grateful to Dr Jochemsen for critical review and helpful comments to the paper.	BuesoRamos CE, 1996, BREAST CANCER RES TR, V37, P179, DOI 10.1007/BF01806499; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Cheng TH, 2007, MOL CELL BIOL, V27, P111, DOI 10.1128/MCB.00235-06; Dimitriadi M, 2008, BRIT J CANCER, V99, P1144, DOI 10.1038/sj.bjc.6604643; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kawai H, 2007, CANCER RES, V67, P6026, DOI 10.1158/0008-5472.CAN-07-1313; LeBron C, 2006, EMBO J, V25, P1196, DOI 10.1038/sj.emboj.7601032; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; Mancini F, 2009, CURR GENOMICS, V10, P42, DOI 10.2174/138920209787581280; Mancini F, 2009, CELL CYCLE, V8, P3854, DOI 10.4161/cc.8.23.10089; Mancini F, 2009, EMBO J, V28, P1926, DOI 10.1038/emboj.2009.154; Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912; Marine JC, 2010, CELL DEATH DIFFER, V17, P93, DOI 10.1038/cdd.2009.68; Meulmeester E, 2005, MOL CELL, V18, P565, DOI 10.1016/j.molcel.2005.04.024; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Ohtsubo C, 2009, CANCER SCI, V100, P1291, DOI 10.1111/j.1349-7006.2009.01180.x; Okamoto K, 2005, MOL CELL BIOL, V25, P9608, DOI 10.1128/MCB.25.21.9608-9620.2005; Okamoto K, 2009, FEBS LETT, V583, P2710, DOI 10.1016/j.febslet.2009.07.021; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Perry ME, 2000, J BIOL CHEM, V275, P5733, DOI 10.1074/jbc.275.8.5733; Pikkarainen S, 2009, J BIOL CHEM, V284, P27195, DOI 10.1074/jbc.M109.037887; Prodosmo A, 2008, J MOL MED-JMM, V86, P585, DOI 10.1007/s00109-008-0322-6; Ralhan R, 2000, AM J PATHOL, V157, P587, DOI 10.1016/S0002-9440(10)64569-5; Salem MMAEL, 2009, FASEB J, V23, P3790, DOI 10.1096/fj.09-132621; Saucedo LJ, 1999, J BIOL CHEM, V274, P8161, DOI 10.1074/jbc.274.12.8161; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Toledo F, 2007, INT J BIOCHEM CELL B, V39, P1476, DOI 10.1016/j.biocel.2007.03.022; Wang YV, 2007, P NATL ACAD SCI USA, V104, P12365, DOI 10.1073/pnas.0701497104; Wang YYV, 2009, CELL CYCLE, V8, P3443, DOI 10.4161/cc.8.21.9744; Zhou JX, 2009, J IMMUNOL, V183, P3188, DOI 10.4049/jimmunol.0803693	35	11	12	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV	2010	29	44					5935	5945		10.1038/onc.2010.324	http://dx.doi.org/10.1038/onc.2010.324			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	675PS	20697359				2022-12-17	WOS:000283843400007
J	Suvasini, R; Somasundaram, K				Suvasini, R.; Somasundaram, K.			Essential role of PI3-kinase pathway in p53-mediated transcription: Implications in cancer chemotherapy	ONCOGENE			English	Article						p53; PI3-kinase; chemosensitivity; chemotherapy	PHOSPHATIDYLINOSITOL 3-KINASE/AKT PATHWAY; DNA-DAMAGE; BREAST-CANCER; TUMOR-CELLS; P53; AKT; INHIBITION; PHOSPHORYLATION; ACTIVATION; APOPTOSIS	The PI3-kinase pathway is the target of inactivation in achieving better cancer chemotherapy. Here, we report that p53-mediated transcription is inhibited by pharmacological inhibitors and a dominant-negative mutant of PI3-kinase, and this inhibition was relieved by a constitutively active mutant of PI3-kinase. Akt/PKB and mTOR, the downstream effectors of PI3-kinase, were also found to be essential. LY294002 (PI3-kinase inhibitor) pre-treatment altered the post-translational modifications and the sub-cellular localization of p53. Although LY294002 increased the chemosensitivity of cells to low concentrations of adriamycin (adriamycin-low), it protected the cells from cytotoxicity induced by high concentrations of adriamycin (adriamycin-high) in a p53-dependent manner. Further, we found that LY294002 completely abolished the activation of p53 target genes (particularly pro-apoptotic) under adriamycin-high conditions, whereas it only marginally repressed the p53 target genes under adriamycin-low conditions; in fact, it further activated the transcription of NOXA, HRK, APAF1 and CASP5 genes. Thus, the differential effect of PI3-kinase on p53 functions seems to be responsible for the differential regulation of DNA damage-induced cytotoxicity and cell death by PI3-kinase. Our finding becomes relevant in the light of ongoing combination chemotherapy trials with the PI3-kinase pathway inhibitors and underscores the importance of p53 status in the careful formulation of combination chemotherapies. Oncogene (2010) 29, 3605-3618; doi: 10.1038/onc.2010.123; published online 26 April 2010	[Suvasini, R.; Somasundaram, K.] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Somasundaram, K (corresponding author), Indian Inst Sci, Dept Microbiol & Cell Biol, CV Raman Ave, Bangalore 560012, Karnataka, India.	skumar@mcbl.iisc.ernet.in			ICMR; DBT; DST; UGC	ICMR(Indian Council of Medical Research (ICMR)); DBT(Department of Biotechnology (DBT) India); DST(Department of Science & Technology (India)); UGC(University Grants Commission, India)	KS is a Wellcome Trust International Senior Research Fellow. Infrastructural support by funding from ICMR, DBT, DST and UGC to MCB is acknowledged. RS gratefully acknowledges SRF from CSIR.	Bar J, 2005, CELL DEATH DIFFER, V12, P1578, DOI 10.1038/sj.cdd.4401677; Das S, 2003, J BIOL CHEM, V278, P18313, DOI 10.1074/jbc.M211704200; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fujiwara Y, 2006, BIOCHEM BIOPH RES CO, V340, P560, DOI 10.1016/j.bbrc.2005.12.039; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Guillard S, 2009, CELL CYCLE, V8, P443, DOI 10.4161/cc.8.3.7643; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KEMLER I, 1989, EMBO J, V8, P2001, DOI 10.1002/j.1460-2075.1989.tb03607.x; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lacroix M, 2006, ENDOCR-RELAT CANCER, V13, P293, DOI 10.1677/erc.1.01172; Lee CH, 2007, EMBO J, V26, P4812, DOI 10.1038/sj.emboj.7601900; Levine AJ, 2006, GENE DEV, V20, P267, DOI 10.1101/gad.1363206; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li XQ, 2005, BREAST CANCER RES, V7, pR589, DOI 10.1186/bcr1259; LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meek DW, 2004, DNA REPAIR, V3, P1049, DOI 10.1016/j.dnarep.2004.03.027; Meek DW, 1997, PATHOL BIOL, V45, P804; Min YH, 2003, LEUKEMIA, V17, P995, DOI 10.1038/sj.leu.2402874; Mungamuri SK, 2006, CANCER RES, V66, P4715, DOI 10.1158/0008-5472.CAN-05-3830; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Price BD, 1996, CANCER RES, V56, P246; Ramaswamy S, 1999, P NATL ACAD SCI USA, V96, P2110, DOI 10.1073/pnas.96.5.2110; Reddy SP, 2008, CLIN CANCER RES, V14, P2978, DOI 10.1158/1078-0432.CCR-07-4821; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Sakai A, 1998, BLOOD, V92, P3410, DOI 10.1182/blood.V92.9.3410.421a06_3410_3415; Somasundaram K, 2000, FRONT BIOSCI, V5, pD424, DOI 10.2741/Somasund; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Vousden KH, 2006, J CELL SCI, V119, P5015, DOI 10.1242/jcs.03293; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973	37	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2010	29	25					3605	3618		10.1038/onc.2010.123	http://dx.doi.org/10.1038/onc.2010.123			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	615CG	20418912				2022-12-17	WOS:000279108600002
J	Solyakov, L; Sayan, E; Riley, J; Pointon, A; Tobin, AB				Solyakov, L.; Sayan, E.; Riley, J.; Pointon, A.; Tobin, A. B.			Regulation of p53 expression, phosphorylation and subcellular localization by a G-protein-coupled receptor	ONCOGENE			English	Article						apoptosis; p53; G-protein-coupled receptor; M-3-muscarinic; mitochondria; SH-SY5Y	DAMAGE-INDUCED PHOSPHORYLATION; DNA-DAMAGE; INDUCED APOPTOSIS; CELL-DEATH; M-3-MUSCARINIC RECEPTOR; RHO-KINASE; IN-VIVO; ACTIVATION; MITOCHONDRIA; CANCER	G-protein-coupled receptors (GPCRs) have been extremely successful drug targets for a multitude of diseases from heart failure to depression. This superfamily of cell surface receptors have not, however, been widely considered as a viable target in cancer treatment. In this study we show that a classical G(q/11)-coupled GPCR, the M-3-muscarinic receptor, was able to regulate apoptosis through receptors that are endogenously expressed in the human neuroblastoma cell line, SH-SY5Y, and when ectopically expressed in Chinese hamster ovary (CHO) cells. Stimulation of the M-3-muscarinic receptor was shown to inhibit the ability of the DNA-damaging chemotherapeutic agent, etoposide, from mediating apoptosis. This protective response in CHO cells correlated with the ability of the receptor to regulate the expression levels of p53. In contrast, stimulation of endogenous muscarinic receptors in SH-SY5Y cells did not regulate p53 expression but rather was able to inhibit p53 translocation to the mitochondria and p53 phosphorylation at serine 15 and 37. This study suggests the possibility that a GPCR can regulate the apoptotic properties of a chemotherapeutic DNA-damaging agent by regulating the expression, subcellular traf. cking and modi. cation of p53 in a manner that is, in part, dependent on the cell type. Oncogene (2009) 28, 3619-3630; doi:10.1038/onc.2009.225; published online 3 August 2009	[Solyakov, L.; Tobin, A. B.] Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England; [Sayan, E.] Univ Leicester, Dept Canc Studies & Mol Med, Leicester LE1 9HN, Leics, England; [Riley, J.; Pointon, A.] MRC Toxicol Unit, Leicester, Leics, England	University of Leicester; University of Leicester	Tobin, AB (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Hodgkin Bldg,Lancaster Rd, Leicester LE1 9HN, Leics, England.	tba@le.ac.uk	SAYAN, A. EMRE/H-7330-2012	SAYAN, A. EMRE/0000-0002-5291-1485	Wellcome Trust [073480, 047600]	Wellcome Trust(Wellcome TrustEuropean Commission)	We thank the Wellcome Trust for their support (Grants 073480 and 047600).	Bean LJH, 2001, ONCOGENE, V20, P1076, DOI 10.1038/sj.onc.1204204; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Bourdon JC, 2007, BRIT J CANCER, V97, P277, DOI 10.1038/sj.bjc.6603886; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Brown JM, 2005, NAT REV CANCER, V5, P231, DOI 10.1038/nrc1560; Budd DC, 2004, BIOCHEM J, V381, P43, DOI 10.1042/BJ20031705; Budd DC, 2003, J BIOL CHEM, V278, P19565, DOI 10.1074/jbc.M211670200; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Chitaley K, 2001, NAT MED, V7, P119, DOI 10.1038/83258; Courtois S, 2004, ONCOGENE, V23, P631, DOI 10.1038/sj.onc.1206929; Cui HJ, 2002, MOL CANCER THER, V1, P679; Dale LB, 2000, J BIOL CHEM, V275, P38213, DOI 10.1074/jbc.M006075200; De Sarno L, 2005, BRAIN RES, V1041, P112, DOI 10.1016/j.brainres.2005.01.081; De Sarno P, 2003, J BIOL CHEM, V278, P11086, DOI 10.1074/jbc.M212157200; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; Diao CTM, 2000, BBA-MOL CELL RES, V1499, P49, DOI 10.1016/S0167-4889(00)00107-5; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fang XJ, 2000, BIOCHEM J, V352, P135, DOI 10.1042/0264-6021:3520135; Haupt S, 2006, ANTI-CANCER DRUG, V17, P725, DOI 10.1097/01.cad.0000217422.52208.fa; Hu T, 1999, MUTAT RES-FUND MOL M, V426, P51, DOI 10.1016/S0027-5107(99)00077-9; Kakudo Y, 2005, CANCER RES, V65, P2108, DOI 10.1158/0008-5472.CAN-04-2935; Klabunde T, 2002, CHEMBIOCHEM, V3, P929, DOI 10.1002/1439-7633(20021004)3:10<928::AID-CBIC928>3.0.CO;2-5; KOH JY, 1991, P NATL ACAD SCI USA, V88, P9431, DOI 10.1073/pnas.88.21.9431; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Li DWC, 2006, ONCOGENE, V25, P3006, DOI 10.1038/sj.onc.1209334; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Meek DW, 1999, ONCOGENE, V18, P7666, DOI 10.1038/sj.onc.1202951; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Murph MM, 2007, MOL CANCER RES, V5, P1201, DOI 10.1158/1541-7786.MCR-06-0338; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nemajerova A, 2005, CELL DEATH DIFFER, V12, P197, DOI 10.1038/sj.cdd.4401526; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Park BS, 2005, APOPTOSIS, V10, P193, DOI 10.1007/s10495-005-6074-7; Paulsen MT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-25; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sayan BS, 2006, J BIOL CHEM, V281, P13566, DOI 10.1074/jbc.M512467200; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Song P, 2007, CANCER RES, V67, P3936, DOI 10.1158/0008-5472.CAN-06-2484; Strom E, 2006, NAT CHEM BIOL, V2, P474, DOI 10.1038/nchembio809; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tobin AB, 2003, BIOCHEM SOC T, V31, P1182; ULLRICH SJ, 1992, ONCOGENE, V7, P1635; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; van Koppen CJ, 2003, PHARMACOL THERAPEUT, V98, P197, DOI 10.1016/S0163-7258(03)00032-9; Vichalkovski A, 2005, CELL SIGNAL, V17, P447, DOI 10.1016/j.cellsig.2004.09.010; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; YAN GM, 1995, MOL PHARMACOL, V47, P248; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhou Y, 2002, J BIOL CHEM, V277, P49481, DOI 10.1074/jbc.M206222200; Zhu WZ, 2001, P NATL ACAD SCI USA, V98, P1607, DOI 10.1073/pnas.98.4.1607	62	11	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 15	2009	28	41					3619	3630		10.1038/onc.2009.225	http://dx.doi.org/10.1038/onc.2009.225			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	507KJ	19648965	Green Accepted			2022-12-17	WOS:000270851800003
J	Klanrit, P; Taebunpakul, P; Flinterman, MB; Odell, EW; Riaz, MA; Melino, G; Salomoni, P; Mymryk, JS; Gaken, J; Farzaneh, F; Tavassoli, M				Klanrit, P.; Taebunpakul, P.; Flinterman, M. B.; Odell, E. W.; Riaz, M. A.; Melino, G.; Salomoni, P.; Mymryk, J. S.; Gaeken, J.; Farzaneh, F.; Tavassoli, M.			PML involvement in the p73-mediated E1A-induced suppression of EGFR and induction of apoptosis in head and neck cancers	ONCOGENE			English	Article						PML; EGFR; p73; E1A; HNSCC	ACUTE PROMYELOCYTIC LEUKEMIA; SQUAMOUS-CELL CARCINOMAS; FACTOR RECEPTOR PROMOTER; P53 TARGET GENES; RAR-ALPHA; E1A-MEDIATED SUPPRESSION; TRANSCRIPTIONAL ACTIVITY; PREMATURE SENESCENCE; MESSENGER-RNA; P73	Epidermal growth factor receptor (EGFR) tyrosine kinase is commonly overexpressed in human cancers; however, the cellular mechanisms regulating EGFR expression remain unclear. p53, p63 and p73 are transcription factors regulating many cellular targets involved in controlling the cell cycle and apoptosis. p53 activates EGFR expression, whereas TAp63 represses EGFR transcription. The involvement of p73 in the regulation of EGFR has not been reported. Here, a strong correlation between EGFR overexpression and increased levels of the oncogenic Delta Np73 isoform in head and neck squamous cell carcinoma (HNSCC) cell lines was observed. Ectopic expression of TAp73, particularly TAp73 beta, resulted in suppression of the EGFR promoter, significant downregulation of EGFR protein and efficient induction of cell death in all six EGFR-overexpressing HNSCC cell lines. EGFR overexpression from a heterologous LTR promoter protected lung cancer cells from TAp73 beta-induced EGFR suppression and apoptosis. Expression of TAp73 beta efficiently induced promyelocytic leukaemia (PML) protein expression and PML knockdown by shRNA attenuated the downregulation of EGFR and induction of apoptosis by p73 in HNSCC cells. Furthermore, PML was found to be important for E1A-induced suppression of EGFR and subsequent killing of HNSCC cells. Our data therefore suggest a novel pathway involving PML and p73 in the regulation of EGFR expression. Oncogene (2009) 28, 3499-3512; doi: 10.1038/onc.2009.191; published online 13 July 2009	[Klanrit, P.; Taebunpakul, P.; Flinterman, M. B.; Riaz, M. A.; Tavassoli, M.] Kings Coll London, Inst Dent, Head & Neck Oncol Grp, London SE1 9RT, England; [Odell, E. W.] Kings Coll London, Inst Dent, Dept Oral Pathol, London SE1 9RT, England; [Melino, G.; Salomoni, P.] Univ Leicester, Toxicol Unit, MRC, Leicester, Leics, England; [Mymryk, J. S.] Univ Western Ontario, Dept Oncol, London Reg Canc Program, London, ON, Canada; [Mymryk, J. S.] Univ Western Ontario, Dept Microbiol & Immunol, London, ON, Canada; [Gaeken, J.; Farzaneh, F.] Kings Coll London, Dept Hematol & Mol Med, London SE1 9RT, England	University of London; King's College London; University of London; King's College London; University of Leicester; Western University (University of Western Ontario); Western University (University of Western Ontario); University of London; King's College London	Tavassoli, M (corresponding author), Kings Coll London, Inst Dent, Head & Neck Oncol Grp, Guys Hosp Campus,Floor 28 Tower Wing, London SE1 9RT, England.	mahvash.tavassoli@kcl.ac.uk	Klanrit, Poramaporn/X-4784-2019; odell, edward w/E-9920-2012; Farzaneh, Farzin/B-4902-2009; gaken, joop/B-3414-2009	odell, edward w/0000-0001-8435-0048; Farzaneh, Farzin/0000-0002-9275-2415; 	Cancer Research UK [C1116]; Rosetrees Trust; Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust; King's College London; Royal Thai Government Scholarship; MRC [MC_U132670601, MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670601, MC_U132670600] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Rosetrees Trust(Rosetrees Trust); Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust; King's College London; Royal Thai Government Scholarship; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	We thank Prof Bert Vogelstein for providing Ad-GFP-p53 and Ad-GFP, Prof Karen Vousden for providing Ad-GFP-TAp73 beta, Prof Alfred Johnson for providing pER1-luc and Associate Prof Kun-Sang Chang for anti-PML clone 3573 antibody. We also thank Prof Alan Lehmann for 1BR3 and 1BR3-LT, Prof Hugh Paterson for 6689, Prof Barry Gusterson for HN5, Prof Kazuya Tominaga for HSC-3 and HSC-3 M3, Prof Fiona Watts for Km3, Prof Andrew Yeudall for HN30 and Prof Stephen Prime for H103 and H357 cell lines. We especially thank Prof Christoph Borner for the critical and helpful reading of this paper. This work was supported by grants from Cancer Research UK, the Rosetrees Trust and Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London. Marcella Flinterman was supported by a grant from Cancer Research UK (C1116). Poramaporn Klanrit and Patrayu Taebunpakul were supported by the Royal Thai Government Scholarship.	Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bernardi R, 2008, ONCOGENE, V27, P6299, DOI 10.1038/onc.2008.305; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Bernassola F, 2005, ONCOGENE, V24, P6982, DOI 10.1038/sj.onc.1208843; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Chen XB, 2001, ONCOGENE, V20, P769, DOI 10.1038/sj.onc.1204149; de Melker AA, 2001, J CELL SCI, V114, P2167; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; Denizot A, 2003, THYROID, V13, P867, DOI 10.1089/105072503322401069; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Flinterman M, 2005, J BIOL CHEM, V280, P5945, DOI 10.1074/jbc.M406661200; Flinterman M, 2003, ONCOGENE, V22, P1965, DOI 10.1038/sj.onc.1206190; Flinterman MB, 2007, ONCOGENE, V26, P6863, DOI 10.1038/sj.onc.1210497; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Goldschneider D, 2004, J CELL SCI, V117, P293, DOI 10.1242/jcs.00834; Guelen L, 2004, ONCOGENE, V23, P1153, DOI 10.1038/sj.onc.1207224; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; GUSTERSON BA, 1991, ONCOGENE, V6, P1785; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; KASTNER P, 1991, CR SOC BIOL, V185, P391; Klanrit P, 2008, CELL CYCLE, V7, P205, DOI 10.4161/cc.7.2.5361; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; Lee CW, 1999, ONCOGENE, V18, P4171, DOI 10.1038/sj.onc.1202793; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Nishi H, 2001, J BIOL CHEM, V276, P41717, DOI 10.1074/jbc.M101241200; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Racek T, 2005, J BIOL CHEM, V280, P40402, DOI 10.1074/jbc.C500193200; SAKAI E, 1992, ONCOGENE, V7, P927; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sayan AE, 2005, BIOCHEM BIOPH RES CO, V330, P186, DOI 10.1016/j.bbrc.2005.02.145; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Specht K, 2001, AM J PATHOL, V158, P419, DOI 10.1016/S0002-9440(10)63985-5; Tyteca S, 2006, EMBO J, V25, P1680, DOI 10.1038/sj.emboj.7601066; Ueda Y, 1999, ONCOGENE, V18, P4993, DOI 10.1038/sj.onc.1202817; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; Wang ZG, 1998, SCIENCE, V279, P1547; Wu LQ, 2004, ONCOGENE, V23, P4032, DOI 10.1038/sj.onc.1207538; Wu Q, 2009, J BIOL CHEM, V284, P8738, DOI 10.1074/jbc.M807590200; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; YAN DH, 1991, ONCOGENE, V6, P343; Yeudall WA, 1997, MOL CARCINOGEN, V18, P89, DOI 10.1002/(SICI)1098-2744(199702)18:2<89::AID-MC4>3.0.CO;2-L; YEUDALL WA, 1995, ORAL ONCOL, V31B, P136, DOI 10.1016/0964-1955(94)00030-8; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Zaika AI, 2002, J EXP MED, V196, P765, DOI 10.1084/jem.20020179; Zhu JH, 1998, CANCER RES, V58, P5061	51	11	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2009	28	39					3499	3512		10.1038/onc.2009.191	http://dx.doi.org/10.1038/onc.2009.191			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	502RR	19597475	Green Accepted			2022-12-17	WOS:000270478300007
J	Gong, Y; Sun, Y; McNutt, MA; Sun, Q; Hou, L; Liu, H; Shen, Q; Ling, Y; Chi, Y; Zhang, B				Gong, Y.; Sun, Y.; McNutt, M. A.; Sun, Q.; Hou, L.; Liu, H.; Shen, Q.; Ling, Y.; Chi, Y.; Zhang, B.			Localization of TEIF in the centrosome and its functional association with centrosome amplification in DNA damage, telomere dysfunction and human cancers	ONCOGENE			English	Article						centrosome; DNA damage; telomere dysfunction; cancer	CHROMOSOMAL INSTABILITY; GENETIC INSTABILITY; TUMOR-VIRUSES; I TAX; PROTEINS; 11Q13; CELLS; MICROTUBULE; ONCOGENE; KINASE	Centrosome amplification and telomere shortening, which are commonly detected in human cancers, have been implicated in the induction of chromosome instability in tumorigenesis. The functions of these two structures are closely related to DNA damage repair machinery, and some factors that operate in the maintenance of telomeres also take part in the regulation of centrosome status, suggesting they are functionally linked. We report that TEIF (telomerase transcriptional elements-interacting factor), a transactivator of the hTERT (human telomerase reverse transcriptase subunit) gene, is distributed in the centrosome throughout the cell cycle, but its transport into the centrosome is increased under some conditions, and its distribution is dependent on its C-terminal domain. Experimental modulation of TEIF expression through overexpression, polypeptide expression or depletion affected centrosome status and increased abnormalities of cell mitosis. Localization of TEIF to the centrosome was also stimulated by treatment with genotoxic agents and experimental telomere dysfunction, accompanying centrosome amplification. Moreover, we demonstrated that the expression level of TEIF is not only closely correlated with centrosome amplification in soft tissue sarcomas but it is also significantly related to tumor histologic grade. Our data confirmed TEIF functions as a centrosome regulator. Its participation in DNA damage response, including telomere dysfunction and tumorigenesis, indicates TEIF is likely to be a factor involved in linking centrosome amplification and telomere dysfunction in cancer development.	[Gong, Y.; Sun, Y.; McNutt, M. A.; Sun, Q.; Hou, L.; Liu, H.; Shen, Q.; Ling, Y.; Chi, Y.; Zhang, B.] Peking Univ, Dept Pathol, Hlth Sci Ctr, Beijing 100191, Peoples R China	Peking University	Zhang, B (corresponding author), Peking Univ, Dept Pathol, Hlth Sci Ctr, 38 Xueyuan Rd, Beijing 100191, Peoples R China.	zhangbo@bjmu.edu.cn			National Natural Science Foundation of China [30570691]; Doctors Program Foundations of Ministry Education [20040001147]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Doctors Program Foundations of Ministry Education	This research was supported by National Natural Science Foundation of China (no. 30570691), and Doctors Program Foundations of Ministry Education (Grant 20040001147).	Andersen JS, 2003, NATURE, V426, P570, DOI 10.1038/nature02166; Bellon M, 2008, JNCI-J NATL CANCER I, V100, P98, DOI 10.1093/jnci/djm269; Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Brown LA, 2006, GYNECOL ONCOL, V100, P264, DOI 10.1016/j.ygyno.2005.08.026; Chikashige Y, 2006, CELL, V125, P59, DOI 10.1016/j.cell.2006.01.048; Churikov D, 2006, MOL CELL BIOL, V26, P6971, DOI 10.1128/MCB.01011-06; Dou Z, 2004, FEBS LETT, V572, P51, DOI 10.1016/j.febslet.2004.06.092; Doxsey S, 2005, ANNU REV CELL DEV BI, V21, P411, DOI 10.1146/annurev.cellbio.21.122303.120418; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Doxsey S, 2001, NAT REV MOL CELL BIO, V2, P688, DOI 10.1038/35089575; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Ewart-Toland A, 2003, NAT GENET, V34, P403, DOI 10.1038/ng1220; Fletcher L, 2006, CANCER LETT, V243, P1, DOI 10.1016/j.canlet.2006.01.006; Fukasawa K, 2005, CANCER LETT, V230, P6, DOI 10.1016/j.canlet.2004.12.028; Gillingham AK, 2000, EMBO REP, V1, P524; Gisselsson D, 2005, CELL CYCLE, V4, P1007, DOI 10.4161/cc.4.8.1884; Gisselsson D, 2005, GENE CHROMOSOME CANC, V42, P22, DOI 10.1002/gcc.20094; Gisselsson D, 2004, BRIT J CANCER, V91, P327, DOI 10.1038/sj.bjc.6601803; Gisselsson D, 2003, ADV CANCER RES, V87, P1; Gisselsson D, 2002, BRIT J CANCER, V87, P202, DOI 10.1038/sj.bjc.6600438; GISSELSSON D, 2001, ATLAS GENETICS CYTOG; Hackett JA, 2002, ONCOGENE, V21, P619, DOI 10.1038/sj.onc.1205061; Hara T, 2008, CANCER SCI, V99, P1155, DOI 10.1111/j.1349-7006.2008.00798.x; Lavia P, 2003, ONCOGENE, V22, P6508, DOI 10.1038/sj.onc.1206861; Lingle WL, 2000, CURR TOP DEV BIOL, V49, P313; Loffler H, 2006, EXP CELL RES, V312, P2633, DOI 10.1016/j.yexcr.2006.06.008; Lou Y, 2004, BIOCHEM BIOPH RES CO, V321, P495, DOI 10.1016/j.bbrc.2004.06.171; Masutomi K, 2003, CELL, V114, P241, DOI 10.1016/S0092-8674(03)00550-6; Matsumoto Y, 2004, SCIENCE, V306, P885, DOI 10.1126/science.1103544; McPherson JP, 2006, HUM MOL GENET, V15, P831, DOI 10.1093/hmg/ddl002; Momotani K, 2008, BIOCHEM J, V412, P265, DOI 10.1042/BJ20071501; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Ohta T, 2002, J CELL BIOL, V156, P87, DOI 10.1083/jcb.200108088; Peset I, 2008, TRENDS CELL BIOL, V18, P379, DOI 10.1016/j.tcb.2008.06.005; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Plug-DeMaggio AW, 2004, ONCOGENE, V23, P3561, DOI 10.1038/sj.onc.1207388; Pumfery A, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-50; Saunders W, 2005, SEMIN CANCER BIOL, V15, P25, DOI 10.1016/j.semcancer.2004.09.003; Slijepcevic P, 2006, DNA REPAIR, V5, P1299, DOI 10.1016/j.dnarep.2006.05.038; Smith S, 1999, J CELL SCI, V112, P3649; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; Tang Zhiwei, 2003, Beijing Da Xue Xue Bao Yi Xue Ban, V35, P402; Tang ZW, 2004, BIOCHEM BIOPH RES CO, V324, P1324, DOI 10.1016/j.bbrc.2004.09.201; van Asseldonk M, 2000, GENOMICS, V66, P35, DOI 10.1006/geno.2000.6194; Wang X, 2007, CELL DEATH DIFFER, V14, P924, DOI 10.1038/sj.cdd.4402105; Wong KF, 1999, CANCER GENET CYTOGEN, V113, P93, DOI 10.1016/S0165-4608(98)00285-4; Zaharieva BM, 2003, J PATHOL, V201, P603, DOI 10.1002/path.1481; Zhao YJ, 2005, BIOCHEM BIOPH RES CO, V333, P908, DOI 10.1016/j.bbrc.2005.05.172	48	11	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2009	28	12					1549	1560		10.1038/onc.2008.503	http://dx.doi.org/10.1038/onc.2008.503			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	424AH	19198626				2022-12-17	WOS:000264537400007
J	Manenti, G; Trincucci, G; Pettinicchio, A; Amendola, E; Scarfo, M; Dragani, TA				Manenti, G.; Trincucci, G.; Pettinicchio, A.; Amendola, E.; Scarfo, M.; Dragani, T. A.			Cis-acting genomic elements of the Pas1 locus control Kras mutability in lung tumors	ONCOGENE			English	Article						mouse; heredity; genetic susceptibility; lung cancer	K-RAS GENE; TRANSGENIC MICE; H-RAS; N-RAS; MOUSE; SUSCEPTIBILITY; CANCER; TUMORIGENESIS; ACTIVATION; CARCINOGENESIS	The Pas1 locus is the major tumor modi. er of lung tumorigenesis in mouse inbred strains. Of six genes contained in a conserved haplotype, three (Casc1, Kras and Ifltd1) have been proposed as Pas1 candidates, but mechanistic evidence is sparse. Herein, we examined urethane-induced lung tumorigenesis in a new mouse model developed by replacing the Kras gene with an Hras gene in the susceptible A/J-type Pas1 locus and crossing these mice with either C57BL/6J or A/J mice. Heterozygous mice carrying the Hras-replacement gene were more susceptible than wild-type mice to lung carcinogenesis, indicating that Hras replacement not only compensates for Kras functions, but is more active. Indeed, most lung tumors carried a Gln61Leu mutation in the Hras-replacement gene, whereas no mutations were observed in the endogenous Hras gene. Thus, the context of the Kras locus determined mutability of ras genes. In mice carrying the Hras-replacement gene, the mutation frequency affecting the wild-type Kras gene was much higher when this gene was located in the A/J type than in the C57BL/6J-type Pas1 locus (12 versus 0%, -log P = 5.0). These findings identify cis-acting elements in the Pas1 locus as the functional components controlling genetic susceptibility to lung tumorigenesis by modulating mutability of the Kras gene.	[Manenti, G.; Trincucci, G.; Pettinicchio, A.; Dragani, T. A.] Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol & Labs, I-20133 Milan, Italy; [Amendola, E.; Scarfo, M.] Staz Zoolog Anton Dohrn, Naples, Italy; [Amendola, E.; Scarfo, M.] Biogem SC Ar L, IRGS, Ariano Irpino, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Stazione Zoologica Anton Dohrn di Napoli	Dragani, TA (corresponding author), Ist Nazl Tumori, Fdn IRCCS, Dept Expt Oncol, Via G Venezian 1, I-20133 Milan, Italy.	tommaso.dragani@istitutotumori.mi.it	Dragani, Tommaso A./K-4493-2016; Manenti, Giacomo/J-3339-2017	Dragani, Tommaso A./0000-0001-5915-4598; Manenti, Giacomo/0000-0002-4887-4482	Associazione and Fondazione Italiana Ricerca Cancro (AIRC and FIRC)	Associazione and Fondazione Italiana Ricerca Cancro (AIRC and FIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was funded in part by grants from Associazione and Fondazione Italiana Ricerca Cancro (AIRC and FIRC). The funders had no role in the design and conduct of the study, in the collection, analysis and interpretation of the data, and in the preparation, review or approval of the article.	CHEN B, 1994, CARCINOGENESIS, V15, P2031, DOI 10.1093/carcin/15.9.2031; De Gregorio L, 1998, INT J CANCER, V79, P269, DOI 10.1002/(SICI)1097-0215(19980619)79:3<269::AID-IJC10>3.3.CO;2-J; Dragani TA, 2000, CANCER RES, V60, P5017; Dragani TA, 1995, ADV CANCER RES, V67, P83, DOI 10.1016/S0065-230X(08)60711-3; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Jones-Bolin SE, 1998, CARCINOGENESIS, V19, P1503, DOI 10.1093/carcin/19.8.1503; Koera K, 1997, ONCOGENE, V15, P1151, DOI 10.1038/sj.onc.1201284; MAHER J, 1995, ONCOGENE, V11, P1639; Manenti G, 2005, CARCINOGENESIS, V26, P875, DOI 10.1093/carcin/bgh299; Manenti G, 2004, ONCOGENE, V23, P4495, DOI 10.1038/sj.onc.1207584; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; Manenti G, 2006, CARCINOGENESIS, V27, P1386, DOI 10.1093/carcin/bgi332; MARONPOT RR, 1991, EXP LUNG RES, V17, P305, DOI 10.3109/01902149109064420; Mascaux C, 2005, BRIT J CANCER, V92, P131, DOI 10.1038/sj.bjc.6602258; Meuwissen R, 2001, ONCOGENE, V20, P6551, DOI 10.1038/sj.onc.1204837; Ogawa K, 1996, CARCINOGENESIS, V17, P341, DOI 10.1093/carcin/17.2.341; Potenza N, 2005, EMBO REP, V6, P432, DOI 10.1038/sj.embor.7400397; To MD, 2006, NAT GENET, V38, P926, DOI 10.1038/ng1836; Tomisawa M, 2003, TOXICOL LETT, V142, P111, DOI 10.1016/S0378-4274(03)00018-3; Umemura T, 1999, CANCER LETT, V145, P101, DOI 10.1016/S0304-3835(99)00237-2; Wang M, 2005, ONCOGENE, V24, P1958, DOI 10.1038/sj.onc.1208295; YOU M, 1992, P NATL ACAD SCI USA, V89, P5804, DOI 10.1073/pnas.89.13.5804; Zhang ZQ, 2003, P NATL ACAD SCI USA, V100, P12642, DOI 10.1073/pnas.2133947100	24	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP	2008	27	43					5753	5758		10.1038/onc.2008.194	http://dx.doi.org/10.1038/onc.2008.194			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	352HM	18560355				2022-12-17	WOS:000259487100010
J	Paulson, QX; Pusapati, RV; Hong, S; Weaks, RL; Conti, CJ; Johnson, DG				Paulson, Q. X.; Pusapati, R. V.; Hong, S.; Weaks, R. L.; Conti, C. J.; Johnson, D. G.			Transgenic expression of E2F3a causes DNA damage leading to ATM-dependent apoptosis	ONCOGENE			English	Article						Rb; ATM; oncogenic stress; DNA-damage response	ONCOGENE-INDUCED SENESCENCE; ATAXIA-TELANGIECTASIA; HUMAN TUMORIGENESIS; SIGNALING PATHWAY; BLADDER-CANCER; LUNG-CANCER; PROLIFERATION; OVEREXPRESSION; RETINOBLASTOMA; GENE	Many early stage human tumors display markers of a DNA-damage response (DDR), including ataxia telangiectasia mutated (ATM) kinase activation. This suggests that DNA damage accumulates during the process of carcinogenesis and that the ATM-dependent response to this damage may function to suppress cancer progression. The E2F3a transcription factor plays an important role in regulating cell proliferation and is amplified in a subset of human cancers. Similar to human premalignant lesions, we find activated ATM and other markers of the DDR in the hyperplastic epidermis of transgenic mice expressing E2F3a through a keratin 5 (K5) promoter. Primary keratinocytes from K5 E2F3a transgenic mice contain increased levels of DNA breaks compared to wild-type cells. E2F3a overexpression also induced DNA damage in primary human fibroblasts that was inhibited by blocking DNA replication. The absence of ATM impaired apoptosis induced by E2F3a and treating K5 E2F3a transgenic mice with caffeine, an inhibitor of ATM and Rad3-related (ATR), promoted skin tumor development. These findings demonstrate that the deregulated expression of E2F3a causes DNA damage under physiological conditions and indicate that the ATM-dependent response to this damage is important for the induction of apoptosis and tumor suppression.	[Paulson, Q. X.; Pusapati, R. V.; Hong, S.; Weaks, R. L.; Conti, C. J.; Johnson, D. G.] Univ Texas MD Anderson Canc Ctr, Div Sci Pk Res, Dept Carcinogenesis, Smithville, TX 78957 USA	University of Texas System; UTMD Anderson Cancer Center	Johnson, DG (corresponding author), Univ Texas MD Anderson Canc Ctr, Div Sci Pk Res, Dept Carcinogenesis, POB 389, Smithville, TX 78957 USA.	djohnson@mdanderson.org		Johnson, David/0000-0002-6223-1790	National Institutes of Health [CA098601, CA79648, U01CA105345, ES07784, CA16672]; NATIONAL CANCER INSTITUTE [R01CA079648, R01CA098601, U01CA105345, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007784] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Mark McArthur for pathological analysis of skin lesions, Jen Smith and Pam Blau for technical assistance, Lezlee Coghlan, Dale Weiss and coworkers for animal care, Chris Brown and Joi Holcomb for graphics and Shawnda Sanders for preparation of the manuscript. This work was supported by National Institutes of Health Grants CA098601 and CA79648( to DGJ), U01CA105345, ES07784, and CA16672. RLW is supported by an American Legion Auxiliary Fellowship.	Ai LB, 2004, CANCER EPIDEM BIOMAR, V13, P150, DOI 10.1158/1055-9965.EPI-082-3; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Davidson IF, 2006, MOL CELL, V24, P433, DOI 10.1016/j.molcel.2006.09.010; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Feber A, 2004, ONCOGENE, V23, P1627, DOI 10.1038/sj.onc.1207274; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grasemann C, 2005, ONCOGENE, V24, P6441, DOI 10.1038/sj.onc.1208792; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Humbert PO, 2000, GENE DEV, V14, P690; Hunt CR, 2007, CANCER RES, V67, P3010, DOI 10.1158/0008-5472.CAN-06-4328; Karaa A, 2007, INT J DERMATOL, V46, P671, DOI 10.1111/j.1365-4632.2007.03260.x; Kinzler KW, 1997, NATURE, V386, P763; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Mallette FA, 2007, GENE DEV, V21, P43, DOI 10.1101/gad.1487307; Mandel HG, 2002, FOOD CHEM TOXICOL, V40, P1231, DOI 10.1016/S0278-6915(02)00093-5; Oeggerli M, 2004, ONCOGENE, V23, P5616, DOI 10.1038/sj.onc.1207749; Orlic M, 2006, GENE CHROMOSOME CANC, V45, P72, DOI 10.1002/gcc.20263; Paulson QX, 2006, CELL CYCLE, V5, P184, DOI 10.4161/cc.5.2.2307; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Powers JT, 2004, MOL CANCER RES, V2, P203; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rogoff HA, 2004, MOL CELL BIOL, V24, P2968, DOI 10.1128/MCB.24.7.2968-2977.2004; Russell JL, 2002, MOL CELL BIOL, V22, P1360, DOI 10.1128/MCB.22.5.1360-1368.2002; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Safar AM, 2005, CLIN CANCER RES, V11, P4400, DOI 10.1158/1078-0432.CCR-04-2378; Suzuki A, 2004, BIOCHEM BIOPH RES CO, V324, P986, DOI 10.1016/j.bbrc.2004.09.145; Tort F, 2006, CANCER RES, V66, P10258, DOI 10.1158/0008-5472.CAN-06-2178; Veltman JA, 2003, CANCER RES, V63, P2872; Vo QN, 2004, ONCOGENE, V23, P9432, DOI 10.1038/sj.onc.1208092; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	36	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 21	2008	27	36					4954	4961		10.1038/onc.2008.138	http://dx.doi.org/10.1038/onc.2008.138			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	339SF	18469863	Bronze			2022-12-17	WOS:000258596900009
J	Sukhai, MA; Thomas, M; Xuan, Y; Chan, LSA; Hamadanizadeh, SA; Zhang, T; Bharadwaj, RR; Schuh, AC; Wells, RA; Kamel-Reid, S				Sukhai, M. A.; Thomas, M.; Xuan, Y.; Chan, L. S. A.; Hamadanizadeh, S. A.; Zhang, T.; Bharadwaj, R. R.; Schuh, A. C.; Wells, R. A.; Kamel-Reid, S.			Evidence of functional interaction between NuMA-RAR alpha and RXR alpha in an in vivo model of acute promyelocytic leukemia	ONCOGENE			English	Article							ACID RECEPTOR-ALPHA; RETINOIC ACID; FUSION PROTEINS; MYELOID-LEUKEMIA; DNA-BINDING; GENE; VARIANT; PLZF; NPM; DIFFERENTIATION	Acute promyelocytic leukemia (APL) is characterized by reciprocal balanced chromosomal translocations involving retinoic acid receptor-alpha (RAR alpha). RAR alpha heterodimerizes with the retinoid X receptor-alpha (RXR alpha) and transcriptionally regulates myeloid differentiation in response to ATRA (all-trans retinoic acid). Several lines of evidence suggest that APL fusion proteins interact with RXR alpha. To elucidate the role of RXR alpha in APL, we conditionally knocked out RXR alpha in the hCG-NuMA-RAR alpha APL mouse model. Phenotype analysis of NuMA-RAR alpha(+) mice demonstrated that these mice developed a myeloproliferative disease-like myeloid leukemia within 4 months of birth. While hemizygous and homozygous RXR alpha conditional knockout mice were phenotypically normal as late as 12 months of age, we observed that the leukemic phenotype in NuMA-RAR alpha(+) mice was dependent on the presence of functional RXR alpha. Bone marrow promyelocyte counts were significantly reduced in NuMA-RAR alpha(+) mice with RXRa knocked down. Significant differences in the accumulations of Gr-1(+) and Mac-1(+) cells were also seen. We further observed that genes previously identified to be cooperating events in APL were also regulated in an RXR alpha-dependent manner. We therefore propose that the APL fusion protein NuMA-RAR alpha cooperates with RXR alpha in the development of leukemia in hCG-NuMA-RAR alpha transgenic mice and suggest a novel role for RXR alpha in the pathogenesis of APL.	[Sukhai, M. A.; Thomas, M.; Xuan, Y.; Hamadanizadeh, S. A.; Zhang, T.; Bharadwaj, R. R.; Schuh, A. C.; Kamel-Reid, S.] Univ Hlth Network, Ontario Canc Inst, Princess Margaret Hosp, Div Appl Mol Oncol, Toronto, ON M5G 2M9, Canada; [Sukhai, M. A.; Thomas, M.; Chan, L. S. A.; Schuh, A. C.; Wells, R. A.; Kamel-Reid, S.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Chan, L. S. A.; Wells, R. A.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Crashley Myelodysplast Syndrome Res Lab, Toronto, ON M4N 3M5, Canada; [Hamadanizadeh, S. A.; Kamel-Reid, S.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Kamel-Reid, S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto	Kamel-Reid, S (corresponding author), Univ Hlth Network, Ontario Canc Inst, Princess Margaret Hosp, Div Appl Mol Oncol, Room 9-622,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	Suzanne.Kamel-Reid@uhn.on.ca	Chan, Lap Shu/AAF-8737-2021	Chan, Lap Shu/0000-0003-1409-8638; Mathew, Mariam/0000-0003-2203-6939; Kamel-Reid, Suzanne/0000-0002-4386-0292				Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASTAIGNE S, 1990, BLOOD, V76, P1704; Catalano A, 2007, BLOOD, V110, P4073, DOI 10.1182/blood-2007-06-095554; Chen J, 1998, DEVELOPMENT, V125, P1943; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Hummel JL, 2002, CELL GROWTH DIFFER, V13, P173; Imai T, 2001, P NATL ACAD SCI USA, V98, P4581, DOI 10.1073/pnas.071056098; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Kamel-Reid S, 2003, ONCOGENE, V22, P6424, DOI 10.1038/sj.onc.1206696; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Li M, 2001, DEVELOPMENT, V128, P675; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Licht JD, 1996, ONCOGENE, V12, P323; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Reis PP, 2002, ONCOGENE, V21, P6480, DOI 10.1038/sj.onc.1205864; RICOTE M, 2006, J LUEKOC BIOL, V4, P850; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Silva MLM, 2005, ONCOL REP, V14, P663; So CW, 2000, LEUKEMIA, V14, P77, DOI 10.1038/sj.leu.2401643; Stephensen CB, 2007, IMMUNOLOGY, V121, P484, DOI 10.1111/j.1365-2567.2007.02595.x; Sukhai MA, 2004, ONCOGENE, V23, P665, DOI 10.1038/sj.onc.1207073; Taschner S, 2007, BLOOD, V109, P971, DOI 10.1182/blood-2006-04-020552.7; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Zeisig BB, 2007, CANCER CELL, V12, P36, DOI 10.1016/j.ccr.2007.06.006; Zhu J, 2007, CANCER CELL, V12, P23, DOI 10.1016/j.ccr.2007.06.004	37	11	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4666	4677		10.1038/onc.2008.106	http://dx.doi.org/10.1038/onc.2008.106			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408763				2022-12-17	WOS:000258236300005
J	Freilinger, A; Rosner, M; Hanneder, M; Hengstschlager, M				Freilinger, A.; Rosner, M.; Hanneder, M.; Hengstschlaeger, M.			Ras mediates cell survival by regulating tuberin	ONCOGENE			English	Article						Ras; survival; tuberin; ERK; RSK	TUMOR-SUPPRESSOR GENE; RIBOSOMAL S6 KINASE; SCLEROSIS COMPLEX; 3-KINASE/AKT PATHWAY; HUMAN-DISEASE; TSC2; PRODUCT; GROWTH; PHOSPHORYLATION; APOPTOSIS	Mutational activation of Ras promotes oncogenesis by controlling cell cycle regulation and cell survival. Ras-mediated activation of both, the PI3K/AKT pathway and the MEK/ERK pathway, can trigger downregulation of the function of tuberin to block the activities of mTOR and p70S6K. Here we demonstrate that Ras-induced cell survival is accompanied by upregulation of p70S6K activity. Ras harbors the potential to negatively affect tuberin-induced apoptosis and p70S6K inactivation. These effects of Ras were found to depend on its potential to regulate the MEK/ERK pathway. Experiments using tuberin-negative fibroblasts revealed that the potential of Ras to counteract apoptosis depends on functional tuberin. Taken together, we provide evidence that the function of Ras to trigger inactivation of tuberin plays a major role in the regulation of cell survival upon mutational activation of the oncogene Ras. This is the first description of a functional interaction between the tumor suppressor tuberin and the oncogene Ras in regulating apoptosis.	[Hengstschlaeger, M.] Med Univ Vienna, Gen Hosp, A-1090 Vienna, Austria	Medical University of Vienna	Hengstschlager, M (corresponding author), Med Univ Vienna, Gen Hosp, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	markus.hengstschlaeger@meduniwien.ac.at						Adachi H, 2003, J UROLOGY, V170, P601, DOI 10.1097/01.ju.0000074621.74361.10; Arrebola F, 2005, APOPTOSIS, V10, P1317, DOI 10.1007/s10495-005-2718-x; Astrinidis A, 2005, ONCOGENE, V24, P7475, DOI 10.1038/sj.onc.1209090; Ballif BA, 2005, P NATL ACAD SCI USA, V102, P667, DOI 10.1073/pnas.0409143102; Cox AD, 2003, ONCOGENE, V22, P8999, DOI 10.1038/sj.onc.1207111; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115; Freilinger A, 2006, ONCOGENE, V25, P6467, DOI 10.1038/sj.onc.1209660; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Henry KW, 1998, J BIOL CHEM, V273, P20535, DOI 10.1074/jbc.273.32.20535; Hornigold N, 1999, ONCOGENE, V18, P2657, DOI 10.1038/sj.onc.1202854; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jiang WG, 2005, EUR J CANCER, V41, P1628, DOI 10.1016/j.ejca.2005.03.023; Kalejta RF, 1997, CYTOMETRY, V29, P286, DOI 10.1002/(SICI)1097-0320(19971201)29:4<286::AID-CYTO4>3.0.CO;2-8; Knowles MA, 2003, CANCER RES, V63, P7652; Knowles MA, 2003, BIOCHEM SOC T, V31, P597, DOI 10.1042/BST0310597; Kolb TM, 2005, TOXICOL SCI, V88, P331, DOI 10.1093/toxsci/kfi310; Kwiatkowski DJ, 2003, ANN HUM GENET, V67, P87, DOI 10.1046/j.1469-1809.2003.00012.x; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Miloloza A, 2000, HUM MOL GENET, V9, P1721, DOI 10.1093/hmg/9.12.1721; Pan DJ, 2004, TRENDS CELL BIOL, V14, P78, DOI 10.1016/j.tcb.2003.12.006; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Rosner M, 2004, J BIOL CHEM, V279, P48707, DOI 10.1074/jbc.M405528200; Rosner M, 2003, ONCOGENE, V22, P4786, DOI 10.1038/sj.onc.1206776; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Soucek T, 1998, ONCOGENE, V16, P2197, DOI 10.1038/sj.onc.1201743; Soucek T, 1998, P NATL ACAD SCI USA, V95, P15653, DOI 10.1073/pnas.95.26.15653; Soucek T, 1997, J BIOL CHEM, V272, P29301, DOI 10.1074/jbc.272.46.29301; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Wohlfart S, 2004, AM J PATHOL, V164, P1081, DOI 10.1016/S0002-9440(10)63195-1; Xiao GH, 1997, J BIOL CHEM, V272, P6097, DOI 10.1074/jbc.272.10.6097	40	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 27	2008	27	14					2072	2083		10.1038/sj.onc.1210844	http://dx.doi.org/10.1038/sj.onc.1210844			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	279MK	17922028				2022-12-17	WOS:000254359100012
J	Li, Y; Lu, J; Cohen, D; Prochownik, EV				Li, Y.; Lu, J.; Cohen, D.; Prochownik, E. V.			Transformation, genomic instability and senescence mediated by platelet/megakaryocyte glycoprotein Ib alpha	ONCOGENE			English	Article						c-Myc; tetraploidy; aneuploidy; von Willebrand's factor	C-MYC TARGET; ONCOGENE-INDUCED SENESCENCE; HUMAN-CELLS; CANCER; GENES; OVEREXPRESSION; TUMORIGENESIS; ANEUPLOIDY; DEFECTS; GROWTH	GpIb alpha, a subunit of the von Willebrand factor receptor, functions during blood clotting to promote platelet adhesion and activation. GpIb alpha is widely expressed, is positively regulated by c-Myc and is essential for the promotion of c-Myc-mediated chromosomal instability. We now show that GpIba is also a classical oncoprotein in which its deregulated expression leads to transformation, reduced growth factor requirements, increased resistance to apoptosis, and, in primary cells, p53-dependent senescence. Finally, GpIb alpha also promotes double-stranded DNA breaks, and induces profound nuclear dysmorphology, indicating that, in addition to its direct transforming function, it displays genotoxicity at several distinct levels. These findings identify novel functions for GpIb alpha and pathways through which c-Myc mediates transformation and global genomic destabilization.	[Li, Y.; Lu, J.; Cohen, D.; Prochownik, E. V.] Childrens Hosp Pittsburgh, Rangos Res Ctr, Hematol Oncol Sect, Pittsburgh, PA 15213 USA; [Prochownik, E. V.] Univ Pittsburgh, Med Ctr, Dept Mol Genet & Biochem, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Prochownik, EV (corresponding author), Childrens Hosp Pittsburgh, Rangos Res Ctr, Hematol Oncol Sect, Room 8125,3460 5th Ave, Pittsburgh, PA 15213 USA.	procev@chp.edu			NATIONAL CANCER INSTITUTE [R01CA105033, R01CA078259] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA105033, R01CA078259] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andalis AA, 2004, GENETICS, V167, P1109, DOI 10.1534/genetics.104.029256; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Andreassen PR, 2003, MUTAT RES-FUND MOL M, V532, P245, DOI 10.1016/j.mrfmmm.2003.08.020; Asazuma N, 1997, BLOOD, V90, P4789, DOI 10.1182/blood.V90.12.4789.4789_4789_4798; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Canobbio H, 2004, CELL SIGNAL, V16, P1329, DOI 10.1016/j.cellsig.2004.05.008; Comai L, 2005, NAT REV GENET, V6, P836, DOI 10.1038/nrg1711; Dai KS, 2005, BLOOD, V106, P1975, DOI 10.1182/blood-2005-01-0440; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ekwall K, 1999, GENETICS, V153, P1153; Feng S, 1999, BLOOD, V93, P4256, DOI 10.1182/blood.V93.12.4256.412k33_4256_4263; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Goshima G, 2007, SCIENCE, V316, P417, DOI 10.1126/science.1141314; Grandori C, 2000, ANNU REV CELL DEV BI, V16, P653, DOI 10.1146/annurev.cellbio.16.1.653; HARLEY CB, 1995, CURR OPIN GENET DEV, V5, P249, DOI 10.1016/0959-437X(95)80016-6; Iarmarcovai G, 2006, TOXICOL LETT, V166, P1, DOI 10.1016/j.toxlet.2006.05.015; Kanaji T, 2004, BLOOD, V104, P3161, DOI 10.1182/blood-2004-03-0893; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Korkola JE, 2006, CANCER RES, V66, P820, DOI 10.1158/0008-5472.CAN-05-2445; Li Q, 1999, MOL CELL BIOL, V19, P5339; Li YJ, 2007, P NATL ACAD SCI USA, V104, P3490, DOI 10.1073/pnas.0610163104; Lopez J A, 1997, Curr Opin Hematol, V4, P323; Maines JZ, 2004, DEVELOPMENT, V131, P775, DOI 10.1242/dev.00932; Meek DW, 2000, PATHOL BIOL, V48, P246; Menssen A, 2007, CELL CYCLE, V6, P339, DOI 10.4161/cc.6.3.3808; Neiman PE, 2006, ONCOGENE, V25, P6325, DOI 10.1038/sj.onc.1209646; Nesbit CE, 2000, ONCOGENE, V19, P3200, DOI 10.1038/sj.onc.1203636; Ozaki Y, 2005, J THROMB HAEMOST, V3, P1745, DOI 10.1111/j.1538-7836.2005.01379.x; Pierce SB, 2004, DEVELOPMENT, V131, P2317, DOI 10.1242/dev.01108; Prochownik EV, 2007, CELL CYCLE, V6, P1024, DOI 10.4161/cc.6.9.4161; Radich JP, 2006, P NATL ACAD SCI USA, V103, P2794, DOI 10.1073/pnas.0510423103; Ravid K, 2002, J CELL PHYSIOL, V190, P7, DOI 10.1002/jcp.10035; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Rogulski K, 2005, ONCOGENE, V24, P7524, DOI 10.1038/sj.onc.1208897; Rogulski KR, 2005, P NATL ACAD SCI USA, V102, P18968, DOI 10.1073/pnas.0507902102; Rothermund K, 2005, CANCER RES, V65, P2097, DOI 10.1158/0008-5472.CAN-04-2928; Saunders W, 2003, CANCER BIOL THER, V2, P253, DOI 10.4161/cbt.2.3.379; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Sedelnikova OA, 2004, NAT CELL BIOL, V6, P168, DOI 10.1038/ncb1095; Sedivy JM, 2007, CANCER CELL, V11, P389, DOI 10.1016/j.ccr.2007.04.014; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Storchova Z, 2006, NATURE, V443, P541, DOI 10.1038/nature05178; Thomas PD, 2003, GENOME RES, V13, P2129, DOI 10.1101/gr.772403; Thorpe PH, 2007, TRENDS GENET, V23, P263, DOI 10.1016/j.tig.2007.03.016; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Weinstock DM, 2006, DNA REPAIR, V5, P1065, DOI 10.1016/j.dnarep.2006.05.028; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; Yin XY, 2002, J BIOL CHEM, V277, P19998, DOI 10.1074/jbc.M200860200; Zhou ZQ, 2001, TRENDS CELL BIOL, V11, pS10, DOI 10.1016/S0962-8924(01)82037-7	54	11	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2008	27	11					1599	1609		10.1038/sj.onc.1210794	http://dx.doi.org/10.1038/sj.onc.1210794			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	271VC	17873907				2022-12-17	WOS:000253815800012
J	Morange, M				Morange, M.			The field of cancer research: an indicator of present transformations in biology	ONCOGENE			English	Review						cause; epigenetics; niche; post-genomics; stem cell	MALIGNANT-TUMORS; SOMATIC MUTATION; STEM-CELLS; EPIGENETICS; PARADIGM; HISTORY; PATHWAY; ORIGIN	'Biology and cancer research have developed together. Invariably, at each stage, the characteristics of the cancer cell have been ascribed to some defect in whatever branch of biology happens at the time to be fashionable and exciting; today, it is molecular genetics'. Tremendous transformations have occurred in cancer research since these few lines were written by John Cairns: the discovery of oncogenes and anti- oncogenes, and the successful development of 'magic bullets' targeting the proteins encoded by these oncogenes. Nevertheless, Cairns' message is still valid. In 1978, he observed the first attempts to apply the tools and concepts of molecular biology to cancer; today, this research. field reflects multiple and diverse efforts that go 'beyond' molecular biology by looking for explanations that have been left aside during its development, or by privileging new approaches, fully original or actively pursued in other fields of biological research. Because of this specific characteristic of cancer research, it is possible to use it as an indicator of trends in biological research in general.	[Morange, M.] ENS, Dept Biol, F-75230 Paris 056, France	UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Morange, M (corresponding author), ENS, Dept Biol, 46 Rue Ulm, F-75230 Paris 056, France.	morange@biologie.ens.fr						[Anonymous], 2013, NICHE CONSTRUCTION N; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Borczuk AC, 2007, ONCOGENE, V26, P610, DOI 10.1038/sj.onc.1209809; CAIRNS J, 1978, CANC SCI SOC, P63; Downward J, 2006, SCIENCE, V314, P433, DOI 10.1126/science.1134727; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Ferres-Marco D, 2006, NATURE, V439, P430, DOI 10.1038/nature04376; Frantz S, 2005, NATURE, V437, P942, DOI 10.1038/437942a; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Kamal A, 2003, NATURE, V425, P407, DOI 10.1038/nature01913; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Kerbel RS, 2006, SCIENCE, V312, P1171, DOI 10.1126/science.1125950; Kiberstis PA, 2006, SCIENCE, V312, P1157, DOI 10.1126/science.312.5777.1157; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Lund AH, 2004, GENE DEV, V18, P2315, DOI 10.1101/gad.1232504; MANCHESTER KL, 1995, TRENDS CELL BIOL, V5, P384, DOI 10.1016/S0962-8924(00)89080-7; Marx J, 2006, SCIENCE, V312, P1160, DOI 10.1126/science.312.5777.1160; Marx J, 2003, SCIENCE, V301, P1308, DOI 10.1126/science.301.5638.1308; Morange M, 1997, J HIST BIOL, V30, P1, DOI 10.1023/A:1004255309721; Morange M, 2006, J BIOSCIENCES, V31, P537, DOI 10.1007/BF02708404; O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372; Pelham RJ, 2006, P NATL ACAD SCI USA, V103, P19848, DOI 10.1073/pnas.0609635104; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Rarnanathan A, 2005, P NATL ACAD SCI USA, V102, P5992, DOI 10.1073/pnas.0502267102; Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384; Soto AM, 2004, BIOESSAYS, V26, P1097, DOI 10.1002/bies.20087; TRIOLO VA, 1965, CANCER RES, V25, P75; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; WEINBERG RA, 1982, CELL, V30, P3, DOI 10.1016/0092-8674(82)90003-4	37	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 6	2007	26	55					7607	7610		10.1038/sj.onc.1210583	http://dx.doi.org/10.1038/sj.onc.1210583			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	239SK	17653097				2022-12-17	WOS:000251537800001
J	Hupe, P; La Rosa, P; Liva, S; Lair, S; Servant, N; Barillot, E				Hupe, P.; La Rosa, P.; Liva, S.; Lair, S.; Servant, N.; Barillot, E.			ACTuDB, a new database for the integrated analysis of array-CGHand clinical data for tumors	ONCOGENE			English	Article						DNA copy number; database; tumors; bioinformatics platform; molecular profiles; clinical data	COMPARATIVE GENOMIC HYBRIDIZATION; DNA COPY NUMBER; HIGH-RESOLUTION ANALYSIS; EXPRESSION PATTERNS; COLORECTAL-CANCER; BLADDER-CANCER; REVEALS; DEREGULATION; ABERRATIONS; REGIONS	In recent years, an increasing number of projects have investigated tumor genome structure, using microarray-based techniques like array comparative genomic hybridization ( array- CGH) or single nucleotide polymorphism ( SNP) arrays. The forthcoming studies have to integrate these former results and compare their findings to the existing sets of copy number data for validation. These sets also form the basis from which many comparative retrospective analyses can be carried out. Nevertheless, exploitation of this mass of data relies on a homogeneous preparation of copy number data, which will make it possible to compare them together, and their integration into a unified bioinformatics environment with ad hoc analysis tools and interfaces. To our knowledge, no such data integration has been proposed yet. Therefore the biologists and clinicians involved in cancer research urgently need such an integrative tool, which motivated us to undertake the construction of a database for array-CGH and other DNA copy number data for tumors ( ACTuDB). When available, the associated clinical, transcriptome and loss of heterozygosity data were also integrated into ACTuDB. ACTuDB contains currently about 1500 genomic profiles for tumors and cell lines for the bladder, brain, breast, colon, liver, lymphoma, neuroblastoma, mouth and pancreas, together with data for replication timing experiments. The CGH array data were processed, using ad hoc algorithms ( probe mapping, breakpoint detection, gain or loss status assignment and visualization) developed at Institut Curie. The database is available from http://bioinfo.curie.fr/actudb/ and can be browsed with a user- friendly interface. This database will be a useful resource for the genomic profiling of tumors, a field of highly active research. We invite research groups involved in tumor genome profiling to submit their data to ACTuDB.	Inst Curie, Serv Informmat, F-75248 Paris 05, France; CNRS, Inst Curie, UMR 144, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite; Universite Paris Cite	Hupe, P (corresponding author), Inst Curie, Serv Informmat, 26 Rue Ulm, F-75248 Paris 05, France.	Philippe.Hupe@curie.fr	Hupe, Philippe/T-8793-2017	Hupe, Philippe/0000-0001-8468-3424; BARILLOT, Emmanuel/0000-0003-2724-2002; Servant, Nicolas/0000-0003-1678-7410				Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Baudis M, 2006, BIOTECHNIQUES, V40, P269, DOI 10.2144/000112102; Blaveri E, 2005, CLIN CANCER RES, V11, P7012, DOI 10.1158/1078-0432.CCR-05-0177; Bredel M, 2005, CANCER RES, V65, P4088, DOI 10.1158/0008-5472.CAN-04-4229; Chen X, 2002, MOL BIOL CELL, V13, P1929, DOI 10.1091/mbc.02-02-0023; de Leeuw RJ, 2004, HUM MOL GENET, V13, P1827, DOI 10.1093/hmg/ddh195; Douglas EJ, 2004, CANCER RES, V64, P4817, DOI 10.1158/0008-5472.CAN-04-0328; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; Griffiths-Jones Sam, 2006, V342, P129, DOI 10.1385/1-59745-123-1:129; Gysin S, 2005, GENE CHROMOSOME CANC, V44, P37, DOI 10.1002/gcc.20216; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Hurst CD, 2004, ONCOGENE, V23, P2250, DOI 10.1038/sj.onc.1207260; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Janoueix-Lerosey I, 2005, CELL CYCLE, V4, P1842, DOI 10.4161/cc.4.12.2257; Karolchik D, 2003, NUCLEIC ACIDS RES, V31, P51, DOI 10.1093/nar/gkg129; Kent WJ, 2002, GENOME RES, V12, P656, DOI [10.1101/gr.229202, 10.1101/gr.229202. Article published online before March 2002]; Kotliarov Y, 2006, CANCER RES, V66, P9428, DOI 10.1158/0008-5472.CAN-06-1691; La Rosa P, 2006, BIOINFORMATICS, V22, P2066, DOI 10.1093/bioinformatics/btl359; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Mosse YP, 2005, GENE CHROMOSOME CANC, V43, P390, DOI 10.1002/gcc.20198; Nakao K, 2004, CARCINOGENESIS, V25, P1345, DOI 10.1093/carcin/bgh134; Patil MA, 2005, CARCINOGENESIS, V26, P2050, DOI 10.1093/carcin/bgi178; Pinkel D, 2005, NAT GENET, V37, pS11, DOI 10.1038/ng1569; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Rouveirol C, 2006, BIOINFORMATICS, V22, P849, DOI 10.1093/bioinformatics/btl004; Snijders AM, 2005, ONCOGENE, V24, P4232, DOI 10.1038/sj.onc.1208601; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Stransky N, 2006, NAT GENET, V38, P1386, DOI 10.1038/ng1923; Veltman JA, 2003, CANCER RES, V63, P2872; Woodfine K, 2004, HUM MOL GENET, V13, P191, DOI 10.1093/hmg/ddh016; Ylstra B, 2006, NUCLEIC ACIDS RES, V34, P445, DOI 10.1093/nar/gkj456	32	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 11	2007	26	46					6641	6652		10.1038/sj.onc.1210488	http://dx.doi.org/10.1038/sj.onc.1210488			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	219JT	17496932				2022-12-17	WOS:000250081500006
J	Phang, BH; Sabapathy, K				Phang, B. H.; Sabapathy, K.			The codon 72 polymorphism-specific effects of human p53 are absent in mouse cells: implications on generation of mouse models	ONCOGENE			English	Article						codon 72 polymorphism; CRM1; growth inhibition; mouse cells; MDM2; p53	IN-VITRO; TUMOR SUPPRESSION; APOPTOSIS; CANCER; VARIANTS; MICE; DIFFERENTIATION; TRANSCRIPTION; CHEMOTHERAPY; INHIBITION	Human p53, unlike mouse p53, contains a polymorphic site at codon 72 in exon 4 encoding either an arginine amino acid ( 72R) or a proline residue ( 72P). The 72R form was shown to induce apoptosis better than the 72P form, partly owing to its ability to efficiently bind to the nuclear-export protein CRM1 and localize to the mitochondria. This polymorphism has also been associated with cancer predisposition and chemo-sensitivity. Further understanding of the in vivo significance of this polymorphism in carcinogenesis requires the generation of mouse models. We have thus evaluated if the polymorphism-specific effects of human p53 are retained in mouse cells. Though being transcriptionally active, both the human polymorphs were found to have lost their ability to differentially suppress growth and bind to CRM1 or MDM2 in mouse cells. Moreover, chimaeric proteins containing mouse exons 2-3 and human exons 4-11 have also lost the polymorphism-specific effects in human cells, suggesting that human exons 2-3 are important in regulating the polymorphism-specific effects. Furthermore, human p53 and the various chimaeric proteins were generally less effective in inhibiting growth of mouse cells compared to mouse p53, suggesting that mouse p53 is more potent than human p53 in suppressing growth, partly due to enhanced binding of MDM2 to human p53. The data together suggest that mouse cells may not provide an appropriate environment for the manifestation of the polymorphism-specific functional differences of human p53, and hence, cautions against the expression of full-length or chimaeric p53 proteins in mice to study the effects of the polymorphism.	Natl Canc Ctr, Lab Mol Carcinogenesis, Div Cellular & Mol Res, Singapore 169610, Singapore; Natl Univ Singapore, Dept Biochem, Singapore 117548, Singapore	National Cancer Centre Singapore (NCCS); National University of Singapore	Sabapathy, K (corresponding author), Natl Canc Ctr, Lab Mol Carcinogenesis, Div Cellular & Mol Res, 11 Hosp Dr, Singapore 169610, Singapore.	cmrksb@nccs.com.sg						Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; BECKMAN G, 1994, HUM HERED, V44, P266, DOI 10.1159/000154228; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; Chen WP, 1998, VIROLOGY, V251, P217, DOI 10.1006/viro.1998.9431; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; Dudgeon C, 2006, CANCER RES, V66, P2928, DOI 10.1158/0008-5472.CAN-05-2063; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Erster S, 2005, BIOCHEM BIOPH RES CO, V331, P843, DOI 10.1016/j.bbrc.2005.03.187; HARRIS N, 1986, MOL CELL BIOL, V6, P4650, DOI 10.1128/MCB.6.12.4650; HARVEY M, 1993, ONCOGENE, V8, P2457; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; Jardine LJ, 1999, ONCOGENE, V18, P7602, DOI 10.1038/sj.onc.1203137; Jaworski M, 2005, CARCINOGENESIS, V26, P1829, DOI 10.1093/carcin/bgi142; Lee MK, 2005, J CELL SCI, V118, P819, DOI 10.1242/jcs.01673; Luo JL, 2001, ONCOGENE, V20, P320, DOI 10.1038/sj.onc.1204080; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; MATLASHEWSKI GJ, 1987, MOL CELL BIOL, V7, P961, DOI 10.1128/MCB.7.2.961; Mendrysa SM, 2003, MOL CELL BIOL, V23, P462, DOI 10.1128/MCB.23.2.462-473.2003; Mendrysa SM, 2006, GENE DEV, V20, P16, DOI 10.1101/gad.1378506; Papadakis E. N., 2000, Molecular Cell Biology Research Communications, V3, P389, DOI 10.1006/mcbr.2000.0241; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Sabapathy K, 1997, EMBO J, V16, P6217, DOI 10.1093/emboj/16.20.6217; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Schuler M, 2005, TRENDS GENET, V21, P182, DOI 10.1016/j.tig.2005.01.001; Siddique M, 2006, ONCOGENE, V25, P3489, DOI 10.1038/sj.onc.1209405; Siddique MM, 2005, CANCER EPIDEM BIOMAR, V14, P2245, DOI 10.1158/1055-9965.EPI-05-0153; Sjalander A, 1996, CARCINOGENESIS, V17, P1313, DOI 10.1093/carcin/17.6.1313; Storey A, 1998, NATURE, V393, P229, DOI 10.1038/30400; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Sullivan A, 2004, ONCOGENE, V23, P3328, DOI 10.1038/sj.onc.1207428; Thomas M, 1999, MOL CELL BIOL, V19, P1092; Toh WH, 2005, J BIOL CHEM, V280, P17329, DOI 10.1074/jbc.M500044200; Tong WM, 2006, INT J CANCER, V119, P745, DOI 10.1002/ijc.21890; Venkatachalam S, 2001, TOXICOL PATHOL, V29, P147, DOI 10.1080/019262301753178555; Vikhanskaya F, 2005, CLIN CANCER RES, V11, P4348, DOI 10.1158/1078-0432.CCR-04-1547; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Weston A, 1997, ENVIRON HEALTH PERSP, V105, P919, DOI 10.2307/3433304; Yu J, 2005, BIOCHEM BIOPH RES CO, V331, P851, DOI 10.1016/j.bbrc.2005.03.189	44	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					2964	2974		10.1038/sj.onc.1210112	http://dx.doi.org/10.1038/sj.onc.1210112			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17130838				2022-12-17	WOS:000246395400002
J	Vesely, DL; Hoffman, B; Liebermann, DA				Vesely, D. L.; Hoffman, B.; Liebermann, D. A.			Phosphatidylinositol 3-kinase/Akt signaling mediates interleukin-6 protection against p53-induced apoptosis in M1 myeloid leukemic cells	ONCOGENE			English	Article						p53; PI3K/Akt; IL-6; apoptosis; Mcl-1; NF-kappa B	NF-KAPPA-B; WILD-TYPE P53; IN-VITRO; DEATH; DIFFERENTIATION; INHIBITION; EXPRESSION; GROWTH; FAS/APO-1; CANCER	M1 myeloid leukemic cells were used to dissect the molecular mechanisms of myeloid cell survival and apoptosis. A salient feature of M1 cells is that they respond to the physiological survival factor interleukin-6 ( IL-6), yet lack the tumor suppressor gene p53. Functional wild-type activation of temperature-sensitive p53 protein ( p53 val) at permissive temperature in M1-t-p53 cells results in rapid apoptosis, which is blocked by IL-6. How p53 induces M1 apoptosis and how IL-6 protects against p53-induced apoptosis are not fully understood. Here it is shown that p53-mediated apoptosis of M1 cells involves rapid activation of the proapoptotic Fas/CD95 death pathway, which activates caspases 8 and 10. Functional p53 also targets the mitochondria, causing upregulation of proapoptotic Bax, downregulation of prosurvival Bcl-2 and activation of caspase 9. IL-6 was found to protect against p53-induced apoptosis via activation of the PI3K/Akt survival pathway, which in turn counters both the Fas/CD95 and mitochondrial apoptotic pathways and activates the prosurvival transcription factor nuclear factor- kappaB ( NF-kappa B). Taken together, this work supports a novel model for leukemic progression where cells that acquire the ability to produce an autocrine survival factor, such as IL-6, can bypass normal p53 surveillance function by targeting Akt, which in turn can exert effects on the regulators of apoptosis, such as the Fas/CD95 pathway, the mitochondria and NF-kappa B.	Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Biochem, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Liebermann, DA (corresponding author), Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, 3307 N Broad St, Philadelphia, PA 19140 USA.	lieberma@temple.edu			NCI NIH HHS [R01 CA081168-06] Funding Source: Medline; NHLBI NIH HHS [1 R01 HL70530-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081168] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Amanullah A, 2002, ONCOGENE, V21, P1600, DOI 10.1038/sj.onc.1205231; Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; Bennett M, 1998, SCIENCE, V282, P290, DOI 10.1126/science.282.5387.290; Birkenkamp KU, 2004, LEUKEMIA, V18, P103, DOI 10.1038/sj.leu.2403145; Chen GA, 2005, P NATL ACAD SCI USA, V102, P12507, DOI 10.1073/pnas.0500397102; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gottlieb RA, 2000, CRIT REV EUKAR GENE, V10, P231; HAWLEY RG, 1992, J EXP MED, V176, P1149, DOI 10.1084/jem.176.4.1149; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hu LM, 2000, CLIN CANCER RES, V6, P880; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; LIEBERMANN DA, 1995, ONCOGENE, V11, P199; LIEBERMANN DA, 1994, STEM CELLS, V12, P352, DOI 10.1002/stem.5530120402; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; Lotem J, 2003, P NATL ACAD SCI USA, V100, P6718, DOI 10.1073/pnas.1031695100; Lotem J, 2004, P NATL ACAD SCI USA, V101, P16022, DOI 10.1073/pnas.0406966101; Manakova TE, 2001, B EXP BIOL MED+, V132, P633, DOI 10.1023/A:1012559724283; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Michalak E, 2005, BIOCHEM BIOPH RES CO, V331, P786, DOI 10.1016/j.bbrc.2005.03.183; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Moqattash S, 1998, P SOC EXP BIOL MED, V219, P8; Niho Y, 1998, Curr Opin Hematol, V5, P163, DOI 10.1097/00062752-199805000-00002; O'Connor L, 2000, CANCER RES, V60, P1217; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Rosmarin AG, 2005, EXP HEMATOL, V33, P131, DOI 10.1016/j.exphem.2004.08.015; SELVAKUMARAN M, 1994, ONCOGENE, V9, P1791; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; Takahashi S, 2005, LEUKEMIA RES, V29, P893, DOI 10.1016/j.leukres.2005.01.008; Tenen DG, 2003, NAT REV CANCER, V3, P89, DOI 10.1038/nrc989; Trikha M, 2003, CLIN CANCER RES, V9, P4653; Uriarte SM, 2005, CELL DEATH DIFFER, V12, P233, DOI 10.1038/sj.cdd.4401549; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; YANO H, 1995, BIOCHEM J, V312, P145, DOI 10.1042/bj3120145; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; Zhang J, 2004, IUBMB LIFE, V56, P395, DOI 10.1080/15216540400008929; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj.onc.1205318	43	11	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 10	2007	26	21					3041	3050		10.1038/sj.onc.1210109	http://dx.doi.org/10.1038/sj.onc.1210109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	166QX	17099722				2022-12-17	WOS:000246395400009
J	Martin, PM; Aeder, SE; Chrestensen, CA; Sturgill, TW; Hussaini, IM				Martin, P. M.; Aeder, S. E.; Chrestensen, C. A.; Sturgill, T. W.; Hussaini, I. M.			Phorbol 12-myristate 13-acetate and serum synergize to promote rapamycin-insensitive cell proliferation via protein kinase C-eta	ONCOGENE			English	Article						PKC; PKC-eta; p70S6K; glioblastoma; rapamycin	BREAST-CANCER CELLS; MESSENGER-RNA TRANSLATION; SIGNAL-TRANSDUCTION; GLIOBLASTOMA CELLS; MAMMALIAN TARGET; IN-VIVO; ACTIVATION; PHOSPHORYLATION; PATHWAY; MTOR	Previously, we have shown that PKC-eta (protein kinase Ceta) positively regulates glioblastoma proliferation and confers resistance to irradiation-induced apoptosis. In this study, we investigated the efficacy of rapamycin in inhibiting cell proliferation in two glioblastoma cell lines U-251MG (PKC-eta expressing) and U-1242MG (PKC-eta deficient) following PKC-eta activation. In U-251MG cells, rapamycin (10 nM) treatment was less effective as an antiproliferative agent when cells were concurrently stimulated with 10% serum and phorbol 12-myristate 13-acetate (PMA, 100 nM), a potent activator of PKC isozymes. Rapamycin-insensitive growth was owing to PKC-eta, as U-1242MG and U-251MG cells infected with a kinase-dead form of PKC-eta (U-251kr) were susceptible to rapamycin-induced inhibition of cell proliferation. Furthermore, U-251MG cells transfected with PKC-eta antisense oligonucleotides were sensitive to rapamycin. PKC-eta-expressing cells stimulated with PMA maintained p70S6K phosphorylation on Thr389 and phosphorylation of rpS6 (ser235/36), suggesting p70S6K kinase activity was still intact. Inhibition of p70S6K expression with small interfering RNA oligonucleotides inhibited cell proliferation greater than 50% in the presence of a combination of PMA and serum. Additionally, p70S6K co-precipitated with PKC-eta, suggesting a physical interaction between PKC-eta and p70S6K regulates the observed phosphorylation. Taken together, these data demonstrate that rapamycin-insensitive glioblastoma proliferation involves PKC-eta signaling.	Univ Virginia, Dept Pathol, Charlottesville, VA 22903 USA; Univ Virginia, Dept Pharmacol, Charlottesville, VA 22903 USA; Univ Virginia, Dept Neurosci, Charlottesville, VA 22903 USA	University of Virginia; University of Virginia; University of Virginia	Martin, PM (corresponding author), Fisk Univ, Dept Biol, Nashville, TN 37208 USA.	pmartin@fisk.edu			NATIONAL CANCER INSTITUTE [R01CA090851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062890] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA90851] Funding Source: Medline; NIGMS NIH HHS [GM62890] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aeder SE, 2004, ONCOGENE, V23, P9062, DOI 10.1038/sj.onc.1208093; Aspeslet LJ, 2000, CLIN THER, V22, pB86, DOI 10.1016/S0149-2918(00)89025-6; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Choe G, 2003, CANCER RES, V63, P2742; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dilling MB, 2002, J BIOL CHEM, V277, P13907, DOI 10.1074/jbc.M110782200; Dutcher Janice P, 2004, Curr Oncol Rep, V6, P111, DOI 10.1007/s11912-004-0022-5; Eshleman JS, 2002, CANCER RES, V62, P7291; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Feldkamp MM, 1997, J NEURO-ONCOL, V35, P223, DOI 10.1023/A:1005800114912; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Geoerger B, 2001, CANCER RES, V61, P1527; Gera JF, 2004, J BIOL CHEM, V279, P2737, DOI 10.1074/jbc.M309999200; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; HAN JW, 1995, J BIOL CHEM, V270, P21396, DOI 10.1074/jbc.270.36.21396; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Huang S, 2001, DRUG RESIST UPDATE, V4, P378, DOI 10.1054/drup.2002.0227; Hussaini IA, 2002, NEURO-ONCOLOGY, V4, P9, DOI 10.1093/neuonc/4.1.9; Hussaini IM, 2000, J BIOL CHEM, V275, P22348, DOI 10.1074/jbc.M003203200; Jacinto E, 2003, NAT REV MOL CELL BIO, V4, P117, DOI 10.1038/nrm1018; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Jiffar T, 2004, LEUKEMIA, V18, P505, DOI 10.1038/sj.leu.2403275; Lang D, 1995, NEUROSCI LETT, V201, P199, DOI 10.1016/0304-3940(95)12178-1; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Levy EI, 2004, J NEUROSURG, V100, P688, DOI 10.3171/jns.2004.100.4.0688; Maasho K, 2004, J IMMUNOL METHODS, V284, P133, DOI 10.1016/j.jim.2003.10.010; Maher EA, 2001, GENE DEV, V15, P1311, DOI 10.1101/gad.891601; Mischel PS, 2003, BRAIN PATHOL, V13, P52; Mischel PS, 2003, CANCER BIOL THER, V2, P242, DOI 10.4161/cbt.2.3.369; Neshat MS, 2001, P NATL ACAD SCI USA, V98, P10314, DOI 10.1073/pnas.171076798; Newton Herbert B, 2004, Expert Rev Anticancer Ther, V4, P105, DOI 10.1586/14737140.4.1.105; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Noh WC, 2004, CLIN CANCER RES, V10, P1013, DOI 10.1158/1078-0432.CCR-03-0043; Parker PJ, 2004, J CELL SCI, V117, P131, DOI 10.1242/jcs.00982; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; Rajasekhar VK, 2003, MOL CELL, V12, P889, DOI 10.1016/S1097-2765(03)00395-2; Rodriguez Alfredo E, 2003, J Invasive Cardiol, V15, P515; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schlegel J, 2002, ANN NY ACAD SCI, V973, P224, DOI 10.1111/j.1749-6632.2002.tb04638.x; Schlegel J, 2002, ANTICANCER RES, V22, P2837; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Schondorf T, 2004, ANTI-CANCER DRUG, V15, P265, DOI 10.1097/01.cad.0000119457.84063.cb; Steck PA, 1999, GENE CHROMOSOME CANC, V24, P135, DOI 10.1002/(SICI)1098-2264(199902)24:2<135::AID-GCC6>3.0.CO;2-A; Stolovich M, 2002, MOL CELL BIOL, V22, P8101, DOI 10.1128/MCB.22.23.8101-8113.2002; Thomas CY, 2003, INT J CANCER, V104, P19, DOI 10.1002/ijc.10880; Xu G, 2004, INT J ONCOL, V24, P893; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249	51	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN	2007	26	3					407	414		10.1038/sj.onc.1209791	http://dx.doi.org/10.1038/sj.onc.1209791			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	126VQ	16832347				2022-12-17	WOS:000243544000009
J	Kostenko, O; Tsacoumangos, A; Crooks, D; Kil, SJ; Carlin, C				Kostenko, O.; Tsacoumangos, A.; Crooks, D.; Kil, S. J.; Carlin, C.			Gab1 signaling is regulated by EGF receptor sorting in early endosomes	ONCOGENE			English	Article						EGF receptor; endocytosis; Gab1; MAPK	EPIDERMAL-GROWTH-FACTOR; PLECKSTRIN HOMOLOGY DOMAIN; ACTIVATED PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; TYROSINE KINASES; DOCKING PROTEIN; GRB2-ASSOCIATED BINDER-1; TRANSFERRIN RECEPTORS; ENDOCYTIC PATHWAY; NOONAN-SYNDROME	Although combinatorial signaling through the ErbB network is implicated in certain types of human cancer, the specifics of how particular receptors contribute to the transformed phenotype are not well understood. The goal of this study was to identify epidermal growth factor (EGF) receptor-dependent cell signaling abnormalities specifically associated with mutations in a previously described 679-LL lysosomal sorting signal, which restrict ligand-dependent receptor downregulation by promoting recycling. Importantly, the 679-LL signal is not conserved in any of the other members of the ErbB receptor family suggesting its physiological function may be tightly regulated during EGF receptor-dependent signaling. Our data indicate that cells expressing receptors with an inactive 679-AA signal are rapidly transported to Rab4(+) early endosomes after they are internalized in contrast to wild-type receptors that are localized to early endocytic antigen 1 (EEA1)(+) early endosomes. Divergent trafficking in early endosomes is associated with prolonged activation of p44/42 mitogen-activated protein kinases (MAPK) but not Akt. Gab1 appears to be the critical signaling molecule facilitating prolonged MAPK signaling, and activated Gab1 is recruited to early endosomes in 679-AA receptor-expressing cells. Activated Gab1 is also recruited to early endosomes in breast cancer cells characterized by high levels of EGF receptor-ErbB2 heterodimers, suggesting 679-AA expressing cells recapitulate certain aspects of EGF receptor signaling and transformation by activated ErbB2. Phosphatidylinositol 3-kinase (PI3K)-dependent membrane translocation known to be important for maintaining Gab1 activity in other settings was dispensable. We conclude that 679-LL has dual functions in EGF receptor trafficking and threshold signaling through a subset of signaling molecules including p44/42 MAPK and Gab1.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Ctr Canc, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Carlin, C (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	cathleen.carlin@case.edu			NIGMS NIH HHS [R01 GM64243] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Baulida J, 1996, J BIOL CHEM, V271, P5251; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Chakraborty A, 2002, HOSP MED, V63, P743, DOI 10.12968/hosp.2002.63.12.1896; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Chen XM, 2001, EMBO REP, V2, P842, DOI 10.1093/embo-reports/kve179; Christoforidis S, 1999, NATURE, V397, P621, DOI 10.1038/17618; Citri A, 2003, EXP CELL RES, V284, P54, DOI 10.1016/S0014-4827(02)00101-5; Crooks D, 2000, MOL BIOL CELL, V11, P3559, DOI 10.1091/mbc.11.10.3559; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Daro E, 1996, P NATL ACAD SCI USA, V93, P9559, DOI 10.1073/pnas.93.18.9559; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Downward J, 2004, SEMIN CELL DEV BIOL, V15, P177, DOI 10.1016/j.semcdb.2004.01.002; FENG Y, 1995, J CELL BIOL, V131, P1435, DOI 10.1083/jcb.131.6.1435; Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Gu HH, 2003, TRENDS CELL BIOL, V13, P122, DOI 10.1016/S0962-8924(03)00002-3; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; Harlow E, 1988, ANTIBODIES LAB MANUA, P139; Hendriks BS, 2003, J BIOL CHEM, V278, P23343, DOI 10.1074/jbc.M300477200; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; HolgadoMadruga M, 1997, P NATL ACAD SCI USA, V94, P12419, DOI 10.1073/pnas.94.23.12419; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Itoh M, 2000, MOL CELL BIOL, V20, P3695, DOI 10.1128/MCB.20.10.3695-3704.2000; Jones SM, 2002, AM J PHYSIOL-CELL PH, V282, pC420, DOI 10.1152/ajpcell.00253.2001; Kameda H, 2001, MOL CELL BIOL, V21, P6895, DOI 10.1128/MCB.21.20.6895-6905.2001; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kil SJ, 1999, J BIOL CHEM, V274, P3141, DOI 10.1074/jbc.274.5.3141; Kil SJ, 2000, J CELL PHYSIOL, V185, P47, DOI 10.1002/1097-4652(200010)185:1<47::AID-JCP4>3.3.CO;2-F; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; Krendel M, 2005, PHYSIOLOGY, V20, P239, DOI 10.1152/physiol.00014.2005; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMB JE, 1983, J BIOL CHEM, V258, P8751; Lenferink AEG, 1998, EMBO J, V17, P3385, DOI 10.1093/emboj/17.12.3385; LIPPINCOTTSCHWARTZ J, 1987, CELL, V49, P669, DOI 10.1016/0092-8674(87)90543-5; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; MARGOLIS B, 1994, J AM SOC NEPHROL, V5, P1288; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Maroun CR, 1999, J BIOL CHEM, V274, P31719, DOI 10.1074/jbc.274.44.31719; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; NAKANISHI S, 1992, J BIOL CHEM, V267, P2157; Olayioye MA, 1998, MOL CELL BIOL, V18, P5042, DOI 10.1128/MCB.18.9.5042; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PRUSS RM, 1977, P NATL ACAD SCI USA, V74, P3918, DOI 10.1073/pnas.74.9.3918; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsacoumango A, 2005, J CELL SCI, V118, P3959, DOI 10.1242/jcs.02527; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; Vitale G, 1998, EMBO J, V17, P1941, DOI 10.1093/emboj/17.7.1941; Wang ZX, 1999, MOL BIOL CELL, V10, P1621, DOI 10.1091/mbc.10.5.1621; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2; WEIDNER KM, 1996, NATURE, V173, P384; WEIEL JE, 1984, BIOCHEM BIOPH RES CO, V119, P598, DOI 10.1016/S0006-291X(84)80291-0; Wiley HS, 2001, TRAFFIC, V2, P12, DOI 10.1034/j.1600-0854.2001.020103.x; Wiley HS, 2003, EXP CELL RES, V284, P78, DOI 10.1016/S0014-4827(03)00002-8; Wilson JM, 2000, MOL BIOL CELL, V11, P2657, DOI 10.1091/mbc.11.8.2657; Wolf I, 2002, MOL CELL BIOL, V22, P231, DOI 10.1128/MCB.22.1.231-244.2002; Yamasaki S, 2003, ONCOGENE, V22, P1546, DOI 10.1038/sj.onc.1206284; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055; Zhao CM, 1999, J BIOL CHEM, V274, P19649, DOI 10.1074/jbc.274.28.19649	71	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	2006	25	50					6604	6617		10.1038/sj.onc.1209675	http://dx.doi.org/10.1038/sj.onc.1209675			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	099CI	16715136				2022-12-17	WOS:000241569700005
J	Ruminy, P; Jardin, F; Picquenot, JM; Gaulard, P; Parmentier, F; Buchonnet, G; Maisonneuve, C; Tilly, H; Bastard, C				Ruminy, P.; Jardin, F.; Picquenot, J. M.; Gaulard, P.; Parmentier, F.; Buchonnet, G.; Maisonneuve, C.; Tilly, H.; Bastard, C.			Two patterns of chromosomal breakpoint locations on the immunoglobulin heavy-chain locus in B-cell lymphomas with t(3;14)(q27;q32): relevance to histology	ONCOGENE			English	Article						non-Hodgkin's B-cell lymphoma; BCL6; t(3;14)(q27;q32)	NON-HODGKINS-LYMPHOMAS; FOLLICULAR LYMPHOMA; GENE FUSION; MESSENGER-RNA; BCL6 GENE; GRADE 3B; TRANSLOCATIONS; EXPRESSION; REARRANGEMENT; 3Q27	The t(3;14)(q27;q32) is the most common translocation involving BCL6 in B-cell lymphoma. Although this translocation was predominantly associated with diffuse large B-cell lymphoma (DLBCL), recent studies have shown that it can also be found in follicular lymphomas (FL), often associated with a large cell component. To further investigate the relationship that might exist between this translocation and the phenotype of the tumors, we studied 34 lymphomas with a t(3;14)(q27;q32). Twenty cases were DLBCL, 14 FL and most cases, regardless of histology, were negative for the expression of CD10 (26/32, 81%). We identified the IGH switch region involved in the translocation for 32 cases. Our data indicate that in DLBCL most breakpoints involve the switch mu (17/19; 89%), whereas in FL most involve a switch gamma (9/13; 70%) (P = 0.0016, Fisher's exact test). This correlation between the histology and the structure of the translocated allele suggests that the lymphomas with S mu and S gamma translocations may originate from different cells, or that the substituted regulatory regions that come to deregulate BCL6 may affect the presentation of the disease.	INSERM, Ctr Henri Becquerel, Grp Etud Proliferat Lymphoides, U614,IFR23, Rouen, France; CHU Henri Mondor, Dept Pathol, INSERM, U617, F-94010 Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Henri Becquerel; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Bastard, C (corresponding author), INSERM, Ctr Henri Becquerel, Grp Etud Proliferat Lymphoides, U614,IFR23, Rue Amiens, Rouen, France.	chrbas@rouen.fnclcc.fr						Akasaka H, 2000, CANCER RES, V60, P2335; Akasaka T, 2000, BLOOD, V96, P2907; Akasaka T, 2003, BLOOD, V102, P1443, DOI 10.1182/blood-2002-08-2482; Barrans SL, 2002, BRIT J HAEMATOL, V117, P322, DOI 10.1046/j.1365-2141.2002.03435.x; BASTARD C, 1994, BLOOD, V83, P2423; Bosga-Bouwer AG, 2003, BLOOD, V101, P1149, DOI 10.1182/blood.V101.3.1149; Butler MP, 2002, CANCER RES, V62, P4089; Falini B, 2000, BLOOD, V95, P2084, DOI 10.1182/blood.V95.6.2084; HORSMAN DE, 1995, BRIT J HAEMATOL, V89, P569, DOI 10.1111/j.1365-2141.1995.tb08365.x; ISLAM KB, 1994, CLIN EXP IMMUNOL, V95, P3; Jaffe ES, 2001, PATHOLOGY GENETICS T; Jardin F, 2003, BLOOD, V102, P1872, DOI 10.1182/blood-2002-12-3630; Jardin F, 2002, LEUKEMIA, V16, P2318, DOI 10.1038/sj.leu.2402657; Katzenberger T, 2004, AM J PATHOL, V165, P481, DOI 10.1016/S0002-9440(10)63313-5; Kawakami K, 2004, INT J HEMATOL, V79, P474, DOI 10.1532/IJH97.03105; Kawamata N, 1998, BRIT J HAEMATOL, V100, P484, DOI 10.1046/j.1365-2141.1998.00603.x; LO CF, 1994, BLOOD, V83, P1757; Lossos IS, 2003, LEUKEMIA, V17, P1390, DOI 10.1038/sj.leu.2402997; Lossos IS, 2001, BLOOD, V98, P945, DOI 10.1182/blood.V98.4.945; MERTENS F, 1995, CANCER GENET CYTOGEN, V83, P176, DOI 10.1016/0165-4608(95)00066-X; Nagaoka H, 2002, J EXP MED, V195, P529, DOI 10.1084/jem.20012144; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; OFFIT K, 1994, NEW ENGL J MED, V331, P74, DOI 10.1056/NEJM199407143310202; OTSUKI T, 1995, BLOOD, V85, P2877, DOI 10.1182/blood.V85.10.2877.bloodjournal85102877; Ott G, 2002, BLOOD, V99, P3806, DOI 10.1182/blood.V99.10.3806; Polo JM, 2004, NAT MED, V10, P1329, DOI 10.1038/nm1134; Schaffer A, 1999, J IMMUNOL, V162, P5327; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95, DOI 10.1002/j.1460-2075.1986.tb04182.x; Ueda C, 2002, BLOOD, V99, P2624, DOI 10.1182/blood-2001-11-0117; Ueda C, 2002, LEUKEMIA LYMPHOMA, V43, P1375, DOI 10.1080/10428190290033305; Willis TG, 2000, BLOOD, V96, P808, DOI 10.1182/blood.V96.3.808.015k30_808_822; WLODARSKA I, 1995, GENE CHROMOSOME CANC, V14, P1, DOI 10.1002/gcc.2870140102; Ye BH, 1995, EMBO J, V14, P6209, DOI 10.1002/j.1460-2075.1995.tb00311.x	35	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 10	2006	25	35					4947	4954		10.1038/sj.onc.1209512	http://dx.doi.org/10.1038/sj.onc.1209512			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	072QE	16619046				2022-12-17	WOS:000239687100012
J	Tussie-Luna, MI; Rozo, L; Roy, AL				Tussie-Luna, M. I.; Rozo, L.; Roy, A. L.			Pro-proliferative function of the long isoform of PML-RAR alpha involved in acute promyelocytic leukemia	ONCOGENE			English	Article						APL; PML-RAR alpha; c-fos; transcription; chromatin	RETINOIC ACID RECEPTOR; PML/RAR-ALPHA; FUSION PROTEINS; CELL DIFFERENTIATION; HISTONE DEACETYLASE; GENE; ACTIVATION; PHOSPHORYLATION; TRANSLOCATION; ACETYLATION	The promyelocytic leukemia (PML) gene codes for a tumor suppressor protein that is associated with distinct subnuclear macromolecular structures called the PML bodies. The PML gene is frequently involved in the t(15; 17) chromosomal translocation of acute promyelocytic leukemia (APL). The translocation results in a fusion gene product, PML-RAR alpha, in which the PML gene fuses to the retinoic acid receptor alpha (RAR alpha) gene. PML-RAR alpha has been shown to promote transcriptional repression of genes involved in myeloid terminal differentiation and to disrupt the architecture of PML bodies, a phenotype reversed by treatment with all trans retinoic acid (ATRA). However, there are several alternatively spliced isoforms of PML-RAR alpha. Here, we addressed the differences between the short and the long isoforms of PML-RAR alpha (L and S) since both are associated with APL. We demonstrate that PML-RAR alpha L, but not PML-RAR alpha S, can directly promote cell growth by transcriptionally activating the pro-proliferative gene, c-fos, in response to mitogenic stimulation. The activity of the PML-RAR alpha L is completely sensitive to ATRA. We further show that this activation is not via direct recruitment of the protein to the c-fos promoter but indirectly by altering the chromosomal environment of the c-fos gene, thereby rendering it more accessible to the signal induced transcriptional activators. Our results suggest that in addition to antagonizing the PML-tumor suppressor or the PML-pro-apoptotic activity, PML-RAR alpha proteins can also directly promote cell growth by activating c-fos.	Tufts Univ, Dept Pathol, Sch Med, Boston, MA 02111 USA; Tufts Univ, Program Immunol, Sch Med, Boston, MA 02111 USA; Tufts Univ, Genet Program, Sch Med, Boston, MA 02111 USA	Tufts University; Tufts University; Tufts University	Roy, AL (corresponding author), Tufts Univ, Dept Pathol, Sch Med, 150 Harrison Ave, Boston, MA 02111 USA.	ananda.roy@tufts.edu		Tussie-Luna, Maria Isabel/0000-0002-5033-408X	NIAID NIH HHS [AI056240] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R03AI056240] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Casini T, 1999, ONCOGENE, V18, P3235, DOI 10.1038/sj.onc.1202630; Codina A, 2005, P NATL ACAD SCI USA, V102, P6009, DOI 10.1073/pnas.0500299102; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Duprez E, 2004, CELL CYCLE, V3, P389; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Ferrucci PF, 1997, P NATL ACAD SCI USA, V94, P10901, DOI 10.1073/pnas.94.20.10901; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hake SB, 2004, BRIT J CANCER, V90, P761, DOI 10.1038/sj.bjc.6601575; Hartman HB, 2005, EMBO REP, V6, P445, DOI 10.1038/sj.embor.7400391; Hauksdottir H, 2001, CELL GROWTH DIFFER, V12, P85; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Insinga A, 2005, CELL CYCLE, V4, P67, DOI 10.4161/cc.4.1.1400; Insinga A, 2004, EMBO J, V23, P1144, DOI 10.1038/sj.emboj.7600109; Jurcic JG, 2001, BLOOD, V98, P2651, DOI 10.1182/blood.V98.9.2651; Kane JR, 1996, LEUKEMIA, V10, P1296; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim DW, 1998, MOL CELL BIOL, V18, P3310, DOI 10.1128/MCB.18.6.3310; Lallemand-Breitenbach V, 2001, J EXP MED, V193, P1361, DOI 10.1084/jem.193.12.1361; Li QJ, 2003, EMBO J, V22, P281, DOI 10.1093/emboj/cdg028; Lin RJ, 2000, MOL CELL, V5, P821, DOI 10.1016/S1097-2765(00)80322-6; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lunghi P, 2005, LEUKEMIA, V19, P234, DOI 10.1038/sj.leu.2403585; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; Meani N, 2005, ONCOGENE, V24, P3358, DOI 10.1038/sj.onc.1208498; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Nissen LJ, 2001, J BIOL CHEM, V276, P5213, DOI 10.1074/jbc.M007824200; Nouzova M, 2004, J PHARMACOL EXP THER, V311, P968, DOI 10.1124/jpet.104.072488; PANDOLFI PP, 1992, EMBO J, V11, P1397, DOI 10.1002/j.1460-2075.1992.tb05185.x; Pandolfi PP, 2001, HUM MOL GENET, V10, P769, DOI 10.1093/hmg/10.7.769; Park DJ, 2003, BLOOD, V102, P3727, DOI 10.1182/blood-2003-02-0412; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Segalla S, 2003, MOL CELL BIOL, V23, P8795, DOI 10.1128/MCB.23.23.8795-8808.2003; Soprano DR, 2004, ANNU REV NUTR, V24, P201, DOI 10.1146/annurev.nutr.24.012003.132407; Sucic M, 2002, J HEMATOTH STEM CELL, V11, P941, DOI 10.1089/152581602321080600; Thomson S, 2001, MOL CELL, V8, P1231, DOI 10.1016/S1097-2765(01)00404-X; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Zelent A, 2001, ONCOGENE, V20, P7186, DOI 10.1038/sj.onc.1204766; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu J, 1999, P NATL ACAD SCI USA, V96, P14807, DOI 10.1073/pnas.96.26.14807; Zhu J, 2001, ONCOGENE, V20, P7257, DOI 10.1038/sj.onc.1204852	54	11	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 8	2006	25	24					3375	3386		10.1038/sj.onc.1209388	http://dx.doi.org/10.1038/sj.onc.1209388			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	055KB	16434964				2022-12-17	WOS:000238448100003
J	Chang, CY; Lin, YM; Lee, WP; Hsu, HH; Chen, EIT				Chang, CY; Lin, YM; Lee, WP; Hsu, HH; Chen, EIT			Involvement of Bcl-X-L deamidation in E1A-mediated cisplatin sensitization of ovarian cancer cells	ONCOGENE			English	Article						E1A; Rb; Bcl-X-L; deamidation; apoptosis	RETINOBLASTOMA GENE-PRODUCT; E1A; APOPTOSIS; PROTEIN; INDUCTION; RB; CHEMOSENSITIVITY; ASSOCIATION; SENSITIVITY; SUPPRESSION	The adenovirus E1A protein has been shown to be involved in the potentiation of apoptosis induced by chemotherapeutic agents, yet the molecular events of E1A-mediated apoptosis are not very clear. A recent report has suggested that deamidation of the Bcl-X-L protein inhibits its antiapoptotic ability and leads to apoptosis induced by alkylating agents in Rb-deficient tumor cells. Since Rb is known to interact with E1A, which interrupts Rb's normal function, we examined Bcl-X-L deamidation and cell death induced by cisplatin in E1A transfectants. We found that the E1A transfectants became sensitive to cisplatin-induced apoptosis compared to the parental cells, SKOV3.ip1. Our data show that cisplatin treatment induced the modi. cation of Bcl-X-L in the E1A transfectants in dosage and time-dependent manner. Furthermore, phosphatase treatment had no effect on the level of Bcl-X-L modi. cation, whereas alkaline lysis buffer appeared to induce the same modi. cation of Bcl-X-L. Ectopic expression of the deamidated forms of Bcl-X-L in SKOV3.ip1 cells revealed that the modi. cation to the Bcl-X-L protein molecules was deamidation. Expression of the E1A mutant ( dl1108) which contains deletion at CR2 domain suppressed Bcl-X-L deamidation and apoptosis induced by cisplatin. We also found that expression of the nondeamidated Bcl-X-L protected E1A transfectants from apoptosis. These findings suggest that Bcl-X-L deamidation contributes to E1A-mediated cisplatin sensitization in SKOV3.ip1 cells.	Natl Yang Ming Univ, Inst Biotechnol Med, Taipei 112, Taiwan; Vet Gen Hosp, Div Internal Med, Taipei, Taiwan; Vet Gen Hosp, Ctr Canc, Taipei, Taiwan	National Yang Ming Chiao Tung University	Chen, EIT (corresponding author), Natl Yang Ming Univ, Inst Biotechnol Med, Lee Lun St,Sect 2, Taipei 112, Taiwan.	chenit@ym.edu.tw						ABRAHAM RT, 1995, BIOL CELL, V83, P105, DOI 10.1016/0248-4900(96)81298-6; Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Amundson SA, 2000, CANCER RES, V60, P6101; Brader KR, 1997, CLIN CANCER RES, V3, P2017; Chattopadhyay D, 2001, J VIROL, V75, P9844, DOI 10.1128/JVI.75.20.9844-9856.2001; Chau BN, 2003, NAT REV CANCER, V3, P130, DOI 10.1038/nrc993; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHEN IT, 1995, ONCOGENE, V11, P1931; Deng J, 2002, CANCER RES, V62, P346; Deverman BE, 2002, CELL, V111, P51, DOI 10.1016/S0092-8674(02)00972-8; Deverman BE, 2003, CELL, V115, P503, DOI 10.1016/S0092-8674(03)00892-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duelli DM, 2000, NAT CELL BIOL, V2, P859, DOI 10.1038/35041112; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Lee WP, 2003, CANCER RES, V63, P6229; Lee WP, 2002, ONCOGENE, V21, P329, DOI 10.1038/sj.onc.1205066; NEVINS JR, 1992, SCIENCE, V258, P424; Poruchynsky MS, 1998, CANCER RES, V58, P3331; Robinson NE, 2002, P NATL ACAD SCI USA, V99, P5283, DOI 10.1073/pnas.082102799; Robinson NE, 2001, P NATL ACAD SCI USA, V98, P12409, DOI 10.1073/pnas.221463198; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Shisler J, 1996, J VIROL, V70, P68, DOI 10.1128/JVI.70.1.68-77.1996; Strausberg RL, 2002, P NATL ACAD SCI USA, V99, P16899, DOI 10.1073/pnas.242603899; Takehara T, 2003, CANCER RES, V63, P3054; UNEO NT, 1997, ONCOGENE, V10, P1053; UNEO NT, 2000, CLIN CANCER RES, V6, P250; Viniegra JG, 2002, ONCOGENE, V21, P7131, DOI 10.1038/sj.onc.1205934; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; White E, 2001, ONCOGENE, V20, P7836, DOI 10.1038/sj.onc.1204861; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; YU DH, 1993, CANCER RES, V53, P891; Zhao R, 2004, CANCER CELL, V5, P37, DOI 10.1016/S1535-6108(03)00333-7	35	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2006	25	18					2656	2665		10.1038/sj.onc.1209294	http://dx.doi.org/10.1038/sj.onc.1209294			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	036TU	16331250				2022-12-17	WOS:000237099400009
J	Dang, LH; Chen, F; Knock, SA; Huang, EH; Feng, J; Appelman, HD; Dang, DT				Dang, LH; Chen, F; Knock, SA; Huang, EH; Feng, J; Appelman, HD; Dang, DT			CDX2 does not suppress tumorigenicity in the human gastric cancer cell line MKN45	ONCOGENE			English	Article						CDX2; gastric cancer; tumorigenicity; MKN45	HOMEODOMAIN PROTEIN CDX2; HOMEOBOX GENE CDX2; INTESTINAL METAPLASIA; COLON-CANCER; ECTOPIC EXPRESSION; BETA-CATENIN; TRANSCRIPTION FACTORS; ABERRANT EXPRESSION; MESSENGER-RNA; GUT	CDX2 is a Drosophila caudal-related homeobox transcription factor that is expressed specifically in the intestine. In mice, ectopic expression of CDX2 in the gastric mucosa gives rise to intestinal metaplasia and in one model, gastric carcinoma. In humans, increased CDX2 expression is associated with gastric intestinal metaplasia and tubular adenocarcinomas. These patterns of expression have shown that CDX2 is important for the initiation of intestinal metaplasia in the gastric mucosa, but the role of CDX2 in established gastric cancer remains unclear. We sought to determine whether CDX2 contributes to tumorigenic potential in established gastric cancer. The CDX2 gene in MKN45 gastric carcinoma cells was disrupted using targeted homologous recombination. The resulting CDX2(-/-) cells are essentially identical to their parental cells, with the exception of CDX2 ablation. We found no significant differences in the proliferation of CDX2(-/-) cells compared to CDX2(-/-) cells, in vitro or in vivo. Molecular analyses show that loss of CDX2 predominantly altered the expression of genes involved in intestinal glandular differentiation and adhesion. However, there were no microscopic differences in tumor differentiation. We conclude that disruption of CDX2 in MKN45 cells does not significantly affect their tumorigenic potential.	Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI USA; Univ Michigan, Dept Surg, Div Colorectal Surg, Ann Arbor, MI USA; Johns Hopkins Univ, Div Gastroenterol, Baltimore, MD USA; Univ Michigan, Dept Pathol, Div Anat Pathol, Ann Arbor, MI USA; Univ Michigan, Div Gastroenterol, Dept Internal Med, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Johns Hopkins University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dang, DT (corresponding author), Univ Michigan, Dept Internal Med, Div Hematol Oncol, 1150 W Med Ctr Dr,MSRB 1,Room 6514, Ann Arbor, MI 48109 USA.	dangd@umich.edu		Huang, Emina/0000-0003-2495-4370	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK059970] Funding Source: NIH RePORTER; NIDDK NIH HHS [K08DK59970] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Almeida R, 2003, J PATHOL, V199, P36, DOI 10.1002/path.1246; Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Bai YQ, 2000, MOL CARCINOGEN, V28, P184, DOI 10.1002/1098-2744(200007)28:3<184::AID-MC7>3.0.CO;2-6; Bai YQ, 2003, ONCOGENE, V22, P7942, DOI 10.1038/sj.onc.1206634; Bai YQ, 2002, CANCER LETT, V176, P47, DOI 10.1016/S0304-3835(01)00753-4; Bjerknes M, 1999, GASTROENTEROLOGY, V116, P7, DOI 10.1016/S0016-5085(99)70222-2; BOLLER K, 1988, DIFFERENTIATION, V39, P51, DOI 10.1111/j.1432-0436.1988.tb00080.x; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CURR OPIN ONCOL, V14, P73, DOI 10.1097/00001622-200201000-00013; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chan TA, 2002, P NATL ACAD SCI USA, V99, P8265, DOI 10.1073/pnas.082240999; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; CHENG H, 1974, AM J ANAT, V141, P461, DOI 10.1002/aja.1001410403; CORREA P, 1994, CANCER RES, V54, pS1941; CORREA P, 1992, CANCER RES, V52, P6735; Cummins JM, 2004, CANCER RES, V64, P3006, DOI 10.1158/0008-5472.CAN-04-0046; CUMMINS JM, 2004, NATURE, V428, P486, DOI [DOI 10.1038/NATURE02501, 10.1038/nature02501]; Dang DT, 2005, CANCER RES, V65, P9485, DOI 10.1158/0008-5472.CAN-05-1930; Dang DT, 2001, ONCOGENE, V20, P4884, DOI 10.1038/sj.onc.1204645; Dang LH, 2004, CANCER BIOL THER, V3, P326, DOI 10.4161/cbt.3.3.704; DANG LH, 2003, IN PRESS ONCOGENE; DONG Z, 2002, SCI STKE, pPL7; Ebert MPA, 2002, ALIMENT PHARM THER, V16, P1059, DOI 10.1046/j.1365-2036.2002.01288.x; Ebert MPA, 2003, J CLIN ONCOL, V21, P1708, DOI 10.1200/JCO.2003.10.017; Ebert MPA, 2002, CARCINOGENESIS, V23, P87, DOI 10.1093/carcin/23.1.87; Eda A, 2002, J GASTROENTEROL, V37, P94, DOI 10.1007/s005350200002; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; FENOGLIOPREISER CM, 2000, PATHOLOGY GENETICS T; Freund JN, 1998, BIOCHEM CELL BIOL, V76, P957, DOI 10.1139/bcb-76-6-957; FRIEDERICH E, 1990, BIOESSAYS, V12, P403, DOI 10.1002/bies.950120902; Gao XP, 1998, MOL CELL BIOL, V18, P2901, DOI 10.1128/MCB.18.5.2901; Grotzinger C, 2001, GUT, V49, P73, DOI 10.1136/gut.49.1.73; Guo RJ, 2004, CANCER BIOL THER, V3, P593, DOI 10.4161/cbt.3.7.913; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; Hinoi T, 2003, J BIOL CHEM, V278, P44608, DOI 10.1074/jbc.M307435200; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Ishikawa A, 2004, LAB INVEST, V84, P629, DOI 10.1038/labinvest.3700087; Ji JF, 2002, ONCOGENE, V21, P6549, DOI 10.1038/sj.onc.1205829; Kaimaktchiev V, 2004, MODERN PATHOL, V17, P1392, DOI 10.1038/modpathol.3800205; Katz JP, 2002, DEVELOPMENT, V129, P2619; Keller MS, 2004, AM J PHYSIOL-GASTR L, V287, pG104, DOI 10.1152/ajpgi.00484.2003; Kim JS, 2004, CANCER RES, V64, P1932, DOI 10.1158/0008-5472.CAN-03-3862; Kim JS, 2002, CANCER RES, V62, P2744; Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874; Kohli M, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh009; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Leung WK, 2002, J PATHOL, V197, P582, DOI 10.1002/path.1147; Mahatan CS, 1999, NUCLEIC ACIDS RES, V27, P4562, DOI 10.1093/nar/27.23.4562; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; McKenna BJ, 2002, J CLIN GASTROENTEROL, V34, P111, DOI 10.1097/00004836-200202000-00002; Mesquita P, 2003, J BIOL CHEM, V278, P51549, DOI 10.1074/jbc.M309019200; Mizoshita T, 2004, PATHOL INT, V54, P392, DOI 10.1111/j.1440-1827.2004.01647.x; Mizoshita T, 2004, J CANCER RES CLIN, V130, P29, DOI 10.1007/s00432-003-0503-1; Mizoshita T, 2003, J CANCER RES CLIN, V129, P727, DOI 10.1007/s00432-003-0499-6; MOTOYAMA T, 1986, ACTA PATHOL JAPON, V36, P65; Mutoh H, 2004, CANCER RES, V64, P7740, DOI 10.1158/0008-5472.CAN-04-1617; Mutoh H, 2002, BIOCHEM BIOPH RES CO, V294, P470, DOI 10.1016/S0006-291X(02)00480-1; Nakajima T, 2002, DIGEST DIS SCI, V47, P2729, DOI 10.1023/A:1021005221934; Niwa T, 2005, J HISTOCHEM CYTOCHEM, V53, P75, DOI 10.1369/jhc.4A6443.2005; OSBORN M, 1988, VIRCHOWS ARCH A, V413, P303, DOI 10.1007/BF00783022; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pinto D, 1999, J BIOL CHEM, V274, P6476, DOI 10.1074/jbc.274.10.6476; Piso P, 2003, EUR SURG RES, V35, P470, DOI 10.1159/000073385; Rawat VPS, 2004, P NATL ACAD SCI USA, V101, P817, DOI 10.1073/pnas.0305555101; Sakate Y, 2004, J SURG RES, V122, P89, DOI 10.1016/j.jss.2004.06.011; Satoh K, 2002, HELICOBACTER, V7, P192, DOI 10.1046/j.1523-5378.2002.00080.x; SEDIVY JM, 1999, SCIENCE, V283, P9, DOI DOI 10.1126/SCIENCE.283.5398.9A); Seno H, 2002, INT J ONCOL, V21, P769; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Sikorski R, 1997, SCIENCE, V277, P1848, DOI 10.1126/science.277.5333.1848; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Sipponen P, 2000, GASTROENTEROL CLIN N, V29, P579, DOI 10.1016/S0889-8553(05)70131-X; Sonoda H, 2004, J SURG ONCOL, V88, P63, DOI 10.1002/jso.20143; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Tsukamoto T, 2004, J CANCER RES CLIN, V130, P135, DOI 10.1007/s00432-003-0519-6; Tsukashita S, 2001, INT J CANCER, V94, P166, DOI 10.1002/ijc.1460; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; Velcich A, 2002, SCIENCE, V295, P1726, DOI 10.1126/science.1069094; WALDMAN T, 1995, CANCER RES, V55, P5187; WALDMAN TA, 2003, METH MOL B, V241, P163; Yamamoto H, 2003, BIOCHEM BIOPH RES CO, V300, P813, DOI 10.1016/S0006-291X(02)02935-2; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Yoon HS, 2003, J BIOL CHEM, V278, P2101, DOI 10.1074/jbc.M211027200; Yuasa Y, 2005, CARCINOGENESIS, V26, P193, DOI 10.1093/carcin/bgh304; Yuasa Y, 2003, NAT REV CANCER, V3, P592, DOI 10.1038/nrc1141; Zhang WQ, 2000, J BIOL CHEM, V275, P18391, DOI 10.1074/jbc.C000062200; Zheng Leizhen, 2004, Gastric Cancer, V7, P61	95	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2006	25	14					2048	2059		10.1038/sj.onc.1209243	http://dx.doi.org/10.1038/sj.onc.1209243			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	026RL	16331267				2022-12-17	WOS:000236359700008
J	Pons, M; Cigudosa, JC; Rodriguez-Perales, S; Bella, JL; Gonzalez, C; Gamallo, C; Quintanilla, M				Pons, M; Cigudosa, JC; Rodriguez-Perales, S; Bella, JL; Gonzalez, C; Gamallo, C; Quintanilla, M			Chromosomal instability and phenotypic plasticity during the squamous-spindle carcinoma transition: association of a specific T(14;15) with malignant progression	ONCOGENE			English	Article						malignant progression; H-Ras; INK4a; chromosomal instability; T(14;15)	SKIN TUMOR PROGRESSION; MOUSE SKIN; GENETIC INSTABILITY; EPIDERMAL CARCINOGENESIS; CELL CARCINOMAS; RAS GENE; IN-VIVO; HA-RAS; CANCER; ANEUPLOIDY	In mouse epidermal carcinogenesis, the latest stage of malignant progression involves the transition from squamous cell carcinoma to a highly aggressive type of tumor with spindle morphology. In this work, we have isolated a minor epithelial cell subpopulation (CarC-R) contained in the highly malignant spindle carcinoma cell line CarC. CarC-R exhibited a drastic reduction in tumorigenicity when compared with CarC, but CarC-R-induced tumors were mainly sarcomatoid, although they subsequently reverted to the epithelial phenotype when tumor explants were recultured in vitro. Several single-cell clones with either stable epithelial or fibroblastic phenotypes were isolated from an explanted CarC-R tumor (CarC-RT). All these cell lines contained the same specific point mutation in H-Ras codon 61, but while CarC spindle cells had lost the normal H-Ras allele, it was retained in CarC-R- and CarC-RT-derived cell lines. Furthermore, CarC cells have inactivated p161NK4a and p191NK4a/ARF transcription, while CarC-R and CarC-RT clones expressed p19 mRNA and protein but not p16. Altogether, these results suggest that CarC-R represents a precursor stage to CarC in malignant progression. Spectral karyotyping analysis revealed that CarC-R was highly aneuploid and contained many chromosomal abnormalities. In contrast, CarC had a diploid or tetraploid modal chromosome number and contained a specific T(14;15) translocation in all of the analysed metaphases. The T(14;15) translocation was present in only a minority (1.9%) of CarC-R cells, but it was widely spread in CarC-RT and its derived cell clones, regardless of their epithelial or fibroblastic phenotype, indicating that T(14;15) segregates with malignancy.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Ciencias, Dept Biol, E-28029 Madrid, Spain; Univ Autonoma Madrid, Fac Med, Hosp Univ Princesa, Ctr Nacl Inves Ocol,Cytogenet Unit, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; Autonomous University of Madrid; Hospital de La Princesa	Quintanilla, M (corresponding author), Univ Autonoma Madrid, CSIC, Inst Invest Biomed, Arturo Duperier 4, E-28029 Madrid, Spain.	mquintanilla@iib.uam.es	pons, marisa/AAA-7983-2019; Cigudosa, Juan C/E-4105-2016; Rodriguez-Perales, Sandra/T-7667-2017; Quintanilla, Miguel/K-9293-2017	Rodriguez-Perales, Sandra/0000-0001-7221-3636; Quintanilla, Miguel/0000-0002-2124-7657				Akhurst RJ, 1999, J PATHOL, V187, P82, DOI 10.1002/(SICI)1096-9896(199901)187:1<82::AID-PATH248>3.0.CO;2-8; ALDAZ CM, 1989, MOL CARCINOGEN, V2, P22, DOI 10.1002/mc.2940020104; ALDAZ CM, 1987, P NATL ACAD SCI USA, V84, P2029, DOI 10.1073/pnas.84.7.2029; Beheshti B, 2001, NEOPLASIA, V3, P62, DOI 10.1038/sj.neo.7900125; BELLA JL, 1995, GENOME, V38, P864, DOI 10.1139/g95-114; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BUCHMANN A, 1991, CANCER RES, V51, P4097; BURNS PA, 1991, ONCOGENE, V6, P2363; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; CONTI CJ, 1986, CARCINOGENESIS, V7, P1845, DOI 10.1093/carcin/7.11.1845; DIAZGUERRA M, 1992, CANCER RES, V52, P680; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Duesberg P, 1999, ANTICANCER RES, V19, P4887; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; DURO D, 1995, ONCOGENE, V11, P21; Frame S, 1998, PHILOS T ROY SOC B, V353, P839, DOI 10.1098/rstb.1998.0248; Frame S, 2000, CURR OPIN GENET DEV, V10, P106, DOI 10.1016/S0959-437X(99)00052-0; FUSENIG NE, 1978, B CANCER, V65, P271; Gotzmann J, 2004, MUTAT RES-REV MUTAT, V566, P9, DOI 10.1016/S1383-5742(03)00033-4; Grady WM, 2004, CANCER METAST REV, V23, P11, DOI 10.1023/A:1025861527711; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; KLEINSZANTO AJP, 1989, CARCINOGENESIS, V10, P2169, DOI 10.1093/carcin/10.11.2169; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; LINARDOPOULOS S, 1995, CANCER RES, V55, P5168; MAO L, 1995, CANCER RES, V55, P2995; Miyoshi Y, 2000, CANCER LETT, V159, P211, DOI 10.1016/S0304-3835(00)00558-9; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Pihan GA, 1999, SEMIN CANCER BIOL, V9, P289, DOI 10.1006/scbi.1999.0131; Portella G, 1998, CELL GROWTH DIFFER, V9, P393; QUELLE DE, 1995, CELL, V83, P993; QUINTANILLA M, 1991, CARCINOGENESIS, V12, P1875, DOI 10.1093/carcin/12.10.1875; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Rodriguez-Puebla ML, 1999, MOL CARCINOGEN, V26, P150, DOI 10.1002/(SICI)1098-2744(199911)26:3<150::AID-MC3>3.0.CO;2-P; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; RUGGERI B, 1992, AM J PATHOL, V140, P1179; Serrano M, 2000, CARCINOGENESIS, V21, P865, DOI 10.1093/carcin/21.5.865; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shih IM, 2001, CANCER RES, V61, P818; STOLER AB, 1993, J CELL BIOL, V122, P1103, DOI 10.1083/jcb.122.5.1103; STONE S, 1995, CANCER RES, V55, P2988; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; YUSPA SH, 1994, J INVEST DERMATOL, V103, pS90, DOI 10.1111/1523-1747.ep12399255	49	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 17	2005	24	51					7608	7618		10.1038/sj.onc.1208903	http://dx.doi.org/10.1038/sj.onc.1208903			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	984VQ	16007119	Green Submitted			2022-12-17	WOS:000233333800010
J	Umar, S; Wang, Y; Sellin, JH				Umar, S; Wang, Y; Sellin, JH			Epithelial proliferation induces novel changes in APC expression	ONCOGENE			English	Article						APC; colon; in vivo	POLYPOSIS-COLI PROTEIN; TUMOR-SUPPRESSOR PROTEIN; COLONIC-MUCOSA HYPERPROLIFERATION; BETA-CATENIN; NUCLEAR EXPORT; SUBCELLULAR-LOCALIZATION; GENE-PRODUCT; IN-VIVO; DOWN-REGULATION; ASSOCIATION	The role of wild-type adenomatous polyposis coli (APC) protein in native epithelia is poorly understood. The present study examined the relationships between wildtype APC and beta-catenin expression in an established model of hyperproliferation, transmissible murine colonic hyperplasia (TMCH). Distal colonic crypts isolated from normal or TMCH mice were: (i) fractionated into cytosolic and nuclear components for Western blotting and immunoprecipitation (IP),( ii) extracted for total RNA isolation for Northern blotting and,(iii) analysed immunohistochemically by confocal microscopy. Western blots performed sequentially through day 12 TMCH with N-terminal APC antibodies revealed increased abundance of similar to 312 kDa (p312) protein by day 6 (4.0 +/- 0.75-fold, n = 6) that peaked by day 9, before declining by day 12. A similar to 130 kDa ( p130) band appeared at day 9 and increased by day 12 (1.5 +/- 0.11-fold, n = 6). A C-terminal antibody detected only p312. APC mRNA level did not change during TMCH and appearance of p130 was not due to alternative splicing. Co-IP with N-terminal anti-APC antibodies, revealed APC's association with b-catenin both at day 6 and day 12. p130, but not p312, associated predominantly with beta-catenin at day 12 during co-IP with anti-beta-catenin. p130 also selectively accumulated in the nucleus, bound to nuclear beta-catenin at day 12. Immunocytochemistry with N-terminal antibodies revealed an increasing crypt base : surface gradient of APC within the apical pole/apical-lateral membranes at day 6. At day 12, intense apical/cytoplasmic and occasional nuclear staining along the longitudinal crypt axis was observed. Full-length APC increases during epithelial hyperproliferation and may represent a homoeostatic response. The dramatic increase in cytoplasmic and sporadic nuclear APC staining at day 12 with N-terminal antibodies may represent p130. The nuclear accumulation of p130 may be a novel mechanism regulating nuclear beta-catenin function during TMCH.	Univ Texas, Med Branch, Dept Internal Med, Div Gastroenterol & Hepatol, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Umar, S (corresponding author), Univ Texas, Med Branch, Dept Internal Med, Div Gastroenterol & Hepatol, 301 Univ Blvd,1108 Strand, Galveston, TX 77555 USA.	shumar@utmb.edu			NCI NIH HHS [CA 099121] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R03CA099121] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x; BARTHOLD SW, 1979, CANCER RES, V39, P24; BARTHOLD SW, 1977, LAB ANIM SCI, V27, P938; BARTHOLD SW, 1978, VET PATHOL, V15, P223, DOI 10.1177/030098587801500209; BARTHOLD SW, 1977, CANCER RES, V37, P4352; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Brocardo M, 2005, EMBO REP, V6, P184, DOI 10.1038/sj.embor.7400329; Browne SJ, 1998, CELL DEATH DIFFER, V5, P206, DOI 10.1038/sj.cdd.4400331; Deka J, 1999, ONCOGENE, V18, P5654, DOI 10.1038/sj.onc.1202944; Efstathiou JA, 1998, P NATL ACAD SCI USA, V95, P3122, DOI 10.1073/pnas.95.6.3122; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; Fagotto F, 1998, CURR BIOL, V8, P181, DOI 10.1016/S0960-9822(98)70082-X; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Galea MA, 2001, J BIOL CHEM, V276, P45833, DOI 10.1074/jbc.M107149200; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; HORII A, 1993, HUM MOL GENET, V2, P283, DOI 10.1093/hmg/2.3.283; Iwamoto M, 2000, CARCINOGENESIS, V21, P1935, DOI 10.1093/carcin/21.11.1935; McCartney BM, 2000, NAT CELL BIOL, V2, pE58, DOI 10.1038/35008685; MIYASHIRO I, 1995, ONCOGENE, V11, P89; Morin PJ, 1996, P NATL ACAD SCI USA, V93, P7950, DOI 10.1073/pnas.93.15.7950; MUNEMITSU S, 1994, CANCER RES, V54, P3676; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165; Neufeld KL, 2000, P NATL ACAD SCI USA, V97, P12085, DOI 10.1073/pnas.220401797; Neufeld KL, 1997, P NATL ACAD SCI USA, V94, P3034, DOI 10.1073/pnas.94.7.3034; Neufeld KL, 2000, EMBO REP, V1, P519; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; OSHIMA M, 1993, CANCER RES, V53, P5589; Reinacher-Schick A, 2001, J CELL BIOL, V152, P491, DOI 10.1083/jcb.152.3.491; Rosin-Arbesfeld R, 2000, NATURE, V406, P1009, DOI 10.1038/35023016; Roura S, 2003, BIOCHEM BIOPH RES CO, V309, P830, DOI 10.1016/j.bbrc.2003.08.075; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; RUBINFELD B, 1995, J BIOL CHEM, V270, P5549, DOI 10.1074/jbc.270.10.5549; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Santoro IM, 1997, CANCER RES, V57, P488; Sellin JH, 2001, CANCER RES, V61, P2899; Smits R, 1999, GENE DEV, V13, P1309, DOI 10.1101/gad.13.10.1309; Spink KE, 2001, EMBO J, V20, P6203, DOI 10.1093/emboj/20.22.6203; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; THLIVERIS A, 1994, CANCER RES, V54, P2991; Umar S, 2003, CELL PROLIFERAT, V36, P361, DOI 10.1046/j.1365-2184.2003.00291.x; Umar S, 2000, AM J PHYSIOL-GASTR L, V278, pG765, DOI 10.1152/ajpgi.2000.278.5.G765; Umar S, 2000, AM J PHYSIOL-GASTR L, V278, pG753, DOI 10.1152/ajpgi.2000.278.5.G753; Umar S, 2000, AM J PHYSIOL-GASTR L, V279, pG223, DOI 10.1152/ajpgi.2000.279.1.G223; VOGELSTEIN B, 1994, COLD SPRING HARB SYM, V59, P517, DOI 10.1101/SQB.1994.059.01.057; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Webb SJ, 1999, FASEB J, V13, P339, DOI 10.1096/fasebj.13.2.339; White RL, 1997, PATHOL BIOL, V45, P240; Wiechens N, 2001, CURR BIOL, V11, P18, DOI 10.1016/S0960-9822(00)00045-2; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Wong MH, 1996, P NATL ACAD SCI USA, V93, P9588, DOI 10.1073/pnas.93.18.9588; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhang F, 2001, MOL CELL BIOL, V21, P8143, DOI 10.1128/MCB.21.23.8143-8156.2001	56	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 6	2005	24	44					6709	6718		10.1038/sj.onc.1208820	http://dx.doi.org/10.1038/sj.onc.1208820			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	971FL	16007167	Bronze			2022-12-17	WOS:000232367800012
J	Dentelli, P; Rosso, A; Garbarino, G; Calvi, C; Lombard, E; Di Stefano, P; Defilippi, P; Pegoraro, L; Brizzi, MF				Dentelli, P; Rosso, A; Garbarino, G; Calvi, C; Lombard, E; Di Stefano, P; Defilippi, P; Pegoraro, L; Brizzi, MF			The interaction between KDR and interleukin-3 receptor (IL-3R) beta common modulates tumor neovascularization	ONCOGENE			English	Article						interleukin-3; vascular endothelial growth factor; endothelial cells; cancer; angiogenesis	ENDOTHELIAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; GM-CSF; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; VESSEL FORMATION; POTENTIAL ROLE; BREAST-CANCER; CELL MOTILITY; RHO GTPASES	As vascular endothelial growth factor (VEGF), interleukin-3 (IL-3), released into the tumor microenvironment stimulates motogenic and mitogenic activity of normal and transformed cells. In the present study, we investigate the effects of IL-3 and VEGF on neoplastic vascular growth. Engagement of IL-3 receptor beta common (IL-3R beta c) contributes to both IL-3- and VEGF-induced Rac1 activation, cell migration and in vitro tube-like structure formation as shown by the expression of the dominant-negative IL-3R beta c construct (Delta 455). In normal and transformed endothelial cells (EC) as well as in HEK 293 cells expressing KDR and IL-3R, VEGF and IL-3 treatment induces the formation of a KDR/IL-3R beta c complex. Moreover, as shown by the IL-3R Delta 455 mutant or by the kinase dead KDR, functional receptors are required for this interaction. Consistent with the contribution of IL-3R beta c in both IL-3- and VEGF-mediated angiogenic signal, a reduced number of vessels inside tumors are found in mice injected with cells expressing the IL-3R Delta 455 mutant. Thus, these findings provide a novel mechanism through which IL-3 and VEGF support cell survival and tumor neovascularization.	Univ Turin, Dept Internal Med, I-10126 Turin, Italy; Univ Turin, Dept Genet Biol & Biochem, I-10126 Turin, Italy	University of Turin; University of Turin	Brizzi, MF (corresponding author), Univ Turin, Dept Internal Med, Corso Dogliotti 14, I-10126 Turin, Italy.	mariafelice.brizzi@unito.it	DEFILIPPI, Paola/L-2232-2014; Brizzi, Maria Felice/J-7882-2016	Defilippi, Paola/0000-0001-6427-4906				Aronica MG, 1996, ONCOGENE, V13, P1017; Bachelder RE, 2001, CANCER RES, V61, P5736; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Benitah SA, 2003, MOL BIOL CELL, V14, P40, DOI 10.1091/mbc.E02-08-0454; Biancone L, 1999, J IMMUNOL, V162, P5263; BOWMAN S, 1990, Technique (Philadelphia), V2, P254; BRIZZI MF, 1994, J BIOL CHEM, V269, P31680; BRIZZI MF, 1993, J CLIN INVEST, V91, P2887, DOI 10.1172/JCI116534; Brizzi MF, 2001, CIRCULATION, V103, P549, DOI 10.1161/01.CIR.103.4.549; Burridge K, 2004, CELL, V116, P167, DOI 10.1016/S0092-8674(04)00003-0; Bussolati B, 2003, FASEB J, V17, P1159, DOI 10.1096/fj.02-0557fje; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Dentelli P, 2004, ONCOGENE, V23, P1681, DOI 10.1038/sj.onc.1207290; Dentelli P, 1999, J IMMUNOL, V163, P2151; Deregibus MC, 2002, J BIOL CHEM, V277, P25195, DOI 10.1074/jbc.M200921200; Dougher M, 1999, ONCOGENE, V18, P1619, DOI 10.1038/sj.onc.1202478; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Groner B, 2000, GROWTH HORM IGF RES, V10, P15, DOI 10.1016/S1096-6374(00)80004-0; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Huang JZ, 2003, P NATL ACAD SCI USA, V100, P7785, DOI 10.1073/pnas.1432908100; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858; Kerbel RS, 2001, J CLIN ONCOL, V19, p45S; KIBBEY MC, 1992, J NATL CANCER I, V84, P1633, DOI 10.1093/jnci/84.21.1633; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Konecny G, 2001, CLIN CANCER RES, V7, P2448; Korpelainen EI, 1999, ONCOGENE, V18, P1, DOI 10.1038/sj.onc.1202288; Liu W, 2000, APOPTOSIS, V5, P323, DOI 10.1023/A:1009679307513; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; Rafii S, 2002, NAT REV CANCER, V2, P826, DOI 10.1038/nrc925; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Ridley AJ, 2001, J CELL SCI, V114, P2713; Rofstad EK, 2000, CANCER RES, V60, P4932; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; Tanimoto T, 2002, J BIOL CHEM, V277, P42997, DOI 10.1074/jbc.M204764200; TERMAN BI, 1991, ONCOGENE, V6, P1677; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; van Golen KL, 2003, BREAST CANCER RES, V5, P174, DOI 10.1186/bcr598; WIMPERIS JZ, 1989, BLOOD, V74, P1525; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zachary I, 2001, CARDIOVASC RES, V49, P568, DOI 10.1016/S0008-6363(00)00268-6	53	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 22	2005	24	42					6394	6405		10.1038/sj.onc.1208786	http://dx.doi.org/10.1038/sj.onc.1208786			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	966RI	16007196				2022-12-17	WOS:000232038200007
J	Mann, K; Hainaut, P				Mann, K; Hainaut, P			Aminothiol WR1065 induces differential gene expression in the presence of wild-type p53	ONCOGENE			English	Article						p53; WR1065; gene arrays; p21; S100A4; PTGF beta	TGF-BETA SUPERFAMILY; MACROPHAGE INHIBITORY CYTOKINE-1; CELL-CYCLE PROGRESSION; SEQUENCE-SPECIFIC DNA; HUMAN CANCER-CELLS; GROWTH-FACTOR-BETA; POLY(ADP-RIBOSE) POLYMERASE; SIGNALING PATHWAY; BINDING ACTIVITY; CARCINOMA CELLS	The aminothiol WR1065 exerts selective cytoprotective effects in normal cells compared to cancer cells and has clinical applications for the protection of normal cells in cancer patients undergoing radio- or chemotherapy. There is evidence that p53 is activated in response to WR1065. To examine the effects of WR1065 on the signalling pathways controlled by p53, isogeneic human colon carcinoma cell lines (HCT116) differing only in the presence or absence of wild-type p53 were used. Treatment with WR1065 resulted in G1 cell cycle arrest in the p53-positive cell line but not in the p53-negative cell line. Long-term exposure resulted in minimal apoptosis of either cell line. Changes in gene expression in p53-positive or -negative cells treated with WR1065 were examined using commercial human stress and cancer gene arrays (Clontech Atlas arrays). Genes found to be specifically upregulated in a p53-dependent manner included coproporphyrinogen oxidase, ICEre1-II cysteine protease, macrophage inhibitory cytokine-1 (also known as placental transforming growth factor beta), S100A4, and Waf1/p21. However, most proapoptotic genes typically upregulated by p53 in response to DNA damage were not activated. These studies show that WR1065 specifically modulates a subset of p53 target genes in a colon carcinoma cell line, consistent with the observation that this agent elicits essentially p53-dependent, cell cycle arrest responses.	Univ Alaska, Dept Biol Sci, Anchorage, AK 99508 USA; Univ Alaska, Biomed Program, Anchorage, AK 99508 USA; Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon, France	University of Alaska System; University of Alaska Anchorage; University of Alaska System; University of Alaska Anchorage; World Health Organization; International Agency for Research on Cancer (IARC)	Mann, K (corresponding author), Univ Alaska, Dept Biol Sci, 3211 Providence Dr, Anchorage, AK 99508 USA.	afkem@uaa.alaska.edu	Hainaut, Pierre/B-6018-2012	Hainaut, Pierre/0000-0002-1303-1610				Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; Baek SJ, 2002, CARCINOGENESIS, V23, P425, DOI 10.1093/carcin/23.3.425; Baek SJ, 2001, MOL PHARMACOL, V59, P901, DOI 10.1124/mol.59.4.901; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; CALABROJONES PM, 1985, INT J RADIAT BIOL, V47, P23, DOI 10.1080/09553008514550041; CAPIZZI RL, 1996, EUR J CANCER, V32, P5; Chang BD, 2002, P NATL ACAD SCI USA, V99, P389, DOI 10.1073/pnas.012602599; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Daoud SS, 2003, CANCER RES, V63, P2782; ELDEIRY WS, 1993, CELL, V75, P17; Fuchs SY, 1998, GENE DEV, V12, P2658, DOI 10.1101/gad.12.17.2658; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Hainaut P, 2001, ANTIOXID REDOX SIGN, V3, P611, DOI 10.1089/15230860152542961; HAINAUT P, 1993, CANCER RES, V53, P4469; HARPER JW, 1993, CELL, V75, P805; Kataoka Y, 2002, INT J RADIAT ONCOL, V53, P180, DOI 10.1016/S0360-3016(01)02820-6; KAUFMANN SH, 1993, CANCER RES, V53, P3976; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; Kemp G, 1996, J CLIN ONCOL, V14, P2101, DOI 10.1200/JCO.1996.14.7.2101; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Lee DH, 2003, CANCER RES, V63, P4648; Lee EJ, 2003, BRIT J CANCER, V88, P754, DOI 10.1038/sj.bjc.6600779; Li PX, 2000, J BIOL CHEM, V275, P20127, DOI 10.1074/jbc.M909580199; Liu T, 2003, CANCER RES, V63, P5034; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Marzatico F, 2000, CANCER CHEMOTH PHARM, V45, P172, DOI 10.1007/s002800050026; MEIER T, 1995, BIOCHEM PHARMACOL, V50, P489, DOI 10.1016/0006-2952(95)00164-U; Meplan C, 2000, BIOCHEM PHARMACOL, V59, P25, DOI 10.1016/S0006-2952(99)00297-X; Merwin JR, 2002, CARCINOGENESIS, V23, P1609, DOI 10.1093/carcin/23.10.1609; Miyafuji Y, 2001, J CELL PHYSIOL, V187, P356, DOI 10.1002/jcp.1084; North S, 2000, ONCOGENE, V19, P1206, DOI 10.1038/sj.onc.1203413; North S, 2002, MOL CARCINOGEN, V33, P181, DOI 10.1002/mc.10038; Paralkar VM, 1998, J BIOL CHEM, V273, P13760, DOI 10.1074/jbc.273.22.13760; Parks D, 1997, NUCLEIC ACIDS RES, V25, P1289, DOI 10.1093/nar/25.6.1289; Pluquet O, 2003, BIOCHEM PHARMACOL, V65, P1129, DOI 10.1016/S0006-2952(02)01655-6; Pluquet O, 2003, J BIOL CHEM, V278, P11879, DOI 10.1074/jbc.M207396200; Pluquet O, 2001, CANCER LETT, V174, P1, DOI 10.1016/S0304-3835(01)00698-X; POLLA BS, 1990, BIOCHEM PHARMACOL, V40, P1469, DOI 10.1016/0006-2952(90)90442-N; POPLIN EA, 1994, CANCER CHEMOTH PHARM, V33, P415, DOI 10.1007/s002800050074; RAINWATER R, 1995, MOL CELL BIOL, V15, P3892; Shen HX, 2001, J PHARMACOL EXP THER, V297, P1067; Tan MJ, 1999, FEBS LETT, V445, P265, DOI 10.1016/S0014-5793(99)00135-0; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Yang H, 2003, MOL CANCER THER, V2, P1023	53	11	13	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 2	2005	24	24					3964	3975		10.1038/sj.onc.1208563	http://dx.doi.org/10.1038/sj.onc.1208563			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	930RY	15750621				2022-12-17	WOS:000229435300012
J	Follows, GA; Tagoh, H; Richards, SJ; Melnik, S; Dickinson, H; de Wynter, E; Lefevre, P; Morgan, GJ; Bonifer, C				Follows, GA; Tagoh, H; Richards, SJ; Melnik, S; Dickinson, H; de Wynter, E; Lefevre, P; Morgan, GJ; Bonifer, C			c-FMS chromatin structure and expression in normal and leukaemic myelopoiesis	ONCOGENE			English	Article						c-FMS; AML; myelopoiesis; AML1-ETO	ACUTE MYELOID-LEUKEMIA; TRANSCRIPTION FACTOR; RECEPTOR; GENE; LOCUS; ONCOGENE; BINDING; CSF1R	The macrophage colony-stimulating factor receptor is encoded by the c-FMS gene, and it has been suggested that altered regulation of c-FMS expression may contribute to leukaemic transformation. c-FMS is expressed in pluripotent haemopoietic precursor cells and is subsequently upregulated during monocytic differentiation, but downregulated during granulopoiesis. We have examined transcription factor occupancy and aspects of chromatin structure of the critical c-FMS regulatory element located within the second intron (FIRE-fms intonic regulatory element) during normal and leukaemic myelopoiesis. Granulocytic differentiation from normal and leukaemic precursors is accompanied by loss of transcription factors at FIRE and downregulated c-FMS expression. The presence of AML1-ETO in leukaemic cells does not prevent this disassembly. In nonleukaemic cells, granulocytic differentiation is accompanied by reversal to a chromatin. ne structure characteristic of c-FMS-nonexpressing cells. In addition, we show that low-level expression of the gene in leukaemic blast cells and granulocytes does not associate with increased CpG methylation across the c-FMS locus.	St James Univ Hosp, Mol Med Unit, Leeds, W Yorkshire, England; Leeds Gen Infirm, Acad Unit Haematol & Oncol, Leeds, W Yorkshire, England; St James Univ Hosp, Dept Cytogenet, Leeds, W Yorkshire, England	Saint James's University Hospital; University of Leeds; Leeds General Infirmary; University of Leeds; Saint James's University Hospital	Follows, GA (corresponding author), Cambridge Inst Med Res, Dept Haematol, Hills Rd, Cambridge, England.	gf246@cam.ac.uk	Bonifer, Constanze/B-3000-2009; Tagoh, Hiromi/B-2954-2009	Tagoh, Hiromi/0000-0001-9905-6992; morgan, gareth/0000-0002-4271-6360; Richards, Stephen/0000-0002-8421-5353; Melnik, Svitlana/0000-0001-7227-3321; Bonifer, Constanze/0000-0002-4267-0825	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; BOULTWOOD J, 1991, P NATL ACAD SCI USA, V88, P6176, DOI 10.1073/pnas.88.14.6176; Casas S, 2003, LEUKEMIA LYMPHOMA, V44, P1935, DOI 10.1080/1042819031000119299; CHEN HH, 2001, SCI STKE, pPL1; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; Dai XM, 2002, BLOOD, V99, P111, DOI 10.1182/blood.V99.1.111; Debernardi S, 2003, GENE CHROMOSOME CANC, V37, P149, DOI 10.1002/gcc.10198; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; Follows GA, 2003, NUCLEIC ACIDS RES, V31, P5805, DOI 10.1093/nar/gkg804; Follows GA, 2003, EMBO J, V22, P2798, DOI 10.1093/emboj/cdg250; GISSELBRECHT S, 1987, NATURE, V329, P259, DOI 10.1038/329259a0; Heidenreich O, 2003, BLOOD, V101, P3157, DOI 10.1182/blood-2002-05-1589; Himes SR, 2001, J LEUKOCYTE BIOL, V70, P812; Kelly LM, 2002, ANNU REV GENOM HUM G, V3, P179, DOI 10.1146/annurev.genom.3.032802.115046; Kontaraki J, 2000, GENE DEV, V14, P2106; Lichtenberger C, 1999, J IMMUNOL METHODS, V227, P75, DOI 10.1016/S0022-1759(99)00076-9; McGlynn H, 1997, LEUKEMIA RES, V21, P919, DOI 10.1016/S0145-2126(97)00024-6; MORRIS JF, 1994, MOL CELL BIOL, V14, P1786, DOI 10.1128/MCB.14.3.1786; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-0569; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; SPRINGALL F, 1993, LEUKEMIA, V7, P978; Tagoh H, 2004, EMBO J, V23, P4275, DOI 10.1038/sj.emboj.7600421; Tagoh H, 2002, GENE DEV, V16, P1721, DOI 10.1101/gad.222002	27	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3643	3651		10.1038/sj.onc.1208655	http://dx.doi.org/10.1038/sj.onc.1208655			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15806141				2022-12-17	WOS:000229221800011
J	Yuan, ZQ; Gaba, AG; Kent, TS; Bennett, A; Miller, A; Weber, TK				Yuan, ZQ; Gaba, AG; Kent, TS; Bennett, A; Miller, A; Weber, TK			Modulation of CDK2-AP1 (p12(DOC-1)) expression in human colorectal cancer	ONCOGENE			English	Article						colorectal cancer; microsatellite instability; CDK2-AP1; siRNA	DNA-REPLICATION ERRORS; MICROSATELLITE INSTABILITY; FUNCTIONAL-ANALYSIS; APOPTOSIS; MUTATIONS; GENE; CARCINOMAS; HMSH2; RNA; IMBALANCE	We have previously demon strated an association between microsatellite instability and decreased CDK2-AP1 (p12(DOC-1)) expression in human colorectal cancer (CRC) cell lines. In those same studies, induction of CDK2-AP1 expression promoted both cell cycle arrest and apoptosis. The goals of our present study were to better understand the mechanisms leading to reduced CDK2-AP1 expression in microsatellite unstable (MSI) CRC and to study further the effect of CDK2-AP1 modulation on cell proliferation and apoptosis utilizing RNA interference (RNAi) techniques. We used direct sequencing to screen for mutations of the poly(T) 8 microsatellite-like region in the 3' end of the CDK2-AP1 gene in 24 CRC cell lines. We then utilized an in vitro human mismatch repair (MMR) recombinant system to assess for correction of the mutation and changes in CDK2-AP1 expression secondary to hMLH1 transfection. We also investigated the effect of CDK2-AP1 modulation in four settings: (1) native CDK2-AP1 absence, (2) endogenous CDK2-AP1 expression, (3) RNAi-induced CDK2-AP1 inhibition and (4) induced CDK2-AP1 over expression. The mutation-del T poly (T)8-at the 3' end of the CDK2-AP1 gene was found in 3/12 (25%) of MSI CRC cell lines, but in none of the microsatellite stable samples (0/12). Interestingly, when wild-type MMR protein-MLH1-was induced in an in vitro human recombinant system, the del T poly (T) 8 mutation was reversed and CDK2-AP1 expression increased. RNAi-mediated CDK2-AP1 inhibition was associated with decreased apoptosis and increased cell proliferation in CDK2-AP1-non deficient CRC cell lines. We conclude that mutations in the microsatellite-like sequence of the CDK2-AP1 gene in MSI CRC are associated with decreased CDK2-AP1 expression. In addition, modulation of CDK2-AP1 expression in human CRC alters cell proliferation and apoptosis.	Albert Einstein Coll Med, Dept Mol Genet, New York, NY 10461 USA; Albert Einstein Coll Med, Dept Med Oncol, New York, NY 10461 USA; Albert Einstein Coll Med, Dept Surg, New York, NY 10461 USA	Yeshiva University; Yeshiva University; Yeshiva University	Weber, TK (corresponding author), Albert Einstein Coll Med, Dept Mol Genet & Surg, 1300 Morris Pk Ave,Ullmann Bldg 1219 Bronx, New York, NY 10461 USA.	tweber@aecom.yu.edu						BEDI A, 1995, CANCER RES, V55, P1811; Boland CR, 1998, CANCER RES, V58, P5248; Brieger A, 2002, GUT, V51, P677, DOI 10.1136/gut.51.5.677; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Bubb VJ, 1996, ONCOGENE, V12, P2641; DIEBOLD J, 1992, VIRCHOWS ARCH B, V62, P283, DOI 10.1007/BF02899694; Dolcetti R, 1999, AM J PATHOL, V154, P1805, DOI 10.1016/S0002-9440(10)65436-3; Farrington SM, 2002, INT J CANCER, V98, P844, DOI 10.1002/ijc.10264; Fujiwara T, 1998, AM J PATHOL, V153, P1063, DOI 10.1016/S0002-9440(10)65651-9; Halling KC, 1999, JNCI-J NATL CANCER I, V91, P1295, DOI 10.1093/jnci/91.15.1295; Hao XP, 1998, VIRCHOWS ARCH, V433, P523, DOI 10.1007/s004280050284; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Irmer H, 2001, NUCLEIC ACIDS RES, V29, P4707, DOI 10.1093/nar/29.22.4707; Johannsdottir JT, 2000, INT J ONCOL, V16, P133; JOHNSTON PG, 1989, HUM PATHOL, V20, P696, DOI 10.1016/0046-8177(89)90158-5; KEE F, 1991, GUT, V32, P509, DOI 10.1136/gut.32.5.509; Kent TS, 2004, ANN SURG ONCOL, V11, P192, DOI 10.1245/ASO.2004.03.056; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; KIM HG, 1994, AM J PATHOL, V145, P148; Kim HS, 2003, GASTROENTEROLOGY, V125, P708, DOI 10.1016/S0016-5085(03)01059-X; LOTHE RA, 1993, CANCER RES, V53, P5849; Lukish JR, 1998, ANN SURG, V227, P51, DOI 10.1097/00000658-199801000-00008; Manjeshwar S, 2003, CANCER RES, V63, P5251; Matsuo K, 2000, FASEB J, V14, P1318, DOI 10.1096/fj.14.10.1318; Shintani S, 2001, CLIN CANCER RES, V7, P2776; Shintani S, 2000, MOL CELL BIOL, V20, P6300, DOI 10.1128/MCB.20.17.6300-6307.2000; SLATTERY ML, 1995, DIS COLON RECTUM, V38, P1053, DOI 10.1007/BF02133978; TODD R, 1995, FASEB J, V9, P1362, DOI 10.1096/fasebj.9.13.7557027; Trojan J, 2002, GASTROENTEROLOGY, V122, P211, DOI 10.1053/gast.2002.30296; Tsuji T, 1998, J BIOL CHEM, V273, P6704, DOI 10.1074/jbc.273.12.6704; Williams NS, 2003, CLIN CANCER RES, V9, P931; Yasuda M, 2003, AM J HUM GENET, V73, P162, DOI 10.1086/376608; Yuan ZQ, 2003, ONCOGENE, V22, P6304, DOI 10.1038/sj.onc.1206609; Zhang H, 1999, CANCER RES, V59, P3021	35	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 19	2005	24	22					3657	3668		10.1038/sj.onc.1208378	http://dx.doi.org/10.1038/sj.onc.1208378			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	927SW	15806176				2022-12-17	WOS:000229221800013
J	Fest, T; Guffei, A; Williams, G; Silva, S; Mai, S				Fest, T; Guffei, A; Williams, G; Silva, S; Mai, S			Uncoupling of genomic instability and tumorigenesis in a mouse model of Burkitt's lymphoma expressing a conditional box II-deleted Myc protein	ONCOGENE			English	Article						genome instability; c-Myc; Burkitt's lymphoma; SCID mice	C-MYC; REPRESSES TRANSCRIPTION; TRANSACTIVATION DOMAIN; APOPTOSIS; TRANSFORMATION; HYPERMUTATION; ACTIVATION; MUTATIONS; INDUCTION; ONCOGENES	Burkitt's lymphomas (BL) are characterized by the constitutive expression of c-Myc protein. In total, 50-60% of all BL cells carry mutant c-Myc proteins. Using a mouse model of spontaneously immortalized pro-B-lymphocytes (Ba/F3), we have investigated genomic instability mediated by the conditional expression of either wild-type (WT) or deletion box II Delta 106-Myc proteins. We found that both proteins mediate common as well as differing types of chromosomal rearrangements as documented by spectral karyotyping (SKY). A higher level of genomic instability is induced by the Delta 106-Myc protein. To examine the tumorigenic potential of WT or Delta 106-driven Ba/F3 cells, in vivo tumorigenesis studies were performed in SCID mice. Under the experimental conditions of this study, WT but not Delta 106-Myc expressing Ba/F3 cells triggered tumorigenesis in SCID mice. Therefore, the genomic instability phenotype induced by Delta 106-Myc can be genetically uncoupled from its tumorigenic potential.	Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Manitoba, Genom Ctr Canc Res & Diag, Winnipeg, MB R3E 0V9, Canada; Lab Univ Hematol, UPRES 2233 1247, F-35043 Rennes, France; Hlth Sci Ctr, Hematopathol Lab, Winnipeg, MB R3A 1R9, Canada	University of Manitoba; University of Manitoba; Children's Hospital Research Institute of Manitoba	Fest, T (corresponding author), Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.	thierry.fest@univ-rennes1.fr; smai@cc.umanitoba.ca	Mai, Sabine/E-5667-2017	Mai, Sabine/0000-0002-5797-2201; fest, thierry/0000-0002-6437-4189				AMIN C, 1993, MOL CELL BIOL, V13, P383, DOI 10.1128/MCB.13.1.383; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Fest T, 2002, ONCOGENE, V21, P2981, DOI 10.1038/sj/onc/1205274; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Gaidano G, 2003, BLOOD, V102, P1833, DOI 10.1182/blood-2002-11-3606; GORUPPI S, 1994, ONCOGENE, V9, P1537; KLEIN G, 1986, AIDS RES HUM RETROV, V2, pS167; Kumagai H, 2003, SCAND J GASTROENTERO, V38, P687, DOI 10.1080/00365520310003435; Kuttler F, 2001, ONCOGENE, V20, P6084, DOI 10.1038/sj.onc.1204827; Lee TC, 1997, P NATL ACAD SCI USA, V94, P12886, DOI 10.1073/pnas.94.24.12886; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; LITTLEWOOD TD, 1995, NUCLEIC ACIDS RES, V23, P1686, DOI 10.1093/nar/23.10.1686; Mai Sabine, 2003, Journal of Environmental Pathology Toxicology and Oncology, V22, P179; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Raffeld M, 1995, Curr Top Microbiol Immunol, V194, P265; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697	21	11	11	0	0	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 21	2005	24	18					2944	2953		10.1038/sj.onc.1208467	http://dx.doi.org/10.1038/sj.onc.1208467			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	919WY	15735723				2022-12-17	WOS:000228649500003
J	Curtin, JC; Spinella, MJ				Curtin, JC; Spinella, MJ			p53 in human embryonal carcinoma: identification of a transferable, transcriptional repression domain in the N-terminal region of p53	ONCOGENE			English	Article						p53; retinoic acid; embryonal carcinoma; repression	HISTONE-DEACETYLASE INHIBITORS; ACUTE PROMYELOCYTIC LEUKEMIA; TUMOR-CELL DIFFERENTIATION; RETINOIC ACID; TERATOCARCINOMA CELLS; TESTICULAR CANCER; NEURONAL DIFFERENTIATION; INDUCED APOPTOSIS; GENE-EXPRESSION; BINDING DOMAIN	Testicular germ cell tumors (TGCTs) arise despite possessing high levels of wild-type p53, suggesting p53 latency. We have previously shown that p53 repression in TGCT-derived human embryonal carcinoma (EC) is relieved upon treatment with all-trans retinoic acid (RA), resulting in enhanced p53 transactivation activity. To further investigate p53 repression in EC, a series of gal4-p53 truncation constructs were generated. Deletion of the core DNA-binding region, residues 117-274, had no effect on basal or RA-induced p53 activity. Progressively, larger truncations were made in the C- or N-terminal direction. Deletion of residues toward the C-terminus of p53 as far as residue 354 did not affect either the basal or RA-inducible activity of gal4-p53. When a small region in the N-terminus was deleted ( residues 105-116), relief of the basal repression of p53 activity characteristic of EC was observed. Fusion of this region to the VP16 activation domain (VPAD) resulted in a 10-20-fold repression of VPAD activity in NT2/D1 human EC cells, indicating that this region acts as a heterologous repressor. Owing to its location in the N-terminal half of p53, we have named this region the p53 N-terminal Repression Domain (p53-NRD). The p53-NRD mediated repression in a variety of cell lines, with the most prominent repression observed in human EC cells. While RA alone had no effect on p53-NRD activity, cotreatment with RA and the histone deacetylase inhibitor trichostatin-A (TSA) completely relieved p53-NRD-mediated repression. In contrast, NRD-mediated repression was not sensitive to RA and TSA in a derived RA-resistant cell line with a retinoic acid receptor gamma (RARgamma) defect, but sensitivity could be restored with transfection of RARgamma. These data indicate that a unique repressor domain resides in p53 at residues 90-116 whose activity can be modulated in the presence of 'differentiation therapy' and 'transcription therapy' agents.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Hanover, NH 03755 USA	Dartmouth College; Dartmouth College; Norris Cotton Cancer Center	Spinella, MJ (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.	michael.spinella@dartmouth.edu	Spinella, Michael/B-7210-2014		NATIONAL CANCER INSTITUTE [K01CA075154] Funding Source: NIH RePORTER; NCI NIH HHS [K01-CA75154] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Andrews PW, 2002, PHILOS T R SOC B, V357, P405, DOI 10.1098/rstb.2002.1058; BARGONETTI J, 1993, GENE DEV, V7, P2565, DOI 10.1101/gad.7.12b.2565; Benard J, 2003, HUM MUTAT, V21, P182, DOI 10.1002/humu.10172; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Burger H, 1999, INT J CANCER, V81, P620, DOI 10.1002/(SICI)1097-0215(19990517)81:4<620::AID-IJC19>3.3.CO;2-J; Burger H, 1998, BRIT J CANCER, V77, P1562, DOI 10.1038/bjc.1998.257; Chaganti RSK, 2000, CANCER RES, V60, P1475; CHO YJ, 1994, SCIENCE, V265, P346, DOI 10.1126/science.8023157; Chresta CM, 1996, CANCER RES, V56, P1834; Curtin JC, 2001, ONCOGENE, V20, P2559, DOI 10.1038/sj.onc.1204370; Einhorn Lawrence H, 2002, Chest Surg Clin N Am, V12, P695, DOI 10.1016/S1052-3359(02)00029-7; Ferrara FF, 2001, CANCER RES, V61, P2; Freemantle SJ, 2003, ONCOGENE, V22, P7305, DOI 10.1038/sj.onc.1206936; Freemantle SJ, 2002, ONCOGENE, V21, P2880, DOI 10.1038/sj.onc.1205408; Glass CK, 2000, GENE DEV, V14, P121; Gu JJ, 2001, ONCOGENE, V20, P3519, DOI 10.1038/sj.onc.1204454; HEIMDAL K, 1993, GENE CHROMOSOME CANC, V6, P92, DOI 10.1002/gcc.2870060205; Ho J, 2003, CELL DEATH DIFFER, V10, P404, DOI 10.1038/sj.cdd.4401191; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Houldsworth J, 1998, ONCOGENE, V16, P2345, DOI 10.1038/sj.onc.1201770; Huyghe E, 2003, J UROLOGY, V170, P5, DOI 10.1097/01.ju.0000053866.68623.da; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Jones RH, 2003, EUR J CANCER, V39, P147, DOI 10.1016/S0959-8049(02)00612-3; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kersemaekers AMF, 2002, J CLIN ONCOL, V20, P1551, DOI 10.1200/JCO.20.6.1551; Kouraklis G., 2002, Current Medicinal Chemistry - Anti-Cancer Agents, V2, P477, DOI 10.2174/1568011023353921; Langenfeld J, 1997, P NATL ACAD SCI USA, V94, P12070, DOI 10.1073/pnas.94.22.12070; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lippman SM, 2001, JNCI-J NATL CANCER I, V93, P605, DOI 10.1093/jnci/93.8.605; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; Lutzker SG, 2001, ONCOGENE, V20, P2982, DOI 10.1038/sj.onc.1204394; Mangelsdorf David J., 1994, P319; MOASSER MM, 1995, ONCOGENE, V10, P1537; Moasser MM, 1996, DIFFERENTIATION, V60, P251, DOI 10.1046/j.1432-0436.1996.6040251.x; NASONBURCHENAL K, 1999, RETINOIDS HDB EXPT P, P301; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Pandolfi PP, 2001, ONCOGENE, V20, P3116, DOI 10.1038/sj.onc.1204299; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; PENG HQ, 1993, CANCER RES, V53, P3574; Petti MC, 2002, BLOOD, V100, P1065, DOI 10.1182/blood-2001-12-0368; Ronca F, 1999, J BIOL CHEM, V274, P18128, DOI 10.1074/jbc.274.25.18128; Shin DM, 1997, CLIN CANCER RES, V3, P875; Shin DM, 2000, J NATL CANCER I, V92, P69, DOI 10.1093/jnci/92.1.69; Spinella MJ, 1999, J BIOL CHEM, V274, P22013, DOI 10.1074/jbc.274.31.22013; Spinella MJ, 1998, ONCOGENE, V16, P3471, DOI 10.1038/sj.onc.1201876; Spinella MJ, 2003, J NUTR, V133, p273S, DOI 10.1093/jn/133.1.273S; Sun SY, 2002, CRIT REV ONCOL HEMAT, V41, P41, DOI 10.1016/S1040-8428(01)00144-5; Varley Jenny, 2003, Methods Mol Biol, V222, P117; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Zamble DB, 1998, P NATL ACAD SCI USA, V95, P6163, DOI 10.1073/pnas.95.11.6163; Zeng XY, 2000, CANCER RES, V60, P6184; Zhou DC, 2002, BLOOD, V99, P1356, DOI 10.1182/blood.V99.4.1356; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	58	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1481	1490		10.1038/sj.onc.1208130	http://dx.doi.org/10.1038/sj.onc.1208130			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME	15674351				2022-12-17	WOS:000227218200001
J	Li, CF; Kandel, C; Baliko, F; Nadesan, P; Brunner, N; Alman, BA				Li, CF; Kandel, C; Baliko, F; Nadesan, P; Brunner, N; Alman, BA			Plasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive bromatosis (desmoid tumor)	ONCOGENE			English	Article						aggressive fibromatosis; plasminogen activator inhibitor-1; beta-catenin; transgenic mice; adenomatous polyposis coli; cell proliferation; cell motility	BREAST-CANCER PATIENTS; GENE-DEFICIENT MICE; BETA-CATENIN; TRANSCRIPTIONAL ACTIVATION; PROGNOSTIC-SIGNIFICANCE; CYTOSOLIC EXTRACTS; CELL-PROLIFERATION; UROKINASE RECEPTOR; ANDROGEN RECEPTOR; COLON-CARCINOMA	Aggressive fibromatosis is a mesenchymal neoplasm associated with mutations, resulting in beta-catenin-mediated transcriptional activation. We found that plasminogen activator inhibitor-1 (PAI-1) was upregulated fourfold in aggressive fibromatosis. We investigated the ability of beta-catenin to regulate a PAI-1 reporter, and found that PAI-1 is an indirect target. To determine the role of PAI-1 in vivo, a mouse containing a targeted deletion in Pai-1 was crossed with a mouse that develops aggressive fibromatosis and gastrointestinal tumors (Apc/Apc1638N mouse). Pai-1 deficiency reduced the number of aggressive fibromatosis tumors formed, but not the number of gastrointestinal tumors. Deficiency of Pai-1 reduced tumor cell proliferation and motility rate. Although PAI-1 can alter cell motility by competing for a common binding site on vitronectin, blocking this site did not alter the motility rate. The number of cells moving through matrigel ( invasion rate) did not change with Pai-1 deficiency, but because of the low motility rate the invasion index (invasion rate/motility) was increased in Pai-1-deficient cells. This suggests a proteolytic effect for PAI-1 regulating cell invasiveness. Our study found that, although PAI-1 has cellular effects that could inhibit or enhance tumor growth, on balance, it acts as a tumor enhancer in aggressive. bromatosis.	Univ Toronto, Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Royal Vet & Agr Univ, DK-1870 Frederiksberg, Denmark; Univ Toronto, Dept Surg, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Copenhagen; University of Toronto	Alman, BA (corresponding author), Univ Toronto, Hosp Sick Children, Program Dev Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	benjamin.alman@sickkids.ca						ABE M, 1994, ANAL BIOCHEM, V216, P276, DOI 10.1006/abio.1994.1042; Alman BA, 1997, AM J PATHOL, V151, P329; Alman BA, 1997, DIAGN MOL PATHOL, V6, P98, DOI 10.1097/00019606-199704000-00005; Almholt K, 2003, ONCOGENE, V22, P4389, DOI 10.1038/sj.onc.1206601; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Binder BR, 2002, NEWS PHYSIOL SCI, V17, P56, DOI 10.1152/nips.01369.2001; CAJOT JF, 1990, P NATL ACAD SCI USA, V87, P6939, DOI 10.1073/pnas.87.18.6939; CARMELIET P, 1993, J CLIN INVEST, V92, P2756, DOI 10.1172/JCI116893; CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Cheon SS, 2002, P NATL ACAD SCI USA, V99, P6973, DOI 10.1073/pnas.102657399; Crandall DL, 2000, J CLIN ENDOCR METAB, V85, P2609, DOI 10.1210/jc.85.7.2609; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; DESCHEEMAEKER KA, 1992, J BIOL CHEM, V267, P15086; Dormans JP, 2001, MED PEDIATR ONCOL, V37, P126, DOI 10.1002/mpo.1181; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GRIMALDI G, 1986, EMBO J, V5, P855, DOI 10.1002/j.1460-2075.1986.tb04295.x; GrondahlHansen J, 1995, CLIN CANCER RES, V1, P1079; GrondahlHansen J, 1997, CLIN CANCER RES, V3, P233; GrondahlHansen J, 1997, BREAST CANCER RES TR, V43, P153, DOI 10.1023/A:1005744914124; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; Gutierrez LS, 2000, CANCER RES, V60, P5839; Hjortland GO, 2003, CLIN EXP METASTAS, V20, P301, DOI 10.1023/A:1024040718238; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kjoller L, 1997, EXP CELL RES, V232, P420, DOI 10.1006/excr.1997.3540; Kong Y, 2004, CANCER RES, V64, P5795, DOI 10.1158/0008-5472.CAN-03-3112; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kute TE, 1998, BREAST CANCER RES TR, V47, P9, DOI 10.1023/A:1005882520982; KUTZ C, 1995, NUCLEIC ACIDS RES, V23, P3710; Kwaan HC, 2000, BRIT J CANCER, V82, P1702; Li C, 2001, J PEDIATR ORTHOPED, V21, P372, DOI 10.1097/00004694-200105000-00021; Look MP, 2002, JNCI-J NATL CANCER I, V94, P116, DOI 10.1093/jnci/94.2.116; Meng XW, 2001, J BIOL CHEM, V276, P40113, DOI 10.1074/jbc.M105317200; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Morita Y, 1999, JPN J CANCER RES, V90, P747, DOI 10.1111/j.1349-7006.1999.tb00810.x; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Nykjaer A, 1997, EMBO J, V16, P2610, DOI 10.1093/emboj/16.10.2610; Pawlowski JE, 2002, J BIOL CHEM, V277, P20702, DOI 10.1074/jbc.M200545200; Poon R, 2001, ONCOGENE, V20, P451, DOI 10.1038/sj.onc.1204107; Rakic JM, 2003, CELL MOL LIFE SCI, V60, P463, DOI 10.1007/s000180300039; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Ryan MP, 1996, BIOCHEM J, V314, P1041, DOI 10.1042/bj3141041; Schmitt M, 1997, THROMB HAEMOSTASIS, V78, P285; Scott RJ, 1996, HUM MOL GENET, V5, P1921, DOI 10.1093/hmg/5.12.1921; Smits R, 1998, GASTROENTEROLOGY, V114, P275, DOI 10.1016/S0016-5085(98)70478-0; Steinmetzer T, 2003, IDRUGS, V6, P138; SUGIURA Y, 1999, CANCER RES, V59, P1237; Tejpar S, 1999, ONCOGENE, V18, P6615, DOI 10.1038/sj.onc.1203041; Tejpar S, 2001, BRIT J CANCER, V85, P98, DOI 10.1054/bjoc.2001.1857; TISCHLER AS, 1992, J HISTOCHEM CYTOCHEM, V40, P1043, DOI 10.1177/40.7.1351491; Tolg C, 2003, ONCOGENE, V22, P6873, DOI 10.1038/sj.onc.1206811; van Oordt CWVH, 1999, GENE CHROMOSOME CANC, V24, P191; Waltz DA, 1997, J CLIN INVEST, V100, P58, DOI 10.1172/JCI119521; Yang JL, 2000, INT J CANCER, V89, P431, DOI 10.1002/1097-0215(20000920)89:5<431::AID-IJC6>3.0.CO;2-V; Zavizion B, 1998, BBA-MOL CELL RES, V1403, P141, DOI 10.1016/S0167-4889(98)00035-4	56	11	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 24	2005	24	9					1615	1624		10.1038/sj.onc.1208193	http://dx.doi.org/10.1038/sj.onc.1208193			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	900ME					2022-12-17	WOS:000227218200015
J	Peng, XJ; Mehta, RG; Tonetti, DA; Christov, K				Peng, XJ; Mehta, RG; Tonetti, DA; Christov, K			Identification of novel RAR beta 2 transcript variants with short 5 '-UTRs in normal and cancerous breast epithelial cells	ONCOGENE			English	Article						RAR beta 2; 5 '-UTR; transcript variants; breast cancer; translation	ACID RECEPTOR-BETA; RETINOIC ACID; CARCINOMA; NUCLEAR; LINES; TRANSLATION; EXPRESSION; ISOFORMS; PROTEIN; TISSUE	Functional significance of RARbeta2 as a putative tumor suppressor gene has been studied in breast cancer and other tumors. The long 5'-untranslated region (5'-UTR) of its transcript with multiple open-reading frames (uORFs) is considered as a regulatory unit for translation. Here, for the first time we identified RARbeta2 transcript variants with short 5'-UTRs in both normal and malignant breast epithelial cells. The 5'-RACE analysis of RARbeta2 mRNA in these cells demonstrated the existence of short RARbeta2 transcript variants that are identical to the sequence of known RARbeta2, but lack all the uORFs present in the full-length 5'-UTR. By RT-PCR analysis, we found that the expression of both transcripts with short and full-length 5'-UTR is mediated by retinoic acid, while cellular sensitivity is preferentially correlated to upregulation of short RARbeta2 transcript variants in response to retinoic acid. The transfection and in vitro translation assay indicated that the short 5'-UTR has no inhibitory effects on translation, while the presence of full-length 5'-UTR inhibited translation by 60%. In addition, no promoter activity was detectable in RARbeta2 full-length 5'-UTR region. Our data suggest that the RARbeta2 transcript variants with short 5'-UTR may serve as major transcripts for RARbeta2 protein translation as well as potential targets for retinoids in breast cancer prevention and therapy studies.	Univ Illinois, Dept Surg Oncol, Chicago, IL 60612 USA; Univ Illinois, Dept Biopharmaceut Sci, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Christov, K (corresponding author), Univ Illinois, Dept Surg Oncol, 840 S Wood St,M-C 820, Chicago, IL 60612 USA.	christov@uic.edu			NATIONAL CANCER INSTITUTE [R01CA082316] Funding Source: NIH RePORTER; NCI NIH HHS [CA 82316] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARMICHAEL J, 1987, CANCER RES, V47, P936; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chen LI, 2002, J BIOL CHEM, V277, P35411, DOI 10.1074/jbc.M202717200; DENG G, 1996, SCIENCE, V249, P1577; DETHE H, 1987, NATURE, V330, P667, DOI 10.1038/330667a0; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; LEROY P, 1991, EMBO J, V10, P59, DOI 10.1002/j.1460-2075.1991.tb07921.x; LI XS, 1995, J CELL PHYSIOL, V165, P449, DOI 10.1002/jcp.1041650302; LIPPMAN SM, 1995, J CELL BIOCHEM, P1; Lotan R, 1996, FASEB J, V10, P1031, DOI 10.1096/fasebj.10.9.8801164; PENG X, 2004, IN PRESS CANC RES; Peng XJ, 2004, INT J ONCOL, V25, P961; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Sirchia SM, 2000, ONCOGENE, V19, P1556, DOI 10.1038/sj.onc.1203456; Sommer KM, 1999, P NATL ACAD SCI USA, V96, P8651, DOI 10.1073/pnas.96.15.8651; SWISSHELM K, 1994, CELL GROWTH DIFFER, V5, P133; TALLMAN MS, 1992, J CLIN PHARMACOL, V32, P868, DOI 10.1002/j.1552-4604.1992.tb04633.x; Widschwendter M, 1997, CANCER RES, V57, P4158; Xu XC, 1997, CANCER RES, V57, P4992; ZELENT A, 1991, EMBO J, V10, P71, DOI 10.1002/j.1460-2075.1991.tb07922.x; ZIMMER A, 1994, J CELL BIOL, V127, P1111, DOI 10.1083/jcb.127.4.1111	22	11	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 10	2005	24	7					1296	1301		10.1038/sj.onc.1208284	http://dx.doi.org/10.1038/sj.onc.1208284			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	895XV	15558014				2022-12-17	WOS:000226898700018
J	Abdel-Rahman, WM; Lohi, H; Knuttila, S; Peltomaki, P				Abdel-Rahman, WM; Lohi, H; Knuttila, S; Peltomaki, P			Restoring mismatch repair does not stop the formation of reciprocal translocations in the colon cancer cell line HCA7 but further destabilizes chromosome number	ONCOGENE			English	Article						mismatch repair; MLH1; recombination; reciprocal translocations; radiation	DOUBLE-STRAND BREAKS; COLORECTAL CANCERS; MICROSATELLITE INSTABILITY; HOMOLOGOUS RECOMBINATION; GENOMIC INSTABILITY; GENETIC INSTABILITY; SOLID TUMORS; DNA-REPAIR; CARCINOMAS; INACTIVATION	An important anticarcinogenic function of the mismatch repair (MMR) system is its role in preventing recombination between similar, but nonidentical (homeologous) sequences, thus preventing chromosomal rearrangements. We recently identified a novel chromosomal instability (CIN) phenotype in an MMR defective colon cancer cell line (HCA7) characterized by an ongoing tendency to multiple reciprocal chromosomal translocations. To analyse the relation between MMR and chromosomal changes more closely, the HCA7 stem clone was divided into three stocks. The first was stably transfected with MLH1 expression plasmid, the second was regularly exposed to the demethylating agent 5-azacytidin to re-express the hypermethylated MLH1 gene, and the third was an unmanipulated control stock. All stocks were propagated in vitro for 55 - 80 passages and, furthermore, some of the early passages were irradiated to induce DNA double-strand breaks. Multiplex-fluorescent in situ hybridization (M-FISH) analysis showed that all three stocks acquired varying numbers of reciprocal translocations and other structural changes at some point. Interestingly, the control stock, which is MMR defective, maintained its numerical chromosomal stability, while some of the MMR-proficient clones showed additional numerical instability. Although the control stock was less sensitive to irradiation, its surviving clones showed marked stability of chromosome structure and number compared to the MMR-competent stocks. These results show that restoring MMR does not prevent the development of reciprocal translocations but rather predisposes cells to numerical CIN after irradiation. Thus, the accumulating data suggest that MMR defect may not be necessary for the development of reciprocal chromosomal translocations but might be permissive.	Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, FIN-00014 Helsinki, Finland; Zagazig Univ, Fac Med, Dept Pathol, Zagazig, Egypt; Univ Helsinki, Haartman Inst, Lab Cytomol Genet, Dept Pathol, Helsinki, Finland; Univ Helsinki, Haartman Inst, Lab Cytomol Genet, Dept Med Genet, Helsinki, Finland; Univ Helsinki, HUSLAB, Helsinki, Finland; Univ Helsinki, Cent Hosp, Helsinki, Finland	University of Helsinki; Egyptian Knowledge Bank (EKB); Zagazig University; University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Abdel-Rahman, WM (corresponding author), Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, POB 63 Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Wael-Abdel-Rahman@helsinki.fi	Lohi, Hannes/F-4596-2011	Lohi, Hannes/0000-0003-1087-5532; Peltomaki, Paivi/0000-0001-8819-2980; Abdel-Rahman, Wael/0000-0002-2149-1043	NATIONAL CANCER INSTITUTE [R01CA082282] Funding Source: NIH RePORTER; NCI NIH HHS [CA82282] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Bardelli A, 2001, P NATL ACAD SCI USA, V98, P5770, DOI 10.1073/pnas.081082898; Bocker T, 1996, J PATHOL, V179, P15; Buermeyer AB, 1999, CANCER RES, V59, P538; Chan TL, 2001, ONCOGENE, V20, P4871, DOI 10.1038/sj.onc.1204653; Chauveinc L, 1999, CANCER GENET CYTOGEN, V114, P1, DOI 10.1016/S0165-4608(99)00038-2; Ciotta C, 1998, J MOL BIOL, V276, P705, DOI 10.1006/jmbi.1997.1559; Deans B, 2003, CANCER RES, V63, P8181; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Dutrillaux B, 1995, ADV CANCER RES, V67, P59, DOI 10.1016/S0065-230X(08)60710-1; Elliott B, 2001, MOL CELL BIOL, V21, P2671, DOI 10.1128/MCB.21.8.2671-2682.2001; Eshleman JR, 1998, ONCOGENE, V17, P719, DOI 10.1038/sj.onc.1201986; Ferguson DO, 2000, P NATL ACAD SCI USA, V97, P6630, DOI 10.1073/pnas.110152897; Georgiades IB, 1999, ONCOGENE, V18, P7933, DOI 10.1038/sj.onc.1203368; Giannini G, 2002, EMBO REP, V3, P248, DOI 10.1093/embo-reports/kvf044; Harfe BD, 2000, MUTAT RES-FUND MOL M, V451, P151, DOI 10.1016/S0027-5107(00)00047-6; Jasin M, 2000, CANCER INVEST, V18, P78, DOI 10.3109/07357900009023065; Kim NG, 2001, CANCER RES, V61, P36; Lambert B, 1998, MUTAT RES-FUND MOL M, V405, P161, DOI 10.1016/S0027-5107(98)00133-X; Lefevre SH, 2001, ONCOGENE, V20, P8092, DOI 10.1038/sj.onc.1205009; Limoli CL, 2001, BRIT J CANCER, V84, P489, DOI 10.1054/bjoc.2000.1604; Moynahan ME, 2001, CANCER RES, V61, P4842; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; Richardson C, 2000, NATURE, V405, P697, DOI 10.1038/35015097; Richardson C, 2004, ONCOGENE, V23, P546, DOI 10.1038/sj.onc.1207098; Risinger JI, 1998, CANCER RES, V58, P2978; Roschke AV, 2002, NEOPLASIA, V4, P19, DOI 10.1038/sj.neo.7900197; SCHLEGEL J, 1995, CANCER RES, V55, P6002; Schweizer P, 2001, CANCER RES, V61, P2813; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; Tsuji T, 2003, J GASTROENTEROL, V38, P1185, DOI 10.1007/s00535-003-1229-1; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Yu VPCC, 2000, GENE DEV, V14, P1400	34	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 20	2005	24	4					706	713		10.1038/sj.onc.1208129	http://dx.doi.org/10.1038/sj.onc.1208129			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	889CF	15580308				2022-12-17	WOS:000226420400018
J	Feinstein, E				Feinstein, E			Ral-GTPases: good chances for a long-lasting fame	ONCOGENE			English	Editorial Material							REQUIREMENT; INVASION		Quark Biotech Inc, Ness Ziona, Israel		Feinstein, E (corresponding author), Quark Biotech Inc, Ness Ziona, Israel.	elenaf@qbi.co.il						Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Campbell PM, 2004, SEMIN CANCER BIOL, V14, P105, DOI 10.1016/j.semcancer.2003.09.015; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Malumbres M, 2003, NAT REV CANCER, V3, P708, DOI 10.1038/nrc1193; Ward Y, 2001, MOL CELL BIOL, V21, P5958, DOI 10.1128/MCB.21.17.5958-5969.2001; Xu LZ, 2003, MOL CELL BIOL, V23, P645, DOI 10.1128/MCB.23.2.645-654.2003	9	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 13	2005	24	3					326	328		10.1038/sj.onc.1208252	http://dx.doi.org/10.1038/sj.onc.1208252			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	887CH	15531910				2022-12-17	WOS:000226279700003
J	Porlan, E; Vega, S; Iglesias, T; Rodriguez-Pena, A				Porlan, E; Vega, S; Iglesias, T; Rodriguez-Pena, A			Unliganded thyroid hormone receptor beta 1 inhibits proliferation of murine broblasts by delaying the onset of the G1 cell-cycle signals	ONCOGENE			English	Article						thyroid hormone; thyroid hormone receptors; TR beta 1; cell cycle; cell proliferation; E2F transcription factor	OLIGODENDROCYTE DIFFERENTIATION; NEURONAL DIFFERENTIATION; GENE-EXPRESSION; MOLECULAR-BASIS; REPRESSION; MICE; RESISTANCE; REGULATOR; CARCINOMA; ALPHA	Thyroid hormone receptors (TRs) are members of the ligand-inducible transcription factor superfamily. The two major functional TRs (alpha1 and beta1) have different spatial and temporal expression patterns and specific physiological functions for these isoforms are now starting to emerge. By expressing these TR isoforms individually in Swiss 3T3 fibroblasts, we found that TRbeta1 expression, in the absence of hormone, provokes a proliferation arrest in G0/G1, lengthening the cycling time. Upon serum stimulation TRbeta1-expressing cells showed a marked delay in the induction of cyclins D and E, in the phosphorylation of retinoblastoma protein, and in the activation of cyclin-dependent kinase 2, accompanied by increased levels of cyclin-dependent kinase inhibitor p27(Kip1). Accordingly, serum-stimulated E2F-1 transcriptional activity was repressed by TRbeta1 in transient transfection experiments. Analysis of the receptor domains required for this effect confirmed that there is no need for a functional ligand-binding domain while the DNA-binding domain is essential. In this work, we demonstrate for the first time that TRbeta1 participates in the molecular mechanisms that control cell proliferation. The unliganded TRbeta1 impairs the normal induction of the G1/S cycle regulators preventing progression into the S phase.	Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)	Rodriguez-Pena, A (corresponding author), CSIC, Inst Cajal, Dr Arce 37, E-28002 Madrid, Spain.	arodriguez@iib.uam.es	porlan, Eva/AAE-6561-2022; Vacas, Teresa Iglesias/ABF-8663-2020; Vega, Sonia/R-1883-2018	porlan, Eva/0000-0003-0934-9711; Vacas, Teresa Iglesias/0000-0002-4326-9005; Rodriguez-Pena, Angeles/0000-0002-2515-4626; Vega, Sonia/0000-0002-3895-6265				Barrera-Hernandez G, 1998, DNA CELL BIOL, V17, P743, DOI 10.1089/dna.1998.17.743; Bauer A, 1998, EMBO J, V17, P4291, DOI 10.1093/emboj/17.15.4291; Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Billon N, 2001, DEV BIOL, V235, P110, DOI 10.1006/dbio.2001.0293; BROWN DD, 1995, RECENT PROG HORM RES, V50, P309; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Carre JL, 1998, J NEUROSCI RES, V54, P584; Chassande O, 1997, MOL ENDOCRINOL, V11, P1278, DOI 10.1210/me.11.9.1278; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Durand B, 2000, BIOESSAYS, V22, P64; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Flamant F, 2003, TRENDS ENDOCRIN MET, V14, P85, DOI 10.1016/S1043-2760(02)00043-7; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Gonzalez-Sancho JM, 2003, CANCER LETT, V192, P121, DOI 10.1016/S0304-3835(02)00614-6; Hashimoto K, 2001, P NATL ACAD SCI USA, V98, P3998, DOI 10.1073/pnas.051454698; HAYASHI Y, 1994, J CLIN INVEST, V94, P607, DOI 10.1172/JCI117376; Herwig S, 1997, EUR J BIOCHEM, V246, P581, DOI 10.1111/j.1432-1033.1997.t01-2-00581.x; KOENIG RJ, 1989, NATURE, V337, P659, DOI 10.1038/337659a0; LEBEL JM, 1994, P NATL ACAD SCI USA, V91, P2644, DOI 10.1073/pnas.91.7.2644; MARKOWITZ S, 1989, J CLIN INVEST, V84, P1683, DOI 10.1172/JCI114349; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Nygard M, 2003, MOL ENDOCRINOL, V17, P79, DOI 10.1210/me.2002-0107; O'Shea PJ, 2002, J ENDOCRINOL, V175, P553, DOI 10.1677/joe.0.1750553; Oberste-Berghaus C, 2000, J BIOL CHEM, V275, P1787, DOI 10.1074/jbc.275.3.1787; Oppenheimer JH, 1997, ENDOCR REV, V18, P462, DOI 10.1210/er.18.4.462; PAAVONEN T, 1982, SCAND J IMMUNOL, V15, P211, DOI 10.1111/j.1365-3083.1982.tb00640.x; PASTOR R, 1994, ONCOGENE, V9, P1081; Perez-Juste G, 1999, J BIOL CHEM, V274, P5026, DOI 10.1074/jbc.274.8.5026; Qi JS, 1997, MOL CELL BIOL, V17, P7195, DOI 10.1128/MCB.17.12.7195; RODRIGUEZ ER, 1994, BIOCHEM BIOPH RES CO, V205, P652, DOI 10.1006/bbrc.1994.2715; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P2936, DOI 10.1073/pnas.80.10.2936; SAMUELS HH, 1979, ENDOCRINOLOGY, V105, P80, DOI 10.1210/endo-105-1-80; SHERR CJ, 1994, COLD SPRING HARB SYM, V59, P11, DOI 10.1101/SQB.1994.059.01.004; STRAIT KA, 1990, J BIOL CHEM, V265, P10514; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Tokumoto YM, 2002, DEV BIOL, V245, P224, DOI 10.1006/dbio.2002.0626; Yap N, 1996, P NATL ACAD SCI USA, V93, P4273, DOI 10.1073/pnas.93.9.4273; YEN PM, 1995, ENDOCRINOLOGY, V136, P2845, DOI 10.1210/en.136.7.2845; Yen PM, 2003, TRENDS ENDOCRIN MET, V14, P327, DOI 10.1016/S1043-2760(03)00114-0	39	11	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2004	23	54					8756	8765		10.1038/sj.onc.1208126	http://dx.doi.org/10.1038/sj.onc.1208126			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	871VQ	15467737	Bronze			2022-12-17	WOS:000225165100005
J	Bounacer, A; McGregor, A; Skinner, J; Bond, J; Poghosyan, Z; Wynford-Thomas, D				Bounacer, A; McGregor, A; Skinner, J; Bond, J; Poghosyan, Z; Wynford-Thomas, D			Mutant Ras-induced proliferation of human thyroid epithelial cells requires three effector pathways	ONCOGENE			English	Article						Ras; Ral; thyroid; epithelial; signalling; tumour	ADP-RIBOSYLATION FACTOR; ACTIVATED PROTEIN-KINASE; PHOSPHOLIPASE-D; EXOCYST COMPLEX; TRANSFORMATION; GTPASE; SUFFICIENT; DIFFERENTIATION; STIMULATION; CONTRIBUTE	Ras mutations occur as an early event in many human tumours of epithelial origin, including thyroid. Using primary human thyroid epithelial cells to model tumour initiation by Ras, we have shown previously that activation of both the MAP kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) effector pathways are necessary, but even when activated together are not sufficient, for Ras-induced proliferation. Here, we show that a third effector, RalGEF, is also activated by Ras in these cells, that this activation is necessary for Ras-induced proliferation, and furthermore that in combination with the MAPK and PI3K effectors, it is able to reproduce the proliferative effect of activated Ras. The requirement for three effector pathways indicates a more robust control of cell proliferation in this normal human epithelial cell type than has been displayed in previous similar studies using rodent and human cell lines. Our findings highlight the importance of the appropriate cellular context in models of Ras-induced tumour development.	Cardiff Univ, Dept Pathol, Canc Res UK Labs, Cardiff CF14 4XN, S Glam, Wales	Cardiff University	Wynford-Thomas, D (corresponding author), Cardiff Univ, Dept Pathol, Canc Res UK Labs, Cardiff CF14 4XN, S Glam, Wales.	kingtd@cardiff.ac.uk						ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BOND JA, 1994, ONCOGENE, V9, P281; BOS JL, 1989, CANCER RES, V49, P4682; Cass LA, 2000, ONCOGENE, V19, P924, DOI 10.1038/sj.onc.1203393; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Chien YC, 2003, EMBO REP, V4, P800, DOI 10.1038/sj.embor.embor899; Cobellis G, 1998, ONCOGENE, V17, P2047, DOI 10.1038/sj.onc.1202130; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cullen PJ, 1999, BIOCHEM SOC T, V27, P683, DOI 10.1042/bst0270683; De Ruiter ND, 2000, MOL CELL BIOL, V20, P8480, DOI 10.1128/MCB.20.22.8480-8488.2000; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; Feig LA, 2003, TRENDS CELL BIOL, V13, P419, DOI 10.1016/S0962-8924(03)00152-1; Gire V, 2000, ONCOGENE, V19, P2269, DOI 10.1038/sj.onc.1203544; Gire V, 1999, ONCOGENE, V18, P4819, DOI 10.1038/sj.onc.1202857; Gire V, 1998, MOL CELL BIOL, V18, P1611, DOI 10.1128/MCB.18.3.1611; Goi T, 2000, EMBO J, V19, P623, DOI 10.1093/emboj/19.4.623; Graham SM, 1999, ONCOGENE, V18, P2107, DOI 10.1038/sj.onc.1202517; Guo W, 2001, NAT CELL BIOL, V3, P353, DOI 10.1038/35070029; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Hannon GJ, 1999, SCIENCE, V283, P1129, DOI 10.1126/science.283.5405.1129; Henry DO, 2000, MOL CELL BIOL, V20, P8084, DOI 10.1128/MCB.20.21.8084-8092.2000; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1989, BRIT J CANCER, V60, P897, DOI 10.1038/bjc.1989.387; LEMOINE NR, 1990, ONCOGENE, V5, P1833; Luo JQ, 1998, P NATL ACAD SCI USA, V95, P3632, DOI 10.1073/pnas.95.7.3632; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; Miller MJ, 1997, J BIOL CHEM, V272, P5600, DOI 10.1074/jbc.272.9.5600; Miller MJ, 1998, MOL CELL BIOL, V18, P3718, DOI 10.1128/MCB.18.7.3718; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moskalenko S, 2003, J BIOL CHEM, V278, P51743, DOI 10.1074/jbc.M308702200; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Ohta Y, 1999, P NATL ACAD SCI USA, V96, P2122, DOI 10.1073/pnas.96.5.2122; Oldham SM, 1996, P NATL ACAD SCI USA, V93, P6924, DOI 10.1073/pnas.93.14.6924; Roth MG, 1999, CHEM PHYS LIPIDS, V98, P141, DOI 10.1016/S0009-3084(99)00026-2; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shen YJ, 2001, MOL CELL BIOL, V21, P595, DOI 10.1128/MCB.21.2.595-602.2001; SUAREZ HG, 1990, ONCOGENE, V5, P565; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; WILLIAMS DW, 1988, BRIT J CANCER, V57, P535, DOI 10.1038/bjc.1988.124; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Xu LZ, 2003, MOL CELL BIOL, V23, P645, DOI 10.1128/MCB.23.2.645-654.2003	52	11	12	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 14	2004	23	47					7839	7845		10.1038/sj.onc.1208085	http://dx.doi.org/10.1038/sj.onc.1208085			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	860GX	15361839				2022-12-17	WOS:000224331600009
J	Deans, AJ; Simpson, KJ; Trivett, MK; Brown, MA; McArthur, GA				Deans, AJ; Simpson, KJ; Trivett, MK; Brown, MA; McArthur, GA			Brca1 inactivation induces p27Kip1-dependent cell cycle arrest and delayed development in the mouse mammary gland	ONCOGENE			English	Article						p27; BRCA1; mammary development; mouse model; cell cycle	DEPENDENT KINASE INHIBITOR; HEREDITARY BREAST-CANCER; TUMOR SUPPRESSION; OVARIAN-CANCER; DNA-REPAIR; P27(KIP1); EXPRESSION; P27; MUTATIONS; LINE	One common characteristic of breast cancers arising in carriers of the predisposition gene BRCA1 is a loss of expression of the CDK inhibitor p27(Kip1) (p27), suggesting that p27 interacts epistatically with BRCA1. To investigate this relationship, we examined expression of p27 in mice expressing a dominant negative allele of Brca1 (MMTV-trBr) in the mammary gland. While these mice rarely develop tumors, they showed a 50% increase in p27 protein and a delay in mammary gland development associated with reduced proliferation. In contrast, on a p27 heterozygote background, MMTV-trBrca1 mice showed an increase in S phase cells, and normal mammary development. p27 was the only protein in the cyclin cyclin-dependent kinase network to show altered expression, suggesting that it may be a central mediator of cell cycle arrest in response to loss of function of BRCA1. Furthermore, in human mammary epithelial MCF7 cells expressing BRCA1-specific RNAi and in the BRCA1-deficient human tumor cell line HCC1937, p27 is elevated at the mRNA level compared to cells expressing wild-type BRCA1. We hypothesize that disruption of BRCA1 induces an increase in p27 that inhibits proliferation. Accordingly, reduction in p27 expression leads to enhancement of cellular proliferation in the absence of BRCA1.	Peter MacCallum Canc Ctr, Trescowthick Res Labs, Mol Oncol Lab, Melbourne, Vic 3002, Australia; Univ Melbourne, Dept Med St Vincents, Parkville, Vic 3052, Australia; Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia; Peter MacCallum Canc Ctr, Dept Pathol, Melbourne 3002, Australia; Univ Queensland, Dept Biochem & Mol Biol, Brisbane, Qld 4072, Australia; Peter MacCallum Canc Ctr, Dept Haematol & Med Oncol, Melbourne 3002, Australia	Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; Peter Maccallum Cancer Center; University of Queensland; Peter Maccallum Cancer Center	McArthur, GA (corresponding author), Peter MacCallum Canc Ctr, Locked Bag 1,A Beckett St, Melbourne, Vic 8006, Australia.	grant.mcarthur@petermac.org	Deans, Andrew/U-3515-2019; Brown, Melissa A/F-1451-2010; Deans, Andrew J/E-5817-2011	Deans, Andrew/0000-0002-5271-4422; Deans, Andrew J/0000-0002-5271-4422; Simpson, Kaylene/0000-0001-9136-1781				Armes JE, 2002, PATHOLOGY, V34, P309, DOI 10.1080/00313020220147113; Brown MA, 2002, TRANSGENIC RES, V11, P467, DOI 10.1023/A:1020348025139; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Chappuis PO, 2000, J CLIN ONCOL, V18, P4045, DOI 10.1200/JCO.2000.18.24.4045; Chen A, 2002, J BIOL CHEM, V277, P22085, DOI 10.1074/jbc.M201252200; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; Craig C, 1997, ONCOGENE, V14, P2283, DOI 10.1038/sj.onc.1201064; Cressman VL, 1999, MOL CELL BIOL, V19, P7061; Crook T, 1998, ONCOGENE, V17, P1681, DOI 10.1038/sj.onc.1202106; Davison EA, 2003, MOL ENDOCRINOL, V17, P2436, DOI 10.1210/me.2003-0199; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dong YS, 2003, MOL CELL, V12, P1087, DOI 10.1016/S1097-2765(03)00424-6; Eisinger F, 1996, CANCER RES, V56, P471; Fan SJ, 2001, ONCOGENE, V20, P8215, DOI 10.1038/sj.onc.1205033; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Fujieda S, 1999, INT J CANCER, V84, P315, DOI 10.1002/(SICI)1097-0215(19990621)84:3<315::AID-IJC20>3.0.CO;2-U; Ganesan S, 2002, CELL, V111, P393, DOI 10.1016/S0092-8674(02)01052-8; Gowen LC, 1996, NAT GENET, V12, P191, DOI 10.1038/ng0296-191; Hakansson S, 1997, AM J HUM GENET, V60, P1068; Humphreys RC, 1997, MOL ENDOCRINOL, V11, P801, DOI 10.1210/me.11.6.801; Jackson RJ, 2002, ONCOGENE, V21, P8486, DOI 10.1038/sj.onc.1205946; Jazaeri AA, 2002, JNCI-J NATL CANCER I, V94, P990, DOI 10.1093/jnci/94.13.990; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Kauraniemi P, 2000, CANCER RES, V60, P5323; KAVANAUGH MP, 1994, P NATL ACAD SCI USA, V91, P7071, DOI 10.1073/pnas.91.15.7071; Kudo Y, 2000, CANCER LETT, V151, P217, DOI 10.1016/S0304-3835(99)00419-X; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Liu DF, 1999, J CLIN LAB ANAL, V13, P291, DOI 10.1002/(SICI)1098-2825(1999)13:6<291::AID-JCLA7>3.0.CO;2-K; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Marcus JN, 1996, CANCER-AM CANCER SOC, V77, P697, DOI 10.1002/(SICI)1097-0142(19960215)77:4<697::AID-CNCR16>3.0.CO;2-W; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Nadeau G, 2000, EMBO REP, V1, P260, DOI 10.1093/embo-reports/kvd059; Niwa Y, 2000, JPN J CANCER RES, V91, P519, DOI 10.1111/j.1349-7006.2000.tb00976.x; Pharoah PDP, 1999, CANCER RES, V59, P868; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Russo J, 2001, Breast J, V7, P278, DOI 10.1046/j.1524-4741.2001.21033.x; Scully R, 1999, MOL CELL, V4, P1093, DOI 10.1016/S1097-2765(00)80238-5; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Slingerland J, 2000, J CELL PHYSIOL, V183, P10, DOI 10.1002/(SICI)1097-4652(200004)183:1<10::AID-JCP2>3.0.CO;2-I; Stoppa-Lyonnet D, 2000, J CLIN ONCOL, V18, P4053, DOI 10.1200/JCO.2000.18.24.4053; Sylvain V, 2002, INT J ONCOL, V20, P845; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaziri SAJ, 2001, J CLIN PATHOL-MOL PA, V54, P259, DOI 10.1136/mp.54.4.259; Wagner T, 1999, GENOMICS, V62, P369, DOI 10.1006/geno.1999.6026; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743; Ye QN, 2001, J CELL BIOL, V155, P911, DOI 10.1083/jcb.200108049	52	11	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 12	2004	23	36					6136	6145		10.1038/sj.onc.1207805	http://dx.doi.org/10.1038/sj.onc.1207805			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	845RC	15208652				2022-12-17	WOS:000223261000013
J	Enomoto, Y; Enomoto, K; Kitamura, T; Kanda, T				Enomoto, Y; Enomoto, K; Kitamura, T; Kanda, T			Keratinocyte-specific POU transcription factor hSkn-1a represses the growth of cervical cancer cell lines	ONCOGENE			English	Article						hSkn-1a; cervical cancer; keratinocyte differentiation; POU-transcription factor	DIFFERENTIATION; EXPRESSION; GENE; PROMOTER; ELEGANS; DOMAIN; OCT-1	The POU transcription factor human Skn-1a (hSkn-1a) specifically promotes the proliferation of keratinocytes and enhances their differentiation. We examined the effects of hSkn-1a on cervical cancer cell lines of epithelial origin, in which the differentiation program is interrupted. From HeLa/Tet-On, a clone that can be induced to make hSkn-1a by doxycycline (HeLa/hSkn-1a) was prepared and characterized. Shortly after the induction, the cells expressed cytokeratin 10 (K10), a major marker protein in differentiating keratinocytes. While maintained for several days in the presence of doxycycline, the HeLa/hSkn-1a cells showed a slightly prolonged time of population doubling, the occasional appearance of. at cells with lowered DNA synthesis, and a low level of apoptotic DNA fragmentation. In SiHa and HeLa S3 cultures, K10 mRNA and apoptotic DNA fragmentation were detected at 48 h after infection with an adenoviral vector capable of expressing hSkn-1a. A colony inhibition assay showed that the growth of HeLa S3, SiHa, CaSki, and C-33A cells was repressed, as seen from the decreased number and average size of the drug-resistant colonies at 2 or 3 weeks after transfection with a plasmid that can express hSkn-1a and neomycin resistance gene. These results suggest that the expression of hSkn-1a represses the growth of the cervical cancer cells through the partial resumption of the differentiation pathway followed by slow suppression of cell replication and apoptosis.	Natl Inst Infect Dis, Div Mol Genet, Shinjuku Ku, Tokyo 1628640, Japan; Univ Tokyo, Fac Med, Dept Urol, Bunkyo Ku, Tokyo 1138655, Japan	National Institute of Infectious Diseases (NIID); University of Tokyo	Kanda, T (corresponding author), Natl Inst Infect Dis, Div Mol Genet, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	kanda@nih.go.jp	Kitamura, Toshio/AAA-2071-2021					Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; Enomoto K, 2003, BIOCHEM BIOPH RES CO, V303, P580, DOI 10.1016/S0006-291X(03)00395-4; FINNEY M, 1990, CELL, V63, P895, DOI 10.1016/0092-8674(90)90493-X; Fischer DF, 1996, MOL CELL BIOL, V16, P5365, DOI 10.1128/mcb.16.10.5365; Fusenig N E, 1995, Recent Results Cancer Res, V139, P1; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; Hietala KA, 1997, J PATHOL, V183, P305; Hildesheim J, 2001, J CELL SCI, V114, P1913; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; Jang SI, 2000, J BIOL CHEM, V275, P15295, DOI 10.1074/jbc.275.20.15295; Kukimoto I, 2001, J VIROL, V75, P9302, DOI 10.1128/JVI.75.19.9302-9311.2001; WATANABE S, 1993, JPN J CANCER RES, V84, P1043, DOI 10.1111/j.1349-7006.1993.tb02799.x; Welter JF, 1996, J BIOL CHEM, V271, P14727, DOI 10.1074/jbc.271.25.14727	15	11	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 24	2004	23	29					5014	5022		10.1038/sj.onc.1207653	http://dx.doi.org/10.1038/sj.onc.1207653			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	831ZX	15077167				2022-12-17	WOS:000222237300007
J	Kadaja, L; Laos, S; Maimets, T				Kadaja, L; Laos, S; Maimets, T			Overexpression of leukocyte marker CD43 causes activation of the tumor suppressor proteins p53 and ARF	ONCOGENE			English	Article						CD43; p53; p19ARF	WISKOTT-ALDRICH SYNDROME; T-CELL-ACTIVATION; SURFACE SIALOGLYCOPROTEIN; MONOCLONAL-ANTIBODIES; COLON ADENOMA; FEEDBACK LOOP; MDM2; PHOSPHORYLATION; LEUKOSIALIN; EXPRESSION	CD43 or leukosialin is a transmembrane sialoglycoprotein, whose extracellular domain participates in cell adhesiveness and the cytoplasmic tail regulates a variety of intracellular signal transduction pathways involved in cell proliferation. CD43 is abundantly expressed on the surface of hematopoietic cells, but CD43 expression is also frequently found in the tumor cells of nonhematopoietic origin. In the early stages of some tumors, the accumulation of tumor suppressor protein p53 has been described. Here, we show that the expression of CD43 causes the induction of functionally active p53 protein. Moreover, we found that the activation of p53 by CD43 is mediated by tumor suppressor protein ARF. The coexpression of CD43 and ARF in ARF-null mouse embryonic fibroblasts resulted in programmed cell death, but that was not the case when CD43 alone was expressed in these cells. These data provide the first evidence of the connection between p53- and CD43-dependent pathways.	Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, EE-51010 Tartu, Estonia; Gothenburg Univ, Dept Med Biochem, S-41390 Gothenburg, Sweden	University of Tartu; University of Gothenburg	Kadaja, L (corresponding author), Univ Tartu, Inst Mol & Cell Biol, Dept Cell Biol, 23 Riia St, EE-51010 Tartu, Estonia.	lkadaja@ebc.ee	Maimets, Toivo/E-9268-2017	Maimets, Toivo/0000-0001-6461-3365				ANDERSSON LC, 1978, BLOOD, V52, P57; ARDMAN B, 1992, P NATL ACAD SCI USA, V89, P5001, DOI 10.1073/pnas.89.11.5001; AXELSSON B, 1988, J IMMUNOL, V141, P2912; BAECKSTROM D, 1991, J BIOL CHEM, V266, P21537; BAECKSTROM D, 1995, J BIOL CHEM, V270, P13688, DOI 10.1074/jbc.270.23.13688; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; CARLSSON SR, 1986, J BIOL CHEM, V261, P2779; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DRAGONE LL, 1995, P NATL ACAD SCI USA, V92, P626, DOI 10.1073/pnas.92.2.626; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fernandez-Rodriguez J, 2002, TUMOR BIOL, V23, P193, DOI 10.1159/000067252; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; HARPER JW, 1993, CELL, V75, P805; Joers A, 1998, ONCOGENE, V17, P2351, DOI 10.1038/sj.onc.1202146; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kubbutat MHG, 1998, MOL MED TODAY, V4, P250, DOI 10.1016/S1357-4310(98)01260-X; Lane DP, 1997, TRENDS BIOCHEM SCI, V22, P372, DOI 10.1016/S0968-0004(97)01119-5; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; MAZARS R, 1991, ONCOGENE, V6, P1685; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; MENTZER SJ, 1987, J EXP MED, V165, P1383, DOI 10.1084/jem.165.5.1383; Miura Y, 2001, BIOCHEM BIOPH RES CO, V288, P80, DOI 10.1006/bbrc.2001.5729; Ostberg JR, 1996, J IMMUNOL, V157, P4876; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARK JK, 1991, NATURE, V350, P706, DOI 10.1038/350706a0; Pedraza-Alva G, 1998, J BIOL CHEM, V273, P14218, DOI 10.1074/jbc.273.23.14218; Persons DL, 2000, J BIOL CHEM, V275, P35778, DOI 10.1074/jbc.M004267200; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1999, J PATHOL, V187, P112; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; REMOLDODONNELL E, 1984, J EXP MED, V159, P1705, DOI 10.1084/jem.159.6.1705; ROGEL A, 1985, MOL CELL BIOL, V5, P2851, DOI 10.1128/MCB.5.10.2851; Rosenstein Y, 1999, IMMUNOL RES, V20, P89, DOI 10.1007/BF02786465; Sambrook J, 1989, MOL CLONING LAB MANU; Santamaria M, 1996, CANCER RES, V56, P3526; Santana MA, 2000, J BIOL CHEM, V275, P31460, DOI 10.1074/jbc.M005231200; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sikut R, 1999, INT J CANCER, V82, P52, DOI 10.1002/(SICI)1097-0215(19990702)82:1<52::AID-IJC10>3.0.CO;2-C; Sikut R, 1997, BIOCHEM BIOPH RES CO, V238, P612, DOI 10.1006/bbrc.1997.7334; Stewart ZA, 2001, BREAST CANCER RES, V3, P5, DOI 10.1186/bcr261; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; Wang SW, 2001, CARCINOGENESIS, V22, P757, DOI 10.1093/carcin/22.5.757; Wang WM, 2000, CELL IMMUNOL, V205, P34, DOI 10.1006/cimm.2000.1716; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	53	11	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 1	2004	23	14					2523	2530		10.1038/sj.onc.1207359	http://dx.doi.org/10.1038/sj.onc.1207359			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	808GQ	14676827				2022-12-17	WOS:000220558000009
J	Theoleyre, O; Deguillien, M; Moriniere, M; Starck, J; Moreau-Gachelin, F; Morle, F; Baklouti, F				Theoleyre, O; Deguillien, M; Moriniere, M; Starck, J; Moreau-Gachelin, F; Morle, F; Baklouti, F			Spi-l/PU.1 but not Fli-1 inhibits erythroid-specific alternative splicing of 4.1R pre-mRNA in murine erythroleukemia cells	ONCOGENE			English	Article						alternative splicing; erythroleukemia; Spi-l/PU.1; Fli-1; protein 4.1R; erythroid differentiation	INSERTION DELETION MUTATIONS; ACTIN-BINDING DOMAIN; TRANSCRIPTION FACTOR; PU.1 TRANSCRIPTION; MOLECULAR ANALYSIS; TERNARY COMPLEX; DIFFERENTIATION; PROTEIN-4.1; SPI-1/PU.1; SPECTRIN	The inclusion of exon 16 in mature protein 4.1R mRNA arises from a stage-specific splicing event that occurs during late erythroid development. We have shown that mouse erythroleukemia (MEL) cells reproduce this erythroid-specific splicing event upon induction of differentiation. We here found that this splicing event is regulated specifically in erythroleukemic cells that have the potential to differentiate and produce hemoglobin, regardless of the nature of the differentiation inducer. Knowing that dysregulated expression of spi-1/pu.1 and fli-1 oncogenes is involved in MEL cell differentiation arrest, we looked at their effect on exon 16 erythroid splicing. We found that exon 16 inclusion requires Spi-1/ PU.1 shutdown in MEL cells, and that enforced expression of Spi-1/PU.1 inhibits exon selection, regardless of the presence or absence of a chemical inducer. By contrast, endogenous overexpression or enforced expression of Fli-1 has no effect on exon selection. We further showed that Spi-1/PU.1 acts similarly on the endogenous and on a transfected exon 16, suggesting a promoter-independent effect of Spi-1/PU.1 on splicing regulation. This study provides the first evidence that Spi-1/PU.1 displays the unique property, not shared with Fli-1, to inhibit erythroid-specific pre-mRNA splicing in erythroleukemia cell context.	Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France; Inst Curie, INSERM, U528, Lab Transduct Signal & Oncogenese, Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie	Baklouti, F (corresponding author), Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, 16 Rue R Dubois, F-69622 Villeurbanne, France.	baklouti@univ-lyon1.fr	BAKLOUTI, Faouzi/E-7670-2013	BAKLOUTI, Faouzi/0000-0002-2830-292X				Baklouti F, 1997, GENOMICS, V39, P289, DOI 10.1006/geno.1996.4512; Baklouti F, 1996, BLOOD, V87, P3934, DOI 10.1182/blood.V87.9.3934.bloodjournal8793934; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; Bolduc L, 2001, J BIOL CHEM, V276, P17597, DOI 10.1074/jbc.M011769200; CHASIS JA, 1993, J CLIN INVEST, V91, P329, DOI 10.1172/JCI116189; CHERN YJ, 1991, J BIOL CHEM, V266, P2009; CONBOY J, 1990, J CLIN INVEST, V86, P524, DOI 10.1172/JCI114739; Davies RC, 1998, GENE DEV, V12, P3217, DOI 10.1101/gad.12.20.3217; Deguillien M, 2001, BLOOD, V98, P3809, DOI 10.1182/blood.V98.13.3809; DELGADO MD, 1994, ONCOGENE, V9, P1723; DISCHER DE, 1995, J CELL BIOL, V130, P897, DOI 10.1083/jcb.130.4.897; Hallier M, 1998, J BIOL CHEM, V273, P4838, DOI 10.1074/jbc.273.9.4838; Hallier M, 1996, J BIOL CHEM, V271, P11177, DOI 10.1074/jbc.271.19.11177; HANSPAL M, 1992, BLOOD, V80, P530; Hong W, 2002, MOL CELL BIOL, V22, P3729, DOI 10.1128/MCB.22.11.3729-3743.2002; HORNE WC, 1993, BLOOD, V82, P2558; LORENZO F, 1994, J CLIN INVEST, V94, P1651, DOI 10.1172/JCI117508; Maillet P, 1999, HUM MUTAT, V14, P145, DOI 10.1002/(SICI)1098-1004(1999)14:2<145::AID-HUMU6>3.0.CO;2-L; MARCHESI SL, 1990, J CLIN INVEST, V86, P516, DOI 10.1172/JCI114738; MoreauGachelin F, 1996, MOL CELL BIOL, V16, P2453; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Nerlov C, 2000, BLOOD, V95, P2543, DOI 10.1182/blood.V95.8.2543.008k19_2543_2551; Oikawa T, 1999, CELL DEATH DIFFER, V6, P599, DOI 10.1038/sj.cdd.4400534; Rao G, 1997, ONCOGENE, V14, P123, DOI 10.1038/sj.onc.1200807; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; SCHUETZE S, 1992, MOL CELL BIOL, V12, P2967, DOI 10.1128/MCB.12.7.2967; Starck J, 1999, MOL CELL BIOL, V19, P121; Tamir A, 1999, MOL CELL BIOL, V19, P4452; TODOKORO K, 1987, P NATL ACAD SCI USA, V84, P4126, DOI 10.1073/pnas.84.12.4126; Yamada T, 1997, BLOOD, V89, P1383, DOI 10.1182/blood.V89.4.1383; Zhang P, 2000, BLOOD, V96, P2641; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705	32	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 29	2004	23	4					920	927		10.1038/sj.onc.1207206	http://dx.doi.org/10.1038/sj.onc.1207206			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	767UV	14647452				2022-12-17	WOS:000188486600007
J	Dinulescu, DM; Wood, LJ; Shen, L; Loriaux, M; Corless, CL; Gross, AW; Ren, RB; Deininger, MWN; Druker, BJ				Dinulescu, DM; Wood, LJ; Shen, L; Loriaux, M; Corless, CL; Gross, AW; Ren, RB; Deininger, MWN; Druker, BJ			c-CBL is not required for leukemia induction by Bcr-Abl in mice	ONCOGENE			English	Article						c-Cbl; Bcr-Abl; leukemia; CML	CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; SIGNAL-TRANSDUCTION PATHWAYS; COLONY-STIMULATING FACTOR; PHILADELPHIA-CHROMOSOME; TYROSINE PHOSPHORYLATION; MYELOPROLIFERATIVE DISEASE; PROTOONCOGENE PRODUCT; HEMATOPOIETIC-CELLS; NEGATIVE REGULATOR	Bcr-Abl tyrosine kinase activity is essential for the pathogenesis of chronic myeloid leukemia (CML). A number of Bcr-Abl substrates have been identified, but it is not clear which of these substrates are required for Bcr-Abl to transform cells. The multifunctional protein c-Cbl is one of the most prominently tyrosine-phosphorylated proteins in Bcr-Abl-expressing cells. Using cell lines and mice with homozygous disruption of the c-CBL locus, we investigated the role of this protein for Bcr-Abl-driven transformation. We find that although c-Cbl(-/-) fibroblast cell lines show a deficit in Bcr-Abl transformation compared to wild-type (Wt) cells, this deficit was less pronounced in c-Cbl(-/-) B cells derived from murine bone marrow. Most importantly, in a transplantation model of CML, Bcr-Abl was capable of inducing fatal leukemia in mice in the absence of c-Cbl protein. Our results indicate that c-Cbl is dispensable for Bcr-Abl-induced leukemo-genesis in mice.	Oregon Hlth & Sci Univ, Inst Canc, Dept Cell & Dev Biol, Div Hematol & Med Oncol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Inst Canc, Div Hematol Oncol, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Sch Nursing, Dept Primary Care, Portland, OR 97239 USA; VA Med Ctr, Dept Pathol, Portland, OR 97239 USA; Brandeis Univ, Dept Biol, Rosenstiel Basic Med Sci Res Ctr, Waltham, MA 02454 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University; Brandeis University	Druker, BJ (corresponding author), Oregon Hlth & Sci Univ, Inst Canc, Dept Cell & Dev Biol, Div Hematol & Med Oncol, L592,3181 Sam Jackson Pk Rd, Portland, OR 97239 USA.	drukerb@ohsu.edu		Wood, Lisa/0000-0003-1145-3649; Druker, Brian/0000-0001-8331-8206				ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BARTRAM CR, 1983, NATURE, V306, P277, DOI 10.1038/306277a0; Beitz LO, 1999, J BIOL CHEM, V274, P32662, DOI 10.1074/jbc.274.46.32662; Bhat A, 1997, J BIOL CHEM, V272, P16170, DOI 10.1074/jbc.272.26.16170; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEJONG R, 1995, J BIOL CHEM, V270, P21468, DOI 10.1074/jbc.270.37.21468; DEKLEIN A, 1986, BLOOD, V68, P1369; Di Cristofano A, 2001, J EXP MED, V194, P275, DOI 10.1084/jem.194.3.275; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALE RP, 1988, LEUKEMIA, V2, P321; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; Gaston I, 2000, EXP HEMATOL, V28, P77, DOI 10.1016/S0301-472X(99)00130-7; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOLDMAN A, 1998, CELLS LAB MANUAL; Gotoh A, 1997, Curr Opin Hematol, V4, P3; Hamilton E, 2001, J BIOL CHEM, V276, P9028, DOI 10.1074/jbc.M009386200; Hariharan I K, 1988, Oncogene Res, V3, P387; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; Hemmeryckx B, 2002, ONCOGENE, V21, P3225, DOI 10.1038/sj.onc.1205452; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; ILARIA RL, 1995, BLOOD, V86, P3897, DOI 10.1182/blood.V86.10.3897.bloodjournal86103897; Jain SK, 1997, ONCOGENE, V14, P2217, DOI 10.1038/sj.onc.1201049; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KEANE MM, 1995, ONCOGENE, V10, P2367; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KELLIHER MA, 1993, ONCOGENE, V8, P1249; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KURZROCK R, 1988, NEW ENGL J MED, V319, P990; Li SG, 1999, J EXP MED, V189, P1399, DOI 10.1084/jem.189.9.1399; Li SG, 2001, BLOOD, V97, P1442, DOI 10.1182/blood.V97.5.1442; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; Melo JV, 1996, BLOOD, V88, P2375, DOI 10.1182/blood.V88.7.2375.bloodjournal8872375; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; MUSHINSKI JF, 1994, ONCOGENE, V9, P2489; Naramura M, 1998, P NATL ACAD SCI USA, V95, P15547, DOI 10.1073/pnas.95.26.15547; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; Okuda K, 1996, ONCOGENE, V13, P1147; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; Rader AE, 2001, CANCER CYTOPATHOL, V93, P269, DOI 10.1002/cncr.9041; Raitano A. B., 1997, BIOCHIM BIOPHYS ACTA, V1333, P201, DOI 10.1016/S0304-419X(97)00023-1; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Sattler M, 2002, ONCOGENE, V21, P1423, DOI 10.1038/sj.onc.1205202; Sattler M, 1996, ONCOGENE, V12, P839; Sattler Martin, 1997, Cytokine and Growth Factor Reviews, V8, P63, DOI 10.1016/S1359-6101(96)00047-0; Sawyers CL, 1997, BAILLIERE CLIN HAEM, V10, P223, DOI 10.1016/S0950-3536(97)80004-2; SEFTON BM, 1981, P NATL ACAD SCI-BIOL, V78, P1552, DOI 10.1073/pnas.78.3.1552; Sexl V, 2000, BLOOD, V96, P2277, DOI 10.1182/blood.V96.6.2277; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; YOUNG JC, 1988, MOL CELL BIOL, V8, P4079, DOI 10.1128/MCB.8.10.4079; Zhang XW, 1998, BLOOD, V92, P3829, DOI 10.1182/blood.V92.10.3829	67	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 4	2003	22	55					8852	8860		10.1038/sj.onc.1206892	http://dx.doi.org/10.1038/sj.onc.1206892			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	750GD	14654781				2022-12-17	WOS:000186982200006
J	Gryz, EA; Meakin, SO				Gryz, EA; Meakin, SO			Acidic substitution of the activation loop tyrosines in TrkA supports nerve growth factor-dependent, but not nerve growth factor-independent, differentiation and cell cycle arrest in the human neuroblastoma cell line, SY5Y	ONCOGENE			English	Article						nerve growth factor; TrkA; tyrosine kinase receptor; kinase activation; activation loop; neurotrophins; mutagenesis; neuroblastomas; neuronal tumors; signalling	PC12 CELLS; NEURONAL DIFFERENTIATION; FACTOR RECEPTOR; N-MYC; SIGNALING ENDOSOMES; NEURITE OUTGROWTH; KINASE ACTIVATION; PROTEIN-KINASE; MESSENGER-RNA; EXPRESSION	TrkA is the receptor tyrosine kinase (RTK) for nerve growth factor (NGF) and stimulates NGF-dependent cell survival and differentiation in primary neurons and also differentiation of neuroblastomas and apoptosis of medulloblastomas. We have previously shown that aspartic acid and glutamic acid substitution (AspGlu and GluAsp) of the activation loop tyrosines in TrkA (Tyr(683) and Tyr(684)) supports NGF-independent neuritogenesis and cell survival in PC12 cell-derived nnr5 cells. In this study, the AspGlu and GluAsp mutant Trks have been analysed for their ability to support NGF-independent and NGF-dependent neuritogenesis, proliferation and cell signalling in the human neuroblastoma cell line, SY5Y. We find that the AspGlu and GluAsp mutant Trks support NGF-dependent, but not NGF-independent, autophosphorylation, neuritogenic responses and/or inhibit cell cycle progression. The NGF-dependent neuritogenic responses are lower for the mutant Trks (approximately 30-60% for AspGlu and 50-60% for GluAsp), relative to wild-type TrkA. While both the AspGlu and GluAsp mutant Trks support NGF-dependent transient phosphorylation of Shc, PLCgamma-1, AKT, FRS2, SH2B as well as prolonged MAP kinase activation, the GluAsp mutant induces stronger NGF-dependent tyrosine phosphorylation of FRS2 and SH2B, as well as a stronger reduction in bromodeoxyuridine (BrdU) incorporation. Collectively, these data suggest that neither absolute levels of receptor autophosphorylation, high levels of TrkA expression nor the activation of a specific signalling pathway is dominant and absolutely essential for neuritogenesis and cell cycle arrest of SY5Y cells.	John P Robarts Res Inst, Cell Biol Grp, Lab Neural Signalling, London, ON N6A 5K8, Canada; Univ Western Ontario, Grad Program Neurosci, London, ON N6A 5C1, Canada; Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Meakin, SO (corresponding author), John P Robarts Res Inst, Cell Biol Grp, Lab Neural Signalling, 100 Perth Dr, London, ON N6A 5K8, Canada.		Meakin, Susan/K-8823-2013	Meakin, Susan/0000-0003-2469-6615				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Bhattacharyya A, 1997, J NEUROSCI, V17, P7007; BIEDLER JL, 1973, CANCER RES, V33, P2643; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Eggert A, 2000, ONCOGENE, V19, P2043, DOI 10.1038/sj.onc.1203518; EHLERS MD, 1995, J CELL BIOL, V130, P149, DOI 10.1083/jcb.130.1.149; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; Grimes ML, 1997, P NATL ACAD SCI USA, V94, P9909, DOI 10.1073/pnas.94.18.9909; Grimes ML, 1996, J NEUROSCI, V16, P7950; Gryz EA, 2000, ONCOGENE, V19, P417, DOI 10.1038/sj.onc.1203330; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; KOGNER P, 1993, CANCER RES, V53, P2044; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; LAVENIUS E, 1995, CELL GROWTH DIFFER, V6, P727; MacDonald JIS, 2000, J BIOL CHEM, V275, P18225, DOI 10.1074/jbc.M001862200; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUSHIMA H, 1993, MOL CELL BIOL, V13, P7447, DOI 10.1128/MCB.13.12.7447; Meakin SO, 1998, J NEUROCHEM, V71, P1875; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; NAKAGAWARA A, 1992, CANCER RES, V52, P1364; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; NAKAGAWARA A, 1993, NEW ENGL J MED, V328, P847, DOI 10.1056/NEJM199303253281205; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; POLUHA W, 1995, ONCOGENE, V10, P185; Qian XZ, 1998, NEURON, V21, P1017, DOI 10.1016/S0896-6273(00)80620-0; RABIN SJ, 1993, MOL CELL BIOL, V13, P2203, DOI 10.1128/MCB.13.4.2203; Ryden M, 1996, BRIT J CANCER, V74, P773, DOI 10.1038/bjc.1996.435; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; SONNENFELD KH, 1982, J NEUROSCI RES, V8, P375, DOI 10.1002/jnr.490080226; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; Wright JH, 1997, MOL BIOL CELL, V8, P1575, DOI 10.1091/mbc.8.8.1575; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yamashiro DJ, 1996, ONCOGENE, V12, P37; Yamashita H, 1999, J BIOL CHEM, V274, P15059, DOI 10.1074/jbc.274.21.15059; Yasui H, 2001, J BIOL CHEM, V276, P15298, DOI 10.1074/jbc.M008546200; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	41	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 27	2003	22	54					8774	8785		10.1038/sj.onc.1206890	http://dx.doi.org/10.1038/sj.onc.1206890			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	748CP	14647472				2022-12-17	WOS:000186844900015
J	Falcone, G; Ciuffini, L; Gauzzi, MC; Provenzano, C; Strano, S; Gallo, R; Castellani, L; Alema, S				Falcone, G; Ciuffini, L; Gauzzi, MC; Provenzano, C; Strano, S; Gallo, R; Castellani, L; Alema, S			V-Src inhibits myogenic differentiation by interfering with the regulatory network of muscle-specific transcriptional activators at multiple levels	ONCOGENE			English	Article						myogenesis; MyoD; cell cycle; tyrosine kinase; p300	CELL-CYCLE ARREST; HELIX-LOOP-HELIX; CHROMATIN REMODELING ENZYMES; TERMINAL DIFFERENTIATION; SKELETAL-MUSCLE; QUAIL MYOTUBES; DNA-BINDING; MOLECULAR-MECHANISMS; GENE-TRANSCRIPTION; TYROSINE KINASE	The conversion of skeletal myoblasts to terminally differentiated myocytes is negatively controlled by several growth factors and oncoproteins. In this study, we have investigated the molecular mechanisms by which v-Src, a prototypic tyrosine kinase, perturbs myogenesis in primary avian myoblasts and in established murine C2C12 satellite cells. We determined the expression levels of the cell cycle regulators pRb, cyclin D1 and D3 and cyclin-dependent kinase inhibitors p21 and p27 in v-Src-transformed myoblasts and found that, in contrast to myogenin, they are normally modulated by differentiative cues, implying that v-Src affects myogenesis independent of cell proliferation. We then examined the levels of expression, DNA-binding ability and transcription-activation potentials of myogenic regulatory factors in transformed myoblasts and in myotubes after reactivation of a temperature-sensitive allele of v-Src. Our results reveal two distinct potential modes of repression targeted to myogenic factors. On the one hand, we show that v-Src reversibly inhibits the expression of MyoD and myogenin in C2C12 cells and of myogenin in quail myoblasts. Remarkably, these loci become resistant to activation of the kinase in the postmitotic compartment. On the other hand, we demonstrate that v-Src efficiently inhibits muscle gene expression by repressing the transcriptional activity of myogenic factors without affecting MyoD DNA-binding activity. Indeed, forced expression of MyoD and myogenin allows terminal differentiation of transformed myoblasts. Finally, we found that ectopic expression of the coactivator p300 restores transcription from extrachromosomal muscle-specific promoters.	CNR, Ist Biol Cellulare, I-00016 Monterotondo, Italy; Univ Cassino, I-03043 Cassino, Italy; INFM, SezB, Cassino, Italy	Consiglio Nazionale delle Ricerche (CNR); University of Cassino; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR)	Falcone, G (corresponding author), CNR, Ist Biol Cellulare, Via Ramarini 32, I-00016 Monterotondo, Italy.	gfalcone@ibc.cnr.it; alema@ibc.cnr.it	Gauzzi, Maria Cristina/N-7038-2017; strano, sabrina/B-6743-2013; Falcone, Germana/A-3735-2016; Strano, Sabrina/K-9654-2016	Gauzzi, Maria Cristina/0000-0002-2996-5231; strano, sabrina/0000-0002-6341-4230; Castellani, Loriana/0000-0002-8519-3504; Falcone, Germana/0000-0002-3508-7623; Alema, Stefano/0000-0002-9869-6354				Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BOETTIGER D, 1989, CURR TOP MICROBIOL, V147, P31; CARUSO M, 1993, ONCOGENE, V8, P267; CASTELLANI L, 1995, J CELL BIOL, V130, P871, DOI 10.1083/jcb.130.4.871; Castellani L, 1996, J CELL SCI, V109, P1335; Chan HM, 2001, J CELL SCI, V114, P2363; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Eckner R, 1996, GENE DEV, V10, P2478, DOI 10.1101/gad.10.19.2478; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FALCONE G, 1984, EMBO J, V3, P1327, DOI 10.1002/j.1460-2075.1984.tb01971.x; Gallo R, 1997, ONCOGENE, V15, P1929, DOI 10.1038/sj.onc.1201344; Gallo R, 1999, MOL BIOL CELL, V10, P3137, DOI 10.1091/mbc.10.10.3137; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Iezzi S, 2002, P NATL ACAD SCI USA, V99, P7757, DOI 10.1073/pnas.112218599; JEN Y, 1992, GENE DEV, V6, P1466, DOI 10.1101/gad.6.8.1466; Johnson SE, 2002, J BIOL CHEM, V277, P28742, DOI 10.1074/jbc.M203680200; JOHNSTON LA, 1992, MOL CELL BIOL, V12, P5123, DOI 10.1128/MCB.12.11.5123; KIESS M, 1995, ONCOGENE, V10, P159; KONG YF, 1995, MOL CELL BIOL, V15, P5205; KONIECZNY SF, 1989, ONCOGENE, V4, P473; La Rocca SA, 2002, ONCOGENE, V21, P4838, DOI 10.1038/sj.onc.1205586; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LASSAR AB, 1991, CELL, V66, P305, DOI 10.1016/0092-8674(91)90620-E; LASSAR AB, 1989, CELL, V58, P659, DOI 10.1016/0092-8674(89)90101-3; Lazaro JB, 2002, GENE DEV, V16, P1792, DOI 10.1101/gad.U-9988R; Liu LN, 1998, CELL GROWTH DIFFER, V9, P699; MAIONE R, 1997, BIOCHIM BIOPHYS ACTA, V1332, P19; MARTELLI F, 1994, ONCOGENE, V9, P3579; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; PINNEY DF, 1995, DEV BIOL, V170, P21, DOI 10.1006/dbio.1995.1192; Polesskaya A, 2000, J BIOL CHEM, V275, P34359, DOI 10.1074/jbc.M003815200; POWNALL ME, 1992, DEV BIOL, V151, P67, DOI 10.1016/0012-1606(92)90214-2; Puri PL, 2002, NAT GENET, V32, P585, DOI 10.1038/ng1023; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Puri PL, 1997, MOL CELL, V1, P35, DOI 10.1016/S1097-2765(00)80005-2; Ramocki MB, 1997, MOL CELL BIOL, V17, P3547, DOI 10.1128/MCB.17.7.3547; Roy K, 2002, J BIOL CHEM, V277, P33818, DOI 10.1074/jbc.M205159200; Russo S, 1997, ONCOGENE, V14, P63, DOI 10.1038/sj.onc.1200805; Sartorelli V, 1999, MOL CELL, V4, P725, DOI 10.1016/S1097-2765(00)80383-4; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; SKAPEK SX, 1995, SCIENCE, V267, P1022, DOI 10.1126/science.7863328; STERNBERG EA, 1988, MOL CELL BIOL, V8, P2896, DOI 10.1128/MCB.8.7.2896; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; Wei Q, 2001, FEBS LETT, V490, P171, DOI 10.1016/S0014-5793(01)02120-2; WEINTRAUB H, 1991, GENE DEV, V5, P1377, DOI 10.1101/gad.5.8.1377; WELHAM MJ, 1990, ONCOGENE, V5, P161; Winter B, 2000, J CELL SCI, V113, P4211; YOON HY, 1994, ONCOGENE, V9, P801; Zabludoff SD, 1998, CELL GROWTH DIFFER, V9, P1; Zhang JM, 1999, EMBO J, V18, P926, DOI 10.1093/emboj/18.4.926	63	11	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 13	2003	22	51					8302	8315		10.1038/sj.onc.1206915	http://dx.doi.org/10.1038/sj.onc.1206915			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	742WR	14614454				2022-12-17	WOS:000186541500009
J	Bartley, PA; Keough, RA; Lutwyche, JK; Gonda, TJ				Bartley, PA; Keough, RA; Lutwyche, JK; Gonda, TJ			Regulation of the gene encoding glutathione S-transferase M1 (GSTM1) by the Myb oncoprotein	ONCOGENE			English	Article						Myb; transactivation; glutathione S-transferase; promoter	C-MYB; GROWTH-FACTORS; MYELOID CELLS; V-MYB; EXPRESSION; TRANSFORMATION; APOPTOSIS; PROTEIN; DIFFERENTIATION; PROMOTER	The identification of Myb 'target' genes will not only aid in the understanding of how overexpression of Myb, or expression of activated forms of Myb, leads to cellular transformation but will also shed light on its role in normal cells. Using a combination of an estrogen-regulated Myb-transformed cell line (ERMYB) and PCR-based subtractive hybridization, we have identified the gene (GSTM1) encoding the detoxification enzyme glutathione S-transferase M1 as being transcriptionally upregulated by Myb. Functional analysis of the GSTM1 promoter using reporter assays indicated that both the DNA binding and transactivation domains of Myb were required for transcriptional activation. Mutational analysis of consensus Myb-binding sites (MBS) in the promoter and electrophoretic mobility gel shift analysis indicated that one of the three potential MBS can bind Myb protein, and is the primary site involved in the regulation of this promoter by Myb.	Inst Med & Vet Sci, Hanson Inst, Adelaide, SA 5000, Australia; Inst Med & Vet Sci, Div Human Immunol, Adelaide, SA 5000, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5005, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; Institute Medical & Veterinary Science Australia; University of Adelaide	Gonda, TJ (corresponding author), Univ Queensland, Ctr Immunol & Canc Res, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.		Gonda, Thomas J/A-3620-2012					Bartley PA, 2001, BLOOD CELL MOL DIS, V27, P409, DOI 10.1006/bcmd.2001.0398; BERGER J, 1988, GENE, V66, P1, DOI 10.1016/0378-1119(88)90219-3; Bert AG, 2000, PLASMID, V44, P173, DOI 10.1006/plas.2000.1474; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; FERRAO P, 1995, ONCOGENE, V11, P1631; Frampton J, 1996, GENE DEV, V10, P2720, DOI 10.1101/gad.10.21.2720; Fu SL, 1997, CELL GROWTH DIFFER, V8, P35; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hogg A, 1997, ONCOGENE, V15, P2885, DOI 10.1038/sj.onc.1201472; HU YL, 1991, ONCOGENE, V6, P1549; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; Kumar A, 2001, GENE, V270, P221, DOI 10.1016/S0378-1119(01)00473-5; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; LAVOIE L, 1992, J BIOL CHEM, V267, P3632; MACMILLAN EM, 1994, BLOOD, V83, P209; Muller C, 1999, BLOOD, V94, P4255, DOI 10.1182/blood.V94.12.4255.424k32_4255_4262; NAKAGOSHI H, 1992, ONCOGENE, V7, P1233; NESS SA, 1996, BIOCHIM BIOPHYS ACTA, V1288, P123; NISHINA Y, 1989, NUCLEIC ACIDS RES, V17, P107, DOI 10.1093/nar/17.1.107; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; RAMSAY RG, 1992, J BIOL CHEM, V267, P5656; RAMSAY RG, 1995, ONCOGENE, V11, P2113; REINHART J, 1993, ARCH BIOCHEM BIOPHYS, V303, P383, DOI 10.1006/abbi.1993.1299; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sattler M, 1999, BLOOD, V93, P2928; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Taylor D, 1996, GENE DEV, V10, P2732, DOI 10.1101/gad.10.21.2732; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; Vanhaecke T, 2000, BIOCHEM PHARMACOL, V60, P1491, DOI 10.1016/S0006-2952(00)00446-9; Weston K, 1998, CURR OPIN GENET DEV, V8, P76, DOI 10.1016/S0959-437X(98)80065-8	33	11	11	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 23	2003	22	48					7570	7575		10.1038/sj.onc.1207136	http://dx.doi.org/10.1038/sj.onc.1207136			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	735KQ	14576818				2022-12-17	WOS:000186113000003
J	Mohan, S; Burk, RD				Mohan, S; Burk, RD			von Hippel-Lindau protein complex is regulated by cell density	ONCOGENE			English	Article						VHL; cell density; cell-cell contact	TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR EXPRESSION; DEPENDENT REGULATION; SOMATIC MUTATIONS; RENAL-CARCINOMA; VHL; PRODUCT; BINDING; UBIQUITINATION; HEMANGIOBLASTOMAS	Mutations in the von Hippel-Lindau (VHL) gene are involved in the VHL family cancer syndrome and sporadic renal cell carcinoma. Previous studies indicated that VHL-induced growth arrest required high cell density and growth on extracellular matrix. In the present study, VHL protein (pVHL) levels were observed to be dramatically increased in cells grown to high cell density compared to cells grown at low cell density. Reverse transcription-polymerase chain reaction and Northern blot analysis indicated that VHL mRNA levels were equivalent in sparse and dense cells. The pVHL was rapidly degraded when cell-cell contact was disturbed by trypsinization or EDTA release. Treatment of cells with a proteasome inhibitor blocked the degradation of pVHL. Using a set of VHL deletions fused to GFP, a cell density-dependent region (CDDR) was identified and localized to the c-terminus of pVHL. In addition, other members of the VBC protein complex also showed a cell density-dependent regulation similar to pVHL. Cell density regulation of VHL did not require elongin binding and density-dependent regulation of other VBC components was not dependent on pVHL. In addition, hypoxia inducible factor-2alpha protein levels were elevated in sparse cells with low levels of pVHL and reduced or absent in confluent cells containing abundant VHL. These results indicate that pVHL levels and thus function are tightly regulated by cell-cell signaling. In addition, care must be taken when interpreting studies of VHL function and subcellular localization of cells grown at subconfluent conditions.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Marion Bessin Liver Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Albert Einstein Canc Res Ctr, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	Burk, RD (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Marion Bessin Liver Res Ctr, Ullmann Bldg,Rm 515,1300 Morris Pk Ave, Bronx, NY 10461 USA.	burk@aecom.yu.edu			NATIONAL CANCER INSTITUTE [R01CA085412] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA85412] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMSLER K, 1994, J CELL PHYSIOL, V159, P331, DOI 10.1002/jcp.1041590216; Baba M, 2001, ONCOGENE, V20, P2727, DOI 10.1038/sj.onc.1204397; CHEN F, 1995, HUM MUTAT, V5, P66, DOI 10.1002/humu.1380050109; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Davidowitz EJ, 2001, MOL CELL BIOL, V21, P865, DOI 10.1128/MCB.21.3.865-874.2001; Feldman DE, 1999, MOL CELL, V4, P1051, DOI 10.1016/S1097-2765(00)80233-6; FOLKMAN J, 1978, NATURE, V273, P345, DOI 10.1038/273345a0; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; Fuqua C, 1996, ANNU REV MICROBIOL, V50, P727, DOI 10.1146/annurev.micro.50.1.727; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; Hornyak TJ, 2000, J INVEST DERMATOL, V115, P106, DOI 10.1046/j.1523-1747.2000.00030.x; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Iliopoulos O, 1998, P NATL ACAD SCI USA, V95, P11661, DOI 10.1073/pnas.95.20.11661; ILIOPOULOS O, 1995, NAT MED, V1, P822, DOI 10.1038/nm0895-822; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; KANNO H, 1994, CANCER RES, V54, P4845; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Kojima N, 2000, BIOCHEM BIOPH RES CO, V277, P152, DOI 10.1006/bbrc.2000.3635; Krieg M, 2000, ONCOGENE, V19, P5435, DOI 10.1038/sj.onc.1203938; Lallemand D, 1998, EMBO J, V17, P5615, DOI 10.1093/emboj/17.19.5615; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lee JY, 1998, CANCER RES, V58, P504; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee YS, 1998, J INVEST DERMATOL, V111, P762, DOI 10.1046/j.1523-1747.1998.00365.x; Lindon C, 2001, DEV BIOL, V240, P574, DOI 10.1006/dbio.2001.0435; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Lubensky IA, 1996, AM J PATHOL, V149, P2089; Mukhopadhyay D, 1998, GENE EXPRESSION, V7, P53; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Pause A, 1998, P NATL ACAD SCI USA, V95, P993, DOI 10.1073/pnas.95.3.993; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Schoenfeld A, 1998, P NATL ACAD SCI USA, V95, P8817, DOI 10.1073/pnas.95.15.8817; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; Schoenfeld AR, 2001, INT J CANCER, V91, P457, DOI 10.1002/1097-0215(20010215)91:4<457::AID-IJC1072>3.0.CO;2-P; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Singh RK, 1996, CELL GROWTH DIFFER, V7, P397; Stebbins CE, 1999, SCIENCE, V284, P455, DOI 10.1126/science.284.5413.455; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298	41	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2003	22	34					5270	5280		10.1038/sj.onc.1206592	http://dx.doi.org/10.1038/sj.onc.1206592			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	711JB	12917628				2022-12-17	WOS:000184734900006
J	Le Bras, M; Bensaad, K; Soussi, T				Le Bras, M; Bensaad, K; Soussi, T			Data mining the p53 pathway in the Fugu genome: evidence for strong conservation of the apoptotic pathway	ONCOGENE			English	Article						p53 tumour suppressor gene; p53 gene family; apoptosis; phylogenetic studies; fugu rubripes; data mining	TUMOR-SUPPRESSOR; DNA-DAMAGE; CELL-CYCLE; MDM2; GENE; IDENTIFICATION; P73; EXPRESSION; HOMOLOG; PROTEIN	The p53 tumour suppressor gene belongs to a small family of related proteins that includes two other members, p63 and p73. Phylogenetic and functional studies suggest that p63 and p73 are ancient genes that have essential roles in normal development, whereas p53 seems to have evolved more recently to prevent cell transformation. In mammalian cells, a plethora of proteins have been found to specifically regulate p53 activity. The genome of the fish Fugu rubripes has been recently published. It is the second vertebrate genome for which the entire sequence is now available. Phylogenetic studies are essential in order to analyse and define signalling pathways important for cell cycle regulation. The presence or absence of a critical member in any pathway can shed light about the evolution of these pathways. The Fugu genome databank has been analysed for several members of the p53 network, including p53, p63 and p73. A good conservation of the network that regulates p53 stability and apoptosis has been found. We also discovered that some cofactors that cooperate with p53 for apoptosis are also well conserved and belong to multigene families not detected in the human genome.	Inst Curie, Lab Genotoxciol Tumeurs, F-75005 Paris, France; Univ Paris 06, F-75005 Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite	Soussi, T (corresponding author), Inst Curie, 26 Rue Ulm, F-75248 Paris 05, France.	Thierry.Soussi@curie.fr		soussi, thierry/0000-0001-8184-3293; LE BRAS, PhD, HDR, Morgane/0000-0003-4317-5591				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Brodsky MH, 2000, CELL, V101, P103, DOI 10.1016/S0092-8674(00)80627-3; Cachot J, 1998, COMP BIOCHEM PHYS C, V120, P351, DOI 10.1016/S0742-8413(98)00039-5; Contente A, 2002, NAT GENET, V30, P315, DOI 10.1038/ng836; Daujat S, 2001, TRENDS GENET, V17, P459, DOI 10.1016/S0168-9525(01)02369-1; DEFROMENTEL CC, 1992, GENE, V112, P241, DOI 10.1016/0378-1119(92)90383-Z; Derry WB, 2001, SCIENCE, V294, P591, DOI 10.1126/science.1065486; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Gilley J, 2001, ONCOGENE, V20, P7447, DOI 10.1038/sj.onc.1204933; Goodman RH, 2000, GENE DEV, V14, P1553; Gorina S, 1996, SCIENCE, V274, P1001, DOI 10.1126/science.274.5289.1001; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; HARDYBESSARD AC, 1998, ONCOGENE, V16, P883; Hebsgaard SM, 1996, NUCLEIC ACIDS RES, V24, P3439, DOI 10.1093/nar/24.17.3439; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jin SK, 2000, P NATL ACAD SCI USA, V97, P7301, DOI 10.1073/pnas.97.13.7301; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Kartasheva NN, 2002, ONCOGENE, V21, P4715, DOI 10.1038/sj.onc.1205584; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kostic C, 2000, ONCOGENE, V19, P3978, DOI 10.1038/sj.onc.1203747; Krause MK, 1997, GENE, V189, P101, DOI 10.1016/S0378-1119(96)00841-4; Lee Y, 2002, GENOME RES, V12, P493, DOI 10.1101/gr.212002; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Marechal V, 1997, ONCOGENE, V14, P1427, DOI 10.1038/sj.onc.1200967; Mayo LD, 2002, TRENDS BIOCHEM SCI, V27, P462, DOI 10.1016/S0968-0004(02)02166-7; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Nakagawa T, 2002, MOL CELL BIOL, V22, P2575, DOI 10.1128/MCB.22.8.2575-2585.2002; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 2002, MOL CELL, V9, P761, DOI 10.1016/S1097-2765(02)00504-X; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Ollmann M, 2000, CELL, V101, P91, DOI 10.1016/S0092-8674(00)80626-1; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Piette J, 1997, ONCOGENE, V15, P1001, DOI 10.1038/sj.onc.1201432; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schumacher B, 2001, CURR BIOL, V11, P1722, DOI 10.1016/S0960-9822(01)00534-6; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shikama N, 1999, MOL CELL, V4, P365, DOI 10.1016/S1097-2765(00)80338-X; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; Steinmetz LM, 2002, NAT GENET, V31, P400, DOI 10.1038/ng929; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Thisse C, 2000, DIFFERENTIATION, V66, P61, DOI 10.1046/j.1432-0436.2000.660201.x; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tokino T, 2000, CRIT REV ONCOL HEMAT, V33, P1, DOI 10.1016/S1040-8428(99)00051-7; VERGAMASCHI D, 2003, NAT GENET, V33, P162; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Yu WP, 2001, ONCOGENE, V20, P5554, DOI 10.1038/sj.onc.1204679; Zhao RB, 2000, GENE DEV, V14, P981	61	11	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2003	22	32					5082	5090		10.1038/sj.onc.1206424	http://dx.doi.org/10.1038/sj.onc.1206424			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	708QF	12902991				2022-12-17	WOS:000184578900016
J	Praml, C; Savelyeva, L; Schwab, M				Praml, C; Savelyeva, L; Schwab, M			Aflatoxin B-1 aldehyde reductase (AFAR) genes cluster at 1p35-1p36.1 in a region frequently altered in human tumour cells	ONCOGENE			English	Article						AFAR; AKR7; 1p; aflatoxin B1 aldehyde reductase; detoxication; chemoprevention	ALDO-KETO REDUCTASE; HUMAN NEUROBLASTOMA-CELLS; RAT-LIVER; SUPERFAMILY; EXPRESSION; MEMBER; CANCER; CLONING; B-1; SELENIUM	Alterations of the distal portion of the short arm of chromosome 1 (1p) are among the earliest abnormalities of human colorectal tumours. Recently, we have cloned the Aflatoxin B, aldehyde reductase (AFAR) gene from a smallest region of overlapping deletion that is frequently (48%) hemizygously deleted in sporadic colorectal cancer. AFAR is expressed in a broad range of tissues. Its closely related rat protein is the major factor conferring resistance of rats towards aflatoxin B-1-induced liver carcinogenesis. Here, we have identified cDNAs covering two additional human AFAR-related genes localized in close proximity to the previously described AFAR at 1p35-36. We have analysed their structure and tissue-related expression. One of them, AFAR3, carries a Selenocysteine-Insertion Element (SECIS)-like structure that during translation may recode an in-frame TGA-stop codon to a selenocysteine. Two additional AFAR-pseudogenes are localized at Xq25 and 1p12, respectively. AFAR exon sequences share an identity of DNA and amino acids of more than 78%. Also large blocks of intronic sequences can be up to 98.6% identical. Knowledge of the AFAR genes and their structure will be essential in genetic and functional studies, where discrimination of the genes and proteins is a prerequisite for evaluating their individual functions.	Deutsch Krebsforschungszentrum, Div Tumour Genet B030, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Schwab, M (corresponding author), Deutsch Krebsforschungszentrum, Div Tumour Genet B030, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	m.schwab@dkfz.de						Almeida RMA, 1996, MYCOPATHOLOGIA, V133, P23, DOI 10.1007/BF00437095; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; Cavalieri EL, 1997, P NATL ACAD SCI USA, V94, P10937, DOI 10.1073/pnas.94.20.10937; CHEN J, 1982, J NUTR, V112, P324, DOI 10.1093/jn/112.2.324; CLARK LC, 1995, J NATL CANCER I, V87, P473, DOI 10.1093/jnci/87.7.473; CORVI R, 1994, P NATL ACAD SCI USA, V91, P5523, DOI 10.1073/pnas.91.12.5523; ELLIS EM, 1993, P NATL ACAD SCI USA, V90, P10350, DOI 10.1073/pnas.90.21.10350; ELLIS EM, 1995, BIOCHEM J, V312, P535, DOI 10.1042/bj3120535; GARLAND M, 1994, NATURAL ANTIOXIDANTS, P263; Gladyshev VN, 1999, J BIOMED SCI, V6, P151, DOI 10.1007/BF02255899; Hengstler JG, 1999, DRUG METAB REV, V31, P917, DOI 10.1081/DMR-100101946; Hinshelwood A, 2002, FEBS LETT, V523, P213, DOI 10.1016/S0014-5793(02)02982-4; Houlston RS, 2000, J MED GENET, V37, P161, DOI 10.1136/jmg.37.3.161; Ireland LS, 1998, BIOCHEM J, V332, P21, DOI 10.1042/bj3320021; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; JUDAH DJ, 1993, BIOCHEM J, V292, P13, DOI 10.1042/bj2920013; Kelly VP, 2002, BIOCHEM J, V366, P847, DOI 10.1042/BJ20020342; Kelly VP, 2000, BIOCHEM J, V348, P389, DOI 10.1042/0264-6021:3480389; Key SCS, 1997, VIROLOGY, V234, P147, DOI 10.1006/viro.1997.8647; Knight LP, 1999, CARCINOGENESIS, V20, P1215, DOI 10.1093/carcin/20.7.1215; Kozma E, 2002, J BIOL CHEM, V277, P16285, DOI 10.1074/jbc.M110808200; Low SC, 1996, TRENDS BIOCHEM SCI, V21, P203, DOI 10.1016/S0968-0004(96)80016-8; MARNETT LJ, 1994, CANCER METAST REV, V13, P303, DOI 10.1007/BF00666100; McLeod R, 1997, CANCER RES, V57, P4257; NEWBERNE PM, 1969, CANCER RES, V29, P236; Nishi N, 2000, ENDOCRINOLOGY, V141, P3194, DOI 10.1210/en.141.9.3194; Praml C, 1998, CANCER RES, V58, P5014; PRAML C, 1995, ONCOGENE, V11, P1357; SAVELYEVA L, 1994, AM J HUM GENET, V55, P334; Schaller M, 1999, EUR J BIOCHEM, V265, P1056, DOI 10.1046/j.1432-1327.1999.00826.x; Schwab M, 1996, GENE CHROMOSOME CANC, V16, P211, DOI 10.1002/(SICI)1098-2264(199608)16:4<211::AID-GCC1>3.0.CO;2-0; SENAPATHY P, 1990, METHOD ENZYMOL, V183, P252; TUDEK B, 1989, CANCER RES, V49, P1236; Zhu BT, 1998, CARCINOGENESIS, V19, P1, DOI 10.1093/carcin/19.1.1; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	35	11	18	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2003	22	30					4765	4773		10.1038/sj.onc.1206684	http://dx.doi.org/10.1038/sj.onc.1206684			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	701FF	12879023				2022-12-17	WOS:000184157000019
J	Sacco, A; Siepi, F; Crescenzi, M				Sacco, A; Siepi, F; Crescenzi, M			HPV E7 expression in skeletal muscle cells distinguishes initiation of the postmitotic state from its maintenance	ONCOGENE			English	Article						cell cycle reactivation; terminal differentiation; papillomavirus; postmitotic state; retinoblastoma protein	PAPILLOMAVIRUS TYPE-16 E7; TERMINALLY DIFFERENTIATED CELLS; A GENE-EXPRESSION; CYCLIN-A; RETINOBLASTOMA PROTEIN; CELLULAR-DIFFERENTIATION; MYOGENIC DIFFERENTIATION; KINASE-ACTIVITY; DNA-SYNTHESIS; S-PHASE	The E7 oncogene is an essential tool used by papillomaviruses to interfere with the cell cycle and cellular differentiation. We investigated the effects of E7 expression on both cellular functions in skeletal muscle cells, a terminally differentiating system. When expressed in myoblasts, E7 impaired differentiation only partially, but allowed continuation of DNA synthesis during and after differentiation. Surprisingly, E7 expression in terminally differentiated myotubes could not reactivate DNA synthesis even though the oncogene bound the retinoblastoma protein, reduced its levels, and increased E2F transcriptional activity. Despite the high cyclin E protein levels induced by E7, the myotubes remained devoid of cyclin E-associated kinase activity. Enforcement of such activity in the presence of E7 brought myotubes into S phase. These results show that E7, unlike other DNA tumor-virus oncogenes, cannot reactivate the cell cycle in postmitotic myotubes. In contrast, E7 allows significant differentiation to occur in the presence of persisting DNA synthesis. These observations distinguish E7 from other functionally related oncogenes and bear significance for the understanding of the natural life cycle of human papillomaviruses. The fact that E7 alone inhibits the initiation but not the maintenance of the postmitotic state indicates that the mechanisms underlying these two functions are at least partially distinct.	Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS)	Crescenzi, M (corresponding author), Ist Super Sanita, Comparat Toxicol & Ecotoxicol Lab, Viale Regina Elena 299, I-00161 Rome, Italy.		Crescenzi, Marco/J-3603-2018	Crescenzi, Marco/0000-0003-0156-1494	Telethon [GP0293Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		ALEMA S, 1994, SEMIN CANCER BIOL, V5, P147; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Berezutskaya E, 1997, CELL GROWTH DIFFER, V8, P1277; BIGNAMI M, 1988, ONCOGENE, V2, P509; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Boyer SN, 1996, CANCER RES, V56, P4620; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Chien WM, 2002, J VIROL, V76, P2964, DOI 10.1128/JVI.76.6.2964-2972.2002; CRESCENZI M, 1995, J CELL PHYSIOL, V162, P26, DOI 10.1002/jcp.1041620105; ENDO T, 1989, UCLA S MOL CELL BIOL, P95; FOGEL M, 1967, P NATL ACAD SCI USA, V58, P967, DOI 10.1073/pnas.58.3.967; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; HALEY KP, 1984, P NATL ACAD SCI-BIOL, V81, P5734, DOI 10.1073/pnas.81.18.5734; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hwang SG, 2002, J BIOL CHEM, V277, P2923, DOI 10.1074/jbc.M109113200; Jian YC, 1998, ONCOGENE, V17, P2027, DOI 10.1038/sj.onc.1202142; Jones DL, 1997, GENE DEV, V11, P2101, DOI 10.1101/gad.11.16.2101; Kyo S, 1997, J GEN VIROL, V78, P401, DOI 10.1099/0022-1317-78-2-401; Latella L, 2001, MOL CELL BIOL, V21, P5631, DOI 10.1128/MCB.21.16.5631-5643.2001; Leone G, 1999, P NATL ACAD SCI USA, V96, P6626, DOI 10.1073/pnas.96.12.6626; Lipinski MM, 1999, ONCOGENE, V18, P7873, DOI 10.1038/sj.onc.1203244; Lochmuller H, 1999, EXP CELL RES, V248, P186, DOI 10.1006/excr.1999.4407; MAIONE R, 1992, ONCOGENE, V7, P85; Martin LG, 1998, J VIROL, V72, P975, DOI 10.1128/JVI.72.2.975-985.1998; McMurray HR, 2001, INT J EXP PATHOL, V82, P15, DOI 10.1046/j.1365-2613.2001.00177.x; Muller C, 1999, P NATL ACAD SCI USA, V96, P7276, DOI 10.1073/pnas.96.13.7276; Munger K, 2001, ONCOGENE, V20, P7888, DOI 10.1038/sj.onc.1204860; Nguyen DX, 2002, J VIROL, V76, P619, DOI 10.1128/JVI.76.2.619-632.2002; OHTSUBO M, 1995, MOL CELL BIOL, V15, P2612; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Pajalunga D, 1999, ONCOGENE, V18, P5054, DOI 10.1038/sj.onc.1202897; Porrello A, 2000, J CELL BIOL, V151, P1295, DOI 10.1083/jcb.151.6.1295; Puri PL, 1998, CANCER RES, V58, P1325; SCHNEIDER JW, 1994, SCIENCE, V264, P1467, DOI 10.1126/science.8197461; Tedesco D, 1997, J VIROL, V71, P2217, DOI 10.1128/JVI.71.3.2217-2224.1997; Tiainen M, 1996, CELL GROWTH DIFFER, V7, P1039; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; YAFFE D, 1967, NATURE, V215, P421, DOI 10.1038/215421a0; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; ZERFASS K, 1995, J VIROL, V69, P6389, DOI 10.1128/JVI.69.10.6389-6399.1995; ZerfassThome K, 1997, MOL CELL BIOL, V17, P407, DOI 10.1128/MCB.17.1.407	43	11	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 26	2003	22	26					4027	4034		10.1038/sj.onc.1206353	http://dx.doi.org/10.1038/sj.onc.1206353			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	693FZ	12821937				2022-12-17	WOS:000183707600006
J	Biggs, PJ; Vogel, H; Sage, M; Martin, LA; Donehower, LA; Bradley, A				Biggs, PJ; Vogel, H; Sage, M; Martin, LA; Donehower, LA; Bradley, A			Allelic phasing of a mouse chromosome 11 deficiency influences p53 tumorigenicity	ONCOGENE			English	Article						p53; tumorigenicity; chromosome 11 deletion; loss of heterozygosity; mouse cancer model	CANCER; BREAST; GENE; SUSCEPTIBILITY; MICE; MUTATIONS; DELETIONS; GENOME; TUMORS; BRCA1	Most tumour suppressor genes (TSGs) have been found through linkage studies in cancer predisposed families where the mutations have a high penetrance, for example, the breast cancer genes BRCA1 and BRCA2. Loss of heterozygosity (LOH) analyses of sporadic breast tumours indicate that there are many other putative TSGs yet to be identified. One such locus is proximal to BRCA1 on human chromosome 17q21. In an attempt to isolate this putative TSG, we have assessed a portion of the orthologous region on mouse chromosome 11 for its tumorigenic potential using segmental haploidy in combination with a p53 mutation. Two populations of animals were studied, with the deleted region being either on the same (cis) or on the homologous chromosome (trans) to a targeted mutant p53 allele. The deficiency elevated the tumour susceptibility of p53 heterozygous mice and modified the tumour spectrum, but only when the deficiency was in trans with the p53 mutation. Even though the genotype of these mice is identical, allelic phasing affects both the tumour spectrum and progression.	Wellcome Trust Sanger Inst, Hinxton CB10 1SA, Cambs, England; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; Baylor Coll Med, Div Mol Virol, Houston, TX 77030 USA	Wellcome Trust Sanger Institute; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Bradley, A (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Hinxton CB10 1SA, Cambs, England.	abradley@sanger.ac.uk	Biggs, Patrick Jon/H-3355-2014	Biggs, Patrick Jon/0000-0002-0285-4101; Vogel, Otto Hannes/0000-0002-0960-3508; Bradley, Allan/0000-0002-2349-8839				Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Balmain A, 2002, NATURE, V417, P235, DOI 10.1038/417235a; Bradley A, 1998, INT J DEV BIOL, V42, P943; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; Liu PT, 1998, GENETICS, V150, P1155; Luo GB, 2000, NAT GENET, V26, P424, DOI 10.1038/82548; MACCOLLIN M, 1993, JAMA-J AM MED ASSOC, V270, P2316, DOI 10.1001/jama.270.19.2316; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Osborne RJ, 2000, CANCER RES, V60, P3706; Ponder BAJ, 2000, BRIT J CANCER, V83, P1301; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; RAMIREZSOLIS R, 1995, NATURE, V378, P720, DOI 10.1038/378720a0; Staff S, 2000, GENE CHROMOSOME CANC, V28, P432, DOI 10.1002/1098-2264(200008)28:4<432::AID-GCC9>3.0.CO;2-J; Su H, 2000, NAT GENET, V24, P92, DOI 10.1038/71756; Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0; Tavtigian SV, 1996, NAT GENET, V12, P333, DOI 10.1038/ng0396-333; Venkatachalam S, 1998, EMBO J, V17, P4657, DOI 10.1093/emboj/17.16.4657; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Zheng BH, 1999, NUCLEIC ACIDS RES, V27, P2354, DOI 10.1093/nar/27.11.2354; Zheng BH, 1999, NAT GENET, V22, P375, DOI 10.1038/11949	27	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2003	22	21					3288	3296		10.1038/sj.onc.1206384	http://dx.doi.org/10.1038/sj.onc.1206384			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	681MM	12761499				2022-12-17	WOS:000183040000011
J	Haviernik, P; Schmidt, M; Hu, XR; Wolff, L				Haviernik, P; Schmidt, M; Hu, XR; Wolff, L			Consistent inactivation of p19(Arf) but not p15(Ink4b) in murine myeloid cells transformed in vivo by deregulated c-Myc	ONCOGENE			English	Article						INK4; tumor suppressor; p15(Ink4b); p19(Arf); c-myc; myeloid leukemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; KINASE INHIBITOR P15(INK4B); CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR GENE; RETINOBLASTOMA-PROTEIN; CDK INHIBITORS; GROWTH SUPPRESSION; BREAST-CANCER; INK4 FAMILY; TGF-BETA	Cyclin-dependent kinase inhibitors p16(INK4a) and p-15(INK4b), encoded by the CDKN2A and B loci, play an important role in negative regulation of the cell cycle. Furthermore, p19(ARF) also encoded by the CDKN2A locus, has been shown to regulate positively the p53 pathway leading to growth arrest and apoptosis. All three genes have been inactivated in human tumors. In myeloid cells, p15(INK4b) mRNA is upregulated during cytokine-induced differentiation and/or growth arrest, and hypermethylation of the p15(INK4b) gene promoter region is a common event in acute myeloid leukemia. In the present study, we examined murine monocyte/macrophage tumors with deregulated c-myc for evidence of Ink4 gene inactivation. p15(Ink4b) mRNA and protein were detected in the majority of leukemias, and p16(Ink4a) mRNA and protein were highly expressed in two of them. pRb was in a hypophosphorylated state in most of the neoplasms indicating that the Cdk inhibitors that were expressed in the cells were functional. The observed expression of p15(Ink4b) is inconsistent with their proliferation state, although it might be expected to be expressed owing to the maturity of the cells. These data suggest, therefore, that deregulated c-Myc bypasses the pRb restriction point and cell cycle arrest in these tumors. An examination of p19(Arf) exons revealed deletions of the gene in up to 94% of the tumors. Since this gene shares exon 2 with p16(Ink4),, it is often difficult to determine which gene is the relevant tumor suppressor. However, the loss of only the p19(Arf)-specific exon 1beta was observed in a tumor that had normal p16(Ink4a), protein expression. In addition, the p19(Arf)-specific exon was deleted in another tumor that expressed a functional chimeric protein, p15Ex1-p16Ex2-3; it was demonstrated here that this fusion protein is capable of inducing G1 arrest. These data overall supports the hypothesis that the critical inactivation event in these hematopoietic neoplasms is elimination of p19(Arf), and not Ink4 function.	NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wolff, L (corresponding author), NCI, Cellular Oncol Lab, NIH, Bethesda, MD 20892 USA.							Adams PD, 2001, BBA-REV CANCER, V1471, pM123, DOI 10.1016/S0304-419X(01)00019-1; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amanullah A, 2000, ONCOGENE, V19, P2967, DOI 10.1038/sj.onc.1203638; Batova A, 1997, CANCER RES, V57, P832; Claassen GF, 2000, P NATL ACAD SCI USA, V97, P9498, DOI 10.1073/pnas.150006697; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Cooper CL, 1997, BLOOD, V89, P3155, DOI 10.1182/blood.V89.9.3155; Drexler HG, 1998, LEUKEMIA, V12, P845, DOI 10.1038/sj.leu.2401043; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Esteller M, 2001, CANCER RES, V61, P3225; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GUTIERREZ MI, 1992, CANCER RES, V52, P1032; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harper JW, 1996, CURR OPIN GENET DEV, V6, P56; Herman JG, 1997, CANCER RES, V57, P837; Herzog CR, 1997, MAMM GENOME, V8, P65, DOI 10.1007/s003359900352; Iravani M, 1997, ONCOGENE, V15, P2609, DOI 10.1038/sj.onc.1201428; Ishiguro A, 1996, BLOOD, V87, P5225, DOI 10.1182/blood.V87.12.5225.bloodjournal87125225; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KEYOMARSI K, 1994, CANCER RES, V54, P380; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Kulkarni MS, 2002, LEUKEMIA, V16, P127, DOI 10.1038/sj.leu.2402328; Lasorella A, 2000, NATURE, V407, P592, DOI 10.1038/35036504; Lasorella A, 1996, MOL CELL BIOL, V16, P2570; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Malumbres M, 2000, BIOL CHEM, V381, P827, DOI 10.1515/BC.2000.105; Malumbres M, 1999, ONCOGENE, V18, P385, DOI 10.1038/sj.onc.1202299; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Malumbres M, 1997, ONCOGENE, V14, P1361, DOI 10.1038/sj.onc.1200969; MARTIN SL, 1995, GENE, V153, P261, DOI 10.1016/0378-1119(94)00785-Q; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Morris EJ, 2001, ADV CANCER RES, V82, P1, DOI 10.1016/S0065-230X(01)82001-7; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; O'Hagan RC, 2000, GENE DEV, V14, P2185, DOI 10.1101/gad.827200; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1995, ONCOGENE, V11, P635; Reinach PS, 2000, CELL PROLIFERAT, V33, P189, DOI 10.1046/j.1365-2184.2000.00162.x; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Schmidt M, 2001, ONCOGENE, V20, P6205, DOI 10.1038/sj.onc.1204821; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SUN XH, 1991, MOL CELL BIOL, V11, P5603, DOI 10.1128/MCB.11.11.5603; Teofili L, 1998, EXP HEMATOL, V26, P1133; Teofili L, 2000, EXP HEMATOL, V28, P519, DOI 10.1016/S0301-472X(00)00139-9; Uchida T, 1997, BLOOD, V90, P1403, DOI 10.1182/blood.V90.4.1403.1403_1403_1409; Weinberg RA, 1997, CELL, V88, P573, DOI 10.1016/S0092-8674(00)81897-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WOLFF L, 1986, CURR TOP MICROBIOL, V132, P33; WOLFF L, 1988, J IMMUNOL, V141, P681; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	69	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 20	2003	22	11					1600	1610		10.1038/sj.onc.1206268	http://dx.doi.org/10.1038/sj.onc.1206268			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	655YH	12642863				2022-12-17	WOS:000181580500002
J	Ochiai, Y; Tamura, Y; Saito, Y; Matsuki, A; Wakabayashi, Y; Aizawa, Y; Niwa, O; Kominami, R				Ochiai, Y; Tamura, Y; Saito, Y; Matsuki, A; Wakabayashi, Y; Aizawa, Y; Niwa, O; Kominami, R			Mapping of genetic modifiers of thymic lymphoma development in p53-knockout mice	ONCOGENE			English	Article						p53 modifier; genetic mapping; thymic lymphoma; skin cancer; consomic mouse	TUMOR-SUPPRESSOR GENE; INTESTINAL NEOPLASIA; P53-DEFICIENT MICE; P53 MUTATIONS; CANCER; TUMORIGENESIS; SUSCEPTIBILITY; RESISTANCE; CANDIDATE; HOMOLOG	The strain dependency of the spectrum and latency of tumors has been reported in p53-deficient (KO) mice, suggesting the presence of modifiers for the outcome of the p53 deficiency. The modifiers provide clues to the oncogenic pathway in cells lacking p53, the most frequently mutated gene in a wide variety of human cancers. To search the modifiers, we induced 160 lymphomas and 69 skin tumors by gamma-irradiation of p53(KO/+) backcross mice between BALB/c and MSM strains and performed genome scan. BALB/c-derived alleles at three loci on chromosome 19, Mp53D1 (modifier of p53-deficiency) at D19Mit5, Mp53D2 at D19Mit90 and Mp53D3 at D19MW23, extended the latency of thymic lymphoma development (P values in Mantel-Cox test were 0.0007, 0.0007 and 0.0003, respectively). Mp53D3 also increased the latency of skin tumors (P value, 0.0008). The linkage of Mp53D2 was confirmed by the experiment using 94 p53-KO mice consomic for chromosome 19, providing a significant linkage. However, the linkage was not confirmed for Mp53D1 or Mp53D3, suggesting epistasis of genes involved in the tumorigenesis.	Niigata Univ, Grad Sch Med & Dent Sci, Dept Gene Regulat, Niigata 9518122, Japan; Niigata Univ, Grad Sch Med & Dent Sci, Dept Cardiovasc & Vital Control, Niigata 9518122, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068315, Japan	Niigata University; Niigata University; Kyoto University	Kominami, R (corresponding author), Niigata Univ, Grad Sch Med & Dent Sci, Dept Gene Regulat, Asahimachi Doori 1-757, Niigata 9518122, Japan.							Balmain A, 2002, CELL, V108, P145, DOI 10.1016/S0092-8674(02)00622-0; Balmain A, 1998, TRENDS GENET, V14, P139, DOI 10.1016/S0168-9525(98)01422-X; Cormier RT, 1997, NAT GENET, V17, P88, DOI 10.1038/ng0997-88; Demant P, 1992, Semin Cancer Biol, V3, P159; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DONEHOWER LA, 1995, MOL CARCINOGEN, V14, P16, DOI 10.1002/mc.2940140105; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Inoue K, 2001, GENE DEV, V15, P2934, DOI 10.1101/gad.929901; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Manly KF, 2001, MAMM GENOME, V12, P930, DOI 10.1007/s00335-001-1016-3; Markel P, 1997, NAT GENET, V17, P280, DOI 10.1038/ng1197-280; Matsumoto Y, 1998, ONCOGENE, V16, P2747, DOI 10.1038/sj.onc.1201810; Miyazawa T, 2002, JPN J CANCER RES, V93, P994, DOI 10.1111/j.1349-7006.2002.tb02475.x; Mori N, 1999, ONCOGENE, V18, P4282, DOI 10.1038/sj.onc.1202719; Nadeau JH, 2001, NAT REV GENET, V2, P165, DOI 10.1038/35056009; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Ponder BAJ, 2001, NATURE, V411, P336, DOI 10.1038/35077207; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Sionov RV, 1999, ONCOGENE, V18, P6145, DOI 10.1038/sj.onc.1203130; Stambolic V, 2001, MOL CELL, V8, P317, DOI 10.1016/S1097-2765(01)00323-9; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0	30	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 20	2003	22	7					1098	1102		10.1038/sj.onc.1206202	http://dx.doi.org/10.1038/sj.onc.1206202			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	644PB	12592396				2022-12-17	WOS:000180926100015
J	Sprowles, A; Wisdom, R				Sprowles, A; Wisdom, R			Oncogenic effect of delta deletion in v-Jun does not result from uncoupling Jun from JNK signaling	ONCOGENE			English	Article						Jun; JNK; transformation	ACTIVATED PROTEIN-KINASES; C-JUN; TRANSCRIPTION FACTORS; MAP KINASES; EMBRYO FIBROBLASTS; DOCKING SITES; HA-RAS; PHOSPHORYLATION; DOMAIN; ONCOPROTEIN	The protein encoded by the v-Jun oncogene shows increased transforming activity compared to c-Jun, its normal cellular counterpart. One major determinant of this increased transforming activity is an in-frame deletion of a region near the amino-terminus of the protein. This region, referred to as the delta domain, functions as a docking site for Jun N-terminal kinase (JNK), the mitogen-activated protein (MAP) kinase that phosphorylates c-Jun to regulate its transcriptional properties. As a consequence of this deletion, v-Jun is unresponsive to JNK signaling, and it is widely believed that it is the uncoupling of v-Jun from JNK signaling that underlies the oncogenic effects of the delta-domain deletion; however, this idea has never been directly tested. Here we use JNK overexpression as well as alanine scanning mutagenesis to test this idea. Point mutants that are uncoupled from JNK signaling do not show enhanced transforming activity, suggesting that disruption of the Jun-JNK interaction is not the mechanism by which the delta-domain deletion enhances transforming activity. Consistent with this idea, we have generated a panel of point mutants that show markedly enhanced transforming activity, despite the fact that they do not perturb the ability of JNK to either dock with or phosphorylate c-Jun in vitro or in vivo. The fact that these mutants cluster in a small region suggests the existence of an additional regulator of Jun function whose activity is disrupted by mutations in this region.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; Univ Calif Davis, Ctr Canc, UC Davis Sch Med, Sacramento, CA 95817 USA	Vanderbilt University; University of California System; University of California Davis	Wisdom, R (corresponding author), Res Bldg 3,Rm 1100 4645 2nd Ave, Sacramento, CA 95817 USA.				NCI NIH HHS [CA64118, T32CA009582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA064118, T32CA009582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADLER V, 1992, P NATL ACAD SCI USA, V89, P5341, DOI 10.1073/pnas.89.12.5341; Akagi T, 2000, P NATL ACAD SCI USA, V97, P7290, DOI 10.1073/pnas.140210297; BAICHWAL VR, 1992, GENE DEV, V6, P1493, DOI 10.1101/gad.6.8.1493; BAICHWAL VR, 1990, CELL, V63, P815, DOI 10.1016/0092-8674(90)90147-7; Bardwell L, 1998, P NATL ACAD SCI USA, V95, P15400, DOI 10.1073/pnas.95.26.15400; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; BLACK EJ, 1994, ONCOGENE, V9, P2363; BOS TJ, 1990, GENE DEV, V4, P1677, DOI 10.1101/gad.4.10.1677; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; CAVALIERI F, 1985, VIROLOGY, V143, P680, DOI 10.1016/0042-6822(85)90412-X; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; DAI TN, 1995, ONCOGENE, V10, P849; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Fantz DA, 2001, J BIOL CHEM, V276, P27256, DOI 10.1074/jbc.M102512200; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; HAVARSTEIN LS, 1992, P NATL ACAD SCI USA, V89, P618, DOI 10.1073/pnas.89.2.618; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Kallunki T, 1996, CELL, V87, P929, DOI 10.1016/S0092-8674(00)81999-6; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kilbey A, 1996, ONCOGENE, V12, P2409; Madhani HD, 1997, CELL, V91, P673, DOI 10.1016/S0092-8674(00)80454-7; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; May GHW, 1998, CURR BIOL, V8, P117, DOI 10.1016/S0960-9822(98)70043-0; May GHW, 1998, J BIOL CHEM, V273, P33429, DOI 10.1074/jbc.273.50.33429; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; PULVERER BJ, 1993, ONCOGENE, V8, P407; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; Ui M, 1998, FEBS LETT, V429, P289, DOI 10.1016/S0014-5793(98)00618-8; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Yang SH, 1999, MOL CELL BIOL, V19, P4028; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740	36	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 30	2003	22	4					498	506		10.1038/sj.onc.1206165	http://dx.doi.org/10.1038/sj.onc.1206165			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	637XC	12555063				2022-12-17	WOS:000180538200003
J	Wang, SN; Mori, Y; Sato, F; Yin, J; Xu, Y; Zou, TT; Olaru, A; Kimos, MC; Perry, K; Selaru, FM; Deacu, E; Sun, MH; Shi, YC; Shibata, D; Abraham, JM; Greenwald, BD; Meltzer, SJ				Wang, SN; Mori, Y; Sato, F; Yin, J; Xu, Y; Zou, TT; Olaru, A; Kimos, MC; Perry, K; Selaru, FM; Deacu, E; Sun, MH; Shi, YC; Shibata, D; Abraham, JM; Greenwald, BD; Meltzer, SJ			An LOH and mutational investigation of the ST7 gene locus in human esophageal carcinoma	ONCOGENE			English	Article						esophageal cancer; ST7; 7q31; LOH; mutation; expression	TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL CARCINOMA; HETEROZYGOSITY; REGION; 7Q31.1	Frequent loss of heterozygosity (LOH) on human chromosome 7q31 has been reported in numerous malignancies. Suppressor of tumorigenicity 7 (ST7) has been identified as a candidate tumor suppressor gene in this region. To identify whether 7q31 and genetic alterations of ST7 were involved in human esophageal carcinogenesis, we performed LOH mapping of a 5.4cM region at 7q31-q35 in 43 primary esophageal carcinomas, as well as mutational analyses of the ST7 gene in tumors with LOH in this region. Of 43 tumors, 12 (28%) showed LOH at 7q31-q35. These included four (22%) of 18 squamous cell carcinomas and eight (32%) of 25 adenocarcinomas. The peak LOH locus was D7S480, lying 4.2 Mb telomeric to ST7 and showing LOH in eight of 37 informative tumors, or 22%. No mutations were found in the entire coding or flanking intronic regions of the ST7 gene among 12 tumors with 7q-LOH. In addition, quantitative RT-PCR analyses of ST7 mRNA expression levels in 11/13 normal-tumor pairs failed to show more than a 50% decrease in tumor ST7 mRNA relative to matched normal tissues. These data suggest that LOH at 7q31-q35 is involved in the origin or progression of at least a subset of esophageal carcinomas, but that ST7 is not the target gene of this somatic event.	Univ Maryland, Sch Med, Div Gastroenterol, Dept Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Greenebaum Canc Ctr, Baltimore, MD 21201 USA; Univ Maryland, Baltimore VA Hosp, Sch Med,Greenbaum Canc Ctr, Div Surg Oncol,Dept Surg, Baltimore, MD 21201 USA; Fudan Univ, Coll Med, Dept Pathol, Shanghai 200433, Peoples R China	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; Fudan University	Meltzer, SJ (corresponding author), Univ Maryland, Sch Med, Div Gastroenterol, Dept Med, 22 S Greene St, Baltimore, MD 21201 USA.			Perry, Kellie/0000-0001-6238-8221; Selaru, Florin/0000-0001-7990-8238	NCI NIH HHS [CA77057, CA95323, CA85069] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA095323, U01CA085069, R01CA077057] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Gunduz M, 2002, ONCOGENE, V21, P4462, DOI 10.1038/sj.onc.1205540; HOLLSTEIN MC, 1990, P NATL ACAD SCI USA, V87, P9958, DOI 10.1073/pnas.87.24.9958; Hughes KA, 2001, NAT GENET, V29, P380, DOI 10.1038/ng783; Liang H, 1998, P NATL ACAD SCI USA, V95, P3781, DOI 10.1073/pnas.95.7.3781; Miller BA, 1996, NIH PUB, V96-4104; Mori Y, 2001, CANCER RES, V61, P6046; Riegman PHJ, 2001, CANCER RES, V61, P3164; Roth MJ, 2001, CANCER RES, V61, P4098; SHIBAGAKI I, 1994, CANCER RES, V54, P2996; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Thomas NA, 2001, NAT GENET, V29, P379, DOI 10.1038/ng784; Tobias ES, 2001, ONCOGENE, V20, P2844, DOI 10.1038/sj.onc.1204433; van Dekken H, 1999, J PATHOL, V188, P263, DOI 10.1002/(SICI)1096-9896(199907)188:3<263::AID-PATH374>3.0.CO;2-Y; ZENKLUSEN JC, 1994, ONCOGENE, V9, P2817; ZENKLUSEN JC, 1994, CANCER RES, V54, P6370; Zenklusen JC, 2001, NAT GENET, V27, P392, DOI 10.1038/86891; ZENKLUSEN JC, 1995, CANCER RES, V55, P1347; Zenklusen Jean C., 1999, Neoplasia (New York), V1, P16, DOI 10.1038/sj.neo.7900011; Zou TT, 2002, ONCOGENE, V21, P4855, DOI 10.1038/sj.onc.1205613	19	11	13	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 23	2003	22	3					467	470		10.1038/sj.onc.1206125	http://dx.doi.org/10.1038/sj.onc.1206125			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	635CB	12545169				2022-12-17	WOS:000180379100017
J	Wang, DL; Lemon, WJ; You, M				Wang, DL; Lemon, WJ; You, M			Linkage disequilibrium mapping of novel lung tumor susceptibility quantitative trait loci in mice	ONCOGENE			English	Article						mouse; linkage disequilibrium; lung tumor; susceptibility; gene mapping	RAS PROTOONCOGENE; CANCER; ASSOCIATION; RELATIVES; RISK; POLYMORPHISMS; GENES	Linkage disequilibrium (LD) has been used to map chromosomal regions regulating quantitative traits, also called quantitative trait loci (QTLs). With the increasing number of available mouse polymorphic genetic markers, LD can be estimated for the purpose of fine-mapping a given QTL or in the identification of novel QTLs. A whole-genome LD analysis was conducted for mapping mouse lung tumor susceptibility QTLs in 25 strains of mice with known susceptibility to lung cancer using 5638 genetic markers. A total of 63 markers were found to be significantly associated with lung tumor susceptibility, many of which were novel QTLs. This study demonstrates the feasibility of using LD to map QTLs on a whole genome level. Further characterization of the newly identified lung tumor susceptibility QTLs may lead to the identification of genes whose human homologue may predispose some individuals to lung cancer.	Ohio State Univ Comprehens Canc, Div Human Canc Genet, Med Res Facil 514, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	You, M (corresponding author), Ohio State Univ Comprehens Canc, Div Human Canc Genet, Med Res Facil 514, 420 W 12th Ave, Columbus, OH 43210 USA.	you-1@medctr.osu.edu			NATIONAL CANCER INSTITUTE [P30CA016058, R01CA058554, R01CA078797] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA78797, P30CA16058, R01CA58554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAPORASO NE, 1992, ENVIRON HEALTH PERSP, V98, P101; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GOFFMAN TE, 1982, JAMA-J AM MED ASSOC, V247, P1020, DOI 10.1001/jama.247.7.1020; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Grupe A, 2001, SCIENCE, V292, P1915, DOI 10.1126/science.1058889; Herzog CR, 1997, J CELL BIOCHEM, P49; Herzog CR, 1997, MAMM GENOME, V8, P65, DOI 10.1007/s003359900352; Johannsson O, 1996, AM J HUM GENET, V58, P441; LI FP, 1988, CANCER RES, V48, P5358; Lin L, 1998, EXP LUNG RES, V24, P481, DOI 10.3109/01902149809087382; LYNCH HT, 1986, CANCER, V57, P1640, DOI 10.1002/1097-0142(19860415)57:8<1640::AID-CNCR2820570833>3.0.CO;2-Q; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; Manenti G, 1999, GENOME RES, V9, P639; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; Manenti G, 1997, CARCINOGENESIS, V18, P1917, DOI 10.1093/carcin/18.10.1917; MCDUFFIE HH, 1991, J CLIN EPIDEMIOL, V44, P69, DOI 10.1016/0895-4356(91)90202-K; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; Ott J, 1999, ANAL HUMAN GENETIC L; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SELLERS TA, 1987, AM J EPIDEMIOL, V126, P237, DOI 10.1093/aje/126.2.237; SHAW GL, 1991, J CLIN EPIDEMIOL, V44, P429, DOI 10.1016/0895-4356(91)90082-K; SHIELDS PG, 1993, LUNG CANCER, P3; STRONG LC, 1984, J NATL CANCER I, V73, P303, DOI 10.1093/jnci/73.2.303; SUGIMURA H, 1990, CANCER RES, V50, P1857; ToFigueras J, 1996, CANCER EPIDEM BIOMAR, V5, P337; TOKUHATA GEORGE K., 1963, JOUR NATL CANCER INST, V30, P289; Tripodis N, 2001, J NATL CANCER I, V93, P1484, DOI 10.1093/jnci/93.19.1484; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X	34	11	12	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6858	6865		10.1038/sj.onc.1205886	http://dx.doi.org/10.1038/sj.onc.1205886			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360413				2022-12-17	WOS:000178315800017
J	O'Connell, KF				O'Connell, KF			The ZYG-1 kinase, a mitotic and meiotic regulator of centriole replication	ONCOGENE			English	Review						centrosome duplication; centriole; ZYG-1; C. elegans; mitosis; meiosis	CAENORHABDITIS-ELEGANS EMBRYOS; XENOPUS EGG EXTRACTS; HAMSTER OVARY CELLS; CENTROSOME DUPLICATION; PROTEIN-KINASE; GAMMA-TUBULIN; C-ELEGANS; REPRODUCTIVE CAPACITY; BODY DUPLICATION; SPINDLE POLES		NIDDKD, Lab Biochem & Genet, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	O'Connell, KF (corresponding author), NIDDKD, Lab Biochem & Genet, NIH, Bldg 8,Room 2A07, Bethesda, MD 20892 USA.			O'Connell, Kevin/0000-0002-9789-288X				Albertson DG, 1993, CHROMOSOME RES, V1, P15, DOI 10.1007/BF00710603; Bobinnec Y, 1998, J CELL BIOL, V143, P1575, DOI 10.1083/jcb.143.6.1575; Bobinnec Y, 2000, J CELL SCI, V113, P3747; Browning H, 1996, DEVELOPMENT, V122, P391; CALLAINI G, 1990, J CELL SCI, V97, P539; Chase D, 2000, DNA SEQUENCE, V11, P327, DOI 10.3109/10425170009033251; Chase D, 2000, GENESIS, V26, P26, DOI 10.1002/(SICI)1526-968X(200001)26:1<26::AID-GENE6>3.0.CO;2-O; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; Fay DS, 2000, DEVELOPMENT, V127, P4049; Fisk HA, 2001, CELL, V106, P95, DOI 10.1016/S0092-8674(01)00411-1; Freed E, 1999, GENE DEV, V13, P2242, DOI 10.1101/gad.13.17.2242; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; GOULD RR, 1977, J CELL BIOL, V73, P601, DOI 10.1083/jcb.73.3.601; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; Hannak E, 2002, J CELL BIOL, V157, P591, DOI 10.1083/jcb.200202047; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; Hinchcliffe EH, 1999, SCIENCE, V283, P851, DOI 10.1126/science.283.5403.851; KEMPHUES KJ, 1988, GENETICS, V120, P977; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; KURIYAMA R, 1981, J CELL BIOL, V91, P814, DOI 10.1083/jcb.91.3.814; Lacey KR, 1999, P NATL ACAD SCI USA, V96, P2817, DOI 10.1073/pnas.96.6.2817; MANIOTIS A, 1991, CELL, V67, P495, DOI 10.1016/0092-8674(91)90524-3; Matsumoto Y, 1999, CURR BIOL, V9, P429, DOI 10.1016/S0960-9822(99)80191-2; MAZIA D, 1960, J BIOPHYS BIOCHEM CY, V7, P1, DOI 10.1083/jcb.7.1.1; Megraw TL, 2000, CURR TOP DEV BIOL, V49, P385; Meraldi P, 1999, NAT CELL BIOL, V1, P88, DOI 10.1038/10054; MORITZ M, 1995, J CELL BIOL, V130, P1149, DOI 10.1083/jcb.130.5.1149; NAVARA CS, 1994, DEV BIOL, V162, P29, DOI 10.1006/dbio.1994.1064; O'Connell KF, 1998, GENETICS, V149, P1303; O'Connell KF, 2001, CELL, V105, P547, DOI 10.1016/S0092-8674(01)00338-5; Oakley BR, 2000, CURR TOP DEV BIOL, V49, P27; Okuda M, 2000, CELL, V103, P127, DOI 10.1016/S0092-8674(00)00093-3; Phalle BD, 1998, J CELL BIOL, V141, P1383, DOI 10.1083/jcb.141.6.1383; PHILLIPS DM, 1967, J CELL BIOL, V33, P73, DOI 10.1083/jcb.33.1.73; Pihan GA, 2001, CANCER RES, V61, P2212; Ruiz F, 1999, CURR BIOL, V9, P43, DOI 10.1016/S0960-9822(99)80045-1; SCHATTEN G, 1994, DEV BIOL, V165, P299, DOI 10.1006/dbio.1994.1256; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Schumacher JM, 1998, J CELL BIOL, V143, P1635, DOI 10.1083/jcb.143.6.1635; SLUDER G, 1989, CELL MOTIL CYTOSKEL, V13, P264, DOI 10.1002/cm.970130405; SLUDER G, 1985, J CELL SCI, V76, P35; SLUDER G, 1985, J CELL BIOL, V100, P887, DOI 10.1083/jcb.100.3.887; SLUDER G, 1989, DEV BIOL, V131, P567, DOI 10.1016/S0012-1606(89)80027-2; Stearns T, 2001, CELL, V105, P417, DOI 10.1016/S0092-8674(01)00366-X; Strome S, 2001, MOL BIOL CELL, V12, P1751, DOI 10.1091/mbc.12.6.1751; SZOLLOSI A, 1986, EUR J CELL BIOL, V40, P100; SZOLLOSI D, 1972, J CELL SCI, V11, P521; WINEY M, 1991, J CELL BIOL, V114, P745, DOI 10.1083/jcb.114.4.745; Wojcik EJ, 2000, CURR BIOL, V10, P1131, DOI 10.1016/S0960-9822(00)00703-X; WOLF N, 1978, J ULTRA MOL STRUCT R, V63, P155, DOI 10.1016/S0022-5320(78)80071-9; WOOD WB, 1980, DEV BIOL, V74, P446, DOI 10.1016/0012-1606(80)90445-5; Wu XY, 1999, P NATL ACAD SCI USA, V96, P1397, DOI 10.1073/pnas.96.4.1397	53	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 9	2002	21	40					6201	6208		10.1038/sj.onc.1205776	http://dx.doi.org/10.1038/sj.onc.1205776			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	590TZ	12214250				2022-12-17	WOS:000177840500009
J	Leonardi, P; Kassin, E; Hernandez-Munoz, I; Diaz, R; Inghirami, G; Pellicer, A				Leonardi, P; Kassin, E; Hernandez-Munoz, I; Diaz, R; Inghirami, G; Pellicer, A			Human rgr: transforming activity and alteration in T-cell malignancies	ONCOGENE			English	Article						oncogene; rgr; lymphomas; gene rearrangement; Jurkat	NUCLEOTIDE DISSOCIATION STIMULATOR; ABL GENE; RAS; ONCOGENE	We have previously identified the oncogene rgr (ralGDS related) in DNA, derived from a rabbit squamous cell carcinoma. Here we describe the identification of the human orthologue of the rabbit rgr gene termed hrgr (human ralGDS related). Four alternatively spliced full-length hrgr transcripts were isolated from normal human testes and liver libraries. Truncation of hrgr confers transforming ability to its cDNA. Using a RT-PCR assay we have been able to detect the expression of an abnormally truncated transcript in several human T-cell lymphoma lines, and in fresh tissue samples of patients with T-cell malignancies. In the DHL cell line, an Anaplastic Large Cell Lymphoma (ALCL) line, a DNA rearrangement was detected within the hrgr gene region. We propose that these T-cell lymphomas, at least in part, owe their malignant phenotypes to genetic alterations of the hrgr gene. These findings also raise the possibility that mutations in the hrgr gene are involved in other malignancies.	NYU, Med Ctr, Dept Pathol, New York, NY 10016 USA; Netherlands Canc Inst, Amsterdam, Netherlands	New York University; Netherlands Cancer Institute	Pellicer, A (corresponding author), NYU, Med Ctr, Dept Pathol, 550 1St Ave, New York, NY 10016 USA.		MARTINEZ, ANTONIO PELLICER/C-4832-2015	Pellicer, Angel/0000-0002-5062-0692	NATIONAL CANCER INSTITUTE [R01CA050434] Funding Source: NIH RePORTER; NCI NIH HHS [CA50434] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRIGHT CF, 1993, EMBO J, V12, P339, DOI 10.1002/j.1460-2075.1993.tb05662.x; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; Bouck N, 1979, Methods Enzymol, V58, P296; CHISSOE SL, 1995, GENOMICS, V27, P67, DOI 10.1006/geno.1995.1008; DAdamo DR, 1997, ONCOGENE, V14, P1295, DOI 10.1038/sj.onc.1200950; Hernandez-Munoz I, 2000, ONCOGENE, V19, P2745, DOI 10.1038/sj.onc.1203586; JIANG XY, 1990, BLOOD, V76, P597; LEON J, 1988, MOL CELL BIOL, V8, P786, DOI 10.1128/MCB.8.2.786; PELLICER A, 1980, SCIENCE, V209, P1414, DOI 10.1126/science.7414320; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439	10	11	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 1	2002	21	33					5108	5116		10.1038/sj.onc.1205694	http://dx.doi.org/10.1038/sj.onc.1205694			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	575YK	12140761				2022-12-17	WOS:000176975900009
J	Zelivianski, S; Igawa, T; Lim, S; Taylor, R; Lin, MF				Zelivianski, S; Igawa, T; Lim, S; Taylor, R; Lin, MF			Identification and characterization of regulatory elements of the human prostatic acid phosphatase promoter	ONCOGENE			English	Article						prostatic acid phosphatase; tissue-specific expression; promoter analysis; DNA injection	GENE-EXPRESSION; TRANSGENIC MICE; PRIMARY MYOBLASTS; ANTIGEN GENE; FACTOR-IX; ANDROGEN; CARCINOMA; THERAPY; PROTEIN; SPECIFICITY	Human prostatic acid phosphatase (PAcP) is a prostate epithelium-specific differentiation antigen. The cellular form of PAcP functions as a neutral protein-tyrosine phosphatase, and is involved in regulating prostate cell growth. Although some information on the PAcP gene structure has been obtained, little is known regarding the cis- and traps-acting factors that regulate its expression. Due to the biological importance of PAcP, we investigated the regulation of its expression. A region upstream of the PAcP gene from -2899 to +87 base pairs was linked to the coding sequence of the chloramphenicol acetyltransferase (CAT) gene. Sequential deletions of the sequence between -2899 and -205 revealed that, in addition to the basic promoter, the region between -1258 and -779 represents a positive regulatory element. This -1258/-779 fragment could enhance the PAcP promoter activity in PC-3 and DU 145 human prostate cancer cells, but not in non-prostate cancer cells, including WI-38 lung diploid cells, A-431 epidermoid carcinoma cells, and HeLa cervix epitheloid carcinoma cells. Furthermore, this cis-element together with the promoter sequence could drive a high level of expression of green fluorescent protein (GFP) in PC-3 cells, but not in HeLa cells. The prostate-specific expression was further examined by injecting naked plasmid DNA into the prostate and the hamstring muscle of mice. The fluorescence pattern clearly showed that the level of GFP expression is consistently higher in prostate cells than in muscle cells of the intact animal. The data collectively indicate that region between -1258 and -779 is involved in governing the cell type-specific expression of the PAcP gene.	Univ Nebraska, Med Ctr,Dept Biochem Mol Biol, Dept Biochem & Mol Biol, Nebraska Med Ctr 984525,Coll Med, Omaha, NE 68198 USA; Univ Nebraska, Med Ctr, Coll Med, Sect Urol Surg, Omaha, NE USA; Univ Nebraska, Med Ctr, UNMC Eppley Canc Ctr, Omaha, NE USA; Omaha VA Hosp, Omaha, NE USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Lin, MF (corresponding author), Univ Nebraska, Med Ctr,Dept Biochem Mol Biol, Dept Biochem & Mol Biol, Nebraska Med Ctr 984525,Coll Med, Omaha, NE 68198 USA.	mlin@unmc.edu	Zelivianski, Stanislav/G-3043-2010		NCI NIH HHS [CA88184] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088184] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALLISON J, 1989, MOL CELL BIOL, V9, P2254, DOI 10.1128/MCB.9.5.2254; BANAS B, 1994, BBA-GENE STRUCT EXPR, V1217, P188, DOI 10.1016/0167-4781(94)90033-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brookes DE, 1998, PROSTATE, V35, P18, DOI 10.1002/(SICI)1097-0045(19980401)35:1<18::AID-PROS3>3.0.CO;2-D; Chu TM, 1998, J CLIN LIGAND ASSAY, V21, P24; Cleutjens KBJM, 1996, J BIOL CHEM, V271, P6379, DOI 10.1074/jbc.271.11.6379; Cleutjens KBJM, 1997, MOL ENDOCRINOL, V11, P1256, DOI 10.1210/me.11.9.1256; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; DAI Y, 1992, P NATL ACAD SCI USA, V89, P10892, DOI 10.1073/pnas.89.22.10892; GARCIAARENAS R, 1995, MOL CELL ENDOCRINOL, V111, P29, DOI 10.1016/0303-7207(95)03544-H; Gotoh A, 1998, J UROLOGY, V160, P220, DOI 10.1016/S0022-5347(01)63094-5; GREENBERG NM, 1994, MOL ENDOCRINOL, V8, P230, DOI 10.1210/me.8.2.230; HENGGE UR, 1995, NAT GENET, V10, P161, DOI 10.1038/ng0695-161; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KITSIS RN, 1991, P NATL ACAD SCI USA, V88, P4138, DOI 10.1073/pnas.88.10.4138; LIN MF, 1988, MOL CELL BIOL, V8, P5477, DOI 10.1128/MCB.8.12.5477; LIN MF, 1993, ARCH BIOCHEM BIOPHYS, V300, P384, DOI 10.1006/abbi.1993.1052; Lin MF, 1998, J BIOL CHEM, V273, P5939, DOI 10.1074/jbc.273.10.5939; Lin MF, 2001, J UROLOGY, V166, P1943, DOI 10.1016/S0022-5347(05)65725-4; MAROULAKOU IG, 1994, P NATL ACAD SCI USA, V91, P11236, DOI 10.1073/pnas.91.23.11236; Meng TC, 1998, J BIOL CHEM, V273, P22096, DOI 10.1074/jbc.273.34.22096; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; Nettelbeck DM, 2000, TRENDS GENET, V16, P174, DOI 10.1016/S0168-9525(99)01950-2; PRIGOZY T, 1993, SOMAT CELL MOLEC GEN, V19, P111, DOI 10.1007/BF01233527; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROMAN M, 1992, SOMAT CELL MOLEC GEN, V18, P247, DOI 10.1007/BF01233861; Ruokonen M, 1996, BIOCHEM BIOPH RES CO, V218, P794, DOI 10.1006/bbrc.1996.0141; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHAFFNER DL, 1995, LAB INVEST, V72, P283; Schuur ER, 1996, J BIOL CHEM, V271, P7043, DOI 10.1074/jbc.271.12.7043; Shan JD, 1997, ENDOCRINOLOGY, V138, P3764, DOI 10.1210/en.138.9.3764; SHARIEF FS, 1994, BIOCHEM MOL BIOL INT, V33, P561; SOLIN T, 1990, BIOCHIM BIOPHYS ACTA, V1048, P72, DOI 10.1016/0167-4781(90)90024-V; VIRKKUNEN P, 1994, BIOCHEM BIOPH RES CO, V202, P49, DOI 10.1006/bbrc.1994.1892; Wolff Jon A., 1992, Human Molecular Genetics, V1, P363, DOI 10.1093/hmg/1.6.363; Zelivianski S, 1998, BIOCHEM BIOPH RES CO, V245, P108, DOI 10.1006/bbrc.1998.8386; Zelivianski S, 2000, BBA-GENE STRUCT EXPR, V1491, P123, DOI 10.1016/S0167-4781(00)00037-3; Zhang XQ, 2001, J BIOL CHEM, V276, P2544, DOI 10.1074/jbc.M006661200	38	11	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2002	21	23					3696	3705		10.1038/sj.onc.1205471	http://dx.doi.org/10.1038/sj.onc.1205471			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	553LE	12032838				2022-12-17	WOS:000175676000005
J	Foster, CJ; Lozano, G				Foster, CJ; Lozano, G			Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland	ONCOGENE			English	Article						proliferation; cell cycle; p53	TUMOR-SUPPRESSOR; S-PHASE; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; INK4A LOCUS; P53 PROTEIN; GENE; AMPLIFICATION; PRODUCT; ASSOCIATION	The protein encoded by the murine double minute 2 (Mdm2) gene inactivates the function of the tumor suppressor p53. The targeted expression of the mdm2 transgene (BLGmdm2) to the mammary epithelium disrupts the cell cycle, causing multiple rounds of DNA synthesis without proper cell division and consequently poor mammary gland development. These phenotypes in the mammary epithelia of the transgenic mice are not dependent on either p53 or the transcription factor E2F1, as mice null for these genes carrying the BLGmdm2 transgene exhibit similar defects to mice carrying the BLGmdm2 transgene alone. p19ARF, an alternative splice product of the INK4a/ARF locus, has been shown to interact directly with MDM2. Therefore, BLGmdm2 transgenic mice null for p19ARF were created to gain insight into the mechanism by which mdm2 overexpression disrupts the cell cycle. The BLGmdm2 phenotype in the absence of p19ARF was worse than BLGmdm2 mice and visible as early as day 15 of pregnancy. By day 5 of lactation the phenotype was very pronounced. Histological analysis of the mammary gland showed a decrease in ductal branching, smaller and fewer lobuloalveolar structures, and a decrease in luminal secretions. Multinucleated and enlarged cells were present due to continued replication in the absence of cytokinesis. Thus, the absence of p19ARF in this in vivo system enhanced the defect caused by mdm2 overexpression.	Univ Texas, MD Anderson Canc Ctr, Sect Canc Genet, Dept Mol Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Lozano, G (corresponding author), Univ Texas, MD Anderson Canc Ctr, Sect Canc Genet, Dept Mol Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gglozano@mdanderson.org		Vivian, Carolyn J./0000-0001-9598-0109	NATIONAL CANCER INSTITUTE [R29CA047296, R01CA047296, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA47296, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boyd MT, 2000, J BIOL CHEM, V275, P31883, DOI 10.1074/jbc.M004252200; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; Evans SC, 2001, ONCOGENE, V20, P4041, DOI 10.1038/sj.onc.1204533; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Jones SN, 1998, P NATL ACAD SCI USA, V95, P15608, DOI 10.1073/pnas.95.26.15608; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kucera GT, 1996, DEV BIOL, V173, P162, DOI 10.1006/dbio.1996.0014; LEACH FS, 1993, CANCER RES, V53, P2231; LUNA RMD, 1995, NATURE, V378, P203; Lundgren K, 1997, GENE DEV, V11, P714, DOI 10.1101/gad.11.6.714; MAO L, 1995, CANCER RES, V55, P2995; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; MCCANN AH, 1995, BRIT J CANCER, V71, P981, DOI 10.1038/bjc.1995.189; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 1997, J CELL BIOCHEM, V64, P343; NAKAYAMA T, 1995, INT J CANCER, V64, P342, DOI 10.1002/ijc.2910640511; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; Reinke V, 1999, CELL GROWTH DIFFER, V10, P147; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; STONE S, 1995, CANCER RES, V55, P2988; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	36	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 16	2002	21	22					3525	3531		10.1038/sj.onc.1205441	http://dx.doi.org/10.1038/sj.onc.1205441			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	555KR	12032854				2022-12-17	WOS:000175793700003
J	Chikatsu, N; Nakamura, Y; Sato, H; Fujita, T; Asano, S; Motokura, T				Chikatsu, N; Nakamura, Y; Sato, H; Fujita, T; Asano, S; Motokura, T			p53 mutations and tetraploids under r- and K-selection	ONCOGENE			English	Article						p53; r-selection; K-selection; multistep tumorigenesis	ACTIVATED RAS ONCOGENE; EMBRYO FIBROBLASTS; NEOPLASTIC TRANSFORMATION; MAMMALIAN-CELLS; GENE-EXPRESSION; MUTATED P53; DNA; CARCINOGENESIS; OVEREXPRESSION; TRANSCRIPTION	Cotransfection of rat embryo fibroblasts with c-myc and activated H-ras oncogenes is one experimental model of the multistep oncogenesis associated with p53 mutations and aneuploidy. Using the model, we found that selection processes, e.g., r- and K-selection, affect emergence of p53 mutants and tetraploids. Culture optimum for logarithmic growth (r-selection) selected p53 mutants as they proliferated rapidly, while in confluent culture (K-selection) tetraploids emerged regardless of the p53 status. Transfection of the mutated p53 gene with dominant negative functions eradicated untransfected cells under both r- and K-selection. However, these p53 mutants can be eradicated under K-selection by cells with normal p53 function and that had been selected under prolonged K-selection. The presence of competitors and the type of selection should determine whether or not p53 mutants and/or tetraploids predominate. These observations strengthen the importance of selection processes in case of cancer.	Univ Tokyo, Fac Med, Dept Internal Med, Bunkyo Ku, Tokyo 1128688, Japan; Univ Tokyo, Inst Med Sci, Adv Clin Res Ctr, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; University of Tokyo	Motokura, T (corresponding author), Univ Tokyo, Fac Med, Dept Internal Med, Bunkyo Ku, 3-28-6 Mejirodai, Tokyo 1128688, Japan.	motokura-tky@umin.ac.jp	Motokura, Toru/X-3682-2019					Backman V, 2000, NATURE, V406, P35, DOI 10.1038/35017638; CAVALIERSMITH T, 1980, BIOSYSTEMS, V12, P43, DOI 10.1016/0303-2647(80)90037-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CROW J F, 1970, P591, DOI 10.1093/bioinformatics/btr330; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; Galipeau PC, 1996, P NATL ACAD SCI USA, V93, P7081, DOI 10.1073/pnas.93.14.7081; Galitski T, 1999, SCIENCE, V285, P251, DOI 10.1126/science.285.5425.251; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; HALAZONETIS TD, 1991, P NATL ACAD SCI USA, V88, P6162, DOI 10.1073/pnas.88.14.6162; HARVEY M, 1993, ONCOGENE, V8, P2457; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; MAC ARTHUR ROBERT H., 1967; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; Motokura T, 1995, J BIOL CHEM, V270, P30857, DOI 10.1074/jbc.270.52.30857; PIANKA ER, 1970, AM NAT, V104, P592, DOI 10.1086/282697; RAMEL S, 1995, PANCREAS, V11, P213, DOI 10.1097/00006676-199510000-00001; SUGANO K, 1993, LAB INVEST, V68, P361; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687; Uchimaru K, 1996, JPN J CANCER RES, V87, P459, DOI 10.1111/j.1349-7006.1996.tb00246.x; Uchimaru K, 1997, BLOOD, V89, P965, DOI 10.1182/blood.V89.3.965; Uchimaru K, 1998, LEUKEMIA RES, V22, P413, DOI 10.1016/S0145-2126(98)00004-6; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Williams AC, 1999, ONCOGENE, V18, P3199, DOI 10.1038/sj.onc.1202660; Yin XY, 1999, ONCOGENE, V18, P1177, DOI 10.1038/sj.onc.1202410; ZHANG K, 1990, P NATL ACAD SCI USA, V87, P6281, DOI 10.1073/pnas.87.16.6281; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	28	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2002	21	19					3043	3049		10.1038/sj.onc.1205413	http://dx.doi.org/10.1038/sj.onc.1205413			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	546FM	12082535				2022-12-17	WOS:000175262700012
J	Thompson, TA; Haag, JD; Lindstrom, MJ; Griep, AE; Lohse, JK; Gould, MN				Thompson, TA; Haag, JD; Lindstrom, MJ; Griep, AE; Lohse, JK; Gould, MN			Decreased susceptibility to NMU-induced mammary carcinogenesis in transgenic rats carrying multiple copies of a rat ras gene driven by the rat Harvey ras promoter	ONCOGENE			English	Article						mammary carcinogenesis; transgenic rats; ras genes; N-methyl-N-nitrosourea	MOLECULAR-WEIGHT; EXPRESSION; METHYLUREA; PROTEIN; P21; ACTIVATION; PROGNOSIS; APOPTOSIS; MUTATION; RECEPTOR	Ras protein over-expression has been observed in human breast cancers although the significance of Ras overexpression in the etiology of breast cancer is unknown and its contribution to breast cancer prognosis is still debated. In this study, the over-expression of both wildtype Harvey and Kirsten Ras proteins as contributors to rat mammary carcinogenesis were examined using a transgenic rat model. Three rat transgenic lines (designated HrHr transgenics) carrying three to six copies of wild-type rat Harvey ras driven by the wildtype rat Harvey ras promoter were produced. In addition, transgenic lines carrying either three or seven copies of the Kirsten ras gene under the same promoter (HrKr) were produced. No pathological changes in the mammary gland were observed in any of the HrHr or HrKr transgenic rat line heterozygote. Two of the Ras transgenic lines, HrHr (R8) and HrKr (4334), had a significant reduction in NMU-induced rat mammary cancer when compared to their non-transgenic litter-mates. All five Ras transgenic lines developed fewer carcinomas than their non-transgenic littermates following NMU exposure. The percentage of NMU-induced G35 to A35 activating mutations in the endogenous Harvey ras gene in mammary carcinomas from the HrHr, HrKr transgenic rats and their non-transgenic littermates was similar ( similar to50%). In contrast, less than 1% of the NMU-induced carcinomas in these Ras transgenic rats had an activating ras mutation in their transgenes. These findings highlight the potential of Ras to function as a modifier gene in repressing mammary carcinogenesis.	Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Environm Toxicol, Madison, WI 53706 USA; Univ Wisconsin, Ctr Biotechnol, Madison, WI 53706 USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gould, MN (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, Dept Oncol, 1400 Univ Ave, Madison, WI 53706 USA.	gould@oncology.wisc.edu	Griep, Anne/ABA-9636-2020; Gould, Michael N/C-7414-2014		NCI NIH HHS [CA77527] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077527] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARIAZI EA, 1995, CARCINOGENESIS, V16, P965, DOI 10.1093/carcin/16.4.965; Asamoto M, 2000, CARCINOGENESIS, V21, P243, DOI 10.1093/carcin/21.2.243; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BENITO M, 1991, SCIENCE, V253, P565, DOI 10.1126/science.1857988; CHA RS, 1994, P NATL ACAD SCI USA, V91, P3749, DOI 10.1073/pnas.91.9.3749; CHAKRABORTY AK, 1991, P NATL ACAD SCI USA, V88, P2217, DOI 10.1073/pnas.88.6.2217; CLAIR T, 1987, CANCER RES, V47, P5290; CLARK GJ, 1995, BREAST CANCER RES TR, V35, P133, DOI 10.1007/BF00694753; COHEN JB, 1988, NATURE, V334, P119, DOI 10.1038/334119a0; FINNEY RE, 1993, SCIENCE, V260, P1524, DOI 10.1126/science.8502998; Gohring UJ, 1999, TUMOR BIOL, V20, P173, DOI 10.1159/000030061; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HAND PH, 1984, P NATL ACAD SCI-BIOL, V81, P5227, DOI 10.1073/pnas.81.16.5227; Jin ZA, 1996, CANCER RES, V56, P4927; KUMAR R, 1989, ONCOGENE RES, V4, P235; LUNDY J, 1986, J CLIN ONCOL, V4, P1321, DOI 10.1200/JCO.1986.4.9.1321; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Nathanson KN, 2001, NAT MED, V7, P552, DOI 10.1038/87876; OHUCHI N, 1986, CANCER RES, V46, P2511; QUERZOLI P, 1988, BREAST CANCER RES TR, V12, P23, DOI 10.1007/BF01805736; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; Schondorf T, 1999, ONCOL REP, V6, P1029; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shackney SE, 1998, CLIN CANCER RES, V4, P913; SPANDIDOS A, 1988, BRIT J CANCER, V58, P67; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; Thompson TA, 1998, CANCER RES, V58, P5097; Tsuda H, 2001, MUTAT RES-FUND MOL M, V477, P173, DOI 10.1016/S0027-5107(01)00118-X; WATSON DMA, 1991, BREAST CANCER RES TR, V17, P161, DOI 10.1007/BF01806365; Zhang ZQ, 2001, NAT GENET, V29, P25, DOI 10.1038/ng721	30	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 25	2002	21	18					2797	2804		10.1038/sj.onc.1205391	http://dx.doi.org/10.1038/sj.onc.1205391			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	542UY	11973638				2022-12-17	WOS:000175063700003
J	Mancini, A; Koch, A; Wilms, R; Tamura, T				Mancini, A; Koch, A; Wilms, R; Tamura, T			The SH2-containing inositol 5-phosphatase (SHIP)-1 is implicated in the control of cell-cell junction and induces dissociation and dispersion of MDCK cells	ONCOGENE			English	Article						SHIP-1; cell-cell-junctions; cell dispersion; c-Met tyrosine kinase; actin rearrangement	HEPATOCYTE GROWTH-FACTOR; MULTIFUNCTIONAL DOCKING SITE; SCATTER FACTOR; FACTOR-RECEPTOR; C-MET; IDENTIFICATION; PHOSPHATASE; 3-KINASE; SHIP; INDUCTION	Hepatocyte growth factor (HGF) induces the breakdown of cell junction and the dispersion of colonies of epithelial cells, providing a model system for the investigation of the molecular mechanisms of one of the important aspects of tumorogenesis. We have previously reported that the SH2-domain-containing inositol 5' phosphatase (SHIP)-1 binds to c-Met, and potentiated HGF-mediated branching tubulogenesis. In this study, we describe the establishment of MDCK cell lines which express MycHis-tagged SHIP-1 at different levels. Expression of SHIP-1 in MDCK cells at a high level resulted in cell morphology characteristic of an epithelial-mesenchymal like transition; cells lost cortical actin, developed actin stress fibers and gained spontaneous motility without treatment of HGF. When the level of MycHis-tagged SHIP-expression was relatively low, transfectants partially lost cortical actin and phalloidin stained puncta appeared at cell-cell junctions even in the absence of HGF. The treatment of MAP kinase inhibitor, PD98059, did not influence SHIP-1 mediated alteration of adherens-junction of MDCK cells, while, phosphatidylinositol 3 (PI 3)-kinase inhibitor, LY294002, drastically reduced SHIP-1 mediated phenotype. Furthermore, expression of a mutant SHIP-l lacking catalytic activity in MDCK cells did not alter the cortical actin distribution and HGF-mediated MAP and Akt kinase-phosphorylation, but suppressed HGF induced cell dispersion, suggesting that phosphatase activity is important for cytoskeleton rearrangement and cell dispersion.	Med Hochschule Hannover, Inst Biochem, D-30623 Hannover, Germany	Hannover Medical School	Tamura, T (corresponding author), Med Hochschule Hannover, Inst Biochem, OE 4310,Carl Neuberg Str 1, D-30623 Hannover, Germany.	Tamura.Teruko@MH-Hannover.de						Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Erneux C, 1998, BBA-MOL CELL BIOL L, V1436, P185, DOI 10.1016/S0005-2760(98)00132-5; Giuriato S, 1997, J BIOL CHEM, V272, P26857, DOI 10.1074/jbc.272.43.26857; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Hartwig JH, 1996, J BIOL CHEM, V271, P32986, DOI 10.1074/jbc.271.51.32986; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Khoury H, 2001, ONCOGENE, V20, P788, DOI 10.1038/sj.onc.1204166; Kong DH, 1997, NAT GENET, V17, P143, DOI 10.1038/ng1097-143; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Ma AD, 1998, MOL CELL BIOL, V18, P4744, DOI 10.1128/MCB.18.8.4744; Mancini A, 1997, ONCOGENE, V15, P1565, DOI 10.1038/sj.onc.1201518; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PELICCI G, 1995, ONCOGENE, V10, P1631; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Rohrschneider LR, 2000, GENE DEV, V14, P505; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; Sakisaka T, 1997, MOL CELL BIOL, V17, P3841, DOI 10.1128/MCB.17.7.3841; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stefan M, 2001, J BIOL CHEM, V276, P3017, DOI 10.1074/jbc.M009333200; STOKER M, 1985, J CELL SCI, V77, P209; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Vollenweider P, 1999, MOL CELL BIOL, V19, P1081; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0	30	11	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 28	2002	21	10					1477	1484		10.1038/sj.onc.1205224	http://dx.doi.org/10.1038/sj.onc.1205224			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	523MA	11896575				2022-12-17	WOS:000173956800002
J	Bacon, AL; Farrington, SM; Dunlop, MG				Bacon, AL; Farrington, SM; Dunlop, MG			Mutation frequency in coding and non-coding repeat sequences in mismatch repair deficient cells derived from normal human tissue	ONCOGENE			English	Article						TGFBR2; mutation rate; BAX; mismatch repair; colon cancer	GROWTH-FACTOR-BETA; II RECEPTOR GENE; MICROSATELLITE INSTABILITY; FRAMESHIFT MUTATIONS; INACTIVATION; PROTEIN; BAX; HEREDITARY; EXPRESSION; CANCERS	Repetitive tracts within the coding regions of TGFBR2 and BAX are frequently mutated in mismatch repair deficient tumours and are implicated in tumour progression. However, there has been little study of the balance between selection pressure and inherent instability at sequences within these genes. To determine whether TGFBR2 and BAX are inherently prone to mutations in the presence of MMR defects, we studied MMR deficient cells derived from B-lymphocytes. By analysing cells derived from normal tissue we aimed to minimize the effects of selection pressures that bias the apparent frequency of mutation. We definitively show that certain sequences, usually repaired by MMR, are inherently unstable. Using a small pool PCR technique we confirmed these cells exhibit microsatellite instability. Additionally, we demonstrate that MMR deficiency results in an excess of mutations, specifically at the poly(A)(10) tract compared to other regions of the TGFBR2 gene (P < 0.001). Conversely, an excess of mutations does not appear to arise at the poly(G)(8) tract of the BAX gene. These studies provide insight into the mechanism by which TGFBR2 and BAX genes become mutated during tumorigenesis. These findings invoke the notion of 'unmasking' specific hypermutable sequences in particular genes adding further complexity to the concept of the imitator phenotype.	Western Gen Hosp, Colon Canc Genet Grp, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland; Univ Edinburgh, Dept Oncol, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh; University of Edinburgh	Dunlop, MG (corresponding author), Western Gen Hosp, Colon Canc Genet Grp, MRC, Human Genet Unit, Crewe Rd, Edinburgh EH4 2XU, Midlothian, Scotland.	Malcolm.Dunlop@hgu.mrc.ac.uk	Dunlop, Malcolm G/F-1973-2011; Farrington, Susan M/C-7319-2013; Farrington, Susan M/Q-2710-2019	Dunlop, Malcolm G/0000-0002-3033-5851; Farrington, Susan M/0000-0001-5955-7389				AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Abdel-Rahman WM, 1999, ONCOGENE, V18, P2139, DOI 10.1038/sj.onc.1202589; Bacon AL, 2000, HUM MOL GENET, V9, P2707, DOI 10.1093/hmg/9.18.2707; BACON AL, 2001, IN PRESS NUCL ACIDS; Boland CR, 1998, CANCER RES, V58, P5248; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Carethers JM, 2000, IN VIVO, V14, P13; Dietmaier W, 1997, CANCER RES, V57, P4749; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Grady WM, 1998, CANCER RES, V58, P3101; Grady WM, 1999, CANCER RES, V59, P320; Inman GJ, 2000, J GEN VIROL, V81, P1567, DOI 10.1099/0022-1317-81-6-1567; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Lu SL, 1996, CANCER RES, V56, P4595; Lu SL, 1998, NAT GENET, V19, P17, DOI 10.1038/ng0598-17; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; Mironov N, 1999, CARCINOGENESIS, V20, P2189, DOI 10.1093/carcin/20.11.2189; Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635; Ouyang H, 1997, CANCER RES, V57, P1851; Papadopoulos N, 1997, HUM MUTAT, V10, P89, DOI 10.1002/(SICI)1098-1004(1997)10:2<89::AID-HUMU1>3.3.CO;2-K; PARSONS R, 1995, SCIENCE, V268, P738, DOI 10.1126/science.7632227; PARSONS R, 1995, CANCER RES, V55, P5548; Pedroni M, 2001, CANCER RES, V61, P896; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; SHIBATA D, 1994, NAT GENET, V6, P273, DOI 10.1038/ng0394-273; Takenoshita S, 1997, ONCOGENE, V14, P1255, DOI 10.1038/sj.onc.1200938; Vilkki S, 2001, CANCER RES, V61, P4541; WANG CY, 1995, CANCER RES, V55, P5101; Wheeler JMD, 1999, P NATL ACAD SCI USA, V96, P10296, DOI 10.1073/pnas.96.18.10296; Zhang L, 2001, CANCER RES, V61, P3801	30	11	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 8	2001	20	51					7464	7471		10.1038/sj.onc.1204973	http://dx.doi.org/10.1038/sj.onc.1204973			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	489DN	11709717				2022-12-17	WOS:000171976900002
J	Itoh, T; Nichols, A; Linn, S				Itoh, T; Nichols, A; Linn, S			Abnormal regulation of DDB2 gene expression in xeroderma pigmentosum group E strains	ONCOGENE			English	Article						DDB2; xeroderma pigmentosum; damage-specific DNA binding protein unscheduled DNA synthesis; p48; skin carcinogenesis	DNA-BINDING PROTEIN; COMPLEMENTATION GROUP-E; GLOBAL GENOMIC REPAIR; ATAXIA-TELANGIECTASIA; DAMAGED DNA; EXCISION-REPAIR; UV-IRRADIATION; CELLS; P48; PHENOTYPE	A damage-specific DNA binding protein (DDB) activity is absent from a subset (DDB-) of cells from individuals initially classified as group E of xeroderma pigmentosum (XP), a hereditary, photosensitive disease with a high incidence of skin malignancies. In these cases, mutations have been identified in the DDB2 gene (DDB2(-)) that codes for the small subunit, p48, of the DDB heterodimer. In four DDB2(-) strains, neither p48 nor DDB activity were observed before or after UV-irradiation, despite an unusually strong up-regulation of DDB2 mRNA levels after UV-irradiation. In a fifth strain, XP82TO, p48 was detectable and both DDB2 mRNA and p48 levels were more up-regulated after UV-irradiation than in normal primary cells. Moreover, DDB activity also became apparent after irradiation. XP82TO showed very mild clinical manifestations compared with the other DDB- patients. These results, coupled with our findings that most, if not all DDB+ cells classified as XP-E were misclassified, suggests a direct correlation between DDB2 levels and the XP-E phenotype.	Univ Calif Berkeley, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Itoh, T (corresponding author), Univ Calif Berkeley, Div Biochem & Mol Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059424] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30ES08196] Funding Source: Medline; NIGMS NIH HHS [GM59424] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOOTSMA D, 1970, MUTAT RES, V9, P507, DOI 10.1016/0027-5107(70)90035-7; Borson ND, 1998, BIOTECHNIQUES, V25, P130, DOI 10.2144/98251rr01; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Cleaver J.E., 1995, METABOLIC MOL BASIS, P4393; de Weerd-Kastelein E A, 1974, Mutat Res, V22, P87, DOI 10.1016/0165-1218(74)90056-1; DUALAN R, 1995, GENOMICS, V29, P62, DOI 10.1006/geno.1995.1215; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P283; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; Gilad S, 1998, AM J HUM GENET, V62, P551, DOI 10.1086/301755; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Itoh T, 1996, J INVEST DERMATOL, V107, P349, DOI 10.1111/1523-1747.ep12363303; Itoh T, 1999, J INVEST DERMATOL, V113, P251, DOI 10.1046/j.1523-1747.1999.00652.x; ITOH T, 1994, MUTAT RES, V314, P233, DOI 10.1016/0921-8777(94)90068-X; Itoh T, 2000, J INVEST DERMATOL, V114, P1022, DOI 10.1046/j.1523-1747.2000.00952.x; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; KATAOKA H, 1991, BIOCHEM BIOPH RES CO, V175, P1139, DOI 10.1016/0006-291X(91)91684-5; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; KEENEY S, 1993, J BIOL CHEM, V268, P21293; KEENEY S, 1992, MUTAT RES, V273, P49, DOI 10.1016/0921-8777(92)90049-9; KLEIJER WJ, 1973, MUTAT RES, V20, P417, DOI 10.1016/0027-5107(73)90062-6; KONDO S, 1988, J INVEST DERMATOL, V90, P152, DOI 10.1111/1523-1747.ep12462130; Lakin ND, 1996, ONCOGENE, V13, P2707; Lavin MF, 1997, ANNU REV IMMUNOL, V15, P177, DOI 10.1146/annurev.immunol.15.1.177; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Liu W, 2000, J BIOL CHEM, V275, P21429, DOI 10.1074/jbc.M000961200; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; Nichols AF, 2000, J BIOL CHEM, V275, P21422, DOI 10.1074/jbc.M000960200; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; REARDON JT, 1993, J BIOL CHEM, V268, P21301; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Shiloh Y, 1997, ANNU REV GENET, V31, P635, DOI 10.1146/annurev.genet.31.1.635; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Tang JY, 2000, MOL CELL, V5, P737, DOI 10.1016/S1097-2765(00)80252-X; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037	37	11	11	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 25	2001	20	48					7041	7050		10.1038/sj.onc.1204909	http://dx.doi.org/10.1038/sj.onc.1204909			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	485DY	11704828				2022-12-17	WOS:000171739300007
J	Herbert, GB; Shi, B; Gartenhaus, RB				Herbert, GB; Shi, B; Gartenhaus, RB			Expression and stabilization of the MCT-1 protein by DNA damaging agents	ONCOGENE			English	Article						MCT-1 expression; stabilization; DNA damage	T-CELL MALIGNANCIES; WILD-TYPE P53; SUBCELLULAR-LOCALIZATION; CANDIDATE ONCOGENE; HTLV-I; GENE; LYMPHOMA; CYCLE; PHOSPHORYLATION; IDENTIFICATION	The contribution of oncogene amplification and/or overexpression to T-cell lymphoid neoplasms has only of late been established with the implication of the TCL1 and MTCP1 genes in T-cell malignancies. Our laboratory has recently discovered a novel oncogene, MCT-1, amplified in a T-cell lymphoma and mapped to chromosome Xq22-24. MCT-1 has been shown to decrease cell-doubling time, dramatically shortening the duration of G(1) transit time and/or G1-S transition, and transforms NIH3T3 fibroblasts. Constitutive expression of MCT-1 results in a strong proliferative signal and is associated with deregulation of protein kinase-mediated G1/S phase checkpoints. In this study we analysed the level and subcellular localization of this novel cell cycle regulatory molecule as a function of cell cycle phase. In human lymphoid tumors expression of MCT-1 is constant throughout the cell cycle and remains cytoplasmic. Cells overexpressing MCT-1 have increased expression of cyclin DI with dysregulation of the GI-S checkpoint. Both cyclin D1 and MCT-1 are involved in regulating passage of cells through the G1 phase of the cell cycle. Since prior work has shown that gamma irradiation induces cyclin DI expression we investigated the induction of MCT-1 to DNA damaging agents. We demonstrate that increases in MCT-1 protein in irradiated human lymphoid cells do not occur at the mRNA level and do not require new protein synthesis.	Northwestern Univ, Dept Med, Div Hematol Oncol, Sch Med, Chicago, IL 60611 USA; Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center	Gartenhaus, RB (corresponding author), Northwestern Univ, Dept Med, Div Hematol Oncol, Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.			Shi, Bo/0000-0002-0780-0372				ALTSCHUL SF, 1990, P NATL ACAD SCI USA, V87, P5509, DOI 10.1073/pnas.87.14.5509; Andersen G, 1997, EMBO J, V16, P958, DOI 10.1093/emboj/16.5.958; Aravind L, 1999, J MOL EVOL, V48, P291, DOI 10.1007/PL00006472; BENYEHUDA D, 1994, BRIT J HAEMATOL, V86, P792, DOI 10.1111/j.1365-2141.1994.tb04831.x; BERNEMAN ZN, 1992, P NATL ACAD SCI USA, V89, P3005, DOI 10.1073/pnas.89.7.3005; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; CHUANG LT, 1994, CANCER RES, V54, P1286; Dierov J, 1999, J CELL BIOCHEM, V74, P544, DOI 10.1002/(SICI)1097-4644(19990915)74:4<544::AID-JCB4>3.3.CO;2-W; EPPERLY M, 1995, RADIAT RES, V143, P245, DOI 10.2307/3579210; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Lam MHC, 1997, J CELL PHYSIOL, V173, P433, DOI 10.1002/(SICI)1097-4652(199712)173:3<433::AID-JCP16>3.0.CO;2-C; Monni O, 1996, BLOOD, V87, P5269, DOI 10.1182/blood.V87.12.5269.bloodjournal87125269; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; Pekarsky Y, 1999, P NATL ACAD SCI USA, V96, P2949, DOI 10.1073/pnas.96.6.2949; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Poommipanit PB, 1999, J BIOL CHEM, V274, P1033, DOI 10.1074/jbc.274.2.1033; Prosniak M, 1998, CANCER RES, V58, P4233; REID RL, 1993, ONCOGENE, V8, P3029; SANDBERG AA, 1994, J UROLOGY, V151, P545, DOI 10.1016/S0022-5347(17)35014-0; Scarpa A, 1999, GENE CHROMOSOME CANC, V26, P203, DOI 10.1002/(SICI)1098-2264(199911)26:3<203::AID-GCC3>3.0.CO;2-E; Sheikh MS, 1999, J BIOL CHEM, V274, P16487, DOI 10.1074/jbc.274.23.16487; STERN MH, 1993, ONCOGENE, V8, P2475; Sugimoto J, 1999, CANCER RES, V59, P2313; VIRGILIO L, 1994, P NATL ACAD SCI USA, V91, P12530, DOI 10.1073/pnas.91.26.12530; Werner CA, 1997, AM J PATHOL, V151, P335; Ye Y, 1998, INT J CANCER, V78, P62, DOI 10.1002/(SICI)1097-0215(19980925)78:1<62::AID-IJC11>3.0.CO;2-7	26	11	12	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 11	2001	20	46					6777	6783		10.1038/sj.onc.1204881	http://dx.doi.org/10.1038/sj.onc.1204881			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	482AA	11709712				2022-12-17	WOS:000171551600014
J	Lee, GH; Matsushita, H; Kitagawa, T				Lee, GH; Matsushita, H; Kitagawa, T			Fine chromosomal localization of the mouse Par2 gene that confers resistance against urethane-induction of pulmonary adenomas	ONCOGENE			English	Article						mouse; lung tumor; resistance gene; fine mapping; chromosome	LUNG CARCINOGENESIS; BALB/CBYJ MICE; SUSCEPTIBILITY; LINKAGE; LOCUS; IDENTIFICATION; TRAITS; MAPS; A/J	BALB/cByJ mice are 14 times more resistant to urethane-induction of pulmonary adenomas than the susceptible Al J strain. Our previous linkage analysis of (A/J x BALB/ cByJ)F-1 x A/J backcross mice provided statistical evidence that a major resistance locus of BALB/cByJ with a dominant effect, designated Par2 (Pulmonary adenoma resistance 2), exists within an approximately 25 cM section of distal chromosome 18, To facilitate molecular identification of the Par 2 locus, the present study was conducted to finely localize its chromosomal position utilizing Par a-congenic mice. Male BALB/cByJ mice were mated with female C57BL/6J mice carrying recessive Par a alleles and their male F1 progeny were backcrossed to female BALB/cByJ mice. A male backcross mouse heterozygous within the Par 2 interval of 25 cM was randomly selected and again backcrossed to female BALB/cByJ mice. This backcross-selection cycle was simply repeated to produce semi-congenic mice with a general BALB/cByJ genetic background except for the Par 2 interval, where the mice were heterozygous with paternal C57BL/6J alleles and maternal BALB/cByJ alleles, After the 6th or 7th backcross, nine male mice possessing a recombination within the paternal Par 2 interval were retained and crossed to female A/J mice. Resultant progeny were treated with urethane and examined for lung tumor development in order to deduce the Pm 2 genotypes of the recombinants through linkage analysis. By comparing the deduced Par 2 genotype of each recombinant with its recombinational breakpoint, the Par2 locus was confined to an approximately 0.5 cM region flanked by D18Mit103 and D18Mit188 loci. Our results indicate that fully congenic mice conventionally established by at least nine simple backcrosses or by the speed congenic method are not necessarily required for fine mapping of quantitative trait loci, In the case of the Par 2 locus, we found that semi-congenic mice after as few as four simple backcrosses were useful for this purpose, The map information obtained in this study should enable subsequent positional cloning of the Par 2 gene.	Toranomon Gen Hosp, Dept Pathol, Tokyo 1058470, Japan; Okinaka Mem Inst Med Res, Tokyo 1058470, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Pathol, Tokyo 1708455, Japan	Toranomon Hospital; Japanese Foundation for Cancer Research	Lee, GH (corresponding author), Toranomon Gen Hosp, Dept Pathol, Tokyo 1058470, Japan.							DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; DIETRICH WF, 1994, NAT GENET, V7, P220, DOI 10.1038/ng0694supp-220; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; Festing MFW, 1998, GENOMICS, V53, P129, DOI 10.1006/geno.1998.5450; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; HOSPITAL F, 1992, GENETICS, V132, P1199; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; JUSTICE MJ, 1992, GENOMICS, V13, P1281, DOI 10.1016/0888-7543(92)90047-V; Karasaki H, 1997, ONCOGENE, V15, P1833, DOI 10.1038/sj.onc.1201357; LANDE R, 1990, GENETICS, V124, P743; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANDER ES, 1989, GENETICS, V121, P185; LEE GH, 1987, HEPATOLOGY, V7, P937, DOI 10.1002/hep.1840070524; LEE GH, 1995, GENETICS, V139, P387; MALKINSON AM, 1985, J NATL CANCER I, V75, P971, DOI 10.1093/jnci/75.5.971; MALKINSON AM, 1983, J NATL CANCER I, V70, P931; Manenti G, 1999, GENOME RES, V9, P639; Manenti G, 1997, CANCER RES, V57, P4164; MOEN CJA, 1992, ONCOGENE, V7, P563; Obata M, 1996, ONCOGENE, V13, P1599; PERAINO C, 1973, JNCI-J NATL CANCER I, V51, P1349, DOI 10.1093/jnci/51.4.1349; WANG M, 2000, P AM ASSOC CANC RES, V41, P279; Zhang ZQ, 2000, EXP LUNG RES, V26, P627, DOI 10.1080/01902140150216710	23	11	11	0	0	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 5	2001	20	30					3979	3985		10.1038/sj.onc.1204562	http://dx.doi.org/10.1038/sj.onc.1204562			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	449JM	11494126				2022-12-17	WOS:000169681500006
J	Ebina, M; Martinez, A; Birrer, MJ; Linnoila, RI				Ebina, M; Martinez, A; Birrer, MJ; Linnoila, RI			In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers	ONCOGENE			English	Article						p53; lung cancer; immunohistochemistry; in situ PCR; in situ RT-PCR	TRANSFORMED-CELLS; MUTATIONS; RAS; ABNORMALITIES; ANTIGEN	Many solid tumors, including non-small cell lung cancers (NSCLCs), are characterized by heterogenous expression of p53 protein in the neoplastic cells. To analyse the molecular implications of this finding, we examined topographic distribution of p53 mutations using in situ polymerase chain reaction (PCR) in primary NSCLCs, showing distinct patterns of variable p53 overexpression by immunohistochemistry, Unique sets of primers for each mutation were designed, and optimal PCR conditions were determined by standard PCR using DNA from cloned mutants or cell lines established from these tumors. Ail tumor cell nuclei, regardless of the status of p53 overexpression, demonstrated homogeneous distribution of mutant p53 with specific primers, indicating that only subgroups of the mutated cells overexpressed p53 protein. In situ reverse transcription (RT)-PCR was applied to detect mutant mRNA in the individual tumor cells using specific primers. We found that in each case the distribution of mutant p53 mRNA coincided with that of immunohistochemical overexpression of p53 protein. Our results suggest that the regulation of mutant p53 expression, but not the genotype, is heterogeneous in the neoplastic cells, The topographic genomapping of p53 in NSCLC using in situ PCR provides a novel approach to view molecular mechanisms of lung carcinogenesis.	Tohoku Univ, Inst Dev Aging & Canc, Div Canc Control, Sendai, Miyagi 9808575, Japan; NCI, Dept Cell & Canc Biol, Med Branch, NIH, Bethesda, MD 20892 USA	Tohoku University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Ebina, M (corresponding author), Tohoku Univ, Inst Dev Aging & Canc, Div Canc Control, Sendai, Miyagi 9808575, Japan.		Martinez, Alfredo/GQH-5998-2022	Martinez, Alfredo/0000-0003-4882-4044				BODNER SM, 1992, ONCOGENE, V7, P743; BRAMBILLA E, 1993, AM J PATHOL, V143, P199; Cha R S, 1992, PCR Methods Appl, V2, P14; EBINA M, 1994, CANCER RES, V54, P2496; GREENBLATT MS, 1994, CANCER RES, V54, P4855; Hall KL, 1997, GYNECOL ONCOL, V65, P330, DOI 10.1006/gyno.1997.4653; HASSE AT, 1990, P NATL ACAD SCI USA, V87, P4971; HORIO Y, 1993, CANCER RES, V53, P1; Kanazawa H, 2000, AM J PATHOL, V156, P1289, DOI 10.1016/S0002-9440(10)64999-1; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; MARTINEZ A, 1995, J HISTOCHEM CYTOCHEM, V43, P739, DOI 10.1177/43.8.7542678; MITSUDOMI T, 1992, ONCOGENE, V7, P171; Nuovo GJ, 1999, P NATL ACAD SCI USA, V96, P12754, DOI 10.1073/pnas.96.22.12754; NUOVO GJ, 1994, PCR IN SITU HYBRIDIZ, P169; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; Park IW, 1999, J NATL CANCER I, V91, P1863, DOI 10.1093/jnci/91.21.1863; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; REIHSAUS E, 1990, ONCOGENE, V5, P137; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Shaw GL, 1996, J CELL BIOCHEM, P173; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494	21	11	13	1	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 3	2001	20	20					2579	2586		10.1038/sj.onc.1204351	http://dx.doi.org/10.1038/sj.onc.1204351			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	431VM	11420668				2022-12-17	WOS:000168652500009
J	Howard, JC; Li, Q; Chu, W; Zochodne, B; Kapoor, M; Ung, Y; Rosen, K; Ben-David, Y				Howard, JC; Li, Q; Chu, W; Zochodne, B; Kapoor, M; Ung, Y; Rosen, K; Ben-David, Y			Bcl-2 expression in F-MuLV-induced erythroleukemias: a role for the anti-apoptotic action of Bcl-2 during tumor progression	ONCOGENE			English	Article						Friend erythroleukemia; Bcl-2; p53; tumor progression	VIRUS-INDUCED ERYTHROLEUKEMIA; CELLULAR P53 GENE; CHROMOSOMAL BREAKPOINT; TOPOISOMERASE-II; IN-VITRO; C-MYC; X-L; CELLS; GROWTH; ERYTHROPOIETIN	Erythroleukemias induced by various strains of Friend virus are multistage malignancies that result from the accumulation of genetic mutations, including the activation of proto-oncogenes and the inactivation of tumor suppressor genes. in this study, we demonstrate that Bcl-2 expression is activated in the majority of F-MuLV-induced erythroleukemia cell lines. In contrast, Bcl-2 was not expressed in any of the FV-P-induced erythroleukemia cell lines and protein levels were low or negligible in FV-A-induced erythroleukemia cell lines examined. In vivo, Bcl-2 expression levels gradually increased in F-MuLV-induced erythroleukemic cells prior to adaptation to culture. High expression of Bcl-2 in F-MuLV-induced erythroleukemic cells was shown to proceed the emergence of p53 mutation suggesting that Bcl-2 expression may delay p53 mutation in the leukemic cells, This is further supported by the demonstration that the majority of F-MuLV-induced erythroleukemia cell lines established from primary tumors induced in p53 mutant mice express low to negligible levels of Bcl-2, We have shown that the high levels of Bcl-2 expression in FV-P-induced erythroleukemic cells inhibited apoptosis induced by etoposide, low serum and p53 expression. Similarly, ectopic Bcl-2 expression within these cells also provided protection from apoptosis induced by etoposide and growth in low serum. These results suggest that the anti-apoptotic action of Bcl-2 may confer a selective in vivo and in vitro growth advantage to F-MuLV-induced erythroleukemic cells, which is not shared by FV-P/ FV-A-induced erythroleukemic cells. The observed induction of Bcl-2 expression in vivo constitutes a novel but late oncogenic event associated with the progression of F-MuLV-induced erythroleukemias.	Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Canc Biol, Toronto, ON M4N 3M5, Canada; Toronto Sunnybrook Reg Canc Ctr, Toronto, ON M4N 3M5, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Ben-David, Y (corresponding author), Univ Toronto, Sunnybrook & Womens Coll, Hlth Sci Ctr, Dept Med Biophys,Div Canc Biol, 2075 Bayview Ave,Room S216, Toronto, ON M4N 3M5, Canada.			Rosen, Kirill/0000-0002-4317-9907				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BELARDELLI F, 1995, APMIS, V103, P161, DOI 10.1111/j.1699-0463.1995.tb01092.x; BEN-DAVID Y, 1990, New Biologist, V2, P1015; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BENDAVID Y, 1991, CELL, V66, P831, DOI 10.1016/0092-8674(91)90428-2; BENDAVID Y, 1990, P NATL ACAD SCI USA, V87, P1332, DOI 10.1073/pnas.87.4.1332; Benito A, 1996, BLOOD, V87, P3837, DOI 10.1182/blood.V87.9.3837.bloodjournal8793837; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; CHOW V, 1987, J VIROL, V61, P2777, DOI 10.1128/JVI.61.9.2777-2781.1987; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; DAVID YB, 1988, ONCOGENE, V3, P179; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DOLE M, 1994, CANCER RES, V54, P3253; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; FRIEND C, 1957, J EXP MED, V105, P307, DOI 10.1084/jem.105.4.307; GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; Gregoli PA, 1997, BLOOD, V90, P630, DOI 10.1182/blood.V90.2.630.630_630_640; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herzog CE, 1995, CLIN CANCER RES, V1, P1391; Howard J, 1996, CELL GROWTH DIFFER, V7, P1651; HOWARD JC, 1993, ONCOGENE, V8, P2721; Howard JC, 1996, ONCOGENE, V12, P1405; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; KABAT D, 1989, CURR TOP MICROBIOL, V148, P1; KAMESAKI S, 1993, CANCER RES, V53, P4251; Lacronique V, 1997, BLOOD, V90, P3050, DOI 10.1182/blood.V90.8.3050; LI JP, 1990, NATURE, V343, P762, DOI 10.1038/343762a0; LIN YP, 1995, MOL CELL BIOL, V15, P6045; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MAJNO G, 1995, AM J PATHOL, V146, P3; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MITCHELL T, 1993, J VIROL, V67, P3665, DOI 10.1128/JVI.67.6.3665-3670.1993; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; MOWAT M, 1985, NATURE, V314, P633, DOI 10.1038/314633a0; MUNROE DG, 1990, MOL CELL BIOL, V10, P3307, DOI 10.1128/MCB.10.7.3307; OLIFF A, 1981, BLOOD, V58, P244; Packham G, 1998, GENE DEV, V12, P2475, DOI 10.1101/gad.12.16.2475; Reed JC, 1995, TOXICOL LETT, V82-3, P155, DOI 10.1016/0378-4274(95)03551-6; RYAN JJ, 1994, P NATL ACAD SCI USA, V91, P5878, DOI 10.1073/pnas.91.13.5878; RYAN JJ, 1993, MOL CELL BIOL, V13, P711, DOI 10.1128/MCB.13.1.711; SCHWARZE MMK, 1995, CANCER RES, V55, P2262; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHIBUYA T, 1983, P NATL ACAD SCI-BIOL, V80, P3721, DOI 10.1073/pnas.80.12.3721; Silva M, 1996, BLOOD, V88, P1576, DOI 10.1182/blood.V88.5.1576.1576; SILVER J, 1986, J VIROL, V57, P526, DOI 10.1128/JVI.57.2.526-533.1986; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; TSUJIMOTO Y, 1984, SCIENCE, V226, P1097, DOI 10.1126/science.6093263; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wong KS, 1999, ONCOGENE, V18, P5525, DOI 10.1038/sj.onc.1202938; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	60	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 26	2001	20	18					2291	2300		10.1038/sj.onc.1204348	http://dx.doi.org/10.1038/sj.onc.1204348			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	427KZ	11402324				2022-12-17	WOS:000168404500011
J	Poetsch, M; Dittberner, T; Cowell, JK; Woenckhaus, C				Poetsch, M; Dittberner, T; Cowell, JK; Woenckhaus, C			TTC4, a novel candidate tumor suppressor gene at 1p31 is often mutated in malignant melanoma of the skin	ONCOGENE			English	Article						TTC4; malignant melanoma; sequencing analysis	TETRATRICOPEPTIDE REPEAT MOTIFS; HUMAN PROTEIN; CELL-LINES; PROGRESSION; IDENTIFICATION; CYTOGENETICS; EXPRESSION; HOMOLOG	A novel candidate tumor suppressor gene, TTC4, on chromosome 1p31 has been described recently. Since aberrations in this region have been detected in malignant melanoma, we investigated DNA of paraffin-embedded sections from 16 typical naevi, 19 atypical naevi, 32 primary melanomas (15 superficial spreading melanomas, 17 nodular melanomas) and 25 metastases and DNA from four melanoma cell lines by PCR and direct sequencing analysis for mutations in all exons of TTC4. Tumors comprised a wide range of thickness (Breslow index) and Clark levels. No mutations could be detected in typical or atypical naevi, but we found se, cn different point mutations in the tumor samples, sis of them causing an amino acid change. Ten melanoma samples belonging to nine patients showed one or more of these mutations. In detail, in sis of 25 metastases, in two of 17 nodular melanomas and in two of 15 superficial spreading melanomas point mutations could be detected, In two cell lines, a loss of a whole exon could be demonstrated and in one cell line we found a point mutation. In addition, three polymorphisms were found. Our findings indicate that TTC4 may participate in the pathogenesis of malignant melanomas of the skin.	Univ Greifswald, Inst Forens Med, D-17489 Greifswald, Germany; Univ Greifswald, Dept Dermatol, D-17489 Greifswald, Germany; Univ Greifswald, Inst Pathol, D-17489 Greifswald, Germany; Cleveland Clin Fdn, Ctr Mol Genet, Cleveland, OH USA	Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Ernst Moritz Arndt Universitat Greifswald; Cleveland Clinic Foundation	Poetsch, M (corresponding author), Univ Greifswald, Inst Forens Med, Kuhstr 30, D-17489 Greifswald, Germany.			Cowell, John/0000-0002-2079-5950				ALBINO AP, 1981, J EXP MED, V154, P1764, DOI 10.1084/jem.154.6.1764; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.3.CO;2-E; CHEN MX, 1994, EMBO J, V13, P4278, DOI 10.1002/j.1460-2075.1994.tb06748.x; DRACOPOLI NC, 1989, P NATL ACAD SCI USA, V86, P4614, DOI 10.1073/pnas.86.12.4614; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Heim S., 1995, CANC CYTOGENETICS CH, V2nd; HONORE B, 1992, J BIOL CHEM, V267, P8485; Isfort RJ, 1997, ONCOGENE, V15, P1797, DOI 10.1038/sj.onc.1201535; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; LAM E, 1995, GENE, V160, P297, DOI 10.1016/0378-1119(95)00216-S; Poetsch M, 1998, LAB INVEST, V78, P883; Poetsch M, 1999, VIRCHOWS ARCH, V435, P105, DOI 10.1007/s004280050406; POETSCH M, 2000, IN PRESS CANC GENET; SCHRICK JJ, 1995, HUM MOL GENET, V4, P559, DOI 10.1093/hmg/4.4.559; SIRACKY J, 1982, NEOPLASMA, V29, P661; Su GF, 1999, GENOMICS, V55, P157, DOI 10.1006/geno.1998.5633; Su GF, 2000, INT J MOL MED, V5, P197; THOMPSON FH, 1995, CANCER GENET CYTOGEN, V83, P93, DOI 10.1016/0165-4608(95)00057-V; WILTSHIRE RN, 1995, CANCER RES, V55, P3954; Zhang H, 1999, PROTEIN SCI, V8, P1658, DOI 10.1110/ps.8.8.1658	21	11	14	0	2	NATURE PUBLISHING GROUP	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 23	2000	19	50					5817	5820		10.1038/sj.onc.1203961	http://dx.doi.org/10.1038/sj.onc.1203961			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	376VP	11126369				2022-12-17	WOS:000165477700014
J	Ma, Y; Geerdes, DW; Vogt, PK				Ma, Y; Geerdes, DW; Vogt, PK			Oncogenic transformation by the FOX protein Qin requires DNA binding	ONCOGENE			English	Article						Qin; BF-1 oncogenic transformation; winged helix domain/forkhead box; DNA binding; transcriptional repression	TRANSCRIPTION FACTORS; CEREBRAL HEMISPHERES; FORK HEAD; EXPRESSION; FAMILY; BF-1; DOMAINS; RETINA; BRAIN	Some functions of the Qin oncoprotein are not dependent on DNA binding, In order to test the requirement for DNA binding in Qin-induced oncogenic transformation, site directed mutations were introduced in the winged helix (WH) DNA binding domain of the Qin protein, In cellular Qin (c-Qin), the glycine at position 233 was either deleted or substituted with the amino acids aspartic acid, alanine, glutamic acid, asparagine, proline or lysine, The same position carries aspartic acid in the viral Qin protein (v-Qin), The adjacent residues, threonine 232 and lysine 234, were separately mutated to proline, Several additional amino acid substitutions believed to be involved in DNA contacts were introduced at the following c-Qin positions: asparagine 189, histidine 193, serine 196 or arginine 236, Most of the substitutions reduced DNA binding of Qin, one mutation, H193A, completely abolished DNA binding, and another mutation, T232P, increased DNA binding affinity, Mutant H193A failed to transform chicken embryo fibroblasts (CEF), all other mutants, even those showing minimal DNA binding, retained oncogenicity for CEF, The efficiencies of focus formation induced by these mutant proteins in cell culture were not significantly different from that of wild type, However, the rate of focus development and the size of foci induced by the Qin mutants were greater with strong DNA binders than with weak DNA binders, Transdominant negative constructs consisting of the winged helix domain of c-Qin or v-Qin interfered with focus formation induced by full length Qin proteins, These results suggest that DNA binding is a prerequisite for transformation by Qin, and strong DNA binding is related to accelerated transformation in CEF.	Scripps Res Inst, Dept Mol & Expt Med, Div Oncovirol, La Jolla, CA 92037 USA	Scripps Research Institute	Vogt, PK (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Oncovirol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Vogt, Peter K./R-7547-2019	Vogt, Peter K./0000-0002-4519-7500	NCI NIH HHS [CA 79616, CA 42564] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079616, R35CA042564] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Chang HW, 1996, ONCOGENE, V13, P441; CHANG HW, 1995, P NATL ACAD SCI USA, V92, P447, DOI 10.1073/pnas.92.2.447; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Dou CL, 2000, MOL CELL BIOL, V20, P6201, DOI 10.1128/MCB.20.17.6201-6211.2000; Dou CL, 1999, CEREB CORTEX, V9, P543, DOI 10.1093/cercor/9.6.543; HATINI V, 1994, J NEUROBIOL, V25, P1293, DOI 10.1002/neu.480251010; Kaestner KH, 2000, GENE DEV, V14, P142; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Li J, 1997, P NATL ACAD SCI USA, V94, P10885, DOI 10.1073/pnas.94.20.10885; LI J, 1995, CANCER RES, V55, P5540; LI J, 1993, P NATL ACAD SCI USA, V90, P4490, DOI 10.1073/pnas.90.10.4490; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; XUAN SH, 1995, NEURON, V14, P1141, DOI 10.1016/0896-6273(95)90262-7; Yuasa J, 1996, NATURE, V382, P632, DOI 10.1038/382632a0	16	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 5	2000	19	42					4815	4821		10.1038/sj.onc.1203834	http://dx.doi.org/10.1038/sj.onc.1203834			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	362BB	11039897				2022-12-17	WOS:000089757800002
J	Kikyo, M; Matozaki, T; Kodama, A; Kawabe, H; Nakanishi, H; Takai, Y				Kikyo, M; Matozaki, T; Kodama, A; Kawabe, H; Nakanishi, H; Takai, Y			Cell-cell adhesion-mediated tyrosine phosphorylation of nectin-2 delta, an immunoglobulin-like cell adhesion molecule at adherens junctions	ONCOGENE			English	Article						cell-cell adhesion; cadherin; nectin; Src; tyrosine phosphorylation	POLIOVIRUS RECEPTOR GENE; CADHERIN-CATENIN COMPLEX; EPIDERMAL GROWTH-FACTOR; SIMPLEX VIRUS TYPE-1; SRC FAMILY KINASES; BETA-CATENIN; BINDING PROTEIN; COMPLEMENTARY-DNA; N-CADHERIN; PHOSPHATASE	We have recently found a novel functional unit of cell-cell adhesion at cadherin-based adherens junctions, consisting of at least nectin, an immunoglobulin-like cell adhesion molecule, and afadin, an actin filament-binding protein which connects nectin to the actin cytoskeleton. Among the members of the nectin family, we have found here that nectin-2 delta is tyrosine-phosphorylated in response to cell-cell adhesion. Expression of E-cadherin induced tyrosine phosphorylation of nectin-2 delta, while disruption of cell-cell adhesion by an anti-E-cadherin antibody reduced the tyrosine phosphorylation of nectin-2 delta. An inhibitor specific for Src family kinase or expression of Csk reduced tyrosine phosphorylation of nectin-2 delta. In addition, Src kinase tyrosine phosphorylates the recombinant cytoplasmic region of nectin-2 delta in vitro. The major tyrosine phosphorylation site of nectin-2 delta was Tyr(505) in the cytoplasmic region, because the mutant nectin-2 delta, of which Tyr(505) was replaced by Phe, showed a loss of tyrosine phosphorylation in vivo and in vitro. These results, together with our recent observations, indicate that the cadherin-catenin system and the nectin-afadin system are closely connected to each other. The cadherin-mediated cell-cell adhesion system may link to the activation of a Src family kinase, that is, at least in part, responsible for the tyrosine phosphorylation of the cytoplasmic region of nectin-2 delta.	Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan	Osaka University	Takai, Y (corresponding author), Osaka Univ, Grad Sch Med, Fac Med, Dept Biochem & Mol Biol, Suita, Osaka 5650871, Japan.		Kawabe, Hiroshi/U-7325-2018	Nakanishi, Hiroyuki/0000-0002-9765-0266; Kawabe, Hiroshi/0000-0001-5650-8696				Aoki J, 1997, EXP CELL RES, V235, P374, DOI 10.1006/excr.1997.3685; Balsamo J, 1996, J CELL BIOL, V134, P801, DOI 10.1083/jcb.134.3.801; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bouchard MJ, 2000, MOL CELL BIOL, V20, P2865, DOI 10.1128/MCB.20.8.2865-2873.2000; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; Cocchi F, 1998, J VIROL, V72, P9992, DOI 10.1128/JVI.72.12.9992-10002.1998; Cocchi F, 2000, J VIROL, V74, P3909, DOI 10.1128/JVI.74.8.3909-3917.2000; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; EBERLE F, 1995, GENE, V159, P267, DOI 10.1016/0378-1119(95)00180-E; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Geraghty RJ, 1998, SCIENCE, V280, P1618, DOI 10.1126/science.280.5369.1618; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Ikeda W, 1999, J CELL BIOL, V146, P1117, DOI 10.1083/jcb.146.5.1117; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; KARTENBECK J, 1991, J CELL BIOL, V113, P881, DOI 10.1083/jcb.113.4.881; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lampugnani MG, 1997, J CELL SCI, V110, P2065; Lopez M, 1998, BLOOD, V92, P4602, DOI 10.1182/blood.V92.12.4602.424k21_4602_4611; LOPEZ M, 1995, GENE, V155, P261, DOI 10.1016/0378-1119(94)00842-G; Mandai K, 1999, J CELL BIOL, V144, P1001, DOI 10.1083/jcb.144.5.1001; Mandai K, 1997, J CELL BIOL, V139, P517, DOI 10.1083/jcb.139.2.517; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; Miyahara M, 2000, J BIOL CHEM, V275, P613, DOI 10.1074/jbc.275.1.613; MORRISON ME, 1992, J VIROL, V66, P2807, DOI 10.1128/JVI.66.5.2807-2813.1992; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; Noguchi T, 1999, EMBO J, V18, P1748, DOI 10.1093/emboj/18.7.1748; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; OKADA M, 1991, J BIOL CHEM, V266, P24249; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Satoh-Horikawa K, 2000, J BIOL CHEM, V275, P10291, DOI 10.1074/jbc.275.14.10291; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; SHIBAMOTO S, 1994, CELL ADHES COMMUN, V1, P295, DOI 10.3109/15419069409097261; Takahashi K, 1999, J CELL BIOL, V145, P539, DOI 10.1083/jcb.145.3.539; TAKAISHI K, 1994, ONCOGENE, V9, P273; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; Warner MS, 1998, VIROLOGY, V246, P179, DOI 10.1006/viro.1998.9218; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	49	11	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 17	2000	19	35					4022	4028		10.1038/sj.onc.1203744	http://dx.doi.org/10.1038/sj.onc.1203744			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	345PX	10962558				2022-12-17	WOS:000088825300007
J	Yamane, K; Katayama, E; Sugasawa, K; Tsuruo, T				Yamane, K; Katayama, E; Sugasawa, K; Tsuruo, T			Retinoblastoma susceptibility protein, Rb, possesses multiple BRCT-Ws, BRCA1 carboxyl-terminus-related W regions with DNA break-binding activity	ONCOGENE			English	Article						Rb; BRCT; BRCA1; cell cycle checkpoint; DNA damage sensor	LARGE T-ANTIGEN; REPLICATION CHECKPOINT CONTROL; FISSION YEAST; GENE-PRODUCT; DAMAGE; REPAIR; DOMAIN; MICE; P53; APOPTOSIS	The BRCT region, the carboxyl-terminus of BRCA1 (the breast cancer susceptibility gene I product), is ubiquitous in several proteins that participate in cell cycle checkpoints and DNA repair. We have previously shown that the BRCT regions pf TopBP1 (DNA topoisomerase II binding protein 1) and BRCA1 bound DNA breaks. A BRCT-related region, BRCT-W1, in the retinoblastoma susceptibility gene product (Rb) also could bind DNA fragments, independently of DNA sequences. Five BRCT-W regions were found in the Rb family. All BRCT-Ws of Rb bound DNA fragments. Electron microscopy and treatment with an exonuclease showed that BRCT-Ws bound double-strand DIVA breaks. Since some BRCTs are exceptional common relating elements in tumor suppression, our findings reveal novel aspects of the tumor suppression mechanism.	Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 1130032, Japan; Japanese Fdn Canc Res, Ctr Canc Chemotherapy, Toshima Ku, Tokyo 1708455, Japan; Univ Tokyo, Inst Med Sci, Dept Fine Morphol, Minato Ku, Tokyo 1088639, Japan; RIKEN, Inst Phys & Chem Res, Wako, Saitama 3510198, Japan	University of Tokyo; Japanese Foundation for Cancer Research; University of Tokyo; RIKEN	Tsuruo, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Biomed Res Lab, Bunkyo Ku, Tokyo 1130032, Japan.							Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Cranston A, 1997, NAT GENET, V17, P114, DOI 10.1038/ng0997-114; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HENSEY CE, 1994, J BIOL CHEM, V269, P1380; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Ito K, 1999, BIOPHYS J, V76, P985, DOI 10.1016/S0006-3495(99)77262-0; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; KUROSAKI T, 1987, J BIOL CHEM, V262, P15990; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOLINETE M, 1993, EMBO J, V12, P2109, DOI 10.1002/j.1460-2075.1993.tb05859.x; Saka Y, 1997, GENE DEV, V11, P3387, DOI 10.1101/gad.11.24.3387; SAKA Y, 1994, EMBO J, V13, P5319, DOI 10.1002/j.1460-2075.1994.tb06866.x; Sterner JM, 1998, MOL CELL BIOL, V18, P2748, DOI 10.1128/MCB.18.5.2748; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; THUKRAL SK, 1994, MOL CELL BIOL, V14, P8315, DOI 10.1128/MCB.14.12.8315; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wang J, 1997, CANCER RES, V57, P351; WANG NP, 1990, CELL GROWTH DIFFER, V1, P233; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Yamane K, 1997, EUR J BIOCHEM, V250, P794, DOI 10.1111/j.1432-1033.1997.00794.x; Yamane K, 1999, ONCOGENE, V18, P5194, DOI 10.1038/sj.onc.1202922; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4	39	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 13	2000	19	16					1982	1991		10.1038/sj.onc.1203528	http://dx.doi.org/10.1038/sj.onc.1203528			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	306TT	10803459				2022-12-17	WOS:000086613200002
J	Nakajima, H; Nakajima, HO; Soonpaa, MH; Jing, SL; Field, LJ				Nakajima, H; Nakajima, HO; Soonpaa, MH; Jing, SL; Field, LJ			Heritable lympho-epithelial thymoma resulting from a transgene insertional mutation	ONCOGENE			English	Article						cancer; lymphoma; insertional mutagenesis; transgenic mice	THYMIC HYPERPLASIA; INSITU HYBRIDIZATION; MICE; ENLARGEMENT; GENES; RATS	Thymoma is the most common tumor of the anterior-superior mediastinum. We have identified a line of transgenic mice which spontaneously and heritably develop thymomas at a very high penetrance. The available data suggest that thymoma formation in these mice results as a consequence of transgene insertional mutagenesis, Immune histologic analyses indicate that the thymomas are of epithelial cell origin. Survival studies indicate that tumor progression is more aggressive in females as compared to males (73.9 vs 41.7% mortality at 20 weeks of age, respectively), Fluorescent in situ hybridizations have localized the transgene integration site to the F2-G region of mouse chromosome 2. Translocation encompassing the syntenic region in humans has been implicated in lympho-epithelial thymoma. These animals may constitute a useful resource for the identification of gene(s) which participate in thymoma progression, as well as a model system for screening anti-thymoma therapeutic agents.	Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; Indiana Univ, James Whitcomb Riley Hosp Children, Sch Med, Krannert Inst Cardiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; James Whitcomb Riley Hospital Children	Field, LJ (corresponding author), Herman B Wells Ctr Pediat Res, 702 Barnhill Dr,Room 2600, Indianapolis, IN 46202 USA.							BATTIFORA H, 1980, HUM PATHOL, V11, P635, DOI 10.1016/S0046-8177(80)80074-8; BLOOM W, 1986, AFS TXB HISTOLOGY; BOTTERI FM, 1987, MOL CELL BIOL, V7, P3178, DOI 10.1128/MCB.7.9.3178; BRUNNER AM, 1992, MOL ENDOCRINOL, V6, P1691, DOI 10.1210/me.6.10.1691; DEMINATTI MM, 1994, ANN GENET-PARIS, V37, P72; FENG GS, 1994, ONCOGENE, V9, P1545; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GULICK J, 1991, J BIOL CHEM, V266, P9180; HENG HHQ, 1993, CHROMOSOMA, V102, P325, DOI 10.1007/BF00661275; HENG HHQ, 1992, P NATL ACAD SCI USA, V89, P9509, DOI 10.1073/pnas.89.20.9509; HOGAN B, 1994, MANIPULATING MOUSE E; LEWIS JE, 1987, CANCER, V60, P2727, DOI 10.1002/1097-0142(19871201)60:11<2727::AID-CNCR2820601125>3.0.CO;2-D; MATANI A, 1973, ARCH PATHOL, V95, P90; MATSUYAMA M, 1988, JPN J CANCER RES, V79, P1031, DOI 10.1111/j.1349-7006.1988.tb00070.x; MOLL J, 1992, EUR J IMMUNOL, V22, P1587, DOI 10.1002/eji.1830220636; MURAKUMO Y, 1993, JPN J CANCER RES, V84, P838, DOI 10.1111/j.1349-7006.1993.tb02054.x; Murakumo Y, 1996, MAMM GENOME, V7, P505, DOI 10.1007/s003359900152; REDDY VB, 1978, SCIENCE, V200, P494, DOI 10.1126/science.205947; Robles AI, 1996, P NATL ACAD SCI USA, V93, P7634, DOI 10.1073/pnas.93.15.7634; Sambrook J., 1989, MOL CLONING; Seiki K, 1997, ARCH HISTOL CYTOL, V60, P29, DOI 10.1679/aohc.60.29	21	11	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					32	38		10.1038/sj.onc.1203266	http://dx.doi.org/10.1038/sj.onc.1203266			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644977				2022-12-17	WOS:000084844300004
J	Zegerman, P; Bannister, AJ; Kouzarides, T				Zegerman, P; Bannister, AJ; Kouzarides, T			The putative tumour suppressor Fus-2 is an N-acetyltransferase	ONCOGENE			English	Article						Fus-2; acetyltransferase; tumour suppressor	CELL LUNG-CANCER; HISTONE ACETYLTRANSFERASE; DELETION; YEAST; ACETYLATION; SUPERFAMILY; NAT2	Acetyltransferases are essential enzymes for a wide variety of cellular processes and mutations in acetyltransferase genes have been associated with the development of certain cancers. For this reason, we conducted a computerized sequence homology search for novel acetyltransferases. Here, we show that the putative tumour suppressor protein Fus-2 has homology to the catalytic domain of acetyltransferases. We demonstrate that Fus-2 can acetylate the N-terminus of proteins using a ping-pong mechanism and that it has a specificity for substrates. Consistent with other N-acetyltransferases, Fus-2 localizes to the cytoplasm, as shown by GFP-tag experiments, Since the Fus-2 gene maps to the chromosomal region 3p21.3, which contains at least one tumour suppressor gene, the N-acetyltransferase functions of Fus-2 may be relevant to its potential role in cancer.	Univ Cambridge, Wellcome CRC Inst, Cambridge CB2 1QR, England; Univ Cambridge, Dept Pathol, Cambridge CB2 1QR, England	University of Cambridge; University of Cambridge	Kouzarides, T (corresponding author), Univ Cambridge, Wellcome CRC Inst, Tennis Court Rd, Cambridge CB2 1QR, England.			Bannister, Andrew/0000-0002-6312-4436; Zegerman, Philip/0000-0002-5707-1083; Kouzarides, Tony/0000-0002-8918-4162				Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; BRAUCH H, 1990, GENE CHROMOSOME CANC, V1, P240, DOI 10.1002/gcc.2870010309; Cascorbi I, 1996, CANCER RES, V56, P3961; Dutnall RN, 1998, CELL, V94, P427, DOI 10.1016/S0092-8674(00)81584-6; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HIBI K, 1992, ONCOGENE, V7, P445; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; JORNVALL H, 1980, FEBS LETT, V111, P214, DOI 10.1016/0014-5793(80)80796-4; KOK K, 1994, CANCER RES, V54, P4183; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Wei MH, 1996, CANCER RES, V56, P1487; WHANGPENG J, 1982, SCIENCE, V215, P181, DOI 10.1126/science.6274023; WONG LJ, 1983, BIOCHEMISTRY-US, V42, P4637; Zenser TV, 1996, CANCER RES, V56, P3941	18	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 6	2000	19	1					161	163		10.1038/sj.onc.1203234	http://dx.doi.org/10.1038/sj.onc.1203234			3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	275WZ	10644992				2022-12-17	WOS:000084844300019
J	Brown, LA; Yang, SH; Hair, A; Galanis, A; Sharrocks, AD				Brown, LA; Yang, SH; Hair, A; Galanis, A; Sharrocks, AD			Molecular characterization of a zebrafish TCF ETS-domain transcription factor	ONCOGENE			English	Article						ETS-domain; ternary complex factor; transcription factors; zebrafish	ACTIVATED PROTEIN-KINASE; TERNARY COMPLEX FACTORS; DNA-BINDING SPECIFICITIES; SERUM RESPONSE ELEMENT; SIGNAL-TRANSDUCTION; FACTORS ELK-1; C-FOS; MAP KINASES; PATHWAYS; P38	The ternary complex factor (TCF) subfamily of ETS-transcription factors represent key nuclear targets of the MAP kinase pathways. Members of this subfamily are classified by the presence of several conserved domains for DNA binding, interaction with SRF, interaction with MAP kinases and transcriptional activation. In this study we have isolated a further member of this subfamily (TCF-1) from zebrafish, The protein product of zebrafish TCF-1 (zTCF-1), shares sequence similarity with the mammalian TCFs in all four conserved domains, with highest overall similarity to SAP-1. Zebrafish TCF-1 is expressed throughout zebrafish embryonic development and exhibits typical TCF DNA binding characteristics, with the B-box being required for interaction with SRF, Of the mammalian TCFs, its DNA binding specificity resembles Elk-1. zTCF-1 is a target for both the growth factor/mitogen-activated and stress-activated MAP kinase cascades in vitro and in vivo. However, differential targeting occurs, with the profile of its activation closely resembling that of mammalian SAP-1, Together, our results demonstrate that the TCFs have been functionally conserved during vertebrate development.	Univ Newcastle Upon Tyne, Sch Med, Dept Biochem & Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England	Newcastle University - UK	Sharrocks, AD (corresponding author), Univ Manchester, Sch Biol Sci, Stoppard Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Galanis, Alex/ABF-4762-2020	Galanis, Alex/0000-0001-9991-3173	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BROWN AL, 1998, UNPUB MECH DEV; Brown LA, 1998, ONCOGENE, V17, P93, DOI 10.1038/sj.onc.1201911; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; CANO E, 1995, J CELL SCI, V108, P3599; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; GILLE H, 1995, CURR BIOL, V5, P1191, DOI 10.1016/S0960-9822(95)00235-1; GILLE H, 1995, EMBO J, V14, P951, DOI 10.1002/j.1460-2075.1995.tb07076.x; GILLE H, 1992, NATURE, V358, P415; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; JANKNECHT R, 1994, ONCOGENE, V9, P1273; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; LOPEZ M, 1994, MOL CELL BIOL, V14, P3292, DOI 10.1128/MCB.14.5.3292; MagnaghiJaulin L, 1996, FEBS LETT, V391, P247, DOI 10.1016/0014-5793(96)00745-4; Maira SM, 1996, EMBO J, V15, P5849, DOI 10.1002/j.1460-2075.1996.tb00972.x; Plant KE, 1996, NUCLEIC ACIDS RES, V24, P3514, DOI 10.1093/nar/24.18.3514; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO VN, 1994, ONCOGENE, V9, P1855; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; SETH A, 1992, J BIOL CHEM, V267, P24796; Sgambato V, 1998, J NEUROSCI, V18, P214; Sharrocks AD, 1997, INT J BIOCHEM CELL B, V29, P1371, DOI 10.1016/S1357-2725(97)00086-1; SHARROCKS AD, 1993, NUCLEIC ACIDS RES, V21, P215, DOI 10.1093/nar/21.2.215; SHARROCKS AD, 1993, MOL CELL BIOL, V13, P123, DOI 10.1128/MCB.13.1.123; SHARROCKS AD, 1995, FEBS LETT, V368, P77, DOI 10.1016/0014-5793(95)00604-8; Shore P, 1996, MOL CELL BIOL, V16, P3338; SHORE P, 1995, J BIOL CHEM, V270, P5805, DOI 10.1074/jbc.270.11.5805; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; SHORE P, 1995, NUCLEIC ACIDS RES, V23, P4698, DOI 10.1093/nar/23.22.4698; Strahl T, 1996, P NATL ACAD SCI USA, V93, P11563, DOI 10.1073/pnas.93.21.11563; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; Yang SH, 1998, MOL CELL BIOL, V18, P710, DOI 10.1128/MCB.18.2.710; ZHAO LJ, 1993, GENE, V137, P345, DOI 10.1016/0378-1119(93)90032-X	43	11	12	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 23	1999	18	56					7985	7993		10.1038/sj.onc.1203197	http://dx.doi.org/10.1038/sj.onc.1203197			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272DE	10637509				2022-12-17	WOS:000084634600007
J	Jardine, LJ; Milne, DM; Dumaz, N; Meek, DW				Jardine, LJ; Milne, DM; Dumaz, N; Meek, DW			Phosphorylation of murine p53, but not human p53, by MAP kinase in vitro and in cultured cells highlights species-dependent variation in post-translational modification	ONCOGENE			English	Article						p53; ERK; MAP kinase; phosphorylation	ACTIVATED PROTEIN-KINASE; WILD-TYPE P53; IN-VITRO; GENE AMPLIFICATION; FUNCTIONAL DOMAIN; STRESS SIGNALS; GROWTH ARREST; T-ANTIGEN; TRANSACTIVATION; APOPTOSIS	The p53 tumour suppressor protein is tightly regulated by protein-protein association, protein turnover and a variety of post-translational modifications. Multisite phosphorylation plays a major role in activating and in finely tuning p53 function. The proline rich domain of murine p53 is a substrate for phosphorylation, lit vitro and in cultured cells, by the p42(ERK2) and p44(ERK1) mitogen-activated protein (MAP) kinases, However, to date there have been no reports of attempts to determine whether p53 from any other species is a substrate for MAP kinase, In this paper we confirm that murine p53 is targeted by recombinant MAP kinase and by MAP kinases in extracts of both murine and human cells. In contrast, human p53 is not a substrate for recombinant MAP kinase nor are there any detectable levels of protein kinase activity in stimulated human cell extracts which phosphorylate the proline rich domain of human p53 in vitro. Finally, although stimulation of murine fibroblasts with o-tetradecanolylphorbol 13-acetate (TPA), an indirect activator of the MAP kinase pathway, leads to site-specific phosphorylation of murine p53, similar treatment of human fibroblasts and epithelial cells showed no significant changes in the phosphorylation pattern. These data are consistent with accumulating evidence that significant species-dependent differences exist in the post-translational modification of p53.	Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland	University of Dundee	Meek, DW (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Biomed Res Ctr, Dundee DD1 9SY, Scotland.		Dumaz, Nicolas/B-5907-2008	Dumaz, Nicolas/0000-0003-3511-2160				Adler V, 1997, P NATL ACAD SCI USA, V94, P1686, DOI 10.1073/pnas.94.5.1686; Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Fukasawa K, 1997, ONCOGENE, V15, P1295, DOI 10.1038/sj.onc.1201482; Gavin AC, 1999, CURR BIOL, V9, P281, DOI 10.1016/S0960-9822(99)80120-1; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; Hollstein M, 1996, NUCLEIC ACIDS RES, V24, P141, DOI 10.1093/nar/24.1.141; Hu MCT, 1997, ONCOGENE, V15, P2277, DOI 10.1038/sj.onc.1201401; Jacobs D, 1999, GENE DEV, V13, P163, DOI 10.1101/gad.13.2.163; Knippschild U, 1997, ONCOGENE, V15, P1727, DOI 10.1038/sj.onc.1201541; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Meek DW, 1998, CELL SIGNAL, V10, P159, DOI 10.1016/S0898-6568(97)00119-8; Meek DW, 1997, PATHOL BIOL, V45, P804; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MILNE DM, 1994, J BIOL CHEM, V269, P9253; Milne DM, 1996, ONCOGENE, V13, P205; MULLER E, 1995, ONCOGENE, V10, P1175; PATSCHINSKY T, 1992, J VIROL, V66, P3846, DOI 10.1128/JVI.66.6.3846-3859.1992; Prives C, 1999, J PATHOL, V187, P112; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Ruaro EM, 1997, P NATL ACAD SCI USA, V94, P4675, DOI 10.1073/pnas.94.9.4675; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Songyang Z, 1996, MOL CELL BIOL, V16, P6486; Soussi T, 1996, J MOL BIOL, V260, P623, DOI 10.1006/jmbi.1996.0425; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7	36	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 9	1999	18	52					7602	7607		10.1038/sj.onc.1203137	http://dx.doi.org/10.1038/sj.onc.1203137			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HQ	10602521	Bronze			2022-12-17	WOS:000084119600023
J	Lopez, P; Vidal, F; Rassoulzadegan, M; Cuzin, F				Lopez, P; Vidal, F; Rassoulzadegan, M; Cuzin, F			A role of inhibin as a tumor suppressor in Sertoli cells: down-regulation upon aging and repression by a viral oncogene	ONCOGENE			English	Article						testis; gonadal tumor; inhibin-activin; polyoma virus; T antigen; gene regulation	LARGE T-ANTIGEN; RECOMBINANT HUMAN INHIBIN; ALPHA-INHIBIN; BINDING-SITE; PROTEIN; GENE; MICE; DNA; EXPRESSION; ACTIVIN	Inhibin, a member of the TGF-beta superfamily, is synthesized in the testis by Sertoli cells and exerts an endocrine regulatory function on pituitary hormone synthesis, A distinct local function has been proposed, negatively controlling cellular growth in the testis (tumor suppressor activity). A critical test for the identification of a tumor suppressor is the reversal of transformed growth properties upon re-expression of the gene in tumor-derived cell lines. Sertoli cell-derived tumoral lines were previously established from tumors that develop in elderly transgenic males which express in the testis the large T antigen of polyoma virus. Both the tumors and the cells in culture exhibited reduced levels of the inhibin alpha subunit mRNA, Stable transfectants were generated, in which this subunit was expressed from a heterologous promoter. All of them exhibited a strict inhibition of growth at confluency, On the other hand, in addition to an aging-related decrease in inhibin synthesis, the alpha subunit gene was down regulated in vivo in cells expressing the viral protein. The conjunction of these two factors accounts for the age-related occurrence of testicular cancers in the transgenic model, again pointing to inhibin as a potent cell growth regulator in the seminiferous epithelium.	Univ Nice, INSERM, U470, F-06108 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Cuzin, F (corresponding author), Univ Nice, INSERM, U470, F-06108 Nice, France.		Rassoulzadegan, Minoo/O-7939-2016	Lopez, Pascal/0000-0002-3936-3058				BARUT B, 1993, J CLIN INVEST, V92, P2346, DOI 10.1172/JCI116839; BOITANI C, 1995, ENDOCRINOLOGY, V136, P5438, DOI 10.1210/en.136.12.5438; CHEN CLC, 1993, ENDOCRINOLOGY, V132, P4, DOI 10.1210/en.132.1.4; CHEN CLC, 1992, MOL BIOL REPROD SERO, P97; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COWIE A, 1984, J VIROL, V52, P750, DOI 10.1128/JVI.52.3.750-760.1984; DELUCIA AL, 1983, J VIROL, V46, P143, DOI 10.1128/JVI.46.1.143-150.1983; DUNBAR CE, 1989, SCIENCE, V245, P1493, DOI 10.1126/science.2789432; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; GAUDRAY P, 1981, NUCLEIC ACIDS RES, V9, P5697, DOI 10.1093/nar/9.21.5697; Grandjean V, 1997, BIOL REPROD, V57, P1115, DOI 10.1095/biolreprod57.5.1115; Grimaldi P, 1996, MOL CELL ENDOCRINOL, V117, P167, DOI 10.1016/0303-7207(95)03744-6; GUERRAGARCIA R, 1989, ARCH ANDROLOGY, V22, P35, DOI 10.3109/01485018908986748; HAKOVIRTA H, 1993, ENDOCRINOLOGY, V133, P1664, DOI 10.1210/en.133.4.1664; HANGOC G, 1992, EXP HEMATOL, V20, P1243; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; JAKUBOWIAK A, 1991, MOL CELL ENDOCRINOL, V82, P265, DOI 10.1016/0303-7207(91)90040-Y; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; LARSSON SH, 1995, CELL, V81, P391, DOI 10.1016/0092-8674(95)90392-5; MATZUK MM, 1992, NATURE, V360, P313, DOI 10.1038/360313a0; PAL D, 1991, BIOL REPROD, V45, P869, DOI 10.1095/biolreprod45.6.869; PAQUISFLUCKLINGER V, 1993, ONCOGENE, V8, P2087; PECH N, 1993, BLOOD, V82, P1502; PELLETIER J, 1991, GENE DEV, V5, P1345, DOI 10.1101/gad.5.8.1345; RASSOULZADEGAN M, 1981, VIROLOGY, V114, P489, DOI 10.1016/0042-6822(81)90228-2; RICH KA, 1983, ENDOCRINOLOGY, V113, P2284, DOI 10.1210/endo-113-6-2284; SKINNER MK, 1993, SERTOLI CELL, P237; SU JGJ, 1992, BIOCHEM BIOPH RES CO, V186, P293, DOI 10.1016/S0006-291X(05)80806-X; TJIAN R, 1978, CELL, V13, P165, DOI 10.1016/0092-8674(78)90147-2; VANDISSELEMILIANI FMF, 1989, ENDOCRINOLOGY, V125, P1899, DOI 10.1210/endo-125-4-1898; Vincent S, 1998, DEVELOPMENT, V125, P4585; VINCENT S, 1993, NUCLEIC ACIDS RES, V21, P1498, DOI 10.1093/nar/21.6.1498; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	33	11	13	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	DEC 2	1999	18	51					7303	7309		10.1038/sj.onc.1203143	http://dx.doi.org/10.1038/sj.onc.1203143			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263HN	10602485				2022-12-17	WOS:000084119400015
J	Xu, XZ; Liao, J; Creek, KE; Pirisi, L				Xu, XZ; Liao, J; Creek, KE; Pirisi, L			Human keratinocytes and tumor-derived cell lines express alternatively spliced forms of transforming growth factor-alpha mRNA, encoding precursors lacking carboxyl-terminal valine residues	ONCOGENE			English	Article						TGF-alpha variant; splicing; CHO cells	HUMAN PAPILLOMAVIRUS TYPE-16; TGF-ALPHA; FACTOR RECEPTOR; MESSENGER-RNAS; SEQUENCES; DNA; TRANSFECTION; ASSOCIATION; INDUCTION; CARCINOMA	The human transforming growth factor-alpha (TGF-alpha) gene is thought to contain five introns and six exons, encoding a transmembrane precursor (proTGF-alpha) from which the mature polypeptide is released by proteolytic cleavage, We identified a novel 32-nucleotide exon (exon alpha) within intron 5 and an alternative splice acceptor site in exon 6, splitting exon 6 into two segments: 6A and 6B, Therefore, in addition to wild type (wt) proTGF-alpha mRNA, which skips exon alpha, two novel proTGF-alpha variants are produced: Variant I (VaI), skipping exons alpha and 6A, and Variant II (VaII) which includes exon a and skips exon 6A, The only significant difference between variant and wt proTGF-alpha proteins is that the two wt carboxyl-terminal valines are replaced in the variants by five or four other amino acids, respectively, Both variant TGF-alpha mRNAs were readily detected in human keratinocytes and tumor-derived cell lines. Their protein products were cleaved as efficiently as wt TGF-alpha in response to the calcium ionophore A23187, However, both variants (but not wt) reduced serum requirements for proliferation in CHO cells. In addition, VaII-expressing CHO cells (not VaI or wt) formed foci in monolayer cultures, These results suggest that variant TGF-alpha precursors induce autonomous growth.	Univ S Carolina, Sch Med, Dept Pathol, Columbia, SC 29208 USA; Univ S Carolina, Sch Med, Childrens Canc Res Lab, Dept Pediat, Columbia, SC 29208 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Pirisi, L (corresponding author), Univ S Carolina, Sch Med, Dept Pathol, Columbia, SC 29208 USA.		xu, xingzhi/E-8158-2012	xu, xingzhi/0000-0002-4459-2082	NCI NIH HHS [CA 62094] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA062094] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baselga J, 1996, J BIOL CHEM, V271, P3279, DOI 10.1074/jbc.271.6.3279; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BOSENBERG MW, 1992, CELL, V71, P1157, DOI 10.1016/S0092-8674(05)80064-9; BRACHMANN R, 1989, CELL, V56, P691, DOI 10.1016/0092-8674(89)90591-6; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; DERYNCK R, 1987, CANCER RES, V47, P707; DERYNCK R, 1985, CANCER CELL, V3, P79; DIPAOLO JA, 1989, ONCOGENE, V4, P395; DIPAOLO JA, 1990, VIROLOGY, V177, P777, DOI 10.1016/0042-6822(90)90548-6; EZZAT S, 1995, J CLIN ENDOCR METAB, V80, P534, DOI 10.1210/jc.80.2.534; Holland SJ, 1996, NATURE, V383, P722, DOI 10.1038/383722a0; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Knebelmann B, 1998, CANCER RES, V58, P226; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; LEE DC, 1995, PHARMACOL REV, V47, P51; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PFEFFER S, 1985, NATURE, V313, P184, DOI 10.1038/313184a0; PIRISI L, 1988, CARCINOGENESIS, V9, P1573, DOI 10.1093/carcin/9.9.1573; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; QIAN JF, 1993, AM J HUM GENET, V53, P168; Seki S, 1997, VIRCHOWS ARCH, V430, P29, DOI 10.1007/BF01008013; Shum L, 1996, J BIOL CHEM, V271, P28502, DOI 10.1074/jbc.271.45.28502; SHUM L, 1994, J CELL BIOL, V125, P903, DOI 10.1083/jcb.125.4.903; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZYZAK LL, 1994, CELL GROWTH DIFFER, V5, P537	29	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 30	1999	18	40					5554	5562		10.1038/sj.onc.1203091	http://dx.doi.org/10.1038/sj.onc.1203091			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	241QU	10523832				2022-12-17	WOS:000082894700008
J	Dubendorff, JW; Lipsick, JS				Dubendorff, JW; Lipsick, JS			Transcriptional regulation by the carboxyl terminus of c-Myb depends upon both the Myb DNA-binding domain and the DNA recognition site	ONCOGENE			English	Article						c-Myb; DNA-binding; v-Myb	V-MYB; GENE-EXPRESSION; FUNCTIONAL DOMAINS; PROTEIN SEQUENCES; COACTIVATOR CBP; LEUCINE-ZIPPER; IN-VITRO; A-MYB; ACTIVATION; TRANSACTIVATION	The c-Myb protein binds to DNA,can regulate transcription, and is required for normal hematopoiesis in vertebrates. Either amino- or carboxy-terminal truncation of this protein is required for efficient oncogenic activation. Previous studies have shown that the carboxyl terminus of c-Myb that is deleted in v-Myb contains negative regulatory domains. We now demonstrate that specific mutations within this carboxyl terminus result in greater transcriptional activation than truncation of the entire carboxyl terminus. Furthermore, this increased transcriptional activation depends upon the presence of the highly conserved Myb DNA-binding domain and is also dependent upon the nature of the Myb-binding sites within the target prompter. In a similar fashion, an activating mutation within the heptad leucine repeat region of c-Myb that, is also present in v-Myb functions only in conjunction,vith the Myb DNA-binding domain and with particular Myb-binding sites. These results suggest a model in which multiple domains of the c-Myb protein are highly interdependent for transcriptional regulation. These interactions are promoter-specific and are not web modeled by heterologous fusion proteins.	Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA	Stanford University	Lipsick, JS (corresponding author), Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA.				NCI NIH HHS [T32 CA09176, R01 CA56509] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056509, T32CA009176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel F.M., 1989, SHORT PROTOCOLS MOL; AZIZ N, 1993, ONCOGENE, V8, P2259; AZIZ N, 1995, P NATL ACAD SCI USA, V92, P6429, DOI 10.1073/pnas.92.14.6429; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RH, 1993, MOL CELL BIOL, V13, P4423, DOI 10.1128/MCB.13.7.4423; CHENG ADY, 1995, GRAVITATION COSMOLOG, V1, P1; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; Dash AB, 1996, GENE DEV, V10, P1858, DOI 10.1101/gad.10.15.1858; DINI PW, 1993, MOL CELL BIOL, V13, P7334, DOI 10.1128/MCB.13.12.7334; DUBENDORFF JW, 1992, GENE DEV, V6, P2524, DOI 10.1101/gad.6.12b.2524; DUBENDORFF JW, 1997, METHOD MOL CELL BIOL, V5, P367; EVAN GI, 1984, MOL CELL BIOL, V4, P2843, DOI 10.1128/MCB.4.12.2843; Facchinetti V, 1997, BIOCHEM J, V324, P729, DOI 10.1042/bj3240729; FENG DF, 1990, METHOD ENZYMOL, V183, P375; Fu SL, 1996, J VIROL, V70, P5600, DOI 10.1128/JVI.70.8.5600-5610.1996; Fu SL, 1997, CELL GROWTH DIFFER, V8, P35; Ganter B, 1998, EMBO J, V17, P255, DOI 10.1093/emboj/17.1.255; GANTER B, 1998, IN PRESS ADV CANC RE; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GRASSER FA, 1992, ONCOGENE, V7, P1005; HU YL, 1991, ONCOGENE, V6, P1549; IBANEZ CE, 1990, MOL CELL BIOL, V10, P2285, DOI 10.1128/MCB.10.5.2285; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KANEIISHII C, 1992, P NATL ACAD SCI USA, V89, P3088, DOI 10.1073/pnas.89.7.3088; Kiewitz A, 1997, FEBS LETT, V415, P258, DOI 10.1016/S0014-5793(97)01134-4; KLEMPNAUER KH, 1987, EMBO J, V6, P2719, DOI 10.1002/j.1460-2075.1987.tb02565.x; LANE T, 1990, MOL CELL BIOL, V10, P2591, DOI 10.1128/MCB.10.6.2591; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NAKAGOSHI H, 1993, J BIOL CHEM, V268, P14161; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOMURA T, 1993, J BIOL CHEM, V268, P21914; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RAMSAY RG, 1991, ONCOGENE, V6, P1875; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SENECA S, 1993, ONCOGENE, V8, P2335; SLEEMAN JP, 1993, ONCOGENE, V8, P1931; Tanaka Y, 1997, FEBS LETT, V413, P162, DOI 10.1016/S0014-5793(97)00900-9; Tavner FJ, 1998, MOL CELL BIOL, V18, P989, DOI 10.1128/MCB.18.2.989; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TONG X, 1995, MOL CELL BIOL, V15, P4735; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; Woo CH, 1998, J VIROL, V72, P6813, DOI 10.1128/JVI.72.8.6813-6821.1998	50	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 10	1999	18	23					3452	3460		10.1038/sj.onc.1202679	http://dx.doi.org/10.1038/sj.onc.1202679			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	205ZF	10376523				2022-12-17	WOS:000080850600003
J	van der Geer, P; Wiley, S; Pawson, T				van der Geer, P; Wiley, S; Pawson, T			Re-engineering the target specificity of the insulin receptor by modification of a PTB domain binding site	ONCOGENE			English	Article						Shc; IRS-1; PTB domain specificity; protein modules	AMYLOID PRECURSOR PROTEIN; JUXTAMEMBRANE REGION; SIGNAL-TRANSDUCTION; SH2 DOMAIN; DISTINCT; IRS-1; MOTIF; SUBSTRATE-1; RECOGNITION; RESIDUES	Shc and IRS-1 (and their relatives) are cytoplasmic docking proteins that possess phosphotyrosine-binding (PTB) domains, through which they bind specific activated receptor tyrosine kinases (RTK), The subsequent phosphorylation of Shc or IRS-1 creates binding sites for the SH2 domains of multiple signaling proteins, leading to the activation of intracellular biochemical pathways, The PTB domains of Shc and IRS-1 both recognize autophosphorylation sites in RTKs with the consensus sequence NPXpY, but show distinct abilities to bind stably to RTKs such as the TrkA nerve growth factor receptor and the insulin receptor. In vitro analysis has suggested that residues N-terminal to the NPXpY motif may determine the affinity with which phosphopeptide ligands are recognized by the Shc and IRS-1 PTB domains, Unlike IRS-1, the Shc PTB domain binds poorly to the insulin-receptor (IR) beta subunit in vitro, owing to its low affinity for the NPXpY autophosphorylation site at Tyr 960 of the IR, As a consequence, Shc does not bind stably to the activated IR in cells. We show that substitution of Ser 955, five residues N-terminal to the Tyr 960 autophosphorylation site (the -5 position), with Ile alters the target specificity of the IR such that it stably associates with Shc in insulin-stimulated cells. A triple substitution of the -5, -8 and -9 residues relative to Tyr 960 of the IR to the corresponding amino acids found in the Shc PTB domain binding site of TrkA results in even stronger binding of the IR to Shc in vivo, The variant IRs with enhanced ability to bind Shc showed an increased ability Ito activate the MAPK pathway in response to insulin stimulation. These results demonstrate that subtle differences in residues N-terminal to NPXpY autophosphorylation sites determine the ability of RTKs tea bind specific PTB domain proteins in vivo, and thus modify the signaling properties of activated receptors.	Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, Toronto, ON M5G 1X5, Canada; Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California San Diego; University of Toronto	Pawson, T (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Programme Mol Biol & Canc, 600 Univ Ave, Toronto, ON M5G 1X5, Canada.		Pawson, Tony J/E-4578-2013	Wiley, Sandra/0000-0003-3979-2474				BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; FEENER EP, 1993, J BIOL CHEM, V268, P11256; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0	22	11	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 20	1999	18	20					3071	3075		10.1038/sj.onc.1202879	http://dx.doi.org/10.1038/sj.onc.1202879			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197WB	10340378				2022-12-17	WOS:000080388000002
J	Prendergast, GC				Prendergast, GC			Myc and Myb: are the veils beginning to lift?	ONCOGENE			English	Article						transformation; apoptosis; transcription; oncogene; proliferation; cell cycle			Wistar Inst, Philadelphia, PA 19104 USA	The Wistar Institute	Prendergast, GC (corresponding author), Wistar Inst, 3601 Spruce St, Philadelphia, PA 19104 USA.								0	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAY 13	1999	18	19					2914	2915		10.1038/sj.onc.1202784	http://dx.doi.org/10.1038/sj.onc.1202784			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	197VZ	10378687				2022-12-17	WOS:000080387800001
J	Iyengar, TD; Ng, SW; Lau, CC; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC				Iyengar, TD; Ng, SW; Lau, CC; Welch, WR; Bell, DA; Berkowitz, RS; Mok, SC			Differential expression of NF1 type I and type II isoforms in sporadic borderline and invasive epithelial ovarian tumors	ONCOGENE			English	Article						ovary; cancer; NF1; retinoic acid	GTPASE-ACTIVATING PROTEIN; RETINOIC ACID; CELL-LINES; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; ALKALINE-PHOSPHATASE; GENE TRANSCRIPTS; CANCER; GROWTH; RAS; GAP	The NF1 gene, a putative tumor suppresser gene, contains a GAP related domain (GRD) which accelerates hydrolysis of ras-bound GTP to GDP, thereby converting the ras oncogene from its active to inactive form, Two forms of the NF1 GRD transcript (Type I and Type II) are differentially expressed in neuroectodermal tumor tissue relative to differentiated neural cells, and in gastric cancer cell lines relative to normal stomach mucosa, We measured relative expression of NF1 Type II and Type I isoforms in cultured normal and malignant human ovarian surface epithelial cells(HOSE) and in invasive and borderline ovarian tumor tissue. We demonstrated an Ii-fold increase in Type II: Type I ratio in 7 HOSE cultures relative to eight ovarian cancer cell lines, Our findings indicate a significant decrease in Type II isoform expression and increase in Type I expression in ovarian cancer cells and tumor tissue relative to HOSE cells. We also demonstrate an increase in Type II: Type I ratio, and a decrease in cell proliferation rate in three ovarian cancer cell lines on treatment with retinoic acid. We propose that differential expression of the NF1 Type I and Type II isoforms is related to cellular differentiation in ovarian epithelial cancer and strategies based on alteration in NF1 isoform expression may have therapeutic potential in ovarian malignancies.	Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Texas Childrens Hosp, Div Hematol Oncol, Houston, TX 77030 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of Pennsylvania; Baylor College of Medicine	Mok, SC (corresponding author), Brigham & Womens Hosp, Dept Obstet Gynecol & Reprod Biol, Lab Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA.				NATIONAL CANCER INSTITUTE [R01CA069453, R01CA063381, R29CA070216] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA63381, R29CA70216, R01CA69453] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALALAWI N, 1993, MOL CELL BIOL, V13, P2497, DOI 10.1128/MCB.13.4.2497; ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; Auersperg N, 1998, SEMIN ONCOL, V25, P281; AZUMA M, 1988, CANCER RES, V48, P7219; BARKER D, 1987, SCIENCE, V236, P1100, DOI 10.1126/science.3107130; BROOKS SE, 1991, GYNECOL ONCOL, V42, P265, DOI 10.1016/0090-8258(91)90356-A; CALIARO MJ, 1994, INT J CANCER, V56, P743, DOI 10.1002/ijc.2910560522; CLIBY W, 1993, CANCER RES, V53, P2393; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; GOLDGAR DE, 1987, AM J HUM GENET, V44, P6; GUTMANN DH, 1993, J NEUROSCI RES, V36, P216, DOI 10.1002/jnr.490360212; HARANT H, 1993, BRIT J CANCER, V68, P530, DOI 10.1038/bjc.1993.381; International Federation of Gynecology and Obstetrics, 1987, AM J OBSTET GYNECOL, V156, P263; IYENGAR TD, 1996, GYNECOL ONCOL, V60, P114; Jing YK, 1997, CANCER RES, V57, P1668; LANGDON SP, 1988, CANCER RES, V48, P6161; Lu KH, 1997, CANCER RES, V57, P387; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P643; MAZARS R, 1991, ONCOGENE, V6, P1685; MCCORMICK F, 1988, COLD SPRING HARB SYM, V53, P849, DOI 10.1101/SQB.1988.053.01.097; NAKAFUKU M, 1993, P NATL ACAD SCI USA, V90, P6706, DOI 10.1073/pnas.90.14.6706; NISHI T, 1991, ONCOGENE, V6, P1555; Phillips NJ, 1996, CANCER RES, V56, P606; REESE DH, 1983, CANCER RES, V43, P5443; RICCARDI VM, 1981, ADV NEUROLOGY, V29; RODABAUGH KJ, 1995, CANCER RES, V55, P2169; SATO T, 1991, CANCER RES, V51, P5118; SEIZINGER BR, 1987, CELL, V49, P589, DOI 10.1016/0092-8674(87)90534-4; SIDELL N, 1988, CANCER RES, V48, P2226; SKUSE GR, 1995, LANCET, V345, P902, DOI 10.1016/S0140-6736(95)90015-2; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Tangir J, 1996, CANCER RES, V56, P2501; TSAO SW, 1995, EXP CELL RES, V218, P499, DOI 10.1006/excr.1995.1184; UCHIDA T, 1992, BIOCHEM BIOPH RES CO, V187, P332, DOI 10.1016/S0006-291X(05)81497-4; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Wertheim I, 1996, ONCOGENE, V12, P2147; WERTHEIM I, 1994, J NATL CANCER I, V86, P1549, DOI 10.1093/jnci/86.20.1549; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	40	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JAN 7	1999	18	1					257	262		10.1038/sj.onc.1202294	http://dx.doi.org/10.1038/sj.onc.1202294			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	159HG	9926941				2022-12-17	WOS:000078166000028
J	Hauser, PJ; Agrawal, D; Pledger, W				Hauser, PJ; Agrawal, D; Pledger, W			Primary keratinocytes have an adhesion dependent S phase checkpoint that is absent in immortalized cell lines	ONCOGENE			English	Article						keratinocyte; differentiation; S phase checkpoint; cyclin dependent kinase; p27(kip1)	CYCLIN-A; MURINE KERATINOCYTES; BALB/C-3T3 CELLS; GROWTH-FACTOR; MICE LACKING; IN-VITRO; EXPRESSION; DIFFERENTIATION; P27(KIP1); PROGRESSION	In order to understand the mechanism through which loss of anchorage inhibits growth, we have investigated the events that occur in murine keratinocytes upon substratum detachment utilizing both primary cells and established immortalized cell lines, Our data has revealed that while both primary and immortalized cells undergo growth arrest in suspension, the nature of this arrest is markedly different, Primary cells exhibit a growth arrest that is characterized by rapid cessation of DNA synthesis resulting in a static S phase population. In contrast, an immortalized non-tumorgenic cell line, Balb MK, exhibits growth arrest as measured by thymidine incorporation, but does not prevent cells that have entered S phase from continuing into G(2)/M, and accumulating as a 4N population. In contrast to both primary and MK cells, the tumorigenic SLC-1 cell line did not accumulate in a specific cell cycle interval and were able to undergo continuous growth in suspension, Examination of cyclin A protein and its associated activity revealed that cyclin A protein levels decreased in primary but not MK cells; suggesting the continued presence of cyclin A may allow continued DNA synthesis observed in MK cells. Furthermore, we demonstrate the accumulation of suspension cultured MK cells as a 4N population correlated with the loss of cyclin A/cdk2 kinase activity, which in turn occurred through the accumulation of p27(kip1), whereas neither p27(kip1) accumulation nor loss of cyclin A activity was observed in SLC-1 cells. Our results clearly reveal that the process of growth inhibition in suspension cultured cells may occur in several forms with distinct characteristics that are dependent on the status of cyclin/cdk complexes and CKI proteins. Tumor derived cells in suspension did not lose cyclin A dependent kinase activity and thus continued to grow and divide.	Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Med Microbiol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Vanderbilt Univ, Dept Cell Biol, Nashville, TN 37240 USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Vanderbilt University	Pledger, W (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr, Tampa, FL 33612 USA.				NCI NIH HHS [CA73780] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073780] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGRAWAL D, 1995, CELL GROWTH DIFFER, V6, P1199; Agrawal D, 1996, MOL CELL BIOL, V16, P4327; ASSELINEAU D, 1990, DIFFERENTIATION, V45, P221, DOI 10.1111/j.1432-0436.1990.tb00476.x; DROZDOFF V, 1993, J CELL BIOL, V123, P909, DOI 10.1083/jcb.123.4.909; EICHNER R, 1984, J CELL BIOL, V98, P1388, DOI 10.1083/jcb.98.4.1388; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; FUCHS E, 1993, J CELL SCI, P197; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hauser PJ, 1997, CELL GROWTH DIFFER, V8, P203; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; JIANG HP, 1994, ONCOGENE, V9, P3397; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NELSON WG, 1983, J CELL BIOL, V97, P244, DOI 10.1083/jcb.97.1.244; OLSON JE, 1993, J CELL PHYSIOL, V154, P333, DOI 10.1002/jcp.1041540217; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; ROTHNAGEL JA, 1994, GENOMICS, V23, P450, DOI 10.1006/geno.1994.1522; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; WALKER DH, 1991, NATURE, V354, P314, DOI 10.1038/354314a0; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; Zhu XY, 1996, J CELL BIOL, V133, P391, DOI 10.1083/jcb.133.2.391	30	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3083	3092		10.1038/sj.onc.1202235	http://dx.doi.org/10.1038/sj.onc.1202235			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872324				2022-12-17	WOS:000077517400002
J	Tanimoto, A; Chen, H; Kao, CY; Moran, E; Sasaguri, Y; Padmanabhan, R				Tanimoto, A; Chen, H; Kao, CY; Moran, E; Sasaguri, Y; Padmanabhan, R			Transactivation of the human cdc2 promoter by adenovirus E1A in cycling cells is mediated by induction of a 110-kDa CCAAT-box-binding factor	ONCOGENE			English	Article						cell cycle control; p34(cdc2) kinase; cell proliferation	RETINOBLASTOMA GENE-PRODUCT; IMR-90 DIPLOID FIBROBLASTS; TUMOR-SUPPRESSOR PROTEIN; E2F TRANSCRIPTION FACTOR; FISSION YEAST; DNA-REPLICATION; MAMMALIAN-CELLS; NF-Y; DEPENDENT KINASES; GROWTH SUPPRESSOR	Cyclin-dependent protein kinases (Cdks) are key regulatory proteins of the eukaryotic cell cycle. Cdc2 is expressed in late G1/S phase and functions in the G2 to M phase transition. Adenovirus E1A proteins are known to induce the expression of p34(cdc)2 and DNA synthesis in normal quiescent cells. In this study, mutational analysis of the human cdc2 promoter revealed that transactivation of the promoter by the E1A proteins in cycling cells is mediated through the two CCAAT box binding motifs. A 110-kDa protein (CBF/cdc2) was identified in nuclear extracts from monkey kidney (CV-1) cells stably expressing E1A as well as from adenovirus-transformed human 293 cells, Further, we show that this E1A-inducible CBF/cdc2 is related to the CBF which was shown to activate the heat shock protein 70 promoter. Analyses of the functional domain(s) of E1A required for the induction of the CBF and transactivation of the cdc2 promoter in these conditions revealed that E1A mutants which were defective in binding the pRB family of proteins or the cellular p300 protein were still active in assays measuring the induction of the CBF and transactivation of the cdc2 promoter, albeit with reduced efficiencies. But the E1A mutant which lost both functional domains was inactive in these assays. These results suggest that E1A has redundant functional domains for the induction of the 110-kDa CBF and activation of human cdc2 gene expression.	Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, Kansas City, KS 66160 USA; Temple Univ, Sch Med, Fels Inst Canc Res & Mol Biol, Philadelphia, PA 19140 USA; Univ Occupat & Environm Hlth, Dept Pathol & Cell Biol, Yahatanishi Ku, Kitakyushu, Fukuoka 807, Japan	University of Kansas; University of Kansas Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Occupational & Environmental Health - Japan	Padmanabhan, R (corresponding author), Univ Kansas, Med Ctr, Dept Biochem & Mol Biol, 3901 Rainbow Blvd, Kansas City, KS 66160 USA.				NATIONAL CANCER INSTITUTE [R01CA055330] Funding Source: NIH RePORTER; NCI NIH HHS [CA-55330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BECK GR, 1998, HUMAN TUMOR VIRUSES; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CHANG ZF, 1994, J BIOL CHEM, V269, P17893; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; Chen HF, 1996, J BIOL CHEM, V271, P13959, DOI 10.1074/jbc.271.24.13959; CHODOSH LA, 1988, CELL, V53, P25, DOI 10.1016/0092-8674(88)90484-9; Cobrinik D, 1996, CURR TOP MICROBIOL, V208, P31; Cress WD, 1996, CURR TOP MICROBIOL, V208, P63; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; DRAETTA G, 1988, ONCOGENE, V2, P553; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GOOD L, 1995, J CELL PHYSIOL, V163, P636, DOI 10.1002/jcp.1041630326; Gopalakrishnan S, 1997, CELL GROWTH DIFFER, V8, P541; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GRANA X, 1995, ONCOGENE, V11, P211; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HOWE JA, 1990, P NATL ACAD SCI USA, V87, P5883, DOI 10.1073/pnas.87.15.5883; HUGGETT AC, 1991, CANCER RES, V51, P5929; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KINGSTON RE, 1991, STABLE TRANSFER GENE; Kramer A, 1997, CANCER RES, V57, P5117; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; KU DH, 1993, J BIOL CHEM, V268, P2255; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LUM LSY, 1992, MOL CELL BIOL, V12, P2599, DOI 10.1128/MCB.12.6.2599; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P16574; Mal A, 1996, NATURE, V380, P262, DOI 10.1038/380262a0; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; MYMRYK JS, 1994, VIRUS RES, V33, P89, DOI 10.1016/0168-1702(94)90019-1; MYMRYK JS, 1994, ONCOGENE, V9, P1187; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PANG JH, 1993, J BIOL CHEM, V268, P2909; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1995, SEMIN CANCER BIOL, V6, P63, DOI 10.1006/scbi.1995.0009; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; QUINLAN MP, 1994, ONCOGENE, V9, P2639; RAYCHAUDHURI P, 1991, GENE DEV, V5, P1200, DOI 10.1101/gad.5.7.1200; REED SI, 1985, COLD SPRING HARB SYM, V50, P627, DOI 10.1101/SQB.1985.050.01.076; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Scolnick DM, 1997, CANCER RES, V57, P3693; SHENK T, 1991, ADV CANCER RES, V57, P47; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; SIMON MC, 1987, MOL CELL BIOL, V7, P2884, DOI 10.1128/MCB.7.8.2884; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Somasundaram K, 1997, ONCOGENE, V14, P1047, DOI 10.1038/sj.onc.1201002; SUBRAMANIAN T, 1988, ONCOGENE, V2, P105; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WANG HGH, 1995, J VIROL, V69, P7917, DOI 10.1128/JVI.69.12.7917-7924.1995; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WU CL, 1995, MOL CELL BIOL, V15, P2536; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	88	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 17	1998	17	24					3103	3114		10.1038/sj.onc.1202236	http://dx.doi.org/10.1038/sj.onc.1202236			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	147VF	9872326				2022-12-17	WOS:000077517400004
J	Lanoix, J; Mullick, A; He, YL; Brave, R; Skup, D				Lanoix, J; Mullick, A; He, YL; Brave, R; Skup, D			Wild-type egr1/Krox24 promotes and dominant-negative mutants inhibit, pluripotent differentiation of p19 embryonal carcinoma cells	ONCOGENE			English	Article						EC cells; differentiation; Krox24; egr1; transcription factors	BINDING TRANSCRIPTION FACTOR; ACID RECEPTORS RARS; RETINOIC ACID; GENE-EXPRESSION; PROTO-ONCOGENE; C-FOS; NEUROECTODERMAL DIFFERENTIATION; MICE LACKING; FACTOR EGR-1; NGFI-A	The zinc-finger transcription factor Krox24 was analysed for its role in differentiation in P19 embryonal carcinoma cells. Reciprocal dominant negative mutants consisting of Krox24 deleted for a crucial region of the zinc-finger domain (Delta Krox24) or of the zinc-finger region alone (Delta Krox24Zf) abolished the activation of transcription by Krox24 in P19 cells. Expression of Krox24 led to spontaneous differentiation of P19 cells in a lineage-independent fashion. Krox24 transfected populations, as well as individual clones randomly picked from them, displayed a nide array of diverse morphologies and expressed markers characteristic of a variety of differentiated cells. The dominant negative mutants blacked differentiation of P19 cells, We conclude that expression of Krox24 is sufficient for pluripotent differentiation of embryonal carcinoma cells, and that expression of Krox24 or other egr family members is essential to this process.	Univ Montreal, Inst Canc Montreal, Ctr Rech Louis Charles Simard, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Bristol Myers Squibb Pharmaceut Res Inst, Dept Oncol, Princeton, NJ 08543 USA	Universite de Montreal; Universite de Montreal; Bristol-Myers Squibb	Skup, D (corresponding author), Univ Montreal, Inst Canc Montreal, Ctr Rech Louis Charles Simard, 1560 Sherbrooke E, Montreal, PQ H2L 4M1, Canada.							BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2846, DOI 10.1128/MCB.13.5.2846; BERARD J, 1994, EMBO J, V13, P5570, DOI 10.1002/j.1460-2075.1994.tb06894.x; BERG RW, 1990, DEV BIOL, V138, P123, DOI 10.1016/0012-1606(90)90182-I; BERNSTEIN SH, 1991, CELL GROWTH DIFFER, V2, P273; BRULET P, 1980, P NATL ACAD SCI-BIOL, V77, P4113, DOI 10.1073/pnas.77.7.4113; CARMAN JA, 1995, DNA CELL BIOL, V14, P581, DOI 10.1089/dna.1995.14.581; Cui MZ, 1996, J BIOL CHEM, V271, P2731, DOI 10.1074/jbc.271.5.2731; DARLAND T, 1991, ONCOGENE, V6, P1367; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDWARDS SA, 1991, DEV BIOL, V148, P165, DOI 10.1016/0012-1606(91)90327-Y; GASHLER A, 1995, PROG NUCLEIC ACID RE, V50, P191, DOI 10.1016/S0079-6603(08)60815-6; HERDEGEN T, 1991, J COMP NEUROL, V313, P178, DOI 10.1002/cne.903130113; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KHACHIGIAN LM, 1995, J BIOL CHEM, V270, P27679, DOI 10.1074/jbc.270.46.27679; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; KRAMER B, 1994, BBA-GENE STRUCT EXPR, V1219, P413, DOI 10.1016/0167-4781(94)90066-3; KRISHNARAJU K, 1995, MOL CELL BIOL, V15, P5499; LANOIX J, 1991, CELL GROWTH DIFFER, V2, P391; LEE SL, 1995, J BIOL CHEM, V270, P9971, DOI 10.1074/jbc.270.17.9971; Lee SL, 1996, SCIENCE, V273, P1219, DOI 10.1126/science.273.5279.1219; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Levi G, 1996, DEVELOPMENT, V122, P113; LOHNES D, 1994, DEVELOPMENT, V120, P2723; LUO JM, 1995, MECH DEVELOP, V53, P61, DOI 10.1016/0925-4773(95)00424-6; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MCBURNEY MW, 1982, DEV BIOL, V89, P503, DOI 10.1016/0012-1606(82)90338-4; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; MENDELSOHN C, 1994, DEVELOPMENT, V120, P2749; MENDELSOHN C, 1994, DEV BIOL, V166, P246, DOI 10.1006/dbio.1994.1311; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; MULLER R, 1984, NATURE, V311, P438, DOI 10.1038/311438a0; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PETERSOHN D, 1995, J BIOL CHEM, V270, P24361, DOI 10.1074/jbc.270.41.24361; PRATT MAC, 1990, MOL CELL BIOL, V10, P6445, DOI 10.1128/MCB.10.12.6445; PRINCE VE, 1991, J VIROL, V65, P1801; ROSSANT J, 1982, J EMBRYOL EXP MORPH, V70, P99; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sambrook J, 1989, MOL CLONING LAB MANU; SCHNEIDERMAUNOURY S, 1993, CELL, V75, P1199, DOI 10.1016/0092-8674(93)90329-O; SCHUURING E, 1989, MOL CELL BIOL, V9, P1357, DOI 10.1128/MCB.9.3.1357; SEYFERT VL, 1990, SCIENCE, V250, P797, DOI 10.1126/science.2237429; SHAM MH, 1993, CELL, V72, P183, DOI 10.1016/0092-8674(93)90659-E; SKERKA C, 1995, J BIOL CHEM, V270, P22500, DOI 10.1074/jbc.270.38.22500; SOLTER D, 1978, P NATL ACAD SCI USA, V75, P5565, DOI 10.1073/pnas.75.11.5565; STARNAUD R, 1989, ONCOGENE, V4, P1077; STARNAUD R, 1993, MOL CELL BIOL, V13, P1590, DOI 10.1128/MCB.13.3.1590; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUVA LJ, 1991, MOL CELL BIOL, V11, P2503, DOI 10.1128/MCB.11.5.2503; THIEL G, 1994, J BIOL CHEM, V269, P15294; Topilko P, 1998, MOL ENDOCRINOL, V12, P107, DOI 10.1210/mend.12.1.0049; VIDRICAIRE G, 1994, DEVELOPMENT, V120, P115	60	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	NOV 12	1998	17	19					2495	2504		10.1038/sj.onc.1202166	http://dx.doi.org/10.1038/sj.onc.1202166			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	137QQ	9824160				2022-12-17	WOS:000076927300009
J	Zhao, JH; Inoue, T; Shoji, W; Nemoto, Y; Obinata, M				Zhao, JH; Inoue, T; Shoji, W; Nemoto, Y; Obinata, M			Direct association of YY-1 with c-Myc and the E-box binding protein in regulation of glycophorin gene expression	ONCOGENE			English	Article						c-Myc; YY-1; E-box binding protein; glycophorin; murine erythroleukemia cells	MURINE ERYTHROLEUKEMIA-CELLS; REGION-LIKE SEQUENCE; MOUSE GLYCOPHORIN; TRANSCRIPTIONAL REPRESSION; LEUCINE ZIPPER; DIFFERENTIATION; YY1; COMMITMENT; MAX; IDENTIFICATION	We previously reported that YY-1, a versatile transcription factor, regulates expression of glycophorin gene by binding to its locus control region-like region (Gp-LCR) in combination with E-box binding protein during murine erythroleukemia (MEL) cell differentiation. In the present work, we demonstrated that YY-I and c-Myc, a nuclear oncoprotein, were physically associated in vivo and that down regulation of c-Myc liberated free W-l from its complex, resulting in the functional binding of W-l to the Gp-LCR. We also showed that the E-box binding protein (EBP) which bound to E-box was physically associated with YY-1, facilitated binding of YY-I to the neighboring site and their combinatorial binding may stimulate the Gp-LCR mediated enhancement of erythroid-specific transcription of glycophorin gene in MEL cells.	Tohoku Univ, Dept Cell Biol, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan	Tohoku University	Obinata, M (corresponding author), Tohoku Univ, Dept Cell Biol, Inst Dev Aging & Canc, Aoba Ku, 4-1 Seiryomachi, Sendai, Miyagi 9808575, Japan.		Watanabe, Mamoru/AHE-0489-2022					AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; AYER DE, 1993, GENE DEV, V7, P2110, DOI 10.1101/gad.7.11.2110; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CROUCH DH, 1990, ONCOGENE, V5, P683; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DUNN BK, 1994, CELL GROWTH DIFFER, V5, P847; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; FREITAG SO, 1988, MOL CELL BIOL, V8, P1614; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; GUALBERTO A, 1992, MOL CELL BIOL, V12, P38; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; HOFFMANLIEBERMANN B, 1991, MOL CELL BIOL, V11, P2375, DOI 10.1128/MCB.11.5.2375; INOUYE CJ, 1994, J BIOL CHEM, V269, P6506; KUME TU, 1988, J MOL BIOL, V202, P779, DOI 10.1016/0022-2836(88)90558-X; LACHMAN HM, 1984, NATURE, V310, P592, DOI 10.1038/310592a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MARUYAMA K, 1987, ONCOGENE, V1, P261; MATSUI Y, 1989, GENE, V77, P325, DOI 10.1016/0378-1119(89)90080-2; MAY M, 1994, EMBO J, V13, P1460, DOI 10.1002/j.1460-2075.1994.tb06400.x; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; NATESAN S, 1993, GENE DEV, V7, P2497, DOI 10.1101/gad.7.12b.2497; Nemoto Y, 1996, J BIOL CHEM, V271, P13542, DOI 10.1074/jbc.271.23.13542; OHMORI Y, 1993, ONCOGENE, V8, P379; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Shaw P E, 1994, Methods Mol Biol, V30, P79; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHOJI W, 1993, JPN J CANCER RES, V84, P885, DOI 10.1111/j.1349-7006.1993.tb02062.x; SHRIVASTAVA A, 1993, SCIENCE, V262, P1889, DOI 10.1126/science.8266081; SMITH MJ, 1990, MOL CELL BIOL, V10, P5333, DOI 10.1128/MCB.10.10.5333; SPOTTS GD, 1990, MOL CELL BIOL, V10, P3952, DOI 10.1128/MCB.10.8.3952; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; TAKADA S, 1992, JPN J CANCER RES, V83, P61, DOI 10.1111/j.1349-7006.1992.tb02352.x; TERAJIMA M, 1995, J BIOCHEM-TOKYO, V118, P593, DOI 10.1093/oxfordjournals.jbchem.a124951; TERAJIMA M, 1994, J BIOCHEM-TOKYO, V116, P1105, DOI 10.1093/oxfordjournals.jbchem.a124634; USHVA A, 1994, CELL, V76, P1115; YAMAMOTO T, 1989, CELL DIFFER DEV, V28, P129, DOI 10.1016/0922-3371(89)90049-X	46	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 27	1998	17	8					1009	1017		10.1038/sj.onc.1202026	http://dx.doi.org/10.1038/sj.onc.1202026			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	113PR	9747880				2022-12-17	WOS:000075560900009
J	Givol, I; Givol, D; Hughes, SH				Givol, I; Givol, D; Hughes, SH			Overexpression of p21(waf1/cip1) arrests the growth of chicken embryo fibroblasts that overexpress E2F1	ONCOGENE			English	Article						retrovirus; growth suppressor; cell cycle; E2F; waf1/cip1	RETINOBLASTOMA SUSCEPTIBILITY GENE; CYCLIN-DEPENDENT KINASES; S-PHASE ENTRY; TRANSCRIPTION FACTOR; CELL-CYCLE; TRANS-ACTIVATION; BINDING PROTEIN; DNA-SYNTHESIS; EXPRESSION; APOPTOSIS	P21(waf1/cip1) is a potent inhibitor of cell cycle progression and can inhibit the growth of both normal cells and cells transformed by a number of oncogenes. However, the ability of p21(waf1/cip1) to inhibit the growth of cells that overexpress the transcriptional transactivator E2F1 is controversial: it has been reported both that E2F1 can and cannot overcome the block in the cell cycle induced by p21(waf1/cip1). To avoid the complications that arise when such experiments are done with permanent cell lines, we tested the effects of overexpressing p21(waf1/cip1) and E2F1 in primary chicken embryo fibroblasts. In this system very high levels of E2F1 overexpression cause considerable apoptosis; however, the surviving cells still overexpress E2F1. These cells are transformed and their growth is blocked by overexpression of p21(waf1/cip1).	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Weizmann Institute of Science	Hughes, SH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA.							Asano M, 1996, GENE DEV, V10, P1422, DOI 10.1101/gad.10.11.1422; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DEGREGORI J, 1995, GENE DEV, V9, P2873, DOI 10.1101/gad.9.23.2873; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FARNHAM PJ, 1993, BIOCHIM BIOPHYS ACTA, V1155, P125, DOI 10.1016/0304-419X(93)90001-S; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Givol I, 1995, ONCOGENE, V11, P2609; GIVOL I, 1994, CELL GROWTH DIFFER, V5, P419; GOODRICH DW, 1993, BIOCHIM BIOPHYS ACTA, V1155, P43, DOI 10.1016/0304-419X(93)90021-4; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Helin Kristian, 1993, Trends in Cell Biology, V3, P43, DOI 10.1016/0962-8924(93)90150-Y; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; Hollingsworth RE, 1993, CURR OPIN CELL BIOL, V5, P194, DOI 10.1016/0955-0674(93)90102-V; HUGHES S, 1984, VIROLOGY, V136, P89, DOI 10.1016/0042-6822(84)90250-2; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JOHNSON DG, 1994, P NATL ACAD SCI USA, V91, P12823, DOI 10.1073/pnas.91.26.12823; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KOVESDI I, 1986, CELL, V45, P219, DOI 10.1016/0092-8674(86)90386-7; KOWALIK TF, 1995, J VIROL, V69, P2491, DOI 10.1128/JVI.69.4.2491-2500.1995; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4923; LATHANGUE NB, 1994, TRENDS BIOCHEM SCI, V19, P108, DOI 10.1016/0968-0004(94)90202-X; Leone G, 1997, NATURE, V387, P422, DOI 10.1038/387422a0; Lloyd AC, 1997, GENE DEV, V11, P663, DOI 10.1101/gad.11.5.663; Lukas J, 1997, GENE DEV, V11, P1479, DOI 10.1101/gad.11.11.1479; Mann DJ, 1996, CURR BIOL, V6, P474, DOI 10.1016/S0960-9822(02)00515-8; Michieli P, 1996, ONCOGENE, V12, P775; Morgan DO, 1996, CURR OPIN CELL BIOL, V8, P767, DOI 10.1016/S0955-0674(96)80076-7; NEVINS JR, 1994, CURR OPIN GENET DEV, V4, P130, DOI 10.1016/0959-437X(94)90101-5; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; Petropoulos CJ, 1996, ONCOGENE, V12, P2611; QIN XQ, 1994, P NATL ACAD SCI USA, V91, P10918, DOI 10.1073/pnas.91.23.10918; SHAN B, 1992, MOL CELL BIOL, V12, P5620, DOI 10.1128/MCB.12.12.5620; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHAN B, 1994, MOL CELL BIOL, V14, P299, DOI 10.1128/MCB.14.1.299; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SINGH P, 1994, EMBO J, V13, P3329, DOI 10.1002/j.1460-2075.1994.tb06635.x; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; YMASAKI L, 1996, CELL, V85, P537; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	53	11	11	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3115	3122		10.1038/sj.onc.1201849	http://dx.doi.org/10.1038/sj.onc.1201849			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671390				2022-12-17	WOS:000074261300004
J	Marston, NJ; Ludwig, RL; Vousden, KH				Marston, NJ; Ludwig, RL; Vousden, KH			Activation of p53 DNA binding activity by point mutation	ONCOGENE			English	Article						p53; DNA binding; cell cycle arrest; apoptosis	HUMAN CANCER-CELLS; WILD-TYPE P53; MONOCLONAL-ANTIBODIES; TRANSCRIPTIONAL ACTIVATION; IMMUNOCHEMICAL ANALYSIS; MUTANT P53; PROTEIN; ARREST; TRANSFORMATION; APOPTOSIS	The p53 tumor suppressor protein can adopt both latent, non-DNA binding and active, DNA binding forms, and p53 activity is thought to be regulated in cells, at least in part, through a conformational shift which leads to sequence specific DNA binding. In vitro, this allosteric regulation of DNA binding by p53 has been shown to be mediated through the C-terminus of the protein. We show here that although deletion of the C-terminal 16 amino acids of p53 did not activate DNA binding, deletion of a further eight amino acids resulted in constitutive activation of DNA binding activity. Simultaneous mutation of the three lysine residues within these eight amino acids also resulted in constitutive DNA binding activity, although this was reduced when only two of these lysines were altered, The deletion or point mutants of p53 showing constitutive DNA binding activity did not display clear evidence of DNA binding site specificity, although some binding site preference was seen with the point mutants. Each of the constitutively active p53 mutants retained transcriptional activity and induced both cell cycle arrest and apoptosis in transiently transfected cells at rates comparable with the wild type protein.	NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Vousden, KH (corresponding author), NCI, Frederick Canc Res & Dev Ctr, ABL Basic Res Program, W 7th St, Frederick, MD 21702 USA.							ABARZUA P, 1995, CANCER RES, V55, P3490; Abarzua P, 1996, ONCOGENE, V13, P2477; Anderson ME, 1997, MOL CELL BIOL, V17, P6255, DOI 10.1128/MCB.17.11.6255; ATTARDI LD, 1996, EMBO J, V15, P3639; BANKS L, 1986, EUR J BIOCHEM, V159, P529, DOI 10.1111/j.1432-1033.1986.tb09919.x; BATES S, 1996, CURRENT OPIN GENET D, V6, P1; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CAELLES C, 1994, NATURE, V370, P220, DOI 10.1038/370220a0; CROOK T, 1994, CELL, V79, P817, DOI 10.1016/0092-8674(94)90071-X; Crook T, 1996, VIROLOGY, V217, P285, DOI 10.1006/viro.1996.0115; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fredersdorf S, 1996, AM J PATHOL, V148, P825; FREIDLANDER P, 1996, MOL CELL BIOL, V16, P4961; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HAINAUT P, 1993, CANCER RES, V53, P4469; HALAZONETIS TD, 1993, EMBO J, V12, P5057, DOI 10.1002/j.1460-2075.1993.tb06199.x; HALAZONETIS TD, 1993, EMBO J, V12, P1021, DOI 10.1002/j.1460-2075.1993.tb05743.x; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HAUPT Y, 1995, GENE DEV, V9, P2170, DOI 10.1101/gad.9.17.2170; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; HUPP TR, 1995, CELL, V83, P237, DOI 10.1016/0092-8674(95)90165-5; HUPP TR, 1995, J BIOL CHEM, V270, P18165, DOI 10.1074/jbc.270.30.18165; HUPP TR, 1994, COLD SPRING HARB SYM, V59, P195, DOI 10.1101/SQB.1994.059.01.024; HUPP TR, 1992, CELL, V71, P875, DOI 10.1016/0092-8674(92)90562-Q; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; JUVEN T, 1993, ONCOGENE, V8, P3411; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LAM EWF, 1993, EMBO J, V12, P2705, DOI 10.1002/j.1460-2075.1993.tb05932.x; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lu X, 1996, ONCOGENE, V13, P413; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Lutzker SG, 1996, NAT MED, V2, P804, DOI 10.1038/nm0796-804; MARSTON NJ, 1995, ONCOGENE, V10, P1709; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MIYASHITA T, 1995, CELL, V80, P293; RENZING J, 1995, ONCOGENE, V10, P1865; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; SABBATINI P, 1995, GENE DEV, V9, P2184, DOI 10.1101/gad.9.17.2184; Selivanova G, 1997, NAT MED, V3, P632, DOI 10.1038/nm0697-632; Shaw P, 1996, ONCOGENE, V12, P921; Sun Y, 1997, ONCOGENE, V14, P385, DOI 10.1038/sj.onc.1200834; TARUNINA M, 1993, ONCOGENE, V8, P3165; VOJTESEK B, 1992, J IMMUNOL METHODS, V151, P237, DOI 10.1016/0022-1759(92)90122-A; WADEEVANS A, 1985, EMBO J, V4, P699, DOI 10.1002/j.1460-2075.1985.tb03686.x; WALDMAN T, 1995, CANCER RES, V55, P5187; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; WEINBERG WC, 1995, ONCOGENE, V10, P2271	50	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUN 18	1998	16	24					3123	3131		10.1038/sj.onc.1201856	http://dx.doi.org/10.1038/sj.onc.1201856			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZV030	9671391				2022-12-17	WOS:000074261300005
J	Voncken, JW; Kaartinen, V; Groffen, J; Heisterkamp, N				Voncken, JW; Kaartinen, V; Groffen, J; Heisterkamp, N			Bcr/Abl associated leukemogenesis in bcr null mutant mice	ONCOGENE			English	Article						P190 Bcr/Abl; bcr null mutant; pre-B leukemia/lymphoma; Ph translocation	POSITIVE HUMAN LEUKEMIAS; TYROSINE PHOSPHORYLATION; RAS TRANSFORMATION; ABL ONCOPROTEINS; TRANSGENIC MICE; KINASE-ACTIVITY; GENE ENCODES; PROTEIN; ONCOGENE; EXON	The BCR gene contributes to Philadelphia-positive leukemogenesis via a number of discrete mechanisms, one of which may be through interaction of its normal gene product with the Bcr/Abl oncoprotein. In the current study this hypothesis was tested in vivo by introducing a Bcr/Abl P190 transgene into mice lacking endogenous bcr protein. Our finding, that the P190 BCR/ABL oncogene is still capable of producing leukemia in these mice with indistinguishable latency and clinical pattern as in genetically matched counterparts, rules out any significant or major contribution of the bcr protein as a whole to leukemia development in these mice.	Dept Pathol, Sect Mol Carcinogenesis, Los Angeles, CA 90027 USA; Childrens Hosp Los Angeles, Res Inst, Los Angeles, CA 90027 USA	Children's Hospital Los Angeles	Heisterkamp, N (corresponding author), Dept Pathol, Sect Mol Carcinogenesis, Ms 103,4650 Sunset Blvd, Los Angeles, CA 90027 USA.		Kaartinen, Vesa/AAU-5396-2021; Heisterkamp, Nora/C-1698-2012	Heisterkamp, Nora/0000-0003-2769-2273; Kaartinen, Vesa/0000-0002-9432-510X	NCI NIH HHS [CA47456, CA 50248] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050248, R55CA047456, R01CA047456] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHUANG TH, 1995, P NATL ACAD SCI USA, V92, P10282, DOI 10.1073/pnas.92.22.10282; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; Haataja L, 1997, J BIOL CHEM, V272, P20384, DOI 10.1074/jbc.272.33.20384; HART MJ, 1992, SCIENCE, V258, P812, DOI 10.1126/science.1439791; HART MJ, 1991, NATURE, V354, P311, DOI 10.1038/354311a0; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; LI WJ, 1989, ONCOGENE, V4, P127; LI WJ, 1988, ONCOGENE, V2, P559; Liu JX, 1996, CANCER RES, V56, P5120; Liu JX, 1996, MOL CELL BIOL, V16, P998; LIU JX, 1993, ONCOGENE, V8, P101; LU D, 1993, BLOOD, V82, P1257; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; McWhirter JR, 1997, ONCOGENE, V15, P1625, DOI 10.1038/sj.onc.1201342; MCWHIRTER JR, 1993, EMBO J, V12, P1533, DOI 10.1002/j.1460-2075.1993.tb05797.x; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/0092-8674(93)90689-N; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; STAM K, 1987, MOL CELL BIOL, V7, P1955, DOI 10.1128/MCB.7.5.1955; VONCKEN JW, 1992, BLOOD, V79, P1029; VONCKEN JW, 1995, CELL, V80, P719, DOI 10.1016/0092-8674(95)90350-X; VONCKEN JW, 1995, BLOOD, V86, P4603, DOI 10.1182/blood.V86.12.4603.bloodjournal86124603	28	11	11	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	APR 16	1998	16	15					2029	2032		10.1038/sj.onc.1201730	http://dx.doi.org/10.1038/sj.onc.1201730			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZH166	9591787				2022-12-17	WOS:000073079400015
J	Aniskovitch, LP; Jacob, ST				Aniskovitch, LP; Jacob, ST			Distinct rat proteins can recognize CCAAT-homologous sequences of the metallothionein promoter and trans-activate this promoter	ONCOGENE			English	Article						metallothionein-I promoter activation; hepatoma protein; liver protein	ENRICHED TRANSCRIPTIONAL ACTIVATOR; C/EBP-RELATED PROTEINS; BINDING-PROTEIN; GENE FAMILY; CYCLIC-AMP; POU-DOMAIN; FACTOR CP2; I GENE; EXPRESSION; LIVER	We have previously purified and characterized a rat liver protein C'BP-1 that is either identical or closely related to C/EBP delta (Aniskovitch and Jacob, 1997), The mouse metallothionein-I (MT-I) promoter contains two C'BP-1 binding sites, one of which includes the MRE-c' region (-135 to -110). The C'BP-1 binding activity was detected by EMSA as a major activity for MRE-c' in nonproliferating adult liver cells but not in rat hepatoma cells, In this study, we purified and characterized a factor, C'BP-2, which had a dominant binding activity for MRE-c' in Morris hepatoma 3924A, a poorly differentiated, fast-growing tissue, C'BP-2 is a 28 kDa protein which exists in solution as a monomer, As observed for C'BP-1, affinity-purified C'BP-2 stimulated transcription from the mMT-I gene promoter, DNase I footprinting revealed two C'BP-2 binding sites in the regions that overlap with the CCAAT homologies of the C'BP-1 binding sites on the mMT-I promoter, C'BP-2 made essential contacts with the CCAAT homology and in the region upstream of this sequence, Competition electrophoretic mobility shift assay and methylation interference analysis revealed that C'BP-2 is a protein closely related, but not identical, to CP2, These data suggest that C'BP-1 and C'BP-2 may play a role in hepatocyte proliferation and/or differentiation.	Ohio State Univ, Coll Med, Dept Biochem Med, Columbus, OH 43210 USA; Chicago Med Sch, Dept Mol Biol & Pharmacol, N Chicago, IL 60064 USA	Ohio State University; Chicago Medical School	Jacob, ST (corresponding author), Ohio State Univ, Coll Med, Dept Biochem Med, Columbus, OH 43210 USA.		Jacob, Samson/H-3135-2011		NCI NIH HHS [CA 61321] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061321] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aniskovitch LP, 1997, ARCH BIOCHEM BIOPHYS, V341, P337, DOI 10.1006/abbi.1997.9976; BALDWIN AS, 1988, CURRENT PROTOCOLS MO; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CARTER AD, 1984, P NATL ACAD SCI-BIOL, V81, P7392, DOI 10.1073/pnas.81.23.7392; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; DATTA PK, 1993, CELL MOL BIOL RES, V39, P439; Datta PK, 1997, BIOCHEM BIOPH RES CO, V230, P159, DOI 10.1006/bbrc.1996.5655; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DOOLEY S, 1992, BIOTECHNIQUES, V13, P540; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KIM CG, 1988, MOL CELL BIOL, V8, P4270, DOI 10.1128/MCB.8.10.4270; KURL RN, 1985, P NATL ACAD SCI USA, V82, P1059, DOI 10.1073/pnas.82.4.1059; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDOLFI NF, 1987, P NATL ACAD SCI USA, V84, P3851, DOI 10.1073/pnas.84.11.3851; LIM LC, 1993, J BIOL CHEM, V268, P18008; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; RIGGS AD, 1970, J MOL BIOL, V53, P401, DOI 10.1016/0022-2836(70)90074-4; ROSE KM, 1981, ISOZYMES-CURR T BIOL, V5, P115; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SWENDEMAN SL, 1994, J BIOL CHEM, V269, P11663; THOMASSIN H, 1992, NUCLEIC ACIDS RES, V20, P3091, DOI 10.1093/nar/20.12.3091; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553; ZIFF EB, 1990, TRENDS GENET, V6, P69, DOI 10.1016/0168-9525(90)90081-G	33	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 19	1998	16	11					1475	1486		10.1038/sj.onc.1201659	http://dx.doi.org/10.1038/sj.onc.1201659			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZC383	9525746				2022-12-17	WOS:000072572400011
J	Eshleman, JR; Donover, PS; Littman, SJ; Swinler, SE; Li, GM; Lutterbaugh, JD; Willson, JKV; Modrich, P; Sedwick, WD; Markowitz, SD; Veigl, ML				Eshleman, JR; Donover, PS; Littman, SJ; Swinler, SE; Li, GM; Lutterbaugh, JD; Willson, JKV; Modrich, P; Sedwick, WD; Markowitz, SD; Veigl, ML			Increased transversions in a novel mutator colon cancer cell line	ONCOGENE			English	Article						colon cancer; HPRT; mutator phenotype; transversions	DNA MISMATCH REPAIR; GROWTH-FACTOR-BETA; ESCHERICHIA-COLI; G.C->T.A TRANSVERSIONS; TUMOR-CELLS; MICROSATELLITE INSTABILITY; NUCLEAR EXTRACTS; HPRT GENE; MUTATIONS; YEAST	We describe a novel mutator phenotype in the Vaco411 colon cancer cell line which increases the spontaneous mutation rate 10-100-fold over background, This mutator results primarily in transversion base substitutions which are found infrequently in repair competent cells, Of the four possible types of transversions, only three were principally recovered, Spontaneous mutations recovered also included transitions and large deletions, but very few frameshifts were recovered, When compared to known mismatch repair defective colon cancer mutators, the distribution of mutations in Vaco411 is significantly different, Consistent with this difference, Vaco411 extracts are proficient in assays of mismatch repair, The Vaco411 mutator appears to be novel, and is not an obvious human homologue of any of the previously characterized bacterial or yeast transversion phenotypes, Several hypotheses by which this mutator may produce transversions are presented.	Univ Hosp Cleveland, Ireland Canc Ctr, Res Labs, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Dept Pathol, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Dept Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Dept Gen Med Sci, Cleveland, OH 44106 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Oncol, Durham, NC 27710 USA	University Hospitals of Cleveland; University Hospitals of Cleveland; University Hospitals of Cleveland; University Hospitals of Cleveland; Duke University; Duke University; Howard Hughes Medical Institute; Duke University	Veigl, ML (corresponding author), Univ Hosp Cleveland, Ireland Canc Ctr, Res Labs, Suite 200,UCRC II,11001 Cedar Ave, Cleveland, OH 44106 USA.		Li, Guo-Min/I-5016-2014	Li, Guo-Min/0000-0002-9842-4578; Modrich, Paul/0000-0001-8708-9885	NCI NIH HHS [CA67409, CA66628-01A1] Funding Source: Medline; NIEHS NIH HHS [ES05540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA066628, R01CA067409] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BHATTACHARYYA NP, 1995, HUM MOL GENET, V4, P2057, DOI 10.1093/hmg/4.11.2057; BHATTACHARYYA NP, 1994, P NATL ACAD SCI USA, V91, P6319, DOI 10.1073/pnas.91.14.6319; BRANCH P, 1995, CANCER RES, V55, P2304; CARIELLO NF, 1994, MUTAT RES, V312, P173, DOI 10.1016/0165-1161(94)90023-X; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Eshleman James R., 1995, Current Opinion in Oncology, V7, P83; Eshleman JR, 1996, ONCOGENE, V12, P1425; Eshleman JR, 1996, HUM MOL GENET, V5, P1489, DOI 10.1093/hmg/5.Supplement_1.1489; ESHLEMAN JR, 1995, ONCOGENE, V10, P33; FANG WH, 1993, J BIOL CHEM, V268, P11838; FAZAKERLEY GV, 1986, EMBO J, V5, P3697, DOI 10.1002/j.1460-2075.1986.tb04702.x; GIVER CR, 1993, ENVIRON MOL MUTAGEN, V22, P138, DOI 10.1002/em.2850220305; Glaab WE, 1997, CARCINOGENESIS, V18, P1, DOI 10.1093/carcin/18.1.1; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; KANG XL, 1992, GENETICS, V130, P285; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KOHALMI SE, 1993, MUTAT RES, V289, P73, DOI 10.1016/0027-5107(93)90132-Y; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; KOLODNER RD, 1995, TRENDS BIOCHEM SCI, V20, P397, DOI 10.1016/S0968-0004(00)89087-8; KUNZ BA, 1989, GENETICS, V122, P535; KUNZ BA, 1991, MOL CELL BIOL, V11, P218, DOI 10.1128/MCB.11.1.218; KUNZ BA, 1994, P NATL ACAD SCI USA, V91, P8165, DOI 10.1073/pnas.91.17.8165; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; LOEB LA, 1991, CANCER RES, V51, P3075; MARKOWITZ SD, 1994, J CLIN INVEST, V93, P1005, DOI 10.1172/JCI117048; MCBAIN JA, 1984, CANCER RES, V44, P5813; MCGREGOR WG, 1991, SOMAT CELL MOLEC GEN, V17, P463, DOI 10.1007/BF01233170; MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P9211, DOI 10.1073/pnas.87.23.9211; MICHAELS ML, 1992, P NATL ACAD SCI USA, V89, P7022, DOI 10.1073/pnas.89.15.7022; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J; PHEAR G, 1989, MOL CELL BIOL, V9, P1810, DOI 10.1128/MCB.9.4.1810; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; SCHAAPER RM, 1988, P NATL ACAD SCI USA, V85, P8126, DOI 10.1073/pnas.85.21.8126; SCHAAPER RM, 1989, EMBO J, V8, P3511, DOI 10.1002/j.1460-2075.1989.tb08516.x; SU SS, 1988, J BIOL CHEM, V263, P6829; Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x; WANG CY, 1995, CANCER RES, V55, P5101; YANOFSKY C, 1966, P NATL ACAD SCI USA, V55, P274, DOI 10.1073/pnas.55.2.274	44	11	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 5	1998	16	9					1125	1130		10.1038/sj.onc.1201629	http://dx.doi.org/10.1038/sj.onc.1201629			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ZA170	9528854				2022-12-17	WOS:000072336000003
J	Kwon, TK; Nordin, AA				Kwon, TK; Nordin, AA			Identification of cdk2 binding sites on the p27(Kip1) cyclin-dependent kinase inhibitor	ONCOGENE			English	Article						cell cycle; cdk inhibitors; p27(Kip1); cdk2; cyclin E; point mutations	CELL-CYCLE; POTENTIAL MEDIATOR; TUMOR SUPPRESSION; ARREST; P21; ACCUMULATION; INDUCTION; CLONING; PCNA; BETA	A cdk2 binding domain on p27(Kip1) located within the sequence of amino acids 53-85 was further characterized by generating a series of point mutations within amino acid residues 62-75. Two regions, FDF (residues 62-64) and GXY (residues 72 and 74), were identified within the beta hairpin region of p27(Kip1)., Mutations within these regions essentially completely inhibited the binding to in vitro translated cdk2 and cdk2/cyclin E complexes formed in vitro or in vivo., The p27(Kip1) GST-fusion protein of the point mutation that replaces phenylalanine at residue 64 to alanine (F64A) showed approximately twofold less inhibition of cdk2 kinase activity. The cellular response to the introduction of the F64A mutant form of p27(Kip1) was compared to that of p27(Kip1) wild type by transfecting HeLa cells with constructs of full length sense and antisense coding sequences, Overexpression of the F64A mutant form of p27(Kip1) bound significantly lower levels of cdk2 as compared to wild type and did not effect the cdk2 related kinase activity of the transfected HeLa cells. Overexpression of wild type p27(Kip1) resulted in a reduction of the level of cdk2 kinase activity and effectively suppressed the growth of the transfected HeLa cells.	NIA, Gerontol Res Ctr, Immunol Lab, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Nordin, AA (corresponding author), NIA, Gerontol Res Ctr, Immunol Lab, NIH, 4940 Eastern Ave,Box 21, Baltimore, MD 21224 USA.							Chen J, 1996, J CLIN INVEST, V97, P1983, DOI 10.1172/JCI118631; Chen JJ, 1996, NUCLEIC ACIDS RES, V24, P1727, DOI 10.1093/nar/24.9.1727; Chen JJ, 1996, MOL CELL BIOL, V16, P4673; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chesnut JD, 1996, J IMMUNOL METHODS, V193, P17, DOI 10.1016/0022-1759(96)00032-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fotedar R, 1996, ONCOGENE, V12, P2155; FRANCOISE G, 1995, ONCOGENE, V10, P2281; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; KATO JY, 1994, CELL, V79, P487, DOI 10.1016/0092-8674(94)90257-7; Kwon TK, 1996, CELL GROWTH DIFFER, V7, P1305; Kwon TK, 1996, BIOCHEM BIOPH RES CO, V220, P703, DOI 10.1006/bbrc.1996.0468; Lin JY, 1996, MOL CELL BIOL, V16, P1786; MICHIELI P, 1994, CANCER RES, V54, P3391; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHUHEI M, 1995, GENE DEV, V9, P650; Steffan NH, 1989, GENE, V77, P51; TOSHIYASU H, 1995, BLOOD, V86, P841; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	34	11	13	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE RG21 6XS, HAMPSHIRE, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 12	1998	16	6					755	762		10.1038/sj.onc.1201586	http://dx.doi.org/10.1038/sj.onc.1201586			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YW403	9488039				2022-12-17	WOS:000071931800007
J	Roy, WJ; Watson, RH; Hitchcock, A; Campbell, IG				Roy, WJ; Watson, RH; Hitchcock, A; Campbell, IG			Frequent loss of heterozygosity on chromosomes 7 and 9 in benign epithelial ovarian tumours	ONCOGENE			English	Article						benign; chromosome 6, 7, 9, 11 and 17; loss of heterozygosity; ovarian tumours; tumour suppressor genes, PCR, microsatellite	LOW-GRADE; CARCINOMA; MUTATION; TUMORS; P53; OVEREXPRESSION; REGION; CDKN2; GENE; RARE	It is presently unclear if ovarian cancers arise through malignant transformation of pre-existing benign tumours, The apparent rarity of loss of heterozygosity (LOH) reported for benign tumours has led to speculation that they lack malignant potential and represent a biological entity distinct from ovarian carcinoma, We reasoned that the absence of detectable LOH may be due to the masking of such losses by contamination with normal tissue present in excess in the majority of benign tumour biopsies, Therefore we utilized a microdissection technique to examine for LOH using 14 microsatellite markers on chromosome arms 6q, 7p, 7q, 9p, 11q and 17p in 31 solitary benign epithelial ovarian tumours, LOH was detected on all chromosome arms with the most frequent LOH occurring on 7p (27%) and 9p (26%), In addition, a point mutation in codon 157 of TP53 was detected in one tumour which is the first report of a TP53 mutation in a solitary benign ovarian tumour, In total 48% of tumours harboured genetic alterations which supports the idea that all benign ovarian tumours may carry a genetic predisposition to malignancy and are therefore not inherently different from their malignant counterparts.	UNIV SOUTHAMPTON,PRINCESS ANNE HOSP,SOUTHAMPTON SO16 5YA,HANTS,ENGLAND	University of Southampton			campbell, Ian G/F-6006-2011	Campbell, Ian/0000-0002-7773-4155				BERCHUCK A, 1994, GYNECOL ONCOL, V52, P232, DOI 10.1006/gyno.1994.1037; CAMPBELL IG, 1994, HUM MOL GENET, V3, P589, DOI 10.1093/hmg/3.4.589; CAMPBELL IG, 1995, INT J CANCER, V63, P222, DOI 10.1002/ijc.2910630213; CHENEVIXTRENCH G, 1994, AM J HUM GENET, V55, P143; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; DODSON MK, 1993, CANCER RES, V53, P4456; ENGLEFIELD P, 1994, BRIT J CANCER, V70, P905, DOI 10.1038/bjc.1994.418; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FOULKES WD, 1995, BRIT J CANCER, V72, P883, DOI 10.1038/bjc.1995.428; FOULKES WD, 1993, BRIT J CANCER, V67, P551, DOI 10.1038/bjc.1993.101; Gabra H, 1996, CANCER RES, V56, P950; Kerr J, 1996, ONCOGENE, V13, P1815; KIM JW, 1995, GYNECOL ONCOL, V57, P199, DOI 10.1006/gyno.1995.1125; MILNER BJ, 1993, CANCER RES, V53, P2128; ORPHANOS V, 1995, BRIT J CANCER, V71, P666, DOI 10.1038/bjc.1995.132; PULS LE, 1992, GYNECOL ONCOL, V47, P53, DOI 10.1016/0090-8258(92)90075-T; Salazar H, 1996, JNCI-J NATL CANCER I, V88, P1810, DOI 10.1093/jnci/88.24.1810; SCHULTZ DC, 1995, CANCER RES, V55, P2150; ZENKLUSEN JC, 1995, ONCOGENE, V11, P359; ZHENG JP, 1995, J NATL CANCER I, V87, P1146, DOI 10.1093/jnci/87.15.1146; ZHENG JP, 1993, CANCER RES, V53, P4138	21	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT 23	1997	15	17					2031	2035		10.1038/sj.onc.1201372	http://dx.doi.org/10.1038/sj.onc.1201372			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YC284	9366520				2022-12-17	WOS:A1997YC28400004
J	Li, M; Pullano, R; Yang, HL; Lee, HK; Miyamoto, NG; Filmus, J; Buick, RN				Li, M; Pullano, R; Yang, HL; Lee, HK; Miyamoto, NG; Filmus, J; Buick, RN			Transcriptional regulation of OCI-5/glypican 3: Elongation control of confluence-dependent induction	ONCOGENE			English	Article						proteoglycan; SGBS; intestine; promoter; elongation; confluence	HEPARAN-SULFATE PROTEOGLYCAN; RNA-POLYMERASE-II; GOLABI-BEHMEL SYNDROME; INCREASING CELL-DENSITY; PROTEIN-KINASE-C; Z-DNA; NERVOUS-SYSTEM; GENOMIC ORGANIZATION; OVERGROWTH SYNDROME; ENHANCER ELEMENTS	OCI-5/Glypican 3, a member of the glypican family of proteoglycans, is the defective gene in the Simpson-Golabi-Behmel overgrowth syndrome. OCI-5 expression is developmentally regulated in the intestinal epithelium, and the mechanism of its regulation was studied in the rat intestinal epithelial cell line IEC-18. A large induction of OCI-5 transcript and protein was observed at high cell density, Among other glypican family members, kappa-glypican also exhibited a confluence-dependent induction in select cell types. Nuclear run-on analysis indicated that cell-density regulation of OCI-5 occurs at the level of transcription, The rat and mouse OCI-5 promoters were cloned and found to be highly conserved, located within CpG islands and contain regions of alternating purine and pyrimidine residues, No TATA-box or recognizable INR element was observed, Consensus binding sites for AP-2, SP-1, zeste and NF-1/CTF are conserved across human, mouse and rat promoters, 5' deletion mapping of the rat promoter identified regions which enhance and repress promoter activity, with no apparent confluence-dependence or tissue-specificity. Nuclear run-on analysis probing different regions of the gene suggests that elongation control plays a role in the induction of OCI-5 by confluence.	UNIV TORONTO,SUNNYBROOK HLTH SCI CTR,DIV CANC RES,TORONTO,ON,CANADA; UNIV TORONTO,DEPT MED BIOPHYS,TORONTO,ON M5G 2M9,CANADA; BERLEX BIOSCI,DEPT IMMUNOL,RICHMOND,CA 94804	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto	Li, M (corresponding author), UNIV TORONTO,PRINCESS MARGARET HOSP,ONTARIO CANC INST,610 UNIV AVE,TORONTO,ON M5G 2M9,CANADA.		Li, Madeline/Q-8300-2017	Li, Madeline/0000-0002-3977-7437				Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BANERJEE R, 1986, P NATL ACAD SCI USA, V83, P4988, DOI 10.1073/pnas.83.14.4988; BENGAL E, 1991, J VIROL, V65, P4910, DOI 10.1128/JVI.65.9.4910-4918.1991; BENTLEY DL, 1995, CURR OPIN GENET DEV, V5, P210, DOI 10.1016/0959-437X(95)80010-7; BIGGIN MD, 1989, TRENDS GENET, V5, P377, DOI 10.1016/0168-9525(89)90173-X; BIRD AP, 1989, NUCLEIC ACIDS RES, V17, P9485, DOI 10.1093/nar/17.22.9485; BLAT C, 1994, EXP CELL RES, V215, P114, DOI 10.1006/excr.1994.1322; BOST LM, 1993, GROWTH FACTORS, V9, P195, DOI 10.3109/08977199309010832; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; DAVID G, 1990, J CELL BIOL, V111, P3165, DOI 10.1083/jcb.111.6.3165; DAVID G, 1993, FASEB J, V7, P1023, DOI 10.1096/fasebj.7.11.8370471; ELLIOTT EM, 1985, CAN J BIOCHEM CELL B, V63, P511, DOI 10.1139/o85-070; FILMUS J, 1988, MOL CELL BIOL, V8, P4243, DOI 10.1128/MCB.8.10.4243; FILMUS J, 1995, BIOCHEM J, V311, P561, DOI 10.1042/bj3110561; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUNG WP, 1987, J BIOL CHEM, V262, P9298; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOLABI M, 1984, AM J MED GENET, V17, P345, DOI 10.1002/ajmg.1320170128; HAMBURGER AW, 1991, PATHOBIOLOGY, V59, P329, DOI 10.1159/000163672; HANES SD, 1991, SCIENCE, V251, P426, DOI 10.1126/science.1671176; HARDINGHAM TE, 1992, FASEB J, V6, P861, DOI 10.1096/fasebj.6.3.1740236; HU YL, 1993, J BIOL CHEM, V268, P27214; HU ZB, 1995, LEUKEMIA, V9, P789; HUGHESBENZIE RM, 1992, AM J MED GENET, V43, P428, DOI 10.1002/ajmg.1320430165; HughesBenzie RM, 1996, AM J MED GENET, V66, P227, DOI 10.1002/(SICI)1096-8628(19961211)66:2<227::AID-AJMG20>3.0.CO;2-U; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; INGBER DE, 1993, CELL, V75, P1249, DOI 10.1016/0092-8674(93)90612-T; INGBER DE, 1994, INT REV CYTOL, V150, P173; Iwasaki T, 1996, J BIOL CHEM, V271, P22183, DOI 10.1074/jbc.271.36.22183; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAMINE J, 1993, J VIROL, V67, P6828, DOI 10.1128/JVI.67.11.6828-6834.1993; KITAOKA T, 1993, CURR EYE RES, V12, P993, DOI 10.3109/02713689309029225; KRAJEWSKI WA, 1995, FEBS LETT, V358, P13, DOI 10.1016/0014-5793(94)01377-D; KRUMM A, 1995, GENE DEV, V9, P559, DOI 10.1101/gad.9.5.559; KRUMM A, 1992, GENE DEV, V6, P2201, DOI 10.1101/gad.6.11.2201; KUMATORI A, 1991, BIOCHEM BIOPH RES CO, V178, P480, DOI 10.1016/0006-291X(91)90132-Q; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LEUNG S, 1989, NUCLEIC ACIDS RES, V17, P1177, DOI 10.1093/nar/17.3.1177; LI M, 1997, IN PRESS EXP CELL RE; Lindsay S, 1997, J MED GENET, V34, P480, DOI 10.1136/jmg.34.6.480; LITWACK ED, 1994, J NEUROSCI, V14, P3713; LORIES V, 1992, J BIOL CHEM, V267, P1116; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NAKATO H, 1995, DEVELOPMENT, V121, P3687; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NORDHEIM A, 1983, NATURE, V303, P674, DOI 10.1038/303674a0; Oesterreich S, 1996, BIOCHEM BIOPH RES CO, V222, P155, DOI 10.1006/bbrc.1996.0714; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; PEREZCASTRO AV, 1995, GENOMICS, V30, P157, DOI 10.1006/geno.1995.9890; Perkinson RA, 1996, J CELL BIOCHEM, V63, P74; Pilia G, 1996, NAT GENET, V12, P241, DOI 10.1038/ng0396-241; RAJAGOPALAN M, 1990, J BIOL CHEM, V265, P17294; RAJCHEL A, 1988, NUCLEIC ACIDS RES, V16, P2347, DOI 10.1093/nar/16.5.2347; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SATO T, 1995, J BIOL CHEM, V270, P10314, DOI 10.1074/jbc.270.17.10314; STIPP CS, 1994, J CELL BIOL, V124, P149, DOI 10.1083/jcb.124.1.149; TERESPOLSKY D, 1995, AM J MED GENET, V59, P329, DOI 10.1002/ajmg.1320590310; TSAO YP, 1989, CELL, V56, P111, DOI 10.1016/0092-8674(89)90989-6; Veugelers M, 1997, GENOMICS, V40, P24, DOI 10.1006/geno.1996.4518; WATANABE K, 1995, J CELL BIOL, V130, P1207, DOI 10.1083/jcb.130.5.1207; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WICE BM, 1995, J BIOL CHEM, V270, P21907, DOI 10.1074/jbc.270.37.21907; Wolfl S, 1996, P NATL ACAD SCI USA, V93, P3664, DOI 10.1073/pnas.93.8.3664; YU M, 1995, ARCH BIOCHEM BIOPHYS, V316, P407, DOI 10.1006/abbi.1995.1054	67	11	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP 25	1997	15	13					1535	1544		10.1038/sj.onc.1201325	http://dx.doi.org/10.1038/sj.onc.1201325			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XX369	9380405				2022-12-17	WOS:A1997XX36900004
J	Cabannes, E; Vives, MF; Bedard, PA				Cabannes, E; Vives, MF; Bedard, PA			Transcriptional and post-transcriptional regulation of kappa B-controlled genes by pp(60v-src)	ONCOGENE			English	Article						gene expression; pp60(v-src); transformation; NF-kappa B	ROUS-SARCOMA VIRUS; CHICKEN SPLEEN-CELLS; SRC-INDUCIBLE GENE; V-REL ONCOPROTEIN; TRANSFORMED-CELLS; PLATELET PROTEIN; TYROSINE KINASES; GROWTH-FACTOR; AVIAN CELLS; T-CELLS	The CEF-4/9E3 gene is expressed aberrantly in chicken embryo fibroblasts transformed by the Rous sarcoma virus, This aberrant expression is dependent on transcriptional activation and on the stabilization of the CEF-4 mRNA, The characterization of the CEF-4 promoter indicated that three distinct regulatory elements corresponding to an AP-1 binding site, a PRDII/kappa-B domain and a CAAT box are involved in the activation by pp60(v-src). Several v-src responsive genes are controlled by AP-1 and members of the Ets family but few appear to be dependent on NF-kappa B. In this study me characterize the expression of genes regulated by NF-kappa B in normal and RSV-transformed CEF, Run-on transcription analysis indicated that pp60(v-src) induces the transcription of several genes controlled by NF-kappa B but at different levels, While the transcription of CEF-4 was strongly stimulated, that of NF-kappa B1, c-rel, p53 or I kappa B-alpha was activated more modestly by pp60(v-src). In addition the CEF-4 mRNA mas the only mRNA species to accumulate significantly in transformed CEF, The ectopic expression of RelA or Rel resulted in the stimulation of the transcription of several known targets of NF-kappa B, However, the mRNA for I kappa B-alpha was the only mRNA species to accumulate considerably in the RelA- or Rel-expressing cells, Hence for most kappa B-controlled genes, transcriptional activation was not sufficient to obtain a significant increase in mRNA expression, Likewise, RelA or Rel enhanced the transcription of the CEF-4 gene without a significant accumulation of the CEF-4 mRNA, However, transformation by v-src caused a massive accumulation of the CEF-4 mRNA but not of other mRNA species in the RelA- and Rel-expressing cells, Transient expression assays, run-on transcription and Northern blotting analyses indicated that the effect of pp60(v-src) on CEF-4 expression was mediated predominantly at the post-transcriptional level in these cells, Therefore transcriptional and post-transcriptional mechanisms determine the restricted pattern of activation of kappa B-controlled genes in RSV-transformed CEF.	YORK UNIV, DEPT BIOL, N YORK, ON M3J 1P3, CANADA; UNIV MONTREAL, DEPT BIOCHIM, MONTREAL, PQ H3C 3J7, CANADA	York University - Canada; Universite de Montreal								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ARIMA N, 1991, J VIROL, V65, P6892, DOI 10.1128/JVI.65.12.6892-6899.1991; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BEDARD PA, 1989, MOL CELL BIOL, V9, P1371, DOI 10.1128/MCB.9.3.1371; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BEG AA, 1995, GENE DEV, V9, P2736, DOI 10.1101/gad.9.22.2736; BLOBEL GA, 1991, P NATL ACAD SCI USA, V88, P1162, DOI 10.1073/pnas.88.4.1162; BRUDER JT, 1993, NUCLEIC ACIDS RES, V21, P5229, DOI 10.1093/nar/21.22.5229; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BULL P, 1990, MOL CELL BIOL, V10, P5473, DOI 10.1128/MCB.10.10.5473; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CAPOBIANCO AJ, 1991, ONCOGENE, V6, P2203; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DEHBI M, 1992, BIOCHEM CELL BIOL, V70, P980, DOI 10.1139/o92-142; DEHBI M, 1992, MOL CELL BIOL, V12, P1490, DOI 10.1128/MCB.12.4.1490; DEHBI M, 1994, ONCOGENE, V9, P2399; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EICHER DM, 1994, J IMMUNOL, V152, P2710; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GILLET G, 1995, EMBO J, V14, P1372, DOI 10.1002/j.1460-2075.1995.tb07123.x; GONNEVILLE L, 1991, ONCOGENE, V6, P1825; Good LF, 1996, J VIROL, V70, P2730, DOI 10.1128/JVI.70.5.2730-2735.1996; GRANGERSCHNARR M, 1992, P NATL ACAD SCI USA, V89, P4236, DOI 10.1073/pnas.89.10.4236; GROUDINE M, 1980, P NATL ACAD SCI-BIOL, V77, P5351, DOI 10.1073/pnas.77.9.5351; HANNINK M, 1990, ONCOGENE, V5, P1843; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; HRDLICKOVA R, 1995, J VIROL, V69, P403; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; JAHNER D, 1991, ONCOGENE, V6, P1259; Johnson R, 1996, MOL CELL BIOL, V16, P4504; KOWALIK TF, 1993, P NATL ACAD SCI USA, V90, P1107, DOI 10.1073/pnas.90.3.1107; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; LACOSTE J, 1995, J VIROL, V69, P564, DOI 10.1128/JVI.69.1.564-569.1995; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LLOYD A, 1991, NATURE, V352, P632, DOI 10.1038/352635a0; LOGEAT F, 1991, EMBO J, V10, P1827, DOI 10.1002/j.1460-2075.1991.tb07708.x; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARONEY AC, 1992, ONCOGENE, V7, P1207; PETROPOULOS CJ, 1991, J VIROL, V65, P3728, DOI 10.1128/JVI.65.7.3728-3737.1991; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Schmitz ML, 1996, MOL CELL BIOL, V16, P4052; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; STOECKLE MY, 1989, MOL CELL BIOL, V9, P4738, DOI 10.1128/MCB.9.11.4738; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SUZUKI T, 1994, J VIROL, V68, P3527, DOI 10.1128/JVI.68.6.3527-3535.1994; VIVES MF, 1995, THESIS U MONTREAL; WASYLYK C, 1994, ONCOGENE, V9, P3665; WELHAM MJ, 1990, ONCOGENE, V5, P161; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	58	11	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 3	1997	15	1					29	43		10.1038/sj.onc.1201162	http://dx.doi.org/10.1038/sj.onc.1201162			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XH586	9233775				2022-12-17	WOS:A1997XH58600004
J	Rahman, N; Arbour, L; Tonin, P; Baruchel, S; PritchardJones, K; Narod, SA; Stratton, MR				Rahman, N; Arbour, L; Tonin, P; Baruchel, S; PritchardJones, K; Narod, SA; Stratton, MR			The familial Wilms' tumour susceptibility gene, FWT1, may not be a tumour suppressor gene	ONCOGENE			English	Article						Wilms' tumour; loss of heterozygosity; dominant oncogene; tumour suppressor gene	MEDULLARY-THYROID CARCINOMA; ENDOCRINE NEOPLASIA TYPE-2A; RET PROTOONCOGENE; MUTATIONS; NEUROFIBROMATOSIS; PREDISPOSITION; ALLELES; CANCER; HETEROZYGOSITY; CHROMOSOME-11	A familial Wilms' tumour susceptibility gene, known as FWT1, has recently been localised to chromosome 17q12-q21 by genetic linkage analysis, Four Wilms' tumours from a family showing strong evidence of linkage to FWT1 were examined for allele loss using polymorphic microsatellite markers on chromosome 17q, In three tumours no loss of heterozygosity was observed, In the remaining case, loss of heterozygosity was detected at all markers analysed, However, the alleles lost in this Wilms' tumour were those segregating with the disease in the family, This is in contrast to the usual pattern observed in familial cancer syndromes, where the allele lost in tumours arising in gene carriers is the wild type inherited from the non mutation carrying parent, Taken together with previous data indicating that LOH on chromosome 17q is rare in sporadic Wilms' tumour, the results suggest that FWT1 is not a tumour suppressor gene, Moreover, loss of alleles linked to the disease and the implied absence of the mutated susceptibility gene in one tumour, suggests that a mutation in FWT1 may be necessary for the initiation of some familial Wilms' tumours but subsequently the maintenance of the neoplastic phenotype becomes independent of the FWT1 mutation.	INST CANC RES,PAEDIAT SECT,SUTTON SM2 5NG,SURREY,ENGLAND; MCGILL UNIV,DEPT MED,DIV MED GENET,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT HUMAN GENET,DIV MED GENET,MONTREAL,PQ,CANADA; MCGILL UNIV,DEPT PEDIAT ONCOL,MONTREAL,PQ,CANADA; MONTREAL CHILDRENS HOSP,RES INST,MONTREAL,PQ H3H 1P3,CANADA; WOMENS COLL HOSP,TORONTO,ON M5S 1B2,CANADA	University of London; Institute of Cancer Research - UK; McGill University; McGill University; McGill University; McGill University; University of Toronto; University Toronto Affiliates; Womens College Hospital	Rahman, N (corresponding author), INST CANC RES,SECT MOL CARCINOGENESIS,15 COTSWOLD RD,SUTTON SM2 5NG,SURREY,ENGLAND.		Narod, Steven A/AAA-6112-2022; Rahman, Nazneen/B-8890-2012; Pritchard-Jones, Kathy/F-4286-2014; Rahman, Nazneen/D-2802-2013	Pritchard-Jones, Kathy/0000-0002-2384-9475; Rahman, Nazneen/0000-0003-4376-0440; Arbour, Laura/0000-0002-9589-0880				BIGGS PJ, 1995, NAT GENET, V12, P441; BRESLOW NE, 1982, JNCI-J NATL CANCER I, V68, P429; CARLSON KM, 1994, P NATL ACAD SCI USA, V91, P1579, DOI 10.1073/pnas.91.4.1579; CAVENEE WK, 1985, SCIENCE, V228, P501, DOI 10.1126/science.3983638; COLLINS N, 1995, ONCOGENE, V10, P1673; ENG C, 1995, GENE CHROMOSOME CANC, V12, P209, DOI 10.1002/gcc.2870120308; GRUNDY P, 1988, NATURE, V336, P374, DOI 10.1038/336374a0; HEMMINKI A, 1994, NAT GENET, V8, P405, DOI 10.1038/ng1294-405; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; HUFF V, 1992, CANCER RES, V52, P6117; HUFF V, 1988, NATURE, V336, P377, DOI 10.1038/336377a0; KELLER HD, 1993, HUM MOL GENET, V2, P851; KNUDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914, DOI 10.1073/pnas.90.23.10914; LANDSVATER RM, 1989, GENOMICS, V4, P246, DOI 10.1016/0888-7543(89)90327-3; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LEVY DB, 1994, CANCER RES, V54, P5953; MAW MA, 1992, CANCER RES, V52, P3094; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1993, GENE CHROMOSOME CANC, V6, P166, DOI 10.1002/gcc.2870060307; NAKAMURA T, 1994, J PATHOL, V172, P255, DOI 10.1002/path.1711720305; NELKIN BD, 1989, CANCER RES, V49, P4114; PAL N, 1990, ONCOGENE, V5, P1665; Rahman N, 1996, NAT GENET, V13, P461, DOI 10.1038/ng0896-461; SANTORO M, 1995, SCIENCE, V267, P381, DOI 10.1126/science.7824936; SCHWARTZ CE, 1991, GENOMICS, V10, P927, DOI 10.1016/0888-7543(91)90181-D; SHUIN T, 1994, CANCER RES, V54, P2852; SMITH SA, 1992, NAT GENET, V2, P128, DOI 10.1038/ng1092-128; TWIST EC, 1994, HUM MOL GENET, V3, P147, DOI 10.1093/hmg/3.1.147; WADEY RB, 1990, ONCOGENE, V5, P901; Xing SH, 1996, ENDOCRINOLOGY, V137, P1512, DOI 10.1210/en.137.5.1512; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411	31	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 26	1997	14	25					3099	3102		10.1038/sj.onc.1201107	http://dx.doi.org/10.1038/sj.onc.1201107			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223674				2022-12-17	WOS:A1997XG10000013
J	Rhodes, N; Innes, CL; Propst, F; Paules, RS				Rhodes, N; Innes, CL; Propst, F; Paules, RS			Serum starved v-mos-transformed cells are unable to appropriately downregulate cyclins and CDKs	ONCOGENE			English	Article						v-mos-transformed cells; cdk; cyclin; quiescence; cell cycle control; cancer	MAP KINASE-KINASE; CDC2 PROTEIN-KINASE; MURINE SARCOMA-VIRUS; HUMAN BREAST-CANCER; S-PHASE; XENOPUS-OOCYTES; PROTOONCOGENE EXPRESSION; DEVELOPMENTAL REGULATION; MAMMALIAN FIBROBLASTS; DEPENDENT KINASES	Serum deprived v-mos-transformed NIH3T3 cells are unable to enter a true quiescent state, but instead, arrest in the early G1 phase of the cell cycle, We have analysed several cell cycle regulatory proteins in these G1 arrested cells and show altered regulation in the expression and activity of certain cyclins and cyclin-dependent kinases, In particular, p34(cdc2), cyclin A, cyclin D and cyclin E are not appropriately down-regulated in serum starved, G1 arrested, v-mos-transformed cells as compared with quiescent NIH3T3 cells, Furthermore, serum starved v-mos-transformed cells have elevated histone H1 kinase activity associated with cyclin A, cyclin E, p33(cdk2), and p34(cdc2), Using a metallothionein-inducible c-mos(mu) expression system, we show that c-mos(mu) induction in quiescent NIH3T3 cells causes elevated expression of p34(cdc2). However, this induction of c-mos(mu) and subsequent expression of p34(cdc2) was not sufficient to promote significant entry of cells into S phase, Analysis of extracts from serum starved v-H-ras, v-src, and tpr-met transformed NIH3T3 cells demonstrates that these oncogene-transformed cells also contain elevated levels of p34(cdc2). We propose that the altered regulation of these critical cell cycle regulatory molecules, and specifically the inability to fully downregulate their activity, contributes significantly to neoplastic transformation and subsequent unregulated growth of tumor cells.	NIEHS, GROWTH CONTROL & CANC GRP, RES TRIANGLE PK, NC 27709 USA; UNIV VIENNA, INST BIOCHEM & MOL CELL BIOL, VIENNA BIOCTR, A-1030 VIENNA, AUSTRIA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Vienna; Vienna Biocenter (VBC)				Paules, Richard S/0000-0001-9106-7486				ARNOLD A, 1991, COLD SPRING HARB SYM, V56, P93; Ausubel FM, 1992, CURRENT PROTOCOLS MO; BLAIR DG, 1981, SCIENCE, V212, P941, DOI 10.1126/science.7233190; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; CANAANI E, 1979, NATURE, V282, P378, DOI 10.1038/282378a0; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CHOO KH, 1986, DNA-J MOLEC CELL BIO, V5, P529, DOI 10.1089/dna.1.1986.5.529; Cobb MH, 1991, CURR OPIN CELL BIOL, V3, P1025, DOI 10.1016/0955-0674(91)90124-H; COLLEDGE WH, 1994, NATURE, V370, P65, DOI 10.1038/370065a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DONOGHUE DJ, 1983, J VIROL, V45, P607, DOI 10.1128/JVI.45.2.607-617.1983; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; FAUST JB, 1992, CANCER RES, V52, P2460; FILMUS J, 1994, ONCOGENE, V9, P3627; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; GABRIELLI BG, 1993, SCIENCE, V259, P1766, DOI 10.1126/science.8456304; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOLDMAN DS, 1987, P NATL ACAD SCI USA, V84, P4509, DOI 10.1073/pnas.84.13.4509; GUADAGNO TM, 1993, SCIENCE, V262, P1572, DOI 10.1126/science.8248807; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; HASHIMOTO N, 1994, NATURE, V370, P68, DOI 10.1038/370068a0; HENGLEIN B, 1994, P NATL ACAD SCI USA, V91, P5490, DOI 10.1073/pnas.91.12.5490; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; HINDS PW, 1994, P NATL ACAD SCI USA, V91, P709, DOI 10.1073/pnas.91.2.709; JEHN B, 1992, MOL CELL BIOL, V12, P3890, DOI 10.1128/MCB.12.9.3890; JOHNSON DG, 1993, NATURE, V365, P349, DOI 10.1038/365349a0; KESHET E, 1988, ONCOGENE, V2, P235; KEYOMARSI K, 1994, CANCER RES, V54, P380; KEYOMARSI K, 1993, P NATL ACAD SCI USA, V90, P1112, DOI 10.1073/pnas.90.3.1112; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LEACH FS, 1993, CANCER RES, V53, P1986; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LI CCH, 1993, ONCOGENE, V8, P1685; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARRACCINO RL, 1992, MOL BIOL CELL, V3, P389, DOI 10.1091/mbc.3.4.389; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MINSHULL J, 1989, J CELL SCI, P77; MINSHULL J, 1990, EMBO J, V9, P2865, DOI 10.1002/j.1460-2075.1990.tb07476.x; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MOTOKURA T, 1993, GENE CHROMOSOME CANC, V7, P89, DOI 10.1002/gcc.2870070205; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MUSGROVE EA, 1993, MOL CELL BIOL, V13, P3577, DOI 10.1128/MCB.13.6.3577; MUTTER GL, 1987, P NATL ACAD SCI USA, V84, P5301, DOI 10.1073/pnas.84.15.5301; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIZAWA M, 1993, EMBO J, V12, P4021, DOI 10.1002/j.1460-2075.1993.tb06080.x; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; OKAZAKI K, 1992, EMBO J, V11, P2447, DOI 10.1002/j.1460-2075.1992.tb05309.x; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; OSKARSSON M, 1980, SCIENCE, V207, P1222, DOI 10.1126/science.6243788; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; PROPST F, 1987, MOL CELL BIOL, V7, P1629, DOI 10.1128/MCB.7.5.1629; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RHODES N, 1994, EXP CELL RES, V213, P210, DOI 10.1006/excr.1994.1192; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TOURAY M, 1991, ONCOGENE, V6, P211; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUI LV, 1993, INT J ONCOL, V2, P493; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WELCH PJ, 1992, P NATL ACAD SCI USA, V89, P3093, DOI 10.1073/pnas.89.7.3093; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHOU RP, 1992, MOL CELL BIOL, V12, P3583, DOI 10.1128/MCB.12.8.3583; ZINDY F, 1992, BIOCHEM BIOPH RES CO, V182, P1144, DOI 10.1016/0006-291X(92)91851-G	89	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	1997	14	25					3017	3027		10.1038/sj.onc.1201158	http://dx.doi.org/10.1038/sj.onc.1201158			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XG100	9223665				2022-12-17	WOS:A1997XG10000004
J	Bosse, P; Bernex, F; DeSepulveda, P; Salaun, P; Panthier, JJ				Bosse, P; Bernex, F; DeSepulveda, P; Salaun, P; Panthier, JJ			Multiple neuroendocrine tumours in transgenic mice induced by c-kit-SV40 T antigen fusion genes	ONCOGENE			English	Article						receptor tyrosine kinase; c-kit; stem cell factor; SV40 T antigen; neuroendocrine system; neoplasia	STEM-CELL FACTOR; NEURON-SPECIFIC ENOLASE; C-KIT RECEPTOR; PROOPIOMELANOCORTIN GENE; EXPRESSION; MOUSE; LINES; PROMOTER; PROTOONCOGENE; ENDOCRINE	Transgenic mice carrying either a 1.008 or a 4.225 kb of the mouse c-kit 5'-flanking sequences linked to the oncogenic large T antigen (TAg) region of the sinian virus 40 (SV40) genome were generated to test if the c-kit promoter could be used to develop useful mouse models. Both constructs promote tumourigenesis in the pituitary and the thyroid with high efficiency. The cell types from which each of these tumours derives were identified. Tumours of the pituitary derive from alpha-MSH-expressing cells located in the intermediate lobe, Transformed cells of the thyroid were calcitonin-positive, implying that the tumours derive from C cells or their precursors, Chromogranin A and neuron-specific enolase, general neuroendocrine cell markers, were expressed in both tumour types. Furthermore a variety of tumours appeared in the transgenic mice. Several of them stained positively for chromogranin A and/or neuron-specific enolase, This suggests a previously unsuspected tissue-specificity of the c-kit 5' flanking sequences for neuroendocrine cells. The Kit-TAg transgenic mouse Lines may represent a valuable model for the study of the development and the biology of neuroendocrine tumours.	ECOLE NATL VET,URA,INRA GENET MOL,F-94704 MAISONS ALFORT,FRANCE	Ecole Nationale Veterinaire d'Alfort (ENVA); INRAE			PANTHIER, Jean-Jacques/I-4366-2014; De sepulveda, paulo/K-6043-2015	PANTHIER, Jean-Jacques/0000-0002-7966-0663; De sepulveda, paulo/0000-0001-8295-5414; Bosse, Philippe/0000-0001-5701-6415				ANTOINE B, 1992, EXP CELL RES, V200, P175, DOI 10.1016/S0014-4827(05)80086-2; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bernex F, 1996, DEVELOPMENT, V122, P3023; BISHOP AE, 1988, PATHOL RES PRACT, V183, P119, DOI 10.1016/S0344-0338(88)80040-2; BISHOP AE, 1982, GASTROENTEROLOGY, V83, P902; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; COHEN PS, 1994, BLOOD, V84, P3465; DEFTOS LJ, 1991, ENDOCR REV, V12, P181, DOI 10.1210/edrv-12-2-181; DESEPULVEDA P, 1995, BIOCHEM BIOPH RES CO, V211, P735, DOI 10.1006/bbrc.1995.1874; GEPTS W, 1984, EVOLUTION TUMOUR PAT, P343; GESCHWIND II, 1966, ENDOCRINOLOGY, V79, P97, DOI 10.1210/endo-79-1-97; HARRISON DJ, 1995, ONCOGENE, V10, P1615; HIBI K, 1991, ONCOGENE, V6, P2291; HINES SJ, 1995, CELL GROWTH DIFFER, V6, P769; HOGAN B, 1994, MANIPULATING MOUSE E, P217; HU NP, 1994, ONCOGENE, V9, P1021; HUIZINGA JD, 1995, NATURE, V373, P347, DOI 10.1038/373347a0; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KITAYAMA H, 1995, BLOOD, V85, P790, DOI 10.1182/blood.V85.3.790.bloodjournal853790; KLOPPEL G, 1994, ANN NY ACAD SCI, V733, P18, DOI 10.1111/j.1749-6632.1994.tb17252.x; KRYSZKE M, 1990, CHROMOSOMES EUCARYOT, V3, P113; Lamonerie T, 1996, GENE DEV, V10, P1284, DOI 10.1101/gad.10.10.1284; LASSAM N, 1992, ONCOGENE, V7, P51; LAUNAY JM, 1983, BIOMED PHARMACOTHER, V37, P322; LEV S, 1994, CRIT REV ONCOGENESIS, V5, P141, DOI 10.1615/CritRevOncog.v5.i2-3.30; LIU B, 1992, MOL CELL BIOL, V12, P3978, DOI 10.1128/MCB.12.9.3978; Longley BJ, 1996, NAT GENET, V12, P312, DOI 10.1038/ng0396-312; LOW MJ, 1993, J BIOL CHEM, V268, P24967; LYON M, 1989, GENETICS VARIANTS ST; MAEDA H, 1992, DEVELOPMENT, V116, P369; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; Motro B, 1996, P NATL ACAD SCI USA, V93, P1808, DOI 10.1073/pnas.93.5.1808; MOTRO B, 1991, DEVELOPMENT, V113, P1207; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; NATALI PG, 1992, INT J CANCER, V52, P713, DOI 10.1002/ijc.2910520508; NATALI PG, 1995, CANCER RES, V55, P1787; Nikitin AY, 1996, GENE DEV, V10, P1870, DOI 10.1101/gad.10.15.1870; OGAWA M, 1993, DEVELOPMENT, V117, P1089; ORRURTREGER A, 1990, DEVELOPMENT, V109, P911; PANTHIER JJ, 1984, P NATL ACAD SCI-BIOL, V81, P5489, DOI 10.1073/pnas.81.17.5489; ROBERTS JL, 1980, BIOCHEM, V17, P3609; SCHMECHEL D, 1978, NATURE, V276, P834, DOI 10.1038/276834a0; SIGMUND CD, 1990, J BIOL CHEM, V265, P19916; TAPIA FJ, 1981, LANCET, V1, P808; TEITZ T, 1993, P NATL ACAD SCI USA, V90, P2910, DOI 10.1073/pnas.90.7.2910; THERRIEN M, 1993, MOL CELL BIOL, V13, P2342, DOI 10.1128/MCB.13.4.2342; TURNER AM, 1992, BLOOD, V80, P374; VANDYKE TA, 1994, SEMIN CANCER BIOL, V5, P47; VICART P, 1994, EXP CELL RES, V214, P35, DOI 10.1006/excr.1994.1231; WIKENHEISER KA, 1993, P NATL ACAD SCI USA, V90, P11029, DOI 10.1073/pnas.90.23.11029; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; WILSON BS, 1984, AM J PATHOL, V115, P458; YASUDA H, 1993, BIOCHEM BIOPH RES CO, V191, P893, DOI 10.1006/bbrc.1993.1301	53	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 5	1997	14	22					2661	2670		10.1038/sj.onc.1201122	http://dx.doi.org/10.1038/sj.onc.1201122			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XB978	9178764				2022-12-17	WOS:A1997XB97800005
J	Sachdev, S; Diehl, JA; McKinsey, TA; Hans, A; Hannink, M				Sachdev, S; Diehl, JA; McKinsey, TA; Hans, A; Hannink, M			A threshold nuclear level of the v-Rel oncoprotein is required for transformation of avian lymphocytes	ONCOGENE			English	Article						Rel/NF-kappa B transcription factors; I kappa B; nuclear import; nuclear export; oncogenesis	NF-KAPPA-B; UBIQUITIN-PROTEASOME PATHWAY; TUMOR-NECROSIS-FACTOR; CHICKEN SPLEEN-CELLS; TATA-BINDING PROTEIN; RETICULOENDOTHELIOSIS VIRUS; DNA-BINDING; C-REL; TRANSCRIPTIONAL ACTIVATION; CYTOPLASMIC RETENTION	The net distribution of eukaryotic transcription factors between the cytoplasm and the nucleus provides an effective mechanism for controlling gene expression. We have utilized cis-acting signals for both nuclear import and nuclear export to experimentally manipulate the distribution of the v-Rel oncoprotein between the nucleus and the cytoplasm. The respective abilities of the v-Rel oncoprotein to localize to the nucleus in chicken embryo fibroblasts, to activate kappa B-dependent transcription in yeast, and to transform avian lymphoid cells were each markedly reduced by the fusion of a cis-acting nuclear export signal onto v-Rel. Our results demonstrate that a threshold nuclear function of v-Rel is required for manifestation of its oncogenic properties. In contrast, while increased expression of the avian I kappa B-alpha protein was able to prevent nuclear localization of v-Rel in chicken embryo fibroblasts, coexpression of I kappa B-alpha with v-Rel in the target cell for v-Rel mediated transformation did not reduce the ability of v-Rel to transform avian lymphoid cells or alter the distribution of v-Rel between the nucleus and the cytoplasm in v-Rel-transformed cells. Our results suggest that the ability of I kappa B-alpha to inhibit nuclear localization of v-Rel is affected by cell-type specific differences between fibroblasts and lymphoid cells.	UNIV MISSOURI,DEPT BIOCHEM,COLUMBIA,MO 65212	University of Missouri System; University of Missouri Columbia					NCI NIH HHS [CA55027] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA055027] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldi L, 1996, J BIOL CHEM, V271, P376, DOI 10.1074/jbc.271.1.376; BALLARD DW, 1990, CELL, V63, P803, DOI 10.1016/0092-8674(90)90146-6; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CAPOBIANCO AJ, 1992, J VIROL, V66, P3758, DOI 10.1128/JVI.66.6.3758-3767.1992; CHANG CC, 1995, MOL CELL BIOL, V15, P5180; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DAVIS N, 1990, J VIROL, V64, P584, DOI 10.1128/JVI.64.2.584-591.1990; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIEHL JA, 1993, MOL CELL BIOL, V13, P1769, DOI 10.1128/MCB.13.3.1769; DIEHL JA, 1993, J VIROL, V67, P7161, DOI 10.1128/JVI.67.12.7161-7171.1993; DOUGHERTY JP, 1986, MOL CELL BIOL, V6, P4387, DOI 10.1128/MCB.6.12.4387; ERNST MK, 1995, MOL CELL BIOL, V15, P872; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GELINAS C, 1988, ONCOGENE, V3, P349; GHATTAS IR, 1991, MOL CELL BIOL, V11, P5848, DOI 10.1128/MCB.11.12.5848; GILMORE TD, 1988, J VIROL, V62, P703, DOI 10.1128/JVI.62.3.703-714.1988; GILMORE TD, 1986, CELL, V44, P791, DOI 10.1016/0092-8674(86)90845-7; GILMORE TD, 1996, IN PRESS ONCOGENE; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; HRDLICKOVA R, 1995, J VIROL, V69, P403; HRDLICKOVA R, 1995, J VIROL, V69, P3369; HRDLICKOVA R, 1994, J VIROL, V68, P2371; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MICHAEL WM, 1995, CELL, V83, P415; MILLER CK, 1988, J VIROL, V62, P1219, DOI 10.1128/JVI.62.4.1219-1226.1988; MILLER CK, 1986, J VIROL, V58, P75, DOI 10.1128/JVI.58.1.75-80.1986; MIYAMOTO S, 1994, P NATL ACAD SCI USA, V91, P12740, DOI 10.1073/pnas.91.26.12740; MORIN PJ, 1995, CELL GROWTH DIFFER, V6, P789; MORRISON LE, 1992, ONCOGENE, V7, P1137; MOSIALOS G, 1991, MOL CELL BIOL, V11, P5867, DOI 10.1128/MCB.11.12.5867; RICE NR, 1993, EMBO J, V12, P4685, DOI 10.1002/j.1460-2075.1993.tb06157.x; RICHARDSON PM, 1991, J VIROL, V65, P3122, DOI 10.1128/JVI.65.6.3122-3130.1991; Rodriguez MS, 1996, ONCOGENE, V12, P2425; Roff M, 1996, J BIOL CHEM, V271, P7844, DOI 10.1074/jbc.271.13.7844; Rottjakob EM, 1996, J VIROL, V70, P3176, DOI 10.1128/JVI.70.5.3176-3188.1996; SACHDEV S, 1995, ONCOGENE, V11, P811; Sambrook J, 1989, MOL CLONING LAB MANU; SARKAR S, 1993, ONCOGENE, V8, P2245; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SIMEK S, 1988, J VIROL, V62, P4730, DOI 10.1128/JVI.62.12.4730-4736.1988; SIMEK SL, 1986, J VIROL, V59, P120, DOI 10.1128/JVI.59.1.120-126.1986; SMARDOVA J, 1995, ONCOGENE, V10, P2017; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; SYLLA BS, 1986, MOL CELL BIOL, V6, P4709, DOI 10.1128/MCB.6.12.4709; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TZEN CY, 1994, EXP CELL RES, V211, P6; WALKER WH, 1992, J VIROL, V66, P5018, DOI 10.1128/JVI.66.8.5018-5029.1992; WATANABE S, 1983, MOL CELL BIOL, V3, P2241, DOI 10.1128/MCB.3.12.2241; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; White DW, 1996, MOL CELL BIOL, V16, P1169; White DW, 1996, ONCOGENE, V13, P891; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	66	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 29	1997	14	21					2585	2594		10.1038/sj.onc.1201108	http://dx.doi.org/10.1038/sj.onc.1201108			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA949	9191058				2022-12-17	WOS:A1997XA94900010
J	Cosgaya, JM; Recio, JA; Aranda, A				Cosgaya, JM; Recio, JA; Aranda, A			Influence of Ras and retinoic acid on nerve growth factor induction of transin gene expression in PC12 cells	ONCOGENE			English	Article						metalloproteinases; neurite extension; retinoic acid; nerve growth factor	PROTEIN-KINASE; FACTOR RECEPTOR; B-RAF; NEURONAL DIFFERENTIATION; SIGNAL-TRANSDUCTION; NGF-INDUCTION; STROMELYSIN; ONCOGENE; INHIBITION; PROMOTER	Nerve growth factor (NGF)- and ras-induced neuronal differentiation of PC12 cells is accompanied by expression of transin, a secreted metalloproteinase. Retinoic acid (RA) is known to exert important effects on neural cell proliferation and differentiation, In this study we have analysed different PC12 sublines which express either activated Ras or dominant negative p21(N17) Ras, to evaluate the influence of retinoic acid (RA) on the response of the transin gene to NGF and Ras. There was a good correlation between neurite extension and induction of transin mRNA levels in the different subclones. NGF did not induce transin mRNA in cells which do not differentiate in response to this neurotrophin. In addition, incubation with RA did not detectably increase basal transin mRNA levels, but caused a significant increase in the transin response to NGF or Ras in cells in which these factors induce a neuronal morphology. Sequences contained within 750 base pairs of the 5' flanking region of the transin gene confer responsiveness to NGF and Ras, but do not mediate the stimulatory effect of RA. In addition, expression of oncogenic Raf increases transin promoter activity in PC12 cells, but a dominant-negative Raf mutant was unable to block NGF-induced transin activity suggesting the existence of a bifurcation downstream of ras in the signaling mechanism leading to transin expression by NGF.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM)			Aranda, Ana/ABG-8820-2020; Cosgaya, Jose M/B-4936-2008	Aranda, Ana/0000-0002-8338-9589; Recio, Juan Angel/0000-0002-7320-3832; Cosgaya, Jose Miguel/0000-0002-6005-2916				BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; Cosgaya JM, 1996, ONCOGENE, V12, P2651; Cosgaya JM, 1996, J NEUROCHEM, V66, P89; COSGAYA JM, 1996, IN PRESS ONCOGENE; CURRAN T, 1984, VIROLOGY, V135, P218, DOI 10.1016/0042-6822(84)90132-6; DARCANGELO G, 1993, MOL CELL BIOL, V13, P3146, DOI 10.1128/MCB.13.6.3146; DESOUZA S, 1995, J BIOL CHEM, V270, P9106, DOI 10.1074/jbc.270.16.9106; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUERRERO I, 1988, BIOCHEM BIOPH RES CO, V150, P1585; GUIGUERE V, 1994, ENDOCR REV, V15, P61; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KASTNER P, 1995, CELL, V83, P859, DOI 10.1016/0092-8674(95)90202-3; Kerr L D, 1992, Matrix Suppl, V1, P176; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KERR LD, 1988, J BIOL CHEM, V263, P16999; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; LOEB DM, 1991, CELL, V66, P961, DOI 10.1016/0092-8674(91)90441-Z; LOSARDO JE, 1995, CLIN EXP METASTAS, V13, P236, DOI 10.1007/BF00133479; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MACHIDA CM, 1989, NEURON, V2, P1587, DOI 10.1016/0896-6273(89)90047-0; MATRISIAN LM, 1986, P NATL ACAD SCI USA, V83, P9413, DOI 10.1073/pnas.83.24.9413; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; NICHOLSON RC, 1990, EMBO J, V9, P4443, DOI 10.1002/j.1460-2075.1990.tb07895.x; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; OSHIMA M, 1991, J BIOL CHEM, V266, P23753; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHEIBE RJ, 1992, J BIOL CHEM, V267, P17611; SCHEIBE RJ, 1991, J CELL BIOL, V113, P1173, DOI 10.1083/jcb.113.5.1173; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; THOMSON TM, 1990, MOL CELL BIOL, V10, P1556, DOI 10.1128/MCB.10.4.1556; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YU CL, 1993, MOL CELL BIOL, V13, P2011, DOI 10.1128/MCB.13.4.2011	43	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1687	1696		10.1038/sj.onc.1200997	http://dx.doi.org/10.1038/sj.onc.1200997			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135070				2022-12-17	WOS:A1997WR89300007
J	Isaacs, JS; Chen, PC; Garza, A; Hansen, MF; Barrett, JC; Weissman, BE				Isaacs, JS; Chen, PC; Garza, A; Hansen, MF; Barrett, JC; Weissman, BE			Failure of HPV E6 to rapidly degrade p53 in human HeLa x PNET cell hybrids	ONCOGENE			English	Article						p53; E6; tumor suppressor genes	HUMAN PAPILLOMAVIRUS TYPE-16; WILD-TYPE P53; MAMMARY EPITHELIAL-CELLS; GENE-MUTATIONS; HUMAN KERATINOCYTES; IN-VITRO; PROTEIN; EXPRESSION; UBIQUITIN; TUMOR	The ability of the E6 protein from high risk human papillomaviruses (HPVs) to degrade p53 via the ubiquitin pathway plays a major role in the development of cervical carcinomas. We have previously generated cell hybrids between a p53 null peripheral neuroepithelioma (PNET) cell line and a cervical carcinoma HeLa cell line which exhibits efficient E6-mediated degradation of p53. All of the resulting hybrids expressed HPV 18 E6 from the HeLa parent and some of the hybrids additionally expressed HPV 16 E6. Surprisingly, in spite of abundant E6 expression, the hybrids expressed relatively high steady-state levels of the wild-type p53 protein. We then examined the hybrids to determine whether other components of the E6-mediated degradation pathway were missing or nonfunctional. Specifically, we determined that the E6-associated protein (E6-AP), essential for E6-mediated degradation, was expressed. We further verified that these hybrids had a functional ubiquitination pathway, which suggests that this phenomenon is not due to a general defect in this pathway. We therefore conclude that other unidentified, possibly cell-specific factors can play a role in the E6-mediated degradative process and may act to inhibit this process.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; BOSTON UNIV,SCH MED,CTR HUMAN GENET,BOSTON,MA 02118; NATL INST ENVIRONM HLTH SCI,MOL CARCINOGENESIS LAB,RES TRIANGLE PK,NC 27709	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Boston University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)					NCI NIH HHS [CA 53318, CA 60122, CA 44470] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA060122, R01CA044470, R01CA053318, R03CA053318] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANKER L, 1993, INT J CANCER, V55, P982, DOI 10.1002/ijc.2910550618; Bernard Bruno A., 1993, P207; BLUMENFELD N, 1994, J BIOL CHEM, V269, P9574; BUTZ K, 1995, ONCOGENE, V10, P927; CHEN PC, 1994, MOL CELL BIOL, V14, P534, DOI 10.1128/MCB.14.1.534; CHEN TM, 1992, ONCOGENE, V7, P1541; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; CRIPPS KJ, 1994, ONCOGENE, V9, P2739; DELMOLINO L, 1993, CARCINOGENESIS, V14, P827, DOI 10.1093/carcin/14.5.827; DONNEHOWER L, 1993, BIOCHIM BIOPHYS ACTA, V1155, P181; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FOURET P, 1995, AM J PATHOL, V146, P599; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GUDAS JM, 1994, CELL GROWTH DIFFER, V5, P295; HAINAUT P, 1993, CANCER RES, V53, P4469; HAINAUT P, 1992, EMBO J, V11, P3513, DOI 10.1002/j.1460-2075.1992.tb05434.x; HALBERT CL, 1991, J VIROL, V65, P473, DOI 10.1128/JVI.65.1.473-478.1991; HALEVY O, 1989, MOL CELL BIOL, V9, P3385, DOI 10.1128/MCB.9.8.3385; HALL IJ, 1996, IN PRESS GENES CHROM; HALL PA, 1993, ONCOGENE, V8, P203; HARPER JW, 1993, CELL, V75, P805; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HUBBERT NL, 1992, J VIROL, V66, P6237, DOI 10.1128/JVI.66.10.6237-6241.1992; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918, DOI 10.1128/MCB.13.8.4918; HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P775, DOI 10.1128/MCB.13.2.775; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; JOHNSON M, 1994, MOL CARCINOGEN, V11, P59, DOI 10.1002/mc.2940110202; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; LANDESMAN Y, 1994, ONCOGENE, V9, P1241; LECHNER MS, 1992, EMBO J, V11, P3045, DOI 10.1002/j.1460-2075.1992.tb05375.x; LEE KA, 1994, ANN ONCOL         S1, V5, P85; LI Y, 1994, ONCOGENE, V9, P2261; LIANG XH, 1993, ONCOGENE, V8, P2645; LOWRY DR, 1994, P NATL ACAD SCI USA, V91, P2436; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; MARSTON NJ, 1994, ONCOGENE, V9, P2707; MASHIYAMA S, 1991, ONCOGENE, V6, P1313; MASUDA H, 1987, P NATL ACAD SCI USA, V84, P7716, DOI 10.1073/pnas.84.21.7716; MAXWELL SA, 1994, CRIT REV ONCOGENESIS, V5, P23, DOI 10.1615/CritRevOncog.v5.i1.20; MEDCALF EA, 1993, ONCOGENE, V8, P2847; MEEK DW, 1994, SEMIN CANCER BIOL, V5, P203; MILNER J, 1994, SEMIN CANCER BIOL, V5, P211; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; OREN M, 1992, FASEB J, V6, P3169, DOI 10.1096/fasebj.6.13.1397838; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; SEDMAN SA, 1992, J VIROL, V66, P4201, DOI 10.1128/JVI.66.7.4201-4208.1992; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; SPANDAU DF, 1994, ONCOGENE, V9, P1861; TERVAHAUTA AI, 1994, CYTOPATHOLOGY, V5, P282, DOI 10.1111/j.1365-2303.1994.tb00432.x; THOMAS M, 1995, ONCOGENE, V10, P261; TOMINAGA O, 1993, ONCOGENE, V8, P2653; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VILLUENDAS R, 1993, BLOOD, V82, P3151; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WEISSMAN B, 1980, CYTOGENET CELL GENET, V28, P227, DOI 10.1159/000131536; WEISSMAN BE, 1983, JNCI-J NATL CANCER I, V70, P667; WEISSMAN BE, 1990, CANCER SURV, V9, P475; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WHITE AE, 1994, GENE DEV, V8, P666, DOI 10.1101/gad.8.6.666; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	67	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR 10	1997	14	14					1669	1678		10.1038/sj.onc.1201001	http://dx.doi.org/10.1038/sj.onc.1201001			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	WR893	9135068				2022-12-17	WOS:A1997WR89300005
J	Leshkowitz, D; Rozenblatt, O; Nakamura, T; Yano, T; Dautry, F; Croce, CM; Canaani, E				Leshkowitz, D; Rozenblatt, O; Nakamura, T; Yano, T; Dautry, F; Croce, CM; Canaani, E			ALL-1 interacts with unr, a protein containing multiple cold shock domains	ONCOGENE			English	Article						yeast two hybrid screening; nucleic acid-binding proteins	NUCLEIC-ACID-BINDING; Y-BOX; N-RAS; DROSOPHILA-TRITHORAX; BACILLUS-SUBTILIS; DNA-BINDING; TRANSCRIPTION FACTOR; ACUTE LEUKEMIAS; GENE; MOTIF	The ALL-1 gene is involved in human acute leukemia through chromosome translocations and fusion to partner genes, or through partial tandem duplications, ALL-1 is the human homologue of Drosophila trithorax which transregulates the homeotic genes of the Antennapedia and bithorax complexes controlling body segment identity, ALL-1 encodes a very large protein of 3968 amino acids which presumably interacts with many proteins, Here we applied yeast two hybrid screening to identify proteins interacting with the N-terminal segment of ALL-1, One protein obtained in this way was the product of the unr gene, This protein consists of multiple repeats homologous to the cold shock domain (CSD), a motif common to some bacterial and eukaryotic nucleic acids-binding proteins, The minimal region on unr required for the interaction with ALL-1 included two CSD and two intervening polypeptides. The interaction was confirmed by in vitro binding studies, and by coimmunoprecipitation from COS cells overexpressing the relevant segments of the two proteins, These results suggest that unr is involved in an interaction of ALL-1 with DNA or RNA.	WEIZMANN INST SCI,DEPT MOL CELL BIOL,IL-76100 REHOVOT,ISRAEL; THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON CANC INST,PHILADELPHIA,PA 19107; INST RECH CANC,CNRS,F-94801 VILLEJUIF,FRANCE	Weizmann Institute of Science; Jefferson University; Centre National de la Recherche Scientifique (CNRS)			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; ALLAIN KS, 1990, GENE CHROMOSOME CANC, V2, P53; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BERNARD OA, 1995, GENE CHROMOSOME CANC, V13, P75, DOI 10.1002/gcc.2870130202; CANAANI E, 1995, ADV CANCER RES, V66, P213, DOI 10.1016/S0065-230X(08)60255-9; CORTES P, 1994, P NATL ACAD SCI USA, V91, P7633, DOI 10.1073/pnas.91.16.7633; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; DONIGER J, 1988, NUCLEIC ACIDS RES, V16, P969, DOI 10.1093/nar/16.3.969; DONIGER J, 1992, NEW BIOL, V4, P389; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Fidanza V, 1996, CANCER RES, V56, P1179; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAI XX, 1992, NUCLEIC ACIDS RES, V20, P601, DOI 10.1093/nar/20.3.601; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GRANT CE, 1993, MOL CELL BIOL, V13, P4186, DOI 10.1128/MCB.13.7.4186; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; JACQUEMINSABLON H, 1994, NUCLEIC ACIDS RES, V22, P2643, DOI 10.1093/nar/22.13.2643; JEFFERS M, 1990, NUCLEIC ACIDS RES, V18, P4891; KUZIN B, 1994, GENE DEV, V8, P2478, DOI 10.1101/gad.8.20.2478; MURRAY MT, 1994, BIOCHEMISTRY-US, V33, P13910, DOI 10.1021/bi00250a046; NICOLAIEW N, 1991, ONCOGENE, V6, P721; OZER J, 1990, J BIOL CHEM, V265, P22143; Prasad R, 1995, P NATL ACAD SCI USA, V92, P12160, DOI 10.1073/pnas.92.26.12160; RAIMONDI SC, 1993, BLOOD, V81, P2237; SAHA V, 1995, P NATL ACAD SCI USA, V92, P9737, DOI 10.1073/pnas.92.21.9737; SCHICHMAN SA, 1995, JAMA-J AM MED ASSOC, V273, P571, DOI 10.1001/jama.273.7.571; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; Sommerville J, 1996, FASEB J, V10, P435, DOI 10.1096/fasebj.10.4.8647342; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; TILLIB S, 1995, MECH DEVELOP, V52, P1; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; WILLIMSKY G, 1992, J BACTERIOL, V174, P6326, DOI 10.1128/JB.174.20.6326-6335.1992; WISTOW G, 1990, NATURE, V344, P823, DOI 10.1038/344823c0; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; YU BD, 1995, NATURE, V378, P505, DOI 10.1038/378505a0	36	11	12	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV 7	1996	13	9					2027	2031						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VR795	8934551				2022-12-17	WOS:A1996VR79500024
J	Ishikawa, H; Ryseck, RP; Bravo, R				Ishikawa, H; Ryseck, RP; Bravo, R			Characterization of ES cells deficient for the p105 precursor (NF-kappa B1): Role of p50 NLS	ONCOGENE			English	Article						ES cells; gene targeting; I kappa B gamma; NF-kappa B; p50 NLS; p105 precursor	NF-KAPPA-B; NUCLEAR-LOCALIZATION SIGNAL; DNA-BINDING ACTIVITY; C-REL PROTOONCOGENE; TRANSCRIPTION FACTOR; TARGETED DISRUPTION; 65-KD SUBUNIT; P65 SUBUNIT; STEM-CELLS; ACTIVATION	Proteolytic processing of the p105 precursor (NF-kappa B1) generates the p50 subunit of NF-kappa B. To address the function of p105 precursor, we have generated embryonic stem (ES) cells which lack the C-terminal inhibiting ankyrin-containing domain of p105 (I kappa B gamma) but contain a functional p50 by homologous recombination. Two forms of p50 were found in ES cells lacking p105. While one was a p50 molecule with the expected size of 415 amino acids, the other was an isoform of 358 amino acids generated by alternative splicing. This isoform lacked the C-terminal 62 amino acids of p50 including the putative nuclear localization signal (NLS), but included five unrelated amino acids. This p50 molecule lacking the NLS behaved similar to wild type p50. Importantly, the p50 isoform-RelA complex interacted efficiently with I kappa B alpha, implying that the NLS of p50 is not essential for these functions. Also, p50 isoform dimers were present in the nucleus. Loss of p105 and the augment of total p50 produced an increase in the nuclear kappa B-binding activity of p50-RelA and p50 dimers. In wild type ES cells, a significant proportion of total p50 is associated with p105. Therefore, the mutation introduced in NF-kappa B1 eliminates both the processing to generate p50 and the trapping of p50 by p105. In contrast to p50, only a small fraction of RelA is associated with p105. These findings indicate that p105 plays a unique role in controlling p50 dimer activity.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST, DEPT ONCOL, PRINCETON, NJ 08543 USA	Bristol-Myers Squibb								BAEUERLE PA, 1988, CELL, V53, P211, DOI 10.1016/0092-8674(88)90382-0; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; CARRASCO D, 1993, DEVELOPMENT, V118, P1221; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; DOETSCHMAN T, 1987, NATURE, V330, P576, DOI 10.1038/330576a0; DONALD R, 1995, J BIOL CHEM, V270, P9, DOI 10.1074/jbc.270.1.9; FINCO TS, 1995, IMMUNITY, V3, P263, DOI 10.1016/1074-7613(95)90112-4; GANCHI PA, 1993, MOL CELL BIOL, V13, P7826, DOI 10.1128/MCB.13.12.7826; GANCHI PA, 1992, MOL BIOL CELL, V3, P1339, DOI 10.1091/mbc.3.12.1339; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GILMORE TD, 1993, TRENDS GENET, V9, P427, DOI 10.1016/0168-9525(93)90106-R; GRILLI M, 1993, INT REV CYTOL, V143, P1; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; INOUE J, 1992, CELL, V68, P1109, DOI 10.1016/0092-8674(92)90082-N; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATTHEWS JR, 1993, NUCLEIC ACIDS RES, V21, P4516, DOI 10.1093/nar/21.19.4516; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; MERCURIO F, 1993, GENE DEV, V7, P705, DOI 10.1101/gad.7.4.705; MORTENSEN RM, 1992, MOL CELL BIOL, V12, P2391, DOI 10.1128/MCB.12.5.2391; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; MULLER M, 1991, BIOCHIM BIOPHYS ACTA, V1088, P171, DOI 10.1016/0167-4781(91)90052-N; NAUMANN M, 1993, EMBO J, V12, P213, DOI 10.1002/j.1460-2075.1993.tb05647.x; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; NAUMANN M, 1993, ONCOGENE, V8, P2275; Nolan GP, 1992, CURR OPIN GENET DEV, V2, P211, DOI 10.1016/S0959-437X(05)80276-X; NOLAN GP, 1991, CELL, V64, P961, DOI 10.1016/0092-8674(91)90320-X; PAGANO M, 1992, ONCOGENE, V7, P1681; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PEREZ P, 1995, MOL CELL BIOL, V15, P3523; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; Sambrook J., 1989, MOL CLONING LAB MANU, V2nd; SCHEINMAN RI, 1993, MOL CELL BIOL, V13, P6089, DOI 10.1128/MCB.13.10.6089; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SUN SC, 1994, P NATL ACAD SCI USA, V91, P1346, DOI 10.1073/pnas.91.4.1346; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; URBAN MB, 1990, GENE DEV, V4, P1975, DOI 10.1101/gad.4.11.1975; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; WEIH F, 1994, ONCOGENE, V9, P3289; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; Wurst W., 1993, Gene targeting: a practical approach., P33; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x	61	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	1996	13	2					255	263						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	VA252	8710364				2022-12-17	WOS:A1996VA25200004
J	Kralova, J; Schatzle, JD; Liss, AS; Bargmann, W; Bose, HR				Kralova, J; Schatzle, JD; Liss, AS; Bargmann, W; Bose, HR			Synergistic stimulation of avian I kappa B alpha transcription by rel and fos/jun factors	ONCOGENE			English	Article						I kappa B alpha; Rel/NF-kappa B; AP-1; transcription synergy	DNA-BINDING PROTEIN; FAMILY MEMBERS; V-REL; INHIBITOR; GENE; SUBUNIT; EXPRESSION; ACTIVATION; DORSAL; P50	Rel/NF-kappa B transcription factors and I kappa B alpha function in an autoregulatory network. Avian I kappa B alpha transcription is increased in response to both c-Rel and v-Rel. This study shows that I kappa B alpha transcription is synergistically stimulated by Rel and AP-1 factors (c-Fos and c-Jun). However, the response to v-Rel and the AP-1 factors was not as vigorous as that of c-Rel and AP-1. A 386 bp region of the I kappa B alpha promoter (containing two NF-kappa B and one AP-1 binding sites) was shown to be both necessary and sufficient for response to both Rel factors alone or Rel factors in conjunction with the AP-1 proteins. In addition, an imperfect NF-kappa B binding site was found to overlap the AP-1 binding site. Mutation of either of the NF-kappa B binding sites or the AP-1 binding site dramatically decreased the response of the I kappa B alpha promoter to Rel proteins alone or Rel and AP-1 factors. Overexpression of c-Rel or v-Rel resulted in the formation of DNA binding complexes associated with the imperfect NF-kappa B binding site which overlaps the AP-1 site. v-Rel associated with the imperfect NF-kappa B site stronger than c-Rel, and overexpression of v-Rel also resulted in the formation of a v-Rel containing complex bound to a consensus AP-1 site. These studies address the difference in c-Rel and v-Rel's ability to synergistically stimulate I kappa B alpha expression in conjunction with the AP-1 factors.	UNIV TEXAS,DEPT MICROBIOL,AUSTIN,TX 78712; UNIV TEXAS,CELL RES INST,AUSTIN,TX 78712	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin			Liss, Andrew/L-9696-2019; Kralova, Jarmila/G-3834-2014	Kralova, Jarmila/0000-0002-4735-8857	NATIONAL CANCER INSTITUTE [F32CA063767, R01CA033192] Funding Source: NIH RePORTER; NCI NIH HHS [CA 33192, CA 63767-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; BOSE HR, 1992, BIOCHIM BIOPHYS ACTA, V1114, P1, DOI 10.1016/0304-419X(92)90002-G; BOURS V, 1992, MOL CELL BIOL, V12, P685, DOI 10.1128/MCB.12.2.685; BOURS V, 1990, NATURE, V348, P76, DOI 10.1038/348076a0; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CHENG Q, 1994, J BIOL CHEM, V269, P13551; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DAVIS N, 1991, SCIENCE, V253, P1268, DOI 10.1126/science.1891714; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DIEHL JA, 1994, MOL CELL BIOL, V14, P6635, DOI 10.1128/MCB.14.10.6635; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GROVE M, 1993, MOL CELL BIOL, V13, P5276, DOI 10.1128/MCB.13.9.5276; GUILIANI C, 1995, J BIOL CHEM, V270, P11453; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; HRDLICKOVA R, 1995, J VIROL, V69, P3369; IP YT, 1991, CELL, V64, P439; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; KASZUBSKA W, 1993, MOL CELL BIOL, V13, P7180, DOI 10.1128/MCB.13.11.7180; KERPPOLA TK, 1991, CELL, V66, P317, DOI 10.1016/0092-8674(91)90621-5; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KRALOVA J, 1994, J VIROL, V68, P2073, DOI 10.1128/JVI.68.4.2073-2083.1994; KRISHNAN A, 1995, IN PRESS GENE; LEBAIL O, 1993, EMBO J, V12, P5043, DOI 10.1002/j.1460-2075.1993.tb06197.x; LIOU HC, 1992, EMBO J, V11, P3003, DOI 10.1002/j.1460-2075.1992.tb05370.x; MURR, 1991, LIO, V5, P1464; RADLERPOHL A, 1993, EMBO J, V12, P1005, DOI 10.1002/j.1460-2075.1993.tb05741.x; SCHATZLE JD, 1995, J VIROL, V69, P5383, DOI 10.1128/JVI.69.9.5383-5390.1995; SCHRECK R, 1990, NUCLEIC ACIDS RES, V18, P6497, DOI 10.1093/nar/18.22.6497; SCOTT ML, 1993, GENE DEV, V7, P1266, DOI 10.1101/gad.7.7a.1266; SIF S, 1994, J VIROL, V68, P7131, DOI 10.1128/JVI.68.11.7131-7138.1994; SIF S, 1993, J VIROL, V67, P7612, DOI 10.1128/JVI.67.12.7612-7617.1993; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; XU X, 1993, MOL CELL BIOL, V13, P6733, DOI 10.1128/MCB.13.11.6733; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; ZHANG Q, 1994, MOL CELL BIOL, V14, P3915, DOI 10.1128/MCB.14.6.3915	44	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 20	1996	12	12					2595	2604						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UW487	8700518				2022-12-17	WOS:A1996UW48700013
J	Zhang, YH; Saez, R; Leal, MA; Chan, AML				Zhang, YH; Saez, R; Leal, MA; Chan, AML			Synergism between two growth regulatory pathways: Cooperative transformation of NIH3T3 cells by G alpha(12) and c-raf-1	ONCOGENE			English	Article						oncogene; NIH3T3; G alpha(12); raf; ras; transformation	EXPRESSION CDNA CLONING; ALPHA-SUBUNITS; GENE-PRODUCT; RAS; ONCOGENES; ACTIVATION; CANCER; TUMORS	The alpha-subunit of the heterotrimeric G-protein, G(12), has been shown to induce cellular transformation when overexpressed or oncogenically activated in rodent fibroblasts. To investigate the interaction between G alpha(12) transforming pathway and the Ras-Raf-MAPK pathway, we examined the ability of mitogenic signaling molecules in cooperating with G alpha(12) in transforming NIH3T3 fibroblasts, We observed a striking cooperative effect on focus-forming ability when G alpha(12) and c-raf-1 cDNAs were co-transfected into NIH3T3 cells, NIH3T3 cells coexpressing both G alpha(12) and c-raf-1 resulted in the constitutive activation of the mitogenic-activated protein kinase (MAPK), In addition, the levels of GTP-bound Ras were elevated in G alpha(12) transformed NIH3T3 cells, Our results provide a model for studying the effects of simultaneous activation of two distinct growth regulatory pathways in cellular transformation.					Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464				BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BOS JL, 1989, CANCER RES, V49, P4682; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHAN AML, 1993, MOL CELL BIOL, V13, P762, DOI 10.1128/MCB.13.2.762; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRESPO P, 1994, J BIOL CHEM, V269, P21103; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CUADRADO A, 1993, ONCOGENE, V8, P2443; FAURE M, 1994, J BIOL CHEM, V269, P7841; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; HAN JW, 1991, SCIENCE, V252, P576, DOI 10.1126/science.1902323; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LACAL JC, 1986, P NATL ACAD SCI USA, V83, P5400, DOI 10.1073/pnas.83.15.5400; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; PENDERGAST GC, 1995, ONCOGENE, V10, P2289; PORRAS A, 1992, J BIOL CHEM, V267, P21124; PUMIGLIA KM, 1995, J BIOL CHEM, V270, P14251, DOI 10.1074/jbc.270.24.14251; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; VOYNOYASENETSKAYA TA, 1994, ONCOGENE, V9, P2559; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; XU HP, 1994, MOL CELL BIOL, V14, P50, DOI 10.1128/MCB.14.1.50; XU NZ, 1993, P NATL ACAD SCI USA, V90, P6741, DOI 10.1073/pnas.90.14.6741	34	11	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN 6	1996	12	11					2377	2383						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UQ220	8649778				2022-12-17	WOS:A1996UQ22000015
J	Berkowitz, EA; Hissong, MA; Lee, DC				Berkowitz, EA; Hissong, MA; Lee, DC			Transcriptional and post-transcriptional induction of the TGF alpha gene in transformed rat liver epithelial cells	ONCOGENE			English	Article						TGF alpha; transcription; DNase 1 hypersensitivity; mRNA stability	GROWTH-FACTOR-ALPHA; HUMAN PANCREATIC-CANCER; TRANSGENIC MICE; C-MYC; MESSENGER-RNA; HUMAN KERATINOCYTES; FACTOR RECEPTOR; PHORBOL ESTER; HEPATOCELLULAR-CARCINOMA; DEVELOPMENTAL EXPRESSION	Although TGF alpha mRNA and protein are frequently elevated in neoplastic cells, neither the level at which deregulation occurs nor the mechanism(s) responsible have been well characterized. As a first step, we examined the induction of TGF alpha mRNA in two series of clonally-derived rat liver epithelial cell lines that were transformed either by exposure to chemical carcinogen or stable transfection of activated Ha-ras. We found that steady-state levels of TGF alpha mRNA in both series of transformed lines were induced 25- to 50-fold over those in the respective normal parental cells. This induction, which occurred without amplification of the TGF alpha gene, was accompanied by at least a five- to 10-fold increase in transcription along the entire length of the gene with no evidence of a transcriptional attenuation or arrest mechanism in the normal cells. Analysis of the TGF alpha promoter and flanking regions did not support a correlation between the extent of methylation and the level of expression, but did reveal several DNase I hypersensitive sites spanning from -14 to +8 kilobases. Two of these sites were differentially observed in cells displaying high and low TGF alpha gene transcription, while a third site correlated with TPA-induced expression. Finally, measurement of TGF alpha mRNA decay in the presence of Actinomycin D revealed a consistent 1.5- to 3.2-fold increase in the half-life of the TGF alpha transcript in the various transformed cell lines. These results indicate that transformation-mediated induction of TGF alpha gene expression in rat liver epithelial cells occurs through both transcriptional and post-transcriptional mechanisms, but is primarily the result of TGF alpha promoter activation.	UNIV N CAROLINA,SCH MED,LINEBERGER COMPREHENS CANC CTR,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NATIONAL CANCER INSTITUTE [R01CA043793] Funding Source: NIH RePORTER; NCI NIH HHS [CA43793] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARNARD JA, 1994, J BIOL CHEM, V269, P22817; BARTON CM, 1991, J PATHOL, V163, P111, DOI 10.1002/path.1711630206; BASERGA R, 1994, CELL, V79, P927, DOI 10.1016/0092-8674(94)90023-X; BEDELL MA, 1995, GENE DEV, V9, P455, DOI 10.1101/gad.9.4.455; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BJORGE JD, 1989, J BIOL CHEM, V264, P4021; BLASBAND AJ, 1990, MOL CELL BIOL, V10, P2111, DOI 10.1128/MCB.10.5.2111; BOCKMAN DE, 1992, GASTROENTEROLOGY, V103, P1883, DOI 10.1016/0016-5085(92)91448-D; CHEN XR, 1992, ONCOGENE, V7, P1805; CHEN XR, 1994, ONCOGENE, V9, P3179; CHINSKY JM, 1989, J BIOL CHEM, V264, P14561; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CIARDIELLO F, 1990, J CELL BIOCHEM, V42, P45, DOI 10.1002/jcb.240420105; CIARDIELLO F, 1990, CELL GROWTH DIFFER, V1, P407; CIARDIELLO F, 1988, MOL ENDOCRINOL, V2, P1202, DOI 10.1210/mend-2-12-1202; COFFEY RJ, 1992, CELL GROWTH DIFFER, V3, P347; COFFEY RJ, 1987, NATURE, V328, P817, DOI 10.1038/328817a0; DEMPSEY PJ, 1992, GASTROENTEROLOGY, V103, P1950, DOI 10.1016/0016-5085(92)91455-D; DERYNCK R, 1987, CANCER RES, V47, P707; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DURNAM DM, 1983, ANAL BIOCHEM, V131, P385, DOI 10.1016/0003-2697(83)90188-4; FILMUS J, 1993, ONCOGENE, V8, P1017; FINZI E, 1992, AM J PATHOL, V141, P643; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; GODWIN AK, 1990, ONCOGENE, V5, P1231; GREWAL T, 1992, MOL CELL BIOL, V12, P2339, DOI 10.1128/MCB.12.5.2339; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROSS-BELLARD MM, 1973, EUR J BIOCHEM, V36, P32, DOI 10.1111/j.1432-1033.1973.tb02881.x; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HALEY JD, 1991, J BIOL CHEM, V266, P1746; HALTER SA, 1992, AM J PATHOL, V140, P1131; HAMBURGER AW, 1993, P SOC EXP BIOL MED, V202, P64; HAN VKM, 1987, MOL CELL BIOL, V7, P2335, DOI 10.1128/MCB.7.7.2335; HU JM, 1992, CELL GROWTH DIFFER, V3, P577; HUBER BE, 1988, ONCOGENE, V3, P245; IMLER JL, 1988, NATURE, V332, P275, DOI 10.1038/332275a0; JACK J, 1991, DEVELOPMENT, V113, P735; JAKOBOVITS EB, 1988, MOL CELL BIOL, V8, P5549, DOI 10.1128/MCB.8.12.5549; JHAPPAN C, 1990, CELL, V61, P1137, DOI 10.1016/0092-8674(90)90076-Q; LAU JLT, 1988, J UROLOGY, V139, P170, DOI 10.1016/S0022-5347(17)42347-0; LEE DC, 1985, NATURE, V313, P489, DOI 10.1038/313489a0; LEE DC, 1995, PHARMACOL REV, V47, P51; LEE LW, 1991, CANCER RES, V51, P5238; LEE SW, 1991, J INVEST DERMATOL, V97, P106, DOI 10.1111/1523-1747.ep12478503; LIU C, 1988, CANCER RES, V48, P850; LIU C, 1990, BRIT J CANCER, V62, P425, DOI 10.1038/bjc.1990.311; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; LYNCH MJ, 1993, CANCER RES, V53, P4041; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; MATSUI Y, 1990, CELL, V61, P1147, DOI 10.1016/0092-8674(90)90077-R; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MCGEADY ML, 1989, ONCOGENE, V4, P1375; MECHTI N, 1991, MOL CELL BIOL, V11, P2832, DOI 10.1128/MCB.11.5.2832; MIETTINEN PJ, 1995, NATURE, V376, P337, DOI 10.1038/376337a0; MILLER H, 1989, MOL CELL BIOL, V9, P5340, DOI 10.1128/MCB.9.12.5340; MUELLER SG, 1989, MOL ENDOCRINOL, V3, P976, DOI 10.1210/mend-3-6-976; MURAKAMI H, 1993, CANCER RES, V53, P1719; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NITSCH D, 1993, MOL CELL BIOL, V13, P4494, DOI 10.1128/MCB.13.8.4494; NOVICKI DL, 1983, IN VITRO CELL DEV B, V19, P191; OWEN RD, 1990, P NATL ACAD SCI USA, V87, P3866, DOI 10.1073/pnas.87.10.3866; OWEN RD, 1990, MOL CELL BIOL, V10, P1; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; QIAN S, 1991, EMBO J, V10, P1415, DOI 10.1002/j.1460-2075.1991.tb07662.x; RAPPOLEE DA, 1988, SCIENCE, V241, P1823, DOI 10.1126/science.3175624; RAYMOND VW, 1989, CANCER RES, V49, P3608; REDDY MA, 1992, MOL ENDOCRINOL, V6, P1051, DOI 10.1210/me.6.7.1051; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; ROSENTHAL A, 1986, CELL, V46, P301, DOI 10.1016/0092-8674(86)90747-6; SAEKI T, 1991, MOL ENDOCRINOL, V5, P1955, DOI 10.1210/mend-5-12-1955; SALOMON DS, 1987, J CELL PHYSIOL, V130, P397, DOI 10.1002/jcp.1041300313; SANDGREN EP, 1990, CELL, V61, P1121, DOI 10.1016/0092-8674(90)90075-P; SANDGREN EP, 1995, CANCER RES, V55, P3915; SANDGREN EP, 1993, MOL CELL BIOL, V13, P320, DOI 10.1128/MCB.13.1.320; SCHMIEGEL W, 1993, P NATL ACAD SCI USA, V90, P863, DOI 10.1073/pnas.90.3.863; SHANKAR V, 1989, MOL CARCINOGEN, V2, P1, DOI 10.1002/mc.2940020102; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; SINGH P, 1993, GASTROENTEROLOGY, V105, P1218, DOI 10.1016/0016-5085(93)90971-E; SOUTTOU B, 1994, CELL GROWTH DIFFER, V5, P615; SPORN MB, 1980, NEW ENGL J MED, V303, P878, DOI 10.1056/NEJM198010093031511; STROM SC, 1991, DIGEST DIS SCI, V36, P642, DOI 10.1007/BF01297033; TAKAGI H, 1992, J CLIN INVEST, V90, P1161, DOI 10.1172/JCI115936; TAKAGI H, 1993, CANCER RES, V53, P4329; TANAKA S, 1991, AM J PATHOL, V139, P123; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TSAO MS, 1985, AM J PATHOL, V118, P306; TSAO MS, 1985, CANCER RES, V45, P5134; TWARDZIK DR, 1982, SCIENCE, V216, P894, DOI 10.1126/science.6177040; TWARDZIK DR, 1993, VIROLOGY, V124, P201; VASSAR R, 1992, MOL CELL BIOL, V12, P4643, DOI 10.1128/MCB.12.10.4643; WATANABE S, 1987, P NATL ACAD SCI USA, V84, P1258, DOI 10.1073/pnas.84.5.1258; WILCOX JN, 1988, MOL CELL BIOL, V8, P3415, DOI 10.1128/MCB.8.8.3415; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YEH YC, 1987, CANCER RES, V47, P896	97	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1991	2002						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649860				2022-12-17	WOS:A1996UK49800018
J	Trapasso, F; Martelli, ML; Battaglia, C; Angotti, E; Mele, E; Stella, A; Samarut, J; Avvedimento, VE; Fusco, A				Trapasso, F; Martelli, ML; Battaglia, C; Angotti, E; Mele, E; Stella, A; Samarut, J; Avvedimento, VE; Fusco, A			The v-erbA oncogene selectively inhibits iodide uptake in rat thyroid cells	ONCOGENE			English	Article						v-erbA; thyroid; differentiation; uptake; rat cells	AVIAN ERYTHROBLASTOSIS VIRUS; MURINE SARCOMA-VIRUS; HORMONE RECEPTOR; RETINOIC ACID; EPITHELIAL-CELLS; MESSENGER-RNA; MAMMALIAN-CELLS; GENE-EXPRESSION; BINDING DOMAIN; TRANSFORMATION	v-erbA is the oncogenic form of the c-erbA protooncogene, which encodes the receptor for thyroid hormones. The expression of the v-erbA oncogene in thyroid differentiated cells, PC Cl 3, inhibits iodide uptake and thyrotropin-dependent growth, whereas it has no effect on the expression of the other thyroid specific markers, i.e. thyroglobulin, thyroperoxidase and thyrotropin receptor. The activity of transcription factor AP-1, evaluated by a specific DNA binding assay and by transcription of AP-induced promoter (TRE) is enhanced in PC v-erbA cells, v-erbA mutants in the DNA binding domain do not affect the iodide uptake of thyroid cells nor AP-1 activity. We suggest that this transcriptional activation mediates the selective effects of v-erbA on the expression of thyroid specific markers.	UNIV REGGIO CALABRIA,FAC MED & CHIRURG CATANZARO,DIPARTIMENTO MED SPERIMENTALE & CLIN,I-88100 CATANZARO,ITALY; ECOLE NORMALE SUPER LYON,LAB BIOL MOL & CELLULAIRE,CNRS,UMR49,INRA,F-69364 LYON 7,FRANCE	Magna Graecia University of Catanzaro; Universita Mediterranea di Reggio Calabria; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); INRAE			Samarut, Jacques/AAD-2587-2019	Fusco, Alfredo/0000-0003-3332-5197				AKAMIZU T, 1990, P NATL ACAD SCI USA, V87, P5677, DOI 10.1073/pnas.87.15.5677; ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARLOW C, 1994, EMBO J, V13, P4241, DOI 10.1002/j.1460-2075.1994.tb06744.x; BATTAGLIA C, 1993, CELL GROWTH DIFFER, V4, P185; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; BERLINGIERI MT, 1992, ONCOGENE, V8, P249; BERLINGIERI MT, 1988, MOL CELL BIOL, V8, P226; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; COLLETTA G, 1983, MOL CELL BIOL, V3, P2099, DOI 10.1128/MCB.3.11.2099; DEJEAN A, 1986, NATURE, V322, P70, DOI 10.1038/322070a0; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DILAURO R, 1982, GENE, V19, P117, DOI 10.1016/0378-1119(82)90196-2; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FUSCO A, 1982, CANCER RES, V42, P618; FUSCO A, 1987, MOL CELL BIOL, V7, P3365, DOI 10.1128/MCB.7.9.3365; FUSCO A, 1983, J VIROL, V56, P284; GALLO A, 1992, GENE DEV, V6, P1621, DOI 10.1101/gad.6.9.1621; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GANDRILLON O, 1995, INT J ONCOL, V6, P215; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAF T, 1983, CELL, V34, P7, DOI 10.1016/0092-8674(83)90130-7; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALL BL, 1992, CELL GROWTH DIFFER, V3, P207; KAHN P, 1986, CELL, V45, P349, DOI 10.1016/0092-8674(86)90320-X; LOMBARDI A, 1988, ENDOCRINOLOGY, V123, P1544, DOI 10.1210/endo-123-3-1544; MACPHERSON I, 1964, VIROLOGY, V23, P291, DOI 10.1016/0042-6822(64)90301-0; Mangelsdorf David J., 1994, P319; MATTEI MG, 1988, HUM GENET, V80, P189, DOI 10.1007/BF00702867; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MURRAY MB, 1988, J BIOL CHEM, V263, P12770; PEREZ P, 1993, J BIOL CHEM, V268, P23538; PRIVALSKY ML, 1988, MOL CELL BIOL, V8, P4510, DOI 10.1128/MCB.8.10.4510; PRIVALSKY ML, 1990, CELL, V63, P1277, DOI 10.1016/0092-8674(90)90423-C; SANTORO M, 1990, ONCOGENE, V5, P1595; SANTORO M, 1993, CELL GROWTH DIFFER, V4, P77; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SEVERNE Y, 1988, EMBO J, V7, P2503, DOI 10.1002/j.1460-2075.1988.tb03097.x; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; TOKUNAGA K, 1986, NUCLEIC ACIDS RES, V14, P2829; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WU C, 1985, NATURE, V317, P84, DOI 10.1038/317084a0; ZARRILLI R, 1990, MOL ENDOCRINOL, V4, P39, DOI 10.1210/mend-4-1-39; [No title captured]	56	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY 2	1996	12	9					1879	1888						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UK498	8649848				2022-12-17	WOS:A1996UK49800006
J	Weintraub, M; Lin, AY; Franklin, J; Tucker, MA; Magrath, IT; Bhatia, KG				Weintraub, M; Lin, AY; Franklin, J; Tucker, MA; Magrath, IT; Bhatia, KG			Absence of germline p53 mutations in familial lymphoma	ONCOGENE			English	Article						p53; germline mutations; familial lymphoma	TUMOR-SUPPRESSOR GENE; ABNORMAL EXPRESSION; MALIGNANT-LYMPHOMAS; HODGKINS-DISEASE; BREAST-CANCER; LEUKEMIA; RELATIVES; NEOPLASMS; PROTEIN; CELLS	p53, a tumor suppressor gene, is frequently mutated in sporadic human cancer, and inherited mutations in p53 predispose to the early onset of cancer, p53 mutations occur frequently in sporadic lymphoma, and, in mice deficient for p53, lymphoma is the most common type of malignancy, Families with an increased incidence of lymphoma have been described, suggesting an inherited predisposition to lymphoma in these circumstances, To determine whether the predisposition to lymphoma in these families results from germline mutations in p53, we analysed exons 4-11 of the p53 gene in 35 individuals from 19 lymphoma-prone kindreds, We found no germline p53 mutations in any of the individuals tested, However, p53 expression assessed by immunohistochemistry, which suggests mutation, was observed in 35% of the tumor samples from the familial Hodgkin's disease cases and in 13% of the familial non-Hodgkin's lymphoma cases, These results suggest that p53 mutations do not play a critical role in heritable susceptibility to lymphoma, p53 may act by different, non-mutation related mechanisms in this setting, or be involved in late events in the pathogenesis of these tumors.	NCI,PEDIAT BRANCH,NIH,BETHESDA,MD 20892; NCI,GENET EPIDEMIOL BRANCH,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Tucker, Margaret A/B-4297-2015					BARNES DM, 1992, LANCET, V340, P259, DOI 10.1016/0140-6736(92)92354-I; BHATIA K, 1993, FASEB J, V7, P951, DOI 10.1096/fasebj.7.10.8344493; BHATIA KG, 1992, CANCER RES, V52, P4273; BIRCH JM, 1994, BRIT J CANCER, V70, P1176, DOI 10.1038/bjc.1994.468; BJERRUM OW, 1986, SCAND J HAEMATOL, V36, P398; CESARMAN E, 1993, AM J PATHOL, V143, P845; CHILOSI M, 1994, BLOOD, V84, P4295, DOI 10.1182/blood.V84.12.4295.bloodjournal84124295; DOGLIONI C, 1991, HEMATOL PATHOL, V5, P67; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; FELIX CA, 1992, J CLIN INVEST, V90, P653, DOI 10.1172/JCI115907; GAIDANO G, 1991, P NATL ACAD SCI USA, V88, P5413, DOI 10.1073/pnas.88.12.5413; GLAVAC D, 1993, HUM MUTAT, V2, P404, DOI 10.1002/humu.1380020513; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GUPTA RK, 1993, P NATL ACAD SCI USA, V90, P2817, DOI 10.1073/pnas.90.7.2817; HAIM N, 1982, CANCER, V49, P2197, DOI 10.1002/1097-0142(19820515)49:10<2197::AID-CNCR2820491036>3.0.CO;2-9; HALL PA, 1994, J PATHOL, V172, P1, DOI 10.1002/path.1711720103; HARVEY M, 1993, FASEB J, V7, P918; HILDESHEIM A, 1995, EUR J CANCER, V31A, P125, DOI 10.1016/0959-8049(94)00465-H; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IMAMURA J, 1994, BLOOD, V84, P2412, DOI 10.1182/blood.V84.8.2412.bloodjournal8482412; JOLLY KW, 1994, ONCOGENE, V9, P97; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; LI FP, 1969, ANN INTERN MED, V71, P747, DOI 10.7326/0003-4819-71-4-747; MACK TM, 1995, NEW ENGL J MED, V332, P413, DOI 10.1056/NEJM199502163320701; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALKIN D, 1992, NEW ENGL J MED, V326, P1309, DOI 10.1056/NEJM199205143262002; OHGAKI H, 1993, INT J CANCER, V54, P408, DOI 10.1002/ijc.2910540310; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; POTTERN LM, 1991, LEUKEMIA RES, V15, P305, DOI 10.1016/0145-2126(91)90005-E; PROKOCIMER M, 1994, BLOOD, V84, P2391; PROSSER J, 1991, BRIT J CANCER, V63, P181, DOI 10.1038/bjc.1991.44; SAID JW, 1992, AM J PATHOL, V141, P1343; SAMESHIMA Y, 1992, J NATL CANCER I, V84, P703, DOI 10.1093/jnci/84.9.703; SANDER CA, 1993, BLOOD, V82, P1994; SHEFFIELD VC, 1993, GENOMICS, V16, P325, DOI 10.1006/geno.1993.1193; TRUMPER LH, 1993, BLOOD, V81, P3097; VILLUENDAS R, 1993, BLOOD, V82, P3151; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126	39	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB 1	1996	12	3					687	691						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TV597	8637726				2022-12-17	WOS:A1996TV59700026
J	Chattopadhyay, P; Banerjee, M; Sarkar, C; Mathur, M; Mohapatra, AK; Sinha, S				Chattopadhyay, P; Banerjee, M; Sarkar, C; Mathur, M; Mohapatra, AK; Sinha, S			Infrequent alteration of the c-myc gene in human glial tumours associated with increased numbers of c-myc positive cells	ONCOGENE			English	Article						gliomas; c-myc rearrangement; c-myc immunohistochemistry	HUMAN GLIOBLASTOMA; AMPLIFICATION; EXPRESSION; LEUKEMIA; LINE; OVEREXPRESSION; REARRANGEMENT; CARCINOMA; ONCOGENES; PROTEIN	Twenty five human glial rumours of different grades of malignancy were examined by Southern blotting and polymerase chain reaction (PCR) for alterations (rearrangements, amplification and deletions) in the c-myc gene, Number of c-myc positive cells per thousand cells were also counted in all the rumours after immunohistochemical staining for c-myc protein was done on fixed sections of the tumours, No rumours exhibited any amplification of the gene, as found by Southern blotting, One astrocytoma and one mixed glioma showed some rearrangements in the 3' end of the gene, as detected by Southern blotting and hydridization, These two tumours had higher number of c-myc positive cells than in other rumours of the same histopathological groups, Deletion in the first promoter region, as determined by PCR, was seen in only one astrocytoma. However, the number of c-myc positive cells in that tumour did not show any deviation from that found in other astrocytomas. In light of present literature, it is speculated that the 3' rearrangements may be the cause of increased number of c-myc immunopositive cells in those tumours by disrupting the 3' end of the gene leading to increased c-myc mRNA stability, Such a mechanism may play a part in small subset of glial and possibly other tumours.	ALL INDIA INST MED SCI,DEPT BIOCHEM,NEW DELHI 110029,INDIA; ALL INDIA INST MED SCI,DEPT PATHOL,NEW DELHI 110029,INDIA; ALL INDIA INST MED SCI,DEPT NEUROSURG,NEW DELHI 110029,INDIA	All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi; All India Institute of Medical Sciences (AIIMS) New Delhi			Banerjee, Moinak/X-4471-2018	Banerjee, Moinak/0000-0002-0842-0398				AGHIB DF, 1991, ONCOGENE, V6, P2371; COLLINS S, 1982, NATURE, V298, P679, DOI 10.1038/298679a0; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dixon WJ, 1983, INTRO STAT ANAL, P92; ENGELHARD HH, 1989, J NEUROSURG, V71, P224, DOI 10.3171/jns.1989.71.2.0224; FLEMING WH, 1986, CANCER RES, V46, P1535; HOLM R, 1993, J PATHOL, V169, P21, DOI 10.1002/path.1711690105; LANG FF, 1994, J NEUROSURG, V81, P427, DOI 10.3171/jns.1994.81.3.0427; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; ORIAN JM, 1992, BRIT J CANCER, V66, P106, DOI 10.1038/bjc.1992.225; PETRONI D, 1992, CARCINOGENESIS, V13, P883, DOI 10.1093/carcin/13.5.883; RAMAEL M, 1993, J PATHOL, V169, P421, DOI 10.1002/path.1711690406; SAGLIO G, 1986, CANCER RES, V46, P1413; Sambrook J, 1987, MOL CLONING LAB MANU; SHINDO H, 1993, ACTA NEUROPATHOL, V86, P345, DOI 10.1007/BF00369446; TRENT J, 1986, P NATL ACAD SCI USA, V83, P470, DOI 10.1073/pnas.83.2.470; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	18	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC 21	1995	11	12					2711	2714						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TP188	8545130				2022-12-17	WOS:A1995TP18800029
J	AVANTAGGIATO, V; TORINO, A; WONG, WT; DIFIORE, PP; SIMEONE, A				AVANTAGGIATO, V; TORINO, A; WONG, WT; DIFIORE, PP; SIMEONE, A			EXPRESSION OF THE RECEPTOR TYROSINE KINASE SUBSTRATE GENES EPS8 AND EPS15 DURING MOUSE DEVELOPMENT	ONCOGENE			English	Article						EPS8; EPS15; DEVELOPMENT; EXPRESSION	GROWTH-FACTOR RECEPTOR; DROSOPHILA-TRITHORAX; INT-1 PROTOONCOGENE; SIGNAL TRANSDUCTION; ACUTE LEUKEMIAS; ONCOGENE INT-1; EGF RECEPTOR; CELLS; DOMAINS; WNT-1	Receptor tyrosine kinases (RTKs) control proliferation and differentiation through their ability to bind and/or phosphorylate intracellular substrates, The repertoire of substrates recruited by different RTK is largely overlapping, It is not clear, therefore, how a cell distinguishes among signals originating from different RTKs. One possibility is that selective availability of substrates participates in the regulation of this process, To gain insight into this issue, we studied the expression pattern, embryogenesis, of the eps8 and eps15 encode two recently identified RTK substrates, Both genes are expressed from E 10 in a restricted fashion, eps8 is first expressed in frontonasal neural crest-derived cells, in the mesenchyme of branchial arches and in the liver primordium. At E 12.5-E 14, eps8 is additionally expressed in the central nervous system (CNS) in a regional restricted pattern at the met-mesencephalic transition area and in the developing submandibular salivary glands, eps15 is expressed at E 10 in the liver primordium, in the spinal ganglia and in the encephalic ganglia derived from the hindbrain neural crest, In addition, at E 12.5-E 14, eps15 is expressed, along all the CNS, in the ventricular zone where undifferentiated neuroblasts are located. The regional pattern of developmental expression of these two substrates sharply contrasts with their ubiquitous expression in adults, raising the possibility that their expression during embryogenesis is linked to selective proliferative and/or differentiative responses of specific neuroectodermal regions and body organs.	CNR,INT INST GENET & BIOPHYS,I-80125 NAPLES,ITALY; NCI,CELLULAR & MOLEC BIOL LAB,BETHESDA,MD 20892; EUROPEAN INST ONCOL,IEO,I-20132 MILAN,ITALY; UNIV BARI,IST MICROBIOL,I-70100 BARI,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); IRCCS European Institute of Oncology (IEO); Universita degli Studi di Bari Aldo Moro			Simeone, Antonio/ABG-5269-2020; Di Fiore, Pier Paolo/K-2130-2012	Simeone, Antonio/0000-0003-2693-9836; Di Fiore, Pier Paolo/0000-0002-2252-0950				BALLYCUIF L, 1992, DEVELOPMENT, V115, P999; BERNARD OA, 1994, ONCOGENE, V9, P1039; DIFIORE PP, 1990, SCIENCE, V248, P79, DOI 10.1126/science.2181668; DIFIORE PP, 1992, EMBO J, V11, P3927, DOI 10.1002/j.1460-2075.1992.tb05486.x; FAZIOLI F, 1993, EMBO J, V12, P3799, DOI 10.1002/j.1460-2075.1993.tb06058.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; GU Y, 1992, CELL, V71, P701, DOI 10.1016/0092-8674(92)90603-A; HEBERT JM, 1990, DEV BIOL, V138, P454, DOI 10.1016/0012-1606(90)90211-Z; JESSELL TM, 1992, CELL, V68, P257, DOI 10.1016/0092-8674(92)90469-S; Kuhlenbeck H., 1973, CENTRAL NERVOUS SYST; MATOSKOVA B, 1995, IN PRESS MOL CELL BI; MATSUI T, 1989, P NATL ACAD SCI USA, V86, P8314, DOI 10.1073/pnas.86.21.8314; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; ORRURTREGER A, 1991, DEVELOPMENT, V113, P1419; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; ROUSSEL MF, 1989, P NATL ACAD SCI USA, V86, P7924, DOI 10.1073/pnas.86.20.7924; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; RUBENSTEIN JLR, 1994, SCIENCE, V266, P578, DOI 10.1126/science.7939711; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; SCHUMACHER C, 1995, IN PRESS J BIOL CHEM; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TKACHUK DC, 1992, CELL, V71, P691, DOI 10.1016/0092-8674(92)90602-9; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS M, 1993, CELL, V73, P321, DOI 10.1016/0092-8674(93)90232-F; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WONG WT, 1994, ONCOGENE, V9, P3057; WONG WT, 1994, ONCOGENE, V9, P1591; ZERLIN M, 1993, ONCOGENE, V8, P2731	31	11	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	SEP 21	1995	11	6					1191	1198						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RX180	7566980				2022-12-17	WOS:A1995RX18000023
J	EPSTEIN, RJ				EPSTEIN, RJ			PREFERENTIAL DETECTION OF CATALYTICALLY INACTIVE C-ERBB-2 BY ANTIBODIES TO UNPHOSPHORYLATED PEPTIDES MIMICKING RECEPTOR TYROSINE AUTOPHOSPHORYLATION SITES	ONCOGENE			English	Article						RECEPTOR TYROSINE KINASES; ONCOGENES; NEOPLASMS; PHOSPHORYLATION; ANTIBODIES	GROWTH-FACTOR RECEPTOR; POSITIVE BREAST-CANCER; HER-2 NEU ONCOGENE; PROTEIN; AMPLIFICATION; EXPRESSION; CARCINOMA; CELLS; PHOSPHOTYROSINE; HER2/NEU	The c-evbB-2 tyrosine kinase is often overexpressed in human breast cancer, but correlations of receptor expression with tumour behaviour have proven elusive in patients without metastases at diagnosis. To address the possibility that receptor function may be more informative than expression, we previously developed function-specific cerbB-2 antibodies using synthetic tyrosine-phosphorylated peptide immunogens (Epstein et al., Proc, Natl. Acad. Sci. USA 1992; 89: 10435-10439). Here the converse approach has been taken to determine the functional status of c-erbB-2 receptors detected by antibodies to dephosphorylated (dep) autophosphorylation sequences. In contrast to antiphosphopeptide (apt) antibodies, dep antibodies to the Tyr(1248) autophosphorylation site exhibited preferential, but not exclusive, binding to tyrosine-dephosphorylated c-erbB-2, Consistent with this, catalytically active and inactive receptors could not be clearly distinguished by in vitro autophosphorylation experiments in which c-erbB-2 was immunoprecipitated using a monoclonal Tyr(1248) dep antibody, A dep antiserum recognizing autophosphorylation sites N-terminal to Tyr(1248) exclusively recognized tyrosine-dephosphorylated c-erbB-2 following antibody preabsorption with homologous phosphopeptides. Although indirect, these data are consistent with a model of sequential c-erbB-2 autophosphorylation in which Tyr(1Z48) iS the final residue modified, Moreover, since many studies of c-erbB-2 expression have used antibodies to dephosphorylated autophosphorylation sites, these results caution against automatically equating such receptor immunoreactivity with in vivo function or clinical significance.	CHARING CROSS HOSP,DEPT MED ONCOL,CANC RES CAMPAIGN LABS,LONDON W6 8RF,ENGLAND	Imperial College London	EPSTEIN, RJ (corresponding author), UNIV LONDON,CHARING CROSS & WESTMINSTER MED SCH,DIV CELL MOLEC & ONCOL RES,LONDON W6 8RF,ENGLAND.							AKIYAMA T, 1991, MOL CELL BIOL, V11, P833, DOI 10.1128/MCB.11.2.833; ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; BANGALORE L, 1992, P NATL ACAD SCI USA, V89, P11637, DOI 10.1073/pnas.89.23.11637; BARGMANN CI, 1986, NATURE, V319, P226, DOI 10.1038/319226a0; BARTKOVA J, 1990, HUM PATHOL, V21, P1164, DOI 10.1016/0046-8177(90)90154-W; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; BERGER MS, 1988, CANCER RES, V48, P1238; BONADONNA G, 1995, NEW ENGL J MED, V332, P901, DOI 10.1056/NEJM199504063321401; BORG A, 1990, CANCER RES, V50, P4332; BORG A, 1989, LANCET, V1, P1268; Campos-Gonzalez R, 1991, GROWTH FACTORS, V4, P305, DOI 10.3109/08977199109043916; CAO HN, 1991, ONCOGENE, V6, P705; DOWNING JR, 1991, MOL CELL BIOL, V11, P2489, DOI 10.1128/MCB.11.5.2489; DRAGO GA, 1994, J BIOL CHEM, V269, P25073; EPSTEIN RJ, 1992, P NATL ACAD SCI USA, V89, P10435, DOI 10.1073/pnas.89.21.10435; EPSTEIN RJ, 1990, J BIOL CHEM, V265, P10746; EPSTEIN RJ, 1992, CELL GROWTH DIFFER, V3, P157; GULLICK WJ, 1985, EMBO J, V4, P2869, DOI 10.1002/j.1460-2075.1985.tb04016.x; GULLICK WJ, 1987, INT J CANCER, V40, P246, DOI 10.1002/ijc.2910400221; GUSTERSON BA, 1988, INT J CANCER, V42, P842, DOI 10.1002/ijc.2910420608; HARDER KW, 1994, BIOCHEM J, V298, P395, DOI 10.1042/bj2980395; HAZAN R, 1990, CELL GROWTH DIFFER, V1, P3; HUANG SS, 1990, J BIOL CHEM, V265, P3340; IGLEHART JD, 1990, CANCER RES, V50, P6701; KURY F, 1990, EUR J CANCER, V26, P946, DOI 10.1016/0277-5379(90)90616-2; MARGOLIS BL, 1989, J BIOL CHEM, V264, P10667; NAIRN AC, 1982, NATURE, V299, P734, DOI 10.1038/299734a0; OREILLY SM, 1991, BRIT J CANCER, V63, P444, DOI 10.1038/bjc.1991.102; OREILLY SM, 1990, EUR J CANCER, V26, P1035, DOI 10.1016/0277-5379(90)90045-U; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; PATERSON MC, 1991, CANCER RES, V51, P556; PERES R, 1987, CANCER RES, V47, P3425; RAMACHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P4232, DOI 10.1021/bi00132a012; RO J, 1989, ONCOGENE, V4, P351; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STERN DF, 1988, EMBO J, V7, P995, DOI 10.1002/j.1460-2075.1988.tb02906.x; TANDON AK, 1989, J CLIN ONCOL, V7, P1120, DOI 10.1200/JCO.1989.7.8.1120; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEVIJVER MJ, 1988, ONCOGENE, V2, P175; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG JYJ, 1985, MOL CELL BIOL, V5, P3640, DOI 10.1128/MCB.5.12.3640; WEINER DB, 1989, NATURE, V339, P230, DOI 10.1038/339230a0; WILDENHAIN Y, 1990, ONCOGENE, V5, P879; WRANN M, 1980, SCIENCE, V210, P1363, DOI 10.1126/science.6254158	47	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	JUL 20	1995	11	2					315	323						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RK957	7624146				2022-12-17	WOS:A1995RK95700012
J	STEINGRIMSDOTTIR, H; BEARE, D; CARR, AM; COLE, J; LEHMANN, AR				STEINGRIMSDOTTIR, H; BEARE, D; CARR, AM; COLE, J; LEHMANN, AR			UV-HYPERMUTABILITY OF XERODERMA-PIGMENTOSUM CELLS DEMONSTRATED WITH A DNA-BASED MUTATION SYSTEM	ONCOGENE			English	Article						MUTATIONS; POLYMERASE CHAIN REACTION; RESTRICTION SITE; ULTRAVIOLET; XERODERMA PIGMENTOSUM	POLYMERASE CHAIN-REACTION; NITROSOUREA-INDUCED MUTATIONS; LYMPHOCYTES-T; COMPLEMENTATION GROUP; MAMMALIAN-CELLS; CIRCULATING LYMPHOCYTES; STRAND SPECIFICITY; GENOTYPIC ANALYSIS; MOLECULAR ANALYSIS; REPAIR-PROFICIENT	We have developed a DNA-based system, to detect mutations at restriction sites without any selection in culture. DNA is exhaustively digested with a restriction enzyme. Primers Ranking a chosen site for this enzyme are used in the polymerase chain reaction (PCR). Only DNA molecules mutated at the chosen site are resistant to digestion and can serve as templates for the PCR. We have initially used this system to demonstrate the generation of mutations by ethyl methanesulphonate (EMS) at a TaqI site in the aprt gene of Chinese hamster cells, and by u.v.-C irradiation at a TaqI site in the hprt gene of human fibroblasts, In repair-deficient xeroderma pigmentosum (XP) cells the u.v.-induced mutant frequency was greatly enhanced. We have been able to detect and analyse mutations in XP cells at TaqI sites in three different genes, hprt, p53 and c-Ha-ras1. Both u.v.-C and u.v.-B irradiation have been used as mutagenic agents with both lymphoblastoid and fibroblast cells from XP patients from complementation group G. The mutant DNA molecules have been sequenced. Following u.v.-C-irradiation, the majority of mutations analysed were GC-->AT transitions, but several double and tandem mutations were also found.	UNIV SUSSEX,MRC,CELL MUTAT UNIT,BRIGHTON BN1 9RR,E SUSSEX,ENGLAND	University of Sussex				Carr, Antony Michael/0000-0002-2028-2389				AGUILAR F, 1993, P NATL ACAD SCI USA, V90, P8586, DOI 10.1073/pnas.90.18.8586; ALBERTINI RJ, 1985, MUTAT RES, V150, P411, DOI 10.1016/0027-5107(85)90138-1; ARLETT CF, 1980, CARCINOGENESIS, V1, P745, DOI 10.1093/carcin/1.9.745; ARLETT CF, 1993, CANCER RES, V53, P609; ARLETT CF, 1983, INDUCED MUTAGENESIS, P249; BIGBEE WL, 1990, MUTAT RES, V240, P165, DOI 10.1016/0165-1218(90)90056-8; BREDBERG A, 1986, P NATL ACAD SCI USA, V83, P8273, DOI 10.1073/pnas.83.21.8273; BRIDGES BA, 1990, MUTAGENESIS, V5, P523, DOI 10.1093/mutage/5.6.523; CHIOCCA SM, 1992, P NATL ACAD SCI USA, V89, P5331, DOI 10.1073/pnas.89.12.5331; COLE J, 1994, MUTAT RES, V304, P33, DOI 10.1016/0027-5107(94)90320-4; COLE J, 1988, MUTAT RES, V204, P493, DOI 10.1016/0165-1218(88)90044-4; DORADO G, 1991, J MOL BIOL, V217, P217, DOI 10.1016/0022-2836(91)90533-C; DROBETSKY EA, 1987, P NATL ACAD SCI USA, V84, P9103, DOI 10.1073/pnas.84.24.9103; FELLEYBOSCO E, 1991, NUCLEIC ACIDS RES, V19, P2913, DOI 10.1093/nar/19.11.2913; HENDERSON L, 1986, MUTAGENESIS, V1, P195, DOI 10.1093/mutage/1.3.195; HOU SM, 1993, MUTAGENESIS, V8, P43, DOI 10.1093/mutage/8.1.43; HSIA HC, 1989, J MOL BIOL, V205, P103, DOI 10.1016/0022-2836(89)90368-9; HULTMAN T, 1989, NUCLEIC ACIDS RES, V17, P4937, DOI 10.1093/nar/17.13.4937; HUSSAIN SP, 1994, ONCOGENE, V9, P2277; HUSSAIN SP, 1994, ONCOGENE, V9, P13; KEIJZER W, 1979, MUTAT RES, V62, P183, DOI 10.1016/0027-5107(79)90231-8; KOVALIC D, 1991, NUCLEIC ACIDS RES, V19, P4560, DOI 10.1093/nar/19.16.4560; MADZAK C, 1991, J MOL BIOL, V218, P667, DOI 10.1016/0022-2836(91)90252-2; MCGREGOR WG, 1991, MOL CELL BIOL, V11, P1927, DOI 10.1128/MCB.11.4.1927; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MENICHINI P, 1991, MUTAT RES, V251, P143, DOI 10.1016/0027-5107(91)90224-C; MEUTH M, 1990, BIOCHIM BIOPHYS ACTA, V1032, P1, DOI 10.1016/0304-419X(90)90009-P; MYERS B, 1994, MUTAGENESIS, V9, P175, DOI 10.1093/mutage/9.3.175; NALBANTOGLU J, 1983, J MOL BIOL, V167, P575, DOI 10.1016/S0022-2836(83)80099-0; NALBANTOGLU J, 1987, MOL CELL BIOL, V7, P1445, DOI 10.1128/MCB.7.4.1445; PALOMBO F, 1992, NUCLEIC ACIDS RES, V20, P1349, DOI 10.1093/nar/20.6.1349; PARRY JM, 1990, MUTAGENESIS, V5, P209, DOI 10.1093/mutage/5.3.209; POURZAND C, 1993, MUTAT RES, V288, P113, DOI 10.1016/0027-5107(93)90213-Y; ROSSI AM, 1990, MUTAT RES, V244, P353, DOI 10.1016/0165-7992(90)90084-W; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANDY MS, 1992, P NATL ACAD SCI USA, V89, P890, DOI 10.1073/pnas.89.3.890; STEINGRIMSDOTTIR H, 1993, MUTAT RES, V294, P29, DOI 10.1016/0921-8777(93)90055-L; STRAUSS GH, 1979, MUTAT RES, V61, P353, DOI 10.1016/0027-5107(79)90140-4; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; VRIELING H, 1989, MOL CELL BIOL, V9, P1277, DOI 10.1128/MCB.9.3.1277; VRIELING H, 1991, NUCLEIC ACIDS RES, V19, P2411, DOI 10.1093/nar/19.9.2411; YAGI T, 1991, CANCER RES, V51, P3177; ZIJLSTRA J, 1990, MUTAGENS CARCINOGENS, P187	43	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAY 18	1995	10	10					2057	2066						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ926	7761106				2022-12-17	WOS:A1995QZ92600020
J	IGLESIAS, T; LLANOS, S; LOPEZBARAHONA, M; SELIGER, B; RODRIGUEZPENA, A; BERNAL, J; MUNOZ, A				IGLESIAS, T; LLANOS, S; LOPEZBARAHONA, M; SELIGER, B; RODRIGUEZPENA, A; BERNAL, J; MUNOZ, A			INDUCTION OF PLATELET-DERIVED GROWTH-FACTOR B/C-SIS BY THE V-ERBA ONCOGENE IN GLIAL-CELLS	ONCOGENE			English	Article						ERBA ONCOGENE; PDGF B/C-SIS; GLIAL CELLS; THYROID HORMONE RECEPTOR; AUTOCRINE STIMULATION	THYROID-HORMONE RECEPTOR; HUMAN-MALIGNANT GLIOMA; CENTRAL-NERVOUS-SYSTEM; C-ERBA; OLIGODENDROCYTE DEVELOPMENT; GENE-EXPRESSION; AB HETERODIMER; MESSENGER-RNA; PDGF-A; PROTEIN	The v-erbA oncogene codes for a mutated form of the thyroid hormone receptor TRlc-eubA-alpha, Thyroid hormone (triiodothyronine, T3) regulates glial functions such as myelination and both astrocytes and oligodendrocytes have been shown to express thyroid hormone receptors (TRs). To study putative effects of v-erbA on glial precursors, we have expressed it in a glial clonal cell line established from early embryonal mouse brain, We have found that v-erbA increases cell survival in serum-free conditions. Moreover, v-erbA-expressing cells show a substantial growth in the presence of insulin or IGF-I, whereas normal and TR/c-erbA-over-expressing cells progressively degenerate. By Northern blotting, immuno-fluorescence, immunoprecipitation, and neutralization experiments, we show that v-erbA actions are mediated by an increase in the levels of PDGF B/c-sis mRNA and protein. We used anti-PDGF receptor and antiphosphotyrosine antibodies to show the constitutive activation of PDGF receptors in B3.1+v-erbA cells, and neutralizing anti-PDGF antibodies to demonstrate that v-erbA enhances the secretion of active PDGF into the culture medium. Our data indicate that v-erbA induces PDGF B/c-sis, a factor involved in the generation df gliomas, the most common central nervous system tumor in humans.	CSIC,INST INVEST BIOMED,E-28029 MADRID,SPAIN; UNIV MAINZ,DIV HAMATOL ONKOL,INNERE MED KLIN 3,D-55131 MAINZ,GERMANY	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Johannes Gutenberg University of Mainz			Munoz, Alberto/O-6393-2014; , Susana/AAA-9282-2019; Bernal, Juan/J-6086-2014	Munoz, Alberto/0000-0003-3890-4251; Bernal, Juan/0000-0002-5867-4951; Llanos, Susana/0000-0002-8555-9326; Iglesias, Teresa/0000-0002-4326-9005; Rodriguez-Pena, Angeles/0000-0002-2515-4626				ARMSTRONG RC, 1990, J NEUROSCI RES, V27, P400, DOI 10.1002/jnr.490270319; BARETTINO D, 1993, EMBO J, V12, P1343, DOI 10.1002/j.1460-2075.1993.tb05779.x; BARRES BA, 1994, NEURON, V12, P935, DOI 10.1016/0896-6273(94)90305-0; BECKMANN MP, 1988, SCIENCE, V241, P1346, DOI 10.1126/science.2842868; BEHAR T, 1988, J NEUROSCI RES, V21, P168, DOI 10.1002/jnr.490210209; BEUG H, 1991, NUCLEAR HORMONE RECE, P355; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; BRENT GA, 1991, ANNU REV PHYSIOL, V53, P17, DOI 10.1146/annurev.ph.53.030191.000313; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; DISELA C, 1989, GENE DEV, V5, P2033; DUSSAULT JH, 1987, ANNU REV PHYSIOL, V49, P321, DOI 10.1146/annurev.ph.49.030187.001541; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V137, P266; FLEMING TP, 1992, ONCOGENE, V7, P1355; FLEMING TP, 1989, P NATL ACAD SCI USA, V86, P8063, DOI 10.1073/pnas.86.20.8063; GANDRILLON O, 1994, ONCOGENE, V9, P749; GLASS CK, 1990, BIOCHIM BIOPHYS ACTA, V1032, P157, DOI 10.1016/0304-419X(90)90002-I; HERMANSON M, 1992, CANCER RES, V52, P3213; HUANG JS, 1984, CELL, V39, P79, DOI 10.1016/0092-8674(84)90193-4; IGLESIAS T, 1994, ENDOCR REV, V5, P697; Legrand J, 1984, NEUROBEHAVIORAL TERA, P331; LENS PF, 1986, MOL CELL BIOL, V6, P3537, DOI 10.1128/MCB.6.10.3537; MCKINNON RD, 1990, NEURON, V5, P603, DOI 10.1016/0896-6273(90)90215-2; MUNOZ A, 1991, MOL ENDOCRINOL, V5, P273, DOI 10.1210/mend-5-2-273; MUNOZ A, 1988, EMBO J, V7, P155, DOI 10.1002/j.1460-2075.1988.tb02795.x; MUNOZ A, 1990, MOL ENDOCRINOL, V4, P312, DOI 10.1210/mend-4-2-312; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1986, CANCER RES, V46, P332; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; NISTER M, 1991, J BIOL CHEM, V266, P16755; NISTER M, 1984, P NATL ACAD SCI-BIOL, V81, P926, DOI 10.1073/pnas.81.3.926; NOBLE M, 1988, NATURE, V333, P560, DOI 10.1038/333560a0; OSTMAN A, 1988, J BIOL CHEM, V263, P16202; PAIN B, 1990, New Biologist, V2, P284; PASTOR R, 1994, ONCOGENE, V9, P1081; PEDERSEN PH, 1994, INT J CANCER, V56, P255, DOI 10.1002/ijc.2910560219; POLLACK IF, 1991, J NEUROSURG, V75, P284, DOI 10.3171/jns.1991.75.2.0284; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; PRESS RD, 1989, CANCER RES, V49, P2914; PUYMIRAT J, 1986, NEUROSCI LETT, V68, P299, DOI 10.1016/0304-3940(86)90506-9; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; RICHARDSON W D, 1991, Current Biology, V1, P162, DOI 10.1016/0960-9822(91)90220-Q; RICHARDSON WD, 1988, CELL, V53, P309, DOI 10.1016/0092-8674(88)90392-3; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SAP J, 1989, NATURE, V340, P242, DOI 10.1038/340242a0; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SASAHARA M, 1991, CELL, V64, P217, DOI 10.1016/0092-8674(91)90223-L; WANG ZY, 1992, J BIOL CHEM, V267, P21999; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WESTPHAL M, 1988, CANCER LETT, V38, P283, DOI 10.1016/0304-3835(88)90020-1; YUSTA B, 1988, ENDOCRINOLOGY, V122, P2278, DOI 10.1210/endo-122-5-2278; ZENKE M, 1990, CELL, V61, P1035, DOI 10.1016/0092-8674(90)90068-P	55	11	11	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1103	1110						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700635				2022-12-17	WOS:A1995QN35300010
J	ONEILL, FJ; FRISQUE, RJ; XU, XL; HU, YX; CARNEY, H				ONEILL, FJ; FRISQUE, RJ; XU, XL; HU, YX; CARNEY, H			IMMORTALIZATION OF HUMAN-CELLS BY MUTANT AND CHIMERIC PRIMATE POLYOMAVIRUS T-ANTIGEN GENES	ONCOGENE			English	Article						TRANSFORMATION; IMMORTALIZATION; POLYOMAVIRUSES; T-ANTIGEN; SV40; JCV; BKV	SV40-TRANSFORMED HUMAN-FIBROBLASTS; PAPILLOMAVIRUS TYPE-16 DNA; MOUSE EMBRYO FIBROBLASTS; VIRUS 40 GENE; SIMIAN VIRUS-40; JC-VIRUS; MALIGNANT TRANSFORMATION; CELLULAR SENESCENCE; VIRAL-DNA; 3' END	Human fibroblasts were morphologically transformed with wild type and mutant SV40 T-antigens (T-Ags) and with SV40/JCV and SV40/BKV chimeric T-Ags. The transformants were then assayed for the attainment of immortal cell growth. Several observations relating T-Ag and T-Ag domains to immortalization were made. Approximately 10% of SV40-transformants became immortal. Transformants generated by transfection or infection of cells with C-terminal T-Ag deletion mutants of SV40 did not immortalize. SV40/JCV and SV40/BKV chimeric T-Ags, containing C-terminal sequences from JCV or BKV, immortalized cells more efficiently than did the intact SV40 T-Ag, suggesting that the C-termini of the JCV and BKV T-Ags contain an enhanced immortalization function. However, chimeras in which the N-terminal or proximal-central portions of T-Ag were composed of JCV sequences failed to immortalize but did induce transformation, Constructs in which the JCV T-Ag Rb binding domain was replaced with SV40 sequences transformed human cells, but again the cells failed to immortalize. Transformants and immortalized cell lines produced by some SV40/JCV chimeras, contained p53 which was unbound by T-Ag. This occurred under conditions where p53 from SV40 and SV40/BKV transformants was bound to T-Ag. This may reflect the reduced stability of the SV40/JCV T-Ags.	UNIV UTAH,DEPT CELLULAR VIRAL & MOLEC BIOL,DEPT PATHOL,SALT LAKE CITY,UT 84132; PENN STATE UNIV,DEPT BIOCHEM & MOLEC BIOL,UNIVERSITY PK,PA 16802	Utah System of Higher Education; University of Utah; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	ONEILL, FJ (corresponding author), VET AFFAIRS MED CTR,RES SERV,SALT LAKE CITY,UT 84148, USA.				NATIONAL CANCER INSTITUTE [R01CA044970] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44970] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BISCHOFF FZ, 1990, CANCER RES, V50, P7979; BRUGGE JS, 1975, J VIROL, V15, P619, DOI 10.1128/JVI.15.3.619-635.1975; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; COLE CN, 1979, J VIROL, V30, P683, DOI 10.1128/JVI.30.3.683-691.1979; COLE CN, 1977, J VIROL, V24, P277, DOI 10.1128/JVI.24.1.277-294.1977; CRISTOFALO VJ, 1985, GERONTOLOGIST, V25, P577, DOI 10.1093/geront/25.6.577; DEFENDI V, 1982, J CELL PHYSL S, V2, P131; DEPPERT W, 1989, VECTORS TOOLS STUDY, P399; DURST M, 1987, ONCOGENE, V1, P251; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GIRARDI AJ, 1965, J CELL COMP PHYSL, V165, P69; GISH WR, 1987, J VIROL, V61, P2864, DOI 10.1128/JVI.61.9.2864-2876.1987; GLUZMAN Y, 1980, P NATL ACAD SCI-BIOL, V77, P3898, DOI 10.1073/pnas.77.7.3898; GROSSI MP, 1982, J GEN VIROL, V63, P393, DOI 10.1099/0022-1317-63-2-393; GURNEY EG, 1986, J VIROL, V57, P1168, DOI 10.1128/JVI.57.3.1168-1172.1986; HAGGERTY S, 1989, J VIROL, V63, P2180, DOI 10.1128/JVI.63.5.2180-2190.1989; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; KAO CH, 1993, J VIROL, V67, P1987, DOI 10.1128/JVI.67.4.1987-1995.1993; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; KUHAR SG, 1991, ONCOGENE, V6, P1499; LIN JY, 1991, J VIROL, V65, P6447, DOI 10.1128/JVI.65.12.6447-6453.1991; LINDER S, 1990, EXP CELL RES, V191, P1, DOI 10.1016/0014-4827(90)90027-8; MANDL C, 1987, J VIROL, V61, P755, DOI 10.1128/JVI.61.3.755-763.1987; MANIATIS T, 1982, MOL CLONING LAB MANU; MARTIN RG, 1975, J VIROL, V15, P599, DOI 10.1128/JVI.15.3.599-612.1975; MCCORMICK JJ, 1988, MUTAT RES, V199, P273; MICHAELMICHALOV.D, 1991, J VIROL, V65, P4160; MONIER R, 1986, PAPOVAVIRIDAE; NEUFELD DS, 1987, MOL CELL BIOL, V7, P2794, DOI 10.1128/MCB.7.8.2794; ONEILL FJ, 1980, J VIROL, V35, P233, DOI 10.1128/JVI.35.1.233-245.1980; ONEILL FJ, 1990, INTERVIROLOGY, V31, P175, DOI 10.1159/000150152; ONEILL FJ, 1988, VIRUS RES, V11, P109, DOI 10.1016/0168-1702(88)90037-8; ONEILL FJ, 1986, VIROLOGY, V154, P344, DOI 10.1016/0042-6822(86)90460-5; ONEILL FJ, 1993, VIRUS RES, V30, P171, DOI 10.1016/0168-1702(93)90005-8; ONEILL FJ, 1992, VIRUS RES, V25, P169, DOI 10.1016/0168-1702(92)90132-S; ONEILL FJ, 1994, VIRUS RES, V34, P237, DOI 10.1016/0168-1702(94)90126-0; ONEILL FJ, 1982, J VIROL, V43, P18, DOI 10.1128/JVI.43.1.18-25.1982; ONEILL FJ, 1981, VIROLOGY, V112, P800, DOI 10.1016/0042-6822(81)90330-5; PATER A, 1980, J VIROL, V36, P480, DOI 10.1128/JVI.36.2.480-487.1980; PEREIRASMITH OM, 1988, P NATL ACAD SCI USA, V85, P6042, DOI 10.1073/pnas.85.16.6042; PETIT CA, 1983, VIROLOGY, V127, P74, DOI 10.1016/0042-6822(83)90372-0; PIPAS JM, 1983, MOL CELL BIOL, V3, P201; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; PURCHIO AF, 1979, J VIROL, V29, P763, DOI 10.1128/JVI.29.2.763-769.1979; RADNA RL, 1989, MOL CELL BIOL, V9, P3093, DOI 10.1128/MCB.9.7.3093; RESNICKSILVERMA.L, 1991, J VIROL, V65, P2843; SAGER R, 1991, ENVIRON HEALTH PERSP, V93, P59, DOI 10.2307/3431170; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; STEIN GH, 1985, J CELL PHYSIOL, V125, P36, DOI 10.1002/jcp.1041250106; STETTER G, 1988, VIROLOGY, V164, P309, DOI 10.1016/0042-6822(88)90543-0; STRAUSS M, 1990, ONCOGENE, V5, P1223; STRAUSS M, 1990, CANCER CELL-MON REV, V2, P360; TAVIS JE, 1994, VIROLOGY, V199, P384, DOI 10.1006/viro.1994.1136; TEGTMEYER P, 1975, J VIROL, V15, P613, DOI 10.1128/JVI.15.3.613-618.1975; TEVETHIA MJ, 1988, VIROLOGY, V162, P76, DOI 10.1016/0042-6822(88)90396-0; TIEMANN F, 1994, J VIROL, V68, P2869, DOI 10.1128/JVI.68.5.2869-2878.1994; TOOZE J, 1981, COLD SPRING HARBOR L; TROWBRIDGE PW, 1993, VIROLOGY, V196, P458, DOI 10.1006/viro.1993.1502; TSUYAMA N, 1991, CELL STRUCT FUNCT, V16, P55, DOI 10.1247/csf.16.55; VANDOREN K, 1984, MOL CELL BIOL, V4, P1653, DOI 10.1128/MCB.4.8.1653; VANHEUVERSWYN H, 1979, J VIROL, V67, P1817; WALKER DL, 1986, POLYOMAVIRUSES; WOODWORTH CD, 1989, J VIROL, V63, P159, DOI 10.1128/JVI.63.1.159-164.1989; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088	66	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	MAR 16	1995	10	6					1131	1139						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QN353	7700639				2022-12-17	WOS:A1995QN35300014
J	ISHIOKA, C; BALLESTER, R; ENGELSTEIN, M; VIDAL, M; KASSEL, J; THE, I; BERNARDS, A; GUSELLA, JF; FRIEND, SH				ISHIOKA, C; BALLESTER, R; ENGELSTEIN, M; VIDAL, M; KASSEL, J; THE, I; BERNARDS, A; GUSELLA, JF; FRIEND, SH			A FUNCTIONAL ASSAY FOR HETEROZYGOUS MUTATIONS IN THE GTPASE-ACTIVATING PROTEIN RELATED DOMAIN OF THE NEUROFIBROMATOSIS TYPE-1 GENE	ONCOGENE			English	Article						NF1; FUNCTIONAL ASSAY IN YEAST FASAY	GAP-RELATED DOMAIN; SACCHAROMYCES-CEREVISIAE; RAS GTPASE; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; GEL-ELECTROPHORESIS; ADENYLATE-CYCLASE; MAMMALIAN GAP; CDC25 GENE; YEAST; PRODUCT	The GTPase-activating protein related domain of the human neurofibromatosis type 1 protein (NF1GRD) can down-regulate RAS in Saccharomyces cerevisiae, Using a technique termed the FASAY method, for Functional Analysis of Separated Alleles in Yeast, we designed a rapid method for detection of heterozygous NF1GRD loss-of-function mutations, In our method, PCR amplified NF1GRD cDNA is directly cloned into a centromeric vector by homologous recombination in a cdc25 temperature-sensitive mutant strain expressing human Ha-ras. This strain is dependent on the Ha-uas for growth, allowing a simple growth assay for NF1GRD loss-of-function mutations, In a test of our method, two alternatively spliced NF1GRD cDNAs (type I and II) inhibited yeast growth whereas four mutants with amino acid substitutions at highly conserved residues did not, This simple method thus permits the rapid screening for heterozygous germline or somatic NF1GRD mutations, In an initial application of this method, no mutations disrupting NF1GRD function were detected in lymphoblasts from 11 previously untested neurofibromatosis type 1 patients.	MASSACHUSETTS GEN HOSP, MOLEC NEUROGENET UNIT, BOSTON, MA 02129 USA; TOHOKU UNIV, INST DEV AGING & CANC, SENDAI, MIYAGI 980, JAPAN; UNIV CALIF SANTA BARBARA, DEPT BIOL SCI, SANTA BARBARA, CA 93106 USA; HARVARD UNIV, CHILDRENS HOSP,SCH MED,DANA FARBER INST, DEP PEDIAT,DIV HEMATOL ONCOL, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Tohoku University; University of California System; University of California Santa Barbara; Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School	ISHIOKA, C (corresponding author), MASSACHUSETTS GEN HOSP, CTR CANC, BOSTON, MA 02129 USA.		The, Inge/B-8884-2011		PHS HHS [WS 22224] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; [Anonymous], 1988, ARCH NEUROL-CHICAGO, V45, P575, DOI 10.1097/00005537-199606000-00007; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BERNARDS A, 1992, DNA CELL BIOL, V11, P727, DOI 10.1089/dna.1992.11.727; BORRESEN AL, 1991, P NATL ACAD SCI USA, V88, P8405, DOI 10.1073/pnas.88.19.8405; BOUTELET F, 1985, EMBO J, V4, P2635, DOI 10.1002/j.1460-2075.1985.tb03981.x; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0; CAMONIS JH, 1986, EMBO J, V5, P375, DOI 10.1002/j.1460-2075.1986.tb04222.x; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; ENG C, 1993, FASEB J, V7, P910, DOI 10.1096/fasebj.7.10.8102106; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GROMPE M, 1993, NAT GENET, V5, P111, DOI 10.1038/ng1093-111; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; GUTMANN DH, 1993, ONCOGENE, V8, P761; ISHIOKA C, 1993, NAT GENET, V5, P124, DOI 10.1038/ng1093-124; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES S, 1991, MOL CELL BIOL, V11, P2641, DOI 10.1128/MCB.11.5.2641; KNUNDSON AG, 1993, P NATL ACAD SCI USA, V90, P10914; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; LUNBERG KS, 1991, GENE, V108, P1; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MARCHUK DA, 1991, GENOMICS, V11, P931, DOI 10.1016/0888-7543(91)90017-9; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MUHLRAD D, 1992, YEAST, V8, P79, DOI 10.1002/yea.320080202; NAGAMINE CM, 1989, AM J HUM GENET, V45, P337; NAKAFUKU M, 1993, P NATL ACAD SCI USA, V90, P6706, DOI 10.1073/pnas.90.14.6706; NISHI T, 1991, ONCOGENE, V6, P1555; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; RICCARDI VM, 1981, NEW ENGL J MED, V305, P1617, DOI 10.1056/NEJM198112313052704; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SHEFFIELD VC, 1991, AM J HUM GENET, V49, P699; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; UPADHYAYA M, 1990, J MED GENET, V27, P738, DOI 10.1136/jmg.27.12.738; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	48	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 2	1995	10	5					841	847						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QL038	7898926				2022-12-17	WOS:A1995QL03800005
J	DEGROOT, RP; SCHOUTEN, GJ; DEWIT, L; BALLOU, LM; VANDEREB, AJ; ZANTEMA, A				DEGROOT, RP; SCHOUTEN, GJ; DEWIT, L; BALLOU, LM; VANDEREB, AJ; ZANTEMA, A			INDUCTION OF THE MITOGEN-ACTIVATED P70 S6 KINASE BY ADENOVIRUS E1A	ONCOGENE			English	Article						E1A; ONCOGENE; TRANSCRIPTION; P70 S6 KINASE; PHOSPHORYLATION; TRANSFORMATION	RETINOBLASTOMA GENE-PRODUCT; E2F TRANSCRIPTION FACTOR; HUMAN CYCLIN-A; CELL-CYCLE; PROTEIN-KINASE; MAP KINASES; C-JUN; PHOSPHORYLATION; GROWTH; TRANSFORMATION	Adenovirus E1A proteins can transform primary cells in culture in conjunction with other oncogenes, such as E1B or activated ras. The modulation of various cell cycle regulators by E1A is thought to be involved in this transformation process. In this paper we show that E1A enhances the expression of the mitogen-inducible p70 S6 kinase (70(s6k)), a kinase which is essential for G1 progression. p70(s6k) mRNA and protein levels are enhanced 3-4-fold in various E1A-expressing cell lines. Similarly, the activity of p70(s6k) is enhanced in E1A-expressing cells in a manner partially independent of enhanced expression of p70(s6k) The induction of p70(s6k) correlates with the presence of conserved region 1 (CR1) of E1A and with morphological transformation by E1A. These results suggest that induction of p70(s6k) by E1A might be involved in transformation by E1A.	LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,LEIDEN,NETHERLANDS; RES INST MOLEC PATHOL,A-1030 VIENNA,AUSTRIA	Leiden University; Leiden University - Excl LUMC; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)								BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BANNERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550; BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; BUCHOU T, 1993, ONCOGENE, V8, P1765; CAO L, 1992, NATURE, V355, P176, DOI 10.1038/355176a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; COBRINIK D, 1993, GENE DEV, V7, P2392, DOI 10.1101/gad.7.12a.2392; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEGROOT R, 1991, MOL CELL BIOL, V11, P192, DOI 10.1128/MCB.11.1.192; DEGROOT RP, 1991, ONCOGENE, V6, P2357; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FERRARI S, 1993, J BIOL CHEM, V268, P16091; FERRARI S, 1992, P NATL ACAD SCI USA, V89, P7282, DOI 10.1073/pnas.89.15.7282; FLINT SJ, 1990, MOL BIOL TUMOR VIRUS, V2, P547; FRANCO R, 1990, J BIOL CHEM, V265, P4321; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; HAGMEYER BM, 1993, EMBO J, V12, P3559, DOI 10.1002/j.1460-2075.1993.tb06030.x; HILL CS, 1993, CELL, V73, P395, DOI 10.1016/0092-8674(93)90238-L; HOUWELING A, 1980, VIROLOGY, V105, P537, DOI 10.1016/0042-6822(80)90054-9; JANKNECHT R, 1993, EMBO J, V12, P5097, DOI 10.1002/j.1460-2075.1993.tb06204.x; KIMELMAN D, 1986, MOL CELL BIOL, V6, P1487, DOI 10.1128/MCB.6.5.1487; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LILLIE JW, 1986, CELL, V46, P1043, DOI 10.1016/0092-8674(86)90704-X; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MORAN E, 1986, MOL CELL BIOL, V7, P3470; MORLEY SJ, 1991, PHARMACOL THERAPEUT, V50, P291, DOI 10.1016/0163-7258(91)90047-P; MUDRYJ M, 1991, CELL, V65, P1243, DOI 10.1016/0092-8674(91)90019-U; MUMMERY CL, 1986, EXP CELL RES, V165, P229, DOI 10.1016/0014-4827(86)90547-1; MUMMERY CL, 1985, DEV BIOL, V109, P402, DOI 10.1016/0012-1606(85)90466-X; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; PEEPER DS, 1993, EMBO J, V12, P1947, DOI 10.1002/j.1460-2075.1993.tb05844.x; PEEPER DS, 1993, MOL BIOL REP, V17, P197, DOI 10.1007/BF00986728; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; REINHARD C, 1994, EMBO J, V13, P1557, DOI 10.1002/j.1460-2075.1994.tb06418.x; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; TERADA N, 1992, BIOCHEM BIOPH RES CO, V186, P1315, DOI 10.1016/S0006-291X(05)81549-9; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDENELSEN P, 1983, VIROLOGY, V128, P377; WANG HGH, 1993, J VIROL, V67, P476, DOI 10.1128/JVI.67.1.476-488.1993; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	59	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HANTS, ENGLAND RG21 2XS	0950-9232			ONCOGENE	Oncogene	FEB 2	1995	10	3					543	548						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QF648	7845679				2022-12-17	WOS:A1995QF64800015
J	ISOBE, M; HINODA, Y; IMAI, K; ADACHI, M				ISOBE, M; HINODA, Y; IMAI, K; ADACHI, M			CHROMOSOMAL LOCALIZATION OF AN SH2 CONTAINING TYROSINE PHOSPHATASE (SH-PTP3) GENE TO CHROMOSOME 12Q24.1	ONCOGENE			English	Note							SH2-CONTAINING PHOSPHOTYROSINE PHOSPHATASE; SEQUENCE SIMILARITY; MOLECULAR-CLONING; EXPRESSION; ACTIVATION; DOMAINS; TRISOMY-12; CORKSCREW; KINASES; CELLS	A genomic DNA fragment, isolated from a human phage library using a human BPTP3 cDNA probe, was shown to be derived from the human SH-PTP3 (also called SH-PTP2, PTP-1D, PTP-2C, or Syp) locus. We have used fluorescent in situ hybridization (FISH) to map SH-PTP3 in chromosome band 12q24.1, a region vicinity to the second locus for autosomal dominant cerebellar ataxia (SCA2).	SAPPORO MED UNIV,SCH MED,DEPT INTERNAL MED,SECT 1,CHUO KU,SAPPORO 060,JAPAN		ISOBE, M (corresponding author), TOYAMA MED & PHARMACEUT UNIV,ORIENTAL MED RES INST,DEPT PATHOBIOCHEM,2630 SUGITANI,TOYAMA 93001,JAPAN.							ADACHI M, 1992, BIOCHEM BIOPH RES CO, V186, P1607, DOI 10.1016/S0006-291X(05)81592-X; ADACHI M, 1992, CANCER RES, V52, P737; ADACHI M, 1992, FEBS LETT, V314, P335, DOI 10.1016/0014-5793(92)81500-L; AHMAD S, 1993, P NATL ACAD SCI USA, V90, P2197, DOI 10.1073/pnas.90.6.2197; BARKER HM, 1993, BIOCHIM BIOPHYS ACTA, V1178, P228, DOI 10.1016/0167-4889(93)90014-G; BASTIEN L, 1993, BIOCHEM BIOPH RES CO, V196, P124, DOI 10.1006/bbrc.1993.2224; EINHORN S, 1990, CANCER GENET CYTOGEN, V48, P183, DOI 10.1016/0165-4608(90)90118-T; FENG GS, 1993, SCIENCE, V259, P1607, DOI 10.1126/science.8096088; FREEMAN RM, 1992, P NATL ACAD SCI USA, V89, P11239, DOI 10.1073/pnas.89.23.11239; GISPERT S, 1993, NAT GENET, V4, P295, DOI 10.1038/ng0793-295; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P21478; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; QUE TH, 1993, BLOOD, V82, P571; SAMANIEGO F, 1990, GENE CHROMOSOME CANC, V1, P289, DOI 10.1002/gcc.2870010406; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEN SH, 1991, NATURE, V352, P736, DOI 10.1038/352736a0; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; YI TL, 1992, MOL CELL BIOL, V12, P836, DOI 10.1128/MCB.12.2.836; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	23	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1751	1753						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183573				2022-12-17	WOS:A1994NL81500030
J	ONYIA, JE; HALLADAY, DL; MESSINA, JL				ONYIA, JE; HALLADAY, DL; MESSINA, JL			IDENTIFICATION OF BETA-ACTIN SEQUENCES NECESSARY FOR INDUCTION BY PHORBOL ESTERS AND CALCIUM IONOPHORES	ONCOGENE			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; SERUM RESPONSE ELEMENT; ACETYLTRANSFERASE GENE-EXPRESSION; SIGNAL-TRANSDUCTION PATHWAYS; 3' UNTRANSLATED REGIONS; FACTOR-ALPHA GENE; CHLORAMPHENICOL ACETYLTRANSFERASE; TRANSCRIPTIONAL REGULATION; MESSENGER-RNAS	Transcription of the cytoskeletal beta-actin gene is rapidly induced by phorbol 12-myristate 13-acetate (PMA) and the calcium ionophore, A23187, in cultured H4IIE hepatoma (H4) cells. PMA directly activates protein kinase C (PKC) and activation of PKC is necessary for the cellular actions of PMA, including induction of beta-actin gene transcription. In the present study, we determined the DNA sequence requirements for induction of the beta-actin gene by PMA and A23187. Constructs containing progressive deletions of normal and mutated human beta-actin 5' sequences fused to the reporter gene, bacterial chloramphenicol acetyltransferase, were analysed in transient transfections of H4 cells. We delineated the PMA response DNA element of the human beta-actin gene to the proximal CCArGG box (-62 to -53) in the 5' flanking region. In contrast, A23187 did not induce expression of transfected gene constructs containing this CCArGG box. Additionally, we demonstrated that CCArGG boxes from two other PMA-induced genes in H4 cells, c-fos and gamma-actin, could confer PMA inducibility to a heterologous promoter. This CCArGG box specifically interacts with one or more proteins present in nuclear extracts of H4 cells. These results indicate that in cultured cells, PMA-dependent induction of the beta-actin gene is mediated through the proximal CCArGG box. This suggests that the CCArGG box is a target for PKC action and may be involved in the control of other PKC regulated genes.	SUNY HLTH SCI CTR,DEPT PHYSIOL,SYRACUSE,NY; SUNY HLTH SCI CTR,CELL & MOLEC BIOL PROGRAM,SYRACUSE,NY	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center					NIDDK NIH HHS [DK40456] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040456] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLUMBERG PM, 1981, CRC CR REV TOXICOL, V8, P199, DOI 10.3109/10408448109109658; BUSCHER M, 1988, ONCOGENE, V3, P301; CHAVRIER P, 1989, MOL CELL BIOL, V9, P787, DOI 10.1128/MCB.9.2.787; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLARKE M, 1977, ANNU REV BIOCHEM, V46, P797, DOI 10.1146/annurev.bi.46.070177.004053; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; DANILITION SL, 1991, NUCLEIC ACIDS RES, V19, P6913, DOI 10.1093/nar/19.24.6913; DEPONTIZILLI L, 1988, P NATL ACAD SCI USA, V85, P1389, DOI 10.1073/pnas.85.5.1389; DEY A, 1991, DNA CELL BIOL, V10, P537, DOI 10.1089/dna.1991.10.537; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DIKE LE, 1988, P NATL ACAD SCI USA, V85, P6792, DOI 10.1073/pnas.85.18.6792; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; EASTMAN A, 1987, BIOTECHNIQUES, V5, P730; ELDER PK, 1984, P NATL ACAD SCI-BIOL, V81, P7476, DOI 10.1073/pnas.81.23.7476; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FREDERICKSON RM, 1989, NUCLEIC ACIDS RES, V17, P253, DOI 10.1093/nar/17.1.253; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GOLDFELD AE, 1991, J EXP MED, V174, P73, DOI 10.1084/jem.174.1.73; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HYDER SM, 1991, GENE, V105, P281, DOI 10.1016/0378-1119(91)90164-7; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMBRA RJ, 1986, NATURE, V323, P555, DOI 10.1038/323555a0; KAWAMOTO T, 1989, NUCLEIC ACIDS RES, V17, P523, DOI 10.1093/nar/17.2.523; KONIG H, 1991, NUCLEIC ACIDS RES, V19, P3607, DOI 10.1093/nar/19.13.3607; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LIU ZJ, 1991, GENE, V108, P211, DOI 10.1016/0378-1119(91)90436-F; LIU ZJ, 1990, MOL CELL BIOL, V10, P3432, DOI 10.1128/MCB.10.7.3432; LOHSE P, 1988, NUCLEIC ACIDS RES, V16, P2787, DOI 10.1093/nar/16.7.2787; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MAGNUSON MA, 1987, J BIOL CHEM, V262, P14917; MALIK RK, 1991, J BIOL CHEM, V266, P8576; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; Messina J. L., 1990, HDB EXPT PHARM, V92, P399; MESSINA JL, 1992, EXP CELL RES, V200, P532, DOI 10.1016/0014-4827(92)90206-N; MESSINA JL, 1989, ENDOCRINOLOGY, V124, P754, DOI 10.1210/endo-124-2-754; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; MESSINA JL, 1992, MOL ENDOCRINOL, V6, P112, DOI 10.1210/me.6.1.112; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; NG SY, 1989, NUCLEIC ACIDS RES, V17, P601, DOI 10.1093/nar/17.2.601; NG SY, 1985, MOL CELL BIOL, V5, P2720, DOI 10.1128/MCB.5.10.2720; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; ORITA S, 1989, GENE, V75, P13; PONTE P, 1983, MOL CELL BIOL, V3, P1783, DOI 10.1128/MCB.3.10.1783; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; QUITSCHKE WW, 1989, J BIOL CHEM, V264, P7539; RENAN MJ, 1986, BIOSCIENCE REP, V6, P819, DOI 10.1007/BF01117105; RENAN MJ, 1985, BIOSCIENCE REP, V5, P739, DOI 10.1007/BF01119872; RESENDEZ E, 1985, MOL CELL BIOL, V5, P1212, DOI 10.1128/MCB.5.6.1212; RIDDLE VGH, 1979, P NATL ACAD SCI USA, V76, P1298, DOI 10.1073/pnas.76.3.1298; RIVERA V M, 1990, New Biologist, V2, P751; ROBIN P, 1991, BIOCHEM BIOPH RES CO, V181, P353, DOI 10.1016/S0006-291X(05)81426-3; ROESLER WJ, 1990, TRENDS ENDOCRIN MET, V1, P347, DOI 10.1016/1043-2760(90)90082-E; RUEDELHUBER T, 1984, NATURE, V312, P700; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SHAKHOV AN, 1990, J EXP MED, V171, P35, DOI 10.1084/jem.171.1.35; SIEGFRIED Z, 1989, ONCOGENE, V4, P3; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; SUGIYAMA H, 1988, GENE, V65, P135; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; Treisman R, 1990, Semin Cancer Biol, V1, P47; VISVADER J, 1988, P NATL ACAD SCI USA, V85, P9474, DOI 10.1073/pnas.85.24.9474; WEEDS A, 1982, NATURE, V296, P811, DOI 10.1038/296811a0; WEINSTOCK RS, 1988, ENDOCRINOLOGY, V123, P366, DOI 10.1210/endo-123-1-366; WEINSTOCK RS, 1993, AM J PHYSIOL, V264, pE519, DOI 10.1152/ajpendo.1993.264.4.E519; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6; YAFFE D, 1985, NUCLEIC ACIDS RES, V13, P3723, DOI 10.1093/nar/13.10.3723	75	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1994	9	6					1713	1722						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NL815	8183567				2022-12-17	WOS:A1994NL81500024
J	ZHU, GC; DECKER, SJ; MACLEAN, D; MCNAMARA, DJ; SINGH, J; SAWYER, TK; SALTIEL, AR				ZHU, GC; DECKER, SJ; MACLEAN, D; MCNAMARA, DJ; SINGH, J; SAWYER, TK; SALTIEL, AR			SEQUENCE SPECIFICITY IN THE RECOGNITION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR BY THE ABL SRC-HOMOLOGY-2 DOMAIN	ONCOGENE			English	Article							C-ABL; ONCOGENE PRODUCT; TYROSINE KINASES; PHOSPHOLIPASE-C; ABELSON VIRUS; CELL-LINE; PROTEINS; BINDING; SH2; TRANSFORMATION	The transforming activity of the abl gene product requires a functional src homology 2 (SH2) domain. An assay was developed to evaluate this function by examining binding of a bacterially-expressed abl SH2 domain to the activated EGF receptor, used as a surrogate tyrosine phosphorylated protein. The sequence specificity of this interaction has been explored with a series of point mutants of EGF receptor. Analysis of equilibrium binding reveals that substitution of Tyr(1086) for Phe in the EGF receptor produced a 10-fold reduced affinity for abl SH2 domain binding as compared to the wildtype receptor. Moreover, a phosphorylated peptide modeled on the sequences surrounding Tyr(1086) specifically inhibits abl SH2 binding, with an IC50 of approximately 10 mu M. Evaluation of a series of additional peptides, modeled on the Tyr(1086) sequence, revealed that the carboxy terminal residues directly next to the phosphotyrosine were particularly critical to this binding. Molecular modeling studies of the pTyr(1086) peptide revealed the potential hydrophobic, ionic and hydrogen bonding interactions involved in the functions of the abl SH2 domain.	WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES, DEPT SIGNAL TRANSDUCT, ANN ARBOR, MI 48105 USA; WARNER LAMBERT PARKE DAVIS, PARKE DAVIS PHARMACEUT RES, DEPT CHEM, ANN ARBOR, MI 48105 USA; UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, SCH MED, DEPT MICROBIOL, ANN ARBOR, MI 48109 USA	Pfizer; Pfizer; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828				ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; HOLM L, 1992, PROTEINS, V14, P213, DOI 10.1002/prot.340140208; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATUDA M, 1990, SCIENCE, V248, P1537; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; MAYER BJ, 1988, COLD SPRING HARB SYM, V53, P907, DOI 10.1101/SQB.1988.053.01.104; MAYER BJ, 1990, P NATL ACAD SCI USA, V87, P2638, DOI 10.1073/pnas.87.7.2638; MILARSKI KL, 1993, J BIOL CHEM, V268, P23634; MITCHELL JBO, 1993, J CHEM SOC FARADAY T, V89, P2619, DOI 10.1039/ft9938902619; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; OHMICHI M, 1993, ENDOCRINOLOGY, V133, P46, DOI 10.1210/en.133.1.46; OHMICHI M, 1991, J BIOL CHEM, V266, P14858; OPPI C, 1987, P NATL ACAD SCI USA, V84, P8200, DOI 10.1073/pnas.84.23.8200; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; Saltiel A R, 1993, Curr Opin Neurobiol, V3, P352, DOI 10.1016/0959-4388(93)90128-L; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZHU G, 1993, J BIOL CHEM, V266, P12964; ZHU GC, 1992, P NATL ACAD SCI USA, V89, P9559, DOI 10.1073/pnas.89.20.9559	32	11	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1994	9	5					1379	1385						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NH401	8152798				2022-12-17	WOS:A1994NH40100009
J	GAO, ZM; KUIKEN, GA; BAARENDS, WM; KOSTER, JG; DESTREE, OHJ				GAO, ZM; KUIKEN, GA; BAARENDS, WM; KOSTER, JG; DESTREE, OHJ			CHARACTERIZATION OF A FUNCTIONAL PROMOTER FOR THE XENOPUS WNT-1 GENE IN-VIVO	ONCOGENE			English	Article							MAMMARY ONCOGENE INT-1; SEGMENT POLARITY GENE; PROTO-ONCOGENE; SV40 ENHANCER; EMBRYONIC-DEVELOPMENT; MOUSE DEVELOPMENT; TUMOR VIRUS; EXPRESSION; LAEVIS; CELLS	The Xenopus homolog of the proto-oncogene wnt-1 (int-1) is transiently expressed during neurula and tailbud stages of early development. To determine the mechanisms involved in the transcriptional regulation of the Xwnt-1 gene, we isolated Xwnt-1 genomic sequences. The promoter activity of the 5' flanking region of the gene was analysed by microinjection of chimeric luciferase reporter constructs into embryos. It is shown that the proximal 220 bp of the Xwnt-1 promoter is able to confer activation of the reporter gene at the early neurula stage. DNaseI footprinting analysis of the proximal promoter region with nuclear protein extracts from neurula stage embryos revealed five protein binding regions. Deletion and mutation analysis shows that one of these five protein binding regions is essential for promoter activity. Gel shift experiments indicate that a sequence element resembling the GT-I and GT-II motifs of the SV40 enhancer is important for the Xwnt-1 promoter activity in vivo.	HUBRECHT LAB,3584 CT UTRECHT,NETHERLANDS; ERASMUS UNIV ROTTERDAM,FAC MED,DEPT ENDOCRINOL & REPROD,3000 DR ROTTERDAM,NETHERLANDS	Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Erasmus University Rotterdam								BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRADLEY RS, 1990, EMBO J, V9, P1569, DOI 10.1002/j.1460-2075.1990.tb08276.x; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; DAVIDSON I, 1988, CELL, V54, P931, DOI 10.1016/0092-8674(88)90108-0; ETKIN LD, 1984, DIFFERENTIATION, V26, P194, DOI 10.1111/j.1432-0436.1984.tb01395.x; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; GIEBELHAUS DH, 1988, CELL, V53, P601, DOI 10.1016/0092-8674(88)90576-4; GLASS CK, 1990, CELL, V63, P729, DOI 10.1016/0092-8674(90)90139-6; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; INGHAM PW, 1988, NATURE, V331, P73, DOI 10.1038/331073a0; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; JUE SF, 1992, MOL CELL BIOL, V12, P321, DOI 10.1128/MCB.12.1.321; KOSTER JG, 1990, BIOMED BIOCHIM ACTA, V49, P855; KRIEG PA, 1985, EMBO J, V4, P3463, DOI 10.1002/j.1460-2075.1985.tb04105.x; MARINI NJ, 1988, DEV BIOL, V127, P421, DOI 10.1016/0012-1606(88)90328-4; Maxam A M, 1980, Methods Enzymol, V65, P499; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; MOLVEN A, 1991, EMBO J, V10, P799, DOI 10.1002/j.1460-2075.1991.tb08012.x; Nieuwkoop P.D., 1967, NORMAL TABLE XENOPUS; NOMIYAMA H, 1987, P NATL ACAD SCI USA, V84, P7881, DOI 10.1073/pnas.84.22.7881; NOORDERMEER J, 1989, NUCLEIC ACIDS RES, V17, P11, DOI 10.1093/nar/17.1.11; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; NUSSE R, 1990, MOL CELL BIOL, V10, P4170, DOI 10.1128/MCB.10.8.4170; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1990, MOL CELL BIOL, V10, P2723, DOI 10.1128/MCB.10.6.2723; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PIETTE J, 1987, EMBO J, V6, P1331, DOI 10.1002/j.1460-2075.1987.tb02372.x; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; ROELINK H, 1990, P NATL ACAD SCI USA, V87, P4519, DOI 10.1073/pnas.87.12.4519; SCHILTHUIS JG, 1990, THESIS U UTRECHT NET; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SIDOW A, 1992, P NATL ACAD SCI USA, V89, P5098, DOI 10.1073/pnas.89.11.5098; SMITH JD, 1988, J BIOL CHEM, V263, P8300; STARNAUD R, 1989, ONCOGENE, V4, P1077; STARNAUD R, 1993, MOL CELL BIOL, V13, P1590, DOI 10.1128/MCB.13.3.1590; THOMAS KR, 1990, NATURE, V346, P847, DOI 10.1038/346847a0; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANOOYEN A, 1985, EMBO J, V4, P2905, DOI 10.1002/j.1460-2075.1985.tb04021.x; VANZONNEVELD AJ, 1988, P NATL ACAD SCI USA, V85, P5525; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; WOLDA SL, 1992, ONCOGENE, V7, P1941; XIAO JH, 1987, GENE DEV, V1, P794, DOI 10.1101/gad.1.8.794	47	11	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1994	9	2					573	581						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW248					2022-12-17	WOS:A1994MW24800025
J	GELMAN, IH; KHAN, S; HANAFUSA, H				GELMAN, IH; KHAN, S; HANAFUSA, H			MORPHOLOGICAL TRANSFORMATION, TUMORIGENICITY AND SRC-SPECIFIC CYTOTOXIC T-LYMPHOCYTE-MEDIATED TUMOR-IMMUNITY INDUCED BY MURINE 3T3 CELLS EXPRESSING SRC ONCOGENES ENCODING NOVEL NON-MYRISTYLATED N-TERMINAL DOMAINS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; ANTI-PHOSPHOTYROSINE ANTIBODIES; TYROSINE PHOSPHORYLATION; MONOCLONAL-ANTIBODIES; REJECTION ANTIGEN; FIBRO-SARCOMA; PROTEINS; PP60SRC; P60SRC; RECEPTOR	We previously reported the development of a src-specific tumor regression system in chickens in which preinfection with rASV1702, a mutant of Rous sarcoma virus (RSV) encoding non-myristylated src product with a novel N-terminal domain, results in the immune suppression of challenge tumors induced by RSV. In order to adapt this sytem to the mouse, we have developed NIH3T3 and Balb/c3T3 (B3T3) cell lines that express 1702src, v-src, c-src, and other src variants, either by transfection or by infection with packaged recombinant Moloney virus (MLV) vectors. The sequence of the 1702 src cDNA, produced by reverse transcription-polymerase chain reaction (RT-PCR), confirmed the previously suggested 1702src N-terminal domain structure, fusing six amino acids from Pr76gag and 39 amino acids of env signal peptide sequence to Ala-76 of src. These cell lines were characterized for src expression and activity, cell compartmentalization of src product, tyrosine phosphorylation substrate specificity and transforming and tumorigenic potential. Based on these parameters, murine cell lines expressing 1702src were characteristically similar to chicken embryo fibroblasts (CEFs) infected with rASV1702. Finally, B3T3/1702src expressors, or membrane fractions of these cells, induced src-specific tumor protection in syngeneic mice against v-src-transformed tumor challenges. Splenic lymphocytes isolated from Balb/c mice inoculated with B3T3/1702src cells showed in vitro cytotoxicity against B3T3/v-src cells but not against untransformed B3T3 cells. Antibodies specific for Lyt2, mouse CD3 and H-2D(d) blocked this cytotoxicity, whereas those specific for L3T4 did not, suggesting MHC class I-restricted, CD8-mediated cell killing. These data indicate that Balb/c3T3-expressed 1702src induces a cellular anti-tumor immunity based on src-specific tumor rejection antigens.	ROCKEFELLER UNIV,DEPT MOLEC ONCOL,NEW YORK,NY 10021	Rockefeller University	GELMAN, IH (corresponding author), MT SINAI MED CTR,DEPT MICROBIOL,BOX 1124,1 GUSTAVE L LEVY PLAZA,NEW YORK,NY 10029, USA.				NATIONAL CANCER INSTITUTE [R35CA044356] Funding Source: NIH RePORTER; NCI NIH HHS [CA44356] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1985, MOL CELL BIOL, V5, P3369, DOI 10.1128/MCB.5.12.3369; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2; CROSS FR, 1983, CELL, V34, P597, DOI 10.1016/0092-8674(83)90392-6; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; DOHERTY PC, 1984, ADV CANCER RES, V42, P1, DOI 10.1016/S0065-230X(08)60455-8; GARBER EA, 1983, NATURE, V302, P161, DOI 10.1038/302161a0; GARBER EA, 1987, P NATL ACAD SCI USA, V84, P80, DOI 10.1073/pnas.84.1.80; GELMAN IH, 1993, CANCER RES, V53, P915; GELMAN IH, 1986, J MOL BIOL, V191, P395, DOI 10.1016/0022-2836(86)90135-X; GELMAN IH, 1989, J VIROL, V63, P2461, DOI 10.1128/JVI.63.6.2461-2468.1989; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; HAMAGUCHI M, 1987, P NATL ACAD SCI USA, V84, P2312, DOI 10.1073/pnas.84.8.2312; HAMAGUCHI M, 1988, MOL CELL BIOL, V8, P3035, DOI 10.1128/MCB.8.8.3035; HANAFUSA H, 1987, ONCOGENES CANCER, P233; HORIO K, 1991, JPN J CANCER RES, V82, P676, DOI 10.1111/j.1349-7006.1991.tb01903.x; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KANNER SB, 1991, MOL CELL BIOL, V11, P713, DOI 10.1128/MCB.11.2.713; KARESS RE, 1981, CELL, V24, P155, DOI 10.1016/0092-8674(81)90511-0; KORMAN AJ, 1987, P NATL ACAD SCI USA, V84, P2150, DOI 10.1073/pnas.84.8.2150; KREUGER JG, 1982, CELL, V28, P889; KRUEGER JG, 1984, MOL CELL BIOL, V4, P454, DOI 10.1128/MCB.4.3.454; KUZUMAKI N, 1988, J NCI, V12, P959; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; PARSONS SJ, 1984, J VIROL, V51, P272, DOI 10.1128/JVI.51.2.272-282.1984; PELLMAN D, 1985, P NATL ACAD SCI USA, V82, P1623, DOI 10.1073/pnas.82.6.1623; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; RESH MD, 1989, CELL, V58, P281, DOI 10.1016/0092-8674(89)90842-8; SHIMIZU J, 1991, J IMMUNOL, V146, P1708; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPRENT J, 1986, NATURE, V322, P541, DOI 10.1038/322541a0; SUDA T, 1989, JPN J CANCER RES, V80, P879, DOI 10.1111/j.1349-7006.1989.tb01730.x; SUDA T, 1988, JPN J CANCER RES, V79, P365, DOI 10.1111/j.1349-7006.1988.tb01600.x; SUDOL M, 1986, NUCLEIC ACIDS RES, V14, P2391, DOI 10.1093/nar/14.5.2391; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TOMITA Y, 1990, J IMMUNOL, V144, P2425; WANG LH, 1984, J VIROL, V49, P881, DOI 10.1128/JVI.49.3.881-891.1984; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373	41	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1993	8	11					2995	3004						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MC093	7692370				2022-12-17	WOS:A1993MC09300013
J	CZIEPLUCH, C; WENZEL, A; SCHURMANN, J; SCHWAB, M				CZIEPLUCH, C; WENZEL, A; SCHURMANN, J; SCHWAB, M			ACTIVATION OF GENE-TRANSCRIPTION BY THE AMINO-TERMINUS OF THE N-MYC PROTEIN DOES NOT REQUIRE ASSOCIATION WITH THE PROTEIN ENCODED BY THE RETINOBLASTOMA SUPPRESSOR GENE RB1	ONCOGENE			English	Article							HUMAN NEUROBLASTOMA-CELLS; HELIX ZIPPER PROTEIN; DNA-BINDING PROTEINS; MAMMALIAN-CELLS; C-MYC; NEOPLASTIC TRANSFORMATION; ADENOVIRUS E1A; LEUCINE ZIPPER; EXPRESSION; YEAST	N-Myc encodes a nuclear phosphoprotein that contains a basic region (BR), a helix-loop-helix (HLH) and a leucine zipper (Zip). These motifs are hallmarks of certain transcription factors. In pursuit of the question if N-Myc can activate transcription, we have employed an experimental model involving the yeast transcription factor Gal4. We have first generated fusion proteins containing the Gal4 DNA-binding domain joined to portions of N-Myc. Subsequently we have analysed if chimeric proteins can transactivate the transcription of a reporter under the control of Gal4 binding sites. Here we show that the amino terminal portion of N-Myc activates transcription. Activation maps to a domain highly conserved among Myc-proteins and to other non-conserved sequences, suggesting functional redundancy. Previous studies had documented in vitro association of the RBI protein with N-Myc (Rustig et al., 1991). We here confirm this observation and identify the region encompassing the transactivation domain as responsible for RBI binding. Analyses of N-Myc transactivation in retinoblastoma cell line WERI lacking a function RBI protein gave results similar to those with cell lines having an intact RBI protein, showing that RBI protein is not required for transactivation by N-Myc. The present findings leave open the question if deregulated expression of N-Myc contributes to tumorigenesis by transcriptional activation of as yet unidentified target genes or by functionally inactivating the protein encoded by the tumor suppressor gene RB1, or by a combination of both.	GERMAN CANC RES CTR,DEPT CLASS & MOLEC CYTOGENET,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)								ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BISHOP JM, 1991, CELL, V64, P235, DOI 10.1016/0092-8674(91)90636-D; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BREIT S, 1989, J NEUROSCI RES, V24, P21, DOI 10.1002/jnr.490240105; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUTURIER J, 1991, J VIROL, V65, P4534, DOI 10.1128/JVI.65.8.4534-4538.1991; DEUSCHLE U, 1989, P NATL ACAD SCI USA, V86, P5400, DOI 10.1073/pnas.86.14.5400; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; FIGGE J, 1988, J VIROL, V62, P1814, DOI 10.1128/JVI.62.5.1814-1818.1988; FOUREL G, 1990, NATURE, V347, P294, DOI 10.1038/347294a0; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HAMANN U, 1991, ONCOGENE, V6, P1745; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HU YF, 1990, GENE DEV, V4, P1741, DOI 10.1101/gad.4.10.1741; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LITTLEWOOD TD, 1992, ONCOGENE, V7, P1783; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MAKELA TP, 1989, MOL CELL BIOL, V9, P1545; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ONDEK B, 1987, EMBO J, V6, P1017, DOI 10.1002/j.1460-2075.1987.tb04854.x; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SCHWAB M, 1983, NATURE, V305, P245, DOI 10.1038/305245a0; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SCHWAB M, 1992, BIOCHIM BIOPHYS ACTA, V1114, P43, DOI 10.1016/0304-419X(92)90005-J; SCHWAB M, 1988, P NATL ACAD SCI USA, V85, P9589; SCHWAB M, 1988, ONCOGENE HDB, P381; SILVER PA, 1984, P NATL ACAD SCI-BIOL, V81, P5951, DOI 10.1073/pnas.81.19.5951; SMITH DB, 1990, CURRENT PROTOCOLS S, V10; WENZEL A, 1991, EMBO J, V10, P3703, DOI 10.1002/j.1460-2075.1991.tb04938.x; WESTON K, 1989, CELL, V58, P85, DOI 10.1016/0092-8674(89)90405-4; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WIGLER M, 1977, CELL, V11, P223, DOI 10.1016/0092-8674(77)90333-6	47	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1993	8	10					2833	2838						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LX343	8378092				2022-12-17	WOS:A1993LX34300026
J	ARNI, S; SENALDI, G; POINCELET, M; HOESSLI, DC				ARNI, S; SENALDI, G; POINCELET, M; HOESSLI, DC			SELECTIVE ASSOCIATION OF THE P59(FYN) TYROSINE KINASE WITH MURINE T-LYMPHOMA MEMBRANE PHOSPHOPROTEINS	ONCOGENE			English	Article							CELL ANTIGEN RECEPTOR; AMINO-TERMINAL DOMAIN; PROTEIN-KINASE; SRC-FAMILY; SIGNAL TRANSDUCTION; MONOCLONAL-ANTIBODIES; HUMAN-LYMPHOCYTES; MICE LACKING; PHOSPHORYLATION; PHOSPHOTYROSINE	The p59fyn oncogene product, a tyrosine kinase of the src family, is a key enzyme in T-lymphocyte transmembrane signalling that is not known to bind with high stoichiometry to any surface receptor protein. By contrast, the p56lck, another important T-cell tyrosine kinase, is directly linked to CD4 or CD8 surface glycoproteins with high stoichiometry. To document the mode of p59fyn interaction with proteins of the plasma membrane, proteins co-precipitating with the kinase in extracts of purified membranes were phosphorylated in vitro. resolved by two-dimensional electrophoresis and compared with those co-precipitating with the p56lck kinase. The p59fyn, but not the p56lck kinase, associates with three phosphotvrosyl-proteins among which a 95- to 100-kDa component also binds to the src-homology 2 (SH2) domain of the v-crk oncoprotein. This p95-100 phosphoprotein is not the p95Vav product of the Vav proto-oncogene; it is recovered much more effectively from P-32i-metabolically labelled cells after treatment with the tyrosine phosphatase inhibitor phenylarsenoxide, suggesting that its phosphorylation state is controlled by tyrosine phosphatases. The p59fyn may be integrated into the plasma membrane by specific phosphotyrosylproteins and so differ from the p56lck tyrosine kinase, which binds preferentially to the CD4 and CD8 transmembrane adhesion glycoproteins.	CTR MED UNIV GENEVA,FAC MED,DEPT PATHOL,1 RUE MICHEL SERVET,CH-1211 GENEVA 4,SWITZERLAND	University of Geneva				Arni, Stephan/0000-0001-5497-8256				APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DUNBAR BS, 1990, METHOD ENZYMOL, V182, P441; EGERTON M, 1992, EMBO J, V11, P3533, DOI 10.1002/j.1460-2075.1992.tb05436.x; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; GARCIAMORALES P, 1990, P NATL ACAD SCI USA, V87, P9255, DOI 10.1073/pnas.87.23.9255; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GLENNEY JR, 1988, J IMMUNOL METHODS, V109, P277, DOI 10.1016/0022-1759(88)90253-0; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P424, DOI 10.1016/0003-2697(88)90209-6; HOESSLI DC, 1990, EUR J IMMUNOL, V20, P1497, DOI 10.1002/eji.1830200714; HOESSLI DC, 1983, P NATL ACAD SCI USA, V83, P439; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Hunter T, 1989, CURR OPIN CELL BIOL, V1, P1168, DOI 10.1016/S0955-0674(89)80068-7; KAPLAN JM, 1990, MOL CELL BIOL, V10, P1000, DOI 10.1128/MCB.10.3.1000; KATAGIRI T, 1989, P NATL ACAD SCI USA, V86, P10064, DOI 10.1073/pnas.86.24.10064; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; KYPTA RM, 1988, EMBO J, V7, P3837, DOI 10.1002/j.1460-2075.1988.tb03269.x; MARGOLIS B, 1992, NATURE, V356, P71, DOI 10.1038/356071a0; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; O'SHEA JJ, 1992, P NATL ACAD SCI USA, V89, P10306, DOI 10.1073/pnas.89.21.10306; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SARTOR O, 1991, J BIOL CHEM, V266, P6462; SEFTON BM, 1991, ONCOGENE, V6, P683; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0	44	11	12	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1993	8	9					2485	2491						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LT368	7689723				2022-12-17	WOS:A1993LT36800020
J	BAI, WL; ARLINGHAUS, RB; SINGH, B				BAI, WL; ARLINGHAUS, RB; SINGH, B			ASSOCIATION OF V-MOS WITH SOLUBLE VIMENTIN IN-VITRO AND IN TRANSFORMED-CELLS	ONCOGENE			English	Article							PROTEIN-KINASE ACTIVITY; MURINE SARCOMA-VIRUS; CELLULAR-TRANSFORMATION; INTERMEDIATE FILAMENTS; MEIOTIC MATURATION; OOCYTE MATURATION; PRODUCT; ONCOGENE; PHOSPHORYLATION; P34CDC2	Our previous studies have shown that vimentin can serve as a substrate for the v-Mos protein kinase in vitro. Furthermore, the amount of vimentin molecules in Moloney murine sarcoma virus (Mo-MuSV) transformed cells is decreased relative to uninfected cells and a lower molecular weight form is observed in these v-mos transformed cells (Singh & Arlinghaus, Virology 173: 144-156, 1989). Vimentin filaments are hyperphosphorylated and disassemble when cells enter mitosis. Here, we show that vimentin was coprecipitated with p85gag-mos from mitotic cell extracts by two different anti-Mos antibodies that do not crossreact with vimentin. However, we were unable to detect vimentin/v-Mos complexes in interphase extracts, possibly due to lack of soluble vimentin. p37env-mos was also found to associate with purified bovine lens vimentin in vitro. The significance of these findings with regard to v-mos-induced cellular transformation is discussed.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC PATHOL, 1515 HOLCOMBE BLVD, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA45125, CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARLINGHAUS RB, 1985, J GEN VIROL, V66, P1845, DOI 10.1099/0022-1317-66-9-1845; BAI W, 1992, ONCOGENE, V7, P493; BAI WL, 1991, ONCOGENE, V6, P1715; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BENZEEV A, 1984, BIOCHIM BIOPHYS ACTA, V780, P197, DOI 10.1016/0304-419X(85)90003-4; BIA W, 1992, ONCOGENE, V7, P1757; BLAIR DG, 1979, VIROLOGY, V95, P303, DOI 10.1016/0042-6822(79)90486-0; BOSCHEK CB, 1981, CELL, V24, P175, DOI 10.1016/0092-8674(81)90513-4; BROWN RL, 1981, P NATL ACAD SCI-BIOL, V78, P5593, DOI 10.1073/pnas.78.9.5593; CARLEY WW, 1981, J CELL BIOL, V90, P797, DOI 10.1083/jcb.90.3.797; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CHAN D, 1989, P NATL ACAD SCI USA, V86, P2747, DOI 10.1073/pnas.86.8.2747; CHOU YH, 1990, CELL, V62, P1063, DOI 10.1016/0092-8674(90)90384-Q; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; FREEMAN RS, 1990, J CELL BIOL, V111, P533, DOI 10.1083/jcb.111.2.533; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4769, DOI 10.1073/pnas.77.8.4769; GREUENS G, 1983, ALL BIOL INT REP, V7, P35; HERZOG NK, 1988, ONCOGENE, V3, P225; KROHNE G, 1982, J CELL BIOL, V94, P749, DOI 10.1083/jcb.94.3.749; LIU JX, 1990, ONCOGENE, V5, P171; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1986, P NATL ACAD SCI USA, V83, P3629, DOI 10.1073/pnas.83.11.3629; SINGH B, 1990, VIROLOGY, V178, P535, DOI 10.1016/0042-6822(90)90351-Q; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1989, VIROLOGY, V173, P144, DOI 10.1016/0042-6822(89)90230-4; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; STEINERT PM, 1985, CELL, V42, P411, DOI 10.1016/0092-8674(85)90098-4; VIKSTROM KL, 1989, P NATL ACAD SCI USA, V86, P549, DOI 10.1073/pnas.86.2.549; YEW N, 1991, MOL CELL BIOL, V11, P604, DOI 10.1128/MCB.11.2.604; YEW N, 1992, ONCOGENE, V355, P649; ZHAO X, 1991, ONCOGENE, V6, P43; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	40	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1993	8	8					2207	2212						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336943				2022-12-17	WOS:A1993LP17100021
J	SKERKA, C; ZIPFEL, PF; SIEBENLIST, U				SKERKA, C; ZIPFEL, PF; SIEBENLIST, U			2 REGULATORY DOMAINS ARE REQUIRED FOR DOWN-REGULATION OF C-MYC TRANSCRIPTION IN DIFFERENTIATING U937 CELLS	ONCOGENE			English	Article							BURKITT-LYMPHOMA; TRANS-ACTIVATION; DNA-REPLICATION; PROTEIN-BINDING; HL60 CELLS; EXPRESSION; GENE; ONCOGENE; PROMOTER; INITIATION	In many differentiating cells, a reduction of c-myc proto-oncogene expression is a prerequisite for terminal differentiation. The downmodulation of c-myc in differentiating cells is due to at least two different mechanisms: (i) an elongation block to c-myc transcription activated during an early phase of differentiation and (ii) an inhibition of transcription initiation activated during a later phase. In order to determine cis-acting target structures of the c-myc gene required for the late-phase downregulation of transcriptional initiation, we permanently transfected U937 cells with constructs containing the bacterial chloramphenicol acetyl transferase (CAT) gene driven by a 2.8 kb c-myc promoter region or deletions thereof. We determined two distinct domains in the c-myc promoter region both of which are essential for efficient terminal downregulation: a proximal domain and a distal domain which are located between base pairs - 606 to - 101, and between - 2392 to - 1396, respectively, relative to P1. The identification of two distinct regulatory elements suggests the requirement and cooperation of two regulatory factors as an essential event for mediating differentiation-induced downregulation of c-myc in monocytic cells. The implications of these results for deregulation of the translocated c-myc allele in Burkitt's lymphoma are discussed.	NIAID,IMMUNOREGULAT LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	SKERKA, C (corresponding author), BERNHARD NOCHT INST TROP MED,BERNARD NOCHT STR 74,W-2000 HAMBURG 36,GERMANY.							ARIGA H, 1989, EMBO J, V8, P4273, DOI 10.1002/j.1460-2075.1989.tb08613.x; AVIGAN MI, 1990, J BIOL CHEM, V265, P18538; Battey, 1986, BASIC METHODS MOL BI; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; Dimitrovsky E., 1986, NATURE, V322, P748; EICK D, 1986, NUCLEIC ACIDS RES, V14, P8331, DOI 10.1093/nar/14.21.8331; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GIDLUND M, 1981, NATURE, V292, P848, DOI 10.1038/292848a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HAY N, 1989, GENE DEV, V3, P293, DOI 10.1101/gad.3.3.293; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; KELLY K, 1985, J CLIN IMMUNOL, V5, P65, DOI 10.1007/BF00915003; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.iy.04.040186.001533; KLEIN G, 1985, NATURE, V315, P190, DOI 10.1038/315190a0; LARSSON LG, 1988, P NATL ACAD SCI USA, V85, P2638, DOI 10.1073/pnas.85.8.2638; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; PELLICI PG, 1986, P NATL ACAD SCI USA, V83, P2984; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; SAKELSA K, 1991, ONCOGENE RES, V6, P73; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; SIEBENLIST U, 1984, CELL, V37, P381, DOI 10.1016/0092-8674(84)90368-4; SLUNGAARD A, 1987, J CLIN INVEST, V79, P1542, DOI 10.1172/JCI112987; SUGGS SV, 1981, P NATL ACAD SCI-BIOL, V78, P6613, DOI 10.1073/pnas.78.11.6613; TAKIMOTO M, 1989, J BIOL CHEM, V264, P8992; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527	37	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1993	8	8					2135	2143						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LP171	8336940				2022-12-17	WOS:A1993LP17100014
J	RIDGWAY, PJ; HALE, TK; BRAITHWAITE, AW				RIDGWAY, PJ; HALE, TK; BRAITHWAITE, AW			P53 CONFERS A SELECTIVE ADVANTAGE ON TRANSFECTED HELA-CELLS	ONCOGENE			English	Article							WILD-TYPE P53; TRANSCRIPTIONAL ACTIVATION; MONOCLONAL-ANTIBODIES; CDNA CLONE; TRANSFORMATION; GROWTH; GENE; EXPRESSION; ANTIGEN; MOUSE	The p53 gene, which is frequently mutated in various tumors, encodes a phosphoprotein thought to have a key role in the regulation of cell proliferation. To explore their biological effects, the HeLa carcinoma line, which does not express p53, was co-transfected with plasmid constructs expressing wild-type or mutant p53 proteins, or unrelated proteins, along with a plasmid conferring resistance to a neomycin-kanamycin antibiotic analog (G418). Both wild-type and mutant forms of p53 stimulated the number of G418-resistant colonies between 5- and 36-fold. Further investigation of colony development revealed that p53 enhanced cell survival, leading to increased colony numbers, but did not stimulate cell growth. Nonetheless, we suggest that an initial slowing of cell growth caused by expression of the unintegrated p53 plasmids renders the transfectants resistant to selection with G418, thus causing a higher frequency of G418-resistant colonies. p53 constructs were found to be expressed transiently in HeLa cells as expected, but the G418-resistant colonies frequently failed to express p53. This loss of p53 expression may be due to negative regulatory effects of p53 on the cytomegalovirus promoter that drives the selection marker.	AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV CELL BIOL,GPO BOX 334,CANBERRA,ACT 2601,AUSTRALIA	Australian National University; John Curtin School of Medical Research								BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BENCHIMOL S, 1982, EMBO J, V1, P1055, DOI 10.1002/j.1460-2075.1982.tb01296.x; BRAITHWAITE AW, 1991, ONCOGENE, V6, P781; BRAITHWAITE AW, 1987, NATURE, V329, P458, DOI 10.1038/329458a0; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DEPPERT W, 1990, ONCOGENE, V5, P1701; ELIYAHU D, 1989, P NATL ACAD SCI USA, V86, P8763, DOI 10.1073/pnas.86.22.8763; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; HARLOW E, 1985, MOL CELL BIOL, V5, P1601, DOI 10.1128/MCB.5.7.1601; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; JENKINS JR, 1984, NUCLEIC ACIDS RES, V12, P5609, DOI 10.1093/nar/12.14.5609; JENKINS JR, 1985, NATURE, V317, P816, DOI 10.1038/317816a0; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JOHNSON P, 1991, MOL CELL BIOL, V11, P1; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; MERCER WE, 1990, P NATL ACAD SCI USA, V87, P6166, DOI 10.1073/pnas.87.16.6166; MERCER WE, 1982, P NATL ACAD SCI-BIOL, V79, P6309, DOI 10.1073/pnas.79.20.6309; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; OROURKE RW, 1990, ONCOGENE, V5, P1829; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; SHOHAT O, 1987, ONCOGENE, V1, P277; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; SOUSSI T, 1990, ONCOGENE, V5, P945; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; WEINTRAUB H, 1991, P NATL ACAD SCI USA, V88, P4570, DOI 10.1073/pnas.88.11.4570; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0	29	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1993	8	4					1069	1074						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KT220	8455934				2022-12-17	WOS:A1993KT22000032
J	TEDESCO, D; FISCHERFANTUZZI, L; VESCO, C				TEDESCO, D; FISCHERFANTUZZI, L; VESCO, C			LIMITS OF TRANSFORMING COMPETENCE OF SV40 NUCLEAR AND CYTOPLASMIC LARGE T-MUTANTS WITH ALTERED RB-BINDING SEQUENCES	ONCOGENE			English	Article							LARGE TUMOR-ANTIGEN; RETINOBLASTOMA SUSCEPTIBILITY GENE; SIMIAN VIRUS-40; DNA-REPLICATION; EMBRYO FIBROBLASTS; TRANSGENIC MICE; ORIGIN-BINDING; HUMAN-CELLS; PROTEIN; PHOSPHORYLATION	Multiple amino acid substitutions were introduced into the SV40 large T region that harbors the retinoblastoma protein (Rb) binding site and the nuclear transport signal, changing either one or both of these determinants. Mutant activities were examined in a set of assays allowing different levels of transforming potential to be, distinguished; phenotypic changes in established and pre-crisis rat embryo fibroblasts (REFs) were detected under isogenic cell conditions, and comparisons made with other established rodent cells. The limit of the transforming ability of mutants with important substitutions in the Rb binding site fell between two transformation levels of the same established rat cells. Such cells could be induced to form dense foci but not agar colonies (their parental pre-crises REFs, as expected, were untransformed either way). Nonetheless, agar colony induction was possible in other cell lines, such as mouse NIH3T3 and (for one of the mutants) rat F2408. All these mutants efficiently immortalized pre-crisis REFs. The transforming ability of cytoplasmic mutants appeared to depend on the integrity of the Rb-binding sequence to approximately the same extent as that of the wild-type large T, although evidence of in vivo Rb-cytoplasmic large T complexes was not found. The presence or absence of small t was critical when the transforming task of mutants was near the limit of their abilities.	CNR,INST BIOL CELLULARE,VIALE MARX 43,I-00137 ROME,ITALY	Consiglio Nazionale delle Ricerche (CNR)								ASSELIN C, 1985, J VIROL, V56, P958, DOI 10.1128/JVI.56.3.958-968.1985; BIKEL I, 1987, CELL, V48, P321, DOI 10.1016/0092-8674(87)90435-1; CHANEY WG, 1986, SOMAT CELL MOLEC GEN, V12, P237, DOI 10.1007/BF01570782; CHEN S, 1987, J VIROL, V61, P3521, DOI 10.1128/JVI.61.11.3521-3527.1987; CHEN S, 1990, J VIROL, V64, P3350, DOI 10.1128/JVI.64.7.3350-3357.1990; CHERINGTON V, 1988, MOL CELL BIOL, V8, P1380, DOI 10.1128/MCB.8.3.1380; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEPPERT W, 1990, J VIROL, V64, P838, DOI 10.1128/JVI.64.2.838-846.1990; DOBBELSTEIN M, 1992, ONCOGENE, V7, P837; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; FANTUZZI LF, 1988, MOL CELL BIOL, V8, P5495; FANTUZZI LF, 1987, ONCOGENE RES, V1, P229; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; GILMORE TD, 1991, TRENDS GENET, V7, P318, DOI 10.1016/0168-9525(91)90421-L; GRAND RJA, 1989, ONCOGENE, V4, P1291; HUNTER T, 1991, CELL, V64, P249, DOI 10.1016/0092-8674(91)90637-E; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KALDERON D, 1984, VIROLOGY, V139, P109, DOI 10.1016/0042-6822(84)90334-9; LANFORD RE, 1985, MOL CELL BIOL, V5, P1043, DOI 10.1128/MCB.5.5.1043; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MANFREDI JJ, 1990, J VIROL, V64, P5250, DOI 10.1128/JVI.64.11.5250-5259.1990; MCVEY D, 1989, NATURE, V341, P503, DOI 10.1038/341503a0; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MONTANO X, 1990, P NATL ACAD SCI USA, V87, P7448, DOI 10.1073/pnas.87.19.7448; PANNUTI A, 1987, J VIROL, V61, P1296, DOI 10.1128/JVI.61.4.1296-1299.1987; PEDEN KWC, 1990, J VIROL, V64, P2912, DOI 10.1128/JVI.64.6.2912-2921.1990; PINKERT CA, 1987, VIROLOGY, V160, P169, DOI 10.1016/0042-6822(87)90057-2; RESNICKSILVERMAN L, 1991, J VIROL, V65, P2845, DOI 10.1128/JVI.65.6.2845-2852.1991; RUTILA JE, 1989, ONCOGENE RES, V4, P303; SCHEIDTMANN KH, 1982, J VIROL, V44, P116, DOI 10.1128/JVI.44.1.116-133.1982; SCHEIDTMANN KH, 1991, J VIROL, V65, P1479, DOI 10.1128/JVI.65.3.1479-1490.1991; SCHNEIDER J, 1988, J VIROL, V62, P1598, DOI 10.1128/JVI.62.5.1598-1605.1988; SLEIGH MJ, 1978, CELL, V14, P79, DOI 10.1016/0092-8674(78)90303-3; SOMPAYRAC L, 1988, VIROLOGY, V163, P391, DOI 10.1016/0042-6822(88)90279-6; SOMPAYRAC L, 1985, MOL CELL BIOL, V5, P1191, DOI 10.1128/MCB.5.5.1191; SRINIVASAN A, 1989, J VIROL, V63, P5459, DOI 10.1128/JVI.63.12.5459-5463.1989; THIMMAPPAYA B, 1979, J VIROL, V30, P668, DOI 10.1128/JVI.30.3.668-673.1979; THOMPSON DL, 1990, VIROLOGY, V178, P15, DOI 10.1016/0042-6822(90)90375-2; VANDYKE TA, 1987, J VIROL, V61, P2029, DOI 10.1128/JVI.61.6.2029-2032.1987; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WILDEMAN AG, 1989, P NATL ACAD SCI USA, V86, P2123, DOI 10.1073/pnas.86.7.2123; YACIUK P, 1991, MOL CELL BIOL, V11, P2116, DOI 10.1128/MCB.11.4.2116; ZHU JY, 1991, J VIROL, V65, P2778, DOI 10.1128/JVI.65.6.2778-2790.1991; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991; ZHU Z, 1984, J VIROL, V51, P170, DOI 10.1128/JVI.51.1.170-180.1984	54	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAR	1993	8	3					549	557						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KN008	8382355				2022-12-17	WOS:A1993KN00800004
J	DOMENGET, C; LEPRINCE, D; PAIN, B; PEYROL, S; LI, RP; STEHELIN, D; SAMARUT, J; JURDIC, P				DOMENGET, C; LEPRINCE, D; PAIN, B; PEYROL, S; LI, RP; STEHELIN, D; SAMARUT, J; JURDIC, P			THE VARIOUS DOMAINS OF V-MYB AND V-ETS ONCOGENES OF E26 RETROVIRUS CONTRIBUTE DIFFERENTLY, BUT COOPERATIVELY, IN TRANSFORMATION OF HEMATOPOIETIC LINEAGES	ONCOGENE			English	Article							AVIAN LEUKEMIA-VIRUS; LONG TERMINAL REPEAT; DNA-BINDING ACTIVITY; C-MYB; NUCLEOTIDE-SEQUENCE; TRANSCRIPTIONAL ACTIVATION; MITOGENIC STIMULATION; MYELOBLASTOSIS VIRUS; CELLULAR PROGENITOR; PROTO-ONCOGENE	The genome of the avian leukemia virus E26 is a unique example of association between two transcription factors which appear as a fused composite nuclear oncoprotein, P135gag-myb-ets. Previous studies with E26 have shown that v-myb and v-ets must cooperate to fully transform both erythrocytic and myelomonocytic precursor cells in vivo and in vitro. To analyse further the contribution of the individual domains involved in the transformation of various hematopoietic lineages, we have constructed several mutant viruses expressing a fusion protein with deletions in either v-myb or v-ets. We show here that integrity of the v-ets oncogene is necessary for transformation of the erythrocytic cells but that neither the DNA-binding domain nor the trans-activating domain of v-myb is required for this transformation. The DNA-binding domain of v-ets is necessary to transform myelomonocytic cells. Furthermore, we show that E26 oncoprotein also transforms granulocytic cells. The v-ets DNA-binding domain is not necessary to transform them, whereas deleting the v-myb DNA-binding domain strongly reduces transformation of these cells. These data show that the v-myb and v-ets DNA-binding domains provide quite different contributions to the transformation of various hematopoietic lineages by E26.	ECOLE NORMALE SUPER LYON,BIOL MOLEC & CELLULAIRE LAB,CNRS,UMR 13,46 ALLEE ITALIE,F-69364 LYON 07,FRANCE; INST PASTEUR,F-69007 LYON,FRANCE; INST PASTEUR,ONCOL MOLEC LAB,CNRS,U1160,INSERM,UNITE 186,F-59019 LILLE,FRANCE	Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			Samarut, Jacques/AAD-2587-2019; Pain, Bertrand/A-7686-2015	Pain, Bertrand/0000-0002-1210-8444; Leprince, Dominique/0000-0002-1999-0775				AURIGEMMA RE, 1992, J VIROL, V66, P3056, DOI 10.1128/JVI.66.5.3056-3061.1992; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BENDAVID Y, 1991, CELL, V66, P381; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BOYLE WJ, 1985, MOL CELL BIOL, V5, P3017, DOI 10.1128/MCB.5.11.3017; CHEN JH, 1985, MOL CELL BIOL, V5, P2933; ENERBACK L, 1986, MAST CELL DIFFERENTI; EVANS JL, 1990, MOL CELL BIOL, V10, P5747, DOI 10.1128/MCB.10.11.5747; Frykberg L, 1988, Oncogene Res, V3, P313; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GAZZOLO L, 1979, CELL, V16, P627, DOI 10.1016/0092-8674(79)90036-9; GEGONNE A, 1992, IN PRESS NEW BIOL; GHYSDAEL J, 1986, EMBO J, V5, P2251, DOI 10.1002/j.1460-2075.1986.tb04492.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GONDA TJ, 1983, J VIROL, V46, P212, DOI 10.1128/JVI.46.1.212-220.1983; GRASSER FA, 1991, MOL CELL BIOL, V11, P3987; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; GUTMAN A, 1991, TRENDS GENET, V7, P49, DOI 10.1016/0168-9525(91)90231-E; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; INTRONA M, 1990, CELL, V63, P1287, DOI 10.1016/0092-8674(90)90424-D; JURDIC P, 1987, J VIROL, V61, P3058, DOI 10.1128/JVI.61.10.3058-3065.1987; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; KLEMPNAUER KH, 1984, CELL, V37, P537, DOI 10.1016/0092-8674(84)90384-2; KLEMPNAUER KH, 1982, CELL, V31, P453, DOI 10.1016/0092-8674(82)90138-6; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1990, ONCOGENE RES, V5, P255; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; LEUTZ A, 1984, EMBO J, V3, P3191, DOI 10.1002/j.1460-2075.1984.tb02278.x; LI RP, 1989, ONCOGENE RES, V5, P137; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; METZ T, 1991, CELL, V66, P95, DOI 10.1016/0092-8674(91)90142-L; METZ T, 1991, GENE DEV, V5, P369, DOI 10.1101/gad.5.3.369; MOELLING K, 1985, CELL, V40, P983, DOI 10.1016/0092-8674(85)90358-7; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MOSCOVICI MG, 1983, VIROLOGY, V129, P65, DOI 10.1016/0042-6822(83)90396-3; MOSCOVICI MG, 1989, J VIROL, V63, P2335, DOI 10.1128/JVI.63.5.2335-2339.1989; MUSCENSKI ML, 1991, CELL, V65, P677; NESS SA, 1989, CELL, V59, P1115, DOI 10.1016/0092-8674(89)90767-8; NOCKA K, 1990, EMBO J, V9, P3287, DOI 10.1002/j.1460-2075.1990.tb07528.x; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAVELCHAPUIS P, 1991, J VIROL, V65, P3928, DOI 10.1128/JVI.65.7.3928-3931.1991; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; SAMARUT J, 1980, J CELL PHYSIOL, V105, P553, DOI 10.1002/jcp.1041050320; SCHNEIKERT J, 1992, IN PRESS ONCOGENE; SCHWARTZ DE, 1983, CELL, V32, P853, DOI 10.1016/0092-8674(83)90071-5; SENECA S, 1991, ONCOGENE, V6, P357; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; VANDENBUNDER B, 1989, DEVELOPMENT, V106, P265; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WASYLYK C, 1991, EMBO J, V10, P1127, DOI 10.1002/j.1460-2075.1991.tb08053.x; YUAN CC, 1989, J VIROL, V63, P205, DOI 10.1128/JVI.63.1.205-215.1989; ZOBEL A, 1991, ONCOGENE, V6, P1397	65	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1992	7	11					2231	2241						11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JW665	1331935				2022-12-17	WOS:A1992JW66500015
J	BAI, WL; SINGH, B; YANG, YD; ARLINGHAUS, RB				BAI, WL; SINGH, B; YANG, YD; ARLINGHAUS, RB			EVIDENCE FOR INTERACTION BETWEEN V-MOS AND A P34CDC2 ISOFORM, P35CDK	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; MATURATION-PROMOTING FACTOR; PROTEIN-KINASE ACTIVITY; CELL-CYCLE; PROTOONCOGENE PRODUCT; MEIOTIC MATURATION; ONCOGENE PRODUCT; XENOPUS OOCYTES; GENE; EGGS	The c-mos gene product (c-Mos) encodes a serine/threonine kinase required for activation of pre-MPF (maturation-promoting factor) to MPF in oocytes undergoing meiosis and also for stabilization of MPF leading to metaphase arrest in unfertilized eggs. In order to determine whether the v-mos gene product (v-Mos) causes neoplastic transformation via interaction with cell cycle control elements, we have searched for proteins that interact with v-Mos. Extracts of NIH3T3 cells transformed by v-Mos encoded by Moloney murine sarcoma virus (Mo-MuSV) were examined by gel filtration by immunoprecipitation with antibodies to a conserved region of p34cdc2, and by binding to beads that contain cross-linked p13scu1, a protein known to bind p34cdc2. Gel filtration detected a 500-kDa complex that contained v-Mos and a p34cdc2 isoform, termed p35cdk. The 500-kDa macromolecular complex also exhibited histone H1 phosphorylation activity, consistent with the presence of a cdc2 isoform. The identity of p35cdk is based on its recognition by anti-cdc2 PSTAIR but not by anti-cdc2 C-terminal antibodies, which detect authentic p34cdc2. Structures containing v-Mos and p35cdk were also detected by experiments involving co-immunoprecipitation of v-Mos with anti-cdc2 PSTAIR antibodies. Furthermore. both v-Mos and the p35cdk co-precipitated with p13scu1-Sepharose beads. Our findings raise the possibility of a v-Mos-p35cdk regulatory interaction in cells transformed by Mo-MuSV.	UNIV TEXAS,MD ANDERSON CANC CTR,DEPT MOLEC PATHOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	NATIONAL CANCER INSTITUTE [P30CA016672, R01CA045125] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672, CA 45125] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAI W, 1992, IN PRESS ONCOGENE; BAI WL, 1991, ONCOGENE, V6, P1715; BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BALL JK, 1973, VIROLOGY, V56, P268, DOI 10.1016/0042-6822(73)90305-X; BLAIR DG, 1979, VIROLOGY, V95, P303, DOI 10.1016/0042-6822(79)90486-0; CHACKALAPARAMPIL I, 1988, CELL, V52, P801, DOI 10.1016/0092-8674(88)90422-9; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAAR I, 1991, J CELL BIOL, V114, P329, DOI 10.1083/jcb.114.2.329; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FREEMAN RS, 1991, MOL CELL BIOL, V11, P1713, DOI 10.1128/MCB.11.3.1713; GALLICK GE, 1984, VIROLOGY, V139, P366, DOI 10.1016/0042-6822(84)90382-9; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HERZOG NK, 1988, ONCOGENE, V3, P225; KANKI JP, 1991, P NATL ACAD SCI USA, V88, P5794, DOI 10.1073/pnas.88.13.5794; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KROHNE G, 1982, J CELL BIOL, V94, P749, DOI 10.1083/jcb.94.3.749; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEWIN B, 1990, CELL, V61, P743, DOI 10.1016/0092-8674(90)90181-D; LIU JX, 1990, ONCOGENE, V5, P171; LOHKA MJ, 1988, P NATL ACAD SCI USA, V85, P3009, DOI 10.1073/pnas.85.9.3009; LORCA T, 1991, EMBO J, V10, P2087, DOI 10.1002/j.1460-2075.1991.tb07741.x; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; ROY LM, 1990, CELL, V61, P825, DOI 10.1016/0092-8674(90)90192-H; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SINGH B, 1988, ONCOGENE, V3, P79; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; WANG J, 1990, NATURE, V343, P555, DOI 10.1038/343555a0; WATANABE N, 1991, NATURE, V352, P247, DOI 10.1038/352247a0; WEHBER M, 1991, DEV BIOL, V148, P393; ZHAO X, 1990, ONCOGENE, V5, P1727; ZHAO X, 1991, ONCOGENE, V6, P1423; ZHOU R, 1991, CELL GROWTH DIFFER, V2, P257; ZHOU RP, 1991, SCIENCE, V251, P671, DOI 10.1126/science.1825142	46	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1992	7	9					1757	1763						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JJ376	1323818				2022-12-17	WOS:A1992JJ37600012
J	HASLAM, SZ; WIRTH, JJ; COUNTERMAN, LJ; FLUCK, MM				HASLAM, SZ; WIRTH, JJ; COUNTERMAN, LJ; FLUCK, MM			CHARACTERIZATION OF THE MAMMARY HYPERPLASIA, DYSPLASIA AND NEOPLASIA INDUCED IN ATHYMIC FEMALE-ADULT MICE BY POLYOMAVIRUS	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL KINASE-ACTIVITY; HUMAN-BREAST CARCINOMAS; MIDDLE T-ANTIGEN; TRANSGENIC MICE; C-MYC; GROWTH-FACTOR; VIRUS ONCOGENICITY; C-ERBB-2 ONCOGENE; PROTO-ONCOGENE; NEU ONCOGENE	We have characterized mammary oncogenesis induced after polyomavirus infection of adult female nude mice regarding histopathogenesis, viral replication and viral and cellular oncogene expression. A unique transient generalized epithelial hyperplasia was observed (starting at 2 weeks post infection), preceding the development of dysplasias (onset 6 weeks post infection) and multiple neoplasias (onset 6 weeks post infection) in all glands. The ductal epithelium was the target for neoplastic transformation, and the occurrence of numerous ductal dysplasias coincided with the appearance of frank tumors. Stromal abnormalities were also seen. Tumor growth was not dependent upon ovarian hormones, and new tumors continued to develop in ovariectomized mice. Viral replication, high although variable, preceded but did not correlate with oncogenesis. Most but not all tumors contained high levels of unintegrated viral DNA. Tumors produced very low levels of live virus. Viral gene expression was markedly increased in the tumors compared with the infected but morphologically normal glands. The expression of c-myc was moderately increased (fourfold); changes in c-int-2 and c-Ha-ras expression were slight and inconsistent, while expression of c-neu and c-int-1 was unchanged.	MICHIGAN STATE UNIV,DEPT MICROBIOL,INTERDEPT PROGRAM CELLULAR & MOLEC BIOL,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT PHYSIOL,INTERDEPT PROGRAM CELLULAR & MOLEC BIOL,E LANSING,MI 48824	Michigan State University; Michigan State University								ALI IU, 1988, SCIENCE, V240, P1795, DOI 10.1126/science.3289120; Ausubel F., 1992, MOL REPROD DEV, DOI DOI 10.1002/MRD.1080010210; BEREBBI M, 1988, ONCOGENE, V2, P149; BEREBBI M, 1990, ONCOGENE, V5, P505; BERGER MS, 1988, CANCER RES, V48, P1238; BOLEN JB, 1984, CELL, V38, P767, DOI 10.1016/0092-8674(84)90272-1; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; BROWN FH, 1982, CANCER RES, V42, P1909; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CLINE MJ, 1987, J CLIN ONCOL, V5, P999, DOI 10.1200/JCO.1987.5.7.999; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; COURTNEIDGE SA, 1985, EMBO J, V4, P1471, DOI 10.1002/j.1460-2075.1985.tb03805.x; COURTNEIDGE SA, 1983, NATURE, V303, P435, DOI 10.1038/303435a0; DAWE CJ, 1987, AM J PATHOL, V127, P243; ESCOT C, 1986, P NATL ACAD SCI USA, V83, P4834, DOI 10.1073/pnas.83.13.4834; GARCIA I, 1989, CANCER RES, V49, P6675; Harper J S 3rd, 1983, Prog Clin Biol Res, V105, P359; KAPLAN DR, 1986, P NATL ACAD SCI USA, V83, P3624, DOI 10.1073/pnas.83.11.3624; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; LEDER A, 1986, CELL, V45, P485, DOI 10.1016/0092-8674(86)90280-1; LIDEREAU R, 1988, ONCOGENE RES, V2, P285; MARIANICOSTANTINI R, 1988, CANCER RES, V48, P199; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; MULLER WJ, 1990, EMBO J, V9, P907, DOI 10.1002/j.1460-2075.1990.tb08188.x; NUSSE R, 1988, TRENDS GENET, V4, P291, DOI 10.1016/0168-9525(88)90172-2; RAPTIS L, 1985, MOL CELL BIOL, V5, P2476, DOI 10.1128/MCB.5.9.2476; SEMBA K, 1985, P NATL ACAD SCI USA, V82, P6497, DOI 10.1073/pnas.82.19.6497; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TALMAGE DA, 1989, CELL, V59, P55, DOI 10.1016/0092-8674(89)90869-6; TREMBLAY PJ, 1989, MOL CELL BIOL, V9, P854, DOI 10.1128/MCB.9.2.854; TSUDA H, 1989, CANCER RES, V49, P3104; VANDEVIJVER M, 1987, MOL CELL BIOL, V7, P2019, DOI 10.1128/MCB.7.5.2019; VANDEVIJVER MJ, 1988, NEW ENGL J MED, V319, P1239, DOI 10.1056/NEJM198811103191902; VARLEY JM, 1987, ONCOGENE, V1, P423; VENTER DJ, 1987, LANCET, V2, P69, DOI 10.1016/S0140-6736(87)92736-X; WHITMAN M, 1987, BIOCHEM J, V247, P165, DOI 10.1042/bj2470165; WHITMAN M, 1985, NATURE, V315, P239, DOI 10.1038/315239a0; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WIRTH JJ, 1992, IN PRESS J VIROL, V6; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0; ZHOU DJ, 1987, CANCER RES, V47, P6123	43	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1992	7	7					1295	1303						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HZ971	1320244				2022-12-17	WOS:A1992HZ97100007
J	REDNER, RL; LEE, AWM; OSAWA, GA; NIENHUIS, AW				REDNER, RL; LEE, AWM; OSAWA, GA; NIENHUIS, AW			VARIABLE PATTERN OF JUN AND FOS GENE-EXPRESSION IN DIFFERENT HEMATOPOIETIC-CELL LINES DURING INTERLEUKIN 3-INDUCED ENTRY INTO THE CELL-CYCLE	ONCOGENE			English	Article								Jun (c-jun, jun-B and jun-D) and fos (c-fos, fos-B and fra) proteins dimerize to form the family of AP-1 transcriptional activators. If each dimer exhibits unique transactivating properties, then any phenotypic change should show a characteristic pattern of jun and fos expression. To test this hypothesis we have assessed jun and fos RNA expression after stimulation of the factor-dependent cell lines 32D and FDCP1. These hematopoietic progenitor lines become quiescent in G0/G1 after interleukin 3 (IL-3) deprivation, and upon stimulation synchronously enter the cell cycle. 32D cells respond to IL-3 with rapid induction of jun-B and c-fos, followed by induction of jun-D and fra-1, but no rise in c-jun expression. FDCP1 cells show a very different pattern, with induction of c-jun, jun-D and fra-1. To investigate the response of a single cell line to different physiological stimuli we used a 32D subclone engineered to respond to colony stimulating factor 1 (CSF-1). This subclone showed identical induction of jun and fos after stimulation with either CSF-1 or IL-3. The conservation of response of a single cell line, but the disparate patterns demonstrated by different cells, suggest a fundamental difference in both the regulation and function of the fos/jun complexes in these cells.	NHLBI, CLIN HEMATOL BRANCH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COOK N, 1989, EMBO J, V8, P2967, DOI 10.1002/j.1460-2075.1989.tb08446.x; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEAN M, 1987, ONCOGENE RES, V1, P279; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERGER JS, 1983, FED PROC, V42, P2762; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HASTHORPE S, 1988, INT J CELL CLONING, V6, P30, DOI 10.1002/stem.5530060105; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; IHLE JN, 1989, INT J CELL CLONING, V7, P68, DOI 10.1002/stem.5530070202; IHLE JN, 1982, J IMMUNOL, V129, P2431; IHLE JN, 1982, J IMMUNOL, V129, P1377; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KATO JY, 1990, BLOOD, V75, P1780; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOVARY K, 1991, MOL CELL BIOL, V11, P2451, DOI 10.1128/MCB.11.5.2451; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEE AW, 1990, P NATL ACAD SCI USA, V87, P7270, DOI 10.1073/pnas.87.18.7270; LONDON L, 1987, J EXP MED, V166, P1419, DOI 10.1084/jem.166.5.1419; MATSUI M, 1990, ONCOGENE, V5, P249; MITCHELL RL, 1985, CELL, V40, P209, DOI 10.1016/0092-8674(85)90324-1; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; PERTOVAARA L, 1989, MOL CELL BIOL, V9, P1255, DOI 10.1128/MCB.9.3.1255; PIERCE JH, 1990, P NATL ACAD SCI USA, V87, P5613, DOI 10.1073/pnas.87.15.5613; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; ROHRSCHNEIDER LR, 1989, MOL CELL BIOL, V9, P5081, DOI 10.1128/MCB.9.11.5081; ROUSSEL MF, 1990, P NATL ACAD SCI USA, V87, P6738, DOI 10.1073/pnas.87.17.6738; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1991, ONCOGENE, V6, P533; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; SHURTLEFF SA, 1990, EMBO J, V9, P2415, DOI 10.1002/j.1460-2075.1990.tb07417.x; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; VARTICOVSKI L, 1989, NATURE, V342, P699, DOI 10.1038/342699a0; YOKOTA T, 1984, P NATL ACAD SCI-BIOL, V81, P1070, DOI 10.1073/pnas.81.4.1070; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	58	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1992	7	1					43	50						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HC227	1371337				2022-12-17	WOS:A1992HC22700006
J	AGHIB, DF; BISHOP, JM				AGHIB, DF; BISHOP, JM			A 3' TRUNCATION OF MYC CAUSED BY CHROMOSOMAL TRANSLOCATION IN A HUMAN T-CELL LEUKEMIA IS TUMORIGENIC WHEN TESTED IN ESTABLISHED RAT FIBROBLASTS	ONCOGENE			English	Note							HUMAN C-MYC; MESSENGER-RNA; GENE; TRANSFORMATION; EXPRESSION; ONCOGENE; ACTIVATION; ADJACENT; SEQUENCE; REGION	We have previously identified in human T-leukemia cells a myc gene with an unusual 3' rearrangement, and we have shown that expression of the gene is deregulated by stabilization of mRNA. Here we report that the rearranged gene transforms established rat fibroblasts to a tumorigenic phenotype. In hybrid genes, the transforming capability segregates with the 3' rearrangement. Transformation is apparently due to a more than fivefold enhancement in myc expression, attributable to stabilization of mRNA. The rearranged allele of myc also contains a point mutation in a region upstream of the gene, identified previously as a potential negative regulator of myc expression. The mutation may increase expression of myc, but not sufficiently to cause cellular transformation. Our findings enlarge the variety of genetic lesions that may activate myc to an oncogene and sustain the view that augmented expression of an otherwise normal allele of myc can be pathogenic.	UNIV CALIF SAN FRANCISCO,DEPT MICROBIOL & IMMUNOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,GW HOOPER RES FDN,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA 44338] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGHIB D, 1987, GENETIC VARIATION VI, V354, P338; AGHIB DF, 1990, ONCOGENE, V5, P707; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BIGNAMI M, 1988, ONCOGENE, V2, P509; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; FINGER LR, 1988, P NATL ACAD SCI USA, V85, P9158, DOI 10.1073/pnas.85.23.9158; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HOLLIS GF, 1988, MOL CELL BIOL, V8, P124, DOI 10.1128/MCB.8.1.124; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LAROCCA SA, 1989, CELL, V58, P123, DOI 10.1016/0092-8674(89)90409-1; LEE WMF, 1985, MOL CELL BIOL, V5, P3345, DOI 10.1128/MCB.5.12.3345; MARTIN P, 1986, EMBO J, V5, P1529, DOI 10.1002/j.1460-2075.1986.tb04393.x; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; RICHMAN A, 1989, SCIENCE, V246, P494, DOI 10.1126/science.2683072; SAGLIO G, 1986, CANCER RES, V46, P1413; SAITO H, 1983, P NATL ACAD SCI-BIOL, V80, P7476, DOI 10.1073/pnas.80.24.7476; Sambrook J., 1989, MOL CLONING LAB MANU; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMALL MB, 1987, MOL CELL BIOL, V7, P1638, DOI 10.1128/MCB.7.5.1638; SYMONDS G, 1989, ONCOGENE, V4, P285; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	24	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	DEC	1991	6	12					2371	2375						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX735	1766681				2022-12-17	WOS:A1991GX73500029
J	GONNEVILLE, L; MARTINS, TJ; BEDARD, PA				GONNEVILLE, L; MARTINS, TJ; BEDARD, PA			COMPLEX EXPRESSION PATTERN OF THE CEF-4 CYTOKINE IN TRANSFORMED AND MITOGENICALLY STIMULATED CELLS	ONCOGENE			English	Article							ROUS-SARCOMA VIRUS; 9E3 MESSENGER-RNA; HUMAN-FIBROBLASTS; GENOMIC STRUCTURE; PLATELET PROTEIN; GENE-EXPRESSION; GROWTH-FACTOR; SEQUENCES; PHOSPHORYLATION; TRANSCRIPTION	The transformation of chicken embryo fibroblasts (CEF) by the Rous sarcoma virus leads to the constitutive expression of the cellular gene designated CEF-4. With specific antisera, we confirmed that transformed cells actively synthesize and secrete a 6 kDa polypeptide corresponding to the CEF-4 gene product. The expression of CEF-4 was investigated by Northern and immunoprecipitation analyses. Upon activation of pp60v-src in cells infected by a ts mutant of RSV, the expression of CEF-4 was biphasic with an early transient and a late constitutive period of expression. CEF-4 was expressed in cells transformed by a variety of oncogenes, but the level of constitutive expression differed quantitatively among transformed cells. Cells transformed by v-myc alone did not express CEF-4. Unlike other members of the interleukin 8 gene family, CEF-4 was induced in response to a broad spectrum of growth factors and inflammatory agents. Dexamethasone repressed the induction of CEF-4 by liposaccharides but had little or no effect on the response to serum or pp60v-src. These data emphasize the complexity of CEF-4 expression and suggest the existence of multiple levels or pathways of CEF-4 regulation in normal and transformed cells.	UNIV MONTREAL,DEPT BIOCHEM,CP 6128 SUCC A,MONTREAL H3C 3J7,QUEBEC,CANADA; HARVARD UNIV,DEPT CELLULAR & DEV BIOL,BIOL LABS,CAMBRIDGE,MA 02138	Universite de Montreal; Harvard University								ANISOWICZ A, 1988, P NATL ACAD SCI USA, V85, P9645, DOI 10.1073/pnas.85.24.9645; ANISOWICZ A, 1987, P NATL ACAD SCI USA, V84, P7188, DOI 10.1073/pnas.84.20.7188; BARKER K, 1990, MOL CELL BIOL, V10, P3813, DOI 10.1128/MCB.10.7.3813; BARKER K, 1989, J VIROL, V63, P2929, DOI 10.1128/JVI.63.7.2929-2935.1989; BATTEGAY EJ, 1990, CELL, V63, P515, DOI 10.1016/0092-8674(90)90448-N; BEDARD PA, 1987, MOL CELL BIOL, V7, P1450, DOI 10.1128/MCB.7.4.1450; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BELL SM, 1990, J BIOL CHEM, V265, P1333; BLOBEL GA, 1991, P NATL ACAD SCI USA, V88, P1162, DOI 10.1073/pnas.88.4.1162; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; DESJARDINS P, 1986, SOMAT CELL MOLEC GEN, V12, P133, DOI 10.1007/BF01560660; DOLBERG DS, 1985, SCIENCE, V230, P676, DOI 10.1126/science.2996144; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; KOWALSKI J, 1989, MOL CELL BIOL, V9, P1946, DOI 10.1128/MCB.9.5.1946; LANGLOIS AJ, 1976, CANCER RES, V36, P3894; LEE TH, 1990, MOL CELL BIOL, V10, P1982, DOI 10.1128/MCB.10.5.1982; LEW W, 1988, J IMMUNOL, V140, P1895; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; OBARU K, 1989, MOL IMMUNOL, V26, P423; RAY A, 1990, MOL CELL BIOL, V10, P5736, DOI 10.1128/MCB.10.11.5736; SCHRODER JM, 1990, J IMMUNOL, V144, P2223; SIMMONS DL, 1989, P NATL ACAD SCI USA, V86, P1178, DOI 10.1073/pnas.86.4.1178; SPRANGLER R, 1989, P NATL ACAD SCI USA, V86, P7017; STOECKLE M Y, 1990, New Biologist, V2, P313; STOECKLE MY, 1989, MOL CELL BIOL, V9, P4738, DOI 10.1128/MCB.9.11.4738; STOECKLE MY, 1988, MOL CELL BIOL, V8, P2675, DOI 10.1128/MCB.8.7.2675; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; Summers MD, 1987, TEXAS AGR EXPT STATI; TANABE O, 1988, J IMMUNOL, V141, P3875; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; YAMAMURA Y, 1989, J CLIN INVEST, V84, P1707, DOI 10.1172/JCI114353; YOSHIMURA T, 1989, MOL IMMUNOL, V26, P87; ZINKEWICHPOETTI K, 1991, LAB INVEST, V63, P807; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582	38	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1991	6	10					1825	1833						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX118	1656364				2022-12-17	WOS:A1991GX11800015
J	ANESKIEVICH, BJ; HAIMOVICH, B; BOETTIGER, D				ANESKIEVICH, BJ; HAIMOVICH, B; BOETTIGER, D			PHOSPHORYLATION OF INTEGRIN IN DIFFERENTIATING TS-ROUS SARCOMA VIRUS-INFECTED MYOGENIC CELLS	ONCOGENE			English	Article							FIBRONECTIN-RECEPTOR COMPLEX; MONOCLONAL-ANTIBODIES; TYROSINE PHOSPHORYLATION; EXOGENOUS FIBRONECTIN; MUSCLE MORPHOGENESIS; SKELETAL-MUSCLE; CSAT ANTIGEN; CHICK-EMBRYO; MYOBLASTS; PROTEIN	The differentiation of primary myogenic cultures requires the attachment of the cells to an extracellular matrix substrate using an integrin family receptor. These integrin receptors can be phosphorylated on both their alpha and beta chains, and it has been postulated that phosphorylation regulates the receptor function. Quail myogenic clones transformed with ts-LA24A differentiated into mature myotubes following a temperature shift to non-permissive temperature which inactivates the viral src kinas. Phosphorylation of integrin beta-1 chain and of at least one alpha chain was detected on both serine and tyrosine. An additional alpha chain(s) with a mobility similar to alpha 5 was not phosphorylated at either temperature. Following the induction of differentiation by a temperature shift, there was a marked decrease in integrin phosphorylation of both alpha and beta integrin chains. This decrease was more prominent for serine than for tyrosine, suggesting that src could not be the only kinase involved. The drop in integrin phosphorylation correlated with the initiation of differentiation, suggesting that integrin phosphorylation could be at least part of the mechanism by which myogenic differentiation is blocked by v-src.	UNIV PENN,SCH MED,DEPT MICROBIOL,36TH ST & HAMILTON WALK,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL CANCER INSTITUTE [R01CA049866, R01CA030383] Funding Source: NIH RePORTER; NCI NIH HHS [CA 30383, CA 49866, CA 16503] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; ALEMA S, 1987, ADV CANCER RES, V49, P1, DOI 10.1016/S0065-230X(08)60792-7; BISCHOFF R, 1967, J CELL BIOL, V36, P111; BOETTIGER D, 1989, UCLA S MOL CELLULAR, P57; BOZYCZKO D, 1989, EXP CELL RES, V183, P72, DOI 10.1016/0014-4827(89)90419-9; BUCK CA, 1986, J CELL BIOL, V103, P2421, DOI 10.1083/jcb.103.6.2421; CARLEY WW, 1981, J CELL BIOL, V97, P797; CHEN LB, 1977, CELL, V37, P357; CHEN WT, 1986, J CELL BIOL, V103, P1649, DOI 10.1083/jcb.103.5.1649; CHI JC, 1975, P NATL ACAD SCI USA, V72, P4999, DOI 10.1073/pnas.72.12.4999; CHI JCH, 1975, J CELL BIOL, V67, P523, DOI 10.1083/jcb.67.3.523; CHIQUET M, 1979, J BIOL CHEM, V254, P5475; CHIQUET M, 1981, DEV BIOL, V88, P220, DOI 10.1016/0012-1606(81)90166-4; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAMSKY CH, 1985, J CELL BIOL, V100, P1528, DOI 10.1083/jcb.100.5.1528; DARRIBERE T, 1990, J CELL BIOL, V110, P1813, DOI 10.1083/jcb.110.5.1813; DUBAND JL, 1988, FEBS LETT, V230, P181, DOI 10.1016/0014-5793(88)80667-7; FALCONE G, 1984, EMBO J, V3, P1327, DOI 10.1002/j.1460-2075.1984.tb01971.x; FISZMAN MY, 1975, NATURE, V254, P429, DOI 10.1038/254429a0; FOSTER RF, 1987, DEV BIOL, V122, P11, DOI 10.1016/0012-1606(87)90327-7; FURCHT LT, 1978, CELL, V13, P263, DOI 10.1016/0092-8674(78)90195-2; GEORGEWEINSTEIN M, 1988, DEV BIOL, V125, P34, DOI 10.1016/0012-1606(88)90056-5; HAIMOVICH B, 1991, CELL REGUL, V2, P271, DOI 10.1091/mbc.2.4.271; HAUSCHKA SD, 1966, P NATL ACAD SCI USA, V55, P119, DOI 10.1073/pnas.55.1.119; HIRST R, 1986, P NATL ACAD SCI USA, V83, P6470, DOI 10.1073/pnas.83.17.6470; HOLTZER H, 1975, P NATL ACAD SCI USA, V72, P4051, DOI 10.1073/pnas.72.10.4051; HYNES RO, 1989, J CELL BIOL, V109, P409, DOI 10.1083/jcb.109.1.409; JAFFREDO T, 1988, DEVELOPMENT, V103, P431; KAUSHAL V, 1986, ANAL BIOCHEM, V157, P291, DOI 10.1016/0003-2697(86)90629-9; KELLIE S, 1987, BIOCHEM SOC T, V15, P791, DOI 10.1042/bst0150791; KIENY M, 1984, J EXP ZOOL, V232, P327, DOI 10.1002/jez.1402320220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIN ZY, 1989, GENE DEV, V3, P986, DOI 10.1101/gad.3.7.986; MENKO AS, 1987, CELL, V51, P51, DOI 10.1016/0092-8674(87)90009-2; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; OCALAN M, 1988, DEV BIOL, V125, P158, DOI 10.1016/0012-1606(88)90068-1; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; STOKER AW, 1984, MOL CELL BIOL, V4, P1508, DOI 10.1128/MCB.4.8.1508; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAMKUN JW, 1986, CELL, V46, P271, DOI 10.1016/0092-8674(86)90744-0; TAPLEY P, 1989, ONCOGENE, V4, P325; WEBER K, 1974, COLD SPRING HARB SYM, V39, P363, DOI 10.1101/SQB.1974.039.01.047; WYKE JA, 1973, VIROLOGY, V54, P152	44	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1381	1390						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1653410				2022-12-17	WOS:A1991GX27200014
J	COULIER, F; BATOZ, M; MARICS, I; DELAPEYRIERE, O; BIRNBAUM, D				COULIER, F; BATOZ, M; MARICS, I; DELAPEYRIERE, O; BIRNBAUM, D			PUTATIVE STRUCTURE OF THE FGF6 GENE-PRODUCT AND ROLE OF THE SIGNAL PEPTIDE	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR RECEPTOR GENES; NUCLEOTIDE-SEQUENCE; ACID SEQUENCES; FACTOR FAMILY; CELL-GROWTH; EXPRESSION; MESODERM; INT-2; HST	The human FGF6 gene is an oncogene related by sequence similarities to the fibroblast growth factor (FGF) gene family, which encodes mitogenic peptides implicated in various physiological processes including angiogenesis, morphogenesis, tissue regeneration and survival and oncogenesis. Nucleotide sequence analysis of the FGF6 gene and of cDNA clones revealed an open reading frame able to code for a protein of 208 residues. The FGF6 protein shares 32-70% residues with the other members of the family within the C-terminal two-thirds of the molecule. In vitro, three in-frame ATG codons are able to initiate the translation of three peptides of 175, 198 and 208 residues. These three peptides differ at their amino termini with respect to the relative position of a hydrophobic leader peptide, which extends from residues 16 to 40, and is therefore absent from the shorter (175 amino acids) form. In-vitro analysis indicates that this signal peptide is able to drive the FGF6 protein through the endoplasmic reticulum, where it becomes glycosylated. The presence of this signal peptide sequence appears essential for the in vivo transforming capacity of the FGF6 gene.			COULIER, F (corresponding author), INSERM, UNITE 119, 27 BD LEI ROURE, F-13009 MARSEILLE, FRANCE.		Coulier, François/G-6098-2015	Coulier, François/0000-0002-6288-7773				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BLAM SB, 1988, ONCOGENE, V3, P129; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIMARIO J, 1989, SCIENCE, V244, P688, DOI 10.1126/science.2717945; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ENSOLI B, 1989, CANCER CELL-MON REV, V1, P93; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GOSPODAROWICZ D, 1987, J CELL PHYSIOL, P15; HANNINK M, 1984, SCIENCE, V226, P1197, DOI 10.1126/science.6095451; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEESEY J, 1987, BIOCH INFORMATION; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARICS I, 1989, ONCOGENE, V4, P335; MERLO GR, 1990, CELL GROWTH DIFFER, V1, P463; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1989, ONCOGENE RES, V5, P101; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1988, ONCOGENE, V3, P9; Sambrook J., 1989, MOL CLONING LAB MANU; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; THEILLET C, 1989, ONCOGENE, V4, P915; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; XERRI L, 1991, AM J PATHOL, V138, P9; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHOU DJ, 1988, ONCOGENE, V2, P279; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	57	11	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1437	1444						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886714				2022-12-17	WOS:A1991GX27200021
J	ENDO, K; BORER, CH; TSUJIMOTO, Y				ENDO, K; BORER, CH; TSUJIMOTO, Y			MODULATION OF LFA-1 SURFACE-ANTIGEN EXPRESSION BY ACTIVATED H-RAS BUT NOT C-MYC ONCOGENE IN EBV-INFECTED HUMAN B-LYMPHOBLAST CELLS	ONCOGENE			English	Article							BURKITTS-LYMPHOMA; ADHESION RECEPTORS; MOLECULAR-CLONING; DOWN-REGULATION; BETA-SUBUNIT; GENE; FAMILY; VIRUS; P150,95; PROTEIN	The lymphocyte-associated antigen 1 (LFA-1) involved in a wide range of cellular adhesion-dependent immunological functions, including interaction of cytotoxic T lymphocytes with their target, is implicated in tumorigenesis. The modulation of the LFA-1 antigen expression was studied in Epstein-Barr virus (EBV)-immortalized human B-lymphoblastoid cell lines, transfected with human oncogenes, H-ras and c-myc. We observed by flow cytometry that the activated H-ras (EJ) gene, but not its normal counterpart, consistently enhanced LFA-1 expression. The RNA analysis revealed that induction of the LFA-1 surface antigen by the EJ gene occurred through the level of the alpha-chain but not the beta-chain mRNA of LFA-1. The LFA-1 molecules induced by the EJ gene were functional; cells with the EJ gene revealed an elevated level of homocytic cellular adhesion, which was blocked by the anti-LFA-1 monoclonal antibody. Flow cytometry analysis indicated that the modulation of the LFA-1 antigen expression was a phenomenon specific to the EJ gene. The high levels of expression of c-myc and blc-2 gene did not affect LFA-1 antigen expression. The system used here provides a tool by which the signal transduction pathway involving the H-ras gene and the molecular mechanism of LFA-1 gene expression can be genetically dissected.	WISTAR INST, 3601 SPRUCE ST, PHILADELPHIA, PA 19104 USA	The Wistar Institute					NATIONAL CANCER INSTITUTE [R01CA051864, R01CA050551] Funding Source: NIH RePORTER; NCI NIH HHS [CA-51864, CA-50551] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BILLAUD M, 1987, LANCET, V2, P1327; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLAYBERGER C, 1987, LANCET, V2, P533; CORBI AL, 1988, J EXP MED, V167, P1597, DOI 10.1084/jem.167.5.1597; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; INGHIRAMI G, 1990, SCIENCE, V250, P682, DOI 10.1126/science.2237417; KEIZER GD, 1985, EUR J IMMUNOL, V15, P1142, DOI 10.1002/eji.1830151114; KISHIMOTO TK, 1989, ADV IMMUNOL, V46, P149, DOI 10.1016/S0065-2776(08)60653-7; KISHIMOTO TK, 1987, CELL, V48, P681, DOI 10.1016/0092-8674(87)90246-7; LOMBARDI L, 1987, CELL, V49, P161, DOI 10.1016/0092-8674(87)90556-3; MARLIN SD, 1987, CELL, V51, P813, DOI 10.1016/0092-8674(87)90104-8; MASUCCI MG, 1987, P NATL ACAD SCI USA, V84, P4567, DOI 10.1073/pnas.84.13.4567; MICHELSON AM, 1983, P NATL ACAD SCI-BIOL, V80, P472, DOI 10.1073/pnas.80.2.472; MIYAMOTO C, 1985, P NATL ACAD SCI USA, V82, P7232, DOI 10.1073/pnas.82.21.7232; NASI S, 1990, ONCOGENE, V5, P117; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PATARROYO M, 1988, INT J CANCER, V41, P901, DOI 10.1002/ijc.2910410623; PULCIANI S, 1982, P NATL ACAD SCI-BIOL, V79, P2845, DOI 10.1073/pnas.79.9.2845; ROONEY CM, 1985, NATURE, V317, P629, DOI 10.1038/317629a0; ROOSSIEN FF, 1990, CANCER RES, V50, P3509; ROTHLEIN R, 1986, J IMMUNOL, V137, P1270; ROUSSET F, 1989, J IMMUNOL, V143, P1490; SANCHEZMADRID F, 1983, J EXP MED, V158, P1785, DOI 10.1084/jem.158.6.1785; SEREMETIS S, 1989, SCIENCE, V243, P660, DOI 10.1126/science.2536954; SHAW S, 1986, NATURE, V323, P262, DOI 10.1038/323262a0; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1989, ONCOGENE, V4, P1331; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806	31	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1391	1396						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1653411				2022-12-17	WOS:A1991GX27200015
J	LEVESQUE, KS; MATTEI, MG; LEVY, LS				LEVESQUE, KS; MATTEI, MG; LEVY, LS			EVOLUTIONARY CONSERVATION AND CHROMOSOMAL LOCALIZATION OF FLVI-1	ONCOGENE			English	Article							PUTATIVE ONCOGENE SPI-1; TRANSCRIPTION FACTOR; ERYTHROLEUKEMIAS; INTEGRATION; VIRUS; PU.1	A locus in feline DNA, termed flvi-1, has been identified as harboring retroviral integrations commonly found in natural feline lymphomas induced by infection with feline leukemia virus (FeLV). Southern blot analysis of human and murine DNA using restriction fragments representing flvi-1 demonstrates its phylogenetic conservation among mammals. flvi-1 is localized to murine chromosome 2, proximal portion of band E, by in situ hybridization to metaphase chromosomes. This position is adjacent to that of another putative proto-oncogene, sfpi-1, although probes representing flvi-1 and sfpi-1 do not cross-hybridize. The repeated implication of flvi-1 in natural feline leukemogenesis, its evolutionary conservation and its chromosomal position support the hypothesis that flvi-1 may represent a previously unidentified proto-oncogene.	TULANE UNIV,SCH MED,DEPT MICROBIOL & IMMUNOL,1430 TULANE AVE,NEW ORLEANS,LA 70112; HOP ENFANTS LA TIMONE,INSERM,U-242,F-13385 MARSEILLE,FRANCE	Tulane University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille					NATIONAL CANCER INSTITUTE [R01CA048801] Funding Source: NIH RePORTER; NCI NIH HHS [CA48801] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		GOEBL MG, 1990, CELL, V61, P1165, DOI 10.1016/0092-8674(90)90676-6; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KUNG HJ, 1991, IN PRESS CURR TOP MI, V171; LEVESQUE KS, 1990, J VIROL, V64, P3455, DOI 10.1128/JVI.64.7.3455-3462.1990; Maniatis T., 1982, MOL CLONING; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1990, ONCOGENE, V5, P941; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; Mullins J.I., 1990, RETROVIRUS BIOL HUMA, P87; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PAUL R, 1989, J VIROL, V63, P4958, DOI 10.1128/JVI.63.11.4958-4961.1989; SPIRO C, 1988, J VIROL, V62, P4129, DOI 10.1128/JVI.62.11.4129-4135.1988	13	11	11	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1377	1379						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1679530				2022-12-17	WOS:A1991GX27200013
J	HUANG, S; AXELROD, DE				HUANG, S; AXELROD, DE			ALTERED POSTTRANSLATIONAL PROCESSING OF P21RAS ONCOPROTEIN IN A TRANSFORMATION-SUPPRESSED CELL-LINE	ONCOGENE			English	Article							MURINE SARCOMA-VIRUS; RAS PROTO-ONCOGENE; SACCHAROMYCES-CEREVISIAE; FATTY ACYLATION; GENE FAMILY; H-RAS; PROTEINS; HARVEY; IDENTIFICATION; MUTANT	We have isolated a transformation-suppressed cell line, R35, which is altered in the maturation of p21ras. It was obtained from the transformed cell line NIH3T3(ras(EJ)) as a revertant with flat morphology and anchorage dependent growth. Immunoprecipitation of steady state labeled ras proteins reveals that the revertant produces p21ras, and in addition, accumulates a protein that migrates as 23 kD. Fusion of revertant cells with non-transformed rat2 cells yields cell hybrids which are retransformed and do not accumulate p23, suggesting that accumulation of p23 and suppression of transformation may be related. The accumulated p23 appears to be a precursor to p21 because (1) pulse labeling and cell fractionation of revertant cells shows that label chases from cytoplasmic p23 to membrane-associated p21, although at a slower rate, and (2) the p23 of revertant cells is indistinguishable from the p23 precursor of p21 in parent cells by partial V8 protease digestion and two dimensional electrophoresis. R35 cells are slower than their transformed parent in palmitylation and polyisoprenylation, but not in methylation of ras proteins. These results suggest that the transformation-suppressed cell line R35 is defective in the rate at which it post-translationally processes ras proteins, possibly because it is slower in polyisoprenylation of the cytoplasmic p23 precursor protein.	RUTGERS STATE UNIV,WAKSMAN INST,POB 759,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick	AXELROD, DE (corresponding author), RUTGERS STATE UNIV,WAKSMAN INST,POB 759,PISCATAWAY,NJ 08855, USA.				NATIONAL CANCER INSTITUTE [R01CA042795] Funding Source: NIH RePORTER; NCI NIH HHS [CA-42795] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Aswad DW, 1989, CURR OPIN CELL BIOL, V1, P1182, DOI 10.1016/S0955-0674(89)80069-9; BARBACID H, 1987, ANN REV BIOCH, V56, P779; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; BUSS JE, 1986, MOL CELL BIOL, V6, P116, DOI 10.1128/MCB.6.1.116; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; COHEN JB, 1989, CELL, V58, P461, DOI 10.1016/0092-8674(89)90427-3; COLBY WW, 1986, MOL CELL BIOL, V6, P730, DOI 10.1128/MCB.6.2.730; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; DER CJ, 1982, P NATL ACAD SCI-BIOL, V79, P3637, DOI 10.1073/pnas.79.11.3637; DESCHENES RJ, 1987, MOL CELL BIOL, V7, P2344, DOI 10.1128/MCB.7.7.2344; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1985, TRENDS BIOCHEM SCI, V10, P350, DOI 10.1016/0968-0004(85)90110-0; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LEE J, 1989, UNPUB; LEE J, 1985, J CELL BIOL, V101, pA116; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MICHAELI T, 1989, EMBO J, V8, P3039, DOI 10.1002/j.1460-2075.1989.tb08454.x; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; POLONIS VR, 1987, ARCH BIOCHEM BIOPHYS, V254, P541, DOI 10.1016/0003-9861(87)90135-4; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; TOPP WC, 1981, VIROLOGY, V113, P408, DOI 10.1016/0042-6822(81)90168-9; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	34	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1211	1218						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1861867				2022-12-17	WOS:A1991GV26000017
J	LEE, NG; YAMAGUCHI, J; SUBRAMANIAN, KN				LEE, NG; YAMAGUCHI, J; SUBRAMANIAN, KN			EFFICIENT REPLICATION OF PLASMIDS CONTAINING THE SV40 ORIGIN IN N-MYC OVEREXPRESSING HUMAN NEUROBLASTOMA-CELLS	ONCOGENE			English	Article								Using test plasmids containing the SV40 origin, we found a wide spectrum of permissiveness to their replication in different human cell lines. N-myc overexpressing neuroblastoma cells were highly permissive. LA-N-1 neuroblastoma cells were the most permissive of all the cell lines that we tested including the homologous CV-1 or COS-1 monkey kidney cells. Other human cell lines expressing various amounts of c-myc, and the 293 cell line expressing adenovirus E1A and E1B exhibited intermediate levels of permissiveness. T24 and EJ bladder carcinoma cells, which do not express the myc genes, were nonpermissive. Transient expression of c-myc or N-myc from plasmid vectors resulted in a modest stimulation of replication. Replication of test plasmids containing different configurations of the SV40 origin region was activated by the myc proteins. The high efficiency of replication in LA-N-1 cells is due to a combination of reasons including the overproduction of N-myc, high efficiency of expression of the SV40 replication initiator protein large T antigen from a cotransfected expression plasmid (containing the T antigen gene under the RSV LTR control), and other unknown host cell replication stimulatory factors. Replication of test plasmids was not detected in N-myc or c-myc overexpressing cells when the T antigen expression plasmid was not provided, showing that the myc proteins cannot substitute for T antigen in SV40 DNA replication.	UNIV ILLINOIS, DEPT MICROBIOL & IMMUNOL, CHICAGO, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	LEE, NG (corresponding author), UNIV ILLINOIS, DEPT GENET, CHICAGO, IL 60612 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035872] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 R01 GM 35872] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; ALT FW, 1986, COLD SPRING HARB SYM, V51, P931, DOI 10.1101/SQB.1986.051.01.106; ALWINE JC, 1985, MOL CELL BIOL, V5, P1034, DOI 10.1128/MCB.5.5.1034; BENTLEY DL, 1986, NATURE, V321, P702, DOI 10.1038/321702a0; BERGSMA DJ, 1982, P NATL ACAD SCI-BIOL, V79, P381, DOI 10.1073/pnas.79.2.381; BERK AJ, 1986, ANNU REV GENET, V20, P45, DOI 10.1146/annurev.ge.20.120186.000401; BERNARDS R, 1986, CELL, V47, P667, DOI 10.1016/0092-8674(86)90509-X; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210; CHANDRASEKHARAPPA SC, 1987, J VIROL, V61, P2973, DOI 10.1128/JVI.61.10.2973-2980.1987; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; CLASSON M, 1990, ONCOGENE, V5, P1371; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DELUCIA AL, 1986, J VIROL, V57, P138, DOI 10.1128/JVI.57.1.138-144.1986; DEPINHO RA, 1986, P NATL ACAD SCI USA, V83, P1827, DOI 10.1073/pnas.83.6.1827; Flint S. J, 1981, DNA TUMOR VIRUSES; FRIEDMAN M, 1986, CONTEMP POLICY ISSUE, V4, P1, DOI 10.1111/j.1465-7287.1986.tb00827.x; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; GUTIERREZ C, 1987, MOL CELL BIOL, V7, P4594, DOI 10.1128/MCB.7.12.4594; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARTZELL SW, 1984, P NATL ACAD SCI-BIOL, V81, P6335, DOI 10.1073/pnas.81.20.6335; HAYDAY AC, 1984, NATURE, V307, P334, DOI 10.1038/307334a0; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HERTZ GZ, 1986, MOL CELL BIOL, V6, P3513, DOI 10.1128/MCB.6.10.3513; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; IGUCHIARIGA SMM, 1987, NUCLEIC ACIDS RES, V15, P4889, DOI 10.1093/nar/15.12.4889; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KINGSTON RE, 1984, CANCER CELL, V2, P539; KOHL NE, 1984, SCIENCE, V226, P1335, DOI 10.1126/science.6505694; KOZBOR D, 1984, CANCER RES, V44, P438; KUMAR R, 1988, MOL CELL BIOL, V8, P1509, DOI 10.1128/MCB.8.4.1509; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LEBKOWSKI JS, 1985, NATURE, V317, P169, DOI 10.1038/317169a0; LEECHEN GJ, 1986, MOL CELL BIOL, V6, P3086, DOI 10.1128/MCB.6.9.3086; LEWIS ED, 1985, NATURE, V317, P172, DOI 10.1038/317172a0; LI JJ, 1986, MOL CELL BIOL, V6, P1117, DOI 10.1128/MCB.6.4.1117; LUSKY M, 1981, NATURE, V293, P79, DOI 10.1038/293079a0; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; NEVINS JR, 1989, ADV VIRUS RES, V37, P35; NISEN PD, 1986, CANCER RES, V46, P6217; PARSONS R, 1990, J VIROL, V64, P509, DOI 10.1128/JVI.64.2.509-518.1990; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; RIGBY PWJ, 1977, J MOL BIOL, V113, P237, DOI 10.1016/0022-2836(77)90052-3; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; SCHWAB M, 1985, NATURE, V316, P160, DOI 10.1038/316160a0; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STANTON LW, 1986, P NATL ACAD SCI USA, V83, P1772, DOI 10.1073/pnas.83.6.1772; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; STUDZINSKI GP, 1986, SCIENCE, V234, P467, DOI 10.1126/science.3532322; TRIFILLIS P, 1990, J VIROL, V64, P1345, DOI 10.1128/JVI.64.3.1345-1347.1990; YANCOPOULOS GD, 1985, P NATL ACAD SCI USA, V82, P5455, DOI 10.1073/pnas.82.16.5455	60	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1161	1169						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650440				2022-12-17	WOS:A1991GV26000010
J	SATO, M; KITAZAWA, T; IWAI, T; SEKI, J; SAKATO, N; KATO, JY; TAKEYA, T				SATO, M; KITAZAWA, T; IWAI, T; SEKI, J; SAKATO, N; KATO, JY; TAKEYA, T			ISOLATION OF CHICKEN-BEK AND A RELATED GENE - IDENTIFICATION OF STRUCTURAL VARIATION IN THE LIGAND-BINDING DOMAINS OF THE FGF-RECEPTOR FAMILY	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; PROTEIN-TYROSINE KINASE; AVIAN-SARCOMA VIRUS; PHOSPHOTYROSINE ANTIBODY; PURIFICATION; EXPRESSION; FLG	cDNA clones carrying the chicken-bek gene and a related gene were isolated. Deducing the amino acid sequence of chicken-bek allowed us to predict that it encodes for a receptor tyrosine kinase related to the fibroblast growth factor (FGF) receptor, and that the chicken-bek gene and Cek3 are closely related. However, a significant structural difference was identified between chicken-bek and Cek3 within the putative extracellular region, in such a manner that the structure of the immunoglobulin-like domain was conserved. A probe specific to the altered structure detected mRNA in the tissues as did a probe common to bek and Cek3, indicating heterogeneity in the FGF-receptor family in a novel manner. Furthermore, another bek-like gene was isolated and the expressions of its mRNA and protein product were analysed in tissues and cultured cells.	KYOTO UNIV,INST CHEM RES,UJI,KYOTO 611,JAPAN; COSMO RES INST,SATTE,SAITAMA 34001,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,SUITA,OSAKA 565,JAPAN	Kyoto University; Osaka University	TAKEYA, T (corresponding author), KYOTO UNIV,INST CHEM RES,UJI,KYOTO 611,JAPAN.							BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; HANAFUSA H, 1969, P NATL ACAD SCI USA, V63, P318, DOI 10.1073/pnas.63.2.318; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; KORNBLUTH S, 1988, MOL CELL BIOL, V8, P5541, DOI 10.1128/MCB.8.12.5541; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; NILSSON B, 1985, EMBO J, V4, P1075, DOI 10.1002/j.1460-2075.1985.tb03741.x; PASQUALE EB, 1990, P NATL ACAD SCI USA, V87, P5812, DOI 10.1073/pnas.87.15.5812; PASQUALE EB, 1989, P NATL ACAD SCI USA, V86, P5449, DOI 10.1073/pnas.86.14.5449; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; RUTA M, 1988, ONCOGENE, V3, P9; SAFRAN A, 1990, ONCOGENE, V5, P635; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEKI J, 1986, CANCER RES, V46, P907; TAKEYA T, 1982, J VIROL, V44, P1; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	19	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1991	6	7					1279	1283						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1650446				2022-12-17	WOS:A1991GV26000026
J	KIM, H; STRONG, TV; ANDERSON, SJ				KIM, H; STRONG, TV; ANDERSON, SJ			EVIDENCE FOR TAU-EXPRESSION IN CELLS OF MONOCYTE LINEAGE AND ITS INVITRO PHOSPHORYLATION BY V-FMS KINASE	ONCOGENE			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; PROTO-ONCOGENE; LOCALIZATION; CYTOSKELETAL; PATHOLOGY; FILAMENTS; CSF-1; LONG	The v-fms encoded kinase, which is known to associate with cytoskeletal elements, was shown to phosphorylate histiocytic proteins that had physical and immunological attributes in common with tau. Tau is a microtubule associated protein that is aberrantly phosphorylated in Alzheimer's disease of the brain. Since c-fms expression is normally exclusive to cells of monocyte lineage, these cells were examined for expression of tau. Heat stable tau was identified in cultured peripheral blood monocytes. This represents the first molecular characterization of tau in cells of non-neural origin.	UNIV ALABAMA,DEPT PATHOL,VOLKER HALL G-023,UAB STN,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	ANDERSON, SJ (corresponding author), UNIV ALABAMA,DEPT PATHOL,VOLKER HALL G-023,UAB STN,BIRMINGHAM,AL 35294, USA.		Strong, Theresa/GSM-6652-2022	Strong, Theresa/0000-0001-6783-8703	NIA NIH HHS [R0I-AG 06969] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG006969] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDERSON SJ, 1984, J VIROL, V51, P730, DOI 10.1128/JVI.51.3.730-741.1984; ANDERSON SJ, 1982, J VIROL, V44, P696, DOI 10.1128/JVI.44.2.696-702.1982; BARBACID M, 1981, J VIROL, V40, P812, DOI 10.1128/JVI.40.3.812-821.1981; BINDER LI, 1985, J CELL BIOL, V96, P1523; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BUTLER M, 1986, J NEUROCHEM, V47, P1517, DOI 10.1111/j.1471-4159.1986.tb00788.x; GRUNDKEIQBAL I, 1986, P NATL ACAD SCI USA, V83, P4913, DOI 10.1073/pnas.83.13.4913; HAGESTEDT T, 1989, J CELL BIOL, V109, P1643, DOI 10.1083/jcb.109.4.1643; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERZOG W, 1978, EUR J BIOCHEM, V92, P1, DOI 10.1111/j.1432-1033.1978.tb12716.x; HORWITZ DA, 1977, CLIN EXP IMMUNOL, V30, P289; JAMESON L, 1981, P NATL ACAD SCI-BIOL, V78, P3413, DOI 10.1073/pnas.78.6.3413; KIM H, 1979, J CELL BIOL, V80, P266, DOI 10.1083/jcb.80.2.266; KOSIK KS, 1988, NEURON, V1, P817, DOI 10.1016/0896-6273(88)90129-8; KOWALL NW, 1987, ANN NEUROL, V22, P639, DOI 10.1002/ana.410220514; LEHTO VP, 1982, LAB INVEST, V47, P391; LINDWALL G, 1984, J BIOL CHEM, V259, P5301; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; MACDONALD BR, 1986, J BONE MINER RES, V1, P227; MULLER R, 1983, NATURE, V304, P454, DOI 10.1038/304454a0; RALPH P, 1976, J EXP MED, V143, P1528, DOI 10.1084/jem.143.6.1528; RETTENMIER CW, 1985, CELL, V40, P971, DOI 10.1016/0092-8674(85)90357-5; SARIBAN E, 1985, NATURE, V316, P64, DOI 10.1038/316064a0; SELDEN SC, 1983, J BIOL CHEM, V258, P7064; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; STRONG TV, 1990, SOMAT CELL MOLEC GEN, V16, P341, DOI 10.1007/BF01232462; WEINGARTEN MD, 1975, P NATL ACAD SCI USA, V72, P1858, DOI 10.1073/pnas.72.5.1858	27	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1085	1087						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1829806				2022-12-17	WOS:A1991GU62200028
J	GALLAND, F; PIRISI, V; DELAPEYRIERE, O; BIRNBAUM, D				GALLAND, F; PIRISI, V; DELAPEYRIERE, O; BIRNBAUM, D			RESTRICTION AND COMPLEXITY OF MCF2 PROTOONCOGENE EXPRESSION	ONCOGENE			English	Article							B-CELL LYMPHOMA; TRANSFORMING SEQUENCE; TRANSCRIPT FERT; DBL-ONCOGENE; X-CHROMOSOME; GERM-CELLS; GENE; SPERMATOGENESIS; DELETION; PRODUCT	MCF2/DBL is an X-linked proto-oncogene encoding a protein with a yet undetermined function. It can be activated in vitro by loss of 5' sequences in NIH3T3 bioassays; in vivo, deletion of the gene has been found in some hemophilia B patients. PCR analysis of its expression in mouse tissues shows a restriction to the gonads and tissues of neuroectodermal origin. It also identifies an exon encoding 42 amino acids that is alternatively spliced in murine, but not human testis.	INSERM,U119,27 BD LEI ROURE,F-13009 MARSEILLE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	BIRNBAUM, D (corresponding author), INSERM,U119,27 BD LEI ROURE,F-13009 MARSEILLE,FRANCE.							ANSON DS, 1988, EMBO J, V7, P2795, DOI 10.1002/j.1460-2075.1988.tb03134.x; ERICKSON RP, 1990, TRENDS GENET, V6, P264, DOI 10.1016/0168-9525(90)90209-O; EVA A, 1985, NATURE, V316, P273, DOI 10.1038/316273a0; EVA A, 1987, ONCOGENE, V1, P355; EVA A, 1988, P NATL ACAD SCI USA, V85, P2061, DOI 10.1073/pnas.85.7.2061; FASSANO O, 1984, MOL CELL BIOL, V4, P1695; FISCHMAN K, 1990, MOL CELL BIOL, V10, P146, DOI 10.1128/MCB.10.1.146; GALLAND F, BIOCHIMIE, V72, P759; GRANT SG, 1990, CYTOGENET CELL GENET, V54, P175, DOI 10.1159/000132988; GRAZIANI G, 1989, ONCOGENE, V4, P823; KESHET E, 1990, MOL CELL BIOL, V10, P5021, DOI 10.1128/MCB.10.9.5021; LETWIN K, 1988, ONCOGENE, V3, P621; MATSUSHIME H, 1990, MOL CELL BIOL, V10, P2261, DOI 10.1128/MCB.10.5.2261; MATTEI MG, 1989, CYTOGENET CELL GENET, V51, P1041; NGUYEN C, 1987, EMBO J, V6, P3285, DOI 10.1002/j.1460-2075.1987.tb02647.x; NOGUCHI T, 1987, EMBO J, V6, P1301, DOI 10.1002/j.1460-2075.1987.tb02368.x; NOGUCHI T, 1988, ONCOGENE, V3, P709; PROPST F, 1988, ONCOGENE, V2, P227; PROPST F, 1988, TRENDS GENET, V4, P183, DOI 10.1016/0168-9525(88)90073-X; RON D, 1988, EMBO J, V7, P2465, DOI 10.1002/j.1460-2075.1988.tb03093.x; RON D, 1989, ONCOGENE, V4, P1067; SCHLESSINGER D, 1990, TRENDS GENET, V6, P248, DOI 10.1016/0168-9525(90)90207-M; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SORRENTINO V, 1988, P NATL ACAD SCI USA, V85, P2191, DOI 10.1073/pnas.85.7.2191; SRIVASTAVA SK, 1986, P NATL ACAD SCI USA, V83, P8868, DOI 10.1073/pnas.83.23.8868; VECCHIO G, 1989, ONCOGENE, V4, P897; WOLFES H, 1989, SCIENCE, V245, P740, DOI 10.1126/science.2475907	27	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					833	839						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	2052360				2022-12-17	WOS:A1991GT82500020
J	GINSBERG, D; HIRAI, S; PINHASIKIMHI, O; YANIV, M; OREN, M				GINSBERG, D; HIRAI, S; PINHASIKIMHI, O; YANIV, M; OREN, M			TRANSFECTED MOUSE C-JUN CAN INHIBIT TRANSFORMATION OF PRIMARY RAT EMBRYO FIBROBLASTS	ONCOGENE			English	Note							DNA-BINDING; GLUCOCORTICOID RECEPTOR; GROWTH-FACTORS; FOS; CELLS; GENE; ONCOGENE; DIFFERENTIATION; EXPRESSION; ENCODES	The c-jun gene, which encodes a transcriptional regulatory protein, is the cellular homologue of the transforming gene of avian sarcoma virus 17. In an attempt to assess the biological activities of mouse c-jun, we studied the consequences of its overproduction in an in vitro transformation assay. A c-jun expression plasmid failed to cooperate with either ras, myc or mutant p53 in this focus formation assay. On the other hand, it dramatically inhibited the ability of various oncogene combinations to elicit foci upon transfection into primary rat embryo fibroblasts. Deletion plasmids lacking either the trans-activating domain or the leucine repeat of c-jun still displayed a pronounced inhibitory activity. On the contrary, a plasmid encoding only the first 187 amino acids of c-jun had no such activity. The data suggests that enhanced c-jun expression may interfere with the induction or proliferation of transformed cells in this system, and that the inhibitory activity residues in the C-terminal half of the molecule.	INST PASTEUR, CNRS, DEPT BIOTECHNOL, F-75724 PARIS 15, FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite	GINSBERG, D (corresponding author), WEIZMANN INST SCI, DEPT CHEM IMMUNOL, IL-76100 REHOVOT, ISRAEL.			ginsberg, doron/0000-0002-1257-4920				ANGEL P, 1989, New Biologist, V1, P35; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CASTELLAZZI M, 1990, ONCOGENE, V5, P1541; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HIRAI SI, 1990, ONCOGENE, V5, P39; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LORD KA, 1990, ONCOGENE, V5, P387; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MATSUI M, 1990, ONCOGENE, V5, P249; MICHALOVITZ D, 1986, MOL CELL BIOL, V6, P3531, DOI 10.1128/MCB.6.10.3531; MOAV B, 1986, GENE, V48, P297, DOI 10.1016/0378-1119(86)90089-2; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; POLLACK R, 1974, P NATL ACAD SCI USA, V71, P4792, DOI 10.1073/pnas.71.12.4792; RULEY HE, 1983, NATURE, V304, P602, DOI 10.1038/304602a0; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHUTTE J, 1989, P NATL ACAD SCI USA, V86, P2257, DOI 10.1073/pnas.86.7.2257; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; Vogt P K, 1990, Adv Cancer Res, V55, P1, DOI 10.1016/S0065-230X(08)60466-2; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	36	11	13	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1991	6	4					669	672						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1903196				2022-12-17	WOS:A1991FR93900025
J	KODURU, PRK; OFFIT, K				KODURU, PRK; OFFIT, K			MOLECULAR-STRUCTURE OF DOUBLE RECIPROCAL TRANSLOCATIONS - SIGNIFICANCE IN B-CELL LYMPHOMAGENESIS	ONCOGENE			English	Note							C-MYC ONCOGENE; BCL-2 GENE; FOLLICULAR LYMPHOMA; BURKITT-LYMPHOMA; CHROMOSOME-TRANSLOCATION; LOCUS; ACTIVATION; LEUKEMIA; REGION; REARRANGEMENTS	The molecular structure of reciprocal translocations associated with low grade and high grade non-Hodgkin's lymphomas occurring together was analysed in two tumors. Sequential biopsies documented histological transformation of a large cell lymphoma to an immunoblastic lymphoma bearing t(14;18)(q32;q21) and t(8;22)(q24;q11). A second tumor, a small non-cleaved cell lymphoma, demonstrated a t(8;14)(q24;q11) as well as t(18;22)(q21;q11). DNA analysis from these tumors showed rearrangements at the Ig heavy chain, kappa and lambda light chains, BCL2 and c-MYC loci. Utilizing multiple enzyme digests and different probes spanning the BCL2, c-MYC and Ig genes, mapping of DNA break-points was performed. In both these tumors primary translocation events dysregulating the BCL2 or c-MYC were identified to have occurred in a pre-B-cell. Based on these results and those published previously, a sequence of B-cell development during which somatic recombination errors lead to the genesis of specific translocations is proposed. From these studies it is inferred that secondary dysregulation of a c-MYC in a lymphoma tumor carrying dysregulated BCL2 gene leads to rapid progression to high grade disease.	MEM SLOAN KETTERING CANC CTR, CANC GENET & CYTOGENET LAB, NEW YORK, NY 10021 USA; CORNELL UNIV, N SHORE UNIV HOSP, COLL MED, SPECIAL CYTOGENET LAB, MANHASSET, NY 11030 USA; MEM SLOAN KETTERING CANC CTR, DEPT MED, LYMPHOMA SERV, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University; Northwell Health; North Shore University Hospital; Memorial Sloan Kettering Cancer Center					NCI NIH HHS [CA 34775] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034775] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADACHI M, 1989, P NATL ACAD SCI USA, V86, P2771, DOI 10.1073/pnas.86.8.2771; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; BAKSHI A, 1985, CELL, V41, P889; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CROCE CM, 1983, P NATL ACAD SCI-BIOL, V80, P6922, DOI 10.1073/pnas.80.22.6922; DEJONG D, 1988, NEW ENGL J MED, V318, P1373, DOI 10.1056/NEJM198805263182106; GAUWERKY CE, 1988, P NATL ACAD SCI USA, V85, P8548, DOI 10.1073/pnas.85.22.8548; GRANINGER WB, 1987, J CLIN INVEST, V80, P1512, DOI 10.1172/JCI113235; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HIETER PA, 1981, NATURE, V294, P536, DOI 10.1038/294536a0; HIETER PA, 1981, NATURE, V290, P368, DOI 10.1038/290368a0; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LEE JT, 1989, J CLIN INVEST, V84, P1454, DOI 10.1172/JCI114320; MAGRATH I, 1983, SCIENCE, V222, P1094, DOI 10.1126/science.6316501; MCDONNELL TJ, 1989, CELL, V57, P79, DOI 10.1016/0092-8674(89)90174-8; MUFTI GJ, 1983, BLOOD, V62, P1142; NERI A, 1988, P NATL ACAD SCI USA, V85, P2748, DOI 10.1073/pnas.85.8.2748; PEGORARO L, 1984, P NATL ACAD SCI-BIOL, V81, P7166, DOI 10.1073/pnas.81.22.7166; PELICCI PG, 1986, P NATL ACAD SCI USA, V83, P2984, DOI 10.1073/pnas.83.9.2984; RAVETCH JV, 1981, CELL, V27, P583, DOI 10.1016/0092-8674(81)90400-1; REED JC, 1987, SCIENCE, V236, P1295, DOI 10.1126/science.3495884; RICHARDSON ME, 1987, BLOOD, V70, P444; SEIDMAN JG, 1978, NATURE, V276, P790, DOI 10.1038/276790a0; SHOWE LC, 1987, P NATL ACAD SCI USA, V84, P2824, DOI 10.1073/pnas.84.9.2824; TSUJIMOTO Y, 1987, P NATL ACAD SCI USA, V84, P1329, DOI 10.1073/pnas.84.5.1329; TSUJIMOTO Y, 1989, P NATL ACAD SCI USA, V86, P1958, DOI 10.1073/pnas.86.6.1958; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; YUNIS JJ, 1987, NEW ENGL J MED, V316, P79, DOI 10.1056/NEJM198701083160204	32	11	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	1991	6	1					145	148						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1992441				2022-12-17	WOS:A1991EY03900020
J	ALBAGDADI, F; SINGH, B; ARLINGHAUS, RB				ALBAGDADI, F; SINGH, B; ARLINGHAUS, RB			EVIDENCE FOR INVOLVEMENT OF THE PROTEIN-KINASE-C PATHWAY IN THE ACTIVATION OF P37V-MOS PROTEIN-KINASE	ONCOGENE			English	Article									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DEPT MOLEC PATHOL,1515 HOLCOMBE BLVD,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center					NCI NIH HHS [CA16672, CA45125] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA045125, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1989, BIOCHEM J, V257, P905, DOI 10.1042/bj2570905; ARLINGHAUS RB, 1985, J GEN VIROL, V66, P1845, DOI 10.1099/0022-1317-66-9-1845; BARRETT CB, 1990, MOL CELL BIOL, V10, P310, DOI 10.1128/MCB.10.1.310; BOLD RJ, 1985, MOL CELL BIOL, V5, P3131, DOI 10.1128/MCB.5.11.3131; DONOGHUE DJ, 1982, P NATL ACAD SCI-BIOL, V79, P800, DOI 10.1073/pnas.79.3.800; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; FINIDORILEPICARD J, 1981, NATURE, V292, P255, DOI 10.1038/292255a0; FREEMAN RS, 1989, P NATL ACAD SCI USA, V86, P5805, DOI 10.1073/pnas.86.15.5805; GALLICK G, 1984, MODERN APPROACHES VA, V6, P407; GALLICK GE, 1984, VIROLOGY, V139, P366, DOI 10.1016/0042-6822(84)90382-9; GALLICK GE, 1985, J GEN VIROL, V66, P945, DOI 10.1099/0022-1317-66-5-945; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; HAMILTON BJ, 1989, P NATL ACAD SCI USA, V86, P597, DOI 10.1073/pnas.86.2.597; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANNINK M, 1985, P NATL ACAD SCI USA, V82, P7894, DOI 10.1073/pnas.82.23.7894; HERZOG NK, 1989, ONCOGENE, V4, P1307; HERZOG NK, 1988, ONCOGENE, V3, P225; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; INAGAKI M, 1984, J BIOL CHEM, V259, P4321; KAWAMOTO S, 1984, BIOCHEM BIOPH RES CO, V125, P258, DOI 10.1016/S0006-291X(84)80362-9; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KLOETZER WS, 1984, VIROLOGY, V138, P143, DOI 10.1016/0042-6822(84)90154-5; KLOETZER WS, 1983, P NATL ACAD SCI-BIOL, V80, P412, DOI 10.1073/pnas.80.2.412; LACAL JC, 1987, SCIENCE, V238, P533, DOI 10.1126/science.2821623; LEE M, 1988, TRENDS GENET, V4, P287, DOI 10.1016/0168-9525(88)90171-0; LIU JX, 1990, ONCOGENE, V5, P171; MALLER JL, 1979, J BIOL CHEM, V254, P579; MAXWELL SA, 1985, J GEN VIROL, V66, P2135, DOI 10.1099/0022-1317-66-10-2135; MAXWELL SA, 1985, VIROLOGY, V143, P321, DOI 10.1016/0042-6822(85)90119-9; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OGISO Y, 1988, BIOCHEM BIOPH RES CO, V154, P339, DOI 10.1016/0006-291X(88)90690-0; OKEEFE SJ, 1989, P NATL ACAD SCI USA, V86, P7038, DOI 10.1073/pnas.86.18.7038; PAPKOFF J, 1983, CELL, V33, P161, DOI 10.1016/0092-8674(83)90345-8; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PAULES RS, 1989, P NATL ACAD SCI USA, V86, P5395, DOI 10.1073/pnas.86.14.5395; ROY LM, 1990, IN PRESS CELL; SADLER SE, 1989, J BIOL CHEM, V264, P856; SAGATA N, 1989, NATURE, V342, P512, DOI 10.1038/342512a0; SAGATA N, 1989, SCIENCE, V245, P643, DOI 10.1126/science.2474853; SAGATA N, 1988, NATURE, V335, P519, DOI 10.1038/335519a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SETH A, 1985, J VIROL, V56, P144, DOI 10.1128/JVI.56.1.144-152.1985; SINGH B, 1988, ONCOGENE, V3, P79; SINGH B, 1987, J VIROL, V61, P3625, DOI 10.1128/JVI.61.11.3625-3629.1987; SINGH B, 1986, J VIROL, V60, P1148, DOI 10.1128/JVI.60.3.1148-1152.1986; SINGH B, 1989, VIROLOGY, V173, P144, DOI 10.1016/0042-6822(89)90230-4; SINGH B, 1988, VIROLOGY, V164, P114, DOI 10.1016/0042-6822(88)90626-5; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STITH BJ, 1987, EXP CELL RES, V169, P514, DOI 10.1016/0014-4827(87)90211-4; VANBEVEREN C, 1981, CELL, V27, P97, DOI 10.1016/0092-8674(81)90364-0; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5	54	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1251	1257						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2168030				2022-12-17	WOS:A1990DX36100020
J	HORI, Y; KAIBUCHI, K; FUKUMOTO, Y; OKU, N; TAKAI, Y				HORI, Y; KAIBUCHI, K; FUKUMOTO, Y; OKU, N; TAKAI, Y			ACTIVATION OF THE SERUM-RESPONSE AND TPA-RESPONSE ELEMENTS BY EXPRESSION OF THE V-ABL PROTEIN - COMPARISON OF THE MODE OF ACTION OF THE V-ABL PROTEIN WITH THOSE OF PROTEIN-KINASE-C, CYCLIC AMP-DEPENDENT PROTEIN-KINASE, AND THE ACTIVATED C-RAF PROTEIN	ONCOGENE			English	Article									KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University					NATIONAL CANCER INSTITUTE [R01CA014054] Funding Source: NIH RePORTER; NCI NIH HHS [5RO1CA14054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COOK WD, 1987, MOL CELL BIOL, V7, P2631, DOI 10.1128/MCB.7.7.2631; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DAVIS RL, 1985, MOL CELL BIOL, V5, P204, DOI 10.1128/MCB.5.1.204; DESCHAMPS J, 1985, SCIENCE, V230, P1174, DOI 10.1126/science.3865371; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GOFF SP, 1980, CELL, V22, P777, DOI 10.1016/0092-8674(80)90554-1; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HUNTER T, 1984, NATURE, V311, P414, DOI 10.1038/311414a0; JAKEN S, 1981, CANCER RES, V41, P2175; KAIBUCHI K, 1989, J BIOL CHEM, V264, P20855; KAIBUCHI K, 1986, J BIOL CHEM, V261, P1187; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MITSUNOBU F, 1989, ONCOGENE, V4, P437; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; OLIFF A, 1985, P NATL ACAD SCI USA, V82, P3306, DOI 10.1073/pnas.82.10.3306; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P3623, DOI 10.1073/pnas.80.12.3623; REESJONES RW, 1989, MOL CELL BIOL, V9, P278, DOI 10.1128/MCB.9.1.278; ROHRSCHNEIDER LR, 1984, J VIROL, V551, P547; ROSENBERG N, 1975, P NATL ACAD SCI USA, V72, P1932, DOI 10.1073/pnas.72.5.1932; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SCHER CD, 1975, NATURE, V253, P729, DOI 10.1038/253729a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; SRINIVASAN A, 1981, P NATL ACAD SCI-BIOL, V78, P2077, DOI 10.1073/pnas.78.4.2077; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; TSUDA T, 1986, FEBS LETT, V208, P39, DOI 10.1016/0014-5793(86)81527-7; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; Wang J Y, 1983, Prog Clin Biol Res, V119, P57; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YAMAMOTO KK, 1988, NATURE, V334, P4914	50	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1201	1206						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2118245				2022-12-17	WOS:A1990DX36100013
J	TAMURA, T; SIMON, E; GESCHWILL, K; NIEMANN, H				TAMURA, T; SIMON, E; GESCHWILL, K; NIEMANN, H			CDC2/PP56-62 ARE INVITRO SUBSTRATES FOR THE TYROSINE KINASE ENCODED BY THE V-FMS ONCOGENE	ONCOGENE			English	Note									PHARMACIA LKB,W-7800 FREIBURG,GERMANY; BFA,INST MIKROBIOL,W-7400 TUBINGEN,GERMANY		TAMURA, T (corresponding author), UNIV GIESSEN,INST VIROL,FRANKFURTER STR 107,W-6300 GIESSEN,GERMANY.							BAILLY E, 1989, EMBO J, V8, P3985, DOI 10.1002/j.1460-2075.1989.tb08581.x; BARBACID M, 1981, J VIROL, V40, P812, DOI 10.1128/JVI.40.3.812-821.1981; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HADWIGER A, 1986, EMBO J, V5, P689, DOI 10.1002/j.1460-2075.1986.tb04268.x; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; LANGAN TA, 1980, PROTEIN PHOSPHORYLAT, P1; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; MORRISON DK, 1988, MOL CELL BIOL, V8, P176, DOI 10.1128/MCB.8.1.176; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; REYNOLDS FH, 1981, J VIROL, V38, P1084, DOI 10.1128/JVI.38.3.1084-1089.1981; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICHERT ND, 1982, J BIOL CHEM, V257, P7143; ROUSSEL MF, 1987, NATURE, V325, P549, DOI 10.1038/325549a0; SCHMITZ M, 1986, VIROLOGY, V148, P23, DOI 10.1016/0042-6822(86)90400-9; SHENOY S, 1989, CELL, V57, P763, DOI 10.1016/0092-8674(89)90791-5; SHERR CJ, 1985, CELL, V41, P665, DOI 10.1016/S0092-8674(85)80047-7; TAMURA T, 1989, J CANCER RES CLIN, V115, P235, DOI 10.1007/BF00391695; TAMURA T, 1983, CELL, V34, P587, DOI 10.1016/0092-8674(83)90391-4; TAMURA T, 1984, FEBS LETT, V177, P151, DOI 10.1016/0014-5793(84)81001-7; TAMURA T, 1988, J VIROL, V62, P2150, DOI 10.1128/JVI.62.6.2150-2157.1988; TAMURA T, 1986, MOL CELL BIOL, V6, P4745, DOI 10.1128/MCB.6.12.4745	28	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1990	5	8					1259	1263						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DX361	2118246				2022-12-17	WOS:A1990DX36100021
J	SCHUURING, E; VANDERLEEDE, BJ; WILLEMS, R; DAAMS, H; VANDERVALK, M; VANDEVIJVER, M; VANLEEUWEN, F; SONNENBERG, A; NUSSE, R				SCHUURING, E; VANDERLEEDE, BJ; WILLEMS, R; DAAMS, H; VANDERVALK, M; VANDEVIJVER, M; VANLEEUWEN, F; SONNENBERG, A; NUSSE, R			DIFFERENTIATION-DEPENDENT EXPRESSION OF PROVIRUS-ACTIVATED INT-1 ONCOGENE IN CLONAL CELL-LINES DERIVED FROM A MOUSE MAMMARY-TUMOR	ONCOGENE			English	Article									NETHERLANDS CANC INST,ANTONI VANLEEUWENHOEKHUIS,DIV MOLEC BIOL,PLESMANLAAN 121,1066 CX AMSTERDAM,NETHERLANDS; NETHERLANDS CANC INST,ANTONIO VANLEEUWENHOEKHUIS,DEPT TUMOR BIOL,1066 CX AMSTERDAM,NETHERLANDS; NETHERLANDS CANC INST,ANTONIO VANLEEUWENHOEKHUIS,DEPT MOLEC GENET,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute; Netherlands Cancer Institute; Netherlands Cancer Institute			van Leeuwen, Frank/AAQ-6799-2020; Willems, Rob JL/E-3681-2010	van Leeuwen, Frank/0000-0003-1107-6513; Willems, Rob JL/0000-0002-7370-0812				BENNETT DC, 1978, CELL, V15, P283, DOI 10.1016/0092-8674(78)90104-6; BROWN AMC, 1987, MOL CELL BIOL, V7, P3971, DOI 10.1128/MCB.7.11.3971; BROWN AMC, 1986, CELL, V46, P1001, DOI 10.1016/0092-8674(86)90699-9; DEXTER DL, 1978, CANCER RES, V38, P3174; DULBECCO R, 1981, P NATL ACAD SCI-BIOL, V78, P2345, DOI 10.1073/pnas.78.4.2345; DUNNINGTON DJ, 1983, J NATL CANCER I, V71, P1227; FUNG YKT, 1985, MOL CELL BIOL, V5, P3337, DOI 10.1128/MCB.5.12.3337; HAGER JC, 1981, CANCER RES, V41, P1720; JAKOBOVITS A, 1986, P NATL ACAD SCI USA, V83, P7806, DOI 10.1073/pnas.83.20.7806; Maniatis T., 1982, MOL CLONING; NUSSE R, 1986, TRENDS GENET, V2, P244, DOI 10.1016/0168-9525(86)90247-7; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; PAPKOFF J, 1989, MOL CELL BIOL, V9, P3377, DOI 10.1128/MCB.9.8.3377; PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978; PARRY G, 1987, J CELL BIOL, V105, P2043, DOI 10.1083/jcb.105.5.2043; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RIJSEWIJK FAM, 1986, NUCLEIC ACIDS RES, V14, P693, DOI 10.1093/nar/14.2.693; ROOP DR, 1985, ANN NY ACAD SCI, V455, P426, DOI 10.1111/j.1749-6632.1985.tb50426.x; ROSS SR, 1985, P NATL ACAD SCI USA, V82, P5880, DOI 10.1073/pnas.82.17.5880; RUDLAND PS, 1980, CONTROL MECHANISMS A, P341; SCHUURING E, 1989, MOL CELL BIOL, V9, P1357, DOI 10.1128/MCB.9.3.1357; SHACKLEFORD GM, 1987, CELL, V50, P89, DOI 10.1016/0092-8674(87)90665-9; SONNENBERG A, 1986, J HISTOCHEM CYTOCHEM, V34, P1037, DOI 10.1177/34.8.2426332; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; SONNENBERG A, 1986, CANCER RES, V46, P5913; SOULE HD, 1981, CANCER RES, V41, P1154; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANOOYEN A, 1984, CELL, V39, P233, DOI 10.1016/0092-8674(84)90209-5; WHITEHEAD RH, 1983, J NATL CANCER I, V71, P1193; WILKINSON DG, 1987, CELL, V50, P79, DOI 10.1016/0092-8674(87)90664-7; YANG J, 1983, INT REV CYTOL, V81, P249, DOI 10.1016/S0074-7696(08)62340-2	33	11	11	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1990	5	4					459	465						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DB853	2326076				2022-12-17	WOS:A1990DB85300002
J	CATO, ACB; MINK, S; NIERLICH, B; PONTA, H; SCHAAP, D; SCHUURING, E; SONNENBERG, A				CATO, ACB; MINK, S; NIERLICH, B; PONTA, H; SCHAAP, D; SCHUURING, E; SONNENBERG, A			TRANSFORMING GROWTH FACTOR-BETA REPRESSES TRANSCRIPTION OF THE MOUSE MAMMARY-TUMOR VIRUS-DNA IN CULTURED MOUSE MAMMARY CELLS	ONCOGENE			English	Article									NETHERLANDS CANC INST,DEPT TUMOUR BIOL,1066 CX AMSTERDAM,NETHERLANDS	Netherlands Cancer Institute	CATO, ACB (corresponding author), KERNFORSCHUNGSZENTRUM KARLSRUHE GMBH,INST GENET & TOXIKOL,POSTFACH 3640,W-7500 KARLSRUHE 1,GERMANY.		Cato, Andrew C. B./H-2071-2013	Cato, Andrew C. B./0000-0001-8508-3834				AFFRAY C, 1980, EUR J BIOCHEM, V107, P303; ANZANO MA, 1985, MOL CELL BIOL, V5, P242, DOI 10.1128/MCB.5.1.242; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CATO ACB, 1986, EMBO J, V5, P2237, DOI 10.1002/j.1460-2075.1986.tb04490.x; CIARDIELLO F, 1988, MOL ENDOCRINOL, V2, P1202, DOI 10.1210/mend-2-12-1202; DERYNCK R, 1986, J BIOL CHEM, V261, P4377; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DICKSON RB, 1987, P NATL ACAD SCI USA, V84, P837, DOI 10.1073/pnas.84.3.837; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUSTIN AS, 1986, CANCER RES, V46, P1015; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HYNES N, 1983, P NATL ACAD SCI-BIOL, V80, P3637, DOI 10.1073/pnas.80.12.3637; HYNES NE, 1984, ADV CANCER RES, V41, P155, DOI 10.1016/S0065-230X(08)60016-0; JAGGI R, 1986, EMBO J, V5, P2609, DOI 10.1002/j.1460-2075.1986.tb04541.x; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; MASON AJ, 1985, NATURE, V318, P659, DOI 10.1038/318659a0; Morris D. W., 1987, ADV VIRAL ONCOL, V7, P123; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; NUSSE R, 1988, PROGR CANCER RES THE, V35, P97; OTT MO, 1984, EMBO J, V3, P2505, DOI 10.1002/j.1460-2075.1984.tb02164.x; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PETERS G, 1986, NATURE, V320, P628, DOI 10.1038/320628a0; RIJSEWIJK F, 1987, EMBO J, V6, P127, DOI 10.1002/j.1460-2075.1987.tb04729.x; RINGOLD G, 1975, VIROLOGY, V65, P135, DOI 10.1016/0042-6822(75)90014-8; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; SHIH C, 1982, CELL, V29, P161, DOI 10.1016/0092-8674(82)90100-3; SOLOMON DS, 1984, CANCER RES, V44, P4069; SONNENBERG A, 1987, EMBO J, V6, P121, DOI 10.1002/j.1460-2075.1987.tb04728.x; SONNENBERG A, 1986, CANCER RES, V46, P5913; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; WEAVER RF, 1979, NUCLEIC ACIDS RES, V7, P1175, DOI 10.1093/nar/7.5.1175; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; ZWIEBEL JA, 1982, CANCER RES, V42, P5117	39	11	12	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					103	110						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2157176				2022-12-17	WOS:A1990CM62000014
J	MOSCINSKI, LC; PRYSTOWSKY, MB				MOSCINSKI, LC; PRYSTOWSKY, MB			IDENTIFICATION OF A SERIES OF DIFFERENTIATION-ASSOCIATED GENE-SEQUENCES FROM GM-CSF STIMULATED BONE-MARROW	ONCOGENE			English	Article									UNIV PENN,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104	University of Pennsylvania					NATIONAL CANCER INSTITUTE [R01CA048648] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U41RR001685] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA01940-13, CA-48648] Funding Source: Medline; NCRR NIH HHS [P41RR01685] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BIRNIE GD, 1984, J ROY SOC MED, V77, P289, DOI 10.1177/014107688407700407; BROXMEYER HE, 1987, BLOOD CELLS, V13, P31; BURGESS AW, 1977, J BIOL CHEM, V252, P1998; CEROTTINI JC, 1974, J EXP MED, V140, P703, DOI 10.1084/jem.140.3.703; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CRAMER E, 1985, BLOOD, V65, P423; DELFORGE A, 1985, ANN NY ACAD SCI, V459, P85, DOI 10.1111/j.1749-6632.1985.tb20818.x; FOURET P, 1989, J EXP MED, V169, P833, DOI 10.1084/jem.169.3.833; GONDO H, 1987, J IMMUNOL, V139, P3840; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; Ihle J N, 1985, Prog Clin Biol Res, V184, P85; JAFFE BD, 1988, ONCOGENE, V2, P167; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MEAD DA, 1985, NUCLEIC ACIDS RES, V13, P1103, DOI 10.1093/nar/13.4.1103; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1986, J CELL PHYSIOL, V128, P421, DOI 10.1002/jcp.1041280311; METCALF D, 1986, BLOOD, V67, P257; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PENTECOST BT, 1987, J BIOL CHEM, V262, P8759; PRYSTOWSKY MB, 1983, EXP HEMATOL, V11, P931; RADO TA, 1987, BLOOD, V70, P989; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPANGELO BL, 1987, ANN NY ACAD SCI, V496, P196, DOI 10.1111/j.1749-6632.1987.tb35766.x; SYMONDS G, 1983, EMBO J, V2, P663, DOI 10.1002/j.1460-2075.1983.tb01481.x; WODNARFILIPOWICZ A, 1984, P NATL ACAD SCI-BIOL, V81, P2295, DOI 10.1073/pnas.81.8.2295; YMER S, 1985, NATURE, V317, P255, DOI 10.1038/317255a0	31	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1990	5	1					31	37						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CM620	2181376				2022-12-17	WOS:A1990CM62000005
J	GHANTA, VK; HIRAMOTO, RN; PARKER, CA; KIDD, VJ; HUMPHREYSBEHER, MG				GHANTA, VK; HIRAMOTO, RN; PARKER, CA; KIDD, VJ; HUMPHREYSBEHER, MG			INVITRO AND INVIVO GROWTH-CONTROL OF TRANSFORMED LYMPHOID-CELLS EXPRESSING PLASMA-MEMBRANE GALACTOSYLTRANSFERASE	ONCOGENE			English	Article									UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT ORAL BIOL,BOX J-424,GAINESVILLE,FL 32610; UNIV ALABAMA,DEPT CELL BIOL & ANAT,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT MICROBIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,DEPT BIOL,BIRMINGHAM,AL 35294; UNIV ALABAMA,CTR COMPREHENS CANC,BIRMINGHAM,AL 35294	State University System of Florida; University of Florida; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NCI NIH HHS [CA-42337] Funding Source: Medline; NIDCR NIH HHS [DE-08778] Funding Source: Medline; NIDDK NIH HHS [DK-36973] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042337] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008778] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036973] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUER CH, 1977, CANCER RES, V37, P1513; BAYNA EM, 1988, CELL, V53, P145, DOI 10.1016/0092-8674(88)90496-5; BERNACKI RJ, 1977, SCIENCE, V195, P577, DOI 10.1126/science.835014; BOSMANN HB, 1974, FEBS LETT, V44, P313, DOI 10.1016/0014-5793(74)81166-X; CACCAM JF, 1970, ARCH BIOCHEM BIOPHYS, V137, P315, DOI 10.1016/0003-9861(70)90445-5; CAPEL ID, 1982, ONCOLOGY, V39, P193, DOI 10.1159/000225635; CHATTERJEE SK, 1979, CANCER RES, V39, P1943; CHATTERJEE SK, 1978, BIOCHEM BIOPH RES CO, V80, P826, DOI 10.1016/0006-291X(78)91319-0; COLLARD JG, 1985, INT J CANCER, V35, P207, DOI 10.1002/ijc.2910350211; DAVEY R, 1986, BRIT J CANCER, V53, P211, DOI 10.1038/bjc.1986.37; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; Fleischer S, 1974, Methods Enzymol, V31, P3; GARVIN AM, 1988, MOL CELL BIOL, V8, P3058, DOI 10.1128/MCB.8.8.3058; GMEINER B, 1985, CANCER BIOCHEM BIOPH, V10, P103; GRIMES WJ, 1973, BIOCHEMISTRY-US, V12, P990, DOI 10.1021/bi00729a031; HUMPHREYSBEHER MG, 1987, J BIOL CHEM, V262, P11706; HUMPHREYSBEHER MG, 1984, J BIOL CHEM, V259, P5797; IP C, 1977, CANCER RES, V37, P3442; JENTOFT N, 1976, GLYCOSLYTRANSFERASES, V2, P343; KESSEL D, 1977, J NATL CANCER I, V59, P29, DOI 10.1093/jnci/59.1.29; KIM YS, 1972, J CLIN INVEST, V51, P2033, DOI 10.1172/JCI107009; KLOHS WD, 1982, EXP CELL RES, V141, P365, DOI 10.1016/0014-4827(82)90225-7; KLOHS WD, 1981, CANCER RES, V41, P2611; MARCHASE RB, 1988, J CELL BIOCHEM, V36, P453, DOI 10.1002/jcb.240360413; PAONE JF, 1980, J SURG ONCOL, V15, P56; PARMIANI G, 1982, INT J CANCER, V29, P323, DOI 10.1002/ijc.2910290316; PATT LM, 1975, CANCER RES, V35, P438; PIERCE M, 1980, INT REV CYTOLOGY; PODOLSKY DK, 1978, NEW ENGL J MED, V299, P703, DOI 10.1056/NEJM197809282991306; PODOLSKY DK, 1984, P NATL ACAD SCI-BIOL, V81, P2529, DOI 10.1073/pnas.81.8.2529; PODOLSKY DK, 1975, BIOCHEM BIOPH RES CO, V65, P545, DOI 10.1016/S0006-291X(75)80181-1; PODOLSKY DK, 1979, J BIOL CHEM, V254, P3983; POTTER M, 1972, PHYSIOL REV, V52, P631, DOI 10.1152/physrev.1972.52.3.631; ROTH S, 1971, J CELL BIOL, V51, P536, DOI 10.1083/jcb.51.2.536; ROTH S, 1977, CELL SURFACE GLYCOSY, P245; SANTER UV, 1979, BIOCHEMISTRY-US, V18, P2533, DOI 10.1021/bi00579a016; SHUR BD, 1984, MOL CELL BIOCHEM, V61, P143; SHUR BD, 1979, DEV BIOL, V71, P243, DOI 10.1016/0012-1606(79)90167-2; UEMURA M, 1988, CANCER RES, V48, P5335; UEMURA M, 1988, CANCER RES, V48, P5325; VOLLER A, 1978, J CLIN PATHOL, V31, P507, DOI 10.1136/jcp.31.6.507; WARREN L, 1978, BIOCHIM BIOPHYS ACTA, V516, P97, DOI 10.1016/0304-419X(78)90005-7; WARREN L, 1959, J BIOL CHEM, V234, P1971; WEISER MM, 1981, CRC CR REV CL LAB SC, V14, P189, DOI 10.3109/10408368109105864; WIDNELL CC, 1968, P NATL ACAD SCI USA, V61, P1050, DOI 10.1073/pnas.61.3.1050	45	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	NOV	1989	4	11					1337	1344						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AX659	2510114				2022-12-17	WOS:A1989AX65900010
J	SCHARTL, M; HOLSTEIN, T; ROBERTSON, SM; BARNEKOW, A				SCHARTL, M; HOLSTEIN, T; ROBERTSON, SM; BARNEKOW, A			PREFERENTIAL EXPRESSION OF A PP60C-SRC RELATED PROTEIN TYROSINE KINASE-ACTIVITY IN NERVE-CELLS OF THE EARLY METAZOAN HYDRA (COELENTERATES)	ONCOGENE			English	Article									INST MED VIROL,D-6300 GIESSEN,FED REP GER; ZOOL INST,D-8000 MUNICH 2,FED REP GER		SCHARTL, M (corresponding author), MAX PLANCK INST BIOCHEM,CTR GENE,KLOPFERSPITZ 18A,D-8033 MARTINSRIED,FED REP GER.			Holstein, Thomas/0000-0003-0480-4674; Schartl, Manfred/0000-0001-9882-5948				ANDERS F, 1984, ADV CANCER RES, V42, P191, DOI 10.1016/S0065-230X(08)60459-5; ANDERSON SK, 1985, MOL CELL BIOL, V5, P1122, DOI 10.1128/MCB.5.5.1122; BARNEKOW A, 1986, DIFFERENTIATION, V33, P29, DOI 10.1111/j.1432-0436.1986.tb00407.x; BARNEKOW A, 1984, MOL CELL BIOL, V4, P1179, DOI 10.1128/MCB.4.6.1179; BARNEKOW A, 1987, COMP BIOCHEM PHYS B, V87, P663, DOI 10.1016/0305-0491(87)90371-3; BARNEKOW A, 1986, EMBO J, V5, P701, DOI 10.1002/j.1460-2075.1986.tb04270.x; BARNEKOW A, 1984, BIOCHIM BIOPHYS ACTA, V782, P94, DOI 10.1016/0167-4781(84)90110-6; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BODE HR, 1978, PROG BIOPHYS MOL BIO, V33, P189; BRUGGE J, 1987, GENE DEV, V1, P287, DOI 10.1101/gad.1.3.287; BRUGGE JS, 1985, NATURE, V316, P554, DOI 10.1038/316554a0; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; CARTWRIGHT CA, 1987, MOL CELL BIOL, V7, P1830, DOI 10.1128/MCB.7.5.1830; COLLETT MS, 1978, P NATL ACAD SCI USA, V75, P2021, DOI 10.1073/pnas.75.4.2021; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; DAVID CN, 1974, J CELL SCI, V16, P359; DAVID CN, 1974, AM ZOOL, V14, P537; DAVID CN, 1986, GENETIC REGULATION D, P389; DELORBE WJ, 1980, J VIROL, V36, P50, DOI 10.1128/JVI.36.1.50-61.1980; DUNNE JF, 1985, DEV BIOL, V109, P41, DOI 10.1016/0012-1606(85)90344-6; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FULTS DW, 1985, MOL CELL BIOL, V5, P27, DOI 10.1128/MCB.5.1.27; GEE CE, 1986, P NATL ACAD SCI USA, V83, P5131, DOI 10.1073/pnas.83.14.5131; GESSLER M, 1984, BIOSCIENCE REP, V4, P757, DOI 10.1007/BF01128817; GIERER A, 1972, NATURE-NEW BIOL, V239, P98, DOI 10.1038/newbio239098a0; GOLDEN A, 1986, P NATL ACAD SCI USA, V83, P852, DOI 10.1073/pnas.83.4.852; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; HOFFMANFALK H, 1983, CELL, V32, P589, DOI 10.1016/0092-8674(83)90478-6; HOLSTEIN T, 1986, DEV BIOL, V115, P9, DOI 10.1016/0012-1606(86)90222-8; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.bi.54.070185.004341; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; LEBEAU JM, 1987, MOL CELL BIOL, V7, P4115, DOI 10.1128/MCB.7.11.4115; LEVY BT, 1984, DEV BIOL, V104, P9, DOI 10.1016/0012-1606(84)90031-9; LEVY JB, 1987, MOL CELL BIOL, V7, P4142, DOI 10.1128/MCB.7.11.4142; LOOMIS WF, 1956, J EXP ZOOL, V132, P555, DOI 10.1002/jez.1401320309; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; MANESS PF, 1986, J NEUROSCI RES, V16, P127, DOI 10.1002/jnr.490160113; Marcum B.A., 1980, P429; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MAUELER W, 1988, ONCOGENE, V2, P421; RAULF F, 1989, IN PRESS J NEUROSCI; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; SCHALLER HC, 1981, P NATL ACAD SCI-BIOL, V78, P7000, DOI 10.1073/pnas.78.11.7000; SCHARTL M, 1982, DIFFERENTIATION, V23, P109, DOI 10.1111/j.1432-0436.1982.tb01273.x; SCHARTL M, 1984, DEV BIOL, V105, P415, DOI 10.1016/0012-1606(84)90298-7; SCHMIDT T, 1986, J CELL SCI, V85, P197; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; SORGE LK, 1984, CELL, V36, P249, DOI 10.1016/0092-8674(84)90218-6; STEHELIN D, 1976, NATURE, V260, P170, DOI 10.1038/260170a0; SUGIYAMA T, 1978, J CELL SCI, V29, P35; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TERADA H, 1988, DEV BIOL, V126, P263, DOI 10.1016/0012-1606(88)90137-6; VANGRIMMELIKHUI.CG, 1982, HISTOCHEMISTRY, V73, P499; VARDIMON L, 1986, MOL CELL BIOL, V6, P4109, DOI 10.1128/MCB.6.11.4109; WALAAS SI, 1988, MOL BRAIN RES, V3, P215, DOI 10.1016/0169-328X(88)90044-7; WESTFALL JA, 1973, J ULTRA MOL STRUCT R, V42, P268, DOI 10.1016/S0022-5320(73)90055-5; ZIEMIECKI A, 1980, J GEN VIROL, V50, P211, DOI 10.1099/0022-1317-50-1-211	59	11	11	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	OCT	1989	4	10					1185	1191						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AU508	2477783				2022-12-17	WOS:A1989AU50800004
J	PARKIN, NT; SONENBERG, N				PARKIN, NT; SONENBERG, N			IDENTIFICATION OF A PROTEIN THAT BINDS SPECIFICALLY TO RNA FROM THE 1ST EXON OF C-MYC	ONCOGENE			English	Article									MCGILL UNIV,DEPT BIOCHEM,3655 DRUMMOND ST,MONTREAL H3G 1Y6,QUEBEC,CANADA; MCGILL UNIV,MCGILL CANC CTR,MONTREAL H3G 1Y6,QUEBEC,CANADA	McGill University; McGill University			Parkin, Neil/P-2724-2019					ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BENTLEY DL, 1988, CELL, V53, P245, DOI 10.1016/0092-8674(88)90386-8; BENTLEY DL, 1986, MOL CELL BIOL, V6, P3481, DOI 10.1128/MCB.6.10.3481; BERNARD O, 1983, EMBO J, V2, P2375, DOI 10.1002/j.1460-2075.1983.tb01749.x; BROOME HE, 1987, MOL CELL BIOL, V7, P2988, DOI 10.1128/MCB.7.8.2988; BUTNICK NZ, 1985, MOL CELL BIOL, V5, P3009, DOI 10.1128/MCB.5.11.3009; CESARMAN E, 1987, SCIENCE, V238, P1272, DOI 10.1126/science.3685977; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHUNG J, 1986, P NATL ACAD SCI USA, V83, P7918, DOI 10.1073/pnas.83.20.7918; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; CORCORAN LM, 1985, CELL, V40, P71, DOI 10.1016/0092-8674(85)90310-1; CORY S, 1986, ADV CANCER RES, V47, P189, DOI 10.1016/S0065-230X(08)60200-6; DARVEAU A, 1985, P NATL ACAD SCI USA, V82, P2315, DOI 10.1073/pnas.82.8.2315; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EISENMAN RN, 1985, MOL CELL BIOL, V5, P114, DOI 10.1128/MCB.5.1.114; ERIKSON J, 1985, P NATL ACAD SCI USA, V82, P4212, DOI 10.1073/pnas.82.12.4212; FAHRLANDER PD, 1985, P NATL ACAD SCI USA, V82, P3746, DOI 10.1073/pnas.82.11.3746; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; HANN SR, 1988, CELL, V52, P185, DOI 10.1016/0092-8674(88)90507-7; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; HAY N, 1987, GENE DEV, V1, P659, DOI 10.1101/gad.1.7.659; HAYASHI K, 1987, NUCLEIC ACIDS RES, V15, P6419, DOI 10.1093/nar/15.16.6419; HOLT JT, 1988, MOL CELL BIOL, V8, P963, DOI 10.1128/MCB.8.2.963; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; IGUCHIARIGA SMM, 1988, EMBO J, V7, P3135, DOI 10.1002/j.1460-2075.1988.tb03180.x; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KAKKIS E, 1987, P NATL ACAD SCI USA, V84, P7031, DOI 10.1073/pnas.84.20.7031; KELLY K, 1988, J BIOL CHEM, V263, P4828; KERPPOLA TK, 1988, MOL CELL BIOL, V8, P4389, DOI 10.1128/MCB.8.10.4389; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373, DOI 10.1128/MCB.8.8.3373; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAND H, 1986, MOL CELL BIOL, V6, P1917, DOI 10.1128/MCB.6.6.1917; LAZARUS P, 1988, ONCOGENE, V3, P517; LEDER P, 1983, SCIENCE, V222, P765, DOI 10.1126/science.6356357; LINDSTEN T, 1988, EMBO J, V7, P2787, DOI 10.1002/j.1460-2075.1988.tb03133.x; LIPP M, 1987, MOL CELL BIOL, V7, P1393, DOI 10.1128/MCB.7.4.1393; Maniatis T., 1982, MOL CLONING; MANLEY JL, 1984, TRANSCRIPTION TRANSL, P71; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; NEPVEU A, 1987, GENE DEV, V1, P938, DOI 10.1101/gad.1.9.938; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NILSEN TW, 1984, MOL CELL BIOL, V4, P2235, DOI 10.1128/MCB.4.10.2235; NUSSENZWEIG MC, 1988, NATURE, V336, P446, DOI 10.1038/336446a0; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PEI R, 1988, MOL CELL BIOL, V8, P2860, DOI 10.1128/MCB.8.7.2860; PELLETIER J, 1985, MOL CELL BIOL, V5, P3222, DOI 10.1128/MCB.5.11.3222; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PERSSON H, 1984, SCIENCE, V225, P718, DOI 10.1126/science.6463648; PIECHACZYK M, 1985, CELL, V42, P589, DOI 10.1016/0092-8674(85)90116-3; PROCHOWNIK EV, 1988, MOL CELL BIOL, V8, P3683, DOI 10.1128/MCB.8.9.3683; RABBITTS PH, 1985, EMBO J, V4, P3727, DOI 10.1002/j.1460-2075.1985.tb04141.x; RAMSAY G, 1984, P NATL ACAD SCI-BIOL, V81, P7742, DOI 10.1073/pnas.81.24.7742; ROSE JK, 1978, P NATL ACAD SCI USA, V75, P2732, DOI 10.1073/pnas.75.6.2732; RUPPERT C, 1986, EMBO J, V5, P1897, DOI 10.1002/j.1460-2075.1986.tb04442.x; SCHWEINFEST CW, 1988, MOL CELL BIOL, V8, P3080, DOI 10.1128/MCB.8.8.3080; SIEBENLIST U, 1988, MOL CELL BIOL, V8, P867, DOI 10.1128/MCB.8.2.867; STEWART TA, 1984, SCIENCE, V226, P707, DOI 10.1126/science.6494906; TAUB R, 1984, CELL, V36, P339, DOI 10.1016/0092-8674(84)90227-7; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WIMAN KG, 1984, P NATL ACAD SCI-BIOL, V81, P6798, DOI 10.1073/pnas.81.21.6798; YANG JQ, 1985, EMBO J, V4, P1441, DOI 10.1002/j.1460-2075.1985.tb03800.x; ZAJAC-KAYE M, 1988, SCIENCE, V240, P1776, DOI 10.1126/science.2454510	71	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUL	1989	4	7					815	822						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE584	2502752				2022-12-17	WOS:A1989AE58400001
J	TULCHIN, N; ORNSTEIN, L; GUILLEM, J; OTOOLE, K; LAMBERT, ME; WEINSTEIN, IB				TULCHIN, N; ORNSTEIN, L; GUILLEM, J; OTOOLE, K; LAMBERT, ME; WEINSTEIN, IB			DISTRIBUTION OF THE C-MYC ONCOPROTEIN IN NORMAL AND NEOPLASTIC TISSUES OF THE RAT COLON	ONCOGENE			English	Article									COLUMBIA UNIV COLL PHYS & SURG, NEW YORK, NY 10032 USA; SCRIPPS CLIN & RES FDN, LA JOLLA, CA 92037 USA	Columbia University; Scripps Research Institute	TULCHIN, N (corresponding author), CUNY MT SINAI SCH MED, DEPT PATHOL, 1 GUSTAVE L LEVY PL, NEW YORK, NY 10029 USA.				NCI NIH HHS [CA 021111] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA021111] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS HD, 1982, CELL, V29, P427, DOI 10.1016/0092-8674(82)90159-3; ADAMS JM, 1983, P NATL ACAD SCI-BIOL, V80, P1982, DOI 10.1073/pnas.80.7.1982; ALITALO K, 1983, NATURE, V306, P274, DOI 10.1038/306274a0; ALITALO K, 1983, P NATL ACAD SCI-BIOL, V80, P1707, DOI 10.1073/pnas.80.6.1707; BATTEY J, 1983, CELL, V34, P779, DOI 10.1016/0092-8674(83)90534-2; BUTNICK NZ, 1985, MOL CELL BIOL, V5, P3009, DOI 10.1128/MCB.5.11.3009; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; DALLAFAVERA R, 1982, NATURE, V299, P61; DELLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P6497, DOI 10.1073/pnas.79.21.6497; DONNER P, 1982, NATURE, V296, P262, DOI 10.1038/296262a0; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; ERIKSON J, 1982, P NATL ACAD SCI-BIOL, V79, P5611, DOI 10.1073/pnas.79.18.5611; ERISMAN MD, 1988, ONCOGENE, V2, P367; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; GUILLEM JG, 1988, CANCER RES, V48, P3964; GUTIERREZ C, 1987, MOL CELL BIOL, V7, P4594, DOI 10.1128/MCB.7.12.4594; HAMLYN PH, 1983, NATURE, V304, P135, DOI 10.1038/304135a0; HANN SR, 1983, CELL, V34, P789, DOI 10.1016/0092-8674(83)90535-4; HAYWARD WS, 1981, NATURE, V290, P475, DOI 10.1038/290475a0; HOLLIS GF, 1984, NATURE, V307, P752, DOI 10.1038/307752a0; JACK AS, 1986, BRIT J CANCER, V53, P713, DOI 10.1038/bjc.1986.123; JONES DJ, 1987, BRIT J CANCER, V56, P779, DOI 10.1038/bjc.1987.287; KLEIN G, 1983, CELL, V32, P311, DOI 10.1016/0092-8674(83)90449-X; LIPKIN M, 1984, CANCER RES, V44, P4201; MARCU KB, 1983, P NATL ACAD SCI-BIOL, V80, P519, DOI 10.1073/pnas.80.2.519; MIYAMOTO C, 1985, P NATL ACAD SCI USA, V82, P7232, DOI 10.1073/pnas.82.21.7232; MORGAN JH, 1985, J NATL CANCER I, V75, P937, DOI 10.1093/jnci/75.5.937; NEPVEU A, 1987, ONCOGENE, V1, P243; ORNSTEIN L, 1986, J CELL BIOL, V103, pA428; REDDY BS, 1985, JNCI-J NATL CANCER I, V75, P791; REDDY EP, 1983, P NATL ACAD SCI-BIOL, V80, P2500, DOI 10.1073/pnas.80.9.2500; SCHUBACH W, 1984, NATURE, V307, P702, DOI 10.1038/307702a0; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SPECTOR DL, 1987, ONCOGENE, V1, P5; STERNBER.LA, 1970, J HISTOCHEM CYTOCHEM, V18, P315, DOI 10.1177/18.5.315; STEWART J, 1986, BRIT J CANCER, V53, P1, DOI 10.1038/bjc.1986.1; TULCHIN N, 1988, ENVIRON MOL MUTAGEN, V11, P107; VENNSTROM B, 1981, J VIROL, V39, P625; WATSON DK, 1983, P NATL ACAD SCI-BIOL, V80, P3642, DOI 10.1073/pnas.80.12.3642; WATT R, 1983, P NATL ACAD SCI-BIOL, V80, P6307, DOI 10.1073/pnas.80.20.6307; WATT R, 1983, NATURE, V303, P725, DOI 10.1038/303725a0; WATT RA, 1985, MOL CELL BIOL, V5, P448, DOI 10.1128/MCB.5.3.448; WESTAWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P843, DOI 10.1073/pnas.81.3.843	43	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC	1988	3	6					697	701						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	R6460	2577872				2022-12-17	WOS:A1988R646000012
J	MOHAMED, AN; NAKEFF, A; MOHAMMAD, RM; KUKURUGA, M; ALKATIB, A				MOHAMED, AN; NAKEFF, A; MOHAMMAD, RM; KUKURUGA, M; ALKATIB, A			MODULATION OF C-MYC ONCOGENE EXPRESSION BY PHORBOL ESTER AND INTERFERON-GAMMA - APPRAISAL BY FLOW-CYTOMETRY	ONCOGENE			English	Article									WAYNE STATE UNIV, SCH MED, DEPT INTERNAL MED, DIV HEMATOL & ONCOL, DETROIT, MI 48201 USA	Wayne State University					NATIONAL CANCER INSTITUTE [P30CA022453] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005384] Funding Source: NIH RePORTER; NCI NIH HHS [T-32 CA-09532, CA22453] Funding Source: Medline; NCRR NIH HHS [SO7 RR-05384-25] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BAUER KD, 1986, CANCER RES, V46, P2428; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CELIS JE, 1984, LEUKEMIA RES, V8, P143, DOI 10.1016/0145-2126(84)90135-8; CLEVENGER CV, 1985, CYTOMETRY, V6, P208, DOI 10.1002/cyto.990060306; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COLLINS SJ, 1987, BLOOD, V70, P1233; DEAN PN, 1974, J CELL BIOL, V60, P523, DOI 10.1083/jcb.60.2.523; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; ERIKSON J, 1983, P NATL ACAD SCI-BIOL, V80, P820, DOI 10.1073/pnas.80.3.820; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FAVERA R D, 1982, Nature (London), V299, P61, DOI 10.1038/299061a0; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GEORGE DL, 1984, CANCER SURV, V3, P497; GONDA TJ, 1984, NATURE, V310, P249, DOI 10.1038/310249a0; HANN SR, 1985, NATURE, V314, P366, DOI 10.1038/314366a0; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HAYASHI K, 1984, GANN, V75, P475; JONAK GJ, 1984, P NATL ACAD SCI-BIOL, V81, P1747, DOI 10.1073/pnas.81.6.1747; KELLY JM, 1985, EUR J BIOCHEM, V153, P367, DOI 10.1111/j.1432-1033.1985.tb09312.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KELLY K, 1984, CURR TOP MICROBIOL, V113, P117; KLEIN E, 1968, CANCER RES, V28, P1300; KLEIN G, 1986, CANCER RES, V46, P3211; LAND H, 1983, SCIENCE, V222, P771, DOI 10.1126/science.6356358; LITTLE CD, 1983, NATURE, V306, P194, DOI 10.1038/306194a0; NAU MM, 1984, CURR TOP MICROBIOL, V113, P172; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; RABBITTS PH, 1985, EMBO J, V4, P2009, DOI 10.1002/j.1460-2075.1985.tb03885.x; REITSMA PH, 1983, NATURE, V306, P492, DOI 10.1038/306492a0; ROSENFELD C, 1977, NATURE, V267, P841, DOI 10.1038/267841a0; SATO H, 1987, SEMIN ONCOL, V14, P192; SUMEGI J, 1985, INT J CANCER, V36, P367; TARELLA C, 1982, CANCER RES, V42, P445; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; THORSBY E, 1970, HISTOCOMPATIBILITY T, P655; WATSON JV, 1985, J IMMUNOL METHODS, V83, P179, DOI 10.1016/0022-1759(85)90071-7; WATSON JV, 1986, CYTOMETRY, V7, P400, DOI 10.1002/cyto.990070503; WATSON JV, 1985, CYTOMETRY, V6, P310, DOI 10.1002/cyto.990060406	40	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT	1988	3	4					429	435						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q7739	3152600				2022-12-17	WOS:A1988Q773900011
J	GAO, CL; WANG, LC; VASS, WC; SETH, A; CHANG, KSS				GAO, CL; WANG, LC; VASS, WC; SETH, A; CHANG, KSS			THE ROLE OF V-MOS IN TRANSFORMATION, ONCOGENICITY, AND METASTATIC POTENTIAL OF MINK LUNG-CELLS	ONCOGENE			English	Article									NCI,CELLULAR ONCOL LAB,BETHESDA,MD 20892; NCI,MOLEC ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ATTIA MA, 1965, CANCER RES, V25, P451; BASSIN RH, 1984, CANCER CELL, V2, P463; BOONE LR, 1983, J VIROL, V45, P484, DOI 10.1128/JVI.45.1.484-488.1983; BRADLEY MO, 1986, P NATL ACAD SCI USA, V83, P5277, DOI 10.1073/pnas.83.14.5277; CHANG KSS, 1982, J GEN VIROL, V58, P115, DOI 10.1099/0022-1317-58-1-115; CHATTOPADHYAY SK, 1980, P NATL ACAD SCI-BIOL, V77, P5774, DOI 10.1073/pnas.77.10.5774; CHATTOPADHYAY SK, 1982, NATURE, V295, P25, DOI 10.1038/295025a0; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; FISCHINGER PJ, 1974, VIROLOGY, V59, P217, DOI 10.1016/0042-6822(74)90217-7; FISCHINGER PJ, 1981, CANCER RES, V41, P958; FRANKEL AE, 1977, J VIROL, V23, P492, DOI 10.1128/JVI.23.3.492-502.1977; GEISER AG, 1986, P NATL ACAD SCI USA, V83, P5209, DOI 10.1073/pnas.83.14.5209; GORER PA, 1950, BRIT J CANCER, V4, P372, DOI 10.1038/bjc.1950.36; GREIG RG, 1985, P NATL ACAD SCI USA, V82, P3698, DOI 10.1073/pnas.82.11.3698; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KRZYZEK RA, 1979, J VIROL, V29, P507, DOI 10.1128/JVI.29.2.507-516.1979; LANDER MR, 1984, J VIROL, V52, P695, DOI 10.1128/JVI.52.2.695-698.1984; LIOTTA LA, 1986, CANCER RES, V46, P1; MERCER RW, 1986, MOL CELL BIOL, V6, P3884, DOI 10.1128/MCB.6.11.3884; MEROMSKY L, 1986, CANCER RES, V46, P5270; NICOLSON GL, 1987, CANCER RES, V47, P1473; NODA M, 1983, P NATL ACAD SCI-BIOL, V80, P5602, DOI 10.1073/pnas.80.18.5602; OSTERTAG W, 1987, ADV CANCER RES, V48, P193, DOI 10.1016/S0065-230X(08)60693-4; PAPKOFF J, 1984, J VIROL, V52, P420, DOI 10.1128/JVI.52.2.420-430.1984; PAPKOFF J, 1982, CELL, V29, P417, DOI 10.1016/0092-8674(82)90158-1; PEEBLES PT, 1976, SCIENCE, V192, P1143, DOI 10.1126/science.179144; PEEBLES PT, 1975, VIROLOGY, V67, P288, DOI 10.1016/0042-6822(75)90427-4; PINCUS T, 1971, J EXP MED, V133, P1219, DOI 10.1084/jem.133.6.1219; PORZIG KJ, 1979, CELL, V16, P875, DOI 10.1016/0092-8674(79)90102-8; POZZATTI R, 1986, SCIENCE, V232, P223, DOI 10.1126/science.3456644; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; RADINSKY R, 1987, P NATL ACAD SCI USA, V84, P5143, DOI 10.1073/pnas.84.15.5143; SELIGER B, 1987, J VIROL, V61, P2567, DOI 10.1128/JVI.61.8.2567-2572.1987; SERGIESCU D, 1986, P NATL ACAD SCI USA, V83, P5764, DOI 10.1073/pnas.83.16.5764; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANDEWOUDE GF, 1979, P NATL ACAD SCI USA, V76, P4464; WANG LC, 1987, CANCER RES, V47, P4192	37	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	SEP	1988	3	3					267	273						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Q4367	2849740				2022-12-17	WOS:A1988Q436700004
J	BIZUB, D; HEIMER, EP; FELIX, A; CHIZZONITE, R; WOOD, A; SKALKA, AM; SLATER, D; ALDRICH, TH; FURTH, ME				BIZUB, D; HEIMER, EP; FELIX, A; CHIZZONITE, R; WOOD, A; SKALKA, AM; SLATER, D; ALDRICH, TH; FURTH, ME			ANTISERA TO THE VARIABLE REGION OF RAS ONCOGENE PROTEINS, AND SPECIFIC DETECTION OF H-RAS EXPRESSION IN AN EXPERIMENTAL-MODEL OF CHEMICAL CARCINOGENESIS	ONCOGENE			English	Article									HOFFMANN LA ROCHE INC, EXPLORATORY RES, DEPT MOLEC ONCOL, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, EXPLORATORY RES, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA; MEM SLOAN KETTERING CANC CTR, GRAD PROGRAM MOLEC BIOL, NEW YORK, NY 10021 USA	Roche Holding; Roche Holding; Memorial Sloan Kettering Cancer Center								ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; BALMAIN A, 1984, NATURE, V307, P658, DOI 10.1038/307658a0; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BARBACID M, 1987, IN PRESS ANN REV BIO; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; BOS JL, 1985, NATURE, V315, P726, DOI 10.1038/315726a0; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; CAPON DJ, 1983, NATURE, V304, P507, DOI 10.1038/304507a0; CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; DEFEO D, 1981, P NATL ACAD SCI-BIOL, V78, P3328, DOI 10.1073/pnas.78.6.3328; ELLIS RW, 1982, MOL CELL BIOL, V2, P1339, DOI 10.1128/MCB.2.11.1339; ELLIS RW, 1981, NATURE, V292, P506, DOI 10.1038/292506a0; EVA A, 1983, P NATL ACAD SCI-BIOL, V80, P4926, DOI 10.1073/pnas.80.16.4926; FASANO O, 1984, P NATL ACAD SCI-BIOL, V81, P4008, DOI 10.1073/pnas.81.13.4008; FELIX AM, 1985, INT J PEPT PROT RES, V26, P130; FURTH ME, 1987, ONCOGENE, V1, P47; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GEORGE DL, 1985, EMBO J, V4, P1199, DOI 10.1002/j.1460-2075.1985.tb03760.x; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GUERRERO I, 1986, LEUKEMIA RES, V10, P851, DOI 10.1016/0145-2126(86)90306-1; GUERRERO I, 1984, P NATL ACAD SCI-BIOL, V81, P202, DOI 10.1073/pnas.81.1.202; HAND PH, 1984, P NATL ACAD SCI-BIOL, V81, P5227, DOI 10.1073/pnas.81.16.5227; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; KERR IB, 1985, BRIT J CANCER, V52, P695, DOI 10.1038/bjc.1985.245; LACAL JC, 1984, P NATL ACAD SCI-BIOL, V81, P5305, DOI 10.1073/pnas.81.17.5305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; LUNDY J, 1986, J CLIN ONCOL, V4, P1321, DOI 10.1200/JCO.1986.4.9.1321; MANNE V, 1985, P NATL ACAD SCI USA, V82, P376, DOI 10.1073/pnas.82.2.376; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MURRAY MJ, 1983, CELL, V33, P749, DOI 10.1016/0092-8674(83)90017-X; NEEDLEMAN SW, 1986, BLOOD, V67, P753; PADUA RA, 1985, MOL CELL BIOL, V5, P582, DOI 10.1128/MCB.5.3.582; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SEFTON BM, 1982, CELL, V31, P465, DOI 10.1016/0092-8674(82)90139-8; SHIH TY, 1982, J VIROL, V42, P253, DOI 10.1128/JVI.42.1.253-261.1982; SHIH TY, 1982, J BIOL CHEM, V257, P1767; SHIMIZU K, 1983, P NATL ACAD SCI-BIOL, V80, P2112, DOI 10.1073/pnas.80.8.2112; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SOUYRI M, 1983, P NATL ACAD SCI-BIOL, V80, P6676, DOI 10.1073/pnas.80.21.6676; SRIVASTAVA SK, 1985, MOL CELL BIOL, V5, P3316, DOI 10.1128/MCB.5.11.3316; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; SUTCLIFFE JG, 1983, SCIENCE, V219, P660, DOI 10.1126/science.6186024; SWANSON ME, 1986, J CELL BIOL, V103, P485, DOI 10.1083/jcb.103.2.485; SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0; TABIN CJ, 1982, NATURE, V300, P143, DOI 10.1038/300143a0; TANAKA T, 1985, P NATL ACAD SCI USA, V82, P3400, DOI 10.1073/pnas.82.10.3400; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TAPAROWSKY E, 1982, NATURE, V300, P762, DOI 10.1038/300762a0; THOR A, 1984, NATURE, V311, P562, DOI 10.1038/311562a0; TIJSSEN P, 1985, LABORATORY TECHNIQUE, pCH14; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUCHIDA N, 1982, SCIENCE, V217, P937, DOI 10.1126/science.6287573; VIOLA MV, 1985, J EXP MED, V161, P1213, DOI 10.1084/jem.161.5.1213; VIOLA MV, 1986, NEW ENGL J MED, V314, P133, DOI 10.1056/NEJM198601163140301; WILLIAMS ARW, 1985, BRIT J CANCER, V52, P687, DOI 10.1038/bjc.1985.244; YUASA Y, 1983, NATURE, V303, P775, DOI 10.1038/303775a0; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0	63	11	15	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	1987	1	2					131	142						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	2449645				2022-12-17	WOS:A1987J635200005
J	LIDEREAU, R; COLE, ST; LARSEN, CJ; MATHIEUMAHUL, D				LIDEREAU, R; COLE, ST; LARSEN, CJ; MATHIEUMAHUL, D			A SINGLE POINT MUTATION RESPONSIBLE FOR C-MOS POLYMORPHISM IN CANCER-PATIENTS	ONCOGENE			English	Note									HOP ST LOUIS,INSERM,U301,F-75475 PARIS,FRANCE; INST PASTEUR,UNITE BIOCHIM REGULAT CELLULAIRES,F-75724 PARIS 15,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	LIDEREAU, R (corresponding author), CTR RENE HUGUENIN,5 RUE GASTON LATOUCHE,F-92211 ST CLOUD,FRANCE.		Mathieu, Daniele/G-6092-2012					BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BURT RW, 1985, NEW ENGL J MED, V312, P1540, DOI 10.1056/NEJM198506133122403; GATTONI S, 1982, MOL CELL BIOL, V2, P42, DOI 10.1128/MCB.2.1.42; GERHARD DS, 1987, NATURE, V325, P73, DOI 10.1038/325073a0; GOLDFARB M, 1982, NATURE, V296, P404, DOI 10.1038/296404a0; HEIGHWAY J, 1986, BRIT J CANCER, V53, P453, DOI 10.1038/bjc.1986.72; HOLLSTEIN M, 1986, NUCLEIC ACIDS RES, V14, P8695, DOI 10.1093/nar/14.21.8695; KRONTIRIS TG, 1985, NATURE, V313, P369, DOI 10.1038/313369a0; LIDEREAU R, 1986, JNCI-J NATL CANCER I, V77, P697, DOI 10.1093/jnci/77.3.697; LIDEREAU R, 1985, P NATL ACAD SCI USA, V82, P7068, DOI 10.1073/pnas.82.20.7068; MULLER R, 1982, NATURE, V299, P640, DOI 10.1038/299640a0; PRAKASH K, 1982, P NATL ACAD SCI-BIOL, V79, P5210, DOI 10.1073/pnas.79.17.5210; PROPST F, 1985, NATURE, V315, P516, DOI 10.1038/315516a0; REVOLTELLA RP, 1985, FEBS LETT, V189, P97, DOI 10.1016/0014-5793(85)80850-4; THEILLET C, 1986, CANCER RES, V46, P4776; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WOOD TG, 1984, P NATL ACAD SCI-BIOL, V81, P7817, DOI 10.1073/pnas.81.24.7817; XU DQ, 1985, P NATL ACAD SCI USA, V82, P2862, DOI 10.1073/pnas.82.9.2862; XU DQ, 1986, P NATL ACAD SCI USA, V83, P3447, DOI 10.1073/pnas.83.10.3447	20	11	11	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1987	1	2					235	237						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J6352	2894001				2022-12-17	WOS:A1987J635200017
J	VENNSTROM, B; BRAVO, R				VENNSTROM, B; BRAVO, R			ANCHORAGE-INDEPENDENT GROWTH OF V-MYC-TRANSFORMED BALB/C 3T3 CELLS IS PROMOTED BY PLATELET-DERIVED GROWTH-FACTOR OR COTRANSFORMATION BY OTHER ONCOGENES	ONCOGENE			English	Article											VENNSTROM, B (corresponding author), EUROPEAN MOLEC BIOL LAB, DIFFERENTIAT PROGRAMME, MEYERHOFSTR 1, D-6900 HEIDELBERG, GERMANY.							ADKINS B, 1984, CELL, V39, P439, DOI 10.1016/0092-8674(84)90451-3; ANZANO MA, 1982, CANCER RES, V42, P4776; ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; ASSOIAN RK, 1984, NATURE, V309, P804, DOI 10.1038/309804a0; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; CAMPISI J, 1984, CELL, V36, P241, DOI 10.1016/0092-8674(84)90217-4; CLEMMONS DR, 1980, P NATL ACAD SCI-BIOL, V77, P6644, DOI 10.1073/pnas.77.11.6644; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; FROLIK CA, 1984, J BIOL CHEM, V259, P995; GOULD KL, 1985, CELL, V42, P849, DOI 10.1016/0092-8674(85)90281-8; GRAF T, 1986, CELL, V45, P357, DOI 10.1016/0092-8674(86)90321-1; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; KACZMAREK L, 1985, SCIENCE, V228, P1313, DOI 10.1126/science.4001943; KAPLAN PL, 1983, CELL, V33, P931, DOI 10.1016/0092-8674(83)90036-3; KEATH EJ, 1984, CELL, V39, P339, DOI 10.1016/0092-8674(84)90012-6; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLARLUND JK, 1985, CELL, V41, P707, DOI 10.1016/S0092-8674(85)80051-9; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LANG RA, 1985, CELL, V43, P531, DOI 10.1016/0092-8674(85)90182-5; MANIATIS T, 1982, MOL CLONING LABORATO; MARQUARDT H, 1983, P NATL ACAD SCI-BIOL, V80, P4684; MOSES HL, 1981, CANCER RES, V41, P2842; MOUGNEAU E, 1984, P NATL ACAD SCI-BIOL, V81, P5758, DOI 10.1073/pnas.81.18.5758; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OZANNE B, 1980, J CELL PHYSIOL, V105, P163, DOI 10.1002/jcp.1041050118; PALMIERI S, 1983, EMBO J, V2, P2385, DOI 10.1002/j.1460-2075.1983.tb01750.x; PLEDGER WJ, 1977, P NATL ACAD SCI USA, V74, P4481, DOI 10.1073/pnas.74.10.4481; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROYERPOKORA B, 1978, CELL, V13, P751, DOI 10.1016/0092-8674(78)90225-8; ROZENGURT E, 1981, P NATL ACAD SCI-BIOL, V78, P4392, DOI 10.1073/pnas.78.7.4392; ROZENGURT E, 1982, J CELL PHYSIOL, V112, P243, DOI 10.1002/jcp.1041120213; ROZENGURT E, 1982, EXP CELL RES, V139, P71, DOI 10.1016/0014-4827(82)90319-6; STERN DF, 1986, MOL CELL BIOL, V6, P870, DOI 10.1128/MCB.6.3.870; TUCKER RF, 1984, P NATL ACAD SCI-BIOL, V81, P6757, DOI 10.1073/pnas.81.21.6757; VENNSTROM B, 1984, EMBO J, V3, P3223, DOI 10.1002/j.1460-2075.1984.tb02282.x; WAGNER EF, 1985, EMBO J, V4, P663, DOI 10.1002/j.1460-2075.1985.tb03680.x	41	11	11	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene		1987	1	3					271	276						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	J9705	3330775				2022-12-17	WOS:A1987J970500006
J	Klimovich, B; Merle, N; Neumann, M; Elmshauser, S; Nist, A; Mernberger, M; Kazdal, D; Stenzinger, A; Timofeev, O; Stiewe, T				Klimovich, Boris; Merle, Nastasja; Neumann, Michelle; Elmshaeuser, Sabrina; Nist, Andrea; Mernberger, Marco; Kazdal, Daniel; Stenzinger, Albrecht; Timofeev, Oleg; Stiewe, Thorsten			p53 partial loss-of-function mutations sensitize to chemotherapy	ONCOGENE			English	Article							CELL-CYCLE ARREST; DNA-BINDING COOPERATIVITY; MUTANT P53; TUMOR SUPPRESSION; APOPTOTIC RESPONSE; CANCER; TUMORIGENESIS; ACTIVATION; MDM2; RECOGNITION	The tumor suppressive transcription factor p53 is frequently inactivated in cancer cells by missense mutations that cluster in the DNA binding domain. 30% hit mutational hotspot residues, resulting in a complete loss of transcriptional activity and mutant p53-driven chemotherapy resistance. Of the remaining 70% of non-hotspot mutants, many are partial loss-of-function (partial-LOF) mutants with residual transcriptional activity. The therapeutic consequences of a partial-LOF have remained largely elusive. Using a p53 mutation engineered to reduce DNA binding, we demonstrate that partial-LOF is sufficient to enhance oncogene-driven tumorigenesis in mouse models of lung and pancreatic ductal adenocarcinoma and acute myeloid leukemia. Interestingly, mouse and human tumors with partial-LOF mutations showed mutant p53 protein accumulation similar as known for hotspot mutants. Different from the chemotherapy resistance caused by p53-loss, the partial-LOF mutant sensitized to an apoptotic chemotherapy response and led to a survival benefit. Mechanistically, the pro-apoptotic transcriptional activity of mouse and human partial-LOF mutants was rescued at high mutant protein levels, suggesting that accumulation of partial-LOF mutants enables the observed apoptotic chemotherapy response. p53 non-hotspot mutants with partial-LOF, therefore, represent tumorigenic p53 mutations that need to be distinguished from other mutations because of their beneficial impact on survival in a therapy context.	[Klimovich, Boris; Merle, Nastasja; Neumann, Michelle; Elmshaeuser, Sabrina; Mernberger, Marco; Timofeev, Oleg; Stiewe, Thorsten] Univ Giessen & Marburg Lung Ctr UGMLC, Inst Mol Oncol, Marburg, Germany; [Klimovich, Boris; Merle, Nastasja; Neumann, Michelle; Elmshaeuser, Sabrina; Mernberger, Marco; Timofeev, Oleg; Stiewe, Thorsten] Philipps Univ, German Ctr Lung Res DZL, Marburg, Germany; [Nist, Andrea; Stiewe, Thorsten] Philipps Univ, Genom Core Facil, Marburg, Germany; [Kazdal, Daniel; Stenzinger, Albrecht] Heidelberg Univ Hosp, Translat Lung Res Ctr Heidelberg TLRC H, Inst Pathol, Heidelberg, Germany; [Kazdal, Daniel; Stenzinger, Albrecht] German Ctr Lung Res DZL, Heidelberg, Germany	Philipps University Marburg; Philipps University Marburg; Ruprecht Karls University Heidelberg	Timofeev, O; Stiewe, T (corresponding author), Univ Giessen & Marburg Lung Ctr UGMLC, Inst Mol Oncol, Marburg, Germany.; Timofeev, O; Stiewe, T (corresponding author), Philipps Univ, German Ctr Lung Res DZL, Marburg, Germany.; Stiewe, T (corresponding author), Philipps Univ, Genom Core Facil, Marburg, Germany.		Kazdal, Daniel/ABG-7629-2020	Kazdal, Daniel/0000-0001-8187-3281; Merle, Nastasja/0000-0003-4957-8463; Stiewe, Thorsten/0000-0003-0134-7826; Timofeev, Oleg/0000-0002-3114-6403	Projekt DEAL	Projekt DEAL	Open Access funding enabled and organized by Projekt DEAL.	Abbas HA, 2010, CELL STEM CELL, V7, P606, DOI 10.1016/j.stem.2010.09.013; Andreeff M, 2016, CLIN CANCER RES, V22, P868, DOI 10.1158/1078-0432.CCR-15-0481; Blanden AR, 2020, ELIFE, V9, DOI [10.7594/eLife.61487, 10.7554/eLife.61487]; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Dehner A, 2005, ANGEW CHEM INT EDIT, V44, P5247, DOI 10.1002/anie.200501887; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 2019, CELL REP, V28, P1370, DOI 10.1016/j.celrep.2019.07.001; Engeland K, 2018, CELL DEATH DIFFER, V25, P114, DOI 10.1038/cdd.2017.172; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Giacomelli AO, 2018, NAT GENET, V50, P1381, DOI 10.1038/s41588-018-0204-y; Jackson JG, 2012, CANCER CELL, V21, P793, DOI 10.1016/j.ccr.2012.04.027; Joerger AC, 2008, ANNU REV BIOCHEM, V77, P557, DOI 10.1146/annurev.biochem.77.060806.091238; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kato S, 2003, P NATL ACAD SCI USA, V100, P8424, DOI 10.1073/pnas.1431692100; Kim MP, 2018, CELL DEATH DIFFER, V25, P161, DOI 10.1038/cdd.2017.185; Kitayner M, 2006, MOL CELL, V22, P741, DOI 10.1016/j.molcel.2006.05.015; Kitayner M, 2010, NAT STRUCT MOL BIOL, V17, P423, DOI 10.1038/nsmb.1800; Klein C, 2001, J BIOL CHEM, V276, P49020, DOI 10.1074/jbc.M107516200; Klimovich B, 2020, CELL CYCLE, V19, P109, DOI 10.1080/15384101.2019.1693748; Kotler E, 2018, MOL CELL, V71, P178, DOI 10.1016/j.molcel.2018.06.012; Kracikova M, 2013, CELL DEATH DIFFER, V20, P576, DOI 10.1038/cdd.2012.155; Leroy B, 2014, HUM MUTAT, V35, P672, DOI 10.1002/humu.22552; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; Mellert H, 2013, CELL REP, V3, P1335, DOI 10.1016/j.celrep.2013.05.011; Mello SS, 2018, CURR OPIN CELL BIOL, V51, P65, DOI 10.1016/j.ceb.2017.11.005; Mendrysa SM, 2006, GENE DEV, V20, P16, DOI 10.1101/gad.1378506; Menendez D, 2006, MOL CELL BIOL, V26, P2297, DOI 10.1128/MCB.26.6.2297-2308.2006; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Muller PAJ, 2014, CANCER CELL, V25, P304, DOI 10.1016/j.ccr.2014.01.021; Paek AL, 2016, CELL, V165, P631, DOI 10.1016/j.cell.2016.03.025; Post SM, 2010, ONCOGENE, V29, P1260, DOI 10.1038/onc.2009.423; Purvis JE, 2012, SCIENCE, V336, P1440, DOI 10.1126/science.1218351; Resnick MA, 2003, P NATL ACAD SCI USA, V100, P9934, DOI 10.1073/pnas.1633803100; Ringshausen I, 2006, CANCER CELL, V10, P501, DOI 10.1016/j.ccr.2006.10.010; Robles AI, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026294; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Ryan KM, 1998, MOL CELL BIOL, V18, P3692, DOI 10.1128/MCB.18.7.3692; Sabapathy K, 2018, NAT REV CLIN ONCOL, V15, P13, DOI 10.1038/nrclinonc.2017.151; Schlereth K, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003726; Schlereth K, 2010, MOL CELL, V38, P356, DOI 10.1016/j.molcel.2010.02.037; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; Stiewe T, 2018, DRUG RESIST UPDATE, V38, P27, DOI 10.1016/j.drup.2018.05.001; Terzian T, 2007, MOL CELL BIOL, V27, P5479, DOI 10.1128/MCB.00555-06; Timofeev O, 2021, CANCERS, V13, DOI 10.3390/cancers13102422; Timofeev O, 2020, CANCER RES, V80, P5231, DOI 10.1158/0008-5472.CAN-20-2002; Timofeev O, 2019, EMBO J, V38, DOI 10.15252/embj.2019102096; Timofeev O, 2013, CELL REP, V3, P1512, DOI 10.1016/j.celrep.2013.04.008; Tiwari B, 2020, GENE DEV, V34, P1439, DOI 10.1101/gad.343186.120; Wang YX, 2011, J CLIN INVEST, V121, P893, DOI 10.1172/JCI44504; Weinberg RL, 2004, J MOL BIOL, V341, P1145, DOI 10.1016/j.jmb.2004.06.071; Zuber J, 2009, GENE DEV, V23, P877, DOI 10.1101/gad.1771409	56	10	10	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 11	2022	41	7					1011	1023		10.1038/s41388-021-02141-5	http://dx.doi.org/10.1038/s41388-021-02141-5		DEC 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	YX7EK	34907344	hybrid, Green Published			2022-12-17	WOS:000730070200002
J	Huang, DQ; Savage, SR; Calinawan, AP; Lin, CW; Zhang, B; Wang, P; Starr, TK; Birrer, MJ; Paulovich, AG				Huang, Dongqing; Savage, Sara R.; Calinawan, Anna P.; Lin, Chenwei; Zhang, Bing; Wang, Pei; Starr, Timothy K.; Birrer, Michael J.; Paulovich, Amanda G.			A highly annotated database of genes associated with platinum resistance in cancer	ONCOGENE			English	Review							ACQUIRED CISPLATIN RESISTANCE; NUCLEOTIDE EXCISION-REPAIR; C-MYC; DNA-REPAIR; CELL-DEATH; MODULATES CHEMOSENSITIVITY; MEDIATED CHEMORESISTANCE; OXIDATIVE-METABOLISM; DRUG-RESISTANCE; CARCINOMA-CELLS	Platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin, is prescribed to 10-20% of all cancer patients. Unfortunately, platinum resistance develops in a significant number of patients and is a determinant of clinical outcome. Extensive research has been conducted to understand and overcome platinum resistance, and mechanisms of resistance can be categorized into several broad biological processes, including (1) regulation of drug entry, exit, accumulation, sequestration, and detoxification, (2) enhanced repair and tolerance of platinum-induced DNA damage, (3) alterations in cell survival pathways, (4) alterations in pleiotropic processes and pathways, and (5) changes in the tumor microenvironment. As a resource to the cancer research community, we provide a comprehensive overview accompanied by a manually curated database of the >900 genes/proteins that have been associated with platinum resistance over the last 30 years of literature. The database is annotated with possible pathways through which the curated genes are related to platinum resistance, types of evidence, and hyperlinks to literature sources. The searchable, downloadable database is available online at .	[Huang, Dongqing; Lin, Chenwei; Paulovich, Amanda G.] Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA; [Savage, Sara R.; Zhang, Bing] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Calinawan, Anna P.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA; [Starr, Timothy K.] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA; [Starr, Timothy K.] Univ Minnesota, Dept Obstet Gynecol & Womens Hlth, Minneapolis, MN USA; [Birrer, Michael J.] Univ Arkansas Med Sci, Little Rock, AR USA	Fred Hutchinson Cancer Center; Baylor College of Medicine; Icahn School of Medicine at Mount Sinai; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Arkansas System; University of Arkansas Medical Sciences	Paulovich, AG (corresponding author), Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA.	apaulovi@fredhutch.org	Lin, Chen/GRR-2799-2022	Paulovich, Amanda/0000-0001-6532-6499; Starr, Timothy/0000-0002-6308-3451	U.S. National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC); DOD [W81XWH-16-2-0038, U24CA210993]; University of Minnesota Grand Challenges grant; Randy Shaver Cancer Research and Community Fund; NIH NCI [R21CA216652]; Scientific Computing Infrastructure at Fred Hutch - ORIP grant [S10OD028685];  [U01CA214114]	U.S. National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DOD(United States Department of Defense); University of Minnesota Grand Challenges grant; Randy Shaver Cancer Research and Community Fund; NIH NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Scientific Computing Infrastructure at Fred Hutch - ORIP grant; 	This work was done in collaboration with the U.S. National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) and supported by grants U01CA214114 (AGP, MJB), DOD W81XWH-16-2-0038 (MJB), U24CA210993 (PW), University of Minnesota Grand Challenges grant, Randy Shaver Cancer Research and Community Fund Grant and NIH NCI R21CA216652 (TKS), and Scientific Computing Infrastructure at Fred Hutch funded by ORIP grant S10OD028685.	Adam-Zahir S, 2014, CHEMOTHERAPY, V60, P310, DOI 10.1159/000430086; Ai ZH, 2016, CANCER LETT, V373, P36, DOI 10.1016/j.canlet.2016.01.009; Alkema NG, 2014, GYNECOL ONCOL, V133, P591, DOI 10.1016/j.ygyno.2014.03.557; Altan B, 2016, ANTICANCER RES, V36, P5237, DOI 10.21873/anticanres.11094; Annunziata CM, 2010, CANCER-AM CANCER SOC, V116, P3276, DOI 10.1002/cncr.25190; Ashrafizadeh M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114002; Baiceanu E, 2015, FUTURE MED CHEM, V7, P2041, DOI 10.4155/fmc.15.131; Balamurugan K, 2016, INT J CANCER, V138, P1058, DOI 10.1002/ijc.29519; Bell EH, 2016, CLIN CANCER RES, V22, P2396, DOI 10.1158/1078-0432.CCR-15-1468; Beretta GL, 2010, BIOCHEM PHARMACOL, V79, P1108, DOI 10.1016/j.bcp.2009.12.002; Biyanee Abhiruchi, 2015, Oncoscience, V2, P731; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Bousova I, 2012, DRUG METAB REV, V44, P267, DOI 10.3109/03602532.2012.713969; Brozovic A, 2004, INT J CANCER, V112, P974, DOI 10.1002/ijc.20522; Burkitt K, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-24; Cancer Genome Atlas Research Network, 2011, Nature, V474, P609, DOI 10.1038/nature10166; Chakraborty PK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14634; Chaney SG, 2005, CRIT REV ONCOL HEMAT, V53, P3, DOI 10.1016/j.critrevonc.2004.08.008; Chaudhuri AR, 2016, NATURE, V535, P382, DOI 10.1038/nature18325; Chauhan SS, 2003, BRIT J CANCER, V88, P1327, DOI 10.1038/sj.bjc.6600861; Chen R, 2020, INT J ONCOL, V56, P932, DOI 10.3892/ijo.2020.4987; Ciarimboli G, 2012, SCIENTIFICA, V2012, DOI 10.6064/2012/473829; Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008; Cooke SL, 2010, ONCOGENE, V29, P4905, DOI 10.1038/onc.2010.245; Cruz JJ, 2007, ANN ONCOL, V18, P421, DOI 10.1093/annonc/mdl175; Cruz-Bermudez A, 2019, FREE RADICAL BIO MED, V135, P167, DOI 10.1016/j.freeradbiomed.2019.03.009; Dai Y, 2017, ONCOTARGET, V8, P1354, DOI 10.18632/oncotarget.13817; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; Dar S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09206-0; Davidson Jean, 2018, Oncotarget, V9, P9608, DOI 10.18632/oncotarget.20033; Dempke W, 2000, ANTI-CANCER DRUG, V11, P225, DOI 10.1097/00001813-200004000-00001; Deramaudt BMJM, 1999, J CELL BIOCHEM, V72, P311, DOI 10.1002/(SICI)1097-4644(19990301)72:3<311::AID-JCB1>3.3.CO;2-7; Dev H, 2018, NAT CELL BIOL, V20, P954, DOI 10.1038/s41556-018-0140-1; Dhillon KK, 2011, CANCER SCI, V102, P663, DOI 10.1111/j.1349-7006.2010.01840.x; Diaz Osterman CJ, 2019, ELIFE, V8, DOI 10.7554/eLife.47327; Dubbury SJ, 2018, NATURE, V564, P141, DOI 10.1038/s41586-018-0758-y; Dungrawala H, 2017, MOL CELL, V67, P374, DOI 10.1016/j.molcel.2017.06.023; FAN SJ, 1995, CANCER RES, V55, P1649; Fan TJ, 2019, CANCERS, V11, DOI 10.3390/cancers11030317; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gaustad JV, 2020, CANCERS, V12, DOI 10.3390/cancers12071979; Georgakilas AG, 2017, TRENDS MOL MED, V23, P310, DOI 10.1016/j.molmed.2017.02.001; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gifford G, 2004, CLIN CANCER RES, V10, P4420, DOI 10.1158/1078-0432.CCR-03-0732; Godwin P, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00120; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Gregorc V, 2011, CLIN CANCER RES, V17, P1964, DOI 10.1158/1078-0432.CCR-10-1376; Guillemette S, 2015, GENE DEV, V29, P489, DOI 10.1101/gad.256214.114; Han JY, 2003, MED ONCOL, V20, P355, DOI 10.1385/MO:20:4:355; Hayakawa J, 2000, CANCER RES, V60, P5988; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Hill SJ, 2018, CANCER DISCOV, V8, P1404, DOI 10.1158/2159-8290.CD-18-0474; Hong Soon-Sun, 2004, Cancer Res Treat, V36, P343, DOI 10.4143/crt.2004.36.6.343; Hsieh AL, 2015, SEMIN CELL DEV BIOL, V43, P11, DOI 10.1016/j.semcdb.2015.08.003; Hustedt N, 2019, GENE DEV, V33, P1397, DOI 10.1101/gad.329508.119; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Izquierdo MA, 1998, CYTOTECHNOLOGY, V27, P137, DOI 10.1023/A:1008004502861; Jego G, 2013, CANCER LETT, V332, P275, DOI 10.1016/j.canlet.2010.10.014; Jones VS, 2016, BBA-REV CANCER, V1865, P255, DOI 10.1016/j.bbcan.2016.03.005; Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012; Kang BW, 2012, CANCER CHEMOTH PHARM, V70, P735, DOI 10.1007/s00280-012-1964-1; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Kirschner K, 2010, ANTICANCER RES, V30, P3223; Kleih M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2081-4; Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023; Lagunas Vilma Maldonado, 2008, Metal-Based Drugs, P576104, DOI 10.1155/2008/576104; Lawrence Toby, 2009, Cold Spring Harb Perspect Biol, V1, pa001651, DOI 10.1101/cshperspect.a001651; Lee S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031102; Legrier ME, 2016, BRIT J CANCER, V114, P177, DOI 10.1038/bjc.2015.398; Li ZQ, 2019, CLIN CANCER RES, V25, P5947, DOI 10.1158/1078-0432.CCR-18-4145; Liang Xiaobing, 2011, Chemother Res Pract, V2011, P715469, DOI 10.1155/2011/715469; Liao YX, 2019, NUCLEIC ACIDS RES, V47, pW199, DOI 10.1093/nar/gkz401; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744; Liu H, 2003, KIDNEY INT, V63, P1687, DOI 10.1046/j.1523-1755.2003.00908.x; Liu Q, 2018, CLIN CANCER RES, V24, P6001, DOI 10.1158/1078-0432.CCR-18-1346; Liu RY, 2011, ONCOGENE, V30, P4814, DOI 10.1038/onc.2011.189; Liu T, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.23; Liu T, 2016, ONCOTARGET, V7, P66851, DOI 10.18632/oncotarget.11694; Lu SC, 2013, BBA-GEN SUBJECTS, V1830, P3143, DOI 10.1016/j.bbagen.2012.09.008; Ma LS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00005; Madamanchi NR, 2001, ARTERIOSCL THROM VAS, V21, P321, DOI 10.1161/01.ATV.21.3.321; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Marchini S, 2013, EUR J CANCER, V49, P520, DOI 10.1016/j.ejca.2012.06.026; Marquard FE, 2020, BIOCHEM PHARMACOL, V172, DOI 10.1016/j.bcp.2019.113729; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Matassa DS, 2016, CELL DEATH DIFFER, V23, P1542, DOI 10.1038/cdd.2016.39; Meng J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2327-1; Miyamoto M, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e33; Musa F, 2016, MOL CANCER THER, V15, P1557, DOI 10.1158/1535-7163.MCT-15-0926; Nallanthighal S, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2442-z; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Obrist F, 2018, EMBO J, V37, DOI 10.15252/embj.201798597; Pan JS, 2009, WORLD J GASTROENTERO, V15, P1702, DOI 10.3748/wjg.15.1702; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Penzvalto Z, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-837; Prathapam T, 2010, J BIOL CHEM, V285, P32529, DOI 10.1074/jbc.M110.151902; Pujade-Lauraine E, 2019, J CLIN ONCOL, V37, P2437, DOI 10.1200/JCO.19.00194; Quereda V, 2019, CANCER CELL, V36, P545, DOI 10.1016/j.ccell.2019.09.004; Rawlings JS, 2004, J CELL SCI, V117, P1281, DOI 10.1242/jcs.00963; Rocha CRR, 2018, CLINICS, V73, DOI 10.6061/clinics/2018/e478s; Ren JH, 2010, CANCER BIOTHER RADIO, V25, P75, DOI 10.1089/cbr.2009.0701; Reyes-Gonzalez JM, 2015, MOL CANCER THER, V14, P2260, DOI 10.1158/1535-7163.MCT-14-0801; Rezvani HR, 2010, NUCLEIC ACIDS RES, V38, P797, DOI 10.1093/nar/gkp1072; Rohwer N, 2013, ONCOGENE, V32, P3569, DOI 10.1038/onc.2012.510; ROSENBERG B, 1965, NATURE, V205, P698, DOI 10.1038/205698a0; Rottenberg S, 2021, NAT REV CANCER, V21, P37, DOI 10.1038/s41568-020-00308-y; Roy S, 2020, EXP BIOL MED, V245, P1073, DOI 10.1177/1535370220934038; Sakai W, 2009, CANCER RES, V69, P6381, DOI 10.1158/0008-5472.CAN-09-1178; Santamaria G, 2006, CARCINOGENESIS, V27, P925, DOI 10.1093/carcin/bgi315; Santos R, 2017, NAT REV DRUG DISCOV, V16, P19, DOI 10.1038/nrd.2016.230; Sarbia M, 2007, BRIT J CANCER, V97, P1404, DOI 10.1038/sj.bjc.6604037; Sawant A, 2017, DNA REPAIR, V51, P46, DOI 10.1016/j.dnarep.2017.01.002; Schmidtova S, 2018, CURR ONCOL REP, V20, DOI 10.1007/s11912-018-0730-x; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Stronach EA, 2011, CANCER RES, V71, P4412, DOI 10.1158/0008-5472.CAN-10-4111; Su YW, 2020, CANCER LETT, V483, P127, DOI 10.1016/j.canlet.2020.02.015; Sun J, 2019, ONCOGENE, V38, P564, DOI 10.1038/s41388-018-0459-x; Sung CY, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109135; Tajeddine N, 2008, ONCOGENE, V27, P4221, DOI 10.1038/onc.2008.63; Tramonti A, 2018, BIOCHEMISTRY-US, V57, P6984, DOI 10.1021/acs.biochem.8b01074; Trop-Steinberg S, 2017, AM J MED SCI, V353, P474, DOI 10.1016/j.amjms.2017.01.019; Valencia T, 2014, CANCER CELL, V26, P121, DOI 10.1016/j.ccr.2014.05.004; Varghese E, 2020, CANCERS, V12, DOI 10.3390/cancers12082252; Varoni EM, 2016, FRONT NUTR, V3, DOI 10.3389/fnut.2016.00008; Vomund S, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122772; Wang HF, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-1536-x; Wang J, 2018, ARTIF CELL NANOMED B, V46, P1505, DOI 10.1080/21691401.2017.1374285; Wang WM, 2016, CELL, V165, P1092, DOI 10.1016/j.cell.2016.04.009; Wangpaichitr M, 2012, MOL CANCER THER, V11, P604, DOI 10.1158/1535-7163.MCT-11-0599; Wu CJ, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-25; Wu W J, 2016, Zhonghua Fu Chan Ke Za Zhi, V51, P515, DOI 10.3760/cma.j.issn.0529-567X.2016.07.007; Wysham WZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030042; Yamada M, 1996, CLIN CANCER RES, V2, P427; Yao CJ, 2013, PHARMAZIE, V68, P5, DOI 10.1691/ph.2013.2674; YOKOMIZO A, 1995, CANCER RES, V55, P4293; Yoshihara M, 2020, INT J CANCER, V146, P2268, DOI 10.1002/ijc.32854; Yuan YG, 2015, CELL PHYSIOL BIOCHEM, V37, P1240, DOI 10.1159/000430247; Yung MMH, 2016, ACTA BIOCH BIOPH SIN, V48, P301, DOI 10.1093/abbs/gmv128; Zeller C, 2012, ONCOGENE, V31, P4567, DOI 10.1038/onc.2011.611; Zhang D, 2015, CANCER BIOL THER, V16, P1005, DOI 10.1080/15384047.2015.1046022; Zhang HF, 2017, MOL CARCINOGEN, V56, P1150, DOI 10.1002/mc.22581; Zhang HD, 2020, CRIT REV BIOCHEM MOL, V55, P219, DOI 10.1080/10409238.2020.1768205; Zhang X, 2010, CANCER SCI, V101, P2163, DOI 10.1111/j.1349-7006.2010.01664.x	149	10	10	4	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 18	2021	40	46					6395	6405		10.1038/s41388-021-02055-2	http://dx.doi.org/10.1038/s41388-021-02055-2		OCT 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	XA1UG	34645978	Green Published, hybrid			2022-12-17	WOS:000706949900001
J	Du, SC; Yang, Z; Lu, XF; Yousuf, S; Zhao, M; Li, WX; Miao, J; Wang, XZ; Yu, H; Zhu, XY; Chen, H; Shi, LS; Xu, E; Xia, XF; Guan, WX				Du, Shangce; Yang, Zhi; Lu, Xiaofeng; Yousuf, Suhail; Zhao, Min; Li, Wenxi; Miao, Ji; Wang, Xingzhou; Yu, Heng; Zhu, Xinya; Chen, Hong; Shi, Linseng; Xu, En; Xia, Xuefeng; Guan, Wenxian			Anoikis resistant gastric cancer cells promote angiogenesis and peritoneal metastasis through C/EBP beta-mediated PDGFB autocrine and paracrine signaling	ONCOGENE			English	Article							TUMOR ANGIOGENESIS; MOLECULAR PATHWAYS; SURVIVAL; DETACHMENT; AUTOPHAGY; GROWTH; AXIS	Anoikis is a type of programmed cell death induced by loss of anchorage to the extracellular matrix (ECM). Anoikis resistance (AR) is crucial for the survival of metastatic cancer cells in blood, lymphatic circulation and distant organs. Compared to ordinary cancer cells, anoikis resistant cancer cells undergo various cellular and molecular alterations, probably characterizing the cells with unique features not limited to anoikis resistance. However, the molecular mechanisms connecting anoikis resistance to other metastatic properties are still poorly understood. Here, the biological interaction between anoikis resistance and angiogenesis as well as their involvement into peritoneal metastasis of gastric cancer (GC) were investigated in vitro and in vivo. The prognostic value of key components involved in this interaction was evaluated in the GC cohort. Compared to ordinary GC cells, GC(AR) cells exhibited stronger metastatic and pro-angiogenic traits corresponding to elevated PDGFB secretion. Mechanistically, transcription factor C/EBP beta facilitated PDGFB transcription by directly binding to and interacting with PDGFB promoter elements, subsequently increasing PDGFB secretion. Secreted PDGFB promoted the survival of detached GC cells through a C/EBP beta-dependent self-feedback loop. Moreover, secreted PDGFB promoted angiogenesis in metastases via activation of the MAPK/ERK signaling pathway in vascular endothelial cells. Both C/EBP beta activation level and PDGFB expression were significantly elevated in GC and correlated with metastatic progression and poor prognosis of patients with GC. Overall, interaction between GC(AR) cells and vascular endothelial cells promotes angiogenesis and peritoneal metastasis of GC based on C/EBP beta-mediated PDGFB autocrine and paracrine signaling. C/EBP beta-PDGFB-PDGFR beta-MAPK axis promises to be potential prognostic biomarkers and therapeutic targets for peritoneal metastasis of GC.	[Du, Shangce; Yang, Zhi; Lu, Xiaofeng; Zhao, Min; Yu, Heng; Zhu, Xinya; Chen, Hong; Shi, Linseng; Guan, Wenxian] Nanjing Med Univ, Dept Gastrointestinal Surg, Drum Tower Clin Med Coll, Nanjing, Peoples R China; [Du, Shangce; Yang, Zhi; Lu, Xiaofeng; Miao, Ji; Wang, Xingzhou; Xu, En; Xia, Xuefeng; Guan, Wenxian] Nanjing Univ, Dept Gastrointestinal Surg, Nanjing Drum Tower Hosp, Affiliated Hosp,Med Sch, Nanjing, Peoples R China; [Yousuf, Suhail] Heidelberg Univ Hosp, Dept Surg, Heidelberg, Germany; [Li, Wenxi] Heidelberg Univ, Fac Med, Heidelberg, Germany	Nanjing Medical University; Nanjing University; Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Guan, WX (corresponding author), Nanjing Med Univ, Dept Gastrointestinal Surg, Drum Tower Clin Med Coll, Nanjing, Peoples R China.; Xu, E; Xia, XF; Guan, WX (corresponding author), Nanjing Univ, Dept Gastrointestinal Surg, Nanjing Drum Tower Hosp, Affiliated Hosp,Med Sch, Nanjing, Peoples R China.	657416504@qq.com; danielxuefeng@hotmail.com; 15850502391@163.com						Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Avivar-Valderas A, 2013, ONCOGENE, V32, P4932, DOI 10.1038/onc.2012.512; Buchheit CL, 2014, NAT REV CANCER, V14, P632, DOI 10.1038/nrc3789; Carro MS, 2010, NATURE, V463, P318, DOI 10.1038/nature08712; Chen N, 2013, AUTOPHAGY, V9, P1214, DOI 10.4161/auto.24870; Chen X, 2019, REDOX BIOL, V21, DOI 10.1016/j.redox.2018.11.019; Cheng P, 2019, MOL THER-NUCL ACIDS, V18, P155, DOI 10.1016/j.omtn.2019.08.013; Chung AS, 2011, ANNU REV CELL DEV BI, V27, P563, DOI 10.1146/annurev-cellbio-092910-154002; de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51; Du SC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0953-7; Eddy RJ, 2017, TRENDS CELL BIOL, V27, P595, DOI 10.1016/j.tcb.2017.03.003; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Gomis RR, 2006, CANCER CELL, V10, P203, DOI 10.1016/j.ccr.2006.07.019; Guo L, 2015, J BIOL CHEM, V290, P755, DOI 10.1074/jbc.R114.619957; Haemmerle M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00411-z; Hong SH, 2013, GASTRIC CANCER, V16, P290, DOI 10.1007/s10120-012-0182-1; Hosaka K, 2016, P NATL ACAD SCI USA, V113, pE5618, DOI 10.1073/pnas.1608384113; Hosaka K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3129; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Jin K, 2017, J PATHOL, V241, P567, DOI 10.1002/path.4871; Jin LT, 2018, MOL CELL, V69, P87, DOI 10.1016/j.molcel.2017.11.025; Jitariu AA, 2018, CRIT REV ONCOL HEMAT, V131, P46, DOI 10.1016/j.critrevonc.2018.08.002; Kastana P, 2019, METHODS MOL BIOL, V1952, P219, DOI 10.1007/978-1-4939-9133-4_18; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kipps E, 2013, NAT REV CANCER, V13, P273, DOI 10.1038/nrc3432; Kirsch M, 2004, CANC TREAT, V117, P285; Kitadai Yasuhiko, 2011, Cancers (Basel), V3, P4245, DOI 10.3390/cancers3044245; Kuczynski EA, 2019, NAT REV CLIN ONCOL, V16, P469, DOI 10.1038/s41571-019-0181-9; La Porta S, 2018, J CLIN INVEST, V128, P834, DOI 10.1172/JCI94674; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Liu TR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05982-z; Liu Y, 2016, CANCER CELL, V30, P668, DOI 10.1016/j.ccell.2016.09.011; Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890; Ma WH, 2018, THERANOSTICS, V8, P5744, DOI 10.7150/thno.28898; Mazzone M, 2019, ANNU REV PHYSIOL, V81, P535, DOI 10.1146/annurev-physiol-020518-114721; McLean MIH, 2014, NAT REV GASTRO HEPAT, V11, P664, DOI 10.1038/nrgastro.2014.143; Nissen LJ, 2007, J CLIN INVEST, V117, P2766, DOI 10.1172/JCI32479; Paoli P, 2013, BBA-MOL CELL RES, V1833, P3481, DOI 10.1016/j.bbamcr.2013.06.026; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pontes-Quero S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09875-7; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Shah MA, 2015, J CLIN ONCOL, V33, P1760, DOI 10.1200/JCO.2014.60.1799; Shen XF, 2018, J ALLERGY CLIN IMMUN, V141, P1929, DOI 10.1016/j.jaci.2018.01.005; Strilic B, 2017, CANCER CELL, V32, P282, DOI 10.1016/j.ccell.2017.07.001; Tamura A, 2017, BLOOD, V130, P1809, DOI 10.1182/blood-2017-03-772962; Thomassen I, 2014, INT J CANCER, V134, P622, DOI 10.1002/ijc.28373; Toubal A, 2013, J CLIN INVEST, V123, P362, DOI 10.1172/JCI64052; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang SY, 2013, GUT, V62, P496, DOI 10.1136/gutjnl-2011-301522; Wang SH, 2019, J PATHOL, V248, P204, DOI 10.1002/path.5246; Wang XH, 2019, CLIN CANCER RES, V25, P3128, DOI 10.1158/1078-0432.CCR-18-2804; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Xu Yong Zhong, 2013, Methods Mol Biol, V977, P79, DOI 10.1007/978-1-62703-284-1_7; Xue Y, 2012, NAT MED, V18, P100, DOI 10.1038/nm.2575; Yonemura Yutaka, 2003, Surg Oncol Clin N Am, V12, P635, DOI 10.1016/S1055-3207(03)00035-8; Zabielska-Koczywas K, 2017, BMC VET RES, V13, DOI 10.1186/s12917-017-1114-4; Zhang Y, 2004, J BIOL CHEM, V279, P48342, DOI 10.1074/jbc.M407953200; Zhang YY, 2012, BIOCHEM BIOPH RES CO, V419, P550, DOI 10.1016/j.bbrc.2012.02.058	58	10	10	1	9	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 23	2021	40	38					5764	5779		10.1038/s41388-021-01988-y	http://dx.doi.org/10.1038/s41388-021-01988-y		AUG 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UU4CG	34341514				2022-12-17	WOS:000680382100002
J	Chen, PX; Li, S; Zhang, K; Zhao, RC; Cui, JF; Zhou, W; Liu, YC; Zhang, L; Cheng, YF				Chen, Pengxiang; Li, Song; Zhang, Ke; Zhao, Renchang; Cui, Jianfeng; Zhou, Wei; Liu, Yuchen; Zhang, Lin; Cheng, Yufeng			N-6-methyladenosine demethylase ALKBH5 suppresses malignancy of esophageal cancer by regulating microRNA biogenesis and RAI1 expression	ONCOGENE			English	Article							UP-REGULATION; NUCLEAR-RNA; METASTASIS; PROLIFERATION; TRANSITION; CARCINOMA; CELLS; YAP	N-6-Methyladenosine (m(6)A) is the most prevalent epigenetic RNA modification and is vital in regulating malignancies. The roles of m(6)A modifiers on noncoding RNAs have not been fully investigated in esophageal cancer. By screening all m(6)A modifiers, ALKBH5 was the most potent member related to patient outcomes and suppressing esophageal cancer malignancy in cell and animal models. It demethylated pri-miR-194-2 and inhibited miR-194-2 biogenesis through an m(6)A/DGCR8-dependent manner. RAI1, previously considered as a circadian clock transcriptional regulator, was the main target of miR-194-2. It enhanced transcription of Hippo pathway upstream genes by binding to their 3 ' UTR and suppressed YAP/TAZ nuclear translocation. The ALKBH5/miR-194-2/RAI1 axis was also validated in clinical samples. In addition, the increased malignancy by low ALKBH5 was abolished by the YAP inhibitor verteporfin. Our findings uncover a critical role of ALKBH5 in miRNAs biogenesis and provide novel insight for developing treatment strategies in esophageal cancer.	[Chen, Pengxiang; Zhou, Wei; Liu, Yuchen; Zhang, Lin; Cheng, Yufeng] Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Radiat Oncol, Jinan, Peoples R China; [Chen, Pengxiang; Li, Song] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Lab Basic Med Sci, Jinan, Peoples R China; [Li, Song] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Dept Med Oncol, Jinan, Peoples R China; [Zhang, Ke] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Dept Gen Med, Jinan, Peoples R China; [Zhao, Renchang] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Thorac Surg Dept, Jinan, Peoples R China; [Cui, Jianfeng] Shandong Univ, Cheeloo Coll Med, Qilu Hosp, Dept Urol, Jinan, Peoples R China	Shandong University; Shandong University; Shandong University; Shandong University; Shandong University; Shandong University	Zhang, L; Cheng, YF (corresponding author), Shandong Univ, Qilu Hosp, Cheeloo Coll Med, Dept Radiat Oncol, Jinan, Peoples R China.	linzhangsdu@163.com; yufengchengsdu@163.com	liu, yuchen/GYQ-6286-2022	Li, Song/0000-0002-5023-9111	National Natural Science Foundation of China [81773228, 81972850, 81601999]; Postdoctoral Science Foundation of China [2018M640637]; Special Fund for Taishan Scholar Project [ts20190973]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Postdoctoral Science Foundation of China(China Postdoctoral Science Foundation); Special Fund for Taishan Scholar Project	Alexandra Marshall from Marshall Medical Communications provided editorial assistance during manuscript preparation. This study was supported by the National Natural Science Foundation of China (81773228 and 81972850 to Y.C.; 81601999 to L.Z.); Postdoctoral Science Foundation of China (2018M640637 to L.Z.), and Special Fund for Taishan Scholar Project (ts20190973 to Y.C.).	Alarcon CR, 2015, NATURE, V519, P482, DOI 10.1038/nature14281; Barfield R, 2019, SLEEP, V42, DOI 10.1093/sleep/zsz101; Batista PJ, 2014, CELL STEM CELL, V15, P707, DOI 10.1016/j.stem.2014.09.019; Boone PM, 2011, AM J MED GENET A, V155A, P2024, DOI 10.1002/ajmg.a.34098; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen H, 2018, AM J RESP CELL MOL, V58, P391, DOI 10.1165/rcmb.2017-0237OC; Chen XY, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1033-z; Chen YH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01239-w; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cui M, 2018, EXP THER MED, V15, P1048, DOI 10.3892/etm.2017.5492; Das R, 2017, CANCER RES, V77, P1021, DOI 10.1158/0008-5472.CAN-16-2529; Dominissini D, 2012, NATURE, V485, P201, DOI 10.1038/nature11112; Fu Y, 2014, NAT REV GENET, V15, P293, DOI 10.1038/nrg3724; Fustin JM, 2013, CELL, V155, P793, DOI 10.1016/j.cell.2013.10.026; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Han B, 2020, NANOTOXICOLOGY, V14, P1, DOI 10.1080/17435390.2019.1661041; Han J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1036-9; Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043; Hou HY, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.153087; Jaffrey SR, 2017, GENOME MED, V9, DOI 10.1186/s13073-016-0395-8; Jia GF, 2011, NAT CHEM BIOL, V7, P885, DOI [10.1038/NCHEMBIO.687, 10.1038/nchembio.687]; Krzeszinski JY, 2014, NATURE, V512, P431, DOI 10.1038/nature13375; Lan Q, 2019, CANCER RES, V79, P1285, DOI 10.1158/0008-5472.CAN-18-2965; Li P, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0402-6; Liu JY, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-349; Liu JZ, 2014, NAT CHEM BIOL, V10, P93, DOI 10.1038/nchembio.1432; Ma JZ, 2017, HEPATOLOGY, V65, P529, DOI 10.1002/hep.28885; Meyer KD, 2015, CELL, V163, P999, DOI 10.1016/j.cell.2015.10.012; Meyer KD, 2012, CELL, V149, P1635, DOI 10.1016/j.cell.2012.05.003; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; Peng W, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1408-4; Qu Y, 2019, EXP THER MED, V18, P2993, DOI 10.3892/etm.2019.7896; Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033; Rustgi AK, 2014, NEW ENGL J MED, V371, P2499, DOI 10.1056/NEJMra1314530; Shen C, 2020, CELL STEM CELL, V27, P64, DOI 10.1016/j.stem.2020.04.009; Song SM, 2014, CANCER RES, V74, P4170, DOI 10.1158/0008-5472.CAN-13-3569; Su XD, 2014, J THORAC DIS, V6, P949, DOI 10.3978/j.issn.2072-1439.2014.07.14; Tang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1128-6; Thongon N, 2016, ONCOTARGET, V7, P26551, DOI 10.18632/oncotarget.8437; Wang C, 2016, BRIT J CANCER, V115, P1548, DOI 10.1038/bjc.2016.367; Wang X, 2014, NATURE, V505, P117, DOI 10.1038/nature12730; Wei HL, 2017, CANCER SCI, V108, P478, DOI 10.1111/cas.13138; Wu X, 2014, ONCOGENE, V33, P1506, DOI 10.1038/onc.2013.108; Xia TL, 2020, CANCER MANAG RES, V12, P5729, DOI 10.2147/CMAR.S245019; Yi YC, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01233-2; Zhang JL, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09712-x; Zhang J, 2014, ONCOL REP, V31, P1157, DOI 10.3892/or.2013.2960; Zhang SC, 2017, CANCER CELL, V31, P591, DOI 10.1016/j.ccell.2017.02.013; Zhang WY, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005049	49	10	10	4	19	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 16	2021	40	37					5600	5612		10.1038/s41388-021-01966-4	http://dx.doi.org/10.1038/s41388-021-01966-4		JUL 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	UR2PS	34312488				2022-12-17	WOS:000678988300002
J	Lin, YH; Wu, MH; Liu, YC; Lyu, PC; Yeh, CT; Lin, KH				Lin, Yang-Hsiang; Wu, Meng-Han; Liu, Yi-Chung; Lyu, Ping-Chiang; Yeh, Chau-Ting; Lin, Kwang-Huei			LINC01348 suppresses hepatocellular carcinoma metastasis through inhibition of SF3B3-mediated EZH2 pre-mRNA splicing	ONCOGENE			English	Article							HEPATITIS-B-VIRUS; LONG NONCODING RNA; X PROTEIN; C-JUN; EMERGING ROLES; HBX PROTEIN; CANCER; REVEALS; GENE; TRANSCRIPTION	Long non-coding RNAs (lncRNA) play crucial roles in hepatocellular carcinoma (HCC) progression. However, the specific functions of lncRNAs in alternative splicing (AS) and the metastatic cascade in liver cancer remain largely unclear. In this study, we identified a novel lncRNA, LINC01348, which was significantly downregulated in HCC and correlated with survival functions in HCC patients. Ectopic expression of LINC01348 induced marked inhibition of cell growth, and metastasis in vitro and in vivo. Conversely, these phenotypes were reversed upon knockdown of LINC01348. Mechanistically, LINC01348 complexed with splicing factor 3b subunit 3 (SF3B3) acted as a modulator of EZH2 pre-mRNA AS, and induced alterations in JNK/c-Jun activity and expression of Snail. Notably, C-terminal truncated HBx (Ct-HBx) negatively regulated LINC01348 through c-Jun signaling. Our data collectively highlight those novel regulatory associations involving LINC01348/SF3B3/EZH2/JNK/c-Jun/Snail are an important determinant of metastasis in HCC cells and support the potential utility of targeting LINC01348 as a therapeutic strategy for HCC.	[Lin, Yang-Hsiang; Yeh, Chau-Ting; Lin, Kwang-Huei] Chang Gung Mem Hosp, Liver Res Ctr, Taoyuan, Taiwan; [Lin, Yang-Hsiang; Wu, Meng-Han; Lin, Kwang-Huei] Chang Gung Univ, Dept Biochem, Coll Med, Taoyuan, Taiwan; [Liu, Yi-Chung] Inst Populat Sci, Natl Hlth Res Inst, Zhunan, Taiwan; [Lyu, Ping-Chiang] Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Dept Life Sci, Hsinchu, Taiwan; [Lin, Kwang-Huei] Chang Gung Univ Sci & Technol, Coll Human Ecol, Res Ctr Chinese Herbal Med, Taoyuan, Taiwan; Chang Gung Univ, Grad Inst Biomed Sci, Coll Med, Taoyuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung University; National Health Research Institutes - Taiwan; National Tsing Hua University; Chang Gung University of Science & Technology; Chang Gung University	Yeh, CT; Lin, KH (corresponding author), Chang Gung Mem Hosp, Liver Res Ctr, Taoyuan, Taiwan.; Lin, KH (corresponding author), Chang Gung Univ, Dept Biochem, Coll Med, Taoyuan, Taiwan.	chautingy@gmail.com; khlin@mail.cgu.edu.tw		Liu, Yi-Chung/0000-0003-1437-0363; Lin, Kwang-Huei/0000-0002-5649-2222	Chang Gung Memorial Hospital, Taoyuan, Taiwan [CMRPD1H0631-0633, CMRPD1K0291, NMRPD1G0941-0943, NMRPD1G0951-0953, CMRPG3H0721-0723, NZRPG3G0171-0173, NMRPG3H0561, NRRPG3J0141]; Ministry of Science and Technology of the Republic of China [MOST 106-2320-B-182-031-MY3, 106-2320-B-182-032-MY3, 109-2320-B-182-011, MOST 106-2321-B-182A-004-MY3, MOST 107-2320-B-182A-028-, MOST 108-2320-B182A-004-]	Chang Gung Memorial Hospital, Taoyuan, Taiwan(Chang Gung Memorial Hospital); Ministry of Science and Technology of the Republic of China(Ministry of Science and Technology, Taiwan)	This work was supported by grants from Chang Gung Memorial Hospital, Taoyuan, Taiwan (CMRPD1H0631-0633, CMRPD1K0291, NMRPD1G0941-0943, and NMRPD1G0951-0953 to K-HL; CMRPG3H0721-0723, NZRPG3G0171-0173, NMRPG3H0561, NRRPG3J0141 to Y-HL) and from the Ministry of Science and Technology of the Republic of China (MOST 106-2320-B-182-031-MY3; 106-2320-B-182-032-MY3; and 109-2320-B-182-011 to K-HL; MOST 106-2321-B-182A-004-MY3, MOST 107-2320-B-182A-028-, MOST 108-2320-B182A-004-to Y-HL).	Chen K, 2017, CLIN CANCER RES, V23, P3428, DOI 10.1158/1078-0432.CCR-16-2020; Chen RY, 2020, CELL DEATH DIFFER, V27, P1259, DOI 10.1038/s41418-019-0413-7; Chen XC, 2018, BMB REP, V51, P280, DOI 10.5483/BMBRep.2018.51.6.025; Cougot D, 2007, J BIOL CHEM, V282, P4277, DOI 10.1074/jbc.M606774200; Di CX, 2019, CELL DEATH DIFFER, V26, P1181, DOI 10.1038/s41418-018-0231-3; Donato F, 1998, INT J CANCER, V75, P347, DOI 10.1002/(SICI)1097-0215(19980130)75:3&lt;347::AID-IJC4&gt;3.0.CO;2-2; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; El Marabti E, 2018, FRONT MOL BIOSCI, V5, DOI 10.3389/fmolb.2018.00080; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; Finci LI, 2018, GENE DEV, V32, P309, DOI 10.1101/gad.311043.117; Gao SB, 2014, MOL CANCER RES, V12, P1388, DOI 10.1158/1541-7786.MCR-14-0034; Ghafouri-Fard S, 2019, BIOMED PHARMACOTHER, V111, P51, DOI 10.1016/j.biopha.2018.12.070; Giannelli G, 2016, J HEPATOL, V65, P798, DOI 10.1016/j.jhep.2016.05.007; Grzenda A, 2013, EPIGENET CHROMATIN, V6, DOI 10.1186/1756-8935-6-3; He RZ, 2019, GENES DIS, V6, P6, DOI 10.1016/j.gendis.2019.01.003; Hodo Y, 2013, CLIN CANCER RES, V19, P1827, DOI 10.1158/1078-0432.CCR-12-1641; Ivanov VN, 2001, MOL CELL, V7, P517, DOI 10.1016/S1097-2765(01)00199-X; Iyer S, 2011, MOL CARCINOGEN, V50, P972, DOI 10.1002/mc.20767; Jiang MC, 2019, AM J CANCER RES, V9, P1354; Kong JL, 2016, CANCER LETT, V380, P476, DOI 10.1016/j.canlet.2016.07.015; Lee S, 2016, ONCOGENE, V35, P1857, DOI 10.1038/onc.2015.251; Li SL, 2019, HEPATOLOGY, V69, P359, DOI 10.1002/hep.30158; Lim JK, 2020, AM J GASTROENTEROL, V115, P1429, DOI 10.14309/ajg.0000000000000651; Long YC, 2017, SCI ADV, V3, DOI 10.1126/sciadv.aao2110; Luo ZL, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9457; Lurje I, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061465; Mai HM, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1213-0; Mu WP, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072-018-0242-9; Park JW, 2019, J HEPATOL, V70, P684, DOI 10.1016/j.jhep.2018.11.029; Pei HD, 2009, CANCER CELL, V16, P259, DOI 10.1016/j.ccr.2009.07.016; Qian Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep33039; Quetier I, 2015, J GEN VIROL, V96, P614, DOI 10.1099/vir.0.070680-0; Romero-Barrios N, 2018, NUCLEIC ACIDS RES, V46, P2169, DOI 10.1093/nar/gky095; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schulze K, 2015, NAT GENET, V47, P505, DOI 10.1038/ng.3252; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shi J, 2005, BRIT J CANCER, V92, P607, DOI 10.1038/sj.bjc.6602333; Singal AG, 2020, J HEPATOL, V72, P250, DOI 10.1016/j.jhep.2019.08.025; Srisuttee R, 2012, ONCOL REP, V28, P276, DOI 10.3892/or.2012.1798; Sze KMF, 2013, HEPATOLOGY, V57, P131, DOI 10.1002/hep.25979; Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011; Tunissiolli Nathalia Martines, 2017, Asian Pac J Cancer Prev, V18, P863; Turashvili G, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-55; Uchino K, 2011, CANCER-AM CANCER SOC, V117, P4475, DOI 10.1002/cncr.25960; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Wahl MC, 2009, CELL, V136, P701, DOI 10.1016/j.cell.2009.02.009; Wang CH, 2000, BIOCHEM BIOPH RES CO, V270, P303, DOI 10.1006/bbrc.2000.2422; Wang J, 2016, TARGET ONCOL, V11, P723, DOI 10.1007/s11523-016-0446-5; Wang Yunwu, 2018, Oncotarget, V9, P11783, DOI 10.18632/oncotarget.24364; Yeh CT, 2012, J HEPATOL, V57, P484, DOI 10.1016/j.jhep.2012.06.003; Yip WK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022888; Zong XY, 2020, CANCER RES, V80, P4371, DOI 10.1158/0008-5472.CAN-20-0458	52	10	10	1	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 15	2021	40	28					4675	4685		10.1038/s41388-021-01905-3	http://dx.doi.org/10.1038/s41388-021-01905-3		JUN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	TK8LG	34140643				2022-12-17	WOS:000662838900001
J	Nathansen, J; Lukiyanchuk, V; Hein, L; Stolte, MI; Borgmann, K; Lock, S; Kurth, I; Baumann, M; Krause, M; Linge, A; Dubrovska, A				Nathansen, Jacqueline; Lukiyanchuk, Vasyl; Hein, Linda; Stolte, Maya-Isabel; Borgmann, Kerstin; Lock, Steffen; Kurth, Ina; Baumann, Michael; Krause, Mechthild; Linge, Annett; Dubrovska, Anna			Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L	ONCOGENE			English	Article							GOOD PROGNOSIS SUBGROUPS; POSTOPERATIVE RADIOCHEMOTHERAPY; HUMAN-PAPILLOMAVIRUS; MARKER EXPRESSION; DNA-DAMAGE; CANCER; CHK1; HPV; MULTICENTER; HNSCC	Head and neck squamous cell carcinoma (HNSCC) is often being diagnosed at an advanced stage, conferring a poor prognosis. The probability of local tumor control after radiotherapy depends on the eradication of cancer stem cells (CSCs) with activated DNA repair. This study provides evidence that the CSC-related transcription factor Oct4 contributes to HNSCC radioresistance by regulating DNA damage response and the CSC phenotype. Knockdown of Oct4 A isoform reduced self-renewal capacity in HNSCC and led to partial tumor cell radiosensitization caused by transcriptional downregulation of the cell cycle checkpoint kinases CHK1 and WEE1 and homologous recombination (HR) repair genes PSMC3IP and RAD54L. Besides, PARP inhibition with Olaparib selectively radiosensitized Oct4 A knockout, but not wild-type HNSCC cells. This finding links Oct4 A to the HR-mediated DNA repair mechanisms. In turn, knockdown of PSMC3IP and RAD54L reduced the HNSCC self-renewal capacity and clonogenic cell survival after irradiation, suggesting the interplay between DNA repair and the CSC phenotype. Similar to the effect of Oct4 knockdown, overexpression of Oct4 also resulted in significant HNSCC radiosensitization and increased DNA damage, suggesting that Oct4-dependent regulation of DNA repair depends on its fine-tuned expression. In line with this observation, HNSCC patients with high and low nuclear Oct4 expression at the invasive tumor front exhibited better loco-regional tumor control after postoperative radio(chemo)therapy compared to the intermediate expression subgroup. Thus, we found that the Oct4-driven transcriptional program plays a critical role in regulating HNSCC radioresistance, and a combination of radiotherapy with PARP inhibitors may induce synthetic lethality in Oct4-deregulated tumors.	[Nathansen, Jacqueline; Lukiyanchuk, Vasyl; Hein, Linda; Lock, Steffen; Kurth, Ina; Baumann, Michael; Krause, Mechthild; Linge, Annett; Dubrovska, Anna] Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, OncoRay Natl Ctr Radiat Res Oncol, Fac Med, Dresden, Germany; [Nathansen, Jacqueline; Lukiyanchuk, Vasyl; Hein, Linda; Lock, Steffen; Kurth, Ina; Baumann, Michael; Krause, Mechthild; Linge, Annett; Dubrovska, Anna] Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, Univ Hosp Carl Gustav Carus, Dresden, Germany; [Nathansen, Jacqueline; Lukiyanchuk, Vasyl; Krause, Mechthild; Dubrovska, Anna] Helmholtz Zentrum Dresden Rossendorf, Inst Radiooncol OncoRay, Dresden, Germany; [Stolte, Maya-Isabel; Borgmann, Kerstin] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Lab Radiobiol & Expt Radiooncol, Hamburg, Germany; [Lock, Steffen; Krause, Mechthild; Linge, Annett; Dubrovska, Anna] German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany; [Lock, Steffen; Kurth, Ina; Baumann, Michael; Krause, Mechthild; Linge, Annett; Dubrovska, Anna] German Canc Res Ctr, Heidelberg, Germany; [Lock, Steffen; Baumann, Michael; Krause, Mechthild; Linge, Annett] Tech Univ Dresden, Dept Radiotherapy & Radiat Oncol, Fac Med, Dresden, Germany; [Lock, Steffen; Baumann, Michael; Krause, Mechthild; Linge, Annett] Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany; [Krause, Mechthild; Linge, Annett] Natl Ctr Tumor Dis NCT, Partner Site Dresden, Dresden, Germany; [Krause, Mechthild; Linge, Annett] Tech Univ Dresden, Fac Med, Dresden, Germany; [Krause, Mechthild; Linge, Annett] Helmholtz Zentrum Dresden Rossendorf HZDR, Dresden, Germany	Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Technische Universitat Dresden; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR); University of Hamburg; University Medical Center Hamburg-Eppendorf; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); Technische Universitat Dresden; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg; Technische Universitat Dresden; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf (HZDR)	Linge, A; Dubrovska, A (corresponding author), Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, OncoRay Natl Ctr Radiat Res Oncol, Fac Med, Dresden, Germany.; Linge, A; Dubrovska, A (corresponding author), Tech Univ Dresden, Helmholtz Zentrum Dresden Rossendorf, Univ Hosp Carl Gustav Carus, Dresden, Germany.; Dubrovska, A (corresponding author), Helmholtz Zentrum Dresden Rossendorf, Inst Radiooncol OncoRay, Dresden, Germany.; Linge, A; Dubrovska, A (corresponding author), German Canc Consortium DKTK, Partner Site Dresden, Heidelberg, Germany.; Linge, A; Dubrovska, A (corresponding author), German Canc Res Ctr, Heidelberg, Germany.; Linge, A (corresponding author), Tech Univ Dresden, Dept Radiotherapy & Radiat Oncol, Fac Med, Dresden, Germany.; Linge, A (corresponding author), Tech Univ Dresden, Univ Hosp Carl Gustav Carus, Dresden, Germany.; Linge, A (corresponding author), Natl Ctr Tumor Dis NCT, Partner Site Dresden, Dresden, Germany.; Linge, A (corresponding author), Tech Univ Dresden, Fac Med, Dresden, Germany.; Linge, A (corresponding author), Helmholtz Zentrum Dresden Rossendorf HZDR, Dresden, Germany.	Annett.Linge@uniklinikum-dresden.de; a.dubrovska@hzdr.de		Kurth, Ina/0000-0001-9261-5165; Linge, Annett/0000-0001-9636-1721; Baumann, Michael/0000-0002-9340-974X	Deutsche Forschungsgemeinschaft (DFG) [SPP 2084, 401326337, 416001651]; Wilhelm Sander-Stiftung [2017.106.1]; BMBF [02NUK032, 02NUK035B, 03Z1NN11]; DFG [BO1868-5]; Hubertus Wald Stiftung; Hamburger Krebsgesellschaft e.V.	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Wilhelm Sander-Stiftung; BMBF(Federal Ministry of Education & Research (BMBF)); DFG(German Research Foundation (DFG)); Hubertus Wald Stiftung; Hamburger Krebsgesellschaft e.V.	We greatly appreciate Liane Stolz-Kieslich for her help with immunochistochemical staining, the members of the Group of Biomarkers for Individualized Radiotherapy for their critical reading of the manuscript and the team of The Core Facilities of the Technology Platform at BIOTEC TU Dresden for their constant technical support. Work in AD lab was partially supported by grants from Deutsche Forschungsgemeinschaft (DFG) (SPP 2084: mu BONE, 401326337 and 416001651), from Wilhelm Sander-Stiftung (2017.106.1) and BMBF (03Z1NN11). Work in KB lab was partially supported by DFG (BO1868-5) and BMBF (Grant 02NUK032 and 02NUK035B), Hubertus Wald Stiftung, and Hamburger Krebsgesellschaft e.V.	Akagi K, 2014, GENOME RES, V24, P185, DOI 10.1101/gr.164806.113; Ang KK, 2010, NEW ENGL J MED, V363, P24, DOI 10.1056/NEJMoa0912217; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Bartucci M, 2012, CELL DEATH DIFFER, V19, P768, DOI 10.1038/cdd.2011.170; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Bertrand G, 2014, STEM CELL REV REP, V10, P114, DOI 10.1007/s12015-013-9467-y; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Butof R, 2013, RADIOTHER ONCOL, V108, P388, DOI 10.1016/j.radonc.2013.06.002; Carpen T, 2020, CANCER IMMUNOL IMMUN, V69, P1615, DOI 10.1007/s00262-020-02570-3; Chen YC, 2009, BIOCHEM BIOPH RES CO, V385, P307, DOI 10.1016/j.bbrc.2009.05.048; Chow LQM, 2020, NEW ENGL J MED, V382, P60, DOI 10.1056/NEJMra1715715; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Digomann D, 2019, CLIN CANCER RES, V25, P3152, DOI 10.1158/1078-0432.CCR-18-2951; Fong YW, 2013, MOL CELL, V52, P291, DOI 10.1016/j.molcel.2013.10.018; Gao Y, 2012, STEM CELLS, V30, P665, DOI 10.1002/stem.1034; Geissler C, 2012, IN VIVO, V26, P593; Hammachi F, 2012, CELL REPORTS, V1, P99, DOI 10.1016/j.celrep.2011.12.002; Hashibe M, 2009, CANCER EPIDEM BIOMAR, V18, P541, DOI 10.1158/1055-9965.EPI-08-0347; Heyer WD, 2006, NUCLEIC ACIDS RES, V34, P4115, DOI 10.1093/nar/gkl481; Jung JW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028068; Kagohara LT, 2020, BRIT J CANCER, V123, P101, DOI 10.1038/s41416-020-0851-5; Kim JY, 2018, INT J ONCOL, V53, P47, DOI 10.3892/ijo.2018.4391; Kim Ran-Ju, 2011, Lab Anim Res, V27, P147, DOI 10.5625/lar.2011.27.2.147; Kimple RJ, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.01.37; Kimple RJ, 2013, CANCER RES, V73, P4791, DOI 10.1158/0008-5472.CAN-13-0587; Koo BS, 2015, ONCOGENE, V34, P2317, DOI 10.1038/onc.2014.174; Krajewska M, 2013, ONCOGENE, V32, P3001, DOI 10.1038/onc.2012.296; Krause M, 2017, ADV DRUG DELIVER REV, V109, P63, DOI 10.1016/j.addr.2016.02.002; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Kurth I, 2015, ONCOTARGET, V6, P34494, DOI 10.18632/oncotarget.5417; Lee J, 2006, J BIOL CHEM, V281, P33554, DOI 10.1074/jbc.M603937200; Leemans CR, 2018, NAT REV CANCER, V18, P269, DOI 10.1038/nrc.2018.11; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Linge A, 2016, RADIOTHER ONCOL, V121, P364, DOI 10.1016/j.radonc.2016.11.008; Linge A, 2016, CLIN CANCER RES, V22, P2639, DOI 10.1158/1078-0432.CCR-15-1990; Liu C, 2020, ORAL ONCOL, V100, DOI 10.1016/j.oraloncology.2019.104469; Lohaus F, 2014, RADIOTHER ONCOL, V113, P317, DOI 10.1016/j.radonc.2014.11.011; Manic G, 2018, GUT, V67, P903, DOI 10.1136/gutjnl-2016-312623; Meng L, 2018, ONCOL LETT, V16, P522, DOI 10.3892/ol.2018.8607; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; O'Sullivan B, 2013, J CLIN ONCOL, V31, P543, DOI 10.1200/JCO.2012.44.0164; Peitzsch C, 2019, CANCERS, V11, DOI 10.3390/cancers11050616; Pezza RJ, 2014, NUCLEIC ACIDS RES, V42, P2346, DOI 10.1093/nar/gkt1234; Pitroda SP, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008291; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Rachmadi Lisnawati, 2019, Oman Med J, V34, P224, DOI 10.5001/omj.2019.43; Razzouk S, 2014, CLIN GENET, V86, P412, DOI 10.1111/cge.12487; Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200; Ruan ZY, 2019, CANCER MANAG RES, V11, P389, DOI 10.2147/CMAR.S180418; Schulz A, 2019, CANCERS, V11, DOI 10.3390/cancers11060862; Shao MH, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/3424956; Shi GL, 2010, STEM CELL RES THER, V1, DOI 10.1186/scrt39; Smith HL, 2020, EXPERT REV MOL MED, V22, DOI 10.1017/erm.2020.3; Song B, 2018, BIOCHEM BIOPH RES CO, V503, P1980, DOI 10.1016/j.bbrc.2018.07.145; Sorensen CS, 2005, NAT CELL BIOL, V7, P195, DOI 10.1038/ncb1212; Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321; Trosko JE, 2019, CANCERS, V11, DOI 10.3390/cancers11010087; Vaddi PK, 2019, CANCERS, V11, DOI 10.3390/cancers11091331; Venkatesha VA, 2012, NEOPLASIA, V14, P519, DOI 10.1593/neo.12538; Ventela S, 2015, ONCOTARGET, V6, P144, DOI 10.18632/oncotarget.2670; Vitale I, 2017, MOL CELL, V66, P306, DOI 10.1016/j.molcel.2017.04.006; Wang X, 2009, STEM CELLS, V27, P1265, DOI 10.1002/stem.58; Wurster S, 2016, ONCOTARGET, V7, P9732, DOI 10.18632/oncotarget.6947; Yaromina A, 2007, RADIOTHER ONCOL, V83, P304, DOI 10.1016/j.radonc.2007.04.020; Zhang Y, 2019, J BONE MINER RES, V34, P2287, DOI 10.1002/jbmr.3857; Zhou YW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0606-x	67	10	10	0	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 17	2021	40	24					4214	4228		10.1038/s41388-021-01842-1	http://dx.doi.org/10.1038/s41388-021-01842-1		JUN 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SU3OE	34079088	Green Published, hybrid			2022-12-17	WOS:000657217400009
J	Pietrobono, S; Gaudio, E; Gagliardi, S; Zitani, M; Carrassa, L; Migliorini, F; Petricci, E; Manetti, F; Makukhin, N; Bond, AG; Paradise, BD; Ciulli, A; Fernandez-Zapico, ME; Bertoni, F; Stecca, B				Pietrobono, Silvia; Gaudio, Eugenio; Gagliardi, Sinforosa; Zitani, Mariapaola; Carrassa, Laura; Migliorini, Francesca; Petricci, Elena; Manetti, Fabrizio; Makukhin, Nikolai; Bond, Adam G.; Paradise, Brooke D.; Ciulli, Alessio; Fernandez-Zapico, Martin E.; Bertoni, Francesco; Stecca, Barbara			Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma	ONCOGENE			English	Article							SELF-RENEWAL; DNA-DAMAGE; STEM-CELL; BET; CANCER; PROTEIN; GROWTH; TUMORIGENICITY; PROLIFERATION; SUPPRESSES	Despite the development of new targeted and immune therapies, the prognosis of metastatic melanoma remains bleak. Therefore, it is critical to better understand the mechanisms controlling advanced melanoma to develop more effective treatment regimens. Hedgehog/GLI (HH/GLI) signaling inhibitors targeting the central pathway transducer Smoothened (SMO) have shown to be clinical efficacious in skin cancer; however, several mechanisms of non-canonical HH/GLI pathway activation limit their efficacy. Here, we identify a novel SOX2-BRD4 transcriptional complex driving the expression of GLI1, the final effector of the HH/GLI pathway, providing a novel mechanism of non-canonical SMO-independent activation of HH/GLI signaling in melanoma. Consistently, we find a positive correlation between the expression of GLI1 and SOX2 in human melanoma samples and cell lines. Further, we show that combined targeting of canonical HH/GLI pathway with the SMO inhibitor MRT-92 and of the SOX2-BRD4 complex using a potent Proteolysis Targeted Chimeras (PROTACs)-derived BRD4 degrader (MZ1), yields a synergistic anti-proliferative effect in melanoma cells independently of their BRAF, NRAS, and NF1 mutational status, with complete abrogation of GLI1 expression. Combination of MRT-92 and MZ1 strongly potentiates the antitumor effect of either drug as single agents in an orthotopic melanoma model. Together, our data provide evidence of a novel mechanism of non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex, and describe the efficacy of a new combinatorial treatment for a subset of melanomas with an active SOX2-BRD4-GLI1 axis.	[Pietrobono, Silvia; Gagliardi, Sinforosa; Zitani, Mariapaola; Carrassa, Laura; Stecca, Barbara] Inst Canc Res & Prevent ISPRO, Core Res Lab, Florence, Italy; [Gaudio, Eugenio; Bertoni, Francesco] USI, Inst Oncol Res, Fac Biomed Sci, Bellinzona, Switzerland; [Migliorini, Francesca; Petricci, Elena; Manetti, Fabrizio] Univ Siena, Dept Biotechnol Chem & Pharm, Siena, Italy; [Makukhin, Nikolai; Bond, Adam G.; Ciulli, Alessio] Univ Dundee, Sch Life Sci, Div Biol Chem & Drug Discovery, James Black Ctr, Dundee, Scotland; [Paradise, Brooke D.; Fernandez-Zapico, Martin E.] Mayo Clin, Schulze Ctr Novel Therapeut, Dept Oncol, Div Oncol Res, Rochester, MN USA; [Bertoni, Francesco] Oncol Inst Southern Switzerland, Bellinzona, Switzerland	Institute of Oncology Research (IOR); Universita della Svizzera Italiana; University of Siena; University of Dundee; Mayo Clinic; Institute of Oncology Research (IOR)	Pietrobono, S; Stecca, B (corresponding author), Inst Canc Res & Prevent ISPRO, Core Res Lab, Florence, Italy.	silvia.pietrobono@ittumori.it; b.stecca@ispro.toscana.it	Petricci, Elena/AAB-9275-2022; Manetti, Fabrizio/Q-9412-2019; Pietrobono, Silvia S/K-3932-2016; Bertoni, Francesco/G-6922-2014	Manetti, Fabrizio/0000-0002-9598-2339; Pietrobono, Silvia S/0000-0002-5544-7286; Carrassa, Laura/0000-0003-2707-4301; Makukhin, Nikolai/0000-0003-2465-0748; Bertoni, Francesco/0000-0001-5637-8983; Migliorini, Francesca/0000-0003-2149-978X; Bond, Adam/0000-0002-1271-1032	Associazione Italiana per la Ricerca sul Cancro (AIRC) [IG-14184, IG-23091]; Institute for Cancer Research, Prevention and Clinical Network (ISPRO); AIRC fellowship [21168]; UK Biotechnology and Biological Sciences Research Council (BBSRC) [BB/J001201/2]; European Research Council (ERC) [ERC-2012-StG-311460]; Medical Research Scotland PhD studentship [1170-2017]	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Institute for Cancer Research, Prevention and Clinical Network (ISPRO); AIRC fellowship(Fondazione AIRC per la ricerca sul cancro); UK Biotechnology and Biological Sciences Research Council (BBSRC)(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); European Research Council (ERC)(European Research Council (ERC)European Commission); Medical Research Scotland PhD studentship	We thank Fritz Aberger (University of Salzburg, Austria) for SOX2 promoter/enhancer reporter plasmids. The BS lab was partially supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) (IG-14184 and IG-23091) and by institutional funding from the Institute for Cancer Research, Prevention and Clinical Network (ISPRO). SP was supported by AIRC fellowship (n. 21168). The AC lab was funded by awards from the UK Biotechnology and Biological Sciences Research Council (BBSRC, grant BB/J001201/2) and the European Research Council (ERC, Starting Grant ERC-2012-StG-311460 DrugE3CRLs). AGB was supported by a Medical Research Scotland PhD studentship (1170-2017).	Andrieu Guillaume, 2016, Drug Discov Today Technol, V19, P45, DOI 10.1016/j.ddtec.2016.06.004; Andrieu GP, 2019, CANCER LETT, V465, P45, DOI 10.1016/j.canlet.2019.08.013; Bora-Singhal N, 2015, NEOPLASIA, V17, P538, DOI 10.1016/j.neo.2015.07.001; Cao JY, 2019, NATURE, V566, P496, DOI 10.1038/s41586-019-0969-x; Chapuy B, 2013, CANCER CELL, V24, P777, DOI 10.1016/j.ccr.2013.11.003; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cochrane CR, 2015, CANCERS, V7, P1554, DOI 10.3390/cancers7030851; Noblejas-Lopez MD, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1387-5; Dhalluin C, 1999, NATURE, V399, P491, DOI 10.1038/20974; Echevarria-Vargas IM, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708446; Erkes DA, 2019, PIGM CELL MELANOMA R, V32, P687, DOI 10.1111/pcmr.12788; Fang XF, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-11; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Floyd SR, 2013, NATURE, V498, P246, DOI 10.1038/nature12147; Gadd MS, 2017, NAT CHEM BIOL, V13, P514, DOI [10.1038/NCHEMBIO.2329, 10.1038/nchembio.2329]; Gallagher SJ, 2014, J INVEST DERMATOL, V134, P2795, DOI 10.1038/jid.2014.243; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hogg SJ, 2017, CELL REP, V18, P2162, DOI 10.1016/j.celrep.2017.02.011; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Huang YS, 2016, CLIN CANCER RES, V22, P4259, DOI 10.1158/1078-0432.CCR-15-2068; Jalili A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069064; Jenkins RW, 2021, J INVEST DERMATOL, V141, P23, DOI 10.1016/j.jid.2020.03.943; Jia YF, 2019, ONCOGENE, V38, P1764, DOI 10.1038/s41388-018-0553-0; Kamath A, 2019, BIORXIV326470, DOI [10.1038/s41388-021-01783-9, DOI 10.1038/S41388-021-01783-9]; Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361; Kumar K, 2015, SCI REP-UK, V5, DOI 10.1038/srep09489; Long J, 2014, J BIOL CHEM, V289, P35494, DOI 10.1074/jbc.M114.595348; Lu LL, 2020, CELL DEATH DIFFER, V27, P255, DOI 10.1038/s41418-019-0353-2; Mazumdar T, 2011, CANCER RES, V71, P5904, DOI 10.1158/0008-5472.CAN-10-4173; O'Reilly KE, 2013, PHARMACEUTICALS, V6, P1429, DOI 10.3390/ph6111429; Paoluzzi L, 2016, CANCER MED-US, V5, P1183, DOI 10.1002/cam4.667; Pietrobono S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19575-2; Pietrobono S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00556; Pietrobono S, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0142-0; Riverso M, 2017, ONCOGENE, V36, P3322, DOI 10.1038/onc.2016.481; Santini R, 2014, ONCOGENE, V33, P4697, DOI 10.1038/onc.2014.71; Santini R, 2012, STEM CELLS, V30, P1808, DOI 10.1002/stem.1160; Segura MF, 2013, CANCER RES, V73, P6264, DOI 10.1158/0008-5472.CAN-13-0122-T; Sekulic A, 2016, CELL, V164, P831, DOI 10.1016/j.cell.2016.02.021; Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016; Song H, 2019, EUR J PHARMACOL, V852, P189, DOI 10.1016/j.ejphar.2019.03.018; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Swift LH, 2014, INT J MOL SCI, V15, P3403, DOI 10.3390/ijms15033403; Tang YJ, 2014, NAT MED, V20, P732, DOI 10.1038/nm.3613; Ullman-Cullere MH, 1999, LAB ANIM SCI, V49, P319; Vardabasso C, 2015, MOL CELL, V59, P75, DOI 10.1016/j.molcel.2015.05.009; Venkataraman S, 2014, ONCOTARGET, V5, P2355; Wu FJ, 2017, CELL CHEM BIOL, V24, P252, DOI 10.1016/j.chembiol.2017.02.010; Wuebben EL, 2017, ONCOTARGET, V8, P44917, DOI 10.18632/oncotarget.16570; Zengerle M, 2015, ACS CHEM BIOL, V10, P1770, DOI 10.1021/acschembio.5b00216; Zhu HR, 2016, CELL REP, V16, P2829, DOI 10.1016/j.celrep.2016.08.032	51	10	10	2	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 3	2021	40	22					3799	3814		10.1038/s41388-021-01783-9	http://dx.doi.org/10.1038/s41388-021-01783-9		MAY 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SM7LL	33958721	hybrid, Green Published			2022-12-17	WOS:000648041500007
J	Mao, LF; Yuan, WJ; Cai, KM; Lai, C; Huang, CH; Xu, Y; Zhong, SW; Yang, C; Wang, R; Zeng, PW; Huang, HY; Chen, ZK; Chen, ZH				Mao, Linfeng; Yuan, Weijie; Cai, Kaimei; Lai, Chen; Huang, Changhao; Xu, Yi; Zhong, Shangwei; Yang, Chen; Wang, Ran; Zeng, Pengwei; Huang, Heyuan; Chen, Zhikang; Chen, Zihua			EphA2-YES1-ANXA2 pathway promotes gastric cancer progression and metastasis	ONCOGENE			English	Article							ANNEXIN A2; POOR-PROGNOSIS; PHOSPHORYLATION; INVASION; NUCLEAR; PROLIFERATION; MIGRATION; COMPLEX; GROWTH; SIGNAL	Erythropoietin-producing hepatocellular receptor A2 (EphA2) is a key member of the receptor tyrosine kinase (RTK) family, while YES Proto-Oncogene 1 (YES1) is a non-receptor tyrosine kinase (nRTK) and annexin A2 (ANXA2) belongs to the calcium-dependent phospholipid-binding protein family annexins. Here, we show that EphA2, YES1, and ANXA2 form a signal axis, in which YES1 activated by EphA2 phosphorylates ANXA2 at Tyr24 site, leading to ANXA2 activation and increased ANXA2 nuclear distribution in gastric cancer (GC) cells. Overexpression (OE) of YES1 increases, while knockdown (KD) of YES1 or ANXA2 decreases GC cell invasion and migration in vitro and tumor growth in mouse models. Reexpression of wildtype (WT) rather than mutant ANXA2 (Tyr24F) in ANXA2 knockdown (ANXA2-KD) GC cells restores YES1-induced cell invasion and migration, while neither WT nor mutant ANXA2 (Tyr24F) can restore cell invasion and migration in YES1-KD GC cells. In addition, the activation of EphA2-YES1-ANXA2 pathway is correlated with poor prognosis. Thus, our results establish EphA2-YES1-ANXA2 axis as a novel pathway that drives GC invasion and metastasis, targeting this pathway would be an efficient way for the treatment of GC.	[Mao, Linfeng; Yuan, Weijie; Lai, Chen; Huang, Changhao; Yang, Chen; Wang, Ran; Zeng, Pengwei; Huang, Heyuan; Chen, Zhikang; Chen, Zihua] Cent South Univ CSU, Xiangya Hosp, Dept Gen Surg, Changsha, Hunan, Peoples R China; [Mao, Linfeng; Yuan, Weijie; Huang, Changhao; Yang, Chen; Zeng, Pengwei; Huang, Heyuan; Chen, Zihua] CSU, Xiangya Hosp, Dept Gastrointestinal Surg, Changsha, Hunan, Peoples R China; [Mao, Linfeng; Cai, Kaimei; Lai, Chen; Huang, Changhao; Xu, Yi; Zhong, Shangwei; Yang, Chen; Wang, Ran; Zeng, Pengwei; Huang, Heyuan; Chen, Zhikang; Chen, Zihua] CSU, Xiangya Hosp, Hunan Prov Key Lab Precis Diag & Treatment Gastro, Changsha, Hunan, Peoples R China; [Yuan, Weijie; Lai, Chen; Wang, Ran; Chen, Zhikang] CSU, Xiangya Hosp, Dept Colorectal & Anus Surg, Changsha, Hunan, Peoples R China; [Chen, Zhikang; Chen, Zihua] CSU, Xiangya Hosp, Int Joint Res Ctr Minimally Invas Endoscop Techno, Changsha, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University	Chen, ZH (corresponding author), Cent South Univ CSU, Xiangya Hosp, Dept Gen Surg, Changsha, Hunan, Peoples R China.; Chen, ZH (corresponding author), CSU, Xiangya Hosp, Dept Gastrointestinal Surg, Changsha, Hunan, Peoples R China.; Chen, ZH (corresponding author), CSU, Xiangya Hosp, Hunan Prov Key Lab Precis Diag & Treatment Gastro, Changsha, Hunan, Peoples R China.; Chen, ZH (corresponding author), CSU, Xiangya Hosp, Int Joint Res Ctr Minimally Invas Endoscop Techno, Changsha, Hunan, Peoples R China.	zihuachenxy@126.com		Zhong, Shangwei/0000-0002-8587-6452; Yang, Chen/0000-0002-2502-4960; Mao, Lin-feng/0000-0001-8113-1253	Natural Science Foundation of China [81974386]; Research and Development program in Key Areas of Hunan Province [2019SK2143]; Natural Science Foundation of Hunan Province [2018JJ6065]; Innovation Research Project of CSU [2019zzts335]	Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Research and Development program in Key Areas of Hunan Province; Natural Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); Innovation Research Project of CSU	This study was supported by Natural Science Foundation of China (81974386), Research and Development program in Key Areas of Hunan Province (2019SK2143), Natural Science Foundation of Hunan Province (2018JJ6065) and Innovation Research Project of CSU (2019zzts335). We thank Advanced Research Center and Cancer Research Institute of CSU for providing some GC cell lines.	Ajani JA, 2016, J NATL COMPR CANC NE, V14, P1286, DOI 10.6004/jnccn.2016.0137; Alam Muhammad S, 2018, Curr Protoc Immunol, V123, pe58, DOI 10.1002/cpim.58; Anselmino N, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030467; Aukrust I, 2017, FEBS OPEN BIO, V7, P160, DOI 10.1002/2211-5463.12173; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chasserot-Golaz S, 2005, MOL BIOL CELL, V16, P1108, DOI 10.1091/mbc.E04-07-0627; Christensen MV, 2018, INT J ONCOL, V52, P5, DOI 10.3892/ijo.2017.4197; Das S, 2010, BIOCHEMISTRY-US, V49, P2216, DOI 10.1021/bi9013038; de Graauw M, 2008, MOL CELL BIOL, V28, P1029, DOI 10.1128/MCB.01247-07; De Robertis M, 2017, CLIN CANCER RES, V23, P159, DOI 10.1158/1078-0432.CCR-16-0709; Eberhard DA, 2001, J CELL SCI, V114, P3155; Emoto K, 2001, ANTICANCER RES, V21, P1339; Eusebi LH, 2020, J GASTROEN HEPATOL, V35, P1495, DOI 10.1111/jgh.15037; Fahling M, 2019, AM J PHYSIOL-RENAL, V316, pF101, DOI 10.1152/ajprenal.00361.2018; Fan YL, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1147-7; Fei F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00182; Garmendia I, 2019, AM J RESP CRIT CARE, V200, P888, DOI 10.1164/rccm.201807-1292OC; Grindheim AK, 2017, BBA-GEN SUBJECTS, V1861, P2515, DOI 10.1016/j.bbagen.2017.08.024; Grindheim AK, 2016, J CELL SCI, V129, P314, DOI 10.1242/jcs.173195; Hamamoto Y, 2020, GASTRIC CANCER, V23, P363, DOI 10.1007/s10120-020-01067-3; Hamanaka N, 2019, CANCER RES, V79, P5734, DOI 10.1158/0008-5472.CAN-18-3376; Hou FT, 2012, MED ONCOL, V29, P2691, DOI 10.1007/s12032-011-0127-2; Huang CH, 2020, INT J CANCER, V146, P1937, DOI 10.1002/ijc.32609; Huang J, 2014, ONCOGENE, V33, P2737, DOI 10.1038/onc.2013.238; HUNTER T, 1987, CELL, V49, P1, DOI 10.1016/0092-8674(87)90745-8; Ieguchi K, 2019, CANCER SCI, V110, P841, DOI 10.1111/cas.13942; JINDAL HK, 1991, J BIOL CHEM, V266, P5169; Jost M, 1996, BBA-MOL CELL RES, V1313, P283, DOI 10.1016/0167-4889(96)00101-2; Kazami T, 2015, ONCOGENE, V34, P4177, DOI 10.1038/onc.2014.345; Kpetemey M, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0428-8; Li JY, 2019, CANCER LETT, V444, P162, DOI 10.1016/j.canlet.2018.12.011; Li RX, 2014, MOL CELL BIOCHEM, V396, P295, DOI 10.1007/s11010-014-2164-6; Li WL, 2018, ONCOGENE, V37, P4903, DOI 10.1038/s41388-018-0341-x; Ma S, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0851-y; Markosyan N, 2019, J CLIN INVEST, V129, P3594, DOI 10.1172/JCI127755; Oliveira L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029963; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Peng Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1164-y; Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Sirvent A, 2015, PROTEOMICS, V15, P232, DOI 10.1002/pmic.201400162; Song W, 2017, ONCOGENE, V36, P5620, DOI 10.1038/onc.2017.170; Sun GQ, 1998, ONCOGENE, V17, P1587, DOI 10.1038/sj.onc.1202076; Touil Y, 2014, CLIN CANCER RES, V20, P837, DOI 10.1158/1078-0432.CCR-13-1854; Wang T, 2019, CANCER BIOL MED, V16, P671, DOI 10.20892/j.issn.2095-3941.2019.0228; Wang Yu-qing, 2012, Cancer Biology Medicine, V9, P248, DOI 10.7497/j.issn.2095-3941.2012.04.005; Xie R, 2019, J ONCOL, V2019, DOI 10.1155/2019/4035460; Yoshida N, 2021, GUT, V70, P67, DOI 10.1136/gutjnl-2019-319631; Zhou Y, 2017, BIOL PHARM BULL, V40, P1616, DOI 10.1248/bpb.b17-00446; Zhou Y, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8679	50	10	10	4	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 20	2021	40	20					3610	3623		10.1038/s41388-021-01786-6	http://dx.doi.org/10.1038/s41388-021-01786-6		MAY 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	SE7RS	33941853	Green Published, hybrid			2022-12-17	WOS:000646512200001
J	Li, HJ; Han, XG; Yang, SB; Wang, YJ; Dong, Y; Tang, TT				Li, Hanjun; Han, Xiuguo; Yang, Shengbing; Wang, Yongjie; Dong, Yang; Tang, Tingting			FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53	ONCOGENE			English	Article								Osteosarcoma has a poor prognosis, and the poor understanding of the genetic drivers of osteosarcoma hinders further improvement in therapeutic approaches. Transcription factor forkhead box P1 (FOXP1) is a crucial modulator in skeletal development and aging. Here, we determined the role and regulatory mechanisms of FOXP1 in osteosarcoma. Higher FOXP1 expression correlated with malignancy in both osteosarcoma cell lines and clinical biopsies. FOXP1 overexpression and knockdown in osteosarcoma cell lines revealed that FOXP1 promoted proliferation, tumor sphere formation, migration and invasion, and inhibited anoikis. Mechanistically, FOXP1 acted as a repressor of P21 and RB (retinoblastoma protein) transcription, and directly interacted with the tumor suppressor p53 to inhibit its activity. Extracellular signal-regulated kinase/c-Jun N-terminal kinase (ERK/JNK) signaling and c-JUN/c-FOS transcription factors were found to be upstream activators of FOXP1. Moreover, FOXP1 silencing via lentivirus or adeno-associated virus (AAV)-mediated delivery of shRNA suppressed osteosarcoma development and progression in cell-derived and patient-derived xenograft animal models. Taken together, we demonstrate that FOXP1, which is transactivated by ERK/JNK-c-JUN/c-FOS, drives osteosarcoma development by regulating the p53-P21/RB signaling cascade, suggesting that FOXP1 is a potential target for osteosarcoma therapy.	[Li, Hanjun; Yang, Shengbing; Tang, Tingting] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants, Dept Orthoped Surg,Sch Med, Shanghai, Peoples R China; [Han, Xiuguo] Shanghai Jiao Tong Univ, Xin Hua Hosp, Dept Orthoped Surg, Sch Med, Shanghai, Peoples R China; [Wang, Yongjie; Dong, Yang] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthopaed, Shanghai, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Tang, TT (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Shanghai Key Lab Orthopaed Implants, Dept Orthoped Surg,Sch Med, Shanghai, Peoples R China.; Dong, Y (corresponding author), Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Dept Orthopaed, Shanghai, Peoples R China.	dongyang6405@163.com; ttt@sjtu.edu.cn	Tang, Tingting/B-1361-2013	Tang, Tingting/0000-0002-1670-7452; Wang, Yongjie/0000-0001-7035-5382; Li, Hanjun/0000-0002-7017-8782	National Natural Science Foundation of China [81802679]; Shanghai Science and Technology Development Fund [18DZ2291200]; China Postdoctoral Science Foundation [2018M632136, 2019T120348]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Science and Technology Development Fund; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This project was supported by the National Natural Science Foundation of China (81802679), the Shanghai Science and Technology Development Fund (18DZ2291200), and China Postdoctoral Science Foundation (2018M632136 and 2019T120348) to HL.	Armesilla-Diaz A, 2009, EXP CELL RES, V315, P3598, DOI 10.1016/j.yexcr.2009.08.004; Bates GJ, 2008, BREAST CANCER RES TR, V111, P453, DOI 10.1007/s10549-007-9812-4; Behjati S, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15936; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Brown PJ, 2016, LEUKEMIA, V30, P605, DOI 10.1038/leu.2015.299; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Chen HJ, 2018, BIOCHEM BIOPH RES CO, V503, P1434, DOI 10.1016/j.bbrc.2018.07.060; Chen X, 2014, CELL REP, V7, P104, DOI 10.1016/j.celrep.2014.03.003; Chokas AL, 2010, J BIOL CHEM, V285, P13304, DOI 10.1074/jbc.M109.088468; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Coventon J, 2017, J BONE ONCOL, V8, P4, DOI 10.1016/j.jbo.2017.07.001; Dasen JS, 2008, CELL, V134, P304, DOI 10.1016/j.cell.2008.06.019; Dekker JD, 2016, P NATL ACAD SCI USA, V113, pE577, DOI 10.1073/pnas.1524677113; Deng Q, 2019, ELIFE, V8, DOI 10.7554/eLife.50208; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Du L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0745-0; Feng XM, 2011, NAT IMMUNOL, V12, P544, DOI 10.1038/ni.2034; Fittall MW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04530-z; Flori M, 2016, BLOOD, V127, P1438, DOI [10.1182/blood-2015-08662635, 10.1182/blood-2015-08-662635]; Fox SB, 2004, CLIN CANCER RES, V10, P3521, DOI 10.1158/1078-0432.CCR-03-0461; Gabut M, 2011, CELL, V147, P132, DOI 10.1016/j.cell.2011.08.023; Gascoyne DM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128513; Gianferante DM, 2017, NAT REV ENDOCRINOL, V13, P480, DOI 10.1038/nrendo.2017.16; Han XG, 2019, ADV FUNCT MATER, V29, DOI 10.1002/adfm.201902246; Han YJ, 2019, J CLIN INVEST, V129, P1895, DOI 10.1172/JCI124590; HANSEN MF, 1985, P NATL ACAD SCI USA, V82, P6216, DOI 10.1073/pnas.82.18.6216; Harrison DJ, 2018, EXPERT REV ANTICANC, V18, P39, DOI 10.1080/14737140.2018.1413939; Hieronymus H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01198-9; Hu H, 2006, NAT IMMUNOL, V7, P819, DOI 10.1038/ni1358; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kansara M, 2014, NAT REV CANCER, V14, P722, DOI 10.1038/nrc3838; Kim JH, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1110-3; Koon HB, 2007, EXPERT OPIN THER TAR, V11, P955, DOI 10.1517/14728222.11.7.955; Leishman E, 2013, DEVELOPMENT, V140, P3809, DOI 10.1242/dev.097477; Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130; Li HJ, 2017, J CLIN INVEST, V127, P1241, DOI 10.1172/JCI89511; Li SR, 2012, DEVELOPMENT, V139, P2500, DOI 10.1242/dev.079699; Lin YH, 2017, TRENDS MOL MED, V23, P737, DOI 10.1016/j.molmed.2017.06.004; Liu P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12988-8; MALKIN D, 1994, ANNU REV GENET, V28, P443; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MILLER CW, 1990, CANCER RES, V50, P7950; Mirabello L, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv101; Mohseny AB, 2011, LAB INVEST, V91, P1195, DOI 10.1038/labinvest.2011.72; Mottok A, 2018, BLOOD, V131, P226, DOI 10.1182/blood-2017-08-799080; Naudin C, 2017, BLOOD, V129, P2493, DOI 10.1182/blood-2016-10-747436; Papachristou DJ, 2003, BONE, V32, P364, DOI 10.1016/S8756-3282(03)00026-7; Perry JA, 2014, P NATL ACAD SCI USA, V111, pE5564, DOI 10.1073/pnas.1419260111; Quist T, 2015, ONCOGENE, V34, P4278, DOI 10.1038/onc.2014.354; Sagaert X, 2006, J CLIN ONCOL, V24, P2490, DOI 10.1200/JCO.2006.05.6150; Sheng H, 2019, CANCER BIOL THER, V20, P537, DOI 10.1080/15384047.2018.1537999; Shu WG, 2007, DEVELOPMENT, V134, P1991, DOI 10.1242/dev.02846; Spaeth JM, 2015, DIABETOLOGIA, V58, P1836, DOI 10.1007/s00125-015-3635-3; Streubel B, 2005, LEUKEMIA, V19, P652, DOI 10.1038/sj.leu.2403644; Takayama K, 2008, BIOCHEM BIOPH RES CO, V374, P388, DOI 10.1016/j.bbrc.2008.07.056; Tao JN, 2014, CANCER CELL, V26, P390, DOI 10.1016/j.ccr.2014.07.023; ter Huurne M, 2020, STEM CELL REP, V14, P175, DOI 10.1016/j.stemcr.2020.01.001; Usui N, 2017, GENE DEV, V31, P2039, DOI 10.1101/gad.305037.117; van Keimpema M, 2017, HAEMATOLOGICA, V102, P573, DOI 10.3324/haematol.2016.156455; van Keimpema M, 2014, BLOOD, V124, P3431, DOI 10.1182/blood-2014-01-553412; WADAYAMA B, 1994, CANCER RES, V54, P3042; Walker MP, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.2005654; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Wang X, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091501; WANG ZQ, 1995, CANCER RES, V55, P6244; Xu SQ, 2018, P NATL ACAD SCI USA, V115, P8799, DOI 10.1073/pnas.1721820115; Xu WT, 2009, CANCER LETT, V281, P32, DOI 10.1016/j.canlet.2009.02.022; Yang JL, 2011, CANCER-AM CANCER SOC, V117, P4925, DOI 10.1002/cncr.26116; Yin ZX, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12308; Zhang YZ, 2010, GENE DEV, V24, P1746, DOI 10.1101/gad.1929210; Zhao HX, 2015, DEV BIOL, V398, P242, DOI 10.1016/j.ydbio.2014.12.007	71	10	10	10	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2785	2802		10.1038/s41388-021-01742-4	http://dx.doi.org/10.1038/s41388-021-01742-4		MAR 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33716296				2022-12-17	WOS:000628816100002
J	Chen, Q; Shen, P; Ge, WL; Yang, TY; Wang, WJ; Meng, LD; Huang, XM; Zhang, YH; Cao, SJ; Miao, Y; Jiang, KR; Zhang, JJ				Chen, Qun; Shen, Peng; Ge, Wan-Li; Yang, Tao-Yue; Wang, Wu-Jun; Meng, Ling-Dong; Huang, Xu-Min; Zhang, Yi-Han; Cao, Shou-Ji; Miao, Yi; Jiang, Kui-Rong; Zhang, Jing-Jing			Roundabout homolog 1 inhibits proliferation via the YY1-ROBO1-CCNA2-CDK2 axis in human pancreatic cancer	ONCOGENE			English	Article							CYCLIN A2; DUCTAL ADENOCARCINOMA; CELL-PROLIFERATION; CDK2	Pancreatic cancer (PC) is highly malignant and has a high mortality with a 5-year survival rate of less than 8%. As a member of the roundabout immunoglobulin superfamily of proteins, ROBO1 plays an important role in embryogenesis and organogenesis and also inhibits metastasis in PC. Our study was designed to explore whether ROBO1 has effects on the proliferation of PC and its specific mechanism. The expression of ROBO1 was higher in cancer tissues than in matched adjacent tissues by immunohistochemistry (IHC) and qRT-PCR. Low ROBO1 expression is associated with PC progression and poor prognosis. Overexpression of ROBO1 can inhibit the proliferation of PC cells in vitro, and the S phase fraction can also be induced. Further subcutaneous tumor formation in nude mice showed that ROBO1 overexpression can significantly inhibit tumor growth. YY1 was found to directly bind to the promoter region of ROBO1 to promote transcription by a luciferase reporter gene assay, a chromatin immunoprecipitation (ChIP) and an electrophoretic mobility shift assay (EMSA). Mechanistic studies showed that YY1 can inhibit the development of PC by directly regulating ROBO1 via the CCNA2/CDK2 axis. Taken together, our results suggest that ROBO1 may be involved in the development and progression of PC by regulating cell proliferation and shows that ROBO1 may be a novel and promising therapeutic target for PC.	[Chen, Qun; Shen, Peng; Ge, Wan-Li; Yang, Tao-Yue; Meng, Ling-Dong; Huang, Xu-Min; Zhang, Yi-Han; Cao, Shou-Ji; Miao, Yi; Jiang, Kui-Rong; Zhang, Jing-Jing] Nanjing Med Univ, Affiliated Hosp 1, Pancreas Ctr, Nanjing, Peoples R China; [Chen, Qun; Shen, Peng; Ge, Wan-Li; Yang, Tao-Yue; Meng, Ling-Dong; Huang, Xu-Min; Zhang, Yi-Han; Cao, Shou-Ji; Miao, Yi; Jiang, Kui-Rong; Zhang, Jing-Jing] Nanjing Med Univ, Pancreas Inst, Nanjing, Peoples R China; [Wang, Wu-Jun] Nanjing Univ Chinese Med, Nanjing, Peoples R China	Nanjing Medical University; Nanjing Medical University; Nanjing University of Chinese Medicine	Jiang, KR; Zhang, JJ (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Pancreas Ctr, Nanjing, Peoples R China.; Jiang, KR; Zhang, JJ (corresponding author), Nanjing Med Univ, Pancreas Inst, Nanjing, Peoples R China.	jiangkuirong@njmu.edu.cn; zhangjingjing@njmu.edu.cn		chen, qun/0000-0002-9034-9825	National Natural Science Foundation of China [81871980, 81572337, 81672449]; National Science Foundation for Distinguished Young Scholars of China [81902455]; Jiangsu Key Medical Discipline [ZDXKA2016005]; Innovation Capability Development Project of Jiangsu Province [BM2015004]; Priority Academic Program AQ3 Development of Jiangsu Higher Education Institutions (PAPD) [JX10231801]; Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Outstanding Talent [JCRCA2016009]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Science Foundation for Distinguished Young Scholars of China(National Natural Science Foundation of China (NSFC)National Science Fund for Distinguished Young Scholars); Jiangsu Key Medical Discipline; Innovation Capability Development Project of Jiangsu Province; Priority Academic Program AQ3 Development of Jiangsu Higher Education Institutions (PAPD); Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Outstanding Talent	This study was supported by the National Natural Science Foundation of China (Nos. 81871980, 81572337, 81672449); the National Science Foundation for Distinguished Young Scholars of China (No. 81902455); the Jiangsu Key Medical Discipline (General Surgery; ZDXKA2016005); the Innovation Capability Development Project of Jiangsu Province (No. BM2015004); the Priority Academic Program AQ3 Development of Jiangsu Higher Education Institutions (PAPD, JX10231801) and the Project of Invigorating Health Care through Science, Technology and Education, Jiangsu Provincial Medical Outstanding Talent (to Yi Miao, JCRCA2016009).	Chantrill LA, 2015, CLIN CANCER RES, V21, P2029, DOI 10.1158/1078-0432.CCR-15-0426; Dachineni R, 2016, MOL CANCER RES, V14, P241, DOI 10.1158/1541-7786.MCR-15-0360; Gao D, 2018, FEBS J, V285, P4229, DOI 10.1111/febs.14665; Gohrig A, 2014, CANCER RES, V74, P1529, DOI 10.1158/0008-5472.CAN-13-1012; Gopinathan L, 2014, CANCER RES, V74, P3870, DOI 10.1158/0008-5472.CAN-13-3440; Honda A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039249; Kleeff J, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.22; Kong RR, 2015, J CLIN INVEST, V125, P4407, DOI 10.1172/JCI81673; Leyva-Diaz E, 2014, CURR BIOL, V24, P494, DOI 10.1016/j.cub.2014.01.042; Liu DF, 2018, INT J CANCER, V142, P1392, DOI 10.1002/ijc.31173; Liu JH, 2018, ANGIOGENESIS, V21, P237, DOI 10.1007/s10456-017-9592-3; Mitchell KA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13732-y; Moore NL, 2014, J STEROID BIOCHEM, V144, P471, DOI 10.1016/j.jsbmb.2014.09.009; Parray A, 2014, INT J CANCER, V135, P2493, DOI 10.1002/ijc.28919; Patten DK, 2018, NAT MED, V24, P1469, DOI 10.1038/s41591-018-0091-x; Peng XF, 2018, CELL BIOL INT, V42, P589, DOI 10.1002/cbin.10935; Pinho AV, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07497-z; Pommier A, 2018, SCIENCE, V360, P1202, DOI 10.1126/science.aao4908; Qin F, 2015, SCI REP-UK, V5, DOI 10.1038/srep09977; Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654; Wang B, 2014, INT J RADIAT ONCOL, V90, P53, DOI 10.1016/j.ijrobp.2014.04.055; XIA Y, 2019, CELL PROLIFERAT, V52; Zhang JJ, 2017, CANCER LETT, V408, P144, DOI 10.1016/j.canlet.2017.08.032; Zhang JJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-130; Zhang QH, 2017, J CELL BIOL, V216, P3133, DOI 10.1083/jcb.201607111	25	10	10	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2772	2784		10.1038/s41388-021-01741-5	http://dx.doi.org/10.1038/s41388-021-01741-5		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33714986				2022-12-17	WOS:000628485300002
J	Martinez-Ordonez, A; Seoane, S; Avila, L; Eiro, N; Macia, M; Arias, E; Pereira, F; Garcia-Caballero, T; Gomez-Lado, N; Aguiar, P; Vizoso, F; Perez-Fernandez, R				Martinez-Ordonez, Anxo; Seoane, Samuel; Avila, Leandro; Eiro, Noemi; Macia, Manuel; Arias, Efigenia; Pereira, Fabio; Garcia-Caballero, Tomas; Gomez-Lado, Noemi; Aguiar, Pablo; Vizoso, Francisco; Perez-Fernandez, Roman			POU1F1 transcription factor induces metabolic reprogramming and breast cancer progression via LDHA regulation	ONCOGENE			English	Article								Metabolic reprogramming is considered hallmarks of cancer. Aerobic glycolysis in tumors cells has been well-known for almost a century, but specific factors that regulate lactate generation and the effects of lactate in both cancer cells and stroma are not yet well understood. In the present study using breast cancer cell lines, human primary cultures of breast tumors, and immune deficient murine models, we demonstrate that the POU1F1 transcription factor is functionally and clinically related to both metabolic reprogramming in breast cancer cells and fibroblasts activation. Mechanistically, we demonstrate that POU1F1 transcriptionally regulates the lactate dehydrogenase A (LDHA) gene. LDHA catalyzes pyruvate into lactate instead of leading into the tricarboxylic acid cycle. Lactate increases breast cancer cell proliferation, migration, and invasion. In addition, it activates normal-associated fibroblasts (NAFs) into cancer-associated fibroblasts (CAFs). Conversely, LDHA knockdown in breast cancer cells that overexpress POU1F1 decreases tumor volume and [F-18]FDG uptake in tumor xenografts of mice. Clinically, POU1F1 and LDHA expression correlate with relapse- and metastasis-free survival. Our data indicate that POU1F1 induces a metabolic reprogramming through LDHA regulation in human breast tumor cells, modifying the phenotype of both cancer cells and fibroblasts to promote cancer progression.	[Martinez-Ordonez, Anxo; Seoane, Samuel; Avila, Leandro; Perez-Fernandez, Roman] Univ Santiago de Compostela, Dept Physiol, Ctr Res Mol Med & Chron Dis CIMUS, Santiago De Compostela, Spain; [Eiro, Noemi; Vizoso, Francisco] Hosp Fdn Jove, Res Unit, Gijon, Spain; [Macia, Manuel; Arias, Efigenia] Univ Santiago de Compostela, Dept Obstet & Gynecol, Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain; [Pereira, Fabio] Univ Santiago de Compostela, Dept Radiat Oncol, Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain; [Garcia-Caballero, Tomas] Univ Santiago de Compostela, Dept Morphol Sci, Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain; [Gomez-Lado, Noemi; Aguiar, Pablo] Univ Santiago de Compostela, Mol Imaging Grp, Dept Psychiat Radiol Publ Hlth Nursing & Med, Santiago De Compostela, Spain; [Gomez-Lado, Noemi; Aguiar, Pablo] Univ Santiago de Compostela, Hlth Res Inst Santiago de Compostela IDIS, Santiago De Compostela, Spain; [Martinez-Ordonez, Anxo] Weill Cornell Med, Dept Pathol & Lab Med, New York, NY USA	Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela; Universidade de Santiago de Compostela; Complexo Hospitalario Universitario de Santiago de Compostela; Universidade de Santiago de Compostela; Cornell University	Perez-Fernandez, R (corresponding author), Univ Santiago de Compostela, Dept Physiol, Ctr Res Mol Med & Chron Dis CIMUS, Santiago De Compostela, Spain.	roman.perez.fernandez@usc.es	Fernández, Pablo Aguiar/ABD-9169-2022; Gómez-Lado, Noemí/AAR-2538-2021; Seoane Ruzo, Samuel/H-6299-2015; Perez-Fernandez, Roman/L-6342-2014; Eiro, Noemi/C-9510-2018	Gómez-Lado, Noemí/0000-0003-2362-3051; Pires Pereira, Fabio/0000-0002-9991-2805; Avila Concepcion, Leandro/0000-0003-4027-4578; Seoane Ruzo, Samuel/0000-0002-9178-0887; Perez-Fernandez, Roman/0000-0002-5894-0615; Arias, Maria Efigenia/0000-0001-8744-9502; Eiro, Noemi/0000-0001-5840-4807	FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigacion [PGC2018-100776-B-I00]; Conselleria de Cultura, Educacion e Ordenacion Universitaria [GPC2014/001]; FPU grant (Ministerio de Educacion) [FPU14/00548]; BioBank Complejo Hospitalario Universitario de Santiago (CHUS) [PT17/0015/0002]	FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigacion; Conselleria de Cultura, Educacion e Ordenacion Universitaria; FPU grant (Ministerio de Educacion)(German Research Foundation (DFG)); BioBank Complejo Hospitalario Universitario de Santiago (CHUS)	This study was supported by FEDER/Ministerio de Ciencia, Innovacion y Universidades-Agencia Estatal de Investigacion-PGC2018-100776-B-I00 and from Conselleria de Cultura, Educacion e Ordenacion Universitaria (GPC2014/001), AM-O was supported by an FPU grant (Ministerio de Educacion-FPU14/00548). We are grateful to Dr. M. Fidalgo and Dr. D. Guallar for helping us to design some experiments, to MJ Otero Fraga for IHC analysis, and the BioBank Complejo Hospitalario Universitario de Santiago (CHUS)(PT17/0015/0002) for their collaboration.	An JY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-04366-5; Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; Baek G, 2014, CELL REP, V9, P2233, DOI 10.1016/j.celrep.2014.11.025; Ben-Batalla I, 2010, ENDOCR-RELAT CANCER, V17, P73, DOI 10.1677/ERC-09-0100; Ben-Batalla I, 2010, J CLIN INVEST, V120, P4289, DOI 10.1172/JCI42015; Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Bhagat TD, 2019, ELIFE, V8, DOI 10.7554/eLife.50663; Brown TP, 2020, ONCOGENE, V39, P3292, DOI 10.1038/s41388-020-1216-5; Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490; Davis RT, 2020, NAT CELL BIOL, V22, P310, DOI 10.1038/s41556-020-0477-0; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; DOLLE P, 1990, CELL, V60, P809, DOI 10.1016/0092-8674(90)90095-V; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Gao ZC, 2016, MED SCI MONITOR, V22, P4121, DOI 10.12659/MSM.896107; Gascard P, 2016, GENE DEV, V30, P1002, DOI 10.1101/gad.279737.116; Gil-Puig C, 2005, EUR J ENDOCRINOL, V153, P335, DOI 10.1530/eje.1.01962; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang XJ, 2016, BREAST, V30, P39, DOI 10.1016/j.breast.2016.08.014; Hui S, 2017, NATURE, V551, P115, DOI 10.1038/nature24057; Husain Z, 2013, J IMMUNOL, V191, P1486, DOI 10.4049/jimmunol.1202702; Ko YH, 2016, J BIOL CHEM, V291, P26291, DOI 10.1074/jbc.M116.740209; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lee YJ, 2016, ONCOTARGET, V7, P70898, DOI 10.18632/oncotarget.12286; LEFEVRE C, 1987, EMBO J, V6, P971, DOI 10.1002/j.1460-2075.1987.tb04847.x; Lehuede C, 2016, CANCER RES, V76, P5201, DOI 10.1158/0008-5472.CAN-16-0266; Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001; Luo HJ, 2015, CANCER LETT, V361, P155, DOI 10.1016/j.canlet.2015.02.018; Martinez-Ordonez A, 2018, ONCOGENE, V37, P1430, DOI 10.1038/s41388-017-0036-8; Martinez-Outschoorn UE, 2014, SEMIN CANCER BIOL, V25, P47, DOI 10.1016/j.semcancer.2014.01.005; Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P1271, DOI 10.4161/cc.10.8.15330; McGuirk S, 2020, TRENDS CANCER, V6, P49, DOI 10.1016/j.trecan.2019.11.009; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; Roland CL, 2014, CANCER RES, V74, P5301, DOI 10.1158/0008-5472.CAN-14-0319; Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Seoane S, 2006, MOL ENDOCRINOL, V20, P735, DOI 10.1210/me.2005-0253; Seoane S, 2019, J PATHOL, V249, P381, DOI 10.1002/path.5324; Seoane S, 2015, ONCOTARGET, V6, P14456, DOI 10.18632/oncotarget.3894; Sherman MH, 2014, CELL, V159, P80, DOI 10.1016/j.cell.2014.08.007; Shim H, 1997, P NATL ACAD SCI USA, V94, P6658, DOI 10.1073/pnas.94.13.6658; Vegran F, 2011, CANCER RES, V71, P2550, DOI 10.1158/0008-5472.CAN-10-2828; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Xie H, 2014, CELL METAB, V19, P795, DOI 10.1016/j.cmet.2014.03.003; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Zhu JJ, 2019, NAT REV MOL CELL BIO, V20, P436, DOI 10.1038/s41580-019-0123-5	49	10	11	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 15	2021	40	15					2725	2740		10.1038/s41388-021-01740-6	http://dx.doi.org/10.1038/s41388-021-01740-6		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RN8NW	33714987	hybrid, Green Published			2022-12-17	WOS:000628485300001
J	Pan, YW; Han, H; Labbe, KE; Zhang, H; Wong, KK				Pan, Yuanwang; Han, Han; Labbe, Kristen E.; Zhang, Hua; Wong, Kwok-Kin			Recent advances in preclinical models for lung squamous cell carcinoma	ONCOGENE			English	Review								Lung squamous cell carcinoma (LUSC) represents a major subtype of non-small cell lung cancer with limited treatment options. Previous studies have elucidated the complex genetic landscape of LUSC and revealed multiple altered genes and pathways. However, in stark contrast to lung adenocarcinoma, few targetable driver mutations have been established so far and targeted therapies for LUSC remain unsuccessful. Immunotherapy has revolutionized LUSC treatment and is currently approved as the new standard of care. To gain a better understanding of the LUSC biology, improved modeling systems are urgently needed. Preclinical models, particularly those mimicking human disease with an intact tumor immune microenvironment, are an invaluable tool to study cancer development and evaluate new therapeutic targets. Here, we discuss recent advances in LUSC preclinical models, with a focus on genetically engineered mouse models (GEMMs) and organoids, in the context of evolving precision medicine and immunotherapy.	[Pan, Yuanwang; Han, Han; Labbe, Kristen E.; Zhang, Hua; Wong, Kwok-Kin] NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, Div Hematol & Med Oncol, New York, NY 10003 USA	New York University; NYU Langone Medical Center	Zhang, H; Wong, KK (corresponding author), NYU, Langone Med Ctr, Laura & Isaac Perlmutter Canc Ctr, Div Hematol & Med Oncol, New York, NY 10003 USA.	Hua.Zhang@nyulangone.org; Kwok-Kin.Wong@nyulangone.org	Zhang, Hua/AAV-2344-2020	Zhang, Hua/0000-0001-7704-4712; Labbe, Kristen/0000-0001-6731-5849; wong, kwok kin/0000-0001-6323-235X	AstraZeneca; Janssen; Pfizer/Array Biopharma; Novartis; Merck; Zentalis; Takeda; BMS; Mirati; Alkermes; Merus; Amgen; Ansun Biopharma; Enliven Therapeutics; Tvardi Therapeutics; Delfi Diagnostics; Dracen Pharmaceuticals	AstraZeneca(AstraZeneca); Janssen(Johnson & JohnsonJohnson & Johnson USAJanssen Biotech Inc); Pfizer/Array Biopharma; Novartis(Novartis); Merck(Merck & Company); Zentalis; Takeda(Takeda Pharmaceutical Company Ltd); BMS(Bristol-Myers Squibb); Mirati; Alkermes; Merus; Amgen(Amgen); Ansun Biopharma; Enliven Therapeutics; Tvardi Therapeutics; Delfi Diagnostics; Dracen Pharmaceuticals	KKW is a founder and equity holder of G1 Therapeutics and has consulting and sponsored research with: AstraZeneca, Janssen, Pfizer/Array Biopharma, Novartis, Merck, Zentalis; as well as sponsored research (only) with: Takeda, BMS, Mirati, Alkermes, Merus, Amgen, Ansun Biopharma, Enliven Therapeutics, Tvardi Therapeutics, Delfi Diagnostics, and Dracen Pharmaceuticals. No potential conflicts of interest were disclosed by the other authors.	Aggarwal C, 2019, J THORAC ONCOL, V14, P1847, DOI 10.1016/j.jtho.2019.05.041; [Anonymous], 2021, CANCER DISCOV, V11, pOF3; Aref AR, 2018, LAB CHIP, V18, P3129, DOI 10.1039/c8lc00322j; Azpilikueta A, 2016, J THORAC ONCOL, V11, P524, DOI 10.1016/j.jtho.2016.01.013; Barkauskas CE, 2017, DEVELOPMENT, V144, P986, DOI 10.1242/dev.140103; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Bendell JC, 2018, CLIN CANCER RES, V24, P3253, DOI 10.1158/1078-0432.CCR-17-3421; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013; Camolotto SA, 2018, ELIFE, V7, DOI 10.7554/eLife.38579; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Chow E, 2006, CLIN GENET, V70, P409, DOI 10.1111/j.1399-0004.2006.00704.x; Chow RD, 2017, NAT NEUROSCI, V20, P1329, DOI 10.1038/nn.4620; Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082; Dijkstra KK, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107588; Dotto GP, 2016, CANCER CELL, V29, P622, DOI 10.1016/j.ccell.2016.04.004; Drost J, 2018, NAT REV CANCER, V18, P407, DOI 10.1038/s41568-018-0007-6; Ekman S, 2012, J THORAC ONCOL, V7, P947, DOI 10.1097/JTO.0b013e31825581bd; Fang R, 2014, J THORAC ONCOL, V9, P254, DOI 10.1097/JTO.0000000000000056; Ferone G, 2016, CANCER CELL, V30, P519, DOI 10.1016/j.ccell.2016.09.001; Fujii M, 2016, CELL STEM CELL, V18, P827, DOI 10.1016/j.stem.2016.04.003; Fukuoka M, 2011, J CLIN ONCOL, V29, P2866, DOI 10.1200/JCO.2010.33.4235; Fumagalli A, 2017, P NATL ACAD SCI USA, V114, pE2357, DOI 10.1073/pnas.1701219114; Gao YJ, 2011, PROTEIN CELL, V2, P99, DOI 10.1007/s13238-011-1021-6; Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824; Gazdar AF, 2016, J THORAC ONCOL, V11, P287, DOI 10.1016/j.jtho.2015.10.009; Gengenbacher N, 2017, NAT REV CANCER, V17, P751, DOI 10.1038/nrc.2017.92; Hai J, 2020, CLIN CANCER RES, V26, P3431, DOI 10.1158/1078-0432.CCR-19-1627; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Han XK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4261; Hellmann MD, 2018, NEW ENGL J MED, V378, P2093, DOI 10.1056/NEJMoa1801946; Henneman L, 2015, P NATL ACAD SCI USA, V112, P8409, DOI 10.1073/pnas.1500223112; Herbst RS, 2020, NEW ENGL J MED, V383, P1328, DOI 10.1056/NEJMoa1917346; Herbst RS, 2018, NATURE, V553, P446, DOI 10.1038/nature25183; Herbst RS, 2015, CLIN CANCER RES, V21, P1514, DOI 10.1158/1078-0432.CCR-13-3473; Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049; Huijbers IJ, 2015, NAT PROTOC, V10, P1755, DOI 10.1038/nprot.2015.114; Huijbers IJ, 2014, EMBO MOL MED, V6, P212, DOI 10.1002/emmm.201303297; Hussenet T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008960; Inoue A, 2013, ANN ONCOL, V24, P54, DOI 10.1093/annonc/mds214; Jenkins RW, 2018, CANCER DISCOV, V8, P196, DOI 10.1158/2159-8290.CD-17-0833; Jeong Y, 2017, CANCER DISCOV, V7, P86, DOI 10.1158/2159-8290.CD-16-0127; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Kellar A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/621324; Kim M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11867-6; Kim Y, 2014, J CLIN ONCOL, V32, P121, DOI 10.1200/JCO.2013.50.8556; Kwon MC, 2013, MOL ONCOL, V7, P165, DOI 10.1016/j.molonc.2013.02.010; Langer CJ, 2019, J THORAC ONCOL, V14, P1839, DOI 10.1016/j.jtho.2019.05.029; Lazarus KA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05790-5; Lee SH, 2018, CELL, V173, P515, DOI 10.1016/j.cell.2018.03.017; Li CG, 2015, SCI REP-UK, V5, DOI 10.1038/srep14237; Li FM, 2015, CANCER CELL, V27, P698, DOI 10.1016/j.ccell.2015.04.001; Liu J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09843-1; Liu Y, 2020, CELL REP, V30, P771, DOI 10.1016/j.celrep.2019.12.071; Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011022; Maresch R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10770; Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802; Middleton G, 2020, NATURE, V583, P807, DOI 10.1038/s41586-020-2481-8; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7; Mollaoglu G, 2018, IMMUNITY, V49, P764, DOI 10.1016/j.immuni.2018.09.020; Momcilovic M, 2018, CANCER CELL, V33, P905, DOI 10.1016/j.ccell.2018.04.002; Morgan KM, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00002; Mukhopadhyay A, 2014, CELL REP, V8, P40, DOI 10.1016/j.celrep.2014.05.036; Neal JT, 2018, CELL, V175, P1972, DOI 10.1016/j.cell.2018.11.021; Neal JT, 2016, ANNU REV PATHOL-MECH, V11, P199, DOI 10.1146/annurev-pathol-012615-044249; NETTESHEIM P, 1971, JNCI-J NATL CANCER I, V47, P697; Ng SR, 2020, P NATL ACAD SCI USA, V117, P513, DOI 10.1073/pnas.1821893117; Nogova L, 2017, J CLIN ONCOL, V35, P157, DOI 10.1200/JCO.2016.67.2048; Ohe Y, 2008, CLIN CANCER RES, V14, P4206, DOI 10.1158/1078-0432.CCR-07-5143; Paik Paul K, 2019, Am Soc Clin Oncol Educ Book, V39, pe198, DOI 10.1200/EDBK_237829; Paik PK, 2015, CANCER DISCOV, V5, P610, DOI 10.1158/2159-8290.CD-14-1129; Paz-Ares L, 2018, NEW ENGL J MED, V379, P2040, DOI 10.1056/NEJMoa1810865; Paz-Ares L, 2021, LANCET ONCOL, V22, P198, DOI 10.1016/S1470-2045(20)30641-0; Platt RJ, 2014, CELL, V159, P440, DOI 10.1016/j.cell.2014.09.014; Premsrirut PK, 2011, CELL, V145, P145, DOI 10.1016/j.cell.2011.03.012; Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774; Redman MW, 2020, LANCET ONCOL, V21, P1589, DOI 10.1016/S1470-2045(20)30475-7; REHM S, 1991, AM J PATHOL, V139, P413; Ren CL, 2019, NEW ENGL J MED, V380, P1981, DOI 10.1056/NEJMc1903253; Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060; Rittmeyer A, 2017, LANCET, V389, P255, DOI 10.1016/S0140-6736(16)32517-X; Rock JR, 2009, P NATL ACAD SCI USA, V106, P12771, DOI 10.1073/pnas.0906850106; Rogers ZN, 2018, NAT GENET, V50, P483, DOI 10.1038/s41588-018-0083-2; Rogers ZN, 2017, NAT METHODS, V14, P737, DOI 10.1038/nmeth.4297; Romero R, 2017, NAT MED, V23, P1362, DOI 10.1038/nm.4407; Roper J, 2017, NAT BIOTECHNOL, V35, P569, DOI 10.1038/nbt.3836; Ruiz EJ, 2019, J EXP MED, V216, P450, DOI 10.1084/jem.20180742; Saborowski M, 2014, GENE DEV, V28, P85, DOI 10.1101/gad.232082.113; Sachs N, 2019, EMBO J, V38, DOI 10.15252/embj.2018100300; Sachs N, 2018, CELL, V172, P373, DOI 10.1016/j.cell.2017.11.010; Sanchez-Danes A, 2018, NAT REV CANCER, V18, P549, DOI 10.1038/s41568-018-0024-5; Sanchez-Rivera FJ, 2014, NATURE, V516, P428, DOI 10.1038/nature13906; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Schuette W, 2005, J CLIN ONCOL, V23, P8389, DOI 10.1200/JCO.2005.02.3739; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030; Shi RS, 2020, CLIN CANCER RES, V26, P1162, DOI 10.1158/1078-0432.CCR-19-1376; Singh AP, 2018, EXPERT OPIN DRUG DIS, V13, P347, DOI 10.1080/17460441.2018.1437137; Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137; Tabernero J, 2015, J CLIN ONCOL, V33, P3401, DOI 10.1200/JCO.2014.60.7341; Tata PR, 2018, DEV CELL, V44, P679, DOI 10.1016/j.devcel.2018.02.024; Tiriac H, 2018, CANCER DISCOV, V8, P1112, DOI 10.1158/2159-8290.CD-18-0349; van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053; Vansteenkiste JF, 2015, J THORAC ONCOL, V10, P1319, DOI 10.1097/JTO.0000000000000607; Wang GC, 2018, SCI ADV, V4, DOI 10.1126/sciadv.aao5508; Wang Y, 2004, CANCER RES, V64, P1647, DOI 10.1158/0008-5472.CAN-03-3273; Winters IP, 2018, NAT REV GENET, V19, P741, DOI 10.1038/s41576-018-0053-7; Xiao ZX, 2013, CANCER CELL, V23, P527, DOI 10.1016/j.ccr.2013.03.009; Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033; Xue W, 2014, NATURE, V514, P380, DOI 10.1038/nature13589; Yang JCH, 2015, LANCET ONCOL, V16, P141, DOI 10.1016/S1470-2045(14)71173-8; Yin H, 2019, NAT REV CLIN ONCOL, V16, P281, DOI 10.1038/s41571-019-0166-8; Yuki K, 2020, TRENDS IMMUNOL, V41, P652, DOI 10.1016/j.it.2020.06.010; Zhang X, 2017, NAT COMMUN, V8, P1, DOI [10.1038/ncomms14542, 10.1038/s41467-017-01968-5, 10.1038/s41467-017-00321-0]; Zhou C, 2015, ANN ONCOL, V26, P1877, DOI 10.1093/annonc/mdv276	116	10	10	2	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 22	2021	40	16					2817	2829		10.1038/s41388-021-01723-7	http://dx.doi.org/10.1038/s41388-021-01723-7		MAR 2021	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RQ5XW	33707749				2022-12-17	WOS:000627660400003
J	Zhao, LN; Bjorklund, M; Caldez, MJ; Zheng, J; Kaldis, P				Zhao, Li Na; Bjorklund, Mikael; Caldez, Matias J.; Zheng, Jie; Kaldis, Philipp			Therapeutic targeting of the mitochondrial one-carbon pathway: perspectives, pitfalls, and potential	ONCOGENE			English	Review							SERINE; METHOTREXATE; METABOLISM; GLYCINE; FOLATE; PROLIFERATION; MECHANISMS; EXPRESSION; INHIBITOR	Most of the drugs currently prescribed for cancer treatment are riddled with substantial side effects. In order to develop more effective and specific strategies to treat cancer, it is of importance to understand the biology of drug targets, particularly the newly emerging ones. A comprehensive evaluation of these targets will benefit drug development with increased likelihood for success in clinical trials. The folate-mediated one-carbon (1C) metabolism pathway has drawn renewed attention as it is often hyperactivated in cancer and inhibition of this pathway displays promise in developing anticancer treatment with fewer side effects. Here, we systematically review individual enzymes in the 1C pathway and their compartmentalization to mitochondria and cytosol. Based on these insight, we conclude that (1) except the known 1C targets (DHFR, GART, and TYMS), MTHFD2 emerges as good drug target, especially for treating hematopoietic cancers such as CLL, AML, and T-cell lymphoma; (2) SHMT2 and MTHFD1L are potential drug targets; and (3) MTHFD2L and ALDH1L2 should not be considered as drug targets. We highlight MTHFD2 as an excellent therapeutic target and SHMT2 as a complementary target based on structural/biochemical considerations and up-to-date inhibitor development, which underscores the perspectives of their therapeutic potential.	[Zhao, Li Na; Kaldis, Philipp] Lund Univ, Dept Clin Sci, Malmo, Sweden; [Bjorklund, Mikael] Zhejiang Univ Univ Edinburgh ZJU UoE Inst, Haining, Zhejiang, Peoples R China; [Bjorklund, Mikael] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Hangzhou, Zhejiang, Peoples R China; [Bjorklund, Mikael] Univ Edinburgh, Coll Med & Vet Med, Dept Biomed Sci, Edinburgh, Midlothian, Scotland; [Caldez, Matias J.] Osaka Univ, World Premier Int Res Ctr Initiat WPI, Immunol Frontier Res Ctr IFReC, Lab Host Def, Osaka, Japan; [Zheng, Jie] Shanghai Tech Univ, Sch Informat Sci & Technol, Shanghai, Peoples R China	Lund University; Zhejiang University; University of Edinburgh; Osaka University; ShanghaiTech University	Zhao, LN; Kaldis, P (corresponding author), Lund Univ, Dept Clin Sci, Malmo, Sweden.	lina.zhao@med.lu.se; philipp.kaldis@med.lu.se	Zhao, Lina/GVR-7716-2022; Kaldis, Philipp/G-2714-2010	Kaldis, Philipp/0000-0002-7247-7591; ZHAO, LINA/0000-0001-6552-0929	A*STAR International Fellowship (AIF) from Singapore; IngaBritt och Arne Lundbergs Forskningsstiftelse [LU2020-0013]; Faculty of Medicine, Lund University; Swedish Foundation for Strategic Research [IRC15-0067]; Swedish Research Council, Strategic Research Area EXODIAB [2009-1039]	A*STAR International Fellowship (AIF) from Singapore; IngaBritt och Arne Lundbergs Forskningsstiftelse; Faculty of Medicine, Lund University; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research); Swedish Research Council, Strategic Research Area EXODIAB(Swedish Research Council)	LNZ was supported by an A*STAR International Fellowship (AIF) from Singapore. This work is supported by the IngaBritt och Arne Lundbergs Forskningsstiftelse LU2020-0013; PK is supported by the Faculty of Medicine, Lund University; the Swedish Foundation for Strategic Research Dnr IRC15-0067, and Swedish Research Council, Strategic Research Area EXODIAB, Dnr 2009-1039. LNZ would like to thank Prof. Chew Lock Yue (NTU) and Prof. Ulf Ryde (LU) for comments on the manuscript.	Agapakis CM, 2012, NAT CHEM BIOL, V8, P527, DOI [10.1038/NCHEMBIO.975, 10.1038/nchembio.975]; Agarwal PK, 2002, P NATL ACAD SCI USA, V99, P2794, DOI 10.1073/pnas.052005999; Agarwal S, 2019, TRANSL ONCOL, V12, P1461, DOI 10.1016/j.tranon.2019.07.011; Alberts B., 2014, MOL BIOL CELL; Albrecht K, 2010, CLIN EXP RHEUMATOL, V28, pS95; Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004; Anderson DD, 2012, J BIOL CHEM, V287, P4790, DOI 10.1074/jbc.M111.302174; Anderson DD, 2011, P NATL ACAD SCI USA, V108, P15163, DOI 10.1073/pnas.1103623108; Anderson DD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005839; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; ASAI A, 2018, CELL PHYSIOL BIOCHEM, V4; Balut C, 2008, KIDNEY INT, V73, P226, DOI 10.1038/sj.ki.5002632; Bertino JR, 1996, STEM CELLS, V14, P5, DOI 10.1002/stem.140005; Bolusani S, 2011, J BIOL CHEM, V286, P5166, DOI 10.1074/jbc.M110.196840; Boron WF, 2004, ADV PHYSIOL EDUC, V28, P160, DOI 10.1152/advan.00045.2004; Brodsky G, 1997, HUM MOL GENET, V6, P2043, DOI 10.1093/hmg/6.12.2043; Bronder JL, 2002, CANCER RES, V62, P5236; Burda P, 2015, J INHERIT METAB DIS, V38, P863, DOI 10.1007/s10545-015-9810-3; Burdelski C, 2015, ONCOTARGET, V6, P8377, DOI 10.18632/oncotarget.3107; CALVERT AH, 1986, J CLIN ONCOL, V4, P1245, DOI 10.1200/JCO.1986.4.8.1245; Cario H, 2011, AM J HUM GENET, V88, P226, DOI 10.1016/j.ajhg.2011.01.007; Carver JR, 2013, SEMIN ONCOL, V40, P229, DOI 10.1053/j.seminoncol.2013.01.005; Chan ESL, 2010, NAT REV RHEUMATOL, V6, P175, DOI 10.1038/nrrheum.2010.5; Chattopadhyay S, 2007, MOL CANCER THER, V6, P404, DOI 10.1158/1535-7163.MCT-06-0343; Chen D, 2017, J BIOL CHEM, V292, P13449, DOI 10.1074/jbc.M117.787267; Choi YK, 2018, BIOMOL THER, V26, P19, DOI 10.4062/biomolther.2017.178; Chu E, 2003, CANCER CHEMOTH PHARM, V52, pS80, DOI 10.1007/s00280-003-0625-9; CYBULSKI RL, 1976, BIOCHEMISTRY-US, V15, P3183, DOI 10.1021/bi00660a004; Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36; Deis SM, 2016, BIOCHEMISTRY-US, V55, P4574, DOI 10.1021/acs.biochem.6b00412; Di Pietro E, 2002, MOL CELL BIOL, V22, P4158, DOI 10.1128/MCB.22.12.4158-4166.2002; DUCH DS, 1993, CANCER RES, V53, P810; Ducker GS, 2016, CELL METAB, V23, P1140, DOI 10.1016/j.cmet.2016.04.016; Eich ML, 2019, TRANSL ONCOL, V12, P1416, DOI 10.1016/j.tranon.2019.07.012; Estrada A, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a028324; Fadaka A., 2017, J ONCOLOGICAL SCI, V3, P45, DOI [10.1016/j.jons.2017.06.002, DOI 10.1016/J.JONS.2017.06.002]; FARBER S, 1948, NEW ENGL J MED, V238, P787, DOI 10.1056/NEJM194806032382301; Florio R, 2011, BBA-PROTEINS PROTEOM, V1814, P1489, DOI 10.1016/j.bbapap.2010.10.010; Fox JT, 2008, VITAM HORM, V79, P1, DOI 10.1016/S0083-6729(08)00401-9; Frantz MC, 2010, ENVIRON MOL MUTAGEN, V51, P462, DOI 10.1002/em.20554; FU C, 2017, CANCER RES, V8; Giardina G, 2015, FEBS J, V282, P1225, DOI 10.1111/febs.13211; Gu YL, 2017, ONCOL RES, V25, P1069, DOI 10.3727/096504016X14829256525028; Guiducci G, 2019, NUCLEIC ACIDS RES, V47, P4240, DOI 10.1093/nar/gkz129; Gustafsson R, 2017, CANCER RES, V77, P937, DOI 10.1158/0008-5472.CAN-16-1476; Hu Y., 2018, FASEB J, V32, P49, DOI [10.1096/fj.201701480R, DOI 10.1096/FJ.201701480R]; Huang X, 2010, BIOCHEMISTRY-US, V49, P2475, DOI 10.1021/bi901457e; Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595; Ju H.Q., 2018, JNCI-J NATL CANCER I; KAWAI J, 2019, J MED CHEM; Kawai J, 2019, ACS MED CHEM LETT, V10, P893, DOI 10.1021/acsmedchemlett.9b00069; KIT S, 1955, CANCER RES, V15, P715; KOSEKI J, 2018, ONCOL RES, V8; KOTOULA V, 2012, AM J HUM GENET, V12; Koufaris C, 2018, CANCER METAB, V6, DOI 10.1186/s40170-018-0185-4; Kremer JM, 2004, ARTHRITIS RHEUM-US, V50, P1370, DOI 10.1002/art.20278; Kreuzaler P, 2020, MOL METAB, V33, P83, DOI 10.1016/j.molmet.2019.08.021; Krupenko NI, 2010, J BIOL CHEM, V285, P23054, DOI 10.1074/jbc.M110.128843; Kujovich JL, 2016, OBSTET GYN CLIN N AM, V43, P247, DOI 10.1016/j.ogc.2016.01.009; Labuschagne CF, 2014, CELL REP, V7, P1248, DOI 10.1016/j.celrep.2014.04.045; Lee D, 2017, J CLIN INVEST, V127, P1856, DOI 10.1172/JCI90253; Lee GY, 2014, CANCER RES, V74, P3114, DOI 10.1158/0008-5472.CAN-13-2683; Lin H, 2018, CELL PHYSIOL BIOCHEM, V51, P991, DOI 10.1159/000495402; Lin JG, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1214-z; Liu Y, 2019, EUR REV MED PHARMACO, V23, P9379, DOI 10.26355/eurrev_201911_19431; Locasale JW, 2013, NAT REV CANCER, V13, P572, DOI 10.1038/nrc3557; Lovelace LL, 2009, PROTEIN SCI, V18, P1628, DOI 10.1002/pro.171; LUCAS S, 2018, NATURE, V1; Marani M, 2016, ONCOTARGET, V7, P4570, DOI 10.18632/oncotarget.6726; McGuirk S, 2020, TRENDS CANCER, V6, P49, DOI 10.1016/j.trecan.2019.11.009; Medwig-Kinney TN, 2020, DEVELOPMENT, V147, DOI 10.1242/dev.185850; MEJIA NR, 1988, BIOCHEM BIOPH RES CO, V155, P1, DOI 10.1016/S0006-291X(88)81040-4; MEJIA NR, 1985, J BIOL CHEM, V260, P4616; Minton DR, 2018, MOL CELL, V69, P610, DOI 10.1016/j.molcel.2018.01.024; Momb J, 2013, P NATL ACAD SCI USA, V110, P549, DOI 10.1073/pnas.1211199110; Morscher RJ, 2018, NATURE, V554, P128, DOI 10.1038/nature25460; Nagura E, 1988, Gan To Kagaku Ryoho, V15, P2882; New Antifolates in Clinical Development, CANC NETWORK; Nilsson R, 2019, GENE, V716, DOI 10.1016/j.gene.2019.144032; NILSSON R, 2014, ONCOL LETT, V5; Ning SL, 2018, GASTROENT RES PRACT, V2018, DOI 10.1155/2018/4369253; Nishimura T, 2019, ONCOGENE, V38, P2464, DOI 10.1038/s41388-018-0589-1; Noguchi K, 2018, ONCOL LETT, V16, P1827, DOI 10.3892/ol.2018.8795; NONAKA H, 2019, ONCOTARGET, V10; Organista-Nava J, 2018, ONCOL LETT, V15, P8405, DOI 10.3892/ol.2018.8429; Patel H, 2003, J BIOL CHEM, V278, P19436, DOI 10.1074/jbc.M301718200; Patel Samir N, 2005, Expert Rev Anti Infect Ther, V3, P849, DOI 10.1586/14787210.3.6.849; Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006; PERI KG, 1993, BIOCHIM BIOPHYS ACTA, V1171, P281, DOI 10.1016/0167-4781(93)90066-M; Peters EJ, 2009, PHARMACOGENET GENOM, V19, P399, DOI 10.1097/FPC.0b013e328329fdec; Peters GJ, 2002, BBA-MOL BASIS DIS, V1587, P194, DOI 10.1016/S0925-4439(02)00082-0; Pikman Y, 2016, J EXP MED, V213, P1285, DOI 10.1084/jem.20151574; Prasannan P, 2003, J BIOL CHEM, V278, P43178, DOI 10.1074/jbc.M304319200; Purcell W Thomas, 2003, Curr Oncol Rep, V5, P114, DOI 10.1007/s11912-003-0098-3; Rabinowitz, 2017, CELL METAB, V25, P27, DOI 10.1016/j.cmet.2016.08.009; Raimondi MV, 2019, MOLECULES, V24, DOI 10.3390/molecules24061140; Rajagopalan PTR, 2002, P NATL ACAD SCI USA, V99, P13481, DOI 10.1073/pnas.172501499; RIOSORLANDI EM, 1988, J BIOL CHEM, V263, P4662; Robert F, 2004, J CLIN ONCOL, V22, p213S; Sarret C, 2019, NPJ GENOM MED, V4, DOI 10.1038/s41525-019-0092-9; Schober AF, 2019, CELL REP, V27, P3359, DOI 10.1016/j.celrep.2019.05.030; SCHWEITZER BI, 1990, FASEB J, V4, P2441, DOI 10.1096/fasebj.4.8.2185970; Sdelci S, 2019, NAT GENET, V51, P990, DOI 10.1038/s41588-019-0413-z; SHEPPARD NG, 2015, CANCER METAB, V5; Shih C, 1997, CANCER RES, V57, P1116; Shin M, 2017, CANCER METAB, V5, DOI 10.1186/s40170-017-0173-0; Shin M, 2014, J BIOL CHEM, V289, P15507, DOI 10.1074/jbc.M114.555573; Shiratori R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55296-3; Shirmanova MV, 2015, BBA-GEN SUBJECTS, V1850, P1905, DOI 10.1016/j.bbagen.2015.05.001; Sneader W, 2005, DRUG DISCOVERY: A HISTORY, P1, DOI 10.1002/0470015535; SNELL K, 1989, CANCER LETT, V44, P217, DOI 10.1016/0304-3835(89)90064-5; Srinivasan B, 2015, FEBS J, V282, P1922, DOI 10.1111/febs.13244; STOVER P, 1991, J BIOL CHEM, V266, P1543; Stover PJ, 1997, J BIOL CHEM, V272, P1842, DOI 10.1074/jbc.272.3.1842; TANI H, 2018, CANCER RES, V8; Tedeschi PM, 2015, MOL CANCER RES, V13, P1361, DOI 10.1158/1541-7786.MCR-15-0117; Toriello HV, 2005, GENET MED, V7, P283, DOI 10.1097/00125817-200504000-00009; Toyama BH, 2013, NAT REV MOL CELL BIO, V14, P55, DOI 10.1038/nrm3496; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; VAZQUEZ A, 2011, GENOME BIOL, V6; Vazquez A, 2013, CANCER RES, V73, P478, DOI 10.1158/0008-5472.CAN-12-3709; Wang H, 2020, BIOL RES, V53, DOI 10.1186/s40659-020-00314-2; Wang JJ, 2015, ONCOL LETT, V9, P940, DOI 10.3892/ol.2014.2773; Wang WY, 2018, EUR J MED CHEM, V158, P502, DOI 10.1016/j.ejmech.2018.09.027; Wang Y, 2006, CURR CANCER THER REV, V2, P271, DOI 10.2174/157339406777934717; Webber S, 1996, CANCER CHEMOTH PHARM, V37, P509, DOI 10.1007/s002800050422; Welin M, 2010, NUCLEIC ACIDS RES, V38, P7308, DOI 10.1093/nar/gkq595; White KA, 2017, J CELL SCI, V130, P663, DOI 10.1242/jcs.195297; Wojtuszkiewicz A, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0158-9; Woo CC, 2016, ONCOTARGET, V7, P53005, DOI 10.18632/oncotarget.10415; Wrobel A, 2020, J ANTIBIOT, V73, P5, DOI 10.1038/s41429-019-0240-6; Wu M, 2017, ONCOTARGETS THER, V10, P3781, DOI 10.2147/OTT.S130409; Xu TY, 2019, AM J CANCER RES, V9, P250; Yan Y, 2019, CLIN EXP PHARMACOL P, V46, P928, DOI 10.1111/1440-1681.13125; Yang X, 2018, CANCER RES, V78, P372, DOI 10.1158/0008-5472.CAN-17-1912; Yeh ETH, 2004, CIRCULATION, V109, P3122, DOI 10.1161/01.CIR.0000133187.74800.B9; Yu C, 2020, J CELL MOL MED, V24, P1568, DOI 10.1111/jcmm.14844; Yuthavong Y, 2012, P NATL ACAD SCI USA, V109, P16823, DOI 10.1073/pnas.1204556109; ZACHARIAE H, 1990, BRIT J DERMATOL, V122, P127, DOI 10.1111/j.1365-2133.1990.tb02890.x; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	140	10	10	6	11	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 1	2021	40	13					2339	2354		10.1038/s41388-021-01695-8	http://dx.doi.org/10.1038/s41388-021-01695-8		MAR 2021	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	RH1BQ	33664451				2022-12-17	WOS:000625833000002
J	Morgan, EL; Patterson, MR; Barba-Moreno, D; Scarth, JA; Wilson, A; Macdonald, A				Morgan, Ethan L.; Patterson, Molly R.; Barba-Moreno, Diego; Scarth, James A.; Wilson, Adam; Macdonald, Andrew			The deubiquitinase (DUB) USP13 promotes Mcl-1 stabilisation in cervical cancer	ONCOGENE			English	Article								Protein ubiquitination is a critical regulator of cellular homeostasis. Aberrations in the addition or removal of ubiquitin can result in the development of cancer and key components of the ubiquitination machinery serve as oncogenes or tumour suppressors. An emerging target in the development of cancer therapeutics are the deubiquitinase (DUB) enzymes that remove ubiquitin from protein substrates. Whether this class of enzyme plays a role in cervical cancer has not been fully explored. By interrogating the cervical cancer data from the TCGA consortium, we noted that the DUB USP13 is amplified in similar to 15% of cervical cancer cases. We confirmed that USP13 expression was increased in cervical cancer cell lines, cytology samples from patients with cervical disease and in cervical cancer tissue. Depletion of USP13 inhibited cervical cancer cell proliferation. Mechanistically, USP13 bound to, deubiquitinated and stabilised Mcl-1, a pivotal member of the anti-apoptotic BCL-2 family. Furthermore, reduced Mcl-1 expression partially contributed to the observed proliferative defect in USP13 depleted cells. Importantly, the expression of USP13 and Mcl-1 proteins correlated in cervical cancer tissue. Finally, we demonstrated that depletion of USP13 expression or inhibition of USP13 enzymatic activity increased the sensitivity of cervical cancer cells to the BH3 mimetic inhibitor ABT-263. Together, our data demonstrates that USP13 is a potential oncogene in cervical cancer that functions to stabilise the pro-survival protein Mcl-1, offering a potential therapeutic target for these cancers.	[Morgan, Ethan L.; Patterson, Molly R.; Barba-Moreno, Diego; Scarth, James A.; Wilson, Adam; Macdonald, Andrew] Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Leeds, W Yorkshire, England; [Morgan, Ethan L.; Patterson, Molly R.; Barba-Moreno, Diego; Scarth, James A.; Wilson, Adam; Macdonald, Andrew] Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds, W Yorkshire, England; [Morgan, Ethan L.] Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA	University of Leeds; University of Leeds; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Morgan, EL; Macdonald, A (corresponding author), Univ Leeds, Fac Biol Sci, Sch Mol & Cellular Biol, Leeds, W Yorkshire, England.; Morgan, EL; Macdonald, A (corresponding author), Univ Leeds, Astbury Ctr Struct Mol Biol, Leeds, W Yorkshire, England.; Morgan, EL (corresponding author), Natl Inst Deafness & Other Commun Disorders, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA.	ethan.morgan@nih.gov; a.macdonald@leeds.ac.uk		Patterson, Molly/0000-0001-6246-7181; Morgan, Ethan/0000-0002-6487-5450; Scarth, James/0000-0002-0076-6853; Macdonald, Andrew/0000-0002-5978-4693	Wellcome Institutional Strategic Support Fund (ISSF) [204825/Z/16/Z]; Medical Research Council (MRC) [MR/K012665, MR/S001697/1]; Biotechnology and Biological Sciences Research Council [BB/M011151/1]; Faculty of Biological Sciences, University of Leeds scholarship; MRC [MR/K012665/1, MR/S001697/1] Funding Source: UKRI	Wellcome Institutional Strategic Support Fund (ISSF); Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Faculty of Biological Sciences, University of Leeds scholarship(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the Wellcome Institutional Strategic Support Fund (ISSF) funding to ELM (204825/Z/16/Z) and Medical Research Council (MRC) funding to AM (MR/K012665 and MR/S001697/1). MRP is funded by Biotechnology and Biological Sciences Research Council studentship (BB/M011151/1). JAS is funded by a Faculty of Biological Sciences, University of Leeds scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Akutsu M, 2016, J CELL SCI, V129, P875, DOI 10.1242/jcs.183954; Alwan HAJ, 2007, J BIOL CHEM, V282, P1658, DOI 10.1074/jbc.M604711200; An J, 2008, CANCER CELL, V14, P394, DOI 10.1016/j.ccr.2008.10.007; Ashkenazi A, 2017, NAT REV DRUG DISCOV, V16, P273, DOI 10.1038/nrd.2016.253; Bansal N, 2008, ANTICANCER RES, V28, P1763; Barghout SH, 2019, LEUKEMIA, V33, P37, DOI 10.1038/s41375-018-0167-0; Boyer SN, 1996, CANCER RES, V56, P4620; Burk RD, 2017, NATURE, V543, P378, DOI 10.1038/nature21386; Chen C, 2014, IMMUNOLOGY, V142, P307, DOI 10.1111/imm.12255; Chen S, 2012, CANCER RES, V72, P4225, DOI 10.1158/0008-5472.CAN-12-1118; Chung YW, 2002, BIOCHEM BIOPH RES CO, V293, P1248; Clague MJ, 2010, CELL, V143, P682, DOI 10.1016/j.cell.2010.11.012; Crawford RAF, 1998, BRIT J CANCER, V78, P210, DOI 10.1038/bjc.1998.466; Crosbie EJ, 2013, LANCET, V382, P889, DOI 10.1016/S0140-6736(13)60022-7; Das D, 2019, MBIO, V10, DOI 10.1128/mBio.00263-19; De Blasio A, 2018, J CELL PHYSIOL, V233, P8482, DOI 10.1002/jcp.26786; del Rio R, 2008, GENES IMMUN, V9, P115, DOI 10.1038/sj.gene.6364455; DETRE S, 1995, J CLIN PATHOL, V48, P876, DOI 10.1136/jcp.48.9.876; Fang XG, 2017, J EXP MED, V214, P245, DOI 10.1084/jem.20151673; Fields Alan P., 2015, Advances in Biological Regulation, V60, P47, DOI 10.1016/j.jbior.2015.10.009; Ge ZQ, 2018, CELL REP, V23, P213, DOI 10.1016/j.celrep.2018.03.047; Griffiths DA, 2013, J VIROL, V87, P13853, DOI 10.1128/JVI.02159-13; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Han C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13525; He CB, 2015, EMBO MOL MED, V7, P1426, DOI 10.15252/emmm.201404976; Hodge CD, 2015, ACS CHEM BIOL, V10, P1718, DOI 10.1021/acschembio.5b00222; Huang XD, 2016, CELL RES, V26, P484, DOI 10.1038/cr.2016.31; Huh K, 2007, J VIROL, V81, P9737, DOI 10.1128/JVI.00881-07; Ianevski A, 2020, NUCLEIC ACIDS RES, V48, pW488, DOI 10.1093/nar/gkaa216; Karim R, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003384; Kiprianova I, 2015, NEOPLASIA, V17, P564, DOI 10.1016/j.neo.2015.07.003; Kiran S, 2018, MOL CELL, V72, P823, DOI 10.1016/j.molcel.2018.09.019; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Lee WS, 2015, INT J ONCOL, V46, P2154, DOI 10.3892/ijo.2015.2890; Lehoux M, 2014, J VIROL, V88, P8545, DOI 10.1128/JVI.00379-14; Leverson JD, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4642; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lian Benedict Shi Xiang, 2018, BMC Res Notes, V11, P197, DOI 10.1186/s13104-018-3302-0; Liu J, 2015, BBA-REV CANCER, V1855, P50, DOI 10.1016/j.bbcan.2014.11.005; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Mazumder S, 2012, CANCER RES, V72, P3069, DOI 10.1158/0008-5472.CAN-11-4106; McHugh Angela, 2018, Oncotarget, V9, P20265, DOI 10.18632/oncotarget.24750; Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886; Morgan EL, 2020, PLOS PATHOG, V16, DOI 10.1371/journal.ppat.1008624; Morgan EL, 2019, CANCERS, V11, DOI 10.3390/cancers11121934; Morgan EL, 2019, PLOS PATHOG, V15, DOI 10.1371/journal.ppat.1007835; Morgan EL, 2018, PLOS PATHOG, V14, DOI 10.1371/journal.ppat.1006975; Muller M, 2015, FUTURE VIROL, V10, P27, DOI 10.2217/fvl.14.99; Mukherjee N, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2646-2; Bello JOM, 2015, VIRUSES-BASEL, V7, P4734, DOI 10.3390/v7082842; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Park MK, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08481-x; Pentland L, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2005752; PIM D, 1992, ONCOGENE, V7, P27; Rahman SFA, 2020, BIOCHEM BIOPHYS REP, V22, DOI 10.1016/j.bbrep.2020.100756; Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Senichkin VV, 2020, CELL DEATH DIFFER, V27, P405, DOI 10.1038/s41418-019-0486-3; Spangle JM, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003237; STRAIGHT SW, 1993, J VIROL, V67, P4521, DOI 10.1128/JVI.67.8.4521-4532.1993; Sun XX, 2015, P NATL ACAD SCI USA, V112, P3734, DOI 10.1073/pnas.1411713112; Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39; Tse C, 2008, CANCER RES, V68, P3421, DOI 10.1158/0008-5472.CAN-07-5836; Turnbull AP, 2017, NATURE, V550, P481, DOI 10.1038/nature24451; Vale C, 2008, J CLIN ONCOL, V26, P5802, DOI 10.1200/JCO.2008.16.4368; Varghese F, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096801; Wang B, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-98; Wang Y, 2017, ONCOGENE, V36, P1644, DOI 10.1038/onc.2016.330; Wasson CW, 2017, ONCOTARGET, V8, P103581, DOI 10.18632/oncotarget.21658; Wei AH, 2020, BLOOD REV, V44, DOI 10.1016/j.blre.2020.100672; Wetherill LF, 2018, ANTIVIR RES, V158, P113, DOI 10.1016/j.antiviral.2018.08.005; Wu LQ, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0936-5; Wu XW, 2020, CELL DEATH DIFFER, V27, P55, DOI 10.1038/s41418-019-0339-0; Xu GW, 2010, BLOOD, V115, P2251, DOI 10.1182/blood-2009-07-231191; Yuan J, 2010, CELL, V140, P384, DOI 10.1016/j.cell.2009.12.032; Zhang BY, 2005, ONCOGENE, V24, P2585, DOI 10.1038/sj.onc.1208453; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874; Zhang SZ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02693-9; Zhang T, 2012, MED ONCOL, V29, P1985, DOI 10.1007/s12032-011-0005-y; Zhao XS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1421; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	81	10	10	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					2112	2129		10.1038/s41388-021-01679-8	http://dx.doi.org/10.1038/s41388-021-01679-8		FEB 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33627786	Green Published, hybrid, Green Submitted			2022-12-17	WOS:000621289100008
J	Wang, L; Liang, D; Xiong, X; Lin, YS; Zhu, JL; Yao, ZM; Wang, SH; Guo, Y; Chen, YP; Geary, K; Pan, YL; Zhou, FY; Gao, SG; Zhang, DZ; Yeung, SCJ; Zhang, H				Wang, Lu; Liang, Du; Xiong, Xiao; Lin, Yusheng; Zhu, Jianlin; Yao, Zhimeng; Wang, Shuhong; Guo, Yi; Chen, Yuping; Geary, Kyla; Pan, Yunlong; Zhou, Fuyou; Gao, Shegan; Zhang, Dianzheng; Yeung, Sai-Ching Jim; Zhang, Hao			Repurposing dextromethorphan and metformin for treating nicotine-induced cancer by directly targeting CHRNA7 to inhibit JAK2/STAT3/SOX2 signaling	ONCOGENE			English	Article								Smoking is one of the most impactful lifestyle-related risk factors in many cancer types including esophageal squamous cell carcinoma (ESCC). As the major component of tobacco and e-cigarettes, nicotine is not only responsible for addiction to smoking but also a carcinogen. Here we report that nicotine enhances ESCC cancer malignancy and tumor-initiating capacity by interacting with cholinergic receptor nicotinic alpha 7 subunit (CHRNA7) and subsequently activating the JAK2/STAT3 signaling pathway. We found that aberrant CHRNA7 expression can serve as an independent prognostic factor for ESCC patients. In multiple ESCC mouse models, dextromethorphan and metformin synergistically repressed nicotine-enhanced cancer-initiating cells (CIC) properties and inhibited ESCC progression. Mechanistically, dextromethorphan non-competitively inhibited nicotine binding to CHRNA7 while metformin downregulated CHRNA7 expression by antagonizing nicotine-induced promoter DNA hypomethylation of CHRNA7. Since dextromethorphan and metformin are two safe FDA-approved drugs with minimal undesirable side-effects, the combination of these drugs has a high potential as either a preventive and/or a therapeutic strategy against nicotine-promoted ESCC and perhaps other nicotine-sensitive cancer types as well.	[Wang, Lu; Liang, Du; Xiong, Xiao; Lin, Yusheng; Zhu, Jianlin; Yao, Zhimeng; Wang, Shuhong; Pan, Yunlong; Zhang, Hao] Jinan Univ, Dept Gen Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China; [Wang, Lu; Liang, Du; Xiong, Xiao; Lin, Yusheng; Zhu, Jianlin; Yao, Zhimeng; Wang, Shuhong; Pan, Yunlong; Zhang, Hao] Jinan Univ, Inst Precis Canc Med & Pathol, Sch Med, Guangzhou, Guangdong, Peoples R China; [Liang, Du] Univ Groningen, Dept Biomed Sci Cells & Syst, Sect Mol Cell Biol & Radiat Oncol, Univ Med Ctr Groningen, Groningen, Netherlands; [Lin, Yusheng] Univ Groningen, Univ Med Ctr Groningen, Dept Hematol, Groningen, Netherlands; [Guo, Yi] Shantou Univ, Endoscopy Ctr, Coll Med, Affiliated Canc Hosp, Shantou, Guangdong, Peoples R China; [Chen, Yuping] Shantou Univ, Dept Thorac Surg, Affiliated Canc Hosp, Coll Med, Shantou, Guangdong, Peoples R China; [Geary, Kyla; Zhang, Dianzheng] Philadelphia Coll Osteopath Med, Dept Biomed Sci, 4170 City Ave, Philadelphia, PA 19131 USA; [Zhou, Fuyou] Henan Univ Sci & Technol, Affiliated Hosp 4, Anyang 455001, Henan, Peoples R China; [Zhou, Fuyou] Anyang Tumor Hosp, Dept Thorac Surg, Anyang 455001, Henan, Peoples R China; [Gao, Shegan] Henan Univ Sci & Technol, Coll Clin Med, Henan Key Lab Canc Epigenet, Affiliated Hosp 1, Luoyang 471003, Peoples R China; [Yeung, Sai-Ching Jim] Univ Texas MD Anderson Canc Ctr, Dept Emergency Med, Houston, TX 77030 USA; [Yeung, Sai-Ching Jim] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA	Jinan University; Jinan University; University of Groningen; University of Groningen; Shantou University; Shantou University; Henan University of Science & Technology; Henan University of Science & Technology; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Zhang, H (corresponding author), Jinan Univ, Dept Gen Surg, Affiliated Hosp 1, Guangzhou, Guangdong, Peoples R China.; Zhang, H (corresponding author), Jinan Univ, Inst Precis Canc Med & Pathol, Sch Med, Guangzhou, Guangdong, Peoples R China.	haolabcancercenter@163.com	Yeung, Sai-Ching/AAI-6178-2021	Yeung, Sai-Ching/0000-0001-5170-0822; Wang, Lu/0000-0003-2617-655X; Lin, Yusheng/0000-0002-3693-3377; Du, Liang/0000-0002-1191-2465	National Natural Science Foundation of China [82072683, 81773087, 81071736, 81572876, 30973508, 82002491]; Natural Science Foundation of Guangdong Province of China [9151018004000000, 2020A1515110049]; Special Project on the Integration of Industry, Education and Research of Guangdong Province [2011A090100024]; China Postdoctoral Science Foundation [2020M673078]; Flagship specialty construction project-General surgery [711003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province of China(National Natural Science Foundation of Guangdong Province); Special Project on the Integration of Industry, Education and Research of Guangdong Province; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Flagship specialty construction project-General surgery	The work was supported by a grant in part by the National Natural Science Foundation of China (82072683, 81773087, 81071736, 81572876, and 30973508 to HZ; 82002491 to LW); the Natural Science Foundation of Guangdong Province of China (9151018004000000 to HZ; 2020A1515110049 to LW); the Science and Technology Planning Project of Guangdong Province of China (2019A030317024 to HZ); Special Project on the Integration of Industry, Education and Research of Guangdong Province (2011A090100024 to HZ); China Postdoctoral Science Foundation (2020M673078 to LW); Flagship specialty construction project-General surgery (Funding no.: 711003).	Al-Wadei MH, 2016, EUR J CANCER, V52, P188, DOI 10.1016/j.ejca.2015.10.003; Bridgeman SC, 2018, DIABETES OBES METAB, V20, P1553, DOI 10.1111/dom.13262; Chen XT, 2013, J CLIN INVEST, V123, P2576, DOI 10.1172/JCI68143; Cummings JL, 2015, JAMA-J AM MED ASSOC, V314, P1242, DOI 10.1001/jama.2015.10214; Cuyas E, 2018, ONCOGENE, V37, P963, DOI 10.1038/onc.2017.367; Damaj MI, 2005, J PHARMACOL EXP THER, V312, P780, DOI 10.1124/jpet.104.075093; Dennis Phillip A, 2005, Cancer Epidemiol Biomarkers Prev, V14, P764, DOI 10.1158/1055-9965.EPI-04-0652; Dong HM, 2017, J PATHOL, V241, P448, DOI 10.1002/path.4839; Egleton RD, 2008, TRENDS PHARMACOL SCI, V29, P151, DOI 10.1016/j.tips.2007.12.006; El-Toukhy S, 2018, TOB CONTROL, V27, pS62, DOI 10.1136/tobaccocontrol-2018-054315; Feng Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.59; Fillon M, 2019, CA-CANCER J CLIN, V69, P83, DOI 10.3322/caac.21468; Guha P, 2014, BREAST CANCER RES TR, V145, P5, DOI 10.1007/s10549-014-2912-z; Hallden S, 2016, J INTERN MED, V279, P388, DOI 10.1111/joim.12454; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Improgo MRD, 2010, PROG NEUROBIOL, V92, P212, DOI 10.1016/j.pneurobio.2010.05.003; Karam-Hage M, 2014, CA-CANCER J CLIN, V64, P273, DOI 10.3322/caac.21231; Kreslake JM, 2008, AM J PUBLIC HEALTH, V98, P1685, DOI 10.2105/AJPH.2007.125542; Lee HW, 2018, P NATL ACAD SCI USA, V115, pE1560, DOI 10.1073/pnas.1718185115; Li H, 2015, LUNG CANCER, V88, P1, DOI 10.1016/j.lungcan.2015.01.017; Lin YS, 2019, CLIN CANCER RES, V25, P3035, DOI 10.1158/1078-0432.CCR-18-3169; Martin E, 2015, CONTEMP CLIN TRIALS, V41, P146, DOI 10.1016/j.cct.2015.01.012; Mineur YS, 2010, TRENDS PHARMACOL SCI, V31, P580, DOI 10.1016/j.tips.2010.09.004; Moerke MJ, 2020, PHARMACOL REV, V72, P527, DOI 10.1124/pr.119.018028; Momi N, 2013, ONCOGENE, V32, P1384, DOI 10.1038/onc.2012.163; Nelson KA, 1997, NEUROLOGY, V48, P1212, DOI 10.1212/WNL.48.5.1212; Nimmakayala RK, 2018, GASTROENTEROLOGY, V155, P892, DOI 10.1053/j.gastro.2018.05.041; Paleari L, 2009, AM J RESP CRIT CARE, V179, P1141, DOI 10.1164/rccm.200806-908OC; Parada E, 2010, FREE RADICAL BIO MED, V49, P1815, DOI 10.1016/j.freeradbiomed.2010.09.017; Sang CN, 2002, ANESTHESIOLOGY, V96, P1053, DOI 10.1097/00000542-200205000-00005; Schaal C, 2014, MOL CANCER RES, V12, P14, DOI 10.1158/1541-7786.MCR-13-0541; Wang L, 2019, CANCER LETT, V450, P22, DOI 10.1016/j.canlet.2019.02.014; Wang SH, 2020, CLIN CANCER RES, V26, P4921, DOI 10.1158/1078-0432.CCR-20-0113; Wright MJ, 2006, PHARMACOL BIOCHEM BE, V85, P507, DOI 10.1016/j.pbb.2006.09.020; Xiong X, 2020, P NATL ACAD SCI USA, V117, P6726, DOI 10.1073/pnas.1913433117; Yan L, 2015, ONCOGENE, V34, P3076, DOI 10.1038/onc.2014.236; Zhang Q, 2020, BRIT J CANCER, V122, P904, DOI 10.1038/s41416-020-0730-0; Zhong T, 2017, ONCOGENE, V36, P2345, DOI 10.1038/onc.2016.391	38	10	10	6	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 18	2021	40	11					1974	1987		10.1038/s41388-021-01682-z	http://dx.doi.org/10.1038/s41388-021-01682-z		FEB 2021	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QZ5PE	33603170	Green Published, hybrid			2022-12-17	WOS:000619433100002
J	Guo, ZY; Dai, YC; Hu, WT; Zhang, YS; Cao, ZF; Pei, WW; Liu, NG; Nie, J; Wu, AQ; Mao, WD; Chang, L; Li, BY; Pei, HL; Hei, TK; Zhou, GM				Guo, Ziyang; Dai, Yingchu; Hu, Wentao; Zhang, Yongsheng; Cao, Zhifei; Pei, Weiwei; Liu, Ningang; Nie, Jing; Wu, Anqing; Mao, Weidong; Chang, Lei; Li, Bingyan; Pei, Hailong; Hei, Tom K.; Zhou, Guangming			The long noncoding RNA CRYBG3 induces aneuploidy by interfering with spindle assembly checkpoint via direct binding with Bub3	ONCOGENE			English	Article								Aneuploidy is a hallmark of genomic instability that leads to tumor initiation, progression, and metastasis. CDC20, Bub1, and Bub3 form the mitosis checkpoint complex (MCC) that binds the anaphase-promoting complex or cyclosome (APC/C), a crucial factor of the spindle assembly checkpoint (SAC), to ensure the bi-directional attachment and proper segregation of all sister chromosomes. However, just how MCC is regulated to ensure normal mitosis during cellular division remains unclear. In the present study, we demonstrated that LNC CRYBG3, an ionizing radiation-inducible long noncoding RNA, directly binds with Bub3 and interrupts its interaction with CDC20 to result in aneuploidy. The 261-317 (S3) residual of the LNC CRYBG3 sequence is critical for its interaction with Bub3 protein. Overexpression of LNC CRYBG3 leads to aneuploidy and promotes tumorigenesis and metastasis of lung cancer cells, implying that LNC CRYBG3 is a novel oncogene. These findings provide a novel mechanistic basis for the pathogenesis of NSCLC after exposure to ionizing radiation as well as a potential target for the diagnosis, treatment, and prognosis of an often fatal disease.	[Guo, Ziyang; Dai, Yingchu; Hu, Wentao; Pei, Weiwei; Liu, Ningang; Nie, Jing; Wu, Anqing; Chang, Lei; Li, Bingyan; Pei, Hailong; Zhou, Guangming] Soochow Univ, State Key Lab Radiat Med & Protect, Collaborat Innovat Ctr Radiol Med Jiangsu Higher, Sch Radiat Med & Protect,Inst Space Life Sci,Med, Suzhou 215123, Peoples R China; [Guo, Ziyang; Hei, Tom K.] Columbia Univ, Ctr Radiol Res, Coll Phys & Surg, Med Ctr, New York, NY 10027 USA; [Zhang, Yongsheng; Cao, Zhifei; Mao, Weidong] Soochow Univ, Med Coll, Affiliated Hosp 2, Dept Pathol, Suzhou 215123, Peoples R China	Soochow University - China; Columbia University; Soochow University - China	Pei, HL; Zhou, GM (corresponding author), Soochow Univ, State Key Lab Radiat Med & Protect, Collaborat Innovat Ctr Radiol Med Jiangsu Higher, Sch Radiat Med & Protect,Inst Space Life Sci,Med, Suzhou 215123, Peoples R China.; Hei, TK (corresponding author), Columbia Univ, Ctr Radiol Res, Coll Phys & Surg, Med Ctr, New York, NY 10027 USA.	hlpei@suda.edu.cn; tkh1@cumc.columbia.edu; gmzhou@suda.edu.cn	li, bing/GWQ-9617-2022; Liu, Ning-Ang/GLN-4757-2022		China National Natural Science Foundation [82073480, 81773463, 81872622]; National Key R&D Program of China [2018YFC0115704]; US National Institutes of Health [R01-ES 011804-10]	China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); National Key R&D Program of China; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by the China National Natural Science Foundation awards (Nos. 82073480, 81773463, 81872622), National Key R&D Program of China (No. 2018YFC0115704), and the US National Institutes of Health grant R01-ES 011804-10.	Bharadwaj R, 2004, ONCOGENE, V23, P2016, DOI 10.1038/sj.onc.1207374; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen HY, 2018, J CANCER, V9, P2580, DOI 10.7150/jca.24896; Collin P, 2013, NAT CELL BIOL, V15, P1378, DOI 10.1038/ncb2855; Duan Z, 2007, MOL CELL BIOL, V27, P6889, DOI 10.1128/MCB.00762-07; Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007; Fang GW, 2002, MOL BIOL CELL, V13, P755, DOI 10.1091/mbc.01-09-0437; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Grabsch H, 2003, J PATHOL, V200, P16, DOI 10.1002/path.1324; Guo ZY, 2019, CHEM BIOL DRUG DES, V93, P874, DOI 10.1111/cbdd.13477; Gurley Kay E, 2015, Cold Spring Harb Protoc, V2015, DOI 10.1101/pdb.prot077446; Guttman M, 2009, NATURE, V458, P223, DOI 10.1038/nature07672; Herzog F, 2009, SCIENCE, V323, P1477, DOI 10.1126/science.1163300; HOLLIDAY R, 1989, TRENDS GENET, V5, P42, DOI 10.1016/0168-9525(89)90020-6; HOYT MA, 1991, CELL, V66, P507, DOI 10.1016/0092-8674(81)90014-3; Hu WT, 2014, RNA BIOL, V11, P1189, DOI 10.4161/rna.34345; Hu WTY, 2014, J RADIAT RES, V55, P10, DOI 10.1093/jrr/rrt078; Kato T, 2012, J SURG ONCOL, V106, P423, DOI 10.1002/jso.23109; LI R, 1991, CELL, V66, P519, DOI 10.1016/0092-8674(81)90015-5; Lischetti T, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.970484; Logarinho E, 2008, MOL BIOL CELL, V19, P1798, DOI 10.1091/mbc.E07-07-0633; Ma MZ, 2016, CANCER RES, V76, P5361, DOI 10.1158/0008-5472.CAN-15-3047; MANCHESTER KL, 1995, TRENDS CELL BIOL, V5, P384, DOI 10.1016/S0962-8924(00)89080-7; McWhorter JE, 1929, ANN SURG, V90, P1, DOI 10.1097/00000658-192907000-00001; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nagano T, 2011, CELL, V145, P178, DOI 10.1016/j.cell.2011.03.014; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; Overlack K, 2017, CURR BIOL, V27, P2915, DOI 10.1016/j.cub.2017.08.033; Park YH, 2015, TOXICOL APPL PHARM, V287, P240, DOI 10.1016/j.taap.2015.06.008; Pei HL, 2018, CANCER RES, V78, P4563, DOI 10.1158/0008-5472.CAN-18-0988; Pei HL, 2018, CELL CYCLE, V17, P1115, DOI 10.1080/15384101.2018.1480217; Pei HL, 2017, CELL CYCLE, V16, P113, DOI 10.1080/15384101.2016.1259039; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Rasnick D, 1999, BIOCHEM J, V340, P621, DOI 10.1042/0264-6021:3400621; Ricke RM, 2008, TRENDS GENET, V24, P457, DOI 10.1016/j.tig.2008.07.002; Rodrigues CFD, 2009, MUTAT RES-FUND MOL M, V670, P42, DOI 10.1016/j.mrfmmm.2009.07.004; Senger DR, 2002, AM J PATHOL, V160, P195, DOI 10.1016/S0002-9440(10)64363-5; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Sudakin V, 2001, J CELL BIOL, V154, P925, DOI 10.1083/jcb.200102093; Sun M, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.256; Sun M, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-68; Tsai MC, 2011, CANCER RES, V71, P3, DOI 10.1158/0008-5472.CAN-10-2483; Wang Y, 2013, CANCER RES, V73, P4801, DOI 10.1158/0008-5472.CAN-12-3273; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; White NM, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-3498; Wilusz JE, 2009, GENE DEV, V23, P1494, DOI 10.1101/gad.1800909; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zhang EB, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1523-0; Zhiwei W, 2013, CURR PHARM DESIGN, V19; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	51	10	10	3	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1821	1835		10.1038/s41388-020-01601-8	http://dx.doi.org/10.1038/s41388-020-01601-8		FEB 2021	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564066	hybrid, Green Published			2022-12-17	WOS:000616489100004
J	Zhao, L; Wu, XH; Zheng, JN; Dong, D				Zhao, Lei; Wu, Xiaohong; Zheng, Junnian; Dong, Dong			DNA methylome profiling of circulating tumor cells in lung cancer at single base-pair resolution	ONCOGENE			English	Article							PROMOTER METHYLATION; METASTASIS; SEQ	DNA methylation plays a pivotal role in regulating cellular processes, and altered DNA methylation pattern is a general hallmark of cancer. However, DNA methylome in circulating tumor cells (CTCs) is still a mystery due to the lack of proper analytical techniques. We introduced an efficient workflow, LCM-mu WGBS, which can efficiently profile the DNA methylation of microdissected CTC samples. LCM-mu WGBS combines the laser capture microdissection (LCM)-based CTC capture method and whole-genome bisulfite sequencing in very small CTC population (mu WGBS) to gain insight into the DNA methylation landscape of CTCs. We herein profiled the DNA methylome of CTCs from lung cancer patients. Deriving from a comprehensive analysis of CTC methylome, a unique "CTC DNA methylation signature" that is distinct from primary lung cancer tissues was identified. Further analysis showed that promoter hypermethylation of epithelial genes is a hallmark of stable epithelial-mesenchymal transition process. Moreover, it has been suggested that CTCs are endowed with a stemness-related feature during dissemination and metastasis. This work constitutes a unique DNA methylation analysis of CTCs at single base-pair resolution, which might facilitate to propose noninvasive CTC DNA methylation biomarkers contributing to clinical diagnosis.	[Zhao, Lei; Zheng, Junnian; Dong, Dong] Xuzhou Med Univ, Canc Inst, Xuzhou, Jiangsu, Peoples R China; [Zhao, Lei; Zheng, Junnian; Dong, Dong] Xuzhou Med Univ, Affiliated Hosp, Ctr Clin Oncol, Xuzhou, Jiangsu, Peoples R China; [Zhao, Lei] East China Normal Univ, Sch Life Sci, Inst Biomed Sci, Shanghai Key Lab Regulatory Biol, Shanghai, Peoples R China; [Wu, Xiaohong] Jiangsu Univ, Affiliated Yixing Hosp, Dept Gen Surg, Yixing 214200, Jiangsu, Peoples R China	Xuzhou Medical University; Xuzhou Medical University; East China Normal University; Jiangsu University	Zheng, JN; Dong, D (corresponding author), Xuzhou Med Univ, Canc Inst, Xuzhou, Jiangsu, Peoples R China.; Zheng, JN; Dong, D (corresponding author), Xuzhou Med Univ, Affiliated Hosp, Ctr Clin Oncol, Xuzhou, Jiangsu, Peoples R China.	jnzheng@xzhmu.edu.cn; ddong@xzhmu.edu.cn	Zhao, Lei/AAN-9084-2021	Zhao, Lei/0000-0001-7298-086X; Zheng, Junnian/0000-0003-0208-6410; , Dong/0000-0002-5642-7068	Xuzhou Medical University [D2019027]; Natural Science Fund for Colleges and Universities in Jiangsu Province [20KJA320007]; Training Project for Youth Teams of Science and Technology Innovation at Xuzhou Medical University [TD202008]	Xuzhou Medical University; Natural Science Fund for Colleges and Universities in Jiangsu Province; Training Project for Youth Teams of Science and Technology Innovation at Xuzhou Medical University	This work was supported by grants from Xuzhou Medical University (grant D2019027), Natural Science Fund for Colleges and Universities in Jiangsu Province (20KJA320007), and the Training Project for Youth Teams of Science and Technology Innovation at Xuzhou Medical University (TD202008).	Allard WJ, 2004, CLIN CANCER RES, V10, P6897, DOI 10.1158/1078-0432.CCR-04-0378; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170; Boral D, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00196-1; Chimonidou M, 2013, MOL CANCER RES, V11, P1248, DOI 10.1158/1541-7786.MCR-13-0096; Chimonidou M, 2013, CLIN CHEM, V59, P270, DOI 10.1373/clinchem.2012.191551; Chimonidou M, 2011, CLIN CHEM, V57, P1169, DOI 10.1373/clinchem.2011.165902; Engelmann D, 2012, CANCER RES, V72, P571, DOI 10.1158/0008-5472.CAN-11-2575; Farlik M, 2015, CELL REP, V10, P1386, DOI 10.1016/j.celrep.2015.02.001; Faugeroux V, 2020, EUR UROL ONCOL, V3, P498, DOI 10.1016/j.euo.2018.12.005; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Hansen KD, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R83, 10.1186/gb-2012-13-10-r83]; Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865; Herrmann C, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks543; Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111; Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230; Keller L, 2019, NAT REV CANCER, V19, P553, DOI 10.1038/s41568-019-0180-2; Korthauer K, 2019, BIOSTATISTICS, V20, P367, DOI 10.1093/biostatistics/kxy007; Krueger F, 2011, BIOINFORMATICS, V27, P1571, DOI 10.1093/bioinformatics/btr167; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Lee CC, 2012, J BIOL CHEM, V287, P2798, DOI 10.1074/jbc.M111.258947; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Liu XQ, 2018, EBIOMEDICINE, V35, P244, DOI 10.1016/j.ebiom.2018.08.005; Miyamoto DT, 2015, SCIENCE, V349, P1351, DOI 10.1126/science.aab0917; Pantel K, 2016, ONCOGENE, V35, P1216, DOI 10.1038/onc.2015.192; Park ES, 2018, LAB CHIP, V18, P1736, DOI 10.1039/c8lc00184g; Pixberg CF, 2017, ONCOGENE, V36, P3223, DOI 10.1038/onc.2016.480; Vidal E, 2017, ONCOGENE, V36, P5648, DOI 10.1038/onc.2017.176; Wu SY, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123976; Yu M, 2013, SCIENCE, V339, P580, DOI 10.1126/science.1228522; Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217; Zhang YJ, 2015, INT J CANCER, V136, P1228, DOI 10.1002/ijc.29070; Zheng GT, 2018, NUCLEIC ACIDS RES, V46, pD950, DOI 10.1093/nar/gkx1008; Zheng XQ, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0419-x; Ziller MJ, 2013, NATURE, V500, P477, DOI 10.1038/nature12433	38	10	10	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 10	2021	40	10					1884	1895		10.1038/s41388-021-01657-0	http://dx.doi.org/10.1038/s41388-021-01657-0		FEB 2021	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QU6VJ	33564067	hybrid, Green Published			2022-12-17	WOS:000616489100001
J	Al-Akhrass, H; Conway, JRW; Poulsen, ASA; Paatero, I; Kaivola, J; Padzik, A; Andersen, OM; Ivaska, J				Al-Akhrass, Hussein; Conway, James R. W.; Poulsen, Annemarie Svane Aavild; Paatero, Ilkka; Kaivola, Jasmin; Padzik, Artur; Andersen, Olav M.; Ivaska, Johanna			A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance	ONCOGENE			English	Article							AMYLOID PRECURSOR PROTEIN; BREAST-CANCER; NERVOUS-SYSTEM; INHIBITION; TRASTUZUMAB; CONTRIBUTES; TRAFFICKING; FULVESTRANT; EXPRESSION; METASTASES	Current evidence indicates that resistance to the tyrosine kinase-type cell surface receptor (HER2)-targeted therapies is frequently associated with HER3 and active signaling via HER2-HER3 dimers, particularly in the context of breast cancer. Thus, understanding the response to HER2-HER3 signaling and the regulation of the dimer is essential to decipher therapy relapse mechanisms. Here, we investigate a bidirectional relationship between HER2-HER3 signaling and a type-1 transmembrane sorting receptor, sortilin-related receptor (SorLA; SORL1). We demonstrate that heregulin-mediated signaling supports SorLA transcription downstream of the mitogen-activated protein kinase pathway. In addition, we demonstrate that SorLA interacts directly with HER3, forming a trimeric complex with HER2 and HER3 to attenuate lysosomal degradation of the dimer in a Ras-related protein Rab4-dependent manner. In line with a role for SorLA in supporting the stability of the HER2 and HER3 receptors, loss of SorLA compromised heregulin-induced cell proliferation and sensitized metastatic anti-HER2 therapy-resistant breast cancer cells to neratinib in cancer spheroids in vitro and in vivo in a zebrafish brain xenograft model.	[Al-Akhrass, Hussein; Conway, James R. W.; Paatero, Ilkka; Kaivola, Jasmin; Padzik, Artur; Ivaska, Johanna] Univ Turku, Turku Biosci Ctr, FI-20520 Turku, Finland; [Al-Akhrass, Hussein; Conway, James R. W.; Paatero, Ilkka; Kaivola, Jasmin; Padzik, Artur; Ivaska, Johanna] Abo Akad Univ, FI-20520 Turku, Finland; [Poulsen, Annemarie Svane Aavild; Andersen, Olav M.] Aarhus Univ, Dept Biomed, Danish Res Inst Translat Neurosci DANDRITE Nord E, Aarhus, Denmark	University of Turku; Abo Akademi University; Aarhus University	Al-Akhrass, H; Ivaska, J (corresponding author), Univ Turku, Turku Biosci Ctr, FI-20520 Turku, Finland.; Al-Akhrass, H; Ivaska, J (corresponding author), Abo Akad Univ, FI-20520 Turku, Finland.	hussein.al-akhrass@utu.fi; joivaska@utu.fi		Ivaska, Johanna/0000-0002-6295-6556; Kaivola, Jasmin/0000-0002-1437-1828; Al-Akhrass, Hussein/0000-0002-9630-3000	Academy of Finland [312517]; Academy of Finland CoE for Translational Cancer Biology; European Research Council CoG grant [615258]; Sigrid Juselius Foundation; Finnish Cancer Organization; Finnish Cultural Foundation Central Fund [190150]; European Union's Horizon 2020 research and innovation program under Marie Sklodowska-Curie grant [841973]; Independent Research Fund Denmark [DFF-4004-00371]; TuDMM Doctoral Program, University of Turku	Academy of Finland(Academy of Finland); Academy of Finland CoE for Translational Cancer Biology; European Research Council CoG grant; Sigrid Juselius Foundation(Sigrid Juselius Foundation); Finnish Cancer Organization; Finnish Cultural Foundation Central Fund; European Union's Horizon 2020 research and innovation program under Marie Sklodowska-Curie grant; Independent Research Fund Denmark; TuDMM Doctoral Program, University of Turku	We thank J. Siivonen and P. Laasola for technical assistance. H. Hamidi is acknowledged for illustrations and editing of the manuscript. The Ivaska laboratory is acknowledged for lively discussions and critical feedback on the manuscript. Guillaume Jacquemet, Jukka Westermarck, Majid Momeny, and Patrick Brest are acknowledged for critical reading of the manuscript. The Cell Imaging and Cytometry and Genome Editing core facilities (Turku Bioscience Centre, University of Turku and Abo Akademi University and Biocenter, Finland); the EuroBioimaging node in Turku and the Zebrafish core facility (Turku Bioscience Centre, University of Turku and Abo Akademi University) are acknowledged for services, instrumentation, and expertise. This study was supported by the Academy of Finland (J. Ivaska grant 312517), the Academy of Finland CoE for Translational Cancer Biology (J. Ivaska), the European Research Council CoG grant 615258 (J. Ivaska), the Sigrid Juselius Foundation (J. Ivaska) and the Finnish Cancer Organization (J. Ivaska). H. AlAkhrass has been supported by the Finnish Cultural Foundation Central Fund 190150. J.R.W. Conway has been supported by the European Union's Horizon 2020 research and innovation program under Marie Sklodowska-Curie grant agreement 841973. O.M. Andersen has been supported by The Independent Research Fund Denmark grant DFF-4004-00371. J. Kaivola has been supported by TuDMM Doctoral Program, University of Turku.	Al-Akhrass H, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01172-5; Amin DN, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000389; Andersen OM, 2005, P NATL ACAD SCI USA, V102, P13461, DOI 10.1073/pnas.0503689102; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Baselga J, 2017, LANCET ONCOL, V18, P904, DOI 10.1016/S1470-2045(17)30376-5; Bertelsen V, 2014, MEMBRANES, V4, P424, DOI 10.3390/membranes4030424; Boulbes DR, 2015, BREAST CANCER RES TR, V151, P501, DOI 10.1007/s10549-015-3414-3; Caldieri G, 2018, PROG MOL SUBCELL BIO, V57, P235, DOI 10.1007/978-3-319-96704-2_9; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Croucher DR, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aaf0793; Ding Y, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06651-x; Falls DL, 2003, EXP CELL RES, V284, P14, DOI 10.1016/S0014-4827(02)00102-7; Fazio M, 2020, NAT REV CANCER, V20, P263, DOI 10.1038/s41568-020-0252-3; Fjorback AW, 2012, J NEUROSCI, V32, P1467, DOI 10.1523/JNEUROSCI.2272-11.2012; Freal A, 2019, NEURON, V104, P305, DOI 10.1016/j.neuron.2019.07.029; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Gijsen M, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000563; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Grant BD, 2009, NAT REV MOL CELL BIO, V10, P597, DOI 10.1038/nrm2755; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Hutcheson IR, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2848; Jacobsen L, 2002, FEBS LETT, V511, P155, DOI 10.1016/S0014-5793(01)03299-9; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Kang JC, 2014, MABS-AUSTIN, V6, P340, DOI 10.4161/mabs.27658; Kodack DP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4682; Kodack DP, 2015, CANCER CELL, V27, P163, DOI 10.1016/j.ccell.2015.01.001; Kodack DP, 2012, P NATL ACAD SCI USA, V109, pE3119, DOI 10.1073/pnas.1216078109; Liu JY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07258-y; Maxfield FR, 2004, NAT REV MOL CELL BIO, V5, P121, DOI 10.1038/nrm1315; Mehmedbasic A, 2015, J BIOL CHEM, V290, P3359, DOI 10.1074/jbc.M114.619940; Mei L, 2014, NEURON, V83, P27, DOI 10.1016/j.neuron.2014.06.007; Mishra R, 2020, P A I C C AUT ROBOT, P124, DOI 10.1109/ICCAR49639.2020.9108074; Navaroli DM, 2012, P NATL ACAD SCI USA, V109, pE471, DOI 10.1073/pnas.1115495109; Nusinow DP, 2020, CELL, V180, P387, DOI 10.1016/j.cell.2019.12.023; Olson EM, 2013, ANN ONCOL, V24, P1526, DOI 10.1093/annonc/mdt036; Paatero I, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.3027; Parachoniak CA, 2011, DEV CELL, V20, P751, DOI 10.1016/j.devcel.2011.05.007; Pereira B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11479; Peuhu E, 2017, DEVELOPMENT, V144, P4103, DOI 10.1242/dev.154229; Pietila M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10275-0; Research C for DE and, 2020, FDA APPR NER MET HER; Rhost S, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1060-5; Roselli S, 2015, ONCOTARGET, V6, P10473, DOI 10.18632/oncotarget.3401; Sato T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127360; Schmidt V, 2016, J CLIN INVEST, V126, P2706, DOI 10.1172/JCI84708; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Schuck P, 1997, ANNU REV BIOPH BIOM, V26, P541, DOI 10.1146/annurev.biophys.26.1.541; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Small SA, 2015, NAT REV NEUROSCI, V16, P126, DOI 10.1038/nrn3896; Tomas A, 2014, TRENDS CELL BIOL, V24, P26, DOI 10.1016/j.tcb.2013.11.002; Tubbesing K, 2020, MOL CANCER RES, P19; Vaught DB, 2012, CANCER RES, V72, P2672, DOI 10.1158/0008-5472.CAN-11-3594; Wang CY, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8597; White RM, 2008, CELL STEM CELL, V2, P183, DOI 10.1016/j.stem.2007.11.002; Willnow TE, 2010, REV NEUROSCIENCE, V21, P315; Willnow TE, 2008, NAT REV NEUROSCI, V9, P899, DOI 10.1038/nrn2516; Xia WL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3480; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Zhang SY, 2013, CANCER RES, V73, P5764, DOI 10.1158/0008-5472.CAN-12-1803; Zhang YQ, 2016, CANCER LETT, V382, P176, DOI 10.1016/j.canlet.2016.08.026	65	10	10	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1300	1317		10.1038/s41388-020-01604-5	http://dx.doi.org/10.1038/s41388-020-01604-5		JAN 2021	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420373	Green Published, Green Submitted, hybrid			2022-12-17	WOS:000607346000002
J	Xu, YY; Guo, J; Liu, J; Xie, Y; Li, X; Jiang, HM; Wang, JJ; Peng, ZY; Wang, JY; Wang, S; Wan, C; Chen, LT; Zhong, YP; Liu, BZ; Liu, ZQ				Xu, Yinyin; Guo, Jing; Liu, Jing; Xie, Ying; Li, Xin; Jiang, Hongmei; Wang, Jingjing; Peng, Ziyi; Wang, Jingya; Wang, Sheng; Wan, Chao; Chen, Lanting; Zhong, Yuping; Liu, Beizhong; Liu, Zhiqiang			Hypoxia-induced CREB cooperates MMSET to modify chromatin and promote DKK1 expression in multiple myeloma	ONCOGENE			English	Article							BONE-DISEASE; DICKKOPF-1 DKK1; IN-VIVO; GROWTH; SUPPRESSION; ANTIBODY; GENE	Myeloma cells produce excessive levels of dickkopf-1 (DKK1), which mediates the inhibition of Wnt signaling in osteoblasts, leading to multiple myeloma (MM) bone disease. Nevertheless, the precise mechanisms underlying DKK1 overexpression in myeloma remain incompletely understood. Herein, we provide evidence that hypoxia promotes DKK1 expression in myeloma cells. Under hypoxic conditions, p38 kinase phosphorylated cAMP-responsive element-binding protein (CREB) and drove its nuclear import to activate DKK1 transcription. In addition, high levels of DKK1 were associated with the presence of focal bone lesions in patients with t(4;14) MM, overexpressing the histone methyltransferase MMSET, which was identified as a downstream target gene of hypoxia-inducible factor (HIF)-1 alpha. Furthermore, we found that CREB could recruit MMSET, leading to the stabilization of HIF-1 alpha protein and the increased dimethylation of histone H3 at lysine 36 on the DKK1 promoter. Knockdown of CREB in myeloma cells alleviated the suppression of osteoblastogenesis by myeloma-secreted DKK1 in vitro. Combined treatment with a CREB inhibitor and the hypoxia-activated prodrug TH-302 (evofosfamide) significantly reduced MM-induced bone destruction in vivo. Taken together, our findings reveal that hypoxia and a cytogenetic abnormality regulate DKK1 expression in myeloma cells, and provide an additional rationale for the development of therapeutic strategies that interrupt DKK1 to cure MM.	[Xu, Yinyin; Liu, Beizhong] Chongqing Med Univ, Clin Lab, Yongchuan Hosp, Chongqing, Peoples R China; [Xu, Yinyin; Wan, Chao; Liu, Beizhong] Chongqing Med Univ, Dept Lab Med, Key Lab Lab Med Diagnost, Minist Educ, Chongqing, Peoples R China; [Guo, Jing; Liu, Jing; Xie, Ying; Li, Xin; Jiang, Hongmei; Wang, Jingjing; Peng, Ziyi; Wang, Jingya; Wang, Sheng; Liu, Zhiqiang] Tianjin Med Univ, Prov & Minist Cosponsored Collaborat Innovat Ctr, Tianjin Key Lab Cellular Homeostasis & Human Dis, Dept Physiol & Pathophysiol,Sch Basic Med Sci, Tianjin, Peoples R China; [Chen, Lanting] Chongqing Med Univ, Dept Hematol, Yongchuan Hosp, Chongqing, Peoples R China; [Zhong, Yuping] Qingdao Municipal Hosp, Dept Hematol, Qingdao, Shandong, Peoples R China; [Liu, Zhiqiang] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Tianjin Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China	Chongqing Medical University; Chongqing Medical University; Tianjin Medical University; Chongqing Medical University; Qingdao Municipal Hospital; Tianjin Medical University	Liu, BZ (corresponding author), Chongqing Med Univ, Clin Lab, Yongchuan Hosp, Chongqing, Peoples R China.; Liu, BZ (corresponding author), Chongqing Med Univ, Dept Lab Med, Key Lab Lab Med Diagnost, Minist Educ, Chongqing, Peoples R China.; Liu, ZQ (corresponding author), Tianjin Med Univ, Prov & Minist Cosponsored Collaborat Innovat Ctr, Tianjin Key Lab Cellular Homeostasis & Human Dis, Dept Physiol & Pathophysiol,Sch Basic Med Sci, Tianjin, Peoples R China.; Liu, ZQ (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Tianjin Key Lab Canc Prevent & Therapy, Tianjin, Peoples R China.	liubeizhong@cqmu.edu.cn; zhiqiangliu@tmu.edu.cn	wang, jing/GVT-8700-2022; WANG, JINGYI/GSJ-1241-2022; Liu, Zhiqiang/E-6950-2014; Wang, Jin/GYA-2019-2022; wang, jing/GRS-7509-2022	Liu, Zhiqiang/0000-0002-0677-8097; Liu, Jing/0000-0002-2112-2416	National Natural Science Foundation of China [81670201, 81870161, 82070221, 81900215, 81772280]; Natural Science Foundation of Tianjin [16JCYBJC42600]; Natural Science Foundation of Beijing [7162067]; Talent Project of Tianjin Medical University [11601501/2016KJ0317]; College Student Innovation Program of Tianjin Medical University [201810062011]; Development Program of Yongchuan Hospital of Chongqing Medical University [YJJC201706]; Innovation Project of Postgraduate Program of Yongchuan Hospital of Chongqing Medical University [YJSCX201901]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Tianjin(Natural Science Foundation of Tianjin); Natural Science Foundation of Beijing(Beijing Natural Science Foundation); Talent Project of Tianjin Medical University; College Student Innovation Program of Tianjin Medical University; Development Program of Yongchuan Hospital of Chongqing Medical University; Innovation Project of Postgraduate Program of Yongchuan Hospital of Chongqing Medical University	This work was supported by the National Natural Science Foundation of China (81670201, 81870161, 82070221, ZL; 81900215, Jingya W; 81772280, BL), the Natural Science Foundation of Tianjin (16JCYBJC42600, ZL), the Natural Science Foundation of Beijing (7162067, ZP), the Talent Project of Tianjin Medical University (11601501/2016KJ0317, ZL), the College Student Innovation Program of Tianjin Medical University (201810062011, XL), the Development Program of Yongchuan Hospital of Chongqing Medical University (YJJC201706, Yinyin X), and the Innovation Project of Postgraduate Program of Yongchuan Hospital of Chongqing Medical University (YJSCX201901, Yinyin X).	Abe Masahiro, 2019, Clin Calcium, V29, P349, DOI 10.20837/4201903349; Adamik J, 2019, JBMR, V3; Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Bhaskar Archana, 2016, Int J Adv Res (Indore), V4, P706; Borsi E, 2015, TRANSL RES, V165, P641, DOI 10.1016/j.trsl.2014.12.001; Charan Jaykaran, 2013, Indian J Psychol Med, V35, P121, DOI 10.4103/0253-7176.116232; Colla S, 2007, BLOOD, V109, P4470, DOI 10.1182/blood-2006-11-056747; Craig JC, 2001, J BIOL CHEM, V276, P11719, DOI 10.1074/jbc.M010263200; Durie BGM, 2006, LEUKEMIA, V20, P1467, DOI 10.1038/sj.leu.2404284; Eda Homare, 2016, Cancer Treat Res, V169, P251; Fulciniti M, 2009, BLOOD, V114, P371, DOI 10.1182/blood-2008-11-191577; Garces JJ, 2020, LEUKEMIA, V34, P589, DOI 10.1038/s41375-019-0588-4; Guo KT, 2014, J CANCER RES CLIN, V140, P1261, DOI 10.1007/s00432-014-1642-2; He J, 2012, CANCER RES, V72, P6393, DOI 10.1158/0008-5472.CAN-12-2664; Heath DJ, 2009, J BONE MINER RES, V24, P425, DOI 10.1359/JBMR.081104; Intini G, 2015, BONE, V75, P151, DOI 10.1016/j.bone.2015.01.008; Liu H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad8949; Liu ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085571; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; Muz B, 2019, HAEMATOLOGICA, V104, DOI 10.3324/haematol.2018.194688; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Pozzi S, 2013, BONE, V53, P487, DOI 10.1016/j.bone.2013.01.012; Qian JF, 2007, BLOOD, V110, P1587, DOI 10.1182/blood-2007-03-082529; Qiang YW, 2008, BLOOD, V112, P196, DOI 10.1182/blood-2008-01-132134; Rajkumar SV, 2020, AM J HEMATOL, V95, P548, DOI 10.1002/ajh.25791; Richardson PG, 2010, BLOOD, V116, P679, DOI 10.1182/blood-2010-02-268862; Schoenhals M, 2017, CELL CYCLE, V16, P1104, DOI 10.1080/15384101.2017.1317408; Silvestris F, 2004, BRIT J HAEMATOL, V126, P475, DOI 10.1111/j.1365-2141.2004.05084.x; Storti P, 2013, LEUKEMIA, V27, P1697, DOI 10.1038/leu.2013.24; Terpos E, 2018, BLOOD CANCER J, V8, DOI 10.1038/s41408-017-0037-4; Tosi P, 2008, EUR J HAEMATOL, V80, P31, DOI 10.1111/j.1600-0609.2007.00974.x; van Andel H, 2019, LEUKEMIA, V33, P1063, DOI 10.1038/s41375-019-0404-1; Wang H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040955; Wu C, 2018, CANCER MED-US, V7, P3899, DOI 10.1002/cam4.1596; Xie Y, 2020, ONCOGENE, V39, P922, DOI 10.1038/s41388-019-1037-6; Xie ZG, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/636514; Yaccoby S, 2007, BLOOD, V109, P2106, DOI 10.1182/blood-2006-09-047712; Yang P, 2012, MOL CELL BIOL, V32, P3121, DOI 10.1128/MCB.00204-12; Zhou FL, 2013, BLOOD REV, V27, P261, DOI 10.1016/j.blre.2013.08.002; Zhu HL, 2016, SCI REP-UK, V6, DOI 10.1038/srep26859	40	10	11	0	12	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 18	2021	40	7					1231	1241		10.1038/s41388-020-01590-8	http://dx.doi.org/10.1038/s41388-020-01590-8		JAN 2021	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QK0LS	33420361	Green Published, hybrid			2022-12-17	WOS:000607346000018
J	Liu, XW; Wang, F; Xu, CW; Chen, XR; Hou, X; Li, Q; Li, PS; Xie, Z; Liu, YD; Chang, LP; Guan, YF; Zhang, XC; Yang, L; Wang, H; Yi, X; Zhang, JJ; Xia, XF; Moran, C; Chen, LK				Liu, Xuewen; Wang, Fang; Xu, Chunwei; Chen, Xinru; Hou, Xue; Li, Qian; Li, Pansong; Xie, Zhi; Liu, Yongdong; Chang, Lianpeng; Guan, Yanfang; Zhang, Xuchao; Yang, Ling; Wang, Hui; Yi, Xin; Zhang, Jianjun; Xia, Xuefeng; Moran, Cesar; Chen, Likun			Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma	ONCOGENE			English	Article							MOLECULAR CHARACTERIZATION; POOR-PROGNOSIS; KRAS MUTATION; LUNG; EGFR; IDENTIFICATION; AMPLIFICATION	Pulmonary sarcomatoid carcinoma (PSC) contains carcinomatous component (CaC) and sarcomatous component (SaC). Herein, we explored the genomic origin and intratumor heterogeneity (ITH) of PSC. We collected 31 resected PSC tumors and obtained CaC and SaC by laser capture microdissection for next-generation sequencing. The majority of PSCs (97%) had component-shared alterations. Driver mutations in EGFR, KRAS, MET, PIK3CA, and EML4-ALK fusion were mostly component-shared. Twenty-seven (87%) PSCs had component-private alterations. Compared with pure lung adenocarcinoma (LUAD), adenocarcinoma component of PSC showed lower EGFR incidence. Compared with other typical sarcomas, numerous genes of SaC exhibited significant differences. CaC and SaC had equivalent and proportional tumor mutation burden (TMB), as well as PD-L1 level. Compared with LUAD, SaC had significant higher TMB and more patients with high PD-L1 expression (tumor proportion score >= 50%). PSC with lower proportion of component-shared alterations (trunk-ratio) had a prolonged disease-free survival (DFS), regardless of the influence of clinical factors. We conclude that most PSCs originate from a monoclone accompanied by genomic ITH which is a potential independent prognostic factor, and more proportion of PSCs may be beneficial from immune checkpoint inhibitors.	[Liu, Xuewen] Cent South Univ, Xiangya Hosp 3, Dept Oncol, Changsha 410013, Hunan, Peoples R China; [Wang, Fang] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Mol Diagnost,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Xu, Chunwei] Nanjing Univ Sch Med, Jinling Hosp, Dept Resp Med, Nanjing 210002, Jiangsu, Peoples R China; [Chen, Xinru; Hou, Xue; Chen, Likun] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Med Oncol,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Li, Qian; Li, Pansong; Chang, Lianpeng; Guan, Yanfang; Yang, Ling; Yi, Xin; Xia, Xuefeng] Geneplus Beijing, Beijing 102206, Peoples R China; [Xie, Zhi; Zhang, Xuchao] Guangdong Gen Hosp GGH, Guangdong Prov Key Lab Translat Med Lung Canc, Guangdong Lung Canc Inst, Guangzhou 510080, Guangdong, Peoples R China; [Xie, Zhi; Zhang, Xuchao] Guangdong Acad Med Sci, Guangzhou 510080, Guangdong, Peoples R China; [Liu, Yongdong] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Pathol, Guangzhou 510080, Guangdong, Peoples R China; [Wang, Hui] Cent South Univ, Hunan Canc Hosp, Dept Radiat Oncol, Changsha 410013, Hunan, Peoples R China; [Wang, Hui] Cent South Univ, Affiliated Canc Hosp, Xiangya Sch Med, Changsha 410013, Hunan, Peoples R China; [Wang, Hui] Hunan Prov Key Lab Translat Radiat Oncol, Changsha 410013, Hunan, Peoples R China; [Zhang, Jianjun] Univ Texas MD Anderson Canc Ctr, Dept Genom Med & Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Moran, Cesar] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA	Central South University; State Key Lab Oncology South China; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Guangdong Academy of Medical Sciences & Guangdong General Hospital; Sun Yat Sen University; Central South University; Central South University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Chen, LK (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Dept Med Oncol,Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.; Moran, C (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.	cesarmoran@mdanderson.org; chenlk@sysucc.org.cn	zhang, xu/GRX-9733-2022; Zhang, xiaoyu/GXA-3206-2022; zhang, xian/GYA-0290-2022; zhang, xu/GYE-3558-2022	Li, Qian/0000-0001-9413-1877	National Natural Science Foundation of China [81572270]; Nature Science Foundation of Hunan Province [2017JJ3188]; Foundation of Hunan Health Committee Research Plan [A2017005]; Foundation of Wisdom Gathering and Talent Cultivating Program from the Third Xiangya Hospital	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Nature Science Foundation of Hunan Province(Natural Science Foundation of Hunan Province); Foundation of Hunan Health Committee Research Plan; Foundation of Wisdom Gathering and Talent Cultivating Program from the Third Xiangya Hospital	This study was supported by the National Natural Science Foundation of China (81572270), Nature Science Foundation of Hunan Province (2017JJ3188), Foundation of Hunan Health Committee Research Plan (A2017005) and Foundation of Wisdom Gathering and Talent Cultivating Program from the Third Xiangya Hospital.	Babacan NA, 2020, CLIN LUNG CANCER, V21, pE456, DOI 10.1016/j.cllc.2020.02.022; Bevilacqua C, 2018, MOL ASPECTS MED, V59, P5, DOI 10.1016/j.mam.2017.09.003; Blaukovitsch M, 2006, VIRCHOWS ARCH, V449, P455, DOI 10.1007/s00428-006-0256-8; Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495; Chang YL, 2011, ANN SURG ONCOL, V18, P2952, DOI 10.1245/s10434-011-1621-7; Chen FM, 2019, ONCOTARGETS THER, V12, P3321, DOI 10.2147/OTT.S196751; Chen K, 2009, NAT METHODS, V6, P677, DOI [10.1038/nmeth.1363, 10.1038/NMETH.1363]; Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514; Cimpeanu E, 2020, WORLD J CLIN CASES, V8, P97, DOI 10.12998/wjcc.v8.i1.97; D'Angelo SP, 2011, J CLIN ONCOL, V29, P2066, DOI 10.1200/JCO.2010.32.6181; Fallet V, 2015, ANN ONCOL, V26, P1748, DOI 10.1093/annonc/mdv232; Gibney GT, 2016, LANCET ONCOL, V17, pE542, DOI 10.1016/S1470-2045(16)30406-5; Goto T, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3059-1; Italiano A, 2009, INT J CANCER, V125, P2479, DOI 10.1002/ijc.24610; Kaira K, 2010, J THORAC ONCOL, V5, P460, DOI 10.1097/JTO.0b013e3181ce3e3c; Kim S, 2015, EUR J CANCER, V51, P2698, DOI 10.1016/j.ejca.2015.08.013; LAUSEN B, 1992, BIOMETRICS, V48, P73, DOI 10.2307/2532740; Leone A, 2011, INT J CANCER, V128, P732, DOI 10.1002/ijc.25335; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li J, 2012, BIOINFORMATICS, V28, P1307, DOI 10.1093/bioinformatics/bts146; Li Y, 2018, LUNG CANCER, V122, P113, DOI 10.1016/j.lungcan.2018.06.001; Liang XH, 2019, INT J CLIN ONCOL, V24, P1061, DOI 10.1007/s10147-019-01454-6; Lin G, 2020, ANN ONCOL, V31, P517, DOI 10.1016/j.annonc.2020.01.014; Lin YB, 2016, AM J CLIN ONCOL-CANC, V39, P215, DOI 10.1097/COC.0000000000000101; Liu XW, 2016, J CLIN ONCOL, V34, P794, DOI 10.1200/JCO.2015.62.0674; Lococo F, 2016, J THORAC ONCOL, V11, P1282, DOI 10.1016/j.jtho.2016.04.020; Manzotti G, 2019, CLIN CANCER RES, V25, P2348, DOI 10.1158/1078-0432.CCR-18-2364; Martin LW, 2007, ANN THORAC SURG, V84, P973, DOI 10.1016/j.athoracsur.2007.03.099; McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018; McGranahan N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1408; Mehrad M, 2018, HISTOPATHOLOGY, V73, P207, DOI 10.1111/his.13505; Nakagomi Takahiro, 2018, Oncotarget, V9, P10635, DOI 10.18632/oncotarget.24365; Nong JY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05327-w; Pelosi G, 2012, LUNG CANCER, V77, P507, DOI 10.1016/j.lungcan.2012.05.093; Pelosi G, 2010, INT J SURG PATHOL, V18, P103, DOI 10.1177/1066896908330049; Roth A, 2014, NAT METHODS, V11, P396, DOI [10.1038/NMETH.2883, 10.1038/nmeth.2883]; Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035; Schrock AB, 2017, J THORAC ONCOL, V12, P932, DOI 10.1016/j.jtho.2017.03.005; Sim JK, 2018, KOREAN J INTERN MED, V33, P737, DOI 10.3904/kjim.2017.245; Terra SBSP, 2016, MODERN PATHOL, V29, P824, DOI 10.1038/modpathol.2016.89; Tong JH, 2016, CLIN CANCER RES, V22, P3048, DOI 10.1158/1078-0432.CCR-15-2061; Travis WD, 2015, J THORAC ONCOL, V10, P1243, DOI 10.1097/JTO.0000000000000630; Vieira T, 2013, J THORAC ONCOL, V8, P1574, DOI 10.1097/01.JTO.0000437008.00554.90; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Weissferdt A, 2017, HUM PATHOL, V63, P14, DOI 10.1016/j.humpath.2016.12.010; Yendamuri S, 2012, SURGERY, V152, P397, DOI 10.1016/j.surg.2012.05.007; Yu YF, 2019, J CANCER RES THER, V15, P909, DOI 10.4103/jcrt.JCRT_591_18	47	10	10	2	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 28	2021	40	4					821	832		10.1038/s41388-020-01573-9	http://dx.doi.org/10.1038/s41388-020-01573-9		DEC 2020	12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	QA4GO	33273725				2022-12-17	WOS:000599064900001
J	Pham, TQ; Robinson, K; Xu, L; Pavlova, MN; Skapek, SX; Chen, EY				Pham, Thao Q.; Robinson, Kristin; Xu, Lin; Pavlova, Maria N.; Skapek, Stephen X.; Chen, Eleanor Y.			HDAC6 promotes growth, migration/invasion, and self-renewal of rhabdomyosarcoma	ONCOGENE			English	Article							CANCER STEM-CELLS; DIFFERENTIATION; DEACETYLATION; METASTASIS; DYNAMICS; REVEALS; PATHWAY; COMPLEX; STATE; RAC1	Rhabdomyosarcoma (RMS) is a devastating pediatric sarcoma. The survival outcomes remain poor for patients with relapsed or metastatic disease. Effective targeted therapy is lacking due to our limited knowledge of the underlying cellular and molecular mechanisms leading to disease progression. In this study, we used functional assays in vitro and in vivo (zebrafish and xenograft mouse models) to demonstrate the crucial role of HDAC6, a cytoplasmic histone deacetylase, in driving RMS tumor growth, self-renewal, and migration/invasion. Treatment with HDAC6-selective inhibitors recapitulates the HDAC6 loss-of-function phenotypes. HDAC6 regulates cytoskeletal dynamics to promote tumor cell migration and invasion. RAC1, a Rho family GTPase, is an essential mediator of HDAC6 function, and is necessary and sufficient for RMS cell migration and invasion. High expression of RAC1 correlates with poor clinical prognosis in RMS patients. Targeting the HDAC6-RAC1 axis represents a promising therapeutic option for improving survival outcomes of RMS patients.	[Pham, Thao Q.; Robinson, Kristin; Pavlova, Maria N.; Chen, Eleanor Y.] Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA; [Xu, Lin; Skapek, Stephen X.] Univ Texas Southwestern Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Xu, Lin] Univ Texas Southwestern Med Ctr Dallas, Quantitat Biomed Res Ctr, Dept Populat & Data Sci, Dallas, TX 75390 USA	University of Washington; University of Washington Seattle; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Chen, EY (corresponding author), Univ Washington, Dept Lab Med & Pathol, Seattle, WA 98195 USA.	eleanor2@uw.edu		Chen, Eleanor/0000-0003-4372-7560	NIH [R01 CA196882]; Children's Cancer Fund; Rally Foundation	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Children's Cancer Fund; Rally Foundation	The authors want to thank Terra Vleeshouwer-Neumann and Amy Chen for technical assistance with some experiments. EYC is supported by NIH R01 CA196882. Lin Xu is supported by Children's Cancer Fund and Rally Foundation.	BARR FG, 1993, NAT GENET, V3, P113, DOI 10.1038/ng0293-113; Chen DM, 2017, CELL STEM CELL, V20, P621, DOI 10.1016/j.stem.2017.02.003; Chen EY, 2014, P NATL ACAD SCI USA, V111, P5349, DOI 10.1073/pnas.1317731111; Chen EY, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003727; Dogterom M, 2019, NAT REV MOL CELL BIO, V20, P38, DOI 10.1038/s41580-018-0067-1; Du FY, 2019, WORLD J STEM CELLS, V11, P398, DOI 10.4252/wjsc.v11.i7.398; Gao YS, 2007, MOL CELL BIOL, V27, P8637, DOI 10.1128/MCB.00393-07; Goto N, 2019, P NATL ACAD SCI USA, V116, P12996, DOI 10.1073/pnas.1900251116; Guo FK, 2006, J BIOL CHEM, V281, P18652, DOI 10.1074/jbc.M603508200; Hayes MN, 2018, CELL STEM CELL, V22, P414, DOI 10.1016/j.stem.2018.02.002; Hosoyama T, 2011, CLIN CANCER RES, V17, P2757, DOI 10.1158/1078-0432.CCR-10-3445; Hu S, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aag0339; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Ignatius MS, 2018, ELIFE, V7, DOI 10.7554/eLife.37202; Ignatius MS, 2012, CANCER CELL, V21, P680, DOI 10.1016/j.ccr.2012.03.043; Jankowski K, 2003, CANCER RES, V63, P7926; Kamai T, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-164; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kozyreva VK, 2014, MOL CANCER RES, V12, P681, DOI 10.1158/1541-7786.MCR-13-0654; Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Lof-Ohlin ZM, 2017, NAT CELL BIOL, V19, P1313, DOI 10.1038/ncb3628; Marampon F, 2017, CANCER LETT, V397, P1, DOI 10.1016/j.canlet.2017.03.028; Miekus K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2012.199; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Phelps MP, 2016, P NATL ACAD SCI USA, V113, P15090, DOI 10.1073/pnas.1610270114; Saygin C, 2019, CELL STEM CELL, V24, P25, DOI 10.1016/j.stem.2018.11.017; Shern JF, 2014, CANCER DISCOV, V4, P216, DOI 10.1158/2159-8290.CD-13-0639; Tran ADA, 2007, J CELL SCI, V120, P1469, DOI 10.1242/jcs.03431; Vleeshouwer-Neumann T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144320; Walter D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019506; Wu JY, 2018, J BIOL CHEM, V293, P1976, DOI 10.1074/jbc.M117.795955; Wu LF, 2011, FEBS LETT, V585, P1322, DOI 10.1016/j.febslet.2011.03.067; Xu L, 2018, CELL REP, V24, P238, DOI 10.1016/j.celrep.2018.06.006; Yang MH, 2013, MOL CANCER RES, V11, P1072, DOI 10.1158/1541-7786.MCR-13-0040-T; Yang W, 2018, CANCER LETT, V415, P164, DOI 10.1016/j.canlet.2017.12.005; Yin ZS, 2018, ONCOL LETT, V16, P7082, DOI 10.3892/ol.2018.9504; Zhang XH, 2007, MOL CELL, V27, P197, DOI 10.1016/j.molcel.2007.05.033; Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613	40	10	10	0	3	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					578	591		10.1038/s41388-020-01550-2	http://dx.doi.org/10.1038/s41388-020-01550-2		NOV 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33199827	Green Accepted			2022-12-17	WOS:000590042900003
J	Yu, JQ; Wang, NZ; Gong, ZQ; Liu, LP; Yang, SL; Chen, GG; Lai, PBS				Yu, Jianqing; Wang, Nuozhou; Gong, Zhongqin; Liu, Liping; Yang, Shengli; Chen, George Gong; Lai, Paul Bo San			Cytochrome P450 1A2 overcomes nuclear factor kappa B-mediated sorafenib resistance in hepatocellular carcinoma	ONCOGENE			English	Article							PROTON PUMP INHIBITORS; TRANSCRIPTION; EXPRESSION; SURVIVAL; PROTEIN	Sorafenib resistance has become the main obstacle in the effective treatment of advanced hepatocellular carcinoma (HCC) patients. Activation of nuclear factor kappa B (NF-kappa B) is a newly identified mechanism that contributes to desensitized sorafenib. Cytochrome P450 1A2 (CYP1A2) functions as a tumor suppressor in HCC and its expression is negatively associated with NF-kappa B in the liver. This study aimed to study whether CYP1A2 could overcome sorafenib resistance. To investigate whether CYP1A2 and NF-kappa B p65 played roles in sorafenib desensitization, we established sorafenib-resistant (SR) HCC cells. SR cells decreased the expression of CYP1A2 along with the upregulation of NF-kappa B p65. CYP1A2 overexpression attenuated SR cell proliferation, increased sorafenib sensitivity, and inhibited the NF-kappa B pathway, whereas CYP1A2 silence showed opposite effects. Sorafenib, in combination with omeprazole, a CYP1A2 inducer, significantly hindered the growth and invasion of SR cells in vitro as well as decreased the tumor growth in vivo. The combination treatment markedly increased CYP1A2 expression and inhibited the sorafenib-induced NF-kappa B signaling. In addition, the overexpression of NF-kappa B p65 stimulated the SR cell growth and desensitized sorafenib in SR cells, where CYP1A2 overexpression reversed the phenomenon. Lastly, the majority of HCC tissue samples displayed decreased CYP1A2 but increased NF-kappa B p65 protein expression. Collectively, CYP1A2 can sensitize SR cells to sorafenib via inhibiting NF-kappa B p65 axis. Omeprazole in combination with sorafenib exerts a synergistic effect in alleviating acquired sorafenib resistance.	[Yu, Jianqing; Wang, Nuozhou; Gong, Zhongqin; Chen, George Gong; Lai, Paul Bo San] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Fac Med, Hong Kong, Peoples R China; [Liu, Liping] Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2, Dept Hepatobiliary & Pancreas Surg, Shenzhen 524000, Guangdong, Peoples R China; [Yang, Shengli] Huazhong Univ Sci & Technol, Tongji Med Coll, Union Hosp, Canc Ctr, Wuhan 430022, Peoples R China; [Chen, George Gong] Chinese Univ Hong Kong, Prince Walves Hosp, Fac Med, Dept Otorhinolaryngol Head & Neck Surg, Hong Kong, Peoples R China; [Chen, George Gong] Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Guangdong, Peoples R China	Chinese University of Hong Kong; Prince of Wales Hospital; Jinan University; Huazhong University of Science & Technology; Chinese University of Hong Kong; Chinese University of Hong Kong, Shenzhen	Chen, GG; Lai, PBS (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Surg, Fac Med, Hong Kong, Peoples R China.; Chen, GG (corresponding author), Chinese Univ Hong Kong, Prince Walves Hosp, Fac Med, Dept Otorhinolaryngol Head & Neck Surg, Hong Kong, Peoples R China.; Chen, GG (corresponding author), Chinese Univ Hong Kong, Shenzhen Res Inst, Shenzhen, Guangdong, Peoples R China.	gchen@cuhk.edu.hk; paullai@cuhk.edu.hk	Lai, Paul BS/K-8556-2015	Lai, Paul BS/0000-0002-9469-6728; Gong, Zhongqin/0000-0002-7030-0581; Chen, George/0000-0001-7276-3830	Research Grants Council of the Hong Kong SAR [CUHK14117015]	Research Grants Council of the Hong Kong SAR(Hong Kong Research Grants Council)	We thank technical supports from Dr. Jianwei Ren, Mr. Rocky Lok-kee Ho and Ms. Suk-ying Chun. This study was supported by a grant from the Research Grants Council of the Hong Kong SAR, CUHK14117015.	Abdel-Wahab AF, 2019, PHARMACOL RES, V150, DOI 10.1016/j.phrs.2019.104511; Blight KJ, 2002, J VIROL, V76, P13001, DOI 10.1128/JVI.76.24.13001-13014.2002; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chen CH, 2019, J CLIN PHARMACOL, V59, P350, DOI 10.1002/jcph.1329; Chen H, 2014, WORLD J GASTROENTERO, V20, P8681, DOI 10.3748/wjg.v20.i26.8681; Chen JCH, 2016, ONCOTARGET, V7, P85450, DOI 10.18632/oncotarget.13398; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Chirillo P, 1996, J VIROL, V70, P641, DOI 10.1128/JVI.70.1.641-646.1996; de Argila CM, 2005, DRUGS, V65, P97; Dudgeon C, 2012, ONCOGENE, V31, P4848, DOI 10.1038/onc.2011.644; FRUCHT H, 1991, DIGEST DIS SCI, V36, P394, DOI 10.1007/BF01298865; Galmiche A, 2014, CANCER LETT, V346, P159, DOI 10.1016/j.canlet.2013.12.028; Haibe-Kains B, 2013, NATURE, V504, P389, DOI 10.1038/nature12831; Hellum BH, 2007, BASIC CLIN PHARMACOL, V100, P23, DOI 10.1111/j.1742-7843.2007.00011.x; Jing HR, 2012, J SURG RES, V176, P63, DOI 10.1016/j.jss.2011.09.001; Kuo HP, 2013, CANCER CELL, V24, P423, DOI 10.1016/j.ccr.2013.08.019; Li F, 2010, BBA-REV CANCER, V1805, P167, DOI 10.1016/j.bbcan.2010.01.002; Li J, 2018, CANCER BIOL THER, V19, P1057, DOI 10.1080/15384047.2018.1480280; Liang L, 2020, ONCOL LETT, V19, P519, DOI 10.3892/ol.2019.11090; Lin WY, 2010, GASTROENTEROLOGY, V138, P2509, DOI 10.1053/j.gastro.2010.03.008; Liu ZZ, 2019, SAUDI J GASTROENTERO, V25, P167, DOI 10.4103/sjg.SJG_290_18; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Lo J, 2015, HEPATOLOGY, V62, P534, DOI 10.1002/hep.27859; Luciani F, 2004, JNCI-J NATL CANCER I, V96, P1702, DOI 10.1093/jnci/djh305; MACNAB GM, 1976, BRIT J CANCER, V34, P509, DOI 10.1038/bjc.1976.205; Neelgundmath M, 2015, BIOORG MED CHEM LETT, V25, P893, DOI 10.1016/j.bmcl.2014.12.065; Papagerakis S, 2014, CANCER PREV RES, V7, P1258, DOI 10.1158/1940-6207.CAPR-14-0002; Qiu YX, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-1005-y; Ray EM, 2017, J HEPATOCELL CARCINO, V4, P131, DOI 10.2147/JHC.S124366; REN JW, 2016, PLOS ONE, V11, DOI DOI 10.1371/JOURNAL.PONE.0153863; Sainz B, 2009, VIROL J, V6, DOI 10.1186/1743-422X-6-103; Shen ZT, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6312-y; Su F, 1996, J VIROL, V70, P4558, DOI 10.1128/JVI.70.7.4558-4566.1996; Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142; Tatebe S, 2015, CIRC J, V79, P1215, DOI 10.1253/circj.CJ-15-0367; Taylor S, 2015, DRUG RESIST UPDATE, V23, P69, DOI 10.1016/j.drup.2015.08.004; Wang NZ, 2020, CANCER LETT, V472, P70, DOI 10.1016/j.canlet.2019.12.026; Wang YT, 2020, EXP CELL RES, V386, DOI 10.1016/j.yexcr.2019.111739; Waris G, 2003, J BIOL CHEM, V278, P40778, DOI 10.1074/jbc.M303248200; Weil R, 1999, MOL CELL BIOL, V19, P6345; Wu JM, 2009, CANCER LETT, V278, P145, DOI 10.1016/j.canlet.2008.12.031; Xie C, 2020, HEPATOLOGY, V71, P1660, DOI 10.1002/hep.30931; Xu YM, 2016, CANCER LETT, V371, P171, DOI 10.1016/j.canlet.2015.11.034; Yamada T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1297-7; Zhang Q, 2017, CELL, V168, P37, DOI 10.1016/j.cell.2016.12.012; Zhu YJ, 2017, ACTA PHARMACOL SIN, V38, P614, DOI 10.1038/aps.2017.5	46	10	10	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 21	2021	40	3					492	507		10.1038/s41388-020-01545-z	http://dx.doi.org/10.1038/s41388-020-01545-z		NOV 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PU9SL	33184472				2022-12-17	WOS:000588868700001
J	Yan, YC; Huang, PB; Mao, K; He, CC; Xu, QD; Zhang, MY; Liu, HH; Zhou, ZY; Zhou, QM; Zhou, QL; Ou, B; Liu, QH; Lin, JH; Chen, RB; Wang, J; Zhang, JL; Xiao, ZY				Yan, Yongcong; Huang, Pinbo; Mao, Kai; He, Chuanchao; Xu, Qiaodong; Zhang, Mengyu; Liu, Haohan; Zhou, Zhenyu; Zhou, Qiming; Zhou, Qianlei; Ou, Bing; Liu, Qinghua; Lin, Jianhong; Chen, Ruibin; Wang, Jie; Zhang, Jianlong; Xiao, Zhiyu			Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENE; CANCER; EXPRESSION; GROWTH; ACTIVATION; RESISTANCE; DEGRADATION; SURVIVAL; PATHWAY; MYC	Hepatitis B x protein (HBx) affects cellular protein expression and participates in the tumorigenesis and progression of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Metabolic reprogramming contributed to the HCC development, but its role in HBV-related HCC remains largely unclear. Tyrosine-protein phosphatase nonreceptor type 13 (PTPN13) is a significant regulator in tumor development, however, its specific role in hepatocarcinogenesis remains to be explored. Here, we found that decreased PTPN13 expression was associated with HBV/HBx. Patients with low PTPN13 expression showed a poor prognosis. Functional assays revealed that PTPN13 inhibited proliferation and tumorigenesis in vitro and in vivo. Further mechanistic studies indicated that HBx inhibited PTPN13 expression by upregulating the expression of DNMT3A and interacting with DNMT3A. Furthermore, we found that DNMT3A bound to the PTPN13 promoter (-343 to -313 bp) in an epigenetically controlled manner associated with elevated DNA methylation and then inhibited PTPN13 transcription. In addition, we identified IGF2BP1 as a novel PTPN13-interacting gene and demonstrated that PTPN13 influences c-Myc expression by directly and competitively binding to IGF2BP1 to decrease the intracellular concentration of functional IGF2BP1. Overexpressing PTPN13 promoted c-Myc mRNA degradation independent of the protein tyrosine phosphatase (PTP) activity of PTPN13. Importantly, we discovered that the PTPN13-IGF2BP1-c-Myc axis was important for cancer cell growth through promoting metabolic reprogramming. We verified the significant negative correlations between PTPN13 expression and c-Myc, PSPH, and SLC7A1 expression in clinical HCC tissue samples. In summary, our findings demonstrate that PTPN13 is a novel regulator of HBV-related hepatocarcinogenesis and may play an important role in HCC. PTPN13 may serve as a prognostic marker and therapeutic target in HBV-related HCC patients.	[Yan, Yongcong; Huang, Pinbo; Mao, Kai; He, Chuanchao; Liu, Haohan; Zhou, Zhenyu; Zhou, Qiming; Zhou, Qianlei; Liu, Qinghua; Lin, Jianhong; Chen, Ruibin; Wang, Jie; Zhang, Jianlong; Xiao, Zhiyu] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou 510120, Peoples R China; [Yan, Yongcong; Liu, Haohan; Zhou, Qiming; Zhou, Qianlei; Liu, Qinghua; Lin, Jianhong; Chen, Ruibin] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangzhou 510120, Peoples R China; [Yan, Yongcong; Liu, Haohan; Zhou, Qiming; Zhou, Qianlei; Liu, Qinghua; Lin, Jianhong; Chen, Ruibin] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, RNA Biomed Inst, Guangzhou 510120, Peoples R China; [Xu, Qiaodong] Shantou Univ, Med Coll, Affiliated Hosp 1, Dept Biliary Pancreat Minimally Invas Surg, Shantou 515041, Peoples R China; [Zhang, Mengyu] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol & Hepatol, Guangzhou 510120, Peoples R China; [Ou, Bing] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Ultrasound, Guangzhou 510120, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; Shantou University; Sun Yat Sen University; Sun Yat Sen University	Huang, PB; Xiao, ZY (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou 510120, Peoples R China.	huangpb@mail2.sysu.edu.cn; xiaozhiy@mail.sysu.edu.cn		Yan, Yongcong/0000-0002-7269-764X	National Natural Science Foundation of China [81572407, 81602112, 81672405, 81702404]; Key project of Natural Science Foundation of Guangdong Province, China [2016A030311051]; Guangdong Basic and Applied Basic Research Foundation [2015A030313096, 2016A030313184, 2017A030313536, 2019A1515011418, 2019A1515011195]; Natural Science Foundation of Guangzhou, China [201607010225]; China Postdoctoral Science Foundation [2020TQ0384]; Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology [[2013]163]; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes [KLB09001]; Guangdong Science and Technology Department [2017B030314026]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key project of Natural Science Foundation of Guangdong Province, China; Guangdong Basic and Applied Basic Research Foundation; Natural Science Foundation of Guangzhou, China; China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology; Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes; Guangdong Science and Technology Department	This work was supported by the National Natural Science Foundation of China (Nos. 81572407, 81602112, 81672405, 81702404); Key project of Natural Science Foundation of Guangdong Province, China (No. 2016A030311051); Guangdong Basic and Applied Basic Research Foundation (Nos. 2015A030313096, 2016A030313184, 2017A030313536, 2019A1515011418, 2019A1515011195); Natural Science Foundation of Guangzhou, China (No. 201607010225); Project funded by China Postdoctoral Science Foundation (2020TQ0384); Grant [2013]163 from Key Laboratory of Malignant Tumor Molecular Mechanism and Translational Medicine of Guangzhou Bureau of Science and Information Technology; Grant KLB09001 from the Key Laboratory of Malignant Tumor Gene Regulation and Target Therapy of Guangdong Higher Education Institutes. Grant from Guangdong Science and Technology Department (2017B030314026).	Bamberg A, 2018, AM J RESP CRIT CARE, V198, P914, DOI 10.1164/rccm.201707-1497OC; Bell JL, 2013, CELL MOL LIFE SCI, V70, P2657, DOI 10.1007/s00018-012-1186-z; Bollu LR, 2017, CLIN CANCER RES, V23, P2136, DOI 10.1158/1078-0432.CCR-16-0934; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Bruix J, 2014, GUT, V63, P844, DOI 10.1136/gutjnl-2013-306627; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Cheng Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0747-z; Cilia E, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002794; Costantini JL, 2009, BLOOD, V114, P4703, DOI 10.1182/blood-2009-03-213058; Dang H, 2017, CANCER CELL, V32, P101, DOI 10.1016/j.ccell.2017.06.002; Dou CW, 2019, ONCOGENE, V38, P1239, DOI 10.1038/s41388-018-0505-8; Freiss G, 2011, ANTI-CANCER AGENT ME, V11, P78, DOI 10.2174/187152011794941262; Gao Y, 2017, HEPATOLOGY, V66, P1413, DOI 10.1002/hep.29316; Glondu-Lassis M, 2010, CANCER RES, V70, P5116, DOI 10.1158/0008-5472.CAN-09-4368; Gutschner T, 2014, HEPATOLOGY, V59, P1900, DOI 10.1002/hep.26997; Hagemann N, 2013, ONCOGENE, V32, P4602, DOI 10.1038/onc.2012.485; Hamyeh M, 2020, THERANOSTICS, V10, P1016, DOI 10.7150/thno.38537; Han XJ, 2013, EXP MOL PATHOL, V95, P270, DOI 10.1016/j.yexmp.2013.07.008; He J, 2019, CANCER LETT, V450, P98, DOI 10.1016/j.canlet.2019.02.033; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hosono Y, 2017, CELL, V171, P1559, DOI 10.1016/j.cell.2017.11.040; Huang PB, 2020, ONCOGENE, V39, P3774, DOI 10.1038/s41388-020-1254-z; Huang PB, 2015, CLIN CANCER RES, V21, P4420, DOI 10.1158/1078-0432.CCR-14-2067; Huang WY, 2015, NUCLEIC ACIDS RES, V43, pD856, DOI 10.1093/nar/gku1151; Huang XW, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0628-y; Huang YD, 2018, CANCERS, V10, DOI 10.3390/cancers10030082; Kassel O, 2004, GENE DEV, V18, P2518, DOI 10.1101/gad.322404; Kuchay S, 2013, NAT CELL BIOL, V15, P472, DOI 10.1038/ncb2731; Kulik L, 2019, GASTROENTEROLOGY, V156, P477, DOI 10.1053/j.gastro.2018.08.065; Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021; Li Z, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04006-0; Liao B, 2017, INT J ONCOL, V51, P1449, DOI 10.3892/ijo.2017.4126; Lu M, 2019, CELL METAB, V29, P886, DOI 10.1016/j.cmet.2018.12.019; Lucci MA, 2010, CELL ONCOL, V32, P361, DOI 10.3233/CLO-2010-0520; Post A, 2013, P NATL ACAD SCI USA, V110, P11427, DOI 10.1073/pnas.1306595110; Revillion F, 2009, INT J CANCER, V124, P638, DOI 10.1002/ijc.23989; Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507; Sun LC, 2015, CELL RES, V25, P429, DOI 10.1038/cr.2015.33; Sun W, 2018, HEPATOLOGY, V67, P2302, DOI 10.1002/hep.29750; Turner M, 2018, NAT IMMUNOL, V19, P120, DOI 10.1038/s41590-017-0028-4; Varum S, 2019, CELL STEM CELL, V24, P637, DOI 10.1016/j.stem.2019.03.011; Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263; Wang SH, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv190; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Wang ZC, 2015, HEPATOLOGY, V62, P1201, DOI 10.1002/hep.27911; Wieckowski E, 2007, J CELL BIOCHEM, V100, P16, DOI 10.1002/jcb.20922; Wolf E, 2015, TRENDS CELL BIOL, V25, P241, DOI 10.1016/j.tcb.2014.10.006; Yeh SH, 2006, CLIN CANCER RES, V12, P1097, DOI 10.1158/1078-0432.CCR-05-1383; Ying J, 2006, LEUKEMIA, V20, P1173, DOI 10.1038/sj.leu.2404193; Zhan H, 2016, TUMOR BIOL, V37, P9691, DOI 10.1007/s13277-016-4843-2; Zhuang L, 2017, J CELL MOL MED, V21, P2852, DOI 10.1111/jcmm.13198	51	10	10	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 7	2021	40	1					28	45		10.1038/s41388-020-01498-3	http://dx.doi.org/10.1038/s41388-020-01498-3		OCT 2020	18	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PR5VS	33051595	Green Published, hybrid			2022-12-17	WOS:000577556100001
J	Zhang, LL; Qin, YQ; Wu, G; Wang, JY; Cao, JW; Wang, YQ; Wu, D; Yang, KY; Zhao, ZG; He, LC; Lyu, JX; Li, HZ; Gu, HH				Zhang, Lingling; Qin, Yaqian; Wu, Guang; Wang, Jieyi; Cao, Jiawei; Wang, Yaqi; Wu, Du; Yang, Kaiyan; Zhao, Zhiguang; He, Licai; Lyu, Jianxin; Li, Hongzhi; Gu, Haihua			PRRG4 promotes breast cancer metastasis through the recruitment of NEDD4 and downregulation of Robo1	ONCOGENE			English	Article							FOCAL ADHESION KINASE; MESENCHYMAL TRANSITION; AXON GUIDANCE; WAGR SYNDROME; PROTEINS; ROUNDABOUT; MIGRATION; PATHWAY; BINDING; FAMILY	Metastasis is responsible for the death of most breast cancer patients. Robo1 has been implicated as a tumor suppressor for various cancers including breast cancer. However, it is not well understood how Robo1 expression is regulated during tumorigenesis. In this study, we uncovered that the transmembrane proline rich gamma-carboxyglutamic acid protein 4 (PRRG4) promotes breast cancer metastasis by downregulating Robo1. Analysis of mRNA expression data in The Cancer Genome Atlas and immunohistochemistry assay on breast tumor samples showed that PRRG4 expression was higher in breast tumors than in normal breast tissues. Experiments with PRRG4 knockdown and overexpression revealed that PRRG4 promoted migration and invasion of breast cancer cells, and enhanced metastasis in an experimental metastasis model. Mechanistically, we found that PRRG4 via its LPSY and PPPY motifs recruited the E3 ubiquitin ligase NEDD4, which induced ubiquitination and degradation of Robo1, thus contributing to migration and invasion of breast cancer cells. In addition, PRRG4 interacted with and enhanced protein tyrosine kinase Src and FAK activation. Overall, our data support a model that PRRG4 via NEDD4 downregulates the Robo1, resulting in the activation of Src and FAK and promoting breast cancer metastasis. PRRG4 may be a novel target for treating metastatic breast cancer.	[Zhang, Lingling; Qin, Yaqian; Wu, Guang; Wang, Jieyi; Cao, Jiawei; Wang, Yaqi; Wu, Du; He, Licai; Lyu, Jianxin; Li, Hongzhi; Gu, Haihua] Wenzhou Med Univ, Sch Lab Med & Life Sci, Key Lab Lab Med, Minist Educ, Wenzhou 325035, Peoples R China; [Yang, Kaiyan] Wenzhou Med Univ, Dept Pathol, Affiliated Hosp 1, Wenzhou 325035, Peoples R China; [Zhao, Zhiguang] Wenzhou Med Univ, Dept Pathol, Affiliated Hosp 2, Wenzhou 325000, Peoples R China	Wenzhou Medical University; Wenzhou Medical University; Wenzhou Medical University	Lyu, JX; Li, HZ; Gu, HH (corresponding author), Wenzhou Med Univ, Sch Lab Med & Life Sci, Key Lab Lab Med, Minist Educ, Wenzhou 325035, Peoples R China.	jxlu313@163.com; lhz@wmu.edu.cn; haihuagu@wmu.edu.cn	zhang, lingling/HDM-2189-2022	Wang, Jieyi/0000-0001-7444-0656; Cao, Jiawei/0000-0001-6268-5912	National Natural Science Foundation of China [81972463, 81772819]; Natural Science Foundation of Zhejiang Province, China [LY20C080001, LY18H080003]; Wenzhou Medical University Startup funds; Key Discipline of Zhejiang Province in Medical Technology (First Class, Category A)	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Zhejiang Province, China(Natural Science Foundation of Zhejiang Province); Wenzhou Medical University Startup funds; Key Discipline of Zhejiang Province in Medical Technology (First Class, Category A)	We thank Dr. Weibao Jiao (Kunming Institute of Zoology, Academia Sinica) for kindly providing us the MDA-MB-231-luciferase cells, and Helen Gu (Department of Economics, Massachusetts Institute of Technology) for proofreading the paper. This work was supported by grants (81972463 and 81772819) from the National Natural Science Foundation of China, and grants (LY20C080001 and LY18H080003) from Natural Science Foundation of Zhejiang Province, China, and was supported in part by Wenzhou Medical University Startup funds and the Key Discipline of Zhejiang Province in Medical Technology (First Class, Category A).	Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Ballard MS, 2012, ADV CANCER RES, V114, P187, DOI 10.1016/B978-0-12-386503-8.00005-3; Bhattacharya R, 2016, J GENET, V95, P551, DOI 10.1007/s12041-016-0678-2; Blockus H, 2016, DEVELOPMENT, V143, P3037, DOI 10.1242/dev.132829; Blockus H, 2014, CURR OPIN NEUROBIOL, V27, P82, DOI 10.1016/j.conb.2014.03.003; Boase NA, 2015, GENE, V557, P113, DOI 10.1016/j.gene.2014.12.020; CALALB MB, 1995, MOL CELL BIOL, V15, P954; Juarez-Cruz JC, 2019, ENDOCR CONNECT, V8, P1539, DOI 10.1530/EC-19-0442; Chang PH, 2012, CANCER RES, V72, P4652, DOI 10.1158/0008-5472.CAN-12-0877; Dallol A, 2002, ONCOGENE, V21, P3020, DOI 10.1038/sj.onc.1205421; Dickinson RE, 2010, REPRODUCTION, V139, P697, DOI 10.1530/REP-10-0017; Diepenbruck M, 2014, J CELL SCI, V127, P1523, DOI 10.1242/jcs.139865; Fang ZH, 2019, EXP CELL RES, V382, DOI 10.1016/j.yexcr.2019.06.007; Fitzmaurice C, 2021, JAMA ONCOL, DOI 10.1001/jamaoncol.2020.8307; Gara RK, 2015, DRUG DISCOV TODAY, V20, P156, DOI 10.1016/j.drudis.2014.09.008; Gilestro GF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003798; Gorla M, 2019, CELL REP, V26, P3298, DOI 10.1016/j.celrep.2019.02.080; HE L, 2017, SCI REP UK, V7; Justice ED, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006865; Kanelis V, 2006, STRUCTURE, V14, P543, DOI 10.1016/j.str.2005.11.018; Ke H, 2018, P NATL ACAD SCI USA, V115, pE3426, DOI 10.1073/pnas.1714573115; Keleman K, 2002, CELL, V110, P415, DOI 10.1016/S0092-8674(02)00901-7; Kong RR, 2015, J CLIN INVEST, V125, P4407, DOI 10.1172/JCI81673; Kulman JD, 1997, P NATL ACAD SCI USA, V94, P9058, DOI 10.1073/pnas.94.17.9058; Kulman JD, 2001, P NATL ACAD SCI USA, V98, P1370, DOI 10.1073/pnas.98.4.1370; Lu W, 2019, DEV CELL, V49, P361, DOI 10.1016/j.devcel.2019.04.010; Marlow R, 2008, CANCER RES, V68, P7819, DOI 10.1158/0008-5472.CAN-08-1357; Myat A, 2002, NEURON, V35, P447, DOI 10.1016/S0896-6273(02)00795-X; Nakatsukasa K, 2008, CELL, V132, P101, DOI 10.1016/j.cell.2007.11.023; Naser R, 2018, CANCERS, V10, DOI 10.3390/cancers10060196; Nayar U, 2019, NAT GENET, V51, P207, DOI 10.1038/s41588-018-0287-5; Ngan E, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15059; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; Patel A, 2016, LIFE SCI, V157, P52, DOI 10.1016/j.lfs.2016.05.036; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; Qin F, 2015, SCI REP-UK, V5, DOI 10.1038/srep09977; Schmid BC, 2007, BREAST CANCER RES TR, V106, P333, DOI 10.1007/s10549-007-9504-0; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Timms JF, 1998, MOL CELL BIOL, V18, P3838, DOI 10.1128/MCB.18.7.3838; Waks Adrienne G, 2019, JAMA, V321, P288, DOI 10.1001/jama.2018.19323; Wallace AG, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.168724; Wang Jing, 2011, Zhonghua Zhong Liu Za Zhi, V33, P447; Wang SZ, 2013, J NEUROSCI, V33, P12242, DOI 10.1523/JNEUROSCI.5736-12.2013; Whitford KL, 2002, NEURON, V33, P47, DOI 10.1016/S0896-6273(01)00566-9; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Xia YW, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12606; Xu S, 2008, CYTOGENET GENOME RES, V122, P181, DOI 10.1159/000172086; Yamamoto T, 2014, AM J MED GENET A, V164, P634, DOI 10.1002/ajmg.a.36325; Yang N, 2012, CELL CYCLE, V11, P2922, DOI 10.4161/cc.21386; Yazicioglu MN, 2013, J BIOL CHEM, V288, P25908, DOI 10.1074/jbc.M113.484683; Yip KT, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-128; Yuan TC, 2017, BIOCHEM BIOPH RES CO, V488, P439, DOI 10.1016/j.bbrc.2017.04.072; Yuasa-Kawada J, 2009, P NATL ACAD SCI USA, V106, P14530, DOI 10.1073/pnas.0801262106; Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001	54	10	10	1	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 3	2020	39	49					7196	7208		10.1038/s41388-020-01494-7	http://dx.doi.org/10.1038/s41388-020-01494-7		OCT 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	PB0GA	33037408				2022-12-17	WOS:000578440800002
J	Ruan, HL; Li, S; Bao, L; Zhang, XP				Ruan, Hailong; Li, Sen; Bao, Lin; Zhang, Xiaoping			Enhanced YB1/EphA2 axis signaling promotes acquired resistance to sunitinib and metastatic potential in renal cell carcinoma	ONCOGENE			English	Article							YB-1 PROMOTES; TRANSLATIONAL ACTIVATION; THERAPEUTIC TARGET; CANCER METASTASIS; INTERFERON-ALPHA; POOR-PROGNOSIS; EPHA2; EXPRESSION; OVEREXPRESSION; PROLIFERATION	VHL mutations are the most common tumorigenic lesions in clear cell renal cell carcinoma (ccRCC) and result in continued activation of the HIF/VEGF pathway and uncontrolled cancer progression. Receptor tyrosine kinase (RTK) inhibitors such as sunitinib have been demonstrated to target tumorigenic signaling pathways, delay tumor progression, and improve patient prognosis in metastatic renal cell carcinoma (mRCC). Although several mechanisms of sunitinib resistance have been reported, the solutions to overcome this resistance remain unclear. In our study, we found that increased expression of Y-box binding protein 1 (YB1, a multidrug resistance associated protein) and EphA2 (a member of the erythropoietin-producing hepatocellular (Eph) receptor family, belonging to the RTK family) mediated sunitinib resistance and mRCC exhibited a large phenotypic dependence on YB1 and EphA2. In addition, our findings confirm that YB1 promotes the invasion, metastasis and sunitinib resistance of ccRCC by regulating the EphA2 signaling pathway. Furthermore, pharmacological inhibition of EphA2 through the small molecule inhibitor ALW-II-41-27 reduced the proliferation of sunitinib-resistant tumor cells, suppressed tumor growth in vivo, and restored the sensitivity of sunitinib-resistant tumor cells to sunitinib in vitro and in vivo. Mechanistically, YB1 increases the protein levels of EphA2 by maintaining the protein stability of EphA2 through inhibition of the proteasomal degradation pathway. Collectively, our findings provide the theoretical rationale that ccRCC metastasis and RTK-directed therapeutic resistance could be prospectively and purposefully targeted.	[Ruan, Hailong; Li, Sen; Bao, Lin; Zhang, Xiaoping] Huazhong Univ Sci & Technol, Dept Urol, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China; [Ruan, Hailong; Li, Sen; Bao, Lin; Zhang, Xiaoping] Huazhong Univ Sci & Technol, Inst Urol, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology	Ruan, HL; Bao, L; Zhang, XP (corresponding author), Huazhong Univ Sci & Technol, Dept Urol, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China.; Ruan, HL; Bao, L; Zhang, XP (corresponding author), Huazhong Univ Sci & Technol, Inst Urol, Union Hosp, Tongji Med Coll, Wuhan 430022, Peoples R China.	hlruan2018@hust.edu.cn; 2417221775@qq.com; xzhang@hust.edu.cn			National Natural Science Foundation of China [81874090]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This study was supported by the National Natural Science Foundation of China (Grant No. 81874090). We thank the members of the Zhang Lab for helpful discussions and suggestions. We are grateful to Huazhong University of Science and Technology for providing a good experimental platform.	Amato KR, 2016, CANCER RES, V76, P305, DOI 10.1158/0008-5472.CAN-15-0717; Chen XY, 2014, CLIN CANCER RES, V20, P2617, DOI 10.1158/1078-0432.CCR-13-3224; Chu PC, 2018, ONCOGENE, V37, P3440, DOI 10.1038/s41388-018-0222-3; Cutz JC, 2006, CLIN CANCER RES, V12, P4043, DOI 10.1158/1078-0432.CCR-06-0252; D'Costa NM, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-1527-y; El-Naggar AM, 2015, CANCER CELL, V27, P682, DOI 10.1016/j.ccell.2015.04.003; Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Gotink KJ, 2011, CLIN CANCER RES, V17, P7337, DOI 10.1158/1078-0432.CCR-11-1667; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Herrem CJ, 2005, CLIN CANCER RES, V11, P226; Joosten SC, 2015, BBA-REV CANCER, V1855, P1, DOI 10.1016/j.bbcan.2014.11.002; Jurchott K, 2003, J BIOL CHEM, V278, P27988, DOI 10.1074/jbc.M212966200; Kosnopfel C, 2018, MOL CANCER RES, V16, P1149, DOI 10.1158/1541-7786.MCR-17-0528; Kuwano M, 2019, CANCER SCI, V110, P1536, DOI 10.1111/cas.14006; Lim JP, 2019, CANCER LETT, V452, P119, DOI 10.1016/j.canlet.2019.03.014; Liu FH, 2006, CANCER RES, V66, P10815, DOI 10.1158/0008-5472.CAN-06-1408; Miao BC, 2015, CANCER DISCOV, V5, P274, DOI 10.1158/2159-8290.CD-14-0295; Miao XB, 2016, EXP CELL RES, V346, P157, DOI 10.1016/j.yexcr.2016.07.003; Miyazaki T, 2003, INT J CANCER, V103, P657, DOI 10.1002/ijc.10860; Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044; Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293; Park K, 2012, MED ONCOL, V29, P3291, DOI 10.1007/s12032-012-0227-7; Ruan HL, 2020, MOL THER, V28, P1299, DOI 10.1016/j.ymthe.2020.03.001; Ruan HL, 2017, EXP CELL RES, V358, P269, DOI 10.1016/j.yexcr.2017.07.004; Ruan HL, 2017, INT J ONCOL, V51, P336, DOI 10.3892/ijo.2017.4010; Shi HC, 2020, ONCOGENE, V39, P530, DOI 10.1038/s41388-019-0962-8; Shibao K, 1999, INT J CANCER, V83, P732; Shiota M, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djw005; Tao Z, 2019, CANCER IMMUNOL RES, V7, P1135, DOI 10.1158/2326-6066.CIR-18-0648; Wang Y, 2015, TUMOR BIOL, V36, P7159, DOI 10.1007/s13277-015-3417-z; Yamashita T, 2017, INT J ONCOL, V51, P579, DOI 10.3892/ijo.2017.4031; Yang Y, 2019, ENDOCRINE, V65, P683, DOI 10.1007/s12020-019-02022-8	33	10	11	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 17	2020	39	38					6113	6128		10.1038/s41388-020-01409-6	http://dx.doi.org/10.1038/s41388-020-01409-6		AUG 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NQ9JF	32814829	Green Published, hybrid			2022-12-17	WOS:000561008600001
J	Esposito, M; Akman, HB; Giron, P; Ceregido, MA; Schepers, R; Paez, LRC; La Monaca, E; De Greve, J; Coux, O; De Trez, C; Lindon, C; Gutierrez, GJ				Esposito, Mara; Akman, H. Begum; Giron, Philippe; Ceregido, M. Angeles; Schepers, Rogier; Ramos Paez, Luis C.; La Monaca, Esther; De Greve, Jacques; Coux, Olivier; De Trez, Carl; Lindon, Catherine; Gutierrez, Gustavo J.			USP13 controls the stability of Aurora B impacting progression through the cell cycle	ONCOGENE			English	Article							TUMOR-SUPPRESSOR CYLD; MITOTIC KINASE; OVEREXPRESSION; ANEUPLOIDY; PHOSPHORYLATION; DEGRADATION; EXPRESSION; PREDICTION; REGULATOR; SEQUENCE	Aurora B kinase plays essential roles in mitosis. Its protein levels increase before the onset of mitosis and sharply decrease during mitosis exit. The latter decrease is due to a balance between the actions of the E3 ubiquitin ligase anaphase-promoting complex or cyclosome (activated by the Cdh1 adapter), and the deubiquitinating enzyme USP35. Aurora B also executes important functions in interphase. Abnormal modulation of Aurora B in interphase leads to cell cycle defects often linked to aberrant chromosomal condensation and segregation. Very little is however known about how Aurora B levels are regulated in interphase. Here we found that USP13-associates with and stabilizes Aurora B in cells, especially before their entry into mitosis. In order for USP13 to exert its stabilizing effect on Aurora B, their association is promoted by the Aurora B-mediated phosphorylation of USP13 at Serine 114. We also present evidence that USP13 instigates Aurora B deubiquitination and/or protect it from degradation in a non-catalytic manner. In addition, we report that genetic or chemical modulation of the cellular levels/activity of USP13 affects unperturbed cell-cycle progression. Overall our study unveils the molecular and cellular connections of the USP13-Aurora B axis, which potentially participates in the rewiring of the cell cycle happening in cancer cells.	[Esposito, Mara; Giron, Philippe; Ceregido, M. Angeles; Schepers, Rogier; Ramos Paez, Luis C.; La Monaca, Esther; Gutierrez, Gustavo J.] Vrije Univ Brussel, Fac Sci & Bioengn Sci, Dept Biol, Lab Pathophysiol Cell Signaling, Pl Laan 2, B-1050 Brussels, Belgium; [Akman, H. Begum; Lindon, Catherine] Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England; [Giron, Philippe; De Greve, Jacques] Vrije Univ Brussel, Fac Med & Pharm, Lab Mol & Med Oncol, Laarbeeklaan 103, B-1090 Brussels, Belgium; [Coux, Olivier] CNRS, CRBM, 1919 Route Mende, F-34293 Montpellier, France; [De Trez, Carl] Vrije Univ Brussel, Fac Sci & Bioengn Sci, Dept Bioengn, Lab Cellular & Mol Immunol, Pl Laan 2, B-1050 Brussels, Belgium; [Ceregido, M. Angeles] GlaxoSmithKline, Ave Pascal 2-4-6, B-1300 Wavre, Belgium; [Schepers, Rogier] VIB KU Leuven, Ctr Canc Biol, Campus Gasthuisberg,Herestr 49-B912, Leuven, Belgium; [Ramos Paez, Luis C.] Ablynx NV, Technol Pk 21, B-9052 Ghent, Belgium; [La Monaca, Esther] Janssen Pharmaceut NV, Turnhoutseweg 30, B-2340 Beerse, Belgium; [Gutierrez, Gustavo J.] Galapagos NV, Generaal Wittelaan L11 A3, B-2800 Mechelen, Belgium	Vrije Universiteit Brussel; University of Cambridge; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Vrije Universiteit Brussel; GlaxoSmithKline; Flanders Institute for Biotechnology (VIB); KU Leuven; Johnson & Johnson; Janssen Pharmaceuticals; Galapagos NV	Gutierrez, GJ (corresponding author), Vrije Univ Brussel, Fac Sci & Bioengn Sci, Dept Biol, Lab Pathophysiol Cell Signaling, Pl Laan 2, B-1050 Brussels, Belgium.; Gutierrez, GJ (corresponding author), Galapagos NV, Generaal Wittelaan L11 A3, B-2800 Mechelen, Belgium.	ggutierr@vub.be	Akman, H. Begum/F-8427-2012; Coux, Olivier/P-6847-2019; Gutierrez, Gustavo/AAO-9957-2021; De Greve, Jacques/J-4939-2012	Akman, H. Begum/0000-0003-4646-4225; Coux, Olivier/0000-0001-8455-3849; Gutierrez, Gustavo/0000-0001-8652-972X; De Trez, Carl/0000-0002-3899-1968; Giron, Philippe/0000-0002-1331-1890; De Greve, Jacques/0000-0002-2389-0742	FWO [G0C7514N]; BELSPO Interuniversity Attraction Poles [IAP-P7 - 07]; VUB (starting ZAP credit & Interdisciplinary Research Program for Excellence on Cancer Research); Innoviris (BB2B program); COST-EU program (Proteostasis); BBSRC [BB/R004137/1] Funding Source: UKRI; MRC [MR/M01102X/1] Funding Source: UKRI	FWO(FWO); BELSPO Interuniversity Attraction Poles; VUB (starting ZAP credit & Interdisciplinary Research Program for Excellence on Cancer Research); Innoviris (BB2B program); COST-EU program (Proteostasis); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Research in GJG's laboratory was funded by grants from FWO (G0C7514N), BELSPO Interuniversity Attraction Poles (IAP-P7 - 07), VUB (starting ZAP credit & Interdisciplinary Research Program for Excellence on Cancer Research), and Innoviris (BB2B program). The collaboration between the laboratories of GJG and CL included a short-term scientific mission (ME) supported by the COST-EU program (Proteostasis). We are indebted to Yvon Elkrim for technical assistance with the flow cytometry analyses, and to Professors Luc Leyns and Peter Tompa (VUB- and VIB- Brussels, Belgium, respectively) for allowing access to some of their laboratories' equipment.	Bassermann F, 2014, BBA-MOL CELL RES, V1843, P150, DOI 10.1016/j.bbamcr.2013.02.028; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Bonet C, 2012, J BIOL CHEM, V287, P29887, DOI 10.1074/jbc.M112.371682; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Carmena M, 2012, NAT REV MOL CELL BIO, V13, P789, DOI 10.1038/nrm3474; Chen BB, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.271; Chen MF, 2011, P NATL ACAD SCI USA, V108, P9119, DOI 10.1073/pnas.1100028108; Chen YJ, 2009, VIRCHOWS ARCH, V455, P431, DOI 10.1007/s00428-009-0838-3; Darling S, 2017, BIOCHEM SOC T, V45, P1125, DOI 10.1042/BST20170087; Fang XG, 2017, J EXP MED, V214, P245, DOI 10.1084/jem.20151673; Floyd S, 2013, J CELL SCI, V126, P2845, DOI 10.1242/jcs.123232; Fournane Sadek, 2012, Genes Cancer, V3, P697, DOI 10.1177/1947601912473477; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Gilberto S, 2017, J CELL BIOL, V216, P2259, DOI 10.1083/jcb.201703170; Gonzalez-Loyola A, 2015, MOL CELL BIOL, V35, P3566, DOI 10.1128/MCB.01286-14; Gully CP, 2012, P NATL ACAD SCI USA, V109, pE1513, DOI 10.1073/pnas.1110287109; Han C, 2016, NAT COMMUN, V7; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Hayashi-Takanaka Y, 2009, J CELL BIOL, V187, P781, DOI 10.1083/jcb.200904137; Jiao QJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027646; Komander D, 2012, ANNU REV BIOCHEM, V81, P203, DOI 10.1146/annurev-biochem-060310-170328; Krenn V, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00225; Li L, 2019, EBIOMEDICINE, V45, P553, DOI 10.1016/j.ebiom.2019.06.011; Li Y, 2017, NAT COMMUN, V8; Lindon C, 2016, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00307; Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037; Liu Y, 2014, ELIFE, V3; Maerki S, 2009, J CELL BIOL, V187, P791, DOI 10.1083/jcb.200906117; Man XJ, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1262-4; Mayya V, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000007; McCloy RA, 2014, CELL CYCLE, V13, P1400, DOI 10.4161/cc.28401; Morgan D. O., 2006, CELL CYCLE PRINCIPLE; Munoz-Barrera M, 2014, P NATL ACAD SCI USA, V111, pE3996, DOI 10.1073/pnas.1408017111; Nguyen HG, 2005, MOL CELL BIOL, V25, P4977, DOI 10.1128/MCB.25.12.4977-4992.2005; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Ota T, 2002, CANCER RES, V62, P5168; Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138; Park J, 2018, BMB REP, V51, P261, DOI 10.5483/BMBRep.2018.51.6.110; Pinto-Fernandez A, 2019, FRONT CHEM, V7, DOI 10.3389/fchem.2019.00592; Ruchaud S, 2007, NAT REV MOL CELL BIO, V8, P798, DOI 10.1038/nrm2257; Sahtoe DD, 2015, TRENDS BIOCHEM SCI, V40, P456, DOI 10.1016/j.tibs.2015.05.002; Scortegagna M, 2011, J BIOL CHEM, V286, P27333, DOI 10.1074/jbc.M111.218214; Song CG, 2017, CELL PHYSIOL BIOCHEM, V42, P965, DOI 10.1159/000478679; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Staibano S, 2003, HISTOPATHOLOGY, V43, P254, DOI 10.1046/j.1365-2559.2003.01706.x; Stegmeier F, 2007, P NATL ACAD SCI USA, V104, P8869, DOI 10.1073/pnas.0703268104; Sumara I, 2007, DEV CELL, V12, P887, DOI 10.1016/j.devcel.2007.03.019; Sun H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15534; Sun L, 2010, J PATHOL, V221, P425, DOI 10.1002/path.2723; Tatsuka M, 1998, CANCER RES, V58, P4811; Teng CL, 2012, CELL CYCLE, V11, P4059, DOI 10.4161/cc.22381; van der Waal MS, 2012, EXP CELL RES, V318, P1407, DOI 10.1016/j.yexcr.2012.03.015; van Leuken RJ, 2008, CELL CYCLE, V7, P2710, DOI 10.4161/cc.7.17.6553; Vischioni B, 2006, MOL CANCER THER, V5, P2905, DOI 10.1158/1535-7163.MCT-06-0301; Wu Y, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108831; Xie X, 2018, J CELL SCI, V131, DOI 10.1242/jcs.210856; Yeh HM, 2013, J IMMUNOL, V191, P3328, DOI 10.4049/jimmunol.1300225; Zeng WFF, 2007, J CLIN PATHOL, V60, P218, DOI 10.1136/jcp.2006.036806; Zhang JS, 2013, NAT CELL BIOL, V15, P1486, DOI 10.1038/ncb2874; Zhang SY, 2018, INT CONF BIG DATA, P1, DOI 10.1109/BigComp.2018.00010; Zhao XS, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1421; Zhou QX, 2020, J EXP MED, V217, DOI 10.1084/jem.20191779	62	10	10	1	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 10	2020	39	37					6009	6023		10.1038/s41388-020-01396-8	http://dx.doi.org/10.1038/s41388-020-01396-8		AUG 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NM2OY	32772043				2022-12-17	WOS:000557315300001
J	Martin-Padron, J; Boyero, L; Rodriguez, MI; Andrades, A; Diaz-Cano, I; Peinado, P; Balinas-Gavira, C; Alvarez-Perez, JC; Coira, IF; Farez-Vidal, ME; Medina, PP				Martin-Padron, Joel; Boyero, Laura; Isabel Rodriguez, Maria; Andrades, Alvaro; Diaz-Cano, Ines; Peinado, Paola; Balinas-Gavira, Carlos; Carlos Alvarez-Perez, Juan; Coira, Isabel F.; Esther Farez-Vidal, Maria; Medina, Pedro P.			Plakophilin 1 enhances MYC translation, promoting squamous cell lung cancer	ONCOGENE			English	Article							PROTEINS; CARCINOMA; MUTATIONS; IDENTIFY; ADHESION; EGFR	Plakophilin 1 (PKP1) is a member of the arm-repeat (armadillo) and plakophilin gene families and it is an essential component of the desmosomes. Although desmosomes have generally been associated with tumor suppressor functions, we have consistently observed that PKP1 is among the top overexpressed proteins in squamous cell lung cancer. To explore this paradox, we developed in vivo and in vitro functional models of PKP1 gain/loss in squamous cell lung cancer. CRISPR-Cas9 PKP1 knockout severely impaired cell proliferation, but it increased cell dissemination. In addition, PKP1 overexpression increased cell proliferation, cell survival, and in vivo xenograft engraftment. We further investigated the molecular mechanism of the mainly oncogenic function of PKP1 by combining transcriptomics, proteomics, and protein-nucleic acid interaction assays. Interestingly, we found that PKP1 enhancesMYCtranslation in collaboration with the translation initiation complex by binding to the 5 '-UTR ofMYCmRNA. We propose PKP1 as an oncogene in SqCLC and a novel posttranscriptional regulator of MYC. PKP1 may be a valuable diagnostic biomarker and potential therapeutic target for SqCLC. Importantly, PKP1 inhibition may indirectly target MYC, a primary anticancer target.	[Martin-Padron, Joel; Boyero, Laura; Isabel Rodriguez, Maria; Andrades, Alvaro; Diaz-Cano, Ines; Peinado, Paola; Balinas-Gavira, Carlos; Carlos Alvarez-Perez, Juan; Coira, Isabel F.; Medina, Pedro P.] Ctr Genom & Oncol Res GENYO, Granada, Spain; [Martin-Padron, Joel; Boyero, Laura; Diaz-Cano, Ines; Esther Farez-Vidal, Maria] Univ Granada, Dept Biochem & Mol Biol 3, Granada, Spain; [Martin-Padron, Joel; Diaz-Cano, Ines; Esther Farez-Vidal, Maria; Medina, Pedro P.] Univ Granada, Inst Biomed Res Ibs Granada, Univ Hosp Complex Granada, Granada, Spain; [Isabel Rodriguez, Maria; Andrades, Alvaro; Peinado, Paola; Balinas-Gavira, Carlos; Carlos Alvarez-Perez, Juan; Coira, Isabel F.; Medina, Pedro P.] Univ Granada, Dept Biochem & Mol Biol 1, Granada, Spain	University of Granada; Instituto de Investigacion Biosanitaria IBS Granada; University of Granada; University of Granada	Medina, PP (corresponding author), Ctr Genom & Oncol Res GENYO, Granada, Spain.; Farez-Vidal, ME (corresponding author), Univ Granada, Dept Biochem & Mol Biol 3, Granada, Spain.; Farez-Vidal, ME; Medina, PP (corresponding author), Univ Granada, Inst Biomed Res Ibs Granada, Univ Hosp Complex Granada, Granada, Spain.; Medina, PP (corresponding author), Univ Granada, Dept Biochem & Mol Biol 1, Granada, Spain.	efarez@ugr.es; pedromedina@ugr.es	Perez, Juan Carlos Alvarez/AAE-4518-2021; Coira, Isabel F./N-4002-2014; Perez, Juan c Alvarez/J-8294-2016; Boyero Corral, Laura/AAA-5316-2020; Baliñas Gavira, Carlos/AAQ-2507-2021; Vico, Pedro Pablo Medina/D-1688-2013; Lara, María Isabel Rodríguez/A-1961-2017; Andrades, Álvaro/A-6890-2017	Perez, Juan Carlos Alvarez/0000-0001-6396-311X; Coira, Isabel F./0000-0003-3368-4691; Perez, Juan c Alvarez/0000-0001-6396-311X; Boyero Corral, Laura/0000-0002-2603-399X; Baliñas Gavira, Carlos/0000-0002-7535-5426; Vico, Pedro Pablo Medina/0000-0002-7834-7093; Lara, María Isabel Rodríguez/0000-0002-2270-0070; Andrades, Álvaro/0000-0001-9042-8964; Peinado Fernandez, Paola/0000-0003-2484-928X				Alatas ET, 2017, INDIAN J DERMATOL VE, V83, P476, DOI 10.4103/ijdvl.IJDVL_411_16; Angulo B, 2008, J PATHOL, V214, P347, DOI 10.1002/path.2267; Bender E, 2014, NATURE, V513, pS2, DOI 10.1038/513S2a; Bhattacharjee A, 2001, P NATL ACAD SCI USA, V98, P13790, DOI 10.1073/pnas.191502998; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Budczies J, 2015, ONCOTARGET, V6, P570, DOI 10.18632/oncotarget.2677; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385; Dusek RL, 2011, NAT REV CANCER, V11, P317, DOI 10.1038/nrc3051; Furukawa C, 2005, CANCER RES, V65, P7102, DOI 10.1158/0008-5472.CAN-04-1877; Gomez-Morales M, 2013, HISTOPATHOLOGY, V63, P103, DOI 10.1111/his.12126; Hatzfeld M, 2000, J CELL BIOL, V149, P209, DOI 10.1083/jcb.149.1.209; Hatzfeld M, 2007, BBA-MOL CELL RES, V1773, P69, DOI 10.1016/j.bbamcr.2006.04.009; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Kim HR, 2012, CANCER-AM CANCER SOC, V118, P729, DOI 10.1002/cncr.26311; Krunic AL, 1998, BRIT J CANCER, V77, P1275, DOI 10.1038/bjc.1998.213; Kundu ST, 2008, INT J CANCER, V123, P2303, DOI 10.1002/ijc.23797; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lonsdale J, 2013, NAT GENET, V45, P580, DOI 10.1038/ng.2653; McGrath JA, 1997, NAT GENET, V17, P240, DOI 10.1038/ng1097-240; Molina JR, 2008, MAYO CLIN PROC, V83, P584, DOI 10.4065/83.5.584; Munoz WA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086784; Perez-Moreno P, 2012, CLIN CANCER RES, V18, P2443, DOI 10.1158/1078-0432.CCR-11-2370; Pirity M, 2006, CURR TOP MICROBIOL, V302, P205; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; RICHARDSON GE, 1993, SEMIN ONCOL, V20, P105; Rietscher K, 2016, J INVEST DERMATOL, V136, P1471, DOI 10.1016/j.jid.2016.03.021; Sanchez-Palencia A, 2011, INT J CANCER, V129, P355, DOI 10.1002/ijc.25704; Schmidt A, 1997, CELL TISSUE RES, V290, P481, DOI 10.1007/s004410050956; Whitfield JR, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00010	30	10	10	4	10	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 6	2020	39	32					5479	5493		10.1038/s41388-019-1129-3	http://dx.doi.org/10.1038/s41388-019-1129-3			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MW4DS	31822797				2022-12-17	WOS:000556990300006
J	Shu, Z; Li, Z; Huang, HH; Chen, Y; Fan, J; Yu, L; Wu, ZH; Tian, L; Qi, Q; Peng, S; Wei, CY; Xie, ZQ; Li, XB; Feng, Q; Sheng, H; Li, GQ; Wei, DP; Shan, CL; Chen, G				Shu, Zhen; Li, Zhen; Huang, Huanhuan; Chen, Yan; Fan, Jun; Yu, Li; Wu, Zhihui; Tian, Ling; Qi, Qi; Peng, Shuang; Wei, Changyong; Xie, Zhongqiu; Li, Xiaobo; Feng, Qi; Sheng, Hao; Li, Guangqiang; Wei, Dongping; Shan, Changliang; Chen, Guo			Cell-cycle-dependent phosphorylation of RRM1 ensures efficient DNA replication and regulates cancer vulnerability to ATR inhibition	ONCOGENE			English	Article							RIBONUCLEOTIDE REDUCTASE; GENOME INTEGRITY; SUBUNIT P53R2; S-PHASE; KINASE; ACTIVATION; STRESS; PROTEIN; SAMHD1; REPAIR	Ribonucleotide reductase (RNR) catalyzes the rate-limiting step of de novo synthesis of deoxyribonucleotide triphosphates (dNTPs) building blocks for DNA synthesis, and is a well-recognized target for cancer therapy. RNR is a heterotetramer consisting of two large RRM1 subunits and two small RRM2 subunits. RNR activity is greatly stimulated by transcriptional activation of RRM2 during S/G2 phase to ensure adequate dNTP supply for DNA replication. However, little is known about the cell-cycle-dependent regulation of RNR activity through RRM1. Here, we report that RRM1 is phosphorylated at Ser 559 by CDK2/cyclin A during S/G2 phase. And this S559 phosphorylation of RRM1enhances RNR enzymatic activity and is required for maintaining sufficient dNTPs during normal DNA replication. Defective RRM1 S559 phosphorylation causes DNA replication stress, double-strand break, and genomic instability. Moreover, combined targeting of RRM1 S559 phosphorylation and ATR triggers lethal replication stress and profound antitumor effects. Thus, this posttranslational phosphorylation of RRM1 provides an alternative mechanism to finely regulating RNR and therapeutic opportunities for cancer treatment.	[Shu, Zhen; Li, Zhen; Chen, Yan; Fan, Jun; Yu, Li; Wu, Zhihui; Tian, Ling; Chen, Guo] Jinan Univ, Sch Med, Dept Med Biochem & Mol Biol, Guangzhou 510632, Peoples R China; [Shu, Zhen; Wei, Changyong; Xie, Zhongqiu] Emory Univ, Dept Radiat Oncol, Sch Med, Atlanta, GA 30322 USA; [Li, Zhen; Feng, Qi; Sheng, Hao; Li, Guangqiang; Shan, Changliang] Jinan Univ, Biomed Translat Res Inst, Guangzhou 510632, Peoples R China; [Huang, Huanhuan; Wei, Dongping] Nanjing Med Univ, Nanjing Hosp 1, Dept Oncol, Nanjing 210006, Peoples R China; [Qi, Qi; Peng, Shuang] Jinan Univ, Sch Med, Dept Pathophysiol & Pharmacol, Guangzhou 510632, Peoples R China; [Li, Xiaobo] Tianjin Med Univ, Minist Educ, Key Lab Immune Microenvironm & Dis, Tianjin 300070, Peoples R China; [Shan, Changliang] Nankai Univ, Coll Pharm, State Key Lab Med Chem Biol, Tianjin 300350, Peoples R China; [Shan, Changliang] Nankai Univ, Tianjin Key Lab Mol Drug Res, Tianjin 300350, Peoples R China	Jinan University; Emory University; Jinan University; Nanjing Medical University; Jinan University; Tianjin Medical University; Nankai University; Nankai University	Chen, G (corresponding author), Jinan Univ, Sch Med, Dept Med Biochem & Mol Biol, Guangzhou 510632, Peoples R China.	gchen84@jnu.edu.cn	Peng, shuang/GPX-0999-2022; Chen, Guo/HGE-9902-2022; Xie, Zhongqiu/AAZ-9680-2020; Qi, Qi/J-3508-2013	Chen, Guo/0000-0001-8886-1873; Xie, Zhongqiu/0000-0002-2869-7669; Li, Guangqiang/0000-0003-2447-1803; Qi, Qi/0000-0003-4460-0713; Peng, Shuang/0000-0002-0163-9047	Natural Science Foundation of Guangdong Province of China [2019A1515011247]; Guangzhou Municipal Science and Technology Program of China [202002030451]; Fundamental Research Funds for the Central Universities [21620421]; National Natural Science Foundation of China [81472793, 81672895]	Natural Science Foundation of Guangdong Province of China(National Natural Science Foundation of Guangdong Province); Guangzhou Municipal Science and Technology Program of China; Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by Natural Science Foundation of Guangdong Province of China (2019A1515011247 to GC), Guangzhou Municipal Science and Technology Program of China (202002030451 to GC), Fundamental Research Funds for the Central Universities (21620421 to GC) and National Natural Science Foundation of China (81472793 and 81672895 to DW).	Arnaoutov A, 2014, SCIENCE, V345, P1512, DOI 10.1126/science.1251550; Aye Y, 2015, ONCOGENE, V34, P2011, DOI 10.1038/onc.2014.155; Buckland RJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004846; Buisson R, 2015, MOL CELL, V59, P1011, DOI 10.1016/j.molcel.2015.07.029; Chabes A, 1999, J BIOL CHEM, V274, P36679, DOI 10.1074/jbc.274.51.36679; Chang LF, 2008, P NATL ACAD SCI USA, V105, P18519, DOI 10.1073/pnas.0803313105; Chen G, 2018, BIO-PROTOCOL, V8, DOI 10.21769/BioProtoc.2994; Chen Z, 2007, SCIENCE, V316, P1916, DOI 10.1126/science.1140958; Chung G, 2015, GENE DEV, V29, P1969, DOI 10.1101/gad.266056.115; Cribier A, 2013, CELL REP, V3, P1036, DOI 10.1016/j.celrep.2013.03.017; D'Angiolella V, 2012, CELL, V149, P1023, DOI 10.1016/j.cell.2012.03.043; De Bont R, 2004, MUTAGENESIS, V19, P169, DOI 10.1093/mutage/geh025; Flynn RL, 2011, TRENDS BIOCHEM SCI, V36, P133, DOI 10.1016/j.tibs.2010.09.005; Grinberg IR, 2018, J BIOL CHEM, V293, P15889, DOI 10.1074/jbc.RA118.004991; Grinberg IR, 2018, ELIFE, V7, DOI 10.7554/eLife.31529; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; Jackson DA, 1998, J CELL BIOL, V140, P1285, DOI 10.1083/jcb.140.6.1285; Le TM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00221-3; Lin YF, 2018, NUCLEIC ACIDS RES, V46, P59; Liu PD, 2014, NATURE, V508, P541, DOI 10.1038/nature13079; Logan DT, 2011, NAT STRUCT MOL BIOL, V18, P251, DOI 10.1038/nsmb0311-251; Ma K, 2012, INT J MOL SCI, V13, P11974, DOI 10.3390/ijms130911974; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; Maya-Mendoza A, 2018, NATURE, V559, P279, DOI 10.1038/s41586-018-0261-5; Minocherhomji S, 2015, NATURE, V528, P286, DOI 10.1038/nature16139; Pontarin G, 2012, P NATL ACAD SCI USA, V109, P13302, DOI 10.1073/pnas.1211289109; Puigvert JC, 2016, FEBS J, V283, P232, DOI 10.1111/febs.13574; Rajeshkumar NV, 2011, CLIN CANCER RES, V17, P2799, DOI 10.1158/1078-0432.CCR-10-2580; Schmidt TT, 2019, NUCLEIC ACIDS RES, V47, P237, DOI 10.1093/nar/gky1154; Schwab RA, 2010, EMBO J, V29, P806, DOI 10.1038/emboj.2009.385; Schwab RAV, 2011, JOVE-J VIS EXP, DOI 10.3791/3255; Sopko R, 2014, DEV CELL, V31, P114, DOI 10.1016/j.devcel.2014.07.027; Sorensen CS, 2012, NUCLEIC ACIDS RES, V40, P477, DOI 10.1093/nar/gkr697; Tanaka S, 2007, NATURE, V445, P328, DOI 10.1038/nature05465; Tang CX, 2015, J BIOL CHEM, V290, P26352, DOI 10.1074/jbc.M115.677435; Tuli R, 2019, EBIOMEDICINE, V40, P375, DOI 10.1016/j.ebiom.2018.12.060; Vassin VM, 2009, J CELL SCI, V122, P4070, DOI 10.1242/jcs.053702; von der Maase H, 2005, J CLIN ONCOL, V23, P4602, DOI 10.1200/JCO.2005.07.757; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Xie MH, 2014, CANCER RES, V74, P212, DOI 10.1158/0008-5472.CAN-13-1536-T; Yan JP, 2015, J BIOL CHEM, V290, P13279, DOI 10.1074/jbc.M115.646588; Zhang JF, 2018, NATURE, V553, P91, DOI 10.1038/nature25015; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zhao XL, 2002, P NATL ACAD SCI USA, V99, P3746, DOI 10.1073/pnas.062502299; Zhou BS, 2013, CANCER RES, V73, P6484, DOI 10.1158/0008-5472.CAN-13-1094; Zhu YH, 2004, MOL CELL BIOL, V24, P6268, DOI 10.1128/MCB.24.14.6268-6277.2004; Zimanyi CM, 2016, ELIFE, V5, DOI 10.7554/eLife.07141	47	10	11	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5721	5733		10.1038/s41388-020-01403-y	http://dx.doi.org/10.1038/s41388-020-01403-y		JUL 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32712628				2022-12-17	WOS:000552667700001
J	Yan, PP; Liu, J; Zhou, R; Lin, C; Wu, KH; Yang, SB; Yang, S; Zhou, JY; Xu, LJ; Wang, H; Zhao, L				Yan, Pingping; Liu, Jian; Zhou, Rui; Lin, Chuang; Wu, Kunhe; Yang, Shibin; Yang, Shuai; Zhou, Jueyu; Xu, Lijun; Wang, Hui; Zhao, Liang			LASP1 interacts with N-WASP to activate the Arp2/3 complex and facilitate colorectal cancer metastasis by increasing tumour budding and worsening the pattern of invasion	ONCOGENE			English	Article							LIM; PROTEINS; PROLIFERATION; MIGRATION; CELLS	LIM and SH3 protein 1 (LASP1) is a metastasis-related protein reported to enhance tumour progression in colorectal cancer (CRC). However, the underlying mechanism is still elusive. As the major biological and pathological functions of LASP1 are accomplished by its LIM and SH3 domains via protein-protein interactions, a yeast two-hybrid system was employed to screen novel LASP1-interacting proteins. N-WASP, a member of the Wiskott-Aldrich syndrome protein (WASP) family, was screened and identified as a LASP1-interacting protein overexpressed in CRC tissues. N-WASP could stimulate the migration and invasion of CRC cells in vitro and increase the formation of subcutaneous tumours, mesenteric implanted tumours and hepatic metastatic tumours. N-WASP could interact with and activate the Arp2/3 complex to stimulate actin polymerization, thus changing the migratory and invasive capabilities of CRC cells. The interaction of LASP1 with N-WASP did not influence the expression of N-WASP but recovered the reduced actin polymerization induced by N-WASP silencing. High N-WASP expression was detected in most clinical colorectal samples, and it was positively correlated with the expression of LASP1 and ARP3, as well as the tumour budding and pattern of invasion, but negatively correlated with host lymphocytic response. Our study suggests a new mechanism for LASP1-mediated CRC metastasis determined by exploring LASP1-interacting proteins and identifies N-WASP as a potential therapeutic target for CRC.	[Yan, Pingping; Liu, Jian; Zhou, Rui; Lin, Chuang; Xu, Lijun; Zhao, Liang] Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China; [Yan, Pingping; Liu, Jian; Zhou, Rui; Xu, Lijun; Zhao, Liang] Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China; [Yan, Pingping; Liu, Jian; Zhou, Rui; Xu, Lijun; Zhao, Liang] Southern Med Univ, Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou, Peoples R China; [Wu, Kunhe] Guangdong Women & Children Hosp, Dept Pathol, Guangzhou 511442, Guangdong, Peoples R China; [Yang, Shibin] Sun Yat Sen Univ, Gastrointestinal Surg Ctr, Affiliated Hosp 1, Guangzhou 510080, Peoples R China; [Yang, Shuai] Sun Yat Sen Univ, Dept Neurosurg, Affiliated Hosp 1, Guangzhou 510080, Peoples R China; [Zhou, Jueyu] Southern Med Univ, Sch Basic Med Sci, Dept Biochem & Mol Biol, Guangzhou 510515, Peoples R China; [Wang, Hui] Guangzhou Med Univ, Dept Med Oncol, Affiliated Tumor Hosp, Guangzhou, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China; Sun Yat Sen University; Sun Yat Sen University; Southern Medical University - China; Guangzhou Medical University	Zhao, L (corresponding author), Southern Med Univ, Nanfang Hosp, Dept Pathol, Guangzhou, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Sch Basic Med Sci, Dept Pathol, Guangzhou, Peoples R China.; Zhao, L (corresponding author), Southern Med Univ, Guangdong Prov Key Lab Mol Tumor Pathol, Guangzhou, Peoples R China.	liangsmu@foxmail.com	xu, li/GNH-3667-2022		National Natural Science Foundation of China [81773082, 81702903, 81872423, 81972813]; Guangdong Natural Science Foundation [2018B030311036, 2019A1515010974]; Fork Ying Tung Education Foundation [161035]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Guangdong Natural Science Foundation(National Natural Science Foundation of Guangdong Province); Fork Ying Tung Education Foundation	This work was supported by the National Natural Science Foundation of China (Nos. 81773082, 81702903, 81872423, 81972813), Guangdong Natural Science Foundation (2018B030311036, 2019A1515010974) and Fork Ying Tung Education Foundation (161035).	Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912; Caie PD, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-156; Carlier MF, 2000, J BIOL CHEM, V275, P21946, DOI 10.1074/jbc.M000687200; Chatterjee D, 2019, ENT-EAR NOSE THROAT, V98, pE112, DOI 10.1177/0145561319848669; Co C, 2007, CELL, V128, P901, DOI 10.1016/j.cell.2006.12.049; Cronin KA, 2018, CANCER-AM CANCER SOC, V124, P2785, DOI [10.1002/cncr.31551, 10.1002/cncr.32802]; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Duvall-Noelle N, 2016, ONCOGENE, V35, P1122, DOI 10.1038/onc.2015.166; Gao QZ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0443-y; Grunewald TGP, 2007, BRIT J CANCER, V96, P296, DOI 10.1038/sj.bjc.6603545; Grunewald TGP, 2006, EXP CELL RES, V312, P974, DOI 10.1016/j.yexcr.2005.12.016; Heerema MGJ, 2016, HISTOPATHOLOGY, V68, P388, DOI 10.1111/his.12754; Kurisu S, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-6-226; Lane J, 2014, CANCER GENOM PROTEOM, V11, P155; Li H, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05280-6; Li YF, 2013, HEAD NECK PATHOL, V7, P211, DOI 10.1007/s12105-012-0412-1; Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Nakagawa H, 2006, FEBS LETT, V580, P3223, DOI 10.1016/j.febslet.2006.04.082; Niu Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep26112; Orth MF, 2015, ONCOTARGET, V6, P26, DOI 10.18632/oncotarget.3083; Panchal SC, 2003, NAT STRUCT BIOL, V10, P591, DOI 10.1038/nsb952; Pollard TD, 2002, CURR OPIN STRUC BIOL, V12, P768, DOI 10.1016/S0959-440X(02)00396-2; Pollard TD, 2007, ANNU REV BIOPH BIOM, V36, P451, DOI 10.1146/annurev.biophys.35.040405.101936; Prall F, 1994, HISTOPATHOLOGY, V78, P635; Rachlin AS, 2006, J CELL SCI, V119, P995, DOI 10.1242/jcs.02825; Rohatgi R, 2001, J BIOL CHEM, V276, P26448, DOI 10.1074/jbc.M103856200; Salvi A, 2015, INT J ONCOL, V46, P1901, DOI 10.3892/ijo.2015.2923; Shao ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep25631; Sun WD, 2017, ONCOL REP, V37, P341, DOI 10.3892/or.2016.5223; Takano K, 2008, EMBO J, V27, P2817, DOI 10.1038/emboj.2008.216; TOMASETTO C, 1995, FEBS LETT, V373, P245, DOI 10.1016/0014-5793(95)01040-L; van Wyk HC, 2019, ANN SURG ONCOL, V26, P4397, DOI 10.1245/s10434-019-07931-6; Wang H, 2014, CLIN CANCER RES, V20, P5835, DOI 10.1158/1078-0432.CCR-14-0485; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Zhao LA, 2010, GUT, V59, P1226, DOI 10.1136/gut.2009.202739; Zhao TS, 2015, CANCER RES, V75, P111, DOI 10.1158/0008-5472.CAN-14-2040; Zhou R, 2018, INT J CANCER, V142, P1853, DOI 10.1002/ijc.31206	38	10	11	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 27	2020	39	35					5743	5755		10.1038/s41388-020-01397-7	http://dx.doi.org/10.1038/s41388-020-01397-7		JUL 2020	13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	NF2QB	32704133				2022-12-17	WOS:000551792300001
J	Prendergast, L; Hong, E; Safina, A; Poe, D; Gurova, K				Prendergast, Laura; Hong, Erin; Safina, Alfiya; Poe, Dante; Gurova, Katerina			Histone chaperone FACT is essential to overcome replication stress in mammalian cells	ONCOGENE			English	Article							CHROMATIN TRANSCRIPTION FACT; FUNCTIONAL COOPERATION; MCM-HELICASE; DNA-DAMAGE; COMPLEX; NUCLEOSOME; PROTEIN; MECHANISM; SPT16; YEAST	The histone chaperone FACT is upregulated during mammary tumorigenesis and necessary for the viability and growth of breast tumor cells. We established that only proliferating tumor cells are sensitive to FACT knockdown, suggesting that FACT functions during DNA replication in tumor cells but not in normal cells. We hypothesized that the basal level of replication stress defines the FACT dependence of cells. Using genetic and chemical tools, we demonstrated that FACT is needed to overcome replication stress. In the absence of FACT during replication stress, the MCM2-7 helicase dissociates from chromatin, resulting in the absence of ssDNA accumulation, RPA binding, and activation of the ATR/CHK1 checkpoint response. Without this response, stalled replication forks are not stabilized, and new origin firing cannot be prevented, leading to the accumulation of DNA damage and cell death. Thus, we propose a novel role for FACT as a factor preventing helicase dissociation from chromatin during replication stress.	[Prendergast, Laura; Hong, Erin; Safina, Alfiya; Poe, Dante; Gurova, Katerina] Roswell Pk Comprehens Canc Ctr, Dept Cell Stress Biol, Buffalo, NY 14263 USA		Gurova, K (corresponding author), Roswell Pk Comprehens Canc Ctr, Dept Cell Stress Biol, Buffalo, NY 14263 USA.	katerina.gurova@roswellpark.org		Prendergast, Laura/0000-0003-0467-657X; Poe, Dante/0000-0002-4813-3035; Gurova, Katerina/0000-0001-9189-0712	NCI NIH HHS [P30 CA016056, R01 CA197967] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe T, 2011, J BIOL CHEM, V286, P30504, DOI 10.1074/jbc.M111.264721; Attwood K, 2017, BREAST CANCER-TARGET, V9, P301, DOI 10.2147/BCTT.S126390; Byun TS, 2005, GENE DEV, V19, P1040, DOI 10.1101/gad.1301205; Carter DR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab1803; Cha RS, 2002, SCIENCE, V297, P602, DOI 10.1126/science.1071398; Corpet A, 2011, EMBO J, V30, P480, DOI 10.1038/emboj.2010.335; Dermawan JKT, 2016, CANCER RES, V76, P2432, DOI 10.1158/0008-5472.CAN-15-2162; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Ekholm-Reed S, 2004, J CELL BIOL, V165, P789, DOI 10.1083/jcb.200404092; Fleyshman D, 2017, ONCOTARGET, V8, P20525, DOI 10.18632/oncotarget.15656; Forment JV, 2015, NAT PROTOC, V10, P1297, DOI 10.1038/nprot.2015.066; Garcia H, 2013, CELL REP, V4, P159, DOI 10.1016/j.celrep.2013.06.013; Garcia H, 2011, ONCOTARGET, V2, P783; Gasparian AV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002530; Groth A, 2005, MOL CELL, V17, P301, DOI 10.1016/j.molcel.2004.12.018; Gurova K, 2018, BBA-GENE REGUL MECH, V1861, P892, DOI 10.1016/j.bbagrm.2018.07.008; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herrera-Moyano E, 2014, GENE DEV, V28, P735, DOI 10.1101/gad.234070.113; Hertel L, 1999, EXP CELL RES, V250, P313, DOI 10.1006/excr.1999.4495; Hoek M, 2003, P NATL ACAD SCI USA, V100, P12183, DOI 10.1073/pnas.1635158100; Kim ST, 1999, J BIOL CHEM, V8, P49; Klusmann I, 2016, CELL REP, V17, P1845, DOI 10.1016/j.celrep.2016.10.036; Koman IE, 2012, CANCER PREV RES, V5, P1025, DOI 10.1158/1940-6207.CAPR-11-0529; Kulaeva OI, 2013, BBA-GENE REGUL MECH, V1829, P76, DOI 10.1016/j.bbagrm.2012.08.015; Kurat CF, 2017, MOL CELL, V65, P117, DOI 10.1016/j.molcel.2016.11.016; Liu Y, 2020, NATURE, V577, P426, DOI 10.1038/s41586-019-1820-0; Lolas IB, 2010, PLANT J, V61, P686, DOI 10.1111/j.1365-313X.2009.04096.x; Lolis AA, 2013, J BIOL CHEM, V288, P7676, DOI 10.1074/jbc.M112.426718; Mejlvang J, 2014, J CELL BIOL, V204, P29, DOI 10.1083/jcb.201305017; Mylonas C, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800085; O'Donnell AF, 2004, NUCLEIC ACIDS RES, V32, P5894, DOI 10.1093/nar/gkh922; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; Prado F, 2017, GENES-BASEL, V8, DOI 10.3390/genes8020049; Qiu ZJ, 2018, RADIOTHER ONCOL, V126, P450, DOI 10.1016/j.radonc.2017.09.043; Safina A, 2013, CELL CYCLE, V12, P2423, DOI 10.4161/cc.25452; Sandlesh P, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101177; Sandlesh P, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0199785; Schlesinger MB, 2000, GENETICS, V155, P1593; Shen ZL, 2018, STEM CELLS DEV, V27, P1693, DOI 10.1089/scd.2018.0150; SOULE HD, 1990, CANCER RES, V50, P6075; Spiesser TW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010203; Tan BCM, 2006, EMBO J, V25, P3975, DOI 10.1038/sj.emboj.7601271; Tan BCM, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-11; Toledo L, 2017, MOL CELL, V66, P735, DOI 10.1016/j.molcel.2017.05.001; True JD, 2016, J BIOL CHEM, V291, P15307, DOI 10.1074/jbc.M116.735134; Tsunaka Y, 2016, GENE DEV, V30, P673, DOI 10.1101/gad.274183.115; VanDemark AP, 2006, MOL CELL, V22, P363, DOI 10.1016/j.molcel.2006.03.025; Voth WP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084092; Wang T, 2018, LIFE SCI ALLIANCE, V1, DOI 10.26508/lsa.201800107; Wittmeyer J, 1999, BIOCHEMISTRY-US, V38, P8961, DOI 10.1021/bi982851d; Wittmeyer J, 1997, MOL CELL BIOL, V17, P4178, DOI 10.1128/MCB.17.7.4178; Yang JY, 2016, CELL REP, V14, P1128, DOI 10.1016/j.celrep.2015.12.096; YARBRO JW, 1992, SEMIN ONCOL, V19, P1; Ye XF, 2003, MOL CELL, V11, P341, DOI 10.1016/S1097-2765(03)00037-6; Yeo CQX, 2016, CELL REP, V15, P132, DOI 10.1016/j.celrep.2016.03.011; Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897	56	10	10	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 9	2020	39	28					5124	5137		10.1038/s41388-020-1346-9	http://dx.doi.org/10.1038/s41388-020-1346-9			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MH4RK	32533099	Green Published, hybrid			2022-12-17	WOS:000546718100004
J	Nollet, EA; Cardo-Vila, M; Ganguly, SS; Tran, JD; Schulz, VV; Cress, A; Corey, E; Miranti, CK				Nollet, Eric A.; Cardo-Vila, Marina; Ganguly, Sourik S.; Tran, Jack D.; Schulz, Veronique V.; Cress, Anne; Corey, Eva; Miranti, Cindy K.			Androgen receptor-induced integrin alpha 6 beta 1 and Bnip3 promote survival and resistance to PI3K inhibitors in castration-resistant prostate cancer	ONCOGENE			English	Article							PLASMINOGEN-ACTIVATOR; GROWTH-FACTOR; AUTOPHAGY; INDUCTION; TRANSCRIPTION; EXPRESSION; PROTEIN; MITOPHAGY; PATHWAYS; CLEAVAGE	The androgen receptor (AR) is the major driver of prostate cancer growth and survival. However, almost all patients relapse with castration-resistant disease (CRPC) when treated with anti-androgen therapy. In CRPC, AR is often aberrantly activated independent of androgen. Targeting survival pathways downstream of AR could be a viable strategy to overcome CRPC. Surprisingly, little is known about how AR drives prostate cancer survival. Furthermore, CRPC tumors in which Pten is lost are also resistant to eradication by PI3K inhibitors. We sought to identify the mechanism by which AR drives tumor survival in CRPC to identify ways to overcome resistance to PI3K inhibition. We found that integrins alpha 6 beta 1 and Bnip3 are selectively elevated in CRPC downstream of AR. While integrin alpha 6 promotes survival and is a direct transcriptional target of AR, the ability of AR to induce Bnip3 is dependent on adhesion to laminin and integrin alpha 6 beta 1-dependent nuclear translocation of HIF1 alpha. Integrins alpha 6 beta 1 and Bnip3 were found to promote survival of CRPC cells selectively on laminin through the induction of autophagy and mitophagy. Furthermore, blocking Bnip3 or integrin alpha 6 beta 1 restored sensitivity to PI3K inhibitors in Pten-negative CRPC. We identified an AR driven pathway that cooperates with laminin and hypoxia to drive resistance to PI3K inhibitors. These findings can help explain in part why PI3K inhibitors have failed in clinical trials to overcome AR-dependent CRPC.	[Nollet, Eric A.; Schulz, Veronique V.; Miranti, Cindy K.] Van Andel Res Inst, Grand Rapids, MI 49503 USA; [Cardo-Vila, Marina; Ganguly, Sourik S.; Tran, Jack D.; Cress, Anne; Miranti, Cindy K.] Univ Arizona, Ctr Canc, Dept Cellular & Mol Med, Tucson, AZ 85721 USA; [Cardo-Vila, Marina; Ganguly, Sourik S.; Tran, Jack D.; Cress, Anne; Miranti, Cindy K.] Univ Arizona, Ctr Canc, Prostate Canc Res Program, Tucson, AZ 85721 USA; [Corey, Eva] Univ Washington, Dept Urol, Seattle, WA 98195 USA	Van Andel Institute; University of Arizona; University of Arizona; University of Washington; University of Washington Seattle	Miranti, CK (corresponding author), Van Andel Res Inst, Grand Rapids, MI 49503 USA.; Miranti, CK (corresponding author), Univ Arizona, Ctr Canc, Dept Cellular & Mol Med, Tucson, AZ 85721 USA.; Miranti, CK (corresponding author), Univ Arizona, Ctr Canc, Prostate Canc Res Program, Tucson, AZ 85721 USA.	cmiranti@email.arizona.edu		Corey, Eva/0000-0002-9244-3807	NIH/NCI [CA159406]; Van Andel Research Institute	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Van Andel Research Institute	We would like to thank Drs. Sander Frank and Don Tindall for feedback and constructive suggestions and Penny Berger for technical expertise. Special thanks to Scott Peterson for supplying the PX-866. These studies were supported by funding from NIH/NCI R01CA154835, P30CA023074 (CKM, SSG, EAN, and VVS), and the Van Andel Research Institute. Additional support was provided by NIH/NCI CA159406 (AC).	Alers S, 2012, MOL CELL BIOL, V32, P2, DOI 10.1128/MCB.06159-11; Anastasiadis Aristotelis G, 2002, Curr Urol Rep, V3, P222, DOI 10.1007/s11934-002-0068-6; Bellot G, 2009, MOL CELL BIOL, V29, P2570, DOI 10.1128/MCB.00166-09; Berger PL, 2014, CANCER RES, V74, P3357, DOI 10.1158/0008-5472.CAN-13-3076; Boddy JL, 2005, CLIN CANCER RES, V11, P7658, DOI 10.1158/1078-0432.CCR-05-0460; Brooks DLP, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0510-x; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chen Q, 2006, CANCER LETT, V244, P274, DOI 10.1016/j.canlet.2005.12.027; Chen XQ, 2010, CANCER RES, V70, P2728, DOI 10.1158/0008-5472.CAN-09-3718; CRESS AE, 1995, CANCER METAST REV, V14, P219, DOI 10.1007/BF00690293; Crumbaker M, 2017, CANCERS, V9, DOI 10.3390/cancers9040034; Demetriou MC, 2004, EXP CELL RES, V294, P550, DOI 10.1016/j.yexcr.2003.11.023; Feng Q, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00858; Frank SB, 2017, BMC BIOTECHNOL, V17, DOI 10.1186/s12896-017-0341-x; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Galletti G, 2017, CANCER TREAT REV, V57, P16, DOI 10.1016/j.ctrv.2017.04.008; Glick D, 2012, MOL CELL BIOL, V32, P2570, DOI 10.1128/MCB.00167-12; Gu YC, 2003, BLOOD, V101, P877, DOI 10.1182/blood-2002-03-0796; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Hanna RA, 2012, J BIOL CHEM, V287, P19094, DOI 10.1074/jbc.M111.322933; Harryman WL, 2016, BBA-REV CANCER, V1866, P221, DOI 10.1016/j.bbcan.2016.09.005; Hiraga T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113523; Hong DS, 2012, CLIN CANCER RES, V18, P4173, DOI 10.1158/1078-0432.CCR-12-0714; Horoszewicz J S, 1980, Prog Clin Biol Res, V37, P115; Ihle NT, 2005, MOL CANCER THER, V4, P1349, DOI 10.1158/1535-7163.MCT-05-0149; Jung SN, 2008, CARCINOGENESIS, V29, P713, DOI 10.1093/carcin/bgn032; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Lamb LE, 2011, CANCER RES, V71, P2739, DOI 10.1158/0008-5472.CAN-10-2745; Lee SH, 2015, J BIOL CHEM, V290, P2759, DOI 10.1074/jbc.M114.607846; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Mazure NM, 2009, AUTOPHAGY, V5, P868, DOI 10.4161/auto.9042; Neri P, 2012, CURR CANCER DRUG TAR, V12, P776, DOI 10.2174/156800912802429337; Pietrocola F, 2013, SEMIN CANCER BIOL, V23, P310, DOI 10.1016/j.semcancer.2013.05.008; Pontes-Junior Jose, 2009, J Carcinog, V8, P3; Ports MO, 2009, CANCER RES, V69, P5007, DOI 10.1158/0008-5472.CAN-09-0354; Qi WQ, 2015, ONCOTARGET, V6, P41976, DOI 10.18632/oncotarget.5659; Robinson D, 2015, CELL, V161, P1215, DOI 10.1016/j.cell.2015.05.001; Rual JF, 2004, GENOME RES, V14, P2128, DOI 10.1101/gr.2973604; Shabsigh A, 2001, J CELL BIOCHEM, V81, P437, DOI 10.1002/1097-4644(20010601)81:3<437::AID-JCB1057>3.3.CO;2-Y; Shaw J, 2008, P NATL ACAD SCI USA, V105, P20734, DOI 10.1073/pnas.0807735105; Sinha RA, 2015, AUTOPHAGY, V11, P1341, DOI 10.1080/15548627.2015.1061849; Sobocinski GP, 2010, BMC IMMUNOL, V11, DOI 10.1186/1471-2172-11-42; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Tang D, 2017, SCI REP-UK, V7, DOI 10.1038/srep43926; Thomas C, 2013, MOL CANCER THER, V12, P2342, DOI 10.1158/1535-7163.MCT-13-0032; Toth RK, 2019, AM J CLIN EXP UROL, V7, P297; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; van Uden P, 2008, BIOCHEM J, V412, P477, DOI 10.1042/BJ20080476; Veeramani S, 2008, ONCOGENE, V27, P5057, DOI 10.1038/onc.2008.143; VELDSCHOLTE J, 1992, BIOCHEMISTRY-US, V31, P2393, DOI 10.1021/bi00123a026; Wang DP, 2011, METHODS MOL BIOL, V776, P25, DOI 10.1007/978-1-61779-243-4_2; White E, 2015, J CLIN INVEST, V125, P42, DOI 10.1172/JCI73941; WU HC, 1994, INT J CANCER, V57, P406, DOI 10.1002/ijc.2910570319; Yoo NJ, 2010, TUMORI J, V96, P138, DOI 10.1177/030089161009600122; Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16; Zhang J, 2012, AUTOPHAGY, V8, P1325, DOI 10.4161/auto.20764; Zhu YY, 2013, J BIOL CHEM, V288, P1099, DOI 10.1074/jbc.M112.399345	57	10	10	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 30	2020	39	31					5390	5404		10.1038/s41388-020-1370-9	http://dx.doi.org/10.1038/s41388-020-1370-9		JUN 2020	15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	MT1TS	32565538	Green Accepted			2022-12-17	WOS:000541695700001
J	Yang, W; Khoury, E; Guo, QY; Prabhu, SA; Emond, A; Huang, F; Goncalves, C; Zhan, Y; Plourde, D; Nichol, JN; Dahabieh, MS; Miller, WH; del Rincon, SV				Yang, William; Khoury, Elie; Guo, Qianyu; Prabhu, Sathyen A.; Emond, Audrey; Huang, Fan; Goncalves, Christophe; Zhan, Yao; Plourde, Dany; Nichol, Jessica N.; Dahabieh, Michael S.; Miller Jr., Wilson H.; del Rincon, Sonia Victoria			MNK1 signaling induces an ANGPTL4-mediated gene signature to drive melanoma progression	ONCOGENE			English	Article							ACTIVATED RECEPTOR BETA/DELTA; MATRIX METALLOPROTEINASES; EIF4E; PHOSPHORYLATION; METASTASIS; INVASION; ANGPTL4; INHIBITION; RESISTANCE; CLUSTERIN	The BRAF(V600E) mutation occurs in more than 50% of cutaneous melanomas, and results in the constitutive activation of the mitogen-activated protein kinases (MAPK) pathway. MAP kinase-interacting serine/threonine-protein kinase 1 and 2 (MNK1/2) are downstream effectors of the activated MAPK pathway, and important molecular targets in invasive and metastatic cancer. Despite the well-known role of MNK1 in regulating mRNA translation, little is known concerning the impact of its aberrant activation on gene transcription. Here, we show that changes in the activity, or abundance, of MNK1 result in changes in the expression of pro-oncogenic and pro-invasive genes. Among the MNK1-upregulated genes, we identify Angiopoietin-like 4 (ANGPTL4), which in turn promotes an invasive phenotype via its ability to induce the expression of matrix metalloproteinases (MMPs). Using a pharmacologic inhibitor of MNK1/2, SEL201, we demonstrate that BRAF(V600E)-mutated cutaneous melanoma cells are reliant on MNK1/2 for invasion and lung metastasis.	[Yang, William; Khoury, Elie; Guo, Qianyu; Prabhu, Sathyen A.; Huang, Fan; Zhan, Yao; Dahabieh, Michael S.; Miller Jr., Wilson H.; del Rincon, Sonia Victoria] McGill Univ, Div Expt Med, Fac Med, Montreal, PQ, Canada; [Yang, William; Khoury, Elie; Guo, Qianyu; Prabhu, Sathyen A.; Emond, Audrey; Huang, Fan; Goncalves, Christophe; Zhan, Yao; Plourde, Dany; Nichol, Jessica N.; Dahabieh, Michael S.; Miller Jr., Wilson H.; del Rincon, Sonia Victoria] McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada; [Miller Jr., Wilson H.] McGill Univ, Rossy Canc Network, Montreal, PQ, Canada	McGill University; Lady Davis Institute; McGill University; McGill University	Miller, WH; del Rincon, SV (corresponding author), McGill Univ, Div Expt Med, Fac Med, Montreal, PQ, Canada.; Miller, WH; del Rincon, SV (corresponding author), McGill Univ, Lady Davis Inst, Jewish Gen Hosp, Montreal, PQ, Canada.; Miller, WH (corresponding author), McGill Univ, Rossy Canc Network, Montreal, PQ, Canada.	wmiller@ldi.jgh.mcgill.ca; sonia.delrincon@mcgill.ca	Yang, William/AAU-2275-2020	Huang, Fan/0000-0002-3850-5317; Miller, Wilson H./0000-0002-7408-1574; Emond, Audrey/0000-0001-8053-2784	Canadian Institutes for Health Research [MOP-142281 PJT-156269, PJT-162260]; Canadian Cancer Society [703811]; Rossy Cancer Network; National Centre for Research and Development, INNOTECH Program [INNOTECH-K1/HI1/I6/157438/NCBR/12]; Cole Foundation Ph.D. fellowship; MICRTP graduate studentships; McGill Integrated Cancer Research Training Program (MICRTP) graduate studentship; McGill Faculty of Medicine graduate studentship	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society(Canadian Cancer Society (CCS)); Rossy Cancer Network; National Centre for Research and Development, INNOTECH Program; Cole Foundation Ph.D. fellowship; MICRTP graduate studentships; McGill Integrated Cancer Research Training Program (MICRTP) graduate studentship; McGill Faculty of Medicine graduate studentship	This research is funded by the Canadian Institutes for Health Research (grants MOP-142281 PJT-156269 to WHM and SVDR, and grant PJT-162260 to SVDR) and the Canadian Cancer Society (grant 703811 WHM and SVDR). The research was further supported by the Rossy Cancer Network. Development of MNK1/2 inhibitors by Selvita S.A. has been co-financed by the National Centre for Research and Development, INNOTECH Program (INNOTECH-K1/HI1/I6/157438/NCBR/12). WY was endowed by MICRTP graduate studentships. QG was financed by a Cole Foundation Ph.D. fellowship, McGill Integrated Cancer Research Training Program (MICRTP) graduate studentship and a McGill Faculty of Medicine graduate studentship. FH was sponsored by MICRTP graduate studentships. We thank Shalom Chaim Spira for editing this manuscript.	Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044; Ascierto PA, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-85; Baron V, 2006, CANCER GENE THER, V13, P115, DOI 10.1038/sj.cgt.7700896; Beyaz S, 2016, CLIN CANCER RES, V22, P5636, DOI 10.1158/1078-0432.CCR-16-0775; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Djeu JY, 2009, ADV CANCER RES, V105, P77, DOI 10.1016/S0065-230X(09)05005-2; Domingues B, 2018, IMMUNOTARGETS THER, V7, P35, DOI 10.2147/ITT.S134842; Fang L, 2016, PPAR RES, V2016, DOI 10.1155/2016/6042162; Geller Alan C, 2003, Semin Oncol Nurs, V19, P2, DOI 10.1053/sonu.2003.50000; Georgiadi A, 2010, CIRC RES, V106, P1712, DOI 10.1161/CIRCRESAHA.110.217380; Gialeli C, 2011, FEBS J, V278, P16, DOI 10.1111/j.1742-4658.2010.07919.x; Guo QY, 2019, CANCER RES, V79, P1646, DOI 10.1158/0008-5472.CAN-18-1602; Guo ZH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10397-9; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hu K, 2016, ONCOTARGET, V7, P7816, DOI 10.18632/oncotarget.6868; Joshi Sonali, 2014, World J Biol Chem, V5, P321, DOI 10.4331/wjbc.v5.i3.321; Kimura R, 2011, BBA-MOL CELL RES, V1813, P1543, DOI 10.1016/j.bbamcr.2011.04.008; Korneeva NL, 2010, MOL CANCER RES, V8, P1571, DOI 10.1158/1541-7786.MCR-10-0091; La Paglia L, 2017, PPAR RES, V2017, DOI 10.1155/2017/8187235; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868; Liao YH, 2017, ONCOGENE, V36, P2228, DOI 10.1038/onc.2016.371; Liu L, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.419; Naruhn S, 2011, MOL PHARMACOL, V80, P828, DOI 10.1124/mol.111.074039; O'Loghlen A, 2007, BBA-MOL CELL RES, V1773, P1416, DOI 10.1016/j.bbamcr.2007.05.009; Pettersson F, 2015, CANCER RES, V75, P1102, DOI 10.1158/0008-5472.CAN-14-1996; Ramalingam S, 2014, ONCOTARGET, V5, P530, DOI 10.18632/oncotarget.1528; Redondo M, 2009, ADV CANCER RES, V105, P21, DOI 10.1016/S0065-230X(09)05002-7; Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690; Robichaud N, 2015, ONCOGENE, V34, P2032, DOI 10.1038/onc.2014.146; Vella V, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00031; Wang JH, 2010, WORLD J GASTROENTERO, V16, P5642, DOI 10.3748/wjg.v16.i44.5642; Zhan Y, 2017, J CLIN INVEST, V127, P4179, DOI 10.1172/JCI91258	34	10	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	18					3650	3665		10.1038/s41388-020-1240-5	http://dx.doi.org/10.1038/s41388-020-1240-5		MAR 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LI5XR	32132651				2022-12-17	WOS:000518095100001
J	Monte, ER; Wilding, A; Leubolt, G; Kerbs, P; Bagnoli, JW; Hartmann, L; Hiddemann, W; Chen-Wichmann, L; Krebs, S; Blum, H; Cusan, M; Vick, B; Jeremias, I; Enard, W; Theurich, S; Wichmann, C; Greif, PA				Redondo Monte, Enric; Wilding, Anja; Leubolt, Georg; Kerbs, Paul; Bagnoli, Johannes W.; Hartmann, Luise; Hiddemann, Wolfgang; Chen-Wichmann, Linping; Krebs, Stefan; Blum, Helmut; Cusan, Monica; Vick, Binje; Jeremias, Irmela; Enard, Wolfgang; Theurich, Sebastian; Wichmann, Christian; Greif, Philipp A.			ZBTB7A prevents RUNX1-RUNX1T1-dependent clonal expansion of human hematopoietic stem and progenitor cells	ONCOGENE			English	Article							AML1-ETO; MUTATIONS; LEUKEMIA; FATE; REPRESSION; LRF	ZBTB7A is frequently mutated in acute myeloid leukemia (AML) with t(8;21) translocation. However, the oncogenic collaboration between mutated ZBTB7A and the RUNX1-RUNX1T1 fusion gene in AML t(8;21) remains unclear. Here, we investigate the role of ZBTB7A and its mutations in the context of normal and malignant hematopoiesis. We demonstrate that clinically relevant ZBTB7A mutations in AML t(8;21) lead to loss of function and result in perturbed myeloid differentiation with block of the granulocytic lineage in favor of monocytic commitment. In addition, loss of ZBTB7A increases glycolysis and hence sensitizes leukemic blasts to metabolic inhibition with 2-deoxy-d-glucose. We observed that ectopic expression of wild-type ZBTB7A prevents RUNX1-RUNX1T1-mediated clonal expansion of human CD34+ cells, whereas the outgrowth of progenitors is enabled by ZBTB7A mutation. Finally, ZBTB7A expression in t(8;21) cells lead to a cell cycle arrest that could be mimicked by inhibition of glycolysis. Our findings suggest that loss of ZBTB7A may facilitate the onset of AML t(8;21), and that RUNX1-RUNX1T1-rearranged leukemia might be treated with glycolytic inhibitors.	[Redondo Monte, Enric; Wilding, Anja; Leubolt, Georg; Kerbs, Paul; Hartmann, Luise; Hiddemann, Wolfgang; Cusan, Monica; Theurich, Sebastian; Greif, Philipp A.] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, D-81377 Munich, Germany; [Redondo Monte, Enric; Wilding, Anja; Leubolt, Georg; Kerbs, Paul; Hartmann, Luise; Hiddemann, Wolfgang; Greif, Philipp A.] German Canc Consortium DKTK, Partner Site Munich, D-81377 Munich, Germany; [Redondo Monte, Enric; Wilding, Anja; Leubolt, Georg; Kerbs, Paul; Hartmann, Luise; Hiddemann, Wolfgang; Greif, Philipp A.] German Canc Res Ctr, D-69121 Heidelberg, Germany; [Bagnoli, Johannes W.; Enard, Wolfgang] Ludwig Maximilians Univ Munchen, Dept Biol 2, Anthropol & Human Genom, D-82152 Martinsried, Germany; [Chen-Wichmann, Linping; Wichmann, Christian] Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Transfus Med Cell Therapeut & Hemostasis, D-81377 Munich, Germany; [Krebs, Stefan; Blum, Helmut] Ludwig Maximilians Univ Munchen, Lab Funct Genome Anal, Gene Ctr, D-81377 Munich, Germany; [Vick, Binje; Jeremias, Irmela] Helmholtz Ctr Munich, Res Unit Apoptosis Hematopoiet Stem Cells, D-81377 Munich, Germany; [Theurich, Sebastian] Ludwig Maximilians Univ Munchen, Gene Ctr, Canc & Immunometab Res Grp, D-81377 Munich, Germany	University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ); University of Munich; University of Munich; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Greif, PA (corresponding author), Ludwig Maximilians Univ Munchen, Univ Hosp, Dept Med 3, D-81377 Munich, Germany.; Greif, PA (corresponding author), German Canc Consortium DKTK, Partner Site Munich, D-81377 Munich, Germany.; Greif, PA (corresponding author), German Canc Res Ctr, D-69121 Heidelberg, Germany.	pgreif@med.lmu.de	Theurich, Sebastian/C-9995-2018; Theurich, Sebastian/AAB-2855-2022; Jeremias, Irmela/Q-5934-2019; Wichmann, Christian/H-2491-2017	Theurich, Sebastian/0000-0001-5706-8258; Jeremias, Irmela/0000-0003-1773-7677; Redondo Monte, Enric/0000-0002-3588-223X; Kerbs, Paul/0000-0001-5525-1374; Bagnoli, Johannes/0000-0003-0393-6157; Vick, Binje/0000-0003-1956-2778	German Research Foundation (DFG) within the Collaborative Research Centre [(SFB) 1243]; Wilhelm Sander-Stiftung [2014.162.2]; Munich Clinician Scientist Program (MCSP) Advanced Track; Projekt DEAL	German Research Foundation (DFG) within the Collaborative Research Centre(German Research Foundation (DFG)); Wilhelm Sander-Stiftung; Munich Clinician Scientist Program (MCSP) Advanced Track; Projekt DEAL	This study was supported by the German Research Foundation (DFG) within the Collaborative Research Centre (SFB) 1243 "Cancer Evolution" (Projects A05, A08, A14, and Z02). PAG and CW acknowledge support by the Wilhelm Sander-Stiftung (Forderantrag Nr. 2014.162.2). PAG received funds from the Munich Clinician Scientist Program (MCSP) Advanced Track. Open access funding provided by Projekt DEAL.	BENZ EJ, 1980, P NATL ACAD SCI-BIOL, V77, P3509, DOI 10.1073/pnas.77.6.3509; Burel SA, 2001, MOL CELL BIOL, V21, P5577, DOI 10.1128/MCB.21.16.5577-5590.2001; Christen F, 2019, BLOOD, V133, P1140, DOI 10.1182/blood-2018-05-852822; COLLINS SJ, 1987, BLOOD, V70, P1233; de Guzman CG, 2002, MOL CELL BIOL, V22, P5506, DOI 10.1128/MCB.22.15.5506-5517.2002; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Faber ZJ, 2016, NAT GENET, V48, P1551, DOI 10.1038/ng.3709; Hartmann L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11733; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Isa A, 2018, KLIN PADIATR, V230, P165; Kawashima N, 2019, ANN HEMATOL, V98, P83, DOI 10.1007/s00277-018-3492-5; Lavallee VP, 2016, BLOOD, V127, P2498, DOI 10.1182/blood-2016-03-703868; Lee SU, 2013, BLOOD, V121, P918, DOI 10.1182/blood-2012-03-418103; Liu XS, 2016, ONCOGENE, V35, P3071, DOI 10.1038/onc.2015.371; Liu XS, 2014, GENE DEV, V28, P1917, DOI 10.1101/gad.245910.114; Lunardi A, 2013, BLOOD, V121, P2845, DOI 10.1182/blood-2012-11-292037; Maeda T, 2007, SCIENCE, V316, P860, DOI 10.1126/science.1140881; Maeda T, 2009, DEV CELL, V17, P527, DOI 10.1016/j.devcel.2009.09.005; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; Mulloy JC, 2002, BLOOD, V99, P15, DOI 10.1182/blood.V99.1.15; Opatz S, 2020, LEUKEMIA, V34, P1553, DOI 10.1038/s41375-019-0697-0; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Rhoades KL, 2000, BLOOD, V96, P2108; ROWLEY JD, 1973, ANN GENET-PARIS, V16, P109; Schwieger M, 2002, J EXP MED, V196, P1227, DOI 10.1084/jem.20020824; Suganuma K, 2010, LEUKEMIA LYMPHOMA, V51, P2112, DOI 10.3109/10428194.2010.512966; Vick B, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120925; Westendorf JJ, 1998, MOL CELL BIOL, V18, P322, DOI 10.1128/MCB.18.1.322; Wichmann C, 2015, LEUKEMIA, V29, P279, DOI 10.1038/leu.2014.179; Yan JS, 2017, LEUKEMIA LYMPHOMA, V58, P1985, DOI 10.1080/10428194.2016.1272690; Yeh JRJ, 2008, DEVELOPMENT, V135, P401, DOI 10.1242/dev.008904; Yuan YZ, 2001, P NATL ACAD SCI USA, V98, P10398, DOI 10.1073/pnas.171321298	32	10	10	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3195	3205		10.1038/s41388-020-1209-4	http://dx.doi.org/10.1038/s41388-020-1209-4		MAR 2020	11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32115572	hybrid, Green Published			2022-12-17	WOS:000517359700001
J	Richter, AM; Woods, ML; Kuster, MM; Walesch, SK; Braun, T; Boettger, T; Dammann, RH				Richter, Antje M.; Woods, Michelle L.; Kuester, Miriam M.; Walesch, Sara K.; Braun, Thomas; Boettger, Thomas; Dammann, Reinhard H.			RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice	ONCOGENE			English	Article							TUMOR-SUPPRESSOR GENES; DNA METHYLATION; P53; MOUSE; EXPRESSION; FAMILY; HYPERMETHYLATION; SUSCEPTIBILITY; APOPTOSIS; MODEL	Kidney cancer incidences are rising globally, thereby fueling the demand for targeted therapies and precision medicine. In our previous work, we have identified and characterized the Ras-Association Domain Family encoding ten members that are often aberrantly expressed in human cancers. In this study, we created and analyzed the Rassf10 knockout mice. Here we show that Rassf10 haploinsufficiency promotes neoplasia formation in two established mouse cancer models (Rassf1A(-/-) and p53(-/-)). Haploinsufficient Rassf10 knockout mice were significantly prone to various diseases including lymphoma (Rassf1A(-/-) background) and thymoma (p53(-/-) background). Especially Rassf10(-/-) and p53-deficient mice exhibited threefold increased rates of kidney cysts compared with p53(-/-) controls. Moreover, we observed that in human kidney cancer, RASSF10 is frequently epigenetically inactivated by its CpG island promoter hypermethylation. Primary tumors of renal clear cell and papillary cell carcinoma confirmed that RASSF10 methylation is associated with decreased expression in comparison to normal kidney tissue. In independent data sets, we could validate that RASSF10 inactivation clinically correlated with decreased survival and with progressed disease state of kidney cancer patients and polycystic kidney size. Functionally, we revealed that the loss of Rassf10 was significantly associated with upregulation of KRAS signaling and MYC expression. In summary, we could show that Rassf10 functions as a haploinsufficient tumor suppressor. In combination with other markers, RASSF10 silencing can serve as diagnostic and prognostic cancer biomarker in kidney diseases.	[Richter, Antje M.; Woods, Michelle L.; Kuester, Miriam M.; Walesch, Sara K.; Dammann, Reinhard H.] Univ Giessen, Inst Genet, D-35392 Giessen, Germany; [Richter, Antje M.; Braun, Thomas; Boettger, Thomas] Max Planck Inst Heart & Lung Res, Bad Nauheim, Germany; [Braun, Thomas; Dammann, Reinhard H.] Univ Giessen & Marburg Lung Ctr, German Ctr Lung Res DZL, D-35392 Giessen, Germany	Justus Liebig University Giessen; Max Planck Society	Richter, AM; Dammann, RH (corresponding author), Univ Giessen, Inst Genet, D-35392 Giessen, Germany.; Richter, AM (corresponding author), Max Planck Inst Heart & Lung Res, Bad Nauheim, Germany.; Dammann, RH (corresponding author), Univ Giessen & Marburg Lung Ctr, German Ctr Lung Res DZL, D-35392 Giessen, Germany.	antje.m.richter@gen.bio.uni-giessen.de; reinhard.dammann@gen.bio.uni-giessen.de	Braun, Thomas/B-2310-2008; Boettger, Thomas/E-3406-2012	Boettger, Thomas/0000-0003-4280-8449; Braun, Thomas/0000-0002-6165-4804	Projekt DEAL	Projekt DEAL	We thank Sylvia Thomas at the MPI for performing the microarrays analysis, Richard Volckmann for his help with R2 data at AMC and Julia Weber and Helga Linder for cloning of the Rassf10 mouse knockout vector. Open access funding provided by Projekt DEAL.	Baylin S, 2002, CANCER CELL, V1, P299, DOI 10.1016/S1535-6108(02)00061-2; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Chen YJ, 2005, WORLD J GASTROENTERO, V11, P1333, DOI 10.3748/wjg.v11.i9.1333; Cheng YY, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/4987103; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Diez-Villanueva A, 2015, EPIGENET CHROMATIN, V8, DOI 10.1186/s13072-015-0014-8; Doetschman Thomas, 2009, V530, P423, DOI 10.1007/978-1-59745-471-1_23; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Donehower LA, 1996, SEMIN CANCER BIOL, V7, P269, DOI 10.1006/scbi.1996.0035; Dudgeon C, 2014, GENE DEV, V28, P2613, DOI 10.1101/gad.252148.114; Eden E, 2009, BMC BIOINFORMATICS, V10, DOI 10.1186/1471-2105-10-48; Fan C, 2017, CELL PHYSIOL BIOCHEM, V41, P1229, DOI 10.1159/000464386; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Goossens N, 2015, TRANSL CANCER RES, V4, P256, DOI 10.3978/j.issn.2218-676X.2015.06.04; Gostissa M, 2013, P NATL ACAD SCI USA, V110, P2934, DOI 10.1073/pnas.1222570110; GRANTHAM JJ, 1990, AM J KIDNEY DIS, V15, P110, DOI 10.1016/S0272-6386(12)80507-5; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241; Haag T, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2087-6; Haag Tanja, 2014, Genes Cancer, V5, P365; Han SM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37101-9; Helmbold P, 2012, J INVEST DERMATOL, V132, P687, DOI 10.1038/jid.2011.380; Henry NL, 2012, MOL ONCOL, V6, P140, DOI 10.1016/j.molonc.2012.01.010; Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138; Hesson LB, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-42; Hill VK, 2011, ONCOGENE, V30, P978, DOI 10.1038/onc.2010.471; Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267; Inoue Kazushi, 2017, Adv Med Biol, V118, P83; Issa IA, 2017, WORLD J GASTROENTERO, V23, P5086, DOI 10.3748/wjg.v23.i28.5086; Jimenez AP, 2017, ONCOTARGET, V8, P88437, DOI 10.18632/oncotarget.18177; Johansson J, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00003; Kiehl S, 2014, SCI REP-UK, V4, DOI 10.1038/srep06899; Kirwan A, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/490531; Klopstock N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005025; Kornberg Z, 2018, TRANSL ANDROL UROL, V7, P459, DOI 10.21037/tau.2018.06.02; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Li X, 2016, ONCOGENE, V35, P2453, DOI 10.1038/onc.2015.300; Liu W, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.24; Loeb LA, 2016, CANCER RES, V76, P2057, DOI 10.1158/0008-5472.CAN-16-0794; Modhukur V, 2018, EPIGENOMICS-UK, V10, P277, DOI 10.2217/epi-2017-0118; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Morales JK, 2010, GENES IMMUN, V11, P599, DOI 10.1038/gene.2010.35; Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y; Partin AW, 2014, J UROLOGY, V192, P1081, DOI 10.1016/j.juro.2014.04.013; Puccini J, 2013, CELL DEATH DIFFER, V20, P964, DOI 10.1038/cdd.2013.35; Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143; Richter AM, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.18; Richter AM, 2019, CANCERS, V11, DOI 10.3390/cancers11121976; Richter AM, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0360-4; Richter AM, 2016, CANCERS, V8, DOI 10.3390/cancers8030026; Richter AM, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00021; Richter Antje M, 2013, Cancers (Basel), V5, P1566, DOI 10.3390/cancers5041566; Richter AM, 2009, BBA-REV CANCER, V1796, P114, DOI 10.1016/j.bbcan.2009.03.004; Rivera J, 2008, IMMUNITY, V28, P1, DOI 10.1016/j.immuni.2007.12.008; Santarosa M, 2004, BBA-REV CANCER, V1654, P105, DOI 10.1016/j.bbcan.2004.01.001; Sauter ER, 2017, EUR J BREAST HEALTH, V13, P162, DOI 10.5152/ejbh.2017.3635; Schagdarsurengin U, 2007, ONCOGENE, V26, P3089, DOI 10.1038/sj.onc.1210107; Schagdarsurengin U, 2009, EPIGENETICS-US, V4, P571, DOI 10.4161/epi.4.8.10056; Schonenberger D, 2016, CANCER RES, V76, P2025, DOI 10.1158/0008-5472.CAN-15-1859; Seeger-Nukpezah T, 2015, NAT REV NEPHROL, V11, P515, DOI 10.1038/nrneph.2015.46; Selleck MJ, 2017, BIOMARK INSIGHTS, V12, DOI 10.1177/1177271917715236; Sherwood V, 2010, BIOCHEM J, V425, P303, DOI 10.1042/BJ20091318; Steinmann Katrin, 2011, Genes Cancer, V2, P65, DOI 10.1177/1947601911405043; Stewart GD, 2013, J UROLOGY, V189, P1110, DOI 10.1016/j.juro.2012.08.219; Sweetman D, 2006, DEV DYNAM, V235, P2185, DOI 10.1002/dvdy.20881; Szasz AM, 2016, ONCOTARGET, V7, P49322, DOI 10.18632/oncotarget.10337; Tommasi S, 2005, CANCER RES, V65, P92; Van Bodegom D, 2006, J BIOL CHEM, V281, P31234, DOI 10.1074/jbc.M606510200; van der Weyden L, 2009, INT J EXP PATHOL, V90, P101, DOI 10.1111/j.1365-2613.2008.00635.x; Vaseva AV, 2018, CANCER CELL, V34, P807, DOI 10.1016/j.ccell.2018.10.001; Vavvas D, 1998, J BIOL CHEM, V273, P5439, DOI 10.1074/jbc.273.10.5439; Vogelmann R, 2005, J CELL SCI, V118, P4901, DOI 10.1242/jcs.02594; Volodko N, 2014, FEBS LETT, V588, P2671, DOI 10.1016/j.febslet.2014.02.041; Wang YF, 2014, BIOMED PHARMACOTHER, V68, P321, DOI 10.1016/j.biopha.2013.12.005; Wei ZR, 2013, BIOCHEM BIOPH RES CO, V432, P632, DOI 10.1016/j.bbrc.2013.02.033; Wystub K, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003793; Xie NN, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/7834175; Xu Q, 2005, ONCOGENE, V24, P5552, DOI 10.1038/sj.onc.1208719; Zamay TN, 2017, CANCERS, V9, DOI 10.3390/cancers9110155	79	10	10	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2020	39	15					3114	3127		10.1038/s41388-020-1195-6	http://dx.doi.org/10.1038/s41388-020-1195-6		FEB 2020	14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LB8NS	32047266	Green Published, hybrid			2022-12-17	WOS:000512843500001
J	Lok, TM; Wang, Y; Xu, WK; Xie, SW; Ma, HT; Poon, RYC				Lok, Tsun Ming; Wang, Yang; Xu, Wendy Kaichun; Xie, Siwei; Ma, Hoi Tang; Poon, Randy Y. C.			Mitotic slippage is determined by p31(comet) and the weakening of the spindle-assembly checkpoint	ONCOGENE			English	Article							CELL-CYCLE; AAA-ATPASE; PROTEIN; TRIP13; ACTIVATION; MAD2; MPS1; INACTIVATION; DEGRADATION; INHIBITION	Mitotic slippage involves cells exiting mitosis without proper chromosome segregation. Although degradation of cyclin B1 during prolonged mitotic arrest is believed to trigger mitotic slippage, its upstream regulation remains obscure. Whether mitotic slippage is caused by APC/C-CDC20 activity that is able to escape spindle-assembly checkpoint (SAC)-mediated inhibition, or is actively promoted by a change in SAC activity remains an outstanding issue. We found that a major culprit for mitotic slippage involves reduction of MAD2 at the kinetochores, resulting in a progressive weakening of SAC during mitotic arrest. A further level of control of the timing of mitotic slippage is through p31(comet)-mediated suppression of MAD2 activation. The loss of kinetochore MAD2 was dependent on APC/C-CDC20, indicating a feedback control of APC/C to SAC during prolonged mitotic arrest. The gradual weakening of SAC during mitotic arrest enables APC/C-CDC20 to degrade cyclin B1, cumulating in the cell exiting mitosis by mitotic slippage.	[Lok, Tsun Ming; Wang, Yang; Xu, Wendy Kaichun; Xie, Siwei; Ma, Hoi Tang; Poon, Randy Y. C.] Hong Kong Univ Sci & Technol, Ctr Canc Res, Div Life Sci, Clear Water Bay, Hong Kong, Peoples R China; [Lok, Tsun Ming; Wang, Yang; Xu, Wendy Kaichun; Xie, Siwei; Ma, Hoi Tang; Poon, Randy Y. C.] Hong Kong Univ Sci & Technol, State Key Lab Mol Neurosci, Clear Water Bay, Hong Kong, Peoples R China; [Xu, Wendy Kaichun] Univ Texas Austin, Dept Mol Biosci, Inst Cellular & Mol Biol, Austin, TX 78712 USA	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology; University of Texas System; University of Texas Austin	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Ctr Canc Res, Div Life Sci, Clear Water Bay, Hong Kong, Peoples R China.; Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, State Key Lab Mol Neurosci, Clear Water Bay, Hong Kong, Peoples R China.	rycpoon@ust.hk	Xu, Wendy Kaichun/AAO-3471-2021	Xu, Wendy Kaichun/0000-0002-5866-3523; Wang, Yang/0000-0001-5065-7412; MA, Hoi Tang/0000-0001-5876-0107	Research Grants Council [16100017, 16102919]; Health and Medical Research Fund [04153526]; Innovation and Technology Commission [ITCPD/17-9]	Research Grants Council(Hong Kong Research Grants Council); Health and Medical Research Fund; Innovation and Technology Commission	This work was supported in part by grants from the Research Grants Council (16100017 to HTM and 16102919 to RYCP), Health and Medical Research Fund (04153526 to HTM), and Innovation and Technology Commission (ITCPD/17-9 to RYCP).	Ausubel FM, 2012, CURRENT PROTOCOLS MO; Baek KH, 2005, ONCOL RES, V15, P161, DOI 10.3727/096504005776367906; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100; Chow JPH, 2011, MOL CELL BIOL, V31, P1478, DOI 10.1128/MCB.00891-10; Cui YP, 2010, J BIOL CHEM, V285, P32988, DOI 10.1074/jbc.M110.140905; Domenech E, 2015, NAT CELL BIOL, V17, P1304, DOI 10.1038/ncb3231; Eytan E, 2014, P NATL ACAD SCI USA, V111, P12019, DOI 10.1073/pnas.1412901111; Garnett MJ, 2009, NAT CELL BIOL, V11, P1363, DOI 10.1038/ncb1983; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gascoigne KE, 2009, J CELL SCI, V122, P2579, DOI 10.1242/jcs.039719; Hashimoto T, 2008, GENES CELLS, V13, P609, DOI 10.1111/j.1365-2443.2008.01192.x; Hashimoto T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018449; Hiruma Y, 2015, SCIENCE, V348, P1264, DOI 10.1126/science.aaa4055; Howell BJ, 2001, J CELL BIOL, V155, P1159, DOI 10.1083/jcb.200105093; Hsu SL, 2006, APOPTOSIS, V11, P765, DOI 10.1007/s10495-006-5880-x; Huang HC, 2009, CANCER CELL, V16, P347, DOI 10.1016/j.ccr.2009.08.020; Ji ZJ, 2015, SCIENCE, V348, P1260, DOI 10.1126/science.aaa4029; Kim M, 2005, MOL CELL BIOL, V25, P9232, DOI 10.1128/MCB.25.21.9232-9248.2005; Lee K, 2011, MOL BIOL CELL, V22, P2470, DOI 10.1091/mbc.E11-03-0228; Ma HT, 2007, NUCLEIC ACIDS RES, V35, DOI 10.1093/nar/gkl1109; Ma HT, 2018, CELL REP, V22, P1439, DOI 10.1016/j.celrep.2018.01.027; Ma HT, 2017, METHODS MOL BIOL, V1524, P189, DOI 10.1007/978-1-4939-6603-5_12; Ma HT, 2016, CELL REP, V14, P1086, DOI 10.1016/j.celrep.2016.01.001; Ma HT, 2012, J BIOL CHEM, V287, P21561, DOI 10.1074/jbc.M112.364356; Ma HT, 2011, J BIOL CHEM, V286, P13052, DOI 10.1074/jbc.M110.201897; Ma HT, 2009, MOL CELL BIOL, V29, P6500, DOI 10.1128/MCB.00669-09; Manchado E, 2010, CANCER CELL, V18, P641, DOI 10.1016/j.ccr.2010.10.028; Mapelli M, 2006, EMBO J, V25, P1273, DOI 10.1038/sj.emboj.7601033; Musacchio A, 2015, CURR BIOL, V25, pR1002, DOI 10.1016/j.cub.2015.08.051; Natsume T, 2016, CELL REP, V15, P210, DOI 10.1016/j.celrep.2016.03.001; Ng LY, 2019, CELL CYCLE, V18, P238, DOI 10.1080/15384101.2018.1563395; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Pesin JA, 2008, ANNU REV CELL DEV BI, V24, P475, DOI 10.1146/annurev.cellbio.041408.115949; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Riffell JL, 2011, MOL CANCER THER, V10, P839, DOI 10.1158/1535-7163.MCT-10-0909; Sakaue-Sawano A, 2008, CELL, V132, P487, DOI 10.1016/j.cell.2007.12.033; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Swe M, 2000, APOPTOSIS, V5, P29, DOI 10.1023/A:1009681408367; Wang KX, 2014, J BIOL CHEM, V289, P23928, DOI 10.1074/jbc.M114.585315; Wong PY, 2016, SCI REP-UK, V6, DOI 10.1038/srep22230; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158; Yang MJ, 2007, CELL, V131, P744, DOI 10.1016/j.cell.2007.08.048; Ye QZ, 2015, ELIFE, V4, DOI 10.7554/eLife.07367; Yu HT, 2006, J CELL BIOL, V173, P153, DOI 10.1083/jcb.200601172; Zeng X, 2010, CANCER CELL, V18, P382, DOI 10.1016/j.ccr.2010.08.010	46	10	10	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2819	2834		10.1038/s41388-020-1187-6	http://dx.doi.org/10.1038/s41388-020-1187-6		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32029899	Green Published, hybrid			2022-12-17	WOS:000511540800001
J	Saksouk, N; Hajdari, S; Perez, Y; Pratlong, M; Barrachina, C; Graber, C; Gregoire, D; Zavoriti, A; Sarrazin, A; Pirot, N; Noel, JY; Khellaf, L; Fabbrizio, E; Julien, E; Cammas, FM				Saksouk, Nehme; Hajdari, Shefqet; Perez, Yannick; Pratlong, Marine; Barrachina, Celia; Graber, Celine; Gregoire, Damien; Zavoriti, Aliki; Sarrazin, Amelie; Pirot, Nelly; Noel, Jean-Yohan; Khellaf, Lakhdar; Fabbrizio, Eric; Julien, Eric; Cammas, Florence M.			The mouse HP1 proteins are essential for preventing liver tumorigenesis	ONCOGENE			English	Article							HISTONE H3 LYSINE-9; REGULATE GENE-EXPRESSION; HEPATOCELLULAR-CARCINOMA; HETEROCHROMATIN; METHYLATION; METHYLTRANSFERASE; DEREGULATION; DROSOPHILA; TRIM24; LEADS	Chromatin organization is essential for appropriate interpretation of the genetic information. Here, we demonstrated that the chromatin-associated proteins HP1 are dispensable for hepatocytes survival but are essential within hepatocytes to prevent liver tumor development in mice with HP1 beta being pivotal in these functions. Yet, we found that the loss of HP1 per se is not sufficient to induce cell transformation but renders cells more resistant to specific stress such as the expression of oncogenes and thus in fine, more prone to cell transformation. Molecular characterization of HP1-Triple KO premalignant livers and BMEL cells revealed that HP1 are essential for the maintenance of heterochromatin organization and for the regulation of specific genes with most of them having well characterized functions in liver functions and homeostasis. We further showed that some specific retrotransposons get reactivated upon loss of HP1, correlating with overexpression of genes in their neighborhood. Interestingly, we found that, although HP1-dependent genes are characterized by enrichment H3K9me3, this mark does not require HP1 for its maintenance and is not sufficient to maintain gene repression in absence of HP1. Finally, we demonstrated that the loss of TRIM28 association with HP1 recapitulated several phenotypes induced by the loss of HP1 including the reactivation of some retrotransposons and the increased incidence of liver cancer development. Altogether, our findings indicate that HP1 proteins act as guardians of liver homeostasis to prevent tumor development by modulating multiple chromatin-associated events within both the heterochromatic and euchromatic compartments, partly through regulation of the corepressor TRIM28 activity.	[Saksouk, Nehme; Hajdari, Shefqet; Perez, Yannick; Zavoriti, Aliki; Pirot, Nelly; Noel, Jean-Yohan; Fabbrizio, Eric; Julien, Eric; Cammas, Florence M.] IRCM, F-34298 Montpellier, France; [Saksouk, Nehme; Hajdari, Shefqet; Perez, Yannick; Zavoriti, Aliki; Pirot, Nelly; Noel, Jean-Yohan; Fabbrizio, Eric; Julien, Eric; Cammas, Florence M.] INSERM, U1194, F-34298 Montpellier, France; [Saksouk, Nehme; Hajdari, Shefqet; Perez, Yannick; Zavoriti, Aliki; Pirot, Nelly; Noel, Jean-Yohan; Fabbrizio, Eric; Julien, Eric; Cammas, Florence M.] Univ Montpellier, F-34090 Montpellier, France; [Saksouk, Nehme; Hajdari, Shefqet; Perez, Yannick; Zavoriti, Aliki; Pirot, Nelly; Noel, Jean-Yohan; Khellaf, Lakhdar; Fabbrizio, Eric; Julien, Eric; Cammas, Florence M.] Inst Reg Canc Montpellier, F-34298 Montpellier, France; [Pratlong, Marine; Barrachina, Celia] Univ Montpellier, MGX, Biocampus Montpellier, CNRS,INSERM, Montpellier, France; [Graber, Celine; Sarrazin, Amelie] IGBMC, Illkirch Graffenstaden, France; [Gregoire, Damien; Fabbrizio, Eric; Julien, Eric; Cammas, Florence M.] CNRS, Route Mende, Montpellier, France; [Gregoire, Damien] Univ Montpellier, CNRS, Inst Genet Mol Montpellier, Montpellier, France; [Sarrazin, Amelie] Univ Montpellier, MRI, BioCampus Montpellier, CNRS,INSERM, Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Cammas, FM (corresponding author), IRCM, F-34298 Montpellier, France.; Cammas, FM (corresponding author), INSERM, U1194, F-34298 Montpellier, France.; Cammas, FM (corresponding author), Univ Montpellier, F-34090 Montpellier, France.; Cammas, FM (corresponding author), Inst Reg Canc Montpellier, F-34298 Montpellier, France.; Cammas, FM (corresponding author), CNRS, Route Mende, Montpellier, France.	Florence.cammas@inserm.fr	SAKSOUK, NEHME/ABA-4057-2021	SAKSOUK, NEHME/0000-0001-5592-6298; cammas, florence/0000-0003-4117-8182; JULIEN, ERIC/0000-0003-2976-666X	French National Research Agency [ANR-10-INBS-04]; Center National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (INSERM); University of Montpellier; Institut regional de Cancerologie de Montpellier (ICM); SIRIC Montpellier Cancer [INCa_Inserm_DGOS_12553]; Erasmus Ph.D. fellowship; Ministry of Education, Science and Technology of the Republic of Kosovo; ANR [ANR 2009 BLAN 021 91, ANR-16CE15-0018-03]; INCa [PLBIO13-146]; ARC [PJA20131200357]; La ligue Regionale contre le Cancer [128-R13021FF-RAB13006FFA]	French National Research Agency(French National Research Agency (ANR)); Center National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); Institut National de la Sante et de la Recherche Medicale (INSERM)(Institut National de la Sante et de la Recherche Medicale (Inserm)); University of Montpellier; Institut regional de Cancerologie de Montpellier (ICM); SIRIC Montpellier Cancer; Erasmus Ph.D. fellowship; Ministry of Education, Science and Technology of the Republic of Kosovo; ANR(French National Research Agency (ANR)); INCa(Institut National du Cancer (INCA) France); ARC(Australian Research Council); La ligue Regionale contre le Cancer	We thank P. Chambon, C. Sardet, T. Forne, D. Fisher, and C. Grimaud for helpful discussions and critical reading of the paper. We thank F. Bernex and L. LeCam, C. Keime, and B. Jost for fruitful discussions. We thank L. Papon, H. Fontaine, and C. Bonhomme for technical assistance and M. Oulad-Abdelghani and the IGBMC for the anti-HP1 and TRIM28 antibodies. We also thank the RHEM technical facility and particularly J. Simony for histological analysis and the IGBMC/ICS transgenic and animal facility for the initial establishment of the HP1 and TRIM28 mouse models. We thank C. Vincent and the IRCM animal core facility for the day to day care of the animal models. Finally, we thank S. Chamroeun for counting positive cells on TMA. We acknowledge the imaging facility MRI, member of the national infrastructure France-BioImaging and supported by the French National Research Agency (ANR-10-INBS-04, "Investments for the future"). This work was supported by funds from the Center National de la Recherche Scientifique (CNRS), the Institut National de la Sante et de la Recherche Medicale (INSERM), the University of Montpellier and the Institut regional de Cancerologie de Montpellier (ICM),) and SIRIC Montpellier Cancer, Grant INCa_Inserm_DGOS_12553. SH was funded by an Erasmus Ph.D. fellowship. We also thank the Ministry of Education, Science and Technology of the Republic of Kosovo for a scholarships to support SH. FC was supported by grants from ANR (ANR 2009 BLAN 021 91; ANR-16CE15-0018-03), INCa (PLBIO13-146), ARC (PJA20131200357), and La ligue Regionale contre le Cancer (128-R13021FF-RAB13006FFA). Sequencing was performed by the MGX facility. Montpellier, France.	Allan RS, 2012, NATURE, V487, P249, DOI 10.1038/nature11173; Bhattacharyya S, 2014, CURR DRUG METAB, V15, P719, DOI 10.2174/1389200215666141125121659; Bishayee A, 2014, ADV EXP MED BIOL, V816, P401, DOI 10.1007/978-3-0348-0837-8_16; Bojkowska K, 2012, HEPATOLOGY, V56, P1279, DOI 10.1002/hep.25767; Bosch-Presegue L, 2017, CELL REP, V21, P2048, DOI 10.1016/j.celrep.2017.10.092; Bregnard C, 2016, EBIOMEDICINE, V8, P184, DOI 10.1016/j.ebiom.2016.05.005; Bruix J, 2011, HEPATOLOGY, V53, P1020, DOI 10.1002/hep.24199; Brustel J, 2017, EMBO J, V36, P2726, DOI 10.15252/embj.201796541; Camacho OV, 2017, ELIFE, V6, DOI 10.7554/eLife.25293; Cammas F, 2000, DEVELOPMENT, V127, P2955; Cizkova K, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/656428; Del Campo JA, 2018, WORLD J HEPATOL, V10, P1, DOI 10.4254/wjh.v10.i1.1; Dialynas GK, 2008, MUTAT RES-FUND MOL M, V647, P13, DOI 10.1016/j.mrfmmm.2008.09.007; Dinant C, 2009, MOL CELL BIOL, V29, P6335, DOI 10.1128/MCB.01048-09; Du Q, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08302-1; Ecco G, 2017, DEVELOPMENT, V144, P2719, DOI 10.1242/dev.132605; Ecco G, 2016, DEV CELL, V36, P611, DOI 10.1016/j.devcel.2016.02.024; EISSENBERG JC, 1992, GENETICS, V131, P345; Eissenberg JC, 2014, TRENDS GENET, V30, P103, DOI 10.1016/j.tig.2014.01.002; Fan DNY, 2013, HEPATOLOGY, V57, P637, DOI 10.1002/hep.26083; Fanti L, 2008, CURR OPIN GENET DEV, V18, P169, DOI 10.1016/j.gde.2008.01.009; Fausto N, 2006, HEPATOLOGY, V43, pS45, DOI 10.1002/hep.20969; Guengerich FP, 2019, J BIOL CHEM, V294, P1671, DOI 10.1074/jbc.TM118.004144; Hardy T, 2016, GUT, V65, P1895, DOI 10.1136/gutjnl-2015-311292; Herquel B, 2013, NAT STRUCT MOL BIOL, V20, P339, DOI 10.1038/nsmb.2496; Herquel B, 2011, P NATL ACAD SCI USA, V108, P8212, DOI 10.1073/pnas.1101544108; Herzog M, 2011, DEV BIOL, V350, P548, DOI 10.1016/j.ydbio.2010.12.014; Huang CY, 2017, GENE DEV, V31, P241, DOI 10.1101/gad.292169.116; Jacobs FMJ, 2014, NATURE, V516, P242, DOI 10.1038/nature13760; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; Janssen A, 2018, ANNU REV CELL DEV BI, V34, P265, DOI 10.1146/annurev-cellbio-100617-062653; Jorgensen S, 2013, NUCLEIC ACIDS RES, V41, P2797, DOI 10.1093/nar/gkt012; Kato M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04132-9; Khetchoumian K, 2007, NAT GENET, V39, P1500, DOI 10.1038/ng.2007.15; Koschmann C, 2017, CANCER RES, V77, P227, DOI 10.1158/0008-5472.CAN-16-2301; Kuo LJ, 2008, IN VIVO, V22, P305; Kurinna S, 2011, INT J BIOCHEM CELL B, V43, P189, DOI 10.1016/j.biocel.2010.03.013; Lee DH, 2013, BIOCHEM BIOPH RES CO, V434, P820, DOI 10.1016/j.bbrc.2013.04.020; Lee Young-Ho, 2015, J Nat Sci, V1, pe127; Lehnertz B, 2003, CURR BIOL, V13, P1192, DOI 10.1016/S0960-9822(03)00432-9; Lomberk G, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-228; Mai S, 2019, GENE CHROMOSOME CANC, V58, P462, DOI 10.1002/gcc.22720; Matsui T, 2010, NATURE, V464, P927, DOI 10.1038/nature08858; Mattout A, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0760-8; Mirabella AC, 2016, CHROMOSOMA, V125, P75, DOI 10.1007/s00412-015-0530-0; Nishibuchi G, 2014, J BIOCHEM, V156, P11, DOI 10.1093/jb/mvu032; Niu ZS, 2016, WORLD J GASTROENTERO, V22, P9069, DOI 10.3748/wjg.v22.i41.9069; O'Geen H, 2007, PLOS GENET, V3, P916, DOI 10.1371/journal.pgen.0030089; Paik YH, 2014, ANTIOXID REDOX SIGN, V20, P2854, DOI 10.1089/ars.2013.5619; Park JW, 2014, BIOCHEM J, V464, P241, DOI 10.1042/BJ20140787; Piacentini L, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000670; Pogribny IP, 2006, CARCINOGENESIS, V27, P1180, DOI 10.1093/carcin/bgi364; Pogribny IP, 2014, CANCER LETT, V342, P223, DOI 10.1016/j.canlet.2012.01.038; Poleshko A, 2013, CELL REP, V5, P292, DOI 10.1016/j.celrep.2013.09.024; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Prakash K, 2018, BIOSYSTEMS, V164, P49, DOI 10.1016/j.biosystems.2017.11.005; Schott S, 2006, DEV BIOL, V298, P176, DOI 10.1016/j.ydbio.2006.06.039; Shi S, 2008, NAT CELL BIOL, V10, P491, DOI 10.1038/ncb1713; Strick-Marchand H, 2002, HEPATOLOGY, V36, P794, DOI 10.1053/jhep.2002.36123; Stunnenberg R, 2015, EMBO J, V34, P2789, DOI 10.15252/embj.201591320; Takaki A, 2015, WORLD J HEPATOL, V7, P968, DOI 10.4254/wjh.v7.i7.968; Towbin BD, 2012, CELL, V150, P934, DOI 10.1016/j.cell.2012.06.051; Vad-Nielsen J, 2015, CANCER BIOL THER, V16, P189, DOI 10.1080/15384047.2014.1001277; Vakoc CR, 2005, MOL CELL, V19, P381, DOI 10.1016/j.molcel.2005.06.011; Weisend CM, 2009, GENESIS, V47, P789, DOI 10.1002/dvg.20568; Wolf G, 2015, GENE DEV, V29, P538, DOI 10.1101/gad.252767.114; Yang P, 2017, TRENDS GENET, V33, P871, DOI 10.1016/j.tig.2017.08.006	67	10	10	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2020	39	13					2676	2691		10.1038/s41388-020-1177-8	http://dx.doi.org/10.1038/s41388-020-1177-8		FEB 2020	16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KX4EF	32020053	Green Submitted			2022-12-17	WOS:000511084200003
J	Clements, ME; Johnson, RW				Clements, Miranda E.; Johnson, Rachelle W.			PREX1 drives spontaneous bone dissemination of ER plus breast cancer cells	ONCOGENE			English	Article							RAC-GEF; RECEPTOR; METASTASIS; P-REX1; PHOSPHORYLATION; ACTIVATION; COMPLEXES; DORMANCY; PROGRAM; GTPASE	A significant proportion of breast cancer patients develop bone metastases, but the mechanisms regulating tumor cell dissemination from the primary site to the skeleton remain largely unknown. Using a novel model of spontaneous bone metastasis derived from human ER+ MCF7 cells, molecular profiling revealed increased PREX1 expression in a cell line established from bone-disseminated MCF7 cells (MCF7b), which were more migratory, invasive, and adhesive in vitro compared with parental MCF7 cells, and this phenotype was mediated by PREX1. MCF7b cells grew poorly in the primary tumor site when reinoculated in vivo, suggesting that these cells are primed to grow in the bone, and were enriched in skeletal sites of metastasis over soft tissue sites. Skeletal dissemination from the primary tumor was reversed with PREX1 knockdown, indicating that PREX1 is a key driver of spontaneous dissemination of tumor cells from the primary site to the bone marrow. In breast cancer patients, PREX1 levels are significantly increased in ER+ tumors and associated with invasive disease and distant metastasis. Together, these findings implicate PREX1 in spontaneous bone dissemination and provide a significant advance to the molecular mechanisms by which breast cancer cells disseminate from the primary tumor site to bone.	[Clements, Miranda E.; Johnson, Rachelle W.] Vanderbilt Univ, Program Canc Biol, Nashville, TN 37232 USA; [Clements, Miranda E.; Johnson, Rachelle W.] Vanderbilt Univ, Med Ctr, Dept Med, Vanderbilt Ctr Bone Biol,Div Clin Pharmacol, Nashville, TN 37232 USA; [Johnson, Rachelle W.] Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Johnson, RW (corresponding author), Vanderbilt Univ, Program Canc Biol, Nashville, TN 37232 USA.; Johnson, RW (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Vanderbilt Ctr Bone Biol,Div Clin Pharmacol, Nashville, TN 37232 USA.; Johnson, RW (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Clin Pharmacol, Nashville, TN 37232 USA.	rachelle.johnson@vumc.org	Clements, Miranda/AAE-6427-2019; Clements, Miranda/AAE-4756-2019	Johnson, Rachelle/0000-0003-2755-9851	Vanderbilt-Ingram Cancer Center [P30 CA68485]; Vanderbilt Digestive Disease Research Center [DK058404]; RPPA Core facility at MD Anderson Cancer Center (NCI) [CA16672]; NIH [R00CA194198, P30CA068485]	Vanderbilt-Ingram Cancer Center; Vanderbilt Digestive Disease Research Center; RPPA Core facility at MD Anderson Cancer Center (NCI); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors wish to acknowledge Mr. Joshua Johnson for histological processing and sectioning of tibiae. Flow Cytometry experiments were performed in the VMC Flow Cytometry Shared Resource, which is supported by the Vanderbilt-Ingram Cancer Center (P30 CA68485) and the Vanderbilt Digestive Disease Research Center (DK058404). The authors wish to acknowledge the expert technical support of the VANGARD core facilities. RPPA data were generated by the RPPA Core facility at MD Anderson Cancer Center (NCI #CA16672). RWJ and MEC are supported in part by and funding for experiments was provided by NIH award R00CA194198 (RWJ). Experiments performed at Vanderbilt were supported in part by scholarship funds from NIH award P30CA068485 Vanderbilt-Ingram Cancer Center Support Grant.	Albain K, 2012, LANCET, V379, P432, DOI 10.1016/S0140-6736(11)61625-5; ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849; Barrio-Real Laura, 2018, Oncotarget, V9, P28612, DOI 10.18632/oncotarget.25584; Bidwell BN, 2012, NAT MED, V18, P1224, DOI 10.1038/nm.2830; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Cheng WY, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005974; Colak D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063204; Coleman RE, 2001, CANCER TREAT REV, V27, P165, DOI 10.1053/ctrv.2000.0210; Coleman RE, 2006, CLIN CANCER RES, V12, p6243S, DOI 10.1158/1078-0432.CCR-06-0931; Dillon LM, 2015, ONCOGENE, V34, P3968, DOI 10.1038/onc.2014.328; Duplessis TT, 2011, ENDOCRINOLOGY, V152, P2517, DOI 10.1210/en.2010-1281; Ganapathy V, 2012, CLIN EXP METASTAS, V29, P493, DOI 10.1007/s10585-012-9466-4; Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088; Gawrzak S, 2018, NAT CELL BIOL, V20, P211, DOI 10.1038/s41556-017-0021-z; Gont A, 2017, ONCOTARGET, V8, P8559, DOI 10.18632/oncotarget.14348; Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302; Gustafsson KL, 2016, SCI REP-UK, V6, DOI 10.1038/srep29473; Han HH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000002909; Johnson RW, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00241; Johnson RW, 2016, NAT CELL BIOL, V18, P1078, DOI 10.1038/ncb3408; Johnson RW, 2015, PHARMACOL THERAPEUT, V150, P169, DOI 10.1016/j.pharmthera.2015.02.002; Johnson RW, 2011, CANCER RES, V71, P822, DOI 10.1158/0008-5472.CAN-10-2993; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Kazanietz MG, 2017, CANCER RES, V77, P5445, DOI 10.1158/0008-5472.CAN-17-1456; Kimbung S, 2014, MOL ONCOL, V8, P119, DOI 10.1016/j.molonc.2013.10.002; Kremer KN, 2017, BLOOD, V130, P982, DOI 10.1182/blood-2017-03-770982; La Rosa P, 2012, MOL ENDOCRINOL, V26, P762, DOI 10.1210/me.2011-1208; Lawson CD, 2018, J CELL BIOL, V217, P447, DOI 10.1083/jcb.201612069; Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260; Lindsay CR, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1560; Liu HJ, 2016, J BIOL CHEM, V291, P17258, DOI 10.1074/jbc.M116.743401; Ma XJ, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2222; Marotti JD, 2017, INT J BREAST CANCER, V2017, DOI 10.1155/2017/4537532; Montero JC, 2011, ONCOGENE, V30, P1059, DOI 10.1038/onc.2010.489; Neuzillet C, 2015, PHARMACOL THERAPEUT, V147, P22, DOI 10.1016/j.pharmthera.2014.11.001; Porter Andrew P, 2016, Small GTPases, V7, P123, DOI 10.1080/21541248.2016.1173767; Qin J, 2009, ONCOGENE, V28, P1853, DOI 10.1038/onc.2009.30; Rahman MS, 2015, BONE RES, V3, DOI 10.1038/boneres.2015.5; Ryan MB, 2016, MOL CANCER RES, V14, P1009, DOI 10.1158/1541-7786.MCR-16-0184; Savci-Heijink CD, 2015, BREAST CANCER RES TR, V150, P547, DOI 10.1007/s10549-015-3352-0; Schroder J, 2017, EUR J CANCER, V79, P139, DOI 10.1016/j.ejca.2017.03.031; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Sowder ME, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-32653-2; Thomas RJ, 1999, ENDOCRINOLOGY, V140, P4451, DOI 10.1210/en.140.10.4451; Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	47	10	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1318	1334		10.1038/s41388-019-1064-3	http://dx.doi.org/10.1038/s41388-019-1064-3			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636389	Green Accepted			2022-12-17	WOS:000526714600011
J	Yu, CY; Han, JX; Zhang, JF; Jiang, PL; Shen, CQ; Guo, FF; Tang, JY; Yan, TT; Tian, XL; Zhu, XQ; Ma, D; Hu, Y; Xie, YH; Du, W; Zhong, M; Chen, JX; Liu, Q; Sun, DF; Chen, YX; Zou, WP; Hong, J; Chen, HY; Fang, JY				Yu, Chen-Yang; Han, Ji-Xuan; Zhang, Junfang; Jiang, Penglei; Shen, Chaoqin; Guo, Fangfang; Tang, Jiayin; Yan, Tingting; Tian, Xianglong; Zhu, Xiaoqiang; Ma, Dan; Hu, Ye; Xie, Yuanhong; Du, Wan; Zhong, Ming; Chen, Jinxian; Liu, Qiang; Sun, Danfeng; Chen, Yingxuan; Zou, Weiping; Hong, Jie; Chen, Haoyan; Fang, Jing-Yuan			A 16q22.1 variant confers susceptibility to colorectal cancer as a distal regulator of ZFP90	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; RISK; EXPRESSION; LOCI; STATISTICS; RS6983267; GENETICS; BINDING; COHORTS	Genome-wide association studies (GWASs) implicate 16q22.1 locus in risk for colorectal cancer (CRC). However, the underlying oncogenic mechanisms remain unknown. Here, through comprehensive filtration, we prioritized rs7198799, a common SNP in the second intron of the CDH1, as the putative causal variant. In addition, we found an association of CRC-risk allele C of rs7198799 with elevated transcript level of biological plausible candidate gene ZFP90 via expression quantitative trait loci analysis. Mechanistically, causal variant rs7198799 resides in an enhancer element and remotely regulate ZFP90 expression by targeting the transcription factor NFATC2. Remarkably, CRISPR/Cas9-guided single-nucleotide editing demonstrated the direct effect of rs7198799 on ZFP90 expression and CRC cellular malignant phenotype. Furthermore, ZFP90 affects several oncogenic pathways, including BMP4, and promotes carcinogenesis in patients and in animal models with ZFP90 specific genetic manipulation. Taken together, these findings reveal a risk SNP-mediated long-range regulation on the NFATC2-ZFP90-BMP4 pathway underlying the initiation of CRC.	[Yu, Chen-Yang; Han, Ji-Xuan; Shen, Chaoqin; Guo, Fangfang; Tang, Jiayin; Yan, Tingting; Tian, Xianglong; Zhu, Xiaoqiang; Ma, Dan; Hu, Ye; Xie, Yuanhong; Du, Wan; Sun, Danfeng; Chen, Yingxuan; Hong, Jie; Chen, Haoyan; Fang, Jing-Yuan] Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Key Lab Gastroenterol & Hepatol,Minist Hlth,Div G, Shanghai Inst Digest Dis,Renji Hosp,Sch Med, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China; [Zhang, Junfang; Jiang, Penglei] Shanghai Ocean Univ, Coll Fishery & Life Sci, Minist Educ, Key Lab Aquacultural Resources & Utilizat, Shanghai 201306, Peoples R China; [Du, Wan; Sun, Danfeng; Zou, Weiping] Univ Michigan, Ctr Excellence Canc Immunol & Immunotherapy, Grad Programs Immunol & Canc Biol, Rogel Canc Ctr,Sch Med,Dept Surg, Ann Arbor, MI 48109 USA; [Du, Wan; Sun, Danfeng; Zou, Weiping] Univ Michigan, Ctr Excellence Canc Immunol & Immunotherapy, Grad Programs Immunol & Canc Biol, Rogel Canc Ctr,Sch Med,Dept Pathol, Ann Arbor, MI 48109 USA; [Zhong, Ming; Chen, Jinxian] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Div Gastrointestinal Surg, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China; [Liu, Qiang] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Pathol, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China	Shanghai Jiao Tong University; Shanghai Ocean University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Hong, J; Chen, HY; Fang, JY (corresponding author), Shanghai Jiao Tong Univ, State Key Lab Oncogenes & Related Genes, Key Lab Gastroenterol & Hepatol,Minist Hlth,Div G, Shanghai Inst Digest Dis,Renji Hosp,Sch Med, 145 Middle Shandong Rd, Shanghai 200001, Peoples R China.	jiehong97@sjtu.edu.cn; haoyanchen@sjtu.edu.cn; jingyuanfang@sjtu.edu.cn	jiang, penglei/GPX-0521-2022; Tang, Jiayin/AAJ-5473-2021	Tang, Jiayin/0000-0002-2510-6448	National Natural Science Foundation of China [81421001, 81530072, 81320108024, 81830081, 81522008, 81874159, 81871901, 31371273, 81770165]; Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning [201268]; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant [20152512, 20161309]; Chenxing Project of Shanghai Jiao Tong University; "Shu Guang" project [17CG17]; Program for Professor of Special Appointment (2015 Youth Eastern Scholar) at Shanghai Institutions of Higher Learning [QD2015003]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning; Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant; Chenxing Project of Shanghai Jiao Tong University; "Shu Guang" project(Chinese Academy of Sciences); Program for Professor of Special Appointment (2015 Youth Eastern Scholar) at Shanghai Institutions of Higher Learning	This work was supported by National Natural Science Foundation of China (81421001, 81530072, 81320108024, 81830081, 81522008, 81874159, 81871901, and 31371273,81770165), the Program for Professor of Special Appointment (Eastern Scholar No. 201268 and 2015 Youth Eastern Scholar No. QD2015003) at Shanghai Institutions of Higher Learning, the Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant (no. 20152512 and 20161309), the Chenxing Project of Shanghai Jiao Tong University to HC, and "Shu Guang" project (17CG17) to JH. Funding for open access charge: National Natural Science Foundation of China (81421001).	Abuli A, 2010, GASTROENTEROLOGY, V139, P788, DOI 10.1053/j.gastro.2010.05.072; Ardlie KG, 2015, SCIENCE, V348, P648, DOI 10.1126/science.1262110; Ay F, 2014, GENOME RES, V24, P999, DOI 10.1101/gr.160374.113; Azofeifa JG, 2018, GENOME RES, V28, P334, DOI 10.1101/gr.225755.117; Buckley M, 2016, NAT PROTOC, V11, P46, DOI 10.1038/nprot.2015.136; Carvajal-Carmona LG, 2011, HUM MOL GENET, V20, P2879, DOI 10.1093/hmg/ddr190; Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338; Claussnitzer M, 2014, CELL, V156, P343, DOI 10.1016/j.cell.2013.10.058; Cookson W, 2009, NAT REV GENET, V10, P184, DOI 10.1038/nrg2537; Couzin J, 2007, SCIENCE, V316, P820, DOI 10.1126/science.316.5826.820; de Volo CPB, 2012, GENE, V498, P328, DOI 10.1016/j.gene.2012.01.028; Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109; Du MM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157521; Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840; Gerlach K, 2012, CANCER RES, V72, P4340, DOI 10.1158/0008-5472.CAN-11-4155; Goring HHH, 2007, NAT GENET, V39, P1208, DOI 10.1038/ng2119; Hata L, 2011, J MOL CELL CARDIOL, V50, P972, DOI 10.1016/j.yjmcc.2011.01.017; Heintzman ND, 2009, CURR OPIN GENET DEV, V19, P541, DOI 10.1016/j.gde.2009.09.006; Houlston RS, 2008, NAT GENET, V40, P1426, DOI 10.1038/ng.262; Kilpinen H, 2013, SCIENCE, V342, P744, DOI 10.1126/science.1242463; Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059; Lai F, 2014, CURR OPIN GENET DEV, V25, P38, DOI 10.1016/j.gde.2013.11.017; Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201; Lu Y, 2019, GASTROENTEROLOGY, V156, P1455, DOI 10.1053/j.gastro.2018.11.066; Manolio TA, 2010, NEW ENGL J MED, V363, P166, DOI 10.1056/NEJMra0905980; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Montgomery SB, 2010, NATURE, V464, P773, DOI 10.1038/nature08903; Neufert C, 2007, NAT PROTOC, V2, P1998, DOI 10.1038/nprot.2007.279; Nishizaki SS, 2017, TRENDS GENET, V33, P34, DOI 10.1016/j.tig.2016.10.008; Peters U, 2015, GUT, V64, P1623, DOI 10.1136/gutjnl-2013-306705; Pomerantz MM, 2009, NAT GENET, V41, P882, DOI 10.1038/ng.403; Rockman MV, 2006, NAT REV GENET, V7, P862, DOI 10.1038/nrg1964; Schadt EE, 2005, NAT GENET, V37, P710, DOI 10.1038/ng1589; Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005; Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387; Smith CG, 2015, CLIN CANCER RES, V21, P3453, DOI 10.1158/1078-0432.CCR-14-3136; Spisak S, 2015, NAT MED, V21, P1357, DOI 10.1038/nm.3975; Stadhouders R, 2013, NAT PROTOC, V8, P509, DOI 10.1038/nprot.2013.018; Tuupanen S, 2009, NAT GENET, V41, P885, DOI 10.1038/ng.406	41	10	12	4	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1347	1360		10.1038/s41388-019-1055-4	http://dx.doi.org/10.1038/s41388-019-1055-4			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31641208	Green Published, hybrid			2022-12-17	WOS:000526714600013
J	Yu, Y; Chen, L; Zhao, GP; Li, HC; Guo, QD; Zhu, ST; Li, P; Min, L; Zhang, ST				Yu, Yang; Chen, Lei; Zhao, Guiping; Li, Hengcun; Guo, Qingdong; Zhu, Shengtao; Li, Peng; Min, Li; Zhang, Shutian			RBBP8/CtIP suppresses P21 expression by interacting with CtBP and BRCA1 in gastric cancer	ONCOGENE			English	Article							CELL-CYCLE; TRANSCRIPTIONAL COREPRESSOR; CTIP; REQUIRES; PHOSPHORYLATION; IDENTIFICATION; RECURRENCE; INHIBITORS; RESECTION; PATTERNS	RB Binding Protein 8 (RBBP8) was previously reported being involved in DNA double-strand break (DSB) repair in cancers. However, there is no systematic study about the specific functions and related mechanisms of RBBP8 in gastric carcinogenesis. Through immunohistochemistry staining of paired gastric cancer (GC) tissues, adjacent high-grade intraepithelial neoplasia (HGIEN) tissues, and non-cancerous tissues, we found RBBP8 expression was upregulated in both HGIEN and GC tissues. Functional experiments showed the knockdown of RBBP8 inhibited cell proliferation and colony formation ability. This is mainly achieved through the role of RBBP8 in facilitating G1/S transition and promoting Cyclin D1 and CDK4 level. Then the interaction between RBBP8, BRCA1, and CtBP was revealed by co-immunoprecipitation (co-IP) and immunofluorescence confocal imaging. Moreover, we found RBBP8 acted as an adapter in this complex and RBBP8 overexpression enhanced the nucleus location of BRCA1. RBBP8 overexpression could inhibit P21 expression and HDAC (histone deacetylase) inhibitor Trichostatin A (TSA) eliminated this effect. The HDAC activity of CtBP-RBBP8-BRCA1 complex was also further verified by HDAC activity assay. Through Chromatin immunoprecipitation (ChIP), we found RBBP8 could induce P21 promoter histone deacetylation and inhibit P21 transcription. In conclusion, we found RBBP8 could promote the G1/S transition of GC cells by inhibiting P21 level. Moreover, we revealed the chromatin modification role of RBBP8, which could suppress the histone acetylation level of P21 promoter by recruiting CtBP co-repressor complex to BRCA1 binding site.	[Yu, Yang; Chen, Lei; Zhao, Guiping; Li, Hengcun; Guo, Qingdong; Zhu, Shengtao; Li, Peng; Min, Li; Zhang, Shutian] Capital Med Univ, Beijing Key Lab Precanc Les Digest Dis, Dept Gastroenterol,Beijing Digest Dis Ctr, Beijing Friendship Hosp,Natl Clin Res Ctr Digest, Beijing 100050, Peoples R China	Capital Medical University	Min, L; Zhang, ST (corresponding author), Capital Med Univ, Beijing Key Lab Precanc Les Digest Dis, Dept Gastroenterol,Beijing Digest Dis Ctr, Beijing Friendship Hosp,Natl Clin Res Ctr Digest, Beijing 100050, Peoples R China.	minli@ccmu.edu.cn; zhangshutian@ccmu.edu.cn	Min, Li/AAG-2088-2021	Min, Li/0000-0001-9595-5536	National Natural Science Foundation of China [81702314]; Funding Program for Excellent Talents of Beijing [2017000021469G212]; Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals [XXZ0201]; Beijing Municipal Administration of Hospitals' Youth Programme [QML20180108]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Funding Program for Excellent Talents of Beijing; Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals; Beijing Municipal Administration of Hospitals' Youth Programme	This work was completely supported by grants from the National Natural Science Foundation of China (81702314); Funding Program for Excellent Talents of Beijing (2017000021469G212); The Digestive Medical Coordinated Development Center of Beijing Municipal Administration of Hospitals (XXZ0201); Beijing Municipal Administration of Hospitals' Youth Programme (QML20180108).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Bang Y, 2009, J CLIN ONCOL S, V27, P15; Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chen X, 2003, MOL BIOL CELL, V14, P3208, DOI 10.1091/mbc.E02-12-0833; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Chinnadurai G, 2009, CANCER RES, V69, P731, DOI 10.1158/0008-5472.CAN-08-3349; Chinnadurai G, 2009, ATLAS GENET CYTOGENE, V13, P282; Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960; D'Angelica M, 2004, ANN SURG, V240, P808, DOI 10.1097/01.sla.0000143245.28656.15; Deng CX, 2000, BIOESSAYS, V22, P728; Deroanne CF, 2002, ONCOGENE, V21, P427, DOI 10.1038/sj.onc.1205108; Gray S. G., 2001, Current Molecular Medicine (Hilversum), V1, P401, DOI 10.2174/1566524013363537; Huertas P, 2009, J BIOL CHEM, V284, P9558, DOI 10.1074/jbc.M808906200; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kim DH, 2003, J BIOCHEM MOL BIOL, V36, P110; Kuppuswamy M, 2008, MOL CELL BIOL, V28, P269, DOI 10.1128/MCB.01077-07; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Limbo O, 2007, MOL CELL, V28, P134, DOI 10.1016/j.molcel.2007.09.009; Liu D, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-1042-y; Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344; Lu ML, 2000, ONCOGENE, V19, P6351, DOI 10.1038/sj.onc.1204025; Miao L, 2014, J GASTROENTEROL, V19, P618; Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; Peterson SE, 2013, MOL CELL, V49, P657, DOI 10.1016/j.molcel.2012.11.020; Sartori AA, 2007, NATURE, V450, P509, DOI 10.1038/nature06337; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Wang YG, 2013, WORLD J GASTROENTERO, V19, P3226, DOI 10.3748/wjg.v19.i21.3226; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yoo CH, 2000, BRIT J SURG, V87, P236, DOI 10.1046/j.1365-2168.2000.01360.x; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Zhang QH, 2006, P NATL ACAD SCI USA, V103, P9029, DOI 10.1073/pnas.0603269103; Zhu GJ, 2014, EXP THER MED, V8, P1501, DOI 10.3892/etm.2014.1982	36	10	10	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	6					1273	1289		10.1038/s41388-019-1060-7	http://dx.doi.org/10.1038/s41388-019-1060-7			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	LE4UH	31636387				2022-12-17	WOS:000526714600008
J	Zhong, R; Tian, JB; Fu, MP; Ma, SM; Liu, L; Li, JY; Shen, N; Ke, JT; Yang, Y; Gong, YJ; Zhu, Y; Wang, Y; Gong, J; Chang, J; Lei, P; Cheng, X; Huang, K; Shen, GX; Miao, XP				Zhong, Rong; Tian, Jianbo; Fu, Mingpeng; Ma, Simin; Liu, Li; Li, Jiaoyuan; Shen, Na; Ke, Juntao; Yang, Yang; Gong, Yajie; Zhu, Ying; Wang, Ying; Gong, Jing; Chang, Jiang; Lei, Ping; Cheng, Xiang; Huang, Kun; Shen, Guanxin; Miao, Xiaoping			LINC01149 variant modulates MICA expression that facilitates hepatitis B virus spontaneous recovery but increases hepatocellular carcinoma risk	ONCOGENE			English	Article							GENOME-WIDE ASSOCIATION; GENETIC-VARIATIONS; LNCRNAS; CANCER; SUSCEPTIBILITY; SEQUENCE; DATABASE; LIGANDS; CATALOG; ASTHMA	Interpreting disease-causing variants, especially in noncoding regions by genome-wide association studies (GWAS), has become one of the most challenging and demanding tasks. We hypothesized that functional lncRNAs variants in GWAS-identified loci might alter expression level of genes associated with persistent HBV infection and hepatocellular carcinoma (HCC). Integrated bioinformatics approaches were used to prioritize potentially functional variants and a two-stage case-control study (2473 HBV positive HCC patients, 2248 persistent HBV carriers and 2294 spontaneously recovered subjects) was performed to assess the roles of these variants. The rs2844512 G > C variant in LINC01149 was identified to facilitate HBV spontaneous recovery (OR = 0.84, 95% CI = 0.77-0.92) but increase the risk of HCC (OR = 1.21, 95% CI = 1.11-1.32) in combined samples. Subsequent biological assays indicated this variant created a binding site for miR-128-3p and upregulated MICA expression by serving as a miRNA sponge, which might recruit NK-cells to lyse infected cells, but release highly soluble MICA by shedding to induce NK-cells exhaustion and tumor immune evasion. These findings highlight a regulatory circuit between LINC01149 and MICA, mediating by miR-128-3p, and the important role of upregulated MICA in conferring susceptibility to persistent HBV infection and HCC.	[Zhong, Rong; Tian, Jianbo; Li, Jiaoyuan; Ke, Juntao; Yang, Yang; Gong, Yajie; Zhu, Ying; Gong, Jing; Chang, Jiang; Miao, Xiaoping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan, Peoples R China; [Zhong, Rong; Tian, Jianbo; Li, Jiaoyuan; Ke, Juntao; Yang, Yang; Gong, Yajie; Zhu, Ying; Gong, Jing; Chang, Jiang; Miao, Xiaoping] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Educ,Key Lab Environm & Hlth, Wuhan, Peoples R China; [Fu, Mingpeng; Ma, Simin; Lei, Ping; Shen, Guanxin] Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Immunol, Wuhan, Peoples R China; [Liu, Li] Guangdong Pharmaceut Univ, Sch Publ Hlth, Dept Epidemiol & Biostat, Guangzhou, Peoples R China; [Shen, Na] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Lab Med, Wuhan, Peoples R China; [Wang, Ying] Wuhan Ctr Dis Prevent & Control, Dept Virol, Wuhan, Peoples R China; [Cheng, Xiang] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Hepatobiliary Surg, Wuhan, Peoples R China; [Huang, Kun] Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Pharm, Wuhan, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Guangdong Pharmaceutical University; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Miao, XP (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat, Wuhan, Peoples R China.; Miao, XP (corresponding author), Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Minist Educ,Key Lab Environm & Hlth, Wuhan, Peoples R China.	miaoxp@mail.hust.edu.cn	Chang, Jiang/AAP-6156-2020; miao, xiaoping/C-4336-2011; 李, 娇元/GVS-6952-2022	miao, xiaoping/0000-0002-6818-9722; Zhong, Rong/0000-0002-5060-895X; Tian, Jianbo/0000-0001-9493-694X; Ma, Simin/0000-0002-0218-2261	National Natural Science Foundation of China [NSFC-81874278, NSFC-81601839]; Wuhan Innovation Development Program of Young Professionals; National Program for Support of Top-notch Young Professionals	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Wuhan Innovation Development Program of Young Professionals; National Program for Support of Top-notch Young Professionals	We thank all the people who help us accomplish this research. This work was supported by National Natural Science Foundation of China (NSFC-81874278, NSFC-81601839), Wuhan Innovation Development Program of Young Professionals for YW and National Program for Support of Top-notch Young Professionals for XM.	Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Clifford RJ, 2010, HEPATOLOGY, V52, P2034, DOI 10.1002/hep.23943; Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111; Du Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10982; Dweep H, 2015, NAT METHODS, V12, P697, DOI 10.1038/nmeth.3485; El-Gazzar A, 2013, J IMMUNOL, V191, P1509, DOI 10.4049/jimmunol.1301071; Engreitz JM, 2016, NATURE, V539, P452, DOI 10.1038/nature20149; Freedman ML, 2011, NAT GENET, V43, P513, DOI 10.1038/ng.840; Gong J, 2018, ANN ONCOL, V29, P632, DOI 10.1093/annonc/mdx789; Gong J, 2015, NUCLEIC ACIDS RES, V43, pD181, DOI 10.1093/nar/gku1000; Groh V, 2002, NATURE, V419, P734, DOI 10.1038/nature01112; Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599; Holdenrieder S, 2006, INT J CANCER, V118, P684, DOI 10.1002/ijc.21382; Hu LM, 2012, HEPATOLOGY, V55, P1426, DOI 10.1002/hep.24799; Hu ZB, 2013, NAT GENET, V45, P1499, DOI 10.1038/ng.2809; Huang QY, 2015, J GENET GENOMICS, V42, P87, DOI 10.1016/j.jgg.2015.02.001; Ioannidis JPA, 2009, NAT REV GENET, V10, P318, DOI 10.1038/nrg2544; Jiang DK, 2015, HEPATOLOGY, V62, P118, DOI 10.1002/hep.27794; Jinushi M, 2008, P NATL ACAD SCI USA, V105, P1285, DOI 10.1073/pnas.0711293105; Joung J, 2017, NATURE, V548, P343, DOI 10.1038/nature23451; Khurana E, 2016, NAT REV GENET, V17, P93, DOI 10.1038/nrg.2015.17; Koguchi Y, 2015, CANCER RES, V75, P5084, DOI 10.1158/0008-5472.CAN-15-2303; Kumar V, 2011, NAT GENET, V43, P455, DOI 10.1038/ng.809; Li JY, 2018, CANCER EPIDEM BIOMAR, V27, P1029, DOI [10.1158/1055-9965.EPI-18-0099, 10.1158/1055-9965.epi-18-0099]; Liang TJ, 2009, HEPATOLOGY, V49, pS13, DOI 10.1002/hep.22881; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Nguyen VTT, 2009, J VIRAL HEPATITIS, V16, P453, DOI 10.1111/j.1365-2893.2009.01117.x; Paralkar VR, 2016, MOL CELL, V62, P104, DOI 10.1016/j.molcel.2016.02.029; Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209; Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10; Takagi A, 2017, BIOCHEM BIOPH RES CO, V492, P27, DOI 10.1016/j.bbrc.2017.08.045; Tan JY, 2015, GENOME RES, V25, P655, DOI 10.1101/gr.181974.114; Te Helen S, 2010, Clin Liver Dis, V14, P1, DOI 10.1016/j.cld.2009.11.009; Thakkinstian A, 2005, AM J EPIDEMIOL, V162, P201, DOI 10.1093/aje/kwi184; Thomson DW, 2016, NAT REV GENET, V17, P272, DOI 10.1038/nrg.2016.20; Tokar T, 2018, NUCLEIC ACIDS RES, V46, pD360, DOI 10.1093/nar/gkx1144; Trepo C, 2014, LANCET, V384, P2053, DOI 10.1016/S0140-6736(14)60220-8; Volders PJ, 2015, NUCLEIC ACIDS RES, V43, P4363, DOI 10.1093/nar/gkv295; Welter D, 2014, NUCLEIC ACIDS RES, V42, pD1001, DOI 10.1093/nar/gkt1229; Wu JD, 2004, J CLIN INVEST, V114, P560, DOI 10.1172/JCI200422206; Yang FQ, 2014, ACTAS UROL ESP, V38, P172, DOI 10.1016/j.acuro.2013.09.015; Zaritskaya L, 2010, EXPERT REV VACCINES, V9, P601, DOI [10.1586/erv.10.49, 10.1586/ERV.10.49]; Zhang F, 2015, INT IMMUNOPHARMACOL, V24, P110, DOI 10.1016/j.intimp.2014.11.005; Zhong R, 2013, CARCINOGENESIS, V34, P936, DOI 10.1093/carcin/bgs395; Zhu M, 2016, HUM MOL GENET, V25, P1225, DOI 10.1093/hmg/ddw003	46	10	11	1	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB	2020	39	9					1944	1956		10.1038/s41388-019-1117-7	http://dx.doi.org/10.1038/s41388-019-1117-7			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KP9VM	31754211				2022-12-17	WOS:000516579800009
J	Singh, K; Pruski, MA; Polireddy, K; Jones, NC; Chen, QZ; Yao, J; Dar, WA; McAllister, F; Ju, C; Eltzschig, HK; Younes, M; Moran, C; Karmouty-Quintana, H; Ying, HQ; Bailey, JM				Singh, Kanchan; Pruski, Melissa A.; Polireddy, Kishore; Jones, Neal C.; Chen, Qingzheng; Yao, Jun; Dar, Wasim A.; McAllister, Florencia; Ju, Cynthia; Eltzschig, Holger K.; Younes, Mamoun; Moran, Cesar; Karmouty-Quintana, Harry; Ying, Haoqiang; Bailey, Jennifer M.			Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer	ONCOGENE			English	Article							YES-ASSOCIATED PROTEIN; TUMOR-ASSOCIATED MACROPHAGES; HIPPO SIGNALING PATHWAY; ONCOGENIC KRAS; CLINICAL-IMPLICATIONS; MOUSE MODELS; GROWTH; YAP; MUTATIONS; PROLIFERATION	Non-small cell lung cancer remains a highly lethal malignancy. Using the tamoxifen inducible Hnf1b:CreER(T2) (H) transgenic mouse crossed to the LsL-Kras(G12D) (K) transgenic mouse, we recently discovered that an Hnf1b positive cell type in the lung is sensitive to adenoma formation when expressing a mutant Kras(G12D) allele. In these mice, we observe adenoma formation over a time frame of three to six months. To study specificity of the inducible Hnf1b:CreER(T2) in the lung, we employed lineage tracing using an mTmG (G) reporter allele. This technique revealed recombined, GFP+ cells were predominantly SPC+. We further employed this technique in HKG mice to determine Hnf1b+ cells give rise to adenomas that express SPC and TTF1. Review of murine lung tissue confirmed a diagnosis of adenoma and early adenocarcinoma, a pathologic subtype of non-small cell lung cancer. Our expanded mouse model revealed loss of Mst1/2 promotes aggressive lung adenocarcinoma and large-scale proteomic analysis revealed upregulation of PKM2 in the lungs of mice with genetic deletion of Mst1/2. PKM2 is a known metabolic regulator in proliferating cells and cancer. Using a human lung adenocarcinoma cell line, we show pharmacologic inhibition of Mst1/2 increases the abundance of PKM2, indicating genetic loss or pharmacologic inhibition of Mst1/2 directly modulates the abundance of PKM2. In conclusion, here we report a novel model of non-small cell lung cancer driven by a mutation in Kras and deletion of Mst1/2 kinases. Tumor development is restricted to a subset of alveolar type II cells expressing Hnf1b. Our data show loss of Mst1/2 regulates levels of a potent metabolic regulator, PKM2.	[Singh, Kanchan; Pruski, Melissa A.; Polireddy, Kishore; Jones, Neal C.; Chen, Qingzheng; Bailey, Jennifer M.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA; [Yao, Jun; Ying, Haoqiang] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Dar, Wasim A.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Div Immunol & Organ Transplantat, Houston, TX 77030 USA; [McAllister, Florencia] Univ Texas MD Anderson Canc Ctr, Dept Clin Canc Prevent, Houston, TX 77030 USA; [Ju, Cynthia; Eltzschig, Holger K.] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Anesthesiol, Houston, TX 77030 USA; [Younes, Mamoun] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Pathol, Houston, TX 77030 USA; [Moran, Cesar] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Karmouty-Quintana, Harry] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Biochem, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Bailey, JM (corresponding author), Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Internal Med, Div Gastroenterol Hepatol & Nutr, Houston, TX 77030 USA.	Jennifer.M.Bailey@uth.tmc.edu	Ying, Haoqiang/AAK-4325-2020; Karmouty-Quintana, Harry/ABC-9144-2020	Karmouty-Quintana, Harry/0000-0003-4753-9823; Younes, Mamoun/0000-0001-9618-3451; Dar, Wasim/0000-0001-8095-248X; Bailey-Lundberg, Jennifer/0000-0002-4750-106X	AACR/Pancreatic Cancer Action Network Pathway to Leadership Award; NIH [T35 DK007676-22]; National Institute of Health Grants [R01 DK097075, POI-HL114457, R01-HL109233, R01-DK109574, R01-HL119837, R01-HL133900]	AACR/Pancreatic Cancer Action Network Pathway to Leadership Award; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institute of Health Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We would like to thank Bingqian Hu and Junlan Zhang for assistance with lung perfusions. We also thank Naveen Manisundaram for intellectual insights and discussions. JMB is supported by the AACR/Pancreatic Cancer Action Network Pathway to Leadership Award. NCJ is supported by NIH T35 DK007676-22. HKE is supported by National Institute of Health Grants R01 DK097075, POI-HL114457, R01-HL109233, R01-DK109574, R01-HL119837, and R01-HL133900.	Abdulkareem FB, 2012, HISTOPATHOLOGY, V61, P74; Aguirre AJ, 2017, CANCER CELL, V32, P185, DOI 10.1016/j.ccell.2017.07.007; [Anonymous], CURR PROTOC PHARM; Bailey JM, 2016, ONCOGENE, V35, P4282, DOI 10.1038/onc.2015.441; Cancer Genome Atlas Research Network, 2018, Nature, V559, pE12, DOI [10.1038/nature13385, 10.1038/s41586-018-0228-6]; Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002; Chen HY, 2015, J CLIN ONCOL, V33, P2303, DOI 10.1200/JCO.2014.59.3590; Cinar B, 2007, EMBO J, V26, P4523, DOI 10.1038/sj.emboj.7601872; Ciuffreda L, 2014, CURR PHARM DESIGN, V20, P3944, DOI 10.2174/13816128113196660763; Clarke CN, 2017, ANN SURG ONCOL, V24, P4051, DOI 10.1245/s10434-017-6054-5; Collins MA, 2012, J CLIN INVEST, V122, P639, DOI 10.1172/JCI59227; Cooper WN, 2009, ONCOGENE, V28, P2988, DOI 10.1038/onc.2009.152; Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389; Creighton CJ, 2015, DRUG DES DEV THER, V9, P3519, DOI 10.2147/DDDT.S38375; De Vas MG, 2015, DEVELOPMENT, V142, P871, DOI 10.1242/dev.110759; Dong GC, 2016, ONCOL LETT, V11, P1980, DOI 10.3892/ol.2016.4168; Du Di, 2018, Oncotarget, V9, P19704, DOI 10.18632/oncotarget.24803; Ehmer U, 2016, MOL CANCER RES, V14, P127, DOI 10.1158/1541-7786.MCR-15-0305; Fritz JM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00587; Gao YJ, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5629; Gomez Daniel Richard, 2018, Oncotarget, V9, P14268, DOI 10.18632/oncotarget.24361; Guo LW, 2015, INT J ONCOL, V46, P1444, DOI 10.3892/ijo.2015.2877; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Hitosugi T, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000431; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI [10.3322/caac.20107, 10.3322/caac.20115]; Jeong H, 2019, CANCER RES, V79, P795, DOI 10.1158/0008-5472.CAN-18-2545; Johansson Leif, 2004, Ann Diagn Pathol, V8, P259, DOI 10.1016/j.anndiagpath.2004.07.001; Ju R, 2012, EUR J CANCER, V48, P1085, DOI 10.1016/j.ejca.2011.06.050; Kapoor A, 2014, CELL, V158, P185, DOI 10.1016/j.cell.2014.06.003; Kim HB, 2018, BMB REP, V51, P119, DOI 10.5483/BMBRep.2018.51.3.018; Kimmelman AC, 2015, CLIN CANCER RES, V21, P1828, DOI 10.1158/1078-0432.CCR-14-2425; Kwak I, 2004, ANNU REV PHYSIOL, V66, P647, DOI 10.1146/annurev.physiol.66.032102.134301; Li H, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.04.001; Li RZ, 2018, CHEM BIOL DRUG DES, V92, P1851, DOI 10.1111/cbdd.13354; Liu VM, 2015, BRAIN PATHOL, V25, P781, DOI 10.1111/bpa.12311; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; Lunt SY, 2015, MOL CELL, V57, P95, DOI 10.1016/j.molcel.2014.10.027; Ma YL, 2015, INT J CANCER, V137, P2275, DOI 10.1002/ijc.29073; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; Meuwissen R, 2005, GENE DEV, V19, P643, DOI 10.1101/gad.1284505; MILLER MS, 1994, CHEM RES TOXICOL, V7, P471, DOI 10.1021/tx00040a001; Moroishi T, 2015, NAT REV CANCER, V15, P73, DOI 10.1038/nrc3876; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Overholtzer M, 2006, P NATL ACAD SCI USA, V103, P12405, DOI 10.1073/pnas.0605579103; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Polireddy K, 2019, CANCER LETT, V453, P122, DOI 10.1016/j.canlet.2019.03.047; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Rizvi S, 2016, J BIOL CHEM, V291, P8031, DOI 10.1074/jbc.M115.698472; Romero R, 2017, NAT MED, V23, P1362, DOI 10.1038/nm.4407; Santinon G, 2016, TRENDS CELL BIOL, V26, P289, DOI 10.1016/j.tcb.2015.11.004; Schneider J, 2003, CANCER LETT, V193, P91, DOI 10.1016/S0304-3835(02)00720-6; Seidel C, 2007, MOL CARCINOGEN, V46, P865, DOI 10.1002/mc.20317; Steinhardt AA, 2008, HUM PATHOL, V39, P1582, DOI 10.1016/j.humpath.2008.04.012; Sutherland KD, 2014, P NATL ACAD SCI USA, V111, P4952, DOI 10.1073/pnas.1319963111; Teoh SL, 2017, CURR DRUG TARGETS, V18, P1880, DOI 10.2174/1389450117666160907153338; Tuveson DA, 1999, ONCOGENE, V18, P5318, DOI 10.1038/sj.onc.1203107; Vasan N, 2014, CLIN CANCER RES, V20, P3921, DOI 10.1158/1078-0432.CCR-13-1762; Wang R, 2011, LUNG CANCER, V74, P188, DOI 10.1016/j.lungcan.2011.04.009; Wang Y, 2010, CANCER SCI, V101, P1279, DOI 10.1111/j.1349-7006.2010.01511.x; Xu CM, 2013, CANCER GENE THER, V20, P453, DOI 10.1038/cgt.2013.40; Xu Chen, 2012, Chinese Journal of Pathology, V41, P667, DOI 10.3760/cma.j.issn.0529-5807.2012.10.005; Yang WW, 2013, CELL CYCLE, V12, P3154, DOI 10.4161/cc.26182; Ye S, 2016, PHARMACOL RES, V103, P270, DOI 10.1016/j.phrs.2015.11.025; Yeung B, 2016, INT J CANCER, V138, P533, DOI 10.1002/ijc.29457; Ying HQ, 2016, GENE DEV, V30, P355, DOI 10.1101/gad.275776.115; Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005; Zhang L, 2009, BIOINFORMATICS, V25, P650, DOI 10.1093/bioinformatics/btn663; Zhang X, 2011, ONCOGENE, V30, P2810, DOI 10.1038/onc.2011.8; Zhou DW, 2011, P NATL ACAD SCI USA, V108, pE1312, DOI 10.1073/pnas.1110428108; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026; Zhou JX, 2013, ANN ONCOL, V24, P1319, DOI 10.1093/annonc/mds626; Zou SS, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6696	73	10	11	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1152	1164		10.1038/s41388-019-1031-z	http://dx.doi.org/10.1038/s41388-019-1031-z			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31570790				2022-12-17	WOS:000511209700015
J	Taniue, K; Hayashi, T; Kamoshida, Y; Kurimoto, A; Takeda, Y; Negishi, L; Iwasaki, K; Kawamura, Y; Goshima, N; Akiyama, T				Taniue, Kenzui; Hayashi, Tomoatsu; Kamoshida, Yuki; Kurimoto, Akiko; Takeda, Yasuko; Negishi, Lumi; Iwasaki, Kei; Kawamura, Yoshifumi; Goshima, Naoki; Akiyama, Tetsu			UHRF1-KAT7-mediated regulation of TUSC3 expression via histone methylation/acetylation is critical for the proliferation of colon cancer cells	ONCOGENE			English	Article							DNA METHYLATION; PROMOTES PROLIFERATION; BURKITT-LYMPHOMA; STRUCTURAL BASIS; GENE-REGULATION; MYST FAMILY; STEM-CELLS; SRA DOMAIN; UHRF1; PROTEIN	The epigenetic factor UHRF1 regulates transcription by modulating DNA methylation and histone modification, and plays critical roles in proliferation, development, and tumorigenesis. Here, we show that Wnt/c-Myc signaling upregulates UHRF1, which in turn downregulates TUSC3, a candidate tumor suppressor gene that is frequently deleted or downregulated in several cancers. We also show that UHRF1-mediated downregulation of TUSC3 is required for the proliferation of colon cancer cells. Furthermore, we demonstrate that UHRF1 suppresses TUSC3 expression by interacting with methylated H3K14 and thereby suppressing the acetylation of H3K14 by the histone acetyltransferase KAT7. Our study provides evidence for the significance of UHRF1-KAT7-mediated regulation of histone methylation/acetylation in the proliferation of tumor cells and in a diverse set of biological processes controlled by Wnt/c-Myc signaling.	[Taniue, Kenzui; Hayashi, Tomoatsu; Kamoshida, Yuki; Kurimoto, Akiko; Takeda, Yasuko; Negishi, Lumi; Iwasaki, Kei; Akiyama, Tetsu] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo, Japan; [Kurimoto, Akiko] Daiichi Sankyo Co Ltd, Oncol Res Labs, Shinagawa Ku, Tokyo, Japan; [Kawamura, Yoshifumi] Japan Biol Informat Consortium, Koto Ku, Tokyo, Japan; [Goshima, Naoki] Natl Inst Adv Ind Sci & Technol, Mol Profiling Res Ctr Drug Discovery, Koto Ku, Tokyo, Japan	University of Tokyo; Daiichi Sankyo Company Limited; National Institute of Advanced Industrial Science & Technology (AIST)	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo, Japan.	akiyama@iam.u-tokyo.ac.jp		Negishi, Lumi/0000-0002-7297-0634	MEXT, Japan [17H06325, 15H01464]; Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development [17cm0106103h0002]	MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Project for Cancer Research and Therapeutic Evolution (P-CREATE) from the Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED))	This work was supported by Grants-in-Aid for Scientific Research on Innovative Areas (Integrative Analysis and Regulation of Cellular Diversity, no. 17H06325 and Non-coding RNA neo-taxonomy, no. 15H01464) from MEXT, Japan, and Project for Cancer Research and Therapeutic Evolution (P-CREATE, no. 17cm0106103h0002) from the Japan Agency for Medical Research and Development.	Ahuja N, 1998, CANCER RES, V58, P5489; Arbieva ZH, 2000, GENOME RES, V10, P244, DOI 10.1101/gr.10.2.244; Arita K, 2012, P NATL ACAD SCI USA, V109, P12950, DOI 10.1073/pnas.1203701109; Avvakumov GV, 2008, NATURE, V455, P822, DOI 10.1038/nature07273; Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Babbio F, 2012, ONCOGENE, V31, P4878, DOI 10.1038/onc.2011.641; Bashyam MD, 2005, NEOPLASIA, V7, P556, DOI 10.1593/neo.04586; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Birnbaum DJ, 2011, GENE CHROMOSOME CANC, V50, P456, DOI 10.1002/gcc.20870; Bookstein R, 1997, BRIT J UROL, V79, P28, DOI 10.1111/j.1464-410X.1997.tb00798.x; Bostick M, 2007, SCIENCE, V317, P1760, DOI 10.1126/science.1147939; Citterio E, 2004, MOL CELL BIOL, V24, P2526, DOI 10.1128/MCB.24.6.2526-2535.2004; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cooke SL, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-288; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003; De Vos M, 2014, J BIOL CHEM, V289, P16223, DOI 10.1074/jbc.M113.527424; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Fan XQ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0149028; Feng YP, 2016, EMBO J, V35, P176, DOI 10.15252/embj.201591293; Ferraro A, 2013, J CLIN ENDOCR METAB, V98, P2834, DOI 10.1210/jc.2012-2926; Gelato KA, 2014, MOL CELL, V54, P905, DOI 10.1016/j.molcel.2014.04.004; Georgiakaki M, 2006, MOL ENDOCRINOL, V20, P2122, DOI 10.1210/me.2005-0149; Goshima N, 2008, NAT METHODS, V5, P1011, DOI 10.1038/nmeth.1273; Hashimoto H, 2008, NATURE, V455, P826, DOI 10.1038/nature07280; Iizuka M, 2006, MOL CELL BIOL, V26, P1098, DOI 10.1128/MCB.26.3.1098-1108.2006; Jenkins Y, 2005, MOL BIOL CELL, V16, P5621, DOI 10.1091/mbc.E05-03-0194; Jiang ZF, 2016, TUMOR BIOL, V37, P12039, DOI 10.1007/s13277-016-5072-4; Kelleher DJ, 2003, MOL CELL, V12, P101, DOI 10.1016/S1097-2765(03)00243-0; Kress TR, 2015, NAT REV CANCER, V15, P593, DOI 10.1038/nrc3984; Kueh AJ, 2011, MOL CELL BIOL, V31, P845, DOI 10.1128/MCB.00159-10; Lalonde ME, 2014, GENE DEV, V28, P1029, DOI 10.1101/gad.236331.113; Lalonde ME, 2013, GENE DEV, V27, P2009, DOI 10.1101/gad.223396.113; Latham JA, 2007, NAT STRUCT MOL BIOL, V14, P1017, DOI 10.1038/nsmb1307; Li XL, 2012, ONCOL REP, V28, P375, DOI 10.3892/or.2012.1792; Margueron R, 2005, CURR OPIN GENET DEV, V15, P163, DOI 10.1016/j.gde.2005.01.005; Maruyama Y, 2012, NUCLEIC ACIDS RES, V40, pD924, DOI 10.1093/nar/gkr1188; Matys V, 2006, NUCLEIC ACIDS RES, V34, pD108, DOI 10.1093/nar/gkj143; Miotto B, 2008, GENE DEV, V22, P2633, DOI 10.1101/gad.1674108; Miotto B, 2006, MOL CELL BIOL, V26, P5969, DOI 10.1128/MCB.00696-06; Miotto B, 2010, MOL CELL, V37, P57, DOI 10.1016/j.molcel.2009.12.012; Mishima Y, 2011, BLOOD, V118, P2443, DOI 10.1182/blood-2011-01-331892; Mohorko E, 2014, STRUCTURE, V22, P590, DOI 10.1016/j.str.2014.02.013; Mohorko E, 2011, J INHERIT METAB DIS, V34, P869, DOI 10.1007/s10545-011-9337-1; Nishiyama A, 2013, NATURE, V502, P249, DOI 10.1038/nature12488; Pils D, 2005, CANCER-AM CANCER SOC, V104, P2417, DOI 10.1002/cncr.21538; Pils D, 2013, CANCER-AM CANCER SOC, V119, P946, DOI 10.1002/cncr.27850; Pronobis MI, 2012, CURR BIOL, V22, pR137, DOI 10.1016/j.cub.2012.01.002; Qin WH, 2011, J CELL BIOCHEM, V112, P439, DOI 10.1002/jcb.22998; Quenneville S, 2011, MOL CELL, V44, P361, DOI 10.1016/j.molcel.2011.08.032; Rolando M, 2013, CELL HOST MICROBE, V13, P395, DOI 10.1016/j.chom.2013.03.004; Sabatino L, 2012, ONCOGENE, V31, P5061, DOI 10.1038/onc.2012.3; Saksouk N, 2009, MOL CELL, V33, P257, DOI 10.1016/j.molcel.2009.01.007; Sapountzi V, 2011, CELL MOL LIFE SCI, V68, P1147, DOI 10.1007/s00018-010-0599-9; Sharif J, 2007, NATURE, V450, P908, DOI 10.1038/nature06397; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Taniue K, 2016, P NATL ACAD SCI USA, V113, P12739, DOI 10.1073/pnas.1605938113; Taniue K, 2016, P NATL ACAD SCI USA, V113, P1273, DOI 10.1073/pnas.1500992113; Taniue K, 2011, EMBO REP, V12, P682, DOI 10.1038/embor.2011.81; TAUB R, 1982, P NATL ACAD SCI-BIOL, V79, P7837, DOI 10.1073/pnas.79.24.7837; Unoki M, 2010, BRIT J CANCER, V103, P217, DOI 10.1038/sj.bjc.6605717; Unoki M, 2009, BRIT J CANCER, V101, P98, DOI 10.1038/sj.bjc.6605123; Vanhara P, 2013, INT J ONCOL, V42, P1383, DOI 10.3892/ijo.2013.1824; Voss AK, 2009, BIOESSAYS, V31, P1050, DOI 10.1002/bies.200900051; Walczak EM, 2014, MOL ENDOCRINOL, V28, P1471, DOI 10.1210/me.2014-1060; Zhang Y, 2014, CANCER EPIDEM BIOMAR, V23, P2019, DOI 10.1158/1055-9965.EPI-13-0994; Zong HL, 2005, FEBS LETT, V579, P3579, DOI 10.1016/j.febslet.2005.05.039	69	10	10	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	5					1018	1030		10.1038/s41388-019-1032-y	http://dx.doi.org/10.1038/s41388-019-1032-y			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KI2VY	31582837				2022-12-17	WOS:000511209700005
J	Wang, YN; Lu, YX; Liu, J; Jin, Y; Bi, HC; Zhao, Q; Liu, ZX; Li, YQ; Hu, JJ; Sheng, H; Jiang, YM; Zhang, C; Tian, F; Chen, Y; Pan, ZZ; Chen, G; Zeng, ZL; Liu, KY; Ogasawara, M; Yun, JP; Ju, HQ; Feng, JX; Xie, D; Gao, S; Jia, WH; Kopetz, S; Xu, RH; Wang, F				Wang, Ying-Nan; Lu, Yun-Xin; Liu, Jie; Jin, Ying; Bi, Hui-Chang; Zhao, Qi; Liu, Ze-Xian; Li, Ying-Qin; Hu, Jia-Jia; Sheng, Hui; Jiang, Yi-Ming; Zhang, Chao; Tian, Feng; Chen, Yang; Pan, Zhi-Zhong; Chen, Gong; Zeng, Zhao-Lei; Liu, Kai-Yan; Ogasawara, Marcia; Yun, Jin-Ping; Ju, Huai-Qiang; Feng, Jian-Xiong; Xie, Dan; Gao, Song; Jia, Wei-Hua; Kopetz, Scott; Xu, Rui-Hua; Wang, Feng			AMPK alpha 1 confers survival advantage of colorectal cancer cells under metabolic stress by promoting redox balance through the regulation of glutathione reductase phosphorylation	ONCOGENE			English	Article							ACTIVATED PROTEIN-KINASE; NEGATIVE REGULATOR; COLON-CANCER; AMPK; GROWTH; EXPRESSION; NUTRIENT; RECEPTOR; GENE	Patients with stage II or III colorectal cancer (CRC) exhibit various clinical outcomes after radical treatments. The 5-year survival rate was between 50 and 87%. However, the underlying mechanisms of the variation remain unclear. Here we show that AMPK alpha 1 is overexpressed in CRC patient specimens and the high expression is correlated with poor patient survival. We further reveal a previously unrecognized function of AMPK alpha 1, which maintains high level of reduced glutathione to keep reduction-oxidation reaction (redox) homeostasis under stress conditions, thus promoting CRC cell survival under metabolic stress in vitro and enhancing tumorigenesis in vivo. Mechanistically, AMPK alpha 1 regulate the glutathione reductase (GSR) phosphorylation possibly through residue Thr507 which enhances its activity. Suppression of AMPK alpha 1 by using nano-sized polymeric vector induces a favorable therapeutic effect, especially when in combination with oxaliplatin. Our study uncovers a novel function of AMPK alpha 1 in redox regulation and identifies a promising therapeutic strategy for treatment of CRC.	[Wang, Ying-Nan; Lu, Yun-Xin; Jin, Ying; Zhao, Qi; Liu, Ze-Xian; Hu, Jia-Jia; Sheng, Hui; Zhang, Chao; Chen, Yang; Zeng, Zhao-Lei; Liu, Kai-Yan; Yun, Jin-Ping; Ju, Huai-Qiang; Feng, Jian-Xiong; Xie, Dan; Gao, Song; Jia, Wei-Hua; Xu, Rui-Hua; Wang, Feng] Sun Yat Sen Univ, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Wang, Ying-Nan; Lu, Yun-Xin; Jin, Ying; Zhao, Qi; Liu, Ze-Xian; Hu, Jia-Jia; Sheng, Hui; Zhang, Chao; Chen, Yang; Pan, Zhi-Zhong; Chen, Gong; Zeng, Zhao-Lei; Liu, Kai-Yan; Yun, Jin-Ping; Ju, Huai-Qiang; Feng, Jian-Xiong; Xie, Dan; Gao, Song; Jia, Wei-Hua; Xu, Rui-Hua; Wang, Feng] Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China; [Liu, Jie; Li, Ying-Qin] Sun Yat Sen Univ, Sch Engn, Dept Biomed Engn, Guangzhou 510006, Guangdong, Peoples R China; [Jin, Ying; Xu, Rui-Hua; Wang, Feng] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China; [Bi, Hui-Chang; Jiang, Yi-Ming] Sun Yat Sen Univ, Sch Pharmaceut Sci, Guangzhou 510006, Guangdong, Peoples R China; [Tian, Feng; Kopetz, Scott] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA; [Pan, Zhi-Zhong; Chen, Gong] Sun Yat Sen Univ, Canc Ctr, Dept Colorectal Surg, Guangzhou 510060, Guangdong, Peoples R China; [Ogasawara, Marcia] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center; Sun Yat Sen University; University of Texas System; UTMD Anderson Cancer Center	Xu, RH; Wang, F (corresponding author), Sun Yat Sen Univ, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.; Xu, RH; Wang, F (corresponding author), Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China.; Xu, RH; Wang, F (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, Guangzhou 510060, Guangdong, Peoples R China.; Kopetz, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.	skopetz@mdanderson.org; xurh@sysucc.org.cn; wangfeng@sysucc.org.cn	Chen, Yang/AFL-4729-2022; xu, rui/GRX-5734-2022; Kopetz, Scott/AAC-1387-2019; Liu, Zexian/D-1153-2011; Xu, Rui-Hua/AAW-4766-2021; Chen, Yang/L-7304-2018	Kopetz, Scott/0000-0001-9647-3416; Liu, Zexian/0000-0001-9698-0610; Xu, Rui-Hua/0000-0001-9771-8534; Chen, Yang/0000-0001-7661-5923; Gao, Song/0000-0001-7427-6681	National Key Research and Development Program of China [2017YFC1308900, 2018YFC1313300]; Natural Science Foundation of Guangdong Province [2014A030312015, 2017A030313485]; National Natural Science Foundation of China [81872011, 81572392]; Science and Technology Program of Guangdong [2019B020227002]; Science and Technology Program of Guangzhou [201904020046, 201803040019, 201704020228]; Guangzhou Health and Medical Collaborative Innovation Project [201704020220]; Sun Yat-sen University Clinical Research 5010 Program [2018014]	National Key Research and Development Program of China; Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Program of Guangdong; Science and Technology Program of Guangzhou; Guangzhou Health and Medical Collaborative Innovation Project; Sun Yat-sen University Clinical Research 5010 Program	This study was supported, in part, by the National Key Research and Development Program of China (2017YFC1308900, 2018YFC1313300), Natural Science Foundation of Guangdong Province (2014A030312015, 2017A030313485); National Natural Science Foundation of China (81872011, 81572392); Science and Technology Program of Guangdong (2019B020227002), Science and Technology Program of Guangzhou (201904020046, 201803040019, 201704020228), Guangzhou Health and Medical Collaborative Innovation Project (201704020220), and the Sun Yat-sen University Clinical Research 5010 Program (2018014). FW is the Young Physician Scientist Program of Sun Yat-sen University Cancer Center.	[Anonymous], 2013, Cancer Discov, V3, pOF15, DOI 10.1158/2159-8290.CD-RW2013-018; Bhandaru M, 2014, J INVEST DERMATOL, V134, P1763, DOI 10.1038/jid.2014.26; Bi HC, 2014, CARCINOGENESIS, V35, P2264, DOI 10.1093/carcin/bgu174; Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9; Chen DL, 2014, HEPATOLOGY, V60, P598, DOI 10.1002/hep.27118; Chen WQ, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0042-6; Chiu YC, 2009, CARCINOGENESIS, V30, P1651, DOI 10.1093/carcin/bgp156; Faubert B, 2015, CANCER LETT, V356, P165, DOI 10.1016/j.canlet.2014.01.018; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Fu X, 2013, MOL CELL BIOL, V33, P4517, DOI 10.1128/MCB.01078-13; Goh V, 2012, J NUCL MED, V53, P687, DOI 10.2967/jnumed.111.098525; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hari DM, 2013, J AM COLL SURGEONS, V217, P181, DOI 10.1016/j.jamcollsurg.2013.04.018; Hoffman NJ, 2015, CELL METAB, V22, P922, DOI 10.1016/j.cmet.2015.09.001; Huang FY, 2006, GYNECOL ONCOL, V103, P219, DOI 10.1016/j.ygyno.2006.02.028; Jeon SM, 2015, ARCH PHARM RES, V38, P346, DOI 10.1007/s12272-015-0549-z; Jeon Sang-Min, 2012, Cell Logist, V2, P197; Jeon SM, 2012, NATURE, V485, P661, DOI 10.1038/nature11066; Ju HQ, 2016, J PINEAL RES, V60, P27, DOI 10.1111/jpi.12285; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Lee YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078709; Li M, 2005, WORLD J GASTROENTERO, V11, P4685, DOI 10.3748/wjg.v11.i30.4685; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005; Ma MZ, 2015, CANCER LETT, V368, P88, DOI 10.1016/j.canlet.2015.07.031; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275; Phoenix Kathryn N, 2012, Genes Cancer, V3, P51, DOI 10.1177/1947601912452883; Saito Y, 2015, CELL STEM CELL, V17, P585, DOI 10.1016/j.stem.2015.08.019; Santoro V, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv394; Schreuders EH, 2015, GUT, V64, P1637, DOI 10.1136/gutjnl-2014-309086; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2015, CELL STEM CELL, V17, P503, DOI 10.1016/j.stem.2015.10.007; Sung JJY, 2015, GUT, V64, P121, DOI 10.1136/gutjnl-2013-306503; Svensson RU, 2012, NATURE, V485, P590, DOI 10.1038/485590a; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Yu K, 2019, NUCLEIC ACIDS RES, V47, pD451, DOI 10.1093/nar/gky1052; Yuan SQ, 2015, STEM CELL RES THER, V6, DOI 10.1186/s13287-015-0174-2; Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004; Zeng ZL, 2014, CLIN CANCER RES, V20, P1042, DOI 10.1158/1078-0432.CCR-13-0171; Zhao G, 2013, MOL CANCER THER, V12, P83, DOI 10.1158/1535-7163.MCT-12-0534-T; Zhou Q, 2015, CHIN J CANCER, V34, P1, DOI 10.1186/s40880-015-0026-6	43	10	10	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2020	39	3					637	650		10.1038/s41388-019-1004-2	http://dx.doi.org/10.1038/s41388-019-1004-2			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	KG1RJ	31530934	Green Published, hybrid			2022-12-17	WOS:000509718300011
J	Wang, J; Li, N; Huang, ZB; Fu, S; Yu, SM; Fu, YM; Zhou, PC; Chen, RC; Zhou, RR; Huang, Y; Hu, XW; Fan, XG				Wang, Juan; Li, Ning; Huang, Ze-Bing; Fu, Sha; Yu, Song-Man; Fu, Yong-Ming; Zhou, Peng-Cheng; Chen, Ruo-Chan; Zhou, Rong-Rong; Huang, Yan; Hu, Xing-Wang; Fan, Xue-Gong			HBx regulates transcription factor PAX8 stabilization to promote the progression of hepatocellular carcinoma	ONCOGENE			English	Article							VIRUS X PROTEIN; AURORA KINASE; UBIQUITIN; DEGRADATION; SKP2; MYC; PHOSPHORYLATION; INHIBITION; EXPRESSION; STABILITY	Transcription factor PAX8 expression is upregulated in several types of cancers. However, little is known about the function of PAX8 in the progression of hepatoma and its regulatory mechanisms. Here, we show that PAX8 silencing inhibits the proliferation and clonogenicity of hepatoma cells and its growth in vivo. The HBV X protein (HBx) does not directly interacts, but stabilizes PAX8 by inhibiting proteasome-dependent ubiquitination and degradation. Furthermore, the E3 ubiquitin ligase complex component Skp2 through its LRR domain directly interacts with the Prd domain of PAX8 and targets PAX8 by recognizing its lysine 275 for ubiquitination and degradation in hepatoma cells. In addition, HBx directly interacts and is colocalized with Skp2 to inhibit its recognition and subsequent ubiquitination and degradation of PAX8 in hepatoma cells. Moreover, HBx upregulates the expression and phosphorylation of Aurora A, a serine-threonine kinase, which interacts with and phosphorylates PAX8 at S209 and T277, compromising the Skp2-recognized PAX8 ubiquitination and destabilization. Thus, HBx stabilizes PAX8 protein by inhibiting the Skp2 targeted PAX8 ubiquitination and enhancing the Aurora A-mediated its phosphorylation, contributing to the progression of hepatoma. Our findings suggest that PAX8 may a new target for design of therapies and uncover new insights into the pathogenesis of hepatoma.	[Wang, Juan; Huang, Ze-Bing; Fu, Sha; Yu, Song-Man; Fu, Yong-Ming; Zhou, Peng-Cheng; Chen, Ruo-Chan; Zhou, Rong-Rong; Huang, Yan; Hu, Xing-Wang; Fan, Xue-Gong] Cent S Univ, Xiangya Hosp, Dept Infect Dis, Changsha, Hunan, Peoples R China; [Wang, Juan; Huang, Ze-Bing; Fu, Sha; Yu, Song-Man; Fu, Yong-Ming; Zhou, Peng-Cheng; Chen, Ruo-Chan; Zhou, Rong-Rong; Huang, Yan; Hu, Xing-Wang; Fan, Xue-Gong] Key Lab Viral Hepatitis, Changsha, Hunan, Peoples R China; [Li, Ning] Cent S Univ, Xiangya Hosp, Dept Blood Transfus, Changsha, Hunan, Peoples R China	Central South University; Central South University	Hu, XW; Fan, XG (corresponding author), Cent S Univ, Xiangya Hosp, Dept Infect Dis, Changsha, Hunan, Peoples R China.; Hu, XW; Fan, XG (corresponding author), Key Lab Viral Hepatitis, Changsha, Hunan, Peoples R China.	lebithu@csu.edu.cn; xgfan@hotmail.com	Hu, Xingwang/ABG-6400-2021	Fu, Sha/0000-0001-7465-4929	International Scientific and Technology Cooperation Program of China [2015DFA31490]; National Natural Sciences Foundation of China [81700561, 81873574, 81402623]; National Science and Technology Major Project of China [2017YFC0908104, 2018ZX10732202]; Independent Exploration and Innovation Project of Graduate Student of Central South University [2016zzts519]	International Scientific and Technology Cooperation Program of China; National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); National Science and Technology Major Project of China; Independent Exploration and Innovation Project of Graduate Student of Central South University	This work was supported by grant from International Scientific and Technology Cooperation Program of China (2015DFA31490), grant from National Natural Sciences Foundation of China (No. 81700561, No. 81873574, No. 81402623), the National Science and Technology Major Project of China (2017YFC0908104, 2018ZX10732202) and Independent Exploration and Innovation Project of Graduate Student of Central South University (No. 2016zzts519).	Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492; Brockmann M, 2016, CANCER CELL, V30, P357, DOI 10.1016/j.ccell.2016.07.002; Campagnolo M, 2007, J BIOMOL STRUCT DYN, V24, P429, DOI 10.1080/07391102.2007.10507131; Chai HJ, 2017, ONCOL LETT, V14, P5871, DOI 10.3892/ol.2017.6949; Chen L, 2014, KAOHSIUNG J MED SCI, V30, P181, DOI 10.1016/j.kjms.2013.07.002; Chen RC, 2017, WORLD J GASTROENTERO, V23, P1787, DOI 10.3748/wjg.v23.i10.1787; de Cristofaro T, 2009, J MOL ENDOCRINOL, V42, P35, DOI 10.1677/JME-08-0100; Decorsiere A, 2016, NATURE, V531, P386, DOI 10.1038/nature17170; Delogu S, 2015, ONCOTARGET, V6, P2222, DOI 10.18632/oncotarget.2945; Di Palma T, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.262; Ding FB, 2014, FRONT BIOSCI-LANDMRK, V19, P886, DOI 10.2741/4254; Gao Y, 2017, HEPATOLOGY, V66, P1413, DOI 10.1002/hep.29316; Ghannam-Shahbari D, 2018, ONCOGENE, V37, P2213, DOI 10.1038/s41388-017-0040-z; Gong J, 2018, ONCOL LETT, V15, P8891, DOI 10.3892/ol.2018.8500; Hoeck JD, 2010, NAT NEUROSCI, V13, P1365, DOI 10.1038/nn.2644; Hou DS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0823-3; Hung N, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-159; Hunter T, 2007, MOL CELL, V28, P730, DOI 10.1016/j.molcel.2007.11.019; Jacobsen A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24982-z; Jamal A, 2015, CELL CYCLE, V14, P2688, DOI 10.1080/15384101.2015.1056946; Kalra N, 2006, FEBS LETT, V580, P431, DOI 10.1016/j.febslet.2005.12.034; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kivinummi K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-18210-3; Lee S, 2016, ONCOGENE, V35, P1857, DOI 10.1038/onc.2015.251; Levrero M, 2016, J HEPATOL, V64, pS84, DOI 10.1016/j.jhep.2016.02.021; Li CG, 2011, ONCOGENE, V30, P4824, DOI 10.1038/onc.2011.190; Li J, 2017, ONCOTARGET, V8, P96027, DOI 10.18632/oncotarget.21630; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; Liu XJ, 2015, BIOCHEM BIOPH RES CO, V459, P214, DOI 10.1016/j.bbrc.2015.02.060; Liu ZG, 2017, EUR J CELL BIOL, V96, P695, DOI 10.1016/j.ejcb.2017.07.004; Llovet JM, 2018, NAT REV CLIN ONCOL, V15, P599, DOI 10.1038/s41571-018-0073-4; Lu LF, 2015, MOL CARCINOGEN, V54, P1467, DOI 10.1002/mc.22223; Ma SJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173700; Mattiroli F, 2014, NAT STRUCT MOL BIOL, V21, P308, DOI 10.1038/nsmb.2792; Minor MM, 2014, VIRUSES-BASEL, V6, P4683, DOI 10.3390/v6114683; Murphy CM, 2016, CELL REP, V16, P2846, DOI 10.1016/j.celrep.2016.08.026; Nandi D, 2006, J BIOSCIENCES, V31, P137, DOI 10.1007/BF02705243; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; POLEEV A, 1992, DEVELOPMENT, V116, P611; Suzuki A, 2015, ENDOCR J, V62, P991, DOI 10.1507/endocrj.EJ15-0226; Varshavsky A, 2017, ANNU REV BIOCHEM, V86, P123, DOI 10.1146/annurev-biochem-061516-044859; VerPlank JJS, 2017, BIOCHEM J, V474, P3355, DOI 10.1042/BCJ20160809; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wang J, 2016, GASTROENT RES PRACT, V2016, DOI 10.1155/2016/8780695; Wang LY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0830-3; Wang ZW, 2012, BBA-REV CANCER, V1825, P11, DOI 10.1016/j.bbcan.2011.09.002; Xu QD, 2019, ONCOL RES, V27, P509, DOI 10.3727/096504018X15278771272963; ZANNINI M, 1992, MOL CELL BIOL, V12, P4230, DOI 10.1128/MCB.12.9.4230; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	49	10	11	2	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2019	38	40					6696	6710		10.1038/s41388-019-0907-2	http://dx.doi.org/10.1038/s41388-019-0907-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	JC0EY	31391550	hybrid			2022-12-17	WOS:000488953500004
J	Sinha, KM; Bagheri-Yarmand, R; Lahiri, S; Lu, Y; Zhang, M; Amra, S; Rizvi, Y; Wan, XH; Navone, N; Ozpolat, B; Logothetis, C; Gagel, RF; Huard, J				Sinha, Krishna M.; Bagheri-Yarmand, Rozita; Lahiri, Sharmistha; Lu, Yue; Zhang, Miao; Amra, Sarah; Rizvi, Yasmeen; Wan, Xinhai; Navone, Nora; Ozpolat, Bulent; Logothetis, Christopher; Gagel, Robert F.; Huard, Johnny			Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer	ONCOGENE			English	Article							TRANSCRIPTION FACTOR OSTERIX; PROTEIN SIGNALING 2; GENE-EXPRESSION; BETA-CATENIN; EPIGENETIC REGULATION; BONE METASTASES; CELLS; PROMOTES; GROWTH; REGULATOR	Epigenetic changes that cause dysregulated gene expression during progression of androgen-independent prostate cancer (PCa) and metastatic skeletal lesions remain elusive. Here, we explored the role of histone demethylase NO66 in the pathogenesis of PCa and bone metastasis-related skeletal lesions. Tissue and cDNA microarrays of PCa were analyzed for NO66 mRNA and protein levels. We examined the effects of gain and loss of NO66 function on cell viability, colony formation, migration, invasion, and tumor-induced skeletal lesions in femoral bone. RNAseq and ChIPseq were performed to elucidate NO66-target genes in PCa. We report that NO66 levels were upregulated in advanced primary prostate tumors compared to normal tissue or tumors with low Gleason scores. Forced expression of N066 promoted cell survival and invasion of PCa cells; whereas, knockdown of NO66 resulted in decreased cell survival and increased sensitivity to docetaxel. NO66-overexpressing PC3 cells implanted into the femoral bone of male SCID mice caused massive bone loss and stimulation of mouse osteoclast-promoting genes, including Dickkopf1, Cathepsin K, Nf-k beta,; and Cater, suggesting a role for NO66 in tumor growth in bone and osteoclast activity. Combined RNAseq and ChIP-seq revealed that NO66 activates the survival gene MCL1, the invasion-associated genes IGFBP5 and MMP3, the pro-oncogenic genes CTNNB1 and CCND1, and the epigenetic modifier gene KMT2A in androgen-independent PCa. Our findings uncover the role of NO66 as a key oncogenic driver in PCa, causing osteolytic lesions through upstream epigenetic regulation of key genes for survival, invasion and metastasis, and pro-osteoclastic factors.	[Sinha, Krishna M.; Bagheri-Yarmand, Rozita; Lahiri, Sharmistha; Rizvi, Yasmeen; Gagel, Robert F.] Univ Texas MD Anderson Canc Ctr, Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA; [Sinha, Krishna M.; Amra, Sarah; Huard, Johnny] Univ Texas MD Anderson Canc Ctr, Dept Orthopaed Surg, McGovern Med Sch, Houston, TX 77030 USA; [Lu, Yue] Univ Texas MD Anderson Canc Ctr, Epigenet & Mol Carcinogenesis, Houston, TX 77030 USA; [Zhang, Miao; Wan, Xinhai; Navone, Nora; Logothetis, Christopher] Univ Texas MD Anderson Canc Ctr, Genitourinary Med Oncol, Houston, TX 77030 USA; [Ozpolat, Bulent] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Huard, Johnny] Steadman Philippon Res Inst, Vail, CO 81657 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Steadman Philippon Research Institute	Sinha, KM (corresponding author), Univ Texas MD Anderson Canc Ctr, Endocrine Neoplasia & Hormonal Disorders, Houston, TX 77030 USA.; Sinha, KM; Huard, J (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Orthopaed Surg, McGovern Med Sch, Houston, TX 77030 USA.; Huard, J (corresponding author), Steadman Philippon Res Inst, Vail, CO 81657 USA.	Krishna.M.Sinha@uth.tmc.edu; Johnny.Huard@uth.tmc.edu		Zhang, Miao/0000-0003-4912-2570; Ozpolat, Bulent/0000-0001-8602-7463; Lu, Yue/0000-0002-5479-9095; Lahiri, Sharmistha/0000-0001-9215-3634; Bagheri-Yarmand, Rozita/0000-0001-5139-6381	National Institutes of Health [P50 CA140388]; Bone Diseases Program of Texas; UTHealth startup fund; Center for Epigenetics at MDACC allowance for Next-Gen sequencing; NATIONAL CANCER INSTITUTE [P50CA140388] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Bone Diseases Program of Texas; UTHealth startup fund; Center for Epigenetics at MDACC allowance for Next-Gen sequencing; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by National Institutes of Health Grant P50 CA140388 (NCI-SPORE-Developmental Research Program) to CL and KMS, Center for Epigenetics at MDACC allowance for Next-Gen sequencing to KMS, the Bone Diseases Program of Texas to RFG, and by UTHealth startup funding to JH.	Adeniji AO, 2013, J STEROID BIOCHEM, V137, P136, DOI 10.1016/j.jsbmb.2013.05.012; Akech J, 2010, ONCOGENE, V29, P811, DOI 10.1038/onc.2009.389; Bagheri-Yarmand R, 2001, J BIOL CHEM, V276, P29403, DOI 10.1074/jbc.M103129200; Begley LA, 2008, NEOPLASIA, V10, P244, DOI 10.1593/neo.07976; Bettin A, 2016, INT J BIOL MARKER, V31, pE153, DOI 10.5301/jbm.5000184; Bragina O, 2010, ONCOL LETT, V1, P319, DOI 10.3892/ol_00000057; Brien GL, 2012, NAT STRUCT MOL BIOL, V19, P1273, DOI 10.1038/nsmb.2449; Cacan E, 2017, J CHEMOTHERAPY, V29, P173, DOI 10.1080/1120009X.2016.1277007; Cai SW, 2015, ONCOTARGET, V6, P3904, DOI 10.18632/oncotarget.2880; Chen GP, 2004, CANCER-AM CANCER SOC, V101, P1345, DOI 10.1002/cncr.20518; Chen XG, 2015, MOL CARCINOGEN, V54, P1086, DOI 10.1002/mc.22177; Chowdhury R, 2014, NATURE, V510, P422, DOI 10.1038/nature13263; Chowdry RP, 2016, CAN J UROL, V23, P8483; Crea F, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-52; D'Souza S, 2012, BLOOD, V119, P1888, DOI 10.1182/blood-2011-11-393348; Ellinger J, 2010, PROSTATE, V70, P61, DOI 10.1002/pros.21038; Feeley BT, 2006, BONE, V38, P154, DOI 10.1016/j.bone.2005.07.015; Feeley BT, 2005, J BONE MINER RES, V20, P2189, DOI 10.1359/JBMR.050802; Ge C, 2016, ONCOGENE, V35, P366, DOI 10.1038/onc.2015.91; Ge W, 2012, NAT CHEM BIOL, V8, P960, DOI [10.1038/NCHEMBIO.1093, 10.1038/nchembio.1093]; Guo X, 2015, TUMOR BIOL, V36, P9303, DOI 10.1007/s13277-015-3676-8; Ji K, 2013, INT J MOL MED, V32, P747, DOI 10.3892/ijmm.2013.1472; Jin HJ, 2013, CANCER RES, V73, P3725, DOI 10.1158/0008-5472.CAN-12-3468; Joly MM, 2016, CANCER RES, V76, P4752, DOI 10.1158/0008-5472.CAN-15-3393; Kim TD, 2016, J CLIN INVEST, V126, P706, DOI 10.1172/JCI78132; Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008-5472.CAN-10-4374; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Liang GD, 2018, BIOCHEM CELL BIOL, V96, P332, DOI 10.1139/bcb-2017-0151; Liang GD, 2018, ACTA HISTOCHEM, V120, P56, DOI 10.1016/j.acthis.2017.11.002; Liu XH, 2007, CANCER RES, V67, P5747, DOI 10.1158/0008-5472.CAN-07-0478; Logothetis CJ, 2008, CLIN CANCER RES, V14, P1599, DOI 10.1158/1078-0432.CCR-07-4603; Logothetis CJ, 2005, NAT REV CANCER, V5, P21, DOI 10.1038/nrc1528; Malik R, 2015, NAT MED, V21, P344, DOI 10.1038/nm.3830; Nandana S, 2017, CANCER RES, V77, P1331, DOI 10.1158/0008-5472.CAN-16-0497; Nishizawa Y, 2017, ANN SURG ONCOL, V24, P841, DOI 10.1245/s10434-016-5395-9; Ortiz A, 2012, RECENT RESULTS CANC, V192, P225, DOI 10.1007/978-3-642-21892-7_11; Park MH, 2012, IMMUNOLOGY, V135, P63, DOI 10.1111/j.1365-2567.2011.03513.x; Pires-Luis AS, 2015, EPIGENETICS-US, V10, P1033, DOI 10.1080/15592294.2015.1103578; Rebollo Juan, 2017, Int J Biomed Sci, V13, P35; Saha B, 2008, PROSTATE, V68, P1681, DOI 10.1002/pros.20836; Shang CL, 2016, ONCOL REP, V35, P3185, DOI 10.3892/or.2016.4715; Sheth S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051655; Sinha KM, 2014, J BONE MINER RES, V29, P855, DOI 10.1002/jbmr.2103; Sinha KM, 2013, J CELL BIOCHEM, V114, P975, DOI 10.1002/jcb.24439; Sinha KM, 2010, EMBO J, V29, P68, DOI 10.1038/emboj.2009.332; Sottnik Joseph L, 2012, Bonekey Rep, V1, P101, DOI 10.1038/bonekey.2012.101; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Suzuki C, 2007, MOL CANCER THER, V6, P542, DOI 10.1158/1535-7163.MCT-06-0659; Tamada H, 2001, J BONE MINER RES, V16, P487, DOI 10.1359/jbmr.2001.16.3.487; Tao Y, 2013, J BIOL CHEM, V288, P16430, DOI 10.1074/jbc.M112.446849; Theurillat JPP, 2014, SCIENCE, V346, P85, DOI 10.1126/science.1250255; Verras M, 2006, CANCER LETT, V237, P22, DOI 10.1016/j.canlet.2005.06.004; Vieira FQ, 2014, ENDOCR-RELAT CANCER, V21, P51, DOI 10.1530/ERC-13-0375; Wan XH, 2012, CLIN CANCER RES, V18, P726, DOI 10.1158/1078-0432.CCR-11-2521; Wang HH, 2012, AM J PATHOL, V180, P1170, DOI 10.1016/j.ajpath.2011.11.020; Wang SW, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0869-2; Wang ZW, 2012, CANCER DISCOV, V2, P489, DOI 10.1158/2159-8290.CD-12-0177; Wolff DW, 2012, INT J CANCER, V130, P1521, DOI 10.1002/ijc.26138; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang B, 2016, CANCER BIOMARK, V17, P223, DOI 10.3233/CBM-160634; Yang YA, 2013, PROTEIN CELL, V4, P331, DOI 10.1007/s13238-013-2093-2; Yepuru M, 2013, CLIN CANCER RES, V19, P5613, DOI 10.1158/1078-0432.CCR-13-1151; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Zeng CM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00119; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076	65	10	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2019	38	25					5038	5049		10.1038/s41388-019-0774-x	http://dx.doi.org/10.1038/s41388-019-0774-x			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IE1KY	30858546				2022-12-17	WOS:000472145900011
J	Ishikawa, M; Osaki, M; Yamagishi, M; Onuma, K; Ito, H; Okada, F; Endo, H				Ishikawa, Mizuho; Osaki, Mitsuhiko; Yamagishi, Makoto; Onuma, Kunishige; Ito, Hisao; Okada, Futoshi; Endo, Hideya			Correlation of two distinct metastasis-associated proteins, MTA1 and S100A4, in angiogenesis for promoting tumor growth	ONCOGENE			English	Article							BREAST-CANCER METASTASIS; HUMAN ENDOTHELIAL-CELLS; HEAVY-CHAIN; EXPRESSION; HYPOXIA; GENE; MTS1; OVEREXPRESSION; MOTILITY; BINDING	Extensive studies on metastasis-associated proteins, S100A4 and MTA1, have been carried out for over two decades, but correlation of both proteins remains obscure. Here we show evidence for the correlation in angiogenesis. First, silencing of each protein by siRNA-mediated knockdown in mouse endothelial MSS31 cells resulted in the inhibition of tube formation. Unexpectedly, the knockdown of MTA1 affected not only its own expression but also the expression of S100A4, whereas silencing of S100A4 did not affect the MTA1 expression. Additionally, non-muscle myosin IIA (NMIIA) phosphorylation, which was partly controlled by S100A4, was found to be upregulated by knockdown of both proteins in MSS31 cells. Moreover, cycloheximide treatment of MSS31 cells revealed that the rate of S100A4 degradation was accelerated by MTA1 knockdown. This finding, together with our observation that cytoplasmic MTA1, but not nuclear MTA1, was colocalized with S100A4, suggested the involvement of MTA1 in S100A4 stability. The direct in vivo angiogenesis assay showed that both protein siRNAs provoked a significant inhibition of new blood vessel formation induced by angiogenic factors, indicating their anti-angiogenic activities. Treatment of human pancreatic tumor (PANC-1) xenograft in mice with mMTA1 siRNA resulted in tumor regression via suppression of angiogenesis in vivo, as also observed in the case of human prostate cancer xenograft treated with mS100A4 siRNA. Taken together, these data led us to conclude that the MTA1-S100A4-NMIIA axis exists in endothelial cells as a novel pathway in promoting tumor vascular formation and could be a target for suppressing tumor growth and metastasis.	[Ishikawa, Mizuho; Osaki, Mitsuhiko; Onuma, Kunishige; Ito, Hisao; Okada, Futoshi] Tottori Univ, Fac Med, Dept Biomed Sci, Div Pathol Biochem, 86 Nishi Cho, Yonago, Tottori 6838503, Japan; [Osaki, Mitsuhiko; Okada, Futoshi] Tottori Univ, Chromosome Engn Res Ctr, 86 Nishi Cho, Yonago, Tottori 6838503, Japan; [Yamagishi, Makoto] Univ Tokyo, Grad Sch Frontier Sci, Dept Computat Biol & Med Sci, Lab Tumor Cell Biol,Minato Ku, Tokyo 1088639, Japan; [Endo, Hideya] Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan	Tottori University; Tottori University; University of Tokyo; University of Tokyo	Endo, H (corresponding author), Univ Tokyo, Inst Med Sci, Dept Canc Biol, Div Cellular & Mol Biol,Minato Ku, Tokyo 1088639, Japan.	endoh@ims.u-tokyo.ac.jp		Onuma, Kunishige/0000-0002-1034-5796; Okada, Futoshi/0000-0003-4733-1037	Arteriosclerosis Research Foundation, Tokyo, Japan	Arteriosclerosis Research Foundation, Tokyo, Japan	We are grateful to Dr. K. Takenaga (Chiba Cancer Center Research Institute, Chiba, Japan) for valuable comments and critical reading of the manuscript. We also thank to Dr. Y. Toh (National Kyushu Cancer Center, Fukuoka, Japan) for valuable information on the MTA1 studies. This work was supported by a grant from the Arteriosclerosis Research Foundation, Tokyo, Japan.	Ambartsumian N, 2001, ONCOGENE, V20, P4685, DOI 10.1038/sj.onc.1204636; Bartoszewska S, 2015, FASEB J, V29, P1467, DOI 10.1096/fj.14-267054; Dannenmann C, 2008, CANCER BIOL THER, V7, P1462, DOI 10.4161/cbt.7.9.6427; Dulyaninova NG, 2005, BIOCHEMISTRY-US, V44, P6867, DOI 10.1021/bi0500776; EBRALIDZE A, 1989, GENE DEV, V3, P1086, DOI 10.1101/gad.3.7.1086; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; FORD HL, 1995, ONCOGENE, V11, P2067; Garrett SC, 2006, J BIOL CHEM, V281, P677, DOI 10.1074/jbc.R500017200; Ghosh G, 2010, J CLIN INVEST, V120, P4141, DOI 10.1172/JCI42980; Hockel M, 2001, JNCI-J NATL CANCER I, V93, P266, DOI 10.1093/jnci/93.4.266; Hunter K, 2006, NAT REV CANCER, V6, P141, DOI 10.1038/nrc1803; Jang KS, 2006, CANCER SCI, V97, P374, DOI 10.1111/j.1349-7006.2006.00186.x; Jiang BH, 1996, AM J PHYSIOL-CELL PH, V271, pC1172, DOI 10.1152/ajpcell.1996.271.4.C1172; Kriajevska M, 2000, BBA-MOL CELL RES, V1498, P252, DOI 10.1016/S0167-4889(00)00100-2; Li DQ, 2009, P NATL ACAD SCI USA, V106, P17493, DOI 10.1073/pnas.0908027106; Liu TL, 2015, EUR J MED RES, V20, DOI 10.1186/s40001-015-0084-x; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Meinert C, 2017, DATA BRIEF, V10, P354, DOI 10.1016/j.dib.2016.12.004; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moon HE, 2006, ONCOL REP, V16, P929; Ochiya T, 2014, ANGIOGENESIS, V17, P17, DOI 10.1007/s10456-013-9372-7; Oida Y, 2006, ONCOL REP, V16, P457; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Rudland SDS, 2006, CLIN CANCER RES, V12, P1192, DOI 10.1158/1078-0432.CCR-05-1580; Schmidt-Hansen B, 2004, ONCOGENE, V23, P5487, DOI 10.1038/sj.onc.1207720; Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1; Takenaga K, 1997, CLIN CANCER RES, V3, P2309; TAKENAGA K, 1994, JPN J CANCER RES, V85, P831, DOI 10.1111/j.1349-7006.1994.tb02955.x; Toh Y, 2000, J EXP CLIN CANC RES, V19, P105; Toh Y, 1999, BRIT J CANCER, V79, P1723, DOI 10.1038/sj.bjc.6690274; TOH Y, 1994, J BIOL CHEM, V269, P22958; Wang YY, 2010, ANN SURG ONCOL, V17, P89, DOI 10.1245/s10434-009-0722-z; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Zhu XX, 2010, J THORAC ONCOL, V5, P1159, DOI 10.1097/JTO.0b013e3181e04d98	38	10	10	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 13	2019	38	24					4715	4728		10.1038/s41388-019-0748-z	http://dx.doi.org/10.1038/s41388-019-0748-z			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	IC7ND	30745574	Green Submitted			2022-12-17	WOS:000471160500005
J	Das, S; Nair, RS; Mishra, R; Sondarva, G; Viswakarma, N; Abdelkarim, H; Gaponenko, V; Rana, B; Rana, A				Das, Subhasis; Nair, Rakesh Sathish; Mishra, Rajakishore; Sondarva, Gautam; Viswakarma, Navin; Abdelkarim, Hazem; Gaponenko, Vadim; Rana, Basabi; Rana, Ajay			Mixed lineage kinase 3 promotes breast tumorigenesis via phosphorylation and activation of p21-activated kinase 1	ONCOGENE			English	Article							I-TASSER; SIGNALING PATHWAYS; PROTEIN-STRUCTURE; PAK1 KINASE; CANCER; TRANSLOCATION; LOCALIZATION; EXPRESSION; MECHANISM; APOPTOSIS	Mixed lineage kinase 3 (MLK3), a MAP3K member has been envisioned as a viable drug target in cancer, yet its detailed function and signaling is not fully elucidated. We identified that MLK3 tightly associates with an oncogene, PAK1. Mammalian PAK1 being a Ste20 (MAP4K) member, we tested whether it is an upstream regulator of MLK3. In contrast to our hypothesis, MLK3 activated PAK1 kinase activity directly, as well as in the cells. Although, MLK3 can phosphorylate PAK1 on Ser133 and Ser204 sites, PAK1S133A mutant is constitutively active, whereas, PAK1S204A is not activated by MLK3. Stable overexpression of PAK1S204A in breast cancer cells, impedes migration, invasion, and NF kappa B activity. In vivo breast cancer cell tumorigenesis is significantly reduced in tumors expressing PAK1S204A mutant. These results suggest that mammalian PAK1 does not act as a MAP4K and MLK3-induced direct activation of PAK1 plays a key role in breast cancer tumorigenesis.	[Das, Subhasis; Nair, Rakesh Sathish; Sondarva, Gautam; Viswakarma, Navin; Rana, Basabi; Rana, Ajay] Univ Illinois, Div Surg Oncol, Dept Surg, Chicago, IL 60612 USA; [Mishra, Rajakishore] Cent Univ Jharkhand, Sch Nat Sci, Ctr Life Sci, Ranchi 835205, Jharkhand, India; [Abdelkarim, Hazem; Gaponenko, Vadim] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60607 USA; [Rana, Basabi; Rana, Ajay] Univ Illinois, Univ Illinois Hosp, Chicago, IL 60612 USA; [Rana, Basabi; Rana, Ajay] Univ Illinois, Hlth Sci Syst Canc Ctr, Chicago, IL 60612 USA; [Rana, Basabi; Rana, Ajay] Jesse Brown VA Med Ctr, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Central University of Jharkhand; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Rana, A (corresponding author), Univ Illinois, Div Surg Oncol, Dept Surg, Chicago, IL 60612 USA.; Rana, A (corresponding author), Univ Illinois, Univ Illinois Hosp, Chicago, IL 60612 USA.; Rana, A (corresponding author), Univ Illinois, Hlth Sci Syst Canc Ctr, Chicago, IL 60612 USA.; Rana, A (corresponding author), Jesse Brown VA Med Ctr, Chicago, IL 60612 USA.	arana@uic.edu	Mishra, Rajakishore/ABC-3550-2020; Rana, Ajay/ABE-3739-2020; Das, Subhasis/O-8421-2017	Rana, Ajay/0000-0003-0951-2566; Das, Subhasis/0000-0003-1032-4407; Gaponenko, Vadim/0000-0002-7891-9223	National Cancer Institute [CA 176846, CA 216410, CA 178063, CA 188427]; Veteran Administration Merit Awards [BX002703, BX003296]; NIH shared instrument grant [S100D018445]; NATIONAL CANCER INSTITUTE [R01CA176846, R01CA178063, R01CA188427] Funding Source: NIH RePORTER; Veterans Affairs [I01BX003296] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veteran Administration Merit Awards; NIH shared instrument grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	We acknowledge funding support from National Cancer Institute to A.R. (CA 176846 and CA 216410), B.R. (CA 178063) and V.G. (CA 188427). Additional support came from Veteran Administration Merit Awards to A.R. (BX002703) and B.R. (BX003296). We also acknowledge the NIH shared instrument grant # S100D018445, awarded to U.A.M.S. Proteomics Core Lab, Little Rock, Arkansas, USA.	Bodner A, 2002, J NEUROCHEM, V82, P1424, DOI 10.1046/j.1471-4159.2002.01088.x; Chen RE, 2007, BBA-MOL CELL RES, V1773, P1311, DOI 10.1016/j.bbamcr.2007.05.003; Chong C, 2001, J BIOL CHEM, V276, P17347, DOI 10.1074/jbc.M009316200; French JD, 2013, AM J HUM GENET, V92, P489, DOI 10.1016/j.ajhg.2013.01.002; Frost JA, 2000, J BIOL CHEM, V275, P19693, DOI 10.1074/jbc.M909860199; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Heo L, 2016, SCI REP-UK, V6, DOI 10.1038/srep32153; Holm C, 2006, JNCI-J NATL CANCER I, V98, P671, DOI 10.1093/jnci/djj185; Jha RK, 2011, J MOL BIOL, V413, P513, DOI 10.1016/j.jmb.2011.08.022; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; Kumar R, 2002, J CELL PHYSIOL, V193, P133, DOI 10.1002/jcp.10167; Lee BN, 1999, P NATL ACAD SCI USA, V96, P12679, DOI 10.1073/pnas.96.22.12679; Letessier A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-245; Lu WG, 1999, ONCOGENE, V18, P797, DOI 10.1038/sj.onc.1202361; Lu WG, 1997, CURR BIOL, V7, P85, DOI 10.1016/S0960-9822(06)00052-2; Mao K, 2008, J MOL CELL CARDIOL, V44, P429, DOI 10.1016/j.yjmcc.2007.10.016; Mayhew MW, 2007, J CELL SCI, V120, P3911, DOI 10.1242/jcs.008177; Misek SA, 2017, MOL CANCER RES, V15, P1085, DOI 10.1158/1541-7786.MCR-16-0318; Mishra P, 2010, MOL ENDOCRINOL, V24, P598, DOI 10.1210/me.2009-0387; Nayal A, 2006, J CELL BIOL, V173, P587, DOI 10.1083/jcb.200509075; Nheu TV, 2002, CANCER J, V8, P328, DOI 10.1097/00130404-200207000-00009; Ong CC, 2011, P NATL ACAD SCI USA, V108, P7177, DOI 10.1073/pnas.1103350108; Parrini MC, 2002, MOL CELL, V9, P73, DOI 10.1016/S1097-2765(01)00428-2; Pierce BG, 2014, BIOINFORMATICS, V30, P1771, DOI 10.1093/bioinformatics/btu097; Qing HT, 2012, TUMOR BIOL, V33, P985, DOI 10.1007/s13277-012-0327-1; Radu M, 2014, NAT REV CANCER, V14, P13, DOI 10.1038/nrc3645; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; Rana Ajay, 2013, Genes Cancer, V4, P334, DOI 10.1177/1947601913485415; Rangasamy V, 2012, P NATL ACAD SCI USA, V109, P8149, DOI 10.1073/pnas.1200804109; Rangasamy V, 2010, CANCER RES, V70, P1731, DOI 10.1158/0008-5472.CAN-09-3492; Rattanasinchai C, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.44; Rider L, 2013, MOL ENDOCRINOL, V27, P1048, DOI 10.1210/me.2012-1322; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Sancho D, 2002, J IMMUNOL, V169, P292, DOI 10.4049/jimmunol.169.1.292; Sathyanarayana P, 2002, MOL CELL, V10, P1527, DOI 10.1016/S1097-2765(02)00734-7; Shoulson I, 2007, NEUROLOGY, V69, P1480, DOI 10.1212/01.wnl.0000277648.63931.c0; Smith CM, 1997, GENOME RES, V7, P835, DOI 10.1101/gr.7.8.835; Tabusa H, 2013, MOL CANCER RES, V11, P109, DOI 10.1158/1541-7786.MCR-12-0466; Wang RA, 2002, EMBO J, V21, P5437, DOI 10.1093/emboj/cdf543; Wang ZP, 2013, J BIOL CHEM, V288, P20093, DOI 10.1074/jbc.M112.426023; Yang JY, 2015, NUCLEIC ACIDS RES, V43, pW174, DOI 10.1093/nar/gkv342; Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213; Zhang CX, 2018, PROTEINS, V86, P136, DOI 10.1002/prot.25414; Zhang Y, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-40; Zhou L, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-15; 2015, J BIOL CHEM, V290, P2170, DOI DOI 10.1074/JBC.M115.655563	46	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 9	2019	38	19					3569	3584		10.1038/s41388-019-0690-0	http://dx.doi.org/10.1038/s41388-019-0690-0			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HX4OU	30664689	Green Accepted			2022-12-17	WOS:000467379600002
J	Gunaratna, RT; Santos, A; Luo, LJ; Nagi, C; Lambertz, I; Spier, M; Conti, CJ; Fuchs-Young, RS				Gunaratna, Ramesh T.; Santos, Andres; Luo, Linjie; Nagi, Chandandeep; Lambertz, Isabel; Spier, Madison; Conti, Claudio J.; Fuchs-Young, Robin S.			Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model	ONCOGENE			English	Article							NF-KAPPA-B; BREAST-CANCER; CELLULAR SENESCENCE; R72P POLYMORPHISM; ANGIOGENIC SWITCH; TUMOR SUPPRESSION; ARGININE ALLELE; INFLAMMATION; EXPRESSION; ASSOCIATION	Female breast cancer (BrCa) is the most common noncutaneous cancer among women in the United States. Human epidemiological studies reveal that a p53 single-nucleotide polymorphism (SNP) at codon 72, encoding proline (P72) or arginine (R72), is associated with differential risk of several cancers, including BrCa. However, the molecular mechanisms by which these variants affect mammary tumorigenesis remain unresolved. To investigate the effects of this polymorphism on susceptibility to mammary cancer, we used a humanized p53 mouse model, homozygous for either P72 or R72. Our studies revealed that R72 mice had a significantly higher mammary tumor incidence and reduced latency in both DMBAinduced and MMTV-Erbb2/Neu mouse mammary tumor models compared to P72 mice. Analyses showed that susceptible mammary glands from E-R72 (R72 x MMTV-Erbb2/Neu) mice developed a senescence-associated secretory phenotype (SASP) with influx of proinflammatory macrophages, ultimately resulting in chronic, protumorigenic inflammation. Mammary tumors arising in E-R72 mice also had an increased influx of tumor-associated macrophages, contributing to angiogenesis and elevated tumor growth rates. These results demonstrate that the p53 R72 variant increased susceptibility to mammary tumorigenesis through chronic inflammation.	[Gunaratna, Ramesh T.; Fuchs-Young, Robin S.] Texas A&M Univ, Interdisciplinary Program Genet, College Stn, TX 77843 USA; [Gunaratna, Ramesh T.; Santos, Andres; Luo, Linjie; Lambertz, Isabel; Spier, Madison; Conti, Claudio J.; Fuchs-Young, Robin S.] Texas A&M Hlth Sci Ctr, Coll Med, Dept Mol & Cellular Med, College Stn, TX 77807 USA; [Gunaratna, Ramesh T.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA; [Santos, Andres] Texas Tech Univ, Hlth Sci Ctr, Paul L Foster Sch Med, El Paso, TX USA; [Nagi, Chandandeep] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Conti, Claudio J.] Univ Carlos III Madrid, Dept Bioingn, Madrid, Spain; [Conti, Claudio J.] Fdn Jimenez Diaz IIS FJD, Fdn Inst Invest Sanitaria, Madrid, Spain; [Conti, Claudio J.] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Princeton University; Texas Tech University System; Texas Tech University; Baylor College of Medicine; Universidad Carlos III de Madrid; Fundacion Jimenez Diaz; CIBER - Centro de Investigacion Biomedica en Red; CIBERER	Fuchs-Young, RS (corresponding author), Texas A&M Univ, Interdisciplinary Program Genet, College Stn, TX 77843 USA.; Fuchs-Young, RS (corresponding author), Texas A&M Hlth Sci Ctr, Coll Med, Dept Mol & Cellular Med, College Stn, TX 77807 USA.	fuchs-young@medicine.tamhsc.edu	Gunaratna, Ramesh/B-2256-2016	Gunaratna, Ramesh/0000-0002-8872-9984	National Institutes of Health [R01MD006228]	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was funded by the National Institutes of Health grant R01MD006228 (to RF-Y).	Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Aizat AAA, 2011, ASIAN PAC J CANCER P, V12, P2909; Alawadi S, 2011, MED ONCOL, V28, P709, DOI 10.1007/s12032-010-9505-4; Andrechek ER, 2003, CANCER RES, V63, P4920; Arendt LM, 2013, CANCER RES, V73, P6080, DOI 10.1158/0008-5472.CAN-13-0926; Azzam GA, 2011, CELL CYCLE, V10, P1352, DOI 10.4161/cc.10.9.15344; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Bonafe M, 2003, CLIN CANCER RES, V9, P4860; Brady NJ, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/4549676; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Capell BC, 2016, GENE DEV, V30, P321, DOI 10.1101/gad.271882.115; Carron EC, 2017, ONCOTARGET, V8, P50731, DOI 10.18632/oncotarget.14913; Catena CS, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00085; Cha YJ, 2018, BREAST CANCER RES TR, V170, P15, DOI 10.1007/s10549-018-4722-1; Chang SH, 2004, P NATL ACAD SCI USA, V101, P591, DOI 10.1073/pnas.2535911100; Costa Carla, 2007, Angiogenesis, V10, P149, DOI 10.1007/s10456-007-9074-0; Crespi E, 2016, CURR OPIN PHARMACOL, V31, P114, DOI 10.1016/j.coph.2016.11.004; Dakouras A, 2008, ANTICANCER RES, V28, P1039; Dastjerdi Mehdi Nikbahkt, 2011, Acta Med Iran, V49, P71; de Ostrovich KK, 2008, AM J PATHOL, V173, P824, DOI 10.2353/ajpath.2008.071005; Denisov EV, 2012, TUMOR SUPPRESSOR GEN; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Ehling J, 2014, GUT, V63, P1960, DOI 10.1136/gutjnl-2013-306294; Eren F, 2010, PATHOL ONCOL RES, V16, P563, DOI 10.1007/s12253-010-9255-9; Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI 10.1001/jamaoncol.2016.5688; Frank AK, 2011, MOL CELL BIOL, V31, P1201, DOI 10.1128/MCB.01136-10; Gage M, 2012, J SURG ONCOL, V105, P444, DOI 10.1002/jso.21856; Garcia PB, 2014, SEMIN CELL DEV BIOL, V27, P74, DOI 10.1016/j.semcdb.2013.12.014; Georgakopoulou EA, 2013, AGING-US, V5, P37; Grochola LF, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001032; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Howe LR, 2005, CANCER RES, V65, P10113, DOI 10.1158/0008-5472.CAN-05-1524; Hursting SD, 2011, CANCER PREV RES, V4, P285, DOI 10.1158/1940-6207.CAPR-11-0056; Jackson JG, 2006, CANCER RES, V66, P8356, DOI 10.1158/0008-5472.CAN-06-1752; Jiang XG, 2014, MOL CELL ENDOCRINOL, V382, P673, DOI 10.1016/j.mce.2013.06.003; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kortlever RM, 2006, NAT CELL BIOL, V8, P877, DOI 10.1038/ncb1448; Koutras A, 2015, PHARMACOGENOMICS, V16, P79, DOI [10.2217/PGS.14.148, 10.2217/pgs.14.148]; Kung CP, 2016, CELL REP, V14, P2413, DOI 10.1016/j.celrep.2016.02.037; Kung CP, 2015, MOL CANCER RES, V13, P250, DOI 10.1158/1541-7786.MCR-14-0385; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Lopez-Arribillaga E, 2015, DEVELOPMENT, V142, P41, DOI 10.1242/dev.107714; Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303; MEDINA D, 1974, J NATL CANCER I, V53, P213, DOI 10.1093/jnci/53.1.213; Morris PG, 2011, CANCER PREV RES, V4, P1021, DOI 10.1158/1940-6207.CAPR-11-0110; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008; Padala C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184448; Papadakis ED, 2002, BRIT J CANCER, V87, P1013, DOI 10.1038/sj.bjc.6600595; Park SW, 2011, LAB INVEST, V91, P63, DOI 10.1038/labinvest.2010.151; Perez LO, 2006, WORLD J GASTROENTERO, V12, P1426, DOI 10.3748/wjg.v12.i9.1426; Pim D, 2004, INT J CANCER, V108, P196, DOI 10.1002/ijc.11548; Pusztaszeri MP, 2006, J HISTOCHEM CYTOCHEM, V54, P385, DOI 10.1369/jhc.4A6514.2005; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Rijnkels M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053270; Rodier F, 2011, J CELL BIOL, V192, P547, DOI 10.1083/jcb.201009094; Rogler A, 2011, PATHOBIOLOGY, V78, P193, DOI 10.1159/000326767; Salminen A, 2012, CELL SIGNAL, V24, P835, DOI 10.1016/j.cellsig.2011.12.006; Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]; Schneider-Stock R, 2004, NEOPLASIA, V6, P529, DOI 10.1593/neo.04178; Shaked H, 2012, P NATL ACAD SCI USA, V109, P14007, DOI 10.1073/pnas.1211509109; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Siddique M, 2006, ONCOGENE, V25, P3489, DOI 10.1038/sj.onc.1209405; Surekha D, 2011, ASIAN PAC J CANCER P, V12, P1893; Svensson S, 2015, CLIN CANCER RES, V21, P3794, DOI 10.1158/1078-0432.CCR-15-0204; Takeuchi S, 2010, CANCER RES, V70, P9381, DOI 10.1158/0008-5472.CAN-10-0801; Volodko N, 2015, WORLD J GASTROENTERO, V21, P10358, DOI 10.3748/wjg.v21.i36.10358; Yoshimura T, 2017, CYTOKINE, V98, P71, DOI 10.1016/j.cyto.2017.02.001; You W, 2018, ADV BREAST CANC RES, V07, P1, DOI [10.4236/abcr.2018.71001, DOI 10.4236/ABCR.2018.71001]; Zhang ZZ, 2010, BREAST CANCER RES TR, V120, P509, DOI 10.1007/s10549-009-0480-4; Zhu F, 2010, CANCER RES, V70, P5851, DOI 10.1158/0008-5472.CAN-09-4646	76	10	10	1	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 2	2019	38	18					3535	3550		10.1038/s41388-018-0630-4	http://dx.doi.org/10.1038/s41388-018-0630-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HW3RI	30651598	hybrid, Green Published			2022-12-17	WOS:000466610000015
J	Kessler, BE; Mishall, KM; Kellett, MD; Clark, EG; Pugazhenthi, U; Pozdeyev, N; Kim, J; Tan, AC; Schweppe, RE				Kessler, Brittelle E.; Mishall, Katie M.; Kellett, Meghan D.; Clark, Erin G.; Pugazhenthi, Umarani; Pozdeyev, Nikita; Kim, Jihye; Tan, Aik Choon; Schweppe, Rebecca E.			Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis	ONCOGENE			English	Article							FOCAL-ADHESION-KINASE; TARGETED THERAPIES; THYROID-CARCINOMA; GROWTH-FACTOR; PHASE-II; CANCER; FAK; DASATINIB; MIGRATION; SURVIVAL	Few therapy options exist for patients with advanced papillary and anaplastic thyroid cancer. We and others have previously identified c-Src as a key mediator of thyroid cancer pro-tumorigenic processes and a promising therapeutic target for thyroid cancer. To increase the efficacy of targeting Src in the clinic, we sought to define mechanisms of resistance to the Src inhibitor, dasatinib, to identify key pathways to target in combination. Using a panel of thyroid cancer cell lines expressing clinically relevant mutations in BRAF or RAS, which were previously developed to be resistant to dasatinib, we identified a switch to a more invasive phenotype in the BRAF-mutant cells as a potential therapy escape mechanism. This phenotype switch is driven by FAK kinase activity, and signaling through the p130Cas>c-Jun signaling axis. We have further shown this more invasive phenotype is accompanied by alterations in the secretome through the increased expression of pro-inflammatory cytokines, including IL-1 beta, and the pro-invasive metalloprotease, MMP-9. Furthermore, IL-1 beta signals via a feedforward autocrine loop to promote invasion through a FAK>p130Cas>c-Jun>MMP-9 signaling axis. We further demonstrate that upfront combined inhibition of FAK and Src synergistically inhibits growth and invasion, and induces apoptosis in a panel of BRAF- and RAS-mutant thyroid cancer cell lines. Together our data demonstrate that acquired resistance to single-agent Src inhibition promotes a more invasive phenotype through an IL-1 beta>FAK>p130Cas>c-Jun >MMP signaling axis, and that combined inhibition of FAK and Src has the potential to block this inhibitor-induced phenotype switch.	[Kessler, Brittelle E.; Mishall, Katie M.; Kellett, Meghan D.; Clark, Erin G.; Pugazhenthi, Umarani; Pozdeyev, Nikita; Schweppe, Rebecca E.] Univ Colorado, Sch Med, Div Endocrinol Metab & Diabet, Dept Med, Aurora, CO 80045 USA; [Kim, Jihye; Tan, Aik Choon] Univ Colorado, Sch Med, Canc Ctr, Aurora, CO 80045 USA; [Kim, Jihye; Tan, Aik Choon; Schweppe, Rebecca E.] Univ Colorado, Sch Med, Dept Med, Div Med Oncol, Aurora, CO 80045 USA; [Pozdeyev, Nikita] Div Bioinformat & Personalized Med, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Schweppe, RE (corresponding author), Univ Colorado, Sch Med, Div Endocrinol Metab & Diabet, Dept Med, Aurora, CO 80045 USA.; Schweppe, RE (corresponding author), Univ Colorado, Sch Med, Dept Med, Div Med Oncol, Aurora, CO 80045 USA.	Rebecca.Schweppe@ucdenver.edu	Tan, Aik Choon/A-3135-2011	Tan, Aik Choon/0000-0003-2955-8369; Kim, Jihye/0000-0002-0338-2329; Schweppe, Rebecca/0000-0001-7502-0151	NIH/NCI [1RO1CA164193, 1R01CA222299]; American Cancer Society [RSG-13-060-01-TBE]; Cancer League of Colorado; Front Range Cancer Challenge Fellowship; NCI Cancer Center support grant [P30CA046934]; NATIONAL CANCER INSTITUTE [R01CA222299, R01CA164193, P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008497] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Cancer League of Colorado; Front Range Cancer Challenge Fellowship; NCI Cancer Center support grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr. Christopher Korch, UCCC, and Randall Wong at the B. Davis Center BioResources Core Facility for STR profiling of the cell lines. We thank Dr. Rytis Prekeris for assistance with the zymography assays. This work was supported by NIH/NCI grant 1RO1CA164193 (RES), 1R01CA222299 (RES), American Cancer Society RSG-13-060-01-TBE (RES), the Cancer League of Colorado (RES), and the Front Range Cancer Challenge Fellowship (KMM). The UCCC DNA Sequencing, Flow Cytometry, and Protein Production/Mab/Tissue Culture Shared Resources are supported by NCI Cancer Center support grant, P30CA046934.	Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Antonelli A, 2011, CURR GENOMICS, V12, P626, DOI 10.2174/138920211798120808; Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4; Barderas R, 2013, MOL CELL PROTEOMICS, V12, P1602, DOI 10.1074/mcp.M112.022848; Beadnell TC, 2016, MOL CANCER THER, V15, P1952, DOI 10.1158/1535-7163.MCT-15-0702; Bolos V, 2010, ONCOTARGETS THER, V3, P83; Caillou B, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022567; Carneiro RM, 2015, CANCER TREAT REV, V41, P690, DOI 10.1016/j.ctrv.2015.06.002; Chan CM, 2012, CLIN CANCER RES, V18, P3580, DOI 10.1158/1078-0432.CCR-11-3359; Chan D, 2012, ONCOL LETT, V3, P807, DOI 10.3892/ol.2012.579; Chen GM, 2018, MOL CANCER THER, V17, P806, DOI 10.1158/1535-7163.MCT-17-0561; Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002; Chen YF, 2011, ACTA PHARM SIN B, V1, P197, DOI 10.1016/j.apsb.2011.10.007; Chen YJ, 2005, NUCLEIC ACIDS RES, V33, pD169; Chow AKM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078675; Defilippi P, 2006, TRENDS CELL BIOL, V16, P257, DOI 10.1016/j.tcb.2006.03.003; Fallahi-Sichani M, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20166796; Fallahi-Sichani M, 2015, MOL SYST BIOL, V11, DOI 10.15252/msb.20145877; Finn RS, 2011, CLIN CANCER RES, V17, P6905, DOI 10.1158/1078-0432.CCR-11-0288; Gelfo V, 2016, ONCOTARGET, V7, P72167, DOI 10.18632/oncotarget.12354; Glickman MS, 2012, CELL, V148, P1089, DOI 10.1016/j.cell.2012.02.015; Golubovskaya VM, 2003, MOL CANCER RES, V1, P755; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Hayes DN, 2012, CLIN CANCER RES, V18, P2056, DOI 10.1158/1078-0432.CCR-11-0563; Hirata E, 2015, CANCER CELL, V27, P574, DOI 10.1016/j.ccell.2015.03.008; Ilic D, 1998, J CELL BIOL, V143, P547; Johnson FM, 2010, J CLIN ONCOL, V28, P4609, DOI 10.1200/JCO.2010.30.5474; Kebebew E, 2005, CANCER-AM CANCER SOC, V103, P1330, DOI 10.1002/cncr.20936; Kemper K, 2014, CANCER RES, V74, P5937, DOI 10.1158/0008-5472.CAN-14-1174; Kessler BEBE, 2016, MOL CANCER RES, P14869; Kim WG, 2012, CLIN CANCER RES, V18, P1281, DOI 10.1158/1078-0432.CCR-11-2892; Lee BY, 2015, PHARMACOL THERAPEUT, V146, P132, DOI 10.1016/j.pharmthera.2014.10.001; Lee CR, 2016, FEBS LETT, V590, P358, DOI 10.1002/1873-3468.12057; Leight JL, 2015, P NATL ACAD SCI USA, V112, P5366, DOI 10.1073/pnas.1505662112; Lu HB, 2013, MOL CANCER THER, V12, P2864, DOI 10.1158/1535-7163.MCT-13-0233; McCulloch CA, 2006, NAT REV DRUG DISCOV, V5, P864, DOI 10.1038/nrd2109; Michailidi C, 2010, PATHOL ONCOL RES, V16, P497, DOI 10.1007/s12253-010-9269-3; Mishall KM, 2017, ONCOTARGET IMPACT J, V8; Mon NN, 2017, ONCOL LETT, V13, P955, DOI 10.3892/ol.2016.5521; Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531; Ng M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2584; Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336; Owens LV, 1996, ANN SURG ONCOL, V3, P100, DOI 10.1007/BF02409059; Paraiso KHT, 2015, CANCER DISCOV, V5, P264, DOI 10.1158/2159-8290.CD-14-0293; Qiao YC, 2016, J BIOL CHEM, V291, P5068, DOI 10.1074/jbc.M115.702571; Ramsdale R, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aab1111; Ryder M, 2008, ENDOCR-RELAT CANCER, V15, P1069, DOI 10.1677/ERC-08-0036; Sandri S, 2016, PHARMACOL RES, V111, P523, DOI 10.1016/j.phrs.2016.07.017; Santarpia L, 2012, EXPERT OPIN THER TAR, V16, P103, DOI 10.1517/14728222.2011.645805; Schweppe RE, 2009, J CLIN ENDOCR METAB, V94, P2199, DOI 10.1210/jc.2008-2511; Segarra M, 2005, FASEB J, V19, P1875, DOI 10.1096/fj.04-3574fje; Shah MH, 2017, J CLIN ONCOL, V32, P6022; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Sipos Jennifer A, 2010, Ther Adv Med Oncol, V2, P3, DOI 10.1177/1758834009352667; Stanam A, 2016, ONCOTARGET, V7, P76087, DOI 10.18632/oncotarget.12590; Taylor KN, 2018, MOL CANCER THER, V17, P719, DOI 10.1158/1535-7163.MCT-17-1177; Titz B, 2016, CELL DISCOV, V2, DOI 10.1038/celldisc.2016.28; Ware KE, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.4; Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1; Wilson C, 2014, ONCOTARGET, V5, P7328, DOI 10.18632/oncotarget.2397; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Wynn TA, 2011, J EXP MED, V208, P1339, DOI 10.1084/jem.20110551; Zhang P, 2015, EUR J ORAL SCI, V123, P249, DOI 10.1111/eos.12191; Zhao W, 2014, J BIOMOL SCREEN, V19, P817, DOI 10.1177/1087057114521867; Zubrilov I, 2015, CANCER LETT, V361, P86, DOI 10.1016/j.canlet.2015.02.041	65	10	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2565	2579		10.1038/s41388-018-0617-1	http://dx.doi.org/10.1038/s41388-018-0617-1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531837	Green Accepted			2022-12-17	WOS:000463335200009
J	Pearson, SJ; Sarkar, TR; McQueen, CM; Elswood, J; Schmitt, EE; Wall, SW; Scribner, KC; Wyatt, G; Barhoumi, R; Behbod, F; Rijnkels, M; Porter, WW				Pearson, Scott J.; Sarkar, Tapasree Roy; McQueen, Cole M.; Elswood, Jessica; Schmitt, Emily E.; Wall, Steven W.; Scribner, Kelly C.; Wyatt, Garhett; Barhoumi, Rola; Behbod, Fariba; Rijnkels, Monique; Porter, Weston W.			ATM-dependent activation of SIM2s regulates homologous recombination and epithelial-mesenchymal transition	ONCOGENE			English	Article							CARCINOMA IN-SITU; SURGICAL ADJUVANT BREAST; DNA-DAMAGE; GENOMIC INSTABILITY; LOCAL RECURRENCE; CELL-CYCLE; C-MET; CANCER; REPAIR; BRCA1	There is increasing evidence that genomic instability is a prerequisite for cancer progression. Here we show that SIM2s, a member of the bHLH/PAS family of transcription factors, regulates DNA damage repair through enhancement of homologous recombination (HR), and prevents epithelial-mesenchymal transitions (EMT) in an Ataxia-telangiectasia mutated (ATM)-dependent manner. Mechanistically, we found that SIM2s interacts with ATM and is stabilized through ATM-dependent phosphorylation in response to IR. Once stabilized, SIM2s interacts with BRCA1 and supports RAD51 recruitment to the site of DNA damage. Loss of SIM2s through the introduction of shSIM2 or the mutation of SIM2s at one of the predicted ATM phosphorylation sites (S115) reduces HR efficiency through disruption of RAD51 recruitment, resulting in genomic instability and induction of EMT. The EMT induced by the mutation of S115 is characterized by a decrease in E-cadherin and an induction of the basal marker, K14, resulting in increased invasion and metastasis. Together, these results identify a novel player in the DNA damage repair pathway and provides a link in ductal carcinoma in situ progression to invasive ductal carcinoma through loss of SIM2s, increased genomic instability, EMT, and metastasis.	[Pearson, Scott J.; Sarkar, Tapasree Roy; McQueen, Cole M.; Elswood, Jessica; Schmitt, Emily E.; Wall, Steven W.; Scribner, Kelly C.; Wyatt, Garhett; Barhoumi, Rola; Rijnkels, Monique; Porter, Weston W.] Texas A&M Univ, Coll Vet Med, Dept Integrat Biosci, College Stn, TX 77843 USA; [Behbod, Fariba] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66160 USA; [Porter, Weston W.] Texas A&M Univ, Vet Integrat Biosci, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; University of Kansas; University of Kansas Medical Center; Texas A&M University System; Texas A&M University College Station	Porter, WW (corresponding author), Texas A&M Univ, Coll Vet Med, Dept Integrat Biosci, College Stn, TX 77843 USA.; Porter, WW (corresponding author), Texas A&M Univ, Vet Integrat Biosci, College Stn, TX 77843 USA.	wporter@cvm.tamu.edu	Schmitt, Emily/GOP-0896-2022	Wall, Steven/0000-0002-4813-9920; Epps (Elswood), Jessica/0000-0003-1966-1557; Wyatt, Garhett/0000-0001-7402-6404	National Cancer Institute [R21CA190941, R01HD083952, R21CA185460]; Department of Defense (DOD-CDMRP) [W81XWH-11-1-0158]; American Association for Cancer Research (AACR)-2014 Breast Cancer Research Foundation-Translational Breast Cancer research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD083952] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R21CA190941] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [T32ES026568] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense (DOD-CDMRP)(United States Department of Defense); American Association for Cancer Research (AACR)-2014 Breast Cancer Research Foundation-Translational Breast Cancer research; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	National Cancer Institute R21CA190941 (WP); R01HD083952 (CO-PI WP, MR); R21CA185460 (FB) Department of Defense (DOD-CDMRP) W81XWH-11-1-0158 (KCS) American Association for Cancer Research (AACR)-2014 Breast Cancer Research Foundation-Translational Breast Cancer research (FB)	Aleman MJ, 2005, P NATL ACAD SCI USA, V102, P12765, DOI 10.1073/pnas.0505484102; [Anonymous], 2018, SOC AC CANC FACTS FI; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Bardos JI, 2005, BBA-REV CANCER, V1755, P107, DOI 10.1016/j.bbcan.2005.05.001; Behbod F, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2358; Bergamaschi A, 2006, GENE CHROMOSOME CANC, V45, P1033, DOI 10.1002/gcc.20366; Bersten DC, 2013, NAT REV CANCER, V13, P827, DOI 10.1038/nrc3621; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Blom N, 2004, PROTEOMICS, V4, P1633, DOI 10.1002/pmic.200300771; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Burgess M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00019; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Burstein HJ, 2004, NEW ENGL J MED, V350, P1430, DOI 10.1056/NEJMra031301; Chapman JR, 2012, J CELL SCI, V125, P3529, DOI 10.1242/jcs.105353; Cowell CF, 2013, MOL ONCOL, V7, P859, DOI 10.1016/j.molonc.2013.07.005; Cowell CF, 2013, MOL ONCOL; Denison MS, 2011, TOXICOL SCI, V124, P1, DOI 10.1093/toxsci/kfr218; Du Y, 2016, NAT MED, V22, P194, DOI 10.1038/nm.4032; Elsarraj HS, 2017, CANCER RES, V77, P3802, DOI 10.1158/0008-5472.CAN-16-2794; Epstein DJ, 2000, DEVELOPMENT, V127, P4701; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher ER, 1999, CANCER-AM CANCER SOC, V86, P429, DOI 10.1002/(SICI)1097-0142(19990801)86:3<429::AID-CNCR11>3.0.CO;2-Y; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Fridlyand J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-96; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; George WD, 2003, LANCET, V362, P95, DOI 10.1016/S0140-6736(03)13859-7; Golding SE, 2004, J BIOL CHEM, V279, P15402, DOI 10.1074/jbc.M314191200; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Gustafson TL, 2009, ONCOGENE, V28, P1561, DOI 10.1038/onc.2008.497; Halvorsen OJ, 2007, CLIN CANCER RES, V13, P892, DOI 10.1158/1078-0432.CCR-06-1207; Heyer WD, 2010, ANNU REV GENET, V44, P113, DOI 10.1146/annurev-genet-051710-150955; Hilton JL, 2002, JNCI-J NATL CANCER I, V94, P1396; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Jonsson G, 2005, CANCER RES, V65, P7612, DOI 10.1158/0008-5472.CAN-05-0570; Kim TM, 2012, MOL CELL BIOL, V32, P3663, DOI 10.1128/MCB.00406-12; Kumar Gaurav, 2005, Mo Med, V102, P138; Kwak HI, 2007, CARCINOGENESIS, V28, P259, DOI 10.1093/carcin/bgl122; Kwei KA, 2010, MOL ONCOL, V4, P255, DOI 10.1016/j.molonc.2010.04.001; Laffin B, 2008, MOL CELL BIOL, V28, P1936, DOI 10.1128/MCB.01701-07; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Loeb LA, 2001, CANCER RES, V61, P3230; Lorkovic ZJ, 2017, NUCLEUS-PHILA, V8, P583, DOI 10.1080/19491034.2017.1384893; Mavaddat N, 2012, CANCER EPIDEM BIOMAR, V21, P134, DOI 10.1158/1055-9965.EPI-11-0775; Metz RP, 2006, J BIOL CHEM, V281, P10839, DOI 10.1074/jbc.M508858200; Morrison C, 2000, EMBO J, V19, P463, DOI 10.1093/emboj/19.3.463; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Okui M, 2005, EXP CELL RES, V309, P220, DOI 10.1016/j.yexcr.2005.05.018; PAGE DL, 1995, CANCER, V76, P1197, DOI 10.1002/1097-0142(19951001)76:7<1197::AID-CNCR2820760715>3.0.CO;2-0; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837; Rudloff U, 2010, J CLIN ONCOL, V28, P3762, DOI 10.1200/JCO.2009.26.8847; Rugo HS, 2016, NEW ENGL J MED, V375, P23, DOI 10.1056/NEJMoa1513749; Ryu T, 2015, NAT CELL BIOL, V17, P1401, DOI 10.1038/ncb3258; Sanders ME, 2005, CANCER, V103, P2481, DOI 10.1002/cncr.21069; Savage KI, 2014, MOL CELL, V54, P445, DOI 10.1016/j.molcel.2014.03.021; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Scribner KC, 2013, ONCOGENE, V32, P2631, DOI 10.1038/onc.2012.286; Scribner KC, 2011, MOL ENDOCRINOL, V25, P635, DOI 10.1210/me.2010-0423; Shook D, 2003, MECH DEVELOP, V120, P1351, DOI 10.1016/j.mod.2003.06.005; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Tirkkonen M, 1997, CANCER RES, V57, P1222; Trenz K, 2005, MUTAGENESIS, V20, P131, DOI 10.1093/mutage/gei018; Tsouroula K, 2016, MOL CELL, V63, P293, DOI 10.1016/j.molcel.2016.06.002; Turner N, 2004, NAT REV CANCER, V4, P814, DOI 10.1038/nrc1457; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Valdez KE, 2011, J PATHOL, V225, P565, DOI 10.1002/path.2969; Van Cleef A, 2014, FACTS VIEWS VIS OBGY, V6, P210; Wang Haibo, 2014, Jacobs J Radiat Oncol, V1; Wang JH, 2016, ONCOTARGET, V7, P7701, DOI 10.18632/oncotarget.6715; Wellberg E, 2010, DEVELOPMENT, V137, P945, DOI 10.1242/dev.041657; Woods SL, 2002, J BIOL CHEM, V277, P10236, DOI 10.1074/jbc.M110752200; Yang RL, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0698-3; Yoshida K, 2004, CANCER SCI, V95, P866, DOI 10.1111/j.1349-7006.2004.tb02195.x; Zamborszky J, 2017, ONCOGENE, V36, P746, DOI 10.1038/onc.2016.243; Zhou CY, 2003, ONCOGENE, V22, P2396, DOI 10.1038/sj.onc.1206319	78	10	10	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 4	2019	38	14					2611	2626		10.1038/s41388-018-0622-4	http://dx.doi.org/10.1038/s41388-018-0622-4			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HR7LI	30531838	Green Accepted			2022-12-17	WOS:000463335200012
J	Hirano, D; Hayakawa, F; Yasuda, T; Tange, N; Yamamoto, H; Kojima, Y; Morishita, T; Imoto, N; Tsuzuki, S; Mano, H; Naoe, T; Kiyoi, H				Hirano, Daiki; Hayakawa, Fumihiko; Yasuda, Takahiko; Tange, Naoyuki; Yamamoto, Hideyuki; Kojima, Yuki; Morishita, Takanobu; Imoto, Naoto; Tsuzuki, Shinobu; Mano, Hiroyuki; Naoe, Tomoki; Kiyoi, Hitoshi			Chromosomal translocation-mediated evasion from miRNA induces strong MEF2D fusion protein expression, causing inhibition of PAX5 transcriptional activity	ONCOGENE			English	Article							LYMPHOBLASTIC-LEUKEMIA; CELL; PHOSPHORYLATION; TARGET; GENES; DIFFERENTIATION; OVEREXPRESSION; REPRESSION; MYOGENESIS; REGULATOR	MEF2D fusion genes are newly discovered recurrent gene abnormalities that are detected in approximately 5% of acute lymphoblastic leukemia cases. We previously demonstrated that the vector-driven expression of MEF2D fusion proteins was markedly stronger than that of wild-type MEF2D; however, the underlying mechanisms and significance of this expression have yet to be clarified. We herein showed that the strong expression of MEF2D fusion proteins was caused by the loss of the target site of miRNA due to gene translocation. We identified the target region of miRNA located in the coding region and selected miR-122 as a candidate of the responsible miRNA. Mutations at a putative binding site of miR-122 increased MEF2D expression, while the transfection of its miRNA mimic reduced the expression of wild-type MEF2D, but not MEF2D fusion proteins. We also found that MEF2D fusion proteins inhibited the transcriptional activity of PAX5, a B-cell differentiation regulator in a manner that depended on fusion-specific strong expression and an association with histone deacetylase 4, which may lead to the differentiation disorders of B cells. Our results provide novel insights into the mechanisms underlying leukemia development by MEF2D fusion genes and the involvement of the deregulation of miRNA-mediated repression in cancer development.	[Hirano, Daiki; Hayakawa, Fumihiko; Tange, Naoyuki; Yamamoto, Hideyuki; Kojima, Yuki; Morishita, Takanobu; Kiyoi, Hitoshi] Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Aichi, Japan; [Hayakawa, Fumihiko] Nagoya Univ, Grad Sch Med, Dept Pathophysiol Lab Sci, Nagoya, Aichi, Japan; [Yasuda, Takahiko] Natl Hosp Org, Nagoya Med Ctr, Clin Res Ctr, Nagoya, Aichi, Japan; [Imoto, Naoto] Ogaki Municipal Hosp, Dept Hematol, Ogaki, Japan; [Tsuzuki, Shinobu] Aichi Med Univ, Sch Med, Dept Biochem, Nagakute, Aichi, Japan; [Mano, Hiroyuki] Univ Tokyo, Dept Cellular Signaling, Grad Sch Med, Tokyo, Japan; [Naoe, Tomoki] Nagoya Med Ctr, Nagoya, Aichi, Japan	Nagoya University; Nagoya University; Nagoya Medical Center; Ogaki Municipal Hospital; Aichi Medical University; University of Tokyo; Nagoya Medical Center	Hayakawa, F (corresponding author), Nagoya Univ, Dept Hematol & Oncol, Grad Sch Med, Nagoya, Aichi, Japan.; Hayakawa, F (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathophysiol Lab Sci, Nagoya, Aichi, Japan.	bun-hy@med.nagoya-u.ac.jp	Naoe, Tomoki/I-1888-2012; Yasuda, Takahiko/AGQ-5448-2022; Imoto, Naoto/AAB-7504-2022	Yasuda, Takahiko/0000-0002-4686-0976; Imoto, Naoto/0000-0003-0567-8761; Tsuzuki, Shinobu/0000-0002-3209-3550	Japan Agency for Medical Research and Development; JSPS KAKENHI	Japan Agency for Medical Research and Development(Japan Agency for Medical Research and Development (AMED)); JSPS KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We are very grateful to Yoko Matsuyama and Chika Wakamatsu for their technical assistance. We would thank to Yukie Konishi, Manami Kira, Rie Kojima, Yuko Kojima, Youko Okada, and Saori Kanamori for their secretarial assistance. This study was supported in part by grants for Practical Research for Innovative Cancer Control (to FH, HM, and HK), for Programs for Development of Innovative Research on Cancer Therapeutics (P-DIRECT) (to TN), for Project for Cancer Research And Therapeutic Evolution (P-CREATE) (to TY), and for Leading Advanced Projects for Medical Innovation (LEAP) (to HM) from the Japan Agency for Medical Research and Development. This work was also supported by JSPS KAKENHI (to FH, TY, and HK).	Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Chen JJ, 2010, NAT REV CANCER, V10, P23, DOI 10.1038/nrc2765; Gaudilliere B, 2002, J BIOL CHEM, V277, P46442, DOI 10.1074/jbc.M206653200; Gregoire S, 2005, MOL CELL BIOL, V25, P2273, DOI 10.1128/MCB.25.6.2273-2287.2005; Gregoire S, 2006, J BIOL CHEM, V281, P4423, DOI 10.1074/jbc.M509471200; Gu Z, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13331; Hao NB, 2017, ONCOTARGET, V8, P81572, DOI 10.18632/oncotarget.19197; Hausser J, 2013, GENOME RES, V23, P604, DOI 10.1101/gr.139758.112; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Hong SH, 2000, MOL CELL BIOL, V20, P6612, DOI 10.1128/MCB.20.17.6612-6625.2000; Imoto N, 2016, J BIOL CHEM, V291, P4723, DOI 10.1074/jbc.M115.637835; Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294; Kurahashi S, 2011, ONCOGENE, V30, P1822, DOI 10.1038/onc.2010.554; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Liu YF, 2016, EBIOMEDICINE, V8, P173, DOI 10.1016/j.ebiom.2016.04.038; Loher P, 2012, BIOINFORMATICS, V28, P3322, DOI 10.1093/bioinformatics/bts615; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Lund AH, 2002, NAT GENET, V32, P160, DOI 10.1038/ng956; Ma LN, 2014, CANCER RES, V74, P1452, DOI 10.1158/0008-5472.CAN-13-2171; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Nebbioso A, 2020, EMBO REP, V21, DOI [10.1038/embor.2009.88, 10.15252/embr.202051028]; Parker BC, 2013, J CLIN INVEST, V123, P855, DOI 10.1172/JCI67144; Persson M, 2009, P NATL ACAD SCI USA, V106, P18740, DOI 10.1073/pnas.0909114106; Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367; Schwieger M, 2009, BLOOD, V114, P2476, DOI 10.1182/blood-2008-05-158196; Suzuki K, 2016, J CLIN ONCOL, V34, P3451, DOI 10.1200/JCO.2016.66.5547; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tay Y, 2011, CELL, V147, P344, DOI 10.1016/j.cell.2011.09.029; Watamoto K, 2003, ONCOGENE, V22, P9176, DOI 10.1038/sj.onc.1206902; Yang Q, 2009, SCIENCE, V323, P124, DOI 10.1126/science.1166088; Yasuda T, 2016, NAT GENET, V48, P569, DOI 10.1038/ng.3535; Yasuda T, 2012, J IMMUNOL, V188, P6127, DOI 10.4049/jimmunol.1103039; Zhao YY, 2015, J NEUROSCI RES, V93, P1891, DOI 10.1002/jnr.23628	37	10	10	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 28	2019	38	13					2263	2274		10.1038/s41388-018-0573-9	http://dx.doi.org/10.1038/s41388-018-0573-9			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HQ7GN	30478446				2022-12-17	WOS:000462588000003
J	De Oliveira, T; Ramakrishnan, M; Diamanti, MA; Ziegler, PK; Brombacher, F; Greten, FR				De Oliveira, Tiago; Ramakrishnan, Mallika; Diamanti, Michaela A.; Ziegler, Paul K.; Brombacher, Frank; Greten, Florian R.			Loss of Stat6 affects chromatin condensation in intestinal epithelial cells causing diverse outcome in murine models of inflammation-associated and sporadic colon carcinogenesis	ONCOGENE			English	Article							MACROPHAGE ACTIVATION; LINKS INFLAMMATION; INDUCED COLITIS; MOUSE MODEL; ER STRESS; CANCER; INHIBITION; RESPONSES; DNA; INTERLEUKIN-4	While great advances have been achieved regarding the genetic basis of colorectal cancer, the complex role of cell-cell communication and cytokine-induced signaling during its pathogenesis remains less understood. Signal transducer and activator of transcription 6 (Stat6) is the main transcription factor of interleukin-4 (IL-4) signaling and its participation in the development of various tumor types has been already reported. Here we aimed to examine the contribution of Stat6 in intestinal epithelial cells (IEC) in mouse models of intestinal carcinogenesis. Wild-type (WT), Stat6 knockout (Stat6(-/-)), and intestinal epithelial cell-specific IL-4R alpha knockout (Il-4r alpha P-Delta(IEC) ) mice were subjected to colitis-associated (AOM/DSS) and colitis-independent (sporadic) carcinogenesis. IEC proliferation, apoptosis and RNA expression were evaluated by immunohistochemical, immunoblot, and RT-PCR analysis. We found that Stat6( -/- )mice developed more tumors in the colitis-associated carcinogenesis model. This was accompanied by a more pronounced inflammatory response during colitis and an elevated Stat3-dependent proliferation of IEC. Increased sensitivity to DSS-induced colitis was caused by elevated cell death in response to the initial carcinogen exposure as Stat6 deficiency led to increased chromatin compaction affecting DNA damage response in IEC upon treatment with alkylating agents independently of IL-4R alpha engagement. Thus, loss of Stat6 caused more severe colitis and increased tumor load, however loss-of-initiated Stat6(-/-) IEC prevented tumor formation in the absence of overt inflammation. Our data unravel unexpected IL-4- independent functions of Stat6 in chromatin compaction in intestinal epithelial cells ultimately providing both tumor suppressive as well as tumor promoting effects in different models of intestinal tumorigenesis.	[De Oliveira, Tiago; Ramakrishnan, Mallika; Diamanti, Michaela A.; Ziegler, Paul K.; Greten, Florian R.] Georg Speyer Haus, Inst Tumor Biol & Expt Therapy, D-60596 Frankfurt, Germany; [Brombacher, Frank] Int Ctr Genet Engn & Biotechnol, Anzio Rd, ZA-7925 Cape Town, South Africa; [Brombacher, Frank] Univ Cape Town, Anzio Rd, ZA-7925 Cape Town, South Africa; [Brombacher, Frank] South African Med Res Ctr, External Unit, Anzio Rd, ZA-7925 Cape Town, South Africa; [Greten, Florian R.] German Canc Consortium DKTK, D-69120 Heidelberg, Germany; [Greten, Florian R.] German Canc Res Ctr, D-69120 Heidelberg, Germany	Octapharma; International Center for Genetic Engineering & Biotechnology (ICGEB); ICGEB Cape Town; University of Cape Town; Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Greten, FR (corresponding author), Georg Speyer Haus, Inst Tumor Biol & Expt Therapy, D-60596 Frankfurt, Germany.; Greten, FR (corresponding author), German Canc Consortium DKTK, D-69120 Heidelberg, Germany.; Greten, FR (corresponding author), German Canc Res Ctr, D-69120 Heidelberg, Germany.	greten@gsh.uni-frankfurt.de	Greten, Florian R/AAF-5196-2020; Ziegler, Paul/AAO-4379-2021	Greten, Florian R/0000-0002-3928-6080; Ziegler, Paul/0000-0002-7703-7747; De Oliveira, Tiago/0000-0002-2502-7897	LOEWE Center for Cell and Gene Therapy Frankfurt (CGT) [III L 4-518/17.004]; Georg-Speyer-Haus; Deutsche Forschungsgemeinschaft [Gr1916/5-1, FOR2438: Gr1916/11-1, SFB 815, 1177, 1292]	LOEWE Center for Cell and Gene Therapy Frankfurt (CGT); Georg-Speyer-Haus; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank Christin Danneil, Hana Kunkel, Preeti Gupta, Kathleen Mohs, and Eva Rudolf for technical assistance as well as Petra Dinse at the Histology Core Facility at the Georg-Speyer-Haus for excellent technical support and all members of the Greten lab for insightful discussion. We also thank Birgitta Michels for help with karyotype analysis. This work was supported in part by the LOEWE Center for Cell and Gene Therapy Frankfurt (CGT, III L 4-518/17.004) and institutional funds from the Georg-Speyer-Haus, as well as grants from the Deutsche Forschungsgemeinschaft (Gr1916/5-1 and FOR2438: Gr1916/11-1; SFB 815, 1177 and 1292) to F.R.G..	Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Blackford AN, 2017, MOL CELL, V66, P801, DOI 10.1016/j.molcel.2017.05.015; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Cao H, 2016, ONCOTARGET, V7, P61183, DOI 10.18632/oncotarget.11282; Clapper ML, 2007, ACTA PHARMACOL SIN, V28, P1450, DOI 10.1111/j.1745-7254.2007.00695.x; Cosin-Roger J, 2016, MUCOSAL IMMUNOL, V9, P986, DOI 10.1038/mi.2015.123; Das S, 2010, BIOCHEMISTRY-US, V49, P2216, DOI 10.1021/bi9013038; Dawson MR, 2009, NATURE, V461, pE4, DOI 10.1038/nature08254; De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279; Diamanti MA, 2017, J EXP MED, V214, P423, DOI 10.1084/jem.20161867; Dinant C, 2009, MOL CELL BIOL, V29, P6335, DOI 10.1128/MCB.01048-09; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Elrod JW, 2005, INFLAMM BOWEL DIS, V11, P883, DOI 10.1097/01.MIB.0000182871.76434.57; Falk M, 2008, BBA-MOL CELL RES, V1783, P2398, DOI 10.1016/j.bbamcr.2008.07.010; Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; Gandhi NA, 2016, NAT REV DRUG DISCOV, V15, P35, DOI 10.1038/nrd4624; Goenka S, 2011, IMMUNOL RES, V50, P87, DOI 10.1007/s12026-011-8205-2; Gooch JL, 2002, NEOPLASIA, V4, P324, DOI 10.1038/sj.neo.7900248; Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gurvich N, 2004, CANCER RES, V64, P1079, DOI 10.1158/0008-5472.CAN-03-0799; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heller NM, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1164795; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Jayakumar A, 2017, NEOPLASIA, V19, P595, DOI 10.1016/j.neo.2017.04.006; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; LaPorte SL, 2008, CELL, V132, P259, DOI 10.1016/j.cell.2007.12.030; Leon-Cabrera SA, 2017, CANCER IMMUNOL RES, V5, P385, DOI 10.1158/2326-6066.CIR-16-0168; Li WX, 2008, TRENDS CELL BIOL, V18, P545, DOI 10.1016/j.tcb.2008.08.008; Liu L, 2017, GASTROENTEROLOGY, V153, P1517, DOI 10.1053/j.gastro.2017.08.045; Luzina IG, 2012, J LEUKOCYTE BIOL, V92, P753, DOI 10.1189/jlb.0412214; Madigan JP, 2002, NUCLEIC ACIDS RES, V30, P3698, DOI 10.1093/nar/gkf496; Madison BB, 2002, J BIOL CHEM, V277, P33275, DOI 10.1074/jbc.M204935200; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Nishitoh H, 2012, J BIOCHEM, V151, P217, DOI 10.1093/jb/mvr143; Pallangyo CK, 2015, J EXP MED, V212, P2253, DOI 10.1084/jem.20150576; Pegoraro G, 2009, NAT CELL BIOL, V11, P1261, DOI 10.1038/ncb1971; Peng JC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000435; Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014; Shi S, 2008, NAT CELL BIOL, V10, P491, DOI 10.1038/ncb1713; Shi S, 2006, NAT GENET, V38, P1071, DOI 10.1038/ng1860; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1998, J IMMUNOL, V161, P4652; Taniguchi K, 2015, NATURE, V519, P57, DOI 10.1038/nature14228; Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492; Varga J, 2017, NAT CELL BIOL, V19, P1133, DOI 10.1038/ncb3611; Wali RK, 1999, CARCINOGENESIS, V20, P2355, DOI 10.1093/carcin/20.12.2355; Whetstone RD, 2016, MOL CARCINOGEN, V55, P1187, DOI 10.1002/mc.22361; Yan DY, 2016, CELL REP, V16, P2914, DOI 10.1016/j.celrep.2016.08.035; Yan SJ, 2011, FASEB J, V25, P232, DOI 10.1096/fj.10-169367; Zhang HS, 2015, J BIOL CHEM, V290, P15327, DOI 10.1074/jbc.M114.633560	56	10	10	3	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 14	2019	38	11					1787	1801		10.1038/s41388-018-0551-2	http://dx.doi.org/10.1038/s41388-018-0551-2			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HO7XX	30353167	Green Published, hybrid			2022-12-17	WOS:000461164400001
J	Yuki, R; Tatewaki, T; Yamaguchi, N; Aoyama, K; Honda, T; Kubota, S; Morii, M; Manabe, I; Kuga, T; Tomonaga, T; Yamaguchi, N				Yuki, Ryuzaburo; Tatewaki, Takashi; Yamaguchi, Noritaka; Aoyama, Kazumasa; Honda, Takuya; Kubota, Sho; Morii, Mariko; Manabe, Ichiro; Kuga, Takahisa; Tomonaga, Takeshi; Yamaguchi, Naoto			Desuppression of TGF-beta signaling via nuclear c-Abl-mediated phosphorylation of TIF1 gamma/TRIM33 at Tyr-524,-610, and-1048	ONCOGENE			English	Article							SRC-FAMILY KINASES; TYROSINE PHOSPHORYLATION; PROTEIN; CHROMATIN; ACTIVATION; TGF-BETA-1; MECHANISM; RECEPTOR; CANCER; SMAD4	Protein-tyrosine kinases regulate a broad range of intracellular processes occurring primarily just beneath the plasma membrane. With the greatest care to prevent dephosphorylation, we have shown that nuclear tyrosine phosphorylation regulates global chromatin structural states. However, the roles for tyrosine phosphorylation in the nucleus are poorly understood. Here we identify transcriptional intermediary factor 1-gamma (TIF1 gamma/TRIM33/Ectodermin), which suppresses transforming growth factor-beta (TGF-beta) signaling through the association with Smad2/3 transcription factor, as a new nuclear substrate of c-Abl tyrosine kinase. Replacement of the three tyrosine residues Tyr-524, -610, and -1048 with phenylalanine (3YF) inhibits c-Abl-mediated phosphorylation of TIF1. and enhances TIF1 gamma's association with Smad3. Importantly, knockdown-rescue experiments show that 3YF strengthens TIF1 gamma's ability to suppress TGF-beta signaling. Intriguingly, activation of c-Abl by epidermal growth factor (EGF) induces desuppression of TGF-beta signaling via enhancing the tyrosine phosphorylation level of TIF1 gamma. TGF-beta together with EGF synergistically provokes desuppressive responses of epithelial-tomesenchymal transition through tyrosine phosphorylation of TIF1 gamma. These results suggest that nuclear c-Abl-mediated tyrosine phosphorylation of TIF1 gamma has a desuppressive role in TGF-beta-Smad2/3 signaling.	[Yuki, Ryuzaburo; Tatewaki, Takashi; Yamaguchi, Noritaka; Aoyama, Kazumasa; Honda, Takuya; Kubota, Sho; Morii, Mariko; Yamaguchi, Naoto] Chiba Univ, Grad Sch Pharmaceut Sci, Lab Mol Cell Biol, Chiba 2608675, Japan; [Yuki, Ryuzaburo; Manabe, Ichiro] Chiba Univ, Grad Sch Med, Lab Dis Biol & Mol Med, Chiba 2608670, Japan; [Kuga, Takahisa; Tomonaga, Takeshi] Natl Inst Biomed Innovat Hlth & Nutr, Lab Proteome Res, Osaka 5670085, Japan	Chiba University; Chiba University	Yamaguchi, N (corresponding author), Chiba Univ, Grad Sch Pharmaceut Sci, Lab Mol Cell Biol, Chiba 2608675, Japan.	nyama@faculty.chiba-u.jp	Kuga, Takahisa/AAX-9334-2020; Manabe, Ichiro/AAE-5105-2021	Honda, Takuya/0000-0002-7141-0088; Kubota, Sho/0000-0001-6119-1259	MEXT [15K07922, 16K08227]; Global COE Program from the MEXT; Program for Leading Graduate School (LGS) from the MEXT	MEXT(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Global COE Program from the MEXT; Program for Leading Graduate School (LGS) from the MEXT	We are grateful to Dr. Eli Canaani (Weizmann Institute of Science), Dr. Hiroyuki Miyoshi (RIKEN BRC, Tsukuba), Dr. Toshiki Tamura (National Institute of Infectious Diseases, Tokyo), and Dr. Masatoshi Tagawa (Chiba Cancer Center Research Institute, Chiba) for their materials. This work was supported in part by grantsin-aid for Scientific Research 15K07922 (to Naoto Y) and 16K08227 (to Noritaka Y), Global COE Program, and Program for Leading Graduate School (LGS) from the MEXT. KA and SK were G-COE Research Assistants. TH and M.M. were LGS Research Assistants. SK, TH, and MM are JSPS Research Fellows.	Agricola E, 2011, MOL CELL, V43, P85, DOI 10.1016/j.molcel.2011.05.020; Aoyama K, 2015, CELL BIOL INT, V39, P446, DOI 10.1002/cbin.10413; Aoyama K, 2013, EXP CELL RES, V319, P3251, DOI 10.1016/j.yexcr.2013.09.003; Aoyama K, 2011, EXP CELL RES, V317, P2874, DOI 10.1016/j.yexcr.2011.09.013; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Bergeron JJM, 2016, ANNU REV BIOCHEM, V85, P573, DOI 10.1146/annurev-biochem-060815-014659; Cans C, 2000, BIOCHEM PHARMACOL, V60, P1203, DOI 10.1016/S0006-2952(00)00434-2; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Docherty NG, 2006, AM J PHYSIOL-RENAL, V290, pF1202, DOI 10.1152/ajprenal.00406.2005; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Fattet L, 2013, J CELL SCI, V126, P3713, DOI 10.1242/jcs.126748; Fukumoto Y, 2010, CYTOTECHNOLOGY, V62, P73, DOI 10.1007/s10616-010-9259-z; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; Greuber EK, 2013, NAT REV CANCER, V13, P559, DOI 10.1038/nrc3563; Hantschel O, 2003, CELL, V112, P845, DOI 10.1016/S0092-8674(03)00191-0; Hasegawa H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0116048; He JC, 2008, INVEST OPHTH VIS SCI, V49, P2936, DOI 10.1167/iovs.07-0900; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Herquel B, 2011, TRANSCR-AUSTIN, V2, P231, DOI 10.4161/trns.2.5.17725; Honda T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19599-1; Hubbard SR, 2000, ANNU REV BIOCHEM, V69, P373, DOI 10.1146/annurev.biochem.69.1.373; Hunter T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020644; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Ishibashi K, 2013, J CELL SCI, V126, P625, DOI 10.1242/jcs.116277; Jia M., 2011, Experimental Oncology, V33, P170; Kasahara K, 2007, J CELL PHYSIOL, V211, P220, DOI 10.1002/jcp.20931; Khatri A, 2016, J CELL SCI, V129, P9, DOI 10.1242/jcs.175521; Krainock M, 2016, J CLIN MED, V19, pE27; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kubota S, 2015, J BIOL CHEM, V290, P10891, DOI 10.1074/jbc.M115.643882; Kubota S, 2013, J BIOL CHEM, V288, P17871, DOI 10.1074/jbc.M112.437756; Kuki K, 2017, BIOCHEM BIOPH RES CO, V490, P1045, DOI 10.1016/j.bbrc.2017.06.163; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Macias MJ, 2015, TRENDS BIOCHEM SCI, V40, P296, DOI 10.1016/j.tibs.2015.03.012; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Moorhead GBG, 2007, NAT REV MOL CELL BIO, V8, P234, DOI 10.1038/nrm2126; Morabito CJ, 2001, DEV BIOL, V234, P204, DOI 10.1006/dbio.2001.0254; Morii M, 2017, J BIOL CHEM, V292, P1648, DOI 10.1074/jbc.M116.753202; Morii M, 2015, CELL BIOL INT, V39, P923, DOI 10.1002/cbin.10460; Nasrollahi S, 2016, SCI REP-UK, V6, DOI 10.1038/srep18831; Obata Y, 2010, J CELL SCI, V123, P2649, DOI 10.1242/jcs.066266; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Quere R, 2014, P NATL ACAD SCI USA, V111, P10592, DOI 10.1073/pnas.1405546111; Saha Debabrata, 1999, Neoplasia (New York), V1, P508; Sato I, 2009, J CELL SCI, V122, P965, DOI 10.1242/jcs.034843; Schlessinger Joseph, 2014, Cold Spring Harb Perspect Biol, V6, DOI 10.1101/cshperspect.a008912; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; Sirvent A, 2008, BIOL CELL, V100, P617, DOI 10.1042/BC20080020; Soeda S, 2013, EXP CELL RES, V319, P1382, DOI 10.1016/j.yexcr.2013.02.023; Sundqvist A, 2013, ONCOGENE, V32, P3606, DOI 10.1038/onc.2012.370; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Takahashi A, 2009, EXP CELL RES, V315, P1117, DOI 10.1016/j.yexcr.2009.02.010; Tamura T, 2000, INT IMMUNOL, V12, P1205, DOI 10.1093/intimm/12.8.1205; Uttamsingh S, 2008, ONCOGENE, V27, P2626, DOI 10.1038/sj.onc.1210915; Wang JYJ, 2014, MOL CELL BIOL, V34, P1188, DOI 10.1128/MCB.01454-13; Wang SN, 2010, AM J PHYSIOL-RENAL, V298, pF142, DOI 10.1152/ajprenal.00320.2009; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Yamaguchi N, 2001, J CELL SCI, V114, P1631; Yamaguchi N, 2017, J CELL BIOCHEM, V118, P1453, DOI 10.1002/jcb.25804; Yamaguchi N, 2015, BIOCHEM J, V471, P67, DOI 10.1042/BJ20150372; Yuki R, 2015, J CELL BIOCHEM, V116, P954, DOI 10.1002/jcb.25046	64	10	10	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 31	2019	38	5					637	655		10.1038/s41388-018-0481-z	http://dx.doi.org/10.1038/s41388-018-0481-z			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HJ6LI	30177833				2022-12-17	WOS:000457300300003
J	Lorenzo-Martin, LF; Citterio, C; Menacho-Marquez, M; Conde, J; Larive, RM; Rodriguez-Fdez, S; Garcia-Escudero, R; Robles-Valero, J; Cuadrado, M; Fernandez-Pisonero, I; Dosil, M; Sevilla, MA; Montero, MJ; Fernandez-Salguero, PM; Paramio, JM; Bustelo, XR				Francisco Lorenzo-Martin, L.; Citterio, Carmen; Menacho-Marquez, Mauricio; Conde, Javier; Larive, Romain M.; Rodriguez-Fdez, Sonia; Garcia-Escudero, Ramon; Robles-Valero, Javier; Cuadrado, Myriam; Fernandez-Pisonero, Isabel; Dosil, Mercedes; Sevilla, Maria A.; Montero, Maria J.; Fernandez-Salguero, Pedro M.; Paramio, Jesus M.; Bustelo, Xose R.			Vav proteins maintain epithelial traits in breast cancer cells using miR-200c-dependent and independent mechanisms	ONCOGENE			English	Article							EXCHANGE FACTOR VAV1; MESENCHYMAL TRANSITION; GENE-EXPRESSION; TGF-BETA; METASTASIS; EMT; FAMILY; DISSEMINATION; NORMALIZATION; CONTRIBUTES	The bidirectional regulation of epithelial-mesenchymal transitions (EMT) is key in tumorigenesis. Rho GTPases regulate this process via canonical pathways that impinge on the stability of cell-to-cell contacts, cytoskeletal dynamics, and cell invasiveness. Here, we report that the Rho GTPase activators Vav2 and Vav3 utilize a new Rac1-dependent and miR-200cdependent mechanism that maintains the epithelial state by limiting the abundance of the Zeb2 transcriptional repressor in breast cancer cells. In parallel, Vav proteins engage a mir-200c-independent expression prometastatic program that maintains epithelial cell traits only under 3D culture conditions. Consistent with this, the depletion of endogenous Vav proteins triggers mesenchymal features in epithelioid breast cancer cells. Conversely, the ectopic expression of an active version of Vav2 promotes mesenchymal-epithelial transitions using E-cadherin-dependent and independent mechanisms depending on the mesenchymal breast cancer cell line used. In silico analyses suggest that the negative Vav anti-EMT pathway is operative in luminal breast tumors. Gene signatures from the Vav-associated proepithelial and prometastatic programs have prognostic value in breast cancer patients.	[Francisco Lorenzo-Martin, L.; Citterio, Carmen; Menacho-Marquez, Mauricio; Conde, Javier; Larive, Romain M.; Rodriguez-Fdez, Sonia; Robles-Valero, Javier; Cuadrado, Myriam; Fernandez-Pisonero, Isabel; Dosil, Mercedes; Bustelo, Xose R.] Ctr Invest Canc, Salamanca 37007, Spain; [Francisco Lorenzo-Martin, L.; Citterio, Carmen; Menacho-Marquez, Mauricio; Conde, Javier; Larive, Romain M.; Rodriguez-Fdez, Sonia; Robles-Valero, Javier; Cuadrado, Myriam; Fernandez-Pisonero, Isabel; Dosil, Mercedes; Bustelo, Xose R.] Inst Biol Mol & Celular Canc, Salamanca 37007, Spain; [Francisco Lorenzo-Martin, L.; Menacho-Marquez, Mauricio; Garcia-Escudero, Ramon; Robles-Valero, Javier; Cuadrado, Myriam; Fernandez-Pisonero, Isabel; Dosil, Mercedes; Sevilla, Maria A.; Montero, Maria J.; Paramio, Jesus M.; Bustelo, Xose R.] Univ Salamanca, CSIC, Ctr Invest Biomed Red Canc CIBERONC, Salamanca 37007, Spain; [Garcia-Escudero, Ramon; Paramio, Jesus M.] CIEMAT, Madrid 28040, Spain; [Dosil, Mercedes] Univ Salamanca, Dept Biochem & Mol Biol, Salamanca 37007, Spain; [Montero, Maria J.] Univ Salamanca, Dept Physiol & Pharmacol, Salamanca 37007, Spain; [Fernandez-Salguero, Pedro M.] Univ Extremadura, Dept Biochem Mol Biol & Genet, Badajoz 06071, Spain; [Menacho-Marquez, Mauricio] Lab Max Planck Biol Estruct Quim & Biofis Mol, Rosario, Argentina; [Larive, Romain M.] Inst Biomol Max Mousseron UMR, F-5247 Montpellier, France	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigacion del Cancer (CIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); CIBER - Centro de Investigacion Biomedica en Red; CIBERONC; Consejo Superior de Investigaciones Cientificas (CSIC); University of Salamanca; Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; University of Salamanca; University of Salamanca; Universidad de Extremadura; Universite de Montpellier	Bustelo, XR (corresponding author), Ctr Invest Canc, Salamanca 37007, Spain.; Bustelo, XR (corresponding author), Inst Biol Mol & Celular Canc, Salamanca 37007, Spain.; Bustelo, XR (corresponding author), Univ Salamanca, CSIC, Ctr Invest Biomed Red Canc CIBERONC, Salamanca 37007, Spain.	xbustelo@usal.es	Paramio, Jesus M/M-8482-2014; Rodriguez-Fdez, Sonia/AAD-9317-2021; Dosil, Mercedes/A-9536-2016; Aranda, Javier Conde/P-5537-2015; Garcia-Escudero, Ramon/A-2735-2012; Robles-Valero, Javier/J-4069-2017; Montero, Maria Jose/C-3084-2018	Paramio, Jesus M/0000-0001-7520-3177; Dosil, Mercedes/0000-0001-8119-8263; Aranda, Javier Conde/0000-0002-2187-479X; Garcia-Escudero, Ramon/0000-0001-5640-6542; Rodriguez-Fdez, Sonia/0000-0001-5369-2969; Robles-Valero, Javier/0000-0001-5218-0187; Fernandez-Pisonero, Isabel/0000-0002-5130-2143; Lorenzo-Martin, L. Francisco/0000-0003-4717-9338; Cuadrado, Myriam/0000-0001-9410-1205; Montero, Maria Jose/0000-0003-2125-0378	Castilla-Leon Government [CSI049U16]; Spanish Ministry of Economy and Competitiveness (MINECO) [SAF2015-64556-R]; Worldwide Cancer Research [14-1248]; Ramon Areces Foundation; Spanish Association against Cancer [GC16173472GARC]; MINECO [BFU2014-52729-P, SAF2015-66015-R, PIE15/00076, SAF2014-51813-R, CD15/00113, BES-2013-063573]; European Regional Development Fund; Spanish Ministry of Education, Culture and Sports [FPU13/02923]	Castilla-Leon Government; Spanish Ministry of Economy and Competitiveness (MINECO)(Spanish Government); Worldwide Cancer Research; Ramon Areces Foundation; Spanish Association against Cancer; MINECO(Spanish Government); European Regional Development Fund(European Commission); Spanish Ministry of Education, Culture and Sports(Spanish Government)	We thank M. Blazquez, A. Abad, and E. Ferminan for lab work, animal work, and microarray analyses, respectively. XRB is supported by grants from the Castilla-Leon Government (CSI049U16), the Spanish Ministry of Economy and Competitiveness (MINECO) (SAF2015-64556-R), Worldwide Cancer Research (14-1248), the Ramon Areces Foundation, and the Spanish Association against Cancer (GC16173472GARC). MD (BFU2014-52729-P), JMP (SAF2015-66015-R, PIE15/00076), and PMF-S (SAF2014-51813-R) are supported by MINECO grants. Spanish funding is partially supported by the European Regional Development Fund. LFL-M, JC, and SR-F were supported by funding from the Spanish Ministry of Education, Culture and Sports (LFL-M, FPU13/02923) and the MINECO (JC, CD15/00113; SR-F, BES-2013-063573).	Abate F, 2017, P NATL ACAD SCI USA, V114, P764, DOI 10.1073/pnas.1608839114; Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Blenis J, 2017, CELL, V171, P10, DOI 10.1016/j.cell.2017.08.019; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Bracken CP, 2016, NAT REV GENET, V17, P719, DOI 10.1038/nrg.2016.134; Bustelo X. R., 2014, SMALL GTPASES, V5, P1, DOI DOI 10.4161/21541248.2014.973757; Bustelo XR, 2007, BIOESSAYS, V29, P356, DOI 10.1002/bies.20558; Bustelo XR, 2012, BIOESSAYS, V34, P748, DOI 10.1002/bies.201200041; Citterio C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002962; Cochrane DR, 2009, MOL CANCER THER, V8, P1055, DOI 10.1158/1535-7163.MCT-08-1046; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Fabbiano S, 2015, MOL CELL BIOL, V35, P3528, DOI 10.1128/MCB.00518-15; Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748; Fluegen G, 2017, NAT CELL BIOL, V19, P120, DOI 10.1038/ncb3465; Hatzis C, 2011, JAMA-J AM MED ASSOC, V305, P1873, DOI 10.1001/jama.2011.593; Heng TSP, 2008, NAT IMMUNOL, V9, P1091, DOI 10.1038/ni1008-1091; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Howe EN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2867; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Itoh M, 2014, BREAST CANCER RES TR, V143, P403, DOI 10.1007/s10549-013-2763-z; Janky R, 2014, PLOS COMPUT BIOL, V10, DOI 10.1371/journal.pcbi.1003731; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Katsura A, 2016, GENES CELLS, V21, P99, DOI 10.1111/gtc.12323; Kim RS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035569; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Larive RM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4881; Larive RM, 2012, MOL BIOL CELL, V23, P2373, DOI 10.1091/mbc.E12-01-0060; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Li M, 2016, SCI REP-UK, V6, DOI 10.1038/srep23100; Li XY, 2008, J EXP MED, V205, P2851, DOI 10.1084/jem.20081561; Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004; Liu M, 2012, TRENDS CELL BIOL, V22, P365, DOI 10.1016/j.tcb.2012.04.004; Luo DY, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-57; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Menacho-Marquez M, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001615; Menacho-Marquez M, 2013, CELL METAB, V18, P199, DOI 10.1016/j.cmet.2013.07.001; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Montemayor C, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008910; Moreno-Bueno G, 2011, EMBO MOL MED, V3, P528, DOI 10.1002/emmm.201100156; Morita T, 2007, J CELL BIOL, V179, P1027, DOI 10.1083/jcb.200708174; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Papadimitriou E, 2012, ONCOGENE, V31, P2862, DOI 10.1038/onc.2011.457; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007; Robles-Valero J, 2017, CANCER CELL, V32, P608, DOI 10.1016/j.ccell.2017.10.004; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sauzeau V, 2006, NAT MED, V12, P841, DOI 10.1038/nm1426; Sauzeau V, 2007, MOL BIOL CELL, V18, P943, DOI 10.1091/mbc.E06-09-0877; Sauzeau V, 2010, J CLIN INVEST, V120, P315, DOI 10.1172/JCI38356; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thaper D, 2017, ONCOGENE, V36, P3964, DOI 10.1038/onc.2017.5; Uhlenbrock K, 2004, J CELL SCI, V117, P4863, DOI 10.1242/jcs.01367; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Wakahashi S, 2013, TRANSL RES, V162, P181, DOI 10.1016/j.trsl.2013.06.005; Wang RZ, 2013, HEPATOLOGY, V58, P642, DOI 10.1002/hep.26373; Wilkes MC, 2003, MOL CELL BIOL, V23, P8878, DOI 10.1128/MCB.23.23.8878-8889.2003; Yoo AS, 2005, SCIENCE, V310, P1330, DOI 10.1126/science.1119481	69	10	10	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 10	2019	38	2					209	227		10.1038/s41388-018-0433-7	http://dx.doi.org/10.1038/s41388-018-0433-7			19	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	HG9XX	30087437	hybrid, Green Published, Green Accepted			2022-12-17	WOS:000455366700005
J	Yoon, S; Lee, EJ; Choi, JH; Chung, T; Kim, DY; Im, JY; Bae, MH; Kwon, JH; Kim, HH; Kim, HC; Park, YN; Wang, HJ; Woo, HG				Yoon, Sarah; Lee, Eun-Ju; Choi, Ji-Hye; Chung, Taek; Kim, Do Young; Im, Jong-Yeop; Bae, Myung-Ho; Kwon, Jung-Hee; Kim, Hyuk-Hoon; Kim, Hyung Chul; Park, Young Nyun; Wang, Hee-Jung; Woo, Hyun Goo			Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer	ONCOGENE			English	Article							HUMAN HEPATOCELLULAR-CARCINOMA; LIPOCALIN 2; RESISTANCE; PROGRESSION; EXPRESSION; ANGIOGENESIS; SENSITIVITY; INDUCTION; MECHANISM; HUMANS	Gene mutations play critical roles during cancer development and progression, and therefore represent targets for precision medicine. Here we recapitulated the pharmacogenomic data to delineate novel candidates for actionable mutations and therapeutic target drugs. As a proof-of-concept, we demonstrated that the loss-of-function of SULF2 by mutation (N491K) or inhibition enhanced sorafenib sensitivity in liver cancer cells and in vivo mouse models. This effect was mediated by deregulation of EGFR signaling and downstream expression of LCN2. We also report that the liver cancer patients non-responding to sorafenib treatment exhibit higher expression of SULF2 and LCN2. In conclusion, we suggest that SULF2 plays a key role in sorafenib susceptibility and resistance in liver cancer via deregulation of LCN2. Diagnostic or therapeutic targeting of SULF2 (e.g., OKN-007) and/or LCN2 can be a novel precision strategy for sorafenib treatment in cancer patients.	[Yoon, Sarah; Lee, Eun-Ju; Choi, Ji-Hye; Im, Jong-Yeop; Woo, Hyun Goo] Ajou Univ, Sch Med, Dept Physiol, Suwon, South Korea; [Choi, Ji-Hye; Im, Jong-Yeop; Woo, Hyun Goo] Ajou Univ, Dept Biomed Sci, Grad Sch, Suwon, South Korea; [Chung, Taek; Park, Young Nyun] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea; [Chung, Taek; Park, Young Nyun] Yonsei Univ, Coll Med, PLUS Project Med Sci BK21, Seoul, South Korea; [Kim, Do Young] Yonsei Univ, Coll Med, Dept Gastroenterol, Seoul, South Korea; [Bae, Myung-Ho; Kwon, Jung-Hee] CbsBioscience Inc, Daejeon, South Korea; [Kim, Hyuk-Hoon] Ajou Univ, Sch Med, Dept Emergency Med, Suwon, South Korea; [Kim, Hyung Chul] NCI, Dev Therapeut Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Wang, Hee-Jung] Ajou Univ, Sch Med, Dept Surg, Suwon, South Korea	Ajou University; Ajou University; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Ajou University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Ajou University	Woo, HG (corresponding author), Ajou Univ, Sch Med, Dept Physiol, Suwon, South Korea.; Woo, HG (corresponding author), Ajou Univ, Dept Biomed Sci, Grad Sch, Suwon, South Korea.	hg@ajou.ac.kr	Woo, Hyun Goo/AEJ-7372-2022; Woo, Hyun Goo | 우현구/I-8954-2019	Woo, Hyun Goo/0000-0002-0916-893X; Woo, Hyun Goo | 우현구/0000-0002-0916-893X	Korea Healthcare Technology R&D Project, Ministry of Health Welfare [HI15C1551, HI14C3392]; National Research Foundation of Korea (NRF) - Korea government (MSIP) [NRF-2017M3A9B6061509, NRF-2017R1E1A1A01074733, NRF-2015R1D1A4A01020022]	Korea Healthcare Technology R&D Project, Ministry of Health Welfare; National Research Foundation of Korea (NRF) - Korea government (MSIP)	This work was supported by grants from the Korea Healthcare Technology R&D Project, Ministry of Health & Welfare (HI15C1551 and HI14C3392) and from the National Research Foundation of Korea (NRF) funded by the Korea government (MSIP) (NRF-2017M3A9B6061509, NRF-2017R1E1A1A01074733, and NRF-2015R1D1A4A01020022).	Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Basu A, 2013, CELL, V154, P1151, DOI 10.1016/j.cell.2013.08.003; Berasain C, 2013, GUT, V62, P1674, DOI 10.1136/gutjnl-2013-304564; Blivet-Van Eggelpoel MJ, 2012, J HEPATOL, V57, P108, DOI 10.1016/j.jhep.2012.02.019; Chen G, 2017, CANCER RES, V77, P632, DOI 10.1158/0008-5472.CAN-15-2556; Chen HA, 2016, HEPATOLOGY, V64, P1637, DOI 10.1002/hep.28773; Ding GX, 2015, PROSTATE, V75, P957, DOI 10.1002/pros.22978; Frese MA, 2009, J BIOL CHEM, V284, P28033, DOI 10.1074/jbc.M109.035808; Haibe-Kains B, 2013, NATURE, V504, P389, DOI 10.1038/nature12831; Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017; Lai JP, 2008, HEPATOLOGY, V47, P1211, DOI 10.1002/hep.22202; Lai JP, 2010, HEPATOLOGY, V52, P1680, DOI 10.1002/hep.23848; Leung L, 2012, PLOS ONE, V7; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Morimoto-Tomita M, 2002, J BIOL CHEM, V277, P49175, DOI 10.1074/jbc.M205131200; Nishida N, 2015, DIGEST DIS, V33, P771, DOI 10.1159/000439102; Park JG, 2015, CLIN MOL HEPATOL, V21, P287, DOI 10.3350/cmh.2015.21.3.287; Peng S, 2014, HEPATOLOGY, V60, P1264, DOI 10.1002/hep.27236; Rosen SD, 2010, EXPERT OPIN THER TAR, V14, P935, DOI 10.1517/14728222.2010.504718; Rudalska R, 2014, NAT MED, V20, P1138, DOI 10.1038/nm.3679; Shiiba M, 2013, INT J ONCOL, V42, P1197, DOI 10.3892/ijo.2013.1815; Sun XF, 2016, HEPATOLOGY, V64, P488, DOI 10.1002/hep.28574; Tang RH, 2009, J BIOL CHEM, V284, P21505, DOI 10.1074/jbc.M109.028472; Tovar V, 2017, GUT, V66, P530, DOI 10.1136/gutjnl-2015-309501; Viau A, 2010, J CLIN INVEST, V120, P4065, DOI 10.1172/JCI42004; Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Yonesaka K, 2008, CLIN CANCER RES, V14, P6963, DOI 10.1158/1078-0432.CCR-08-0957; Yoo J, 2012, AM J PHYSIOL-GASTR L, V302, pG805, DOI 10.1152/ajpgi.00522.2011; Zhang Y, 2012, CANCER EPIDEMIOL, V36, pE294, DOI 10.1016/j.canep.2012.05.012; Zhao P, 2013, MOL METAB, V2, P161, DOI 10.1016/j.molmet.2013.04.003	31	10	10	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 9	2018	37	32					4443	4454		10.1038/s41388-018-0291-3	http://dx.doi.org/10.1038/s41388-018-0291-3			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GP8FA	29720727				2022-12-17	WOS:000441144300008
J	Gattelli, A; Sola, MEG; Roloff, TC; Cardiff, RD; Kordon, EC; Chodosh, LA; Hynes, NE				Gattelli, Albana; Garcia Sola, Martin E.; Roloff, Tim C.; Cardiff, Robert D.; Kordon, Edith C.; Chodosh, Lewis A.; Hynes, Nancy E.			Chronic expression of wild-type Ret receptor in the mammary gland induces luminal tumors that are sensitive to Ret inhibition	ONCOGENE			English	Article							BREAST-CANCER CELLS; TRANSGENIC MICE; GENE; RESISTANCE; LANDSCAPE; FUSIONS; GROWTH	The receptor tyrosine kinase Ret, a key gain-of-function mutated oncoprotein in thyroid carcinomas, has recently been implicated in other cancer types. While Ret copy number gains and mutations have been reported at low frequencies in breast tumors, we and others have reported that Ret is overexpressed in about 40% of human tumors and this correlates with poor patient prognosis. Ret activation regulates numerous intracellular pathways related to proliferation and inflammation, but it is not known whether abnormal Ret expression is sufficient to induce mammary carcinomas. Using a novel doxycycline-inducible transgenic mouse model with the MMTV promoter controlling Ret expression, we show that overexpression of wild-type Ret in the mammary epithelium produces mammary tumors, displaying a morphology that recapitulates characteristics of human luminal breast tumors. Ret-evoked tumors are estrogen receptor positive and negative for progesterone receptor. Moreover, tumors rapidly regress after doxycycline withdrawal, indicating that Ret is the driving oncoprotein. Using next-generation sequencing, we examined the levels of transcripts in these tumors, confirming a luminal signature. Ret-evoked tumors have been passaged in mice and used to test novel therapeutic approaches. Importantly, we have determined that tumors are resistant to endocrine therapy, but respond successfully to treatment with a Ret kinase inhibitor. Our data provide the first compelling evidence for an oncogenic role of non-mutated Ret in the mammary gland and are an incentive for clinical development of Ret as a cancer biomarker and therapeutic target.	[Gattelli, Albana; Garcia Sola, Martin E.; Kordon, Edith C.] UBA, Fac Ciencias Exactas & Nat, Buenos Aires, DF, Argentina; [Gattelli, Albana; Garcia Sola, Martin E.; Kordon, Edith C.] UBA, CONICET, Inst Fisiol Biol Mol & Neurociencias IFIBYNE, RA-1428 CABA Buenos Aires, Argentina; [Gattelli, Albana; Roloff, Tim C.; Hynes, Nancy E.] Friedrich Miescher Inst Biomed Res FMI, Maulbeerstr 66, CH-4058 Basel, Switzerland; [Cardiff, Robert D.] UCD, Ctr Genom Pathol, Sch Med, Pathol & Lab Med, Cty Rd 98 & Hutchison Dr, Davis, CA USA; [Chodosh, Lewis A.] Univ Penn Upenn, Perelman Sch Med, Dept Canc Biol, 614 BRB II-III,421 Curie Blvd, Philadelphia, PA USA; [Hynes, Nancy E.] Univ Basel, CH-4002 Basel, Switzerland	University of Buenos Aires; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Friedrich Miescher Institute for Biomedical Research; University of Pennsylvania; Pennsylvania Medicine; University of Basel	Gattelli, A (corresponding author), UBA, Fac Ciencias Exactas & Nat, Buenos Aires, DF, Argentina.; Gattelli, A (corresponding author), UBA, CONICET, Inst Fisiol Biol Mol & Neurociencias IFIBYNE, RA-1428 CABA Buenos Aires, Argentina.; Gattelli, A; Hynes, NE (corresponding author), Friedrich Miescher Inst Biomed Res FMI, Maulbeerstr 66, CH-4058 Basel, Switzerland.; Hynes, NE (corresponding author), Univ Basel, CH-4002 Basel, Switzerland.	albanaga@fbmc.fcen.uba.ar; Nancy.Hynes@fmi.ch		Gattelli, Albana/0000-0003-1260-5413; Garcia Sola, Martin E/0000-0002-0229-8870	Susan G. Komen for the Cure(R) [KG101234, SAC110041]; Fundacion para el Progreso de la Medicina Cordoba [02]; Krebsliga beider Basel [10-2030]; Novartis Research Foundation	Susan G. Komen for the Cure(R)(Susan G. Komen Breast Cancer Foundation); Fundacion para el Progreso de la Medicina Cordoba; Krebsliga beider Basel; Novartis Research Foundation	AG was supported by grant KG101234 from Susan G. Komen for the Cure (R) and grant GF No 02 from Fundacion para el Progreso de la Medicina Cordoba. NEH was supported by grants from Susan G. Komen for the Cure (R) SAC110041, from Krebsliga beider Basel 10-2030 and by the Novartis Research Foundation.	Akeno-Stuart N, 2007, CANCER RES, V67, P6956, DOI 10.1158/0008-5472.CAN-06-4605; Avalle Lidia, 2012, JAKSTAT, V1, P65, DOI 10.4161/jkst.20045; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Boulay A, 2008, CANCER RES, V68, P3743, DOI 10.1158/0008-5472.CAN-07-5100; Cardiff RD, 1999, J MAMMARY GLAND BIOL, V4, P105, DOI 10.1023/A:1018712905244; Chan SR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3100; Esseghir S, 2007, CANCER RES, V67, P11732, DOI 10.1158/0008-5472.CAN-07-2343; Gattelli A, 2013, EMBO MOL MED, V5, P1335, DOI 10.1002/emmm.201302625; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Gunther EJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0551com; Hynes NE, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003186; IWAMOTO T, 1990, ONCOGENE, V5, P535; Kang J, 2012, ONCOGENE, V31, P402, DOI 10.1038/onc.2011.553; Kohno T, 2013, CANCER SCI, V104, P1396, DOI 10.1111/cas.12275; Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644; Moody SE, 2002, CANCER CELL, V2, P451, DOI 10.1016/S1535-6108(02)00212-X; Morandi A, 2013, CANCER RES, V73, P3783, DOI 10.1158/0008-5472.CAN-12-4265; Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Plaza-Menacho I, 2010, ONCOGENE, V29, P4648, DOI 10.1038/onc.2010.209; Rakha EA, 2007, J CLIN ONCOL, V25, P4772, DOI 10.1200/JCO.2007.12.2747; Sarkisian CJ, 2007, NAT CELL BIOL, V9, P493, DOI 10.1038/ncb1567; Spanheimer PM, 2014, CLIN CANCER RES, V20, P2115, DOI 10.1158/1078-0432.CCR-13-2221; Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807	25	10	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 19	2018	37	29					4046	4054		10.1038/s41388-018-0235-y	http://dx.doi.org/10.1038/s41388-018-0235-y			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GN5LP	29695833				2022-12-17	WOS:000439101300010
J	Debernardi, J; Hollville, E; Lipinski, M; Wiels, J; Robert, A				Debernardi, Justine; Hollville, Emilie; Lipinski, Marc; Wiels, Joelle; Robert, Aude			Differential role of FL-BID and t-BID during verotoxin-1-induced apoptosis in Burkitt's lymphoma cells	ONCOGENE			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; CYTOCHROME-C; SHIGA TOXINS; HELA-CELLS; IN-VITRO; BAX; ACTIVATION; CRISTAE; GLOBOTRIAOSYLCERAMIDE; IDENTIFICATION	The globotriaosylceramide Gb3 is a glycosphingolipid expressed on a subpopulation of germinal center B lymphocytes which has been recognized as the B cell differentiation antigen CD77. Among tumoral cell types, Gb3/CD77 is strongly expressed in Burkitt's lymphoma (BL) cells as well as other solid tumors including breast, testicular and ovarian carcinomas. One known ligand of Gb3/CD77 is Verotoxin-1 (VT-1), a Shiga toxin produced in specific E. coli strains. Previously, we have reported that in BL cells, VT-1 induces apoptosis via a caspase-dependent and mitochondria-dependent pathway. Yet, the respective roles of various apoptogenic factors remained to be deciphered. Here, this apoptotic pathway was found to require cleavage of the BID protein by caspase-8 as well as activation of two other apoptogenic proteins, BAK and BAX. Surprisingly however, t-BID, the truncated form of BID resulting from caspase-8 cleavage, played no role in the conformational changes of BAK and BAX. Rather, their activation occurred under the control of full length BID (FL-BID). Indeed, introducing a non-cleavable form of BID (BID-D59A) into BID-deficient BL cells restored BAK and BAX activation following VT-1 treatment. Still, t-BID was involved along with FL-BID in the BAK-dependent and BAX-dependent cytosolic release of CYT C and SMAC/DIABLO from the mitochondrial intermembrane space: FL-BID was found to control the homo-oligomerization of both BAK and BAX, likely contributing to the initial release of CYT C and SMAC/DIABLO, while t-BID was needed for their hetero-oligomerization and ensuing release amplification. Together, our results reveal a functional cooperation between BAK and BAX during VT-1-induced apoptosis and, unexpectedly, that activation of caspase-8 and production of t-BID were not mandatory for initiation of the cell death process.	[Debernardi, Justine; Hollville, Emilie; Lipinski, Marc; Wiels, Joelle; Robert, Aude] Univ Paris Saclay, Univ Paris Sud, CNRS, Inst Gustave Roussy,UMR 8126, F-94805 Villejuif, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; UNICANCER; Gustave Roussy	Wiels, J (corresponding author), Univ Paris Saclay, Univ Paris Sud, CNRS, Inst Gustave Roussy,UMR 8126, F-94805 Villejuif, France.	joelle.wiels@gustaveroussy.fr	robert, aude/F-9584-2015; Hollville, Emilie/ABD-4798-2021; Hollville, Emilie/AAA-3597-2022; Hollville, Emilie/GQZ-8301-2022; Wiels, Joëlle/AGL-2319-2022	robert, aude/0000-0003-3095-4190; Hollville, Emilie/0000-0001-5711-8542; Wiels, Joëlle/0000-0002-3313-2937	Fondation de France [2014 00047509]; Ligue National Contre le Cancer; Fondation ARC	Fondation de France(Fondation de France); Ligue National Contre le Cancer(Ligue nationale contre le cancer); Fondation ARC	We thank Yann Lecluse (Imaging and Cytometry Platform, Institut Gustave Roussy) for expert technical assistance in performing flow cytometry analyses. We are very grateful to Hana Raslova and Julie Riviere (INSERM UMR 1170, Institut Gustave-Roussy) for their help in producing lentivirus and to Evelyne May and Martine Raphael (UMR 8126 CNRS) for helpful discussions and suggestions. This work was supported by grants from the Fondation de France 2014 00047509 (JW), the Ligue National Contre le Cancer (doctoral fellowship to JD) and the Fondation ARC (doctoral fellowship to EH).	Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Arab S, 1997, ONCOL RES, V9, P553; Bergan J, 2012, TOXICON, V60, P1085, DOI 10.1016/j.toxicon.2012.07.016; Cabon L, 2012, CELL DEATH DIFFER, V19, P245, DOI 10.1038/cdd.2011.91; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Ching JCY, 2002, INFECT IMMUN, V70, P4669, DOI 10.1128/IAI.70.8.4669-4677.2002; Cullen SP, 2007, J CELL BIOL, V176, P435, DOI 10.1083/jcb.200612025; Dewson G, 2008, MOL CELL, V30, P369, DOI 10.1016/j.molcel.2008.04.005; Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025; Fujii J, 2003, INFECT IMMUN, V71, P2724, DOI 10.1128/IAI.71.5.2724-2735.2003; Garibal J, 2010, CELL SIGNAL, V22, P467, DOI 10.1016/j.cellsig.2009.10.018; Ghiotto F, 2010, CYTOM PART A, V77A, P11, DOI 10.1002/cyto.a.20819; Goonesinghe A, 2005, BIOCHEM J, V387, P109, DOI 10.1042/BJ20041389; Grosse L, 2016, EMBO J, V35, P402, DOI 10.15252/embj.201592789; Gupta V, 2012, J BIOL CHEM, V287, P37195, DOI 10.1074/jbc.M112.396390; Iyer S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11734; JACEWICZ M, 1986, J EXP MED, V163, P1391, DOI 10.1084/jem.163.6.1391; Johannes L, 2010, NAT REV MICROBIOL, V8, P105, DOI 10.1038/nrmicro2279; Karch J, 2013, ELIFE, V2, DOI 10.7554/eLife.00772; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Konig HG, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-7; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Lee SY, 2005, INFECT IMMUN, V73, P5115, DOI 10.1128/IAI.73.8.5115-5126.2005; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li Mark Xiang, 2015, F1000Prime Rep, V7, P42, DOI 10.12703/P7-42; MANGENEY M, 1991, EUR J IMMUNOL, V21, P1131, DOI 10.1002/eji.1830210507; NUDELMAN E, 1983, SCIENCE, V220, P509, DOI 10.1126/science.6836295; OHYAMA C, 1990, INT J CANCER, V45, P1040, DOI 10.1002/ijc.2910450610; Pei YH, 2007, APOPTOSIS, V12, P1681, DOI 10.1007/s10495-007-0091-7; Raemy E, 2016, CELL DEATH DIFFER, V23, P1165, DOI 10.1038/cdd.2015.166; Renault TT, 2014, CHEM BIOL, V21, P114, DOI 10.1016/j.chembiol.2013.10.009; Saito M, 2000, NAT CELL BIOL, V2, P553, DOI 10.1038/35019596; Salvador-Gallego R, 2016, EMBO J, V35, P389, DOI 10.15252/embj.201593384; Sarig R, 2003, J BIOL CHEM, V278, P10707, DOI 10.1074/jbc.M210296200; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Tait SWG, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008706; Tesh VL, 2012, CELL MICROBIOL, V14, P1, DOI 10.1111/j.1462-5822.2011.01684.x; Tesh VL, 2010, FUTURE MICROBIOL, V5, P431, DOI 10.2217/FMB.10.4; Tetaud C, 2003, J BIOL CHEM, V278, P45200, DOI 10.1074/jbc.M303868200; Todt F, 2015, EMBO J, V34, P67, DOI 10.15252/embj.201488806; Valentijn AJ, 2004, J BIOL CHEM, V279, P32848, DOI 10.1074/jbc.M313375200; Zheng JH, 2016, FEBS J, V283, P2690, DOI 10.1111/febs.13527	42	10	11	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	18					2410	2421		10.1038/s41388-018-0123-5	http://dx.doi.org/10.1038/s41388-018-0123-5			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GE7BW	29440708	Green Published, hybrid			2022-12-17	WOS:000431386000005
J	Jiang, J; Tang, SL; Xia, JH; Wen, JK; Chen, S; Shu, XD; Huen, MSY; Deng, YQ				Jiang, Jun; Tang, Shulin; Xia, Jianhong; Wen, Jikai; Chen, Shuang; Shu, Xiaodong; Huen, Michael S. Y.; Deng, Yiqun			C9orf140, a novel Axin1-interacting protein, mediates the negative feedback loop of Wnt/beta-catenin signaling	ONCOGENE			English	Article							BETA-CATENIN; PHOSPHATASE 2A; UP-REGULATION; P42.3 GENE; IN-VIVO; EXPRESSION; PATHWAY; CANCER; IDENTIFICATION; CELLS	Wnt/beta-catenin signaling activity is maintained in homeostasis by an expanding list of molecular determinants. However, the molecular components and the regulatory mechanisms involved in its fine-tuning remain to be determined. Here, we identified C9orf140, a tumor-specific protein, as a novel Axin1-interacting protein by tandem-affinity purification and mass spectrometry. We further showed that C9orf140 is a negative regulator of Wnt/beta-catenin signaling in cultured cells as well as in zebrafish embryos. It functions upstream of beta-catenin, outcompetes PP2A for binding to Axin1, influences the balance between phosphorylation and de-phosphorylation of beta-catenin, and ultimately compromises Wnt3A-induced beta-catenin accumulation. Interestingly, Wnt-induced C9orf140 expression via beta-catenin. We propose that C9orf140 mediates a negative feedback loop of Wnt/beta-catenin signaling by interacting with Axin1. Our results advance the current understanding of the exquisite control of Wnt/beta-catenin signaling cascade, and provide evidence of the new role of C9orf140.	[Jiang, Jun; Tang, Shulin; Wen, Jikai; Chen, Shuang; Deng, Yiqun] South China Agr Univ, Coll Life Sci, Guangdong Prov Key Lab Prot Funct & Regulat Agr O, Guangzhou 510642, Guangdong, Peoples R China; [Jiang, Jun; Huen, Michael S. Y.] Univ Hong Kong, Sch Biomed Sci, LKS Fac Med, Pokfulam, Hong Kong, Peoples R China; [Xia, Jianhong; Shu, Xiaodong] Chinese Acad Sci, Guangzhou Inst Biomed & Hlth, Key Lab Regenerat Biol, South China Inst Stem Cell Biol & Regenerat Med, Guangzhou 510530, Guangdong, Peoples R China	South China Agricultural University; University of Hong Kong; Chinese Academy of Sciences; Guangzhou Institute of Biomedicine & Health, CAS	Deng, YQ (corresponding author), South China Agr Univ, Coll Life Sci, Guangdong Prov Key Lab Prot Funct & Regulat Agr O, Guangzhou 510642, Guangdong, Peoples R China.	yqdeng@scau.edu.cn	wen, jikai/AAV-9818-2021; Deng, Yiqun/K-7709-2013	wen, jikai/0000-0002-4010-4416; Deng, Yiqun/0000-0002-6838-3779	Natural Science Foundation of Guangdong Province [2015A030312005]; Training program for outstanding young teachers in higher education institutions of Guangdong Province [YQ2014027]; National Natural Science Foundation of China [31672611]; Pearl River S&T Nova Program of Guangzhou [201610010063]	Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); Training program for outstanding young teachers in higher education institutions of Guangdong Province; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Pearl River S&T Nova Program of Guangzhou	We thank Dr. Shengcai Lin for providing the Axin1 and Wnt1 constructs used in this study and Dr. Hans Clevers for providing crucial reagents. This work was supported by the Natural Science Foundation of Guangdong Province [Research Team Project No. 2015A030312005 to YD]; Training program for outstanding young teachers in higher education institutions of Guangdong Province [No. YQ2014027 to JJ]; the National Natural Science Foundation of China [No. 31672611 to YD]; and the Pearl River S&T Nova Program of Guangzhou [No. 201610010063 to JJ].	Azzolin L, 2012, CELL, V151, P1443, DOI 10.1016/j.cell.2012.11.027; Cao WJ, 2015, ANTI-CANCER AGENT ME, V15, P157, DOI 10.2174/1871520614666140818200202; Carruba G, 1999, ANN NY ACAD SCI, V886, P212, DOI 10.1111/j.1749-6632.1999.tb09419.x; Chen P, 2015, J DIGEST DIS, V16, P568, DOI 10.1111/1751-2980.12282; Chen YQ, 2012, CELL RES, V22, P333, DOI 10.1038/cr.2011.134; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Cui Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025872; Dong LF, 2015, DRUG METAB DISPOS, V43, P1458, DOI 10.1124/dmd.115.065565; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Freeman M, 2000, NATURE, V408, P313, DOI 10.1038/35042500; Gao CX, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-13; Hagemann AIH, 2014, J CELL SCI, V127, P3970, DOI 10.1242/jcs.148767; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; KELLY GM, 1995, DEVELOPMENT, V121, P1787; Kimelman D, 2006, ONCOGENE, V25, P7482, DOI 10.1038/sj.onc.1210055; Li S, 2015, FAM CANCER, V14, P325, DOI 10.1007/s10689-014-9775-7; Li ZF, 2011, P NATL ACAD SCI USA, V108, P3116, DOI 10.1073/pnas.1009353108; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo W, 2004, NEUROSIGNALS, V13, P99, DOI 10.1159/000076563; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; Major MB, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.2000037; Pendas-Franco N, 2008, ONCOGENE, V27, P4467, DOI 10.1038/onc.2008.88; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Su YY, 2008, MOL CELL, V32, P652, DOI 10.1016/j.molcel.2008.10.023; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Weng YR, 2014, CARCINOGENESIS, V35, P1389, DOI 10.1093/carcin/bgu057; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P11312, DOI 10.1073/pnas.1203015109; Xu X, 2007, ONCOGENE, V26, P7371, DOI 10.1038/sj.onc.1210538; Zhang JH, 2012, THEOR BIOL MED MODEL, V9, DOI 10.1186/1742-4682-9-53; Zhang W, 2009, J BIOL CHEM, V284, P22649, DOI 10.1074/jbc.M109.013698	36	10	11	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY	2018	37	22					2992	3005		10.1038/s41388-018-0166-7	http://dx.doi.org/10.1038/s41388-018-0166-7			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GH8RM	29531269	hybrid, Green Published			2022-12-17	WOS:000433936300007
J	Tan, EHP; Sng, MK; How, ISB; Chan, JSK; Chen, JP; Tan, CK; Wahli, W; Tan, NS				Tan, Eddie Han Pin; Sng, Ming Keat; How, Ivan Shun Bo; Chan, Jeremy Soon Kiat; Chen, Jiapeng; Tan, Chek Kun; Wahli, Walter; Tan, Nguan Soon			ROS release by PPAR beta/delta-null fibroblasts reduces tumor load through epithelial antioxidant response	ONCOGENE			English	Article							ACTIVATED-RECEPTOR-DELTA; COLORECTAL-CANCER; COLON CARCINOGENESIS; MEDIATED INHIBITION; OXIDATIVE STRESS; IMMUNE CELLS; LUNG INJURY; INFLAMMATION; MICE; GAMMA	Tumor stroma has an active role in the initiation, growth, and propagation of many tumor types by secreting growth factors and modulating redox status of the microenvironment. Although PPAR beta/delta in fibroblasts was shown to modulate oxidative stress in the wound microenvironment, there has been no evidence of a similar effect in the tumor stroma. Here, we present evidence of oxidative stress modulation by intestinal stromal PPAR beta/delta, using a FSPCre-Pparb/d(-/-) mouse model and validated it with immortalized cell lines. The FSPCre-Pparb/d(-/-) mice developed fewer intestinal polyps and survived longer when compared with Pparb/d(fl/fl) mice. The pre-treatment of FSPCre-Pparb/d(-/-) and Pparb/d(fl/fl) with antioxidant N-acetyl-cysteine prior DSS-induced tumorigenesis resulted in lower tumor load. Gene expression analyses implicated an altered oxidative stress processes. Indeed, the FSPCre-Pparb/d(-/-) intestinal tumors have reduced oxidative stress than Pparb/d(fl/fl) tumors. Similarly, the colorectal cancer cells and human colon epithelial cells also experienced lower oxidative stress when co-cultured with fibroblasts depleted of PPAR beta/delta expression. Therefore, our results establish a role for fibroblast PPAR beta/delta in epithelial-mesenchymal communication for ROS homeostasis.	[Tan, Eddie Han Pin; Sng, Ming Keat; How, Ivan Shun Bo; Chan, Jeremy Soon Kiat; Tan, Nguan Soon] Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore; [Sng, Ming Keat; Chen, Jiapeng; Tan, Chek Kun; Wahli, Walter; Tan, Nguan Soon] Nanyang Technol Univ, Lee Kong Chian Sch Med, Novena Campus, Singapore, Singapore; [Wahli, Walter] INRA ToxAlim, UMR1331, Chemin Tournefeuille, Toulouse 3, France; [Wahli, Walter] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland; [Tan, Nguan Soon] Inst Mol & Cell Biol, Proteos, Agcy Sci Technol & Res, Singapore, Singapore; [Tan, Nguan Soon] KK Womens & Children Hosp, KK Res Ctr, Singapore, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; INRAE; University of Lausanne; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); KK Women's & Children's Hospital	Tan, EHP; Tan, NS (corresponding author), Nanyang Technol Univ, Sch Biol Sci, Singapore, Singapore.; Tan, NS (corresponding author), Nanyang Technol Univ, Lee Kong Chian Sch Med, Novena Campus, Singapore, Singapore.; Tan, NS (corresponding author), Inst Mol & Cell Biol, Proteos, Agcy Sci Technol & Res, Singapore, Singapore.; Tan, NS (corresponding author), KK Womens & Children Hosp, KK Res Ctr, Singapore, Singapore.	HTAN024@e.ntu.edu.sg; nstan@ntu.edu.sg	Wahli, Walter/I-3194-2019; Tan, Nguan Soon/A-2220-2011; Wahli, Walter/B-1398-2009; Sng, Ming Keat/J-7266-2013	Tan, Nguan Soon/0000-0003-0136-7341; Wahli, Walter/0000-0002-5966-9089; Sng, Ming Keat/0000-0002-5529-4371; Tan, Eddie Han Pin/0000-0002-4475-0255	Singapore Ministry of Education under Singapore Ministry of Education Academic Research Fund Tier 2 [MOE2014-T2-1-012]; Academic Research Fund Tier 1 [RG134/15]; Lee Kong Chian School of Medicine, Nanyang Technological University Start-up Grant	Singapore Ministry of Education under Singapore Ministry of Education Academic Research Fund Tier 2(Ministry of Education, Singapore); Academic Research Fund Tier 1; Lee Kong Chian School of Medicine, Nanyang Technological University Start-up Grant(Nanyang Technological University)	This work was supported by Singapore Ministry of Education under Singapore Ministry of Education Academic Research Fund Tier 2 (MOE2014-T2-1-012) and Academic Research Fund Tier 1 (RG134/15) to NST, and by the Lee Kong Chian School of Medicine, Nanyang Technological University Start-up Grant to WW.	Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Borland MG, 2017, TOXICOL SCI, V159, P436, DOI 10.1093/toxsci/kfx147; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Chaiswing L, 2010, ANTIOXID REDOX SIGN, V13, P449, DOI 10.1089/ars.2009.3020; Chan JSK, 2018, ONCOGENE, V37, P160, DOI 10.1038/onc.2017.319; Chan JSK, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.492; Cho HY, 2010, AM J RESP CRIT CARE, V182, P170, DOI 10.1164/rccm.200907-1047OC; Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611; Espinosa-Diez C, 2015, REDOX BIOL, V6, P183, DOI 10.1016/j.redox.2015.07.008; Finkel T, 2011, J CELL BIOL, V194, P7, DOI 10.1083/jcb.201102095; Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703; Gorrini C, 2013, NAT REV DRUG DISCOV, V12, P931, DOI 10.1038/nrd4002; Harman FS, 2004, NAT MED, V10, P481, DOI 10.1038/nm1026; He TC, 1999, CELL, V99, P335, DOI 10.1016/S0092-8674(00)81664-5; Holmstrom KM, 2014, NAT REV MOL CELL BIO, V15, P411, DOI 10.1038/nrm3801; Iglesias J, 2012, J CLIN INVEST, V122, P4105, DOI 10.1172/JCI42127; Jess T, 2012, CLIN GASTROENTEROL H, V10, P639, DOI 10.1016/j.cgh.2012.01.010; Khansari N, 2009, RECENT PATENTS INFLA, V3, P73, DOI 10.2174/187221309787158371; Khor TO, 2008, CANCER PREV RES, V1, P187, DOI 10.1158/1940-6207.CAPR-08-0028; Kilgore KS, 2008, CURR OPIN INVEST DR, V9, P463; Kim ER, 2014, WORLD J GASTROENTERO, V20, P9872, DOI 10.3748/wjg.v20.i29.9872; Kim HJ, 2011, J BIOL CHEM, V286, P44585, DOI 10.1074/jbc.M111.222562; Kim MY, 2012, BIOCHEM PHARMACOL, V84, P1627, DOI 10.1016/j.bcp.2012.09.008; Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554; Liu J, 2011, PPAR RES, V2011, DOI 10.1155/2011/372854; Liu X, 2016, GENE DEV, V30, P1943, DOI 10.1101/gad.283499.116; Manda G, 2015, REDOX BIOL, V5, P347, DOI 10.1016/j.redox.2015.06.014; Marin HE, 2006, CANCER RES, V66, P4394, DOI 10.1158/0008-5472.CAN-05-4277; Montagner A, 2014, EMBO MOL MED, V6, P80, DOI 10.1002/emmm.201302666; Osterreicher CH, 2011, P NATL ACAD SCI USA, V108, P308, DOI 10.1073/pnas.1017547108; Okada H, 2003, KIDNEY INT, V64, P1722, DOI 10.1046/j.1523-1755.2003.00290.x; Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105; Park EY, 2004, CANCER RES, V64, P3701, DOI 10.1158/0008-5472.CAN-03-3924; Peters JM, 2015, TRENDS ENDOCRIN MET, V26, P595, DOI 10.1016/j.tem.2015.09.004; Pickup MW, 2015, MOL ONCOL, V9, P179, DOI 10.1016/j.molonc.2014.08.004; Pinchuk I V, 2010, Curr Gastroenterol Rep, V12, P310, DOI 10.1007/s11894-010-0135-y; Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394; Ramsey MR, 2006, NAT CELL BIOL, V8, P1213, DOI 10.1038/ncb1106-1213; Reddy RC, 2010, AM J RESP CRIT CARE, V182, P134, DOI 10.1164/rccm.201004-0457ED; Roncoroni L, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-40; Saw CLL, 2011, EXPERT OPIN THER TAR, V15, P281, DOI 10.1517/14728222.2011.553602; Shalapour S, 2015, J CLIN INVEST, V125, P3347, DOI 10.1172/JCI80007; Sporn MB, 2012, NAT REV CANCER, V12, P564, DOI 10.1038/nrc3278; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Tan NS, 2016, PROG LIPID RES, V64, P98, DOI 10.1016/j.plipres.2016.09.001; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Udagawa T, 2010, CURR OPIN PHARMACOL, V10, P369, DOI 10.1016/j.coph.2010.06.010; Wang DZ, 2006, P NATL ACAD SCI USA, V103, P19069, DOI 10.1073/pnas.0607948103; Wang DZ, 2014, P NATL ACAD SCI USA, V111, P7084, DOI 10.1073/pnas.1324233111; Wang XL, 2015, J CONTROL RELEASE, V197, P138, DOI 10.1016/j.jconrel.2014.11.001; Yu SQ, 2012, PROSTATE, V72, P437, DOI 10.1002/pros.21445; Zhang WB, 2017, CARCINOGENESIS, V38, P748, DOI 10.1093/carcin/bgx035; ZUO X, 2014, JNCI-J NATL CANCER I, V106, P52, DOI DOI 10.1093/JNCI/DJU052; Zuo XS, 2009, JNCI-J NATL CANCER I, V101, P762, DOI 10.1093/jnci/djp078	54	10	10	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2018	37	15					2067	2078		10.1038/s41388-017-0109-8	http://dx.doi.org/10.1038/s41388-017-0109-8			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GC6KH	29367760	Green Published, hybrid			2022-12-17	WOS:000429899400009
J	Azoitei, N; Cobbaut, M; Becher, A; Van Lint, J; Seufferlein, T				Azoitei, Ninel; Cobbaut, Mathias; Becher, Alexander; Van Lint, Johan; Seufferlein, Thomas			Protein kinase D2: a versatile player in cancer biology	ONCOGENE			English	Review							NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITION; CHROMOGRANIN-A SECRETION; D-DEPENDENT ACTIVATION; D PKD ACTIVATION; GROWTH-FACTOR-I; OXIDATIVE STRESS; TUMOR-GROWTH; TNF-ALPHA; MATRIX METALLOPROTEINASES	Protein kinase D2 (PKD2) is a serine/threonine kinase that belongs to the PKD family of calcium-calmodulin kinases, which comprises three isoforms: PKD1, PKD2, and PKD3. PKD2 is activated by many stimuli including growth factors, phorbol esters, and G-protein-coupled receptor agonists. PKD2 participation to uncontrolled growth, survival, neovascularization, metastasis, and invasion has been documented in various tumor types including pancreatic, colorectal, gastric, hepatic, lung, prostate, and breast cancer, as well as glioma multiforme and leukemia. This review discusses the versatile functions of PKD2 from the perspective of cancer hallmarks as described by Hanahan and Weinberg. The PKD2 status, signaling pathways affected in different tumor types and the molecular mechanisms that lead to tumorigenesis and tumor progression are presented. The latest developments of small-molecule inhibitors selective for PKD/PKD2, as well as the need for further chemotherapies that prevent, slow down, or eliminate tumors are also discussed in this review.	[Azoitei, Ninel; Becher, Alexander; Seufferlein, Thomas] Univ Ulm, Ctr Internal Med 1, Ulm, Germany; [Cobbaut, Mathias; Van Lint, Johan] Katholieke Univ Leuven, Lab Prot Phosphorylat & Prote, Dept Cellular & Mol Med, Leuven Canc Inst, Leuven, Belgium	Ulm University; KU Leuven	Azoitei, N (corresponding author), Univ Ulm, Ctr Internal Med 1, Ulm, Germany.	ninel.azoitei@uni-ulm.de	Seufferlein, Thomas TW/P-7147-2018; Van Lint, Johan/P-9073-2019	Becher, Alexander/0000-0003-1552-1581; Cobbaut, Mathias/0000-0003-0279-0336; Van Lint, Johan/0000-0002-0275-571X	German Research Foundation [AZ.96/1-1, AZ.96/1-3, SE.676/10-1]; German Cancer Aid [109373]; LUNGTARGET [259770]; IWT - Agentschap voor Innovatie door Wetenschap en Technologie	German Research Foundation(German Research Foundation (DFG)); German Cancer Aid(Deutsche Krebshilfe); LUNGTARGET; IWT - Agentschap voor Innovatie door Wetenschap en Technologie(Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT))	This work was supported by the German Research Foundation (grants AZ.96/1-1 and AZ.96/1-3 to NA, grant SE.676/10-1 to TS), the German Cancer Aid (grant 109373 to TS), FP7 grant 259770 - LUNGTARGET (to JVL and TS) and IWT - Agentschap voor Innovatie door Wetenschap en Technologie (to MC).	Adams JM, 2007, ONCOGENE, V26, P1324, DOI 10.1038/sj.onc.1210220; Aicart-Ramos C, 2016, J BIOL CHEM, V291, P23516, DOI 10.1074/jbc.M116.735399; Aikawa, 2003, J CELL BIOL, V16, P647; Alpsoy A, 2015, TUMOR BIOL, V36, P4417, DOI 10.1007/s13277-015-3081-3; Anel AMD, 2005, J CELL BIOL, V169, P83, DOI 10.1083/jcb.200412089; Armacki M, 2014, ONCOGENE, V33, P1167, DOI 10.1038/onc.2013.43; Auer A, 2005, MOL BIOL CELL, V16, P4375, DOI 10.1091/mbc.E05-03-0251; Avkiran M, 2008, CIRC RES, V102, P157, DOI 10.1161/CIRCRESAHA.107.168211; Azoitei N, 2014, CANCER RES, V74, P7125, DOI 10.1158/0008-5472.CAN-14-1017; Azoitei N, 2011, NEURO-ONCOLOGY, V13, P710, DOI 10.1093/neuonc/nor084; Azoitei N, 2010, GUT, V59, P1316, DOI 10.1136/gut.2009.206813; Baeriswyl V, 2009, SEMIN CANCER BIOL, V19, P329, DOI 10.1016/j.semcancer.2009.05.003; Baron CL, 2002, SCIENCE, V295, P325, DOI 10.1126/science.1066759; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bernhart E, 2014, NEURO-ONCOLOGY, V16, P933, DOI 10.1093/neuonc/not303; Bernhart E, 2013, EXP CELL RES, V319, P2037, DOI 10.1016/j.yexcr.2013.03.029; Biswas MHU, 2010, CANCER RES, V70, P2095, DOI 10.1158/0008-5472.CAN-09-4155; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Borges S, 2015, MOL CANCER THER, V14, P1306, DOI 10.1158/1535-7163.MCT-14-0945; Bossard C, 2007, J CELL BIOL, V179, P1123, DOI 10.1083/jcb.200703166; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Bryceson YT, 2009, BLOOD, V114, P2657, DOI 10.1182/blood-2009-01-201632; Chen J, 2012, IMMUNOBIOLOGY, V217, P385, DOI 10.1016/j.imbio.2011.10.016; Chen J, 2008, CANCER RES, V68, P3844, DOI 10.1158/0008-5472.CAN-07-5156; Chen J, 2011, CARCINOGENESIS, V32, P1198, DOI 10.1093/carcin/bgr113; Chiu T, 2001, AM J PHYSIOL-CELL PH, V280, pC929, DOI 10.1152/ajpcell.2001.280.4.C929; Chiu T, 2001, FEBS LETT, V489, P101, DOI 10.1016/S0014-5793(01)02076-2; Choi JW, 2004, CANCER RES, V64, P35, DOI 10.1158/0008-5472.CAN-03-0145; Chouaib S, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00021; Cobbaut M, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00800-w; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Culver C, 2010, MOL CELL BIOL, V30, P4901, DOI 10.1128/MCB.00409-10; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Dequiedt F, 2005, J EXP MED, V201, P793, DOI 10.1084/jem.20042034; Donaldson JG, 2005, BIOCHEM SOC T, V33, P639, DOI 10.1042/BST0330639; Dou GR, 2008, FASEB J, V22, P1606, DOI 10.1096/fj.07-9998com; Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481; Durand N, 2016, J CLIN MED, V5, DOI 10.3390/jcm5020020; Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Eiseler T, 2016, J BIOL CHEM, V291, P462, DOI 10.1074/jbc.M115.673582; Eiseler T, 2012, J BIOL CHEM, V287, P32367, DOI 10.1074/jbc.M112.370999; Eiseler T, 2010, J BIOL CHEM, V285, P18672, DOI 10.1074/jbc.M109.093880; Eiseler T, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2232; Eisenberg-Lerner A, 2007, CELL DEATH DIFFER, V14, P1908, DOI 10.1038/sj.cdd.4402212; Evans IM, 2010, BIOCHEM J, V429, P565, DOI 10.1042/BJ20100578; Fanelli MF, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.4_suppl.21; Fielitz J, 2008, P NATL ACAD SCI USA, V105, P3059, DOI 10.1073/pnas.0712265105; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Fugmann T, 2007, J CELL BIOL, V178, P15, DOI 10.1083/jcb.200612017; Gabhann FM, 2008, MICROCIRCULATION, V15, P715, DOI 10.1080/10739680802095964; Gamber GG, 2011, BIOORG MED CHEM LETT, V21, P1447, DOI 10.1016/j.bmcl.2011.01.014; Geng J, 2009, BIOCHEM BIOPH RES CO, V388, P517, DOI 10.1016/j.bbrc.2009.08.025; George Kara M, 2011, Pharmaceutics, V3, P186, DOI 10.3390/pharmaceutics3020186; Goginashvili A, 2015, SCIENCE, V347, P878, DOI 10.1126/science.aaa2628; Gruber T, 2009, MOL IMMUNOL, V46, P2071, DOI 10.1016/j.molimm.2009.02.030; Guha S, 2002, CANCER RES, V62, P1632; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hao Q, 2013, ANTICANCER RES, V33, P393; Hao Q, 2009, AM J PHYSIOL-CELL PH, V296, pC821, DOI 10.1152/ajpcell.00504.2008; Hao Q, 2009, J BIOL CHEM, V284, P799, DOI 10.1074/jbc.M807546200; Hausser A, 2005, NAT CELL BIOL, V7, P880, DOI 10.1038/ncb1289; Hausser A, 2006, J CELL SCI, V119, P3613, DOI 10.1242/jcs.03104; Hayashi A, 1999, BBA-MOL CELL RES, V1450, P99, DOI 10.1016/S0167-4889(99)00040-3; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Hollenbach M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068033; Huck B, 2014, J BIOL CHEM, V289, P3138, DOI 10.1074/jbc.M113.502633; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Iglesias T, 1998, FEBS LETT, V437, P19, DOI 10.1016/S0014-5793(98)01189-2; Ijichi S, 2005, J BIOMED OPT, V10, DOI 10.1117/1.1899184; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Jackson LN, 2006, BIOCHEM BIOPH RES CO, V348, P945, DOI 10.1016/j.bbrc.2006.07.142; Jaggi M, 2005, CANCER RES, V65, P483; Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103; Janssens K, 2009, CELL SIGNAL, V21, P282, DOI 10.1016/j.cellsig.2008.10.012; JOHANNES FJ, 1995, EUR J BIOCHEM, V227, P303, DOI 10.1111/j.1432-1033.1995.tb20389.x; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Kim Y, 2008, J CLIN INVEST, V118, P124, DOI 10.1172/JCI33255; Kleger A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014599; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Koch T, 2003, J BIOL CHEM, V278, P9979, DOI 10.1074/jbc.M206709200; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; LaValle CR, 2012, MOL CANCER THER, V11, P1389, DOI 10.1158/1535-7163.MCT-11-0887; Li J, 2004, J BIOL CHEM, V279, P28466, DOI 10.1074/jbc.M314307200; Liljedahl M, 2001, CELL, V104, P409, DOI 10.1016/S0092-8674(01)00228-8; Liu ZC, 2014, CELL TISSUE RES, V358, P491, DOI 10.1007/s00441-014-1953-2; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Malhotra V, 2011, COLD SPRING HARB PER, V3; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Marchiq I, 2016, J MOL MED, V94, P155, DOI 10.1007/s00109-015-1307-x; Marklund U, 2003, IMMUNITY, V19, P491, DOI 10.1016/S1074-7613(03)00260-7; Matthews SA, 2003, J BIOL CHEM, V278, P9086, DOI 10.1074/jbc.M211295200; Matthews SA, 2010, BIOCHEM J, V432, P153, DOI 10.1042/BJ20101188; McDonald PC, 2016, FRONT CELL DEV BIOL, V4, DOI 10.3389/fcell.2016.00027; Meredith EL, 2010, J MED CHEM, V53, P5400, DOI 10.1021/jm100075z; Meredith EL, 2010, J MED CHEM, V53, P5422, DOI 10.1021/jm100076w; Mihailovic T, 2004, CANCER RES, V64, P8939, DOI 10.1158/0008-5472.CAN-04-0981; Minet E, 1999, FEBS LETT, V460, P251, DOI 10.1016/S0014-5793(99)01359-9; Mitchell R, 2003, J BIOL CHEM, V278, P33818, DOI 10.1074/jbc.M305825200; Miwa D, 2013, ANGIOGENESIS, V16, P675, DOI 10.1007/s10456-013-9345-x; Monovich L, 2010, FEBS LETT, V584, P631, DOI 10.1016/j.febslet.2009.12.014; Moulick K, 2011, NAT CHEM BIOL, V7, P818, DOI 10.1038/nchembio.670; Muller M, 2015, SCI REP-UK, V5, DOI 10.1038/srep11742; Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413; Neckers Len, 2002, Expert Opin Emerg Drugs, V7, P277, DOI 10.1517/14728214.7.2.277; Nhek S, 2010, MOL BIOL CELL, V21, P2327, DOI 10.1091/mbc.E10-02-0090; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Ochi N, 2011, J CELL PHYSIOL, V226, P1074, DOI 10.1002/jcp.22421; Patel S, 2014, ADV EXP MED BIOL, V806, P409, DOI 10.1007/978-3-319-06068-2_20; Pearson Mark A, 2004, Expert Rev Anticancer Ther, V4, P1113, DOI 10.1586/14737140.4.6.1113; Pfeifhofer C, 2003, J EXP MED, V197, P1525, DOI 10.1084/jem.20020234; Pfeifhofer C, 2006, J IMMUNOL, V176, P6004, DOI 10.4049/jimmunol.176.10.6004; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Pusapati GV, 2010, MOL BIOL CELL, V21, P1011, DOI 10.1091/mbc.E09-09-0814; Qiang YW, 2004, BLOOD, V103, P301, DOI 10.1182/blood-2003-06-2066; Qin LL, 2006, J BIOL CHEM, V281, P32550, DOI 10.1074/jbc.M604853200; Rey O, 2001, J BIOL CHEM, V276, P49228, DOI 10.1074/jbc.M109395200; Rey O, 2003, BIOCHEM BIOPH RES CO, V302, P817, DOI 10.1016/S0006-291X(03)00269-9; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Scheiter M, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00066; Scott KL, 2009, NATURE, V459, P1085, DOI 10.1038/nature08109; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Shabelnik M. Yu., 2011, Experimental Oncology, V33, P206; Sharlow ER, 2008, J BIOL CHEM, V283, P33516, DOI 10.1074/jbc.M805358200; Sidorenko SP, 1996, IMMUNITY, V5, P353, DOI 10.1016/S1074-7613(00)80261-7; Sipos B, 2002, INT J CANCER, V102, P592, DOI 10.1002/ijc.10753; Soria G, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-130; Spitaler M, 2006, IMMUNITY, V24, P535, DOI 10.1016/j.immuni.2006.02.013; Steiner TS, 2010, CELL IMMUNOL, V264, P135, DOI 10.1016/j.cellimm.2010.05.012; Storz P, 2004, MOL PHARMACOL, V66, P870, DOI 10.1124/mol.104.000687; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Storz P, 2003, EMBO J, V22, P109, DOI 10.1093/emboj/cdg009; Storz P, 2005, MOL CELL BIOL, V25, P8520, DOI 10.1128/MCB.25.19.8520-8530.2005; Sturany S, 2002, J BIOL CHEM, V277, P29431, DOI 10.1074/jbc.M200934200; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Sumara G, 2009, CELL, V136, P235, DOI 10.1016/j.cell.2008.11.018; Tandon M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119346; Tandon M, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0075601, 10.1371/journal.pone.0081521]; Trauzold A, 2003, ONCOGENE, V22, P8939, DOI 10.1038/sj.onc.1207001; VALVERDE AM, 1994, P NATL ACAD SCI USA, V91, P8572, DOI 10.1073/pnas.91.18.8572; Van Lint J, 2002, TRENDS CELL BIOL, V12, P193, DOI 10.1016/S0962-8924(02)02262-6; Vivier E, 2008, NAT IMMUNOL, V9, P503, DOI 10.1038/ni1582; von Blume J, 2007, EMBO J, V26, P4619, DOI 10.1038/sj.emboj.7601891; von Wicher G, 2008, CELL SIGNAL, V20, P925, DOI 10.1016/j.cellsig.2008.01.003; von Wichert G, 2000, CANCER RES, V60, P4573; Wang QMJ, 2006, TRENDS PHARMACOL SCI, V27, P317, DOI 10.1016/j.tips.2006.04.003; Wang Y, 2002, MOL CELL BIOL, V22, P916, DOI 10.1128/MCB.22.3.916-926.2001; Wang YS, 2010, CURR OPIN INVEST DR, V11, P1466; Wei N, 2014, MOL CANCER THER, V13, P1130, DOI 10.1158/1535-7163.MCT-13-0880; Wille Christoph, 2014, Bioarchitecture, V4, P111, DOI 10.4161/bioa.29273; Wille C, 2014, MOL BIOL CELL, V25, P324, DOI 10.1091/mbc.E13-06-0334; Wong C, 2005, J BIOL CHEM, V280, P33262, DOI 10.1074/jbc.M503198200; Yan CL, 2010, AM J PATHOL, V176, P2247, DOI 10.2353/ajpath.2010.090048; Yeaman C, 2004, NAT CELL BIOL, V6, P106, DOI 10.1038/ncb1090; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Yoo J, 2011, BIOCHEM BIOPH RES CO, V413, P30, DOI 10.1016/j.bbrc.2011.08.029; Yoo YG, 2004, J BIOL CHEM, V279, P53365, DOI 10.1074/jbc.M408554200; Young TA, 2005, EXP EYE RES, V80, P651, DOI 10.1016/j.exer.2004.11.015; Zeng HY, 2006, J EXP MED, V203, P719, DOI 10.1084/jem.20051523; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559; Zhang W, 2005, J BIOL CHEM, V280, P19036, DOI 10.1074/jbc.M414674200; Zheng H, 2011, J BIOL CHEM, V286, P35733, DOI 10.1074/jbc.M111.263608; Zhou XP, 2014, CANCER LETT, V355, P121, DOI 10.1016/j.canlet.2014.09.008; Zhu Y, 2016, ONCOTARGET, V7, P5327, DOI 10.18632/oncotarget.6633; Zou ZP, 2012, J CELL SCI, V125, P4800, DOI 10.1242/jcs.106542; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x	175	10	10	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2018	37	10					1263	1278		10.1038/s41388-017-0052-8	http://dx.doi.org/10.1038/s41388-017-0052-8			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ0RI	29259300	Green Published			2022-12-17	WOS:000427279300001
J	Shi, F; Shang, L; Yang, LY; Jiang, YY; Wang, XM; Hao, JJ; Zhang, Y; Huang, DK; Cai, Y; Xu, X; Zhan, QM; Jia, XM; Cao, Y; Wang, MR				Shi, F.; Shang, L.; Yang, L-Y; Jiang, Y-Y; Wang, X-M; Hao, J-J; Zhang, Y.; Huang, D-K; Cai, Y.; Xu, X.; Zhan, Q-M; Jia, X-M; Cao, Y.; Wang, M-R			Neuropilin-1 contributes to esophageal squamous cancer progression via promoting P65-dependent cell proliferation	ONCOGENE			English	Article							NF-KAPPA-B; GROWTH-FACTOR; CLINICOPATHOLOGICAL FEATURES; HEPATOCELLULAR-CARCINOMA; INCREASED EXPRESSION; PANCREATIC-CANCER; SEMAPHORIN 3A; E-CADHERIN; RECEPTOR; ACTIVATION	Neuropilin-1 (NRP1) is a non-kinase receptor recently implicated in tumor progression. Here we revealed that over-expression of NRP1 correlates with poor prognosis in esophageal squamous cell carcinoma (ESCC). NRP1-knockdown suppressed ESCC cell proliferation and xenograft tumor growth. Reduced NRP1 expression downregulated P65 mRNA and protein expression, and ectopic expression of P65-restored cell proliferation in NRP1-silenced cells. NRP1 regulates P65 transcription by activating cAMP responsive element binding protein (CREB). NRP1 interacted with and activated epidermal growth factor receptor (EGFR), and b1/b2 domain of NRP1 is responsible for the activation of EGFR. We also found that EGFR regulated CREB transcriptional activity via AKT. These data suggest that NRP1 is an upstream regulator in the P65-dependent proliferation signaling pathway and a candidate therapeutic target for ESCC.	[Shi, F.; Shang, L.; Yang, L-Y; Jiang, Y-Y; Wang, X-M; Hao, J-J; Zhang, Y.; Cai, Y.; Xu, X.; Zhan, Q-M; Wang, M-R] Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China; [Shi, F.; Shang, L.; Yang, L-Y; Jiang, Y-Y; Wang, X-M; Hao, J-J; Zhang, Y.; Cai, Y.; Xu, X.; Zhan, Q-M; Wang, M-R] Chinese Acad Med Sci, Beijing 100021, Peoples R China; [Shi, F.; Shang, L.; Cao, Y.] Cent S Univ, Xiangya Hosp, Sch Basic Med Sci,Canc Res Inst, Key Lab Carcinogenesis & Invas,Chinese Minist Ed, Changsha 410078, Hunan, Peoples R China; [Jia, X-M] Anhui Med Univ, Dept Histol & Embryol, Hefei 230032, Anhui, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Central South University; Anhui Medical University	Wang, MR (corresponding author), Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, State Key Lab Mol Oncol, Beijing 100021, Peoples R China.; Wang, MR (corresponding author), Chinese Acad Med Sci, Beijing 100021, Peoples R China.; Cao, Y (corresponding author), Cent S Univ, Xiangya Hosp, Sch Basic Med Sci,Canc Res Inst, Key Lab Carcinogenesis & Invas,Chinese Minist Ed, Changsha 410078, Hunan, Peoples R China.; Jia, XM (corresponding author), Anhui Med Univ, Dept Histol & Embryol, Hefei 230032, Anhui, Peoples R China.	jiaxueme@126.com; ycao98@vip.sina.com; wangmr2015@126.com	Zhang, Yu/G-2453-2011	Zhang, Yu/0000-0003-1375-1594	National Natural Science Foundation of China [31471327, 81330052, 81520108023]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2016-I2M-1-001]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); CAMS Innovation Fund for Medical Sciences (CIFMS)	This study was supported by National Natural Science Foundation of China (31471327, 81330052, 81520108023) and CAMS Innovation Fund for Medical Sciences (CIFMS) (2016-I2M-1-001).	Al-Saad S, 2008, BRIT J CANCER, V99, P1476, DOI 10.1038/sj.bjc.6604713; Berge M, 2011, J HEPATOL, V55, P866, DOI 10.1016/j.jhep.2011.01.033; Brand TM, 2011, DISCOV MED, V12, P419; Chaudhary B, 2014, CANCER IMMUNOL IMMUN, V63, P81, DOI 10.1007/s00262-013-1500-0; Chu WM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101931; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Dong JC, 2015, J CELL MOL MED, V19, P2286, DOI 10.1111/jcmm.12623; Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377; Ghosh S, 2008, HUM PATHOL, V39, P1835, DOI 10.1016/j.humpath.2008.06.004; Glinka Y, 2012, BIOCHEM BIOPH RES CO, V425, P775, DOI 10.1016/j.bbrc.2012.07.151; Gu CH, 2002, J BIOL CHEM, V277, P18069, DOI 10.1074/jbc.M201681200; Guttmann-Raviv N, 2006, CANCER LETT, V231, P1, DOI 10.1016/j.canlet.2004.12.047; Han ZX, 2015, MOL MED REP, V12, P513, DOI 10.3892/mmr.2015.3405; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86; Hong TM, 2007, CLIN CANCER RES, V13, P4759, DOI 10.1158/1078-0432.CCR-07-0001; Hu CX, 2016, TARGET ONCOL, V11, P501, DOI 10.1007/s11523-016-0422-0; Izzo JG, 2007, CANCER EPIDEM BIOMAR, V16, P1200, DOI 10.1158/1055-9965.EPI-06-1083; Jia H, 2010, BRIT J CANCER, V102, P541, DOI 10.1038/sj.bjc.6605539; Jiang HY, 2015, MOL MED REP, V12, P2114, DOI 10.3892/mmr.2015.3580; Lee E, 2013, NEOPLASIA, V15, P112, DOI 10.1593/neo.121638; Li LH, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0291-5; Li X, 2016, ONCOTARGET, V7, P86225, DOI 10.18632/oncotarget.13368; Li ZW, 2008, CURR OPIN HEMATOL, V15, P391, DOI 10.1097/MOH.0b013e328302c7f4; Lin DC, 2011, CLIN CANCER RES, V17, P4285, DOI 10.1158/1078-0432.CCR-10-3236; Lu J, 2015, MOL MED REP, V12, P2668, DOI 10.3892/mmr.2015.3752; Matkar PN, 2016, ONCOTARGET, V7, P69489, DOI 10.18632/oncotarget.11060; Muhl L, 2017, J CELL SCI, V130, P1365, DOI 10.1242/jcs.200493; Naik A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03280-0; Nakamura F, 2002, ADV EXP MED BIOL, V515, P55; Ohsaka A, 2015, BIOCHEM BIOPH RES CO, V459, P443, DOI 10.1016/j.bbrc.2015.02.124; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Qiao L, 2006, HUM GENE THER, V17, P280, DOI 10.1089/hum.2006.17.280; Rizzolio S, 2011, CURR MED CHEM, V18, P3563, DOI 10.2174/092986711796642544; Rizzolio S, 2012, CANCER RES, V72, P5801, DOI 10.1158/0008-5472.CAN-12-0995; Sakamoto KM, 2015, MOL GENET METAB, V114, P397, DOI 10.1016/j.ymgme.2014.11.017; Sakamoto KM, 2009, CLIN CANCER RES, V15, P2583, DOI 10.1158/1078-0432.CCR-08-1137; Scartozzi M, 2007, J CLIN ONCOL, V25, P3930, DOI 10.1200/JCO.2007.11.5022; Shahrabi-Farahani S, 2016, AM J PATHOL, V186, P1055, DOI 10.1016/j.ajpath.2015.11.021; Shang L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111045; Shang L, 2013, FRONT MED-PRC, V7, P401, DOI 10.1007/s11684-013-0286-y; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shi F, 2014, CLIN CANCER RES, V20, P6153, DOI 10.1158/1078-0432.CCR-14-0583; Snuderl M, 2013, CELL, V152, P1065, DOI 10.1016/j.cell.2013.01.036; Song X, 2012, MED ORAL PATOL ORAL, V17, pE962, DOI 10.4317/medoral.18168; Wang XM, 2013, MOL CANCER RES, V11, P986, DOI 10.1158/1541-7786.MCR-12-0704; Wang YN, 2010, ONCOGENE, V29, P3997, DOI 10.1038/onc.2010.157; Weichert W, 2007, BRIT J CANCER, V97, P523, DOI 10.1038/sj.bjc.6603878; Wey JS, 2005, BRIT J CANCER, V93, P233, DOI 10.1038/sj.bjc.6602663; Wild JRL, 2012, INT J EXP PATHOL, V93, P81, DOI 10.1111/j.1365-2613.2012.00810.x; Xin Y, 2012, CLIN CANCER RES, V18, P6040, DOI 10.1158/1078-0432.CCR-12-1652; Xu Y, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-155; Zhang YF, 2016, PATHOL ONCOL RES, V22, P367, DOI 10.1007/s12253-015-0003-z	53	10	10	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 15	2018	37	7					935	943		10.1038/onc.2017.399	http://dx.doi.org/10.1038/onc.2017.399			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FW4KH	29059172				2022-12-17	WOS:000425281800010
J	Shao, C; Chien, SJ; Farah, E; Li, Z; Ahmad, N; Liu, X				Shao, C.; Chien, S-J; Farah, E.; Li, Z.; Ahmad, N.; Liu, X.			Plk1 phosphorylation of Numb leads to impaired DNA damage response	ONCOGENE			English	Article							MAMMALIAN NUMB; SELF-RENEWAL; P53; PROTEIN; DEGRADATION; BINDING; CELLS; MDM2; UBIQUITINATION; IDENTIFICATION	Although Numb is well-recognized as a cell-fate determinant in stem/progenitor cells, accumulating evidence supports that Numb also has a critical role in adult tissues and cancers, in particular, in the context of regulation of tumor suppressor p53. Herein, we identified Numb as a novel substrate of Polo-like kinase 1 (Plk1). Of significance, we showed that Plk1-mediated phosphorylation of Numb leads to its enhanced proteasomal degradation and impaired Numb/p53 pathway, thus providing another mechanism how Plk1 antagonizes p53 during DNA damage response. In addition, the novel phosphorylation event identified by us further supports the notion that post-translational modifications of Numb uncouple Numb from p53 and lead to p53 destabilization. Finally, our data generated from both human cancer cell lines and mouse xenograft model showed that cancer cells carrying the unphosphorylated form of Numb by Plk1 are more sensitive to doxorubicin, a classical chemotherapeutic drug. Therefore, our work may provide future strategies for improving the efficacy of chemotherapy by targeting Numb phosphorylation by Plk1.	[Shao, C.; Farah, E.; Li, Z.; Liu, X.] Purdue Univ, Dept Biochem, 175S Univ St, W Lafayette, IN 47907 USA; [Chien, S-J] Purdue Univ, Dept Comparat Pathobiol, W Lafayette, IN 47907 USA; [Ahmad, N.] Univ Wisconsin, Dept Dermatol, Madison, WI USA; [Liu, X.] Purdue Univ, Ctr Canc Res, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; University of Wisconsin System; University of Wisconsin Madison; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Liu, X (corresponding author), Purdue Univ, Dept Biochem, 175S Univ St, W Lafayette, IN 47907 USA.	liu8@purdue.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887	NIH [R01 CA157429, R01 CA192894, R01 CA196835, R01 CA196634, R01 AR059130, R01 CA176748]; Purdue University Center for Cancer Research [P30 CA023168]; NATIONAL CANCER INSTITUTE [R01CA157429, R01CA176748, R01CA196634, R01CA192894, R01CA196835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR059130] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Purdue University Center for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by NIH grants R01 CA157429 (X Liu), R01 CA192894 (X Liu), R01 CA196835 (X Liu), R01 CA196634 (X Liu), R01 AR059130 (N Ahmad) and R01 CA176748 (N Ahmad). The work was also partially supported by Purdue University Center for Cancer Research (P30 CA023168).	Ando K, 2004, J BIOL CHEM, V279, P25549, DOI 10.1074/jbc.M314182200; Ang XLL, 2005, ONCOGENE, V24, P2860, DOI 10.1038/sj.onc.1208614; Colaluca IN, 2008, NATURE, V451, P76, DOI 10.1038/nature06412; Dhami GK, 2013, MOL CELL, V50, P565, DOI 10.1016/j.molcel.2013.04.028; Dho SE, 1999, J BIOL CHEM, V274, P33097, DOI 10.1074/jbc.274.46.33097; Frise E, 1996, P NATL ACAD SCI USA, V93, P11925, DOI 10.1073/pnas.93.21.11925; George RM, 2013, P NATL ACAD SCI USA, V110, P18549, DOI 10.1073/pnas.1311628110; Juven-Gershon T, 1998, MOL CELL BIOL, V18, P3974, DOI 10.1128/MCB.18.7.3974; KASTAN MB, 1995, CANCER METAST REV, V14, P3, DOI 10.1007/BF00690207; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Liu D, 2016, HEPATOLOGY, V64, P390, DOI 10.1002/hep.28594; Liu XS, 2010, EMBO REP, V11, P626, DOI 10.1038/embor.2010.90; Liu XQ, 2006, MOL CELL BIOL, V26, P2093, DOI 10.1128/MCB.26.6.2093-2108.2006; McGill MA, 2003, J BIOL CHEM, V278, P23196, DOI 10.1074/jbc.M302827200; Nishimura T, 2007, DEV CELL, V13, P15, DOI 10.1016/j.devcel.2007.05.003; Pece S, 2011, BBA-REV CANCER, V1815, P26, DOI 10.1016/j.bbcan.2010.10.001; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Sakurai Y, 2014, MOL PHARMACEUT, V11, P2713, DOI 10.1021/mp500245z; Schmit TL, 2012, CANCER RES, V72, P3864, DOI 10.1158/0008-5472.CAN-12-0714; Sczaniecka M, 2012, J BIOL CHEM, V287, P14052, DOI 10.1074/jbc.M111.303875; Shao T, 2015, CELL CYCLE, V14, P755, DOI 10.1080/15384101.2014.998050; Siddique HR, 2015, HEPATOLOGY, V62, P1466, DOI 10.1002/hep.27987; Smith CA, 2007, EMBO J, V26, P468, DOI 10.1038/sj.emboj.7601495; Strebhardt K, 2010, NAT REV DRUG DISCOV, V9, P643, DOI 10.1038/nrd3184; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang HY, 2007, NATURE, V449, P96, DOI 10.1038/nature06056; Wang Z, 2010, TRANSL ONCOL, V3, P1, DOI 10.1593/tlo.09250; Yang XM, 2009, J BIOL CHEM, V284, P18588, DOI 10.1074/jbc.C109.001560; Yogosawa S, 2003, BIOCHEM BIOPH RES CO, V302, P869, DOI 10.1016/S0006-291X(03)00282-1; Zhang H, 2015, CANCER RES, V75, P2363, DOI 10.1158/0008-5472.CAN-14-2928; Zhu K, 2016, STRUCTURE, V24, P1110, DOI 10.1016/j.str.2016.04.012	31	10	12	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 8	2018	37	6					810	820		10.1038/onc.2017.379	http://dx.doi.org/10.1038/onc.2017.379			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FV5ND	29059161	Green Accepted			2022-12-17	WOS:000424628100012
J	Venkatesan, N; Wong, JF; Tan, KP; Chung, HH; Yau, YH; Cukuroglu, E; Allahverdi, A; Nordenskiold, L; Goke, J; Geifman-Shochat, S; Lin, VCL; Madhusudhan, MS; Su, IH				Venkatesan, N.; Wong, J. F.; Tan, K. P.; Chung, H. H.; Yau, Y. H.; Cukuroglu, E.; Allahverdi, A.; Nordenskiold, L.; Goke, J.; Geifman-Shochat, S.; Lin, V. C. L.; Madhusudhan, M. S.; Su, I-h			EZH2 promotes neoplastic transformation through VAV interaction-dependent extranuclear mechanisms	ONCOGENE			English	Article							GROUP PROTEIN EZH2; C-MYC PROMOTER; ACUTE LYMPHOBLASTIC-LEUKEMIA; EMBRYONIC STEM-CELLS; POLYCOMB GROUP GENE; PROSTATE-CANCER; TYROSINE PHOSPHORYLATION; BREAST-CANCER; H3K27 METHYLATION; E-CADHERIN	Recently, we reported that the histone methyltransferase, EZH2, controls leukocyte migration through interaction with the cytoskeleton remodeling effector, VAV, and direct methylation of the cytoskeletal regulatory protein, Talin. However, it is unclear whether this extranuclear, epigenetic-independent function of EZH2 has a profound impact on the initiation of cellular transformation and metastasis. Here, we show that EZH2 increases Talin1 methylation and cleavage, thereby enhancing adhesion turnover and promoting accelerated tumorigenesis. This transforming capacity is abolished by targeted disruption of EZH2 interaction with VAV. Furthermore, our studies demonstrate that EZH2 in the cytoplasm is closely associated with cancer stem cell properties, and that overexpression of EZH2, a mutant EZH2 lacking its nuclear localization signal (EZH2 Delta NLS), or a methylmimicking Talin1 mutant substantially promotes JAK2-dependent STAT3 activation and cellular transformation. Taken together, our results suggest a critical role for the VAV interaction-dependent, extranuclear action of EZH2 in neoplastic transformation.	[Venkatesan, N.; Wong, J. F.; Chung, H. H.; Yau, Y. H.; Allahverdi, A.; Nordenskiold, L.; Geifman-Shochat, S.; Lin, V. C. L.; Su, I-h] Nanyang Technol Univ, Coll Sci, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore; [Tan, K. P.; Madhusudhan, M. S.] Agcy Sci Technol & Res, Biopolis, Bioinformat Inst, Singapore, Singapore; [Tan, K. P.] Nanyang Technol Univ, Sch Comp Engn, Singapore, Singapore; [Cukuroglu, E.; Goke, J.] Agcy Sci Technol & Res, Biopolis, Genome Inst Singapore, Singapore, Singapore; [Goke, J.] Natl Canc Ctr Singapore, Singapore, Singapore; [Madhusudhan, M. S.] Indian Inst Sci Educ & Res, Pune, Maharashtra, India; [Madhusudhan, M. S.] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore	Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National Cancer Centre Singapore (NCCS); Indian Institute of Science Education & Research (IISER) Pune; National University of Singapore	Su, IH (corresponding author), Nanyang Technol Univ, Coll Sci, Sch Biol Sci, 60 Nanyang Dr, Singapore 637551, Singapore.	ihsu@ntu.edu.sg	Chun Ling, Valerie Lin/A-2188-2011; Hoe, YAU Yin/A-2817-2011; Su, I-hsin/A-2207-2011; NORDENSKIÖLD, LARS/ABD-4725-2020; Allahverdi, Abdollah/AAE-1244-2022	Hoe, YAU Yin/0000-0001-8136-2393; Su, I-hsin/0000-0002-5894-9580; NORDENSKIÖLD, LARS/0000-0002-3681-209X; Wong, Jong Fu/0000-0001-6539-5865; Goke, Jonathan/0000-0002-0825-4991	Singapore Agency for Science Technology and Research (A*STAR) through a Biomedical Research Council (BMRC) grant [10/1/22/19/666]; Singapore Ministry of Education [MOE2009-T21-034, MOE2013-T2-2-038]; Ministry of Health, National Medical Research Council [NMRC-CBRG/0057/201]	Singapore Agency for Science Technology and Research (A*STAR) through a Biomedical Research Council (BMRC) grant(Agency for Science Technology & Research (A*STAR)); Singapore Ministry of Education(Ministry of Education, Singapore); Ministry of Health, National Medical Research Council	We thank S Stromblad for critical reading, discussions and comments on the manuscript; Y Zhang (Harvard University) for the EZH2, SUZ12 and EED baculovirus expression vectors; we thank Y Or for providing BALB/c mice and technical support, LY Lu for advice on statistical analysis and A Sullivan from Obrizus Communications for editing the manuscript. This work was supported by the Singapore Agency for Science Technology and Research (A*STAR) through a Biomedical Research Council (BMRC) grant (10/1/22/19/666) to LN, Singapore Ministry of Education (MOE2009-T21-034 and MOE2013-T2-2-038) and Ministry of Health, National Medical Research Council (NMRC-CBRG/0057/201)to I-hS.	Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Boddicker RL, 2016, BLOOD, V128, P1234, DOI 10.1182/blood-2016-03-707141; Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Cao Q, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4127; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chang KH, 2012, BLOOD, V120, P800, DOI 10.1182/blood-2011-06-361709; Chen YH, 2012, AM J TRANSL RES, V4, P364; Chen YT, 2016, CANCER CHEMOTH PHARM, V77, P757, DOI 10.1007/s00280-016-2990-1; Chou RH, 2011, AM J TRANSL RES, V3, P243; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Citterio C, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002962; Dasgupta M, 2015, P NATL ACAD SCI USA, V112, P3985, DOI 10.1073/pnas.1503152112; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; de Vries NA, 2015, CELL REP, V10, P383, DOI 10.1016/j.celrep.2014.12.028; Ezhkova E, 2009, CELL, V136, P1122, DOI 10.1016/j.cell.2008.12.043; Gialeli C, 2011, FEBS J, V278, P16, DOI 10.1111/j.1742-4658.2010.07919.x; Gonzalez ME, 2014, P NATL ACAD SCI USA, V111, P3098, DOI 10.1073/pnas.1308953111; Groysman M, 1998, ONCOGENE, V17, P1597, DOI 10.1038/sj.onc.1202074; Gunawan M, 2015, NAT IMMUNOL, V16, P505, DOI 10.1038/ni.3125; HARRINGTON EA, 1994, CURR OPIN GENET DEV, V4, P120, DOI 10.1016/0959-437X(94)90100-7; He AB, 2012, GENE DEV, V26, P37, DOI 10.1101/gad.173930.111; Herranz N, 2008, MOL CELL BIOL, V28, P4772, DOI 10.1128/MCB.00323-08; Hobert O, 1996, MOL CELL BIOL, V16, P3066; Hobert O, 1996, MECH DEVELOP, V55, P171, DOI 10.1016/0925-4773(96)00499-6; Hock H, 2012, GENE DEV, V26, P751, DOI 10.1101/gad.191163.112; Hsieh FC, 2005, BIOCHEM BIOPH RES CO, V335, P292, DOI 10.1016/j.bbrc.2005.07.075; Huq MDM, 2007, MOL CELL PROTEOMICS, V6, P677, DOI 10.1074/mcp.M600223-MCP200; Jain N, 2013, P NATL ACAD SCI USA, V110, P11349, DOI 10.1073/pnas.1300801110; Jiao LY, 2015, SCIENCE, V350, DOI 10.1126/science.aac4383; Juan AH, 2009, MOL CELL, V36, P61, DOI 10.1016/j.molcel.2009.08.008; Kamminga LM, 2006, BLOOD, V107, P2170, DOI 10.1182/blood-2005-09-3585; Kataoka K, 2015, NAT GENET, V47, P1304, DOI 10.1038/ng.3415; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Kim E, 2013, CANCER CELL, V23, P839, DOI 10.1016/j.ccr.2013.04.008; Kim KH, 2016, NAT MED, V22, P128, DOI 10.1038/nm.4036; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Lee JM, 2012, MOL CELL, V48, P572, DOI 10.1016/j.molcel.2012.09.004; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Lee TC, 1999, J BIOL CHEM, V274, P595, DOI 10.1074/jbc.274.2.595; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lock JG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090593; Masuda H, 2012, BREAST CANCER RES TR, V136, P331, DOI 10.1007/s10549-012-2289-9; MATSUGUCHI T, 1995, EMBO J, V14, P257, DOI 10.1002/j.1460-2075.1995.tb06999.x; McCabe MT, 2012, NATURE, V492, P108, DOI 10.1038/nature11606; Menacho-Marquez M, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001615; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Nagano Makoto, 2012, Int J Cell Biol, V2012, P310616, DOI 10.1155/2012/310616; Natsume A, 2013, CANCER RES, V73, P4559, DOI 10.1158/0008-5472.CAN-13-0109; Nicolaidou V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039871; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Pasini D, 2004, EMBO J, V23, P4061, DOI 10.1038/sj.emboj.7600402; Rangel LBA, 2003, CLIN CANCER RES, V9, P2567; Ren G, 2012, CANCER RES, V72, P3091, DOI 10.1158/0008-5472.CAN-11-3546; Rodriguez JL, 2006, BIOCHEM J, V398, P431, DOI 10.1042/BJ20060380; Rudolph MG, 2006, ANNU REV IMMUNOL, V24, P419, DOI 10.1146/annurev.immunol.23.021704.115658; Sauvageau M, 2010, CELL STEM CELL, V7, P299, DOI 10.1016/j.stem.2010.08.002; Su I, 2006, CURR OPIN IMMUNOL, V18, P152, DOI 10.1016/j.coi.2006.01.012; Su I, 2005, CELL, V121, P425, DOI 10.1016/j.cell.2005.02.029; Su IH, 2003, NAT IMMUNOL, V4, P124, DOI 10.1038/ni876; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Tanos B, 2008, ONCOGENE, V27, P6939, DOI 10.1038/onc.2008.345; Thalappilly S, 2010, ONCOGENE, V29, P2528, DOI 10.1038/onc.2010.1; Toh TB, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0596-9; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Vergani L, 2004, INT J BIOCHEM CELL B, V36, P1447, DOI 10.1016/j.biocel.2003.11.015; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wassef M, 2015, GENE DEV, V29, P2547, DOI 10.1101/gad.269522.115; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Yoo KH, 2012, INT J BIOL SCI, V8, P59, DOI 10.7150/ijbs.8.59; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zhang Y, 2011, J BIOL CHEM, V286, P42414, DOI 10.1074/jbc.M111.271064; Zhao ED, 2016, NAT IMMUNOL, V17, P95, DOI 10.1038/ni.3313; Zhu PP, 2016, NAT STRUCT MOL BIOL, V23, P631, DOI 10.1038/nsmb.3235	81	10	10	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 25	2018	37	4					461	477		10.1038/onc.2017.309	http://dx.doi.org/10.1038/onc.2017.309			17	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT7KP	28967906	Green Accepted			2022-12-17	WOS:000423331600005
J	Ortiz, GJ; Li, Y; Post, SM; Pant, V; Xiong, S; Larsson, CA; El-Naggar, AK; Johnson, DG; Lozano, G				Ortiz, G. J.; Li, Y.; Post, S. M.; Pant, V.; Xiong, S.; Larsson, C. A.; El-Naggar, A. K.; Johnson, D. G.; Lozano, G.			Contrasting effects of an Mdm2 functional polymorphism on tumor phenotypes	ONCOGENE			English	Article							SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS-CELL CARCINOMA; CODON 72 POLYMORPHISM; CANCER-RISK; P53 PATHWAY; PROMOTER POLYMORPHISM; EMBRYONIC LETHALITY; MDM2-DEFICIENT MICE; IONIZING-RADIATION; COLORECTAL-CANCER	MDM2, an E3 ubiquitin ligase, is a potent inhibitor of the p53 tumor suppressor and is elevated in many human cancers that retain wild-type p53. MDM2 SNP309G is a functional polymorphism that results in elevated levels of MDM2 (due to enhanced SP1 binding to the MDM2 promoter) thus decreasing p53 activity. Mdm2SNP309G/G mice are more prone to spontaneous tumor formation than Mdm2SNP309T/T mice, providing direct evidence for the impact of this SNP in tumor development. We asked whether environmental factors impact SNP309G function and show that SNP309G cooperates with ionizing radiation to exacerbate tumor development. Surprisingly, ultraviolet B light or Benzo(a) pyrene exposure of skin shows that SNP309G allele actually protects against squamous cell carcinoma susceptibility. These contrasting differences led us to interrogate the mechanism by which Mdm2 SNP309 regulates tumor susceptibility in a tissue-specific manner. Although basal Mdm2 levels were significantly higher in most tissues in Mdm2SNP309G/G mice compared with Mdm2SNP309T/T mice, they were significantly lower in Mdm2SNP309G/G keratinocytes, the cell-type susceptible to squamous cell carcinoma. The assessment of potential transcriptional regulators in ENCODE ChIP-seq database identified transcriptional repressor E2F6 as a possible negative regulator of MDM2 expression. Our data show that E2F6 suppresses Mdm2 expression in cells harboring the SNP309G allele but not the SNP309T allele. Thus, Mdm2 SNP309G exhibits tissue-specific regulation and differentially impacts cancer risk.	[Ortiz, G. J.; Pant, V.; Xiong, S.; Larsson, C. A.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA; [Ortiz, G. J.; Larsson, C. A.; Johnson, D. G.; Lozano, G.] Univ Texas Grad Sch Biomed Sci Houston, Houston, TX USA; [Li, Y.; Johnson, D. G.] Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, Virginia Harris Cockrell Canc Res Ctr, Smithville, TX USA; [Post, S. M.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA; [El-Naggar, A. K.] Univ Texas MD Anderson Canc, Dept Pathol, Div Pathol Lab Med Unit 085, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Lozano, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd, Houston, TX 77030 USA.; Johnson, DG (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Epigenet & Mol Carcinogenesis, 1808 Pk Rd 1C,POB 389,Unit 116, Smithville, TX 78957 USA.	djohnson@mdanderson.org; gglozano@mdanderson.org	Xiong, Shunbin/AAR-5823-2021; Ortiz, Guadalupe/P-9425-2017	Pant, Vinod/0000-0002-3286-1804; Larsson, Connie/0000-0002-7829-0023; Ortiz, Guadalupe/0000-0002-8728-5090	NIH [R01ES015587, CA47296]; Cancer Prevention Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE [P30CA016672, R01CA047296] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015587] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Institute of Texas (CPRIT); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Laura Pageon (MD Anderson Cancer Center) for her pathology advice, Jen Orona for assistance with mouse studies and the members of the Lozano lab for their support and technical advice. NIH Grants R01ES015587 (DGJ), CA47296 (GL) and the Cancer Prevention Institute of Texas (CPRIT) supported this study.	Alvarez S, 2006, INT J RADIAT BIOL, V82, P761, DOI 10.1080/09553000600949624; Asomaning K, 2008, CLIN CANCER RES, V14, P4010, DOI 10.1158/1078-0432.CCR-07-4187; Azzam EI, 2012, CANCER LETT, V327, P48, DOI 10.1016/j.canlet.2011.12.012; Azzam GA, 2011, CELL CYCLE, V10, P1352, DOI 10.4161/cc.10.9.15344; Bassi DE, 2007, CURR PROTOC PHARM; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bouaoun L, 2016, HUM MUTAT, V37, P865, DOI 10.1002/humu.23035; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Cotignola J, 2012, J INVEST DERMATOL, V132, P1471, DOI 10.1038/jid.2012.15; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eischen CM, 2014, HUM MUTAT, V35, P728, DOI 10.1002/humu.22524; Fazel R, 2009, NEW ENGL J MED, V361, P849, DOI 10.1056/NEJMoa0901249; Glick A, 2007, MOL CARCINOGEN, V46, P605, DOI 10.1002/mc.20345; Hakkinen Lari, 2001, Methods in Cell Science, V23, P189, DOI 10.1023/A:1016385109922; Hu ZB, 2007, CANCER EPIDEM BIOMAR, V16, P2717, DOI 10.1158/1055-9965.EPI-07-0634; Hunter DJ, 2005, NAT REV GENET, V6, P287, DOI 10.1038/nrg1578; Ichihashi M, 2003, TOXICOLOGY, V189, P21, DOI 10.1016/S0300-483X(03)00150-1; Jackson JG, 2006, MOL CELL BIOL, V26, P2501, DOI 10.1128/MCB.26.7.2501-2510.2006; Johne A, 2003, CANCER EPIDEM BIOMAR, V12, P68; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; Knappskog S, 2011, CANCER CELL, V19, P273, DOI 10.1016/j.ccr.2010.12.019; Kuehl P, 2001, NAT GENET, V27, P383, DOI 10.1038/86882; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lazarus P, 1998, CARCINOGENESIS, V19, P509, DOI 10.1093/carcin/19.3.509; Li Guojun, 2006, Curr Oncol Rep, V8, P130, DOI 10.1007/s11912-006-0048-y; Liu GY, 2012, INT J UROL, V19, P914, DOI 10.1111/j.1442-2042.2012.03067.x; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lu MX, 2012, MOL CARCINOGEN, V51, pE132, DOI 10.1002/mc.21882; LUNA RMD, 1995, NATURE, V378, P203; MAUTHE RJ, 1995, CARCINOGENESIS, V16, P133, DOI 10.1093/carcin/16.1.133; Menendez D, 2006, P NATL ACAD SCI USA, V103, P1406, DOI 10.1073/pnas.0508103103; MIYASHITA T, 1995, CELL, V80, P293; Pant V, 2014, GENE DEV, V28, P1739, DOI 10.1101/gad.247452.114; Pant V, 2013, GENE DEV, V27, P1857, DOI 10.1101/gad.227249.113; Pastinen T, 2004, PHYSIOL GENOMICS, V16, P184, DOI 10.1152/physiolgenomics.00163.2003; Pittman AM, 2009, GENOME RES, V19, P987, DOI 10.1101/gr.092668.109; Post SM, 2010, CANCER CELL, V18, P220, DOI 10.1016/j.ccr.2010.07.010; Qin JX, 2015, J DERMATOL SCI, V79, P171, DOI 10.1016/j.jdermsci.2015.04.008; Qin JZ, 2002, ONCOGENE, V21, P2991, DOI 10.1038/sj.onc.1205404; Ramzi NH, 2014, INDIAN J MED RES, V139, P873; Ray-Coquard I, 2012, LANCET ONCOL, V13, P1133, DOI 10.1016/S1470-2045(12)70474-6; RAYCROFT L, 1990, SCIENCE, V249, P1049, DOI 10.1126/science.2144364; Russell JL, 2006, ONCOGENE, V25, P867, DOI 10.1038/sj.onc.1209120; Skobowiat C, 2011, AM J PHYSIOL-ENDOC M, V301, pE484, DOI [10.1152/ajpendo.00217.2011, 10.1152/ajpendo.00217.2011.]; Stracquadanio G, 2016, NAT REV CANCER, V16, P251, DOI 10.1038/nrc.2016.15; Sur IK, 2012, SCIENCE, V338, P1360, DOI 10.1126/science.1228606; Wang YX, 2011, J CLIN INVEST, V121, P893, DOI 10.1172/JCI44504; Wasylishen AR, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026211; Wo XM, 2011, J GENET GENOMICS, V38, P341, DOI 10.1016/j.jgg.2011.07.005; Wong CF, 2004, BIOCHEM BIOPH RES CO, V324, P497, DOI 10.1016/j.bbrc.2004.09.084; Yang X, 2016, MOL CLIN ONCOL, V5, P175, DOI 10.3892/mco.2016.868; Yu HP, 2011, MOL CARCINOGEN, V50, P697, DOI 10.1002/mc.20806	53	10	14	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 18	2018	37	3					332	340		10.1038/onc.2017.344	http://dx.doi.org/10.1038/onc.2017.344			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FS9QS	28925402	Green Accepted, Green Submitted			2022-12-17	WOS:000422753900006
J	Liao, SY; Chiang, CW; Hsu, CH; Chen, YT; Jen, J; Juan, HF; Lai, WW; Wang, YC				Liao, S-Y; Chiang, C-W; Hsu, C-H; Chen, Y-T; Jen, J.; Juan, H-F; Lai, W-W; Wang, Y-C			CK1 delta/GSK3 beta/FBXW7 alpha axis promotes degradation of the ZNF322A oncoprotein to suppress lung cancer progression	ONCOGENE			English	Article							EPITHELIAL-MESENCHYMAL TRANSITION; FBW7 UBIQUITIN LIGASE; TUMOR-SUPPRESSOR; BETA-CATENIN; PHOSPHORYLATION; RECOGNITION; PROTEOLYSIS; MECHANISMS; GROWTH; MCL1	Overexpression of Cys2His2 zinc-finger 322A (ZNF322A) oncogenic transcription factor is associated with lung tumorigenesis. However, the mechanism of ZNF322A overexpression remains poorly understood. Here, we discover that protein stability of ZNF322A is regulated by coordinated phosphorylation and ubiquitination through the CK1 delta/GSK3 beta/FBXW7 alpha axis. CK1 delta and GSK3 beta kinases sequentially phosphorylate ZNF322A at serine-396 and then serine-391. Moreover, the doubly phosphorylated ZNF322A protein creates a destruction motif for the ubiquitin ligase FBXW7 alpha leading to ZNF322A protein destruction. Overexpression of FBXW7a induces ZNF322A protein degradation, thereby blocks ZNF322A transcription activity and suppresses ZNF322A-induced tumor growth and metastasis in vitro and in vivo. Clinically, overexpression of ZNF322A correlates with low FBXW7a or defective CK1 delta/GSK3 beta-mediated phosphorylation in lung cancer patients. Multivariate Cox regression analysis indicates that patients with ZNF322A high/FBXW7 low expression profile can be used as an independent factor to predict the clinical outcome in lung cancer patients. Our results reveal a new mechanism of ZNF322A oncoprotein destruction regulated by the CK1 delta/GSK3 beta/FBXW7 alpha axis. Deregulation of this signaling axis results in ZNF322A overexpression and promotes cancer progression.	[Liao, S-Y; Chiang, C-W; Wang, Y-C] Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, 1 Univ Rd, Tainan 70101, Taiwan; [Chiang, C-W] Natl Cheng Kung Univ, Coll Med, Inst Mol Med, Tainan, Taiwan; [Hsu, C-H] Natl Taiwan Univ, Dept Agr Chem, Taipei, Taiwan; [Chen, Y-T; Jen, J.; Wang, Y-C] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Univ Rd, Tainan 70101, Taiwan; [Juan, H-F] Natl Taiwan Univ, Grad Inst Biomed Elect & Bioinformat, Inst Mol & Cellular Biol, Dept Life Sci, Taipei, Taiwan; [Lai, W-W] Natl Cheng Kung Univ, Coll Med, Natl Cheng Kung Univ Hosp, Dept Surg, Tainan, Taiwan	National Cheng Kung University; National Cheng Kung University; National Taiwan University; National Cheng Kung University; National Taiwan University; National Cheng Kung University; National Cheng Kung University Hospital	Wang, YC (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, 1 Univ Rd, Tainan 70101, Taiwan.; Wang, YC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Univ Rd, Tainan 70101, Taiwan.	ycw5798@mail.ncku.edu.tw	Wang, Yi-Ching/J-8702-2019; HSU, CHUN-HUA/W-4554-2019; , 賴吾為/T-8615-2019	Wang, Yi-Ching/0000-0002-7694-2067; HSU, CHUN-HUA/0000-0002-0008-7383; , 賴吾為/0000-0001-9174-8310	Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital; Taiwan Ministry of Science and Technology [104-2627-B-006-001, 104-2627-B-002-001]; Taiwan Ministry of Education [D105-35A07]	Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital; Taiwan Ministry of Science and Technology; Taiwan Ministry of Education(Ministry of Education, Taiwan)	We are grateful for the support from the Human Biobank, Research Center of Clinical Medicine, National Cheng Kung University Hospital. We thank Mr Chien-Hsun Lin for providing technical support. We acknowledge Dr Ruey-Hwa Chen, Institute of Biological Chemistry, Academia Sinica for discussion and comments on the manuscript. This work was supported in part by the Taiwan Ministry of Science and Technology grants (104-2627-B-006-001; 104-2627-B-002-001) and the Aim for the Top University Project grant from the Taiwan Ministry of Education (D105-35A07).	Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463; Davis RJ, 2014, CANCER CELL, V26, P455, DOI 10.1016/j.ccell.2014.09.013; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Gan WJ, 2015, MOL CELL, V59, P917, DOI 10.1016/j.molcel.2015.07.026; Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022; Hergovich A, 2006, MOL CELL BIOL, V26, P5784, DOI 10.1128/MCB.00232-06; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Jen J, 2016, ONCOGENE, V35, P2357, DOI 10.1038/onc.2015.296; Jia D, 2013, BLOOD, V121, P707, DOI 10.1182/blood-2012-05-433045; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Kao SH, 2014, ONCOGENE, V33, P3172, DOI 10.1038/onc.2013.279; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Marin O, 2003, P NATL ACAD SCI USA, V100, P10193, DOI 10.1073/pnas.1733909100; Pontano LL, 2008, MOL CELL BIOL, V28, P7245, DOI 10.1128/MCB.01085-08; Skaar JR, 2013, NAT REV MOL CELL BIO, V14, P369, DOI 10.1038/nrm3582; Thollet A, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-291; Vendrell JA, 2012, CANCER RES, V72, P3593, DOI 10.1158/0008-5472.CAN-11-3095; Wang R, 2013, CELL RES, V23, P803, DOI 10.1038/cr.2013.42; Wang ZW, 2014, NAT REV CANCER, V14, P233, DOI 10.1038/nrc3700; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2008, NAT REV CANCER, V8, P83, DOI 10.1038/nrc2290; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Xu Y, 2010, ONCOGENE, V29, P3124, DOI 10.1038/onc.2010.77; Yu J, 2013, ONCOGENE, V32, P307, DOI 10.1038/onc.2012.54; Zhao D, 2010, CANCER RES, V70, P4728, DOI 10.1158/0008-5472.CAN-10-0040; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	28	10	11	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 12	2017	36	41					5722	5733		10.1038/onc.2017.168	http://dx.doi.org/10.1038/onc.2017.168			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FJ6DJ	28581525				2022-12-17	WOS:000412843900006
J	Ohm, AM; Tan, AC; Heasley, LE; Reyland, ME				Ohm, A. M.; Tan, A-C; Heasley, L. E.; Reyland, M. E.			Co-dependency of PKC delta and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer	ONCOGENE			English	Article							TYROSINE PHOSPHORYLATION; TUMOR-SUPPRESSOR; NUCLEAR IMPORT; SALIVARY-GLAND; BREAST-CANCER; DNA-DAMAGE; CELLS; APOPTOSIS; MUTATIONS; MIGRATION	Recent studies suggest that the presence of a KRAS mutation may be insufficient for defining a clinically homogenous molecular group, as many KRAS mutant tumors lose reliance on K-Ras for survival. Identifying pathways that support K-Ras dependency may define clinically relevant KRAS subgroups and lead to the identification of new drug targets. We have analyzed a panel of 17 KRAS mutant lung cancer cell lines classified as K-Ras-dependent or -independent for co-dependency on protein kinase C delta (PKC delta). We show that functional dependency on K-Ras and PKC delta co-segregate, and that dependency correlates with a more epithelial-like phenotype. Furthermore, we show that the pro-apoptotic and pro-tumorigenic functions of PKC delta also segregate based on K-Ras dependency, as K-Ras-independent cells are more sensitive to topoisomerase inhibitors, and depletion of PKC delta in this subgroup suppresses apoptosis through increased activation of extracellular signal-regulated kinase (ERK). In contrast, K-Ras-dependent lung cancer cells are largely insensitive to topoisomerase inhibitors, and depletion of PKC delta can increase apoptosis and decrease activation of ERK in this subgroup. We have previously shown that nuclear translocation of PKC delta is necessary and sufficient for proapoptotic signaling. Our current studies show that K-Ras-dependent cells are refractive to PKC delta-driven apoptosis. Analysis of this subgroup showed increased PKC delta expression and an increase in the nuclear: cytoplasmic ratio of PKC delta. In addition, targeting PKCd to the nucleus induces apoptosis in K-Ras-independent, but not K-Ras-dependent non-small-cell lung cancer (NSCLC) cells. Our studies provide tools for identification of the subset of patients with KRAS mutant tumors most amenable to targeting of the K-Ras pathway, and identify PKC delta as a potential target in this tumor population. These subgroups are likely to be of clinical relevance, as high PKC delta expression correlates with increased overall survival and a more epithelial tumor phenotype in patients with KRAS mutant lung adenocarcinomas.	[Ohm, A. M.; Heasley, L. E.; Reyland, M. E.] Univ Colorado, Sch Dent Med, Dept Craniofacial Biol, Anschutz Med Campus,MS 8120,POB 6511, Aurora, CO 80045 USA; [Tan, A-C] Univ Colorado, Sch Med, Div Med Oncol, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Reyland, ME (corresponding author), Univ Colorado, Sch Dent Med, Dept Craniofacial Biol, Anschutz Med Campus,MS 8120,POB 6511, Aurora, CO 80045 USA.	Mary.Reyland@UCDenver.edu	Tan, Aik Choon/A-3135-2011	Tan, Aik Choon/0000-0003-2955-8369	United Against Lung Cancer research award; NIH Lung SPORE [P50 CA58187, R01DE015648]; NATIONAL CANCER INSTITUTE [P30CA046934, P50CA058187] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015648] Funding Source: NIH RePORTER	United Against Lung Cancer research award; NIH Lung SPORE; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We gratefully acknowledge the intellectual contributions of Dr Ross Camidge. This work was supported by a United Against Lung Cancer research award, a pilot grant from NIH Lung SPORE Grant P50 CA58187 and R01DE015648 to MER.	Adwan TS, 2011, J BIOL CHEM, V286, P35716, DOI 10.1074/jbc.M111.255950; Allen-Petersen BL, 2014, ONCOGENE, V33, P1306, DOI 10.1038/onc.2013.59; Allen-Petersen BL, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.20; Antal CE, 2015, CELL, V160, P489, DOI 10.1016/j.cell.2015.01.001; Bailey TA, 2014, J BIOL CHEM, V289, P30443, DOI 10.1074/jbc.M114.608992; Beau-Faller M, 2009, BRIT J CANCER, V100, P985, DOI 10.1038/sj.bjc.6604925; Cai QS, 2009, J BIOL CHEM, V284, P2150, DOI 10.1074/jbc.M803235200; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; D'Costa AM, 2006, ONCOGENE, V25, P378, DOI 10.1038/sj.onc.1209065; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; DeVries-Seimon TA, 2007, J BIOL CHEM, V282, P22307, DOI 10.1074/jbc.M703661200; Garg R, 2014, ONCOGENE, V33, P5225, DOI 10.1038/onc.2013.524; Hu CT, 2013, CELL SIGNAL, V25, P1457, DOI 10.1016/j.cellsig.2013.03.011; Humphries MJ, 2008, ONCOGENE, V27, P3045, DOI 10.1038/sj.onc.1210967; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465; Kharait S, 2006, BIOCHEM BIOPH RES CO, V343, P848, DOI 10.1016/j.bbrc.2006.03.044; Kho DH, 2009, GUT, V58, P509, DOI 10.1136/gut.2008.150938; Kolb RH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050281; Koo KH, 2015, ONCOTARGET, V6, P21328, DOI 10.18632/oncotarget.4049; Lagory EL, 2010, J BIOL CHEM, V285, P1879, DOI 10.1074/jbc.M109.055392; Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Mauro LV, 2010, PANCREAS, V39, pE31, DOI 10.1097/MPA.0b013e3181bce796; McCormick F, 2015, CLIN CANCER RES, V21, P1797, DOI 10.1158/1078-0432.CCR-14-2662; Mogi A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/583929; Nguyen HM, 2012, J NEUROSCI, V32, P3474, DOI 10.1523/JNEUROSCI.4167-11.2012; Osaki S, 2000, CANCER GENE THER, V7, P300, DOI 10.1038/sj.cgt.7700096; Pagliarini R, 2015, EMBO REP, V16, P280, DOI 10.15252/embr.201439949; Park M, 2013, CLIN CANCER RES, V19, P4961, DOI 10.1158/1078-0432.CCR-13-0131; Paugh BS, 2008, FASEB J, V22, P455, DOI 10.1096/fj.07-8276com; Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612; Reno EM, 2008, HUM PATHOL, V39, P21, DOI 10.1016/j.humpath.2007.05.023; Reyland ME, 2016, PHARMACOL THERAPEUT, V165, P1, DOI 10.1016/j.pharmthera.2016.05.001; Reyland ME, 2000, CELL DEATH DIFFER, V7, P1200, DOI 10.1038/sj.cdd.4400744; Riely Gregory J, 2009, Proc Am Thorac Soc, V6, P201, DOI 10.1513/pats.200809-107LC; Singh A, 2009, CELL CYCLE, V8, P2676, DOI 10.4161/cc.8.17.9336; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Symonds JM, 2016, ONCOTARGET, V7, P17905, DOI 10.18632/oncotarget.7560; Symonds JM, 2011, CANCER RES, V71, P2087, DOI 10.1158/0008-5472.CAN-10-1511; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wie SM, 2014, J BIOL CHEM, V289, P10900, DOI 10.1074/jbc.M114.551366; Wilson FH, 2015, CANCER CELL, V27, P397, DOI 10.1016/j.ccell.2015.02.005; Xia SH, 2007, J BIOL CHEM, V282, P13199, DOI 10.1074/jbc.M610225200; Xia SH, 2009, CELL SIGNAL, V21, P502, DOI 10.1016/j.cellsig.2008.12.002; Yoshida K, 2008, TRENDS MOL MED, V14, P305, DOI 10.1016/j.molmed.2008.05.003; Young A, 2013, CANCER DISCOV, V3, P112, DOI 10.1158/2159-8290.CD-12-0231; Zhu T, 2010, ONCOGENE, V29, P1050, DOI 10.1038/onc.2009.344	49	10	11	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 27	2017	36	30					4370	4378		10.1038/onc.2017.27	http://dx.doi.org/10.1038/onc.2017.27			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB8AH	28368426	Green Accepted			2022-12-17	WOS:000406360600013
J	Guo, X; Koff, JL; Moffitt, AB; Cinar, M; Ramachandiran, S; Chen, Z; Switchenko, JM; Mosunjac, M; Neill, SG; Mann, KP; Bagirov, M; Du, Y; Natkunam, Y; Khoury, HJ; Rossi, MR; Harris, W; Flowers, CR; Lossos, IS; Boise, LH; Dave, SS; Kowalski, J; Bernal-Mizrachi, L				Guo, X.; Koff, J. L.; Moffitt, A. B.; Cinar, M.; Ramachandiran, S.; Chen, Z.; Switchenko, J. M.; Mosunjac, M.; Neill, S. G.; Mann, K. P.; Bagirov, M.; Du, Y.; Natkunam, Y.; Khoury, H. J.; Rossi, M. R.; Harris, W.; Flowers, C. R.; Lossos, I. S.; Boise, L. H.; Dave, S. S.; Kowalski, J.; Bernal-Mizrachi, L.			Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype	ONCOGENE			English	Article							NF-KAPPA-B; ANTI-CD20 MONOCLONAL-ANTIBODY; GENE-EXPRESSION; DNA-DAMAGE; SOMATIC MUTATIONS; MARGINAL ZONE; LYMPHOMA; ACTIVATION; COMPLEX; PROTEIN	Diffuse large B-cell lymphoma (DLBCL) has been categorized into two molecular subtypes that have prognostic significance, namely germinal center B-cell like (GCB) and activated B-cell like (ABC). Although ABC-DLBCL has been associated with NF-kappa B activation, the relationships between activation of specific NF-.B signals and DLBCL phenotype remain unclear. Application of novel gene expression classifiers identified two new DLBCL categories characterized by selective p100 (NF-kappa B2) and p105 (NF-kappa B1) signaling. Interestingly, our molecular studies showed that p105 signaling is predominantly associated with GCB subtype and histone mutations. Conversely, most tumors with p100 signaling displayed ABC phenotype and harbored ABC-associated mutations in genes such as MYD88 and PIM1. In vitro, MYD88 L265P mutation promoted p100 signaling through TAK1/IKKa and GSK3/Fbxw7a pathways, suggesting a novel role for this protein as an upstream regulator of p100. p100 signaling was engaged during activation of normal B cells, suggesting p100' s role in ABC phenotype development. Additionally, silencing p100 in ABC-DLBCL cells resulted in a GCB-like phenotype, with suppression of Blimp, IRF4 and XBP1 and upregulation of BCL6, whereas introduction of p52 or p100 into GC cells resulted in differentiation toward an ABC-like phenotype. Together, these findings identify specific roles for p100 and p105 signaling in defining DLBCL molecular subtypes and posit MYD88/p100 signaling as a regulator for B-cell activation.	[Guo, X.; Koff, J. L.; Cinar, M.; Ramachandiran, S.; Khoury, H. J.; Harris, W.; Flowers, C. R.; Boise, L. H.; Kowalski, J.; Bernal-Mizrachi, L.] Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, 1365 Clifton Rd,Bldg C,3rd Floor, Atlanta, GA 30322 USA; [Moffitt, A. B.; Dave, S. S.] Duke Univ, Duke Inst Genome Sci & Policy, Dept Med, Durham, NC USA; [Chen, Z.; Switchenko, J. M.; Kowalski, J.] Emory Univ, Winship Canc Inst, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA; [Mosunjac, M.; Neill, S. G.; Mann, K. P.; Bagirov, M.] Emory Univ, Dept Pathol & Lab Med, Atlanta, GA 30322 USA; [Du, Y.] Emory Univ, Dept Pharmacol, Atlanta, GA 30322 USA; [Natkunam, Y.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Rossi, M. R.] Emory Univ, Dept Radiat Oncol, Atlanta, GA 30322 USA; [Lossos, I. S.] Univ Miami, Sylvester Comprehens Canc Ctr, Div Hematol Oncol & Mol & Cellular Pharmacol, Miami, FL USA	Emory University; Duke University; Emory University; Emory University; Emory University; Stanford University; Emory University; University of Miami	Bernal-Mizrachi, L (corresponding author), Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, 1365 Clifton Rd,Bldg C,3rd Floor, Atlanta, GA 30322 USA.	lbernal@emory.edu	Flowers, Christopher R/F-1953-2010; Natkunam, Yasodha/L-5454-2015; Boise, Lawrence/AAD-2314-2019	Flowers, Christopher R/0000-0002-9524-3990; Natkunam, Yasodha/0000-0002-9816-1018; Kowalski, Jeanne/0000-0003-3458-3024; Boise, Lawrence/0000-0001-9436-8815; Moffitt, Andrea/0000-0001-5964-7851	NIH [R21 CA158686, K24 CA208132, CA109335, CA122105, CA127910, CA129968]; GCCDSW; Dwoskin and Rizzo Family and Fidelity; Byron Davis Research Fund	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); GCCDSW; Dwoskin and Rizzo Family and Fidelity; Byron Davis Research Fund	We thank Dr Sagar Lonial and Dr Jing Chen for their critical review and helpful comments. We thank Dr Anne J Novak for providing the L265P MYD88 lentivirus. CRF was supported by NIH (R21 CA158686 and K24 CA208132) and GCCDSW. ISL by the NIH (CA109335 and CA122105) and the Dwoskin and Rizzo Family and Fidelity. JK was supported by GCCDSW. LHB received funding support from the NIH (CA127910 and CA129968) and a GCCDSW. LB-M received funding from the Byron Davis Research Fund.	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Angus SP, 2012, ONCOGENE, V31, P4709, DOI 10.1038/onc.2011.622; Ansell SM, 2014, BLOOD CANCER J, V4, DOI 10.1038/bcj.2014.4; Asanuma K, 2006, NAT CELL BIOL, V8, P485, DOI 10.1038/ncb1400; Basak S, 2008, MOL CELL BIOL, V28, P3139, DOI 10.1128/MCB.01469-07; Bernal-Mizrachi L, 2006, P NATL ACAD SCI USA, V103, P9220, DOI 10.1073/pnas.0507809103; Bowles JA, 2006, BLOOD, V108, P2648, DOI 10.1182/blood-2006-04-020057; Braggio E, 2012, MODERN PATHOL, V25, P651, DOI 10.1038/modpathol.2011.213; Chan YW, 2009, J CELL BIOL, V185, P859, DOI 10.1083/jcb.200812167; Chang H, 2007, MOL CANCER THER, V6, P24, DOI 10.1158/1535-7163.MCT-06-0443; Chattopadhyay S, 2007, MOL BIOL CELL, V18, P4085, DOI 10.1091/mbc.E06-12-1148; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Compagno M, 2009, NATURE, V459, P717, DOI 10.1038/nature07968; Davis RE, 2001, J EXP MED, V194, P1861, DOI 10.1084/jem.194.12.1861; De Antoni A, 2005, CURR BIOL, V15, P214, DOI 10.1016/j.cub.2005.01.038; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Eckfeld K, 2004, CANCER RES, V64, P8688, DOI 10.1158/0008-5472.CAN-04-2065; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Gasparini C, 2014, CELL MOL LIFE SCI, V71, P2083, DOI 10.1007/s00018-013-1545-4; Gerondakis S, 2006, ONCOGENE, V25, P6781, DOI 10.1038/sj.onc.1209944; Gerondakis S, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000182; Hale JS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010127; Harvey D, 2011, RHEUMATOLOGY, V50, P1720, DOI 10.1093/rheumatology/ker199; Hummel M, 2006, NEW ENGL J MED, V354, P2419, DOI 10.1056/NEJMoa055351; Jazirehi AR, 2005, CANCER RES, V65, P264; Joshi B, 2004, EUR J BIOCHEM, V271, P2189, DOI 10.1111/j.1432-1033.2004.04149.x; Kamphausen E, 2010, CANCER IMMUNOL IMMUN, V59, P1273, DOI 10.1007/s00262-010-0856-7; Kaser A, 2001, BIOL CHEM, V382, P1637, DOI 10.1515/BC.2001.199; Klein U, 2008, NAT REV IMMUNOL, V8, P22, DOI 10.1038/nri2217; Klon AE, 2002, J MOL BIOL, V320, P677, DOI 10.1016/S0022-2836(02)00469-2; Lam LT, 2008, BLOOD, V111, P3701, DOI 10.1182/blood-2007-09-111948; Lenz G, 2008, NEW ENGL J MED, V359, P2313, DOI 10.1056/NEJMoa0802885; Lenz G, 2010, NEW ENGL J MED, V362, P1417, DOI 10.1056/NEJMra0807082; Lepin EJM, 2000, EUR J IMMUNOL, V30, P3552, DOI 10.1002/1521-4141(200012)30:12<3552::AID-IMMU3552>3.0.CO;2-L; Liao YC, 2007, J CELL BIOL, V176, P43, DOI 10.1083/jcb.200608015; Lo JC, 2006, BLOOD, V107, P1048, DOI 10.1182/blood-2005-06-2452; Lohr JG, 2012, P NATL ACAD SCI USA, V109, P3879, DOI 10.1073/pnas.1121343109; Loiodice I, 2004, MOL BIOL CELL, V15, P3333, DOI 10.1091/mbc.E03-12-0878; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Marill J, 2000, MOL PHARMACOL, V58, P1341, DOI 10.1124/mol.58.6.1341; McCool KW, 2012, IMMUNOL REV, V246, P311, DOI 10.1111/j.1600-065X.2012.01101.x; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Nandi AK, 2007, BIOCHEM BIOPH RES CO, V358, P181, DOI 10.1016/j.bbrc.2007.04.125; Navarro F, 1999, EUR J IMMUNOL, V29, P277, DOI 10.1002/(SICI)1521-4141(199901)29:01<277::AID-IMMU277>3.0.CO;2-4; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Piao L, 2011, GENE CHROMOSOME CANC, V50, P13, DOI 10.1002/gcc.20828; Ramachandiran S, 2015, INT J CANCER, V136, P2341, DOI 10.1002/ijc.29301; Roman Y, 2007, BIOCHEMISTRY-US, V46, P11369, DOI 10.1021/bi7005477; Roodink I, 2008, AM J PATHOL, V173, P1873, DOI 10.2353/ajpath.2008.080136; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Shaffer AL, 2012, ANNU REV IMMUNOL, V30, P565, DOI 10.1146/annurev-immunol-020711-075027; Shih VFS, 2011, CELL RES, V21, P86, DOI 10.1038/cr.2010.161; Shimizu N, 2011, CELL METAB, V13, P170, DOI 10.1016/j.cmet.2011.01.001; Shipp MA, 2002, NAT MED, V8, P68, DOI 10.1038/nm0102-68; Staudt LM, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000109; Teras LR, 2016, CA-CANCER J CLIN, V66, P443, DOI 10.3322/caac.21357; Thompson MP, 2003, LEUKEMIA, V17, P2196, DOI 10.1038/sj.leu.2403130; Wolf A, 2006, NAT CELL BIOL, V8, P1432, DOI 10.1038/ncb1504; Wu RP, 2010, P NATL ACAD SCI USA, V107, P7479, DOI 10.1073/pnas.1002890107; Zhang BC, 2007, BLOOD, V110, P743, DOI 10.1182/blood-2006-11-058446; Zhang BC, 2015, CELL REP, V11, P715, DOI 10.1016/j.celrep.2015.03.059; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110; Zhao B, 2014, CELL REP, V8, P1595, DOI 10.1016/j.celrep.2014.07.037; Zhu DX, 2013, AM J HEMATOL, V88, P730, DOI 10.1002/ajh.23490; Zhu H, 2008, J CELL BIOL, V183, P835, DOI 10.1083/jcb.200807046	71	10	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 20	2017	36	29					4224	4232		10.1038/onc.2017.90	http://dx.doi.org/10.1038/onc.2017.90			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FB0LE	28368397				2022-12-17	WOS:000405835800013
J	Jhan, JR; Andrechek, ER				Jhan, J-R; Andrechek, E. R.			Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis	ONCOGENE			English	Article							TRASTUZUMAB RESISTANCE; TRANSCRIPTION FACTORS; ADJUVANT BEVACIZUMAB; MOLECULAR PORTRAITS; TARGETED THERAPIES; LUNG-CANCER; IN-VITRO; INHIBITION; MODELS; CONTRIBUTES	Current therapeutic outcomes for breast cancer underscore the complexity of treating a heterogeneous disease. Indeed, studies have shown that differences in gene expression among patients with the same subtype of breast cancer are correlated with the response to treatment. This strongly suggests that there is an urgent need to treat breast cancer with a personalized approach. Here we employed cell signaling pathway signatures to predict pathway activity in subtypes of MMTV-Myc mammary tumors. We then split tumors into subsets and developed individualized combinatorial treatments for two subtypes with distinct pathway activation patterns. Elevation of the EGFR, RAS and TGF beta pathways was observed in one subtype whereas these pathways were not predicted to be active in the other subtype that had high predicted activity of the Myc, Stat3 and Akt pathways. In a proof-of-principle experiment, treatment of these two subtypes with targeted therapies inhibited tumor growth only in the subtype of tumor where the therapy was designed to be active. We then analyzed gene expression profiles of human breast cancer patients and patientderived xenograft (PDX) samples to predict pathway activity, and validated our approach of developing individualized treatments in mice with PDX tumors. Importantly, our combinatorial therapy resulted in tumor regression, including regression in PDX samples from triple-negative breast cancer. Together our data is a proof-of-principle experiment that demonstrates that cell signaling pathway signature-guided treatment for breast cancer is viable.	[Jhan, J-R; Andrechek, E. R.] Michigan State Univ, Dept Physiol, 2194 Biomed Phys Sci Bldg,567 Wilson Rd, E Lansing, MI 48824 USA	Michigan State University	Andrechek, ER (corresponding author), Michigan State Univ, Dept Physiol, 2194 Biomed Phys Sci Bldg,567 Wilson Rd, E Lansing, MI 48824 USA.	andrech1@msu.edu			Susan Komen Career Catalyst [KG110510]; NIH [R011CA160514]	Susan Komen Career Catalyst; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank the members of the Andrechek laboratory for helpful discussions. Funding for this project was provided by grants from Susan Komen Career Catalyst (KG110510) and NIH R011CA160514 to ERA.	Alok J., 2004, BIOINFORMATICS, V20, P3246; Andrechek ER, 2015, ONCOGENE, V34, P217, DOI 10.1038/onc.2013.540; Andrechek ER, 2009, P NATL ACAD SCI USA, V106, P16387, DOI 10.1073/pnas.0901250106; Barbie TU, 2014, J CLIN INVEST, V124, P5411, DOI 10.1172/JCI75661; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bear HD, 2015, LANCET ONCOL, V16, P1037, DOI 10.1016/S1470-2045(15)00041-8; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bertucci F, 2016, LANCET ONCOL, V17, P600, DOI 10.1016/S1470-2045(16)00011-5; Bhatt AP, 2010, BLOOD, V115, P4455, DOI 10.1182/blood-2009-10-251082; Bild AH, 2006, NATURE, V439, P353, DOI 10.1038/nature04296; Cameron D, 2013, LANCET ONCOL, V14, P933, DOI 10.1016/S1470-2045(13)70335-8; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Carvalho CM, 2008, J AM STAT ASSOC, V103, P1438, DOI 10.1198/016214508000000869; Chang JT, 2009, MOL CELL, V34, P104, DOI 10.1016/j.molcel.2009.02.030; Ciriello G, 2015, CELL, V163, P506, DOI 10.1016/j.cell.2015.09.033; DaCosta BS, 2004, MOL PHARM, V65, P744, DOI DOI 10.1124/M0L.65.3.744; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106; Eo HS, 2012, MOL CELLS, V34, P393, DOI 10.1007/s10059-012-0177-0; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Finn RS, 2015, LANCET ONCOL, V16, P25, DOI 10.1016/S1470-2045(14)71159-3; Fujiwara K, 2011, CANCER RES, V71, P1924, DOI 10.1158/0008-5472.CAN-10-2386; Gatza ML, 2014, NAT GENET, V46, P1051, DOI 10.1038/ng.3073; Gatza ML, 2010, P NATL ACAD SCI USA, V107, P6994, DOI 10.1073/pnas.0912708107; Gonzalez-Angulo AM, 2011, CLIN CANCER RES, V17, P1082, DOI 10.1158/1078-0432.CCR-10-2560; Hoefflin R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11845; Hollern DP, 2013, ONCOGENE, V32, P1296, DOI 10.1038/onc.2012.142; Hollern DP, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3672; Hollern DP, 2014, MOL CELL BIOL, V34, P3229, DOI 10.1128/MCB.00737-14; Iwamaru A, 2007, ONCOGENE, V26, P2435, DOI 10.1038/sj.onc.1210031; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Morrow PK, 2011, J CLIN ONCOL, V29, P3126, DOI 10.1200/JCO.2010.32.2321; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Narayan M, 2009, CANCER RES, V69, P2191, DOI 10.1158/0008-5472.CAN-08-1056; O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418; Perou CM, 1999, P NATL ACAD SCI USA, V96, P9212, DOI 10.1073/pnas.96.16.9212; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846; Shattuck DL, 2008, CANCER RES, V68, P1471, DOI 10.1158/0008-5472.CAN-07-5962; Sorlie T, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-127; Tang Y, 2009, NAT MED, V15, P757, DOI 10.1038/nm.1979; Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998; Xia WL, 2007, CANCER RES, V67, P1170, DOI 10.1158/0008-5472.CAN-06-2101; Yamaguchi T, 2011, INT J ONCOL, V39, P23, DOI 10.3892/ijo.2011.1015; Yang D, 2010, P NATL ACAD SCI USA, V107, P13836, DOI 10.1073/pnas.1008366107; Yates LR, 2015, NAT MED, V21, P751, DOI 10.1038/nm.3886; Zhang XM, 2013, CANCER RES, V73, P4885, DOI 10.1158/0008-5472.CAN-12-4081; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741; 2007, CLIN CANCER RES, V13, P4429, DOI DOI 10.1158/1078-0432.CCR-06-3045	56	10	11	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3553	3561		10.1038/onc.2016.503	http://dx.doi.org/10.1038/onc.2016.503			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28135251				2022-12-17	WOS:000403878600005
J	Weitsman, G; Mitchell, NJ; Evans, R; Cheung, A; Kalber, TL; Bofinger, R; Fruhwirth, GO; Keppler, M; Wright, ZVF; Barber, PR; Gordon, P; de Koning, T; Wulaningsih, W; Sander, K; Vojnovic, B; Ameer-Beg, S; Lythgoe, M; Arnold, JN; Arstad, E; Festy, F; Hailes, HC; Tabor, AB; Ng, T				Weitsman, G.; Mitchell, N. J.; Evans, R.; Cheung, A.; Kalber, T. L.; Bofinger, R.; Fruhwirth, G. O.; Keppler, M.; Wright, Z. V. F.; Barber, P. R.; Gordon, P.; de Koning, T.; Wulaningsih, W.; Sander, K.; Vojnovic, B.; Ameer-Beg, S.; Lythgoe, M.; Arnold, J. N.; Arstad, E.; Festy, F.; Hailes, H. C.; Tabor, A. B.; Ng, T.			Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; NEGATIVE BREAST-CANCER; TUMOR-CELL MIGRATION; PHASE-II TRIAL; COLORECTAL-CANCER; PEPTIDE LIGAND; DELIVERY; MACROPHAGES; PHOSPHORYLATION; QUANTIFICATION	Despite decades of research in the epidermal growth factor receptor (EGFR) signalling field, and many targeted anti-cancer drugs that have been tested clinically, the success rate for these agents in the clinic is low, particularly in terms of the improvement of overall survival. Intratumoral heterogeneity is proposed as a major mechanism underlying treatment failure of these moleculetargeted agents. Here we highlight the application of fluorescence lifetime microscopy (FLIM)-based biosensing to demonstrate intratumoral heterogeneity of EGFR activity. For sensing EGFR activity in cells, we used a genetically encoded CrkII-based biosensor which undergoes conformational changes upon tyrosine-221 phosphorylation by EGFR. We transfected this biosensor into EGFR-positive tumour cells using targeted lipopolyplexes bearing EGFR-binding peptides at their surfaces. In a murine model of basal-like breast cancer, we demonstrated a significant degree of intratumoral heterogeneity in EGFR activity, as well as the pharmacodynamic effect of a radionuclide-labeled EGFR inhibitor in situ. Furthermore, a significant correlation between high EGFR activity in tumour cells and macrophage-tumour cell proximity was found to in part account for the intratumoral heterogeneity in EGFR activity observed. The same effect of macrophage infiltrate on EGFR activation was also seen in a colorectal cancer xenograft. In contrast, a non-small cell lung cancer xenograft expressing a constitutively active EGFR conformational mutant exhibited macrophage proximity-independent EGFR activity. Our study validates the use of this methodology to monitor therapeutic response in terms of EGFR activity. In addition, we found iNOS gene induction in macrophages that are cultured in tumour cell-conditioned media as well as an iNOS activity-dependent increase in EGFR activity in tumour cells. These findings point towards an immune microenvironment-mediated regulation that gives rise to the observed intratumoral heterogeneity of EGFR signalling activity in tumour cells in vivo.	[Weitsman, G.; Evans, R.; Cheung, A.; Fruhwirth, G. O.; Keppler, M.; Ameer-Beg, S.; Ng, T.] Kings Coll London, Randall Div, Richard Dimbleby Dept Canc Res, Rm 232D,New Hunts House,Guys Med Sch Campus, London SE1 1UL, Greater London, England; [Weitsman, G.; Evans, R.; Cheung, A.; Fruhwirth, G. O.; Keppler, M.; de Koning, T.; Ameer-Beg, S.; Arnold, J. N.; Ng, T.] Kings Coll London, Div Canc Studies, Rm 232D,New Hunts House,Guys Med Sch Campus, London SE1 1UL, Greater London, England; [Mitchell, N. J.; Bofinger, R.; Wright, Z. V. F.; Hailes, H. C.; Tabor, A. B.] UCL, Dept Chem, London WC1H 0AJ, Greater London, England; [Cheung, A.; Gordon, P.; Ng, T.] Kings Coll London, Breast Canc Now Res Unit, London, England; [Kalber, T. L.; Lythgoe, M.] UCL, Div Med, UCL Ctr Adv Biomed Imaging, London, England; [Barber, P. R.; Vojnovic, B.] Canc Res UK, Dept Oncol, Gray Labs, London, England; [Barber, P. R.; Vojnovic, B.] MRC, Oxford Inst Radiat Oncol, Oxford, England; [Wulaningsih, W.] Kings Coll London, Div Canc Studies, Canc Epidemiol Grp, London, England; [Sander, K.; Arstad, E.] UCL, Inst Nucl Med, London, England; [Festy, F.] Kings Coll London, Dent Inst, Tissue Engn & Biophoton, Guys Hosp Campus, London, England; [Ng, T.] UCL, UCL Canc Inst, Paul Ogorman Bldg, London, England; [Fruhwirth, G. O.] Kings Coll London, St Thomas Hosp, Div Imaging Sci & Biomed Engn, Dept Imaging Chem & Biol, London SE1 7EH, England; [Mitchell, N. J.] Univ Nottingham, Sch Chem, Univ Pk, Nottingham NG7 2RD, England	University of London; King's College London; University of London; King's College London; University of London; University College London; University of London; King's College London; University of London; University College London; Cancer Research UK; University of Oxford; University of London; King's College London; University of London; University College London; University of London; King's College London; University of London; University College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Nottingham	Ng, T (corresponding author), Kings Coll London, Randall Div, Richard Dimbleby Dept Canc Res, Rm 232D,New Hunts House,Guys Med Sch Campus, London SE1 1UL, Greater London, England.; Ng, T (corresponding author), Kings Coll London, Div Canc Studies, Rm 232D,New Hunts House,Guys Med Sch Campus, London SE1 1UL, Greater London, England.; Tabor, AB (corresponding author), UCL, Dept Chem, London WC1H 0AJ, Greater London, England.	a.b.tabor@ucl.ac.uk; tony.ng@kcl.ac.uk	Fruhwirth, Gilbert/AAP-5559-2021; Arnold, James/ABE-3900-2021; Vojnovic, Borivoj/AAV-4756-2021; Evans, Rachel/GYU-7083-2022; Mitchell, Nicholas/N-7555-2015	Fruhwirth, Gilbert/0000-0002-1438-2674; Arnold, James/0000-0002-6949-0613; Vojnovic, Borivoj/0000-0001-9013-3816; Mitchell, Nicholas/0000-0002-9041-1852; Evans, Rachel/0000-0002-3723-2249; Kalber, Tammy/0000-0002-3378-3748; Ameer-Beg, Simon/0000-0001-5227-575X; Arstad, Erik/0000-0002-3240-2106; Ng, Tony/0000-0003-3894-5619; Hailes, Helen/0000-0001-5574-4742; Lythgoe, Mark/0000-0002-4945-0171; Bofinger, Robin/0000-0002-3866-1301	Cancer Research-UK [C1519/A6906, C5255/A15935]; King's College London-UCL Comprehensive Cancer Imaging Centre (CRUK EPSRC); EU; EC GRANT [259881]; The European Research Council [335326]; National Institute of Health Research (NIHR) Biomedical Research Centre; St Thomas' NHS Foundation Trust; King's College London; EPSRC [EP/L006472/1] Funding Source: UKRI; Cancer Research UK [15677, 16463, 21840] Funding Source: researchfish; Engineering and Physical Sciences Research Council [EP/L006472/1] Funding Source: researchfish	Cancer Research-UK(Cancer Research UK); King's College London-UCL Comprehensive Cancer Imaging Centre (CRUK EPSRC)(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EU(European Commission); EC GRANT; The European Research Council(European Research Council (ERC)); National Institute of Health Research (NIHR) Biomedical Research Centre(National Institute for Health Research (NIHR)); St Thomas' NHS Foundation Trust; King's College London(General Electric); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); Cancer Research UK(Cancer Research UK); Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	This work was supported by Cancer Research-UK (grants C1519/A6906 and C5255/A15935); the King's College London-UCL Comprehensive Cancer Imaging Centre (CRUK & EPSRC) and in association with the MRC and DoH; by the EU FP7 grants IMAGINT (EC GRANT: 259881); by The European Research Council (335326). National Institute of Health Research (NIHR) Biomedical Research Centre based at Guy's and St Thomas' NHS Foundation Trust and King's College London.	Arrowsmith J, 2011, NAT REV DRUG DISCOV, V10, P1, DOI 10.1038/nrd3375; Barber PR, 2009, J R SOC INTERFACE, V6, pS93, DOI 10.1098/rsif.2008.0451.focus; Bronte V, 2005, J EXP MED, V201, P1257, DOI 10.1084/jem.20042028; Carey LA, 2012, J CLIN ONCOL, V30, P2615, DOI 10.1200/JCO.2010.34.5579; Charan J, 2013, J PHARMACOL PHARMACO, V4, P303, DOI 10.4103/0976-500X.119726; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Dickler MN, 2008, CLIN CANCER RES, V14, P7878, DOI 10.1158/1078-0432.CCR-08-0141; Fan QM, 2014, CANCER LETT, V352, P160, DOI 10.1016/j.canlet.2014.05.008; Fan YS, 2013, GENET TEST MOL BIOMA, V17, P515, DOI 10.1089/gtmb.2012.0510; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Fruhwirth GO, 2014, J NUCL MED, V55, P686, DOI 10.2967/jnumed.113.127480; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; Gerlinger M, 2010, BRIT J CANCER, V103, P1139, DOI 10.1038/sj.bjc.6605912; Grosse SM, 2010, FASEB J, V24, P2301, DOI 10.1096/fj.09-144220; Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Hurley CA, 2004, J ORG CHEM, V69, P980, DOI 10.1021/jo035422g; Hurley CA, 2008, ORG BIOMOL CHEM, V6, P2554, DOI 10.1039/b719702k; Irshad S, 2011, CURR OPIN ONCOL, V23, P566, DOI 10.1097/CCO.0b013e32834bf8ae; Kasic T, 2011, EUR J IMMUNOL, V41, P1843, DOI 10.1002/eji.201040868; Keese M, 2005, J BIOL CHEM, V280, P27826, DOI 10.1074/jbc.M504485200; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Kudsiova L, 2011, MOL PHARMACEUT, V8, P1831, DOI 10.1021/mp2001796; Kullberg M, 2013, J CONTROL RELEASE, V172, P730, DOI 10.1016/j.jconrel.2013.08.300; Kurokawa K, 2001, J BIOL CHEM, V276, P31305, DOI 10.1074/jbc.M104341200; Li ZH, 2005, FASEB J, V19, P1978, DOI 10.1096/fj.05-4058com; Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295; Medina OP, 2011, J CONTROL RELEASE, V149, P292, DOI 10.1016/j.jconrel.2010.10.024; Mickler FM, 2012, NANO LETT, V12, P3417, DOI 10.1021/nl300395q; Mitchell N, 2013, BIOMATERIALS, V34, P1179, DOI 10.1016/j.biomaterials.2012.09.070; Modi S, 2006, CLIN BREAST CANCER, V7, P270, DOI 10.3816/CBC.2006.n.040; Molon B, 2011, J EXP MED, V208, P1949, DOI 10.1084/jem.20101956; Mustapa MFM, 2007, BIOCHEMISTRY-US, V46, P12930, DOI 10.1021/bi701014y; Mustapa MFM, 2009, BIOCONJUGATE CHEM, V20, P518, DOI 10.1021/bc800450r; Ng T, 1999, SCIENCE, V283, P2085, DOI 10.1126/science.283.5410.2085; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Nobis M, 2013, CANCER RES, V73, P4674, DOI 10.1158/0008-5472.CAN-12-4545; Nuciforo P, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0561-8; Ongarora BG, 2012, J MED CHEM, V55, P3725, DOI 10.1021/jm201544y; Oppenheim DE, 2014, BRIT J CANCER, V110, P1221, DOI 10.1038/bjc.2014.35; Pal A, 2006, MOL IMAGING BIOL, V8, P262, DOI 10.1007/s11307-006-0049-0; Park SY, 2010, INT J PHARMACEUT, V383, P178, DOI 10.1016/j.ijpharm.2009.08.039; Peter M, 2005, BIOPHYS J, V88, P1224, DOI 10.1529/biophysj.104.050153; Pietras K, 2002, CANCER RES, V62, P5476; Pietras K, 2001, CANCER RES, V61, P2929; Prabhakar U, 2013, CANCER RES, V73, P2412, DOI 10.1158/0008-5472.CAN-12-4561; Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015; Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182; Song SX, 2009, FASEB J, V23, P1396, DOI 10.1096/fj.08-117002; Switzer CH, 2012, MOL CANCER RES, V10, P1203, DOI 10.1158/1541-7786.MCR-12-0124; Tagawa T, 2002, GENE THER, V9, P564, DOI 10.1038/sj.gt.3301686; de Ilarduya CT, 2010, EUR J PHARM SCI, V40, P159, DOI 10.1016/j.ejps.2010.03.019; Wang AZ, 2008, CHEMMEDCHEM, V3, P1311, DOI 10.1002/cmdc.200800091; Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823	56	10	11	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 22	2017	36	25					3618	3628		10.1038/onc.2016.522	http://dx.doi.org/10.1038/onc.2016.522			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY3NL	28166195	Green Published, Green Submitted, Green Accepted, hybrid			2022-12-17	WOS:000403878600011
J	Amar, D; Izraeli, S; Shamir, R				Amar, D.; Izraeli, S.; Shamir, R.			Utilizing somatic mutation data from numerous studies for cancer research: proof of concept and applications	ONCOGENE			English	Article							HEDGEHOG SIGNALING PATHWAY; GENE-EXPRESSION PROFILES; INTEGRATED ANALYSIS; IDENTIFICATION; CYTOSCAPE; ONTOLOGY; BIOLOGY; SMAD4; KRAS	Large cancer projects measure somatic mutations in thousands of samples, gradually assembling a catalog of recurring mutations in cancer. Many methods analyze these data jointly with auxiliary information with the aim of identifying subtype-specific results. Here, we show that somatic gene mutations alone can reliably and specifically predict cancer subtypes. Interpretation of the classifiers provides useful insights for several biomedical applications. We analyze the COSMIC database, which collects somatic mutations from The Cancer Genome Atlas (TCGA) as well as from many smaller scale studies. We use multi-label classification techniques and the Disease Ontology hierarchy in order to identify cancer subtype-specific biomarkers. Cancer subtype classifiers based on TCGA and the smaller studies have comparable performance, and the smaller studies add a substantial value in terms of validation, coverage of additional subtypes, and improved classification. The gene sets of the classifiers are used for threefold contribution. First, we refine the associations of genes to cancer subtypes and identify novel compelling candidate driver genes. Second, using our classifiers we successfully predict the primary site of metastatic samples. Third, we provide novel hypotheses regarding detection of subtype-specific synthetic lethality interactions. From the cancer research community perspective, our results suggest that curation efforts, such as COSMIC, have great added and complementary value even in the era of large international cancer projects.	[Amar, D.; Shamir, R.] Tel Aviv Univ, Blavatnik Sch Comp Sci, Tel Aviv Univ Campus, IL-69978 Tel Aviv, Israel; [Izraeli, S.] Sheba Med Ctr, Safra Childrens Hosp, Dept Pediat Hematol Oncol, Ramat Gan, Israel; [Izraeli, S.] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel	Tel Aviv University; Chaim Sheba Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Shamir, R (corresponding author), Tel Aviv Univ, Blavatnik Sch Comp Sci, Tel Aviv Univ Campus, IL-69978 Tel Aviv, Israel.	rshamir@tau.ac.il	Shamir, Ron/E-6514-2011	Shamir, Ron/0000-0003-1889-9870	Israel Science Foundation [317/13]; IDEA grant from the Dotan Center in Hemato-Oncology; Israeli Center of Research Excellence (I-CORE), Gene Regulation in Complex Human Disease [41/11]; Azrieli Foundation; Edmond J. Safra Center for Bioinformatics at Tel Aviv University	Israel Science Foundation(Israel Science Foundation); IDEA grant from the Dotan Center in Hemato-Oncology; Israeli Center of Research Excellence (I-CORE), Gene Regulation in Complex Human Disease; Azrieli Foundation; Edmond J. Safra Center for Bioinformatics at Tel Aviv University	This study was supported in part by the Israel Science Foundation (grant 317/13), an IDEA grant from the Dotan Center in Hemato-Oncology, and the Israeli Center of Research Excellence (I-CORE), Gene Regulation in Complex Human Disease, Center No 41/11. DA is grateful to the Azrieli Foundation for the award of an Azrieli Fellowship. DA was also supported in part by fellowships from the Edmond J. Safra Center for Bioinformatics at Tel Aviv University. Part of the work was done while DA and RS were visiting the Simons Institute for the Theory of Computing.	Amar D, 2015, NUCLEIC ACIDS RES, V43, P7779, DOI 10.1093/nar/gkv810; Amar D, 2014, NUCLEIC ACIDS RES, V42, P4208, DOI 10.1093/nar/gku102; Bardeesy N, 2006, GENE DEV, V20, P3130, DOI 10.1101/gad.1478706; Breiman L., 2001, Machine Learning, V45, P5, DOI 10.1023/A:1010933404324; Cancer Genome Atlas Research Network, 2013, Nat Genet, V45, P1113, DOI 10.1038/ng.2764; Chawla NV, 2002, J ARTIF INTELL RES, V16, P321, DOI 10.1613/jair.953; CORTES C, 1995, MACH LEARN, V20, P273, DOI 10.1007/BF00994018; Creighton CJ, 2013, NATURE, V499, P43, DOI 10.1038/nature12222; Dees ND, 2012, GENOME RES, V22, P1589, DOI 10.1101/gr.134635.111; Ding JR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9554; Durinck S, 2005, BIOINFORMATICS, V21, P3439, DOI 10.1093/bioinformatics/bti525; Eser S, 2014, BRIT J CANCER, V111, P1; Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075; Furth N, 2015, GENE DEV, V29, P2325, DOI 10.1101/gad.268185.115; Gonzalez-Perez A, 2013, NAT METHODS, V10, P723, DOI 10.1038/nmeth.2562; Guo J, 2016, NUCLEIC ACIDS RES, V44, pD1011, DOI 10.1093/nar/gkv1108; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hofree M, 2013, NAT METHODS, V10, P1108, DOI [10.1038/NMETH.2651, 10.1038/nmeth.2651]; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Jerby-Arnon L, 2014, CELL, V158, P1199, DOI 10.1016/j.cell.2014.07.027; Ji ZY, 2007, J BIOL CHEM, V282, P14048, DOI 10.1074/jbc.M611089200; Kelleher FC, 2011, CARCINOGENESIS, V32, P445, DOI 10.1093/carcin/bgq280; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Lan A, 2011, NUCLEIC ACIDS RES, V39, pW424, DOI 10.1093/nar/gkr359; Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912; Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213; Lee YS, 2013, BIOINFORMATICS, V29, P3036, DOI 10.1093/bioinformatics/btt529; Leiserson MDM, 2015, NAT GENET, V47, P106, DOI 10.1038/ng.3168; Liu Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep10204; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Montojo J, 2010, BIOINFORMATICS, V26, P2927, DOI 10.1093/bioinformatics/btq562; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Onishi H, 2014, WORLD J GASTROENTERO, V20, P2335, DOI 10.3748/wjg.v20.i9.2335; Raphael BJ, 2014, GENOME MED, V6, DOI 10.1186/gm524; Schriml LM, 2012, NUCLEIC ACIDS RES, V40, pD940, DOI 10.1093/nar/gkr972; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Tascilar M, 2001, CLIN CANCER RES, V7, P4115; Torgo L, 2011, DATA MINING R LEARNI, P289; Truty MJ, 2007, PANCREATOLOGY, V7, P423, DOI 10.1159/000108959; Tsoumakas G, 2011, J MACH LEARN RES, V12, P2411; Tsoumakas  Grigorios, 2008, P ECML PKDD 2008 WOR, V21, P53; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61; Ulitsky I, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-8; Vandin F, 2012, BIOCOMPUT-PAC SYM, P55; Visser S, 2010, CELL CYCLE, V9, P3892, DOI 10.4161/cc.9.19.13386; Vlasblom J, 2014, BIOINFORMATICS, P1; Whitehurst AW, 2007, NATURE, V446, P815, DOI 10.1038/nature05697; Wright M. N., 2015, RANGER FAST IMPLEMEN; Zhang ML, 2007, PATTERN RECOGN, V40, P2038, DOI 10.1016/j.patcog.2006.12.019; Zhang ML, 2014, IEEE T KNOWL DATA EN, V26, P1819, DOI 10.1109/TKDE.2013.39; Zhao ZM, 2016, P NATL ACAD SCI USA, V113, P2140, DOI 10.1073/pnas.1525677113	51	10	10	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 15	2017	36	24					3375	3383		10.1038/onc.2016.489	http://dx.doi.org/10.1038/onc.2016.489			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EX6GL	28092680	Green Published, hybrid			2022-12-17	WOS:000403340700002
J	Jiang, T; Pan, CQ; Low, BC				Jiang, T.; Pan, C. Q.; Low, B. C.			BPGAP1 spatially integrates JNK/ERK signaling crosstalk in oncogenesis	ONCOGENE			English	Article							GROWTH-FACTOR RECEPTOR; SCAFFOLD PROTEINS; RHO-GTPASES; FUNCTIONAL PLASTICITY; CELL-PROLIFERATION; JNK ACTIVATION; CANCER CELLS; PATHWAYS; TARGETS; BINDING	Simultaneous hyperactivation of stress-activated protein kinase/c-Jun N-terminal protein kinase (SAPK/JNK) and mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signaling cascades has been reported in carcinogenesis. However, how they are integrated to promote oncogenesis remains unknown. By analyzing breast invasive carcinoma database (The Cancer Genome Altas), we found that the mRNA expression levels of both JNK1 and ERK2 are positively correlated with the mRNA level of EEA1, an endosome associated protein, indicating the potential JNK/ERK crosstalk at endosome. Unbiased screen of different endosome-associated Rab GTPases reveals that late endosome serves as a unique platform to integrate JNK/ERK signaling. Furthermore, we identify that BPGAP1 (a BCH domain-containing, Cdc42GAP-like Rho GTPase-activating protein) promotes MEK partner 1 (MP1)-induced ERK activation on late endosome through scaffolding MP1/MEK1 complex. This regulatory function requires phosphorylation of BPGAP1 by JNK at its C terminal tail (Ser424) to unlock its autoinhibitory conformation. Consequently, phosphorylated BPGAP1 facilitates endosomal ERK signaling transduction to the nucleus, driving cell proliferation and transformation via the ERK-Myc-CyclinA axis. BPGAP1 therefore provides a crucial spatiotemporal checkpoint where JNK and MP1/MEK1 work in concert to regulate endosomal and nuclear ERK signaling in cell proliferation control.	[Jiang, T.; Low, B. C.] Natl Univ Singapore, Dept Biol Sci, Singapore, Singapore; [Pan, C. Q.; Low, B. C.] Natl Univ Singapore, Mechanobiol Inst, T Lab Level 10,5A Engn Dr 1, Singapore 117411, Singapore; [Low, B. C.] Natl Univ Singapore, Univ Scholars Programme, Singapore, Singapore	National University of Singapore; National University of Singapore; National University of Singapore	Pan, CQ; Low, BC (corresponding author), Natl Univ Singapore, Mechanobiol Inst, T Lab Level 10,5A Engn Dr 1, Singapore 117411, Singapore.	mbipqc@nus.edu; dbslowbc@nus.edu.sg	Low, Boon Chuan/AAU-7685-2021; Low, Boon Chuan/H-8049-2012	Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X	NUS Research Scholarship, a Ministry of Education Tier 2 [R154-000-236-112]; Mechanobiology Institute of Singapore; National Research Foundation; Ministry of Education Singapore; National Medical Research Council; CBRG New Investigator Grant (CBRG-NIG) [R-714-000-115-511]	NUS Research Scholarship, a Ministry of Education Tier 2; Mechanobiology Institute of Singapore; National Research Foundation; Ministry of Education Singapore(Ministry of Education, Singapore); National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); CBRG New Investigator Grant (CBRG-NIG)	This work was supported by an NUS Research Scholarship (to TJ), a Ministry of Education Tier 2 grant (R154-000-236-112 to BCL) and the Mechanobiology Institute of Singapore (to BCL), funded through the National Research Foundation and the Ministry of Education Singapore. This work was also supported by National Medical Research Council, CBRG New Investigator Grant (CBRG-NIG) (R-714-000-115-511 to CQP). We thank Proteins and Proteomics Center (National University of Singapore) for mass spectrometric analysis. We thank Nisha Mohd Rafiq (National University of Singapore) for the technical support. We also thank Professor Andrew Catling (LSU Health Sciences Center), Professor Kanga Sabapathy (National Cancer Center, Singapore), and Professor Yih-Cherng Liou (National University of Singapore) for providing MP1, phospho-JNK1, CyclinA and CyclinE antibodies, respectively.	Adler V, 2005, BIOCHEMISTRY-US, V44, P10784, DOI 10.1021/bi050619j; Alsayed Y, 2005, BLOOD, V106, p150A; Arthur JSC, 2013, NAT REV IMMUNOL, V13, P679, DOI 10.1038/nri3495; Brown MD, 2009, CELL SIGNAL, V21, P462, DOI 10.1016/j.cellsig.2008.11.013; Chang F, 2003, LEUKEMIA, V17, P1263, DOI 10.1038/sj.leu.2402945; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Dang CV, 1999, MOL CELL BIOL, V19, P1; De Araujo ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053768; de Graauw M, 2014, ONCOGENE, V33, P2610, DOI 10.1038/onc.2013.219; Engstrom W, 2010, CELL PROLIFERAT, V43, P56, DOI 10.1111/j.1365-2184.2009.00654.x; Fujii S, 2011, ONCOGENE, V30, P4118, DOI 10.1038/onc.2011.118; Good MC, 2011, SCIENCE, V332, P680, DOI 10.1126/science.1198701; Grijelmo C, 2007, CELL SIGNAL, V19, P1722, DOI 10.1016/j.cellsig.2007.03.008; Hornberg JJ, 2006, BIOSYSTEMS, V83, P81, DOI 10.1016/j.biosystems.2005.05.014; Hutagalung AH, 2011, PHYSIOL REV, V91, P119, DOI 10.1152/physrev.00059.2009; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Johnstone CN, 2004, GENE, V336, P59, DOI 10.1016/j.gene.2004.01.025; Jun S, 2013, CELL REP, V5, P314, DOI 10.1016/j.celrep.2013.09.026; Kang JS, 2008, J CELL BIOL, V182, P497, DOI 10.1083/jcb.200801119; Koyano F, 2014, NATURE, V510, P162, DOI 10.1038/nature13392; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Lopez-Bergami P, 2008, INT J BIOCHEM CELL B, V40, P1055, DOI 10.1016/j.biocel.2007.11.011; Lopez-Bergami P, 2007, CANCER CELL, V11, P447, DOI 10.1016/j.ccr.2007.03.009; Lua BL, 2005, J CELL SCI, V118, P2707, DOI 10.1242/jcs.02383; Ma CX, 2015, NAT REV CANCER, V15, P261, DOI 10.1038/nrc3920; Miaczynska M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009035; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; Mingo-Sion AM, 2004, ONCOGENE, V23, P596, DOI 10.1038/sj.onc.1207147; Palfy M, 2012, TRENDS CELL BIOL, V22, P447, DOI 10.1016/j.tcb.2012.06.004; Pan CQ, 2012, CELL SIGNAL, V24, P2143, DOI 10.1016/j.cellsig.2012.06.002; Pan CQ, 2012, FEBS LETT, V586, P2674, DOI 10.1016/j.febslet.2012.04.023; Pan CQ, 2010, J CELL SCI, V123, P903, DOI 10.1242/jcs.064162; Parameswaran N, 2013, J IMMUNOL, V190, P2017, DOI 10.4049/jimmunol.1201292; Pennock S, 2003, MOL CELL BIOL, V23, P5803, DOI 10.1128/MCB.23.16.5803-5815.2003; Pullikuth A, 2005, MOL CELL BIOL, V25, P5119, DOI 10.1128/MCB.25.12.5119-5133.2005; Ramirez A, 2014, ONCOTARGET, V5, P3590, DOI 10.18632/oncotarget.1962; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Shang X, 2003, J BIOL CHEM, V278, P45903, DOI 10.1074/jbc.M304514200; Sharma C, 2005, J CELL BIOCHEM, V94, P708, DOI 10.1002/jcb.20344; Shen YH, 2003, J BIOL CHEM, V278, P26715, DOI 10.1074/jbc.M303264200; Sirokmany G, 2006, J BIOL CHEM, V281, P6096, DOI 10.1074/jbc.M510619200; Skarpen E, 2008, FASEB J, V22, P466, DOI 10.1096/fj.07-8650com; Song JY, 2008, INT J GYNECOL CANCER, V18, P1051, DOI 10.1111/j.1525-1438.2007.01164.x; Song P, 2015, BIOMED PHARMACOTHER, V69, P70, DOI 10.1016/j.biopha.2014.11.008; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Taub N, 2007, MOL BIOL CELL, V18, P4698, DOI 10.1091/mbc.E07-02-0098; Teis D, 2002, DEV CELL, V3, P803, DOI 10.1016/S1534-5807(02)00364-7; Teis D, 2006, J CELL BIOL, V175, P861, DOI 10.1083/jcb.200607025; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Vomastek T, 2007, MOL CELL BIOL, V27, P8296, DOI 10.1128/MCB.00598-07; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; West RJH, 2015, J CELL BIOL, V208, P931, DOI 10.1083/jcb.201404066; White CD, 2009, FEBS LETT, V583, P1817, DOI 10.1016/j.febslet.2009.05.007; Wu P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041354; Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y; Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105	59	10	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 1	2017	36	22					3178	3192		10.1038/onc.2016.466	http://dx.doi.org/10.1038/onc.2016.466			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EW6KA	28092672				2022-12-17	WOS:000402617900010
J	Tonelli, C; Morelli, MJ; Sabo, A; Verrecchia, A; Rotta, L; Capra, T; Bianchi, S; Campaner, S; Amati, B				Tonelli, C.; Morelli, M. J.; Sabo, A.; Verrecchia, A.; Rotta, L.; Capra, T.; Bianchi, S.; Campaner, S.; Amati, B.			Genome-wide analysis of p53-regulated transcription in Myc-driven lymphomas	ONCOGENE			English	Article							DNA-DAMAGE RESPONSE; TUMOR SUPPRESSION; P53 RESTORATION; GENE; CHEMORESISTANCE; PATHWAY; BINDING; MECHANISMS; ALIGNMENT	The tumour suppressor p53 is a transcription factor that controls cellular stress responses. Here, we dissected the transcriptional programmes triggered upon restoration of p53 in Myc-driven lymphomas, based on the integrated analysis of p53 genomic occupancy and gene regulation. p53 binding sites were identified at promoters and enhancers, both characterized by the preexistence of active chromatin marks. Only a small fraction of these sites showed the 20 base-pair p53 consensus motif, suggesting that p53 recruitment to genomic DNA was primarily mediated through protein-protein interactions in a chromatin context. p53 also targeted distal sites devoid of activation marks, at which binding was prevalently driven by sequence recognition. In all instances, the relevant motif was the canonical unsplit consensus element, with no clear evidence for p53 recruitment by split motifs. At promoters, p53 binding to the consensus motif was associated with gene induction, but not repression, indicating that the latter was most likely indirect. Altogether, our data highlight key features of genome recognition by p53 and provide unprecedented insight into the pathways associated with p53 reactivation and tumour regression, paving the way for their therapeutic application.	[Tonelli, C.; Verrecchia, A.; Rotta, L.; Capra, T.; Amati, B.] European Inst Oncol IEO, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy; [Morelli, M. J.; Sabo, A.; Bianchi, S.; Campaner, S.; Amati, B.] Fdn Ist Italiano Tecnol IIT, Ctr Genom Sci IIT SEMM, Milan, Italy	IRCCS European Institute of Oncology (IEO); Istituto Italiano di Tecnologia - IIT	Amati, B (corresponding author), European Inst Oncol IEO, Dept Expt Oncol, Via Adamello 16, I-20139 Milan, Italy.	bruno.amati@ieo.it	Verrecchia, Alessandro/AAQ-6454-2020; Sabò, Arianna/J-9531-2018; Amati, Bruno/AAM-3418-2020; Capra, Thelma/AAN-4064-2020; Rotta, Luca/AAB-9751-2019; Morelli, Marco/AAN-1879-2020	Verrecchia, Alessandro/0000-0002-8596-6650; Sabò, Arianna/0000-0002-9542-0045; Rotta, Luca/0000-0001-6915-1120; Morelli, Marco/0000-0003-1862-667X; Tonelli, Claudia/0000-0002-5626-3403; CAMPANER, Stefano/0000-0003-4547-6849; Amati, Bruno/0000-0002-2958-1799	European Research Council (ERC); Italian Health Ministry; Italian Association for Cancer Research (AIRC); Fondazione Cariplo	European Research Council (ERC)(European Research Council (ERC)European Commission); Italian Health Ministry(Ministry of Health, Italy); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Fondazione Cariplo(Fondazione Cariplo)	This work was supported by grants from the European Research Council (ERC), the Italian Health Ministry, Fondazione Cariplo and the Italian Association for Cancer Research (AIRC) to Bruno Amati.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Bieging KT, 2014, NAT REV CANCER, V14, P359, DOI 10.1038/nrc3711; Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112; Campaner S, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-6; Chang GS, 2014, CELL REP, V8, P513, DOI 10.1016/j.celrep.2014.06.030; Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; FRITSCHE M, 1993, ONCOGENE, V8, P307; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Grant CE, 2011, BIOINFORMATICS, V27, P1017, DOI 10.1093/bioinformatics/btr064; He HSHS, 2012, GENOME RES, V22, P1015, DOI 10.1101/gr.133280.111; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li MM, 2012, MOL CELL, V46, P30, DOI 10.1016/j.molcel.2012.01.020; Liao Y, 2014, BIOINFORMATICS, V30, P923, DOI 10.1093/bioinformatics/btt656; Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Mathelier A, 2014, NUCLEIC ACIDS RES, V42, pD142, DOI 10.1093/nar/gkt997; Menendez D, 2013, NUCLEIC ACIDS RES, V41, P7286, DOI 10.1093/nar/gkt504; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Nikulenkov F, 2012, CELL DEATH DIFFER, V19, P1992, DOI 10.1038/cdd.2012.89; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Renault VM, 2011, ONCOGENE, V30, P3207, DOI 10.1038/onc.2011.35; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Ringshausen I, 2006, CANCER CELL, V10, P501, DOI 10.1016/j.ccr.2006.10.010; Sabo A, 2014, NATURE, V511, P488, DOI 10.1038/nature13537; Sabo PJ, 2006, NAT METHODS, V3, P511, DOI 10.1038/NMETH890; Sammons MA, 2015, GENOME RES, V25, P179, DOI 10.1101/gr.181883.114; Schlereth K, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003726; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2001, BLOOD CELL MOL DIS, V27, P206, DOI 10.1006/bcmd.2000.0372; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Smeenk L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017574; Su D, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004885; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tonelli C, 2015, ONCOTARGET, V6, P24611, DOI 10.18632/oncotarget.5232; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang YX, 2011, J CLIN INVEST, V121, P893, DOI 10.1172/JCI44504; Wei CL, 2006, CELL, V124, P207, DOI 10.1016/j.cell.2005.10.043; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137	48	10	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 25	2017	36	21					2921	2929		10.1038/onc.2016.443	http://dx.doi.org/10.1038/onc.2016.443			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EV7ZP	28092679	Green Published, hybrid			2022-12-17	WOS:000402000400001
J	Masre, SF; Rath, N; Olson, MF; Greenhalgh, DA				Masre, S. F.; Rath, N.; Olson, M. F.; Greenhalgh, D. A.			ROCK2/ras(Ha) co-operation induces malignant conversion via p53 loss, elevated NF-kappa B and tenascin C-associated rigidity, but p21 inhibits ROCK2/NF-kappa B-mediated progression	ONCOGENE			English	Article							CYCLIC TENSILE STRAIN; TUMOR-CELL INVASION; CANCER-CELLS; EPIDERMAL HYPERPLASIA; SIGNALING PATHWAYS; TISSUE STIFFNESS; BREAST-CANCER; AKT ACTIVITY; RHO-GTPASES; DNA-DAMAGE	To study ROCK2 activation in carcinogenesis, mice expressing 4-hydroxytamoxifen (4HT)-activated ROCK2 (K14. ROCKer) were crossed with mice expressing epidermal-activated ras(Ha) (HK1.ras(1205)). At 8 weeks, 4HT-treated K14. ROCKer/HK1.ras(1205) cohorts exhibited papillomas similar to HK1.ras1205 controls; however, K14. ROCKer/HK1.ras(1205) histotypes comprised a mixed papilloma/well-differentiated squamous cell carcinoma (wdSCC), exhibiting p53 loss, increased proliferation and novel NF-kB expression. By 12 weeks, K14. ROCKer/HK1. ras(1205) wdSCCs exhibited increased NF-kB and novel tenascin C, indicative of elevated rigidity; yet despite continued ROCK2 activities/p-Mypt1 inactivation, progression to SCC required loss of compensatory p21 expression. K14. ROCKer/ HK1. ras1205 papillomatogenesis also required a wound promotion stimulus, confirmed by breeding K14. ROCKer into promotioninsensitive HK1. ras(1276) mice, suggesting a permissive K14. ROCKer/ HK1. ras1205 papilloma context (wound-promoted/NF-.B+/p53 -/ p21(+)) preceded K14. ROCKer-mediated (p-Mypt1/ tenascinC/rigidity) malignant conversion. Malignancy depended on ROCKer/ pMypt1 expression, as cessation of 4HT treatment induced disorganized tissue architecture and p21-associated differentiation in wdSCCs; yet tenascin C retention in connective tissue extracellular matrix suggests the rigidity laid down for conversion persists. Novel papilloma outgrowths appeared expressing intense, basal layer p21 that confined endogenous ROCK2/p-Mypt1/NF-k\B to supra-basal layers, and was paralleled by restored basal layer p53. In later SCCs, 4HT cessation became irrelevant as endogenous ROCK2 expression increased, driving progression via p21 loss, elevated NF-kB expression and tenascin C-associated rigidity, with p-Mypt1 inactivation/actinomyosin-mediated contractility to facilitate invasion. However, p21-associated inhibition of early-stage malignant progression and the intense expression in papilloma outgrowths, identifies a novel, significant antagonism between p21 and rasHa/ROCK2/NF-kB signalling in skin carcinogenesis. Collectively, these data show that ROCK2 activation induces malignancy in rasHa-initiated/promoted papillomas in the context of p53 loss and novel NF-kB expression, whereas increased tissue rigidity and cell motility/contractility help mediate tumour progression.	[Masre, S. F.; Greenhalgh, D. A.] Glasgow Univ, Coll Med Vet & Life Sci, Sch Med Dent & Nursing, Sect Dermatol & Mol Carcinogenesis, Glasgow, Lanark, Scotland; [Masre, S. F.] Natl Univ Malaysia, Univ Kebangsaan, Fac Allied Hlth Sci, Biomed Sci Programme,Sch Diagnost & Appl Hlth Sci, Kuala Lumpur, Malaysia; [Rath, N.; Olson, M. F.] Canc Res UK, Beatson Inst Canc Res, Mol Cell Biol Lab, Glasgow, Lanark, Scotland; [Rath, N.; Olson, M. F.] Univ Glasgow, Inst Canc Sci, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow; Universiti Kebangsaan Malaysia; Beatson Institute; Cancer Research UK; University of Glasgow	Greenhalgh, DA (corresponding author), Univ Glasgow, Glasgow Royal Infirm, Sect Dermatol & Mol Carcinogenesis, Level 2,New Lister Bldg,10 Alexandra Parade, Glasgow G31 2ER, Lanark, Scotland.	david.greenhalgh@glasgow.ac.uk	Olson, Michael/ABA-4240-2021; Masre, Siti Fathiah/M-3576-2017	Olson, Michael/0000-0003-3428-3507; Masre, Siti Fathiah/0000-0002-4202-2289	Government of Malaysia; Scott Endowment Fund, Dermatology, Glasgow University; Cancer Research UK; Cancer Research UK [18276] Funding Source: researchfish	Government of Malaysia; Scott Endowment Fund, Dermatology, Glasgow University; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank Dr Jean Quinn for help and advice; Stuart Lannigan and Denis Duggan for assistance with animal husbandry. This work was supported by: The Government of Malaysia; the Scott Endowment Fund, Dermatology, Glasgow University; and Cancer Research UK.	Balmain A, 2014, J INVEST DERMATOL, V134, P2; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; Benitah SA, 2003, MOL BIOL CELL, V14, P3041, DOI 10.1091/mbc.E03-01-0016; Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079; Chiquet M, 2004, BBA-MOL CELL RES, V1693, P193, DOI 10.1016/j.bbamcr.2004.08.001; Croft DR, 2006, MOL CELL BIOL, V26, P4612, DOI 10.1128/MCB.02061-05; DuFort CC, 2011, NAT REV MOL CELL BIO, V12, P308, DOI 10.1038/nrm3112; Ehedego H, 2015, CANCER RES, V75, P1144, DOI 10.1158/0008-5472.CAN-14-1356; Gao CX, 2015, ELIFE, V4, DOI 10.7554/eLife.10072; Ghosh JC, 2005, CLIN CANCER RES, V11, P4580, DOI 10.1158/1078-0432.CCR-04-2624; GREENHALGH DA, 1993, CANCER RES, V53, P5071; GREENHALGH DA, 1993, MOL CARCINOGEN, V7, P99, DOI 10.1002/mc.2940070208; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Ibbetson SJ, 2013, AM J PATHOL, V183, P930, DOI 10.1016/j.ajpath.2013.05.014; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Jachetti E, 2015, CANCER RES, V75, P2095, DOI 10.1158/0008-5472.CAN-14-2346; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Keely PJ, 2011, J MAMMARY GLAND BIOL, V16, P205, DOI 10.1007/s10911-011-9226-0; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Kumper S, 2011, CANCER CELL, V19, P695, DOI 10.1016/j.ccr.2011.05.021; Leonard B, 2015, CANCER RES, V75, P4538, DOI 10.1158/0008-5472.CAN-15-2171-T; Lock FE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008190; Lowy CM, 2015, CELL ADHES MIGR, V9, P112, DOI 10.1080/19336918.2015.1008331; Macdonald FH, 2014, ONCOGENE, V33, P4132, DOI 10.1038/onc.2013.372; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Rath N, 2012, EMBO REP, V13, P900, DOI 10.1038/embor.2012.127; Sadok A, 2015, CANCER RES, V75, P2272, DOI 10.1158/0008-5472.CAN-14-2156; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Samuel MS, 2011, CANCER CELL, V19, P776, DOI 10.1016/j.ccr.2011.05.008; Samuel MS, 2009, GENESIS, V47, P440, DOI 10.1002/dvg.20519; Sarasa-Renedo A, 2006, EXP CELL RES, V312, P1361, DOI 10.1016/j.yexcr.2005.12.025; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Shah KN, 2015, MOL CANCER THER, V14, P2411, DOI 10.1158/1535-7163.MCT-14-0689; Shi MY, 2015, APOPTOSIS, V20, P843, DOI 10.1007/s10495-015-1106-4; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Vaezi A, 2002, DEV CELL, V3, P367, DOI 10.1016/S1534-5807(02)00259-9; Valastyan S, 2011, J CELL SCI, V124, P999, DOI 10.1242/jcs.081513; Wang J, 2005, CANCER RES, V65, P6601, DOI 10.1158/0008-5472.CAN-04-4184; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Yao DG, 2008, J CELL SCI, V121, P1758, DOI 10.1242/jcs.021147; Yao DG, 2006, CANCER RES, V66, P1302, DOI 10.1158/0008-5472.CAN-05-2341; Zheng BQ, 2011, CLIN CANCER RES, V17, P7574, DOI 10.1158/1078-0432.CCR-11-1714; Zhu JJ, 2015, NATURE, V525, P206, DOI 10.1038/nature15251	50	10	10	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 4	2017	36	18					2529	2542		10.1038/onc.2016.402	http://dx.doi.org/10.1038/onc.2016.402			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ET9AN	27991921	Green Accepted			2022-12-17	WOS:000400597300004
J	Murga-Zamalloa, CA; Mendoza-Reinoso, V; Sahasrabuddhe, AA; Rolland, D; Hwang, SR; McDonnell, SRP; Sciallis, AP; Wilcox, RA; Bashur, V; Elenitoba-Johnson, K; Lim, MS				Murga-Zamalloa, C. A.; Mendoza-Reinoso, V.; Sahasrabuddhe, A. A.; Rolland, D.; Hwang, S. R.; McDonnell, S. R. P.; Sciallis, A. P.; Wilcox, R. A.; Bashur, V.; Elenitoba-Johnson, K.; Lim, M. S.			NPM-ALK phosphorylates WASp Y102 and contributes to oncogenesis of anaplastic large cell lymphoma	ONCOGENE			English	Article							ALDRICH-SYNDROME PROTEIN; ACTIN POLYMERIZATION; KINASE ALK; INVADOPODIUM FORMATION; IMMUNOLOGICAL SYNAPSE; TYROSINE KINASE; WIP; MACROPHAGES; PODOSOMES; DYNAMICS	Mechanisms by which NPM-ALK signaling regulates cell migration, invasion and contributes to the oncogenesis of anaplastic large cell lymphoma (ALCL) are not completely understood. In an attempt to identify novel actin signaling pathways regulated by NPM-ALK, a comprehensive phosphoproteome analysis of ALCL cell lines was performed in the presence or absence of NPM-ALK activity. Numerous phosphoproteins involved in actin dynamics including Wiskott-Aldrich syndrome protein (WASp) were regulated by NPM-ALK. Network analysis revealed that WASp is a central component of the NPM-ALK-dependent actin signaling pathway. Here we show that NPM-ALK phosphorylates WASp at its known activation site (Y290) as well as at a novel residue (Y102). Phosphorylation of WASp at Y102 negatively regulates its interaction with Wiskott-Aldrich interacting protein and decreases its protein stability. Phosphorylation of WASp at Y102 enhances anchorage-independent growth and tumor growth in an in vivo xenograft model and enhances invasive properties of ALCL. We show that knock-down of WASp or expression of Y102F mutant of WASp decreases colony formation and in vivo tumor growth. Our results show that WASp is a novel substrate of ALK and has a critical role in regulating invasiveness and oncogenesis of ALCL.	[Murga-Zamalloa, C. A.; Mendoza-Reinoso, V.; Sahasrabuddhe, A. A.; Rolland, D.; Hwang, S. R.; McDonnell, S. R. P.; Sciallis, A. P.; Bashur, V.; Elenitoba-Johnson, K.; Lim, M. S.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Rolland, D.; Elenitoba-Johnson, K.; Lim, M. S.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA; [Wilcox, R. A.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Pennsylvania; University of Michigan System; University of Michigan	Lim, MS (corresponding author), Hosp Univ Penn, 3400 Spruce St, Philadelphia, PA 19104 USA.	Megan.Lim@uphs.upenn.edu	Rolland, Delphine/ABG-2497-2021; Murga-Zamalloa, Carlos/AAX-9387-2021	Murga-Zamalloa, Carlos/0000-0002-2238-5066; Elenitoba-Johnson, Kojo/0000-0002-1082-1545; Hwang, Steven/0000-0002-6536-1291; Rolland, Delphine/0000-0002-7801-6534; Mendoza-Reinoso, Veronica/0000-0003-1776-4229; Lim, Megan/0000-0002-0415-2867	Department of Pathology, University of Michigan [R01 CA140806-01, R01 DE119249, R01 CA136905]; HONORS-ASH award	Department of Pathology, University of Michigan(University of Michigan System); HONORS-ASH award	This work was supported by the Department of Pathology, University of Michigan and R01 CA140806-01 (MSL), R01 DE119249, R01 CA136905 (KSJ-EJ) and HONORS-ASH award (CMZ).	Ambrogio C, 2005, BLOOD, V106, P3907, DOI 10.1182/blood-2005-03-1204; Ambrogio C, 2008, CANCER RES, V68, P8899, DOI 10.1158/0008-5472.CAN-08-2568; Amin HM, 2007, BLOOD, V110, P2259, DOI 10.1182/blood-2007-04-060715; Baba Y, 1999, BLOOD, V93, P2003, DOI 10.1182/blood.V93.6.2003.406k13_2003_2012; Badolato R, 1998, J IMMUNOL, V161, P1026; Bai RY, 1998, MOL CELL BIOL, V18, P6951, DOI 10.1128/MCB.18.12.6951; Bischof D, 1997, MOL CELL BIOL, V17, P2312, DOI 10.1128/MCB.17.4.2312; Blundell MP, 2009, P NATL ACAD SCI USA, V106, P15738, DOI 10.1073/pnas.0904346106; Bodour K, 2004, J EXP MED, V199, P99, DOI 10.1084/jem.20030976; Chou HC, 2006, CURR BIOL, V16, P2337, DOI 10.1016/j.cub.2006.10.037; Cory GOC, 2003, MOL CELL, V11, P1229, DOI 10.1016/S1097-2765(03)00172-2; Cory GOC, 1996, J IMMUNOL, V157, P3791; Cougoule C, 2012, EUR J CELL BIOL, V91, P938, DOI 10.1016/j.ejcb.2012.07.002; de la Fuente MA, 2007, P NATL ACAD SCI USA, V104, P926, DOI 10.1073/pnas.0610275104; Donella-Deana A, 2005, BIOCHEMISTRY-US, V44, P8533, DOI 10.1021/bi0472954; Dovas Athanassios, 2010, Commun Integr Biol, V3, P101; Dupre L, 2002, IMMUNITY, V17, P157, DOI 10.1016/S1074-7613(02)00360-6; Gligorijevic B, 2012, J CELL SCI, V125, P724, DOI 10.1242/jcs.092726; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Jin P, 2011, DEV CELL, V20, P623, DOI 10.1016/j.devcel.2011.04.007; Kim AS, 2000, NATURE, V404, P151, DOI 10.1038/35004513; Kolluri R, 1996, P NATL ACAD SCI USA, V93, P5615, DOI 10.1073/pnas.93.11.5615; Lagarrigue F, 2010, CANCER RES, V70, P6978, DOI 10.1158/0008-5472.CAN-10-0861; Lane J, 2014, CANCER GENOM PROTEOM, V11, P155; Lim MS, 2009, BLOOD, V114, P1585, DOI 10.1182/blood-2009-02-204735; Linder S, 1999, P NATL ACAD SCI USA, V96, P9648, DOI 10.1073/pnas.96.17.9648; Linder S, 2003, IMMUNOL CELL BIOL, V81, P130, DOI 10.1046/j.0818-9641.2002.01147.x; McDonnell SRP, 2012, ONCOGENE, V31, P3733, DOI 10.1038/onc.2011.542; Meacham CE, 2009, NAT GENET, V41, P1133, DOI 10.1038/ng.451; MORRIS SW, 1994, SCIENCE, V263, P1281, DOI 10.1126/science.8122112; Ochs HD, 2006, J ALLERGY CLIN IMMUN, V117, P725, DOI 10.1016/j.jaci.2006.02.005; Oda A, 2001, BLOOD, V97, P2633, DOI 10.1182/blood.V97.9.2633; Ott GR, 2011, J MED CHEM, V54, P6328, DOI 10.1021/jm200758k; Ramesh N, 1997, P NATL ACAD SCI USA, V94, P14671, DOI 10.1073/pnas.94.26.14671; Sasahara Y, 2002, MOL CELL, V10, P1269, DOI 10.1016/S1097-2765(02)00728-1; Slupianek A, 2001, CANCER RES, V61, P2194; Stewart DM, 1999, J IMMUNOL, V162, P5019; SULLIVAN KE, 1994, J PEDIATR-US, V125, P876, DOI 10.1016/S0022-3476(05)82002-5; Symons M, 1996, CELL, V84, P723, DOI 10.1016/S0092-8674(00)81050-8; Tripathy R, 2011, BIOORG MED CHEM LETT, V21, P7261, DOI 10.1016/j.bmcl.2011.10.055; Volkman BF, 2002, CELL, V111, P565, DOI 10.1016/S0092-8674(02)01076-0; Wolf K, 2003, BLOOD, V102, P3262, DOI 10.1182/blood-2002-12-3791; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Zamo A, 2002, ONCOGENE, V21, P1038, DOI 10.1038/sj.onc.1205152; Zicha D, 1998, BRIT J HAEMATOL, V101, P659, DOI 10.1046/j.1365-2141.1998.00767.x	45	10	10	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 13	2017	36	15					2085	2094		10.1038/onc.2016.366	http://dx.doi.org/10.1038/onc.2016.366			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ES8DK	27694894				2022-12-17	WOS:000399782500005
J	Ihara, T; Hosokawa, Y; Kumazawa, K; Ishikawa, K; Fujimoto, J; Yamamoto, M; Muramkami, T; Goshima, N; Ito, E; Watanabe, S; Semba, K				Ihara, T.; Hosokawa, Y.; Kumazawa, K.; Ishikawa, K.; Fujimoto, J.; Yamamoto, M.; Muramkami, T.; Goshima, N.; Ito, E.; Watanabe, S.; Semba, K.			An in vivo screening system to identify tumorigenic genes	ONCOGENE			English	Article							PROTEIN-KINASE-A; CARNEY COMPLEX; LYSOPHOSPHATIDIC ACID; COUPLED RECEPTORS; TUMOR-GROWTH; CANCER; EXPRESSION; ADENOSINE; CELL	Screening for oncogenes has mostly been performed by in vitro transformation assays. However, some oncogenes might not exhibit their transforming activities in vitro unless putative essential factors from in vivo microenvironments are adequately supplied. Here, we have developed an in vivo screening system that evaluates the tumorigenicity of target genes. This system uses a retroviral high-efficiency gene transfer technique, a large collection of human cDNA clones corresponding to similar to 70% of human genes and a luciferase-expressing immortalized mouse mammary epithelial cell line (NMuMG-luc). From 845 genes that were highly expressed in human breast cancer cell lines, we focused on 205 genes encoding membrane proteins and/or kinases as that had the greater possibility of being oncogenes or drug targets. The 205 genes were divided into five subgroups, each containing 34-43 genes, and then introduced them into NMuMG-luc cells. These cells were subcutaneously injected into nude mice and monitored for tumor development by in vivo imaging. Tumors were observed in three subgroups. Using DNA microarray analyses and individual tumorigenic assays, we found that three genes, ADORA2B, PRKACB and LPAR3, were tumorigenic. ADORA2B and LPAR3 encode G-protein-coupled receptors and PRKACB encodes a protein kinase A catalytic subunit. Cells overexpressing ADORA2B, LPAR3 or PRKACB did not show transforming phenotypes in vitro, suggesting that transformation by these genes requires in vivo microenvironments. In addition, several clinical data sets, including one for breast cancer, showed that the expression of these genes correlated with lower overall survival rate.	[Ihara, T.; Hosokawa, Y.; Kumazawa, K.; Yamamoto, M.; Semba, K.] Waseda Univ, Sch Adv Sci & Engn, Dept Life Sci & Med Biosci, Tokyo, Japan; [Ishikawa, K.; Fujimoto, J.] Japan Biol Informat Consortium, Tokyo, Japan; [Muramkami, T.] Takasaki Univ Hlth & Welf, Lab Tumor Biol, Fac Pharm, Takasaki, Gunma, Japan; [Goshima, N.] Natl Inst Adv Ind Sci & Technol, Mol Profiling Res Ctr Drug Discovery Molprof, Quantitat Prote Team, Tokyo, Japan; [Goshima, N.] Div Transcriptome Anal, Fukushima, Japan; [Ito, E.; Watanabe, S.] Div Gene Express Anal, Fukushima, Japan; [Semba, K.] Fukushima Med Univ, Div Gene Funct Anal, Translat Res Ctr, Fukushima, Japan	Waseda University; National Institute of Advanced Industrial Science & Technology (AIST); Fukushima Medical University	Semba, K (corresponding author), Waseda Univ, Sch Adv Sci & Engn, Dept Life Sci & Med Biosci, Shinjuku Ku, 2-2 Wakamatsu Cho, Tokyo 1628480, Japan.	ksemba@waseda.jp	直樹, 五島/M-8363-2018; Yamamoto, Mizuki/AAW-1688-2020	Yamamoto, Mizuki/0000-0003-3731-1702	JSPS KAKENHI Grant [23241064]	JSPS KAKENHI Grant(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank our laboratory members, especially Kumiko Semba for secretarial assistance and Sakura Azuma-Tamamura for technical assistance. This work was conducted as part of the Fukushima Translational Research Project and supported, in part, by JSPS KAKENHI Grant Number 23241064, and a Grant-in-Aid for Scientific Research (A).	Antonioli L, 2013, NAT REV CANCER, V13, P842, DOI 10.1038/nrc3613; Beristain AG, 2015, ONCOGENE, V34, P1160, DOI 10.1038/onc.2014.41; Correa R, 2015, EUR J ENDOCRINOL, V173, pM85, DOI 10.1530/EJE-15-0209; Desmet CJ, 2013, P NATL ACAD SCI USA, V110, P5139, DOI 10.1073/pnas.1222085110; Doi A, 2015, MOL ONCOL, V9, P355, DOI 10.1016/j.molonc.2014.09.005; Dorsam RT, 2007, NAT REV CANCER, V7, P79, DOI 10.1038/nrc2069; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; Feigin ME, 2013, FEBS J, V280, P4729, DOI 10.1111/febs.12473; Feoktistov I, 1997, PHARMACOL REV, V49, P381; Fredholm BB, 2007, CELL DEATH DIFFER, V14, P1315, DOI 10.1038/sj.cdd.4402132; Goshima N, 2008, NAT METHODS, V5, P1011, DOI 10.1038/nmeth.1273; Griffin KJ, 2004, J MED GENET, V41, P923, DOI 10.1136/jmg.2004.028043; HYNES NE, 1985, MOL CELL BIOL, V5, P268, DOI 10.1128/MCB.5.1.268; Ito E, 2007, FEBS LETT, V581, P3909, DOI 10.1016/j.febslet.2007.07.016; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kirschner LS, 2005, CANCER RES, V65, P4506, DOI 10.1158/0008-5472.CAN-05-0580; Liu SY, 2009, CANCER CELL, V15, P539, DOI 10.1016/j.ccr.2009.03.027; Matsui Atsuka, 2013, Biomol Concepts, V4, P567, DOI 10.1515/bmc-2013-0026; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Mutoh T, 2012, BRIT J PHARMACOL, V165, P829, DOI 10.1111/j.1476-5381.2011.01622.x; Naviglio S, 2009, EXPERT OPIN THER TAR, V13, P83, DOI [10.1517/14728220802602349, 10.1517/14728220802602349 ]; Ntantie E, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003374; O'Hayre M, 2014, CURR OPIN CELL BIOL, V27, P126, DOI 10.1016/j.ceb.2014.01.005; Padmanabhan A, 2013, J BIOL CHEM, V288, P14158, DOI 10.1074/jbc.M112.432377; PARMA J, 1993, NATURE, V365, P649, DOI 10.1038/365649a0; Polanska UM, 2013, J CELL PHYSIOL, V228, P1651, DOI 10.1002/jcp.24347; Saito M, 2012, FEBS LETT, V586, P1708, DOI 10.1016/j.febslet.2012.05.003; Stagg J, 2010, P NATL ACAD SCI USA, V107, P1547, DOI 10.1073/pnas.0908801107; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; YOUNG D, 1986, CELL, V45, P711, DOI 10.1016/0092-8674(86)90785-3	30	10	10	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 6	2017	36	14					2023	2029		10.1038/onc.2016.351	http://dx.doi.org/10.1038/onc.2016.351			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ER6EQ	27694896				2022-12-17	WOS:000398898500012
J	Staffas, A; Arabanian, LS; Wei, SY; Jansson, A; Stahlman, S; Johansson, P; Fogelstrand, L; Cammenga, J; Kuchenbauer, F; Palmqvist, L				Staffas, A.; Arabanian, L. S.; Wei, S. Y.; Jansson, A.; Stahlman, S.; Johansson, P.; Fogelstrand, L.; Cammenga, J.; Kuchenbauer, F.; Palmqvist, L.			Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice	ONCOGENE			English	Article							TYROSINE KINASE INHIBITOR; HEMATOPOIETIC STEM-CELL; BONE-MARROW-CELLS; HOXA9; GENE; EXPRESSION; MUTATION; RECEPTOR; LIGAND; AC220	HOXA9, MEIS1 and FLT3 are genes frequently upregulated in human acute myeloid leukemia. Hoxa9 and Meis1 also cooperate to induce aggressive AML with high Flt3 expression in mice, suggesting an important role for Flt3 in Hoxa9/Meis1-induced leukemogenesis. To define the role of Flt3 in AML with high Hoxa9/Meis1, we treated mice with Hoxa9/Meis1-induced AML with the Flt3 inhibitor AC220, used an Flt3-ligand (FL -/-) knockout model, and investigated whether overexpression of Flt3 could induce leukemia together with overexpression of Hoxa9. Flt3 inhibition by AC220 did not delay AML development in mice transplanted with bone marrow cells overexpressing Hoxa9 and Meis1. In addition, Hoxa9/Meis1 cells induced AML in FL -/- mice as rapid as in wild-type mice. However, FL -/- mice had reduced organ infiltration compared with wild-type mice, suggesting some Flt3 dependent effect on leukemic invasiveness. Interestingly, leukemic Hoxa9/Meis1 cells from sick mice expressed high levels of Flt3 regardless of presence of its ligand, showing that Flt3 is a passive marker on these cells. In line with this, combined engineered overexpression of Flt3 and Hoxa9 did not accelerate the progression to AML. We conclude that the Hoxa9- and Meis1-associated upregulation of Flt3 is not a requirement for leukemic progression induced by Hoxa9 and Meis1.	[Staffas, A.; Arabanian, L. S.; Wei, S. Y.; Stahlman, S.; Johansson, P.; Fogelstrand, L.; Palmqvist, L.] Univ Gothenburg, Inst Biomed, Dept Clin Chem & Transfus Med, Gothenburg, Sweden; [Staffas, A.; Jansson, A.; Stahlman, S.; Johansson, P.; Fogelstrand, L.; Palmqvist, L.] Sahlgrens Univ Hosp, Dept Clin Chem, Bruna Straket 16, S-41345 Gothenburg, Sweden; [Wei, S. Y.] Sahlgrens Univ Hosp, Dept Med, Gothenburg, Sweden; [Cammenga, J.] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden; [Cammenga, J.] Linkoping Univ Hosp, Dept Hematol, Linkoping, Sweden; [Kuchenbauer, F.] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany	University of Gothenburg; Sahlgrenska University Hospital; Sahlgrenska University Hospital; Linkoping University; Linkoping University; Ulm University	Palmqvist, L (corresponding author), Sahlgrens Univ Hosp, Dept Clin Chem, Bruna Straket 16, S-41345 Gothenburg, Sweden.	lars.palmqvist@clinchem.gu.se		Kuchenbauer, Florian/0000-0002-9820-3409	Swedish Cancer Society [CAN2014/525]; Vastra Gotalandsregionen [ALFGBG-431881]; Deutsche Krebshilfe [109420]; European Hematology Association; Deutsche Forschungsgemeinschaft [SFB 1074]; Assar Gabrielsson's foundation	Swedish Cancer Society(Swedish Cancer Society); Vastra Gotalandsregionen; Deutsche Krebshilfe(Deutsche Krebshilfe); European Hematology Association; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Assar Gabrielsson's foundation	We wish to thank Carina Wasslavik, Christina Nilsson, and Susanne Li for valuable technical assistance. This work was supported by grants to LP from the Swedish Cancer Society (CAN2014/525) and the Vastra Gotalandsregionen (ALFGBG-431881). FK was supported by grants from Deutsche Krebshilfe grant 109420 ( Max-Eder program), fellowship 2010/04 by the European Hematology Association, and by the Deutsche Forschungsgemeinschaft (SFB 1074, project A5). SYW was supported by a grant from Assar Gabrielsson's foundation.	Argiropoulos B, 2008, EXP HEMATOL, V36, P845, DOI 10.1016/j.exphem.2008.02.011; Balgobind BV, 2011, LEUKEMIA, V25, P1239, DOI 10.1038/leu.2011.90; BRASEL K, 1995, LEUKEMIA, V9, P1212; Christensen JL, 2001, P NATL ACAD SCI USA, V98, P14541, DOI 10.1073/pnas.261562798; Drabkin H, 2002, LEUKEMIA, V16, P186, DOI 10.1038/sj.leu.2402354; Frohling S, 2002, BLOOD, V100, P4372, DOI 10.1182/blood-2002-05-1440; Huang YS, 2012, BLOOD, V119, P388, DOI 10.1182/blood-2011-03-341081; Imamura T, 2002, BRIT J HAEMATOL, V119, P119, DOI 10.1046/j.1365-2141.2002.03803.x; Kampa-Schittenhelm KM, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-19; Kikushige Y, 2008, J IMMUNOL, V180, P7358, DOI 10.4049/jimmunol.180.11.7358; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Konig H, 2015, EXPERT OPIN THER TAR, V19, P37, DOI 10.1517/14728222.2014.960843; Kroon E, 1998, EMBO J, V17, P3714, DOI 10.1093/emboj/17.13.3714; Kuchenbauer F, 2005, HAEMATOLOGICA, V90, P1617; Li ZJ, 2013, BLOOD, V121, P1422, DOI 10.1182/blood-2012-07-442004; Lisovsky M, 1996, LEUKEMIA, V10, P1012; McKenna HJ, 2000, BLOOD, V95, P3489, DOI 10.1182/blood.V95.11.3489; Morgado E, 2007, BLOOD, V109, P4020, DOI 10.1182/blood-2006-01-039586; Nakao M, 1996, LEUKEMIA, V10, P1911; Palmqvist L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000768; Palmqvist L, 2006, BLOOD, V108, P1030, DOI 10.1182/blood-2005-12-007005; Pineault N, 2003, BLOOD, V101, P4529, DOI 10.1182/blood-2002-08-2484; Rathinam C, 2010, CANCER CELL, V18, P341, DOI 10.1016/j.ccr.2010.09.008; SB H, 2013, DESIGNING CLIN RES E; Shen Y, 2011, BLOOD, V118, P5593, DOI 10.1182/blood-2011-03-343988; Smith BD, 2004, BLOOD, V103, P3669, DOI 10.1182/blood-2003-11-3775; Staffas A, 2011, BLOOD, V118, P5905, DOI 10.1182/blood-2011-05-353185; Stirewalt DL, 2003, NAT REV CANCER, V3, P650, DOI 10.1038/nrc1169; Stone RM, 2005, BLOOD, V105, P54, DOI 10.1182/blood-2004-03-0891; Taylor SJ, 2012, BLOOD, V120, P4049, DOI 10.1182/blood-2012-06-436675; Thorsteinsdottir U, 2002, BLOOD, V99, P121, DOI 10.1182/blood.V99.1.121; Wang GG, 2005, BLOOD, V106, P254, DOI 10.1182/blood-2004-12-4664; Zarrinkar PP, 2009, BLOOD, V114, P2984, DOI 10.1182/blood-2009-05-222034	33	10	10	2	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2017	36	11					1516	1524		10.1038/onc.2016.318	http://dx.doi.org/10.1038/onc.2016.318			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EP5ZR	27617578				2022-12-17	WOS:000397458100006
J	Thapa, N; Tan, X; Choi, S; Wise, T; Anderson, RA				Thapa, N.; Tan, X.; Choi, S.; Wise, T.; Anderson, R. A.			PIPKI gamma and talin couple phosphoinositide and adhesion signaling to control the epithelial to mesenchymal transition	ONCOGENE			English	Article							PHOSPHATIDYLINOSITOL-PHOSPHATE KINASE; DIRECTIONALLY MIGRATING CELLS; I-GAMMA; E-CADHERIN; TUMOR-METASTASIS; TRAFFICKING; GROWTH; 5-KINASE; BINDING; CANCER	Epithelial cells acquire migratory/invasive and stemness traits upon conversion to the mesenchymal phenotype. The expression of E-cadherin is a key to this transition; yet precise understanding of the pathways involved in integrating E-cadherin loss to the gain of mesenchymal traits remains poorly understood. Here, we show that phosphoinositide-generating enzyme, PIPKI gamma, expression is upregulated upon epithelial-mesenchymal transition (EMT) and together with the cytoskeletal protein talin assemble into a signaling complex upon E-cadherin loss. PIPKI gamma and talin together control the adhesion and phosphoinositide signaling that regulates conversion to the mesenchymal phenotypes. PIPKI gamma and talin regulate the stability of E-cadherin transcriptional repressors, snail and slug, induced by transforming growth factor-beta 1 or extracellular matrix protein. Loss of PIPKI gamma or talin or their interaction impaired EMT and the acquisition of cell motility and stemness. This demonstrates a mechanism where a phosphoinositide-generating enzyme PIPKI gamma couples with a cytoskeletal protein talin to control the acquisition of mesenchymal phenotypes.	[Thapa, N.; Tan, X.; Choi, S.; Wise, T.; Anderson, R. A.] Univ Wisconsin, Sch Med & Publ Hlth, Mol & Cellular Pharmacol Program, 3750 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Anderson, RA (corresponding author), Univ Wisconsin, Sch Med & Publ Hlth, Mol & Cellular Pharmacol Program, 3750 Med Sci Ctr,1300 Univ Ave, Madison, WI 53706 USA.	raanders@wisc.edu	Tan, Xiaojun/N-2142-2017	Tan, Xiaojun/0000-0003-3300-2240; Wise, Thomas/0000-0001-7007-6279; Anderson, Richard/0000-0001-6265-8359	National Institute of Health (NIH) [CA104708, GM057549]; American Heart Association (AHA) [10POST4290052, 13PRE14690057]; Howard Hughes Medical Institute (HHMI) International Student Research Fellowship; NATIONAL CANCER INSTITUTE [R01CA104708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057549] Funding Source: NIH RePORTER	National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association (AHA)(American Heart Association); Howard Hughes Medical Institute (HHMI) International Student Research Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by National Institute of Health (NIH) grants (CA104708 and GM057549) to RAA; American Heart Association (AHA) grants to NT (10POST4290052) and SC (13PRE14690057); and Howard Hughes Medical Institute (HHMI) International Student Research Fellowship to XT.	Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Ben-Aissa K, 2012, J BIOL CHEM, V287, P16311, DOI 10.1074/jbc.M111.304881; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Calderwood DA, 2013, NAT REV MOL CELL BIO, V14, P503, DOI 10.1038/nrm3624; Chen YM, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-5; Choi SY, 2015, BBA-MOL CELL BIOL L, V1851, P711, DOI 10.1016/j.bbalip.2015.01.009; Choi S, 2013, EMBO J, V32, P2617, DOI 10.1038/emboj.2013.191; Davis FM, 2014, TRENDS PHARMACOL SCI, V35, P479, DOI 10.1016/j.tips.2014.06.006; Derynck R, 2014, CURR OPIN CELL BIOL, V31, P56, DOI 10.1016/j.ceb.2014.09.001; Granato DC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098208; Heck JN, 2007, CRIT REV BIOCHEM MOL, V42, P15, DOI 10.1080/10409230601162752; Jung HY, 2015, CLIN CANCER RES, V21, P962, DOI 10.1158/1078-0432.CCR-13-3173; Kao SH, 2014, ONCOGENE, V33, P3172, DOI 10.1038/onc.2013.279; Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758; Ling K, 2003, J CELL BIOL, V163, P1339, DOI 10.1083/jcb.200310067; Ling K, 2002, NATURE, V420, P89, DOI 10.1038/nature01082; Ling K, 2007, J CELL BIOL, V176, P343, DOI 10.1083/jcb.200606023; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Medici D, 2008, MOL BIOL CELL, V19, P4875, DOI 10.1091/mbc.E08-05-0506; Nieves B, 2010, J CELL SCI, V123, P1216, DOI 10.1242/jcs.056549; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Park J, 2014, ONCOGENE, V33, P1649, DOI 10.1038/onc.2013.118; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976; Saltel F, 2009, J CELL BIOL, V187, P715, DOI 10.1083/jcb.200908134; Schill NJ, 2014, J CELL SCI, V127, P2189, DOI 10.1242/jcs.132423; Seguin L, 2015, TRENDS CELL BIOL, V25, P234, DOI 10.1016/j.tcb.2014.12.006; Shintani Y, 2008, J CELL BIOL, V180, P1277, DOI 10.1083/jcb.200708137; Sun Y, 2007, J CELL BIOL, V178, P297, DOI 10.1083/jcb.200701078; Sun Y, 2013, BIOESSAYS, V35, P513, DOI 10.1002/bies.201200171; Sun Y, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2471; Thapa N, 2015, J BIOL CHEM, V290, P18843, DOI 10.1074/jbc.M114.596742; Thapa N, 2013, J BIOL CHEM, V288, P34707, DOI 10.1074/jbc.M113.512848; Thapa N, 2012, CELL ADHES MIGR, V6, P409, DOI 10.4161/cam.21192; Thapa N, 2012, DEV CELL, V22, P116, DOI 10.1016/j.devcel.2011.10.030; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Vitorino P, 2015, NATURE, V519, P425, DOI 10.1038/nature14323; Xiong XH, 2012, MOL BIOL CELL, V23, P87, DOI 10.1091/mbc.E11-05-0449; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	40	10	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 16	2017	36	7					899	911		10.1038/onc.2016.267	http://dx.doi.org/10.1038/onc.2016.267			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8JG	27452517	Green Accepted			2022-12-17	WOS:000394169100003
J	Xu, MM; Pu, Y; Weichselbaum, RR; Fu, YX				Xu, M. Michelle; Pu, Y.; Weichselbaum, R. R.; Fu, Y-X			Integrating conventional and antibody-based targeted anticancer treatment into immunotherapy	ONCOGENE			English	Review							CYCLIC GMP-AMP; IMMUNOGENIC CELL-DEATH; CYTOSOLIC DNA SENSOR; I INTERFERON; CALRETICULIN EXPOSURE; IMMUNE-SYSTEM; TUMOR MICROENVIRONMENT; ANTI-CD20 ANTIBODY; METASTATIC CANCER; RADIATION	In advanced cancer, current conventional therapies or immunotherapies cannot eradicate all tumor cells for most patients. Integration of these two treatments for synergistic effects could eradicate more tumor cells and increase the overall survival rates. However, since how conventional treatments impact on immune system remains unclear, proper integration is still a challenge. Intensive chemo/radiotherapy may impair ongoing immune responses, while lower intensity of therapy might not kill enough tumor cells, both leading to tumor relapse. Current understanding of mechanisms of resistance to conventional and targeted cancer therapies has focused on cell intrinsic pathways that trigger DNA damage/repair or signaling pathways related to cell growth. Recent reports show that host T cells properly primed against tumor-specific antigens after conventional treatment, which can integrate with direct cytotoxic effects induced by radiation or chemotherapy to profoundly control tumors. Following cytotoxic anticancer treatment, tumor-derived DAMPs (damage-associated molecular patterns) can be sensed by innate cells, which drives type I interferon production for cross-priming of CD8(+) T cells. Some types and protocols of chemotherapy or radiation can increase tumor-infiltrating lymphocytes that overcome resistance to immunotherapy. As such, a deeper understanding of the immune mechanisms of conventional and targeted cancer therapies will lead toward novel combinatorial anticancer strategies with improved clinical benefit.	[Xu, M. Michelle; Weichselbaum, R. R.; Fu, Y-X] Univ Chicago, Dept Pathol & Radiat Oncol, Chicago, IL 60637 USA; [Xu, M. Michelle; Fu, Y-X] Univ Chicago, Ludwig Ctr Metastasis Res, Chicago, IL 60637 USA; [Pu, Y.; Fu, Y-X] Univ Texas Southwestern Med Ctr Dallas, Dept Pathol & Immunol, Dallas, TX 75390 USA	University of Chicago; University of Chicago; University of Texas System; University of Texas Southwestern Medical Center Dallas	Weichselbaum, RR; Fu, YX (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Pathol, 6000 Harry Hines Blvd,ND6 200, Dallas, TX 75235 USA.	rrw@radonc.uchicago.edu; yang-xin.fu@utsouthwestern.edu			US National Institutes of Health [CA141975]; Ludwig Foundation; NATIONAL CANCER INSTITUTE [R01CA134563, R01CA141975] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ludwig Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was, in part, supported by US National Institutes of Health Grants CA141975 (to Y-XF), a grant from the Ludwig Foundation (to RRW) and a generous gift from The Foglia Foundation (to Y-XF and RRW).	Abes R, 2010, BLOOD, V116, P926, DOI 10.1182/blood-2009-10-248609; Aguirre-Ghiso JA, 2007, NAT REV CANCER, V7, P834, DOI 10.1038/nrc2256; Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; Ahn J, 2012, P NATL ACAD SCI USA, V109, P19386, DOI 10.1073/pnas.1215006109; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Arnould L, 2006, BRIT J CANCER, V94, P259, DOI 10.1038/sj.bjc.6602930; Baselga J, 2001, ANN ONCOL, V12, P35, DOI 10.1023/A:1011163824080; Baselga J, 2001, EUR J CANCER, V37, pS16; Benavides LC, 2009, CLIN CANCER RES, V15, P2895, DOI 10.1158/1078-0432.CCR-08-1126; Biswas S, 2007, J CLIN INVEST, V117, P1305, DOI 10.1172/JCI30740; Burnette BC, 2011, CANCER RES, V71, P2488, DOI 10.1158/0008-5472.CAN-10-2820; Cartron G, 2004, BLOOD, V104, P2635, DOI 10.1182/blood-2004-03-1110; Casares N, 2005, J EXP MED, V202, P1691, DOI 10.1084/jem.20050915; Chakraborty M, 2004, CANCER RES, V64, P4328, DOI 10.1158/0008-5472.CAN-04-0073; Chao MP, 2010, CELL, V142, P699, DOI 10.1016/j.cell.2010.07.044; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Corrales L, 2015, CELL REP, V11, P1018, DOI 10.1016/j.celrep.2015.04.031; Correale P, 2012, INT J CANCER, V130, P1577, DOI 10.1002/ijc.26181; Crouse J, 2015, NAT REV IMMUNOL, V15, P231, DOI 10.1038/nri3806; Deng L, 2015, CLIN CANC RES; Deng LF, 2014, IMMUNITY, V41, P843, DOI 10.1016/j.immuni.2014.10.019; Diamond MS, 2011, J EXP MED, V208, P1989, DOI 10.1084/jem.20101158; DiLillo DJ, 2015, CELL, V161, P1035, DOI 10.1016/j.cell.2015.04.016; Dovedi SJ, 2013, BLOOD, V121, P251, DOI 10.1182/blood-2012-05-432393; Formenti SC, 2013, JNCI-J NATL CANCER I, V105, P256, DOI 10.1093/jnci/djs629; Fu J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4306; Fuertes MB, 2011, J EXP MED, V208, P2005, DOI 10.1084/jem.20101159; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Galluzzi L, 2014, ONCOTARGET, V5, P12472, DOI 10.18632/oncotarget.2998; Gameiro SR, 2014, ONCOTARGET, V5, P403, DOI 10.18632/oncotarget.1719; Gandhi SJ, 2015, CANCER LETT, V368, P185, DOI 10.1016/j.canlet.2015.03.024; Ganss R, 2002, CANCER RES, V62, P1462; Gao DX, 2013, SCIENCE, V341, P903, DOI 10.1126/science.1240933; Garg AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00588; Garg AD, 2012, EMBO J, V31, P1062, DOI 10.1038/emboj.2011.497; Gasser S, 2005, NATURE, V436, P1186, DOI 10.1038/nature03884; Gehrmann M, 2005, CELL DEATH DIFFER, V12, P38, DOI 10.1038/sj.cdd.4401510; Goss PE, 2010, NAT REV CANCER, V10, P871, DOI 10.1038/nrc2933; Hartlova A, 2015, IMMUNITY, V42, P332, DOI 10.1016/j.immuni.2015.01.012; Haynes NM, 2008, CURR OPIN IMMUNOL, V20, P545, DOI 10.1016/j.coi.2008.05.008; Hong WK, 2010, EMIL FREI III CANC M; Jube S, 2012, CANCER RES, V72, P3290, DOI 10.1158/0008-5472.CAN-11-3481; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008; Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380; Kurts C, 2010, NAT REV IMMUNOL, V10, P403, DOI 10.1038/nri2780; Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]; Lee YJ, 2009, BLOOD, V114, P589, DOI 10.1182/blood-2009-02-206870; Liang H, 2013, J IMMUNOL, V190, P5874, DOI 10.4049/jimmunol.1202612; Lim SH, 2011, BLOOD, V118, P2530, DOI 10.1182/blood-2011-01-330357; Liu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137345; Liu RR, 2012, CANCER IMMUNOL IMMUN, V61, P855, DOI 10.1007/s00262-011-1146-8; Liu XJ, 2015, NAT MED, V21, P1209, DOI 10.1038/nm.3931; Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]; Lugade AA, 2005, J IMMUNOL, V174, P7516, DOI 10.4049/jimmunol.174.12.7516; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Martins I, 2009, CELL CYCLE, V8, P3723, DOI 10.4161/cc.8.22.10026; Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624; Michaud M, 2011, SCIENCE, V334, P1573, DOI 10.1126/science.1208347; Minard-Colin V, 2008, BLOOD, V112, P1205, DOI 10.1182/blood-2008-01-135160; Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523; Orr MT, 2010, CELL, V142, P847, DOI 10.1016/j.cell.2010.08.031; Park S, 2010, CANCER CELL, V18, P160, DOI 10.1016/j.ccr.2010.06.014; Prise KM, 2009, NAT REV CANCER, V9, P351, DOI 10.1038/nrc2603; Rafiq K, 2002, J CLIN INVEST, V110, P71, DOI 10.1172/JCI200215640; Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494; Roghanian A, 2015, CANCER CELL, V27, P473, DOI 10.1016/j.ccell.2015.03.005; Salama JK, 2012, CANCER-AM CANCER SOC, V118, P2962, DOI 10.1002/cncr.26611; Schaue D, 2012, INT J RADIAT ONCOL, V83, P1306, DOI 10.1016/j.ijrobp.2011.09.049; Sistigu A, 2014, NAT MED, V20, P1301, DOI 10.1038/nm.3708; Stagg J, 2011, P NATL ACAD SCI USA, V108, P7142, DOI 10.1073/pnas.1016569108; Sun LJ, 2013, SCIENCE, V339, P786, DOI 10.1126/science.1232458; Suzuki Y, 2012, CANCER RES, V72, P3967, DOI 10.1158/0008-5472.CAN-12-0851; Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690; Trinchieri G, 2010, J EXP MED, V207, P2053, DOI 10.1084/jem.20101664; Uchida JJ, 2004, J EXP MED, V199, P1659, DOI 10.1084/jem.20040119; Westover KD, 2015, LUNG CANCER, V89, P87, DOI 10.1016/j.lungcan.2015.04.009; Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017; Wu CY, 2014, CLIN CANCER RES, V20, P644, DOI 10.1158/1078-0432.CCR-13-1334; Wu JX, 2014, ANNU REV IMMUNOL, V32, P461, DOI 10.1146/annurev-immunol-032713-120156; Yang XM, 2014, CANCER CELL, V25, P37, DOI 10.1016/j.ccr.2013.12.004; Yang XM, 2013, MOL THER, V21, P91, DOI 10.1038/mt.2012.184; Zelenay S, 2013, TRENDS IMMUNOL, V34, P329, DOI 10.1016/j.it.2013.03.005; Zhang X, 2013, MOL CELL, V51, P226, DOI 10.1016/j.molcel.2013.05.022; Zitvogel L, 2015, NAT REV IMMUNOL, V15, P405, DOI 10.1038/nri3845; Zitvogel L, 2010, CLIN CANCER RES, V16, P3100, DOI 10.1158/1078-0432.CCR-09-2891	86	10	10	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 2	2017	36	5					585	592		10.1038/onc.2016.231	http://dx.doi.org/10.1038/onc.2016.231			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EK8IS	27425593	Green Accepted			2022-12-17	WOS:000394167700001
J	Leslie, PL; Zhang, Y				Leslie, P. L.; Zhang, Y.			MDM2 oligomers: antagonizers of the guardian of the genome	ONCOGENE			English	Review							UBIQUITIN LIGASE ACTIVITY; AUTOREGULATORY FEEDBACK LOOP; HUMAN TUMOR-CELLS; ACTIVITY IN-VIVO; DNA-DAMAGE; RING DOMAIN; P53 ACTIVITY; E3 LIGASE; ACIDIC DOMAIN; PROMOTES UBIQUITINATION	Over two decades of MDM2 research has resulted in the accumulation of a wealth of knowledge of many aspects of MDM2 regulation and function, particularly with respect to its most prominent target, p53. For example, recent knock-in mouse studies have shown that MDM2 heterooligomer formation with its homolog, MDMX, is necessary and sufficient in utero to suppress p53 but is dispensable during adulthood. However, despite crucial advances such as these, several aspects regarding basic in vivo functions of MDM2 remain unknown. In one such example, although abundant evidence suggests that MDM2 forms homooligomers and heterooligomers with MDMX, the function and regulation of these homo-and heterooligomers in vivo remain incompletely understood. In this review, we discuss the current state of our knowledge of MDM2 oligomerization as well as current efforts to target the MDM2 oligomer as a broad therapeutic option for cancer treatment.	[Leslie, P. L.; Zhang, Y.] Univ North Carolina Chapel Hill, Dept Radiat Oncol, 450 West Dr, Chapel Hill, NC 27599 USA; [Leslie, P. L.; Zhang, Y.] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, 450 West Dr, Chapel Hill, NC 27599 USA; [Leslie, P. L.] Univ North Carolina Chapel Hill, Sch Med, Curriculum Genet & Mol Biol, Chapel Hill, NC USA; [Zhang, Y.] Xuzhou Med Coll, Lab Biol Canc Therapy, Xuzhou, Peoples R China	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Xuzhou Medical University	Zhang, Y (corresponding author), Univ North Carolina Chapel Hill, Dept Radiat Oncol, 450 West Dr, Chapel Hill, NC 27599 USA.; Zhang, Y (corresponding author), Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, 450 West Dr, Chapel Hill, NC 27599 USA.	ypzhang@med.unc.edu			National Institutes of Health [CA127770, CA167637]; University of North Carolina Genetics and Molecular Biology Training Grant [5T32 GM007092]; NSFC; Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy; NATIONAL CANCER INSTITUTE [R01CA167637, R01CA100302, R01CA155235, R01CA127770] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007092] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of North Carolina Genetics and Molecular Biology Training Grant; NSFC(National Natural Science Foundation of China (NSFC)); Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported, in whole or in part, by National Institutes of Health Grants CA127770 and CA167637 (to YZ). This work was also supported by a fellowship from the University of North Carolina Genetics and Molecular Biology Training Grant 5T32 GM007092 (to PL), and grants from the NSFC and Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy (to YZ).	Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; Aziz MH, 2011, ONCOGENE, V30, P4678, DOI 10.1038/onc.2011.185; Badciong JC, 2002, J BIOL CHEM, V277, P49668, DOI 10.1074/jbc.M208593200; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bista M, 2013, P NATL ACAD SCI USA, V110, P17814, DOI 10.1073/pnas.1317398110; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Burgess A, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00007; Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419; Chang YS, 2013, P NATL ACAD SCI USA, V110, pE3445, DOI 10.1073/pnas.1303002110; Chavez-Reyes A, 2003, CANCER RES, V63, P8664; Chen LH, 2005, EMBO J, V24, P3411, DOI 10.1038/sj.emboj.7600812; Chen LH, 2005, MOL CELL BIOL, V25, P6509, DOI 10.1128/MCB.25.15.6509-6520.2005; Chen L, 2015, P NATL ACAD SCI USA, V112, P10002, DOI 10.1073/pnas.1502159112; Chen LH, 2015, P NATL ACAD SCI USA, V112, P4624, DOI 10.1073/pnas.1420833112; Cheng Q, 2014, MOL CELL BIOL, V34, P2800, DOI 10.1128/MCB.00246-14; Cheng Q, 2011, MOL CELL BIOL, V31, P4951, DOI 10.1128/MCB.05553-11; Cheng Q, 2009, EMBO J, V28, P3857, DOI 10.1038/emboj.2009.294; Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dang JJ, 2002, CANCER RES, V62, P1222; de Graaf P, 2003, J BIOL CHEM, V278, P38315, DOI 10.1074/jbc.M213034200; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Dolezelova P, 2012, CELL CYCLE, V11, P953, DOI 10.4161/cc.11.5.19445; Egorova O, 2014, BIOCHEM BIOPH RES CO, V447, P696, DOI 10.1016/j.bbrc.2014.04.065; Fahraeus R, 2014, ONCOGENE, V33, P4365, DOI 10.1038/onc.2013.410; Francoz S, 2006, P NATL ACAD SCI USA, V103, P3232, DOI 10.1073/pnas.0508476103; Garcia D, 2011, GENE DEV, V25, P1746, DOI 10.1101/gad.16722111; Gilkes DM, 2006, EMBO J, V25, P5614, DOI 10.1038/sj.emboj.7601424; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Graves B, 2012, P NATL ACAD SCI USA, V109, P11788, DOI 10.1073/pnas.1203789109; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Herman AG, 2011, CANCER DISCOV, V1, P312, DOI 10.1158/2159-8290.CD-11-0104; Hjerrild M, 2001, BIOCHEM J, V355, P347, DOI 10.1042/0264-6021:3550347; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 2000, ONCOGENE, V19, P1473, DOI 10.1038/sj.onc.1203464; Hu BL, 2006, J BIOL CHEM, V281, P33030, DOI 10.1074/jbc.C600147200; Huang L, 2011, P NATL ACAD SCI USA, V108, P12001, DOI 10.1073/pnas.1102309108; Itahana K, 2007, CANCER CELL, V12, P355, DOI 10.1016/j.ccr.2007.09.007; Iyappan S, 2010, J BIOL CHEM, V285, P33065, DOI 10.1074/jbc.M110.115113; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; KASTAN MB, 1991, CANCER RES, V51, P6304; Kawai H, 2003, J BIOL CHEM, V278, P45946, DOI 10.1074/jbc.M308295200; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kawai H, 2007, CANCER RES, V67, P6026, DOI 10.1158/0008-5472.CAN-07-1313; Khoo KH, 2014, NAT REV DRUG DISCOV, V13, DOI 10.1038/nrd4288; Kostic M, 2006, J MOL BIOL, V363, P433, DOI 10.1016/j.jmb.2006.08.027; Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kubbutat MHG, 1999, CELL GROWTH DIFFER, V10, P87; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lamberti A, 2015, ELECTROPHORESIS, V36, P552, DOI 10.1002/elps.201400424; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lee JH, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4814; Lehmann S, 2012, J CLIN ONCOL, V30, P3633, DOI 10.1200/JCO.2011.40.7783; LENG P, 1995, ONCOGENE, V10, P1275; Leslie PL, 2015, J BIOL CHEM, V290, P12941, DOI 10.1074/jbc.M115.644435; Li BZ, 2010, CELL CYCLE, V9, P1411, DOI 10.4161/cc.9.7.11255; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Li X, 2012, ONCOGENE, V31, P3721, DOI 10.1038/onc.2011.534; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; Linke K, 2008, CELL DEATH DIFFER, V15, P841, DOI 10.1038/sj.cdd.4402309; Lohrum MAE, 2000, NAT CELL BIOL, V2, P179, DOI 10.1038/35004057; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; LUNA RMD, 1995, NATURE, V378, P203; MARCHETTI A, 1995, J PATHOL, V175, P31, DOI 10.1002/path.1711750106; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Marine JC, 2005, BIOCHEM BIOPH RES CO, V331, P750, DOI 10.1016/j.bbrc.2005.03.151; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Michaelis M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.129; Moll UM, 2003, MOL CANCER RES, V1, P1001; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Momand J, 2011, GENE, V486, P23, DOI 10.1016/j.gene.2011.06.030; Muller PAJ, 2013, NAT CELL BIOL, V15, P2, DOI 10.1038/ncb2641; Nahi H, 2004, BRIT J HAEMATOL, V127, P285, DOI 10.1111/j.1365-2141.2004.05210.x; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Noguchi T, 2013, BIOORG MED CHEM LETT, V23, P3802, DOI 10.1016/j.bmcl.2013.04.094; Okamoto K, 2009, FEBS LETT, V583, P2710, DOI 10.1016/j.febslet.2009.07.021; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OLINER JD, 1992, NATURE, V358, P80, DOI 10.1038/358080a0; Pan Y, 2003, MOL CELL BIOL, V23, P5113, DOI 10.1128/MCB.23.15.5113-5121.2003; Pant V, 2011, P NATL ACAD SCI USA, V108, P11995, DOI 10.1073/pnas.1102241108; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Patton JT, 2006, CANCER RES, V66, P3169, DOI 10.1158/0008-5472.CAN-05-3832; Pellegrino M, 2015, CANCER RES, V75, P4560, DOI 10.1158/0008-5472.CAN-15-0439; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Phillips A, 2010, J BIOL CHEM, V285, P29111, DOI 10.1074/jbc.M110.129726; Poyurovsky MV, 2007, EMBO J, V26, P90, DOI 10.1038/sj.emboj.7601465; Ray-Coquard I, 2012, LANCET ONCOL, V13, P1133, DOI 10.1016/S1470-2045(12)70474-6; REIFENBERGER G, 1993, CANCER RES, V53, P2736; Riedinger C, 2009, FUTURE MED CHEM, V1, P1075, DOI 10.4155/FMC.09.75; Ringshausen I, 2006, CANCER CELL, V10, P501, DOI 10.1016/j.ccr.2006.10.010; SCHMID P, 1991, DEVELOPMENT, V113, P857; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shinozaki T, 2003, ONCOGENE, V22, P8870, DOI 10.1038/sj.onc.1207176; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Simon R, 2002, ONCOGENE, V21, P2476, DOI 10.1038/sj.onc.1205304; Singh RK, 2007, J BIOL CHEM, V282, P10901, DOI 10.1074/jbc.M610879200; Stad R, 2000, J BIOL CHEM, V275, P28039; Steinman HA, 2005, ONCOGENE, V24, P7935, DOI 10.1038/sj.onc.1208930; Takimoto R, 2002, CANCER BIOL THER, V1, P47, DOI 10.4161/cbt.1.1.41; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; Toledo F, 2007, INT J BIOCHEM CELL B, V39, P1476, DOI 10.1016/j.biocel.2007.03.022; Tollini LA, 2014, CANCER CELL, V26, P235, DOI 10.1016/j.ccr.2014.06.006; Uldrijan S, 2007, EMBO J, V26, P102, DOI 10.1038/sj.emboj.7601469; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; Wade M, 2012, ONCOGENE, V31, P4789, DOI 10.1038/onc.2011.625; Wade M, 2006, J BIOL CHEM, V281, P33036, DOI 10.1074/jbc.M605405200; Wade M, 2013, NAT REV CANCER, V13, P83, DOI 10.1038/nrc3430; Wade M, 2010, TRENDS CELL BIOL, V20, P299, DOI 10.1016/j.tcb.2010.01.009; Wang XJ, 2011, J BIOL CHEM, V286, P23725, DOI 10.1074/jbc.M110.213868; Wang XQ, 2001, FEBS LETT, V490, P202, DOI 10.1016/S0014-5793(01)02124-X; Winter M, 2004, BIOCHEMISTRY-US, V43, P16356, DOI 10.1021/bi0489255; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Xiong SB, 2006, P NATL ACAD SCI USA, V103, P3226, DOI 10.1073/pnas.0508500103; Xiong XF, 2014, ELIFE, V3, DOI 10.7554/eLife.02236; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yang YL, 2005, CANCER CELL, V7, P547, DOI 10.1016/j.ccr.2005.04.029; YONISHROUACH E, 1991, NATURE, V352, P345, DOI 10.1038/352345a0; [张燕 Zhang Yan], 2003, [水土保持通报, Bulletin of Soil and Water Conservation], V23, P23; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang ZM, 2014, ACS MED CHEM LETT, V5, P124, DOI 10.1021/ml400359z; Zheng JG, 2015, GENE DEV, V29, P1524, DOI 10.1101/gad.261792.115; Zhu QZ, 2001, J BIOL CHEM, V276, P29695, DOI 10.1074/jbc.M102634200; Zuckerman V, 2009, J BIOL CHEM, V284, P4031, DOI 10.1074/jbc.M809211200	131	10	10	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 1	2016	35	48					6157	6165		10.1038/onc.2016.88	http://dx.doi.org/10.1038/onc.2016.88			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	ED4YH	27041565	Green Submitted, Green Accepted			2022-12-17	WOS:000388857700001
J	El Ghamrasni, S; Cardoso, R; Li, L; Guturi, KKN; Bjerregaard, VA; Liu, Y; Venkatesan, S; Hande, MP; Henderson, JT; Sanchez, O; Hickson, ID; Hakem, A; Hakem, R				El Ghamrasni, S.; Cardoso, R.; Li, L.; Guturi, K. K. N.; Bjerregaard, V. A.; Liu, Y.; Venkatesan, S.; Hande, M. P.; Henderson, J. T.; Sanchez, O.; Hickson, I. D.; Hakem, A.; Hakem, R.			Rad54 and Mus81 cooperation promotes DNA damage repair and restrains chromosome missegregation	ONCOGENE			English	Article							LARGE T-ANTIGEN; DOWN-REGULATION; RECOMBINATION; PROTEIN; INSTABILITY; DISRUPTION; INTEGRITY; CELLS; GENE	Rad54 and Mus81 mammalian proteins physically interact and are important for the homologous recombination DNA repair pathway; however, their functional interactions in vivo are poorly defined. Here, we show that combinatorial loss of Rad54 and Mus81 results in hypersensitivity to DNA-damaging agents, defects on both the homologous recombination and non-homologous DNA end joining repair pathways and reduced fertility. We also observed that while Mus81 deficiency diminished the cleavage of common fragile sites, very strikingly, Rad54 loss impaired this cleavage to even a greater extent. The inefficient repair of DNA double-strand breaks (DSBs) in Rad54(-/-) Mus81(-/-) cells was accompanied by elevated levels of chromosome missegregation and cell death. Perhaps as a consequence, tumor incidence in Rad54(-/-) Mus81(-/-) mice remained comparable to that in Mus81(-/-) mice. Our study highlights the importance of the cooperation between Rad54 and Mus81 for mediating DNA DSB repair and restraining chromosome missegregation.	[El Ghamrasni, S.; Cardoso, R.; Li, L.; Guturi, K. K. N.; Hakem, A.; Hakem, R.] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; [El Ghamrasni, S.; Cardoso, R.; Li, L.; Guturi, K. K. N.; Hakem, A.; Hakem, R.] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada; [Bjerregaard, V. A.; Liu, Y.; Hickson, I. D.] Univ Copenhagen, Panum Inst, Ctr Chromosome Stabil, Dept Cellular & Mol Med, Copenhagen, Denmark; [Bjerregaard, V. A.; Liu, Y.; Hickson, I. D.] Univ Copenhagen, Panum Inst, Ctr Hlth Ageing, Copenhagen, Denmark; [Venkatesan, S.; Hande, M. P.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore; [Venkatesan, S.; Hande, M. P.] Natl Univ Singapore, Tembusu Coll, Singapore, Singapore; [Henderson, J. T.] Univ Toronto, Leslie Dan Fac Pharm, Div Biomol Sci, Dept Pharmaceut Sci, Toronto, ON, Canada; [Sanchez, O.] Univ Ontario, Inst Technol, Dept Pathol, Oshawa, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Copenhagen; University of Copenhagen; National University of Singapore; National University of Singapore; University of Toronto; Ontario Tech University	Hakem, R (corresponding author), Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.; Hakem, R (corresponding author), Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON M5G 2M9, Canada.	rhakem@uhnres.utoronto.ca	Hickson, Ian/AAJ-7548-2020; Venkatesan, Shriram/AFL-5405-2022; Hande, M. Prakash/B-1645-2008; El Ghamrasni, Samah/AAA-1350-2022; Venkatesan, Shriram/AAY-9319-2021	Venkatesan, Shriram/0000-0003-0778-2474; Hande, M. Prakash/0000-0002-4511-6256; El Ghamrasni, Samah/0000-0003-4346-1360; Venkatesan, Shriram/0000-0003-0778-2474; Hakem, Razqallah/0000-0001-5948-7931; Hickson, Ian/0000-0002-0583-566X	Canadian Institute of Health Research	Canadian Institute of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by the Canadian Institute of Health Research (RH). We thank P McPherson and members of the RH laboratory for helpful discussions and critical reading of the manuscript. In addition, we thank S Hakem for editing the manuscript and R Kanaar for providing Rad54<SUP>-/-</SUP> mice.	Agarwal S, 2011, J CELL BIOL, V192, P735, DOI 10.1083/jcb.201011025; Ahuja D, 2005, ONCOGENE, V24, P7729, DOI 10.1038/sj.onc.1209046; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Ceballos SJ, 2011, BBA-GENE REGUL MECH, V1809, P509, DOI 10.1016/j.bbagrm.2011.06.006; Chu WK, 2009, NAT REV CANCER, V9, P644, DOI 10.1038/nrc2682; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Dendouga N, 2005, MOL CELL BIOL, V25, P7569, DOI 10.1128/MCB.25.17.7569-7579.2005; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Durkin SG, 2007, ANNU REV GENET, V41, P169, DOI 10.1146/annurev.genet.41.042007.165900; El Ghamrasni S, 2015, ONCOGENE, V34, P1780, DOI 10.1038/onc.2014.121; El Ghamrasni S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001385; Essers J, 2000, EMBO J, V19, P1703, DOI 10.1093/emboj/19.7.1703; Essers J, 1997, CELL, V89, P195, DOI 10.1016/S0092-8674(00)80199-3; Garner E, 2013, CELL REP, V5, P207, DOI 10.1016/j.celrep.2013.08.041; Hakem R, 2008, EMBO J, V27, P589, DOI 10.1038/emboj.2008.15; Hanada K, 2006, EMBO J, V25, P4921, DOI 10.1038/sj.emboj.7601344; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; Heyer WD, 2006, NUCLEIC ACIDS RES, V34, P4115, DOI 10.1093/nar/gkl481; Hiyama T, 2006, NUCLEIC ACIDS RES, V34, P880, DOI 10.1093/nar/gkj495; Hussain Syed A, 2004, Expert Rev Anticancer Ther, V4, P1179, DOI 10.1586/14737140.4.6.1179; Interthal H, 2000, MOL GEN GENET, V263, P812, DOI 10.1007/s004380000241; Jackson SP, 2009, NATURE, V461, P1071, DOI 10.1038/nature08467; Mao ZY, 2009, NEOPLASIA, V11, P683, DOI 10.1593/neo.09312; Matsuda M, 1999, ONCOGENE, V18, P3427, DOI 10.1038/sj.onc.1202692; Mazin AV, 2010, DNA REPAIR, V9, P286, DOI 10.1016/j.dnarep.2009.12.006; Mazina OM, 2008, P NATL ACAD SCI USA, V105, P18249, DOI 10.1073/pnas.0807016105; McManus KJ, 2009, P NATL ACAD SCI USA, V106, P3276, DOI 10.1073/pnas.0813414106; McPherson JP, 2004, SCIENCE, V304, P1822, DOI 10.1126/science.1094557; McPherson JP, 2004, EMBO J, V23, P3677, DOI 10.1038/sj.emboj.7600371; Munoz-Galvan S, 2012, MOL CELL BIOL, V32, P1592, DOI 10.1128/MCB.00111-12; Naim V, 2013, NAT CELL BIOL, V15, P1008, DOI 10.1038/ncb2793; Ozeri-Galai E, 2012, TRENDS GENET, V28, P295, DOI 10.1016/j.tig.2012.02.006; Pamidi A, 2007, CANCER RES, V67, P8527, DOI 10.1158/0008-5472.CAN-07-1161; Pepe A, 2014, CELL REP, V7, P1048, DOI 10.1016/j.celrep.2014.04.007; Prakash R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016600; Sarbajna S, 2014, TRENDS BIOCHEM SCI, V39, P409, DOI 10.1016/j.tibs.2014.07.003; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Wechsler T, 2011, NATURE, V471, P642, DOI 10.1038/nature09790; Wesoly J, 2006, MOL CELL BIOL, V26, P976, DOI 10.1128/MCB.26.3.976-989.2006; Wu F, 2008, CANCER-AM CANCER SOC, V112, P2002, DOI 10.1002/cncr.23396; Wu F, 2011, CANCER SCI, V102, P472, DOI 10.1111/j.1349-7006.2010.01790.x; Wu F, 2010, ANTICANCER RES, V30, P5011; Ying SM, 2013, NAT CELL BIOL, V15, P1001, DOI 10.1038/ncb2773; ZHU JY, 1991, J VIROL, V65, P6872, DOI 10.1128/JVI.65.12.6872-6880.1991	44	10	10	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 15	2016	35	37					4836	4845		10.1038/onc.2016.16	http://dx.doi.org/10.1038/onc.2016.16			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DW0LA	26876210				2022-12-17	WOS:000383330700002
J	Anadon, C; Guil, S; Simo-Riudalbas, L; Moutinho, C; Setien, F; Martinez-Cardus, A; Moran, S; Villanueva, A; Calaf, M; Vidal, A; Lazo, PA; Zondervan, I; Savola, S; Kohno, T; Yokota, J; de Pouplana, LR; Esteller, M				Anadon, C.; Guil, S.; Simo-Riudalbas, L.; Moutinho, C.; Setien, F.; Martinez-Cardus, A.; Moran, S.; Villanueva, A.; Calaf, M.; Vidal, A.; Lazo, P. A.; Zondervan, I.; Savola, S.; Kohno, T.; Yokota, J.; Ribas de Pouplana, L.; Esteller, M.			Gene amplification-associated overexpression of the RNA editing enzyme ADAR1 enhances human lung tumorigenesis (vol 35, pg 4407, 2016)	ONCOGENE			English	Correction													Martinez, Anna/AAA-4939-2020; Esteller, Manel/L-5956-2014; Lazo, Pedro A./M-6435-2014; Moran, Sebastian/G-5293-2013	Esteller, Manel/0000-0003-4490-6093; Lazo, Pedro A./0000-0001-8997-3025; Moran, Sebastian/0000-0003-4192-8983; Martinez Cardus, Anna/0000-0002-3937-8794				Anadon C, 2016, ONCOGENE, V35, P4407, DOI 10.1038/onc.2015.469	1	10	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2016	35	33								10.1038/onc.2016.27	http://dx.doi.org/10.1038/onc.2016.27			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DU3ZU	27345394	Green Published, hybrid			2022-12-17	WOS:000382152100015
J	Adrados, I; Larrasa-Alonso, J; Galarreta, A; Lopez-Antona, I; Menendez, C; Abad, M; Gil, J; Moreno-Bueno, G; Palmero, I				Adrados, I.; Larrasa-Alonso, J.; Galarreta, A.; Lopez-Antona, I.; Menendez, C.; Abad, M.; Gil, J.; Moreno-Bueno, G.; Palmero, I.			The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes	ONCOGENE			English	Article							ONCOGENE-INDUCED SENESCENCE; TUMOR-SUPPRESSOR; TRANSCRIPTIONAL REGULATION; REPRESSIVE COMPLEXES; EPIGENETIC CONTROL; STEM-CELLS; 6 FAMILY; EXPRESSION; CONTRIBUTES; P53	Cellular senescence is an antiproliferative response with essential functions in tumor suppression and tissue homeostasis. Here we show that SIX1, a member of the SIX family of homeobox transcriptional factors, is a novel repressor of senescence. Our data show that SIX1 is specifically downregulated in fibroblasts upon oncogenic stress and other pro-senescence stimuli, as well as in senescent skin premalignant lesions. Silencing of SIX1 in human fibroblasts suffices to trigger senescence, which is mediated by p16INK4A and lacks a canonical senescence-associated secretory phenotype. Interestingly, SIX1-associated senescence is further characterized by the expression of a set of development and differentiation-related genes that significantly overlap with genes associated with SIX1 in organogenesis or human tumors, and show coincident regulation in oncogene-induced senescence. Mechanistically, we show that gene regulation by SIX1 during senescence is mediated, at least in part, by cooperation with Polycomb repressive complexes. In summary, our results identify SIX1, a key development regulator altered in human tumors, as a critical repressor of cellular senescence, providing a novel connection between senescence, differentiation and tumorigenesis.	[Adrados, I.; Larrasa-Alonso, J.; Galarreta, A.; Lopez-Antona, I.; Menendez, C.; Abad, M.; Moreno-Bueno, G.; Palmero, I.] UAM, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain; [Gil, J.] Imperial Coll London, MRC Clin Sci Ctr, Cell Proliferat Grp, Hammersmith Campus, London, England; [Moreno-Bueno, G.] UAM, IdiPAZ Inst Invest Sanitaria La Paz, Dept Bioquim, Madrid, Spain; [Moreno-Bueno, G.] Fdn MD Anderson Int, Madrid, Spain; [Adrados, I.] Scripps Res Inst, 130 Scripps Way, Jupiter, FL 33458 USA; [Larrasa-Alonso, J.] CNIC, Madrid 28029, Spain; [Menendez, C.; Abad, M.] CNIO, Madrid 28029, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Imperial College London; Autonomous University of Madrid; University of Texas System; UTMD Anderson Cancer Center; Scripps Research Institute; Centro Nacional de Investigaciones Cardiovasculares (CNIC); Centro Nacional de Investigaciones Oncologicas (CNIO)	Palmero, I (corresponding author), UAM, CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	ipalmero@iib.uam.es	Abad, Maria/AAI-2366-2019; Adrados Moran, Isabel/B-2411-2018; Gil, Jesus/C-7739-2012; Moreno-Bueno, Gema/K-9354-2016; Vivancos, Ana/AAG-8331-2019	Abad, Maria/0000-0002-1462-2498; Gil, Jesus/0000-0002-4303-6260; Moreno-Bueno, Gema/0000-0002-5030-6687; Vivancos, Ana/0000-0003-2888-6512; Galarreta, Antonio/0000-0003-2358-7927; Menendez, Maria del Camino/0000-0002-3535-2490; Adrados, Isabel/0000-0003-3337-6883; Lopez-Antona, Irene/0000-0002-5393-6924	Spanish Government [SAF2012-32117]; Instituto de Salud Carlos III [PI13/00132, RETIC-RD12/0036/0007]; Regional Government of Madrid [S2010/BMD-2303]; Spanish Government FPI program; Medical Research Council [MC_U120085810] Funding Source: researchfish; MRC [MC_U120085810] Funding Source: UKRI	Spanish Government(Spanish GovernmentEuropean Commission); Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Regional Government of Madrid; Spanish Government FPI program; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Manuel Serrano, Daniel Peeper and Rene Bernards for cells and reagents, and Masashi Narita for reagents and sharing unpublished data. This work was supported by grants from the Spanish Government (SAF2012-32117) to IP, Instituto de Salud Carlos III (PI13/00132 and RETIC-RD12/0036/0007) and Regional Government of Madrid (S2010/BMD-2303) to GM-B. IA is the recipient of a fellowship from the Spanish Government FPI program.	Abad M, 2011, AGING CELL, V10, P158, DOI 10.1111/j.1474-9726.2010.00651.x; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Acosta JC, 2013, NAT CELL BIOL, V15, P978, DOI 10.1038/ncb2784; Auvergne RM, 2013, CELL REP, V3, P2127, DOI 10.1016/j.celrep.2013.04.035; Banito A, 2009, GENE DEV, V23, P2134, DOI 10.1101/gad.1811609; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Buckingham M, 2014, DEV CELL, V28, P225, DOI 10.1016/j.devcel.2013.12.020; Chandra T, 2012, MOL CELL, V47, P203, DOI 10.1016/j.molcel.2012.06.010; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Christensen KL, 2008, ADV CANCER RES, V101, P93, DOI 10.1016/S0065-230X(08)00405-3; Coletta RD, 2010, BMC DEV BIOL, V10, DOI 10.1186/1471-213X-10-4; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Coppe JP, 2011, J BIOL CHEM, V286, P36396, DOI 10.1074/jbc.M111.257071; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Delgado-Olguin P, 2012, NAT GENET, V44, P343, DOI 10.1038/ng.1068; Di Croce L, 2013, NAT STRUCT MOL BIOL, V20, P1147, DOI 10.1038/nsmb.2669; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Eid JE, 2015, SEMIN CANCER BIOL, V32, P18, DOI 10.1016/j.semcancer.2014.05.005; Farabaugh SM, 2012, ONCOGENE, V31, P552, DOI 10.1038/onc.2011.259; Gil J, 2006, NAT REV MOL CELL BIO, V7, P667, DOI 10.1038/nrm1987; Gomez-Cabello D, 2013, AGING CELL, V12, P923, DOI 10.1111/acel.12117; Gomez-Cabello D, 2010, CANCER RES, V70, P1866, DOI 10.1158/0008-5472.CAN-09-2088; Imai Y, 2014, CELL REP, V7, P194, DOI 10.1016/j.celrep.2014.03.006; Irelan JT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005067; Iwanaga R, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3219; Kirschner K, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005053; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kumar JP, 2009, CELL MOL LIFE SCI, V66, P565, DOI 10.1007/s00018-008-8335-4; Laclef C, 2003, MECH DEVELOP, V120, P669, DOI 10.1016/S0925-4773(03)00065-0; Lanigan F, 2011, ONCOGENE, V30, P2901, DOI 10.1038/onc.2011.34; Laugesen A, 2014, CELL STEM CELL, V14, P735, DOI 10.1016/j.stem.2014.05.006; Le Grand F, 2012, J CELL BIOL, V198, P815, DOI 10.1083/jcb.201201050; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Li X, 2003, NATURE, V426, P247, DOI 10.1038/nature02083; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Liu Y, 2013, ADV MATH PHYS, V2013, DOI 10.1155/2013/787891; Martin N, 2013, EMBO J, V32, P982, DOI 10.1038/emboj.2013.37; McCoy EL, 2009, J CLIN INVEST, V119, P2663, DOI 10.1172/JCI37691; Menendez C, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12241; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Munoz-Espin D, 2014, NAT REV MOL CELL BIO, V15, P482, DOI 10.1038/nrm3823; Munoz-Espin D, 2013, CELL, V155, P1104, DOI 10.1016/j.cell.2013.10.019; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Orten DJ, 2008, HUM MUTAT, V29, P537, DOI 10.1002/humu.20691; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Patrick AN, 2013, NAT STRUCT MOL BIOL, V20, P447, DOI 10.1038/nsmb.2505; Pemberton H, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-2-r23; Perez-Mancera PA, 2014, NAT REV CANCER, V14, P547, DOI 10.1038/nrc3773; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Salama R, 2014, GENE DEV, V28, P99, DOI 10.1101/gad.235184.113; Sehic D, 2012, PEDIATR BLOOD CANCER, V59, P62, DOI 10.1002/pbc.24025; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Sousa-Victor P, 2014, NATURE, V506, P316, DOI 10.1038/nature13013; Storer M, 2013, CELL, V155, P1119, DOI 10.1016/j.cell.2013.10.041; Tadjuidje E, 2013, CELL MOL LIFE SCI, V70, P1897, DOI 10.1007/s00018-012-1144-9; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Wong EYM, 2013, HEARING RES, V297, P13, DOI 10.1016/j.heares.2012.09.009; Xia Y, 2013, NAT CELL BIOL, V15, P1507, DOI 10.1038/ncb2872; Xu PX, 2013, PEDIATR NEPHROL, V28, P843, DOI 10.1007/s00467-012-2246-1; Xu PX, 2003, DEVELOPMENT, V130, P3085, DOI 10.1242/dev.00536; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yu YL, 2006, CANCER RES, V66, P1982, DOI 10.1158/0008-5472.CAN-05-2360	65	10	10	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 7	2016	35	27					3485	3494		10.1038/onc.2015.408	http://dx.doi.org/10.1038/onc.2015.408			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DR0UD	26500063	Green Accepted, Green Submitted			2022-12-17	WOS:000379621500001
J	Zhou, L; Lyons-Rimmer, J; Ammoun, S; Muller, J; Lasonder, E; Sharma, V; Ercolano, E; Hilton, D; Taiwo, I; Barczyk, M; Hanemann, CO				Zhou, L.; Lyons-Rimmer, J.; Ammoun, S.; Mueller, J.; Lasonder, E.; Sharma, V.; Ercolano, E.; Hilton, D.; Taiwo, I.; Barczyk, M.; Hanemann, C. O.			The scaffold protein KSR1, a novel therapeutic target for the treatment of Merlin-deficient tumors	ONCOGENE			English	Article							KINASE SUPPRESSOR; HUMAN SCHWANNOMA; MAPK SCAFFOLD; GENE ENCODES; RAS; ACTIVATION; ERK; PROLIFERATION; TUMORIGENESIS; INHIBITION	Merlin has broad tumor-suppressor functions as its mutations have been identified in multiple benign tumors and malignant cancers. In all schwannomas, the majority of meningiomas and 1/3 of ependymomas Merlin loss is causative. In neurofibromatosis type 2, a dominantly inherited tumor disease because of the loss of Merlin, patients suffer from multiple nervous system tumors and die on average around age 40. Chemotherapy is not effective and tumor localization and multiplicity make surgery and radiosurgery challenging and morbidity is often considerable. Thus, a new therapeutic approach is needed for these tumors. Using a primary human in vitro model for Merlin-deficient tumors, we report that the Ras/Raf/mitogen-activated protein, extracellular signal-regulated kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) scaffold, kinase suppressor of Ras 1 (KSR1), has a vital role in promoting schwannomas development. We show that KSR1 overexpression is involved in many pathological phenotypes caused by Merlin loss, namely multipolar morphology, enhanced cell-matrix adhesion, focal adhesion and, most importantly, increased proliferation and survival. Our data demonstrate that KSR1 has a wider role than MEK1/2 in the development of schwannomas because adhesion is more dependent on KSR1 than MEK1/2. Immunoprecipitation analysis reveals that KSR1 is a novel binding partner of Merlin, which suppresses KSR1's function by inhibiting the binding between KSR1 and c-Raf. Our proteomic analysis also demonstrates that KSR1 interacts with several Merlin downstream effectors, including E3 ubiquitin ligase CRL4(DCAF1). Further functional studies suggests that KSR1 and DCAF1 may co-operate to regulate schwannomas formation. Taken together, these findings suggest that KSR1 serves as a potential therapeutic target for Merlin-deficient tumors.	[Zhou, L.; Lyons-Rimmer, J.; Ammoun, S.; Ercolano, E.; Taiwo, I.; Hanemann, C. O.] Univ Plymouth, Peninsula Sch Med & Dent, Inst Translat & Stratified Med, John Bull Bldg,Plymouth Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England; [Mueller, J.] Univ Warwick, Warwick Med Sch, Coventry, W Midlands, England; [Mueller, J.] Aston Univ, Aston Med Sch, Aston Med Res Inst, Birmingham, W Midlands, England; [Lasonder, E.; Sharma, V.] Univ Plymouth, Peninsula Sch Med & Dent, Sch Biomed & Healthcare Sci, Plymouth, Devon, England; [Hilton, D.] Derriford Hosp, Dept Neuropathol, Plymouth, Devon, England; [Barczyk, M.] MRC Lab Mol Biol, Cell Biol, Cambridge, England	University of Plymouth; University of Warwick; Aston University; University of Plymouth; Derriford Hospital; MRC Laboratory Molecular Biology	Zhou, L (corresponding author), Univ Plymouth, Peninsula Sch Med & Dent, Inst Translat & Stratified Med, John Bull Bldg,Plymouth Sci Pk,Res Way, Plymouth PL6 8BU, Devon, England.	lu.zhou@plymouth.ac.uk	Hanemann, C Oliver/AAV-6257-2020	Hanemann, C Oliver/0000-0002-1951-1025; Lasonder, Edwin/0000-0003-2582-3444	Children's Tumor Foundation young investigator award; Brain Tumor Research Charity PhD studentship; Medical Research Council [G0600790] Funding Source: researchfish; MRC [G0600790] Funding Source: UKRI	Children's Tumor Foundation young investigator award; Brain Tumor Research Charity PhD studentship; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	LZ is supported by a Children's Tumor Foundation young investigator award. JL-R is supported by Brain Tumor Research Charity PhD studentship.	Ammoun S, 2015, MOL ONCOL, V9, P236, DOI 10.1016/j.molonc.2014.08.005; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Ammoun S, 2012, GLIA, V60, P1721, DOI 10.1002/glia.22391; Ammoun S, 2010, NEUROBIOL DIS, V37, P141, DOI 10.1016/j.nbd.2009.09.017; Brennan JA, 2002, J BIOL CHEM, V277, P5369, DOI 10.1074/jbc.M109875200; Canal F, 2011, FASEB J, V25, P2362, DOI 10.1096/fj.10-173153; Dougherty MK, 2009, MOL CELL, V34, P652, DOI 10.1016/j.molcel.2009.06.001; DOWNWARD J, 1995, CELL, V83, P831, DOI 10.1016/0092-8674(95)90198-1; Evans DGR, 2009, ORPHANET J RARE DIS, V4, DOI 10.1186/1750-1172-4-16; Flaiz C, 2007, J NEUROPATH EXP NEUR, V66, P608, DOI 10.1097/nen.0b013e318093e555; Hanemann CO, 2008, BRAIN, V131, P606, DOI 10.1093/brain/awm249; Hanemann CO, 2006, NEUROPATH APPL NEURO, V32, P605, DOI 10.1111/j.1365-2990.2006.00769.x; Hilton DA, 2009, HISTOPATHOLOGY, V55, P744, DOI 10.1111/j.1365-2559.2009.03440.x; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Kortum RL, 2004, MOL CELL BIOL, V24, P4407, DOI 10.1128/MCB.24.10.4407-4416.2004; Li B, 2013, NEOPLASMA, V60, P406, DOI 10.4149/neo_2013_052; Li W, 2014, CANCER CELL, V26, P48, DOI 10.1016/j.ccr.2014.05.001; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Llobet D, 2011, AM J PATHOL, V178, P1529, DOI 10.1016/j.ajpath.2010.12.041; Lozano J, 2003, CANCER RES, V63, P4232; McKay MM, 2010, METHODS MOL BIOL, V661, P323, DOI 10.1007/978-1-60761-795-2_19; McKay MM, 2009, P NATL ACAD SCI USA, V106, P11022, DOI 10.1073/pnas.0901590106; Morrison DK, 2001, J CELL SCI, V114, P1609; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Ory S, 2003, CURR BIOL, V13, P1356, DOI 10.1016/S0960-9822(03)00535-9; Pelton PD, 1998, ONCOGENE, V17, P2195, DOI 10.1038/sj.onc.1202141; Rong R, 2004, P NATL ACAD SCI USA, V101, P18200, DOI 10.1073/pnas.0405971102; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; Stebbing J, 2015, ONCOGENE, V34, P2103, DOI 10.1038/onc.2014.129; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Szatmari E, 2007, J NEUROSCI, V27, P11389, DOI 10.1523/JNEUROSCI.3473-07.2007; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Utermark T, 2003, BRAIN PATHOL, V13, P352; Zhang H, 2013, BRIT J CANCER, V109, P2675, DOI 10.1038/bjc.2013.628; Zhou L, 2012, FEBS LETT, V586, P1403, DOI 10.1016/j.febslet.2012.03.016; Zhou L, 2011, NEOPLASIA, V13, P1101, DOI 10.1593/neo.111060	36	10	10	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 30	2016	35	26					3443	3453		10.1038/onc.2015.404	http://dx.doi.org/10.1038/onc.2015.404			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DQ5UI	26549023	Green Accepted, Green Submitted			2022-12-17	WOS:000379270100009
J	Humtsoe, JO; Pham, E; Louie, RJ; Chan, DA; Kramer, RH				Humtsoe, J. O.; Pham, E.; Louie, R. J.; Chan, D. A.; Kramer, R. H.			ErbB3 upregulation by the HNSCC 3D microenvironment modulates cell survival and growth	ONCOGENE			English	Article							MULTICELLULAR TUMOR SPHEROIDS; HYPOXIA-INDUCIBLE FACTORS; TYROSINE KINASE; CARCINOMA-CELLS; NECK-CANCER; MESENCHYMAL TRANSITION; BREAST-CANCER; EXPRESSION; RECEPTOR; THERAPY	Head and neck squamous carcinomas (HNSCC) present as dense epithelioid three-dimensional (3D) tumor nests that can mediate signals via the human epidermal growth factor receptor (ErbB) tyrosine kinase family to promote intratumoral survival and growth. We examined the role of the tumor microenvironment on ErbB receptor family expression and found that the status of intercellular organization altered the receptor profile. We showed that HNSCC cells forced into tumor island-like 3D aggregates strongly upregulated ErbB3 at the level of transcription. Not only was the elevated ErbB3 responsive to HRG-beta 1-induced enhanced signaling mechanism, but also analysis by siRNA-knockdown and kinase inhibitor strategies revealed that the ErbB3/AKT signaling pathway was sufficient to enhance tumor cell survival and growth potential. Elevated ErbB3 expression in the high-density 3D culture system was strongly associated with hypoxia-induced HIF-1 alpha. Hypoxia-regulated ErbB3 expression was mediated by the HIF-1 alpha-binding consensus sequence in the ErbB3 proximal promoter. The findings show that the local 3D tumor microenvironment can trigger reprograming and switching of ErbB family members and thereby influence ErbB3-driven tumor growth.	[Humtsoe, J. O.; Pham, E.; Kramer, R. H.] Univ Calif San Francisco, Dept Cell & Tissue Biol, 521 Parnassus Ave, San Francisco, CA 94143 USA; [Louie, R. J.; Chan, D. A.] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Kramer, RH (corresponding author), Univ Calif San Francisco, Dept Cell & Tissue Biol, 521 Parnassus Ave, San Francisco, CA 94143 USA.	randall.kramer@ucsf.edu			UCSF REAC Award; Cancer Research Coordinating Committee; National Institutes of Health [R01 DE022565]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE022565] Funding Source: NIH RePORTER	UCSF REAC Award; Cancer Research Coordinating Committee; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Dr Colleen Sweeney (University of California at Davis) for the kind gift of the ErbB3-promoter constructs and Dr Fan Yang (University of California San Francisco) for providing samples of xenograft specimens. This research was supported by grants from UCSF REAC Award (to RHK), Cancer Research Coordinating Committee (to RHK), and National Institutes of Health, R01 DE022565 (to RHK).	Abbott A, 2003, NATURE, V424, P870, DOI 10.1038/424870a; Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780; Agani F, 2013, CURR CANCER DRUG TAR, V13, P245, DOI 10.2174/1568009611313030003; Amin DN, 2012, BIOCHEM J, V447, P417, DOI 10.1042/BJ20120724; Amin DN, 2010, SEMIN CELL DEV BIOL, V21, P944, DOI 10.1016/j.semcdb.2010.08.007; Bates RC, 2000, CRIT REV ONCOL HEMAT, V36, P61, DOI 10.1016/S1040-8428(00)00077-9; Breslin S, 2013, DRUG DISCOV TODAY, V18, P240, DOI 10.1016/j.drudis.2012.10.003; Cavalot A, 2007, HEAD NECK-J SCI SPEC, V29, P655, DOI 10.1002/hed.20574; Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010; Chen QM, 2004, BIOCHEM BIOPH RES CO, V315, P850, DOI 10.1016/j.bbrc.2004.01.143; Ciardiello F, 2003, EUR J CANCER, V39, P1348, DOI 10.1016/S0959-8049(03)00235-1; Cohen RB, 2014, CANCER TREAT REV, V40, P567, DOI 10.1016/j.ctrv.2013.10.002; Del Sordo R, J ORAL PATHOL MED, V39, P79; Dery MAC, 2005, INT J BIOCHEM CELL B, V37, P535, DOI 10.1016/j.biocel.2004.08.012; Dubessy C, 2000, CRIT REV ONCOL HEMAT, V36, P179, DOI 10.1016/S1040-8428(00)00085-8; Friedrich J, 2007, INT J RADIAT BIOL, V83, P849, DOI 10.1080/09553000701727531; Funayama T, 1998, ONCOLOGY-BASEL, V55, P161, DOI 10.1159/000011851; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; He J, 2012, EMBO REP, V13, P1116, DOI 10.1038/embor.2012.162; Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012; Humtsoe JO, 2010, ONCOGENE, V29, P1214, DOI 10.1038/onc.2009.419; Humtsoe JO, 2012, EXP CELL RES, V318, P379, DOI 10.1016/j.yexcr.2011.11.011; Iorio MV, 2009, CANCER RES, V69, P2195, DOI 10.1158/0008-5472.CAN-08-2920; Jain A, 2010, CANCER RES, V70, P1989, DOI 10.1158/0008-5472.CAN-09-3326; Jathal Maitreyee K., 2011, Immunology Endocrine & Metabolic Agents in Medicinal Chemistry, V11, P131; Krig SR, 2010, ONCOGENE, V29, P5500, DOI 10.1038/onc.2010.289; Krig SR, ONCOGENE, V29, P5500; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Luca AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059689; MATSUMOTO K, 1989, J ORAL PATHOL MED, V18, P498, DOI 10.1111/j.1600-0714.1989.tb01350.x; Narayan M, 2009, CANCER RES, V69, P2191, DOI 10.1158/0008-5472.CAN-08-1056; Paatero I, 2014, J BIOL CHEM, V289, P22459, DOI 10.1074/jbc.M113.533497; Page H, 2013, CELL TISSUE RES, V352, P123, DOI 10.1007/s00441-012-1441-5; Perez-Sayans M, 2011, CANCER LETT, V313, P1, DOI 10.1016/j.canlet.2011.08.017; Pickl M, 2009, ONCOGENE, V28, P461, DOI 10.1038/onc.2008.394; Rabinowits G, 2012, ORAL ONCOL, V48, P1085, DOI 10.1016/j.oraloncology.2012.06.016; Rogers SJ, 2005, CANCER METAST REV, V24, P47, DOI 10.1007/s10555-005-5047-1; Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002; Santini MT, 2000, CRIT REV ONCOL HEMAT, V36, P75, DOI 10.1016/S1040-8428(00)00078-0; Sasabe E, 2010, FREE RADICAL BIO MED, V48, P1321, DOI 10.1016/j.freeradbiomed.2010.02.013; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, ONCOGENE, V29, P625; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Shames DS, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056765; Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107; SHINTANI S, 1995, CANCER LETT, V95, P79, DOI 10.1016/0304-3835(95)03866-U; SHWEIKI D, 1995, P NATL ACAD SCI USA, V92, P768, DOI 10.1073/pnas.92.3.768; Sithanandam G, 2008, CANCER GENE THER, V15, P413, DOI 10.1038/cgt.2008.15; Takikita M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-126; Wilson TR, 2011, CANCER CELL, V20, P158, DOI 10.1016/j.ccr.2011.07.011; Xia C, 2007, CANCER RES, V67, P10823, DOI 10.1158/0008-5472.CAN-07-0783; Xia WY, 1997, CLIN CANCER RES, V3, P3; Xia WY, 1999, CLIN CANCER RES, V5, P4164; Zhu CH, 2001, J BIOL CHEM, V276, P14407, DOI 10.1074/jbc.M009708200; Ziober BL, 2001, CRIT REV ORAL BIOL M, V12, P499, DOI 10.1177/10454411010120060401; Zou YF, 2010, J RADIAT RES, V51, P47, DOI 10.1269/jrr.09070; Zuo JH, 2010, MOL CANCER RES, V8, P170, DOI 10.1158/1541-7786.MCR-09-0354	59	10	10	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 24	2016	35	12					1554	1564		10.1038/onc.2015.220	http://dx.doi.org/10.1038/onc.2015.220			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DH8RJ	26073080				2022-12-17	WOS:000373063600008
J	Hawkins, ED; Oliaro, J; Ramsbottom, KM; Newbold, A; Humbert, PO; Johnstone, RW; Russell, SM				Hawkins, E. D.; Oliaro, J.; Ramsbottom, K. M.; Newbold, A.; Humbert, P. O.; Johnstone, R. W.; Russell, S. M.			Scribble acts as an oncogene in E mu-myc-driven lymphoma	ONCOGENE			English	Article							ASYMMETRIC CELL-DIVISION; PROMOTES MAMMARY TUMORIGENESIS; POLARITY PROTEIN SCRIBBLE; TRANSGENIC MICE; SELF-RENEWAL; C-MYC; DROSOPHILA-MELANOGASTER; MOLECULAR-CLONING; BREAST-CANCER; PAR COMPLEX	Scribble complex proteins maintain apicobasal polarity, regulate cell fate determination and function as tumour suppressors in epithelial tissue. Despite evidence that the function of Scribble is maintained in the lymphocyte lineage, we still understand little about its role as a tumour suppressor in haematological malignancies. Using the E mu-myc model of Burkitt's lymphoma we investigated the role of Scribble in lymphomagenesis. We found that contrary to its well-documented tumour suppressor role in epithelial tissue, loss of Scribble expression delayed the expansion of peripheral B cells and delayed the onset of E mu-myc-driven lymphoma. This was despite upregulated ERK phosphorylation levels in Scribble-deficient tumours, which are associated with loss of Scribble expression and the development of more aggressive Burkitt's lymphoma. Interestingly, the developmental stage of lymphoma was unaffected by Scribble expression challenging any role for Scribble in fate determination in the haematopoetic lineage. These data provide evidence for oncogenic properties of Scribble in Myc-driven B-cell lymphomagenesis, reinforcing recent findings that overexpression of a mutant form of Scribble can act as an oncogene in epithelial cells. Our results support the growing appreciation that the tumour regulatory functions of Scribble, and other polarity protein family members, are context dependent.	[Hawkins, E. D.; Oliaro, J.; Ramsbottom, K. M.; Newbold, A.; Johnstone, R. W.; Russell, S. M.] Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic, Australia; [Hawkins, E. D.; Oliaro, J.; Ramsbottom, K. M.; Newbold, A.; Humbert, P. O.; Johnstone, R. W.; Russell, S. M.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Melbourne, Vic, Australia; [Newbold, A.; Johnstone, R. W.] Peter MacCallum Canc Ctr, Canc Therapeut Programs, Melbourne, Vic, Australia; [Humbert, P. O.] Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Melbourne, Vic, Australia; [Humbert, P. O.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia; [Humbert, P. O.] Univ Melbourne, Dept Biochem & Mol Biol, Melbourne, Vic, Australia; [Humbert, P. O.] Peter MacCallum Canc Ctr, Cell Cycle & Canc Genet Lab, Melbourne, Vic, Australia; [Russell, S. M.] Swinburne Univ Technol, Ctr Microphoton, Hawthorn, Vic 3122, Australia; [Hawkins, E. D.] Univ London Imperial Coll Sci Technol & Med, Sir Alexander Fleming Bldg, London SW7 2AZ, England	Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne; University of Melbourne; Peter Maccallum Cancer Center; Swinburne University of Technology; Imperial College London	Hawkins, ED (corresponding author), Univ London Imperial Coll Sci Technol & Med, Cell & Mol Biol, Sir Alexander Fleming Bldg,Imperial Coll Rd, London SW7 2AZ, England.; Russell, SM (corresponding author), Peter MacCallum Canc Ctr, Immune Signalling Lab, Canc Immunol, St Andrews Pl, East Melbourne, Vic 3002, Australia.	e.hawkins@imperial.ac.uk; Sarah.Russell@petermac.org	Russell, Sarah M/B-9341-2009; Johnstone, Ricky w/H-3748-2014; Humbert, Patrick O/L-4264-2016	Russell, Sarah M/0000-0001-5826-9641; Johnstone, Ricky w/0000-0001-7053-9237; Humbert, Patrick O/0000-0002-1366-6691; Oliaro, Jane/0000-0002-2097-6428; Hawkins, Edwin/0000-0002-3686-8261	Australian National Health and Medical Research Council (NHRMC); Human Frontiers Science Program; Australian Research Council (ARC); Australian Cancer Research Foundation (ACRF, ACRF Cell Biology Program)	Australian National Health and Medical Research Council (NHRMC)(National Health and Medical Research Council (NHMRC) of Australia); Human Frontiers Science Program(Human Frontier Science Program); Australian Research Council (ARC)(Australian Research Council); Australian Cancer Research Foundation (ACRF, ACRF Cell Biology Program)	This work was funded by the Australian National Health and Medical Research Council (NHRMC, project grants and fellowships to EDH, JO, SMR, POH, RWJ), the Human Frontiers Science Program, the Australian Research Council (ARC, fellowship to SMR) and the Australian Cancer Research Foundation (ACRF, ACRF Cell Biology Program).	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Albertson R, 2003, NAT CELL BIOL, V5, P166, DOI 10.1038/ncb922; ALEXANDER WS, 1989, ONCOGENE, V4, P575; Anastas JN, 2012, ONCOGENE, V31, P3696, DOI 10.1038/onc.2011.528; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Caussinus E, 2005, NAT GENET, V37, P1125, DOI 10.1038/ng1632; Chang JT, 2007, SCIENCE, V315, P1687, DOI 10.1126/science.1139393; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Dow LE, 2007, ONCOGENE, V26, P2272, DOI 10.1038/sj.onc.1210016; Ellenbroek SIJ, 2012, SEMIN CANCER BIOL, V22, P208, DOI 10.1016/j.semcancer.2012.02.012; Elsum IA, 2013, J CELL SCI, V126, P3990, DOI 10.1242/jcs.129387; Feigin ME, 2014, CANCER RES, V74, P3180, DOI 10.1158/0008-5472.CAN-13-3415; Florian MC, 2010, STEM CELLS, V28, P1623, DOI 10.1002/stem.481; Gardiol D, 2006, INT J CANCER, V119, P1285, DOI 10.1002/ijc.21982; Godde NJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004323; Gramling MW, 2012, CELL DEATH DIFFER, V19, P1220, DOI 10.1038/cdd.2012.1; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; Hawkins ED, 2008, ONCOGENE, V27, P7003, DOI 10.1038/onc.2008.350; Hawkins ED, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087376; Hawkins ED, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2796; Humphries LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045276; Iden S, 2012, CANCER CELL, V22, P389, DOI 10.1016/j.ccr.2012.08.004; Kamei Y, 2007, HUM PATHOL, V38, P1273, DOI 10.1016/j.humpath.2007.01.026; Kelly PN, 2007, BLOOD, V109, P4907, DOI 10.1182/blood-2006-10-051847; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Lee CY, 2006, NATURE, V439, P594, DOI 10.1038/nature04299; Ludford-Menting MJ, 2005, IMMUNITY, V22, P737, DOI 10.1016/j.immuni.2005.04.009; MECHLER BM, 1985, EMBO J, V4, P1551, DOI 10.1002/j.1460-2075.1985.tb03816.x; Montcouquiol M, 2003, NATURE, V423, P173, DOI 10.1038/nature01618; Montcouquiol M, 2006, J NEUROSCI, V26, P5265, DOI 10.1523/JNEUROSCI.4680-05.2006; Murdoch JN, 2003, HUM MOL GENET, V12, P87, DOI 10.1093/hmg/ddg014; Nagasaka K, 2010, ONCOGENE, V29, P5311, DOI 10.1038/onc.2010.265; Oliaro J, 2010, J IMMUNOL, V185, P367, DOI 10.4049/jimmunol.0903627; Pearson HB, 2011, J CLIN INVEST, V121, P4257, DOI 10.1172/JCI58509; Pike KA, 2011, P NATL ACAD SCI USA, V108, P1116, DOI 10.1073/pnas.1018224108; Powell AE, 2010, STEM CELL RES, V4, P3, DOI 10.1016/j.scr.2009.09.005; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Sandoval GJ, 2013, CANCER IMMUNOL RES, V1, P426, DOI 10.1158/2326-6066.CIR-13-0065; Ting SB, 2012, BLOOD, V119, P2510, DOI 10.1182/blood-2011-11-393272; Vaira V, 2012, ONCOGENE, V31, P27, DOI 10.1038/onc.2011.209; Wirtz-Peitz F, 2008, CELL, V135, P161, DOI 10.1016/j.cell.2008.07.049; WOODS DF, 1989, DEV BIOL, V134, P222, DOI 10.1016/0012-1606(89)90092-4; Young LC, 2013, MOL CELL, V52, P679, DOI 10.1016/j.molcel.2013.10.004; Zarbalis K, 2004, PLOS BIOL, V2, P1177, DOI 10.1371/journal.pbio.0020219; Zen K, 2009, ONCOGENE, V28, P2910, DOI 10.1038/onc.2009.148; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045	48	10	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 3	2016	35	9					1193	1197		10.1038/onc.2015.167	http://dx.doi.org/10.1038/onc.2015.167			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	DF4WH	25982280				2022-12-17	WOS:000371351700013
J	Bikkavilli, RK; Avasarala, S; Van Scoyk, M; Arcaroli, J; Brzezinski, C; Zhang, W; Edwards, MG; Rathinam, MKK; Zhou, T; Tauler, J; Borowicz, S; Lussier, YA; Parr, BA; Cool, CD; Winn, RA				Bikkavilli, R. K.; Avasarala, S.; Van Scoyk, M.; Arcaroli, J.; Brzezinski, C.; Zhang, W.; Edwards, M. G.; Rathinam, M. K. K.; Zhou, T.; Tauler, J.; Borowicz, S.; Lussier, Y. A.; Parr, B. A.; Cool, C. D.; Winn, R. A.			Wnt7a is a novel inducer of beta-catenin-independent tumor-suppressive cellular senescence in lung cancer (vol 34, pg 5317, 2015)	ONCOGENE			English	Correction													Lussier, Yves/N-4891-2017	Lussier, Yves/0000-0001-9854-1005				Bikkavilli RK, 2015, ONCOGENE, V34, P5317, DOI 10.1038/onc.2015.2	1	10	12	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 16	2015	34	42					5406	5406		10.1038/onc.2015.165	http://dx.doi.org/10.1038/onc.2015.165			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CU4EI	26473947	Green Published, Bronze			2022-12-17	WOS:000363479200010
J	del Rincon, SV; Widschwendter, M; Sun, D; Ekholm-Reed, S; Tat, J; Teixeira, LK; Ellederova, Z; Grolieres, E; Reed, SI; Spruck, C				del Rincon, S. V.; Widschwendter, M.; Sun, D.; Ekholm-Reed, S.; Tat, J.; Teixeira, L. K.; Ellederova, Z.; Grolieres, E.; Reed, S. I.; Spruck, C.			Cks overexpression enhances chemotherapeutic efficacy by overriding DNA damage checkpoints	ONCOGENE			English	Article							CYCLIN-DEPENDENT KINASE; CELL-CYCLE; UBIQUITIN LIGASE; GENE-EXPRESSION; INDEPENDENT FUNCTION; BLADDER-CANCER; PROGRESSION; P27(KIP1); SKP2; PHOSPHORYLATION	Cdc kinase subunit (Cks) proteins Cks1 and Cks2 are adaptor-like proteins that bind many cyclin-dependent kinases. A wealth of clinical data has shown that Cks proteins are overexpressed in many types of human cancers and this often correlates with increased tumor aggressiveness. Previously, we showed that Cks overexpression abrogates the intra-S-phase checkpoint, a major barrier to oncogene-mediated transformation. Interestingly, the intra-S-phase checkpoint is crucial for the cellular response to replication stress, a major pathway of apoptosis induction by many chemotherapeutic agents. Here, we demonstrate cancer cells that overexpress Cks1 or Cks2 override the intra-S-phase checkpoint in the presence of replication stress-inducing chemotherapies such as 5-Fluorouracil (5-FU) and methotrexate (MTX) leading to enhanced sensitivity in vitro and in vivo. Furthermore, enforced expression of Cks1 in an MTX-resistant breast cancer cell line was found to restore drug sensitivity. Our results suggest that Cks proteins are important determinants of apoptosis induction of replication stress-inducing chemotherapies such as 5-FU.	[del Rincon, S. V.; Sun, D.; Ellederova, Z.; Grolieres, E.; Spruck, C.] Sanford Burnham Med Res Inst, Ctr Canc, Tumor Initiat & Maintenance Program, La Jolla, CA 92037 USA; [Widschwendter, M.] UCL, Dept Gynaecol Oncol, London, England; [Ekholm-Reed, S.; Tat, J.; Teixeira, L. K.; Reed, S. I.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute; University of London; University College London; Scripps Research Institute	Spruck, C (corresponding author), Sanford Burnham Med Res Inst, Ctr Canc, Tumor Initiat & Maintenance Program, 10901 North Torrey Pines Rd, La Jolla, CA 92037 USA.	cspruck@sanfordburnham.org	Teixeira, Leonardo Karam/S-8773-2016	Teixeira, Leonardo Karam/0000-0001-6117-423X; Widschwendter, Martin/0000-0002-7778-8380	American Cancer Society [RSG-06-020-01]; National Institutes of Health [7R01HD049539-05]; Department of Defense Breast Cancer Research Program [W81XWH-06-1-0344]; National Cancer Institute [CA074224]; UCLH/UCL Comprehensive Biomedical Research Centre grant; Department of Health NIHR Biomedical Research Centres funding scheme; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD049539] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA078343, P30CA030199, R01CA074224] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Breast Cancer Research Program(United States Department of Defense); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UCLH/UCL Comprehensive Biomedical Research Centre grant; Department of Health NIHR Biomedical Research Centres funding scheme(National Institute for Health Research (NIHR)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We wish to thank C Torres and Y Altman (Sanford-Burnham Medical Research Institute) for technical assistance with flow cytometry analyses. This work was supported by grants from the American Cancer Society (RSG-06-020-01) and National Institutes of Health (7R01HD049539-05) to CS, Department of Defense Breast Cancer Research Program (W81XWH-06-1-0344) to SVdR, and National Cancer Institute (CA074224) to SIR. Additional support came from a UCLH/UCL Comprehensive Biomedical Research Centre grant and was undertaken at UCLH/UCL, which received a portion of its funding from the Department of Health NIHR Biomedical Research Centres funding scheme.	Bartek J, 2004, NAT REV MOL CELL BIO, V5, P792, DOI 10.1038/nrm1493; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Bhatt KV, 2007, ONCOGENE, V26, P1056, DOI 10.1038/sj.onc.1209861; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Chaves S, 2010, MOL CELL BIOL, V30, P5284, DOI 10.1128/MCB.00952-10; Chen R, 2011, J INT MED RES, V39, P533, DOI 10.1177/147323001103900222; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Inui N, 2003, BIOCHEM BIOPH RES CO, V303, P978, DOI 10.1016/S0006-291X(03)00469-8; Kaiser P, 1999, GENE DEV, V13, P1190, DOI 10.1101/gad.13.9.1190; Kawakami K, 2007, J UROLOGY, V178, P301, DOI 10.1016/j.juro.2007.03.002; Kawakami K, 2006, ONCOL REP, V16, P521; Keller UB, 2007, EMBO J, V26, P2562, DOI 10.1038/sj.emboj.7601691; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; Kunz C, 2009, PLOS BIOL, V7, P967, DOI 10.1371/journal.pbio.1000091; Lee SW, 2013, HEPATO-GASTROENTEROL, V60, P932, DOI 10.5754/hge121214; Li MH, 2004, INT J ONCOL, V24, P305; Liberal V, 2012, P NATL ACAD SCI USA, V109, P2754, DOI 10.1073/pnas.1102434108; Lin HM, 2007, ONCOL REP, V17, P1541; Liu Z, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-51; Martin-Ezquerra G, 2011, HISTOL HISTOPATHOL, V26, P71, DOI 10.14670/HH-26.71; Martinsson-Ahlzen HS, 2008, MOL CELL BIOL, V28, P5698, DOI 10.1128/MCB.01833-07; Masuda T, 2003, CLIN CANCER RES, V9, P5693; Menghi F, 2011, ONCOLOGIST, V16, P1440, DOI 10.1634/theoncologist.2010-0249; Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Patra D, 1999, J BIOL CHEM, V274, P36839, DOI 10.1074/jbc.274.52.36839; Perez-Magan E, 2012, J NEUROPATH EXP NEUR, V71, P882, DOI 10.1097/NEN.0b013e31826bf704; Reynard GJ, 2000, MOL CELL BIOL, V20, P5858, DOI 10.1128/MCB.20.16.5858-5864.2000; Shapira M, 2005, CANCER-AM CANCER SOC, V103, P1336, DOI 10.1002/cncr.20917; Shen DY, 2013, LIVER INT, V33, P137, DOI 10.1111/liv.12014; Slotky M, 2005, BREAST CANCER RES, V7, pR737, DOI 10.1186/bcr1278; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Spruck CH, 2003, SCIENCE, V300, P647, DOI 10.1126/science.1084149; Tanaka F, 2011, INT J ONCOL, V39, P361, DOI 10.3892/ijo.2011.1056; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Wang JJ, 2013, DIS ESOPHAGUS, V26, P729, DOI 10.1111/dote.12013; Wang XC, 2009, BIOCHEM BIOPH RES CO, V379, P1107, DOI 10.1016/j.bbrc.2009.01.028; Wang XZ, 2009, STUD FUZZ SOFT COMP, V245, P1; Wiese AH, 2007, CANCER DETECT PREV, V31, P282, DOI 10.1016/j.cdp.2007.07.003; Yamamoto S, 2010, HISTOPATHOLOGY, V56, P740, DOI 10.1111/j.1365-2559.2010.03551.x; Yu VPCC, 2005, MOL CELL, V17, P145, DOI 10.1016/j.molcel.2004.11.020	43	10	10	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 9	2015	34	15					1961	1967		10.1038/onc.2014.137	http://dx.doi.org/10.1038/onc.2014.137			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CF7GY	24858038	Green Accepted			2022-12-17	WOS:000352725600010
J	AbuAli, G; Chaisaklert, W; Stelloo, E; Pazarentzos, E; Hwang, MS; Qize, D; Harding, SV; Al-Rubaish, A; Alzahrani, A; Al-Ali, A; Sanders, TAB; Aboagye, EO; Grimm, S				AbuAli, G.; Chaisaklert, W.; Stelloo, E.; Pazarentzos, E.; Hwang, M-S; Qize, D.; Harding, S. V.; Al-Rubaish, A.; Alzahrani, Aj; Al-Ali, A.; Sanders, T. A. B.; Aboagye, E. O.; Grimm, S.			The anticancer gene ORCTL3 targets stearoyl-CoA desaturase-1 for tumour-specific apoptosis	ONCOGENE			English	Article							CANCER-CELL METABOLISM; PROTEIN; DEATH; MEMBRANE; OBESITY; IDENTIFICATION; TRANSFORMATION; PROLIFERATION; METASTASIS; ADHESION	ORCTL3 is a member of a group of genes, the so-called anticancer genes, that cause tumour-specific cell death. We show that this activity is triggered in isogenic renal cells upon their transformation independently of the cells' proliferation status. For its cell death effect ORCTL3 targets the enzyme stearoyl-CoA desaturase-1 (SCD1) in fatty acid metabolism. This is caused by transmembrane domains 3 and 4, which are more efficacious in vitro than a low molecular weight drug against SCD1, and critically depend on their expression level. SCD1 is found upregulated upon renal cell transformation indicating that its activity, while not impacting proliferation, represents a critical bottleneck for tumourigenesis. An adenovirus expressing ORCTL3 leads to growth inhibition of renal tumours in vivo and to substantial destruction of patients' kidney tumour cells ex vivo. Our results indicate fatty acid metabolism as a target for tumour-specific apoptosis in renal tumours and suggest ORCTL3 as a means to accomplish this.	[AbuAli, G.; Chaisaklert, W.; Stelloo, E.; Pazarentzos, E.; Hwang, M-S; Qize, D.; Grimm, S.] Univ London Imperial Coll Sci Technol & Med, Div Expt Med, London W12 0NN, England; [Harding, S. V.; Sanders, T. A. B.] Kings Coll London, Diabet & Nutr Sci Div, London, England; [Al-Rubaish, A.; Alzahrani, Aj; Al-Ali, A.] Univ Dammam, Coll Med, Prince Mohammed Ctr Res & Consultat Studies, Dammam, Saudi Arabia; [Aboagye, E. O.] Univ London Imperial Coll Sci Technol & Med, Div Canc, London W12 0NN, England	Imperial College London; University of London; King's College London; Imam Abdulrahman Bin Faisal University; Imperial College London	Grimm, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Pharmacol & Therapeut, Du Cane Rd, London W12 0NN, England.	s.grimm@imperial.ac.uk	Harding, Scott/K-9005-2012	Harding, Scott/0000-0002-7728-2339; Sanders, Thomas/0000-0001-9529-095X; Pazarentzos, Evangelos/0000-0002-5453-1646; Al-Rubaish, Abdullah Mohammed/0000-0002-9136-2853; ABOAGYE, Eric/0000-0003-2276-6771	Ministry of Higher Education in Saudi Arabia; Cancer Research UK; Development and Promotion of Science and Technology Talents Project (DPST), Royal Thai Government, Thailand; AstraZeneca Ltd.; National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London; MRC [MR/J007986/1] Funding Source: UKRI; Cancer Research UK [12011, 10337, 16584] Funding Source: researchfish; Medical Research Council [MR/J007986/1] Funding Source: researchfish; National Institute for Health Research [NIHR/CS/009/009] Funding Source: researchfish	Ministry of Higher Education in Saudi Arabia; Cancer Research UK(Cancer Research UK); Development and Promotion of Science and Technology Talents Project (DPST), Royal Thai Government, Thailand; AstraZeneca Ltd.(AstraZeneca); National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Institute for Health Research(National Institute for Health Research (NIHR))	GA was supported by the Ministry of Higher Education in Saudi Arabia. EP was supported by the Cancer Research UK, WC by the Development and Promotion of Science and Technology Talents Project (DPST), Royal Thai Government, Thailand and MSH by a stipend from AstraZeneca Ltd. We thank Joel Abraham for in vivo work and the Imperial's tissue bank, Dr David Hrouda, Ms Taneisha McFarlane, and Prof Gerry Thomas, for help. Tissue samples were provided by the Imperial College Healthcare NHS Trust Tissue Bank. Other investigators may have received samples from these same tissues. The research was supported by the National Institute for Health Research (NIHR) Biomedical Research Centre based at Imperial College Healthcare NHS Trust and Imperial College London. The views expressed are those of the author (s) and not necessarily those of the NHS, the NIHR or the Department of Health. We thank Mr Robert Gray for lipid extraction and primary GC analysis.	Brown JM, 2010, CURR OPIN LIPIDOL, V21, P192, DOI 10.1097/MOL.0b013e32833854ac; Burikhanov R, 2009, CELL, V138, P377, DOI 10.1016/j.cell.2009.05.022; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Ceschi M, 2007, SWISS MED WKLY, V137, P50; Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; DanenVanOorschot AAAM, 1997, P NATL ACAD SCI USA, V94, P5843; FUJITA J, 1988, CANCER RES, V48, P5251; Funaki NO, 2001, ONCOL REP, V8, P527; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gong ZH, 2007, CANCER-AM CANCER SOC, V109, P1192, DOI 10.1002/cncr.22534; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Grimm S, 2010, TRENDS MOL MED, V16, P88, DOI 10.1016/j.molmed.2009.12.002; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Igal RA, 2010, CARCINOGENESIS, V31, P1509, DOI 10.1093/carcin/bgq131; Irshad S, 2009, CELL DEATH DIFFER, V16, P890, DOI 10.1038/cdd.2009.21; Iwasawa R, 2011, EMBO J, V30, P556, DOI 10.1038/emboj.2010.346; JENSEN FC, 1964, P NATL ACAD SCI USA, V52, P53, DOI 10.1073/pnas.52.1.53; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; LEPAGE G, 1986, J LIPID RES, V27, P114; Linehan WM, 2011, CANC PRINCIPLES PRAC, P1161; Mahul-Mellier AL, 2012, CELL DEATH DIFFER, V19, P891, DOI 10.1038/cdd.2011.185; Meter Van, 2011, CELL CYCLE, V10, P3153; Minville-Walz M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014363; Morgan-Lappe SE, 2007, CANCER RES, V67, P4390, DOI 10.1158/0008-5472.CAN-06-4132; Muthana M, 2013, CANCER RES, V73, P490, DOI 10.1158/0008-5472.CAN-12-3056; Nalca A, 1999, J BIOL CHEM, V274, P29976, DOI 10.1074/jbc.274.42.29976; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Nevels Michael, 2007, Methods Mol Med, V131, P187; Noon AP, 2010, CANCER-AM CANCER SOC, V116, P780, DOI 10.1002/cncr.24841; Rohn JL, 2002, J BIOL CHEM, V277, P50820, DOI 10.1074/jbc.M208557200; Singer EA, 2011, CURR OPIN ONCOL, V23, P283, DOI 10.1097/CCO.0b013e32834479c0; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Valente MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019337; WESSELS HP, 1988, CELL, V55, P61, DOI 10.1016/0092-8674(88)90009-8; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Zeisig R, 2007, ARCH BIOCHEM BIOPHYS, V459, P98, DOI 10.1016/j.abb.2006.09.030	38	10	10	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 26	2015	34	13					1718	1728		10.1038/onc.2014.93	http://dx.doi.org/10.1038/onc.2014.93			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CE5CS	24769897	Green Accepted			2022-12-17	WOS:000351848400012
J	Bunda, S; Qin, K; Kommaraju, K; Heir, P; Ohh, M				Bunda, S.; Qin, K.; Kommaraju, K.; Heir, P.; Ohh, M.			Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway	ONCOGENE			English	Article						apoptosis; Cbl; chemoresistance; juvenile myelomonocytic leukaemia; Lyn; PI3K	C-CBL; MYELODYSPLASTIC SYNDROME; IN-VIVO; SRC; ACTIVATION; HYPERSENSITIVITY; CELLS; RAS; UBIQUITINATION; CHEMOTHERAPY	Juvenile myelomonocytic leukaemia (JMML) is an aggressive myeloproliferative neoplasm in children characterized by granulocyte macrophage colony-stimulating factor (GM-CSF) hypersensitivity and resistance to chemotherapy. We recently identified c-Cbl (henceforth referred to as Cbl) as a GM-CSF receptor (GMR) responsive protein that targets Src for ubiquitin-mediated destruction upon GM-CSF stimulation and showed that a loss of negative regulation of Src is pivotal in the hyperactivation of GMR signalling in JMML cells. However, the mechanism regulating the chemoresistant nature of JMML has remained largely unknown. Here, we show that the JMML-associated Cbl mutant in complex with the Src family kinase Lyn promotes Cbl's adapter function, leading to increased association to PI3K regulatory subunit p85 and Lyn-dependent AKT pro-survival signalling. Notably, molecular or pharmacologic inhibition of the Lyn-PI3K/AKT pathway, but not the Ras/mitogen-activated protein kinase signalling axis, markedly increased the sensitivity of the otherwise chemoresistant Cbl mutant-JMML cells to chemotherapeutic agents currently used in the treatment of JMML patients. These results support the potential translational benefit of combining modalities that inhibit Lyn-PI3K/AKT signalling with traditional antileukaemia agents in the management of JMML.	[Bunda, S.; Qin, K.; Kommaraju, K.; Heir, P.; Ohh, M.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada	University of Toronto	Ohh, M (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	michael.ohh@utoronto.ca			Canadian Institutes of Health Research [MOP119356]; Cancer Research Society; CIHR; Kidney Cancer Foundation fellowship award	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society; CIHR(Canadian Institutes of Health Research (CIHR)); Kidney Cancer Foundation fellowship award	We thank Dr Tim Hercus for helpful discussions and for providing GMR reagents. We thank Stephanie Sybingco for the generation of shCbl and shLyn stable cell lines. This work was supported by grants from the Canadian Institutes of Health Research (MOP119356) and the Cancer Research Society. SB is a recipient of the CIHR and Kidney Cancer Foundation fellowship award.	Aplenc R, 2011, J CLIN ONCOL, V29, P839, DOI 10.1200/JCO.2010.30.7231; Balasis ME, 2011, CLIN CANCER RES, V17, P2852, DOI 10.1158/1078-0432.CCR-10-2544; Beckwith M, 1996, BLOOD, V88, P3502, DOI 10.1182/blood.V88.9.3502.bloodjournal8893502; Bergstraesser E, 2007, PEDIATR BLOOD CANCER, V49, P629, DOI 10.1002/pbc.21038; Bunda S, 2013, CANCER RES, V73, P2540, DOI 10.1158/0008-5472.CAN-12-3425; CASTLEBERRY RP, 1994, NEW ENGL J MED, V331, P1680, DOI 10.1056/NEJM199412223312503; CHAN HSL, 1987, J CLIN ONCOL, V5, P1960, DOI 10.1200/JCO.1987.5.12.1960; Chan RJ, 2005, BLOOD, V105, P3737, DOI 10.1182/blood-2004-10-4002; de Vries ACH, 2010, HAEMATOL-HEMATOL J, V95, P179, DOI 10.3324/haematol.2009.016865; Demetri GD, 2009, CLIN CANCER RES, V15, P6232, DOI 10.1158/1078-0432.CCR-09-0224; DombroskyFerlan PM, 1997, ONCOGENE, V14, P2019, DOI 10.1038/sj.onc.1201031; Duan L, 2004, IMMUNITY, V21, P7, DOI 10.1016/j.immuni.2004.06.012; EMANUEL PD, 1991, BLOOD, V77, P925; Emanuel PD, 2008, ACTA HAEMATOL-BASEL, V119, P207, DOI 10.1159/000140632; Flotho C, 2007, CURR DRUG TARGETS, V8, P715, DOI 10.2174/138945007780830773; Guthridge MA, 2004, BLOOD, V103, P820, DOI 10.1182/blood-2003-06-1999; Hasle H, 1996, LEUKEMIA, V10, P1269; Hasle H, 2007, CURR OPIN PEDIATR, V19, P1, DOI 10.1097/MOP.0b013e3280128ce8; Kang HJ, 2004, LEUKEMIA RES, V28, P167, DOI 10.1016/S0145-2126(03)00217-0; Lancet JE, 2011, CLIN CANCER RES, V17, P1140, DOI 10.1158/1078-0432.CCR-10-1878; Le DT, 2004, BLOOD, V103, P4243, DOI 10.1182/blood-2003-08-2650; Lee JH, 2011, J IMMUNOL, V187, P1807, DOI 10.4049/jimmunol.1100296; Loh ML, 2010, HEMATOL-AM SOC HEMAT, P357, DOI 10.1182/asheducation-2010.1.357; Lyubynska N, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001069; Mak AB, 2012, METHODS, V57, P409, DOI 10.1016/j.ymeth.2012.06.005; Niemeyer CM, 2010, NAT GENET, V42, P794, DOI 10.1038/ng.641; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Perugini M, 2010, BLOOD, V115, P3346, DOI 10.1182/blood-2009-08-235846; Sanada M, 2009, NATURE, V460, P904, DOI 10.1038/nature08240; Song JJ, 2010, CELL SIGNAL, V22, P377, DOI 10.1016/j.cellsig.2009.10.007; Stokoe D, 1997, EMBO J, V16, P2384, DOI 10.1093/emboj/16.9.2384; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Woods WG, 2002, J CLIN ONCOL, V20, P434, DOI 10.1200/JCO.20.2.434; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Zhou ZR, 2008, PROTEIN SCI, V17, P1805, DOI 10.1110/ps.036384.108	35	10	11	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					789	797		10.1038/onc.2013.596	http://dx.doi.org/10.1038/onc.2013.596			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24469048	Bronze			2022-12-17	WOS:000348853800012
J	Yeung, F; Ramsey, CS; Popko-Scibor, AE; Allison, DF; Gray, LG; Shin, M; Kumar, M; Li, D; McCubrey, JA; Mayo, MW				Yeung, F.; Ramsey, C. S.; Popko-Scibor, A. E.; Allison, D. F.; Gray, L. G.; Shin, M.; Kumar, M.; Li, D.; McCubrey, J. A.; Mayo, M. W.			Regulation of the mitogen-activated protein kinase kinase (MEK)-1 by NAD(+)-dependent deacetylases	ONCOGENE			English	Article							HIGH EXPRESSION; CANCER; SIRT1; TRANSCRIPTION; TUMORIGENESIS; METABOLISM; PROGNOSIS; SIRTUINS; SIGNAL; CELLS	Sirtuins are class III deacetylases that regulate many essential processes, including cellular stress, genome stability and metabolism. Although these NAD(+)-dependent deacetylases control adaptive cellular responses, identification of sirtuin-regulated signaling targets remain under-studied. Here, we demonstrate that acetylation of the mitogen-activated protein kinase kinase-1 (MEK1) stimulates its kinase activity, and that acetylated MEK1 is under the regulatory control of the sirtuin family members SIRT1 and SIRT2. Treatment of cells with sirtuin inhibitors, or siRNA knockdown of SIRT1 or SIRT2 proteins, increases MEK1 acetylation and subsequent phosphorylation of the extracellular signal-regulated kinase. Generation of an acetyl-specific MEK1 antibody demonstrates that endogenous acetylated MEK1 is extensively enriched in the nucleus following epidermal growth factor stimulation. An acetyl-mimic of MEK1 increases inappropriate growth properties, suggesting that acetylation of MEK1 has oncogenic potential.	[Yeung, F.; Ramsey, C. S.; Popko-Scibor, A. E.; Allison, D. F.; Gray, L. G.; Shin, M.; Kumar, M.; Li, D.; Mayo, M. W.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [McCubrey, J. A.] E Carolina Univ, Dept Microbiol & Immunol, Greenville, NC USA	University of Virginia; University of North Carolina; East Carolina University	Mayo, MW (corresponding author), Univ Virginia, Dept Biochem & Mol Genet, Box 800733, Charlottesville, VA 22908 USA.	mwm3y@virginia.edu		McCubrey, James/0000-0001-6027-3156	National Cancer Institute [CA132580, CA104397];  [CA110552]; NATIONAL CANCER INSTITUTE [R01CA132580, R01CA104397, F32CA110552, T32CA009156] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs JS Smith, PT Stukenberg, JJ Wamsley and Ms A Sherman for scientific and editorial review. HA-MEK1, HA-MEK1(S218/222D) and Flag-ERK1 were gifts from Dr M Weber, University of Virginia. p300 was provided by Dr D Livingston, Dana-Farber Cancer Institute. Gal4-ELK1 was a gift from Dr C Der, University of North Carolina. V5-SIRT1 and Flag-SIRT2 were gifts from E Verdin, Gladstone Institute. The pBabe-puro vector was provided by Dr Robert Weinberg, Whitehead Institute, MIT. Work was supported by the National Cancer Institute (CA132580 and CA104397) to MWM, and CA110552 awarded to FY.	Allison DF, 2012, P NATL ACAD SCI USA, V109, P16888, DOI 10.1073/pnas.1208468109; Bajpe PK, 2015, ONCOGENE, V34, P531, DOI 10.1038/onc.2013.588; Blalock WL, 2000, ONCOGENE, V19, P526, DOI 10.1038/sj.onc.1203337; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Catalanotti F, 2009, NAT STRUCT MOL BIOL, V16, P294, DOI 10.1038/nsmb.1564; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; Duffy A, 2009, TARGET ONCOL, V4, P267, DOI 10.1007/s11523-009-0125-x; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Haigis MC, 2010, ANNU REV PATHOL-MECH, V5, P253, DOI 10.1146/annurev.pathol.4.110807.092250; Huang PY, 2010, PROTEIN CELL, V1, P218, DOI 10.1007/s13238-010-0019-9; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Keshet Y, 2010, METHODS MOL BIOL, V661, P3, DOI 10.1007/978-1-60761-795-2_1; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kyriakis JM, 2012, PHYSIOL REV, V92, P689, DOI 10.1152/physrev.00028.2011; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lawrence MC, 2008, P NATL ACAD SCI USA, V105, P13315, DOI 10.1073/pnas.0806465105; Li M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-5; Park ER, 2007, CELL SIGNAL, V19, P1488, DOI 10.1016/j.cellsig.2007.01.018; RESING KA, 1995, BIOCHEMISTRY-US, V34, P2610, DOI 10.1021/bi00008a027; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Verdin E, 2010, TRENDS BIOCHEM SCI, V35, P669, DOI 10.1016/j.tibs.2010.07.003; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Xiao XS, 2011, CHINESE J CANCER RES, V23, P201, DOI 10.1007/s11670-011-0201-5; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	26	10	10	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 5	2015	34	6					798	804		10.1038/onc.2014.39	http://dx.doi.org/10.1038/onc.2014.39			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	CA4DG	24681949	Green Accepted, Green Submitted			2022-12-17	WOS:000348853800013
J	Moy, I; Todorovic, V; Dubash, AD; Coon, JS; Parker, JB; Buranapramest, M; Huang, CC; Zhao, H; Green, KJ; Bulun, SE				Moy, I.; Todorovic, V.; Dubash, A. D.; Coon, J. S.; Parker, J. B.; Buranapramest, M.; Huang, C. C.; Zhao, H.; Green, K. J.; Bulun, S. E.			Estrogen-dependent sushi domain containing 3 regulates cytoskeleton organization and migration in breast cancer cells	ONCOGENE			English	Article						sushi domain containing 3; estrogen receptor; aromatase inhibitors; breast cancer; migration	FOCAL ADHESION KINASE; AROMATASE INHIBITORS; MESENCHYMAL TRANSITION; RHO-GTPASES; RECEPTOR; EXPRESSION; CADHERIN; THERAPY; PREDICTORS; DYNAMICS	Aromatase inhibitors (AIs) are the standard endocrine therapy for postmenopausal breast cancer; however, currently used biomarkers, such as, estrogen receptor-alpha/progesterone receptor (ER alpha/PR), predict only slightly more than half of the potential responders to AI treatment. To identify novel markers of AI responsiveness, a genome-wide microarray analysis was performed using primary breast tumor samples from 50 postmenopausal women who later developed metastatic breast cancer. Sushi domain containing 3 (SUSD3) is a significantly differentially expressed gene, with 3.38-fold higher mRNA levels in AI-responsive breast tumors vs non-responders (P<0.001). SUSD3 was highly expressed in ER alpha-positive breast tumors and treatment with estradiol increased SUSD3 expression in ERa-positive breast cancer cells. Treatment with an antiestrogen or ER alpha knockdown abolished basal and estradiol-dependent SUSD3 expression. Recruitment of ERa upstream of the transcription start site of SUSD3 was demonstrated by chromatin immunoprecipitation-PCR. Flow cytometric analysis of SUSD3-knockdown cells revealed blunted estradiol effects on progression into S and M phases. SUSD3 was localized to the plasma membrane of breast cancer cells. SUSD3 knockdown decreased the appearance of actin-rich protrusions, stress fibers and large basal focal adhesions, while increasing the presence of cortical actin concomitant with a decrease in Rho and focal adhesion kinase activity. SUSD3-deficient cells demonstrated diminished cell spreading, cell-cell adhesion and motility. In conclusion, SUSD3 is a novel promoter of estrogen-dependent cell proliferation and regulator of cell-cell and cell-substrate interactions and migration in breast cancer. It may serve as a novel predictor of response to endocrine therapy and potential therapeutic target.	[Moy, I.; Coon, J. S.; Parker, J. B.; Buranapramest, M.; Zhao, H.; Bulun, S. E.] Northwestern Univ, Dept Obstet & Gynecol, Div Reprod Biol, Feinberg Sch Med, Chicago, IL 60610 USA; [Todorovic, V.; Dubash, A. D.; Green, K. J.] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60610 USA; [Huang, C. C.] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60610 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Bulun, SE (corresponding author), Northwestern Univ, Dept Obstet & Gynecol, Div Reprod Biol, 303 East Super,Suite 4-123, Chicago, IL 60610 USA.	s-bulun@northwestern.edu		Zhao, Hong/0000-0003-4616-3123	AVON Foundation; Northwestern Memorial Foundation Dixon Priority Initiative Grant; National Cancer Institute [CA122151]; NCI CCSG [P30 CA060553]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD038691] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA070085, P30CA060553, R01CA122151, R01CA067167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169] Funding Source: NIH RePORTER	AVON Foundation; Northwestern Memorial Foundation Dixon Priority Initiative Grant; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI CCSG; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by grants from the AVON Foundation (to SEB), a Northwestern Memorial Foundation Dixon Priority Initiative Grant (SEB) and National Cancer Institute (CA122151, to KJG). The imaging work performed at Northwestern University Cell Imaging Facility was supported by NCI CCSG P30 CA060553 awarded to the Robert H Lurie Comprehensive Cancer Center. We thank Satya Khuon for her assistance in our confocal work. We thank Mitch Dowsett, Helen Cotterill, Roger A'Hern, Ben Haynes and Ian Smith from the Royal Marsden Hospital in London, England, for making the patient samples available.	Abba MC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-37; Ahn RW, 2010, CLIN CANCER RES, V16, P3607, DOI 10.1158/1078-0432.CCR-10-0068; Anderson H, 2011, ANN ONCOL, V22, P1770, DOI 10.1093/annonc/mdq700; Anderson H, 2007, J STEROID BIOCHEM, V106, P49, DOI 10.1016/j.jsbmb.2007.05.024; Anderson WF, 2002, BREAST CANCER RES TR, V76, P27, DOI 10.1023/A:1020299707510; Apweiler R, 2011, NUCLEIC ACIDS RES, V39, pD214, DOI 10.1093/nar/gkq1020; Bernhard J, 1999, J CLIN ONCOL, V17, P1672, DOI 10.1200/JCO.1999.17.6.1672; Burbelo P, 2004, BREAST CANCER RES TR, V84, P43, DOI 10.1023/B:BREA.0000018422.02237.f9; Burstein HJ, 2010, J CLIN ONCOL, V28, P3784, DOI 10.1200/JOP.000082; Butt AJ, 2005, ENDOCR-RELAT CANCER, V12, pS47, DOI 10.1677/erc.1.00993; Chakravarty D, 2010, CANCER RES, V70, P4092, DOI 10.1158/0008-5472.CAN-09-3834; Chan KT, 2009, J CELL BIOL, V185, P357, DOI 10.1083/jcb.200809110; Cheng YH, 2011, J MOL ENDOCRINOL, V46, P139, DOI 10.1530/JME-10-0064; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; Chumsri S, 2011, J STEROID BIOCHEM, V125, P13, DOI 10.1016/j.jsbmb.2011.02.001; Coombes RC, 2007, LANCET, V369, P559, DOI 10.1016/S0140-6736(07)60200-1; Deramaudt TB, 2011, MOL BIOL CELL, V22, P964, DOI 10.1091/mbc.E10-08-0725; Eiermann W, 2001, ANN ONCOL, V12, P1527, DOI 10.1023/A:1013128213451; Galanina N, 2011, CANCER J, V17, P96, DOI 10.1097/PPO.0b013e318212dee3; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; Hajra KM, 2002, GENE CHROMOSOME CANC, V34, P255, DOI 10.1002/gcc.10083; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hudson TY, 2004, METHOD CELL BIOL, V78, P757; Jacobberger JW, 2000, IMMUNOPHENOTYPING, P361; Juan G, 2004, CURR PROTOC CYTOMETR; Kim JB, 2000, J CELL BIOL, V151, P1193, DOI 10.1083/jcb.151.6.1193; Kim JM, 2006, DNA RES, V13, P275, DOI 10.1093/dnares/dsl016; KNIGHT WA, 1980, CLIN ENDOCRINOL META, V9, P361, DOI 10.1016/S0300-595X(80)80038-7; Lee TI, 2006, NAT PROTOC, V1, P729, DOI 10.1038/nprot.2006.98; Li Y, 2010, ENDOCRINOLOGY, V151, P5146, DOI 10.1210/en.2009-1506; Lin Z, 2010, ONCOGENE, V29, P1114, DOI 10.1038/onc.2009.409; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Makrilia N, 2009, CANCER INVEST, V27, P1023, DOI 10.3109/07357900902769749; Miller WR, 2006, MATURITAS, V54, P335, DOI 10.1016/j.maturitas.2006.04.020; Miller WR, 2010, EXPERT OPIN PHARMACO, V11, P1873, DOI 10.1517/14656566.2010.487863; Moy I, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077543; Parker JB, 2012, MOL CELL BIOL, V32, P1654, DOI 10.1128/MCB.06033-11; Parris TZ, 2010, CLIN CANCER RES, V16, P3860, DOI 10.1158/1078-0432.CCR-10-0889; Provenzano PP, 2009, CELL ADHES MIGR, V3, P347, DOI 10.4161/cam.3.4.9458; Sanchez AM, 2010, MOL ENDOCRINOL, V24, P2114, DOI 10.1210/me.2010-0252; Schug J, 2008, CURR PROTOC BIOINFOR; Sieg DJ, 1999, J CELL SCI, V112, P2677; Smith IE, 2006, J CLIN ONCOL, V24, P2444, DOI 10.1200/JCO.2005.05.3694; Smith IE, 2005, J CLIN ONCOL, V23, P5108, DOI 10.1200/JCO.2005.04.005; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Spiering D, 2011, CELL ADHES MIGR, V5, P170, DOI 10.4161/cam.5.2.14403; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; Stuart-Harris R, 2009, BREAST, V18, P351, DOI 10.1016/j.breast.2009.09.002; Tang Y, 2008, FRONT BIOSCI-LANDMRK, V13, P759, DOI 10.2741/2718; Thurlimann B, 2005, NEW ENGL J MED, V353, P2747; Tilghman RW, 2005, J CELL SCI, V118, P2613, DOI 10.1242/jcs.02380; Tomar A, 2009, CURR OPIN CELL BIOL, V21, P676, DOI 10.1016/j.ceb.2009.05.006; Watson AP, 2013, MOL CANCER RES, V11, P74, DOI 10.1158/1541-7786.MCR-12-0501-T; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Weigel MT, 2010, ENDOCR-RELAT CANCER, V17, pR245, DOI 10.1677/ERC-10-0136; Williams N, 2008, LANCET ONCOL, V9, P45, DOI 10.1016/S1470-2045(07)70385-6	56	10	11	0	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 15	2015	34	3					362	372		10.1038/onc.2013.553	http://dx.doi.org/10.1038/onc.2013.553			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AZ3RY	24413080	Green Accepted			2022-12-17	WOS:000348145500010
J	Haricharan, S; Hein, SM; Dong, J; Toneff, MJ; Aina, OH; Rao, PH; Cardiff, RD; Li, Y				Haricharan, S.; Hein, S. M.; Dong, J.; Toneff, M. J.; Aina, O. H.; Rao, P. H.; Cardiff, R. D.; Li, Y.			Contribution of an alveolar cell of origin to the high-grade malignant phenotype of pregnancy-associated breast cancer	ONCOGENE			English	Article						pregnancy; breast cancer; alveolar cells; PABC	MAMMARY-GLAND DEVELOPMENT; CARCINOMA IN-SITU; PROGENITOR CELLS; STEM-CELLS; COLLAGEN; TARGETS; ADULT; WOMEN; ERBB2; YOUNG	Pregnancy-associated breast cancers (PABCs) are tumors diagnosed during pregnancy or up to 5 years following parturition, and are usually high-grade, connective tissue-rich, and estrogen receptor (ER)/progesterone receptor-negative. Little is known about the cellular origin of PABCs or the mechanisms by which PABCs are initiated. Using the RCAS retrovirus to deliver the ErbB2 oncogene into the mammary epithelium of our previously reported MMTV-tva transgenic mice, we detected high-grade, poorly differentiated, stroma-rich and ER-negative tumors during pregnancy and lactation. These high-grade and stroma-rich tumors were less frequent in involuted mice or in age-matched nulliparous mice. More importantly, by generating a WAP-tva transgenic line for expression of ErbB2 selectively in WAP(+) mammary alveolar cells, we found that tumors had similar morphological phenotypes (high grade, poorly differentiated, stroma-rich and ER-negative), irrespective of the time since pregnancy and even in the absence of pregnancy. These data suggest that PABCs arise preferentially from an alveolar cell population that expands during pregnancy and lactation. This somatic mouse model may also be useful for preclinical testing of new prophylactic and therapeutic strategies against PABC.	[Haricharan, S.; Hein, S. M.; Dong, J.; Toneff, M. J.; Li, Y.] Baylor Coll Med, Lester & Sue Smith Breast Ctr, Houston, TX 77030 USA; [Haricharan, S.; Hein, S. M.; Dong, J.; Toneff, M. J.; Li, Y.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Aina, O. H.; Cardiff, R. D.] Univ Calif Davis, Ctr Comparat Med, Davis, CA 95616 USA; [Rao, P. H.] Baylor Coll Med, Dept Pediat, Hematol Oncol Sect, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California Davis; Baylor College of Medicine	Li, Y (corresponding author), Baylor Coll Med, Lester & Sue Smith Breast Ctr, One Baylor Plaza,N1220, Houston, TX 77030 USA.	liyi@bcm.edu	Li, Yi/A-7635-2009	Li, Yi/0000-0002-9976-518X	NIH [CA124820, U54CA149196]; CDMRP [BC085050, BC073703]; NCI [U01 CA141582]; Nancy Owens Memorial Foundation; Dan L. Duncan Cancer Center [P30CA125123]; Sue & Lester Breast Center [P50-CA058183]; NATIONAL CANCER INSTITUTE [U01CA141582, R01CA124820, U54CA149196, P50CA058183, P30CA125123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [K12GM084897] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); CDMRP(United States Department of Defense); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Nancy Owens Memorial Foundation; Dan L. Duncan Cancer Center; Sue & Lester Breast Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We acknowledge the Varmus Laboratory for the resources in the generation and initial characterization of WAP-tva mice. This work was supported in part by funds from NIH CA124820 (to YL) and U54CA149196 (to YL; PI: Stephan Wong); from CDMRP BC085050 (to YL) and BC073703 (to YL); NCI U01 CA141582 (to RDC); and from the Nancy Owens Memorial Foundation (to YL); as well as by the resources from the Dan L. Duncan Cancer Center (P30CA125123) and the Sue & Lester Breast Center (P50-CA058183).	BARTOW SA, 1987, CANCER, V60, P2751, DOI 10.1002/1097-0142(19871201)60:11<2751::AID-CNCR2820601127>3.0.CO;2-M; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Brisken C, 2002, J MAMMARY GLAND BIOL, V7, P39, DOI 10.1023/A:1015718406329; Bu W, 2011, ONCOGENE, V30, P4399, DOI 10.1038/onc.2011.147; Bu W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078720; Bu W, 2009, J MAMMARY GLAND BIOL, V14, P401, DOI 10.1007/s10911-009-9154-4; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; Cruz GI, 2013, BREAST CANCER RES TR, V137, P237, DOI 10.1007/s10549-012-2313-0; Du ZJ, 2006, P NATL ACAD SCI USA, V103, P17396, DOI 10.1073/pnas.0608607103; Fornetti J, 2012, CELL CYCLE, V11, P639, DOI 10.4161/cc.11.4.19358; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Genin AS, 2012, BREAST, V21, P550, DOI 10.1016/j.breast.2012.05.002; Holland EC, 1998, P NATL ACAD SCI USA, V95, P1218, DOI 10.1073/pnas.95.3.1218; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Keller PJ, 2012, P NATL ACAD SCI USA, V109, P2772, DOI 10.1073/pnas.1017626108; Khaled WT, 2007, DEVELOPMENT, V134, P2739, DOI 10.1242/dev.003194; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Liu XW, 1997, GENE DEV, V11, P179, DOI 10.1101/gad.11.2.179; Lyons TR, 2011, NAT MED, V17, P1109, DOI 10.1038/nm.2416; Lyons TR, 2009, J MAMMARY GLAND BIOL, V14, P87, DOI 10.1007/s10911-009-9119-7; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; Mathelin C, 2008, ANTICANCER RES, V28, P2447; Medina D, 2004, CLIN CANCER RES, V10, p380S, DOI 10.1158/1078-0432.CCR-031211; Middleton LP, 2003, CANCER, V98, P1055, DOI 10.1002/cncr.11614; Molyneux G, 2010, CELL STEM CELL, V7, P403, DOI 10.1016/j.stem.2010.07.010; Murphy CG, 2012, CANCER-AM CANCER SOC, V118, P3254, DOI 10.1002/cncr.26654; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; O'Brien J, 2011, INT J DEV BIOL, V55, P745, DOI 10.1387/ijdb.113379jo; O'Brien J, 2010, AM J PATHOL, V176, P1241, DOI 10.2353/ajpath.2010.090735; Pilewskie M, 2012, ANN SURG ONCOL, V19, P1167, DOI 10.1245/s10434-011-2104-6; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Reddy JP, 2009, J MAMMARY GLAND BIOL, V14, P405, DOI 10.1007/s10911-009-9157-1; ROBINSON GW, 1995, DEVELOPMENT, V121, P2079; Schedin P, 2006, NAT REV CANCER, V6, P281, DOI 10.1038/nrc1839; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Smith GH, 2003, CELL PROLIFERAT, V36, P3, DOI 10.1046/j.1365-2184.36.s.1.2.x; Stensheim H, 2009, J CLIN ONCOL, V27, P45, DOI 10.1200/JCO.2008.17.4110; Toneff MJ, 2010, NEOPLASIA, V12, P718, DOI 10.1593/neo.10516; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Watson CJ, 2008, DEVELOPMENT, V135, P995, DOI 10.1242/dev.005439; Welch HG, 1997, ANN INTERN MED, V127, P1023, DOI 10.7326/0003-4819-127-11-199712010-00014; Yamaji D, 2009, GENE DEV, V23, P2382, DOI 10.1101/gad.1840109	42	10	11	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 11	2014	33	50					5729	5739		10.1038/onc.2013.521	http://dx.doi.org/10.1038/onc.2013.521			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AW2AB	24317513	Green Submitted, Green Accepted			2022-12-17	WOS:000346089300008
J	Yan, BX; Ma, JX; Zhang, J; Guo, Y; Riedel, H; Mueller, MD; Remick, SC; Yu, JJ				Yan, B-x; Ma, J-x; Zhang, J.; Guo, Y.; Riedel, H.; Mueller, M. D.; Remick, S. C.; Yu, J. J.			PSP94 contributes to chemoresistance and its peptide derivative PCK3145 represses tumor growth in ovarian cancer	ONCOGENE			English	Article						PSP94; chemoresistance; PCK3145; signaling pathway; ovarian cancer	PROSTATIC SECRETORY PROTEIN; MESSENGER-RNA LEVELS; STEM-CELLS; DRUG-RESISTANCE; MOLECULAR-MECHANISMS; BREAST-CANCER; LET-7; EXPRESSION; LIN28B; ERCC1	Tumor drug resistance remains a major challenge in the treatment of cancer. Here, we show that Prostatic secretory protein 94 (PSP94) levels are reduced in ovarian cancer patients with high levels of excision repair cross-complementing 1 (ERCC1), a marker for chemoresistance. We find that PSP94 is decreased in an ovarian cancer drug-resistant cell line, and plays an important role in the development of drug resistance in vitro. Our studies indicate that PSP94 can partially reverse drug resistance in mouse tumor models in vivo and that a PSP94 peptide derivative PCK3145 suppresses chemoresistant cancer cell and tumor growth in vitro and in vivo. Our investigation of the involved molecular mechanisms suggests that PSP94 may confer drug resistance by modulating the Lin28b/Let-7 signaling pathway. We introduce PSP94 and its peptide derivative PCK3145 as potential target to reverse chemoresistance in ovarian cancer and have begun to identify their relevant molecular targets in specific signaling pathways.	[Yan, B-x; Ma, J-x; Guo, Y.; Riedel, H.; Mueller, M. D.; Remick, S. C.; Yu, J. J.] W Virginia Univ, Sch Pharm, Dept Biochem, Sch Med,Dept Basic Pharmaceut Sci, Morgantown, WV 26506 USA; [Yan, B-x; Zhang, J.] W Virginia Univ, Mary Babb Randolph Canc Ctr, Robert C Byrd Hlth Sci Ctr, Morgantown, WV 26506 USA; [Ma, J-x] IcesnowYanyan Biosci Assoc, Beijing, Peoples R China; [Zhang, J.] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD USA; [Yan, B-x; Ma, J-x] Beijing Anim Sci Inst, Beijing, Peoples R China	West Virginia University; West Virginia University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Yan, BX (corresponding author), W Virginia Univ, Sch Pharm, Dept Biochem, Sch Med,Dept Basic Pharmaceut Sci, 1 Med Ctr Dr, Morgantown, WV 26506 USA.	bxueyan@hotmail.com			Molecular Medicine Core Facility, Mary Babb Randolph Cancer Center, West Virginia University; Icesnow Yanyan Bioscience Association, Beijing	Molecular Medicine Core Facility, Mary Babb Randolph Cancer Center, West Virginia University; Icesnow Yanyan Bioscience Association, Beijing	We acknowledge the Molecular Medicine Core Facility, Mary Babb Randolph Cancer Center, West Virginia University and Icesnow Yanyan Bioscience Association, Beijing for supporting this study.	ABRAHAMSSON PA, 1990, ANDROLOGIA, V22, P122; Baijal-Gupta M, 2000, J ENDOCRINOL, V165, P425, DOI 10.1677/joe.0.1650425; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bitarte N, 2011, STEM CELLS, V29, P1661, DOI 10.1002/stem.741; Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Chan PSF, 1999, PROSTATE, V41, P99; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Chen TS, 2010, ADV DRUG DELIVER REV, V62, P1257, DOI 10.1016/j.addr.2010.07.008; DABHOLKAR M, 1994, J CLIN INVEST, V94, P703, DOI 10.1172/JCI117388; FUCHTNER C, 1993, GYNECOL ONCOL, V48, P203, DOI 10.1006/gyno.1993.1034; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; Hagan JP, 2009, NAT STRUCT MOL BIOL, V16, P1021, DOI 10.1038/nsmb.1676; Hawkins Robert E, 2005, Clin Prostate Cancer, V4, P91, DOI 10.3816/CGC.2005.n.016; Honma K, 2008, NAT MED, V14, P939, DOI 10.1038/nm.1858; Jeong SH, 2009, EXP MOL MED, V41, P912, DOI 10.3858/emm.2009.41.12.097; Ji JF, 2010, J HEPATOL, V53, P974, DOI 10.1016/j.jhep.2010.07.001; King CE, 2011, ONCOGENE, V30, P4185, DOI 10.1038/onc.2011.131; Lage H, 2008, CELL MOL LIFE SCI, V65, P3145, DOI 10.1007/s00018-008-8111-5; Li QD, 2000, ANTICANCER RES, V20, P645; LILJA H, 1988, PROSTATE, V12, P29, DOI 10.1002/pros.2990120105; Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706; Lv KZ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040008; Olaussen KA, 2007, CURR OPIN PULM MED, V13, P284, DOI 10.1097/MCP.0b013e32816b5c63; Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Piskounova E, 2011, CELL, V147, P1066, DOI 10.1016/j.cell.2011.10.039; Rabik CA, 2007, CANCER TREAT REV, V33, P9, DOI 10.1016/j.ctrv.2006.09.006; Redmond KM, 2008, FRONT BIOSCI-LANDMRK, V13, P5138, DOI 10.2741/3070; Reed E, 2003, CLIN CANCER RES, V9, P5299; Schickel R, 2008, ONCOGENE, V27, P5959, DOI 10.1038/onc.2008.274; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shukeir N, 2004, CANCER RES, V64, P5370, DOI 10.1158/0008-5472.CAN-04-0788; Shukeir N, 2003, CANCER RES, V63, P2072; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; WEIBER H, 1990, AM J PATHOL, V137, P593; Whitaker HC, 2010, PROSTATE, V70, P333, DOI 10.1002/pros.21059; XUAN JW, 1995, ONCOGENE, V11, P1041; Yeung J, 2010, CANCER CELL, V18, P606, DOI 10.1016/j.ccr.2010.10.032; Yi Guo B Y, 2012, AACR AM ASS CANC RES, V53; Yu JJ, 1996, INT J ONCOL, V8, P313	43	10	10	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 6	2014	33	45					5288	5294		10.1038/onc.2013.466	http://dx.doi.org/10.1038/onc.2013.466			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AT7MD	24186202				2022-12-17	WOS:000345120400006
J	Lane, A; Segura-Cabrera, A; Komurov, K				Lane, A.; Segura-Cabrera, A.; Komurov, K.			A comparative survey of functional footprints of EGFR pathway mutations in human cancers	ONCOGENE			English	Article						oncogenic networks; functional footprints; EGFR oncogenes	AKT PHOSPHORYLATION; TARGETING EGFR; GENE; KNOWLEDGEBASE; DATABASE; ENCYCLOPEDIA; INHIBITORS; GEFITINIB; NETWORKS; SURVIVAL	Genes functioning in epidermal growth factor receptor (EGFR) signaling pathways are among the most frequently activated oncogenes in human cancers. We have conducted a comparative analysis of functional footprints (that is, effect on signaling and transcriptional landscapes in cells) associated with oncogenic and tumor suppressor mutations in EGFR pathway genes in human cancers. We have found that mutations in the EGFR pathway differentially have an impact on signaling and metabolic pathways in cancer cells in a mutation- and tissue-selective manner. For example, although signaling and metabolic profiles of breast tumors with PIK3CA or AKT1 mutations are, as expected, highly similar, they display markedly different, sometimes even opposite, profiles to those with ERBB2 or EGFR amplifications. On the other hand, although low-grade gliomas and glioblastomas, both brain cancers, driven by EGFR amplifications are highly functionally similar, their functional footprints are significantly different from lung and breast tumors driven by EGFR or ERBB2. Overall, these observations argue that, contrary to expectations, the mechanisms of tumorigenicity associated with mutations in different genes along the same pathway, or in the same gene across different tissues, may be highly different. We present evidence that oncogenic functional footprints in cancer cell lines have significantly diverged from those in tumor tissues, which potentially explains the discrepancy of our findings with the current knowledge. Nevertheless, our analyses reveal a common inflammatory response signature in EGFR-driven human cancers of different tissue origins. Our results may have implications in the design of therapeutic strategies in cancers driven by these oncogenes.	[Lane, A.; Segura-Cabrera, A.; Komurov, K.] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA; [Komurov, K.] Cincinnati Childrens Hosp Med Ctr, Div Biomed Informat, Cincinnati, OH 45229 USA; [Komurov, K.] Cincinnati Childrens Hosp Med Ctr, Div Human Genet, Cincinnati, OH 45229 USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center	Komurov, K (corresponding author), Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Div Expt Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Kakajan.Komurov@cchmc.org		Segura-Cabrera, Aldo/0000-0003-3044-8028	Marlene-Ride Cincinnati Breast Cancer Foundation; Cincinnati Children's; CONACYT-Mexico from Estancias Posdoctorales al Extranjero [203863]	Marlene-Ride Cincinnati Breast Cancer Foundation; Cincinnati Children's; CONACYT-Mexico from Estancias Posdoctorales al Extranjero	This work was supported in part by Marlene-Ride Cincinnati Breast Cancer Foundation Award and Cincinnati Children's Trustee Award to KK. We thank Biplab DasGupta for helpful discussions of the results. ASG acknowledges CONACYT-Mexico for support from Estancias Posdoctorales al Extranjero (grant number 203863).	Akavia UD, 2010, CELL, V143, P1005, DOI 10.1016/j.cell.2010.11.013; Bader GD, 2001, NUCLEIC ACIDS RES, V29, P242, DOI 10.1093/nar/29.1.242; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Breitkreutz BJ, 2008, NUCLEIC ACIDS RES, V36, pD637, DOI 10.1093/nar/gkm1001; Cerami EG, 2011, NUCLEIC ACIDS RES, V39, pD685, DOI 10.1093/nar/gkq1039; Chen YQ, 2008, NATURE, V452, P429, DOI 10.1038/nature06757; Ciardiello F, 2004, CURR OPIN ONCOL, V16, P130, DOI 10.1097/00001622-200403000-00008; Cresswell P, 2005, IMMUNOL REV, V207, P145, DOI 10.1111/j.0105-2896.2005.00316.x; Dahabreh IJ, 2010, CLIN CANCER RES, V16, P291, DOI 10.1158/1078-0432.CCR-09-1660; De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361; Fukuoka M, 2011, J CLIN ONCOL, V29, P2866, DOI 10.1200/JCO.2010.33.4235; Gallay N, 2009, LEUKEMIA, V23, P1029, DOI 10.1038/leu.2008.395; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gerstein MB, 2012, NATURE, V489, P91, DOI 10.1038/nature11245; Griffith OL, 2008, NUCLEIC ACIDS RES, V36, pD107, DOI 10.1093/nar/gkm967; Hegi ME, 2011, MOL CANCER THER, V10, P1102, DOI 10.1158/1535-7163.MCT-11-0048; Joshi-Tope G, 2005, NUCLEIC ACIDS RES, V33, pD428, DOI 10.1093/nar/gki072; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; Komurov K, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-282; Komurov K, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000889; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260; Maglott D, 2007, NUCLEIC ACIDS RES, V35, pD26, DOI 10.1093/nar/gkl993; Mishra GR, 2006, NUCLEIC ACIDS RES, V34, pD411, DOI 10.1093/nar/gkj141; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Oda K, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100014; Parekh DB, 2000, BIOCHEM J, V352, P425, DOI 10.1042/0264-6021:3520425; Pearson G, 2000, J BIOL CHEM, V275, P37303, DOI 10.1074/jbc.C000570200; Salama AKS, 2013, CLIN CANCER RES, V19, P4326, DOI 10.1158/1078-0432.CCR-13-0779; Saxena R, 2012, MED RES REV, V32, P166, DOI 10.1002/med.20209; Schellenberger J, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-213; Segal E, 2003, NAT GENET, V34, P166, DOI 10.1038/ng1165; Taylor TE, 2012, CURR CANCER DRUG TAR, V12, P197; Troiani T, 2012, CURR DRUG TARGETS, V13, P802, DOI 10.2174/138945012800564158; Uribe P, 2006, J INVEST DERMATOL, V126, P161, DOI 10.1038/sj.jid.5700011; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Vincent EE, 2011, BRIT J CANCER, V104, P1755, DOI 10.1038/bjc.2011.132; Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122; Vyas JM, 2008, NAT REV IMMUNOL, V8, P607, DOI 10.1038/nri2368; Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wishart DS, 2009, NUCLEIC ACIDS RES, V37, pD603, DOI 10.1093/nar/gkn810; Wolpert F, 2012, J NEUROIMMUNOL, V250, P27, DOI 10.1016/j.jneuroim.2012.05.010; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073	45	10	10	0	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 23	2014	33	43					5078	5089		10.1038/onc.2013.452	http://dx.doi.org/10.1038/onc.2013.452			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OF	24166508				2022-12-17	WOS:000343768400003
J	El-Gazzar, A; Cai, X; Reeves, RS; Dai, Z; Caballero-Benitez, A; McDonald, DL; Vazquez, J; Gooley, TA; Sale, GE; Spies, T; Groh, V				El-Gazzar, A.; Cai, X.; Reeves, R. S.; Dai, Z.; Caballero-Benitez, A.; McDonald, D. L.; Vazquez, J.; Gooley, T. A.; Sale, G. E.; Spies, T.; Groh, V.			Effects on tumor development and metastatic dissemination by the NKG2D lymphocyte receptor expressed on cancer cells	ONCOGENE			English	Article						NKG2D receptor; breast cancer; xenotransplant; angiogenesis; metastasis	NK CELLS; T-CELLS; ACTIVATION; LIGANDS; INHIBITION; APOPTOSIS; GROWTH; MICA	The stimulatory NKG2D lymphocyte receptor together with its tumor-associated ligands enable the immune system to recognize and destroy cancer cells. However, with dynamic changes unfolding, cancers exploit NKG2D and its ligands for immune evasion and suppression. Recent findings have added yet another functional dimension, wherein cancer cells themselves co-opt NKG2D for their own benefit to complement the presence of its ligands for self-stimulation of parameters of tumorigenesis. Those findings are here extended to in vivo tumorigenicity testing by employing orthotopic xenotransplant breast cancer models in mice. Using human cancer lines with ectopic NKG2D expression and RNA interference (RNAi)-mediated protein depletion among other controls, we show that NKG2D self-stimulation has tumor-promoting capacity. NKG2D signals had no notable effects on cancer cell proliferation and survival but acted at the level of angiogenesis, thus promoting tumor growth, tumor cell intravasation and dissemination. NKG2D-mediated effects on tumor initiation may represent another factor in the observed overall enhancement of tumor development. Altogether, these results may have an impact on immunotherapy approaches, which currently do not account for such NKG2D effects in cancer patients and thus could be misdirected as underlying assumptions are incomplete.	[El-Gazzar, A.; Cai, X.; Reeves, R. S.; Dai, Z.; Caballero-Benitez, A.; McDonald, D. L.; Vazquez, J.; Gooley, T. A.; Sale, G. E.; Spies, T.; Groh, V.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98112 USA	Fred Hutchinson Cancer Center	Spies, T (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave North, Seattle, WA 98112 USA.	tspies@fhcrc.org		El-Gazzar, Ahmed/0000-0002-2859-7246	Erwin Schrodinger Fellowship from the Austrian Science Fund (FWF) [J3078]; NIH/NCI Pacific Ovarian Cancer Research Consortium (POCRC) SPORE [P50 CA083636]; NIH/NCI [R01 CA174470]; NATIONAL CANCER INSTITUTE [R01CA174470, P50CA083636] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI030581] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056465] Funding Source: NIH RePORTER	Erwin Schrodinger Fellowship from the Austrian Science Fund (FWF); NIH/NCI Pacific Ovarian Cancer Research Consortium (POCRC) SPORE; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Drs Steven Kelly and Sue Knoblaugh and all members of the Comparative Medicine Shared Resource laboratory for their expert veterinarian, pathology and histopathology support; Drs Julie Randolph-Habecker and Peggy Porter for their expert immunohistochemistry and histopathology advice, and all members of the Experimental Histopathology Shared Resource laboratory for their outstanding technical support. AE-G was supported by an Erwin Schrodinger Fellowship from the Austrian Science Fund (FWF; project number J3078). This study was supported by an NIH/NCI Pacific Ovarian Cancer Research Consortium (POCRC) SPORE (P50 CA083636) developmental research program grant (to VG) and NIH/NCI grant R01 CA174470 (to TS).	Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Ben-Batalla I, 2010, J CLIN INVEST, V120, P4289, DOI 10.1172/JCI42015; Benitez AC, 2011, P NATL ACAD SCI USA, V108, P4081, DOI 10.1073/pnas.1018603108; Cho HM, 2010, CANCER RES, V70, P10121, DOI 10.1158/0008-5472.CAN-10-1047; Eagle RA, 2007, NAT REV IMMUNOL, V7, P737, DOI 10.1038/nri2144; Gonzalez S, 2006, CURR TOP MICROBIOL, V298, P121; Groh V, 1999, P NATL ACAD SCI USA, V96, P6879, DOI 10.1073/pnas.96.12.6879; Jiang BH, 2009, ADV CANCER RES, V102, P19, DOI 10.1016/S0065-230X(09)02002-8; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kooijman R, 2006, CYTOKINE GROWTH F R, V17, P305, DOI 10.1016/j.cytogfr.2006.02.002; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; Lehner M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031210; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Nausch N, 2008, ONCOGENE, V27, P5944, DOI 10.1038/onc.2008.272; NOEL A, 1992, BIOCHEM PHARMACOL, V43, P1263, DOI 10.1016/0006-2952(92)90501-9; Raulet DH, 2013, ANNU REV IMMUNOL, V31, P413, DOI 10.1146/annurev-immunol-032712-095951; Song DG, 2013, HUM GENE THER, V24, P295, DOI 10.1089/hum.2012.143; Upshaw JL, 2006, SEMIN IMMUNOL, V18, P167, DOI 10.1016/j.smim.2006.03.001; von Strandmann EP, 2006, BLOOD, V107, P1955, DOI 10.1182/blood-2005-05-2177; Yang J, 2009, P NATL ACAD SCI USA, V106, P3913, DOI 10.1073/pnas.0810617106; Zhang T, 2011, CANCER RES, V71, P2066, DOI 10.1158/0008-5472.CAN-10-3200	21	10	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 9	2014	33	41					4932	4940		10.1038/onc.2013.435	http://dx.doi.org/10.1038/onc.2013.435			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR7OA	24141776	Green Accepted			2022-12-17	WOS:000343767900006
J	Hede, SM; Savov, V; Weishaupt, H; Sangfelt, O; Swartling, FJ				Hede, S-M; Savov, V.; Weishaupt, H.; Sangfelt, O.; Swartling, F. J.			Oncoprotein stabilization in brain tumors	ONCOGENE			English	Review						glioma; medulloblastoma; ubiquitin-proteasome system; brain tumor development; E3 ligases	F-BOX PROTEIN; NF-KAPPA-B; ANAPHASE-PROMOTING COMPLEX; E3 UBIQUITIN LIGASES; SMALL-MOLECULE INHIBITORS; GROWTH-FACTOR-B; C-MYC; BETA-CATENIN; SONIC HEDGEHOG; SIGNALING PATHWAY	Proteins involved in promoting cell proliferation and viability need to be timely expressed and carefully controlled for the proper development of the brain but also efficiently degraded in order to prevent cells from becoming brain cancer cells. A major pathway for targeted protein degradation in cells is the ubiquitin-proteasome system (UPS). Oncoproteins that drive tumor development and tumor maintenance are often deregulated and stabilized in malignant cells. This can occur when oncoproteins escape degradation by the UPS because of mutations in either the oncoprotein itself or in the UPS components responsible for recognition and ubiquitylation of the oncoprotein. As the pathogenic accumulation of an oncoprotein can lead to effectively sustained cell growth, viability and tumor progression, it is an indisputable target for cancer treatment. The most common types of malignant brain tumors in children and adults are medulloblastoma and glioma, respectively. Here, we review different ways of how deregulated proteolysis of oncoproteins involved in major signaling cancer pathways contributes to medulloblastoma and glioma development. We also describe means of targeting relevant oncoproteins in brain tumors with treatments affecting their stability or therapeutic strategies directed against the UPS itself.	[Hede, S-M; Savov, V.; Weishaupt, H.; Swartling, F. J.] Uppsala Univ, Rudbeck Lab, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden; [Sangfelt, O.] Karolinska Inst, Dept Cell & Mol Biol, Stockholm, Sweden	Uppsala University; Karolinska Institutet	Swartling, FJ (corresponding author), Uppsala Univ, Rudbeck Lab, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.	fredrik.swartling@igp.uu.se	Swartling, Fredrik J/B-8170-2014	Swartling, Fredrik J/0000-0002-8460-4367	Swedish Childhood Cancer Foundation; Swedish Cancer Society; Swedish Research Council; Swedish Society of Medicine; Swedish Brain Foundation; Ake Widgers Stiftelse; Ake Olssons Stifelse; Lions Cancerforskningsfond; Stiftelsen Lars Hiertas Minne; Radiumhemmets Forskningsfonder; Karolinska Institute Foundations; Association for International Cancer Research; Worldwide Cancer Research [13-0175] Funding Source: researchfish	Swedish Childhood Cancer Foundation(European Commission); Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Society of Medicine; Swedish Brain Foundation; Ake Widgers Stiftelse; Ake Olssons Stifelse; Lions Cancerforskningsfond; Stiftelsen Lars Hiertas Minne; Radiumhemmets Forskningsfonder; Karolinska Institute Foundations(Karolinska Institutet); Association for International Cancer Research; Worldwide Cancer Research	This work was supported by research from the Swedish Childhood Cancer Foundation (FJS, OS), the Swedish Cancer Society (FJS, OS), the Swedish Research Council (FJS, OS), the Swedish Society of Medicine (FJS), the Swedish Brain Foundation (FJS), Ake Widgers Stiftels (FJS), Ake Olssons Stiftelse (OS), Lions Cancerforskningsfond (FJS), Stiftelsen Lars Hiertas Minne (FJS), Radiumhemmets Forskningsfonder (OS), Karolinska Institute Foundations (OS) and the Association for International Cancer Research (FJS). We apologize to authors not cited due to space restrictions in this review.	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Aldosari N, 2002, ARCH PATHOL LAB MED, V126, P540; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Arabi A, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1975; Ayrault O, 2009, MOL CANCER RES, V7, P33, DOI 10.1158/1541-7786.MCR-08-0369; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Bhatia N, 2006, J BIOL CHEM, V281, P19320, DOI 10.1074/jbc.M513203200; Bjerke L, 2013, CANCER DISCOV, V3, P512, DOI 10.1158/2159-8290.CD-12-0426; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Bredel M, 2005, CANCER RES, V65, P8679, DOI 10.1158/0008-5472.CAN-05-1204; Bredel M, 2011, NEW ENGL J MED, V364, P627, DOI 10.1056/NEJMoa1006312; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Brockmann M, 2013, CANCER CELL, V24, P75, DOI 10.1016/j.ccr.2013.05.005; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Buckley SM, 2012, CELL STEM CELL, V11, P783, DOI 10.1016/j.stem.2012.09.011; Buczkowicz P, 2011, J NEUROPATH EXP NEUR, V70, P430, DOI 10.1097/NEN.0b013e31821b94db; Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cepeda D, 2013, EMBO MOL MED, V5, P1067, DOI 10.1002/emmm.201202341; Chan CH, 2013, CELL, V154, P556, DOI 10.1016/j.cell.2013.06.048; Chang YC, 1998, CELL GROWTH DIFFER, V9, P79; Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009; Chen Q, 2008, BLOOD, V111, P4690, DOI 10.1182/blood-2007-09-112904; Chen ZJJ, 2009, MOL CELL, V33, P275, DOI 10.1016/j.molcel.2009.01.014; Chesler L, 2006, CANCER RES, V66, P8139, DOI 10.1158/0008-5472.CAN-05-2769; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; CHOI OR, 1986, MOL CELL BIOL, V6, P1751, DOI 10.1128/MCB.6.5.1751; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; Clague MJ, 2012, J CELL SCI, V125, P277, DOI 10.1242/jcs.090985; Cohen P, 2010, CELL, V143, P686, DOI 10.1016/j.cell.2010.11.016; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; De Boeck M, 2012, UPSALA J MED SCI, V117, P153, DOI 10.3109/03009734.2012.654858; Di K, 2013, ONCOGENE, V32, P5038, DOI 10.1038/onc.2012.531; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; DRISCOLL J, 1990, J BIOL CHEM, V265, P4789; Eichhorn PJA, 2012, NAT MED, V18, P429, DOI 10.1038/nm.2619; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Fan QW, 2012, METHODS MOL BIOL, V821, P349, DOI 10.1007/978-1-61779-430-8_22; Fan X, 2004, CANCER RES, V64, P7787, DOI 10.1158/0008-5472.CAN-04-1446; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; Fang DY, 2001, NAT IMMUNOL, V2, P870, DOI 10.1038/ni0901-870; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Fouladkou F, 2008, P NATL ACAD SCI USA, V105, P8585, DOI 10.1073/pnas.0803233105; Frange P, 2009, J NEURO-ONCOL, V95, P271, DOI 10.1007/s11060-009-9927-z; Frederick L, 2000, CANCER RES, V60, P1383; Friday BB, 2012, NEURO-ONCOLOGY, V14, P215, DOI 10.1093/neuonc/nor198; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fukushima H, 2012, CELL REP, V1, P434, DOI 10.1016/j.celrep.2012.04.002; Garcia D, 2011, GENE DEV, V25, P1746, DOI 10.1101/gad.16722111; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Gilmore TD, 2006, ONCOGENE, V25, P6680, DOI 10.1038/sj.onc.1209954; Guardavaccaro D, 2004, ONCOGENE, V23, P2037, DOI 10.1038/sj.onc.1207413; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Guo H, 2012, CELL REPORTS, V1, P472, DOI 10.1016/j.celrep.2012.04.008; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Harhaj EW, 2011, CELL RES, V21, P22, DOI 10.1038/cr.2010.166; Hart M, 1999, CURR BIOL, V9, P207, DOI 10.1016/S0960-9822(99)80091-8; Hartman Z, 2013, ONCOGENE, V32, P4169, DOI 10.1038/onc.2012.418; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hede SM, 2009, GLIA, V57, P1143, DOI 10.1002/glia.20837; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hermanson M, 1996, CANCER RES, V56, P164; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hoeck JD, 2010, NAT NEUROSCI, V13, P1365, DOI 10.1038/nn.2644; Hsu JY, 2002, NAT CELL BIOL, V4, P358, DOI 10.1038/ncb785; Huang HT, 2000, AM J PATHOL, V156, P433, DOI 10.1016/S0002-9440(10)64747-5; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; Hussain SF, 2006, NEURO-ONCOLOGY, V8, P261, DOI 10.1215/15228517-2006-008; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146; Jackson EL, 2006, NEURON, V51, P187, DOI 10.1016/j.neuron.2006.06.012; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jandke A, 2011, DEV BIOL, V358, P201, DOI 10.1016/j.ydbio.2011.07.030; Johnsen JI, 2008, ONCOGENE, V27, P2910, DOI 10.1038/sj.onc.1210938; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Jung YS, 2012, FEBS LETT, V586, P1397, DOI 10.1016/j.febslet.2012.03.052; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Katoh M, 2007, CLIN CANCER RES, V13, P4042, DOI 10.1158/1078-0432.CCR-06-2316; Kawauchi D, 2012, CANCER CELL, V21, P168, DOI 10.1016/j.ccr.2011.12.023; Kenney AM, 2004, DEVELOPMENT, V131, P217, DOI 10.1242/dev.00891; Kim HS, 2012, CANCER RES, V72, P6065, DOI 10.1158/0008-5472.CAN-12-2594; Kim J, 2010, P NATL ACAD SCI USA, V107, P13432, DOI 10.1073/pnas.1006822107; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Knoepfler PS, 2002, GENE DEV, V16, P2699, DOI 10.1101/gad.1021202; Koch U, 2013, DEVELOPMENT, V140, P689, DOI 10.1242/dev.080614; Koochekpour S, 1997, CANCER RES, V57, P5391; Kool M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003088; Korshunov A, 2012, ACTA NEUROPATHOL, V123, P515, DOI 10.1007/s00401-011-0918-8; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kuchay S, 2013, NAT CELL BIOL, V15, P472, DOI 10.1038/ncb2731; Kunkele A, 2012, NEURO-ONCOLOGY, V14, P859, DOI 10.1093/neuonc/nos115; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Larsson LG, 2010, EXP CELL RES, V316, P1429, DOI 10.1016/j.yexcr.2010.03.025; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Lee J, 1997, DEVELOPMENT, V124, P2537; Lee JH, 2010, NEUROBIOL DIS, V38, P167, DOI 10.1016/j.nbd.2009.12.022; Lehman NL, 2006, CELL CYCLE, V5, P1569, DOI 10.4161/cc.5.14.2925; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Li W, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001487; Lokker NA, 2002, CANCER RES, V62, P3729; Louvi A, 2006, NAT REV NEUROSCI, V7, P93, DOI 10.1038/nrn1847; Love Ian M, 2012, Genes Cancer, V3, P249, DOI 10.1177/1947601912455198; Maddika S, 2011, NAT CELL BIOL, V13, P728, DOI 10.1038/ncb2240; Mao JH, 2008, SCIENCE, V321, P1499, DOI 10.1126/science.1162981; Margottin-Goguet F, 2003, DEV CELL, V4, P813, DOI 10.1016/S1534-5807(03)00153-9; Marmor MD, 2004, ONCOGENE, V23, P2057, DOI 10.1038/sj.onc.1207390; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; Menn B, 2006, J NEUROSCI, V26, P7907, DOI 10.1523/JNEUROSCI.1299-06.2006; Metzger MB, 2012, J CELL SCI, V125, P531, DOI 10.1242/jcs.091777; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Mosesson Y, 2003, J BIOL CHEM, V278, P21323, DOI 10.1074/jbc.C300096200; Nakajima H, 2008, BIOCHEM BIOPH RES CO, V368, P1007, DOI 10.1016/j.bbrc.2008.01.166; Natarajan S, 2013, CANCER RES, V73, P5381, DOI 10.1158/0008-5472.CAN-13-0033; Northcott PA, 2012, NAT REV CANCER, V12, P818, DOI 10.1038/nrc3410; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, ACTA NEUROPATHOL, V122, P231, DOI 10.1007/s00401-011-0846-7; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Ohshima-Hosoyama S, 2011, J NEURO-ONCOL, V105, P475, DOI 10.1007/s11060-011-0619-0; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Palumbo A, 2011, NEW ENGL J MED, V364, P1046, DOI 10.1056/NEJMra1011442; Peart MJ, 2010, CELL CYCLE, V9, P3956, DOI 10.4161/cc.9.19.13162; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Penas C, 2012, FRONT ONCOL, V1, DOI 10.3389/fonc.2011.00060; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Puram SV, 2011, SEMIN CELL DEV BIOL, V22, P586, DOI 10.1016/j.semcdb.2011.03.006; Reavie L, 2013, CANCER CELL, V23, P362, DOI 10.1016/j.ccr.2013.01.025; Reich M, 2006, NAT GENET, V38, P500, DOI 10.1038/ng0506-500; Roth RB, 2006, NEUROGENETICS, V7, P67, DOI 10.1007/s10048-006-0032-6; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Ruschak AM, 2011, J NATL CANCER I, V103, P1007, DOI 10.1093/jnci/djr160; Saifo MS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-310; Sanchez I, 2001, NEURON, V29, P563, DOI 10.1016/S0896-6273(01)00232-X; Schiffer D, 2002, NEUROSCI LETT, V328, P125, DOI 10.1016/S0304-3940(02)00483-4; Schmidt MHH, 2003, P NATL ACAD SCI USA, V100, P6505, DOI 10.1073/pnas.1031790100; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Skaar JR, 2009, CELL, V137, P1358, DOI 10.1016/j.cell.2009.05.040; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884; Sturm D, 2012, CANCER CELL, V22, P425, DOI 10.1016/j.ccr.2012.08.024; Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003; Swartling FJ, 2013, CANCER METAST REV, V32, P5, DOI 10.1007/s10555-012-9407-3; Swartling FJ, 2012, CANCER CELL, V21, P601, DOI 10.1016/j.ccr.2012.04.012; Swartling FJ, 2012, UPSALA J MED SCI, V117, P122, DOI 10.3109/03009734.2012.658975; Swartling FJ, 2010, GENE DEV, V24, P1059, DOI 10.1101/gad.1907510; Swords RT, 2010, BLOOD, V115, P3796, DOI 10.1182/blood-2009-11-254862; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tan YM, 2008, CANCER LETT, V271, P1, DOI 10.1016/j.canlet.2008.04.036; Teixeira LK, 2013, ANNU REV BIOCHEM, V82, P387, DOI 10.1146/annurev-biochem-060410-105307; Thomas LR, 2011, ADV CANCER RES, V110, P77, DOI 10.1016/B978-0-12-386469-7.00004-9; Thomas WD, 2009, ONCOGENE, V28, P1605, DOI 10.1038/onc.2009.3; Uhrbom L, 1998, CANCER RES, V58, P5275; Valentijn LJ, 2012, P NATL ACAD SCI USA, V109, P19190, DOI 10.1073/pnas.1208215109; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Vlachostergios PJ, 2012, CELL DIV, V7, DOI 10.1186/1747-1028-7-18; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang BW, 2006, P NATL ACAD SCI USA, V103, P33, DOI 10.1073/pnas.0509927103; Wang CB, 2010, DEVELOPMENT, V137, P2001, DOI 10.1242/dev.052126; Wang HM, 2004, LAB INVEST, V84, P941, DOI 10.1038/labinvest.3700123; Wang SI, 1997, CANCER RES, V57, P4183; Wang XJ, 2007, CELL, V128, P129, DOI 10.1016/j.cell.2006.11.039; Wang XJ, 2012, FEBS LETT, V586, P1390, DOI 10.1016/j.febslet.2012.02.049; Wang ZW, 2011, BIOESSAYS, V33, P851, DOI 10.1002/bies.201100101; Weiss WA, 2003, CANCER RES, V63, P1589; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wolff JE, 2012, PEDIATR BLOOD CANCER, V59, P27, DOI 10.1002/pbc.23402; Wu H, 2011, NAT MED, V17, P347, DOI 10.1038/nm.2283; Wu L, 2012, CHEM BIOL, V19, P1515, DOI 10.1016/j.chembiol.2012.09.015; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yokouchi M, 2001, J BIOL CHEM, V276, P35185, DOI 10.1074/jbc.M102219200; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhao XD, 2008, NAT CELL BIOL, V10, P643, DOI 10.1038/ncb1727; Zhao YC, 2012, NEOPLASIA, V14, P360, DOI 10.1593/neo.12532; Zhou L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023936; Zhukova N, 2013, J CLIN ONCOL, V31, P2927, DOI 10.1200/JCO.2012.48.5052; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025; Zurawel RH, 1998, CANCER RES, V58, P896	198	10	10	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 25	2014	33	39					4709	4721		10.1038/onc.2013.445	http://dx.doi.org/10.1038/onc.2013.445			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AR0ED	24166497				2022-12-17	WOS:000343239500001
J	Macdonald, FH; Yao, D; Quinn, JA; Greenhalgh, DA				Macdonald, F. H.; Yao, D.; Quinn, J. A.; Greenhalgh, D. A.			PTEN ablation in Ras(Ha)/Fos skin carcinogenesis invokes p53-dependent p21 to delay conversion while p53-independent p21 limits progression via cyclin D1/E2 inhibition	ONCOGENE			English	Article						epidermis; transgenic; carcinogenesis; ras(Ha); fos; PTEN	UP-REGULATION; DNA-DAMAGE; TUMOR SUPPRESSION; CELL-CYCLE; MALIGNANT CONVERSION; GENE-EXPRESSION; FOS; P53; DIFFERENTIATION; P21(WAF1/CIP1)	To investigate tumour progression mechanism in transgenic mouse skin carcinogenesis, inducible PTEN ablation (Delta 5PTEN(flx)) was targeted to the epidermis of mice expressing activated ras(Ha)/fos oncogenes (HK1.ras and HK1.fos). RU486-treated HK1.ras/fos-Delta 5PTEN(flx) epidermis exhibited significant keratinocyte proliferation resulting in hyperplasia and proliferating cysts. While HK1.ras/fos-Delta 5PTEN(flx) papillomatogenesis was accelerated, malignant conversion was delayed and tumours exhibited well-differentiated squamous cell carcinoma (wdSCC) histotypes, suggesting inhibition of early-stage malignant progression. Immediate elevated p53/p21 expression was observed in HK1.ras/fos-Delta 5PTEN(flx) hyperplasia, cysts and papillomas, and while malignant conversion required p53 loss, elevated p21 expression persisted in most wdSCCs to limit further progression, unless p21 was also lost and wdSCC progressed to more aggressive carcinomas. In contrast, TPA-promoted (that is, c-fos-activated) bi-genic HK1.ras-Delta 5PTEN(flx) cohorts lost p53/p21 expression during early papillomatogenesis and rapidly produced poorly differentiated carcinomas (pdSCCs) with high BrdU-labelling and elevated cyclin D1/E2 expression levels, indicative of a progression mechanism driven by failures in cell-cycle control. Intriguingly, HK1.ras/fos-Delta 5PTEN(flx) wdSCCs did not exhibit similar failures, as western and immunofluorescence analysis found downregulated cyclin E2 whenever p21 persisted; further, while westerns detected elevated cyclin D1, immunofluorescence identified reduced expression in proliferative basal layer nuclei and a redistributed expression profile throughout p21-positive wdSCC keratinocytes. These data demonstrate that rapid early epidermal responses to ras(Ha)/fos/Delta PTEN co-operation involve induction of p53/p21 to alter differentiation and divert excessive proliferation into cyst formation. Further, despite three potent oncogenic insults p53 loss was required for malignant conversion, and following p53 loss persistent, p53-independent p21 expression possessed the potency to limit early-stage malignant progression via cyclin D1/E2 inhibition.	[Macdonald, F. H.; Yao, D.; Quinn, J. A.; Greenhalgh, D. A.] Univ Glasgow, Coll Med Vet & Life Sci, Sch Med Dent & Nursing, Dermatol Sect, Glasgow G11 6NU, Lanark, Scotland	University of Glasgow	Greenhalgh, DA (corresponding author), Univ Glasgow, Coll Med Vet & Life Sci, Sch Med Dent & Nursing, Dermatol Sect, Robertson Bldg Level 6,56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.	david.greenhalgh@glasgow.ac.uk	Quinn, Jean/J-6440-2015	Quinn, Jean/0000-0002-8267-0993; Yao, Denggao/0000-0002-3031-126X	British Skin Foundation from Cancer Research UK [610, 3013, C1361/A2395]; Scott Endowment	British Skin Foundation from Cancer Research UK; Scott Endowment	We would like to thank Professor Hong Wu, Department of Molecular and Medical Pharmacology, UCLA, for the original gift of PTEN mice. Professor Dennis Roop, Center for Regenerative Medicine and Stem Cell Biology, Uiversity of Colorado, for the gift of K14.creP mice. Graham Chadwick for assistance with figure preparation; Dennis Duggan for assistance with animal husbandry and Ms Claire Gilbert for assistance with cyclin immunefluorescence analysis. This work was supported by: British Skin Foundation (Grants 610 & 3013), based on initial funding from Cancer Research UK (grant C1361/A2395) and the Scott Endowment to GU Dermatology.	Akli S, 2004, CANCER RES, V64, P3198, DOI 10.1158/0008-5472.CAN-03-3672; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; Berton TR, 2000, GENESIS, V26, P160, DOI 10.1002/(SICI)1526-968X(200002)26:2<160::AID-GENE20>3.0.CO;2-#; Birkbak NJ, 2011, CANCER RES, V71, P3447, DOI 10.1158/0008-5472.CAN-10-3667; Brown K, 1998, CURR BIOL, V8, P516, DOI 10.1016/S0960-9822(98)70203-9; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Devgan V, 2006, J BIOL CHEM, V281, P30463, DOI 10.1074/jbc.M604684200; Driessens G, 2012, NATURE, V488, P527, DOI 10.1038/nature11344; Fistarol SK, 2002, EUR J DERMATOL, V12, P411; Floor SL, 2012, TRENDS MOL MED, V18, P509, DOI 10.1016/j.molmed.2012.06.005; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Ghaffar SA, 2007, CLIN EXP DERMATOL, V32, P223, DOI 10.1111/j.1365-2230.2006.02303.x; Ghosh JC, 2005, CLIN CANCER RES, V11, P4580, DOI 10.1158/1078-0432.CCR-04-2624; GREENHALGH DA, 1993, CANCER RES, V53, P5071; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He G, 2006, BRIT J CANCER, V95, P1514, DOI 10.1038/sj.bjc.6603448; Hinds PW, 2006, MOL CELL, V22, P432, DOI 10.1016/j.molcel.2006.05.006; Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037; Jirawatnotai S, 2012, CANCER RES, V72, P4289, DOI 10.1158/0008-5472.CAN-11-3549; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; Koul D, 2007, MOL CELL BIOCHEM, V300, P77, DOI 10.1007/s11010-006-9371-8; Leong WF, 2009, MOL CANCER RES, V7, P354, DOI 10.1158/1541-7786.MCR-08-0373; Macias E, 2008, AM J PATHOL, V173, P526, DOI 10.2353/ajpath.2008.071124; Mao JH, 2004, GENE DEV, V18, P1800, DOI 10.1101/gad.1213804; Meek DW, 2009, NAT REV CANCER, V9, P714, DOI 10.1038/nrc2716; Mehic D, 2005, J INVEST DERMATOL, V124, P212, DOI 10.1111/j.0022-202X.2004.23558.x; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Ming M, 2011, CANCER RES, V71, P5287, DOI 10.1158/0008-5472.CAN-10-4614; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Mulholland DJ, 2006, ONCOGENE, V25, P329, DOI 10.1038/sj.onc.1209020; Niemann C, 2002, DEVELOPMENT, V129, P95; Ohtani N, 2007, P NATL ACAD SCI USA, V104, P15034, DOI 10.1073/pnas.0706949104; Schlingemann J, 2003, INT J CANCER, V104, P699, DOI 10.1002/ijc.11008; Sprouffske K, 2011, CANCER PREV RES, V4, P1135, DOI 10.1158/1940-6207.CAPR-10-0374; Subauste MC, 2005, J BIOL CHEM, V280, P5676, DOI 10.1074/jbc.M405561200; Suzuki A, 2003, CANCER RES, V63, P674; Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217; Takeuchi S, 2010, CANCER RES, V70, P9381, DOI 10.1158/0008-5472.CAN-10-0801; Tibarewal P, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002138; Topley GI, 1999, P NATL ACAD SCI USA, V96, P9089, DOI 10.1073/pnas.96.16.9089; Torchia EC, 2012, ONCOGENE, V31, P2680, DOI 10.1038/onc.2011.441; Vasudevan KM, 2007, CANCER RES, V67, P10343, DOI 10.1158/0008-5472.CAN-07-1827; Wang XJ, 1998, MOL CARCINOGEN, V23, P185, DOI 10.1002/(SICI)1098-2744(199811)23:3<185::AID-MC7>3.0.CO;2-5; Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e; Weinberg WC, 1999, CANCER RES, V59, P2050; Yao DG, 2008, J CELL SCI, V121, P1758, DOI 10.1242/jcs.021147; Yao DG, 2006, CANCER RES, V66, P1302, DOI 10.1158/0008-5472.CAN-05-2341; Yoo LI, 2006, CANCER RES, V66, P1929, DOI 10.1158/0008-5472.CAN-05-1986	52	10	10	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 7	2014	33	32					4132	4143		10.1038/onc.2013.372	http://dx.doi.org/10.1038/onc.2013.372			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AN4YK	24037529				2022-12-17	WOS:000340595700004
J	Sangar, F; Schreurs, AS; Umana-Diaz, C; Claperon, A; Desbois-Mouthon, C; Calmel, C; Mauger, O; Zaanan, A; Miquel, C; Flejou, JF; Praz, F				Sangar, F.; Schreurs, A-S; Umana-Diaz, C.; Claperon, A.; Desbois-Mouthon, C.; Calmel, C.; Mauger, O.; Zaanan, A.; Miquel, C.; Flejou, J-F; Praz, F.			Involvement of small ArfGAP1 (SMAP1), a novel Arf6-specific GTPase-activating protein, in microsatellite instability oncogenesis	ONCOGENE			English	Article						colorectal cancer; microsatellite instability; small ArfGAP1 (SMAP1); cell invasion; cell cycle; epithelial-to-mesenchymal transition	COLORECTAL CANCERS; MESSENGER-RNA; ARF6; INTERACTS; CLATHRIN; CELLS; REQUIREMENT; ENDOCYTOSIS; MUTATIONS; MIGRATION	Small ArfGAP1 (stromal membrane-associated protein 1, SMAP1), a GTPase-activating protein specific for ADP-ribosylation factor 6 (Arf6), which is a small GTPase acting on membrane trafficking and actin remodeling, is frequently mutated in various tumors displaying microsatellite instability (MSI), notably in MSI colorectal cancers (CRC). Genotyping of 93 MSI CRCs (40 stage II, 32 stage III and 21 stage IV) allowed us to underscore that SMAP1 mutation frequency was inversely correlated with disease stage (P = 0.01). Analysis of 46 cancer cell lines showed that SMAP1 mutations occurred only in MSI tumors, and consisted exclusively in short insertion or deletion in the coding 10-adenine repeat, generating a premature termination codon located downstream the ArfGAP domain. SMAP1 transcript levels were significant decreased (P = 0.006), and truncated SMAP1 protein could not be detected in cells displaying biallelic SMAP1 mutations, owing to its sensitivity to proteasome degradation. To investigate the role of SMAP1 mutations, we used the SMAP1-null HCT116 cell line and we established three isogenic SMAP1-complemented clones. Cell proliferation was first assessed in vivo using subcutaneous xenografts into immunodeficient mice. Tumors developed in all animals regardless of the cell line injected, but tumor volumes were significantly smaller for both SMAP1-complemented clones compared with HCT116 (P < 0.0001, at the time of killing). In vitro, SMAP1 mutations also increased cell clonogenicity (P = 0.02-0.04), cell proliferation (P = 0.008) by shortening the G2/M phase and decreased cell invasiveness (P = 0.03-0.003). In keeping, SMAP1-complemented HCT116 gained several mesenchymal markers (Snail, Slug and vimentin) considered as a hallmark of epithelial-to-mesenchymal transition. These observations are reminiscent of some clinical characteristics of MSI CRCs, notably their larger size and lower rate of metastasis. Our observations suggest that SMAP1 loss-of-function mutations in MSI CRC may contribute to the emerging oncogenic pathway involving abnormal Arf6 regulation.	[Sangar, F.; Schreurs, A-S; Umana-Diaz, C.; Claperon, A.; Desbois-Mouthon, C.; Calmel, C.; Mauger, O.; Zaanan, A.; Flejou, J-F; Praz, F.] INSERM, UMR S 938, St Antoine Res Ctr, Paris, France; [Sangar, F.; Schreurs, A-S; Umana-Diaz, C.; Claperon, A.; Desbois-Mouthon, C.; Calmel, C.; Mauger, O.; Zaanan, A.; Flejou, J-F; Praz, F.] Univ Paris 06, UMR S 938, St Antoine Res Ctr, Paris, France; [Miquel, C.] Univ Paris 05, St Anne Hosp, Dept Pathol, Paris, France; [Flejou, J-F] St Antoine Hosp, AP HP, Dept Pathol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Praz, F (corresponding author), INSERM UPMC UMR S 938, Ctr Rech St Antoine, Batiment Kourilsky,184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	francoise.praz@upmc.fr	Desbois-Mouthon, Christele/M-7076-2017; PRAZ, Françoise/A-7291-2008; PRAZ, Françoise/AAF-7761-2020	Desbois-Mouthon, Christele/0000-0002-0772-1711; PRAZ, Françoise/0000-0002-5353-8889; PRAZ, Françoise/0000-0002-5353-8889	'Ministe re de l'Enseignement Superieur et de la Recherche; 'Fondation ARC pour la Recherche sur le Cancer; Association pour la Recherche sur le Cancer [5091]; Ligue Nationale Contre le Cancer [RS10/75-72, RS11/75-89]	'Ministe re de l'Enseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission); 'Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer)	We thank Drs Mathieu Boissan, Philippe Chavrier, Marie-Lise Lacombe and Guillaume Montagnac for their constant support and helpful discussions, as well as Dr Peggy Cuilliere-Dartigues for sharing some data. We are grateful to Martine Mergey, Anne-Marie Faussat and Philippe Fontanges for their invaluable help in RT-PCRq analyses, cytometry and confocal microscopy, respectively. We further acknowledge the expert technical assistance of Fatiha Merabtene in performing immunohistochemical analyses of mouse and human tumor samples. We are indebted to the members of INSERM UMR_S 903 for sharing the ImageJ plugin. Fatiha Sangar received a 3-year fellowship from 'Ministe re de l'Enseignement Superieur et de la Recherche' followed by a 6-month funding from 'Fondation ARC pour la Recherche sur le Cancer'. This work has been supported by grants from the Association pour la Recherche sur le Cancer (# 5091) and from the Ligue Nationale Contre le Cancer (RS10/75-72 and RS11/75-89).	Claperon A, 2012, ONCOGENE, V31, P1376, DOI 10.1038/onc.2011.334; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Duval A, 2002, CANCER RES, V62, P2447; El-Bchiri J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002583; Gardner LB, 2010, MOL CANCER RES, V8, P295, DOI 10.1158/1541-7786.MCR-09-0502; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Hempen PM, 2003, CANCER RES, V63, P994; Isken O, 2007, GENE DEV, V21, P1833, DOI 10.1101/gad.1566807; Kon S, 2008, EXP CELL RES, V314, P1415, DOI 10.1016/j.yexcr.2007.11.006; Loire E, 2009, MOL BIOL EVOL, V26, P111, DOI 10.1093/molbev/msn230; Marcos I, 2002, GENE, V292, P167, DOI 10.1016/S0378-1119(02)00645-5; Miquel C, 2007, ONCOGENE, V26, P5919, DOI 10.1038/sj.onc.1210419; Montagnac G, 2009, CURR BIOL, V19, P184, DOI 10.1016/j.cub.2008.12.043; Muralidharan-Chari V, 2009, CANCER RES, V69, P2201, DOI 10.1158/0008-5472.CAN-08-1301; Natsume W, 2006, MOL BIOL CELL, V17, P2592, DOI 10.1091/mbc.E05-10-0909; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Peltomaki P, 2005, FAM CANCER, V4, P227, DOI 10.1007/s10689-004-7993-0; Sabe H, 2003, J BIOCHEM, V134, P485, DOI 10.1093/jb/mvg181; Tanabe K, 2005, MOL BIOL CELL, V16, P1617, DOI 10.1091/mbc.E04-08-0683; Tanabe K, 2006, CANCER SCI, V97, P801, DOI 10.1111/j.1349-7006.2006.00251.x; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Woerner SM, 2010, NUCLEIC ACIDS RES, V38, pD682, DOI 10.1093/nar/gkp839; Zaanan A, 2011, CELL ONCOL, V34, P155, DOI 10.1007/s13402-011-0024-x	23	10	10	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2758	2767		10.1038/onc.2013.211	http://dx.doi.org/10.1038/onc.2013.211			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23752192				2022-12-17	WOS:000337231700009
J	Han, H; Bourboulia, D; Jensen-Taubman, S; Isaac, B; Wei, B; Stetler-Stevenson, WG				Han, H.; Bourboulia, D.; Jensen-Taubman, S.; Isaac, B.; Wei, B.; Stetler-Stevenson, W. G.			An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells	ONCOGENE			English	Article						side population; lung cancer; TIMP-2; ABCG2; chemosensitivity; cell migration	STEM-LIKE CELLS; TISSUE INHIBITOR; ABC TRANSPORTERS; TUMOR; RESISTANCE; OVARIAN; TIMP-2; LINES; GROWTH	The side population (SP) in human lung cancer cell lines and tumors is enriched with cancer stem cells. An endogenous inhibitor of angiogenesis known as tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), characterized for its ability to inhibit matrix metalloproteinases (MMPs), has been shown by several laboratories to impede tumor progression through MMP-dependent or -independent mechanisms. We recently reported that forced expression of TIMP-2, as well as the modified form Ala+TIMP-2 (that lacks MMP inhibitory activity) significantly blocks growth of A549 human lung cancer cells in vivo. However, the mechanisms underlying TIMP-2 antitumor effects are not fully characterized. Here, we examine the hypothesis that the TIMP-2 antitumor activity may involve regulation of the SP in human lung cancer cells. Indeed, using Hoechst dye efflux assay and flow cytometry, as well as quantitative reverse transcriptase-PCR analysis, we found that endogenous TIMP-2 mRNA levels showed a significant inverse correlation with SP fraction size in six non-small cell lung cancer cell lines. In A549 cells expressing increased levels of TIMP-2, a significant decrease in SP was observed, and this decrease was associated with lowered gene expression of ABCG2, ABCB1 and AKR1C1. Functional analysis of A549 cells showed that TIMP-2 overexpression increased chemosensitivity to cytotoxic drugs. The SP isolated from TIMP-2-overexpressing A549 cells also demonstrated impaired migratory capacity compared with the SP from empty vector control. More importantly, our data provide strong evidence that these TIMP-2 functions occur independent of MMP inhibition, as A549 cells overexpressing Ala+TIMP-2 exhibited identical behavior to those overexpressing TIMP-2 alone. Our findings provide the first indication that TIMP-2 modulates SP phenotype and function, and suggests that TIMP-2 may act as an endogenous suppressor of the SP in human lung cancer cells.	[Han, H.; Bourboulia, D.; Jensen-Taubman, S.; Isaac, B.; Wei, B.; Stetler-Stevenson, W. G.] NCI, Radiat Oncol Branch, Ctr Canc Res, NIH,Adv Technol Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bourboulia, D (corresponding author), NCI, Extracellular Matrix Pathol Sect, Radiat Oncol Branch,Adv Technol Ctr, Ctr Canc Res,NIH, 8717 Grovemont Circle, Bethesda, MD 20892 USA.	bourmpouliad@mail.nih.gov	Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808; Issac, Biju/0000-0002-7311-678X	NCI Center for Cancer Research Intramural Research Grant [ZIA SC009179-22]; NATIONAL CANCER INSTITUTE [ZIABC011204, ZIASC009179] Funding Source: NIH RePORTER	NCI Center for Cancer Research Intramural Research Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Laboratory of Molecular Technology, NCI Frederick for the microarray experiment. We also thank the members of the Extracellular Matrix Pathology Section, Radiation Oncology Branch, NCI for critical discussions. This work was supported by the NCI Center for Cancer Research Intramural Research Grant # ZIA SC009179-22.	Akunuru S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016951; An Y, 2009, EXPERT OPIN DRUG MET, V5, P1529, DOI 10.1517/17425250903228834; Bourboulia D, 2011, AM J PATHOL, V179, P2589, DOI 10.1016/j.ajpath.2011.07.035; Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911-009-9109-9; Deng HB, 2004, CANCER CHEMOTH PHARM, V54, P301, DOI 10.1007/s00280-004-0815-0; Ding XW, 2010, LIFE SCI, V86, P631, DOI 10.1016/j.lfs.2010.02.012; Fernandez CA, 2003, J BIOL CHEM, V278, P40989, DOI 10.1074/jbc.M306176200; Fernandez CA, 2010, J BIOL CHEM, V285, P41886, DOI 10.1074/jbc.M110.166439; Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Halon A, 2012, J HISTOCHEM CYTOCHEM, V60, P491, DOI 10.1369/0022155412446978; HEPPNER GH, 1983, CANCER METAST REV, V2, P5, DOI 10.1007/BF00046903; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Lopez J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-48; Mitsutake N, 2007, ENDOCRINOLOGY, V148, P1797, DOI 10.1210/en.2006-1553; Salcido CD, 2010, BRIT J CANCER, V102, P1636, DOI 10.1038/sj.bjc.6605668; Seo DC, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-75; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Shimano K, 2003, AM J PATHOL, V163, P3, DOI 10.1016/S0002-9440(10)63624-3; Stetler-Stevenson WG, 2008, CANCER METAST REV, V27, P57, DOI 10.1007/s10555-007-9105-8; Sung JM, 2008, BIOCHEM BIOPH RES CO, V371, P163, DOI 10.1016/j.bbrc.2008.04.038; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Vermeulen L, 2008, CELL DEATH DIFFER, V15, P947, DOI 10.1038/cdd.2008.20; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wanichwatanadecha P, 2012, J GEN VIROL, V93, P1081, DOI 10.1099/vir.0.038265-0; Wu C, 2008, CANCER LETT, V268, P1, DOI 10.1016/j.canlet.2008.03.048; Yoh K, 2004, CLIN CANCER RES, V10, P1691, DOI 10.1158/1078-0432.CCR-0937-3; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	30	10	11	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1198	1206		10.1038/onc.2013.61	http://dx.doi.org/10.1038/onc.2013.61			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23474755	Green Accepted			2022-12-17	WOS:000331933800013
J	Pedersen, K; Canals, F; Prat, A; Tabernero, J; Arribas, J				Pedersen, K.; Canals, F.; Prat, A.; Tabernero, J.; Arribas, J.			PELO negatively regulates HER receptor signalling and metastasis	ONCOGENE			English	Article						breast cancer; EGFR; metastasis; p95HER2; PELO; PI3K	GROWTH-FACTOR RECEPTOR; BREAST-CANCER METASTASIS; MOLECULAR CHARACTERIZATION; KINASE INHIBITOR; PROTEIN; NETWORK; PHOSPHORYLATION; PROTEOMICS; CARCINOMA; MIGRATION	The HER family is composed of four receptor tyrosine kinases, which are frequently deregulated in several types of cancer. Activated HER receptors initiate intracellular signalling pathways by attracting to the plasma membrane a plethora of adaptor and signalling molecules. Although there are more than a dozen HER-interacting proteins that regulate signal transduction and have been extensively studied, recent proteomic studies have shown the existence of many novel but largely uncharacterized factors that may bind HER receptors. In this report, we describe a cell-based identification of several new HER2-binding proteins, including HAX1, YWHAZ, PELO and ACP1. Analysis of these factors showed that one of them, PELO, binds to active HER2 and epidermal growth factor receptor and thereby attenuates phosphatidylinositol 3-kinase (PI3K)/AKT signalling, likely through regulation of the recruitment of p85-PI3K to activated receptor. Functional characterization of PELO showed that it negatively regulates cell migration and metastasis in vivo. These results reveal that PELO is a novel regulator of HER-signalling and therefore is likely to have a role in inhibiting tumour progression and invasion.	[Pedersen, K.; Canals, F.; Arribas, J.] Vall Hebron Inst Oncol, Preclin Res Program, Barcelona 08035, Spain; [Prat, A.] VHIO, Translat Genom Res Program, Barcelona 08035, Spain; [Tabernero, J.] VHIO, Clin Res Program, Barcelona 08035, Spain; [Arribas, J.] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Bellaterra, Spain; [Arribas, J.] ICREA, Barcelona, Spain	Vall d'Hebron Institut d'Oncologia (VHIO); Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; ICREA	Pedersen, K (corresponding author), Vall Hebron Inst Oncol, Preclin Res Program, Psg Vall Hebron 119-129, Barcelona 08035, Spain.	kp@kim-pedersen.com; jarribas@vhio.net	Tabernero, Josep/AAG-5026-2019; Prat, Aleix/P-8561-2014; Arribas, Jose R/A-1595-2015; Arribas, Joaquin/M-4482-2014	Tabernero, Josep/0000-0002-2495-8139; Prat, Aleix/0000-0003-2377-540X; Arribas, Joaquin/0000-0002-0504-0664	Instituto de Salud Carlos III [PI081154]; Instituto de Salud Carlos III (network of cooperative cancer research) [RTICC-RD06/0020/0022]; Breast Cancer Research Foundation; Asociacion Espanola Contra el Cancer (AECC); AVON Foundation; AECC; ICREA Funding Source: Custom	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Instituto de Salud Carlos III (network of cooperative cancer research); Breast Cancer Research Foundation; Asociacion Espanola Contra el Cancer (AECC); AVON Foundation; AECC; ICREA(ICREA)	This work was supported by the Instituto de Salud Carlos III (Intrasalud PI081154 and the network of cooperative cancer research (RTICC-RD06/0020/0022)), the Breast Cancer Research Foundation, the Asociacion Espanola Contra el Cancer (AECC) and AVON Foundation. KP was supported by the postdoctoral program from the AECC.	Adham IM, 2003, MOL CELL BIOL, V23, P1470, DOI 10.1128/MCB.23.4.1470-1476.2003; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Burnicka-Turek O, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-28; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Davis L, 1998, GENETICS, V149, P45; EBERHART CG, 1995, DEVELOPMENT, V121, P3477; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Garcia-Castillo J, 2009, J BIOL CHEM, V284, P25302, DOI 10.1074/jbc.M109.001982; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moasser MM, 2001, CANCER RES, V61, P7184; Morandell S, 2008, PROTEOMICS, V8, P4383, DOI 10.1002/pmic.200800204; Mukherjee M, 2012, EMBO J, V31, P1308, DOI 10.1038/emboj.2011.496; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Oppel F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-137; Pedersen K, 2009, MOL CELL BIOL, V29, P3319, DOI 10.1128/MCB.01803-08; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rhodes N, 2008, CANCER RES, V68, P2366, DOI 10.1158/0008-5472.CAN-07-5783; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; Segatto O, 2011, J CELL SCI, V124, P1785, DOI 10.1242/jcs.083303; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	33	10	10	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1190	1197		10.1038/onc.2013.35	http://dx.doi.org/10.1038/onc.2013.35			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23435426				2022-12-17	WOS:000331933800012
J	Kumar, SM; Dai, J; Li, S; Yang, R; Yu, H; Nathanson, KL; Liu, S; Zhou, H; Guo, J; Xu, X				Kumar, S. M.; Dai, J.; Li, S.; Yang, R.; Yu, H.; Nathanson, K. L.; Liu, S.; Zhou, H.; Guo, J.; Xu, X.			Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation	ONCOGENE			English	Article						melanoma; neural crest; transformation; melanocytes; BRAF(V600E)	ONCOGENE-INDUCED SENESCENCE; STEM-CELLS; SELF-RENEWAL; EXPRESSION; CANCER; CYCLE; GENE; MAINTENANCE; MUTATIONS; PATHWAYS	Adult stem cells are multipotent and persist in small numbers in adult tissues throughout the lifespan of an organism. Unlike differentiated cells, adult stem cells are intrinsically resistant to senescence. It is unclear how adult stem cells in solid organs respond to oncogenic stimulation and whether these cells have a role in tumor initiation. We report here that expression of BRAF(V600E) in human neural crest progenitor cells (hNCPCs) did not induce growth arrest as seen in human melanocytes, but instead, increased their cell proliferation capacity. These cells (hNCPCs(V600E)) acquired anchorage-independent growth ability and were weakly tumorigenic in vivo. Unlike in human melanocytes, BRAF(V600E) expression in hNCPCs did not induce p16(INK4a) expression. BRAF(V600E) induced elevated expression of CDK2, CDK4, MITF and EST1/2 protein in hNCPCs, and also induced melanocytic differentiation of these cells. Furthermore, overexpression of MITF in hNCPCs(V600E) dramatically increased their tumorigenicity and resulted in fully transformed tumor cells. These findings indicate that hNCPCs are susceptible to BRAF(V600E)-induced transformation, and MITF potentiates the oncogenic effect of BRAF(V600E) in these progenitor cells. These results suggest that the hNCPCs are potential targets for BRAF(V600E)-induced melanocytic tumor formation.	[Kumar, S. M.; Dai, J.; Yang, R.; Yu, H.; Liu, S.; Xu, X.] Univ Penn, Perelman Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; [Kumar, S. M.; Dai, J.; Yang, R.; Yu, H.; Liu, S.; Xu, X.] Univ Penn, Perelman Sch Med, Dept Lab Med, Philadelphia, PA 19104 USA; [Dai, J.; Li, S.; Guo, J.] Peking Univ, Canc Hosp & Inst, Dept Renal Canc & Melanoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China; [Nathanson, K. L.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA; [Zhou, H.] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Peking University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Guo, J (corresponding author), Peking Univ, Canc Hosp & Inst, Dept Renal Canc & Melanoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China.	guoj307@126.com; xug@mail.med.upenn.edu		Yu, Hong/0000-0002-1272-4511; Liu, Shujing/0000-0002-2958-093X; Nathanson, Katherine/0000-0002-6740-0901	US National Institutes of Health [AR-054593, CA-116103]; NATIONAL CANCER INSTITUTE [P01CA114046, P30CA016520, P01CA025874, P50CA174523, R21CA116103] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054593] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Drs M Herlyn from the Wistar Institute, Philadelphia, PA for melanoma cell lines, R Marais from the Institute of Cancer Research, London, UK for BRAF<SUP>V600E</SUP> plasmids, S Carreira from Marie Curie Research Institute, UK for MITF promoter-luciferase plasmids, F Liu from university of California for QCXIP-MiTF and QCXIP vectors, K Huang for editing the manuscript. CHTN for providing tissues and the immunohistochemical lab at the Department of Pathology and Laboratory medicine, University of Pennsylvania for immunohistochemical stains. This work is supported by US National Institutes of Health grants AR-054593, CA-116103 to XX.	Amoh Y, 2005, P NATL ACAD SCI USA, V102, P5530, DOI 10.1073/pnas.0501263102; Baird DM, 2008, BIOCHIMIE, V90, P116, DOI 10.1016/j.biochi.2007.08.003; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bernardo ME, 2007, CANCER RES, V67, P9142, DOI 10.1158/0008-5472.CAN-06-4690; Bloethner S, 2007, GENE CHROMOSOME CANC, V46, P1019, DOI 10.1002/gcc.20488; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Duband JL, 2006, ADV EXP MED BIOL, V589, P45; Elder DE, 2009, TUMORIGENIC MELANOCY; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; Foroni C, 2007, CANCER RES, V67, P3725, DOI 10.1158/0008-5472.CAN-06-4577; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Greshock J, 2004, GENOME RES, V14, P179; Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716; Hu YF, 2006, STEM CELLS, V24, P2692, DOI 10.1634/stemcells.2006-0233; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kruger GM, 2002, NEURON, V35, P657, DOI 10.1016/S0896-6273(02)00827-9; Kumar SM, 2005, AM J PATHOL, V166, P823, DOI 10.1016/S0002-9440(10)62303-6; Kumar SM, 2007, CANCER RES, V67, P3177, DOI 10.1158/0008-5472.CAN-06-3312; Li LN, 2003, P NATL ACAD SCI USA, V100, P9958, DOI 10.1073/pnas.1733025100; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Milagre C, 2010, CANCER RES, V70, P5549, DOI 10.1158/0008-5472.CAN-09-4254; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008-5472.CAN-04-4194; Shiras A, 2007, STEM CELLS, V25, P1478, DOI 10.1634/stemcells.2006-0585; Sieber-Blum M, 2004, DEV DYNAM, V231, P258, DOI 10.1002/dvdy.20129; Sieber-Blum M, 2004, ANAT REC PART A, V276A, P34, DOI 10.1002/ar.a.10132; Sieber-Blum Maya, 2004, Birth Defects Res C Embryo Today, V72, P162, DOI 10.1002/bdrc.20008; Squarzoni P, 2011, DEVELOPMENT, V138, P1421, DOI 10.1242/dev.057323; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Vaquerizas JM, 2004, BIOINFORMATICS, V20, P3656, DOI 10.1093/bioinformatics/bth401; Wajapeyee N, 2010, CELL, V141, P746, DOI 10.1016/j.cell.2010.05.014; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776; Wong CE, 2006, J CELL BIOL, V175, P1005, DOI 10.1083/jcb.200606062; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Yaswen P, 2007, CELL, V128, P233, DOI 10.1016/j.cell.2007.01.005; Yu H, 2006, AM J PATHOL, V168, P1879, DOI 10.2353/ajpath.2006.051170; Yu H, 2010, J INVEST DERMATOL, V130, P1227, DOI 10.1038/jid.2009.322; Yu H, 2009, AM J PATHOL, V174, P2367, DOI 10.2353/ajpath.2009.081057	53	10	10	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					832	841		10.1038/onc.2012.642	http://dx.doi.org/10.1038/onc.2012.642			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23334329	Green Accepted			2022-12-17	WOS:000331626900004
J	Li, W; Anderson, RA				Li, W.; Anderson, R. A.			Star-PAP controls HPV E6 regulation of p53 and sensitizes cells to VP-16	ONCOGENE			English	Article						p53; HPV E6; VP-16; Star-PAP; polyadenylation; cell growth and proliferation	CERVICAL-CANCER CELLS; MESSENGER-RNA; E7 ONCOPROTEIN; E6-MEDIATED DEGRADATION; EXPRESSION; RESTORATION; APOPTOSIS; ALPHA; TRANSCRIPTS; COMBINATION	Cervical cancer is the most common genital malignancy and the high-risk human papillomaviruses (HPV type 16, 18 and 31, and so on) are major agents for its cause. A key switch for the onset of cervical cancers by HPVs is the cellular degradation of the tumor-suppressor p53 that is mediated by the HPV-generated E6 protein. E6 forms a complex with the E3 ubiquitin-ligase E6-associated protein (E6AP) leading to p53 degradation. The components that control E6 expression and the mechanisms for regulation of the expression in host cells remain undefined. Here we show that the nuclear noncanonical poly(A) polymerase (PAP) speckle targeted PIPKI alpha regulated PAP (Star-PAP) controls E6 mRNA polyadenylation and expression and modulates wild-type p53 levels as well as cell cycle profile in high-risk HPV-positive cells. In the absence of Star-PAP, treatment of cells with the chemotherapeutic drug VP-16 dramatically reduced E6 and increased p53 levels. This diminished both cell proliferation and anchorage-independent growth required for cancer progression, indicating a synergism between VP-16 treatment and the loss of Star-PAP. This identifies Star-PAP as a potential drug target for the treatment of HPV-positive cancer cells. These data provide a mechanistic basis for increasing the sensitivity and efficiency of chemotherapy in the treatment of cancers that have low levels of wild-type p53.	[Li, W.; Anderson, R. A.] Univ Wisconsin Madison, Mol & Cellular Pharmacol Program, Sch Med & Publ Hlth, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Anderson, RA (corresponding author), Univ Wisconsin Madison, Mol & Cellular Pharmacol Program, 1300 Univ Ave,3750 Med Sci Ctr, Madison, WI 53706 USA.	raanders@wisc.edu		Li, Weimin/0000-0002-2170-7094; Anderson, Richard/0000-0001-6265-8359	US National Institutes of Health [GM051968]; American Heart Association [12SDG12100035]; NATIONAL CANCER INSTITUTE [R01CA104708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM114386, R01GM051968] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the Anderson laboratory for discussion and comments, and thank Dr Paul F Lambert's laboratory at UW-Madison for SiHa and CaSki cell lines. This work was supported by a grant (GM051968) from the US National Institutes of Health and a Scientist Development Grant (12SDG12100035) from the American Heart Association.	Clifford B, 2003, CANCER RES, V63, P4074; Fiedler M, 2004, FASEB J, V18, P1120, DOI 10.1096/fj.03-1332fje; Gonzales ML, 2008, J BIOL CHEM, V283, P12665, DOI 10.1074/jbc.M800656200; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Kanduc D, 2002, J VIROL, V76, P7040, DOI 10.1128/JVI.76.14.7040-7048.2002; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Koivusalo R, 2005, MOL PHARMACOL, V68, P372, DOI 10.1124/mol.105.011189; Laishram RS, 2011, NUCLEIC ACIDS RES, V39, P7961, DOI 10.1093/nar/gkr549; Laishram RS, 2010, EMBO J, V29, P4132, DOI 10.1038/emboj.2010.287; Lappalainen K, 1996, ANTICANCER RES, V16, P2485; Li WM, 2007, CIRC RES, V100, P79, DOI 10.1161/01.RES.0000253094.03023.3f; Li W, 2012, MOL CELL, V45, P25, DOI 10.1016/j.molcel.2011.11.017; Li W, 2009, P NATL ACAD SCI USA, V106, P486, DOI 10.1073/pnas.0804177106; Liu YM, 2000, J CELL BIOCHEM, V78, P334, DOI 10.1002/(SICI)1097-4644(20000801)78:2<334::AID-JCB15>3.3.CO;2-6; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Mellman DL, 2008, NATURE, V451, P1013, DOI 10.1038/nature06666; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Murray EL, 2008, METHOD ENZYMOL, V448, P483, DOI 10.1016/S0076-6879(08)02624-4; Oh KJ, 2006, J VIROL, V80, P7079, DOI 10.1128/JVI.02380-05; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; SALLES FJ, 1995, PCR METH APPL, V4, P317; Sauter ER, 2002, CANCER GENE THER, V9, P807, DOI 10.1038/sj.cgt.7700492; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; Sigal A, 2000, CANCER RES, V60, P6788; Skladanowski A, 1997, CANCER RES, V57, P818; Sotlar K, 2004, J MED VIROL, V74, P107, DOI 10.1002/jmv.20153; Tang S, 2006, J VIROL, V80, P4249, DOI 10.1128/JVI.80.9.4249-4263.2006; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vinther J, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-83; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang YX, 2011, J CLIN INVEST, V121, P893, DOI 10.1172/JCI44504; Wesierska-Gadek J, 2002, INT J CANCER, V101, P128, DOI 10.1002/ijc.10580; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zheng ZM, 2006, FRONT BIOSCI-LANDMRK, V11, P2286, DOI 10.2741/1971	34	10	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					928	932		10.1038/onc.2013.14	http://dx.doi.org/10.1038/onc.2013.14			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23416977	Green Accepted			2022-12-17	WOS:000331626900014
J	Calero-Nieto, FJ; Joshi, A; Bonadies, N; Kinston, S; Chan, WI; Gudgin, E; Pridans, C; Landry, JR; Kikuchi, J; Huntly, BJ; Gottgens, B				Calero-Nieto, F. J.; Joshi, A.; Bonadies, N.; Kinston, S.; Chan, W-I; Gudgin, E.; Pridans, C.; Landry, J-R; Kikuchi, J.; Huntly, B. J.; Gottgens, B.			HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias	ONCOGENE			English	Article						gene regulation; haematopoiesis; HOX; leukaemia; LMO2	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; T-CELL LEUKEMIA; TRANSCRIPTION FACTOR; STEM-CELL; ONCOGENIC PATHWAYS; CALM/AF10 FUSION; GENE; CANCER; PROMOTER	The Lim Domain Only 2 (LMO2) leukaemia oncogene encodes an LIM domain transcriptional cofactor required for early haematopoiesis. During embryogenesis, LMO2 is also expressed in developing tail and limb buds, an expression pattern we now show to be recapitulated in transgenic mice by an enhancer in LMO2 intron 4. Limb bud expression depended on a cluster of HOX binding sites, while posterior tail expression required the HOX sites and two E-boxes. Given the importance of both LMO2 and HOX genes in acute leukaemias, we further demonstrated that the regulatory hierarchy of HOX control of LMO2 is activated in leukaemia mouse models as well as in patient samples. Moreover, Lmo2 knock-down impaired the growth of leukaemic cells, and high LMO2 expression at diagnosis correlated with poor survival in cytogenetically normal AML patients. Taken together, these results establish a regulatory hierarchy of HOX control of LMO2 in normal development, which can be resurrected during leukaemia development. Redeployment of embryonic regulatory hierarchies in an aberrant context is likely to be relevant in human pathologies beyond the specific example of ectopic activation of LMO2.	[Calero-Nieto, F. J.; Joshi, A.; Bonadies, N.; Kinston, S.; Chan, W-I; Gudgin, E.; Pridans, C.; Landry, J-R; Huntly, B. J.; Gottgens, B.] Univ Cambridge, Dept Haematol, Wellcome Trust, Cambridge CB2 0XY, England; [Calero-Nieto, F. J.; Joshi, A.; Bonadies, N.; Kinston, S.; Chan, W-I; Gudgin, E.; Pridans, C.; Landry, J-R; Huntly, B. J.; Gottgens, B.] Univ Cambridge, MRC Cambridge Stem Cell Inst, Cambridge Inst Med Res, Cambridge CB2 0XY, England; [Kikuchi, J.] Jichi Med Sch, Div Stem Cell Regulat, Ctr Mol Med, Shimotsuke, Tochigi, Japan	University of Cambridge; Wellcome Trust Sanger Institute; University of Cambridge; Jichi Medical University	Calero-Nieto, FJ (corresponding author), Univ Cambridge, Dept Haematol, Wellcome Trust, Hills Rd, Cambridge CB2 0XY, England.	fjc28@cam.ac.uk; bg200@cam.ac.uk	Bonadies, Nicolas/F-2388-2017; huntly, brian JP/E-6725-2014; Pridans, Clare/AAF-9953-2020	Bonadies, Nicolas/0000-0001-8761-2066; huntly, brian JP/0000-0003-0312-161X; Pridans, Clare/0000-0001-9423-557X; Joshi, Anagha/0000-0003-1184-3305; Gottgens, Berthold/0000-0001-6302-5705; Calero-Nieto, Fernando/0000-0003-3358-8253	Leukaemia and Lymphoma Research; MRC; BBSRC; CRUK; Leukaemia and Lymphoma Society; Swiss National Science Foundation; EMBO long term fellowship; EG holds a Kay Kendall Clinical Research Training Fellowship; BBSRC [BB/I00050X/1] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/I00050X/1] Funding Source: researchfish; Cancer Research UK [12765] Funding Source: researchfish; Medical Research Council [MC_PC_12009] Funding Source: researchfish; National Centre for the Replacement [G0900729/1] Funding Source: researchfish	Leukaemia and Lymphoma Research; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); CRUK(Cancer Research UK); Leukaemia and Lymphoma Society; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); EMBO long term fellowship(European Molecular Biology Organization (EMBO)); EG holds a Kay Kendall Clinical Research Training Fellowship; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Centre for the Replacement	We are grateful to Terry Rabbitts for providing the Lmo2 LacZ knock-in mice, Dr Shubha Anand for discussion of results and technical help; Ms Frances Stedham for technical support; and Dr Val Wilson for advice on early embryonic expression patterns. Work in the authors' laboratories is supported by grants from Leukaemia and Lymphoma Research, the MRC, BBSRC, CRUK and Leukaemia and Lymphoma Society. NB was supported by the Swiss National Science Foundation, AJ is the recipient of an EMBO long term fellowship and EG holds a Kay Kendall Clinical Research Training Fellowship.	Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Berger MF, 2008, CELL, V133, P1266, DOI 10.1016/j.cell.2008.05.024; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Bohlander SK, 2000, LEUKEMIA, V14, P93, DOI 10.1038/sj.leu.2401614; Bonadies N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016330; Cambray N, 2007, DEVELOPMENT, V134, P2829, DOI 10.1242/dev.02877; Carlson KM, 2000, LEUKEMIA, V14, P100, DOI 10.1038/sj.leu.2401629; Coustan-Smith E, 2009, LANCET ONCOL, V10, P147, DOI 10.1016/S1470-2045(08)70314-0; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Crable SC, 2003, BLOOD, V101, P4757, DOI 10.1182/blood-2002-09-2702; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; Deshpande AJ, 2006, CANCER CELL, V10, P363, DOI 10.1016/j.ccr.2006.08.023; Dik WA, 2005, LEUKEMIA, V19, P1948, DOI 10.1038/sj.leu.2403891; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; FISCH P, 1992, ONCOGENE, V7, P2389; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gottgens B, 1997, ONCOGENE, V15, P2419, DOI 10.1038/sj.onc.1201426; Hammond SM, 2005, LEUKEMIA RES, V29, P89, DOI 10.1016/j.leukres.2004.05.013; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Huang YS, 2012, BLOOD, V119, P388, DOI 10.1182/blood-2011-03-341081; Huntly BJP, 2005, NATURE, V435, P1169, DOI 10.1038/4351169a; Kvinlaug BT, 2011, CANCER RES, V71, P4117, DOI 10.1158/0008-5472.CAN-11-0176; La Celle PT, 2001, J BIOL CHEM, V276, P32844, DOI 10.1074/jbc.M104598200; Landry JR, 2009, BLOOD, V113, P5783, DOI 10.1182/blood-2008-11-187757; Landry JR, 2005, BLOOD, V106, P2680, DOI 10.1182/blood-2004-12-4755; McCormack MP, 2010, SCIENCE, V327, P879, DOI 10.1126/science.1182378; Mead PE, 2001, DEVELOPMENT, V128, P2301; Metzeler KH, 2008, BLOOD, V112, P4193, DOI 10.1182/blood-2008-02-134411; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Oram SH, 2010, ONCOGENE, V29, P5796, DOI 10.1038/onc.2010.320; Raimondi SC, 2007, ATLAS GENET CYTOGENE, V11, P639; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Tan BT, 2006, LAB INVEST, V86, P1203, DOI 10.1038/labinvest.3700488; Treanor LM, 2011, BLOOD, V118, P24, DOI 10.1182/blood.V118.21.47.47; Tripic T, 2009, BLOOD, V113, P2191, DOI 10.1182/blood-2008-07-169417; Van Vlierberghe P, 2008, BLOOD, V111, P4668, DOI 10.1182/blood-2007-09-111872; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wei J, 2008, CANCER CELL, V13, P483, DOI 10.1016/j.ccr.2008.04.020; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320; Zeng CY, 1998, P NATL ACAD SCI USA, V95, P10637, DOI 10.1073/pnas.95.18.10637; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725	46	10	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2013	32	48					5471	5480		10.1038/onc.2013.175	http://dx.doi.org/10.1038/onc.2013.175			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263BE	23708655	Green Published, hybrid			2022-12-17	WOS:000327780800004
J	Zinkel, SS; Yin, XM; Gross, A				Zinkel, S. S.; Yin, X. M.; Gross, A.			Rejuvenating Bi(d)ology	ONCOGENE			English	Review						Bid; apoptosis; mitochondria; DNA damage; ATM/ATR	HEMATOPOIETIC STEM-CELLS; CYTOCHROME-C RELEASE; NECROSIS-FACTOR-ALPHA; ENDOPLASMIC-RETICULUM CA2+; INDUCED LIVER-INJURY; DNA-DAMAGE RESPONSE; INDUCED APOPTOSIS; REPLICATIVE STRESS; ATAXIA-TELANGIECTASIA; MITOCHONDRIAL RELEASE	The BH3-only Bid protein is a critical sentinel of cellular stress in the liver and the hematopoietic system. Bid's initial 'claim to fame' came from its ability-as a caspase-truncated product-to trigger the mitochondrial apoptotic program following death receptor activation. Today we know that Bid can response to multiple types of proteases, which are activated under different conditions such as T-cell activation, ischemical reperfusion injury and lysosomal injury. Activation of the mitochondrial apoptotic program by Bid-via its recently identified receptor mitochondrial carrier homolog 2-involves multiple mechanisms, including release of cytochrome c and second mitochondria-derived activator of caspase (Smac), alteration of mitochondrial cristae organization, generation of reactive oxygen species and engagement of the permeability transition pore. Bid is also emerging-in its full-length form-as a pivotal sentinel of DNA damage in the bone marrow regulated by the ataxia telangiectasia mutated (ATM)/ataxia telangiectasia and Rad3-related (ATR) kinases. The ATM/ATR-Bid pathway is critically involved in preserving the quiescence and survival of hematopoietic stem cells both in the absence and presence of external stress, and a large part of this review will be dedicated to recent advances in this area of research.	[Zinkel, S. S.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37212 USA; [Zinkel, S. S.] Vanderbilt Univ, Sch Med, Dept Cell Biol, Nashville, TN 37212 USA; [Zinkel, S. S.] Vanderbilt Univ, Sch Med, Dept Dev Biol, Nashville, TN 37212 USA; [Yin, X. M.] Indiana Univ, Sch Med, Dept Pathol & Lab Med, Indianapolis, IN USA; [Gross, A.] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel	Vanderbilt University; Vanderbilt University; Vanderbilt University; Indiana University System; Indiana University-Purdue University Indianapolis; Weizmann Institute of Science	Gross, A (corresponding author), Weizmann Inst Sci, Dept Regulat Biol, Herzel St, IL-76100 Rehovot, Israel.	atan.gross@weizmann.ac.il	Gross, Atan/ABC-2640-2020	zinkel, sandra/0000-0002-2818-9795	Israel Science Foundation; USA-Israel Binational Science Foundation; German-Israel Foundation; NATIONAL CANCER INSTITUTE [K08CA098394] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088347] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); USA-Israel Binational Science Foundation(US-Israel Binational Science Foundation); German-Israel Foundation(German-Israeli Foundation for Scientific Research and Development); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	AG is supported by the Israel Science Foundation, USA-Israel Binational Science Foundation and the German-Israel Foundation, and is the incumbent of the Armour Family Career Development Chair of Cancer Research.	Akashi K, 2003, BLOOD, V101, P383, DOI 10.1182/blood-2002-06-1780; Bai L, 2005, AM J PATHOL, V166, P1523, DOI 10.1016/S0002-9440(10)62368-1; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Broaddus VC, 2005, J BIOL CHEM, V280, P12486, DOI 10.1074/jbc.M408190200; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Chen XY, 2007, MOL CELL BIOL, V27, P541, DOI 10.1128/MCB.01166-06; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Ding WX, 2004, HEPATOLOGY, V40, P403, DOI 10.1002/hep.20310; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Edlich F, 2011, CELL, V145, P104, DOI 10.1016/j.cell.2011.02.034; Grinberg M, 2005, MOL CELL BIOL, V25, P4579, DOI 10.1128/MCB.25.11.4579-4590.2005; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Hikita H, 2009, HEPATOLOGY, V50, P1972, DOI 10.1002/hep.23207; Hikita H, 2009, HEPATOLOGY, V50, P1217, DOI 10.1002/hep.23126; Hock H, 2004, NATURE, V431, P1002, DOI 10.1038/nature02994; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Ito K, 2007, J IMMUNOL, V178, P103, DOI 10.4049/jimmunol.178.1.103; Jang YY, 2007, BLOOD, V110, P3056, DOI 10.1182/blood-2007-05-087759; Jones RG, 2007, IMMUNITY, V27, P268, DOI 10.1016/j.immuni.2007.05.023; Jost PJ, 2009, NATURE, V460, P1035, DOI 10.1038/nature08229; Juntilla MM, 2010, BLOOD, V115, P4030, DOI 10.1182/blood-2009-09-241000; Kamer I, 2005, CELL, V122, P593, DOI 10.1016/j.cell.2005.06.014; Kaufmann T, 2007, CELL, V129, P423, DOI 10.1016/j.cell.2007.03.017; Kaufmann T, 2009, IMMUNITY, V30, P56, DOI 10.1016/j.immuni.2008.10.017; Kim TH, 2004, MOL BIOL CELL, V15, P3061, DOI 10.1091/mbc.E03-12-0864; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li SC, 2002, J BIOL CHEM, V277, P26912, DOI 10.1074/jbc.M200726200; Liu J, 2004, APOPTOSIS, V9, P533, DOI 10.1023/B:APPT.0000038034.16230.ea; Liu Y, 2012, CELL DEATH DIFFER, V19, P1602, DOI 10.1038/cdd.2012.38; Liu Y, 2011, CELL DEATH DIFFER, V18, P841, DOI 10.1038/cdd.2010.151; Liu Y, 2011, MOL CELL BIOL, V31, P4298, DOI 10.1128/MCB.05737-11; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Mandal M, 2008, P NATL ACAD SCI USA, V105, P20840, DOI 10.1073/pnas.0807557106; Maryanovich M, 2012, NAT CELL BIOL, V14, P535, DOI 10.1038/ncb2468; McKenzie MD, 2008, DIABETES, V57, P1284, DOI 10.2337/db07-1692; Mohrin M, 2010, CELL STEM CELL, V7, P174, DOI 10.1016/j.stem.2010.06.014; Ni HM, 2008, AM J PATHOL, V173, P962, DOI 10.2353/ajpath.2008.080358; Ni HM, 2010, HEPATOLOGY, V52, P338, DOI 10.1002/hep.23672; Ni HM, 2009, J BIOL CHEM, V284, P4373, DOI 10.1074/jbc.M807259200; Oakes SA, 2005, P NATL ACAD SCI USA, V102, P105, DOI 10.1073/pnas.0408352102; Orford KW, 2008, NAT REV GENET, V9, P115, DOI 10.1038/nrg2269; Ott M, 2007, CELL DEATH DIFFER, V14, P1243, DOI 10.1038/sj.cdd.4402135; Parmar K, 2007, P NATL ACAD SCI USA, V104, P5431, DOI 10.1073/pnas.0701152104; Sarig R, 2003, J BIOL CHEM, V278, P10707, DOI 10.1074/jbc.M210296200; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schmich K, 2011, HEPATOLOGY, V53, P282, DOI 10.1002/hep.23987; Schneider JG, 2006, CELL METAB, V4, P377, DOI 10.1016/j.cmet.2006.10.002; Schungel S, 2009, HEPATOLOGY, V50, P1558, DOI 10.1002/hep.23176; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Scorrano L, 2002, DEV CELL, V2, P55, DOI 10.1016/S1534-5807(01)00116-2; Shen HM, 2011, EXP HEMATOL, V39, P947, DOI 10.1016/j.exphem.2011.06.004; Shi Y, 2002, CELL DEATH DIFFER, V9, P93, DOI 10.1038/sj/cdd/4400957; Sugiyama T, 2006, IMMUNITY, V25, P977, DOI 10.1016/j.immuni.2006.10.016; Sun XM, 2002, J BIOL CHEM, V277, P11345, DOI 10.1074/jbc.M109893200; Tesio M, 2011, BLOOD, V117, P419, DOI 10.1182/blood-2009-06-230359; Vail ME, 2002, ONCOGENE, V21, P1548, DOI 10.1038/sj.onc.1205212; Valentin-Vega YA, 2012, BLOOD, V119, P1490, DOI 10.1182/blood-2011-08-373639; Walter D, 2008, HEPATOLOGY, V48, P1942, DOI 10.1002/hep.22541; Wang K, 1996, GENE DEV, V10, P2859, DOI 10.1101/gad.10.22.2859; Wang X, 2002, MOL CELL, V9, P411, DOI 10.1016/S1097-2765(02)00439-2; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Wei MC, 2000, GENE DEV, V14, P2060; White C, 2005, NAT CELL BIOL, V7, P1021, DOI 10.1038/ncb1302; Willer CJ, 2009, NAT GENET, V41, P25, DOI 10.1038/ng.287; Yamaguchi R, 2008, MOL CELL, V31, P557, DOI 10.1016/j.molcel.2008.07.010; Yin XM, 2006, GENE, V369, P7, DOI 10.1016/j.gene.2005.10.038; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zaltsman Y, 2010, NAT CELL BIOL, V12, P553, DOI 10.1038/ncb2057; Zhao YG, 2003, GASTROENTEROLOGY, V125, P854, DOI 10.1016/S0016-5085(03)01066-7; Zhao YG, 2001, J BIOL CHEM, V276, P27432, DOI 10.1074/jbc.M102465200; Zhao Y, 2007, J CELL PHYSIOL, V213, P556, DOI 10.1002/jcp.21136; Zinkel SS, 2005, CELL, V122, P579, DOI 10.1016/j.cell.2005.06.022; Zinkel SS, 2003, GENE DEV, V17, P229, DOI 10.1101/gad.1045603	81	10	12	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 4	2013	32	27					3213	3219		10.1038/onc.2012.454	http://dx.doi.org/10.1038/onc.2012.454			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	23069655	Green Accepted			2022-12-17	WOS:000321301600001
J	Snow, JJ; Lee, MH; Verheyden, J; Kroll-Conner, PL; Kimble, J				Snow, J. J.; Lee, M-H; Verheyden, J.; Kroll-Conner, P. L.; Kimble, J.			C. elegans FOG-3/Tob can either promote or inhibit germline proliferation, depending on gene dosage and genetic context	ONCOGENE			English	Article						FOG-3; Tob/BTG; proliferation; tumor formation; germ cells; C. elegans	RNA-BINDING PROTEIN; MITOTIC REGION; EARLY EVENT; STEM-CELLS; TOB; PHOSPHORYLATION; EXPRESSION; FAMILY; FATE; BTG1	Vertebrate Tob/BTG proteins inhibit cell proliferation when overexpressed in tissue-culture cells, and they can function as tumor suppressors in mice. The single Caenorhabditis elegans Tob/BTG ortholog, FOG-3, by contrast, was identified from its loss-of-function phenotype as a regulator of sperm fate specification. Here we report that FOG-3 also regulates proliferation in the germline tissue. We first demonstrate that FOG-3 is a positive regulator of germline proliferation. Thus, fog-3 null mutants possess fewer germ cells than normal, a modest but reproducible decrease observed for each of two distinct fog-3 null alleles. A similar decrease also occurred in fog-3/+ heterozygotes, again for both fog-3 alleles, revealing a haplo-insufficient effect on proliferation. Therefore, FOG-3 normally promotes proliferation, and two copies of the fog-3 gene are required for this function. We next overexpressed FOG-3 by removal of FBF, the collective term for FBF-1 and FBF-2, two nearly identical PUF RNA-binding proteins. We find that overexpressed FOG-3 blocks proliferation in fbf-1 fbf-2 mutants; whereas germ cells stop dividing and instead differentiate in fbf-1 fbf-2 double mutants, they continue to proliferate in fog-3; fbf-1 fbf-2 triple mutants. Therefore, like its vertebrate Tob/BTG cousins, overexpressed FOG-3 is 'antiproliferative'. Indeed, some fog-3; fbf-1 fbf-2 mutants possess small tumors, suggesting that FOG-3 can act as a tumor suppressor. Finally, we show that FOG-3 and FBF work together to promote tumor formation in animals carrying oncogenic Notch mutations. A similar effect was not observed when germline tumors were induced by manipulation of other regulators; therefore, this FOG-3 tumor-promoting effect is context dependent. We conclude that FOG-3 can either promote or inhibit proliferation in a manner that is sensitive to both genetic context and gene dosage. The discovery of these FOG-3 effects on proliferation has implications for our understanding of vertebrate Tob/BTG proteins and their influence on normal development and tumorigenesis.	[Snow, J. J.; Kimble, J.] Univ Wisconsin, Program Cellular & Mol Biol, Madison, WI 53706 USA; [Lee, M-H; Kroll-Conner, P. L.; Kimble, J.] Univ Wisconsin, Howard Hughes Med Inst, Madison, WI 53706 USA; [Verheyden, J.; Kimble, J.] Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Kimble, J (corresponding author), Univ Wisconsin, Howard Hughes Med Inst, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	jekimble@wisc.edu		Lee, Myon Hee/0000-0001-9020-2391	NIH [5T32GM007215, R01GM069454, 5F32GM095036]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069454, T32GM007215, F32GM095036] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the Japanese consortium for generation of fog-3(tm4376) and the CGC for strains. We also thank members of the Kimble lab for helpful discussions, Laura Vanderploeg for help with figures and Anne Helsley for help preparing the manuscript. JJS was supported by NIH Training Grant 5T32GM007215 in Molecular Biosciences. JK is supported by NIH R01GM069454. JV is supported by NIH 5F32GM095036. JK is an investigator of the Howard Hughes Medical Institute.	Albrecht M, 2004, FEBS LETT, V569, P18, DOI 10.1016/j.febslet.2004.03.126; BARTON MK, 1987, GENETICS, V115, P107; Berry LW, 1997, DEVELOPMENT, V124, P925; BRENNER S, 1974, GENETICS, V77, P71; Busson M, 2005, ONCOGENE, V24, P1698, DOI 10.1038/sj.onc.1208373; Byrd DT, 2009, SEMIN CELL DEV BIOL, V20, P1107, DOI 10.1016/j.semcdb.2009.09.005; Chen PJ, 2000, DEV BIOL, V217, P77, DOI 10.1006/dbio.1999.9521; Cinquin O, 2010, P NATL ACAD SCI USA, V107, P2048, DOI 10.1073/pnas.0912704107; Crittenden SL, 2006, MOL BIOL CELL, V17, P3051, DOI 10.1091/mbc.E06-03-0170; Crittenden SL, 2002, NATURE, V417, P660, DOI 10.1038/nature754; el-Ghissassi F, 2002, ONCOGENE, V21, P6772, DOI 10.1038/sj.onc.1205888; ELLIS RE, 1995, GENETICS, V139, P561; Farioli-Vecchioli S, 2007, FASEB J, V21, P2215, DOI 10.1096/fj.06-7548com; Ficazzola MA, 2001, CARCINOGENESIS, V22, P1271, DOI 10.1093/carcin/22.8.1271; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Ito Y, 2005, CANCER LETT, V220, P237, DOI 10.1016/j.canlet.2004.08.017; Iwanaga K, 2003, CANCER LETT, V202, P71, DOI 10.1016/j.canlet.2003.08.019; Jia SJ, 2007, DEV DYNAM, V236, P913, DOI 10.1002/dvdy.21092; Kadyk LC, 1998, DEVELOPMENT, V125, P1803; Kawakubo H, 2006, CANCER RES, V66, P7075, DOI 10.1158/0008-5472.CAN-06-0379; Kawamura-Tsuzuku J, 2004, ONCOGENE, V23, P6630, DOI 10.1038/sj.onc.1207890; Kershner AM, 2010, P NATL ACAD SCI USA, V107, P3936, DOI 10.1073/pnas.1000495107; Kimble J, 2007, ANNU REV CELL DEV BI, V23, P405, DOI 10.1146/annurev.cellbio.23.090506.123326; Lamont LB, 2004, DEV CELL, V7, P697, DOI 10.1016/j.devcel.2004.09.013; Lamont LB, 2007, DEV DYNAM, V236, P871, DOI 10.1002/dvdy.21081; Lee MH, 2011, P NATL ACAD SCI USA, V108, P9125, DOI 10.1073/pnas.1106027108; Majid S, 2009, CARCINOGENESIS, V30, P662, DOI 10.1093/carcin/bgp042; Mauxion F, 2009, TRENDS BIOCHEM SCI, V34, P640, DOI 10.1016/j.tibs.2009.07.008; Podbilewicz B., 2006, WORMBOOK; Rodier A, 2001, ONCOGENE, V20, P2691, DOI 10.1038/sj.onc.1204398; Rodier A, 1999, EXP CELL RES, V249, P337, DOI 10.1006/excr.1999.4486; Struckmann K, 2004, CANCER RES, V64, P1632, DOI 10.1158/0008-5472.CAN-03-1687; Thompson BE, 2006, P NATL ACAD SCI USA, V103, P620, DOI 10.1073/pnas.0510264103; Thompson BE, 2005, DEVELOPMENT, V132, P3471, DOI 10.1242/dev.01921; Toyota M, 2008, CANCER RES, V68, P4123, DOI 10.1158/0008-5472.CAN-08-0325; Winkler GS, 2010, J CELL PHYSIOL, V222, P66, DOI 10.1002/jcp.21919; Yanagie H, 2009, BIOMED PHARMACOTHER, V63, P275, DOI 10.1016/j.biopha.2008.04.010; Yoneda M, 2009, CANCER SCI, V100, P225, DOI 10.1111/j.1349-7006.2008.01030.x; Yoshida Y, 2003, GENE DEV, V17, P1201, DOI 10.1101/gad.1088003; Zhang BL, 1997, NATURE, V390, P477, DOI 10.1038/37297	41	10	13	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 23	2013	32	21					2614	2621		10.1038/onc.2012.291	http://dx.doi.org/10.1038/onc.2012.291			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	156FH	22797076	Green Accepted			2022-12-17	WOS:000319806700002
J	Rybanska, I; Ishaq, O; Chou, J; Prakash, M; Bakhsheshian, J; Huso, DL; Franco, S				Rybanska, I.; Ishaq, O.; Chou, J.; Prakash, M.; Bakhsheshian, J.; Huso, D. L.; Franco, S.			PARP1 and DNA-PKcs synergize to suppress p53 mutation and telomere fusions during T-lineage lymphomagenesis	ONCOGENE			English	Article						telomere; DNA-PKcs; PARP1; p53; lymphoma; mutation	DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; POLY(ADP-RIBOSE) POLYMERASE; V(D)J RECOMBINATION; CATALYTIC SUBUNIT; ONCOGENIC TRANSLOCATIONS; GENOMIC INSTABILITY; CHROMOSOME BREAKS; DAMAGE CHECKPOINT; REPAIR PROTEINS	Poly(ADP-ribose) polymerase 1 (PARP1) interacts genetically with the DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to suppress early-onset T-lineage lymphomas in the mouse, but the underlying mechanisms have remained unknown. To address this question, we analyzed a series of lymphomas arising in PARP1(-/-)/DNA-PKcs(-/-) (P1(-/-)/D-/-) mice. We found that, despite defective V(D)J recombination, P1(-/-)/D-/- lymphomas lacked clonal reciprocal translocations involving antigen-receptor loci. Instead, tumor cells were characterized by aneuploidy driven by two main mechanisms: p53 inactivation and abnormal chromosome disjunction due to telomere fusions (TFs). Aberrant accumulation of p53 was observed in 13/19 (68.4%) lymphomas. Sequence analysis revealed five p53 mutations: three missense point mutations (one transition in exon 8 and two transversions in exons 5 and 8, respectively), one in-frame 5-11 microindel in exon 7 and a 410-bp deletion encompassing exons 5-8, resulting in a truncated protein. Analysis of tumor metaphases using sequential telomere fluorescent in-situ hybridization and spectral karyotyping revealed that nine out of nine lymphomas contained TFs. Mutant but not wild-type p53 status was associated with frequent clonal and nonclonal TFs, suggesting that p53 normally limits the extent of telomere dysfunction during transformation. Chromosomes involved in TFs were more likely to be aneuploid than chromosomes not involved in TFs in the same metaphases, regardless of the p53 status, indicating that TFs promote aneuploidy via a mechanism that is distinct from p53 loss. Finally, analysis of radiation responses in P1(-/-)/D-/-, and control primary cells and tissues indicates that loss of PARP1 increases in vivo radiosensitivity and genomic instability in DNA-PKcs-deficient mice without impairing p53 stabilization and effector functions, suggesting a more severe defect in double-strand break (DSB) repair in double mutants. Together, our findings uncover defective DSB repair leading to tumor suppressor inactivation and abnormal segregation of fused chromosomes as two novel mechanisms promoting tumorigenesis in thymocytes lacking PARP1 and DNA-PKcs. Oncogene (2013) 32, 1761-1771; doi: 10.1038/onc.2012.199; published online 21 May 2012	[Rybanska, I.; Ishaq, O.; Chou, J.; Prakash, M.; Bakhsheshian, J.; Franco, S.] Johns Hopkins Univ, Dept Radiat Oncol & Mol Radiat Sci, Sidney Kimmel Canc Ctr, Baltimore, MD 21287 USA; [Rybanska, I.; Ishaq, O.; Chou, J.; Prakash, M.; Bakhsheshian, J.; Franco, S.] Johns Hopkins Univ, Dept Oncol, Sidney Kimmel Canc Ctr, Baltimore, MD 21287 USA; [Huso, D. L.] Johns Hopkins Univ, Dept Mol & Comparat Pathobiol, Baltimore, MD 21287 USA; [Huso, D. L.] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD 21287 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Franco, S (corresponding author), Johns Hopkins Univ, Dept Radiat Oncol & Mol Radiat Sci, Sidney Kimmel Canc Ctr, 1550 Orleans St,CRB 2 Room 405, Baltimore, MD 21287 USA.	sfranco2@jhmi.edu		Bakhsheshian, Joshua/0000-0003-2983-6082	NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA006973] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahel D, 2009, SCIENCE, V325, P1240, DOI 10.1126/science.1177321; Ariumi Y, 1999, ONCOGENE, V18, P4616, DOI 10.1038/sj.onc.1202823; Bailey SM, 1999, P NATL ACAD SCI USA, V96, P14899, DOI 10.1073/pnas.96.26.14899; Bailey SM, 2004, DNA REPAIR, V3, P349, DOI 10.1016/j.dnarep.2003.11.007; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Bassing CH, 2003, CELL, V114, P359, DOI 10.1016/S0092-8674(03)00566-X; Bassing CH, 2002, CELL, V109, pS45, DOI 10.1016/S0092-8674(02)00675-X; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; Bryant HE, 2009, EMBO J, V28, P2601, DOI 10.1038/emboj.2009.206; Celeste A, 2003, CELL, V114, P371, DOI 10.1016/S0092-8674(03)00567-1; Cesare AJ, 2010, NAT REV GENET, V11, P319, DOI 10.1038/nrg2763; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Davoli T, 2010, CELL, V141, P81, DOI 10.1016/j.cell.2010.01.031; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; di Fagagna FD, 1999, NAT GENET, V23, P76; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Espejel S, 2004, J CELL BIOL, V167, P627, DOI 10.1083/jcb.200407178; Espejel S, 2004, EMBO REP, V5, P503, DOI 10.1038/sj.embor.7400127; Espejel S, 2002, EMBO J, V21, P6275, DOI 10.1093/emboj/cdf593; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Franco S, 2008, J EXP MED, V205, P557, DOI 10.1084/jem.20080044; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Gomez M, 2006, MOL BIOL CELL, V17, P1686, DOI 10.1091/mbc.E05-07-0672; Goytisolo FA, 2001, MOL CELL BIOL, V21, P3642, DOI 10.1128/MCB.21.11.3642-3651.2001; Guidos CJ, 1996, GENE DEV, V10, P2038, DOI 10.1101/gad.10.16.2038; Gurley KE, 1996, CARCINOGENESIS, V17, P2537, DOI 10.1093/carcin/17.12.2537; Gurley KE, 1998, CANCER RES, V58, P3111; Helleday T, 2011, MOL ONCOL, V5, P387, DOI 10.1016/j.molonc.2011.07.001; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hottiger MO, 2010, TRENDS BIOCHEM SCI, V35, P208, DOI 10.1016/j.tibs.2009.12.003; Jordan JJ, 2010, MOL CANCER RES, V8, P701, DOI 10.1158/1541-7786.MCR-09-0442; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LEVINE AJ, 1991, NATURE, V351, P453, DOI 10.1038/351453a0; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Maser RS, 2007, MOL CELL BIOL, V27, P2253, DOI 10.1128/MCB.01354-06; Maser RS, 2002, SCIENCE, V297, P565, DOI 10.1126/science.297.5581.565; McIlrath J, 2001, CANCER RES, V61, P912; Meek K, 2008, ADV IMMUNOL, V99, P33, DOI 10.1016/S0065-2776(08)00602-0; Mills KD, 2003, IMMUNOL REV, V194, P77, DOI 10.1034/j.1600-065X.2003.00060.x; Mitchell J, 2009, INT J RADIAT ONCOL, V75, P1520, DOI 10.1016/j.ijrobp.2009.07.1722; Miyazaki M, 2008, IMMUNITY, V28, P231, DOI 10.1016/j.immuni.2007.12.013; Morales JC, 2006, P NATL ACAD SCI USA, V103, P3310, DOI 10.1073/pnas.0511259103; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Orsburn B, 2010, MOL CELL BIOL, V30, P2341, DOI 10.1128/MCB.00091-10; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Piskunova Tatiana S, 2008, Curr Gerontol Geriatr Res, P754190, DOI 10.1155/2008/754190; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Qi L, 2005, NAT CELL BIOL, V7, P706, DOI 10.1038/ncb1276; Robertson KD, 1998, MOL CELL BIOL, V18, P6457, DOI 10.1128/MCB.18.11.6457; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Scaringe WA, 2008, HUM MOL GENET, V17, P2910, DOI 10.1093/hmg/ddn190; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Schultz N, 2003, NUCLEIC ACIDS RES, V31, P4959, DOI 10.1093/nar/gkg703; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shibata A, 2005, ONCOGENE, V24, P1328, DOI 10.1038/sj.onc.1208289; Shibata A, 2009, MUTAT RES-FUND MOL M, V664, P20, DOI 10.1016/j.mrfmmm.2009.02.001; Simbulan-Rosenthal CM, 1999, P NATL ACAD SCI USA, V96, P13191, DOI 10.1073/pnas.96.23.13191; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Stimpson KM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001061; Stracker TH, 2008, MOL CELL, V31, P21, DOI 10.1016/j.molcel.2008.04.028; Taccioli GE, 1998, IMMUNITY, V9, P355, DOI 10.1016/S1074-7613(00)80618-4; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; Veuger SJ, 2003, CANCER RES, V63, P6008; Veuger SJ, 2004, ONCOGENE, V23, P7322, DOI 10.1038/sj.onc.1207984; WANG ZQ, 1995, GENE DEV, V9, P509, DOI 10.1101/gad.9.5.509; Yang YG, 2004, ONCOGENE, V23, P3872, DOI 10.1038/sj.onc.1207491; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	69	10	12	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	2013	32	14					1761	1771		10.1038/onc.2012.199	http://dx.doi.org/10.1038/onc.2012.199			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	118RQ	22614020	Green Accepted			2022-12-17	WOS:000317043900003
J	Lee, CG; Park, GY; Han, YK; Lee, JH; Chun, SH; Park, HY; Lim, KH; Kim, EG; Choi, YJ; Yang, K; Lee, CW				Lee, C. G.; Park, G-Y; Han, Y. K.; Lee, J. H.; Chun, S. H.; Park, H-Y; Lim, K-H; Kim, E-G; Choi, Y-J; Yang, K.; Lee, C-W			Roles of 14-3-3 eta in mitotic progression and its potential use as a therapeutic target for cancers	ONCOGENE			English	Article						14-3-3; mitosis; cell death; aneuploid; caspase	CELL-DEATH; SPINDLE DAMAGE; CHECKPOINT; APOPTOSIS; PROTEINS; 14-3-3-PROTEINS; CATASTROPHE; CHROMOSOME; 14-3-3-SIGMA; CYTOKINESIS	14-3-3 proteins are involved in several cellular processes, including the G1/S and G2/M cell cycle transitions. However, their roles during mitosis are not well understood. Here, we showed that depletion of 14-3-3 eta, a 14-3-3 protein isoform, enhanced mitotic cell death, resulting in sensitization to microtubule inhibitors and inhibition of aneuploidy formation. The enhanced mitotic cell death by depletion of 14-3-3 eta appeared to be both caspase-dependent and independent. Furthermore, enhanced mitotic cell death and a reduction in aneuploidy following 14-3-3 eta depletion were independent of the mitotic checkpoint, which is thought to be the primary signaling event in the regulation of the cell death induced by microtubule inhibitors. When 14-3-3 eta depletion was combined with microtubule inhibitors in HCT116 and U87MG cells, it sensitized both cancer cell lines to microtubule inhibitors. These results collectively suggest that 14-3-3 eta may be required for mitotic progression and may be considered as a novel anti-cancer strategy in combination with microtubule inhibitors. Oncogene (2013) 32, 1560-1569; doi:10.1038/onc.2012.170; published online 7 May 2012	[Lee, C. G.; Park, G-Y; Han, Y. K.; Lee, J. H.; Chun, S. H.; Choi, Y-J; Yang, K.] Dongnam Inst Radiol & Med Sci, Res Ctr, Pusan 619953, South Korea; [Lee, C. G.; Park, H-Y; Lim, K-H; Kim, E-G; Lee, C-W] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, Suwon 440746, South Korea; [Lee, C. G.; Lee, C-W] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Ctr Mol Med, Suwon 440746, South Korea; [Lee, C-W] Sungkyunkwan Univ, Samsung Adv Inst Hlth Sci & Technol, Suwon 440746, South Korea	Korea Institute of Radiological & Medical Sciences; Sungkyunkwan University (SKKU); Samsung; Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU)	Lee, CW (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, Suwon 440746, South Korea.	cglee@dirams.re.kr; cwlee1234@skku.edu		Lee, Chang-Woo/0000-0002-0943-1646	National Research Foundation; Korea government (MEST) [2011-0030833, 2010-0007555]; National R and D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea [0920290]; National R and D Program through the Dong-nam Institute of Radiological and Medical Sciences (DIRAMS); Ministry of Education, Science and Technology [50593-2011, 50594-2011, 50597-2012]	National Research Foundation; Korea government (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaKorean Government); National R and D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea; National R and D Program through the Dong-nam Institute of Radiological and Medical Sciences (DIRAMS); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	We thank Ye Won Lee, Dr Jung Ki Kim, Min Young Kim and Min Su Ju for administrative support. This study was supported by National Research Foundation grant funded by the Korea government (MEST) (2011-0030833 and 2010-0007555), a grant from National R and D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (0920290) and National R and D Program through the Dong-nam Institute of Radiological and Medical Sciences (DIRAMS) funded by the Ministry of Education, Science and Technology (50593-2011, 50594-2011 and 50597-2012).	Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Cregan SP, 2004, ONCOGENE, V23, P2785, DOI 10.1038/sj.onc.1207517; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Di Leonardo A, 1997, CANCER RES, V57, P1013; Didier C, 2008, ONCOGENE, V27, P3811, DOI 10.1038/sj.onc.1211041; Ha GH, 2009, CELL DEATH DIFFER, V16, P483, DOI 10.1038/cdd.2008.182; Hermeking H, 2006, SEMIN CANCER BIOL, V16, P183, DOI 10.1016/j.semcancer.2006.03.002; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Liu Y, 2007, MOL ENDOCRINOL, V21, P3050, DOI 10.1210/me.2007-0323; Meek SEM, 2004, J BIOL CHEM, V279, P32046, DOI 10.1074/jbc.M403044200; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; MURRAY AW, 1995, CURR OPIN GENET DEV, V5, P5, DOI 10.1016/S0959-437X(95)90046-2; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Niikura Y, 2007, J CELL BIOL, V178, P283, DOI 10.1083/jcb.200702134; Nitta M, 2004, ONCOGENE, V23, P6548, DOI 10.1038/sj.onc.1207873; Nunez G, 1998, ONCOGENE, V17, P3237, DOI 10.1038/sj.onc.1202581; Saurin AT, 2008, NAT CELL BIOL, V10, P891, DOI 10.1038/ncb1749; Shin HJ, 2003, CANCER CELL, V4, P483, DOI 10.1016/S1535-6108(03)00302-7; Stevens JB, 2007, CANCER RES, V67, P7686, DOI 10.1158/0008-5472.CAN-07-0472; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Tsujimoto Y, 1998, GENES CELLS, V3, P697, DOI 10.1046/j.1365-2443.1998.00223.x; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Wilker EW, 2007, NATURE, V446, P329, DOI 10.1038/nature05584; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Yang XL, 2009, J NEUROL SCI, V276, P54, DOI 10.1016/j.jns.2008.08.040	35	10	11	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 21	2013	32	12					1560	1569		10.1038/onc.2012.170	http://dx.doi.org/10.1038/onc.2012.170			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110PC	22562251				2022-12-17	WOS:000316456000009
J	Brune, M; Muller, M; Melino, G; Bierhaus, A; Schilling, T; Nawroth, PP				Brune, M.; Mueller, M.; Melino, G.; Bierhaus, A.; Schilling, T.; Nawroth, P. P.			Depletion of the receptor for advanced glycation end products (RAGE) sensitizes towards apoptosis via p53 and p73 posttranslational regulation	ONCOGENE			English	Article						RAGE; apoptosis; CD95; p53; p73	FACTOR-KAPPA-B; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTION FACTOR; BINDING-PROTEINS; CELL-SURFACE; EXPRESSION; MOUSE; CANCER; DEATH; INFLAMMATION	The receptor for advanced glycation endproduct (RAGE) is involved in diabetic complications and chronic inflammation, conditions known to affect the sensitivity towards apoptosis. Here, we studied the effect of genetically depleting RAGE on the susceptibility towards apoptosis. In murine osteoblastic cells, RAGE knockout increased both spontaneous and induced apoptosis. Decreased levels of B-cell lymphoma 2 protein and increased intrinsic apoptosis were observed in Rage(-/-) cells. Furthermore, loss of RAGE increased expression of the death receptor CD95 (Fas, Apo-1), CD95-dependent caspase activation and extrinsic apoptosis, whereas NF-kB-p65 nuclear translocation was diminished. Importantly, depletion of RAGE reduced the ubiquitination and degradation of p53 and p73 and increased their nuclear translocation. The increase of p53 and p73 transactivational activity was essential for the RAGE-dependent regulation of apoptosis, because knockdown of p53 and p73 significantly decreased apoptosis in RAGE-deficient but not in RAGE-expressing cells. Thus, the RAGE-mediated posttranslational regulation of p53 and p73 orchestrates a sequence of events culminating in control of intrinsic and extrinsic apoptosis signaling pathways. Oncogene (2013) 32, 1460-1468; doi:10.1038/onc.2012.150; published online 30 April 2012	[Brune, M.; Bierhaus, A.; Schilling, T.; Nawroth, P. P.] Heidelberg Univ, Dept Internal Med & Clin Chem 1, D-69120 Heidelberg, Germany; [Mueller, M.] Heidelberg Univ, Dept Internal Med 4, D-69120 Heidelberg, Germany; [Mueller, M.] Univ Regensburg, Dept Internal Med 1, D-93053 Regensburg, Germany; [Melino, G.] MRC, Toxicol Unit, Leicester, Leics, England; [Melino, G.] Univ Rome, Dept Expt Med & Biochem Sci, IDI IRCCS, Biochem Lab, Rome, Italy	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg; University of Regensburg; University of Leicester; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Sapienza University Rome	Brune, M (corresponding author), Heidelberg Univ, Dept Internal Med & Clin Chem 1, Neuenheimer Feld 410, D-69120 Heidelberg, Germany.	maik.brune@med.uni-heidelberg.de	Martina, Mueller-Schilling/R-4162-2016		Dietmar Hopp Stiftung 'Altern-Mobilitat erhalten, Regeneration ermoglichen'; Deutsche Forschungsgemeinschaft [SFB938]; Deutsche Forschungsgemeinschaft, Transregional Collaborative Research Centre [SFB/TRR77]; Tumorzentrum Heidelberg/Mannheim; Helmholtz Alliance on Immunotherapy of Cancer; Initiative and Networking Fund of the Helmholtz Association; Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI	Dietmar Hopp Stiftung 'Altern-Mobilitat erhalten, Regeneration ermoglichen'; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Forschungsgemeinschaft, Transregional Collaborative Research Centre(German Research Foundation (DFG)); Tumorzentrum Heidelberg/Mannheim; Helmholtz Alliance on Immunotherapy of Cancer; Initiative and Networking Fund of the Helmholtz Association; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Dr Subrata Biswas for isolation of MOC, Thomas Fleming for assistance with chromatin immunoprecipitation and electroporation, Dr Andreas Koch for assistance with flow cytometry, as well as Katja Lorenz and Petra Hill for expert technical assistance. This work was supported by a grant of the Dietmar Hopp Stiftung 'Altern-Mobilitat erhalten, Regeneration ermoglichen' to MB, PN, AB and TS, by a grant of the Deutsche Forschungsgemeinschaft SFB938 to AB and by the grant of the Deutsche Forschungsgemeinschaft, Transregional Collaborative Research Centre SFB/TRR77, the Tumorzentrum Heidelberg/Mannheim and the Helmholtz Alliance on Immunotherapy of Cancer funded by the Initiative and Networking Fund of the Helmholtz Association to MM.	Alikhani M, 2007, BONE, V40, P345, DOI 10.1016/j.bone.2006.09.011; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bentires-Alj M, 2001, ONCOGENE, V20, P2805, DOI 10.1038/sj.onc.1204343; Bierhaus A, 2005, J MOL MED, V83, P876, DOI 10.1007/s00109-005-0688-7; Bierhaus A, 2009, DIABETOLOGIA, V52, P2251, DOI 10.1007/s00125-009-1458-9; Borcsok I, 1998, J EXP MED, V188, P1563, DOI 10.1084/jem.188.9.1563; Chan H, 1999, MOL CELL BIOL, V19, P2098, DOI 10.1128/mcb.19.3.2098; Cheng B, 2011, EXP CLIN ENDOCR DIAB, V119, P480, DOI 10.1055/s-0031-1279714; Constien R, 2001, GENESIS, V30, P36, DOI 10.1002/gene.1030; Ding KH, 2006, BIOCHEM BIOPH RES CO, V340, P1091, DOI 10.1016/j.bbrc.2005.12.107; Dudley E, 1999, EUR J IMMUNOL, V29, P878, DOI 10.1002/(SICI)1521-4141(199903)29:03<878::AID-IMMU878>3.0.CO;2-9; Eggers K, 2011, EXP CLIN ENDOCR DIAB, V119, P353, DOI 10.1055/s-0030-1268426; Galluzzi L, 2009, CELL DEATH DIFFER, V16, P1093, DOI 10.1038/cdd.2009.44; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Gulcelik NE, 2011, EXP CLIN ENDOCR DIAB, V119, P414, DOI 10.1055/s-0030-1270466; Hiwatashi K, 2009, ANTICANCER RES, V29, P1287; Hofbauer LC, 2007, J BONE MINER RES, V22, P1317, DOI 10.1359/JBMR.070510; Huttunen HJ, 2000, J BIOL CHEM, V275, P40096, DOI 10.1074/jbc.M006993200; Ishihara K, 2003, FEBS LETT, V550, P107, DOI 10.1016/S0014-5793(03)00846-9; Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149; Kang R, 2011, AUTOPHAGY, V7, P442, DOI 10.4161/auto.7.4.14681; Kang R, 2011, AUTOPHAGY, V7, P91, DOI [10.4161/auto.7.1.13852, 10.1038/cdd.2009.149]; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kikuchi H, 2006, ONCOGENE, V25, P7608, DOI 10.1038/sj.onc.1209748; Lavrik IN, 2007, J BIOL CHEM, V282, P13664, DOI 10.1074/jbc.M700434200; Lavrik IN, 2006, BLOOD, V108, P559, DOI 10.1182/blood-2005-07-007096; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; MIYASHITA T, 1994, ONCOGENE, V9, P1799; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Mundt HM, 2010, BIOCHEM BIOPH RES CO, V396, P335, DOI 10.1016/j.bbrc.2010.04.093; Munsch D, 2000, J BIOL CHEM, V275, P3867, DOI 10.1074/jbc.275.6.3867; NEEPER M, 1992, J BIOL CHEM, V267, P14998; Paul RG, 1996, INT J BIOCHEM CELL B, V28, P1297, DOI 10.1016/S1357-2725(96)00079-9; RENSINGEHL A, 1995, J INFLAMM, V45, P161; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI14002; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; Seitz SJ, 2010, INT J CANCER, V126, P2049, DOI 10.1002/ijc.24861; Soro-Paavonen A, 2008, DIABETES, V57, P2461, DOI 10.2337/db07-1808; Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-17; Stolzing A, 2010, CELLS TISSUES ORGANS, V191, P453, DOI 10.1159/000281826; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Tsoporis JN, 2010, CIRC RES, V106, P93, DOI 10.1161/CIRCRESAHA.109.195834; Villa-Morales M, 2006, ONCOGENE, V25, P2022, DOI 10.1038/sj.onc.1209234; Zhou Z, 2006, J EXP MED, V203, P1067, DOI 10.1084/jem.20051947	44	10	10	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	MAR 14	2013	32	11					1460	1468		10.1038/onc.2012.150	http://dx.doi.org/10.1038/onc.2012.150			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	110OZ	22543586				2022-12-17	WOS:000316455600012
J	Cho, KW; Park, JH; Park, CW; Lee, D; Lee, E; Kim, DJ; Kim, KJ; Yoon, SH; Park, Y; Kim, E; Cho, S; Jang, S; Park, BC; Chi, SW; Yoo, SH; Jang, MH; Kim, HN; Kim, E; Jo, K; Park, YW				Cho, K-W; Park, J. H.; Park, C-W; Lee, D.; Lee, E.; Kim, D. J.; Kim, K. J.; Yoon, S. H.; Park, Y.; Kim, E.; Cho, S.; Jang, S.; Park, B-C; Chi, S-W; Yoo, S. H.; Jang, M. H.; Kim, H. N.; Kim, E.; Jo, K.; Park, Y. W.			Identification of a pivotal endocytosis motif in c-Met and selective modulation of HGF-dependent aggressiveness of cancer using the 16-mer endocytic peptide	ONCOGENE			English	Article						c-Met; endocytosis; dileucine motif; peptide delivery; cancer	GLUCOSE-TRANSPORTER GLUT4; DILEUCINE MOTIF; RECEPTOR; CLATHRIN; PHOSPHORYLATION; TRAFFICKING; PENETRATIN; BINDING; DOMAIN; INTERNALIZATION	Since c-Met has an important role in the development of cancer, it is considered as an attractive target for cancer therapy. Although molecular mechanisms for oncogenic property of c-Met have been actively investigated, regulatory elements for c-Met endocytosis and its effect on c-Met signaling remain unclear. In this study, we identified a pivotal endocytic motif in c-Met and tested it for selective modulation of HGF-induced c-Met response. Using various chimeric constructs with the cytoplasmic tail of c-Met, we were able to demonstrate that a dileucine motif located in the C-terminus of c-Met acts to regulate its endocytosis. Synthetic peptide Ant-3S, consisting of antennapedia-derived protein transduction domain (designated as Ant) and c-Met-derived 16 amino-acids (designated as 3S, spanning amino-acids 1378 to 1393), rapidly moved into cancer cells and disrupted c-Met trafficking. Importantly, an extension of c-Met retention time on the membrane by Ant-3S peptide significantly decreased phosphorylation-dependent c-Met signal transduction. Additionally, the peptide effectively inhibited HGF-induced cell growth, scattering and migration. The underlying molecular mechanism for these observations has been investigated and revealed that the dileucine motif interacts with endocytic machinery, including adaptin beta and caveolin-1, for sustained and enhanced signal transduction. Finally, Ant-3S peptide specifically blocked internalization of interleukin-2 receptor alpha-subunit/3S chimeric protein, but not the other receptors, including Glut4, Glut8 and transferrin receptor. Such results indicate the presence of a selective endocytic assembly for c-Met. It also suggests a potential for c-Met-specific anti-cancer therapy using the identified endocytic motif in this study. Oncogene (2013) 32, 1018-1029; doi:10.1038/onc.2012.122; published online 23 April 2012	[Cho, K-W; Park, J. H.; Park, C-W; Lee, D.; Lee, E.; Kim, D. J.; Kim, K. J.; Yoon, S. H.; Park, Y.; Kim, E.; Cho, S.; Jang, S.; Park, B-C; Park, Y. W.] Korea Res Inst Biosci & Biotechnol, Aging Res Ctr, Taejon, South Korea; [Park, J. H.; Kim, E.] Chungnam Natl Univ, Coll Biol Sci & Biotechnol, Taejon, South Korea; [Chi, S-W] Korea Res Inst Biosci & Biotechnol, Med Prote Res Ctr, Taejon, South Korea; [Yoo, S. H.; Jang, M. H.; Kim, H. N.] A&R Therapeut, Taejon, South Korea; [Jo, K.] Natl Canc Ctr, Natl OncoVenture, Goyang 410769, Gyeonggi Do, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Chungnam National University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); National Cancer Center - Korea (NCC)	Jo, K (corresponding author), Natl Canc Ctr, Natl OncoVenture, 323 Ilsan Ro, Goyang 410769, Gyeonggi Do, South Korea.	kiwonjo@ncc.re.kr; ywpark@kribb.re.kr		Kim, Eunhee/0000-0002-7738-1222	Ministry of Knowledge Economy (Regional R&D Cluster Project) of Korea [B0009735]	Ministry of Knowledge Economy (Regional R&D Cluster Project) of Korea(Ministry of Trade, Industry & Energy (MOTIE), Republic of Korea)	We thank the members of the Kiwon and Young Woo laboratory for their inputs and discussions. We thank Julie Kim and Oh Gordon Chong for editing. This work was supported by the Ministry of Knowledge Economy (Regional R&D Cluster Project B0009735) of Korea.	Abella JV, 2005, MOL CELL BIOL, V25, P9632, DOI 10.1128/MCB.25.21.9632-9645.2005; Al-Hasani H, 1999, FEBS LETT, V460, P338, DOI 10.1016/S0014-5793(99)01369-1; Ball LJ, 2000, EMBO J, V19, P4903, DOI 10.1093/emboj/19.18.4903; Branco MC, 2011, CURR OPIN CHEM BIOL, V15, P427, DOI 10.1016/j.cbpa.2011.03.021; Byland R, 2007, MOL BIOL CELL, V18, P414, DOI 10.1091/mbc.E06-06-0535; Cantiani L, 2007, CANCER RES, V67, P7675, DOI 10.1158/0008-5472.CAN-06-4697; Clark SG, 1997, P NATL ACAD SCI USA, V94, P10438, DOI 10.1073/pnas.94.19.10438; Craig HM, 2000, VIROLOGY, V271, P9, DOI 10.1006/viro.2000.0277; Craven SE, 2000, J BIOL CHEM, V275, P20045, DOI 10.1074/jbc.M910153199; Czajlik A, 2002, J PEPT SCI, V8, P151, DOI 10.1002/psc.380; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Diviani D, 2003, J BIOL CHEM, V278, P19331, DOI 10.1074/jbc.M302110200; Doray B, 2007, MOL BIOL CELL, V18, P1887, DOI 10.1091/mbc.E07-01-0012; FERRACINI R, 1991, J BIOL CHEM, V266, P19558; Flessner LB, 2009, TRAFFIC, V10, P324, DOI 10.1111/j.1600-0854.2008.00866.x; Garippa RJ, 1996, J BIOL CHEM, V271, P20660, DOI 10.1074/jbc.271.34.20660; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Gomes DA, 2008, J BIOL CHEM, V283, P4344, DOI 10.1074/jbc.M706550200; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Grepin R, 2010, J ONCOL, V2010, DOI 10.1155/2010/835680; Joffre C, 2011, NAT CELL BIOL, V13, P827, DOI 10.1038/ncb2257; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; Kamei T, 1999, ONCOGENE, V18, P6776, DOI 10.1038/sj.onc.1203114; Kelly BT, 2008, NATURE, V456, P976, DOI 10.1038/nature07422; Kermorgant S, 2004, EMBO J, V23, P3721, DOI 10.1038/sj.emboj.7600396; Kermorgant S, 2003, J BIOL CHEM, V278, P28921, DOI 10.1074/jbc.M302116200; Kermorgant S, 2008, J CELL BIOL, V182, P855, DOI 10.1083/jcb.200806076; Kirisits A, 2007, INT J BIOCHEM CELL B, V39, P2173, DOI 10.1016/j.biocel.2007.07.012; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Li N, 2007, J BIOL CHEM, V282, P16764, DOI 10.1074/jbc.M610835200; Lindberg M, 2003, EUR J BIOCHEM, V270, P3055, DOI 10.1046/j.1432-1033.2003.03685.x; Lindgren M, 2000, BIOCONJUGATE CHEM, V11, P619, DOI 10.1021/bc990156s; Lindsay MA, 2002, CURR OPIN PHARMACOL, V2, P587, DOI 10.1016/S1471-4892(02)00199-6; Lisinski I, 2001, BIOCHEM J, V358, P517, DOI 10.1042/0264-6021:3580517; Liu GS, 1999, J MOL CELL CARDIOL, V31, P1937, DOI 10.1006/jmcc.1999.1026; Liu ZX, 2002, J BIOL CHEM, V277, P10452, DOI 10.1074/jbc.M107551200; Mettlen M, 2009, MOL BIOL CELL, V20, P3251, DOI 10.1091/mbc.E09-03-0256; Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Polo S, 2006, CELL, V124, P897, DOI 10.1016/j.cell.2006.02.025; Rosca EV, 2011, CURR PHARM BIOTECHNO, V12, P1101; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; Schmidt U, 2006, J CELL SCI, V119, P2321, DOI 10.1242/jcs.02943; Schroeder B, 2010, EMBO J, V29, P3039, DOI 10.1038/emboj.2010.190; Shewan AM, 2000, BIOCHEM J, V350, P99, DOI 10.1042/0264-6021:3500099; Shojaei F, 2010, CANCER RES, V70, P10090, DOI 10.1158/0008-5472.CAN-10-0489; Singleton PA, 2007, J BIOL CHEM, V282, P30643, DOI 10.1074/jbc.M702573200; Sorkin A, 2009, NAT REV MOL CELL BIO, V10, P609, DOI 10.1038/nrm2748; Stein A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002524; Tong JF, 2009, MOL CELL PROTEOMICS, V8, P2131, DOI 10.1074/mcp.M900148-MCP200; Wang W, 2003, J BIOL CHEM, V278, P36848, DOI 10.1074/jbc.M301540200	52	10	10	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					1018	1029		10.1038/onc.2012.122	http://dx.doi.org/10.1038/onc.2012.122			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	22525273				2022-12-17	WOS:000316523200009
J	Campbell, HG; Mehta, R; Neumann, AA; Rubio, C; Baird, M; Slatter, TL; Braithwaite, AW				Campbell, H. G.; Mehta, R.; Neumann, A. A.; Rubio, C.; Baird, M.; Slatter, T. L.; Braithwaite, A. W.			Activation of p53 following ionizing radiation, but not other stressors, is dependent on the proline-rich domain (PRD)	ONCOGENE			English	Article						p53; apoptosis; DNA repair	LI-FRAUMENI-SYNDROME; FUNCTIONAL DOMAIN; TUMOR-SUPPRESSOR; MICE LACKING; APOPTOSIS; E1A; TRANSACTIVATION; PROTEINS; REGION; CELLS	The tumor suppressor protein, p53 is one of the most important cellular defences against malignant transformation. In response to cellular stressors p53 can induce apoptosis, cell cycle arrest or senescence as well as aid in DNA repair. Which p53 function is required for tumor suppression is unclear. The proline-rich domain (PRD) of p53 (residues 58-101) has been reported to be essential for the induction of apoptosis. To determine the importance of the PRD in tumor suppression in vivo we previously generated a mouse containing a 33-amino-acid deletion (residues 55-88) in p53 (m Delta pro). We showed that m Delta pro mice are protected from T-cell tumors but not late-onset B-cell tumors. Here, we characterize the functionality of the PRD and show that it is important for mediating the p53 response to DNA damage induced by gamma-radiation, but not the p53-mediated responses to Ha-Ras expression or oxidative stress. We conclude that the PRD is important for receiving incoming activating signals. Failure of PRD mutants to respond to the activating signaling produced by DNA damage leads to impaired downstream signaling, accumulation of mutations, which potentially leads to late-onset tumors. Oncogene (2013) 32, 827-836; doi:10.1038/onc.2012.102; published online 9 April 2012	[Campbell, H. G.; Mehta, R.; Neumann, A. A.; Rubio, C.; Braithwaite, A. W.] Univ Sydney, Childrens Med Res Inst, Sydney, NSW 2006, Australia; [Baird, M.] Univ Otago, Dept Microbiol & Immunol, Sch Med Sci, Dunedin, New Zealand; [Slatter, T. L.; Braithwaite, A. W.] Univ Otago, Sch Med, Dept Pathol, Dunedin, New Zealand	Children's Medical Research Institute - Australia; University of Sydney; University of Otago; University of Otago	Braithwaite, AW (corresponding author), Childrens Med Res Inst, Cell Transformat Unit, Locked Bag 23, Wentworthville, NSW 2145, Australia.	abraithwaite@cmri.org.au						Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Braithwaite AW, 2005, CARCINOGENESIS, V26, P1161, DOI 10.1093/carcin/bgi091; BRAITHWAITE AW, 1983, J VIROL, V45, P192, DOI 10.1128/JVI.45.1.192-199.1983; Cordenonsi M, 2007, SCIENCE, V315, P840, DOI 10.1126/science.1135961; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Edwards SJ, 2003, ONCOGENE, V22, P4517, DOI 10.1038/sj.onc.1206726; Hammond EM, 2002, MOL CELL BIOL, V22, P1834, DOI 10.1128/MCB.22.6.1834-1843.2002; Hansen RS, 1996, ONCOGENE, V13, P995; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; HORN PL, 1984, J CELL PHYSIOL, V121, P309, DOI 10.1002/jcp.1041210207; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Khanna KK, 1998, NAT GENET, V20, P398, DOI 10.1038/3882; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; Lee JH, 2004, SCIENCE, V304, P93, DOI 10.1126/science.1091496; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Michalak EM, 2008, CELL DEATH DIFFER, V15, P1019, DOI 10.1038/cdd.2008.16; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sakamuro D, 1997, ONCOGENE, V15, P887, DOI 10.1038/sj.onc.1201263; Salvador JM, 2002, IMMUNITY, V16, P499, DOI 10.1016/S1074-7613(02)00302-3; Samuelson AV, 1997, P NATL ACAD SCI USA, V94, P12094, DOI 10.1073/pnas.94.22.12094; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Slatter TL, 2010, CELL DEATH DIFFER, V17, P540, DOI 10.1038/cdd.2009.136; TEODORO JG, 1995, ONCOGENE, V11, P467; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Toledo F, 2007, MOL CELL BIOL, V27, P1425, DOI 10.1128/MCB.00999-06; Venot C, 1998, EMBO J, V17, P4668, DOI 10.1093/emboj/17.16.4668; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; Xu J., 2001, PREPARATION CULTURE	37	10	10	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	FEB 14	2013	32	7					827	836		10.1038/onc.2012.102	http://dx.doi.org/10.1038/onc.2012.102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	112GQ	22484427				2022-12-17	WOS:000316581100003
J	Darlington, Y; Nguyen, TA; Moon, SH; Herron, A; Rao, P; Zhu, C; Lu, X; Donehower, LA				Darlington, Y.; Nguyen, T-A; Moon, S-H; Herron, A.; Rao, P.; Zhu, C.; Lu, X.; Donehower, L. A.			Absence of Wip1 partially rescues Atm deficiency phenotypes in mice	ONCOGENE			English	Article						WIP1; PPM1D; ATM; ataxia telangiectasia; p53; thymic lymphoma	DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; TUMOR-SUPPRESSOR; PHOSPHATASE; PPM1D; CELLS; P53; IDENTIFICATION; TUMORIGENESIS	Wild-type p53-induced phosphatase 1 (WIP1) is a serine/threonine phosphatase that dephosphorylates proteins in the ataxia telangiectasia mutated (ATM)-initiated DNA damage response pathway. WIP1 may have a homeostatic role in ATM signaling by returning the cell to a normal pre-stress state following completion of DNA repair. To better understand the effects of WIP1 on ATM signaling, we crossed Atm-deficient mice to Wip1-deficient mice and characterized phenotypes of the double knockout progeny. We hypothesized that the absence of Wip1 might rescue Atm deficiency phenotypes. Atm null mice, like ATM-deficient humans with the inherited syndrome ataxia telangiectasia, exhibit radiation sensitivity, fertility defects, and are T-cell lymphoma prone. Most double knockout mice were largely protected from lymphoma development and had a greatly extended lifespan compared with Atm null mice. Double knockout mice had increased p53 and H2AX phosphorylation and p21 expression compared with their Atm null counterparts, indicating enhanced p53 and DNA damage responses. Additionally, double knockout splenocytes displayed reduced chromosomal instability compared with Atm null mice. Finally, doubly null mice were partially rescued from gametogenesis defects observed in Atm null mice. These results indicate that inhibition of WIP1 may represent a useful strategy for cancer treatment in general and A-T patients in particular. Oncogene (2012) 31, 1155-1165; doi:10.1038/onc.2011.303; published online 18 July 2011	[Darlington, Y.; Nguyen, T-A; Moon, S-H; Donehower, L. A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Darlington, Y.; Nguyen, T-A; Donehower, L. A.] Interdept Grad Program Cell & Mol Biol, Houston, TX USA; [Moon, S-H; Donehower, L. A.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Herron, A.] Dept Pathol & Immunol, Houston, TX USA; [Herron, A.] Ctr Comparat Med, Houston, TX USA; [Rao, P.; Donehower, L. A.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Zhu, C.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Lu, X.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Donehower, LA (corresponding author), Baylor Coll Med, Dept Mol Virol & Microbiol, 1 Baylor Plaza, Houston, TX 77030 USA.	larryd@bcm.tmc.edu	Nguyen, Thuy-Ai/Q-4082-2019	Nguyen, Thuy-Ai/0000-0001-8778-0078	NIH [R01 CA100420, R01 CA136549]; DOD [BC050781]; NATIONAL CANCER INSTITUTE [R01CA100420, R01CA136549] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Corrine Spencer and Yi- Jue Zhao for technical assistance. This work was supported by NIH grants (R01 CA100420) to LAD and (R01 CA136549) to XL, and a DOD Breast Cancer Research Program Predoctoral Traineeship Award (BC050781) to T-AN	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Belova GI, 2005, CANCER BIOL THER, V4, P1154, DOI 10.4161/cbt.4.10.2204; Borghesani PR, 2000, P NATL ACAD SCI USA, V97, P3336, DOI 10.1073/pnas.050584897; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Demidov ON, 2007, CELL STEM CELL, V1, P180, DOI 10.1016/j.stem.2007.05.020; Ehrbrecht A, 2006, J PATHOL, V208, P554, DOI 10.1002/path.1925; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gurley KE, 2001, CURR BIOL, V11, P191, DOI 10.1016/S0960-9822(01)00048-3; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Harrison M, 2004, TRENDS MOL MED, V10, P359, DOI 10.1016/j.molmed.2004.06.010; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Le Guezennec X, 2010, TRENDS BIOCHEM SCI, V35, P109, DOI 10.1016/j.tibs.2009.09.005; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Loukopoulos P, 2007, CANCER SCI, V98, P392, DOI 10.1111/j.1349-7006.2007.00395.x; Lu XB, 2005, CELL CYCLE, V4, P1060; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Macurek L, 2010, ONCOGENE, V29, P2281, DOI 10.1038/onc.2009.501; Moon SH, 2010, J BIOL CHEM, V285, P12935, DOI 10.1074/jbc.M109.071696; Moretti P, 2005, HUM MOL GENET, V14, P205, DOI 10.1093/hmg/ddi016; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; Rao PH, 1998, BLOOD, V92, P1743; Rayter S, 2008, ONCOGENE, V27, P1036, DOI 10.1038/sj.onc.1210729; Rotman G, 1998, HUM MOL GENET, V7, P1555, DOI 10.1093/hmg/7.10.1555; Saito-Ohara F, 2003, CANCER RES, V63, P1876; SAVITSKY K, 1995, HUM MOL GENET, V4, P2025, DOI 10.1093/hmg/4.11.2025; Sedgwick R, 1991, HDB CLIN NEUROLOGY, P347; Shen KC, 2005, CANCER RES, V65, P8747, DOI 10.1158/0008-5472.CAN-05-1471; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Shreeram S, 2006, J EXP MED, V203, P2793, DOI 10.1084/jem.20061563; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Tan DSP, 2009, CLIN CANCER RES, V15, P2269, DOI 10.1158/1078-0432.CCR-08-2403; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; Williamson CT, 2010, MOL CANCER THER, V9, P347, DOI 10.1158/1535-7163.MCT-09-0872; Xia Y, 2009, J BIOL CHEM, V284, P17428, DOI 10.1074/jbc.M109.007823; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yamaguchi H, 2006, BIOCHEMISTRY-US, V45, P13193, DOI 10.1021/bi061356b; Yoda A, 2008, J BIOL CHEM, V283, P18969, DOI 10.1074/jbc.M800560200	54	10	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	2012	31	9					1155	1165		10.1038/onc.2011.303	http://dx.doi.org/10.1038/onc.2011.303			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	901EW	21765465	Green Accepted			2022-12-17	WOS:000300945900008
